<SEC-DOCUMENT>0001019687-14-004132.txt : 20141110
<SEC-HEADER>0001019687-14-004132.hdr.sgml : 20141110
<ACCEPTANCE-DATETIME>20141110113059
ACCESSION NUMBER:		0001019687-14-004132
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20140930
FILED AS OF DATE:		20141110
DATE AS OF CHANGE:		20141110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		141207353

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aemd_10q-093014.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">x</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; </FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended September
30, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">o</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____to_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMMISSION FILE NUMBER 000-21846</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NEVADA</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13-3632859</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9635 GRANITE RIDGE DRIVE, SAN DIEGO, CA
92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 UNIVERSITY CENTER LANE, SUITE 660,
SAN DIEGO, CA 92122</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name, former address and former
fiscal year, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp; &nbsp;YES &nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
NO </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp; &nbsp;YES&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
NO </FONT><FONT STYLE="font-family: Wingdings">&#111;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &quot;large accelerated
filer,&quot; &quot;accelerated filer&quot; and &quot;smaller reporting company&quot; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp; </FONT><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer&nbsp; </FONT><FONT STYLE="font: 10pt Wingdings">o</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-accelerated
        filer&nbsp; </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Do not check if a smaller reporting company)</P></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting company&nbsp; </FONT><FONT STYLE="font: 10pt Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp; YES&nbsp; </FONT><FONT STYLE="font-family: Wingdings">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
NO </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of November 7, 2014, the registrant had outstanding
295,160,194 shares of common stock, $.001 par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART I.</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL STATEMENTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED BALANCE SHEETS AT SEPTEMBER&nbsp;30,&nbsp;2014 (UNAUDITED) AND MARCH&nbsp;31,&nbsp;2014</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTH PERIODS ENDED SEPTEMBER 30, 2014 AND 2013 (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONTROLS AND PROCEDURES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART II.&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL PROCEEDINGS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 1A.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DEFAULTS UPON SENIOR SECURITIES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MINE SAFETY DISCLOSURES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 5.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 6.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBITS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">36</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PART I. FINANCIAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; padding-left: 9pt">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">526,187</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,250,279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">41,141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,699</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 27pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">892,189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,479,346</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,185</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Patents and patents pending, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,988</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,988</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,089,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,695,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">LIABILITIES AND STOCKHOLDERS' DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">609,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">517,651</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888,778</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">839,070</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 9pt">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes payable, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">483,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367,655</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 9pt">Derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,679,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,216,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,855,374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 27pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,387,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,648,817</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -27pt; padding-left: 27pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -27pt; padding-left: 27pt">Noncurrent liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 27pt">Convertible notes payable, noncurrent portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">990,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">776,451</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 27pt">&nbsp;Total noncurrent liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">990,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">776,451</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 31.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,378,476</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,425,268</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Commitments and Contingencies (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Stockholders' Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Common stock, par value $0.001 per share; 500,000,000 shares authorized as of September 30, 2014 and March 31, 2014; 262,713,781 and 224,973,980 shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,984</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,654,853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,659,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(79,335,907</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(74,832,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 37pt">Total Aethlon Medical, Inc. stockholders&rsquo; deficit before noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,418,342</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,948,436</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">129,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">218,270</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,289,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,730,166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total liabilities and deficit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,089,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,695,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three and Six Month Periods Ended
September 30, 2014 and 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> September 30, <BR> 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -7pt; padding-left: 7pt">REVENUES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left; text-indent: -7pt; padding-left: 14pt">Government contract revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">479,075</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">644,887</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">530,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">840,483</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 7pt">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 14pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">710,434</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">651,581</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 14pt">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">544,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">404,849</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,165,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">863,480</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 7pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">227,092</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">142,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">428,097</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">339,014</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 28pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,080,267</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">874,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,303,571</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,854,075</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 7pt">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(601,192</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(229,796</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,773,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,013,592</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 7pt">OTHER EXPENSE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 14pt">Loss on debt conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,493</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,531,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 14pt">(Gain)/loss on change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,992,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,382,877</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -7pt; padding-left: 14pt">Interest and other debt expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 14pt">Loss on extension of warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">143,363</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">143,363</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 21pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">287,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,119,874</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,819,285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,639,576</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 7pt">NET LOSS BEFORE NONCONTROLLING INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(888,193</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,349,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,592,485</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,653,168</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7pt; padding-left: 7pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -7pt; padding-left: 7pt">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40,784</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(89,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(847,409</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,349,670</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,503,350</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,653,168</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -7pt; padding-left: 7pt">BASIC AND DILUTED LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -7pt; padding-left: 7pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">259,369,911</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">187,643,582</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">243,494,916</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">182,004,220</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Six Months Ended September 30, 2014
and 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(4,592,485</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(3,653,168</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -27pt; padding-left: 0.5in">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 27pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,601</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 45pt">Fair market value of common stock, warrants and options issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,382,877</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Loss on extension of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Loss on debt conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,531,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Amortization of debt discount and deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,502</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 45pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 63pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(162,495</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,404</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 63pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,202</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 63pt">Accounts payable and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,170</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 63pt">Due to related parties</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">91,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,394,366</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(744,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Proceeds from the issuance of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Proceeds from the issuance of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">670,274</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">228,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">670,274</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">628,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(724,092</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(116,520</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,250,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">125,274</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">526,187</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,754</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (CONTINUED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Six Months Ended September 30, 2014
and 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months <BR> Ended <BR> September 30, <BR> 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash paid during the period for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Supplemental disclosures of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Debt and accrued interest converted to common stock</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">1,007,631</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">420,460</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Reclassification of warrant derivative liability into equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,679,067</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">106,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Reclassification of accounts payable to convertible notes payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">47,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Deferred financing costs recorded in connection with debt amendment</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Reclassification of accrued interest to convertible notes payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,766</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,027</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 30, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORGANIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. and subsidiary (&quot;Aethlon&quot;, the
&quot;Company&quot;, &quot;we&quot; or &quot;us&quot;) is a medical device company focused on creating innovative devices that
address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments
is the Aethlon ADAPT&trade; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges
single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that
selectively remove harmful particles from the entire circulatory system without loss of essential blood components. On June 25,
2013, the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that allows us to
initiate human feasibility studies of the Aethlon Hemopurifier&reg; in the United States. Under the feasibility study protocol,
we will enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of this study will allow us the opportunity to initiate pivotal studies that are
required for market clearance to treat HCV and other disease conditions in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Successful outcomes of human trials will also be required by
the regulatory agencies of certain foreign countries where we intend to sell this device. Some of our patents may expire before
FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or
other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R) treatment technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2013, our subsidiary, Exosome Sciences, Inc. (&ldquo;ESI&rdquo;),
commenced operations with a focus on advancing exosome-based strategies to diagnose and monitor the progression of cancer, infectious
disease and other life-threatening conditions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQB marketplace administered
by the OTC Markets Group under the symbol &quot;AEMD.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited condensed consolidated financial
statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (&ldquo;GAAP&rdquo;)
for interim financial information and with the instructions to Form 10-Q and applicable sections of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of
management, all adjustments&nbsp;necessary to make the financial statements not misleading have been included. The condensed consolidated
balance sheet as of March 31, 2014 was derived from our audited financial statements. Operating results for the six months ended
September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending March 31, 2015. For further
information, refer to our Annual Report on Form 10-K for the year ended March 31, 2014, which includes audited financial statements
and footnotes as of March 31, 2014 and 2013 and for the years then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 2. LIQUIDITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements have been
prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and
satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses from operations and at September
30, 2014 are in default on certain debt agreements, have negative working capital of approximately $2,496,000, and have an accumulated
deficit of approximately $79,336,000. These factors, among other matters, raise substantial doubt about our ability to continue
as a going concern. A significant amount of additional capital will be necessary to advance the development of our products to
the point at which they may become commercially viable. We intend to fund operations, working capital and other cash requirements
for the fiscal year ending March 31, 2015 through debt and/or equity financing arrangements as well as through revenues and related
cash receipts under our government contracts (see Note 12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014, we
converted a past due convertible note in the amount of $660,000 and related accrued interest into equity and also
restructured and extended a formerly past due convertible note in the amount of $225,000. We also eliminated the antidilution
price protection on all the remaining outstanding notes and warrants which held such price protection. The combination of all
of those actions allowed us to reclassify our derivative liability in the amount of $10,679,067 into equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently addressing our liquidity issue by seeking additional
investment capital through private placements of common stock and debt and by applying for additional grants issued by government
agencies in the United States. We believe that our cash on hand and funds expected to be received from additional private investments
will be sufficient to meet our liquidity needs for fiscal 2015. However, no assurance can be given that we will receive any funds
in the form of revenues or in connection with capital raising activities in addition to the funds we have already received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The successful outcome of future contract-based and fundraising
activities cannot be determined at this time and there is no assurance that, even if achieved, we will have sufficient funds to
execute our intended business plan or generate positive operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements do not include any adjustments
related to this uncertainty and as to the recoverability and classification of asset carrying amounts or the amount and classification
of liabilities that might result should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summary of our significant accounting policies presented
below is designed to assist the reader in understanding our condensed consolidated financial statements. Such financial statements
and related notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting
policies conform to GAAP in all material respects, and have been consistently applied in preparing the accompanying&nbsp;condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPLES OF CONSOLIDATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying condensed consolidated financial statements
include the accounts of Aethlon Medical, Inc. and its majority-owned and controlled subsidiary, ESI. All significant intercompany
balances and transactions have been eliminated in consolidation. The Company classifies the noncontrolling interests in ESI as
part of consolidated net loss in the six months ended September 30, 2014 and includes the accumulated amount of noncontrolling
interests as part of stockholders&rsquo; equity. During the fiscal year ended March 31, 2014, ESI raised capital in the amount
of $1,500,000 in exchange for the issuance of 300,000 shares of ESI common stock to ESI&rsquo;s investors, representing 20% of
ESI&rsquo;s issued and outstanding capital stock. As a result, Aethlon Medical, Inc.&rsquo;s ownership of ESI was reduced to 80%.
If a further change in Aethlon Medical Inc.&rsquo;s ownership of ESI results in loss of control and deconsolidation, any retained
ownership interest will be remeasured with the gain or loss reported in our statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The losses at ESI during the six months ended September 30,
2014 reduced the noncontrolling interests on our consolidated balance sheet by $89,135 from $218,270 at March 31, 2014 to $129,135
at September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">USE OF ESTIMATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We prepare our condensed consolidated financial statements in
conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported
amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among others,
realization of long-lived assets, estimating fair value associated with debt and equity transactions and valuation of deferred
tax assets. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CASH AND CASH EQUIVALENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting standards define &quot;cash and cash equivalents&quot;
as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so near their maturity
that they present insignificant risk of changes in value because of changes in interest rates. For the purpose of financial statement
presentation, we consider all highly liquid investment instruments with original maturities of three months or less when purchased,
or any investment redeemable without penalty or loss of interest to be cash equivalents. As of September 30, 2014 and March 31,
2014, we had no assets that were classified as cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONCENTRATIONS OF CREDIT RISKS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash is maintained at two financial institutions in checking
accounts and related cash management accounts. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation
(&quot;FDIC&quot;) up to $250,000. Our September 30, 2014 cash balances were approximately $276,000 over such insured amount. We
do not believe that the Company is exposed to any significant risk with respect to its cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of our accounts receivable at September 30, 2014 and March
31, 2014 and all of our revenue in the six month periods ended September 30, 2014 and 2013 were directly from the U.S. Department
of Defense or from a subcontract under Battelle (defined herein), which is a prime contractor with the U.S. Department of Defense,
and as such no allowance for uncollectable accounts receivable is deemed necessary at September 30, 2014 or March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FAIR VALUE OF FINANCIAL INSTRUMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of our cash, accounts receivable, accounts
payable, and other current liabilities approximate their estimated fair values due to the short-term maturities of those financial
instruments. The carrying amount of the notes payable approximates their fair value due to the short maturity of the notes and
since the interest rate approximates current market interest rates for similar instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management has concluded that it is not practical to determine
the estimated fair value of amounts due to related parties because the transactions cannot be assumed to have been consummated
at arm's length, the terms are not deemed to be market terms, there are no quoted values available for these instruments, and an
independent valuation would not be practicable due to the lack of data regarding similar instruments, if any, and the associated
potential costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 9 with respect to derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROPERTY AND EQUIPMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the related assets, which range from two to five years. Repairs
and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement of property
and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss included in
the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INCOME TAXES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to the difference between the consolidated financial statements and their respective tax basis. Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards. We record a valuation
allowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable future, it is
more likely than not that some portion of the deferred tax assets may not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-lived assets are reviewed for impairment whenever events
or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a long-lived asset
is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized. We believe
no impairment charges were necessary during the three and six month periods ended September 30, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LOSS PER COMMON SHARE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per share is computed by dividing net income available
to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss
per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional
common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were
dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential
common shares have been excluded as their effect would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2014 and 2013, a total of 139,672,815 and
137,935,529 potential common shares, consisting of shares underlying outstanding stock options, warrants and convertible notes
payable were excluded as their inclusion would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SEGMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Historically, we operated in one segment that was based on our
development of therapeutic devices. However in the December 2013 quarter, we initiated the operations of ESI to develop diagnostic
tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic applications (See
Note 14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DEFERRED FINANCING COSTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs related to the issuance of debt are capitalized and amortized
to interest expense over the life of the related debt using the effective interest method.&nbsp;&nbsp;We recorded amortization
expense related to our deferred offering costs of $21,502 and $863 during the six month periods ended September 30, 2014 and 2013,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">REVENUE RECOGNITION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DARPA Contract -- With respect to revenue recognition, we entered
into a government contract with DARPA and have recognized revenue under such contract. We adopted the Milestone method of revenue
recognition for the DARPA contract under ASC 605-28 &ldquo;Revenue Recognition &ndash; Milestone Method&rdquo; and we believe we
meet the requirements under ASC 605-28 for reporting contract revenue under the Milestone Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to account for this contract, we identify the deliverables
included within the contract and evaluate which deliverables represent separate units of accounting based on if certain criteria
are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated
among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A milestone is an event having all of the following characteristics:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) There is substantive uncertainty at the date the arrangement
is entered into that the event will be achieved. A vendor&rsquo;s assessment that it expects to achieve a milestone does not necessarily
mean that there is not substantive uncertainty associated with achieving the milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) The event can only be achieved based in whole or in part
on either: (a) the vendor&rsquo;s performance; or (b) a specific outcome resulting from the vendor&rsquo;s performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) If achieved, the event would result in additional payments
being due to the vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A milestone does not include events for which the occurrence
is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&rsquo;s performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The policy for recognizing deliverable consideration contingent
upon achievement of a milestone must be applied consistently to similar deliverables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assessment of whether a milestone is substantive is performed
at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of the following
for the milestone to be considered substantive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) The consideration is commensurate with either: (a) the vendor&rsquo;s
performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items as a result of a specific
outcome resulting from the vendor&rsquo;s performance to achieve the milestone;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) The consideration relates solely to past performance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) The consideration is reasonable relative to all of the deliverables
and payment terms (including other potential milestone consideration) within the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A milestone is not considered substantive if any portion of
the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it does not relate
solely to past performance). To recognize the milestone consideration in its entirety as revenue in the period in which the milestone
is achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated into substantive and
non-substantive components. In addition, if a portion of the consideration earned from achieving a milestone may be refunded or
adjusted based on future performance, the related milestone is not considered substantive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 12 for the additional disclosure information required
under ASC 605-28.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Battelle Subcontract -- We entered into a subcontract agreement
with Battelle Memorial Institute (&ldquo;Battelle&rdquo;) in March 2013. Battelle was chosen by DARPA to be the prime contractor
on the systems integration portion of the original DARPA contract and we are one of several subcontractors on that systems integration
project. The Battelle subcontract is cost-reimbursable under a time and materials basis. We began generating revenues under the
subcontract during the six months ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our revenue under this contract is a function of cost reimbursement
plus an overhead mark-up for hours devoted to the project by specific employees (with specific hourly rates for those employees).
Battelle engages us as needed. Each payment requires approval by the program manager at Battelle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STOCK-BASED COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employee stock options and rights to purchase shares under stock
participation plans are accounted for under the fair value method. Accordingly, share-based compensation is measured when all granting
activities have been completed, generally the grant date, based on the fair value of the award. The exercise price of options is
generally equal to the market price of the Company's common stock (defined as the closing price as quoted on the OTCBB on the date
of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity incentive awards granted prior
to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance with the original provisions of
the then current accounting standards, and (b) compensation cost for all equity incentive awards granted subsequent to April 1,
2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent accounting standards. We use
a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table summarizes share-based compensation expenses
relating to shares and options granted and the effect on loss per common share during the six month periods ended September 30,
2014 and 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Six Months Ended September 30, 2014</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Six Months Ended</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 30, 2013</P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 68%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vesting of Stock Options</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">260,680</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">124,243</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incremental fair value of option Modifications</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,914</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vesting Expense Associated with CEO Restricted Stock Grant</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">64,444</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total Stock-Based Compensation Expense</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">260,680</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">190,601</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average number of common shares outstanding &ndash; basic and diluted</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">243,494,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">182,004,220</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic and diluted loss per common share</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for transactions involving services provided by third
parties where we issue equity instruments as part of the total consideration using the fair value of the consideration received
(i.e. the value of the goods or services) or the fair value of the equity instruments issued, whichever is more reliably measurable.
In transactions, when the value of the goods and/or services are not readily determinable and (1) the fair value of the equity
instruments is more reliably measurable and (2) the counterparty receives equity instruments in full or partial settlement of the
transactions, we use the following methodology:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) For transactions where goods have already been delivered
or services rendered, the equity instruments are issued on or about the date the performance is complete (and valued on the date
of issuance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) For transactions where the instruments are issued on a fully
vested, non-forfeitable basis, the equity instruments are valued on or about the date of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c) For any transactions not meeting the criteria in (a) or (b)
above, we re-measure the consideration at each reporting date based on its then current stock value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We review share-based compensation on a quarterly basis for
changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture
rate for all expense amortization after March 31, 2006 is recognized in the period the forfeiture estimate is changed. The effect
of forfeiture adjustments for the six months ended September 30, 2014 was insignificant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PATENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patents include both foreign and domestic patents. There were
several patents pending at September 30, 2014. We capitalize the cost of patents and patents pending, some of which were acquired,
and amortize such costs over the shorter of the remaining legal life or their estimated economic life, upon issuance of the patent.
The unamortized costs of patents and patents pending are subject to our review for impairment under our long-lived asset policy
above.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STOCK PURCHASE WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We grant warrants in connection with the issuance of convertible
notes payable and the issuance of common stock for cash. When such warrants are classified as equity and issued in connection with
debt, we measure the relative estimated fair value of such warrants and record it as a discount from the face amount of the convertible
notes payable. Such discounts are amortized to interest expense over the term of the notes using the effective interest method.
Warrants issued in connection with common stock for cash, if classified as equity, are considered issued in connection with equity
transactions and the warrant fair value is recorded to additional paid-in-capital. Lastly, warrants not meeting equity classification
are recorded as derivative instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DERIVATIVE INSTRUMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We evaluate free-standing derivative instruments (or embedded
derivatives) to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to
settle instruments indexed to our common shares on a first-in-first-out basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The classification of a derivative instrument is reassessed
at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified
as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Instruments classified as derivative liabilities are remeasured
each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations
in other (income) expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The convertible feature of certain notes payable provides for
a rate of conversion that is below market value. Such feature is normally characterized as a &quot;Beneficial Conversion Feature&quot;
(&quot;BCF&quot;). We measure the estimated fair value of the BCF in circumstances in which the conversion feature is not required
to be separated from the host instrument and accounted for separately, and record that value in the consolidated financial statements
as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the term of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">REGISTRATION PAYMENT ARRANGEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for contingent obligations to make future payments
or otherwise transfer consideration under a registration payment arrangement separately from any related financing transaction
agreements, and any such contingent obligations are recognized only when it is determined that it is probable we will become obligated
for future payments and the amount, or range of amounts, of such future payments can be reasonably estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESEARCH AND DEVELOPMENT EXPENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred research and development expenses during the three
and six month periods ended September 30, 2014 and 2013, which are included in various operating expense line items in the accompanying
condensed consolidated statements of operations. Our research and development expenses in those periods were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; padding-bottom: 2.5pt">Three months ended</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">250,388</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">293,580</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Six months ended</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">637,723</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">626,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OFF-BALANCE SHEET ARRANGEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not entered into any off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management is evaluating significant recent accounting pronouncements
that are not yet effective for the Company, including the new accounting standard on revenue recognition, ASU 2014-09 (Topic 606),
and has not yet concluded whether any such pronouncements will have a significant effect on the Company&rsquo;s future consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 4. NOTES PAYABLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notes payable consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Principal Balance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Accrued Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Principal Balance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Accrued Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left">12% Notes payable, past due</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">185,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">367,687</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">185,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">353,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">10% Note payable, past due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Directors&rsquo; Note(s)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 27pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">190,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">374,312</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">390,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">374,704</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014, we recorded
interest expense of $19,959 related to the contractual interest rates of our notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12% NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From August 1999 through May 2005, we entered into various borrowing
arrangements for the issuance of notes payable from private placement offerings (the &quot;12% Notes&quot;). On April 21, 2010,
a holder of $100,000 of the 12% Notes converted the principal balance and $71,758 of accrued interest into 687,033 shares of common
stock at an agreed conversion price of $0.25 per share. At September 30, 2014, the 12% Notes in the principal amount of $185,000
were past due, in default, and bearing interest at the default rate of 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10% NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2014,&nbsp;one 10% Note in the amount of $5,000
is past due and in default, remains outstanding and bears interest at the default rate of 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management's plans to satisfy the remaining outstanding balance
on these 12% and 10% Notes include converting the notes to common stock at market value or repayment when funds are available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DIRECTORS&rsquo; NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2013, we borrowed $400,000 from two of our directors
under two 90 day notes for $200,000 each bearing 10% interest (the &ldquo;Notes&rdquo;). At the discretion of the holders, if not
paid off by October 9, 2013, the noteholders were entitled to (i) convert the principal and accrued interest under the Notes into
shares of common stock at $0.088 per share (the &ldquo;Conversion Price&rdquo;) and (ii) receive warrants to purchase common stock
equal to 50% of the principal converted under the Notes, with an exercise price of $0.132 per share. Additionally, there was a
provision for a penalty interest rate of 12%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">That potential conversion price and warrant exercise price were
based on the same pricing mechanism that we have used in prior equity unit financings since March 2012 (see Note 6) which are based
on 80% of the then current market price of our common stock and with the warrant exercise price based on 120% of the same then
current market price. We initially reserved 6,931,818 shares of common stock to support the conversion of the Notes and accrued
interest in full as well as the exercise of the warrants in full (should such conversion and/or issuance occur).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the fiscal year ended March 31, 2014, the principal of
$200,000 and accrued interest of $9,367 were paid on one of the Notes, which extinguished all potential common stock and warrant
issuance provisions related to that Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014, the holder of
the second Note converted the principal of $200,000 and accrued interest of $20,349 into 2,503,966 shares of our common stock per
the conversion formula of the Note (see Note 6).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. CONVERTIBLE NOTES PAYABLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Convertible Notes Payable consisted of the following at September
30, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Principal</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Unamortized <BR> Discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Net <BR> Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Accrued <BR> Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible Notes Payable &ndash; Current Portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-indent: -9pt; padding-left: 9pt">October &amp; November 2009 10% Convertible Notes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">28,598</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">April 2010 10% Convertible Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">July and August 2011 10% Convertible Notes, past due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,728</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Law Firm Note</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 22pt">Total &ndash; Convertible Notes Payable &ndash; Current Portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">169,993</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible Notes Payable &ndash; Non-Current Portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Amended and Restated Series A 12% Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">September 2010 12% Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">April 2011 12% Convertible Notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">448,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">448,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 22pt">Total &ndash; Convertible Notes Payable &ndash; Non-Current Portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">990,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">990,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 44pt">Total Convertible Notes Payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,473,941</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,473,941</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">201,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no discounts remaining on any of our Convertible
Notes Payable as of September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014, we recorded
interest expense of $97,362 related to the contractual interest rates of our convertible notes and interest expense of $21,502
related to the amortization of deferred financing costs related to the convertible notes for a total interest related to convertible
notes of $118,864.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Convertible Notes Payable consisted of the following at March
31, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Principal</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Unamortized <BR> Discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Net <BR> Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Accrued <BR> Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible Notes Payable &ndash; Current Portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amended and Restated Series A 12% Convertible Notes, past due</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">885,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">885,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">575,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">2008 10% Convertible Notes, past due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">October &amp; November 2009 10% Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">April 2010 10% Convertible Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,438</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">July and August 2011 10% Convertible Notes, past due</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Law Firm Note</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 22pt">Total &ndash; Convertible Notes Payable &ndash; Current Portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,367,655</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,367,655</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">749,812</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible Notes Payable &ndash; Non-Current Portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">September 2010 12% Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">April 2011 12% Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">448,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">448,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">September 2011 12% Convertible Notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 22pt">Total &ndash; Convertible Notes Payable &ndash; Non-Current Portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">776,451</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">776,451</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47,151</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 44pt">Total Convertible Notes Payable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,144,106</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,144,106</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">796,963</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no discounts remaining on any of our Convertible
Notes Payable as of March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AMENDED AND RESTATED SERIES A 12% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2010, we entered into Amended and Restated Series A
12% Convertible Promissory Notes (the &quot;Amended and Restated Notes&quot;) with the holders of certain promissory notes previously
issued by us, extending the due date to December 31, 2010 on the aggregate principal balance of $900,000. During the fiscal year
ended March 31, 2013, the holders of $15,000 of the Notes converted their principal and related accrued interest into common stock.
The balance remaining at March 31, 2014 was $885,000 and past due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Weiner Note Conversion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 24, 2014, we entered into an agreement
with the Ellen R. Weiner Family Revocable Trust (the &ldquo;Trust&rdquo;), a holder of a Series A 12% Convertible Note (the &ldquo;Note&rdquo;),
which previously was classified as being in default. As per the agreement, the Trust converted past due principal of $660,000 and
accrued interest balance of $343,200 into restricted common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additionally, the Trust agreed to waive
anti-dilution price protection underlying warrants previously issued to the Trust. On June 26, 2014, three other parties who held
similar warrants also agreed to waive their anti-dilution price protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under its agreement, the Trust converted the entire $1,003,200
past due principal and interest balance on the Note, which previously was in default, into an aggregate of 23,318,254 restricted
shares of our common stock and five-year warrants to acquire up to 6,809,524 shares of our common stock at an exercise price of
$.042 per share (which exercise price was the result of certain contractual price adjustments previously made during 2011) and
up to 397,222 shares of our common stock at an exercise price of $.108 per share (collectively, the &ldquo;Conversion Securities&rdquo;).
Based on the fair value of the warrants and shares issued to the Trust for the accrued interest, we recorded a loss on settlement
of notes of $1,791,421.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In exchange for the Trust&rsquo;s conversion in full of the
Note and accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants, in addition
to the Conversion Securities, we issued to the Trust 75,000 restricted shares of common stock as a service fee, changed the exercise
price of all of the previously issued warrants to $.042 per share and extended the expiration date of all of the previously issued
warrants to July 1, 2018. We valued the 75,000 share service fee at $12,000 based on our closing price on the date of the agreement
and recorded that value as interest expense during the June 2014 period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bird Estate Extension</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 8, 2014, we executed a written restructuring agreement
(the &ldquo;Agreement&rdquo;) with the Estate of Allan Bird (the &ldquo;Estate&rdquo;), a holder of a Series A 12% Convertible
Note (the &ldquo;Note&rdquo;), which previously was classified as being in default. Since the negotiations for the Agreement were
completed in the month of June, we recorded the impact of the Agreement as of June 30, 2014. In the Agreement, the Estate agreed
to extend the expiration date of the Note to April 1, 2016, to convert approximately $116,970 of accrued interest to equity, and
to waive anti-dilution price protection underlying the Note and warrants previously issued to the Estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Agreement, the Estate converted the entire $116,970
past due interest balance on the Note, which previously was in default, into an aggregate of 2,591,846 restricted shares of our
common stock. The Estate received five-year warrants to acquire up to 2,321,429 shares of our common stock at an exercise price
of $.042 per share (which exercise price was the result of certain contractual price adjustments previously made during 2011).
Based on our common stock prices during a period of negotiation with the Estate including during calendar year 2013, the Estate
also received five-year warrants to acquire up to 135,417 shares of our common stock at an exercise price of $.108 (collectively
known as the &ldquo;Conversion Securities&rdquo;). Based on the fair value of the warrants and shares issued to the Estate for
the accrued interest, we recorded a loss on settlement of notes of $663,209.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In exchange for the Estate&rsquo;s extension of the Note, conversion
of accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants, in addition to the
Conversion Securities, we also issued to the Estate 25,000 restricted shares of common stock as an extension fee and extended the
expiration date of all of the previously issued warrants to July 1, 2018. We valued the 25,000 share extension fee at $4,500 based
on our closing price and recorded that value as a deferred financing cost, which we will amortize over the extended two year life
of the note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2008 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 17, 2014, we issued to the holder of the remaining
2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit warrants to acquire
up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 6). The units were issued
to the Note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest due under the Note,
which represented the entire amount outstanding under the Note and the Note was retired. We recorded a loss on debt conversion
of $65,493 on this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OCTOBER &amp; NOVEMBER 2009 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October and November 2009, we raised $430,000 from the sale
to accredited investors of 10% convertible notes (&quot;October &amp; November 2009 10% Convertible Notes&quot;). The October &amp;
November 2009 10% Convertible Notes matured at various dates between April 2011 and May 2011 and are convertible into our common
stock at a fixed&nbsp;conversion price of $0.25 per share. The investors also received matching three year warrants to purchase
unregistered shares of our common stock at an exercise price of $0.25 per share. We measured the fair value of the warrants and
the beneficial conversion feature of the Notes and recorded a 100% discount against the principal of the notes. Such discount was
fully amortized at March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In July 2012, we issued 461,409 shares of common stock and 230,705
warrants to purchase common stock to the holder of a $25,000 note in this grouping in exchange for the conversion of such note
and related accrued interest of $8,000 (for a total of $33,000). The warrants expired in 2012 and are exercisable at $0.107 per
share (see Note 6). We recorded a loss on conversion of $45,796.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the conversions into principal of
the October and November 2009 10% Convertible Notes by fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid">Activity in October &amp; November 2009 10% Convertible Notes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: left">Initial principal balance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">450,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(175,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,250</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Conversions during the six months ended September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of September 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2012, we agreed to extend the expiration date and
to change the exercise price of certain warrants of one of the note holders by two years in exchange for the extension of $50,000
of the October &amp; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same
two year period. We recorded a charge of $77,265 relating to this modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2013, we agreed to extend the expiration date of
certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &amp; November
2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management
assessed the change in the value of the notes and related warrants before and after that extension and determined that the change
in value related to the change in terms was not significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we issued to the holder of
the remaining October &amp; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting of an aggregate
of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common stock at an exercise
price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of $189,087 of unpaid principal
and accrued interest due under two promissory notes (the remaining October &amp; November 2009 10% Convertible Note and the April
2010 10% Convertible Note). The amounts converted represented the entire principal and interest outstanding under the notes and
the notes held by that holder were retired (see Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">APRIL 2010 10% CONVERTIBLE NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2010, we raised $75,000 from the sale to an accredited
investor of a 10% convertible note. The convertible note was originally scheduled to mature in October 2011 and is convertible
into our common stock at a fixed conversion price of $0.25 per share prior to maturity. The investor also received three year warrants
to purchase 300,000 unregistered shares of our common stock at a price of $0.25 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We measured the fair value of the warrants and the beneficial
conversion feature of the notes and recorded a 100% discount against the principal of the notes. We amortized this discount using
the effective interest method over the term of the note. As of September 30, 2014, there have not been any conversions of the April
2010 10% Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2012, we agreed to extend the expiration date and
to change the exercise price of certain warrants of the note holder by two years in exchange for his extension of $50,000 of the
October &amp; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note by that same two year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2013, we agreed to extend the expiration date of
certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &amp; November
2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management
assessed the change in the value of the notes and related warrants before and after that extension and determined that the change
in value related to the change in terms was not significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we issued to the holder of
the remaining October &amp; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting of an aggregate
of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common stock at an exercise
price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of $189,087 of unpaid principal
and accrued interest due under two promissory notes (the remaining October &amp; November 2009 10% Convertible Note and the April
2010 10% Convertible Note). The amounts converted represented the entire principal and interest outstanding under the notes and
the notes held by that holder were retired (see Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SEPTEMBER 2010 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 3, 2010, we entered into a Subscription Agreement
with three accredited investors (the &ldquo;Purchasers&rdquo;)&nbsp;providing for the issuance and sale of convertible promissory
notes and corresponding warrants in the aggregate principal amount of $1,430,000. The initial closing under the Subscription Agreement
resulted in the issuance and sale of (i) convertible promissory notes in the aggregate principal amount of $743,600, (ii) five-year
warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.31125 per share, and (iii)
five-year warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.43575 per share.
The convertible promissory notes bear interest compounded monthly at the annual rate of ten percent (10%) and mature on April 1,
2016 (see below). The aggregate gross cash proceeds were $650,000, the balance of the principal amount representing a due diligence
fee and an original issuance discount. The convertible promissory notes are convertible at the option of the holders into shares
of our common stock at a price per share equal to eighty percent (80%) of the average of the three lowest closing bid prices of
the common stock as reported by Bloomberg L.P. for the principal market on which the common stock trades or is quoted for the ten
(10) trading days preceding the proposed conversion date. Subject to adjustment as described in the notes, the conversion price
may not be more than $0.30 nor less than $0.20. There are no registration requirements with respect to the shares of common stock
underlying the notes or the warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2014, we entered into separate Amendments to Convertible
Notes and Warrants (collectively, the &ldquo;Amendments&rdquo;) with three accredited investors (collectively, the &ldquo;Investors&rdquo;)
who own certain convertible promissory notes (collectively, the &ldquo;Notes&rdquo;) and warrants (collectively, the &ldquo;Warrants&rdquo;)
previously issued by us on various dates between December 5, 2007 and September 23, 2011, including the September 2010 Convertible
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Amendments, the Notes were past maturity and were
in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended the maturity
date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result of the Amendments,
the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per annum, which represents
a reduction from the default interest rates of fifteen percent at which interest had been accruing. By entering into the Amendments,
we also agreed to increase the currently outstanding principal amount of the Notes by 12% from a total of $693,260 to a total of
$776,451.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the period from October 2011 to February 2014, the Investors
had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding under the
Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions applicable
to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly, pursuant
to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&rsquo;s Common Stock, which represents
the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected at $.042
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Amendments also set the conversion price of the Notes, as
well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per share. By virtue
of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015 and September 23,
2016 to January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the activity in the September 2010
10% Convertible Notes by fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid">Activity in the September 2010 10% Convertible Notes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: left">Initial principal balance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">743,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(405,500</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Increase in principal balance due to 12% extension fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,972</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Conversions during the six months ended September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of September 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">317,072</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">APRIL 2011 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2011, we entered into a Subscription Agreement with
two accredited investors (the &ldquo;Purchasers&rdquo;) providing for the issuance and sale of convertible promissory notes and
corresponding warrants in the aggregate principal amount of $385,000. The closing under the Subscription Agreement resulted in
the issuance and sale by us of (i) convertible promissory notes in the aggregate principal amount of $385,000, (ii) five-year warrants
to purchase an aggregate of&nbsp;4,004,000 shares of our common stock at an exercise price of $0.125 per share, and (iii) five-year
warrants to purchase an aggregate of&nbsp;4,004,000 shares of our common stock at an exercise price of $0.175 per share. The convertible
promissory notes bear interest compounded monthly at the annual rate of 10% and mature on April 1, 2016 (see below). The aggregate
gross cash proceeds to us were $350,000, the balance of the principal amount representing a due diligence fee and an original issuance
discount. The convertible promissory notes are convertible at the option of the holders into shares of our common stock at a price
per share equal to eighty percent (80%) of the average of the three lowest closing bid prices of the common stock as reported by
Bloomberg L.P. for the principal market on which the common stock trades or is quoted for the ten (10) trading days preceding the
proposed conversion date. Subject to adjustment as described in the notes, the conversion price may not be more than $0.20 nor
less than $0.10. There are no registration requirements with respect to the shares of common stock underlying the notes or the
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we issued (i) five-year warrants to purchase an
aggregate of 812,500 shares of our common stock at an exercise price of $0.125 per share, and (ii) five-year warrants to purchase
an aggregate of&nbsp;812,500 shares of our common stock at an exercise price of $0.175 per share to the Purchasers. These warrants
were issued as an antidilution adjustment under certain common stock purchase warrants held by the Purchasers that were acquired
from us in September 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2014, we entered into separate Amendments to Convertible
Notes and Warrants (collectively, the &ldquo;Amendments&rdquo;) with three accredited investors (collectively, the &ldquo;Investors&rdquo;)
who own certain convertible promissory notes (collectively, the &ldquo;Notes&rdquo;) and warrants (collectively, the &ldquo;Warrants&rdquo;)
previously issued by us on various dates between December 5, 2007 and September 23, 2011, including the April 2011 Convertible
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Amendments, the Notes were past maturity and were
in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended the maturity
date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result of the Amendments,
the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per annum, which represents
a reduction from the default interest rates of 15% at which interest had been accruing. By entering into the Amendments, we also
agreed to increase the currently outstanding principal amount of the Notes by 12% from a total of $693,260 to a total of $776,451.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the period from October 2011 to February 2014, the Investors
had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding under the
Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions applicable
to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly, pursuant
to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&rsquo;s Common Stock, which represents
the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected at $.042
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Amendments also set the conversion price of the Notes, as
well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per share. By virtue
of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015 and September 23,
2016 to January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2014, there have not been any conversions
of the April 2011 10% Convertible Notes and the 12% extension fee noted above increased the principal balance by $48,048 to a principal
balance of $448,448.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JULY &amp; AUGUST 2011 10% CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2011, we raised
$357,656 in five separate 10% convertible notes. Those notes had a fixed conversion price of $0.09 per share and carried an interest
rate of 10%. The convertible notes matured in July and August 2012. We also issued those investors five year warrants to purchase
3,973,957 shares of common stock at $0.125 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We measured the fair value of the warrants and the beneficial
conversion feature of the notes and recorded a $257,926 discount against the principal of the notes. We amortized this discount
using the effective interest method over the term of the note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective March 31, 2014, the holders of three of the five notes
totaling $100,000 converted all of their principal and accrued interest into 1,438,700 shares of our common stock at the contractual
conversion price of $0.09 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2014, we entered into a forbearance agreement with
the holder of the remaining two notes in which we agreed to repay his notes by October 31, 2014 and in which we also agreed to
extend his warrants by two years. We recorded a charge of $143,363 in the September 2014 period related to this warrant extension
due to the change in the fair value of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we paid off in full the remaining
outstanding principal balance and interest balances on the two remaining notes with cash payments of $382,748 (see Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SEPTEMBER 2011 CONVERTIBLE NOTES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2011, we issued $253,760 of convertible notes,
convertible at $0.07 per share. Such notes originally matured in September 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2014, we entered into separate Amendments to Convertible
Notes and Warrants (collectively, the &ldquo;Amendments&rdquo;) with three accredited investors (collectively, the &ldquo;Investors&rdquo;)
who own certain convertible promissory notes (collectively, the &ldquo;Notes&rdquo;) and warrants (collectively, the &ldquo;Warrants&rdquo;)
previously issued by us on various dates between December 5, 2007 and September 23, 2011, including the September 2011 Convertible
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the Amendments, the Notes were past maturity and were
in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended the maturity
date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result of the Amendments,
the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per annum, which represents
a reduction from the default interest rates of 15% at which interest had been accruing. By entering into the Amendments, we also
agreed to increase the currently outstanding principal amount of the Notes by 12%, which in the case of the September 2011 Notes,
they increased from $9,760 to $10,931</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the period from October 2011 to February 2014, the Investors
had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding under the
Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions applicable
to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly, pursuant
to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&rsquo;s Common Stock, which represents
the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected at $.042
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Amendments also set the conversion price of the Notes, as
well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per share. By virtue
of the Amendments, the expiration dates of the Warrants also were extended to January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the conversions into principal of
the September 2011 Convertible Notes by fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid">Activity in the September 2011 Convertible Notes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: left">Initial principal balance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">253,760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(60,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversions during the fiscal year ended March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Increase in principal balance due to extension fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Conversions during the six months ended September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of September 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted in the above table, the remaining balance of the September
2011 Convertible Notes converted into equity during the six months ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAW FIRM NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 22, 2012, we entered into a Promissory Note with our
corporate law firm for the amount of $75,000, which represented the majority of the amount we owed to that firm at that time. The
Promissory Note originally had a maturity date of December 31, 2012 and bears interest at 5% per annum. The note is convertible
at the option of the holder into shares of our common stock at a 10% discount to the market price of the common stock on the date
prior to conversion with a floor price on such conversions of $0.08 per share. The holder subsequently agreed to extend the Maturity
Date of the Note first to October 1, 2013, then to September 30, 2013, and now the expiration date of this note is again extended
to October 1, 2014. As of September 30, 2014, there have not been any conversions of the Law Firm Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we paid off in full the
outstanding principal balance and interest balance on the note with a cash payment of $50,000 and an issuance of 170,020
common shares (see Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. EQUITY TRANSACTIONS&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMMON STOCK AND WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following are Aethlon Medical, Inc.&rsquo;s Equity Transactions
in the Six Months Ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the three months ended June 30, 2014, we completed unit subscription
agreements with seven accredited investors pursuant to which we issued 2,192,444 shares of our common stock and 1,096,222 warrants
to purchase our common stock for net cash proceeds of $320,800. Such warrants have exercise prices ranging from $0.193 to $0.236
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As discussed above in Note 5, during the three months ended
June 30, 2014, we issued 15,714,286 shares of restricted common stock to the holder of one of the Series A 12% Convertible Notes
in exchange for the conversion in full of the $660,000 principal balance of that note, 7,603,968 shares of restricted common stock
in exchange for conversion of $343,200 of accrued interest and 75,000 shares of restricted common stock as a restructuring fee.
During that period, we also issued the other holder of the Series A 12% Convertible Notes 2,591,846 shares of restricted common
stock in exchange for conversion of $116,970 of accrued interest and 25,000 shares of restricted common stock as a restructuring
fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended June 30, 2014, we issued 219,127
shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an average price of $0.17
per share in payment for legal services, internal controls consulting services and regulatory consulting services collectively
valued at $38,268 based on the value of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
359,956 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an average price
of $0.14 per share in payment for legal and scientific consulting services valued at $49,090 based on the value of the services
provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
390,301 shares of restricted common stock at an average price of $0.19 per share in payment for investor relations consulting services
valued at $75,000 based on the value of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
1,937,505 shares of restricted common stock to the holders of three convertible notes in exchange for the partial or full conversion
of principal and interest in the aggregate amount of $81,375 at a conversion price of $0.042 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 24, 2014, we issued an aggregate of 2,503,966 shares
of restricted common stock and a seven-year warrant to issue up to 1,251,983 shares of common stock at an exercise price of $0.132
per share to Dr. Chetan Shah, a director. The common stock and warrant were issued to Dr. Shah upon the conversion of an aggregate
of $220,349 of unpaid principal and accrued interest due under a 10% Convertible Note previously issued to Dr. Shah by us on July
9, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 17, 2014, we issued to the holder of the remaining
2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit warrants to acquire
up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 5). The units were issued
to the note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest due under the promissory
note, which represented the entire amount outstanding under the note. We recorded a loss on debt conversion of $65,493 on this
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
to four investors 2,673,231 shares of restricted common stock through the cash exercise of eight warrants for $259,474 of cash
at an average exercise price of approximately $0.10 per share. As an inducement to those investors, we issued them replacement
warrants to acquire up to an aggregate of 2,673,231 shares of common stock on the same terms as the warrants they exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
and sold to three accredited investors units consisting of (a) one hundred thousand (100,000) restricted shares of our common stock,
par value $.001 per share, at prices per share ranging from $0.091 to $0.094 and (b) a five-year warrant to purchase fifty thousand
(50,000) shares of common stock at exercise prices ranging from $0.136 to $0.143 per share. In total, the investors purchased for
cash an aggregate of $90,000 of units. The investors acquired an aggregate of 974,982 shares of common stock and warrants to acquire
up to an aggregate of 487,491 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DUE TO RELATED PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of our officers and other related parties have advanced
us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working capital deficiencies. These unsecured
and non-interest-bearing liabilities have been included as due to related parties in the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other related party transactions are disclosed elsewhere in
these notes to consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. OTHER CURRENT LIABILITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current liabilities were comprised of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">March 31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Accrued interest</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">570,741</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,165,335</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued legal fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Accrued liquidated damages</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103,598</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">147,774</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,216,604</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,855,374</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of this report, various promissory and convertible
notes payable in the aggregate principal amount of $473,422 (as identified in Notes 4 and 5 above) have reached maturity and are
past due. We are continually reviewing other financing arrangements to retire all past due notes. At September 30, 2014, we had
accrued interest in the amount of $471,041 associated with these defaulted notes in accrued liabilities payable (see Notes 4 and
5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. FAIR VALUE MEASUREMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We follow FASB ASC 820, &quot;FAIR VALUE MEASUREMENTS AND DISCLOSURES&quot;
(&ldquo;ASC 820&rdquo;) in connection with assets and liabilities measured at fair value on a recurring basis subsequent to initial
recognition. The guidance applies to our derivative liabilities. We had no assets or liabilities measured at fair value on a non-recurring
basis for any period reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC 820 requires that assets and liabilities carried at fair
value will be classified and disclosed in one of the following three categories: We measure the fair value of applicable financial
and non-financial assets based on the following fair value hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1: Quoted market prices in active markets for identical
assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2: Observable market based inputs or unobservable inputs
that are corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3: Unobservable inputs that are not corroborated by market
data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The hierarchy noted above requires us to minimize the use of
unobservable inputs and to use observable market data, if available, when determining fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of our recorded derivative liabilities is determined
based on unobservable inputs that are not corroborated by market data, which is a Level 3 classification. We record derivative
liabilities on our balance sheet at fair value with changes in fair value recorded in our consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2014, we no longer had any derivative liabilities
as all of the holders of the financial instruments that had price antidilution protection waived such price antidilution protection.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our fair value measurements at the March 31, 2014 reporting
date are classified based on the valuation technique level noted in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Description</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Quoted Prices <BR> in Active Markets for <BR> (Level 1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Significant Other Observable <BR> (Level 2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Significant <BR> Unobservable <BR> (Level 3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left; padding-bottom: 2.5pt">Derivative Liabilities</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">10,679,067</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">10,679,067</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,679,067</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,679,067</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, in connection with our warrant and embedded conversion option derivative
instruments utilizing the Binomial Lattice option pricing model:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The following outlines
the significant weighted average assumptions used to estimate the fair value information presented, in connection with our warrant
and embedded conversion option derivative instruments utilizing the Binomial Lattice option pricing model:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months Ended September 30, 2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 73%; text-align: left">Risk free interest rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">0.02% - 0.62%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Average expected life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0.25 &ndash; 3 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">78.9% - 104.5%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">None</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below sets forth a summary of changes in the fair
value of our Level 3 financial instruments for the six months ended September 30, 2014: &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">April 1, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Recorded New Derivative <BR> Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in estimated fair value recognized in results of operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Reclassification <BR> of Derivative <BR> Liability to Paid <BR> in capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 25%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,679,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(10,679,067</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below sets forth a summary of changes in the fair
value of our Level 3 financial instruments for the six months ended September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Change in</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Reclassification</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">estimated fair</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">of Derivative</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Recorded</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">value recognized</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Liability to</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">April 1,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">New Derivative</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">in results</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Paid in</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">of operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 25%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -11pt; padding-left: 11pt">Derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,588,239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,382,877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(106,501</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,864,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. STOCK COMPENSATION&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table breaks out the components of our share-based
compensation expenses relating to shares and options granted and the effect on basic and diluted loss per common share during the
three and six months ended September 30, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 32%; text-align: left">Vesting of stock options</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">89,793</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">73,856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">260,680</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">124,243</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -11pt; padding-left: 11pt">Incremental fair value of option modifications</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,914</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -11pt; padding-left: 11pt">Vesting expense associated with CEO restricted stock grant</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">Total share-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">89,793</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">74,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">260,680</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">190,601</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">Total share-based compensation expense included in net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">89,793</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,856</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">260,680</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">190,601</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">259,369,911</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">187,643,582</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">243,494,916</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">182,004,220</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">Basic and diluted loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the stock-based compensation expense recorded during
the six months ended September 30, 2014 and 2013, which totaled $260,680 and $190,601, respectively, is included in payroll and
related expense in the accompanying condensed consolidated statements of operations.&nbsp; Stock-based compensation expense recorded
during the six months ended September 30, 2014 and 2013 had no impact on basic and diluted loss per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We review share-based compensation on a quarterly basis for
changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of
forfeiture adjustments for the three and six month periods ended September 30, 2014 was insignificant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 6, 2014, our Board of Directors approved the following
grants of options to certain officers and directors of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To Mr. James A. Joyce, an option to acquire an aggregate of 1,500,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $246,000.&nbsp;&nbsp;The option vested as to 500,000 shares on the grant date for a vesting expense of $82,000 and will vest as to an additional 500,000 shares on each of the first two anniversaries of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To Mr. Rodney S. Kenley, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000.&nbsp;&nbsp;The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To Mr. James B. Frakes, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000. The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To Dr. Richard H. Tullis, an option to acquire an aggregate of 50,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $8,200. The option vested as to 16,667 shares on the grant date for a vesting expense of $2,733 and will vest as to an additional 16,667 shares on the first anniversary of the grant date and 16,666 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the above grants to our officers, on June 6,
2014, our Board of Directors also approved the grant of options to five employees to acquire an aggregate of 370,000 shares of
our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The aggregate
fair value of those stock options at the date of grant was $60,680. Those options vested as to 123,333 shares on the grant date
for a vesting expense of $20,227 and will vest as to an additional 123,333 shares on the first anniversary of the grant date and
123,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June
6, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the share-based compensation expense for the
specific stock option grants noted above, our total share-based compensation expense for the three and six months ended September
30, 2014 includes ongoing vesting expense associated with stock grants from prior periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes to 2012 Board Compensation Program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2012, the Board approved a Board Compensation Program
(the &ldquo;2012 Program&rdquo;), which modified and superseded the 2005 Directors Compensation Program that had been in effect
previously. On June 6, 2014, the Board approved certain changes to the 2012 Program. Under the modified 2012 Program, in which
only non-employee Directors may participate, a new eligible Director will receive an initial grant of $50,000 worth of options
to acquire shares of common stock, with such grant being valued at the exercise price based on the average of the closing bid prices
of our common stock for the five trading days preceding the first day of the fiscal year. These options will have a term of ten
years and will vest 1/3 upon grant and 1/3 upon each of the first two anniversaries of the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the beginning of each fiscal year, each existing Director
eligible to participate in the 2012 Program also will receive a grant of $35,000 worth of options valued at the exercise price
based on the average of the closing bid prices of the Common Stock for the five trading days preceding the first day of the fiscal
year. Such options will vest on the first anniversary of the date of grant. In lieu of per meeting fees, under the 2012 Program
eligible Directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program also provides for the following
annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000, Audit Committee member - $4,000, Compensation
Committee member - $4,000 and Lead independent director - $15,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the modified 2012 Program on June 6, 2014, we
issued 184,211 stock options to each of our three outside directors. Those grants vest over the fiscal year ending March 31, 2015
and have an exercise price of $0.19 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the foregoing actions - the changes in base salaries,
the option grants and the changes to the Directors Compensation Program discussed herein - were approved and recommended by the
Company&rsquo;s Compensation Committee prior to approval by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial Lattice option
pricing models at, and during the six months ended September 30, 2014:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 73%; text-align: left">Risk free interest rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">2.6%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Average expected life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">90.23%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">None</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The expected volatility was based on the historic volatility.
The expected life of options granted was based on the &quot;simplified method&quot; as described in the SEC's guidance due to changes
in the vesting terms and contractual life of current option grants compared to our historical grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2013, we granted to a scientific advisory board member
and a scientific consultant a three year option to purchase 125,000 shares of our common stock at a price of $0.11 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2013, <FONT STYLE="background-color: white">our compensation
committee and Board of Directors approved the issuance of four stock option grants to four of our executives. The options carried
an exercise price of $0.10 per share, have a ten year life and vest over the following schedule: 25% on July 1, 2014, 25% on July
1, 2015, 25% on July 1, 2016 and 25% on July 1, 2017. The numbers of shares underlying each of the stock option grants were as
follows: 2,000,000 shares to our chief executive officer and 500,000 shares each to our president, chief science officer and chief
financial officer (see Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information, which is based on historical data, with respect to stock option grants utilizing the
Binomial Lattice option pricing models at, and during the six months ended September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 73%; text-align: left">Risk free interest rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">0.38% - 2.50%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Average expected life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3 years - 10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">94.6% - 102.7%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">None</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The expected volatility was based on the historic volatility.
The expected life of options granted was based on the &quot;simplified method&quot; as described in the SEC's guidance due to changes
in the vesting terms and contractual life of current option grants compared to our historical grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options outstanding that have vested and are expected to vest
as of September 30, 2014 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Number of Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual Term in Years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%">Vested</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">24,294,227</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">3.96</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expected to vest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,711,811</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,006,038</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activity during the six months ended
September 30, 2014 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Range of<BR> Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average <BR> Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%; text-align: left">Stock options outstanding at March 31, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">26,133,407</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$0.076 - $0.41</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,972,631</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cancelled/Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Stock options outstanding at September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,006,038</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$0.076 - $0.41</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at September 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,294,227</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$0.076 - $0.41</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.26</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2014, there was approximately $497,783 of unrecognized
compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of 2.19 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 30, 2014, our stock options had a negative intrinsic
value since the closing price of our common stock on that date of $0.12 per share was below the weighted average exercise price
of our stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of warrant activity during the six months ended September
30, 2014 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Range of<BR> Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%">Warrants outstanding at March 31, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">70,709,475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">$0.042 - $0.25</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.13</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,166,104</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.086 &ndash; $0.12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,375,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.042 - $0.24</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.07</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cancelled/Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,136,364</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">$0.13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.13</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Warrants outstanding at September 30, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,782,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">$0.042 - $0.25</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">82,782,621</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.042 - $0.25</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice option pricing models
at, and during, the six months ended September 30, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="width: 73%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.79% - 2.29%&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Average expected life&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5 years &ndash; 7 years</FONT></TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected volatility&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">90.1% - 95.8%</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected dividends&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As discussed in Note 1, we entered into a contract with the
DARPA on September 30, 2011. Under the DARPA award, we have been engaged to develop a therapeutic device to reduce the incidence
of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from DARPA was a
fixed-price contract with potential total payments to us of $6,794,389 over the course of five years. Fixed price contracts require
the achievement of multiple, incremental milestones to receive the full award during each year of the contract. Under the terms
of the contract, we will perform certain incremental work towards the achievement of specific milestones against which we will
invoice the government for fixed payment amounts.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Originally, only the base year (year one contract) was effective
for the parties, however, DARPA subsequently exercised the option on the second, third and fourth years of the contract. DARPA
has the option to enter into the contract for year five. The milestones are comprised of planning, engineering and clinical targets,
the achievement of which in some cases will require the participation and contribution of third party participants under the contract.
There can be no assurance that we alone, or with third party participants, will meet such milestones to the satisfaction of the
government and in compliance with the terms of the contract or that we will be paid the full amount of the contract revenues during
any year of the contract term. We commenced work under the contract in October 2011.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to budget restrictions within the Department of Defense,
on February 10, 2014, DARPA reduced the scope of our contract in years three through five of the contract. The reduction in scope
focused our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible payments
under the contract by $858,491 over years three through five. We recently completed a re-budgeting of the expected costs on the
remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs due to
the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014, we invoiced
DARPA for three milestones totaling $444,723. The details of those milestones were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone 2.4.2.2 &ndash; Determine capacity requirements of
affinity resin to multiple simultaneous targets. The milestone payment was $197,362. Management considers this milestone to be
substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&nbsp;&nbsp;We demonstrated
that we were able to determine the capacity requirements of affinity resin to multiple simultaneous targets.&nbsp;&nbsp;The report
was accepted by the contracting officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone 2.4.2.4 &ndash; Finish construction and delivery of
25 experimental cartridges for testing by the system integrator. The milestone payment was $50,000. Management considers this milestone
to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&nbsp;&nbsp;We
demonstrated that we delivered the 25 cartridges to the systems integrator as part of our submission for approval.&nbsp;&nbsp;The
report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone M9 &ndash; Target capture &gt; 90% in 24 hours for
at least 3 targets ex vivo in blood or blood components using the optimized cartridge. The milestone payment was $197,361. Management
considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's
efforts.&nbsp;&nbsp;We demonstrated that we were able to capture approximately 90% in 24 hours for at least 3f targets ex vivo
in blood or blood components using the optimized cartridge.&nbsp;&nbsp;The report was accepted by the contracting officer's representative
and the invoice was submitted thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the six months ended September 30, 2013, we invoiced DARPA
for four milestones totaling $808,739.&nbsp;&nbsp;The details of those milestones were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone 2.3.2.2 &ndash; Formulate initial design work based
on work from the previous phase. Begin to build and test selected instrument design and tubing sets. The milestone payment was
$195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based
solely on another party's efforts.&nbsp;&nbsp;We demonstrated that we were able to formulate the initial design work and to build
and test selected instrument design and tubing sets as part of our submission for approval.&nbsp;&nbsp;The report was accepted
by the contracting officer's representative and the invoice was submitted thereafter.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone 2.3.2.2 &ndash; Write and test software and conduct
ergonomic research. Begin discussions with the systems integrator. The milestone payment was $195,581. Management considers this
milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&nbsp;&nbsp;We
obtained wrote and tested software and conducted ergonomic research and began discussions with the systems integrator. The report
was accepted by the contracting officer's representative and the invoice was submitted thereafter.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone 2.3.3.2 &ndash; Cartridge construction with optimized
affinity matrix design for each potential target. Complete the capture agent screening. The milestone payment was $208,781. Management
considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's
efforts.&nbsp;&nbsp;We completed the cartridge construction with optimized affinity matrix design for each potential target and
completed the capture agent screening. The report was accepted by the contracting officer's representative and the invoice was
submitted thereafter.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone M5 &ndash; Target capture &gt; 90% in 24 hours for
at least three targets in blood or blood components. The milestone payment was $208,781. Management considers this milestone to
be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&nbsp;&nbsp;We
demonstrated that we were able to capture approximately 90% in 24 hours for at least three of the agreed targets in blood or blood
components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. COMMITMENTS AND CONTINGENCIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEASE COMMITMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rented approximately 2,300 square feet of executive office
space at 8910 University Center Lane, Suite 660, San Diego, CA 92122 at the rate of $6,475 per month on a four year lease that
expired in September 2014. We continued leasing that space for the month of October and, effective November 1, 2014, moved into
a new facility of approximately 2,576 square feet located at 9635 Granite Ridge Drive, San Diego<I>, </I>CA 92123 under a 39 month
lease with an initial rental rate of $6,054 per month. We believe this new leased facility will be satisfactory for our office
needs over the term of the lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also rent approximately 1,700 square feet of laboratory space
at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $3,917 per month on a one year lease that
previously was scheduled to expire in October 2014 and was recently extended to in October 2015. We believe this new leased facility
will be satisfactory for our laboratory needs over the term of the lease</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Exosome Sciences, Inc. subsidiary rents approximately 2,055
square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at the rate of $3,596 per month on a one
year lease that previously was scheduled to expire in October 2014 and was recently extended to in October 2015. We believe this
new leased facility will be satisfactory for ESI&rsquo;s operational needs over the term of the lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rent expense approximated $84,000 and $68,000 for the six month
periods ended September 30, 2014 and 2013, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEGAL MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, claims are made against us in the ordinary
course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and
unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or
more products or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The occurrence of an unfavorable outcome in any specific period
could have a material adverse effect on our results of operations for that period or future periods. Other than as mentioned here,
we are not presently a party to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. SEGMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We operate our businesses principally through two reportable
segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities.
Our reportable segments have been determined based on the nature of the potential products being developed. ESI did not have any
operations in the six months ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon&rsquo;s revenue is generated primarily from government
contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI
segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables set forth certain information regarding
our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this
Report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">530,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">840,483</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Revenues</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">530,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">840,483</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,294,453</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,013,592</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(445,674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Operating Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,773,200</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,013,592</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Net Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,202,873</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,653,168</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(356,539</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Net Loss Before Non-Controlling Interests</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,592,485</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,653,168</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cash:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">47,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,754</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">478,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">526,187</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,754</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Total Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">443,027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">411,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">646,242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,089,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">411,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital Expenditures:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Capital Expenditures</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Depreciation and Amortization:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Depreciation and Amortization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">156,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">216,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">156,799</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">216,502</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. SUBSEQUENT EVENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management has evaluated events subsequent to September 30,
2014 through the date that the accompanying condensed consolidated financial statements were filed with the Securities and Exchange
Commission for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Government Contracts</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we collected $247,361 under
our DARPA contract, and under the Battelle subcontract we billed $9,595 and we collected $11,311.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Debt Reduction</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we paid off the remaining
principal and interest balances on the two remaining July &amp; August 2011 10% Convertible Notes, which had been classified as
being in default, with cash payments totaling $382,748 (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we paid off in
full the outstanding principal balance and interest balance on the Law Firm Note with a cash payment of $50,000 and an
issuance of 170,020 common shares (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Common Stock Issuances</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we issued 317,119 shares of
common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an average price of $0.124 per
share in payment for legal and scientific consulting services valued at $39,170 based on the value of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Equity Unit Investments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we issued and sold to eight
accredited investors units (the &ldquo;Units&rdquo;) consisting of (a) one hundred thousand (100,000) restricted shares of the
Registrant&rsquo;s common stock, par value $.001 per share (the &ldquo;Common Stock&rdquo;), at prices per share ranging from $0.105
to $0.114 and (b) a five-year warrant to purchase fifty thousand (50,000) shares of Common Stock at exercise prices ranging from
$0.154 to $0.167 per share (the &ldquo;Unit Warrants&rdquo;). In total, the investors purchased for cash an aggregate of $501,700
of Units. The investors acquired an aggregate of 4,506,250 shares of Common Stock and Unit Warrants to acquire up to an aggregate
of 2,253,125 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we issued to an accredited
investor Units consisting of an aggregate of 1,835,798 shares of Common Stock and Unit Warrants to acquire up to an aggregate of
1,837,798 shares of Common Stock at an exercise price of $0.103 per share. The Units were issued to the investor upon the conversion
of an aggregate of $189,087 of unpaid principal and accrued interest due under two promissory notes (the remaining October &amp;
November 2009 10% Convertible Note and the April 2010 10% Convertible Note &ndash; see Note 5) previously issued to the investor
by the Registrant. The amounts converted represented the entire principal and interest outstanding under the notes and the notes
held by that holder were retired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Warrant Exercises and Issuance of New Warrants Upon Exercise
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsequent to September 30, 2014, we issued
an aggregate of 5,671,119 shares of Common Stock and seven-year warrants (the &ldquo;Exchange Warrants&rdquo;) to issue up to an
aggregate of 5,671,119 shares of Common Stock at exercise prices ranging from $0.093 to $0.116 per share to eight accredited investors.
One of the investors is Dr. Chetan Shah, a director of the Registrant. The Common Stock and Exchange Warrants were issued to the
investors upon the cash exercise of previously issued warrants held by them. The investors paid an aggregate of $579,251 upon exercise
of the previously outstanding warrants at exercise prices ranging from $0.093 to $0.115 per share. The foregoing transaction was
privately negotiated with the group of participating warrant holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Note Conversions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsequent to September 30, 2014, we issued
an aggregate of 3,522,976 shares of Common Stock to two accredited investors upon the conversion of an aggregate of $147,965 of
unpaid principal and accrued interest due under promissory notes previously issued to the investors by the Registrant. The conversion
price per share was $0.042</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Warrant Exercises</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsequent to September 30, 2014, we issued
an aggregate of 16,423,131 shares of Common Stock to three accredited investors upon the exercise of warrants previously issued
with an exercise price of $0.042 per share. The warrants were exercised on a cashless or &ldquo;net&rdquo; basis. Accordingly,
we did not receive any proceeds from such exercises. The cashless exercise of such warrants resulted in the cancellation of previously
issued warrants to purchase an aggregate of 20,050,643 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Issuance of Convertible Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we entered into a Subscription
Agreement with two accredited investors providing for the issuance and sale of (i) convertible promissory notes in the aggregate
principal amount of $527,780 and (ii) five year warrants to purchase up to 2,356,160 shares of Common Stock at a fixed exercise
price of $0.168 per share. The convertible promissory notes bear interest at the annual rate of 10% and mature on April 1, 2016.
The aggregate gross cash proceeds to us were $415,000 after subtracting legal fees of $35,000; the balance of the principal amount
of the notes represents a $27,780 due diligence fee and an original issuance discount. The convertible promissory notes are convertible
at the option of the holders into shares of our common stock at a fixed price of $0.112 per share, for up to an aggregate of 4,712,321
shares of Common Stock. There are no registration requirements with respect to the shares of common stock underlying the notes
or the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following discussion of our financial condition and results
of operations should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated financial statements
and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. This item contains forward-looking statements that
involve risks and uncertainties. Actual results may differ materially from those indicated in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All statements, other than statements of historical fact, included
in this Form 10-Q are, or may be deemed to be, &quot;forward-looking statements&quot; within the meaning of Section 27A of the
Securities Act of 1933, as amended (&quot;the Securities Act&quot;), and Section 21E of the Exchange Act. Such forward-looking
statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance,
or achievements of Aethlon Medical, Inc. (&quot;we&quot;, &quot;us&quot; or &quot;the Company&quot;) to be materially different
from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this
Form 10-Q. Such potential risks and uncertainties include, without limitation, completion of our capital-raising activities, FDA
approval of our products, other regulations, patent protection of our proprietary technology, product liability exposure, uncertainty
of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with
the Securities and Exchange Commission. The forward-looking statements are made as of the date of this Form 10-Q, and we assume
no obligation to update the forward-looking statements, or to update the reasons actual results could differ from those projected
in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. (&quot;Aethlon&quot;, the &quot;Company&quot;,
&quot;we&quot; or &quot;us&quot;) is a medical device company focused on creating innovative devices that address unmet medical
needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments is the Aethlon ADAPT&trade;
(Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges single or multiple affinity
drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles
from the entire circulatory system without loss of essential blood components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, the U.S. Food and Drug Administration (&quot;FDA&quot;)
approved our Investigational Device Exemption (&quot;IDE&quot;) application to initiate a ten patient human clinical trial in one
location in the United States. Successful outcomes of that human trial as well as at least one follow-on human trial will be required
by the FDA in order to commercialize our products in the US. The regulatory agencies of certain foreign countries where we intend
to sell this device will also require one or more human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of our patents may expire before we receive FDA approval
to market our products in the United States or we receive approval to market our products in a foreign country. However, we believe
that certain patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R)
treatment technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In October 2013, our majority owned subsidiary, Exosome Sciences,
Inc. (ESI), commenced operations with a focus on advancing exosome-based strategies to diagnose and monitor the progression of
cancer, infectious disease and other life-threatening conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQB marketplace administered
by the OTC Markets Group under the symbol &quot;AEMD.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the informational requirements of the Securities
Exchange Act and must file reports, proxy statements and other information with the SEC. The reports, information statements and
other information we file with the Commission can be inspected and copied at the Commission Public Reference Room, 100 F Street,
N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800)
SEC-0330. The Commission also maintains a Web site (http://www.sec.gov) that contains reports, proxy and information statements
and other information regarding registrants, like us, which file electronically with the Commission. Our headquarters are located
at 9635 Granite Ridge Drive, San Diego, CA 92123. Our phone number at that address is (858) 459-7800. Our Web site is http://www.aethlonmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESULTS OF OPERATIONS&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THREE MONTHS ENDED SEPTEMBER 30, 2014 COMPARED TO THE THREE
MONTHS ENDED SEPTEMBER 30, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded government contract revenue in the three months
ended September 30, 2014 and 2013.&nbsp;&nbsp;This revenue arose from work performed under our government contract with DARPA and
our subcontract with Battelle as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months Ended 9/30/14</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months Ended 9/30/13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%; text-align: left">DARPA Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">444,723</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">613,143</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(168,420</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Battelle Subcontract</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,352</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,608</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">479,075</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">644,887</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(165,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>DARPA Contract</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We entered into a contract with the DARPA on September 30, 2011.
Under the DARPA award, we have been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream
infection that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential
total payments to us of $6,794,389 over the course of five years. Fixed price contracts require the achievement of multiple, incremental
milestones to receive the full award during each year of the contract. Under the terms of the contract, we will perform certain
incremental work towards the achievement of specific milestones against which we will invoice the government for fixed payment
amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Originally, only the base year (year one contract) was effective
for the parties, however, DARPA subsequently exercised the option on the second, third and fourth years of the contract. DARPA
has the option to enter into the contract for year five. The milestones are comprised of planning, engineering and clinical targets,
the achievement of which in some cases will require the participation and contribution of third party participants under the contract.
There can be no assurance that we alone, or with third party participants, will meet such milestones to the satisfaction of the
government and in compliance with the terms of the contract or that we will be paid the full amount of the contract revenues during
any year of the contract term. We commenced work under the contract in October 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to budget restrictions within the Department of Defense,
on February 10, 2014, DARPA reduced the scope of our contract in years three through five of the contract. The reduction in scope
focused our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible payments
under the contract by $858,491 over years three through five. We recently completed a re-budgeting of the expected costs on the
remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs due to
the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014 we invoiced
DARPA for three milestones totaling $444,723 while in the three months ended September 30, 2013, we invoiced DARPA for three milestones
totaling $613,143.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated operating expenses for the three months ended September
30, 2014 were $1,080,267 in comparison with $874,683 for the comparable quarter a year ago.&nbsp;&nbsp;This increase of $205,584,
or 23.5%, was due to increases in payroll and related expenses of $139,505 and increases in general and administrative expenses
of $84,769, which were partially offset by a decrease in professional fees of $18,690.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $139,505 increase in payroll and related expenses was primarily
due to the ESI payroll of $137,257. Other factors were an increase in stock-based compensation of $14,980 and a decrease in cash-based
compensation at Aethlon of $12,732.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $84,769 increase in general and administrative expenses
was due to general and administrative expenses at ESI of $45,986. We also had an increase of $56,617 in our non-DARPA-related general
and administrative expenses. Those increases were partially offset by a decrease in our DARPA-related general and administrative
expenses of $17,834.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $18,690 decrease in our professional fees was due to a decrease
in our DARPA-related professional fees of $48,188, which was partially offset by increases of $20,675 in ESI professional fees
and of $8,823 of our non-DARPA-related professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other expense consists primarily of losses on extinguishment
of debt, the change in the fair value of our derivative liability, other expense and interest expense. Other expense for the three
months ended September 30, 2014 was other expense of $287,001 in comparison with other expense of $3,119,874 for the comparable
quarter a year ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loss on Extinguishment of Debt and Other</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded a loss on extinguishment of debt of $65,493 for
the three months ended September 30, 2014 that related to the conversion to equity of $45,906 in principal and accrued interest
related to a note payable. The three months ended September 30, 2013 contained $17,467 in losses on debt conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The three months ended September 30, 2014 also included a charge
of $143,363 for the change in fair value related to the extension of the warrants of a note holder in exchange for a postponement
in the agreed payment date of his notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Change in Fair Value of Derivative Liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not record a change in the fair value of derivative liabilities
in the three months ended September 30, 2014. For the three months ended September 30, 2013, the change in the estimated fair value
of derivative liability was a loss of $2,992,002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest expense was $78,145 for the three months ended September
30, 2014 compared to $110,405 in the corresponding prior period, a decrease of $32,260. The various components of our interest
expense are shown in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Quarter Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Quarter Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/14</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">66,585</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">108,723</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(42,138</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of Deferred Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,560</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of Note Discounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,145</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(32,260</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted in the above table, the most significant factor in
the $32,260 decrease in interest expense was the $42,138 decrease in the interest expense that was primarily due to lower levels
of notes outstanding in the 2014 period. Other smaller factors in the change in our total interest were an increase in the amortization
of deferred financing costs of $11,560 and a $1,682 reduction in the amortization of note discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the increased expenses noted above, our net loss
before noncontrolling interests was approximately $888,000 for the quarter ended September 30, 2014 compared to the net loss before
noncontrolling interests of approximately $3,350,000 in the quarter ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic and diluted loss attributable to common stockholders were
($0.00) for the three month period ended September 30, 2014 compared to ($0.02) for the three month period ended September 30,
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIX MONTHS ENDED SEPTEMBER 30, 2014 COMPARED TO THE SIX MONTHS
ENDED SEPTEMBER 30, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded government contract revenue in the six months ended
September 30, 2014 and 2013.&nbsp;&nbsp;This revenue arose from work performed under our government contract with DARPA and our
subcontract with Battelle as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months Ended 9/30/14</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Six Months Ended 9/30/13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%; text-align: left">DARPA Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">444,723</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">808,739</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(364,016</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Battelle Subcontract</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,648</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,904</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">530,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">840,483</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(310,112</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>DARPA Contract</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We entered into a contract with the DARPA on September 30, 2011.
Under the DARPA award, we have been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream
infection that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential
total payments to us of $6,794,389 over the course of five years. Fixed price contracts require the achievement of multiple, incremental
milestones to receive the full award during each year of the contract. Under the terms of the contract, we will perform certain
incremental work towards the achievement of specific milestones against which we will invoice the government for fixed payment
amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Originally, only the base year (year one contract) was effective
for the parties, however, DARPA subsequently exercised the option on the second, third and fourth years of the contract. DARPA
has the option to enter into the contract for year five. The milestones are comprised of planning, engineering and clinical targets,
the achievement of which in some cases will require the participation and contribution of third party participants under the contract.
There can be no assurance that we alone, or with third party participants, will meet such milestones to the satisfaction of the
government and in compliance with the terms of the contract or that we will be paid the full amount of the contract revenues during
any year of the contract term. We commenced work under the contract in October 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to budget restrictions within the Department of Defense,
on February 10, 2014, DARPA reduced the scope of our contract in years three through five of the contract. The reduction in scope
focused our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible payments
under the contract by $858,491 over years three through five. We recently completed a re-budgeting of the expected costs on the
remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs due to
the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended September 30, 2014 we invoiced DARPA
for three milestones totaling $444,723 while in the six months ended September 30, 2013, we invoiced DARPA for four milestones
totaling $808,739.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated operating expenses for the six months ended September
30, 2014 were $2,303,571 in comparison with $1,854,075 for the comparable period a year ago.&nbsp;&nbsp;This increase of $449,496,
or 24.2%, was due to increases in payroll and related expenses of $301,560, increases in professional fees of $58,853 and increases
in general and administrative expenses of $89,083.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $301,560 increase in payroll and related expenses was primarily
due to the ESI payroll of $260,968. Other factors were an increase in stock-based compensation of $70,079 due to vesting of stock
option grants while cash-based compensation at Aethlon decreased by $29,487 from the 2013 period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $58,853 increase in our professional fees was partially
due to ESI professional fees of $87,719 and an increase of $69,269 for non-DARPA-related professional fees at Aethlon. Those increases
at Aethlon were primarily due to a $71,432 increase in legal fees, largely due to increased patent-related activity. Those increases
were offset by a decrease in DARPA-related professional fees of $98,135.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $89,083 increase in general and administrative expenses
was primarily due to general and administrative expenses at ESI of $96,987. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other expense consists primarily of losses on extinguishment
of debt, the change in the fair value of our derivative liability, other expense and interest expense. Other (income) expense for
the six months ended September 30, 2014 was other expense of $2,819,285 in comparison with other expense of $2,639,576 for the
comparable period a year ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loss on Extinguishment of Debt and Other</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded a loss on extinguishment of debt of $2,531,123 for
the six months ended September 30, 2014. That loss arose from the payments of accrued interest on our 12% Series A convertible
notes that were in the form of units (common stock plus warrants) combined with a loss that related to the conversion to equity
of $45,906 in principal and accrued interest related to a note payable. The three months ended September 30, 2013 contained $40,256
in losses on debt conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The three months ended September 30, 2014 also included a charge
of $143,363 for the change in fair value related to the extension of the warrants of a note holder in exchange for a postponement
in the agreed payment date of his notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Change in Fair Value of Derivative Liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not record a change in the fair value of derivative liabilities
in the six months ended September 30, 2014 and all derivative liabilities were extinguished as of June 30, 2014. For the six months
ended September 30, 2013, the change in the estimated fair value of derivative liability was a loss of $2,382,877.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest expense was $144,799 for the six months ended September
30, 2014 compared to $216,443 in the corresponding prior period, a decrease of $71,644. The various components of our interest
expense are shown in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/14</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">9/30/13</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 49%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">123,297</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">211,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(88,568</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of Deferred Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,502</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of Note Discounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">144,799</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">216,443</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(71,644</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted in the above table, the most significant factor in
the $71,644 decrease in interest expense was the $88,568 decrease in the interest expense that was primarily due to lower levels
of notes outstanding in the 2014 period. Other smaller factors in the change in our total interest were an increase in the amortization
of deferred financing costs of $20,639, which was partially offset by a reduction in the amortization of note discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the increased expenses noted above, our net loss
before noncontrolling interests for the six months ended September 30, 2014 was approximately $4,592,000 compared to approximately
$3,653,000 for the six month period ended September 30 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic and diluted loss attributable to common stockholders were
($0.02) for the six month period ended September 30, 2014 compared to ($0.02) for the period ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LIQUIDITY AND CAPITAL RESOURCES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2014, we had a cash balance of $526,187 and
a working capital deficit of $2,495,767. This compares to a cash balance of $1,250,279 and a working capital deficit of $14,169,471
at March 31, 2014. Between October 1, 2014 and November 7, 2014, we raised aggregate proceeds of $1,080,951 through private equity
transactions and raised $415,000 through the issuance of convertible notes. Over that same period, we collected $247,361 under
our DARPA contract and under the Battelle subcontract we billed $9,595 and collected $11,311. Our cash at September 30, 2014 plus
additional funds raised to date subsequent to September 30, 2014 are not sufficient to meet our funding requirements during the
next twelve months. Significant additional financing must be obtained in order to provide a sufficient source of operating capital
and to allow the Company to continue to operate as a going concern. In addition, we will need to raise capital to complete the
recently approved human clinical trial in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect revenue from operations will be sufficient
to satisfy our funding requirements in the near term, and accordingly, our ability to continue operations and meet our cash obligations
as they become due and payable is expected to depend for at least the next several years on our ability to sell securities, borrow
funds or a combination thereof. Future capital requirements will depend upon many factors, including progress with pre-clinical
testing and clinical trials, the number and breadth of our clinical programs, the time and costs involved in preparing, filing,
prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs involved in obtaining regulatory
approvals, competing technological and market developments, as well as our ability to establish collaborative arrangements, effective
commercialization, marketing activities and other arrangements. We expect to continue to incur increasing negative cash flows and
net losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Should the U.S. Government elect not to exercise the options
for year five of our DARPA contract, the effects may be material to us. The loss of revenues from the DARPA contract would have
a material impact on our revenues, operating cash flows and liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash flows from operating, investing and financing activities,
as reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">(In thousands) <BR> For the six months ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash (used in) provided by:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(1,394</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(745</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net (decrease) in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(724</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(117</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NET CASH FROM OPERATING ACTIVITIES. We used cash in our operating
activities due to our losses from operations. Net cash used in operating activities was approximately $1,394,000 in the six months
ended September 30, 2014 compared to $745,000 in the six months ended September 30, 2013, an increase of $649,000.&nbsp;&nbsp;The
$649,000 increase was primarily due to our increased operating loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NET CASH FROM INVESTING ACTIVITIES. We did not have any investing
activities during either period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NET CASH FROM FINANCING ACTIVITIES. Net cash generated from
financing activities increased from approximately $628,000 in the six months ended September 30, 2013 to $670,000 in the six months
ended September 30, 2014. The only financing activity in the 2014 periods was the issuance of common stock, while in the 2013 period,
financing activities included $400,000 in proceeds from the issuance of notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An increase in working capital during the six months ended September
30, 2014 in the amount of approximately $11,684,000 changed our negative working capital position to approximately ($2,496,000)
at September 30, 2014 from a negative working capital of approximately ($14,169,000) at March 31, 2014.&nbsp;&nbsp;The most significant
factors in the increase in working capital noted above were a decrease in derivative liability of approximately $10,679,000 and
a reduction in the current portion of our convertible notes payable and notes payable of approximately $1,096,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the date of this filing, we plan to invest significantly
into purchases of our raw materials and into our contract manufacturing arrangement subject to successfully raising additional
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRITICAL ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of condensed consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires the Company to make a number
of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during
the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other
factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results
may differ from these estimates under different future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the estimates and assumptions that are most
important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective
or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies
relate to revenue recognition, measurement of stock purchase warrants issued with notes payable, beneficial conversion feature
of convertible notes payable, impairment of intangible assets and long lived assets, stock compensation, and the classification
of warrant obligations, and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting
policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences,
there could be a material impact on our future financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no changes to our critical accounting policies
as disclosed in our Form 10-K for the year ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OFF-BALANCE SHEET ARRANGEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no obligations required to be disclosed herein as off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a Smaller Reporting Company as defined by rule 12b-2 of the
Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are
not required to provide the information requested by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 4. CONTROLS AND PROCEDURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DISCLOSURE CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the supervision and with the participation of our management,
including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design and operation
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of a date as of
the end of the period covered by this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on such evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are not effective in recording,
processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file
or submit under the Exchange Act and are not effective in ensuring that information required to be disclosed by us in the reports
that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive
Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no changes in our internal control over financial
reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PART II. OTHER INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 1. LEGAL PROCEEDINGS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, claims are made against us in the ordinary
course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and
unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or
more products or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The occurrence of an unfavorable outcome in any specific period
could have a material adverse effect on our results of operations for that period or future periods. Other than as set forth here,
we are not presently a party to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 1A. RISK FACTORS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a Smaller Reporting Company as defined by rule 12b-2 of the
Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are
not required to provide the information requested by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
the following securities which were not registered under the Securities Act of 1933, as amended. We did not employ any form of
general solicitation or advertising in connection with the offer and sale of the securities described below. In addition, we believe
the purchasers of the securities are &quot;ACCREDITED INVESTORS&quot; for the purpose of Rule 501 of the Securities Act. For these
reasons, among others, the offer and sale of the following securities were made in reliance on the exemption from registration
provided by Section 4(2) of the Securities Act or Regulation D promulgated by the SEC under the Securities Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
390,301 shares of restricted common stock at an average price of $0.24 per share in payment for investor relations consulting services
valued at $75,000 based on the value of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
1,937,505 shares of restricted common stock to the holders of three convertible notes in exchange for the partial or full conversion
of principal and interest in the aggregate amount of $81,375 at a conversion price of $0.042 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 24, 2014, we issued an aggregate of 2,503,966 shares
of restricted common stock and a seven-year warrant to issue up to 1,251,983 shares of common stock at an exercise price of $0.132
per share to Dr. Chetan Shah, a director. The common stock and warrant were issued to Dr. Shah upon the conversion of an aggregate
of $220,349 of unpaid principal and accrued interest due under a 10% Convertible Note previously issued to Dr. Shah by us on July
9, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 17, 2014, we issued to the holder of the remaining
2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit warrants to acquire
up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 5). The units were issued
to the note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest due under the promissory
note, which represented the entire amount outstanding under the note. We recorded a loss on debt conversion of $65,493 on this
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
to four investors 2,673,231 shares of restricted common stock through the cash exercise of eight warrants for $259,474 of cash
at an average exercise price of approximately $0.10 per share. As an inducement to those investors, we issued them replacement
warrants to acquire up to an aggregate of 2,673,231 shares of common stock on the same terms as the warrants they exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2014, we issued
and sold to three accredited investors units consisting of (a) one hundred thousand (100,000) restricted shares of our common stock,
par value $.001 per share, at prices per share ranging from $0.091 to $0.094 and (b) a five-year warrant to purchase fifty thousand
(50,000) shares of common stock at exercise prices ranging from $0.136 to $0.143 per share. In total, the investors purchased for
cash an aggregate of $591,700 of units. The investors acquired an aggregate of 974,982 shares of common stock and warrants to acquire
up to an aggregate of 487,491 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of this report, various promissory and convertible
notes payable in the aggregate principal amount of $473,422 have reached maturity and are past due. We are continually reviewing
other financing arrangements to retire all past due notes. At September 30, 2014, we had accrued interest in the amount of $471,041
associated with these notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 4. MINE SAFETY DISCLOSURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 5. OTHER INFORMATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to September 30, 2014, we entered
into a Subscription Agreement with two accredited investors providing for the issuance and sale of (i) convertible promissory notes
in the aggregate principal amount of $527,780 and (ii) five-year warrants to purchase up to 2,356,160 shares of Common Stock at
a fixed exercise price of $0.168 per share. The convertible promissory notes bear interest at the annual rate of 10% and mature
on April 1, 2016. The aggregate gross cash proceeds to us were $415,000 after subtracting legal fees of $35,000; the balance of
the principal amount of the notes represents a $27,780 due diligence fee and an original issuance discount. The convertible promissory
notes are convertible at the option of the holders into shares of our common stock at a fixed price of $0.112 per share, for up
to an aggregate of 4,712,321 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 6.&nbsp;&nbsp;EXHIBITS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Exhibits. The following documents are filed as part of this
report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles of Incorporation of Aethlon Medical, Inc., as amended (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws of Aethlon Medical, Inc., as amended (2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant dated July 8, 2014 (3)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant dated July 24, 2014 (4)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant issued August and September 2014 *</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Class A Common Stock Purchase Warrant dated November 6, 2014 *</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Restructuring Agreement dated July 8, 2014 (3)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Subscription Agreement dated November 6, 2014 *</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Convertible Promissory Note dated November 6, 2014 *</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Executive Officer pursuant to Securities Exchange Act rules 13a- 14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Financial Officer pursuant to Securities Exchange Act rules 13a- 14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interactive Data Files</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Filed herewith.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by reference to the filing of such exhibit with the Company's Annual Report on Form 10-K for the year ended March 31, 2012.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by reference to the filing of such exhibit with the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2012.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by reference to the filing of such exhibit with the Company&rsquo;s Current Report on Form 8-K filed July 10, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 30px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by reference to the filing of such exhibit with the Company&rsquo;s Current Report on Form 8-K filed July 28, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AETHLON MEDICAL, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 10, 2014</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;JAMES B. FRAKES</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHIEF FINANCIAL OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHIEF ACCOUNTING OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>aemd_10q-ex0403.htm
<DESCRIPTION>COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>EXHIBIT 4.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE
UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant Shares: ____________</TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right">Initial Exercise Date: ________, 2014</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 3.5in; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">THIS COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _________________ (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to the close of business on the five-year
anniversary of the Initial Exercise Date (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to <U>&#9;</U> shares (the &ldquo;<U>Warrant
Shares</U>&rdquo;) of common stock, par value $.001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;). The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized terms not otherwise defined
herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Unit Subscription Agreement, dated as of ___________, 2014 between the Company and the original
Holder, as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the New York Stock Exchange is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE AMEX LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York
Stock Exchange or the OTC Bulletin Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or
such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of
the Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto;
and, within 3 Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment
of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier&rsquo;s check drawn on a United States
bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in
full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within 3 Trading Days of the date
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase
of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may
be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be equal to <B>$0.xx</B>,
subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cashless
Exercise</U>. This Warrant may also be exercised at any time after the Initial Exercise Date at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(A) =</P></TD>
    <TD STYLE="width: 80%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the closing price of the Common Stock on the Trading Day immediately preceding the date of such election;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B) =</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the Exercise Price of this Warrant, as adjusted; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(X) =</FONT></TD>
    <TD STYLE="padding-bottom: 12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the number of Warrant Shares issuable upon exercise of this Warrant in accordance with the terms of this Warrant by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Exercise
Limitations</U>. Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise,
to the extent that after giving effect to such issuance after exercise, the Holder (together with the Holder&rsquo;s affiliates,
and any other person or entity acting as a group together with the Holder or any of the Holder&rsquo;s affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of this Section, beneficial ownership shall
be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Holder
is solely responsible for any schedules required to be filed in accordance therewith. The Company shall have no obligation to
verify or confirm the accuracy of such filings.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days&rsquo; prior
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2.d), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2.d) shall continue to apply. Any such increase or decrease will not be effective until the 61<SUP>st</SUP> day
after such notice is delivered to the Company. The limitations contained in this paragraph shall apply to a successor holder of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery of Certificates Upon Exercise</U>. Certificates for shares purchased hereunder shall be transmitted by the
Company&rsquo;s transfer agent (the &ldquo;<U>Transfer Agent</U>&rdquo;) to the Holder by crediting the account of the Holder&rsquo;s
prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (&ldquo;<U>DWAC</U>&rdquo;) system
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the shares are eligible for resale without
volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of certificates to the address specified
by the Holder in the Notice of Exercise within 4 Trading Days from the delivery to the Company of the Notice of Exercise Form,
surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above, together with any letters,
documents or materials completed and signed by Holder as required by the Company's Transfer Agent or counsel necessary to cause
the issuance of the certificates to the Holder (the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). This Warrant shall be deemed
to have been exercised on the date the Exercise Price is received by the Company. The Warrant Shares shall be deemed to have been
issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of
such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price (or
by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2.e)(iv) prior
to the issuance of such shares, have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates
representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant
Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise,
the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole share.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Charges,
Taxes and Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; <U>provided</U>, <U>however</U>, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of
any Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant or any other convertible securities of the Company), (ii) subdivides all outstanding shares of Common
Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) all outstanding shares of Common
Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company to all holders of Common Stock, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise
Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3.a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company effects any merger or
consolidation of the Company with or into another Person, (ii) the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities,
cash or property or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (each &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such merger, consolidation
or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in
such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the
Holder&rsquo;s right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental
Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this
Section 3.c) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction
analogous to a Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that
is (1) an all cash transaction, (2) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3 under the Exchange Act, or
(3) a Fundamental Transaction involving a person or entity not traded on a national securities exchange, the Nasdaq Global Select
Market, the Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any successor entity shall pay at the Holder&rsquo;s
option, exercisable at any time concurrently with or within 30 days after the consummation of the Fundamental Transaction, an amount
of cash equal to the value of this Warrant as determined in accordance with the Black Scholes Option Pricing Model obtained from
the &ldquo;OV&rdquo; function on Bloomberg L.P. using (A) a price per share of Common Stock equal to the closing price of the Common
Stock for the Trading Day immediately preceding the date of consummation of the applicable Fundamental Transaction, (B) a risk-free
interest rate corresponding to the U.S. Treasury rate for a 30 day period immediately prior to the consummation of the applicable
Fundamental Transaction, (C) an expected volatility equal to the 100 day volatility obtained from the &ldquo;HVT&rdquo; function
on Bloomberg L.P. determined as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of such transaction and
the Termination Date; provided that in each case where Bloomberg L.P. data is being relied upon, Holder shall provide to the Company
a copy of such information for the Company's records.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing
thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder is entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4.d) herein and to the provisions of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation,
any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed
by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having
a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4.a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this
Warrant, as the case may be, comply with the provisions of the Purchase Agreement.</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 1in">The Company
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock one
hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a special
meeting to increase the number of authorized common stock. Management of the Company shall recommend to shareholders to vote in
favor of increasing the number of authorized common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 1in">The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty
of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the
purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly
authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect
of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 31.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 1in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 1in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice Holder&rsquo;s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including
those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and Holders holding Warrants issued pursuant to the Purchase Agreement at least equal to a majority of the Warrant Shares
issuable upon exercise of all then outstanding Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">By:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&nbsp;&nbsp;&nbsp;AETHLON
Medical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font: 10pt Times New Roman, Times, Serif"> </FONT>The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">[ &nbsp;] in lawful
money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">[ &nbsp;] [if permitted]
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2.c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2.c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other
name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(4) <U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities
Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Investing Entity: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: __________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory: _____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(To assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">FOR VALUE RECEIVED,
[____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________
whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">Dated: ______________,
_______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: justify; padding-left: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="width: 75%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_____________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_____________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_____________________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Signature Guaranteed: ___________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE: The signature to this Assignment Form
must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>aemd_10q-ex0404.htm
<DESCRIPTION>CLASS A COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>EXHIBIT 4.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Right to Purchase <B>_________</B> shares of Common Stock of Aethlon Medical, Inc. (subject to adjustment as provided herein)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CLASS A COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">No. ___________</TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right">Issue Date: <B>November
6, 2014</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 3.5in; text-align: left; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>AETHLON MEDICAL, INC.</B>,
a corporation organized under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for value
received, <B>____________________________</B>, ______________________________________, Fax: ____________, or its assigns (the &ldquo;<B>Holder</B>&rdquo;),
is entitled, subject to the terms set forth below, to purchase from the Company at any time after the Issue Date until 5:00 p.m.,
E.S.T on the fifth anniversary of the Issue Date (the &ldquo;<B>Expiration Date</B>&rdquo;), up to <B>________</B> fully paid and
non-assessable shares of Common Stock at a per share purchase price of <B>$0.168</B>. The aforedescribed purchase price per share,
as adjusted from time to time as herein provided, is referred to herein as the &ldquo;<B>Purchase Price</B>.&rdquo; The number
and character of such shares of Common Stock and the Purchase Price are subject to adjustment as provided herein. The Company may
reduce the Purchase Price for some or all of the Warrants, temporarily or permanently, provided such reduction is made as to all
outstanding Warrants for all Holders of such Warrants. Capitalized terms used and not otherwise defined herein shall have the meanings
set forth in that certain Subscription Agreement (the &ldquo;<B>Subscription Agreement</B>&rdquo;), dated as of November 6, 2014,
entered into by the Company, the Holder and the other signatories thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As used herein the
following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term
&ldquo;<B>Company</B>&rdquo; shall mean Aethlon Medical, Inc., a Nevada corporation, and any corporation which shall succeed or
assume the obligations of Aethlon Medical, Inc. hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term &ldquo;<B>Common
Stock</B>&rdquo; includes (i)&nbsp;the Company's Common Stock, $0.001 par value per share, as authorized on the date of the Subscription
Agreement, and (ii) any other securities into which or for which any of the securities described in (i)&nbsp;may be converted or
exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term &ldquo;<B>Other
Securities</B>&rdquo; refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate
or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise
of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities pursuant to <U>Section&nbsp;4</U> or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term &ldquo;<B>Warrant
Shares</B>&rdquo; shall mean the Common Stock issuable upon exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise of
Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Number
of Shares Issuable upon Exercise</U>. From and after the Issue Date through and including the Expiration Date, the Holder hereof
shall be entitled to receive, upon exercise of this Warrant in whole in accordance with the terms of <U>Section&nbsp;1.2</U> or
upon exercise of this Warrant in part in accordance with <U>Section&nbsp;1.3</U>, shares of Common Stock of the Company, subject
to adjustment pursuant to <U>Section&nbsp;4 </U>below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Full Exercise</U>.
This Warrant may be exercised in full by the Holder hereof by delivery to the Company of an original or facsimile copy of the form
of subscription attached as <U>Exhibit&nbsp;A</U> hereto (the &ldquo;<B>Subscription Form</B>&rdquo;) duly executed by such Holder
and delivery within two days thereafter of payment, in cash, wire transfer or by certified or official bank check payable to the
order of the Company, in the amount obtained by multiplying the number of shares of Common Stock for which this Warrant is then
exercisable by the Purchase Price then in effect. The original Warrant is not required to be surrendered to the Company until it
has been fully exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial
Exercise</U>. This Warrant may be exercised in part (but not for a fractional share) by delivery of a Subscription Form in the
manner and at the place provided in <U>Section&nbsp;1.2</U>, except that the amount payable by the Holder on such partial exercise
shall be the amount obtained by multiplying (a)&nbsp;the number of whole shares of Common Stock designated by the Holder in the
Subscription Form by (b)&nbsp;the Purchase Price then in effect. On any such partial exercise, provided the Holder has surrendered
the original Warrant, the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder hereof a
new Warrant of like tenor, in the name of the Holder hereof or as such Holder (upon payment by such Holder of any applicable transfer
taxes) may request, the whole number of shares of Common Stock for which such Warrant may still be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fair Market
Value</U>. For purposes of this Warrant, the <B>Fair Market Value</B> of a share of Common Stock as of a particular date (the
&quot;<B>Determination Date</B>&quot;) shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company's
Common Stock is traded on an exchange or is quoted on the NASDAQ Global Market, NASDAQ Global Select Market, the NASDAQ Capital
Market, the New York Stock Exchange or the American Stock Exchange, LLC, then the average of the closing sale prices of the Common
Stock for the five (5) Trading Days immediately prior to (but not including) the Determination Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company's
Common Stock is not traded on an exchange or on the NASDAQ Global Market, NASDAQ Global Select Market, the NASDAQ Capital Market,
the New York Stock Exchange or the NYSE MKT, but is traded on the OTC Bulletin Board or in the over-the-counter market or Pink
Sheets, then the average of the closing bid and ask prices reported for the five (5) Trading Days immediately prior to (but not
including) the Determination Date;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as
provided in clause (d)&nbsp;below and <U>Section 3.1</U>, if the Company's Common Stock is not publicly traded, then as the Holder
and the Company agree, or in the absence of such an agreement, by arbitration in accordance with the rules then standing of the
American Arbitration Association, before a single arbitrator to be chosen from a panel of persons qualified by education and training
to pass on the matter to be decided; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Determination
Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation, dissolution or winding up
pursuant to the Company's charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the charter
in the event of such liquidation, dissolution or winding up, plus all other amounts to be payable per share in respect of the Common
Stock in liquidation under the charter, assuming for the purposes of this clause (d)&nbsp;that all of the shares of Common Stock
then issuable upon exercise of all of the Warrants are outstanding at the Determination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Acknowledgment</U>. The Company will, at the time of the exercise of the Warrant, upon the request of the Holder hereof, acknowledge
in writing its continuing obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after
such exercise in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure
shall not affect the continuing obligation of the Company to afford to such Holder any such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Stock Certificates, etc. on Exercise</U>. The Company agrees that, provided the purchase price listed in the Subscription Form
is received as specified in <U>Section 2</U>, the shares of Common Stock purchased upon exercise of this Warrant shall be deemed
to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which delivery
of a Subscription Form shall have occurred and payment made for such shares as aforesaid. As soon as practicable after the exercise
of this Warrant in full or in part, and in any event within three (3) business days thereafter (&ldquo;<B>Warrant Share Delivery
Date</B>&rdquo;), the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be issued
in the name of and delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes)
may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and validly issued,
fully paid and non-assessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise,
plus, in lieu of any fractional share to which such Holder would otherwise be entitled, cash equal to such fraction multiplied
by the then Fair Market Value of one full share of Common Stock, together with any other stock or other securities and property
(including cash, where applicable) to which such Holder is entitled upon such exercise pursuant to <U>Section&nbsp;1</U> or otherwise.
The Company understands that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in
economic loss to the Holder. As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and
not as a penalty) to the Holder for late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount of $100
per business day after the Warrant Share Delivery Date for each $10,000 of Purchase Price of Warrant Shares for which this Warrant
is exercised which are not timely delivered. The Company shall pay any payments incurred under this Section in immediately available
funds upon demand. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that the Company
fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder may revoke all or
part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company and the Holder
shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this Warrant,
except that the liquidated damages described above shall be payable through the date notice of revocation or rescission is given
to the Company.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Buy-In</U>.
In addition to any other rights available to the Holder, if the Company fails to deliver to a Holder the Warrant Shares by the
Warrant Shares Delivery Date as required pursuant to this Warrant, and if after the Warrant Shares Delivery Date the Holder or
a broker on the Holder&rsquo;s behalf, purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by Holder of the Warrant Shares which the Holder was entitled to receive from the Company (a &quot;<B>Buy-In</B>&quot;),
then the Company shall pay in cash to the Holder (in addition to any remedies available to or elected by the Holder) the amount
by which (A) the Holder's total purchase price (including brokerage commissions, if any) for the shares of common stock so purchased
exceeds (B) the aggregate Purchase Price of the Warrant Shares required to have been delivered to the Holder together with interest
thereon at a rate of 15% per annum, accruing until such amount and any accrued interest thereon is paid in full (which amount shall
be paid as liquidated damages and not as a penalty). For example, if a Holder purchases shares of Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to $10,000 of Purchase Price of Warrant Shares to have been received upon exercise
of this Warrant, the Company shall be required to pay the Holder $1,000, plus interest. The Holder shall provide the Company written
notice and evidence reasonably acceptable to the Company indicating the amounts payable to the Holder in respect of the Buy-In.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment upon
exercise may be made at the option of the Holder either in (i) cash, by wire transfer or by certified or official bank check payable
to the order of the Company equal to the applicable aggregate Purchase Price, (ii) by delivery of Common Stock issuable upon exercise
of the Warrants in accordance with Section&nbsp;(b)&nbsp;below or (iii)&nbsp;by a combination of any of the foregoing methods,
for the number of Common Stock specified in such form (as such exercise number shall be adjusted to reflect any adjustment in the
total number of shares of Common Stock issuable to the holder per the terms of this Warrant) and the holder shall thereupon be
entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock (or Other
Securities) determined as provided herein. Notwithstanding the immediately preceding sentence, payment upon exercise may be made
in the manner described in Section 2(b) below, only with respect to Warrant Shares <U>not</U> included for unrestricted public
resale in an effective registration statement on the date notice of exercise is given by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Fair
Market Value of one share of Common Stock is greater than the Purchase Price (at the date of calculation as set forth below), in
lieu of exercising this Warrant for cash, the holder may elect to receive shares equal to the value (as determined below) of this
Warrant (or the portion thereof being cancelled) by delivery of a properly endorsed Subscription Form delivered to the Company
by any means described in <U>Section 13</U>, in which event the Company shall issue to the holder a number of shares of Common
Stock computed using the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">X=<U>Y (A-B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in; text-align: right">Where&nbsp;</TD>
    <TD STYLE="width: 0.3in">X=</TD>
    <TD STYLE="text-align: justify">the
number of shares of Common Stock to be issued to the Holder</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.3in">Y=</TD><TD STYLE="text-align: justify">the number of shares of Common Stock purchasable under the Warrant or, if only a portion of the
Warrant is being exercised, the portion of the Warrant being exercised (at the date of such calculation)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.3in">A=</TD><TD STYLE="text-align: left">Fair Market Value</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.3in">B=</TD><TD STYLE="text-align: left">Purchase Price (as adjusted to the date of such calculation)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">For purposes of
Rule 144 promulgated under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless
exercise transaction in the manner described above shall be deemed to have been acquired by the Holder, and the holding period
for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Subscription
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
for Reorganization, Consolidation, Merger, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental&nbsp;Transaction</U>.&nbsp;
If, at any time while this Warrant is outstanding,&nbsp;(A) the Company&nbsp; effects any merger or&nbsp; consolidation&nbsp; of
the Company with or into another entity,&nbsp;(B) the Company effects any sale of all or substantially&nbsp;all of its&nbsp;assets&nbsp;in
one or a&nbsp;series&nbsp;of&nbsp;related transactions,&nbsp; (C) any&nbsp;tender&nbsp;offer or&nbsp;exchange&nbsp;offer&nbsp;(whether
by the Company or another entity) is completed pursuant to which holders of Common Stock&nbsp;are&nbsp;permitted&nbsp;to&nbsp;tender&nbsp;or&nbsp;exchange
their shares&nbsp;for&nbsp;other securities, cash or&nbsp;property, (D) the Company consummates a stock purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, or spin-off) with one or more persons
or entities whereby such other persons or entities acquire more than the 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by such other persons or entities making or party to, or associated or affiliated with the other
persons or entities making or party to, such stock purchase agreement or other business combination), (E) any &quot;person&quot;
or &quot;group&quot; (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act) is or shall become the
&quot;beneficial owner&quot; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate Common
Stock of the Company,&nbsp;or&nbsp;(F)&nbsp;the Company effects any reclassification of the Common Stock or any compulsory&nbsp;share&nbsp;exchange
pursuant&nbsp;to which the Common Stock is effectively converted&nbsp;into or exchanged&nbsp;for other&nbsp;securities,&nbsp;cash
or property (in any such case, a &quot;<B>Fundamental&nbsp; Transaction</B>&quot;),&nbsp;then, upon any&nbsp;subsequent&nbsp;exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental&nbsp;Transaction,&nbsp;at the option of the Holder, (a) upon exercise of
this Warrant,&nbsp;the number of shares of Common Stock of the successor or acquiring corporation or of the Company,&nbsp;if it
is the surviving&nbsp;corporation,&nbsp;and any additional consideration (the &quot;<B>Alternate Consideration</B>&quot;)&nbsp;receivable&nbsp;upon
or as a&nbsp;result&nbsp;of such reorganization, reclassification, merger, consolidation&nbsp;or&nbsp;disposition&nbsp;of&nbsp;assets
by a Holder of the number of shares of Common&nbsp;Stock for which this Warrant is exercisable immediately prior to such event&nbsp;or
(b) if the&nbsp;Company&nbsp;is acquired&nbsp;in (1) a transaction where the consideration paid to the holders of the Common Stock
consists solely of cash, (2) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3 under the 1934 Act, or (3) a transaction
involving a person or entity not traded on a national securities exchange, the Nasdaq Global Select Market, the Nasdaq Global Market
or the Nasdaq Capital Market,&nbsp;cash&nbsp;equal&nbsp;to the Black-Scholes Value.&nbsp; For&nbsp;purposes&nbsp;of any such exercise,
the determination&nbsp;of the Purchase Price shall be&nbsp;appropriately&nbsp;adjusted to apply to such Alternate Consideration&nbsp;based
on the amount of Alternate&nbsp;Consideration&nbsp;issuable in respect of one share of Common Stock in such Fundamental&nbsp;Transaction,&nbsp;and
the Company shall apportion&nbsp;the Purchase Price among&nbsp;the&nbsp;Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate&nbsp;Consideration.&nbsp; If holders of Common Stock are given
any choice as to the securities, cash or&nbsp;property&nbsp;to be received in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental&nbsp;Transaction.&nbsp;
To the extent necessary to effectuate the foregoing&nbsp;provisions,&nbsp;any successor to the Company or surviving entity in such
Fundamental Transaction shall issue to the Holder a new&nbsp;warrant&nbsp;consistent&nbsp;with the&nbsp;foregoing&nbsp;provisions&nbsp;and
evidencing&nbsp;the Holder's&nbsp;right to exercise&nbsp;such warrant&nbsp;into&nbsp;Alternate Consideration.&nbsp; The terms of
any agreement&nbsp;pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or
surviving&nbsp;entity to comply with the&nbsp;provisions&nbsp;of this&nbsp;<U>Section 3.1</U> and insuring&nbsp;that this Warrant
(or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous&nbsp;to&nbsp;a Fundamental
Transaction. &ldquo;<B>Black-Scholes Value</B>&rdquo; shall be determined in accordance with the Black-Scholes Option Pricing Model
obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. using (i) a price per share of Common Stock equal to the VWAP of
the Common Stock for the Trading Day immediately preceding the date of consummation of the applicable Fundamental Transaction,
(ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant
as of the date of such request and (iii) an expected volatility equal to the 100 day volatility obtained from the HVT function
on Bloomberg L.P. determined as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuation
of Terms</U>. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred
to in this <U>Section&nbsp;3</U>, this Warrant shall continue in full force and effect and the terms hereof shall be applicable
to the Other Securities and property receivable on the exercise of this Warrant after the consummation of such reorganization,
consolidation or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding
upon the issuer of any Other Securities, including, in the case of any such transfer, the person acquiring all or substantially
all of the properties or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant
as provided in <U>Section&nbsp;4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Extraordinary
Events Regarding Common Stock</U>. In the event that the Company shall (a)&nbsp;issue additional shares of Common Stock as a dividend
or other distribution on outstanding Common Stock, (b)&nbsp;subdivide its outstanding shares of Common Stock, or (c)&nbsp;combine
its outstanding shares of the Common Stock into a smaller number of shares of Common Stock, then, in each such event, the Purchase
Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Purchase Price by a fraction,
the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator
of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall
thereafter be the Purchase Price then in effect. The Purchase Price, as so adjusted, shall be readjusted in the same manner upon
the happening of any successive event or events described herein in this <U>Section&nbsp;4</U>. The number of shares of Common
Stock that the Holder of this Warrant shall thereafter, on the exercise hereof, be entitled to receive shall be adjusted to a number
determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this <U>Section
4</U>) be issuable on such exercise by a fraction of which (a) the numerator is the Purchase Price that would otherwise (but for
the provisions of this <U>Section 4</U>) be in effect, and (b) the denominator is the Purchase Price in effect on the date of such
exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
as to Adjustments</U>. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable
on the exercise of the Warrants or the Purchase Price, the Company at its expense will promptly cause its Chief Financial Officer
or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based, including a statement of (a)&nbsp;the consideration received or receivable by the Company for any additional shares of
Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b)&nbsp;the number of shares of Common
Stock (or Other Securities) outstanding or deemed to be outstanding, and (c)&nbsp;the Purchase Price and the number of shares of
Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder
of the Warrant and any Warrant Agent of the Company (appointed pursuant to <U>Section&nbsp;10</U> hereof). Holder will be entitled
to the benefit of the adjustment regardless of the giving of such notice. The timely giving of such notice to Holder is a material
obligation of the Company.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Stock, etc. Issuable on Exercise of Warrant; Financial Statements</U>. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to
time issuable on the exercise of the Warrant. This Warrant entitles the Holder hereof, upon written request, to receive copies
of all financial and other information distributed or required to be distributed to the holders of the Company's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment;
Exchange of Warrant</U>. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby,
may be transferred by any registered holder hereof (a &quot;<B>Transferor</B>&quot;). On the surrender for exchange of this Warrant,
with the Transferor's endorsement in the form of Exhibit&nbsp;B attached hereto (the &ldquo;<B>Transferor Endorsement Form</B>&quot;)
and together with an opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance
with applicable securities laws, the Company will issue and deliver to or on the order of the Transferor thereof a new Warrant
or Warrants of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form
(each a &quot;<B>Transferee</B>&quot;), calling in the aggregate on the face or faces thereof for the number of shares of Common
Stock called for on the face or faces of the Warrant so surrendered by the Transferor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Warrant</U>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or
security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation
of this Warrant, the Company at its expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of like tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Exercise</U>. The Holder shall not be entitled to exercise this Warrant on an exercise date in connection with that number of shares
of Common Stock which would be in excess of the sum of (i)&nbsp;the number of shares of Common Stock beneficially owned by the
Holder and its affiliates on an exercise date, and (ii)&nbsp;the number of shares of Common Stock issuable upon the exercise of
this Warrant with respect to which the determination of this limitation is being made on an exercise date, which would result in
beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock on such date.
For the purposes of the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the 1934 Act and Rule 13d-3 thereunder. Subject to the foregoing, the Holder shall not be limited to aggregate exercises which
would result in the issuance of more than 4.99%. The restriction described in this paragraph&nbsp;may be waived, in whole or in
part, upon sixty-one (61) days prior notice from the Holder to the Company to increase such percentage to up to 9.99%, but not
in excess of 9.99%. The Holder may decide whether to convert a Convertible Note or exercise this Warrant to achieve an actual 4.99%
or up to 9.99% ownership position as described above, but not in excess of 9.99%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Agent</U>. The Company may, by written notice to the Holder of the Warrant, appoint an agent (a &ldquo;<B>Warrant Agent</B>&rdquo;)
for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to <U>Section&nbsp;1</U>,
exchanging this Warrant pursuant to <U>Section&nbsp;7</U>, and replacing this Warrant pursuant to <U>Section&nbsp;8</U>, or any
of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by
such Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
on the Company's Books</U>. Until this Warrant is transferred on the books of the Company, the Company may treat the registered
holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: if to the Company, to: Aethlon Medical, Inc., 9635 Granite Ridge Drive, San Diego, CA 92123, Attn:
James A. Joyce, CEO, facsimile: (858) 272-2738, with a copy by telecopier only to: Post Law Group, PC, 5900 Wilshire Boulevard,
Suite 620, Los Angeles, CA 90036, Attn: Jennifer A. Post, Esq., facsimile: (800) 783-2983, and (ii) if to the Holder, to the address
and facsimile number listed on the first paragraph of this Warrant, with a copy by fax only to: Grushko &amp; Mittman, P.C., 515
Rockaway Avenue, Valley Stream, New York 11581, facsimile: (212) 697-3575.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Law Governing
This Warrant</U>. This Warrant shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Warrant shall be brought only in the state courts of New York or in the federal courts located in the state and county
of New York. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon <U>forum non conveniens</U>. The
Company and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's
fees and costs. In the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">[SIGNATURE PAGE FOLLOWS]</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF,
the Company has executed this Warrant as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">By:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Exhibit&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(to be signed only on exercise of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TO: AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned, pursuant to the provisions
set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>___</TD><TD STYLE="text-align: justify">________ shares of the Common Stock
covered by such Warrant; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">___</TD><TD STYLE="text-align: justify">the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise
procedure set forth in Section&nbsp;2 of the Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned herewith makes payment of the
full purchase price for such shares at the price per share provided for in such Warrant, which is $___________. Such payment takes
the form of (check applicable box or boxes):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>___</TD><TD STYLE="text-align: justify">$__________ in lawful money of the United
States; and/or</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">___</TD><TD STYLE="text-align: justify">the cancellation of such portion of the attached Warrant as is exercisable for a total of _______
shares of Common Stock (using a Fair Market Value of $_______ per share for purposes of this calculation); and/or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">___</TD><TD STYLE="text-align: justify">the cancellation of such number of shares of Common Stock as is necessary, in accordance with the
formula set forth in Section&nbsp;2 of the Warrant, to exercise this Warrant with respect to the maximum number of shares of Common
Stock purchasable pursuant to the cashless exercise procedure set forth in Section&nbsp;2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After application of the cashless exercise
feature as described above, _____________ shares of Common Stock are required to be delivered pursuant to the instructions below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned requests that the certificates
for such shares be issued in the name of, and delivered to ____________________________ whose address is _____________________________________________<U>__________________</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned represents and warrants that
all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to
registration of the Common Stock under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or pursuant to
an exemption from registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dated:___________________</FONT></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Signature must conform to name of holder as specified on the face
        of the Warrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Address)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM OF TRANSFEROR ENDORSEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">For value received,
the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading &quot;Transferees&quot; the
right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of AETHLON MEDICAL, INC.
to which the within Warrant relates specified under the headings &quot;Percentage Transferred&quot; and &quot;Number Transferred,&quot;
respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on
the books of AETHLON MEDICAL, INC. with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Transferees</U></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Percentage Transferred</U></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Number Transferred</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: __________________, _______</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Signed in the presence of:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">ACCEPTED AND AGREED:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">[TRANSFEREE]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name)</P></TD>
    <TD STYLE="width: 50%">
        _______________________________<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Signature must conform to name of holder as specified on the face
        of the warrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(address)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(address)</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>




<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>aemd_10q-ex1002.htm
<DESCRIPTION>SUBSCRIPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0"><B>EXHIBIT 10.2</B></P>

<P STYLE="margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SUBSCRIPTION AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS SUBSCRIPTION
AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of November 6, 2014, by and among Aethlon Medical, Inc., a Nevada
corporation (the &ldquo;<B>Company</B>&rdquo;), and the subscribers identified on <B>Schedule 1</B> hereto (each a &ldquo;<B>Subscriber</B>&rdquo;
and collectively &ldquo;<B>Subscribers</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
the Company and the Subscribers are executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by the provisions of Section 4(a)(2), Section 4(a)(6) and/or Regulation D (&ldquo;<B>Regulation D</B>&rdquo;) as promulgated
by the United States Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act of 1933,
as amended (the &ldquo;<B>1933 Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the
Subscribers, as provided herein, and such Subscriber shall purchase for an aggregate $450,000 (the &ldquo;<B>Purchase Price</B>&rdquo;)
(i) $500,000 principal amount (&ldquo;<B>Principal Amount</B>&rdquo;) of promissory notes of the Company (&ldquo;<B>Note</B>&rdquo;
or &ldquo;<B>Notes</B>&rdquo;), a form of which is annexed hereto as <B>Exhibit A</B>, convertible into shares of the Company&rsquo;s
Common Stock, $0.001 par value (the &ldquo;<B>Common Stock</B>&rdquo;), at a per share conversion price set forth in the Notes
(&ldquo;<B>Conversion Price</B>&rdquo;); and (ii) share purchase warrants (the &ldquo;<B>Warrants</B>&rdquo;), in the form attached
hereto as <B>Exhibit B, </B>to purchase shares of the Company&rsquo;s Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;) (the
&ldquo;<B>Offering</B>&rdquo;). The Notes, shares of Common Stock issuable upon conversion of the Notes (the &ldquo;<B>Conversion
Shares</B>&rdquo;), the Warrants and the Warrant Shares are collectively referred to herein as the &ldquo;<B>Securities.</B>&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
the aggregate proceeds of the sale of the Notes and the Warrants contemplated hereby shall be held in escrow by Grushko &amp; Mittman,
P.C., 515 Rockaway Avenue, Valley Stream, New York 11581 (the &ldquo;<B>Escrow Agent</B>&rdquo;) pursuant to the terms of an Escrow
Agreement to be executed by the parties substantially in the form attached hereto as <B>Exhibit C</B> (the &ldquo;<B>Escrow Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the mutual covenants and other agreements contained in this Agreement the Company and the Subscriber hereby
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing Date</U>.
The <B>&ldquo;Closing Date&rdquo;</B> shall be the date that the Purchase Price is transmitted by wire transfer or otherwise credited
to or for the benefit of the Company. The consummation of the transactions contemplated herein shall take place at the office of
Grushko &amp; Mittman, P.C., 515 Rockaway Avenue, Valley Stream, New York 11581, upon the satisfaction or waiver of all conditions
to closing set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notes</U>. Subject
to the satisfaction or waiver of the terms and conditions of this Agreement, on the Closing Date, each Subscriber shall purchase
and the Company, and the Company shall sell to each Subscriber a Note in the Principal Amount designated on <B>Schedule 1 </B>hereto
for each such Subscriber&rsquo;s Purchase Price indicated thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrants</U>.
On the Closing Date, the Company will issue and deliver the Warrants to the Subscribers. One Class A Warrant will be issued for
each two (2) Shares of Common Stock which will be issuable on the Closing Date assuming the complete conversion of the Notes on
the Closing Date at the Conversion Price. The exercise price to acquire a Warrant Share upon exercise of a Class A Warrant shall
be equal to $0.168, subject to reduction as described in the Class A Warrant. The Warrants shall be exercisable until five years
after the issue date of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subscriber's Representations
and Warranties</U>. Such Subscriber hereby represents and warrants to and agrees with the Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and Standing of
the Subscriber</U>. Subscriber, to the extent applicable, is a corporation duly incorporated, validly existing and in good standing
under the laws of the jurisdiction of its incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization and
Power</U>. Subscriber has the requisite power and authority to enter into and perform this Agreement and the other Transaction
Documents [as defined in Section 5(c)] and to purchase the Notes and Warrants being sold to it hereunder. The execution, delivery
and performance of this Agreement and the other Transaction Documents by Subscriber and the consummation by it of the transactions
contemplated hereby and thereby have been duly authorized by all necessary corporate action, and no further consent or authorization
of Subscriber or its Board of Directors or stockholders, if applicable, is required. This Agreement and the other Transaction Documents
have been duly authorized, executed and delivered by Subscriber and constitute, or shall constitute when executed and delivered,
a valid and binding obligation of Subscriber, enforceable against Subscriber in accordance with the terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Conflicts</U>. The execution,
delivery and performance of this Agreement and the other Transaction Documents and the consummation by Subscriber of the transactions
contemplated hereby and thereby or relating hereto do not and will not (i) result in a violation of Subscriber&rsquo;s charter
documents, bylaws or other organizational documents, if applicable, (ii) conflict with nor constitute a default (or an event which
with notice or lapse of time or both would become a default) under any agreement to which Subscriber is a party, nor (iii) result
in a violation of any law, rule, or regulation, or any order, judgment or decree of any court or governmental agency applicable
to Subscriber or its properties (except for such conflicts, defaults and violations as would not, individually or in the aggregate,
have a material adverse effect on Subscriber). Subscriber is not required to obtain any consent, authorization or order of, or
make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its
obligations under this Agreement and the other Transaction Documents nor to purchase the Securities in accordance with the terms
hereof, provided that for purposes of the representation made in this sentence, Subscriber is assuming and relying upon the accuracy
of the representations and agreements of the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information on
Company</U>. Such Subscriber has been furnished with or has had access at the EDGAR Website of the Commission to the Company's
Form 10-K filed on July 15, 2014 for the fiscal year ended March 31, 2014, and the financial statements included therein, together
with all subsequent filings made with the Commission available at the EDGAR website (hereinafter referred to collectively as the
&quot;Reports&quot;). In addition, such Subscriber may have received in writing from the Company such other information concerning
its operations, financial condition and other matters as such Subscriber has requested in writing, identified thereon as OTHER
WRITTEN INFORMATION (such other information is collectively, the &quot;Other Written Information&quot;), and considered all factors
such Subscriber deems material in deciding on the advisability of investing in the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information on
Subscriber</U>. Subscriber is, and will be at the time of the conversion of the Notes and exercise of the Warrants, an &quot;accredited
investor&quot;, as such term is defined in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments
and business matters, has made investments of a speculative nature and has purchased securities of United States publicly-owned
companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax
and other business matters as to enable Subscriber to utilize the information made available by the Company to evaluate the merits
and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative
investment. Subscriber has the authority and is duly and legally qualified to purchase and own the Securities. Subscriber is able
to bear the risk of such investment for an indefinite period and to afford a complete loss thereof. The information set forth on
<B>Schedule 1</B> hereto regarding Subscriber is accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase of Notes
and Warrants</U>. On the Closing Date, Subscriber will purchase its Note and Warrants as principal for its own account for investment
only and not with a view toward, or for resale in connection with, the public sale or any distribution thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with
Securities Act</U>. Subscriber understands and agrees that the Securities have not been registered under the 1933 Act or any applicable
state securities laws, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based
in part on the accuracy of the representations and warranties of the Subscriber contained herein), and that such Securities must
be held indefinitely unless a subsequent disposition is registered under the 1933 Act or any applicable state securities laws or
is exempt from such registration. In any event, and subject to compliance with applicable securities laws, the Subscriber may enter
into lawful hedging transactions in the course of hedging the position they assume and the Subscriber may also enter into lawful
short positions or other derivative transactions relating to the Securities, or interests in the Securities, and deliver the Securities,
or interests in the Securities, to close out their short or other positions or otherwise settle other transactions, or loan or
pledge the Securities, or interests in the Securities, to third parties who in turn may dispose of these Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion Shares
and Warrant Shares Legend</U>. The Conversion Shares and Warrant Shares shall bear the following or similar legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&ldquo;<B>THE ISSUANCE AND SALE OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL
SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS
SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notes and Warrants
Legend</U>. The Notes and Warrants shall bear the following legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&ldquo;<B>NEITHER THE ISSUANCE AND
SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE AND/OR EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Communication
of Offer</U>. The offer to sell the Securities was directly communicated to Subscriber by the Company. At no time was Subscriber
presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form
of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with
such communicated offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restricted Securities</U>.
Subscriber understands that the Securities have not been registered under the 1933 Act and Subscriber will not sell, offer to sell,
assign, pledge, hypothecate or otherwise transfer any of the Securities unless pursuant to an effective registration statement
under the 1933 Act, or unless an exemption from registration is available. Notwithstanding anything to the contrary contained in
this Agreement, Subscriber may transfer (without restriction and without the need for an opinion of counsel) the Securities to
its Affiliates (as defined below) provided that each such Affiliate is an &ldquo;accredited investor&rdquo; under Regulation D
and such Affiliate agrees to be bound by the terms and conditions of this Agreement. For the purposes of this Agreement, an &ldquo;<B>Affiliate</B>&rdquo;
of any person or entity means any other person or entity directly or indirectly controlling, controlled by or under direct or indirect
common control with such person or entity. Affiliate includes each Subsidiary of the Company. For purposes of this definition,
&ldquo;<B>control</B>&rdquo; means the power to direct the management and policies of such person or firm, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Governmental
Review</U>. Subscriber understands that no United States federal or state agency or any other governmental or state agency has
passed on or made recommendations or endorsement of the Securities or the suitability of the investment in the Securities nor have
such authorities passed upon or endorsed the merits of the offering of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Correctness of
Representations</U>. Subscriber represents that the foregoing representations and warranties are true and correct as of the date
hereof and, unless Subscriber otherwise notifies the Company prior to the Closing Date, shall be true and correct as of the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The
foregoing representations and warranties shall survive the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Representations and Warranties</U>. The Company represents and warrants to and agrees with each Subscriber that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Due Incorporation</U>.
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its
incorporation and has the requisite corporate power to own its properties and to carry on its business as presently conducted.
The Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature
of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the
failure to so qualify would not have a Material Adverse Effect. For purposes of this Agreement, a &ldquo;<B>Material Adverse Effect</B>&rdquo;
shall mean a material adverse effect on the financial condition, results of operations, prospects, properties or business of the
Company and its Subsidiaries taken as a whole. For purposes of this Agreement, &ldquo;<B>Subsidiary</B>&rdquo; means, with respect
to any entity at any date, any corporation, limited or general partnership, limited liability company, trust, estate, association,
joint venture or other business entity&nbsp;of which more than 30% of (i)&nbsp;the outstanding capital stock having (in the absence
of contingencies) ordinary voting power to elect a majority of the board of directors or other managing body of such entity, (ii)&nbsp;in
the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited liability
company or (iii)&nbsp;in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly
through one or more intermediaries, by such entity. As of the Closing Date, all of the Company&rsquo;s Subsidiaries and the Company&rsquo;s
ownership interest therein is set forth on <B>Schedule 5(a)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Outstanding
Stock</U>. All issued and outstanding shares of capital stock and equity interests in the Company have been duly authorized and
validly issued and are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority;
Enforceability</U>. This Agreement, the Notes, the Conversion Shares, the Warrants, the Escrow Agreement, and any other agreements
delivered together with this Agreement or in connection herewith (collectively &ldquo;<B>Transaction Documents</B>&rdquo;) have
been duly authorized, executed and delivered by the Company and are valid and binding agreements of the Company enforceable in
accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws
of general applicability relating to or affecting creditors' rights generally and to general principles of equity. The Company
has full corporate power and authority necessary to enter into and deliver the Transaction Documents and to perform its obligations
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization
and Additional Issuances</U>. The authorized and outstanding capital stock of the Company and Subsidiaries on a fully diluted basis
as of the date of this Agreement and the Closing Date (not including the Securities) are set forth on <B>Schedule 5(d)</B>. Except
as set forth on <B><U>Schedule 5(d)</U></B>, there are no options, warrants, or rights to subscribe to, securities, rights, understandings
or obligations convertible into or exchangeable for or giving any right to subscribe for any shares of capital stock or other equity
interest of the Company or any of the Subsidiaries. The only officer, director, employee and consultant stock option or stock incentive
plans or similar plans currently in effect or contemplated by the Company are described on <B>Schedule 5(d)</B>.There are no outstanding
agreements or pre-emptive or similar rights affecting the Company's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consents</U>.
No consent, approval, authorization or order of any court, governmental agency or body or arbitrator having jurisdiction over the
Company, or any of its Affiliates, the OTC Bulletin Board (the &ldquo;<B>Bulletin Board</B>&rdquo;) or the Company's shareholders
is required for the execution by the Company of the Transaction Documents and compliance and performance by the Company of its
obligations under the Transaction Documents, including, without limitation, the issuance and sale of the Securities. The Transaction
Documents and the Company&rsquo;s performance of its obligations thereunder have been unanimously approved by the Company&rsquo;s
Board of Directors. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any governmental authority in the world, including without limitation, the United States, or elsewhere is required
by the Company or any Affiliate of the Company in connection with the consummation of the transactions contemplated by this Agreement,
except as would not otherwise have a Material Adverse Effect on the consummation of any of the other agreements, covenants or commitments
of the Company or any Subsidiary contemplated by the other Transaction Documents. Any such qualifications and filings will, in
the case of qualifications, be effective on the Closing and will, in the case of filings, be made within the time prescribed by
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Violation
or Conflict</U>. Assuming the representations and warranties of the Subscriber in Section 4 are true and correct, neither the issuance
and sale of the Securities nor the performance of the Company&rsquo;s obligations under this Agreement and all other agreements
entered into by the Company relating thereto by the Company will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;violate,
conflict with, result in a breach of, or constitute a default (or an event which with the giving of notice or the lapse of time
or both would be reasonably likely to constitute a default) under (A) the articles or certificate of incorporation, charter or
bylaws of the Company, (B) to the Company's knowledge, any decree, judgment, order, law, treaty, rule, regulation or determination
applicable to the Company of any court, governmental agency or body, or arbitrator having jurisdiction over the Company or over
the properties or assets of the Company or any of its Affiliates, (C) the terms of any bond, debenture, note or any other evidence
of indebtedness, or any agreement, stock option or other similar plan, indenture, lease, mortgage, deed of trust or other instrument
to which the Company or any of its Affiliates is a party, by which the Company or any of its Affiliates is bound, or to which any
of the properties of the Company or any of its Affiliates is subject, or (D) the terms of any &quot;lock-up&quot; or similar provision
of any underwriting or similar agreement to which the Company, or any of its Affiliates is a party except the violation, conflict,
breach, or default of which would not have a Material Adverse Effect; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;result in
the creation or imposition of any lien, charge or encumbrance upon the Securities or any of the assets of the Company or any of
its Affiliates except in favor of Subscribers as described herein; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as set forth in <B>Schedule 5(f) </B>and which the Company specifically acknowledges as outstanding and subject to reset, result
in the activation of any anti-dilution rights or a reset or repricing of any debt, equity or security instrument of any creditor
or equity holder of the Company, or the holder of the right to receive any debt, equity or security instrument of the Company except
for the Subscriber, nor result in the acceleration of the due date of any obligation of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;result in
the triggering of any piggy-back or other registration rights of any person or entity holding securities of the Company or having
the right to receive securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The
Securities</U>. The Securities upon issuance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are, or will
be, free and clear of any security interests, liens, claims or other encumbrances, subject only to restrictions upon transfer under
the 1933 Act and any applicable state securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have been, or will
be, duly and validly authorized and on the dates of issuance of the Conversion Shares upon conversion of the Notes, and the Warrant
Shares upon exercise of the Warrants, such Conversion Shares and Warrant Shares will be duly and validly issued, fully paid and
non-assessable and if registered pursuant to the 1933 Act and resold pursuant to an effective registration statement or if such
resale is exempt from registration under Rule 144 will be free trading, unrestricted and unlegended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will not
have been issued or sold in violation of any preemptive or other similar rights of the holders of any securities of the Company
or rights to acquire securities of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will not
subject the holders thereof to personal liability by reason of being such holders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;assuming
the representations and warranties of the Subscribers as set forth in Section 4 hereof are true and correct, will not result in
a violation of Section 5 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
There is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court,
governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its Affiliates that would affect the
execution by the Company or the complete and timely performance by the Company of its obligations under the Transaction Documents.
Except as disclosed in the Reports, there is no pending or, to the best knowledge of the Company, basis for or threatened action,
suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company,
or any of its Affiliates which litigation if adversely determined would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Market
Manipulation</U>. The Company and its Affiliates have not taken, and will not take, directly or indirectly, any action designed
to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the Common Stock
to facilitate the sale or resale of the Securities or affect the price at which the Securities may be issued or resold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information
Concerning Company</U>. The Reports and Other Written Information contain all material information relating to the Company and
its operations and financial condition as of their respective dates as of which information is required to be disclosed therein.
Since June 30, 2014 and except as modified in the Reports and Other Written Information or in the Schedules hereto, there has been
no Material Adverse Event relating to the Company's business, financial condition or affairs. The Reports and Other Written Information
including the financial statements included therein do not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, taken as a whole, not misleading in light of the
circumstances and when made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the financial condition of the Company as of the Closing Date, (i) the Company&rsquo;s fair saleable value of its assets
exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature; (ii) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs
taking into account the particular capital requirements of the business conducted by the Company, and projected capital requirements
and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company does not intend to incur
debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on
or in respect of its debt).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Defaults</U>.
The Company is not in violation of its articles of incorporation or bylaws. Except as set forth in <B>Schedule 5(l),</B> the Company
is (i) not in default under or in violation of any other material agreement or instrument to which it is a party or by which it
or any of its properties are bound or affected, which default or violation would have a Material Adverse Effect, (ii) not in default
with respect to any order of any court, arbitrator or governmental body or subject to or party to any order of any court or governmental
authority arising out of any action, suit or proceeding under any statute or other law respecting antitrust, monopoly, restraint
of trade, unfair competition or similar matters, or (iii) not in violation of any statute, rule or regulation of any governmental
authority which violation would have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Integrated
Offering</U>. Neither the Company, nor any of its Affiliates, nor any person acting on its or their behalf, has directly or indirectly
made any offers or sales of any security of the Company nor solicited any offers to buy any security of the Company under circumstances
that would cause the offer of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for
purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and
regulations of the Bulletin Board. No prior offering will impair the exemptions relied upon in this Offering or the Company&rsquo;s
ability to timely comply with its obligations hereunder. Neither the Company nor any of its Affiliates will take any action or
steps that would cause the offer or issuance of the Securities to be integrated with other offerings which would impair the exemptions
relied upon in this Offering or the Company&rsquo;s ability to timely comply with its obligations hereunder. The Company will not
conduct any offering other than the transactions contemplated hereby that may be integrated with the offer or issuance of the Securities
that would impair the exemptions relied upon in this Offering or the Company&rsquo;s ability to timely comply with its obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No General
Solicitation</U>. Neither the Company, nor any of its Affiliates, nor to its knowledge, any person acting on its or their behalf,
has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act)
in connection with the offer or sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Undisclosed
Liabilities</U>. Since June 30, 2014, except as disclosed in the Reports, the Company has no liabilities or obligations which are
material, individually or in the aggregate, other than those incurred in the ordinary course of the Company businesses since June
30, 2014 and which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Undisclosed
Events or Circumstances</U>. Since June 30, 2014, except as disclosed in the Reports and except as set forth in <B>Schedule 5(p),</B>
no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial
condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof
by the Company but which has not been so publicly announced or disclosed in the Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Banking</U>.
<B><U>Schedule 5(q)</U></B> contains a list of all financial institutions at which the Company and Subsidiaries maintain deposit,
checking and other accounts. The list includes the accurate addresses of such financial institutions and account numbers of such
accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dilution</U>.
The Company's executive officers and directors understand the nature of the Securities being sold hereby and recognize that the
issuance of the Securities will have a potential dilutive effect on the equity holdings of other holders of the Company&rsquo;s
equity or rights to receive equity of the Company. The board of directors of the Company has concluded, in its good faith business
judgment, that the issuance of the Securities is in the best interests of the Company. The Company specifically acknowledges that
its obligation to issue the Conversion Shares upon conversion of the Notes and the Warrant Shares upon exercise of the Warrants
is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other
shareholders of the Company or parties entitled to receive equity of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Disagreements
with Accountants and Lawyers.</U> There are no material disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise between the Company and the accountants and lawyers previously and presently employed by the Company, including
but not limited to disputes or conflicts over payment owed to such accountants and lawyers, nor have there been any such disagreements
during the two years prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment Company</U>.
Neither the Company nor any Affiliate of the Company is an &ldquo;investment company&rdquo; within the meaning of the Investment
Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign Corrupt
Practices.</U> Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company,
has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related
to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees
or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution
made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or
(iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reporting Company/Shell
Company</U>. The Company is a publicly-held company subject to reporting obligations pursuant to Section 13 of the Securities Exchange
Act of 1934, as amended (the &quot;<B>1934 Act</B>&quot;) and has a class of Common Stock registered pursuant to Section 12(g)
of the 1934 Act. Pursuant to the provisions of the 1934 Act, the Company has timely filed all reports and other materials required
to be filed thereunder with the Commission during the preceding twelve months. As of the Closing Date, the Company is not a &ldquo;shell
company&rdquo; nor a &ldquo;former shell company&rdquo; as those terms are employed in Rule 144 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing</U>. The
Company's Common Stock is quoted on the Bulletin Board under the symbol AEMD. The Company has not received any pending oral or
written notice that its Common Stock is not eligible nor will become ineligible for quotation on the Bulletin Board nor that its
Common Stock does not meet all requirements for the continuation of such quotation and the Company satisfies all the requirements
for the continued quotation of its Common Stock on the Bulletin Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC Status</U>.
The Company&rsquo;s transfer agent is a participant in, and the Common Stock is eligible for transfer pursuant to, the Depository
Trust Company Automated Securities Transfer Program. The name, address, telephone number, fax number, contact person and email
address of the Company transfer agent is set forth on <B>Schedule 5(x)</B> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company Predecessor
and Subsidiaries</U>. Except as set forth in <B>Schedule 5(a),</B> the Company makes each of the representations contained in Sections
5(a), (b), (c), (d), (e), (f), (h), (j), (l), (o), (p), (q), (s), (t) and (u) of this Agreement, as same relate or could be applicable
to each Subsidiary. All representations made by or relating to the Company of a historical or prospective nature and all undertakings
described in Sections 9(g) through 9(l) shall relate, apply and refer to the Company and its predecessors. Except as set forth
on <B>Schedule 5(a)</B>, the Company represents that it owns all of the equity of the Subsidiaries and rights to receive equity
of the Subsidiaries identified on <B>Schedule 5(a)</B>, free and clear of all liens, encumbrances and claims. Except as set forth
on <B>Schedule 5(a)</B>, no person or entity other than the Company has the right to receive any equity interest in the Subsidiaries.
The Company further represents that the Subsidiaries have not been known by any other name for the prior five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(z)&nbsp;&nbsp;&nbsp;&nbsp;<U>Correctness of
Representations</U>. The Company represents that the foregoing representations and warranties are true and correct as of the date
hereof in all material respects, and, unless the Company otherwise notifies the Subscribers prior to the Closing Date, shall be
true and correct in all material respects as of the Closing Date; provided, that, if such representation or warranty is made as
of a different date, in which case such representation or warranty shall be true as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(AA)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The foregoing representations and warranties shall survive the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
D Offering/Legal Opinion</U>. The offer and issuance of the Securities to the Subscribers is being made pursuant to the exemption
from the registration provisions of the 1933 Act afforded by Section 4(a)(2) or Section 4(a)(6) of the 1933 Act and/or Rule 506
of Regulation D promulgated thereunder. On the Closing Date, the Company will provide an opinion reasonably acceptable to the
Subscribers from the Company's legal counsel opining on the availability of an exemption from registration under the 1933 Act
as it relates to the offer and issuance of the Securities and other matters reasonably requested by Subscribers. A form of the
legal opinion is annexed hereto as <B>Exhibit D</B>. The Company will provide, at the Company's expense, to the Subscriber such
other legal opinions, if any, as are reasonably necessary in each Subscriber&rsquo;s and such counsel&rsquo;s opinion for the
issuance and resale of the Conversion Shares and Warrant Shares pursuant to an effective registration statement, Rule 144 under
the 1933 Act or an exemption from registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion of Notes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the conversion
of a Note or part thereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering
an opinion of counsel, to assure that the Company's transfer agent shall issue stock certificates in the name of a Subscriber (or
its permitted nominee) or such other persons as designated by Subscriber and in such denominations to be specified at conversion
representing the number of shares of Common Stock issuable upon such conversion. The Company warrants that no instructions other
than these instructions have been or will be given to the transfer agent of the Company's Common Stock and that the certificates
representing such shares shall contain no legend other than the legend set forth in Section 4(h). If and when a Subscriber sells
the Conversion Shares, assuming (i) a registration statement including such Conversion Shares for registration has been filed with
the Commission, is effective and the prospectus, as supplemented or amended, contained therein is current and (ii) Subscriber or
its agent confirms in writing to the transfer agent that Subscriber has complied with the prospectus delivery requirements, the
Company will reissue the Conversion Shares without restrictive legend and the Conversion Shares will be free-trading, and freely
transferable. In the event that the Conversion Shares are sold in a manner that complies with an exemption from registration, the
Company will promptly instruct its counsel to issue to the transfer agent an opinion permitting removal of the legend indefinitely,
if pursuant to Rule 144(b)(1)(i) of the 1933 Act, provided that Subscriber delivers all reasonably requested representations in
support of such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Subscriber will
give notice of its decision to exercise its right to convert its Note, interest, or part thereof by telecopying or otherwise delivering
a completed Notice of Conversion (a form of which is annexed as <B>Exhibit A</B> to the Note) to the Company via confirmed telecopier
transmission or otherwise pursuant to Section 13(a) of this Agreement. Subscriber will not be required to surrender the Note until
the Note has been fully converted or satisfied. Each date on which a Notice of Conversion is telecopied to the Company in accordance
with the provisions hereof by 6 PM Eastern Time (&ldquo;ET&rdquo;) (or if received by the Company after 6 PM ET, then the next
business day) shall be deemed a &ldquo;<B>Conversion Date</B>.&rdquo; The Company will itself or cause the Company&rsquo;s transfer
agent to transmit the Company's Common Stock certificates representing the Conversion Shares issuable upon conversion of the Note
to Subscriber via express courier for receipt by Subscriber within five (5) business days after the Conversion Date (such fifth
day being the &quot;<B>Delivery Date</B>&quot;). In the event the Conversion Shares are electronically transferable, then delivery
of the Shares <U>must</U> be made by electronic transfer provided request for such electronic transfer has been made by the Subscriber.
A Note representing the balance of the Note not so converted will be provided by the Company to Subscriber if requested by Subscriber,
provided Subscriber delivers the original Note to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company understands
that a delay in the delivery of the Conversion Shares in the form required pursuant to Section 7.1 hereof later than the Delivery
Date could result in economic loss to the Subscribers. As compensation to Subscribers for such loss, the Company agrees to pay
(as liquidated damages and not as a penalty) to each applicable Subscriber for late issuance of Conversion Shares in the form required
pursuant to Section 7.1 hereof upon Conversion of the Note, the amount of $100 per business day after the Delivery Date for each
$10,000 of Note principal amount and interest (and proportionately for other amounts) being converted of the corresponding Conversion
Shares which are not timely delivered. The Company shall pay any payments incurred under this Section upon demand. Furthermore,
in addition to any other remedies which may be available to the Subscribers, in the event that the Company fails for any reason
to effect delivery of the Conversion Shares within seven (7) business days after the Delivery Date, the relevant Subscriber will
be entitled to revoke all or part of the relevant Notice of Conversion by delivery of a notice to such effect to the Company whereupon
the Company and Subscriber shall each be restored to their respective positions immediately prior to the delivery of such notice,
except that the damages payable in connection with the Company&rsquo;s default shall be payable through the date notice of revocation
or rescission is given to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory
Redemption at Subscriber&rsquo;s Election</U>. Upon the occurrence of (i) an Event of Default (as defined in the Note or in this
Agreement), that continues for more than twenty (20) business days, (ii) a Change in Control (as defined below), or (iii) the liquidation,
dissolution or winding up of the Company, then at the Subscriber's election, the Company must pay to each Subscriber thirty (30)
business days after request by each Subscriber (&ldquo;<B>Calculation Period</B>&rdquo;), a sum of money determined by multiplying
up to the outstanding principal amount of the Note designated by each such Subscriber by 120%, plus accrued but unpaid interest
(&quot;<B>Mandatory Redemption Payment</B>&quot;). The Mandatory Redemption Payment must be received by each Subscriber not later
than thirty (30) business days after request (&quot;<B>Mandatory Redemption Payment Date</B>&quot;). Upon receipt of the Mandatory
Redemption Payment, the corresponding Note principal and interest will be deemed paid and no longer outstanding. For purposes of
this Section 7.2, &ldquo;<B>Change in Control</B>&rdquo; shall mean (i) the Company no longer having a class of shares publicly
traded or listed on a Principal Market (as defined in Section 9(b)), (ii) the Company becoming a Subsidiary of another entity (other
than a corporation formed by the Company for purposes of reincorporation in another U.S. jurisdiction), (iii) a majority of the
board of directors of the Company as of the Closing Date no longer serving as directors of the Company except due to natural causes,
and (iv) the sale, lease or transfer of substantially all the assets of the Company or Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Conversion</U>. A Subscriber shall not be entitled to convert on a Conversion Date that amount of a Note nor may the Company make
any payment including principal, interest, or liquidated or other damages by delivery of Conversion Shares in connection with
that number of Conversion Shares which would be in excess of the sum of (i) the number of shares of Common Stock beneficially
owned by such Subscriber and its Affiliates on a Conversion Date or payment date, and (ii) the number of Conversion Shares issuable
upon the conversion of the Note with respect to which the determination of this provision is being made on a calculation date,
which would result in beneficial ownership by Subscriber and its Affiliates of more than 4.99% of the outstanding shares of Common
Stock of the Company on such Conversion Date. For the purposes of the immediately preceding sentence, beneficial ownership shall
be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.
Subject to the foregoing, the Subscriber shall not be limited to aggregate conversions of only 4.99% and aggregate conversions
by the Subscriber may exceed 4.99%. The Subscriber may increase the permitted beneficial ownership amount up to 9.99% upon and
effective after 61 days prior written notice to the Company. Subscriber may allocate which of the equity of the Company deemed
beneficially owned by Subscriber shall be included in the 4.99% amount described above and which shall be allocated to the excess
above 4.99%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Injunction Posting of Bond</U>. In the event a Subscriber shall elect to convert a Note or part thereof,
or exercise a Warrant, the Company may not refuse conversion or exercise based on any claim that Subscriber or anyone associated
or affiliated with Subscriber has been engaged in any violation of law, or for any other reason, unless, a final non-appealable
injunction from a court made on notice to Subscriber, restraining and or enjoining conversion of all or part of such Note or exercise
of such Warrant shall have been sought and obtained by the Company or the Company has posted a surety bond for the benefit of
Subscriber in the amount of 120% of the greater of the outstanding principal and accrued but unpaid interest of the Note, or aggregate
purchase price of the Conversion Shares, or 120% of the aggregate exercise price of the Warrants which are sought to be subject
to the injunction, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds
of which shall be payable to Subscriber to the extent the judgment or decision is in Subscriber&rsquo;s favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESERVED</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments.</U>
The Conversion Price, Warrant exercise price and amount of Conversion Shares and Warrant Shares shall be equitably adjusted and
as otherwise described in this Agreement, the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">7.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Redemption</U>.
The Note shall not be redeemable or callable by the Company, except as described in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commission</U>.
The Company on the one hand, and each Subscriber (for himself only) on the other hand, agree to indemnify the other against and
hold the other harmless from any and all liabilities to any persons claiming brokerage commissions or finder&rsquo;s fees on account
of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions
contemplated hereby or in connection with any investment in the Company at any time, whether or not such investment was consummated
and arising out of such party&rsquo;s actions. The Company represents that there are no parties entitled to receive fees, commissions,
or similar payments in connection with the Offering except for a due diligence fee described on <B>Schedule 8(a)</B> hereto which
the Company agrees will be paid by the Company on the Closing Date (&ldquo;<B>Due Diligence Fee</B>&rdquo;). The Due Diligence
Fee recipient may participate in this Offering and may utilize its Note in lieu of a cash payment for such Due Diligence Fee recipient&rsquo;s
Purchase Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subscriber&rsquo;s Legal Fees</U>. The Company shall pay to Grushko &amp; Mittman, P.C., a cash fee of
$15,000 (&ldquo;<B>Subscriber&rsquo;s Legal Fees</B>&rdquo;) as reimbursement for services rendered to the Subscribers in connection
with this Agreement and the purchase and sale of the Notes and Warrants (the &ldquo;<B>Offering</B>&rdquo;). The Subscriber&rsquo;s
Legal Fees and expenses will be payable out of funds held pursuant to the Escrow Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants of the
Company</U>. The Company covenants and agrees with the Subscribers as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stop Orders</U>.
Subject to the prior notice requirement described in Section 9(n), the Company will advise the Subscribers, within twenty-four
hours after it receives notice of issuance by the Commission, any state securities commission or any other regulatory authority
of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension
of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any proceeding
for any such purpose. The Company will not issue any stop transfer order or other order impeding the sale, resale or delivery of
any of the Securities, except as may be required by any applicable federal or state securities laws and unless contemporaneous
notice of such instruction is given to the Subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing/Quotation</U>.
The Company shall promptly secure the quotation or listing of the Conversion Shares and Warrant Shares upon each national securities
exchange, or automated quotation system upon which the Company&rsquo;s Common Stock is quoted or listed and upon which such Conversion
Shares and Warrant Shares are or become eligible for quotation or listing (subject to official notice of issuance) and shall maintain
same so long as any Notes and Warrants are outstanding. The Company will maintain the quotation or listing of its Common Stock
on the American Stock Exchange, Nasdaq Capital Market, Nasdaq Global Market, Nasdaq Global Select Market, Bulletin Board, or New
York Stock Exchange (whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock (the
&ldquo;<B>Principal Market</B>&rdquo;), and will comply in all respects with the Company's reporting, filing and other obligations
under the bylaws or rules of the Principal Market, as applicable. The Company will provide Subscribers with copies of all notices
it receives notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market. As of the
date of this Agreement and the Closing Date, the Bulletin Board is and will be the Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Market Regulations</U>.
If required, the Company shall notify the Commission, the Principal Market and applicable state authorities, in accordance with
their requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings
as may be required and permitted by applicable law, rule and regulation, for the legal and valid issuance of the Securities to
the Subscribers and promptly provide copies thereof to the Subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing Requirements</U>.
From the date of this Agreement and until the last to occur of (i) all the Conversion Shares have been resold or transferred by
the Subscribers pursuant to a registration statement or pursuant to Rule 144(b)(1)(i), or (ii) the Notes and Warrants are no longer
outstanding (the date of such latest occurrence being the &ldquo;<B>End Date</B>&rdquo;), the Company will (A) cause its Common
Stock to continue to be registered under Section 12(b) or 12(g) of the 1934 Act, (B) comply in all respects with its reporting
and filing obligations under the 1934 Act, (C) voluntarily comply with all reporting requirements that are applicable to an issuer
with a class of shares registered pursuant to Section 12(g) of the 1934 Act, if the Company is not subject to such reporting requirements,
and (D) comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company will use
its best efforts not to take any action or file any document (whether or not permitted by the 1933 Act or the 1934 Act or the rules
thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said
acts until the End Date. Until the End Date, the Company will continue the listing or quotation of the Common Stock on a Principal
Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules
of the Principal Market. The Company agrees to timely file a Form D with respect to the Securities if required under Regulation
D and to provide a copy thereof to Subscribers promptly after such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Proceeds</U>.
The proceeds of the Offering will be employed by the Company specifically for the purposes as disclosed on <B>Schedule 9(e)</B>.
Except as disclosed on <B>Schedule 9(e)</B>, the Purchase Price may not and will not be used for accrued and unpaid officer and
director salaries, payment of financing related debt, redemption of outstanding notes or equity instruments of the Company nor
non-trade obligations outstanding on the Closing Date. For so long as any Note is outstanding, the Company will not prepay any
financing related debt obligations, except equipment payments, nor redeem any equity instruments of the Company without the prior
consent of the Subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation</U>.
Prior to the Closing Date, the Company undertakes to reserve on behalf of Subscribers from its authorized but unissued Common Stock,
a number of shares of Common Stock equal to 150% of the amount of Common Stock necessary to allow Subscribers to be able to convert
the entire Notes and 100% of the amount of Warrant Shares issuable upon exercise of the Warrants (&ldquo;<B>Required Reservation</B>&rdquo;).
Failure to have sufficient shares reserved pursuant to this Section 9(f) at any time shall be a material default of the Company&rsquo;s
obligations under this Agreement and an Event of Default under the Notes. If at any time Notes and Warrants are outstanding the
Company has insufficient Common Stock reserved on behalf of the Subscribers in an amount less than 125% of the amount necessary
for full conversion of the outstanding Notes principal and interest at the conversion price that would be in effect on every such
date and 100% of the Warrant Shares (&ldquo;<B>Minimum Required Reservation</B>&rdquo;), the Company will promptly reserve the
Minimum Required Reservation, or if there are insufficient authorized and available shares of Common Stock to do so, the Company
will take all action necessary to increase its authorized capital to be able to fully satisfy its reservation requirements hereunder,
including the filing of a preliminary proxy with the Commission not later than fifteen business days after the first day the Company
has less than the Minimum Required Reservation. The Company agrees to provide notice to the Subscribers not later than three days
after the date the Company has less than the Minimum Required Reservation reserved on behalf of the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC Program</U>.
At all times that Notes or Warrants are outstanding, the Company will employ as the transfer agent for the Common Stock, Conversion
Shares and Warrant Shares a participant in the Depository Trust Company Automated Securities Transfer Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
From the date of this Agreement and until the End Date, the Company will promptly pay and discharge, or cause to be paid and discharged,
when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property
or business of the Company; provided, however, that any such tax, assessment, charge or levy need not be paid if the validity thereof
shall currently be contested in good faith by appropriate proceedings and if the Company shall have set aside on its books adequate
reserves with respect thereto, and provided, further, that the Company will pay all such taxes, assessments, charges or levies
forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
From the date of this Agreement and until the End Date, the Company will keep its assets which are of an insurable character insured
by financially sound and reputable insurers against loss or damage by fire, explosion and other risks customarily insured against
by companies in the Company&rsquo;s line of business and location, in amounts and to the extent and in the manner customary for
companies in similar businesses similarly situated and located and to the extent available on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Books and
Records.</U> From the date of this Agreement and until the End Date, the Company will keep true records and books of account in
which full, true and correct entries will be made of all dealings or transactions in relation to its business and affairs in accordance
with generally accepted accounting principles applied on a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governmental
Authorities.</U> From the date of this Agreement and until the End Date, the Company shall duly observe and conform in all material
respects to all valid requirements of governmental authorities relating to the conduct of its business or to its properties or
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. From the date of this Agreement and until the End Date, the Company shall maintain in full force and effect its corporate
existence, rights and franchises and all licenses and other rights to use intellectual property owned or possessed by it and reasonably
deemed to be necessary to the conduct of its business, unless it is sold for value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Properties.</U>
From the date of this Agreement and until the End Date, the Company will keep its properties in good repair, working order and
condition, reasonable wear and tear excepted, and from time to time make all necessary and proper repairs, renewals, replacements,
additions and improvements thereto; and the Company will at all times comply with each provision of all leases and claims to which
it is a party or under which it occupies or has rights to property if the breach of such provision could reasonably be expected
to have a Material Adverse Effect. The Company will not abandon any of its assets except for those assets which have negligible
or marginal value or for which it is prudent to do so under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality/Public
Announcement.</U> From the date of this Agreement and until the End Date, the Company agrees that except in connection with a Form
8-K, Form 10-Q, Form 10-K and the registration statement or statements regarding the Subscribers&rsquo; Securities or in correspondence
with the Commission regarding same, it will not disclose publicly or privately the identity of the Subscribers unless expressly
agreed to in writing by Subscribers or only to the extent required by law and then only upon not less than three days prior notice
to Subscribers. In any event and subject to the foregoing, the Company undertakes to file a Form 8-K describing the Offering not
later than the fourth (4<SUP>th</SUP>) business day after the Closing Date; provided, however, that the Company may instead disclose
the Offering in a Quarterly Report on Form 10-Q so long as such report is filed no later than the fourth (4<SUP>th</SUP>) business
day after the Closing Date. Prior to the filing date of such Form 8-K (or 10-Q, as applicable), a draft in the final form (or a
draft of the description to be included in the 10-Q, if no 8-K will be filed to disclose the Offering) will be provided to Subscribers
for Subscribers&rsquo; review and approval. In the Form 8-K, if filed, the Company will specifically disclose the amount of Common
Stock outstanding immediately after the Closing. Upon&nbsp; delivery&nbsp;by the Company to the Subscribers after the Closing Date
of any notice or information, in writing, electronically or otherwise, and while a Note, Conversion Shares or Warrants are held
by Subscribers, unless the&nbsp; Company&nbsp;has in good faith determined that the matters relating to such notice do not constitute&nbsp;material,&nbsp;non-public
information relating to the&nbsp;Company or Subsidiaries,&nbsp;the&nbsp;Company&nbsp; shall within one business day after any such
delivery publicly disclose such&nbsp; material,&nbsp; non-public&nbsp; information&nbsp;on a Report&nbsp;on&nbsp;Form&nbsp;8-K.&nbsp;
<B>In the&nbsp;event&nbsp;that the&nbsp;Company&nbsp;believes&nbsp;that a notice&nbsp;or communication to Subscribers contains
material, non-public information relating to the Company or Subsidiaries, the Company shall so indicate to Subscribers prior to
delivery of such notice or information. Subscribers will be granted sufficient time to notify the Company that Subscribers elects
not to receive such information. In such case, the Company will not deliver such information to Subscribers. In the absence of
any such indication,&nbsp;Subscribers shall be allowed to presume that all matters relating to such notice and information do not
constitute&nbsp;material, non-public information relating to the Company or Subsidiaries.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Non-Public
Information</U>. The Company covenants and agrees that except for the Reports, Other Written Information and schedules and exhibits
to this Agreement and the Transaction Documents, which information the Company undertakes to publicly disclose on the Form 8-K
described in Section 9(n) above, neither it nor any other person acting on its behalf will at any time provide Subscribers or its
agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto
Subscribers shall have agreed in writing to accept such information. The Company understands and confirms that Subscribers shall
be relying on the foregoing representations in effecting transactions in securities of the Company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Negative Covenants</U>.
So long as a Note is outstanding, without the consent of the Subscribers, the Company will not and will not permit any of its Subsidiaries
to directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>create,
incur, assume or suffer to exist any pledge, hypothecation, assignment, deposit arrangement, lien, charge, claim, security interest,
security title, mortgage, security deed or deed of trust, easement or encumbrance, or preference, priority or other security agreement
or preferential arrangement of any kind or nature whatsoever (including any lease or title retention agreement, any financing
lease having substantially the same economic effect as any of the foregoing, and the filing of, or agreement to give, any financing
statement perfecting a security interest under the Uniform Commercial Code or comparable law of any jurisdiction) (each, a &ldquo;<B>Lien</B>&rdquo;)
upon any of its property, whether now owned or hereafter acquired except for: (A) the Excepted Issuances (as defined in Section
12(a) hereof), and (B) (a) Liens imposed by law for taxes that are not yet due or are being contested in good faith and for which
adequate reserves have been established in accordance with generally accepted accounting principles; (b) carriers&rsquo;, warehousemen&rsquo;s,
mechanics&rsquo;, material men&rsquo;s, repairmen&rsquo;s and other like Liens imposed by law, arising in the ordinary course
of business and securing obligations that are not overdue by more than 30 days or that are being contested in good faith and by
appropriate proceedings; (c) pledges and deposits made in the ordinary course of business in compliance with workers&rsquo; compensation,
unemployment insurance and other social security laws or regulations; (d) deposits to secure the performance of bids, trade contracts,
leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case
in the ordinary course of business; (e) Liens created with respect to the financing of the purchase of new property in the ordinary
course of the Company&rsquo;s business up to the amount of the purchase price of such property; and (f) easements, zoning restrictions,
rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business that do not
secure any monetary obligations and do not materially detract from the value of the affected property (each of (a) through (f),
a &ldquo;<B>Permitted Lien</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend its certificate of incorporation, bylaws or its charter documents so as to
materially and adversely affect any rights of the Subscribers (an increase in the amount of authorized shares and an increase
in the number of directors will not be deemed adverse to the rights of the Subscribers);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;repay, repurchase
or offer to repay, repurchase or otherwise acquire or make any dividend or distribution in respect of any of its Common Stock,
preferred stock, or other equity securities other than to the extent permitted or required under the Transaction Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prepay or redeem
any financing related debt or past due obligations or securities outstanding as of the Closing Date, or past due obligations (except
with respect to vendor obligations, or any such obligations which in management&rsquo;s good faith, reasonable judgment must be
repaid to avoid disruption of the Company&rsquo;s businesses);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Seniority</U>.
Except for Permitted Liens, until the Notes are fully satisfied or converted, the Company shall not grant nor allow any security
interest to be taken in any assets of the Company or any Subsidiary or any Subsidiary&rsquo;s assets; nor issue any debt, equity
or other instrument which would give the holder thereof directly or indirectly, a right in any assets of the Company or any Subsidiary
or any right to payment equal to or superior to any right of the Subscribers as holders of the Notes in or to such assets or payment,
nor issue or incur any debt not in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
For so long as the Subscribers hold any Securities, the Company will maintain a United States address and United States fax number
for notice purposes under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants
of the Company Regarding Indemnification.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
The Company agrees to indemnify, hold harmless, reimburse and defend the Subscribers, the Subscribers&rsquo; officers, directors,
agents, counsel, Affiliates, members, managers, control persons, and principal shareholders, against any claim, cost, expense,
liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Subscribers
or any such person which results, arises out of or is based upon (i) any material misrepresentation by Company or breach of any
representation or warranty by Company in this Agreement or in any Exhibits or Schedules attached hereto in any Transaction Document,
or other agreement delivered pursuant hereto or in connection herewith, now or after the date hereof; or (ii) after any applicable
notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed
by the Company hereunder, or any other agreement entered into by the Company and Subscribers relating hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
Procedures</U>. Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified
party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party
in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have
to such indemnified party other than under this Section 10(b) and shall only relieve it from any liability which it may have to
such indemnified party under this Section 10(b), except and only if and to the extent the indemnifying party is prejudiced by such
omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of
the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume
and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from the indemnifying
party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not
be liable to such indemnified party under this Section 10(b) for any legal expenses subsequently incurred by such indemnified party
in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided,
however, that, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnifying
party shall have reasonably concluded that there may be reasonable defenses available to indemnified party which are different
from or additional to those available to the indemnifying party or if the interests of the indemnified party reasonably may be
deemed to conflict with the interests of the indemnifying party, the indemnified parties, as a group, shall have the right to select
one separate counsel, reasonably satisfactory to the indemnified and indemnifying party, and to assume such legal defenses and
otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other
expenses related to such participation to be reimbursed by the indemnifying party as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Post-Closing
Obligations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Unlegended Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within three
(3) business days (such third business day being the &ldquo;<B>Unlegended Shares Delivery Date</B>&rdquo;) after the business day
on which the Company has received (i) a notice that Conversion Shares, or any other Common Stock held by Subscriber has been sold
pursuant to a registration statement or Rule 144 under the 1933 Act, (ii) a representation that the prospectus delivery requirements,
or the requirements of Rule 144, as applicable and if required, have been satisfied, (iii) the original share certificates representing
the shares of Common Stock that have been sold, and (iv) in the case of sales under Rule 144, customary representation letters
of the Subscriber and, if required, Subscriber&rsquo;s broker regarding compliance with the requirements of Rule 144, the Company
at its expense, (y) shall deliver, and shall cause legal counsel selected by the Company to deliver to its transfer agent (with
copies to Subscriber) an appropriate instruction and opinion of such counsel, directing the delivery of shares of Common Stock
without any legends including the legend set forth in Section 4(h) above (the &ldquo;<B>Unlegended Shares</B>&rdquo;); and (z)
cause the transmission of the certificates representing the Unlegended Shares together with a legended certificate representing
the balance of the submitted Common Stock certificate, if any, to the Subscriber at the address specified in the notice of sale,
via express courier, by electronic transfer or otherwise on or before the Unlegended Shares Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In lieu of
delivering physical certificates representing the Unlegended Shares, upon request of Subscriber, so long as the certificates therefor
do not bear a legend and the Subscriber is not obligated to return such certificate for the placement of a legend thereon, the
Company shall cause its transfer agent to electronically transmit the Unlegended Shares by crediting the account of Subscriber&rsquo;s
prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission system, if such transfer agent participates
in such DWAC system. Such delivery must be made on or before the Unlegended Shares Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company understands
that a delay in the delivery of the Unlegended Shares pursuant to Section 11 hereof later than the Unlegended Shares Delivery Date
could result in economic loss to a Subscriber. As compensation to a Subscriber for such loss, the Company agrees to pay late payment
fees (as liquidated damages and not as a penalty) to the Subscriber for late delivery of Unlegended Shares in the amount of $100
per business day after the Delivery Date for each $10,000 of purchase price of the Unlegended Shares subject to the delivery default.
If during any 360 day period, the Company fails to deliver Unlegended Shares as required by this Section 11.1 for an aggregate
of thirty days, then each Subscriber or assignee holding Securities subject to such default may, at its option, require the Company
to redeem all or any portion of the Shares subject to such default at a price per share equal to the greater of (i) 120%, or (ii)
a fraction in which the numerator is the highest closing price of the Common Stock during the aforedescribed thirty day period
and the denominator of which is the lowest conversion price during such thirty day period, multiplied by the price paid by Subscriber
for such Common Stock (&ldquo;<B>Unlegended Redemption Amount</B>&rdquo;). The Company shall pay any payments incurred under this
Section in immediately available funds upon demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event
a Subscriber shall request delivery of Unlegended Shares as described in Section 11.1 and the Company is required to deliver such
Unlegended Shares pursuant to Section 11.1, the Company may not refuse to deliver Unlegended Shares based on any claim that such
Subscriber or anyone associated or affiliated with such Subscriber has been engaged in any violation of law, or for any other reason,
unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery of such Unlegended
Shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit of such Subscriber
in the amount of 120% of the amount of the aggregate purchase price of the Common Stock which are subject to the injunction or
temporary restraining order, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and
the proceeds of which shall be payable to such Subscriber to the extent Subscriber obtains judgment in Subscriber&rsquo;s favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition
to any other rights available to Subscriber, if the Company fails to deliver to a Subscriber Unlegended Shares by the Unlegended
Shares Delivery Date as required pursuant to this Agreement and if after the Unlegended Shares Delivery Date, Subscriber or a broker
on Subscriber&rsquo;s behalf purchases (in an open market transaction or otherwise) shares of common stock to deliver in satisfaction
of a sale by Subscriber of the shares of Common Stock which the Subscriber was entitled to receive from the Company (a &quot;<B>Buy-In</B>&quot;),
then the Company shall pay in cash to the Subscriber (in addition to any remedies available to or elected by the Subscriber) the
amount by which (A) the Subscriber's total purchase price (including brokerage commissions, if any) for the shares of common stock
so purchased exceeds (B) the aggregate purchase price of the shares of Common Stock delivered to the Company for reissuance as
Unlegended Shares together with interest thereon at a rate of 15% per annum accruing until such amount and any accrued interest
thereon is paid in full (which amount shall be paid as liquidated damages and not as a penalty). For example, if a Subscriber purchases
shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to $10,000 of purchase price of
shares of Common Stock delivered to the Company for reissuance as Unlegended Shares, the Company shall be required to pay the Subscriber
$1,000, plus interest. The Subscriber shall provide the Company written notice and evidence reasonably acceptable to the Company
indicating the amounts payable to the Subscriber in respect of the Buy-In.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>144 Default</U>. In the event
commencing six months after the Closing Date and ending twenty-four months thereafter, the Subscriber is not permitted to resell
any of the Conversion Shares without any restrictive legend or if such sales are permitted but subject to volume limitations or
further restrictions on resale as a result of the unavailability to Subscriber of Rule 144(b)(1)(i) under the 1933 Act or any successor
rule, or such Shares are not registered on an effective registration statement under the Act (a &ldquo;<B>144 Default</B>&rdquo;),
for any reason except for Subscriber&rsquo;s status as an Affiliate or &ldquo;control person&rdquo; of the Company, or as a result
of a change in current applicable securities laws, then the Company shall pay such Subscriber as liquidated damages and not as
a penalty an amount equal to two percent (2%) for each thirty days (or such lesser pro-rata amount for any period less than thirty
days) thereafter of the purchase price of the Conversion Shares subject to such 144 Default during the pendency of the 144 Default.
Liquidated Damages shall not be payable pursuant to this Section 11.2 in connection with Shares for such times as such Shares may
be sold by the holder thereof without volume or other restrictions pursuant to Section 144(b)(1)(i) of the 1933 Act or pursuant
to an effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Company, to: Aethlon Medical, Inc., 9635 Granite Ridge Drive, Suite 100, San Diego,
CA 92123, Attn: James A. Joyce, CEO, facsimile: (858) 272-2738, with a copy by telecopier only to: Post Law Group, PC. 5900 Wilshire
Boulevard, Suite 620, Los Angeles, CA 90036, Attn: Jennifer A. Post, Esq., facsimile: (800) 783&ndash;2983, and (ii) if to the
Subscribers, to: the addresses and fax numbers indicated on <B>Schedule 1</B> hereto, with an additional copy by fax only to: Grushko
&amp; Mittman, P.C., 515 Rockaway Avenue, Valley Stream, New York 11581, facsimile: (212) 697-3575.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement;
Assignment</U>. This Agreement and other documents delivered in connection herewith represent the entire agreement between the
parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties. Neither
the Company nor the Subscribers have relied on any representations not contained or referred to in this Agreement and the documents
delivered herewith. No right or obligation of the Company shall be assigned without prior notice to and the written consent of
the Subscribers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts/Execution</U>.
This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts,
each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same
instrument. This Agreement may be executed by facsimile signature and delivered by facsimile transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Law Governing
this Agreement</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county
of New York. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon <U>forum non conveniens</U>. <B>The
parties executing this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company
agree to submit to the in personam jurisdiction of such courts and hereby irrevocably waive trial by jury. </B>The prevailing party
shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of
this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law
shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal
service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement or
any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any other manner permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific
Enforcement, Consent to Jurisdiction</U>. The Company and Subscribers acknowledge and agree that irreparable damage would occur
in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent or cure breaches
of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any
other remedy to which any of them may be entitled by law or equity. Subject to Section 13(d) hereof, the Company hereby irrevocably
waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
in New York of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit,
action or proceeding is improper. Nothing in this Section shall affect or limit any right to serve process in any other manner
permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Damages</U>.
In the event the Subscriber is entitled to receive any liquidated damages pursuant to the Transactions Documents, the Subscriber
may elect to receive the greater of actual damages or such liquidated damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Payments</U>. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed
to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law.
In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted
by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to the Subscribers and
thus refunded to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calendar
Days</U>. All references to &ldquo;days&rdquo; in the Transaction Documents shall mean calendar days unless otherwise stated. The
terms &ldquo;business days&rdquo; and &ldquo;trading days&rdquo; shall mean days that the New York Stock Exchange is open for trading
for three or more hours. Time periods shall be determined as if the relevant action, calculation or time period were occurring
in New York City. Any deadline that falls on a non-business day in any of the Transaction Documents shall be automatically extended
to the next business day and interest, if any, shall be calculated and payable through such extended period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Captions:
Certain Definitions</U>. The captions of the various sections and paragraphs of this Agreement have been inserted only for the
purposes of convenience; such captions are not a part of this Agreement and shall not be deemed in any manner to modify, explain,
enlarge or restrict any of the provisions of this Agreement. As used in this Agreement the term &ldquo;<U>person</U>&rdquo; shall
mean and include an individual, a partnership, a joint venture, a corporation, a limited liability company, a trust, an unincorporated
organization and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent</U>.
As used in this Agreement and the Transaction Documents and any other agreement delivered in connection herewith, &ldquo;consent
of the Subscribers&rdquo; or similar language means the consent of holders of not less than 70% of the outstanding principal amount
of the Notes on the date consent is requested (such amount being a &ldquo;<B>Majority in Interest</B>&rdquo;). A Majority in Interest
may consent to take or forebear from any action permitted under or in connection with the Transaction Documents, modify any Transaction
Documents or waive any default or requirement applicable to the Company, Subsidiaries or Subscribers under the Transaction Documents
provided the effect of such action does not waive any accrued interest or damages and further provided that the relative rights
of the Subscribers to each other remains unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
In the event that any term or provision of this Agreement shall be finally determined to be superseded, invalid, illegal or otherwise
unenforceable pursuant to applicable law by an authority having jurisdiction and venue, that determination shall not impair or
otherwise affect the validity, legality or enforceability: (i) by or before that authority of the remaining terms and provisions
of this Agreement, which shall be enforced as if the unenforceable term or provision were deleted, or (ii) by or before any other
authority of any of the terms and provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successor
Laws</U>. References in the Transaction Documents to laws, rules, regulations and forms shall also include successors to and functionally
equivalent replacements of such laws, rules, regulations and forms. A successor rule to Rule 144(b)(1)(i) shall include any rule
that would be available to a non-Affiliate of the Company for the sale of Common Stock not subject to volume restrictions and after
a six month holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation
of Purchase Price</U>. The Purchase Price will be allocated at Subscriber&rsquo;s election, among the components of the Securities
so that each component of the Securities will be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Liability</U>. In no event shall the liability of the Subscribers or permitted successor hereunder or under any Transaction Document
or other agreement delivered in connection herewith be greater in amount than the dollar amount of the net proceeds actually received
by such Subscriber or successor upon the sale of Conversion shares (as defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Subscribers</U>.&nbsp;&nbsp; &nbsp;&nbsp;The Company acknowledges that the obligations of each Subscriber under the Transaction
Documents are several and not joint with the obligations of any other Subscriber, and no Subscriber shall be responsible in any
way for the performance of the obligations of any other Subscriber under the Transaction Documents. The Company acknowledges that
each Subscriber has represented that the decision of each Subscriber to purchase Securities has been made by such Subscriber independently
of any other Subscriber and independently of any information, materials, statements or opinions as to the business, affairs, operations,
assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company which may
have been made or given by any other Subscriber or by any agent or employee of any other Subscriber, and no Subscriber or any of
its agents or employees shall have any liability to any other Subscriber (or any other person) relating to or arising from any
such information, materials, statements or opinions.&nbsp; The Company acknowledges that nothing contained in any Transaction Document,
and no action taken by any Subscriber pursuant hereto or thereto shall be deemed to constitute the Subscribers as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Subscribers are in any way acting
in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.&nbsp;
The Company acknowledges that it has elected to provide all Subscribers with the same terms and Transaction Documents for the convenience
of the Company and not because Company was required or requested to do so by the Subscribers.&nbsp; The Company acknowledges that
such procedure with respect to the Transaction Documents in no way creates a presumption that the Subscribers are in any way acting
in concert or as a group with respect to the Transaction Documents or the transactions contemplated&nbsp;thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal Treatment</U>.
No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the
Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OMNIBUS INVESTOR SIGNATURE PAGE TO<BR>
AETHLON MEDICAL, INC.<BR>
<U>SUBSCRIPTION AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, in its
capacity as an Investor, hereby executes and delivers the Subscription Agreement to which this signature page is attached and agrees
to be bound by the Subscription Agreement on the date set forth on the first page of the Subscription Agreement. This counterpart
signature page, together with all counterparts of the Subscription Agreement and signature pages of the other parties named therein,
shall constitute one and the same instrument in accordance with the terms of the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">A Nevada corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">By: __________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in">Dated: November 6, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U STYLE="text-decoration: none">__________________________________________</U><BR>
        [Print Name of Investor]</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purchase Price: <U STYLE="text-decoration: none">$____________</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________________<BR>
        [Signature]</P></TD>
    <TD STYLE="font-size: 10pt"><B>Principal Amount of Note: <U STYLE="text-decoration: none">$____________</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name: _____________________________________</TD>
    <TD STYLE="font-size: 10pt"><B>Class A Warrants: _____________</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title: ______________________________________</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: ______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Taxpayer ID# (if applicable): _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>aemd_10q-ex1003.htm
<DESCRIPTION>CONVERTIBLE PROMISSORY NOTE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0 0 0pt"><B>EXHIBIT 10.3</B></P>

<P STYLE="margin: 0 0 0pt">&nbsp;</P>

<P STYLE="margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>NEITHER THE ISSUANCE AND SALE OF
THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE
FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><B>Principal Amount: $___________</B></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"><B>Issue Date: November 6, 2014</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>CONVERTIBLE PROMISSORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, AETHLON
MEDICAL, INC., a Nevada corporation (hereinafter called &ldquo;<B>Borrower</B>&rdquo;), hereby promises to pay to the order of
<U>&#9;</U>, <U>&#9;&#9;</U>, Fax: <U>&#9; </U>(the &ldquo;<B>Holder</B>&rdquo;), without demand, the sum of ______________________________
($_____________) (&ldquo;<B>Principal Amount</B>&rdquo;), with interest accruing thereon, on April 1, 2016 (the &ldquo;<B>Maturity
Date</B>&rdquo;), if not sooner paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">This Note has been entered
into pursuant to the terms of a subscription agreement between the Borrower, the Holder and the other signatories thereto (&ldquo;<B>Other
Holders</B>&rdquo;) dated at or about the date hereof (the &ldquo;<B>Subscription Agreement</B>&rdquo;), who have been issued Notes
pursuant to the Subscription Agreement (&ldquo;<B>Other Notes</B>&rdquo;) and shall be governed by the terms of such Subscription
Agreement. Unless otherwise separately defined herein, all capitalized terms used in this Note shall have the same meaning as is
set forth in the Subscription Agreement. The following terms shall apply to this Note:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>ARTICLE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">GENERAL PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest Rate</U>.
Cash interest payable on this Note shall compound annually and accrue at the annual rate of ten percent (10%) from the Issue Date
through the Maturity Date. Interest shall be payable in arrears on the Maturity Date, accelerated or otherwise, when the principal
and remaining accrued but unpaid interest shall be due and payable, or sooner as described below. Interest will be payable in
cash or at the election of the Holder, may be converted to Common Stock pursuant to Article II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Courier; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Grace Period</U>. The Borrower shall not have any grace period to pay any monetary amounts due under this Note. During the pendency
of an Event of Default (as described in Article III), a default interest rate of eighteen percent (18%) per annum shall be in
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion Privileges</U>. The
Conversion Rights set forth in <U>Article II</U> shall remain in full force and effect immediately from the date hereof and until
the Note is paid in full regardless of the occurrence of an Event of Default. This Note shall be payable in full on the Maturity
Date, unless previously converted into Common Stock in accordance with <U>Article II</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>ARTICLE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>CONVERSION RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">The Holder shall have the
right to convert the principal and any interest due under this Note into Shares of the Borrower's Common Stock, $.001 par value
per share (&ldquo;<B>Common Stock</B>&rdquo;) as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion into the Borrower's
Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Holder shall have
the right from and after the date of the issuance of this Note and then at any time until this Note is fully paid, to convert any
outstanding and unpaid principal portion of this Note, and/or accrued interest, at the election of the Holder (the date of giving
of such notice of conversion being a &quot;<B>Conversion Date</B>&quot;) into fully paid and non-assessable shares of Common Stock
as such stock exists on the date of issuance of this Note, or any shares of capital stock of Borrower into which such Common Stock
shall hereafter be changed or reclassified, at the conversion price as defined in <U>Section 2.1(b)</U> hereof (the &quot;<B>Conversion
Price</B>&quot;), determined as provided herein. Upon delivery to the Borrower of a completed Notice of Conversion, a form of which
is annexed hereto as <U>Exhibit A</U>, Borrower shall issue and deliver to the Holder within three (3) business days after the
Conversion Date (such third day being the &ldquo;<B>Delivery Date</B>&rdquo;) that number of shares of Common Stock for the portion
of the Note converted in accordance with the foregoing. At the election of the Holder, the Borrower will deliver accrued but unpaid
interest on the Note, if any, through the Conversion Date directly to the Holder on or before the Delivery Date. The number of
shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing that portion of the principal
of the Note and interest, if any, to be converted, by the Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to adjustment as provided in <U>Section 2.1(c)</U> hereof, the conversion price per share shall be equal to $0.112, subject to
adjustment as described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Conversion Price and number and kind of shares or other securities to be issued upon conversion determined pursuant to <U>Section
2.1(a)</U>, shall be subject to adjustment from time to time upon the happening of certain events while this conversion right
remains outstanding, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger,
Sale of Assets, etc</U>. If (A) the Borrower effects any merger or consolidation of the Borrower with or into another entity,
(B) the Borrower effects any sale of all or substantially all of its assets in one or a series of related transactions, (C) any
tender offer or exchange offer (whether by the Borrower or another entity) is completed pursuant to which holders of Common Stock
are permitted to tender or exchange their shares for other securities, cash or property, (D) the Borrower consummates a stock
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with one or more persons or entities whereby such other persons or entities acquire more than the 50%
of the outstanding shares of Common Stock (not including any shares of Common Stock held by such other persons or entities making
or party to, or associated or affiliated with the other persons or entities making or party to, such stock purchase agreement
or other business combination), (E) any &quot;person&quot; or &quot;group&quot; (as these terms are used for purposes of Sections
13(d) and 14(d) of the 1934 Act) is or shall become the &quot;beneficial owner&quot; (as defined in Rule 13d-3 under the 1934
Act), directly or indirectly, of 50% of the aggregate Common Stock of the Borrower, or (F) the Borrower effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property (in any such case, a &quot;<B>Fundamental Transaction</B>&quot;),this Note, as to the unpaid
principal portion thereof and accrued interest thereon, shall thereafter be deemed to evidence the right to convert into such
number and kind of shares or other securities and property as would have been issuable or distributable on account of such Fundamental
Transaction, upon or with respect to the securities subject to the conversion right immediately prior to such Fundamental Transaction.
The foregoing provision shall similarly apply to successive Fundamental Transactions of a similar nature by any such successor
or purchaser. Without limiting the generality of the foregoing, the anti-dilution provisions of this Section shall apply to such
securities of such successor or purchaser after any such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reclassification,
etc.</U> If the Borrower at any time shall, by reclassification or otherwise, change the Common Stock into the same or a different
number of securities of any class or classes that may be issued or outstanding, this Note, as to the unpaid principal portion
thereof and accrued interest thereon, shall thereafter be deemed to evidence the right to purchase an adjusted number of such
securities and kind of securities as would have been issuable as the result of such change with respect to the Common Stock immediately
prior to such reclassification or other change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Splits,
Combinations and Dividends</U>. If the shares of Common Stock are subdivided or combined into a greater or smaller number of shares
of Common Stock, or if a dividend is paid on the Common Stock in shares of Common Stock, the Conversion Price shall be proportionately
reduced in case of subdivision of shares or stock dividend or proportionately increased in the case of combination of shares, in
each such case by the ratio which the total number of shares of Common Stock outstanding immediately after such event bears to
the total number of shares of Common Stock outstanding immediately prior to such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever the Conversion
Price is adjusted pursuant to <U>Section 2.1(c)</U> above, the Borrower shall promptly mail to the Holder a notice setting forth
the Conversion Price after such adjustment and setting forth a statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the period
the conversion right exists, Borrower will reserve from its authorized and unissued Common Stock not less than an amount of Common
Stock equal to 150% of the amount of shares of Common Stock issuable upon the full conversion of this Note. Borrower represents
that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. Borrower agrees that its issuance
of this Note shall constitute full authority to its officers, agents, and transfer agents who are charged with the duty of executing
and issuing stock certificates to execute and issue the necessary certificates for shares of Common Stock upon the conversion of
this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Method of Conversion</U>.
This Note may be converted by the Holder in whole or in part as described in <U>Section 2.1(a)</U> hereof and the Subscription
Agreement. Upon partial conversion of this Note, a new Note containing the same date and provisions of this Note shall, at the
request of the Holder, be issued by the Borrower to the Holder for the principal balance of this Note and interest which shall
not have been converted or paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Conversion</U>. The Holder shall not be entitled to convert on a Conversion Date that amount of the Note in connection with that
number of shares of Common Stock which would be in excess of the sum of (i) the number of shares of Common Stock beneficially
owned by the Holder and its affiliates on a Conversion Date, (ii) any Common Stock issuable in connection with the unconverted
portion of the Note, and (iii) the number of shares of Common Stock issuable upon the conversion of the Note with respect to which
the determination of this provision is being made on a Conversion Date, which would result in beneficial ownership by the Holder
and its affiliates of more than 4.99% of the outstanding shares of Common Stock of the Borrower on such Conversion Date. For the
purposes of the provision to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. Subject to the foregoing, the Holder
shall not be limited to aggregate conversions of 4.99%. The Holder shall have the authority and obligation to determine whether
the restriction contained in this <U>Section 2.3</U> will limit any conversion hereunder and to the extent that the Holder determines
that the limitation contained in this Section applies, the determination of which portion of the Notes are convertible shall be
the responsibility and obligation of the Holder. The Holder may waive the conversion limitation described in this <U>Section 2.3</U>,
in whole or in part, upon and effective after 61 days prior written notice to the Borrower to increase such percentage to up to
9.99%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Borrower&rsquo;s Obligations</U>. Upon the conversion of this Note or part thereof,
the Borrower shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel
to assure that the Borrower&rsquo;s transfer agent shall issue stock certificates in the name of a Holder (or its permitted nominee)
or such other persons as designated by Holder and in such denominations to be specified at conversion representing the number
of shares of Common Stock issuable upon such conversion. The Borrower warrants that no instructions other than these instructions
have been or will be given to the Borrower&rsquo;s transfer agent and that the certificates representing such shares shall contain
no legend other than the legend set forth in Section 4(h) of the Subscription Agreement. If and when a Holder sells the Conversion
Shares, assuming (i) a registration statement including such Conversion Shares for registration has been filed with the Commission,
is effective and the prospectus, as supplemented or amended, contained therein is current and (ii) Holder or its agent confirms
in writing to the transfer agent that Holder has complied with the prospectus delivery requirements, the Borrower will reissue
the Conversion Shares without restrictive legend. In the event that the Conversion Shares are sold in a manner that complies with
an exemption from registration, the Borrower will promptly instruct its counsel to issue to the transfer agent an opinion permitting
removal of the legend, provided that Holder delivers reasonably requested representations in support of such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Late Delivery.</U> The Borrower
understands that a delay in the delivery of the Conversion Shares in the form required pursuant to Section 2.4 hereof later than
the Delivery Date (as defined in the Subscription Agreement) could result in economic loss to the Holder. As compensation to Holder
for such loss, the Borrower agrees to pay (as liquidated damages and not as a penalty) to Holder for late issuance of Conversion
Shares in the form required pursuant to this Note upon Conversion of the Note, the amount of $100 per Trading Day (increasing to
$200 per Trading Day after ten (10) Trading Days) after the Delivery Date for each $10,000 of Note principal amount and interest
(and proportionately for other amounts) being converted of the corresponding Conversion Shares which are not timely delivered.
The Borrower shall pay any payments incurred under this Section upon demand. Furthermore, in addition to any other remedies which
may be available to the Holder, in the event that the Borrower fails for any reason to effect delivery of the Conversion Shares
on or before the Delivery Date, the Holder will be entitled to revoke all or part of the relevant Notice of Holder by delivery
of a notice to such effect to the Borrower whereupon the Borrower and Holder shall each be restored to their respective positions
immediately prior to the delivery of such notice, except that the damages payable in connection with the Borrower&rsquo;s default
shall be payable through the date notice of revocation or rescission is given to the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Buy-In</U>. In
addition to any other rights available to Holders, if the Borrower fails to deliver to a Holder Conversion Shares by the Delivery
Date as required pursuant to this Note and the Subscription Agreement and if after the Delivery Date, Holder or a broker on Holder&rsquo;s
behalf purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by Holder
of the Common Stock which the Holder was entitled to receive from the Company upon such conversion (a &ldquo;<B>Buy-In</B>&rdquo;),
then the Borrower shall pay in cash to each Holder (in addition to any remedies available to or elected by the Holder) the amount
by which (A) Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased
exceeds (B) the aggregate principal and/or interest amount of the Note for which such conversion request was not timely honored
together with interest thereon at a rate of 15% per annum, accruing until such amount and any accrued interest thereon is paid
in full (which amount shall be paid as liquidated damages and not as a penalty). For example, if a Holder purchases shares of Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of $10,000 of Note principal
and/or interest, the Borrower shall be required to pay Holder $1,000 plus interest. Holder shall provide the Borrower written notice
and evidence reasonably acceptable to the Borrower indicating the amounts payable to Holder in respect of the Buy-In.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>ARTICLE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>EVENT OF DEFAULT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">The occurrence of any of
the following events of default (&quot;<B>Event of Default</B>&quot;) shall, at the option of the Holder hereof, make all sums
of principal and interest then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon
demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Failure to Pay
Principal or Interest</U>. The Borrower fails to pay any installment of principal, interest or other sum due under this Note when
due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Breach of Covenant</U>.
The Borrower breaches any material covenant or other term or condition of the Subscription Agreement, Transaction Documents or
this Note in any material respect and such breach, if subject to cure, continues for a period of ten (10) business days after written
notice to the Borrower from the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Breach of Representations
and Warranties</U>. Any material representation or warranty of the Borrower made herein, in the Subscription Agreement, Transaction
Documents, or in any agreement, statement or certificate given in writing pursuant hereto or in connection therewith shall be false
or misleading in any material respect as of the date made and the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation</U>.
Any dissolution, liquidation or winding up of Borrower or any substantial portion of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cessation
of Operations</U>. Any cessation of operations by Borrower or Borrower admits it is otherwise generally unable to pay its debts
as such debts become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance of
Assets</U>. The failure by Borrower to maintain any material intellectual property rights, personal, real property or other assets
which are necessary to conduct its business (whether now or in the future).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Receiver or Trustee</U>.
The Borrower or any Subsidiary of Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the
appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver or trustee
shall otherwise be appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Judgments</U>.
Any money judgment, writ or similar final process shall be entered or filed against Borrower or any of its property or other assets
for more than $100,000, unless stayed vacated or satisfied within forty-five (45) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bankruptcy</U>.
Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings or relief under any bankruptcy law or any
law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the
Borrower or any Subsidiary of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delisting</U>. Delisting of the Common Stock from any Principal Market; failure
to comply with the requirements for continued listing on a Principal Market for a period of ten (10) consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Payment</U>.
Other than defaults disclosed on Schedule 5(l) to the Subscription Agreement, a default by the Borrower under any one or more obligations
in an aggregate monetary amount in excess of $100,000 for more than twenty (20) days after the due date, unless the Borrower is
contesting the validity of such obligation in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stop Trade</U>.
An SEC or judicial stop trade order or Principal Market trading suspension that lasts for five or more consecutive trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Failure to Deliver
Common Stock or Replacement Note</U>. Borrower's failures to timely deliver Common Stock to the Holder pursuant to and in the form
required by this Note and Sections 7 and 11 of the Subscription Agreement, or, if required, a replacement Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
Default</U>. Failure by the Borrower to have reserved for issuance upon conversion of the Note or upon exercise of the Warrants
issued in connection with the Subscription Agreement, the number of shares of Common Stock as required in the Subscription Agreement,
this Note and the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial Statement
Restatement</U>. The restatement after the date hereof of any financial statements filed by the Borrower with the Securities and
Exchange Commission for any date or period from two years prior to the Issue Date of this Note and until this Note is no longer
outstanding, if the result of such restatement would, by comparison to the unrestated financial statements, have constituted a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Note Default</U>.
The occurrence of any Event of Default under any Other Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Event
Described in Subscription Agreement</U>. The occurrence of an Event of Default as described in the Subscription Agreement that,
if susceptible to cure, is not cured during any designated cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cross Default</U>. A default by the Borrower
of a material term, covenant, warranty or undertaking of any other agreement to which the Borrower and Holder are parties, or
the occurrence of a material event of default under any such other agreement to which Borrower and Holder are parties which is
not cured after any required notice and/or cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>ARTICLE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Failure
or Indulgence Not Waiver</U>. No failure or delay on the part of the Holder hereof in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the first business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Borrower to: Aethlon Medical, Inc., 9635 Granite Ridge Drive, Suite 100, San Diego,
CA 92123, Attn: James A. Joyce, CEO, facsimile: (858) 272-2738, with a copy by telecopier only to: Post Law Group, PC., 5900 Wilshire
Boulevard, Suite 620, Los Angeles, CA 90036, Attn: Jennifer A. Post, Esq., facsimile: (800) 783&ndash;2983, and (ii) if to the
Holder, to the name, address and facsimile number set forth on the front page of this Note, with a copy by fax only to Grushko
&amp; Mittman, P.C., 515 Rockaway Avenue, Valley Stream, New York 11581, facsimile: (212) 697-3575.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
Provision</U>. The term &ldquo;Note&rdquo; and all reference thereto, as used throughout this instrument, shall mean this instrument
as originally executed, or if later amended or supplemented, then as so amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignability</U>.
This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to the benefit of the Holder and its
successors and assigns. The Borrower may not assign its obligations under this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cost of
Collection</U>. If default is made in the payment of this Note, Borrower shall pay the Holder hereof reasonable costs of collection,
including reasonable attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Note shall be governed by and construed in accordance with the laws of the State of New York without regard to conflicts
of laws principles that would result in the application of the substantive laws of another jurisdiction. Any action brought by
either party against the other concerning the transactions contemplated by this Agreement must be brought only in the civil or
state courts of New York or in the federal courts located in the State and county of New York. Both parties and the individual
signing this Agreement on behalf of the Borrower agree to submit to the jurisdiction of such courts. The prevailing party shall
be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note
is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the
extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision
which may prove invalid or unenforceable under any law shall not affect the validity or unenforceability of any other provision
of this Note. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal
action against the Borrower in any other jurisdiction to collect on the Borrower's obligations to Holder, to realize on any collateral
or any other security for such obligations, or to enforce a judgment or other decision in favor of the Holder. <B>This Note shall
be deemed an unconditional obligation of Borrower for the payment of money and, without limitation to any other remedies of Holder,
may be enforced against Borrower by summary proceeding pursuant to New York Civil Procedure Law and Rules Section 3213 or any similar
rule or statute in the jurisdiction where enforcement is sought. For purposes of such rule or statute, any other document or agreement
to which Holder and Borrower are parties or which Borrower delivered to Holder, which may be convenient or necessary to determine
Holder&rsquo;s rights hereunder or Borrower&rsquo;s obligations to Holder are deemed a part of this Note, whether or not such other
document or agreement was delivered together herewith or was executed apart from this Note.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Payments</U>. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges
in excess of the maximum rate permitted by applicable law. In the event that the rate of interest required to be paid or other
charges hereunder exceed the maximum rate permitted by applicable law, any payments in excess of such maximum rate shall be credited
against amounts owed by the Borrower to the Holder and thus refunded to the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Business
Days</U>. Whenever any payment or any action to be made shall be due on a Saturday, Sunday or a public holiday under the laws of
the State of New York, such payment may be due or action shall be required on the next succeeding business day and, for such payment,
such next succeeding day shall be included in the calculation of the amount of accrued interest payable on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Redemption</U>.
This Note may not be prepaid, redeemed or called without the consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Status</U>. The Holder shall not have rights as a shareholder of the Borrower with respect to unconverted portions of this Note.
However, the Holder will have the rights of a shareholder of the Borrower with respect to the Shares of Common Stock to be received
after delivery by the Holder of a Conversion Notice to the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>[THIS SPACE INTENTIONALLY
LEFT BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
Borrower has caused this Note to be signed in its name by an authorized officer as of the 6<SUP>th</SUP> day of November, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 45pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">By:_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 45pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">WITNESS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>NOTICE
OF CONVERSION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">(To be executed by the Registered Holder in order to convert the
Note)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">The undersigned hereby elects to convert $_________
of the principal and $_________ of the interest due on the Note issued by AETHLON MEDICAL, INC. on November 6, 2014 into Shares
of Common Stock of AETHLON MEDICAL, INC.(the &ldquo;Borrower&rdquo;) according to the conditions set forth in such Note, as of
the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Date of Conversion:__________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Conversion Price:____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Number of Shares of Common Stock Beneficially
Owned on the Conversion Date: Less than 5% of the outstanding Common Stock of AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Shares To Be Delivered:_______________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Signature:__________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Print Name:_________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Address:___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>aemd_10q-ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, James Joyce, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on
Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this Report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 10, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;JAMES A. JOYCE</FONT></TD>
    <TD STYLE="width: 60%; padding-bottom: 1.1pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">JAMES A. JOYCE</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CHIEF EXECUTIVE OFFICER </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(PRINCIPAL EXECUTIVE OFFICER )</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>aemd_10q-ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, James Frakes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on
Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this Report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 91%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="width: 91%"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 10, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;JAMES B. FRAKES</FONT></TD>
    <TD STYLE="width: 60%; padding-bottom: 1.1pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CHIEF FINANCIAL OFFICER </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(PRINCIPAL FINANCIAL OFFICER) </FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>aemd_10q-ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Quarterly
Report of Aethlon Medical, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-Q for the  six month period ended September 30,
2014 as filed with the Securities and Exchange Commission on the date hereof, I, James A. Joyce, Chief Executive Officer of
the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. Based on my knowledge, the Quarterly
Report on Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended,
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.1pt"><FONT STYLE="font-size: 10pt">Dated: November 10, 2014</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ JAMES A. JOYCE</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">James A. Joyce</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been provided to Aethlon Medical, Inc. and will be retained
by Aethlon Medical, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>aemd_10q-ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Quarterly
Report of Aethlon Medical, Inc. (the &ldquo;Registrant&rdquo;) on Form 10-Q for the  six month period ended September 30,
2014 as filed with the Securities and Exchange Commission on the date hereof, I, James B. Frakes, Chief Financial Officer of
the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. Based on my knowledge, the Quarterly
Report on Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended,
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.1pt"><FONT STYLE="font-size: 10pt">Dated: November 10, 2014</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ JAMES B. FRAKES</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>aemd-20140930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:aemd="http://aethlonmedical.com/20140930">
    <link:schemaRef xlink:href="aemd-20140930.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_NotesPayablePastDue10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:NotesPayablePastDue10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_NotesPayablePastDue12PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:NotesPayablePastDue12PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:AmendedRestatedSeriesA12PercentConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_ConvertibleNotes10Percent2008Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes10Percent2008Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_OctoberNovember2009ConvertibleNotes10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:OctoberNovember2009ConvertibleNotes10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_April2010ConvertibleNote10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:April2010ConvertibleNote10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_September2010ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:September2010ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_April2011ConvertibleNotes10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:April2011ConvertibleNotes10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_September2011ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:September2011ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_LawFirmNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:LawFirmNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:AmendedRestatedSeriesA12PercentConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:OctoberNovember2009ConvertibleNotes10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_April2010ConvertibleNote10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:April2010ConvertibleNote10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_September2010ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:September2010ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_April2011ConvertibleNotes10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:April2011ConvertibleNotes10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_LawFirmNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:LawFirmNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_NotesPayablePastDue12PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:NotesPayablePastDue12PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_NotesPayablePastDue10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:NotesPayablePastDue10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_DirectorsNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:DirectorsNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2010Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_ConvertibleNotes2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_ConvertibleNotes2010Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2010Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_ConvertibleNotes2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_ConvertibleNotes2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_ConvertibleNotes2010Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2010Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_ConvertibleNotes2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:ConvertibleNotes2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_VestingOfStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOfStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VestingOfStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOfStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_IncrementalFairValueOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:IncrementalFairValueOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_IncrementalFairValueOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:IncrementalFairValueOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_VestingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VestingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_DirectorsNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aemd:DirectorsNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_JulyAugust201110PercentNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:JulyAugust201110PercentNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">aemd:NoteBalanceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:HolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_ConversionAccruedInterestMember_custom_HolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">aemd:ConversionAccruedInterestMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:HolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_RestructuringFeeMember_custom_HolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">aemd:RestructuringFeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:HolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">aemd:NoteBalanceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:HolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_RestructuringFeeMember_custom_HolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">aemd:RestructuringFeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:HolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:OctoberNovember2009ConvertibleNotes10PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_September2010ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:September2010ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_custom_September2011ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:September2011ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_FourInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:FourInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_ThreeInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:ThreeInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_custom_MileStoneTwoPointFourPointTwoPointTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MileStoneTwoPointFourPointTwoPointTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_custom_MileStoneTwoPointFourPointTwoPointFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MileStoneTwoPointFourPointTwoPointFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-06-30_custom_MilestoneMNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MilestoneMNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_custom_MileStoneTwoPointThreePointTwoPointTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MileStoneTwoPointThreePointTwoPointTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_custom_MileStoneTwoPointThreePointThreePointTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MileStoneTwoPointThreePointThreePointTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30_custom_MilestoneMFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">aemd:MilestoneMFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_VestingOfStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOfStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VestingOfStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOfStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_IncrementalFairValueOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:IncrementalFairValueOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_IncrementalFairValueOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:IncrementalFairValueOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_VestingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VestingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_custom_JulyAugust201110PercentNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aemd:JulyAugust201110PercentNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2014-04-01to2014-09-30">Aethlon Medical Inc</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2014-04-01to2014-09-30">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2014-04-01to2014-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2014-04-01to2014-09-30">2014-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2014-04-01to2014-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2014-04-01to2014-09-30">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2014-04-01to2014-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2014-04-01to2014-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2014-04-01to2014-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2014-04-01to2014-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2014-04-01to2014-09-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2014-04-01to2014-09-30">2015</dei:DocumentFiscalYearFocus>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1473941</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">2144106</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">317072</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-03-31_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">450250</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-03-31_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">743600</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-03-31_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">253760</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">483421</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1367655</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">885000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_ConvertibleNotes10Percent2008Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_LawFirmNoteMember" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-09-30_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-09-30_custom_LawFirmNoteMember" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-09-30_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">283421</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-03-31_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">257655</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">190000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">390000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-03-31_NotesPayablePastDue10PercentMember" unitRef="USD" decimals="0">5000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-03-31_NotesPayablePastDue12PercentMember" unitRef="USD" decimals="0">185000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-09-30_NotesPayablePastDue12PercentMember" unitRef="USD" decimals="0">185000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-09-30_NotesPayablePastDue10PercentMember" unitRef="USD" decimals="0">5000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-09-30_custom_DirectorsNotesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-03-31_custom_DirectorsNotesMember" unitRef="USD" decimals="0">200000</us-gaap:NotesPayableCurrent>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">374312</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">374704</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-03-31_NotesPayablePastDue10PercentMember" unitRef="USD" decimals="0">6375</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-03-31_NotesPayablePastDue12PercentMember" unitRef="USD" decimals="0">353813</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-09-30_NotesPayablePastDue12PercentMember" unitRef="USD" decimals="0">367687</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-09-30_NotesPayablePastDue10PercentMember" unitRef="USD" decimals="0">6625</aemd:AccruedInterestOnNotesPayable>
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-09-30_custom_DirectorsNotesMember" unitRef="USD" xsi:nil="true" />
    <aemd:AccruedInterestOnNotesPayable contextRef="AsOf2014-03-31_custom_DirectorsNotesMember" unitRef="USD" decimals="0">14516</aemd:AccruedInterestOnNotesPayable>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-09-30" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-03-31" unitRef="USDPerShare" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">262713781</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-03-31" unitRef="Shares" decimals="INF">224973980</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">262713781</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-03-31" unitRef="Shares" decimals="INF">224973980</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Assets contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1089269</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1695102</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">411190</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">443027</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">411190</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">646242</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:Assets>
    <us-gaap:DepositsAssets contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">18988</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">18988</us-gaap:DepositsAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">107907</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">112489</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">70185</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">84279</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">892189</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1479346</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">41141</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">50699</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:DeferredFinanceCostsNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">66189</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">83191</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">258672</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">95177</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-03-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2014-09-30_NotesPayablePastDue12PercentMember" unitRef="Pure" decimals="INF">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2014-09-30_NotesPayablePastDue10PercentMember" unitRef="Pure" decimals="INF">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2014-11-07" unitRef="Shares" decimals="INF">295160194</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">526187</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1250279</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">125274</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">8754</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">47865</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">8754</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">478322</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:Cash>
    <us-gaap:Revenues contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">530371</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">840483</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">530371</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">840483</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">479075</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">644887</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-1773200</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-1013592</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-1294453</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-1013592</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">-445674</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-601192</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-229796</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-4592485</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-3653168</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-4202873</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">-3653168</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">-356539</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-888193</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-3349670</us-gaap:ProfitLoss>
    <aemd:WorkingCapital contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-2496000</aemd:WorkingCapital>
    <aemd:ConvertibleNotesPayableConversionsOne contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">-70000</aemd:ConvertibleNotesPayableConversionsOne>
    <aemd:ConvertibleNotesPayableConversionsTwo contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">-175000</aemd:ConvertibleNotesPayableConversionsTwo>
    <aemd:ConvertibleNotesPayableConversionsThree contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">-130250</aemd:ConvertibleNotesPayableConversionsThree>
    <aemd:ConvertibleNotesPayableConversionsThree contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">-405500</aemd:ConvertibleNotesPayableConversionsThree>
    <aemd:ConvertibleNotesPayableConversionsThree contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">-15000</aemd:ConvertibleNotesPayableConversionsThree>
    <aemd:ConvertibleNotesPayableConversionsFour contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">-25000</aemd:ConvertibleNotesPayableConversionsFour>
    <aemd:ConvertibleNotesPayableConversionsFour contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">-30000</aemd:ConvertibleNotesPayableConversionsFour>
    <aemd:ConvertibleNotesPayableConversionsFour contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">-60000</aemd:ConvertibleNotesPayableConversionsFour>
    <aemd:ConvertibleNotesPayableConversionsFive contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">0</aemd:ConvertibleNotesPayableConversionsFive>
    <aemd:ConvertibleNotesPayableConversionsFive contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">-25000</aemd:ConvertibleNotesPayableConversionsFive>
    <aemd:ConvertibleNotesPayableConversionsFive contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">-169000</aemd:ConvertibleNotesPayableConversionsFive>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">990520</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">776451</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-03-31_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">317072</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-03-31_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">448448</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-03-31_custom_September2011ConvertibleNotesMember" unitRef="USD" decimals="0">10931</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-09-30_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">225000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-09-30_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">317072</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2014-09-30_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">448448</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">10679067</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">106501</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2013-04-01to2013-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">106501</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2014-04-01to2014-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">10679067</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">276000</us-gaap:CashUninsuredAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-04-01to2014-09-30" unitRef="Shares" decimals="INF">141225399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">138279424</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">139672815</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">137935529</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">21502</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">863</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">19959</us-gaap:InterestExpenseDebt>
    <aemd:ConvertibleNotesPayableConversionsSix contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2009Member" unitRef="USD" decimals="0">0</aemd:ConvertibleNotesPayableConversionsSix>
    <aemd:ConvertibleNotesPayableConversionsSix contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">0</aemd:ConvertibleNotesPayableConversionsSix>
    <aemd:ConvertibleNotesPayableConversionsSix contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">-10931</aemd:ConvertibleNotesPayableConversionsSix>
    <aemd:IncreaseInConvertibleNotePayableExtensionFee contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2010Member" unitRef="USD" decimals="0">33972</aemd:IncreaseInConvertibleNotePayableExtensionFee>
    <aemd:IncreaseInConvertibleNotePayableExtensionFee contextRef="From2014-04-01to2014-09-30_custom_ConvertibleNotes2011Member" unitRef="USD" decimals="0">1171</aemd:IncreaseInConvertibleNotePayableExtensionFee>
    <us-gaap:InterestExpenseLongTermDebt contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">97362</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">3387956</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">15648817</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">10679067</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">888778</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">839070</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">609153</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">517651</us-gaap:AccountsPayableCurrent>
    <us-gaap:Liabilities contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">4378476</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">16425268</us-gaap:Liabilities>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">990520</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">776451</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1089269</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1695102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-3289207</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">-14730166</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">129135</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">218270</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-3418342</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">-14948436</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-79335907</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">-74832557</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">75654853</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">59659137</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">262712</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">224984</us-gaap:CommonStockValue>
    <us-gaap:OperatingExpenses contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">2303571</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">1854075</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1080267</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">874683</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">428097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">339014</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">227092</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">142323</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">1165040</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">863480</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">544354</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">404849</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">710434</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">651581</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">308821</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">327511</us-gaap:ProfessionalFees>
    <us-gaap:InterestAndDebtExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">144799</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">216443</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">78145</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">110405</us-gaap:InterestAndDebtExpense>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-2382877</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-2992002</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-04-01to2014-09-30" unitRef="Shares" decimals="INF">243494916</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">182004220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">259369911</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">187643582</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-04-01to2014-09-30" unitRef="USDPerShare" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-04-01to2013-09-30" unitRef="USDPerShare" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="USDPerShare" decimals="INF">-0.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="USDPerShare" decimals="INF">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-4503350</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-3653168</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-847409</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-3349670</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-89135</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-40784</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherExpenses contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">2819285</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">2639576</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">287001</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">3119874</us-gaap:OtherExpenses>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">18676</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">4727</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">260680</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">190601</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">162358</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">264343</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">21502</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">4578</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-1394366</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-744520</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">49708</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">91042</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">163646</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-33170</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-9558</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">25202</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">162495</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">11404</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">670274</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">628000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">670274</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">228000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-724092</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-116520</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <aemd:DebtAndAccruedInterestConvertedToCommonStock contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">1007631</aemd:DebtAndAccruedInterestConvertedToCommonStock>
    <aemd:DebtAndAccruedInterestConvertedToCommonStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">420460</aemd:DebtAndAccruedInterestConvertedToCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;1. NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ORGANIZATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon Medical, Inc. and subsidiary (&amp;#34;Aethlon&amp;#34;,&#13;the &amp;#34;Company&amp;#34;, &amp;#34;we&amp;#34; or &amp;#34;us&amp;#34;) is a medical device company focused on creating innovative devices that&#13;address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments&#13;is the Aethlon ADAPT&amp;#153; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges&#13;single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that&#13;selectively remove harmful particles from the entire circulatory system without loss of essential blood components. On June 25,&#13;2013, the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that allows us to&#13;initiate human feasibility studies of the Aethlon Hemopurifier&amp;#174; in the United States. Under the feasibility study protocol,&#13;we will enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety&#13;of Hemopurifier therapy. Successful completion of this study will allow us the opportunity to initiate pivotal studies that are&#13;required for market clearance to treat HCV and other disease conditions in the United States.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Successful outcomes of human trials will also&#13;be required by the regulatory agencies of certain foreign countries where we intend to sell this device. Some of our patents may&#13;expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications&#13;and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R) treatment technology.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2013, our subsidiary, Exosome Sciences,&#13;Inc. (&amp;#147;ESI&amp;#148;), commenced operations with a focus on advancing exosome-based strategies to diagnose and monitor the progression&#13;of cancer, infectious disease and other life-threatening conditions.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our common stock is quoted on the OTCQB marketplace&#13;administered by the OTC Markets Group under the symbol &amp;#34;AEMD.&amp;#34;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America&#13;(&amp;#147;GAAP&amp;#148;) for interim financial information and with the instructions to Form 10-Q and applicable sections of Regulation&#13;S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#13;In the opinion of management, all adjustments&amp;#160;necessary to make the financial statements not misleading have been included.&#13;The condensed consolidated balance sheet as of March 31, 2014 was derived from our audited financial statements. Operating results&#13;for the six months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending&#13;March 31, 2015. For further information, refer to our Annual Report on Form 10-K for the year ended March 31, 2014, which includes&#13;audited financial statements and footnotes as of March 31, 2014 and 2013 and for the years then ended.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 2. LIQUIDITY&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of&#13;assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses from operations and&#13;at September 30, 2014 are in default on certain debt agreements, have negative working capital of approximately $2,496,000, and&#13;have an accumulated deficit of approximately $79,336,000. These factors, among other matters, raise substantial doubt about our&#13;ability to continue as a going concern. A significant amount of additional capital will be necessary to advance the development&#13;of our products to the point at which they may become commercially viable. We intend to fund operations, working capital and other&#13;cash requirements for the fiscal year ending March 31, 2015 through debt and/or equity financing arrangements as well as through&#13;revenues and related cash receipts under our government contracts (see Note 12).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended September 30,&#13;2014, we converted a past due convertible note in the amount of $660,000 and related accrued interest into equity and also&#13;restructured and extended a formerly past due convertible note in the amount of $225,000. We also eliminated the antidilution&#13;price protection on all the remaining outstanding notes and warrants which held such price protection. The combination of all&#13;of those actions allowed us to reclassify our derivative liability in the amount of $10,679,067 into equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are currently addressing our liquidity issue&#13;by seeking additional investment capital through private placements of common stock and debt and by applying for additional grants&#13;issued by government agencies in the United States. We believe that our cash on hand and funds expected to be received from additional&#13;private investments will be sufficient to meet our liquidity needs for fiscal 2015. However, no assurance can be given that we&#13;will receive any funds in the form of revenues or in connection with capital raising activities in addition to the funds we have&#13;already received.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The successful outcome of future&#13;contract-based and fundraising activities cannot be determined at this time and there is no assurance that, even if achieved,&#13;we will have sufficient funds to execute our intended business plan or generate positive operating results.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements do not&#13;include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts&#13;or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of our significant accounting policies&#13;presented below is designed to assist the reader in understanding our condensed consolidated financial statements. Such financial&#13;statements and related notes are the representations of our management, who are responsible for their integrity and objectivity.&#13;These accounting policies conform to GAAP in all material respects, and have been consistently applied in preparing the accompanying&amp;#160;condensed&#13;consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PRINCIPLES OF CONSOLIDATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying condensed consolidated financial&#13;statements include the accounts of Aethlon Medical, Inc. and its majority-owned and controlled subsidiary, ESI. All significant&#13;intercompany balances and transactions have been eliminated in consolidation. The Company classifies the noncontrolling interests&#13;in ESI as part of consolidated net loss in the six months ended September 30, 2014 and includes the accumulated amount of noncontrolling&#13;interests as part of stockholders&amp;#146; equity. During the fiscal year ended March 31, 2014, ESI raised capital in the amount&#13;of $1,500,000 in exchange for the issuance of 300,000 shares of ESI common stock to ESI&amp;#146;s investors, representing 20% of&#13;ESI&amp;#146;s issued and outstanding capital stock. As a result, Aethlon Medical, Inc.&amp;#146;s ownership of ESI was reduced to 80%.&#13;If a further change in Aethlon Medical Inc.&amp;#146;s ownership of ESI results in loss of control and deconsolidation, any retained&#13;ownership interest will be remeasured with the gain or loss reported in our statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The losses at ESI during the six months ended&#13;September 30, 2014 reduced the noncontrolling interests on our consolidated balance sheet by $89,135 from $218,270 at March 31,&#13;2014 to $129,135 at September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;USE OF ESTIMATES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our condensed consolidated financial&#13;statements in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements&#13;and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among&#13;others, realization of long-lived assets, estimating fair value associated with debt and equity transactions and valuation of deferred&#13;tax assets. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CASH AND CASH EQUIVALENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards define &amp;#34;cash and cash&#13;equivalents&amp;#34; as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so&#13;near their maturity that they present insignificant risk of changes in value because of changes in interest rates. For the purpose&#13;of financial statement presentation, we consider all highly liquid investment instruments with original maturities of three months&#13;or less when purchased, or any investment redeemable without penalty or loss of interest to be cash equivalents. As of September&#13;30, 2014 and March 31, 2014, we had no assets that were classified as cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CONCENTRATIONS OF CREDIT RISKS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at two financial institutions&#13;in checking accounts and related cash management accounts. Accounts at these institutions are secured by the Federal Deposit Insurance&#13;Corporation (&amp;#34;FDIC&amp;#34;) up to $250,000. Our September 30, 2014 cash balances were approximately $276,000 over such insured&#13;amount. We do not believe that the Company is exposed to any significant risk with respect to its cash.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of our accounts receivable at September&#13;30, 2014 and March 31, 2014 and all of our revenue in the six month periods ended September 30, 2014 and 2013 were directly from&#13;the U.S. Department of Defense or from a subcontract under Battelle (defined herein), which is a prime contractor with the U.S.&#13;Department of Defense, and as such no allowance for uncollectable accounts receivable is deemed necessary at September 30, 2014&#13;or March 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amount of our cash, accounts receivable,&#13;accounts payable, and other current liabilities approximate their estimated fair values due to the short-term maturities of those&#13;financial instruments. The carrying amount of the notes payable approximates their fair value due to the short maturity of the&#13;notes and since the interest rate approximates current market interest rates for similar instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has concluded that it is not practical&#13;to determine the estimated fair value of amounts due to related parties because the transactions cannot be assumed to have been&#13;consummated at arm's length, the terms are not deemed to be market terms, there are no quoted values available for these instruments,&#13;and an independent valuation would not be practicable due to the lack of data regarding similar instruments, if any, and the associated&#13;potential costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 9 with respect to derivative liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PROPERTY AND EQUIPMENT&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation&#13;is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five&#13;years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement&#13;of property and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss&#13;included in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;INCOME TAXES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized&#13;for the future tax consequences attributable to the difference between the consolidated financial statements and their respective&#13;tax basis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets&#13;and liabilities for financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards.&#13;We record a valuation allowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable&#13;future, it is more likely than not that some portion of the deferred tax assets may not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment&#13;whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a&#13;long-lived asset is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized.&#13;We believe no impairment charges were necessary during the three and six month periods ended September 30, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;LOSS PER COMMON SHARE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing&#13;net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation.&#13;Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number&#13;of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common&#13;shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional&#13;potential common shares have been excluded as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2014 and 2013, a total of&#13;139,672,815 and 137,935,529 potential common shares, consisting of shares underlying outstanding stock options, warrants and convertible&#13;notes payable were excluded as their inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SEGMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, we operated in one segment that&#13;was based on our development of therapeutic devices. However in the December 2013 quarter, we initiated the operations of ESI to&#13;develop diagnostic tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic&#13;applications (See Note 14).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DEFERRED FINANCING COSTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs related to the issuance of debt are capitalized&#13;and amortized to interest expense over the life of the related debt using the effective interest method.&amp;#160;&amp;#160;We recorded&#13;amortization expense related to our deferred offering costs of $21,502 and $863 during the six month periods ended September 30,&#13;2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DARPA Contract -- With respect to revenue recognition,&#13;we entered into a government contract with DARPA and have recognized revenue under such contract. We adopted the Milestone method&#13;of revenue recognition for the DARPA contract under ASC 605-28 &amp;#147;Revenue Recognition &amp;#150; Milestone Method&amp;#148; and we&#13;believe we meet the requirements under ASC 605-28 for reporting contract revenue under the Milestone Method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In order to account for this contract, we identify&#13;the deliverables included within the contract and evaluate which deliverables represent separate units of accounting based on if&#13;certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received&#13;is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the&#13;separate units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is an event having all of the following&#13;characteristics:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) There is substantive uncertainty at the&#13;date the arrangement is entered into that the event will be achieved. A vendor&amp;#146;s assessment that it expects to achieve a&#13;milestone does not necessarily mean that there is not substantive uncertainty associated with achieving the milestone.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The event can only be achieved based in&#13;whole or in part on either: (a) the vendor&amp;#146;s performance; or (b) a specific outcome resulting from the vendor&amp;#146;s performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) If achieved, the event would result in additional&#13;payments being due to the vendor.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone does not include events for which&#13;the occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&amp;#146;s performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The policy for recognizing deliverable consideration&#13;contingent upon achievement of a milestone must be applied consistently to similar deliverables.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assessment of whether a milestone is substantive&#13;is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of&#13;the following for the milestone to be considered substantive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) The consideration is commensurate with either:&#13;(a) the vendor&amp;#146;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items&#13;as a result of a specific outcome resulting from the vendor&amp;#146;s performance to achieve the milestone;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The consideration relates solely to past&#13;performance; and&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) The consideration is reasonable relative&#13;to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is not considered substantive if&#13;any portion of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it&#13;does not relate solely to past performance). To recognize the milestone consideration in its entirety as revenue in the period&#13;in which the milestone is achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated&#13;into substantive and non-substantive components. In addition, if a portion of the consideration earned from achieving a milestone&#13;may be refunded or adjusted based on future performance, the related milestone is not considered substantive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 12 for the additional disclosure information&#13;required under ASC 605-28.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Battelle Subcontract -- We entered into a subcontract&#13;agreement with Battelle Memorial Institute (&amp;#147;Battelle&amp;#148;) in March 2013. Battelle was chosen by DARPA to be the prime&#13;contractor on the systems integration portion of the original DARPA contract and we are one of several subcontractors on that systems&#13;integration project. The Battelle subcontract is cost-reimbursable under a time and materials basis. We began generating revenues&#13;under the subcontract during the six months ended September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenue under this contract is a function&#13;of cost reimbursement plus an overhead mark-up for hours devoted to the project by specific employees (with specific hourly rates&#13;for those employees). Battelle engages us as needed. Each payment requires approval by the program manager at Battelle.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;STOCK-BASED COMPENSATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employee stock options and rights to purchase&#13;shares under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is&#13;measured when all granting activities have been completed, generally the grant date, based on the fair value of the award. The&#13;exercise price of options is generally equal to the market price of the Company's common stock (defined as the closing price as&#13;quoted on the OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity&#13;incentive awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance&#13;with the original provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards&#13;granted subsequent to April 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent&#13;accounting standards. We use a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes share-based compensation&#13;expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September&#13;30, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Six Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2013&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 68%"&gt;Vesting of Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;124,243&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Incremental fair value of option Modifications&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,914&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Vesting Expense Associated with CEO Restricted Stock Grant&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;64,444&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Weighted average number of common shares outstanding &amp;#150; basic and diluted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;243,494,916&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;182,004,220&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Basic and diluted loss per common share&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for transactions involving services&#13;provided by third parties where we issue equity instruments as part of the total consideration using the fair value of the consideration&#13;received (i.e. the value of the goods or services) or the fair value of the equity instruments issued, whichever is more reliably&#13;measurable. In transactions, when the value of the goods and/or services are not readily determinable and (1) the fair value of&#13;the equity instruments is more reliably measurable and (2) the counterparty receives equity instruments in full or partial settlement&#13;of the transactions, we use the following methodology:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;a) For transactions where goods have already&#13;been delivered or services rendered, the equity instruments are issued on or about the date the performance is complete (and valued&#13;on the date of issuance).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;b) For transactions where the instruments are&#13;issued on a fully vested, non-forfeitable basis, the equity instruments are valued on or about the date of the contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;c) For any transactions not meeting the criteria&#13;in (a) or (b) above, we re-measure the consideration at each reporting date based on its then current stock value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly&#13;basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting&#13;the forfeiture rate for all expense amortization after March 31, 2006 is recognized in the period the forfeiture estimate is changed.&#13;The effect of forfeiture adjustments for the six months ended September 30, 2014 was insignificant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PATENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents include both foreign and domestic patents.&#13;There were several patents pending at September 30, 2014. We capitalize the cost of patents and patents pending, some of which&#13;were acquired, and amortize such costs over the shorter of the remaining legal life or their estimated economic life, upon issuance&#13;of the patent. The unamortized costs of patents and patents pending are subject to our review for impairment under our long-lived&#13;asset policy above.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;STOCK PURCHASE WARRANTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We grant warrants in connection with the issuance&#13;of convertible notes payable and the issuance of common stock for cash. When such warrants are classified as equity and issued&#13;in connection with debt, we measure the relative estimated fair value of such warrants and record it as a discount from the face&#13;amount of the convertible notes payable. Such discounts are amortized to interest expense over the term of the notes using the&#13;effective interest method. Warrants issued in connection with common stock for cash, if classified as equity, are considered issued&#13;in connection with equity transactions and the warrant fair value is recorded to additional paid-in-capital. Lastly, warrants not&#13;meeting equity classification are recorded as derivative instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DERIVATIVE INSTRUMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We evaluate free-standing derivative instruments&#13;(or embedded derivatives) to properly classify such instruments within equity or as liabilities in our financial statements. Our&#13;policy is to settle instruments indexed to our common shares on a first-in-first-out basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The classification of a derivative instrument&#13;is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument&#13;is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract&#13;may be reclassified.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Instruments classified as derivative liabilities&#13;are remeasured each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement&#13;of operations in other (income) expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE&#13;NOTES PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The convertible feature of certain notes payable&#13;provides for a rate of conversion that is below market value. Such feature is normally characterized as a &amp;#34;Beneficial Conversion&#13;Feature&amp;#34; (&amp;#34;BCF&amp;#34;). We measure the estimated fair value of the BCF in circumstances in which the conversion feature&#13;is not required to be separated from the host instrument and accounted for separately, and record that value in the consolidated&#13;financial statements as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the&#13;term of the notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;REGISTRATION PAYMENT ARRANGEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for contingent obligations to make&#13;future payments or otherwise transfer consideration under a registration payment arrangement separately from any related financing&#13;transaction agreements, and any such contingent obligations are recognized only when it is determined that it is probable we will&#13;become obligated for future payments and the amount, or range of amounts, of such future payments can be reasonably estimated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We incurred research and development expenses&#13;during the three and six month periods ended September 30, 2014 and 2013, which are included in various operating expense line&#13;items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods&#13;were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;Three months ended&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;250,388&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;293,580&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Six months ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;637,723&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;626,638&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;OFF-BALANCE SHEET ARRANGEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have not entered into any off-balance sheet&#13;arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management is evaluating significant recent&#13;accounting pronouncements that are not yet effective for the Company, including the new accounting standard on revenue recognition,&#13;ASU 2014-09 (Topic 606), and has not yet concluded whether any such pronouncements will have a significant effect on the Company&amp;#146;s&#13;future consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NOTE 4. NOTES PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Notes payable consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal Balance&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal Balance&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%"&gt;12% Notes payable, past due&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;185,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;367,687&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;185,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;353,813&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;10% Note payable, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,625&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,375&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Directors&amp;#146; Note(s)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;200,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;14,516&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-indent: 27pt"&gt;Total&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;374,312&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;390,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;374,704&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended September 30, 2014,&#13;we recorded interest expense of $19,959 related to the contractual interest rates of our notes payable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;12% NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From August 1999 through May 2005, we entered&#13;into various borrowing arrangements for the issuance of notes payable from private placement offerings (the &amp;#34;12% Notes&amp;#34;).&#13;On April 21, 2010, a holder of $100,000 of the 12% Notes converted the principal balance and $71,758 of accrued interest into 687,033&#13;shares of common stock at an agreed conversion price of $0.25 per share. At September 30, 2014, the 12% Notes in the principal&#13;amount of $185,000 were past due, in default, and bearing interest at the default rate of 15%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;10% NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2014,&amp;#160;one 10% Note in&#13;the amount of $5,000 is past due and in default, remains outstanding and bears interest at the default rate of 15%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management's plans to satisfy the remaining&#13;outstanding balance on these 12% and 10% Notes include converting the notes to common stock at market value or repayment when funds&#13;are available.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DIRECTORS&amp;#146; NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2013, we borrowed $400,000 from two&#13;of our directors under two 90 day notes for $200,000 each bearing 10% interest (the &amp;#147;Notes&amp;#148;). At the discretion of&#13;the holders, if not paid off by October 9, 2013, the noteholders were entitled to (i) convert the principal and accrued interest&#13;under the Notes into shares of common stock at $0.088 per share (the &amp;#147;Conversion Price&amp;#148;) and (ii) receive warrants&#13;to purchase common stock equal to 50% of the principal converted under the Notes, with an exercise price of $0.132 per share. Additionally,&#13;there was a provision for a penalty interest rate of 12%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;That potential conversion price and warrant&#13;exercise price were based on the same pricing mechanism that we have used in prior equity unit financings since March 2012 (see&#13;Note 6) which are based on 80% of the then current market price of our common stock and with the warrant exercise price based on&#13;120% of the same then current market price. We initially reserved 6,931,818 shares of common stock to support the conversion of&#13;the Notes and accrued interest in full as well as the exercise of the warrants in full (should such conversion and/or issuance&#13;occur).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended March 31, 2014,&#13;the principal of $200,000 and accrued interest of $9,367 were paid on one of the Notes, which extinguished all potential common&#13;stock and warrant issuance provisions related to that Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended September 30, 2014,&#13;the holder of the second Note converted the principal of $200,000 and accrued interest of $20,349 into 2,503,966 shares of our&#13;common stock per the conversion formula of the Note (see Note 6).&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;5. CONVERTIBLE NOTES PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Convertible Notes Payable consisted of the following at September&#13;30, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Unamortized &lt;br /&gt;&#13;Discount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Net &lt;br /&gt;&#13;Amount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued &lt;br /&gt;&#13;Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 44%; padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Current Portion:&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;28,598&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2010 10% Convertible Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;35,188&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;July and August 2011 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;283,421&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;283,421&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;96,728&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Law Firm Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;9,479&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;483,422&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;483,422&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;169,993&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Non-Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Amended and Restated Series A 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;225,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;225,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2010 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,513&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;13,454&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Non-Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;990,520&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;990,520&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;31,967&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 44pt; text-indent: -9pt"&gt;Total Convertible Notes Payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;1,473,941&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;1,473,941&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;201,960&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;There were no discounts remaining on any of our Convertible Notes&#13;Payable as of September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;During the six months ended September 30, 2014, we recorded interest&#13;expense of $97,362 related to the contractual interest rates of our convertible notes and interest expense of $21,502 related to&#13;the amortization of deferred financing costs related to the convertible notes for a total interest related to convertible notes&#13;of $118,864.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Convertible Notes Payable consisted of the following at March 31,&#13;2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Unamortized &lt;br /&gt;&#13;Discount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Net &lt;br /&gt;&#13;Amount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued &lt;br /&gt;&#13;Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 44%; padding-left: 9pt; text-indent: -9pt"&gt;Amended and Restated Series A 12% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;885,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;885,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;575,250&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;2008 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,167&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26,097&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2010 10% Convertible Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,438&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;July and August 2011 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;90,256&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Law Firm Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;7,604&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;1,367,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;1,367,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;749,812&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Non-Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2010 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;35,034&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,117&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;10,931&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;10,931&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Non-Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;776,451&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;776,451&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;47,151&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 44pt; text-indent: -9pt"&gt;Total Convertible Notes Payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;2,144,106&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;2,144,106&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;796,963&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were no discounts remaining on any of&#13;our Convertible Notes Payable as of March 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;AMENDED AND RESTATED SERIES A 12% CONVERTIBLE&#13;NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2010, we entered into Amended and Restated&#13;Series A 12% Convertible Promissory Notes (the &amp;#34;Amended and Restated Notes&amp;#34;) with the holders of certain promissory notes&#13;previously issued by us, extending the due date to December 31, 2010 on the aggregate principal balance of $900,000. During the&#13;fiscal year ended March 31, 2013, the holders of $15,000 of the Notes converted their principal and related accrued interest into&#13;common stock. The balance remaining at March 31, 2014 was $885,000 and past due.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Weiner Note Conversion&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 24, 2014, we entered into an agreement&#13;with the Ellen R. Weiner Family Revocable Trust (the &amp;#147;Trust&amp;#148;), a holder of a Series A 12% Convertible Note (the &amp;#147;Note&amp;#148;),&#13;which previously was classified as being in default. As per the agreement, the Trust converted past due principal of $660,000 and&#13;accrued interest balance of $343,200 into restricted common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, the Trust agreed to waive anti-dilution&#13;price protection underlying warrants previously issued to the Trust. On June 26, 2014, three other parties who held similar warrants&#13;also agreed to waive their anti-dilution price protection.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under its agreement, the Trust converted the&#13;entire $1,003,200 past due principal and interest balance on the Note, which previously was in default, into an aggregate of 23,318,254&#13;restricted shares of our common stock and five-year warrants to acquire up to 6,809,524 shares of our common stock at an exercise&#13;price of $.042 per share (which exercise price was the result of certain contractual price adjustments previously made during 2011)&#13;and up to 397,222 shares of our common stock at an exercise price of $.108 per share (collectively, the &amp;#147;Conversion Securities&amp;#148;).&#13;Based on the fair value of the warrants and shares issued to the Trust for the accrued interest, we recorded a loss on settlement&#13;of notes of $1,791,421.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In exchange for the Trust&amp;#146;s conversion&#13;in full of the Note and accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants,&#13;in addition to the Conversion Securities, we issued to the Trust 75,000 restricted shares of common stock as a service fee, changed&#13;the exercise price of all of the previously issued warrants to $.042 per share and extended the expiration date of all of the previously&#13;issued warrants to July 1, 2018. We valued the 75,000 share service fee at $12,000 based on our closing price on the date of the&#13;agreement and recorded that value as interest expense during the June 2014 period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Bird Estate Extension&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 8, 2014, we executed a written restructuring&#13;agreement (the &amp;#147;Agreement&amp;#148;) with the Estate of Allan Bird (the &amp;#147;Estate&amp;#148;), a holder of a Series A 12% Convertible&#13;Note (the &amp;#147;Note&amp;#148;), which previously was classified as being in default. Since the negotiations for the Agreement were&#13;completed in the month of June, we recorded the impact of the Agreement as of June 30, 2014. In the Agreement, the Estate agreed&#13;to extend the expiration date of the Note to April 1, 2016, to convert approximately $116,970 of accrued interest to equity, and&#13;to waive anti-dilution price protection underlying the Note and warrants previously issued to the Estate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the Agreement, the Estate converted the&#13;entire $116,970 past due interest balance on the Note, which previously was in default, into an aggregate of 2,591,846 restricted&#13;shares of our common stock. The Estate received five-year warrants to acquire up to 2,321,429 shares of our common stock at an&#13;exercise price of $.042 per share (which exercise price was the result of certain contractual price adjustments previously made&#13;during 2011). Based on our common stock prices during a period of negotiation with the Estate including during calendar year 2013,&#13;the Estate also received five-year warrants to acquire up to 135,417 shares of our common stock at an exercise price of $.108 (collectively&#13;known as the &amp;#147;Conversion Securities&amp;#148;). Based on the fair value of the warrants and shares issued to the Estate for&#13;the accrued interest, we recorded a loss on settlement of notes of $663,209.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In exchange for the Estate&amp;#146;s extension&#13;of the Note, conversion of accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants,&#13;in addition to the Conversion Securities, we also issued to the Estate 25,000 restricted shares of common stock as an extension&#13;fee and extended the expiration date of all of the previously issued warrants to July 1, 2018. We valued the 25,000 share extension&#13;fee at $4,500 based on our closing price and recorded that value as a deferred financing cost, which we will amortize over the&#13;extended two year life of the note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;2008 10% CONVERTIBLE NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 17, 2014, we issued to the holder&#13;of the remaining 2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit&#13;warrants to acquire up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 6).&#13;The units were issued to the Note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest&#13;due under the Note, which represented the entire amount outstanding under the Note and the Note was retired. We recorded a loss&#13;on debt conversion of $65,493 on this transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;OCTOBER &amp;#38; NOVEMBER 2009 10% CONVERTIBLE&#13;NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October and November 2009, we raised $430,000&#13;from the sale to accredited investors of 10% convertible notes (&amp;#34;October &amp;#38; November 2009 10% Convertible Notes&amp;#34;).&#13;The October &amp;#38; November 2009 10% Convertible Notes matured at various dates between April 2011 and May 2011 and are convertible&#13;into our common stock at a fixed&amp;#160;conversion price of $0.25 per share. The investors also received matching three year warrants&#13;to purchase unregistered shares of our common stock at an exercise price of $0.25 per share. We measured the fair value of the&#13;warrants and the beneficial conversion feature of the Notes and recorded a 100% discount against the principal of the notes. Such&#13;discount was fully amortized at March 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, we issued 461,409 shares of common&#13;stock and 230,705 warrants to purchase common stock to the holder of a $25,000 note in this grouping in exchange for the conversion&#13;of such note and related accrued interest of $8,000 (for a total of $33,000). The warrants expired in 2012 and are exercisable&#13;at $0.107 per share (see Note 6). We recorded a loss on conversion of $45,796.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the conversions into&#13;principal of the October and November 2009 10% Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;450,250&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2010&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(70,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2011&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(175,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(130,250&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2012, we agreed to extend the expiration&#13;date and to change the exercise price of certain warrants of one of the note holders by two years in exchange for the extension&#13;of $50,000 of the October &amp;#38; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below)&#13;by that same two year period. We recorded a charge of $77,265 relating to this modification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2013, we agreed to extend the expiration&#13;date of certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &amp;#38;&#13;November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management&#13;assessed the change in the value of the notes and related warrants before and after that extension and determined that the change&#13;in value related to the change in terms was not significant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to September 30, 2014, we issued&#13;to the holder of the remaining October &amp;#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting&#13;of an aggregate of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common&#13;stock at an exercise price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of&#13;$189,087 of unpaid principal and accrued interest due under two promissory notes (the remaining October &amp;#38; November 2009 10%&#13;Convertible Note and the April 2010 10% Convertible Note). The amounts converted represented the entire principal and interest&#13;outstanding under the notes and the notes held by that holder were retired (see Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;APRIL 2010 10% CONVERTIBLE NOTE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2010, we raised $75,000 from the sale&#13;to an accredited investor of a 10% convertible note. The convertible note was originally scheduled to mature in October 2011 and&#13;is convertible into our common stock at a fixed conversion price of $0.25 per share prior to maturity. The investor also received&#13;three year warrants to purchase 300,000 unregistered shares of our common stock at a price of $0.25 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measured the fair value of the warrants and&#13;the beneficial conversion feature of the notes and recorded a 100% discount against the principal of the notes. We amortized this&#13;discount using the effective interest method over the term of the note. As of September 30, 2014, there have not been any conversions&#13;of the April 2010 10% Convertible Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2012, we agreed to extend the expiration&#13;date and to change the exercise price of certain warrants of the note holder by two years in exchange for his extension of $50,000&#13;of the October &amp;#38; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note by that same two year&#13;period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2013, we agreed to extend the expiration&#13;date of certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &amp;#38;&#13;November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management&#13;assessed the change in the value of the notes and related warrants before and after that extension and determined that the change&#13;in value related to the change in terms was not significant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to September 30, 2014, we issued&#13;to the holder of the remaining October &amp;#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting&#13;of an aggregate of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common&#13;stock at an exercise price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of&#13;$189,087 of unpaid principal and accrued interest due under two promissory notes (the remaining October &amp;#38; November 2009 10%&#13;Convertible Note and the April 2010 10% Convertible Note). The amounts converted represented the entire principal and interest&#13;outstanding under the notes and the notes held by that holder were retired (see Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SEPTEMBER 2010 10% CONVERTIBLE NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 3, 2010, we entered into a Subscription&#13;Agreement with three accredited investors (the &amp;#147;Purchasers&amp;#148;)&amp;#160;providing for the issuance and sale of convertible&#13;promissory notes and corresponding warrants in the aggregate principal amount of $1,430,000. The initial closing under the Subscription&#13;Agreement resulted in the issuance and sale of (i) convertible promissory notes in the aggregate principal amount of $743,600,&#13;(ii) five-year warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.31125 per share,&#13;and (iii) five-year warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.43575&#13;per share. The convertible promissory notes bear interest compounded monthly at the annual rate of ten percent (10%) and mature&#13;on April 1, 2016 (see below). The aggregate gross cash proceeds were $650,000, the balance of the principal amount representing&#13;a due diligence fee and an original issuance discount. The convertible promissory notes are convertible at the option of the holders&#13;into shares of our common stock at a price per share equal to eighty percent (80%) of the average of the three lowest closing bid&#13;prices of the common stock as reported by Bloomberg L.P. for the principal market on which the common stock trades or is quoted&#13;for the ten (10) trading days preceding the proposed conversion date. Subject to adjustment as described in the notes, the conversion&#13;price may not be more than $0.30 nor less than $0.20. There are no registration requirements with respect to the shares of common&#13;stock underlying the notes or the warrants.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2014, we entered into separate&#13;Amendments to Convertible Notes and Warrants (collectively, the &amp;#147;Amendments&amp;#148;) with three accredited investors (collectively,&#13;the &amp;#147;Investors&amp;#148;) who own certain convertible promissory notes (collectively, the &amp;#147;Notes&amp;#148;) and warrants&#13;(collectively, the &amp;#147;Warrants&amp;#148;) previously issued by us on various dates between December 5, 2007 and September 23,&#13;2011, including the September 2010 Convertible Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Amendments, the Notes were past&#13;maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended&#13;the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result&#13;of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per&#13;annum, which represents a reduction from the default interest rates of fifteen percent at which interest had been accruing. By&#13;entering into the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12% from a&#13;total of $693,260 to a total of $776,451.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period from October 2011 to February&#13;2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding&#13;under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions&#13;applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,&#13;pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&amp;#146;s Common Stock, which&#13;represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected&#13;at $.042 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Amendments also set the conversion price&#13;of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per&#13;share. By virtue of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015&#13;and September 23, 2016 to January 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the activity in the&#13;September 2010 10% Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in the September 2010 10% Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;743,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(405,500&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(30,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Increase in principal balance due to 12% extension fee&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,972&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;APRIL 2011 10% CONVERTIBLE NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2011, we entered into a Subscription&#13;Agreement with two accredited investors (the &amp;#147;Purchasers&amp;#148;) providing for the issuance and sale of convertible promissory&#13;notes and corresponding warrants in the aggregate principal amount of $385,000. The closing under the Subscription Agreement resulted&#13;in the issuance and sale by us of (i) convertible promissory notes in the aggregate principal amount of $385,000, (ii) five-year&#13;warrants to purchase an aggregate of&amp;#160;4,004,000 shares of our common stock at an exercise price of $0.125 per share, and (iii)&#13;five-year warrants to purchase an aggregate of&amp;#160;4,004,000 shares of our common stock at an exercise price of $0.175 per share.&#13;The convertible promissory notes bear interest compounded monthly at the annual rate of 10% and mature on April 1, 2016 (see below).&#13;The aggregate gross cash proceeds to us were $350,000, the balance of the principal amount representing a due diligence fee and&#13;an original issuance discount. The convertible promissory notes are convertible at the option of the holders into shares of our&#13;common stock at a price per share equal to eighty percent (80%) of the average of the three lowest closing bid prices of the common&#13;stock as reported by Bloomberg L.P. for the principal market on which the common stock trades or is quoted for the ten (10) trading&#13;days preceding the proposed conversion date. Subject to adjustment as described in the notes, the conversion price may not be more&#13;than $0.20 nor less than $0.10. There are no registration requirements with respect to the shares of common stock underlying the&#13;notes or the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, we issued (i) five-year warrants&#13;to purchase an aggregate of 812,500 shares of our common stock at an exercise price of $0.125 per share, and (ii) five-year warrants&#13;to purchase an aggregate of&amp;#160;812,500 shares of our common stock at an exercise price of $0.175 per share to the Purchasers.&#13;These warrants were issued as an antidilution adjustment under certain common stock purchase warrants held by the Purchasers that&#13;were acquired from us in September 2010.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2014, we entered into separate&#13;Amendments to Convertible Notes and Warrants (collectively, the &amp;#147;Amendments&amp;#148;) with three accredited investors (collectively,&#13;the &amp;#147;Investors&amp;#148;) who own certain convertible promissory notes (collectively, the &amp;#147;Notes&amp;#148;) and warrants&#13;(collectively, the &amp;#147;Warrants&amp;#148;) previously issued by us on various dates between December 5, 2007 and September 23,&#13;2011, including the April 2011 Convertible Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Amendments, the Notes were past&#13;maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended&#13;the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result&#13;of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per&#13;annum, which represents a reduction from the default interest rates of 15% at which interest had been accruing. By entering into&#13;the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12% from a total of $693,260&#13;to a total of $776,451.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period from October 2011 to February&#13;2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding&#13;under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions&#13;applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,&#13;pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&amp;#146;s Common Stock, which&#13;represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected&#13;at $.042 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Amendments also set the conversion price&#13;of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per&#13;share. By virtue of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015&#13;and September 23, 2016 to January 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2014, there have not been&#13;any conversions of the April 2011 10% Convertible Notes and the 12% extension fee noted above increased the principal balance by&#13;$48,048 to a principal balance of $448,448.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;JULY &amp;#38; AUGUST 2011 10% CONVERTIBLE NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2011, we raised $357,656 in five separate 10% convertible notes. Those notes had a fixed conversion price of $0.09 per share and&#13;carried an interest rate of 10%. The convertible notes matured in July and August 2012. We also issued those investors five year&#13;warrants to purchase 3,973,957 shares of common stock at $0.125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measured the fair value of the warrants and&#13;the beneficial conversion feature of the notes and recorded a $257,926 discount against the principal of the notes. We amortized&#13;this discount using the effective interest method over the term of the note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective March 31, 2014, the holders of three&#13;of the five notes totaling $100,000 converted all of their principal and accrued interest into 1,438,700 shares of our common stock&#13;at the contractual conversion price of $0.09 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2014, we entered into a forbearance&#13;agreement with the holder of the remaining two notes in which we agreed to repay his notes by October 31, 2014 and in which we&#13;also agreed to extend his warrants by two years. We recorded a charge of $143,363 in the September 2014 period related to this&#13;warrant extension due to the change in the fair value of the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to September 30, 2014, we paid off&#13;in full the remaining outstanding principal balance and interest balances on the two remaining notes with cash payments of $382,748&#13;(see Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SEPTEMBER 2011 CONVERTIBLE NOTES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2011, we issued $253,760 of convertible&#13;notes, convertible at $0.07 per share. Such notes originally matured in September 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2014, we entered into separate&#13;Amendments to Convertible Notes and Warrants (collectively, the &amp;#147;Amendments&amp;#148;) with three accredited investors (collectively,&#13;the &amp;#147;Investors&amp;#148;) who own certain convertible promissory notes (collectively, the &amp;#147;Notes&amp;#148;) and warrants&#13;(collectively, the &amp;#147;Warrants&amp;#148;) previously issued by us on various dates between December 5, 2007 and September 23,&#13;2011, including the September 2011 Convertible Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Amendments, the Notes were past&#13;maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended&#13;the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result&#13;of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per&#13;annum, which represents a reduction from the default interest rates of 15% at which interest had been accruing. By entering into&#13;the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12%, which in the case of&#13;the September 2011 Notes, they increased from $9,760 to $10,931&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period from October 2011 to February&#13;2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding&#13;under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions&#13;applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,&#13;pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&amp;#146;s Common Stock, which&#13;represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected&#13;at $.042 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Amendments also set the conversion price&#13;of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per&#13;share. By virtue of the Amendments, the expiration dates of the Warrants also were extended to January 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the conversions into&#13;principal of the September 2011 Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in the September 2011 Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;253,760&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(15,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(60,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(169,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Increase in principal balance due to extension fee&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,171&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(10,931&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As noted in the above table, the remaining balance&#13;of the September 2011 Convertible Notes converted into equity during the six months ended September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;LAW FIRM NOTE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 22, 2012, we entered into a Promissory&#13;Note with our corporate law firm for the amount of $75,000, which represented the majority of the amount we owed to that firm&#13;at that time. The Promissory Note originally had a maturity date of December 31, 2012 and bears interest at 5% per annum. The&#13;note is convertible at the option of the holder into shares of our common stock at a 10% discount to the market price of the common&#13;stock on the date prior to conversion with a floor price on such conversions of $0.08 per share. The holder subsequently agreed&#13;to extend the Maturity Date of the Note first to October 1, 2013, then to September 30, 2013, and now the expiration date of this&#13;note is again extended to October 1, 2014. As of September 30, 2014, there have not been any conversions of the Law Firm Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we paid off in full the outstanding principal balance and interest balance on the note with a cash payment of $50,000 and an issuance&#13;of 170,020 common shares (see Note 15).&lt;/font&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;6. EQUITY TRANSACTIONS&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;COMMON STOCK AND WARRANTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following are Aethlon Medical, Inc.&amp;#146;s&#13;Equity Transactions in the Six Months Ended September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the three months ended June 30, 2014, we&#13;completed unit subscription agreements with seven accredited investors pursuant to which we issued 2,192,444 shares of our common&#13;stock and 1,096,222 warrants to purchase our common stock for net cash proceeds of $320,800. Such warrants have exercise prices&#13;ranging from $0.193 to $0.236 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As discussed above in Note 5, during the three&#13;months ended June 30, 2014, we issued 15,714,286 shares of restricted common stock to the holder of one of the Series A 12% Convertible&#13;Notes in exchange for the conversion in full of the $660,000 principal balance of that note, 7,603,968 shares of restricted common&#13;stock in exchange for conversion of $343,200 of accrued interest and 75,000 shares of restricted common stock as a restructuring&#13;fee. During that period, we also issued the other holder of the Series A 12% Convertible Notes 2,591,846 shares of restricted common&#13;stock in exchange for conversion of $116,970 of accrued interest and 25,000 shares of restricted common stock as a restructuring&#13;fee.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended June 30, 2014,&#13;we issued 219,127 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an&#13;average price of $0.17 per share in payment for legal services, internal controls consulting services and regulatory consulting&#13;services collectively valued at $38,268 based on the value of the services provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2014, we issued 359,956 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan&#13;at an average price of $0.14 per share in payment for legal and scientific consulting services valued at $49,090 based on the value&#13;of the services provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2014, we issued 390,301 shares of restricted common stock at an average price of $0.19 per share in payment for investor relations&#13;consulting services valued at $75,000 based on the value of the services provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2014, we issued 1,937,505 shares of restricted common stock to the holders of three convertible notes in exchange for the partial&#13;or full conversion of principal and interest in the aggregate amount of $81,375 at a conversion price of $0.042 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2014, we issued an aggregate of&#13;2,503,966 shares of restricted common stock and a seven-year warrant to issue up to 1,251,983 shares of common stock at an exercise&#13;price of $0.132 per share to Dr. Chetan Shah, a director. The common stock and warrant were issued to Dr. Shah upon the conversion&#13;of an aggregate of $220,349 of unpaid principal and accrued interest due under a 10% Convertible Note previously issued to Dr.&#13;Shah by us on July 9, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 17, 2014, we issued to the holder&#13;of the remaining 2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit&#13;warrants to acquire up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 5).&#13;The units were issued to the note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest&#13;due under the promissory note, which represented the entire amount outstanding under the note. We recorded a loss on debt conversion&#13;of $65,493 on this transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2014, we issued to four investors 2,673,231 shares of restricted common stock through the cash exercise of eight warrants for $259,474&#13;of cash at an average exercise price of approximately $0.10 per share. As an inducement to those investors, we issued them replacement&#13;warrants to acquire up to an aggregate of 2,673,231 shares of common stock on the same terms as the warrants they exercised.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,&#13;2014, we issued and sold to three accredited investors units consisting of (a) one hundred thousand (100,000) restricted shares&#13;of our common stock, par value $.001 per share, at prices per share ranging from $0.091 to $0.094 and (b) a five-year warrant to&#13;purchase fifty thousand (50,000) shares of common stock at exercise prices ranging from $0.136 to $0.143 per share. In total, the&#13;investors purchased for cash an aggregate of $90,000 of units. The investors acquired an aggregate of 974,982 shares of common&#13;stock and warrants to acquire up to an aggregate of 487,491 shares of Common Stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;7. RELATED PARTY TRANSACTIONS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DUE TO RELATED PARTIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain of our officers and other related parties&#13;have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working capital deficiencies.&#13;These unsecured and non-interest-bearing liabilities have been included as due to related parties in the accompanying consolidated&#13;balance sheets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other related party transactions are disclosed&#13;elsewhere in these notes to consolidated financial statements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;8. OTHER CURRENT LIABILITIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities were comprised of&#13;the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;Accrued interest&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;570,741&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;1,165,335&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Accrued legal fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;179,465&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;179,465&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Accrued liquidated damages&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;362,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;362,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Other accrued liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;103,598&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;147,774&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Total other current liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,216,604&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,855,374&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of the date of this report, various promissory&#13;and convertible notes payable in the aggregate principal amount of $473,422 (as identified in Notes 4 and 5 above) have reached&#13;maturity and are past due. We are continually reviewing other financing arrangements to retire all past due notes. At September&#13;30, 2014, we had accrued interest in the amount of $471,041 associated with these defaulted notes in accrued liabilities payable&#13;(see Notes 4 and 5).&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;9. FAIR VALUE MEASUREMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We follow FASB ASC 820, &amp;#34;FAIR VALUE MEASUREMENTS&#13;AND DISCLOSURES&amp;#34; (&amp;#147;ASC 820&amp;#148;) in connection with assets and liabilities measured at fair value on a recurring basis&#13;subsequent to initial recognition. The guidance applies to our derivative liabilities. We had no assets or liabilities measured&#13;at fair value on a non-recurring basis for any period reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 820 requires that assets and liabilities&#13;carried at fair value will be classified and disclosed in one of the following three categories: We measure the fair value of applicable&#13;financial and non-financial assets based on the following fair value hierarchy:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1: Quoted market prices in active markets&#13;for identical assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2: Observable market based inputs or unobservable&#13;inputs that are corroborated by market data.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3: Unobservable inputs that are not corroborated&#13;by market data.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The hierarchy noted above requires us to minimize&#13;the use of unobservable inputs and to use observable market data, if available, when determining fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of our recorded derivative liabilities&#13;is determined based on unobservable inputs that are not corroborated by market data, which is a Level 3 classification. We record&#13;derivative liabilities on our balance sheet at fair value with changes in fair value recorded in our consolidated statements of&#13;operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2014, we no longer had any&#13;derivative liabilities as all of the holders of the financial instruments that had price antidilution protection waived such price&#13;antidilution protection.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our fair value measurements at the March 31,&#13;2014 reporting date are classified based on the valuation technique level noted in the table below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;Description&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;March 31, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Quoted Prices &lt;br /&gt;&#13;in Active Markets for &lt;br /&gt;&#13;(Level 1)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Significant Other Observable &lt;br /&gt;&#13;(Level 2)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Significant &lt;br /&gt;&#13;Unobservable &lt;br /&gt;&#13;(Level 3)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%"&gt;Derivative Liabilities&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Total Assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following outlines the significant weighted&#13;average assumptions used to estimate the fair value information presented, in connection with our warrant and embedded conversion&#13;option derivative instruments utilizing the Binomial Lattice option pricing model:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The following&#13;outlines the significant weighted average assumptions used to estimate the fair value information presented, in connection with&#13;our warrant and embedded conversion option derivative instruments utilizing the Binomial Lattice option pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.02% - 0.62%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0.25 &amp;#150; 3 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;78.9% - 104.5%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth a summary of changes&#13;in the fair value of our Level 3 financial instruments for the six months ended September 30, 2014: &amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;April 1, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Recorded New Derivative &lt;br /&gt;&#13;Liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Change in estimated fair value recognized in results of operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Reclassification &lt;br /&gt;&#13;of Derivative &lt;br /&gt;&#13;Liability to Paid &lt;br /&gt;&#13;in capital&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 30%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Derivative liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(10,679,067&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth a summary of changes&#13;in the fair value of our Level 3 financial instruments for the six months ended September 30, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Change in&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Reclassification&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;estimated fair&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;of Derivative&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Recorded&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;value recognized&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Liability to&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;April 1,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;New Derivative&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;in results&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Paid in&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;of operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;capital&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 30%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Derivative liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,588,239&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,382,877&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(106,501&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,864,615&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;10. STOCK COMPENSATION&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table breaks out the components&#13;of our share-based compensation expenses relating to shares and options granted and the effect on basic and diluted loss per common&#13;share during the three and six months ended September 30, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Three Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Three Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Six Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Six Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 36%"&gt;Vesting of stock options&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;73,856&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;124,243&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Incremental fair value of option modifications&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;957&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,914&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Vesting expense associated with CEO restricted stock grant&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;64,444&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Total share-based compensation expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;74,813&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Total share-based compensation expense included in net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;73,856&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Weighted average number of common shares outstanding &amp;#150; basic and diluted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;259,369,911&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;187,643,582&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;243,494,916&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;182,004,220&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Basic and diluted loss per common share&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the stock-based compensation expense&#13;recorded during the six months ended September 30, 2014 and 2013, which totaled $260,680 and $190,601, respectively, is included&#13;in payroll and related expense in the accompanying condensed consolidated statements of operations.&amp;#160; Stock-based compensation&#13;expense recorded during the six months ended September 30, 2014 and 2013 had no impact on basic and diluted loss per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly&#13;basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of&#13;adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The&#13;effect of forfeiture adjustments for the three and six month periods ended September 30, 2014 was insignificant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 6, 2014, our Board of Directors approved&#13;the following grants of options to certain officers and directors of the Company:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px"&gt;o&lt;/td&gt;&#13;    &lt;td&gt;To Mr. James A. Joyce, an option to acquire an aggregate of 1,500,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $246,000.&amp;#160;&amp;#160;The option vested as to 500,000 shares on the grant date for a vesting expense of $82,000 and will vest as to an additional 500,000 shares on each of the first two anniversaries of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px"&gt;o&lt;/td&gt;&#13;    &lt;td&gt;To Mr. Rodney S. Kenley, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000.&amp;#160;&amp;#160;The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px"&gt;o&lt;/td&gt;&#13;    &lt;td&gt;To Mr. James B. Frakes, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000. The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px"&gt;o&lt;/td&gt;&#13;    &lt;td&gt;To Dr. Richard H. Tullis, an option to acquire an aggregate of 50,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $8,200. The option vested as to 16,667 shares on the grant date for a vesting expense of $2,733 and will vest as to an additional 16,667 shares on the first anniversary of the grant date and 16,666 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024. &lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the above grants to our officers,&#13;on June 6, 2014, our Board of Directors also approved the grant of options to five employees to acquire an aggregate of 370,000&#13;shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant.&#13;The aggregate fair value of those stock options at the date of grant was $60,680. Those options vested as to 123,333 shares on&#13;the grant date for a vesting expense of $20,227 and will vest as to an additional 123,333 shares on the first anniversary of the&#13;grant date and 123,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will&#13;expire June 6, 2024.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the share-based compensation&#13;expense for the specific stock option grants noted above, our total share-based compensation expense for the three and six months&#13;ended September 30, 2014 includes ongoing vesting expense associated with stock grants from prior periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Changes to 2012 Board Compensation Program&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, the Board approved a Board Compensation&#13;Program (the &amp;#147;2012 Program&amp;#148;), which modified and superseded the 2005 Directors Compensation Program that had been in&#13;effect previously. On June 6, 2014, the Board approved certain changes to the 2012 Program. Under the modified 2012 Program, in&#13;which only non-employee Directors may participate, a new eligible Director will receive an initial grant of $50,000 worth of options&#13;to acquire shares of common stock, with such grant being valued at the exercise price based on the average of the closing bid prices&#13;of our common stock for the five trading days preceding the first day of the fiscal year. These options will have a term of ten&#13;years and will vest 1/3 upon grant and 1/3 upon each of the first two anniversaries of the date of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the beginning of each fiscal year, each existing&#13;Director eligible to participate in the 2012 Program also will receive a grant of $35,000 worth of options valued at the exercise&#13;price based on the average of the closing bid prices of the Common Stock for the five trading days preceding the first day of the&#13;fiscal year. Such options will vest on the first anniversary of the date of grant. In lieu of per meeting fees, under the 2012&#13;Program eligible Directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program also provides for the&#13;following annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000, Audit Committee member -&#13;$4,000, Compensation Committee member - $4,000 and Lead independent director - $15,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of the modified 2012 Program on&#13;June 6, 2014, we issued 184,211 stock options to each of our three outside directors. Those grants vest over the fiscal year ending&#13;March 31, 2015 and have an exercise price of $0.19 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the foregoing actions - the changes in&#13;base salaries, the option grants and the changes to the Directors Compensation Program discussed herein - were approved and recommended&#13;by the Company&amp;#146;s Compensation Committee prior to approval by the Board.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following outlines the significant weighted&#13;average assumptions used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial&#13;Lattice option pricing models at, and during the six months ended September 30, 2014:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;2.6%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;10 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;90.23%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The expected volatility was based on the historic&#13;volatility. The expected life of options granted was based on the &amp;#34;simplified method&amp;#34; as described in the SEC's guidance&#13;due to changes in the vesting terms and contractual life of current option grants compared to our historical grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2013, we granted to a scientific advisory&#13;board member and a scientific consultant a three year option to purchase 125,000 shares of our common stock at a price of $0.11&#13;per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2013, &lt;font style="background-color: white"&gt;our&#13;compensation committee and Board of Directors approved the issuance of four stock option grants to four of our executives. The&#13;options carried an exercise price of $0.10 per share, have a ten year life and vest over the following schedule: 25% on July 1,&#13;2014, 25% on July 1, 2015, 25% on July 1, 2016 and 25% on July 1, 2017. The numbers of shares underlying each of the stock option&#13;grants were as follows: 2,000,000 shares to our chief executive officer and 500,000 shares each to our president, chief science&#13;officer and chief financial officer (see Note 10).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following outlines the significant weighted&#13;average assumptions used to estimate the fair value information, which is based on historical data, with respect to stock option&#13;grants utilizing the Binomial Lattice option pricing models at, and during the six months ended September 30, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.38% - 2.50%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;3 years - 10 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;94.6% - 102.7%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The expected volatility was based on the historic&#13;volatility. The expected life of options granted was based on the &amp;#34;simplified method&amp;#34; as described in the SEC's guidance&#13;due to changes in the vesting terms and contractual life of current option grants compared to our historical grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options outstanding that have vested and are&#13;expected to vest as of September 30, 2014 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Term in Years&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Vested&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;24,294,227&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.26&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;3.96&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected to vest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;4,711,811&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.15&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;Total&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 0.25in; text-align: right"&gt;29,006,038&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the six months ended September&#13;30, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average &lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Stock options outstanding at March 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;26,133,407&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.25&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,972,631&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Stock options outstanding at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;29,006,038&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Stock options exercisable at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;24,294,227&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.26&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2014, there was approximately&#13;$497,783 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted&#13;average period of 2.19 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 30, 2014, our stock options had&#13;a negative intrinsic value since the closing price of our common stock on that date of $0.12 per share was below the weighted&#13;average exercise price of our stock options.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;11. WARRANTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of warrant activity during the six&#13;months ended September 30, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Warrants outstanding at March 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;70,709,475&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.13&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(2,166,104&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.086 &amp;#150; $0.12&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Issued&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15,375,614&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.24&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1,136,364&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.13&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.13&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Warrants outstanding at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;82,782,621&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Warrants exercisable at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;82,782,621&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following outlines the significant weighted&#13;average assumptions used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice&#13;option pricing models at, and during, the six months ended September 30, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.79% - 2.29%&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5 years &amp;#150; 7 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;90.1% - 95.8%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <aemd:DarpaContractAndRelatedRevenueRecognition contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As discussed in Note 1, we entered into a contract&#13;with the DARPA on September 30, 2011. Under the DARPA award, we have been engaged to develop a therapeutic device to reduce the&#13;incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from DARPA&#13;was a fixed-price contract with potential total payments to us of $6,794,389 over the course of five years. Fixed price contracts&#13;require the achievement of multiple, incremental milestones to receive the full award during each year of the contract. Under the&#13;terms of the contract, we will perform certain incremental work towards the achievement of specific milestones against which we&#13;will invoice the government for fixed payment amounts.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Originally, only the base year (year one contract)&#13;was effective for the parties, however, DARPA subsequently exercised the option on the second, third and fourth years of the contract.&#13;DARPA has the option to enter into the contract for year five. The milestones are comprised of planning, engineering and clinical&#13;targets, the achievement of which in some cases will require the participation and contribution of third party participants under&#13;the contract. There can be no assurance that we alone, or with third party participants, will meet such milestones to the satisfaction&#13;of the government and in compliance with the terms of the contract or that we will be paid the full amount of the contract revenues&#13;during any year of the contract term. We commenced work under the contract in October 2011.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to budget restrictions within the Department&#13;of Defense, on February 10, 2014, DARPA reduced the scope of our contract in years three through five of the contract. The reduction&#13;in scope focused our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible&#13;payments under the contract by $858,491 over years three through five. We recently completed a re-budgeting of the expected costs&#13;on the remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs&#13;due to the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended September 30, 2014,&#13;we invoiced DARPA for three milestones totaling $444,723. The details of those milestones were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone 2.4.2.2 &amp;#150; Determine capacity&#13;requirements of affinity resin to multiple simultaneous targets. The milestone payment was $197,362. Management considers this&#13;milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&amp;#160;&amp;#160;We&#13;demonstrated that we were able to determine the capacity requirements of affinity resin to multiple simultaneous targets.&amp;#160;&amp;#160;The&#13;report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone 2.4.2.4 &amp;#150; Finish construction&#13;and delivery of 25 experimental cartridges for testing by the system integrator. The milestone payment was $50,000. Management&#13;considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's&#13;efforts.&amp;#160;&amp;#160;We demonstrated that we delivered the 25 cartridges to the systems integrator as part of our submission for&#13;approval.&amp;#160;&amp;#160;The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone M9 &amp;#150; Target capture &amp;#62; 90%&#13;in 24 hours for at least 3 targets ex vivo in blood or blood components using the optimized cartridge. The milestone payment was&#13;$197,361. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based&#13;solely on another party's efforts.&amp;#160;&amp;#160;We demonstrated that we were able to capture approximately 90% in 24 hours for at&#13;least 3f targets ex vivo in blood or blood components using the optimized cartridge.&amp;#160;&amp;#160;The report was accepted by the&#13;contracting officer's representative and the invoice was submitted thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the six months ended September 30, 2013,&#13;we invoiced DARPA for four milestones totaling $808,739.&amp;#160;&amp;#160;The details of those milestones were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone 2.3.2.2 &amp;#150; Formulate initial&#13;design work based on work from the previous phase. Begin to build and test selected instrument design and tubing sets. The milestone&#13;payment was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor&#13;was it based solely on another party's efforts.&amp;#160;&amp;#160;We demonstrated that we were able to formulate the initial design work&#13;and to build and test selected instrument design and tubing sets as part of our submission for approval.&amp;#160;&amp;#160;The report&#13;was accepted by the contracting officer's representative and the invoice was submitted thereafter.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone 2.3.2.2 &amp;#150; Write and test software&#13;and conduct ergonomic research. Begin discussions with the systems integrator. The milestone payment was $195,581. Management considers&#13;this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&amp;#160;&amp;#160;We&#13;obtained wrote and tested software and conducted ergonomic research and began discussions with the systems integrator. The report&#13;was accepted by the contracting officer's representative and the invoice was submitted thereafter.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone 2.3.3.2 &amp;#150; Cartridge construction&#13;with optimized affinity matrix design for each potential target. Complete the capture agent screening. The milestone payment was&#13;$208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based&#13;solely on another party's efforts.&amp;#160;&amp;#160;We completed the cartridge construction with optimized affinity matrix design for&#13;each potential target and completed the capture agent screening. The report was accepted by the contracting officer's representative&#13;and the invoice was submitted thereafter.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone M5 &amp;#150; Target capture &amp;#62; 90%&#13;in 24 hours for at least three targets in blood or blood components. The milestone payment was $208,781. Management considers&#13;this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&amp;#160;&amp;#160;We&#13;demonstrated that we were able to capture approximately 90% in 24 hours for at least three of the agreed targets in blood or blood&#13;components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.&lt;/p&gt;</aemd:DarpaContractAndRelatedRevenueRecognition>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;LEASE COMMITMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We rented approximately 2,300 square feet of&#13;executive office space at 8910 University Center Lane, Suite 660, San Diego, CA 92122 at the rate of $6,475 per month on a four&#13;year lease that expired in September 2014. We continued leasing that space for the month of October and, effective November 1,&#13;2014, moved into a new facility of approximately 2,576 square feet located at 9635 Granite Ridge Drive, San Diego&lt;i&gt;, &lt;/i&gt;CA 92123&#13;under a 39 month lease with an initial rental rate of $6,054 per month. We believe this new leased facility will be satisfactory&#13;for our office needs over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also rent approximately 1,700 square feet&#13;of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $3,917 per month on a&#13;one year lease that previously was scheduled to expire in October 2014 and was recently extended to in October 2015. We believe&#13;this new leased facility will be satisfactory for our laboratory needs over the term of the lease&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our Exosome Sciences, Inc. subsidiary rents&#13;approximately 2,055 square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at the rate of $3,596&#13;per month on a one year lease that previously was scheduled to expire in October 2014 and was recently extended to in October 2015.&#13;We believe this new leased facility will be satisfactory for ESI&amp;#146;s operational needs over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense approximated $84,000 and $68,000&#13;for the six month periods ended September 30, 2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;LEGAL MATTERS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, claims are made against us&#13;in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent&#13;uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from&#13;selling one or more products or engaging in other activities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The occurrence of an unfavorable outcome in&#13;any specific period could have a material adverse effect on our results of operations for that period or future periods. Other&#13;than as mentioned here, we are not presently a party to any pending or threatened legal proceedings.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;14. SEGMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We operate our businesses principally through&#13;two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic&#13;business activities. Our reportable segments have been determined based on the nature of the potential products being developed.&#13;ESI did not have any operations in the six months ended September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon&amp;#146;s revenue is generated primarily&#13;from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead&#13;to the ESI segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables set forth certain information&#13;regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented&#13;in this Report:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Revenues:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 68%; padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;530,371&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;840,483&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Revenues&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;530,371&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;840,483&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Operating Losses:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,294,453&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,013,592&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;(445,674&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Operating Loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;(1,773,200&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(1,013,592&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Net Losses:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(4,202,873&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(3,653,168&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;(356,539&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Net Loss Before Non-Controlling Interests&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;(4,592,485&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(3,653,168&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cash:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,865&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,754&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;478,322&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Cash&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;526,187&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;8,754&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Total Assets:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;443,027&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;411,190&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;646,242&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;1,089,269&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;411,190&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Capital Expenditures:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Capital Expenditures&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Depreciation and Amortization:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,885&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,727&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;9,791&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Depreciation and Amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;18,676&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,727&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Interest Expense:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;156,799&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;216,502&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Interest Expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;156,799&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;216,502&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;15. SUBSEQUENT EVENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Management has evaluated events&#13;subsequent to September 30, 2014 through the date that the accompanying condensed consolidated financial statements were filed&#13;with the Securities and Exchange Commission for transactions and other events which may require adjustment of and/or disclosure&#13;in such financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Government Contracts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we collected $247,361 under our DARPA contract, and under the Battelle subcontract we billed $9,595 and we collected $11,311.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Debt Reduction&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we paid off the remaining principal and interest balances on the two remaining July &amp;#38; August 2011 10% Convertible Notes, which&#13;had been classified as being in default, with cash payments totaling $382,748 (see Note 5).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we paid off in full the outstanding principal balance and interest balance on the Law Firm Note with a cash payment of $50,000&#13;and an issuance of 170,020 common shares (see Note 5).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Common Stock Issuances&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we issued 317,119 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an&#13;average price of $0.124 per share in payment for legal and scientific consulting services valued at $39,170 based on the value&#13;of the services provided.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Equity Unit Investments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we issued and sold to eight accredited investors units (the &amp;#147;Units&amp;#148;) consisting of (a) one hundred thousand (100,000)&#13;restricted shares of the Registrant&amp;#146;s common stock, par value $.001 per share (the &amp;#147;Common Stock&amp;#148;), at prices&#13;per share ranging from $0.105 to $0.114 and (b) a five-year warrant to purchase fifty thousand (50,000) shares of Common Stock&#13;at exercise prices ranging from $0.154 to $0.167 per share (the &amp;#147;Unit Warrants&amp;#148;). In total, the investors purchased&#13;for cash an aggregate of $501,700 of Units. The investors acquired an aggregate of 4,506,250 shares of Common Stock and Unit Warrants&#13;to acquire up to an aggregate of 2,253,125 shares of Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we issued to an accredited investor Units consisting of an aggregate of 1,835,798 shares of Common Stock and Unit Warrants to&#13;acquire up to an aggregate of 1,837,798 shares of Common Stock at an exercise price of $0.103 per share. The Units were issued&#13;to the investor upon the conversion of an aggregate of $189,087 of unpaid principal and accrued interest due under two promissory&#13;notes (the remaining October &amp;#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note &amp;#150; see Note&#13;5) previously issued to the investor by the Registrant. The amounts converted represented the entire principal and interest outstanding&#13;under the notes and the notes held by that holder were retired.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Warrant Exercises and Issuance&#13;of New Warrants Upon Exercise &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to&#13;September 30, 2014, we issued an aggregate of 5,671,119 shares of Common Stock and seven-year warrants (the &amp;#147;Exchange Warrants&amp;#148;)&#13;to issue up to an aggregate of 5,671,119 shares of Common Stock at exercise prices ranging from $0.093 to $0.116 per share to&#13;eight accredited investors. One of the investors is Dr. Chetan Shah, a director of the Registrant. The Common Stock and Exchange&#13;Warrants were issued to the investors upon the cash exercise of previously issued warrants held by them. The investors paid an&#13;aggregate of $579,251 upon exercise of the previously outstanding warrants at exercise prices ranging from $0.093 to $0.115 per&#13;share. The foregoing transaction was privately negotiated with the group of participating warrant holders.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Note Conversions&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to&#13;September 30, 2014, we issued an aggregate of 3,522,976 shares of Common Stock to two accredited investors upon the conversion&#13;of an aggregate of $147,965 of unpaid principal and accrued interest due under promissory notes previously issued to the investors&#13;by the Registrant. The conversion price per share was $0.042&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Warrant&#13;Exercises&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to&#13;September 30, 2014, we issued an aggregate of 16,423,131 shares of Common Stock to three accredited investors upon the exercise&#13;of warrants previously issued with an exercise price of $0.042 per share. The warrants were exercised on a cashless or &amp;#147;net&amp;#148;&#13;basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise of such warrants resulted in the&#13;cancellation of previously issued warrants to purchase an aggregate of 20,050,643 shares of Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Issuance of Convertible Notes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 8pt"&gt;Subsequent to September 30, 2014,&#13;we entered into a Subscription Agreement with two accredited investors providing for the issuance and sale of (i) convertible&#13;promissory notes in the aggregate principal amount of $527,780 and (ii) five year warrants to purchase up to 2,356,160 shares&#13;of Common Stock at a fixed exercise price of $0.168 per share. The convertible promissory notes bear interest at the annual rate&#13;of 10% and mature on April 1, 2016. The aggregate gross cash proceeds to us were $415,000 after subtracting legal fees of $35,000;&#13;the balance of the principal amount of the notes represents a $27,780 due diligence fee and an original issuance discount. The&#13;convertible promissory notes are convertible at the option of the holders into shares of our common stock at a fixed price of&#13;$0.112 per share, for up to an aggregate of 4,712,321 shares of Common Stock. There are no registration requirements with respect&#13;to the shares of common stock underlying the notes or the warrants.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PRINCIPLES OF CONSOLIDATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying condensed consolidated financial&#13;statements include the accounts of Aethlon Medical, Inc. and its majority-owned and controlled subsidiary, ESI. All significant&#13;intercompany balances and transactions have been eliminated in consolidation. The Company classifies the noncontrolling interests&#13;in ESI as part of consolidated net loss in the six months ended September 30, 2014 and includes the accumulated amount of noncontrolling&#13;interests as part of stockholders&amp;#146; equity. During the fiscal year ended March 31, 2014, ESI raised capital in the amount&#13;of $1,500,000 in exchange for the issuance of 300,000 shares of ESI common stock to ESI&amp;#146;s investors, representing 20% of&#13;ESI&amp;#146;s issued and outstanding capital stock. As a result, Aethlon Medical, Inc.&amp;#146;s ownership of ESI was reduced to 80%.&#13;If a further change in Aethlon Medical Inc.&amp;#146;s ownership of ESI results in loss of control and deconsolidation, any retained&#13;ownership interest will be remeasured with the gain or loss reported in our statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The losses at ESI during the six months ended&#13;September 30, 2014 reduced the noncontrolling interests on our consolidated balance sheet by $89,135 from $218,270 at March 31,&#13;2014 to $129,135 at September 30, 2014.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;USE OF ESTIMATES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our condensed consolidated financial&#13;statements in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements&#13;and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among&#13;others, realization of long-lived assets, estimating fair value associated with debt and equity transactions and valuation of deferred&#13;tax assets. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CASH AND CASH EQUIVALENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards define &amp;#34;cash and cash&#13;equivalents&amp;#34; as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so&#13;near their maturity that they present insignificant risk of changes in value because of changes in interest rates. For the purpose&#13;of financial statement presentation, we consider all highly liquid investment instruments with original maturities of three months&#13;or less when purchased, or any investment redeemable without penalty or loss of interest to be cash equivalents. As of September&#13;30, 2014 and March 31, 2014, we had no assets that were classified as cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CONCENTRATIONS OF CREDIT RISKS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash is maintained at two financial institutions&#13;in checking accounts and related cash management accounts. Accounts at these institutions are secured by the Federal Deposit Insurance&#13;Corporation (&amp;#34;FDIC&amp;#34;) up to $250,000. Our September 30, 2014 cash balances were approximately $276,000 over such insured&#13;amount. We do not believe that the Company is exposed to any significant risk with respect to its cash.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of our accounts receivable at September&#13;30, 2014 and March 31, 2014 and all of our revenue in the six month periods ended September 30, 2014 and 2013 were directly from&#13;the U.S. Department of Defense or from a subcontract under Battelle (defined herein), which is a prime contractor with the U.S.&#13;Department of Defense, and as such no allowance for uncollectable accounts receivable is deemed necessary at September 30, 2014&#13;or March 31, 2014.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amount of our cash, accounts receivable,&#13;accounts payable, and other current liabilities approximate their estimated fair values due to the short-term maturities of those&#13;financial instruments. The carrying amount of the notes payable approximates their fair value due to the short maturity of the&#13;notes and since the interest rate approximates current market interest rates for similar instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has concluded that it is not practical&#13;to determine the estimated fair value of amounts due to related parties because the transactions cannot be assumed to have been&#13;consummated at arm's length, the terms are not deemed to be market terms, there are no quoted values available for these instruments,&#13;and an independent valuation would not be practicable due to the lack of data regarding similar instruments, if any, and the associated&#13;potential costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 9 with respect to derivative liabilities.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PROPERTY AND EQUIPMENT&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation&#13;is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five&#13;years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement&#13;of property and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss&#13;included in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;INCOME TAXES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized&#13;for the future tax consequences attributable to the difference between the consolidated financial statements and their respective&#13;tax basis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets&#13;and liabilities for financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards.&#13;We record a valuation allowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable&#13;future, it is more likely than not that some portion of the deferred tax assets may not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment&#13;whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a&#13;long-lived asset is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized.&#13;We believe no impairment charges were necessary during the three and six month periods ended September 30, 2014 and 2013.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;LOSS PER COMMON SHARE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing&#13;net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation.&#13;Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number&#13;of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common&#13;shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional&#13;potential common shares have been excluded as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2014 and 2013, a total of&#13;139,672,815 and 137,935,529 potential common shares, consisting of shares underlying outstanding stock options, warrants and convertible&#13;notes payable were excluded as their inclusion would be antidilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SEGMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Historically, we operated in one segment that&#13;was based on our development of therapeutic devices. However in the December 2013 quarter, we initiated the operations of ESI to&#13;develop diagnostic tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic&#13;applications (See Note 14).&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DEFERRED FINANCING COSTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs related to the issuance of debt are capitalized&#13;and amortized to interest expense over the life of the related debt using the effective interest method.&amp;#160;&amp;#160;We recorded&#13;amortization expense related to our deferred offering costs of $21,502 and $863 during the six month periods ended September 30,&#13;2014 and 2013, respectively.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DARPA Contract -- With respect to revenue recognition,&#13;we entered into a government contract with DARPA and have recognized revenue under such contract. We adopted the Milestone method&#13;of revenue recognition for the DARPA contract under ASC 605-28 &amp;#147;Revenue Recognition &amp;#150; Milestone Method&amp;#148; and we&#13;believe we meet the requirements under ASC 605-28 for reporting contract revenue under the Milestone Method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In order to account for this contract, we identify&#13;the deliverables included within the contract and evaluate which deliverables represent separate units of accounting based on if&#13;certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received&#13;is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the&#13;separate units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is an event having all of the following&#13;characteristics:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) There is substantive uncertainty at the&#13;date the arrangement is entered into that the event will be achieved. A vendor&amp;#146;s assessment that it expects to achieve a&#13;milestone does not necessarily mean that there is not substantive uncertainty associated with achieving the milestone.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The event can only be achieved based in&#13;whole or in part on either: (a) the vendor&amp;#146;s performance; or (b) a specific outcome resulting from the vendor&amp;#146;s performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) If achieved, the event would result in additional&#13;payments being due to the vendor.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone does not include events for which&#13;the occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&amp;#146;s performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The policy for recognizing deliverable consideration&#13;contingent upon achievement of a milestone must be applied consistently to similar deliverables.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assessment of whether a milestone is substantive&#13;is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of&#13;the following for the milestone to be considered substantive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) The consideration is commensurate with either:&#13;(a) the vendor&amp;#146;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items&#13;as a result of a specific outcome resulting from the vendor&amp;#146;s performance to achieve the milestone;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) The consideration relates solely to past&#13;performance; and&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) The consideration is reasonable relative&#13;to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A milestone is not considered substantive if&#13;any portion of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it&#13;does not relate solely to past performance). To recognize the milestone consideration in its entirety as revenue in the period&#13;in which the milestone is achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated&#13;into substantive and non-substantive components. In addition, if a portion of the consideration earned from achieving a milestone&#13;may be refunded or adjusted based on future performance, the related milestone is not considered substantive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;See Note 12 for the additional disclosure information&#13;required under ASC 605-28.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Battelle Subcontract -- We entered into a subcontract&#13;agreement with Battelle Memorial Institute (&amp;#147;Battelle&amp;#148;) in March 2013. Battelle was chosen by DARPA to be the prime&#13;contractor on the systems integration portion of the original DARPA contract and we are one of several subcontractors on that systems&#13;integration project. The Battelle subcontract is cost-reimbursable under a time and materials basis. We began generating revenues&#13;under the subcontract during the six months ended September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our revenue under this contract is a function&#13;of cost reimbursement plus an overhead mark-up for hours devoted to the project by specific employees (with specific hourly rates&#13;for those employees). Battelle engages us as needed. Each payment requires approval by the program manager at Battelle.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;STOCK-BASED COMPENSATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Employee stock options and rights to purchase&#13;shares under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is&#13;measured when all granting activities have been completed, generally the grant date, based on the fair value of the award. The&#13;exercise price of options is generally equal to the market price of the Company's common stock (defined as the closing price as&#13;quoted on the OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity&#13;incentive awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance&#13;with the original provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards&#13;granted subsequent to April 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent&#13;accounting standards. We use a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes share-based compensation&#13;expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September&#13;30, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Six Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2013&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 68%"&gt;Vesting of Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;124,243&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Incremental fair value of option Modifications&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,914&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Vesting Expense Associated with CEO Restricted Stock Grant&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;64,444&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Weighted average number of common shares outstanding &amp;#150; basic and diluted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;243,494,916&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;182,004,220&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Basic and diluted loss per common share&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for transactions involving services&#13;provided by third parties where we issue equity instruments as part of the total consideration using the fair value of the consideration&#13;received (i.e. the value of the goods or services) or the fair value of the equity instruments issued, whichever is more reliably&#13;measurable. In transactions, when the value of the goods and/or services are not readily determinable and (1) the fair value of&#13;the equity instruments is more reliably measurable and (2) the counterparty receives equity instruments in full or partial settlement&#13;of the transactions, we use the following methodology:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;a) For transactions where goods have already&#13;been delivered or services rendered, the equity instruments are issued on or about the date the performance is complete (and valued&#13;on the date of issuance).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;b) For transactions where the instruments are&#13;issued on a fully vested, non-forfeitable basis, the equity instruments are valued on or about the date of the contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;c) For any transactions not meeting the criteria&#13;in (a) or (b) above, we re-measure the consideration at each reporting date based on its then current stock value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly&#13;basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting&#13;the forfeiture rate for all expense amortization after March 31, 2006 is recognized in the period the forfeiture estimate is changed.&#13;The effect of forfeiture adjustments for the six months ended September 30, 2014 was insignificant.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PATENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents include both foreign and domestic patents.&#13;There were several patents pending at September 30, 2014. We capitalize the cost of patents and patents pending, some of which&#13;were acquired, and amortize such costs over the shorter of the remaining legal life or their estimated economic life, upon issuance&#13;of the patent. The unamortized costs of patents and patents pending are subject to our review for impairment under our long-lived&#13;asset policy above.&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:DerivativesEmbeddedDerivatives contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;STOCK PURCHASE WARRANTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We grant warrants in connection with the issuance&#13;of convertible notes payable and the issuance of common stock for cash. When such warrants are classified as equity and issued&#13;in connection with debt, we measure the relative estimated fair value of such warrants and record it as a discount from the face&#13;amount of the convertible notes payable. Such discounts are amortized to interest expense over the term of the notes using the&#13;effective interest method. Warrants issued in connection with common stock for cash, if classified as equity, are considered issued&#13;in connection with equity transactions and the warrant fair value is recorded to additional paid-in-capital. Lastly, warrants not&#13;meeting equity classification are recorded as derivative instruments.&lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;DERIVATIVE INSTRUMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We evaluate free-standing derivative instruments&#13;(or embedded derivatives) to properly classify such instruments within equity or as liabilities in our financial statements. Our&#13;policy is to settle instruments indexed to our common shares on a first-in-first-out basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The classification of a derivative instrument&#13;is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument&#13;is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract&#13;may be reclassified.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Instruments classified as derivative liabilities&#13;are remeasured each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement&#13;of operations in other (income) expense.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <aemd:BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE&#13;NOTES PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The convertible feature of certain notes payable&#13;provides for a rate of conversion that is below market value. Such feature is normally characterized as a &amp;#34;Beneficial Conversion&#13;Feature&amp;#34; (&amp;#34;BCF&amp;#34;). We measure the estimated fair value of the BCF in circumstances in which the conversion feature&#13;is not required to be separated from the host instrument and accounted for separately, and record that value in the consolidated&#13;financial statements as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the&#13;term of the notes.&lt;/p&gt;</aemd:BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock>
    <aemd:RegistrationPaymentArrangementsPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;REGISTRATION PAYMENT ARRANGEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for contingent obligations to make&#13;future payments or otherwise transfer consideration under a registration payment arrangement separately from any related financing&#13;transaction agreements, and any such contingent obligations are recognized only when it is determined that it is probable we will&#13;become obligated for future payments and the amount, or range of amounts, of such future payments can be reasonably estimated.&lt;/p&gt;</aemd:RegistrationPaymentArrangementsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We incurred research and development expenses&#13;during the three and six month periods ended September 30, 2014 and 2013, which are included in various operating expense line&#13;items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods&#13;were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;Three months ended&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;250,388&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;293,580&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Six months ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;637,723&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;626,638&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <aemd:OffbalanceSheetArrangementsPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;OFF-BALANCE SHEET ARRANGEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have not entered into any off-balance sheet&#13;arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.&lt;/p&gt;</aemd:OffbalanceSheetArrangementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management is evaluating significant recent&#13;accounting pronouncements that are not yet effective for the Company, including the new accounting standard on revenue recognition,&#13;ASU 2014-09 (Topic 606), and has not yet concluded whether any such pronouncements will have a significant effect on the Company&amp;#146;s&#13;future consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes share-based compensation&#13;expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September&#13;30, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Six Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2013&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 68%"&gt;Vesting of Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;124,243&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Incremental fair value of option Modifications&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,914&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Vesting Expense Associated with CEO Restricted Stock Grant&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;64,444&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Total Stock-Based Compensation Expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Weighted average number of common shares outstanding &amp;#150; basic and diluted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;243,494,916&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;182,004,220&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Basic and diluted loss per common share&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <aemd:ScheduleOfNotesPayableTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Notes payable consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal Balance&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal Balance&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%"&gt;12% Notes payable, past due&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;185,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;367,687&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;185,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;353,813&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;10% Note payable, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,625&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,375&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Directors&amp;#146; Note(s)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;200,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;14,516&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-indent: 27pt"&gt;Total&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;374,312&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;390,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;374,704&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</aemd:ScheduleOfNotesPayableTableTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Convertible Notes Payable consisted of the following at September&#13;30, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Unamortized &lt;br /&gt;&#13;Discount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Net &lt;br /&gt;&#13;Amount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued &lt;br /&gt;&#13;Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 44%; padding-left: 9pt; text-indent: -9pt"&gt;October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;28,598&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2010 10% Convertible Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;35,188&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;July and August 2011 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;283,421&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;283,421&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;96,728&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Law Firm Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;9,479&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;483,422&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;483,422&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;169,993&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Non-Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Amended and Restated Series A 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;225,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;225,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2010 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,513&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;13,454&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Non-Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;990,520&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;990,520&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;31,967&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 44pt; text-indent: -9pt"&gt;Total Convertible Notes Payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;1,473,941&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;1,473,941&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;201,960&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Convertible Notes Payable consisted of the following at March 31,&#13;2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Unamortized &lt;br /&gt;&#13;Discount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Net &lt;br /&gt;&#13;Amount&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Accrued &lt;br /&gt;&#13;Interest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 44%; padding-left: 9pt; text-indent: -9pt"&gt;Amended and Restated Series A 12% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;885,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;885,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;575,250&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;2008 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,167&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26,097&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2010 10% Convertible Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,438&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;July and August 2011 10% Convertible Notes, past due&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;90,256&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Law Firm Note&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;75,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;7,604&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;1,367,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;1,367,655&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;749,812&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;Convertible Notes Payable &amp;#150; Non-Current Portion:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2010 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;35,034&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;April 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;448,448&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,117&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;September 2011 12% Convertible Notes&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;10,931&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right"&gt;10,931&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -9pt"&gt;Total &amp;#150; Convertible Notes Payable &amp;#150; Non-Current Portion&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;776,451&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right"&gt;776,451&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 22pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;47,151&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 44pt; text-indent: -9pt"&gt;Total Convertible Notes Payable&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;2,144,106&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right"&gt;2,144,106&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 44pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;796,963&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <aemd:ActivityInConvertibleNotesTextBlock contextRef="From2014-04-01to2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following table shows the conversions into principal of the October&#13;and November 2009 10% Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in October &amp;#38; November 2009 10% Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;450,250&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2010&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(70,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2011&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(175,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(130,250&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</aemd:ActivityInConvertibleNotesTextBlock>
    <aemd:ActivityInConvertibleNotesTextBlock contextRef="From2014-04-01to2014-09-30_custom_September2010ConvertibleNotesMember">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following table shows the activity in the September 2010 10%&#13;Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in the September 2010 10% Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;743,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(405,500&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(30,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Increase in principal balance due to 12% extension fee&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;33,972&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;317,072&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;/p&gt;</aemd:ActivityInConvertibleNotesTextBlock>
    <aemd:ActivityInConvertibleNotesTextBlock contextRef="From2014-04-01to2014-09-30_custom_September2011ConvertibleNotesMember">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following table shows the conversions into principal of the September&#13;2011 Convertible Notes by fiscal year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;Activity in the September 2011 Convertible Notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;Initial principal balance&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;253,760&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(15,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(60,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the fiscal year ended March 31, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(169,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Increase in principal balance due to extension fee&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,171&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Conversions during the six months ended September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(10,931&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Balance as of September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;/p&gt;</aemd:ActivityInConvertibleNotesTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities were comprised of the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;Accrued interest&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;570,741&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;1,165,335&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Accrued legal fees&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;179,465&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;179,465&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Accrued liquidated damages&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;362,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;362,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Other accrued liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;103,598&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;147,774&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Total other current liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,216,604&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,855,374&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Our fair value measurements at the March 31, 2014 reporting date&#13;are classified based on the valuation technique level noted in the table below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;Description&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;March 31, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Quoted Prices &lt;br /&gt;&#13;in Active Markets for &lt;br /&gt;&#13;(Level 1)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Significant Other Observable &lt;br /&gt;&#13;(Level 2)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Significant &lt;br /&gt;&#13;Unobservable &lt;br /&gt;&#13;(Level 3)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%"&gt;Derivative Liabilities&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Total Assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The following outlines the&#13;significant weighted average assumptions used to estimate the fair value information presented, in connection with our warrant&#13;and embedded conversion option derivative instruments utilizing the Binomial Lattice option pricing model:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.02% - 0.62%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0.25 &amp;#150; 3 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;78.9% - 104.5%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The table below sets forth a summary of changes in the fair value&#13;of our Level 3 financial instruments for the six months ended September 30, 2014: &amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;April 1, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Recorded New Derivative &lt;br /&gt;&#13;Liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Change in estimated fair value recognized in results of operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Reclassification &lt;br /&gt;&#13;of Derivative &lt;br /&gt;&#13;Liability to Paid &lt;br /&gt;&#13;in capital&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, &lt;br /&gt;&#13;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 30%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Derivative liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,679,067&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(10,679,067&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The table below sets forth a summary of changes in the fair value&#13;of our Level 3 financial instruments for the six months ended September 30, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Change in&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Reclassification&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;estimated fair&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;of Derivative&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Recorded&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;value recognized&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Liability to&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;April 1,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;New Derivative&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;in results&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Paid in&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;of operations&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;capital&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 30%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Derivative liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,588,239&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,382,877&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(106,501&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,864,615&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table breaks out the components&#13;of our share-based compensation expenses relating to shares and options granted and the effect on basic and diluted loss per common&#13;share during the three and six months ended September 30, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Three Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Three Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Six Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Six Months Ended&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;September 30, 2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 36%"&gt;Vesting of stock options&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;73,856&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;124,243&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Incremental fair value of option modifications&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;957&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,914&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Vesting expense associated with CEO restricted stock grant&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;64,444&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Total share-based compensation expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;74,813&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Total share-based compensation expense included in net loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;89,793&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;73,856&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;260,680&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;190,601&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Weighted average number of common shares outstanding &amp;#150; basic and diluted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;259,369,911&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;187,643,582&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;243,494,916&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;182,004,220&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 11pt; text-indent: -11pt"&gt;Basic and diluted loss per common share&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.00&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following outlines the significant weighted average assumptions&#13;used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial Lattice option&#13;pricing models at, and during the six months ended September 30, 2014:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;2.6%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;10 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;90.23%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following outlines the significant weighted average assumptions&#13;used to estimate the fair value information, which is based on historical data, with respect to stock option grants utilizing the&#13;Binomial Lattice option pricing models at, and during the six months ended September 30, 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.38% - 2.50%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;3 years - 10 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;94.6% - 102.7%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Options outstanding that have vested and are expected to vest as&#13;of September 30, 2014 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Term in Years&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Vested&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;24,294,227&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.26&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;3.96&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Expected to vest&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;4,711,811&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.15&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;Total&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 0.25in; text-align: right"&gt;29,006,038&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the six months ended September&#13;30, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average &lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Stock options outstanding at March 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;26,133,407&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.25&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,972,631&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Stock options outstanding at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;29,006,038&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Stock options exercisable at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;24,294,227&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;$0.076 - $0.41&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.26&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of warrant activity during the six months ended September&#13;30, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 52%"&gt;Warrants outstanding at March 31, 2014&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;70,709,475&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;0.13&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(2,166,104&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.086 &amp;#150; $0.12&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Issued&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15,375,614&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.24&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(1,136,364&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.13&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.13&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Warrants outstanding at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;82,782,621&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Warrants exercisable at September 30, 2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;82,782,621&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.042 - $0.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.10&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <aemd:WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The following outlines the significant weighted average assumptions&#13;used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice option pricing models&#13;at, and during, the six months ended September 30, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 74%"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: center"&gt;0.79% - 2.29%&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td&gt;Average expected life&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5 years &amp;#150; 7 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Expected volatility&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;90.1% - 95.8%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td&gt;Expected dividends&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</aemd:WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2014-04-01to2014-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables set forth certain information&#13;regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented&#13;in this Report:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2014&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Revenues:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 68%; padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;530,371&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;840,483&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Revenues&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;530,371&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;840,483&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Operating Losses:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,294,453&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,013,592&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;(445,674&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Operating Loss&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;(1,773,200&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(1,013,592&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Net Losses:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(4,202,873&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(3,653,168&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;(356,539&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Net Loss Before Non-Controlling Interests&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;(4,592,485&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(3,653,168&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Cash:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,865&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,754&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;478,322&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Cash&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;526,187&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;8,754&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Total Assets:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;443,027&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;411,190&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;646,242&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;1,089,269&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;411,190&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Capital Expenditures:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Capital Expenditures&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;Depreciation and Amortization:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,885&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,727&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;9,791&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Depreciation and Amortization&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;18,676&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,727&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;Interest Expense:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;Aethlon&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;156,799&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;216,502&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; text-indent: -10pt"&gt;ESI&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 20pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#150;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 30pt; text-indent: -10pt"&gt;Total Interest Expense&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right"&gt;156,799&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 30pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;216,502&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">637723</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">626638</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">250388</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">293580</us-gaap:ResearchAndDevelopmentExpense>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">483421</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1367655</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">885000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_ConvertibleNotes10Percent2008Member" unitRef="USD" decimals="0">25000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">50000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">75000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_LawFirmNoteMember" unitRef="USD" decimals="0">75000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">50000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-09-30_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">75000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-09-30_custom_LawFirmNoteMember" unitRef="USD" decimals="0">75000</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-09-30_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">283421</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:ConvertibleNotesPayableCurrentBeforeDiscount contextRef="AsOf2014-03-31_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">257655</aemd:ConvertibleNotesPayableCurrentBeforeDiscount>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_ConvertibleNotes10Percent2008Member" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_LawFirmNoteMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-09-30_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-09-30_custom_LawFirmNoteMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-09-30_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountCurrentPortion contextRef="AsOf2014-03-31_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">169993</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">749812</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">575250</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_ConvertibleNotes10Percent2008Member" unitRef="USD" decimals="0">19167</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">26097</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">31438</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_LawFirmNoteMember" unitRef="USD" decimals="0">7604</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-09-30_custom_OctoberNovember2009ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">28598</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-09-30_custom_April2010ConvertibleNote10PercentMember" unitRef="USD" decimals="0">35188</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-09-30_custom_LawFirmNoteMember" unitRef="USD" decimals="0">9479</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-09-30_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">96728</aemd:AccruedInterestCurrentPortion>
    <aemd:AccruedInterestCurrentPortion contextRef="AsOf2014-03-31_custom_JulyAugust201110PercentNoteMember" unitRef="USD" decimals="0">90256</aemd:AccruedInterestCurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">990520</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">776451</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-03-31_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">317072</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-03-31_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">448448</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-03-31_custom_September2011ConvertibleNotesMember" unitRef="USD" decimals="0">10931</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-09-30_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">225000</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-09-30_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">317072</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:ConvertibleNotesPayableNoncurrentPortion contextRef="AsOf2014-09-30_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">448448</aemd:ConvertibleNotesPayableNoncurrentPortion>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-03-31_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-03-31_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-03-31_custom_September2011ConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-09-30_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-09-30_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:DebtInstrumentUnamortizedDiscountNonCurrent contextRef="AsOf2014-09-30_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">0</aemd:DebtInstrumentUnamortizedDiscountNonCurrent>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">31967</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">47151</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-03-31_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">35034</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-03-31_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">12117</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-03-31_custom_September2011ConvertibleNotesMember" unitRef="USD" decimals="0">0</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-09-30_custom_AmendedRestatedSeriesA12PercentConvertibleNotesMember" unitRef="USD" decimals="0">9000</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-09-30_custom_September2010ConvertibleNotesMember" unitRef="USD" decimals="0">9513</aemd:AccruedInterestNoncurrentPortion>
    <aemd:AccruedInterestNoncurrentPortion contextRef="AsOf2014-09-30_custom_April2011ConvertibleNotes10PercentMember" unitRef="USD" decimals="0">13454</aemd:AccruedInterestNoncurrentPortion>
    <aemd:TotalConvertibleNotesPayable contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1473941</aemd:TotalConvertibleNotesPayable>
    <aemd:TotalConvertibleNotesPayable contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">2144106</aemd:TotalConvertibleNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2014-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <aemd:TotalAccruedInterest contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">201960</aemd:TotalAccruedInterest>
    <aemd:TotalAccruedInterest contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">796963</aemd:TotalAccruedInterest>
    <aemd:StockIssuedSubscribedSharesIssued contextRef="From2014-04-01to2014-06-30" unitRef="Shares" decimals="INF">2192444</aemd:StockIssuedSubscribedSharesIssued>
    <aemd:WarantsIssuedToAccreditedInvestors contextRef="From2014-04-01to2014-06-30" unitRef="Shares" decimals="INF">1096222</aemd:WarantsIssuedToAccreditedInvestors>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">320800</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">359956</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-04-01to2014-06-30" unitRef="Shares" decimals="INF">219127</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-07-01to2014-09-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">390301</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">49090</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">38268</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-07-01to2014-09-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">75000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderOneMember" unitRef="Shares" decimals="INF">15714286</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_custom_ConversionAccruedInterestMember_custom_HolderOneMember" unitRef="Shares" decimals="INF">7603968</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_custom_RestructuringFeeMember_custom_HolderOneMember" unitRef="Shares" decimals="INF">75000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderTwoMember" unitRef="Shares" decimals="INF">2591846</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_custom_RestructuringFeeMember_custom_HolderTwoMember" unitRef="Shares" decimals="INF">25000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2014-07-01to2014-09-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">1937505</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderOneMember" unitRef="USD" decimals="0">660000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2014-07-01to2014-09-30_custom_ConversionAccruedInterestMember_custom_HolderOneMember" unitRef="USD" decimals="0">343200</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2014-07-01to2014-09-30_custom_NoteBalanceMember_custom_HolderTwoMember" unitRef="USD" decimals="0">116970</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2014-07-01to2014-09-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">81375</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-07-01to2014-09-30_custom_FourInvestorsMember" unitRef="Shares" decimals="INF">2673231</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-07-01to2014-09-30_custom_ThreeInvestorsMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-07-01to2014-09-30_custom_FourInvestorsMember" unitRef="USD" decimals="0">259474</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-07-01to2014-09-30_custom_ThreeInvestorsMember" unitRef="USD" decimals="0">90000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2014-07-01to2014-09-30_custom_ThreeInvestorsMember" unitRef="Shares" decimals="INF">974982</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2014-07-01to2014-09-30_custom_ThreeInvestorsMember" unitRef="USD" decimals="0">487491</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <aemd:LossOnExtensionOfWarrants contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">143363</aemd:LossOnExtensionOfWarrants>
    <aemd:LossOnExtensionOfWarrants contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">0</aemd:LossOnExtensionOfWarrants>
    <aemd:LossOnExtensionOfWarrants contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">143363</aemd:LossOnExtensionOfWarrants>
    <aemd:LossOnExtensionOfWarrants contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">0</aemd:LossOnExtensionOfWarrants>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">400000</us-gaap:ProceedsFromNotesPayable>
    <aemd:ReclassificationOfAccountsPayableToConvertibleNotePayable contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">0</aemd:ReclassificationOfAccountsPayableToConvertibleNotePayable>
    <aemd:ReclassificationOfAccountsPayableToConvertibleNotePayable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">47000</aemd:ReclassificationOfAccountsPayableToConvertibleNotePayable>
    <aemd:DeferredFinancingCostsRecordedInConnectionWithDebtAmendment contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">5000</aemd:DeferredFinancingCostsRecordedInConnectionWithDebtAmendment>
    <aemd:DeferredFinancingCostsRecordedInConnectionWithDebtAmendment contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">0</aemd:DeferredFinancingCostsRecordedInConnectionWithDebtAmendment>
    <aemd:ReclassificationOfAccruedInterestToConvertibleNotesPayable contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">25766</aemd:ReclassificationOfAccruedInterestToConvertibleNotesPayable>
    <aemd:ReclassificationOfAccruedInterestToConvertibleNotesPayable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">20027</aemd:ReclassificationOfAccruedInterestToConvertibleNotesPayable>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1216604</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1855374</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">570741</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">1165335</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">179465</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">179465</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <aemd:AccruedLiquidatedDamages contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">362800</aemd:AccruedLiquidatedDamages>
    <aemd:AccruedLiquidatedDamages contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">362800</aemd:AccruedLiquidatedDamages>
    <us-gaap:OtherLiabilities contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">103598</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">147774</us-gaap:OtherLiabilities>
    <aemd:AccruedInterestOnNotesPayableInDefault contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">471041</aemd:AccruedInterestOnNotesPayableInDefault>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">10679067</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-03-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-03-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-03-31_FairValueInputsLevel3Member" unitRef="USD" decimals="0">10679067</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">5864615</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-03-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">3588239</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2014-03-31" unitRef="USD" decimals="0">10679067</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2014-03-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2014-03-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2014-03-31_FairValueInputsLevel3Member" unitRef="USD" decimals="0">10679067</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0062</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0002</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember">P3Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember">P3M</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">1.045</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.789</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2014-04-01to2014-09-30_FairValueInputsLevel3Member" unitRef="Pure" decimals="INF">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="From2013-04-01to2013-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="From2014-04-01to2014-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="From2013-04-01to2013-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-2382877</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="From2014-04-01to2014-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">260680</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">190601</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-09-30_custom_VestingOfStockOptionsMember" unitRef="USD" decimals="0">260680</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_custom_VestingOfStockOptionsMember" unitRef="USD" decimals="0">124243</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-09-30_custom_IncrementalFairValueOfOptionsMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_custom_IncrementalFairValueOfOptionsMember" unitRef="USD" decimals="0">1914</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-04-01to2014-09-30_custom_VestingExpenseMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_custom_VestingExpenseMember" unitRef="USD" decimals="0">64444</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">89793</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">74813</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30_custom_VestingOfStockOptionsMember" unitRef="USD" decimals="0">89793</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_custom_VestingOfStockOptionsMember" unitRef="USD" decimals="0">73856</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30_custom_IncrementalFairValueOfOptionsMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_custom_IncrementalFairValueOfOptionsMember" unitRef="USD" decimals="0">957</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30_custom_VestingExpenseMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_custom_VestingExpenseMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2014-04-01to2014-09-30" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2013-04-01to2013-09-30" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2014-07-01to2014-09-30" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="From2013-07-01to2013-09-30" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MinimumMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">0.9023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">1.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MinimumMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember">P3Y11M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember">P9Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">29006038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-03-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">26133407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">2972631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">-100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <aemd:Exercised contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.00</aemd:Exercised>
    <aemd:Granted contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.19</aemd:Granted>
    <aemd:Cancelledexpired contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.19</aemd:Cancelledexpired>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">497783</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2014-04-01to2014-09-30">P2Y2M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="From2014-04-01to2014-09-30" unitRef="USDPerShare" decimals="INF">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-03-31" unitRef="Shares" decimals="INF">70709475</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">82782621</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">70709475</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-2166104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">15375614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-1136364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">82782621</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aemd:WarrantsOutstandingRangeOfExercisePriceMinimum contextRef="AsOf2014-03-31" unitRef="USDPerShare" decimals="INF">0.042</aemd:WarrantsOutstandingRangeOfExercisePriceMinimum>
    <aemd:WarrantsOutstandingRangeOfExercisePriceMinimum contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.042</aemd:WarrantsOutstandingRangeOfExercisePriceMinimum>
    <aemd:WarrantsOutstandingRangeOfExercisePriceMaximum contextRef="AsOf2014-03-31" unitRef="USDPerShare" decimals="INF">0.25</aemd:WarrantsOutstandingRangeOfExercisePriceMaximum>
    <aemd:WarrantsOutstandingRangeOfExercisePriceMaximum contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.25</aemd:WarrantsOutstandingRangeOfExercisePriceMaximum>
    <aemd:WarrantsExercisedRangeOfExercisePriceMinimum contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.086</aemd:WarrantsExercisedRangeOfExercisePriceMinimum>
    <aemd:WarrantsExercisedRangeOfExercisePriceMaximum contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.12</aemd:WarrantsExercisedRangeOfExercisePriceMaximum>
    <aemd:WarrantsIssuedRangeOfExercisePriceMinimum contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.042</aemd:WarrantsIssuedRangeOfExercisePriceMinimum>
    <aemd:WarrantsIssuedRangeOfExercisePriceMaximum contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.24</aemd:WarrantsIssuedRangeOfExercisePriceMaximum>
    <aemd:WarrantsCancelledExpiredRangeOfExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.13</aemd:WarrantsCancelledExpiredRangeOfExercisePrice>
    <aemd:WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.042</aemd:WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum>
    <aemd:WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.25</aemd:WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-03-31" unitRef="USDPerShare" decimals="INF">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-03-31_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <aemd:WarrantsExercisedWeightedAverageExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.10</aemd:WarrantsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <aemd:WarrantsCancelledexpiredWeightedAverageExercisePrice contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.13</aemd:WarrantsCancelledexpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:FairValueAssumptionsExpectedDividendPayments contextRef="From2014-04-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ContractsRevenue contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">444723</us-gaap:ContractsRevenue>
    <us-gaap:ContractsRevenue contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">808739</us-gaap:ContractsRevenue>
    <aemd:NumberOfMilestonesUnderYearOneContract contextRef="From2014-04-01to2014-09-30" unitRef="Pure" decimals="INF">3</aemd:NumberOfMilestonesUnderYearOneContract>
    <aemd:NumberOfMilestonesAchievedUnderYearOneContract2 contextRef="From2013-04-01to2013-09-30" unitRef="Pure" decimals="INF">4</aemd:NumberOfMilestonesAchievedUnderYearOneContract2>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2014-01-01to2014-06-30_custom_MileStoneTwoPointFourPointTwoPointTwoMember" unitRef="USD" decimals="0">197362</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2014-01-01to2014-06-30_custom_MileStoneTwoPointFourPointTwoPointFourMember" unitRef="USD" decimals="0">5000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2014-01-01to2014-06-30_custom_MilestoneMNineMember" unitRef="USD" decimals="0">197361</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2013-01-01to2013-06-30_custom_MileStoneTwoPointThreePointTwoPointTwoMember" unitRef="USD" decimals="0">195581</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2013-01-01to2013-06-30_custom_MileStoneTwoPointThreePointThreePointTwoMember" unitRef="USD" decimals="0">208781</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="From2013-01-01to2013-06-30_custom_MilestoneMFiveMember" unitRef="USD" decimals="0">208781</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">84000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">68000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-04-01to2014-09-30" unitRef="Shares" decimals="INF">243494916</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">182004220</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">259369911</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">187643582</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <aemd:SharebasedCompensationExpenseIncludedInNetLoss contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">260680</aemd:SharebasedCompensationExpenseIncludedInNetLoss>
    <aemd:SharebasedCompensationExpenseIncludedInNetLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">190601</aemd:SharebasedCompensationExpenseIncludedInNetLoss>
    <aemd:SharebasedCompensationExpenseIncludedInNetLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">89793</aemd:SharebasedCompensationExpenseIncludedInNetLoss>
    <aemd:SharebasedCompensationExpenseIncludedInNetLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">74813</aemd:SharebasedCompensationExpenseIncludedInNetLoss>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">18676</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">4727</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">8885</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">4727</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">9791</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestExpense contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">156799</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">216502</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2014-04-01to2014-09-30_custom_AethlonMember" unitRef="USD" decimals="0">156799</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-04-01to2013-09-30_custom_AethlonMember" unitRef="USD" decimals="0">216502</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2014-04-01to2014-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-04-01to2013-09-30_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:InterestExpense>
    <aemd:LossOnDebtConversion contextRef="From2014-04-01to2014-09-30" unitRef="USD" decimals="0">-2531123</aemd:LossOnDebtConversion>
    <aemd:LossOnDebtConversion contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">-40256</aemd:LossOnDebtConversion>
    <aemd:LossOnDebtConversion contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-65493</aemd:LossOnDebtConversion>
    <aemd:LossOnDebtConversion contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-17467</aemd:LossOnDebtConversion>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">24294227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">4711811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">0.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">24294227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <aemd:StockOptionsOutstandingMinimumRangeOfExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.076</aemd:StockOptionsOutstandingMinimumRangeOfExercisePrice>
    <aemd:StockOptionsOutstandingMinimumRangeOfExercisePrice contextRef="AsOf2014-03-31_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.076</aemd:StockOptionsOutstandingMinimumRangeOfExercisePrice>
    <aemd:StockOptionsOutstandingMaximumRangeOfExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.41</aemd:StockOptionsOutstandingMaximumRangeOfExercisePrice>
    <aemd:StockOptionsOutstandingMaximumRangeOfExercisePrice contextRef="AsOf2014-03-31_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.41</aemd:StockOptionsOutstandingMaximumRangeOfExercisePrice>
    <aemd:StockOptionsExercisableRangeOfExercisePricesMinimum contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.076</aemd:StockOptionsExercisableRangeOfExercisePricesMinimum>
    <aemd:StockOptionsExercisableRangeOfExercisePricesMaximum contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.41</aemd:StockOptionsExercisableRangeOfExercisePricesMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-03-31_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2014-09-30_us-gaap_StockOptionMember" unitRef="USDPerShare" decimals="INF">.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>aemd-20140930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9ag5o7xRiXhun8uCZndcWa+AecOdxZR/mZlBsGx0bQn6TyYir1Q0Qy3dDJKGgeIJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:aemd="http://aethlonmedical.com/20140930" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20140930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Disclosure - Document And Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
	  <link:definition>00000006 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000007 - Disclosure - 2. LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000009 - Disclosure - 4. NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
	  <link:definition>00000010 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000011 - Disclosure - 6. EQUITY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - 7. RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - 8. OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000014 - Disclosure - 9. FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensation" id="StockCompensation">
	  <link:definition>00000015 - Disclosure - 10. STOCK COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/Warrants" id="Warrants">
	  <link:definition>00000016 - Disclosure - 11. WARRANTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" id="DarpaContractAndRelatedRevenueRecognition">
	  <link:definition>00000017 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/Segments" id="Segments">
	  <link:definition>00000019 - Disclosure - 14. SEGMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000020 - Disclosure - 15. SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000022 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NotesPayableTables" id="NotesPayableTables">
	  <link:definition>00000023 - Disclosure - 4. NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" id="ConvertibleNotesPayableTables">
	  <link:definition>00000024 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000025 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000026 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationTables" id="StockCompensationTables">
	  <link:definition>00000027 - Disclosure - 10. STOCK COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000028 - Disclosure - 11. WARRANTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SegmentsTables" id="SegmentsTables">
	  <link:definition>00000029 - Disclosure - 14. SEGMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000030 - Disclosure - 2. LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" id="SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense">
	  <link:definition>00000031 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" id="NotesPayableDetails-NotesPayable">
	  <link:definition>00000033 - Disclosure - 4. NOTES PAYABLE (Details - Notes payable)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000034 - Disclosure - 4. NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" id="ConvertibleNotesPayableDetails">
	  <link:definition>00000035 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" id="ConvertibleNotesPayableDetails-Activity">
	  <link:definition>00000036 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details - Activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>00000037 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" id="OtherCurrentLiabilityDetailsNarrative">
	  <link:definition>00000040 - Disclosure - 8. OTHER CURRENT LIABILITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" id="FairValueMeasurementsDetails-FairValue">
	  <link:definition>00000041 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Details - Fair value)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" id="FairValueMeasurementDetails-Assumptions">
	  <link:definition>00000042 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" id="FairValueMeasurementDetails-Level3">
	  <link:definition>00000043 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Level 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" id="StockCompensationDetails-Share-basedCompensation">
	  <link:definition>00000044 - Disclosure - 10. STOCK COMPENSATION (Details - Share-based compensation)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" id="StockCompensationDetails-Assumptions">
	  <link:definition>00000045 - Disclosure - 10. STOCK COMPENSATION (Details - Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" id="StockCompensationDetails-OptionInformation">
	  <link:definition>00000046 - Disclosure - 10. STOCK COMPENSATION (Details - Option information)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" id="StockCompensationDetails-OptionActivity">
	  <link:definition>00000047 - Disclosure - 10. STOCK COMPENSATION (Details - Option activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
	  <link:definition>00000048 - Disclosure - 10. STOCK COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" id="WarrantsDetails-WarrantActivity">
	  <link:definition>00000049 - Disclosure - 11. WARRANTS (Details - Warrant activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" id="WarrantsDetails-Assumptions">
	  <link:definition>00000050 - Disclosure - 11. WARRANTS (Details - Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" id="DarpaContractAndRelatedRevenueRecognitionDetailsNarrative">
	  <link:definition>00000051 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000052 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SegmentsDetails" id="SegmentsDetails">
	  <link:definition>00000053 - Disclosure - 14. SEGMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20140930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20140930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20140930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20140930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="aemd_NotesPayablePastDue10PercentMember" name="NotesPayablePastDue10PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IpLawFirmNotePastDueMember" name="IpLawFirmNotePastDueMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LawFirmNoteMember" name="LawFirmNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_TonaquintNoteMember" name="TonaquintNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NotesPayablePastDue12PercentMember" name="NotesPayablePastDue12PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" name="AmendedRestatedSeriesA12PercentConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotes10Percent2008Member" name="ConvertibleNotes10Percent2008Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_December10ConvertibleNotes2006Member" name="December10ConvertibleNotes2006Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OctoberNovember2009ConvertibleNotes10PercentMember" name="OctoberNovember2009ConvertibleNotes10PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_April2010ConvertibleNote10PercentMember" name="April2010ConvertibleNote10PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_September2010ConvertibleNotesMember" name="September2010ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_April2011ConvertibleNotes10PercentMember" name="April2011ConvertibleNotes10PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember" name="JulyAndAugust2011ConvertibleNotes10PercentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_September2011ConvertibleNotesMember" name="September2011ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_February2012ConvertibleNotesMember" name="February2012ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OfficerAndOurChiefFinancialOfficerMember" name="OfficerAndOurChiefFinancialOfficerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesApril2010Member" name="ConvertibleNotesApril2010Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_November2011ConvertibleNotesMember" name="November2011ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_September201010PercentConvertibleNotesMember" name="September201010PercentConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_FinancingAgreement1000000Member" name="FinancingAgreement1000000Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_FinancingAgreement715000Member" name="FinancingAgreement715000Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_EquityInvestmentsMember" name="EquityInvestmentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SixthMilestoneMember" name="SixthMilestoneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SeventhMember" name="SeventhMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_EighthMember" name="EighthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LaboratorySpaceMember" name="LaboratorySpaceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember" name="MileStoneTwoPointTwoPointTwoPointThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointTwoPointOnePointFourMember" name="MileStoneTwoPointTwoPointOnePointFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneMTwoMember" name="MileStoneMTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointThreePointThreePointOneMember" name="MileStoneTwoPointThreePointThreePointOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LawFirmNote2Member" name="LawFirmNote2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DebtDiscountsMember" name="DebtDiscountsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesAndDebtDiscountMember" name="ConvertibleNotesAndDebtDiscountMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DirectorsNotesMember" name="DirectorsNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotes2009Member" name="ConvertibleNotes2009Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotes2010Member" name="ConvertibleNotes2010Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotes2011Member" name="ConvertibleNotes2011Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AethlonMedicalIncMember" name="AethlonMedicalIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ExosomeSciencesIncMember" name="ExosomeSciencesIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_VestingOfStockOptionsMember" name="VestingOfStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IncrementalFairValueOfOptionsMember" name="IncrementalFairValueOfOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_VestingExpenseMember" name="VestingExpenseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_JulyAugust201110PercentNoteMember" name="JulyAugust201110PercentNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NoteBalanceMember" name="NoteBalanceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_HolderOneMember" name="HolderOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConversionAccruedInterestMember" name="ConversionAccruedInterestMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RestructuringFeeMember" name="RestructuringFeeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_HolderTwoMember" name="HolderTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AethlonMember" name="AethlonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ESIMember" name="ESIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_FourInvestorsMember" name="FourInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ThreeInvestorsMember" name="ThreeInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointFourPointTwoPointTwoMember" name="MileStoneTwoPointFourPointTwoPointTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointFourPointTwoPointFourMember" name="MileStoneTwoPointFourPointTwoPointFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MilestoneMNineMember" name="MilestoneMNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointThreePointTwoPointTwoMember" name="MileStoneTwoPointThreePointTwoPointTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MileStoneTwoPointThreePointThreePointTwoMember" name="MileStoneTwoPointThreePointThreePointTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MilestoneMFiveMember" name="MilestoneMFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConsolidatedBalanceSheetsAbstract" name="ConsolidatedBalanceSheetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConsolidatedStatementsOfOperationsAbstract" name="ConsolidatedStatementsOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LossOnDebtConversion" name="LossOnDebtConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LossOnExtensionOfWarrants" name="LossOnExtensionOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" name="CondensedConsolidatedStatementsOfCashFlowsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_CashPaidDuringPeriodForAbstract" name="CashPaidDuringPeriodForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DebtAndAccruedInterestConvertedToCommonStock" name="DebtAndAccruedInterestConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" name="ReclassificationOfAccountsPayableToConvertibleNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" name="DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" name="ReclassificationOfAccruedInterestToConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DarpaContractAndRelatedRevenueRecognition" name="DarpaContractAndRelatedRevenueRecognition" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" name="BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RegistrationPaymentArrangementsPolicyTextBlock" name="RegistrationPaymentArrangementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OffbalanceSheetArrangementsPolicyTextBlock" name="OffbalanceSheetArrangementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ScheduleOfNotesPayableTableTextBlock" name="ScheduleOfNotesPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ActivityInConvertibleNotesTextBlock" name="ActivityInConvertibleNotesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" name="WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LiquidityDetailsAbstract" name="LiquidityDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedInterestOnNotesPayable" name="AccruedInterestOnNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableCurrentBeforeDiscount" name="ConvertibleNotesPayableCurrentBeforeDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" name="DebtInstrumentUnamortizedDiscountCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedInterestCurrentPortion" name="AccruedInterestCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableNoncurrentPortion" name="ConvertibleNotesPayableNoncurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DebtInstrumentUnamortizedDiscountNonCurrent" name="DebtInstrumentUnamortizedDiscountNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedInterestNoncurrentPortion" name="AccruedInterestNoncurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_TotalConvertibleNotesPayable" name="TotalConvertibleNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_TotalAccruedInterest" name="TotalAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsOne" name="ConvertibleNotesPayableConversionsOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsTwo" name="ConvertibleNotesPayableConversionsTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsThree" name="ConvertibleNotesPayableConversionsThree" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsFour" name="ConvertibleNotesPayableConversionsFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsFive" name="ConvertibleNotesPayableConversionsFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IncreaseInConvertibleNotePayableExtensionFee" name="IncreaseInConvertibleNotePayableExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ConvertibleNotesPayableConversionsSix" name="ConvertibleNotesPayableConversionsSix" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockIssuedSubscribedSharesIssued" name="StockIssuedSubscribedSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarantsIssuedToAccreditedInvestors" name="WarantsIssuedToAccreditedInvestors" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedLiquidatedDamages" name="AccruedLiquidatedDamages" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedInterestOnNotesPayableInDefault" name="AccruedInterestOnNotesPayableInDefault" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SharebasedCompensationExpenseIncludedInNetLoss" name="SharebasedCompensationExpenseIncludedInNetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AmountAbstract" name="AmountAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePriceAbstract" name="RangeOfExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" name="StockOptionsOutstandingMinimumRangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" name="StockOptionsOutstandingMaximumRangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_Exercised" name="Exercised" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_Granted" name="Granted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_Cancelledexpired" name="Cancelledexpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" name="StockOptionsExercisableRangeOfExercisePricesMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" name="StockOptionsExercisableRangeOfExercisePricesMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePrice" name="RangeOfExercisePrice" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" name="WarrantsOutstandingRangeOfExercisePriceMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" name="WarrantsOutstandingRangeOfExercisePriceMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsExercisedRangeOfExercisePriceMinimum" name="WarrantsExercisedRangeOfExercisePriceMinimum" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsExercisedRangeOfExercisePriceMaximum" name="WarrantsExercisedRangeOfExercisePriceMaximum" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsIssuedRangeOfExercisePriceMinimum" name="WarrantsIssuedRangeOfExercisePriceMinimum" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsIssuedRangeOfExercisePriceMaximum" name="WarrantsIssuedRangeOfExercisePriceMaximum" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsCancelledExpiredRangeOfExercisePrice" name="WarrantsCancelledExpiredRangeOfExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" name="WarrantsCancelledExpiredRangeOfExercisePriceMaximum" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" name="WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" name="WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WeightedAverageExercisePrice" name="WeightedAverageExercisePrice" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsExercisedWeightedAverageExercisePrice" name="WarrantsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" name="WarrantsCancelledexpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NumberOfMilestonesUnderYearOneContract" name="NumberOfMilestonesUnderYearOneContract" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NumberOfMilestonesAchievedUnderYearOneContract2" name="NumberOfMilestonesAchievedUnderYearOneContract2" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SegmentsDetailsAbstract" name="SegmentsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>aemd-20140930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20140930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Liquidity" xlink:href="aemd-20140930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20140930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20140930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurements" xlink:href="aemd-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20140930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20140930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20140930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20140930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableTables" xlink:href="aemd-20140930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:href="aemd-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20140930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20140930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20140930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:href="aemd-20140930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayableDetails-NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails-Activity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20140930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:href="aemd-20140930.xsd#FairValueMeasurementsDetails-FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Level3" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20140930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20140930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20140930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20140930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20140930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Disclosure - Document And Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnDebtConversion" xlink:label="loc_aemdLossOnDebtConversion" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_aemdLossOnDebtConversion" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnExtensionOfWarrants" xlink:label="loc_aemdLossOnExtensionOfWarrants" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherExpenses" xlink:to="loc_aemdLossOnExtensionOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnExtensionOfWarrants" xlink:label="loc_aemdLossOnExtensionOfWarrants" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aemdLossOnExtensionOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnDebtConversion" xlink:label="loc_aemdLossOnDebtConversion" />
      <link:calculationArc order="1200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aemdLossOnDebtConversion" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Liquidity" xlink:title="00000007 - Disclosure - 2. LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. EQUITY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - 9. FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 10. STOCK COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - 11. WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000017 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 14. SEGMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 15. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableTables" xlink:title="00000023 - Disclosure - 4. NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:title="00000026 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 10. STOCK COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 11. WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 14. SEGMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:title="00000030 - Disclosure - 2. LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:title="00000031 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:title="00000033 - Disclosure - 4. NOTES PAYABLE (Details - Notes payable)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 4. NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:title="00000035 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:title="00000036 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details - Activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000037 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedLiquidatedDamages" xlink:label="loc_aemdAccruedLiquidatedDamages" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_aemdAccruedLiquidatedDamages" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - 8. OTHER CURRENT LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="00000041 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Details - Fair value)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:title="00000042 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:title="00000043 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Level 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:title="00000044 - Disclosure - 10. STOCK COMPENSATION (Details - Share-based compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:title="00000045 - Disclosure - 10. STOCK COMPENSATION (Details - Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:title="00000046 - Disclosure - 10. STOCK COMPENSATION (Details - Option information)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000047 - Disclosure - 10. STOCK COMPENSATION (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - 10. STOCK COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000049 - Disclosure - 11. WARRANTS (Details - Warrant activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:title="00000050 - Disclosure - 11. WARRANTS (Details - Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000051 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000053 - Disclosure - 14. SEGMENTS (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>aemd-20140930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20140930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Liquidity" xlink:href="aemd-20140930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20140930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20140930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurements" xlink:href="aemd-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20140930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20140930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20140930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20140930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableTables" xlink:href="aemd-20140930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:href="aemd-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20140930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20140930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20140930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:href="aemd-20140930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayableDetails-NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails-Activity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20140930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:href="aemd-20140930.xsd#FairValueMeasurementsDetails-FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Level3" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20140930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20140930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20140930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20140930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20140930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Disclosure - Document And Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Liquidity" xlink:title="00000007 - Disclosure - 2. LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. EQUITY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - 9. FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 10. STOCK COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - 11. WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000017 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 14. SEGMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 15. SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableTables" xlink:title="00000023 - Disclosure - 4. NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:label="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2010ConvertibleNotesMember" xlink:label="loc_aemdSeptember2010ConvertibleNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2010ConvertibleNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2011ConvertibleNotesMember" xlink:label="loc_aemdSeptember2011ConvertibleNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2011ConvertibleNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ActivityInConvertibleNotesTextBlock" xlink:label="loc_aemdActivityInConvertibleNotesTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdActivityInConvertibleNotesTextBlock_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:title="00000026 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 10. STOCK COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 11. WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 14. SEGMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:title="00000030 - Disclosure - 2. LIQUIDITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:title="00000031 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingOfStockOptionsMember" xlink:label="loc_aemdVestingOfStockOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOfStockOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncrementalFairValueOfOptionsMember" xlink:label="loc_aemdIncrementalFairValueOfOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdIncrementalFairValueOfOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingExpenseMember" xlink:label="loc_aemdVestingExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:title="00000033 - Disclosure - 4. NOTES PAYABLE (Details - Notes payable)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue12PercentMember" xlink:label="loc_aemdNotesPayablePastDue12PercentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue12PercentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue10PercentMember" xlink:label="loc_aemdNotesPayablePastDue10PercentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue10PercentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DirectorsNotesMember" xlink:label="loc_aemdDirectorsNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdDirectorsNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayable" xlink:label="loc_aemdAccruedInterestOnNotesPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestOnNotesPayable_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 4. NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue12PercentMember" xlink:label="loc_aemdNotesPayablePastDue12PercentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue12PercentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue10PercentMember" xlink:label="loc_aemdNotesPayablePastDue10PercentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue10PercentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DirectorsNotesMember" xlink:label="loc_aemdDirectorsNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdDirectorsNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayable" xlink:label="loc_aemdAccruedInterestOnNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestOnNotesPayable_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:title="00000035 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:label="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2010ConvertibleNote10PercentMember" xlink:label="loc_aemdApril2010ConvertibleNote10PercentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdApril2010ConvertibleNote10PercentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_JulyAugust201110PercentNoteMember" xlink:label="loc_aemdJulyAugust201110PercentNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdJulyAugust201110PercentNoteMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LawFirmNoteMember" xlink:label="loc_aemdLawFirmNoteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdLawFirmNoteMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:label="loc_aemdAmendedRestatedSeriesA12PercentConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdAmendedRestatedSeriesA12PercentConvertibleNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2010ConvertibleNotesMember" xlink:label="loc_aemdSeptember2010ConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2010ConvertibleNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2011ConvertibleNotes10PercentMember" xlink:label="loc_aemdApril2011ConvertibleNotes10PercentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdApril2011ConvertibleNotes10PercentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes10Percent2008Member" xlink:label="loc_aemdConvertibleNotes10Percent2008Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes10Percent2008Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2011ConvertibleNotesMember" xlink:label="loc_aemdSeptember2011ConvertibleNotesMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2011ConvertibleNotesMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableCurrentBeforeDiscount" xlink:label="loc_aemdConvertibleNotesPayableCurrentBeforeDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableCurrentBeforeDiscount_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" xlink:label="loc_aemdDebtInstrumentUnamortizedDiscountCurrentPortion_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdDebtInstrumentUnamortizedDiscountCurrentPortion_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestCurrentPortion" xlink:label="loc_aemdAccruedInterestCurrentPortion_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestCurrentPortion_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableNoncurrentPortion" xlink:label="loc_aemdConvertibleNotesPayableNoncurrentPortion_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableNoncurrentPortion_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountNonCurrent" xlink:label="loc_aemdDebtInstrumentUnamortizedDiscountNonCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdDebtInstrumentUnamortizedDiscountNonCurrent_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestNoncurrentPortion" xlink:label="loc_aemdAccruedInterestNoncurrentPortion_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestNoncurrentPortion_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalConvertibleNotesPayable" xlink:label="loc_aemdTotalConvertibleNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdTotalConvertibleNotesPayable_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalAccruedInterest" xlink:label="loc_aemdTotalAccruedInterest_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdTotalAccruedInterest_190" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:title="00000036 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details - Activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2009Member" xlink:label="loc_aemdConvertibleNotes2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2010Member" xlink:label="loc_aemdConvertibleNotes2010Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2010Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2011Member" xlink:label="loc_aemdConvertibleNotes2011Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2011Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsOne" xlink:label="loc_aemdConvertibleNotesPayableConversionsOne_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsOne_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsTwo" xlink:label="loc_aemdConvertibleNotesPayableConversionsTwo_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsTwo_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsThree" xlink:label="loc_aemdConvertibleNotesPayableConversionsThree_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsThree_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFour" xlink:label="loc_aemdConvertibleNotesPayableConversionsFour_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsFour_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFive" xlink:label="loc_aemdConvertibleNotesPayableConversionsFive_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsFive_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncreaseInConvertibleNotePayableExtensionFee" xlink:label="loc_aemdIncreaseInConvertibleNotePayableExtensionFee_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIncreaseInConvertibleNotePayableExtensionFee_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsSix" xlink:label="loc_aemdConvertibleNotesPayableConversionsSix_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsSix_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000037 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_FourInvestorsMember" xlink:label="loc_aemdFourInvestorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdFourInvestorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ThreeInvestorsMember" xlink:label="loc_aemdThreeInvestorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdThreeInvestorsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaapDebtConversionByUniqueDescriptionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NoteBalanceMember" xlink:label="loc_aemdNoteBalanceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdNoteBalanceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConversionAccruedInterestMember" xlink:label="loc_aemdConversionAccruedInterestMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdConversionAccruedInterestMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RestructuringFeeMember" xlink:label="loc_aemdRestructuringFeeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdRestructuringFeeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderOneMember" xlink:label="loc_aemdHolderOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdHolderOneMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderTwoMember" xlink:label="loc_aemdHolderTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdHolderTwoMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockIssuedSubscribedSharesIssued" xlink:label="loc_aemdStockIssuedSubscribedSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdStockIssuedSubscribedSharesIssued_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarantsIssuedToAccreditedInvestors" xlink:label="loc_aemdWarantsIssuedToAccreditedInvestors_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWarantsIssuedToAccreditedInvestors_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_110" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - 8. OTHER CURRENT LIABILITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="00000041 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:title="00000042 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_40" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:title="00000043 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Level 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:label="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:title="00000044 - Disclosure - 10. STOCK COMPENSATION (Details - Share-based compensation)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingOfStockOptionsMember" xlink:label="loc_aemdVestingOfStockOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOfStockOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncrementalFairValueOfOptionsMember" xlink:label="loc_aemdIncrementalFairValueOfOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdIncrementalFairValueOfOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingExpenseMember" xlink:label="loc_aemdVestingExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SharebasedCompensationExpenseIncludedInNetLoss" xlink:label="loc_aemdSharebasedCompensationExpenseIncludedInNetLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdSharebasedCompensationExpenseIncludedInNetLoss_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare_170" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:title="00000045 - Disclosure - 10. STOCK COMPENSATION (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:title="00000046 - Disclosure - 10. STOCK COMPENSATION (Details - Option information)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000047 - Disclosure - 10. STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmountAbstract" xlink:label="loc_aemdAmountAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAmountAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdAmountAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdAmountAbstract_20" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdAmountAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdAmountAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdAmountAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePriceAbstract" xlink:label="loc_aemdRangeOfExercisePriceAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePriceAbstract_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Exercised" xlink:label="loc_aemdExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdExercised_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Granted" xlink:label="loc_aemdGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdGranted_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Cancelledexpired" xlink:label="loc_aemdCancelledexpired_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdCancelledexpired_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:label="loc_aemdStockOptionsExercisableRangeOfExercisePricesMinimum_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdStockOptionsExercisableRangeOfExercisePricesMinimum_20" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:label="loc_aemdStockOptionsExercisableRangeOfExercisePricesMaximum_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePriceAbstract_20" xlink:to="loc_aemdStockOptionsExercisableRangeOfExercisePricesMaximum_20" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePriceAbstract" xlink:label="loc_aemdWeightedAverageExercisePriceAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - 10. STOCK COMPENSATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000049 - Disclosure - 11. WARRANTS (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePrice" xlink:label="loc_aemdRangeOfExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsExercisedRangeOfExercisePriceMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsExercisedRangeOfExercisePriceMinimum_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsExercisedRangeOfExercisePriceMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsExercisedRangeOfExercisePriceMaximum_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsIssuedRangeOfExercisePriceMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsIssuedRangeOfExercisePriceMinimum_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsIssuedRangeOfExercisePriceMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsIssuedRangeOfExercisePriceMaximum_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePrice" xlink:label="loc_aemdWarrantsCancelledExpiredRangeOfExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsCancelledExpiredRangeOfExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsCancelledExpiredRangeOfExercisePriceMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsCancelledExpiredRangeOfExercisePriceMaximum_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdRangeOfExercisePrice_40" xlink:to="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePrice" xlink:label="loc_aemdWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWeightedAverageExercisePrice_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePrice_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="loc_aemdWarrantsExercisedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePrice_40" xlink:to="loc_aemdWarrantsExercisedWeightedAverageExercisePrice_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePrice_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:label="loc_aemdWarrantsCancelledexpiredWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePrice_40" xlink:to="loc_aemdWarrantsCancelledexpiredWeightedAverageExercisePrice_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aemdWeightedAverageExercisePrice_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:title="00000050 - Disclosure - 11. WARRANTS (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendPayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendPayments_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000051 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointTwoMember" xlink:label="loc_aemdMileStoneTwoPointFourPointTwoPointTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointFourPointTwoPointTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointFourMember" xlink:label="loc_aemdMileStoneTwoPointFourPointTwoPointFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointFourPointTwoPointFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMNineMember" xlink:label="loc_aemdMilestoneMNineMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMilestoneMNineMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointTwoPointTwoMember" xlink:label="loc_aemdMileStoneTwoPointThreePointTwoPointTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointThreePointTwoPointTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointThreePointTwoMember" xlink:label="loc_aemdMileStoneTwoPointThreePointThreePointTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointThreePointThreePointTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMFiveMember" xlink:label="loc_aemdMilestoneMFiveMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMilestoneMFiveMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractsRevenue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesUnderYearOneContract" xlink:label="loc_aemdNumberOfMilestonesUnderYearOneContract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfMilestonesUnderYearOneContract_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesAchievedUnderYearOneContract2" xlink:label="loc_aemdNumberOfMilestonesAchievedUnderYearOneContract2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfMilestonesAchievedUnderYearOneContract2_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000053 - Disclosure - 14. SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AethlonMember" xlink:label="loc_aemdAethlonMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdAethlonMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ESIMember" xlink:label="loc_aemdESIMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdESIMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="loc_us-gaapPaymentsForCapitalImprovements_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForCapitalImprovements_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_130" xlink:type="arc" order="7" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>aemd-20140930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue10PercentMember" xlink:label="aemd_NotesPayablePastDue10PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NotesPayablePastDue10PercentMember" xlink:to="aemd_NotesPayablePastDue10PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NotesPayablePastDue10PercentMember_lbl" xml:lang="en-US">10% Note payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">CreditFacility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IpLawFirmNotePastDueMember" xlink:label="aemd_IpLawFirmNotePastDueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IpLawFirmNotePastDueMember" xlink:to="aemd_IpLawFirmNotePastDueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IpLawFirmNotePastDueMember_lbl" xml:lang="en-US">IP Law Firm Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LawFirmNoteMember" xlink:label="aemd_LawFirmNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LawFirmNoteMember" xlink:to="aemd_LawFirmNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LawFirmNoteMember_lbl" xml:lang="en-US">Law Firm Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TonaquintNoteMember" xlink:label="aemd_TonaquintNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TonaquintNoteMember" xlink:to="aemd_TonaquintNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_TonaquintNoteMember_lbl" xml:lang="en-US">Tonaquint Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue12PercentMember" xlink:label="aemd_NotesPayablePastDue12PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NotesPayablePastDue12PercentMember" xlink:to="aemd_NotesPayablePastDue12PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NotesPayablePastDue12PercentMember_lbl" xml:lang="en-US">12% Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:label="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:to="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember_lbl" xml:lang="en-US">Amended and Restated Series A 12% Convertible notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes10Percent2008Member" xlink:label="aemd_ConvertibleNotes10Percent2008Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes10Percent2008Member" xlink:to="aemd_ConvertibleNotes10Percent2008Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotes10Percent2008Member_lbl" xml:lang="en-US">2008 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_December10ConvertibleNotes2006Member" xlink:label="aemd_December10ConvertibleNotes2006Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_December10ConvertibleNotes2006Member" xlink:to="aemd_December10ConvertibleNotes2006Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_December10ConvertibleNotes2006Member_lbl" xml:lang="en-US">December 2006 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:label="aemd_OctoberNovember2009ConvertibleNotes10PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:to="aemd_OctoberNovember2009ConvertibleNotes10PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OctoberNovember2009ConvertibleNotes10PercentMember_lbl" xml:lang="en-US">October and November 2009 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2010ConvertibleNote10PercentMember" xlink:label="aemd_April2010ConvertibleNote10PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_April2010ConvertibleNote10PercentMember" xlink:to="aemd_April2010ConvertibleNote10PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_April2010ConvertibleNote10PercentMember_lbl" xml:lang="en-US">April 2010 10% Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2010ConvertibleNotesMember" xlink:label="aemd_September2010ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September2010ConvertibleNotesMember" xlink:to="aemd_September2010ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_September2010ConvertibleNotesMember_lbl" xml:lang="en-US">September 2010 12% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2011ConvertibleNotes10PercentMember" xlink:label="aemd_April2011ConvertibleNotes10PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_April2011ConvertibleNotes10PercentMember" xlink:to="aemd_April2011ConvertibleNotes10PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_April2011ConvertibleNotes10PercentMember_lbl" xml:lang="en-US">April 2011 12% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_JulyAndAugust2011ConvertibleNotes10PercentMember" xlink:label="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember" xlink:to="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember_lbl" xml:lang="en-US">July and August 2011 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2011ConvertibleNotesMember" xlink:label="aemd_September2011ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September2011ConvertibleNotesMember" xlink:to="aemd_September2011ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_September2011ConvertibleNotesMember_lbl" xml:lang="en-US">September 2011 12% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_February2012ConvertibleNotesMember" xlink:label="aemd_February2012ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_February2012ConvertibleNotesMember" xlink:to="aemd_February2012ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_February2012ConvertibleNotesMember_lbl" xml:lang="en-US">February 2012 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OfficerAndOurChiefFinancialOfficerMember" xlink:label="aemd_OfficerAndOurChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OfficerAndOurChiefFinancialOfficerMember" xlink:to="aemd_OfficerAndOurChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OfficerAndOurChiefFinancialOfficerMember_lbl" xml:lang="en-US">Officer And Our Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesApril2010Member" xlink:label="aemd_ConvertibleNotesApril2010Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesApril2010Member" xlink:to="aemd_ConvertibleNotesApril2010Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_ConvertibleNotesApril2010Member_lbl" xml:lang="en-US">April 2010 10% Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_November2011ConvertibleNotesMember" xlink:label="aemd_November2011ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_November2011ConvertibleNotesMember" xlink:to="aemd_November2011ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_November2011ConvertibleNotesMember_lbl" xml:lang="en-US">November2011ConvertibleNotes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September201010PercentConvertibleNotesMember" xlink:label="aemd_September201010PercentConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September201010PercentConvertibleNotesMember" xlink:to="aemd_September201010PercentConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_September201010PercentConvertibleNotesMember_lbl" xml:lang="en-US">September 2010 10 Percent Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">ShortTermDebtType [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">FairValueByFairValueHierarchyLevel [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_FinancingAgreement1000000Member" xlink:label="aemd_FinancingAgreement1000000Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FinancingAgreement1000000Member" xlink:to="aemd_FinancingAgreement1000000Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_FinancingAgreement1000000Member_lbl" xml:lang="en-US">Financing Agreement 1000000 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_FinancingAgreement715000Member" xlink:label="aemd_FinancingAgreement715000Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FinancingAgreement715000Member" xlink:to="aemd_FinancingAgreement715000Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_FinancingAgreement715000Member_lbl" xml:lang="en-US">Financing Agreement 715000 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_EquityInvestmentsMember" xlink:label="aemd_EquityInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_EquityInvestmentsMember" xlink:to="aemd_EquityInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_EquityInvestmentsMember_lbl" xml:lang="en-US">Equity Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SixthMilestoneMember" xlink:label="aemd_SixthMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SixthMilestoneMember" xlink:to="aemd_SixthMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SixthMilestoneMember_lbl" xml:lang="en-US">Sixth Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SeventhMember" xlink:label="aemd_SeventhMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SeventhMember" xlink:to="aemd_SeventhMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SeventhMember_lbl" xml:lang="en-US">Seventh Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_EighthMember" xlink:label="aemd_EighthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_EighthMember" xlink:to="aemd_EighthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_EighthMember_lbl" xml:lang="en-US">Eighth Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LaboratorySpaceMember" xlink:label="aemd_LaboratorySpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LaboratorySpaceMember" xlink:to="aemd_LaboratorySpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LaboratorySpaceMember_lbl" xml:lang="en-US">Laboratory Space Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category Of Item Purchased [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeBuildingMember" xlink:label="us-gaap_OfficeBuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeBuildingMember" xlink:to="us-gaap_OfficeBuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeBuildingMember_lbl" xml:lang="en-US">Office Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointTwoPointTwoPointThreeMember" xlink:label="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember" xlink:to="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember_lbl" xml:lang="en-US">MileStone 2.2.2.3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointTwoPointOnePointFourMember" xlink:label="aemd_MileStoneTwoPointTwoPointOnePointFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointTwoPointOnePointFourMember" xlink:to="aemd_MileStoneTwoPointTwoPointOnePointFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointTwoPointOnePointFourMember_lbl" xml:lang="en-US">MileStone 2.2.1.4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneMTwoMember" xlink:label="aemd_MileStoneMTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneMTwoMember" xlink:to="aemd_MileStoneMTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneMTwoMember_lbl" xml:lang="en-US">MileStone M-2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointThreePointOneMember" xlink:label="aemd_MileStoneTwoPointThreePointThreePointOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointThreePointOneMember" xlink:to="aemd_MileStoneTwoPointThreePointThreePointOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointThreePointThreePointOneMember_lbl" xml:lang="en-US">MileStone 2.3.3.1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LawFirmNote2Member" xlink:label="aemd_LawFirmNote2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LawFirmNote2Member" xlink:to="aemd_LawFirmNote2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LawFirmNote2Member_lbl" xml:lang="en-US">Law Firm Note 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesMember" xlink:label="aemd_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesMember" xlink:to="aemd_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtDiscountsMember" xlink:label="aemd_DebtDiscountsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtDiscountsMember" xlink:to="aemd_DebtDiscountsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DebtDiscountsMember_lbl" xml:lang="en-US">Debt Discounts [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesAndDebtDiscountMember" xlink:label="aemd_ConvertibleNotesAndDebtDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesAndDebtDiscountMember" xlink:to="aemd_ConvertibleNotesAndDebtDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesAndDebtDiscountMember_lbl" xml:lang="en-US">Convertible notes and debt discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DirectorsNotesMember" xlink:label="aemd_DirectorsNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DirectorsNotesMember" xlink:to="aemd_DirectorsNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DirectorsNotesMember_lbl" xml:lang="en-US">Directors Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2009Member" xlink:label="aemd_ConvertibleNotes2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2009Member" xlink:to="aemd_ConvertibleNotes2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotes2009Member_lbl" xml:lang="en-US">2009 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2010Member" xlink:label="aemd_ConvertibleNotes2010Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2010Member" xlink:to="aemd_ConvertibleNotes2010Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotes2010Member_lbl" xml:lang="en-US">2010 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2011Member" xlink:label="aemd_ConvertibleNotes2011Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2011Member" xlink:to="aemd_ConvertibleNotes2011Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotes2011Member_lbl" xml:lang="en-US">2011 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AethlonMedicalIncMember" xlink:label="aemd_AethlonMedicalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMedicalIncMember" xlink:to="aemd_AethlonMedicalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AethlonMedicalIncMember_lbl" xml:lang="en-US">Aethlon Medical, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ExosomeSciencesIncMember" xlink:label="aemd_ExosomeSciencesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ExosomeSciencesIncMember" xlink:to="aemd_ExosomeSciencesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ExosomeSciencesIncMember_lbl" xml:lang="en-US">Exosome Sciences, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingOfStockOptionsMember" xlink:label="aemd_VestingOfStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_VestingOfStockOptionsMember" xlink:to="aemd_VestingOfStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_VestingOfStockOptionsMember_lbl" xml:lang="en-US">Vesting of Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncrementalFairValueOfOptionsMember" xlink:label="aemd_IncrementalFairValueOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IncrementalFairValueOfOptionsMember" xlink:to="aemd_IncrementalFairValueOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IncrementalFairValueOfOptionsMember_lbl" xml:lang="en-US">Incremental fair value of option modifications [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingExpenseMember" xlink:label="aemd_VestingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_VestingExpenseMember" xlink:to="aemd_VestingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_VestingExpenseMember_lbl" xml:lang="en-US">Vesting Expense Associated with CEO Restricted Stock Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_JulyAugust201110PercentNoteMember" xlink:label="aemd_JulyAugust201110PercentNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_JulyAugust201110PercentNoteMember" xlink:to="aemd_JulyAugust201110PercentNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_JulyAugust201110PercentNoteMember_lbl" xml:lang="en-US">July and August 2011 10% Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NoteBalanceMember" xlink:label="aemd_NoteBalanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NoteBalanceMember" xlink:to="aemd_NoteBalanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NoteBalanceMember_lbl" xml:lang="en-US">Principal balance of note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderOneMember" xlink:label="aemd_HolderOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_HolderOneMember" xlink:to="aemd_HolderOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_HolderOneMember_lbl" xml:lang="en-US">Holder One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConversionAccruedInterestMember" xlink:label="aemd_ConversionAccruedInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConversionAccruedInterestMember" xlink:to="aemd_ConversionAccruedInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConversionAccruedInterestMember_lbl" xml:lang="en-US">Conversion of accrued interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RestructuringFeeMember" xlink:label="aemd_RestructuringFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RestructuringFeeMember" xlink:to="aemd_RestructuringFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RestructuringFeeMember_lbl" xml:lang="en-US">Restructuring Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderTwoMember" xlink:label="aemd_HolderTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_HolderTwoMember" xlink:to="aemd_HolderTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_HolderTwoMember_lbl" xml:lang="en-US">Holder Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AethlonMember" xlink:label="aemd_AethlonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMember" xlink:to="aemd_AethlonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AethlonMember_lbl" xml:lang="en-US">Aethlon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ESIMember" xlink:label="aemd_ESIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ESIMember" xlink:to="aemd_ESIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ESIMember_lbl" xml:lang="en-US">ESI [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_FourInvestorsMember" xlink:label="aemd_FourInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FourInvestorsMember" xlink:to="aemd_FourInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_FourInvestorsMember_lbl" xml:lang="en-US">Four investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ThreeInvestorsMember" xlink:label="aemd_ThreeInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ThreeInvestorsMember" xlink:to="aemd_ThreeInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ThreeInvestorsMember_lbl" xml:lang="en-US">Three investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointTwoMember" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointFourPointTwoPointTwoMember" xlink:to="aemd_MileStoneTwoPointFourPointTwoPointTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointTwoMember_lbl" xml:lang="en-US">Milestone 2.4.2.2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointFourMember" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointFourPointTwoPointFourMember" xlink:to="aemd_MileStoneTwoPointFourPointTwoPointFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointFourMember_lbl" xml:lang="en-US">MileStone 2.4.2.4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMNineMember" xlink:label="aemd_MilestoneMNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MilestoneMNineMember" xlink:to="aemd_MilestoneMNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MilestoneMNineMember_lbl" xml:lang="en-US">Milestone M9 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointTwoPointTwoMember" xlink:label="aemd_MileStoneTwoPointThreePointTwoPointTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointTwoPointTwoMember" xlink:to="aemd_MileStoneTwoPointThreePointTwoPointTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointThreePointTwoPointTwoMember_lbl" xml:lang="en-US">MileStone 2.3.2.2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointThreePointTwoMember" xlink:label="aemd_MileStoneTwoPointThreePointThreePointTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointThreePointTwoMember" xlink:to="aemd_MileStoneTwoPointThreePointThreePointTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MileStoneTwoPointThreePointThreePointTwoMember_lbl" xml:lang="en-US">MileStone 2.3.3.2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMFiveMember" xlink:label="aemd_MilestoneMFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MilestoneMFiveMember" xlink:to="aemd_MilestoneMFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MilestoneMFiveMember_lbl" xml:lang="en-US">Milestone M5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DocumentAndEntityInformationAbstract" xlink:label="aemd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DocumentAndEntityInformationAbstract" xlink:to="aemd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Term Of Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConsolidatedBalanceSheetsAbstract" xlink:label="aemd_ConsolidatedBalanceSheetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConsolidatedBalanceSheetsAbstract" xlink:to="aemd_ConsolidatedBalanceSheetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConsolidatedBalanceSheetsAbstract_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Patents and patents pending, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Noncurrent liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, noncurrent portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total noncurrent liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001 per share; 500,000,000 shares authorized as of September 30, 2014 and March 31, 2014; 262,713,781 and 224,973,980 shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Aethlon Medical, Inc. stockholders' deficit before noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConsolidatedStatementsOfOperationsAbstract" xlink:label="aemd_ConsolidatedStatementsOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConsolidatedStatementsOfOperationsAbstract" xlink:to="aemd_ConsolidatedStatementsOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConsolidatedStatementsOfOperationsAbstract_lbl" xml:lang="en-US">Debt discount recorded in connection with beneficial conversion feature of convertible notes and related warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Government contract revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnDebtConversion" xlink:label="aemd_LossOnDebtConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LossOnDebtConversion" xlink:to="aemd_LossOnDebtConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aemd_LossOnDebtConversion_lbl" xml:lang="en-US">Loss on debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">(Gain)/loss on change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest and other debt expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnExtensionOfWarrants" xlink:label="aemd_LossOnExtensionOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LossOnExtensionOfWarrants" xlink:to="aemd_LossOnExtensionOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LossOnExtensionOfWarrants_lbl" xml:lang="en-US">Loss on extension of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS BEFORE NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:label="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US">Debt and accrued interest converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Fair market value of common stock, warrants and options issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from the issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_CashPaidDuringPeriodForAbstract" xlink:label="aemd_CashPaidDuringPeriodForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CashPaidDuringPeriodForAbstract" xlink:to="aemd_CashPaidDuringPeriodForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtAndAccruedInterestConvertedToCommonStock" xlink:label="aemd_DebtAndAccruedInterestConvertedToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtAndAccruedInterestConvertedToCommonStock" xlink:to="aemd_DebtAndAccruedInterestConvertedToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_DebtAndAccruedInterestConvertedToCommonStock_lbl" xml:lang="en-US">Debt and accrued interest converted to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:label="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:to="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_lbl" xml:lang="en-US">Reclassification of warrant derivative liability into equity</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" xlink:label="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" xlink:to="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable_lbl" xml:lang="en-US">Reclassification of accounts payable to convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" xlink:label="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" xlink:to="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment_lbl" xml:lang="en-US">Deferred financing costs recorded in connection with debt amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:label="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:to="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable_lbl" xml:lang="en-US">Reclassification of accrued interest to convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DarpaContractAndRelatedRevenueRecognition" xlink:label="aemd_DarpaContractAndRelatedRevenueRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DarpaContractAndRelatedRevenueRecognition" xlink:to="aemd_DarpaContractAndRelatedRevenueRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DarpaContractAndRelatedRevenueRecognition_lbl" xml:lang="en-US">DARPA CONTRACT AND RELATED REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">PRINCIPLES OF CONSOLIDATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">CONCENTRATIONS OF CREDIT RISKS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">DEFERRED FINANCING COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xml:lang="en-US">STOCK PURCHASE WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">DERIVATIVE INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" xlink:label="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" xlink:to="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock_lbl" xml:lang="en-US">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RegistrationPaymentArrangementsPolicyTextBlock" xlink:label="aemd_RegistrationPaymentArrangementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RegistrationPaymentArrangementsPolicyTextBlock" xlink:to="aemd_RegistrationPaymentArrangementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RegistrationPaymentArrangementsPolicyTextBlock_lbl" xml:lang="en-US">REGISTRATION PAYMENT ARRANGEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OffbalanceSheetArrangementsPolicyTextBlock" xlink:label="aemd_OffbalanceSheetArrangementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OffbalanceSheetArrangementsPolicyTextBlock" xlink:to="aemd_OffbalanceSheetArrangementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OffbalanceSheetArrangementsPolicyTextBlock_lbl" xml:lang="en-US">OFF-BALANCE SHEET ARRANGEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ScheduleOfNotesPayableTableTextBlock" xlink:label="aemd_ScheduleOfNotesPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ScheduleOfNotesPayableTableTextBlock" xlink:to="aemd_ScheduleOfNotesPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ActivityInConvertibleNotesTextBlock" xlink:label="aemd_ActivityInConvertibleNotesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ActivityInConvertibleNotesTextBlock" xlink:to="aemd_ActivityInConvertibleNotesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ActivityInConvertibleNotesTextBlock_lbl" xml:lang="en-US">Activity in Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair value measurements based on the valuation technique</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Significant weighted average assumptions used to estimate the fair value information utilizing the Binomial Lattice option pricing model</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Summary of changes in the fair value of our Level 3 financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Components of share-based compensation expenses relating to shares and options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted average assumptions used to estimate the fair value information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US">Stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of warrant activity exercisable and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" xlink:label="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" xlink:to="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock_lbl" xml:lang="en-US">Weighted average assumptions used to estimate the fair value, with respect to warrants utilizing the Binomial Lattice option pricing model</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LiquidityDetailsAbstract" xlink:label="aemd_LiquidityDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LiquidityDetailsAbstract" xlink:to="aemd_LiquidityDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_LiquidityDetailsAbstract_lbl" xml:lang="en-US">Reclassification of warrant derivative liability into equity</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WorkingCapital" xlink:label="aemd_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WorkingCapital" xlink:to="aemd_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:to="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_2_lbl" xml:lang="en-US">Derivative liability reclassified into equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total Stock-Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially antidilutive shares excluded from EPS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CreditFacilityAxis_2_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_2_lbl" xml:lang="en-US">Principal Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayable" xlink:label="aemd_AccruedInterestOnNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestOnNotesPayable" xlink:to="aemd_AccruedInterestOnNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedInterestOnNotesPayable_lbl" xml:lang="en-US">Accrued Interest on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense related to notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableCurrentBeforeDiscount" xlink:label="aemd_ConvertibleNotesPayableCurrentBeforeDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableCurrentBeforeDiscount" xlink:to="aemd_ConvertibleNotesPayableCurrentBeforeDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableCurrentBeforeDiscount_lbl" xml:lang="en-US">Convertible Notes Payable - Current Portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" xlink:label="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" xlink:to="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion_lbl" xml:lang="en-US">Unamortized discount - current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible Notes Payable, net - Current Portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestCurrentPortion" xlink:label="aemd_AccruedInterestCurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestCurrentPortion" xlink:to="aemd_AccruedInterestCurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedInterestCurrentPortion_lbl" xml:lang="en-US">Accrued interest - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableNoncurrentPortion" xlink:label="aemd_ConvertibleNotesPayableNoncurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableNoncurrentPortion" xlink:to="aemd_ConvertibleNotesPayableNoncurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableNoncurrentPortion_lbl" xml:lang="en-US">Convertible Notes Payable - Non-Current Portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountNonCurrent" xlink:label="aemd_DebtInstrumentUnamortizedDiscountNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtInstrumentUnamortizedDiscountNonCurrent" xlink:to="aemd_DebtInstrumentUnamortizedDiscountNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DebtInstrumentUnamortizedDiscountNonCurrent_lbl" xml:lang="en-US">Unamortized discount - Non-current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable, net - Non-Current Portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestNoncurrentPortion" xlink:label="aemd_AccruedInterestNoncurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestNoncurrentPortion" xlink:to="aemd_AccruedInterestNoncurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedInterestNoncurrentPortion_lbl" xml:lang="en-US">Accrued interest - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalConvertibleNotesPayable" xlink:label="aemd_TotalConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TotalConvertibleNotesPayable" xlink:to="aemd_TotalConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_TotalConvertibleNotesPayable_lbl" xml:lang="en-US">Total Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Total Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalAccruedInterest" xlink:label="aemd_TotalAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TotalAccruedInterest" xlink:to="aemd_TotalAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_TotalAccruedInterest_lbl" xml:lang="en-US">Total Accrued Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Initial principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsOne" xlink:label="aemd_ConvertibleNotesPayableConversionsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsOne" xlink:to="aemd_ConvertibleNotesPayableConversionsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsOne_lbl" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2010</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsTwo" xlink:label="aemd_ConvertibleNotesPayableConversionsTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsTwo" xlink:to="aemd_ConvertibleNotesPayableConversionsTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsTwo_lbl" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2011</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsThree" xlink:label="aemd_ConvertibleNotesPayableConversionsThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsThree" xlink:to="aemd_ConvertibleNotesPayableConversionsThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsThree_lbl" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFour" xlink:label="aemd_ConvertibleNotesPayableConversionsFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsFour" xlink:to="aemd_ConvertibleNotesPayableConversionsFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsFour_lbl" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2013</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFive" xlink:label="aemd_ConvertibleNotesPayableConversionsFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsFive" xlink:to="aemd_ConvertibleNotesPayableConversionsFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsFive_lbl" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2014</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncreaseInConvertibleNotePayableExtensionFee" xlink:label="aemd_IncreaseInConvertibleNotePayableExtensionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IncreaseInConvertibleNotePayableExtensionFee" xlink:to="aemd_IncreaseInConvertibleNotePayableExtensionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IncreaseInConvertibleNotePayableExtensionFee_lbl" xml:lang="en-US">Increase in principal balance due to 12% extension fee</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsSix" xlink:label="aemd_ConvertibleNotesPayableConversionsSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsSix" xlink:to="aemd_ConvertibleNotesPayableConversionsSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesPayableConversionsSix_lbl" xml:lang="en-US">Conversions during the three months ended June 30, 2014</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ConvertibleNotesPayable_3_lbl" xml:lang="en-US">Balance as of September 30, 2014</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US">Interest expense related to convertible notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of deferred finance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockIssuedSubscribedSharesIssued" xlink:label="aemd_StockIssuedSubscribedSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockIssuedSubscribedSharesIssued" xlink:to="aemd_StockIssuedSubscribedSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockIssuedSubscribedSharesIssued_lbl" xml:lang="en-US">Stock issued subscribed, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarantsIssuedToAccreditedInvestors" xlink:label="aemd_WarantsIssuedToAccreditedInvestors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarantsIssuedToAccreditedInvestors" xlink:to="aemd_WarantsIssuedToAccreditedInvestors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarantsIssuedToAccreditedInvestors_lbl" xml:lang="en-US">Warants issued to accredited investors</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from subscription and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for services, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued for services, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock issued in exchange of note, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Stock issued in exchange of note, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted common stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted common stock issued, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock acquired, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Stock acquired, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedLiquidatedDamages" xlink:label="aemd_AccruedLiquidatedDamages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedLiquidatedDamages" xlink:to="aemd_AccruedLiquidatedDamages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedLiquidatedDamages_lbl" xml:lang="en-US">Accrued liquidated damages</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayableInDefault" xlink:label="aemd_AccruedInterestOnNotesPayableInDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestOnNotesPayableInDefault" xlink:to="aemd_AccruedInterestOnNotesPayableInDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedInterestOnNotesPayableInDefault_lbl" xml:lang="en-US">Accrued Interest On Notes Payable in default</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Fair Value Assumptions and Methodology for Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Average expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US">Recorded new derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US">Change in estimated fair value recognized in results of operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:to="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity_3_lbl" xml:lang="en-US">Reclassification of derivative liability to paid in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_3_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SharebasedCompensationExpenseIncludedInNetLoss" xlink:label="aemd_SharebasedCompensationExpenseIncludedInNetLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SharebasedCompensationExpenseIncludedInNetLoss" xlink:to="aemd_SharebasedCompensationExpenseIncludedInNetLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SharebasedCompensationExpenseIncludedInNetLoss_lbl" xml:lang="en-US">Total share-based compensation expense included in net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Average expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmountAbstract" xlink:label="aemd_AmountAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AmountAbstract" xlink:to="aemd_AmountAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AmountAbstract_lbl" xml:lang="en-US">Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Stock options outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Stock options outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePriceAbstract" xlink:label="aemd_RangeOfExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePriceAbstract" xlink:to="aemd_RangeOfExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePriceAbstract_lbl" xml:lang="en-US">Range of Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:label="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_lbl" xml:lang="en-US">Stock options outstanding Minimum beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:label="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_lbl" xml:lang="en-US">Stock options outstanding at Maximum beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Exercised" xlink:label="aemd_Exercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Exercised" xlink:to="aemd_Exercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_Exercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Granted" xlink:label="aemd_Granted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Granted" xlink:to="aemd_Granted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_Granted_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Cancelledexpired" xlink:label="aemd_Cancelledexpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Cancelledexpired" xlink:to="aemd_Cancelledexpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_Cancelledexpired_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_2_lbl" xml:lang="en-US">Stock options outstanding Minimum ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_2_lbl" xml:lang="en-US">Stock options outstanding Maximum ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_lbl" xml:lang="en-US">Stock options exercisable Minimum ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_lbl" xml:lang="en-US">Stock options exercisable Maximum ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePriceAbstract" xlink:label="aemd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePriceAbstract" xlink:to="aemd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock options outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition of unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Summary Of Warrant Activity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Warrants Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePrice" xlink:label="aemd_RangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePrice" xlink:to="aemd_RangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_RangeOfExercisePrice_lbl" xml:lang="en-US">Range of Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_lbl" xml:lang="en-US">Warrants outstanding, beginning - Range of Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_lbl" xml:lang="en-US">Warrants outstanding, beginning - Range of Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMinimum" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsExercisedRangeOfExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMinimum_lbl" xml:lang="en-US">Warrants Exercised - Range of Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMaximum" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsExercisedRangeOfExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMaximum_lbl" xml:lang="en-US">Warrants Exercised - Range of Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMinimum" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsIssuedRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsIssuedRangeOfExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMinimum_lbl" xml:lang="en-US">Warrants Issued - Range of Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMaximum" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsIssuedRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsIssuedRangeOfExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMaximum_lbl" xml:lang="en-US">Warrants Issued - Range of Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePrice" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledExpiredRangeOfExercisePrice" xlink:to="aemd_WarrantsCancelledExpiredRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePrice_lbl" xml:lang="en-US">Warrants Cancelled/Expired - Range of Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum_lbl" xml:lang="en-US">Warrants Cancelled/Expired - Range of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_2_lbl" xml:lang="en-US">Warrants outstanding, ending - Range of Exercise Price Minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_2_lbl" xml:lang="en-US">Warrants outstanding, ending - Range of Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_lbl" xml:lang="en-US">Warrants Exercisable, ending - Range of Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_lbl" xml:lang="en-US">Warrants Exercisable, ending - Range of Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePrice" xlink:label="aemd_WeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePrice" xlink:to="aemd_WeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_WeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants outstanding Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="aemd_WarrantsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedWeightedAverageExercisePrice" xlink:to="aemd_WarrantsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants Exercised Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants Issued Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:label="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:to="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants Cancelled/Expired Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Warrants outstanding Weighted Average Exercise Price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants exercisable Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US">Contract revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesUnderYearOneContract" xlink:label="aemd_NumberOfMilestonesUnderYearOneContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfMilestonesUnderYearOneContract" xlink:to="aemd_NumberOfMilestonesUnderYearOneContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NumberOfMilestonesUnderYearOneContract_lbl" xml:lang="en-US">Number Of Milestones Under Year One Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesAchievedUnderYearOneContract2" xlink:label="aemd_NumberOfMilestonesAchievedUnderYearOneContract2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfMilestonesAchievedUnderYearOneContract2" xlink:to="aemd_NumberOfMilestonesAchievedUnderYearOneContract2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NumberOfMilestonesAchievedUnderYearOneContract2_lbl" xml:lang="en-US">Number Of Milestones Achieved Under Year One Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="us-gaap_PaymentsForCapitalImprovements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCapitalImprovements" xlink:to="us-gaap_PaymentsForCapitalImprovements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCapitalImprovements_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestOnNotesPayable" xlink:to="aemd_AccruedInterestOnNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedInterestOnNotesPayable_doc" xml:lang="en-US">Accrued Interest on notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestOnNotesPayableInDefault" xlink:to="aemd_AccruedInterestOnNotesPayableInDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedInterestOnNotesPayableInDefault_doc" xml:lang="en-US">Accrued Interest On Notes Payable in default</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ActivityInConvertibleNotesTextBlock" xlink:to="aemd_ActivityInConvertibleNotesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ActivityInConvertibleNotesTextBlock_doc" xml:lang="en-US">Activity in Convertible Notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMedicalIncMember" xlink:to="aemd_AethlonMedicalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AethlonMedicalIncMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:to="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember_doc" xml:lang="en-US">April2010ConvertibleNote10PercentMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AmountAbstract" xlink:to="aemd_AmountAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AmountAbstract_doc" xml:lang="en-US">Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_April2010ConvertibleNote10PercentMember" xlink:to="aemd_April2010ConvertibleNote10PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_April2010ConvertibleNote10PercentMember_doc" xml:lang="en-US">Authorized shares Increased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_April2011ConvertibleNotes10PercentMember" xlink:to="aemd_April2011ConvertibleNotes10PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_April2011ConvertibleNotes10PercentMember_doc" xml:lang="en-US">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" xlink:to="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock_doc" xml:lang="en-US">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Cancelledexpired" xlink:to="aemd_Cancelledexpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_Cancelledexpired_doc" xml:lang="en-US">Range of exercise price - cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CashPaidDuringPeriodForAbstract" xlink:to="aemd_CashPaidDuringPeriodForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_CashPaidDuringPeriodForAbstract_doc" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract_doc" xml:lang="en-US">Convertible Notes Payable Details Narrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConsolidatedBalanceSheetsAbstract" xlink:to="aemd_ConsolidatedBalanceSheetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConsolidatedBalanceSheetsAbstract_doc" xml:lang="en-US">Debt and accrued interest converted to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConsolidatedStatementsOfOperationsAbstract" xlink:to="aemd_ConsolidatedStatementsOfOperationsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConsolidatedStatementsOfOperationsAbstract_doc" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes10Percent2008Member" xlink:to="aemd_ConvertibleNotes10Percent2008Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotes10Percent2008Member_doc" xml:lang="en-US">December10ConvertibleNotes2006Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2009Member" xlink:to="aemd_ConvertibleNotes2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotes2009Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2010Member" xlink:to="aemd_ConvertibleNotes2010Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotes2010Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotes2011Member" xlink:to="aemd_ConvertibleNotes2011Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotes2011Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesAndDebtDiscountMember" xlink:to="aemd_ConvertibleNotesAndDebtDiscountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesAndDebtDiscountMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesMember" xlink:to="aemd_ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsFive" xlink:to="aemd_ConvertibleNotesPayableConversionsFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsFive_doc" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2014</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsFour" xlink:to="aemd_ConvertibleNotesPayableConversionsFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsFour_doc" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2013.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsOne" xlink:to="aemd_ConvertibleNotesPayableConversionsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsOne_doc" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2010.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsThree" xlink:to="aemd_ConvertibleNotesPayableConversionsThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsThree_doc" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2012.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsTwo" xlink:to="aemd_ConvertibleNotesPayableConversionsTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsTwo_doc" xml:lang="en-US">Conversions during the fiscal year ended March 31, 2011.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DarpaContractAndRelatedRevenueRecognition" xlink:to="aemd_DarpaContractAndRelatedRevenueRecognition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DarpaContractAndRelatedRevenueRecognition_doc" xml:lang="en-US">DARPA CONTRACT AND RELATED REVENUE RECOGNITION</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtAndAccruedInterestConvertedToCommonStock" xlink:to="aemd_DebtAndAccruedInterestConvertedToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DebtAndAccruedInterestConvertedToCommonStock_doc" xml:lang="en-US">Debt and accrued interest converted to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtDiscountsMember" xlink:to="aemd_DebtDiscountsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DebtDiscountsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_December10ConvertibleNotes2006Member" xlink:to="aemd_December10ConvertibleNotes2006Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_December10ConvertibleNotes2006Member_doc" xml:lang="en-US">February2012ConvertibleNotesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DirectorsNotesMember" xlink:to="aemd_DirectorsNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DirectorsNotesMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DocumentAndEntityInformationAbstract" xlink:to="aemd_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_EighthMember" xlink:to="aemd_EighthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_EighthMember_doc" xml:lang="en-US">Interest expense related to contractual interest rates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_EquityInvestmentsMember" xlink:to="aemd_EquityInvestmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_EquityInvestmentsMember_doc" xml:lang="en-US">IpLawFirmNotePastDueMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Exercised" xlink:to="aemd_Exercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_Exercised_doc" xml:lang="en-US">Range of exercise price - exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ExosomeSciencesIncMember" xlink:to="aemd_ExosomeSciencesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ExosomeSciencesIncMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_February2012ConvertibleNotesMember" xlink:to="aemd_February2012ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_February2012ConvertibleNotesMember_doc" xml:lang="en-US">Note 5. Convertible Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FinancingAgreement1000000Member" xlink:to="aemd_FinancingAgreement1000000Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_FinancingAgreement1000000Member_doc" xml:lang="en-US">Loss on settlement of convertible note termination</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FinancingAgreement715000Member" xlink:to="aemd_FinancingAgreement715000Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_FinancingAgreement715000Member_doc" xml:lang="en-US">Notes payable, all current liabilities and unsecured</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IpLawFirmNotePastDueMember" xlink:to="aemd_IpLawFirmNotePastDueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_IpLawFirmNotePastDueMember_doc" xml:lang="en-US">OfficerAndOurChiefFinancialOfficerMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember" xlink:to="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_JulyAndAugust2011ConvertibleNotes10PercentMember_doc" xml:lang="en-US">Aggregate maximum liquidated damages amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LaboratorySpaceMember" xlink:to="aemd_LaboratorySpaceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LaboratorySpaceMember_doc" xml:lang="en-US">Other Current Liability Details Narrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LawFirmNote2Member" xlink:to="aemd_LawFirmNote2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LawFirmNote2Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LawFirmNoteMember" xlink:to="aemd_LawFirmNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LawFirmNoteMember_doc" xml:lang="en-US">Note 8. Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LiquidityDetailsAbstract" xlink:to="aemd_LiquidityDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LiquidityDetailsAbstract_doc" xml:lang="en-US">Range of Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneMTwoMember" xlink:to="aemd_MileStoneMTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneMTwoMember_doc" xml:lang="en-US">Registration payment of financing arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointThreePointOneMember" xlink:to="aemd_MileStoneTwoPointThreePointThreePointOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointThreePointThreePointOneMember_doc" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointTwoPointOnePointFourMember" xlink:to="aemd_MileStoneTwoPointTwoPointOnePointFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointTwoPointOnePointFourMember_doc" xml:lang="en-US">Note 11. Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember" xlink:to="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointTwoPointTwoPointThreeMember_doc" xml:lang="en-US">September201010PercentConvertibleNotesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NotesPayablePastDue10PercentMember" xlink:to="aemd_NotesPayablePastDue10PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NotesPayablePastDue10PercentMember_doc" xml:lang="en-US">Note 10. Stock Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NotesPayablePastDue12PercentMember" xlink:to="aemd_NotesPayablePastDue12PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NotesPayablePastDue12PercentMember_doc" xml:lang="en-US">Note 3. Summary Of Significant Accounting Policies</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_November2011ConvertibleNotesMember" xlink:to="aemd_November2011ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_November2011ConvertibleNotesMember_doc" xml:lang="en-US">November 2011 Convertible notes member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:to="aemd_OctoberNovember2009ConvertibleNotes10PercentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_OctoberNovember2009ConvertibleNotes10PercentMember_doc" xml:lang="en-US">StockOptionsOutstandingRangeOfExercisePrices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OfficerAndOurChiefFinancialOfficerMember" xlink:to="aemd_OfficerAndOurChiefFinancialOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_OfficerAndOurChiefFinancialOfficerMember_doc" xml:lang="en-US">Note 16. Subsequent Events</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePrice" xlink:to="aemd_RangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePrice_doc" xml:lang="en-US">Warrants Cancelled/Expired Range of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePriceAbstract" xlink:to="aemd_RangeOfExercisePriceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePriceAbstract_doc" xml:lang="en-US">Range of Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RegistrationPaymentArrangementsPolicyTextBlock" xlink:to="aemd_RegistrationPaymentArrangementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RegistrationPaymentArrangementsPolicyTextBlock_doc" xml:lang="en-US">REGISTRATION PAYMENT ARRANGEMENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September201010PercentConvertibleNotesMember" xlink:to="aemd_September201010PercentConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_September201010PercentConvertibleNotesMember_doc" xml:lang="en-US">Weighted average period for recognition of unrecognized compensation cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September2010ConvertibleNotesMember" xlink:to="aemd_September2010ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_September2010ConvertibleNotesMember_doc" xml:lang="en-US">September2010ConvertibleNotesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_September2011ConvertibleNotesMember" xlink:to="aemd_September2011ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_September2011ConvertibleNotesMember_doc" xml:lang="en-US">September2011ConvertibleNotesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SeventhMember" xlink:to="aemd_SeventhMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_SeventhMember_doc" xml:lang="en-US">Seventh member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SixthMilestoneMember" xlink:to="aemd_SixthMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_SixthMilestoneMember_doc" xml:lang="en-US">Sixth milestone member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_doc" xml:lang="en-US">Stock options exercisable Maximum ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_doc" xml:lang="en-US">Stock options exercisable Minimum ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_doc" xml:lang="en-US">Stock options outstanding at Maximum beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_doc" xml:lang="en-US">Stock options outstanding Minimum beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TonaquintNoteMember" xlink:to="aemd_TonaquintNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_TonaquintNoteMember_doc" xml:lang="en-US">TonaquintNoteMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum_doc" xml:lang="en-US">Warrants Cancelled/Expired Range of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:to="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants Cancelled/Expired Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_doc" xml:lang="en-US">Warrants Exercisable Range of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_doc" xml:lang="en-US">Warrants Exercisable at Range of Exercise Price Minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsExercisedRangeOfExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMaximum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsExercisedRangeOfExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsExercisedRangeOfExercisePriceMinimum_doc" xml:lang="en-US">Warrants Exercised Range of Exercise Price Minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisedWeightedAverageExercisePrice" xlink:to="aemd_WarrantsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants Exercised Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsIssuedRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsIssuedRangeOfExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMaximum_doc" xml:lang="en-US">Warrants Issued Range of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsIssuedRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsIssuedRangeOfExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsIssuedRangeOfExercisePriceMinimum_doc" xml:lang="en-US">Warrants Issued Range of Exercise Price Minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_doc" xml:lang="en-US">Warrants Outstanding Range Of Exercise Price Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_doc" xml:lang="en-US">Warrants Outstanding Range Of Exercise Price Minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" xlink:to="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock_doc" xml:lang="en-US">Weighted average assumptions used to estimate the fair value, with respect to warrants utilizing the Binomial Lattice option pricing model</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePrice" xlink:to="aemd_WeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePriceAbstract" xlink:to="aemd_WeightedAverageExercisePriceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WeightedAverageExercisePriceAbstract_doc" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WorkingCapital" xlink:to="aemd_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WorkingCapital_doc" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OffbalanceSheetArrangementsPolicyTextBlock" xlink:to="aemd_OffbalanceSheetArrangementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_OffbalanceSheetArrangementsPolicyTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ScheduleOfNotesPayableTableTextBlock" xlink:to="aemd_ScheduleOfNotesPayableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ScheduleOfNotesPayableTableTextBlock_doc" xml:lang="en-US">Schedule of notes payable table text block</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_VestingOfStockOptionsMember" xlink:to="aemd_VestingOfStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_VestingOfStockOptionsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IncrementalFairValueOfOptionsMember" xlink:to="aemd_IncrementalFairValueOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_IncrementalFairValueOfOptionsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_VestingExpenseMember" xlink:to="aemd_VestingExpenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_VestingExpenseMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_JulyAugust201110PercentNoteMember" xlink:to="aemd_JulyAugust201110PercentNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_JulyAugust201110PercentNoteMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableConversionsSix" xlink:to="aemd_ConvertibleNotesPayableConversionsSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableConversionsSix_doc" xml:lang="en-US">Conversions during the three months ended June 30, 2014</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IncreaseInConvertibleNotePayableExtensionFee" xlink:to="aemd_IncreaseInConvertibleNotePayableExtensionFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_IncreaseInConvertibleNotePayableExtensionFee_doc" xml:lang="en-US">Increase in principal balance due to 12% extension fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockIssuedSubscribedSharesIssued" xlink:to="aemd_StockIssuedSubscribedSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockIssuedSubscribedSharesIssued_doc" xml:lang="en-US">Stock issued subscribed, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarantsIssuedToAccreditedInvestors" xlink:to="aemd_WarantsIssuedToAccreditedInvestors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarantsIssuedToAccreditedInvestors_doc" xml:lang="en-US">Warants issued to accredited investors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NoteBalanceMember" xlink:to="aemd_NoteBalanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NoteBalanceMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConversionAccruedInterestMember" xlink:to="aemd_ConversionAccruedInterestMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConversionAccruedInterestMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RestructuringFeeMember" xlink:to="aemd_RestructuringFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RestructuringFeeMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_HolderOneMember" xlink:to="aemd_HolderOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_HolderOneMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_HolderTwoMember" xlink:to="aemd_HolderTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_HolderTwoMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedLiquidatedDamages" xlink:to="aemd_AccruedLiquidatedDamages_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedLiquidatedDamages_doc" xml:lang="en-US">Accrued liquidated damages</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMember" xlink:to="aemd_AethlonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AethlonMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ESIMember" xlink:to="aemd_ESIMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ESIMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesApril2010Member" xlink:to="aemd_ConvertibleNotesApril2010Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesApril2010Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableCurrentBeforeDiscount" xlink:to="aemd_ConvertibleNotesPayableCurrentBeforeDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableCurrentBeforeDiscount_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" xlink:to="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DebtInstrumentUnamortizedDiscountCurrentPortion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestCurrentPortion" xlink:to="aemd_AccruedInterestCurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedInterestCurrentPortion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesPayableNoncurrentPortion" xlink:to="aemd_ConvertibleNotesPayableNoncurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ConvertibleNotesPayableNoncurrentPortion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtInstrumentUnamortizedDiscountNonCurrent" xlink:to="aemd_DebtInstrumentUnamortizedDiscountNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DebtInstrumentUnamortizedDiscountNonCurrent_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedInterestNoncurrentPortion" xlink:to="aemd_AccruedInterestNoncurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedInterestNoncurrentPortion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TotalConvertibleNotesPayable" xlink:to="aemd_TotalConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_TotalConvertibleNotesPayable_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TotalAccruedInterest" xlink:to="aemd_TotalAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_TotalAccruedInterest_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_FourInvestorsMember" xlink:to="aemd_FourInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_FourInvestorsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ThreeInvestorsMember" xlink:to="aemd_ThreeInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ThreeInvestorsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LossOnDebtConversion" xlink:to="aemd_LossOnDebtConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LossOnDebtConversion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LossOnExtensionOfWarrants" xlink:to="aemd_LossOnExtensionOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LossOnExtensionOfWarrants_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" xlink:to="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" xlink:to="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:to="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Granted" xlink:to="aemd_Granted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_Granted_doc" xml:lang="en-US">Range of exercise price - granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsCancelledExpiredRangeOfExercisePrice" xlink:to="aemd_WarrantsCancelledExpiredRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsCancelledExpiredRangeOfExercisePrice_doc" xml:lang="en-US">Warrants Cancelled/Expired Range of Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointFourPointTwoPointTwoMember" xlink:to="aemd_MileStoneTwoPointFourPointTwoPointTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointTwoMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointFourPointTwoPointFourMember" xlink:to="aemd_MileStoneTwoPointFourPointTwoPointFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointFourPointTwoPointFourMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MilestoneMNineMember" xlink:to="aemd_MilestoneMNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MilestoneMNineMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointTwoPointTwoMember" xlink:to="aemd_MileStoneTwoPointThreePointTwoPointTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointThreePointTwoPointTwoMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MileStoneTwoPointThreePointThreePointTwoMember" xlink:to="aemd_MileStoneTwoPointThreePointThreePointTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MileStoneTwoPointThreePointThreePointTwoMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MilestoneMFiveMember" xlink:to="aemd_MilestoneMFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_MilestoneMFiveMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfMilestonesUnderYearOneContract" xlink:to="aemd_NumberOfMilestonesUnderYearOneContract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NumberOfMilestonesUnderYearOneContract_doc" xml:lang="en-US">Number Of Milestones Under Year One Contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfMilestonesAchievedUnderYearOneContract2" xlink:to="aemd_NumberOfMilestonesAchievedUnderYearOneContract2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NumberOfMilestonesAchievedUnderYearOneContract2_doc" xml:lang="en-US">Number Of Milestones Achieved Under Year One Contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SharebasedCompensationExpenseIncludedInNetLoss" xlink:to="aemd_SharebasedCompensationExpenseIncludedInNetLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_SharebasedCompensationExpenseIncludedInNetLoss_doc" xml:lang="en-US">Total share-based compensation expense included in net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ConvertibleNotesApril2010Member" xlink:to="aemd_ConvertibleNotesApril2010Member_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ConvertibleNotesApril2010Member_3_lbl" xml:lang="en-US">ConvertibleNotesApril2010Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_JulyAugust201110PercentNoteMember" xlink:to="aemd_JulyAugust201110PercentNoteMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_JulyAugust201110PercentNoteMember_3_lbl" xml:lang="en-US">JulyAugust201110PercentNoteMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LossOnDebtConversion" xlink:to="aemd_LossOnDebtConversion_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LossOnDebtConversion_3_lbl" xml:lang="en-US">LossOnDebtConversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_3_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_2_lbl" xml:lang="en-US">Other Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DebtAndAccruedInterestConvertedToCommonStock" xlink:to="aemd_DebtAndAccruedInterestConvertedToCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DebtAndAccruedInterestConvertedToCommonStock_3_lbl" xml:lang="en-US">DebtAndAccruedInterestConvertedToCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LiquidityDetailsAbstract" xlink:to="aemd_LiquidityDetailsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LiquidityDetailsAbstract_3_lbl" xml:lang="en-US">LiquidityDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice_4_lbl" xml:lang="en-US">StockOptionsOutstandingMinimumRangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:to="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice_4_lbl" xml:lang="en-US">StockOptionsOutstandingMaximumRangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Exercised" xlink:to="aemd_Exercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_Exercised_3_lbl" xml:lang="en-US">Exercised [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Granted" xlink:to="aemd_Granted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_Granted_3_lbl" xml:lang="en-US">Granted [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Cancelledexpired" xlink:to="aemd_Cancelledexpired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_Cancelledexpired_3_lbl" xml:lang="en-US">Cancelledexpired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMinimum_3_lbl" xml:lang="en-US">StockOptionsExercisableRangeOfExercisePricesMinimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:to="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockOptionsExercisableRangeOfExercisePricesMaximum_3_lbl" xml:lang="en-US">StockOptionsExercisableRangeOfExercisePricesMaximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePriceAbstract" xlink:to="aemd_WeightedAverageExercisePriceAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WeightedAverageExercisePriceAbstract_3_lbl" xml:lang="en-US">WeightedAverageExercisePriceAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePrice" xlink:to="aemd_RangeOfExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePrice_3_lbl" xml:lang="en-US">RangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMinimum_4_lbl" xml:lang="en-US">WarrantsOutstandingRangeOfExercisePriceMinimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsOutstandingRangeOfExercisePriceMaximum_4_lbl" xml:lang="en-US">WarrantsOutstandingRangeOfExercisePriceMaximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum_3_lbl" xml:lang="en-US">WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:to="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum_3_lbl" xml:lang="en-US">WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WeightedAverageExercisePrice" xlink:to="aemd_WeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WeightedAverageExercisePrice_3_lbl" xml:lang="en-US">WeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendPayments_2_lbl" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>aemd-20140930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_10q%2D093014.xfr; Date: 2014%2D11%2D10T16:22:50 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20140930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20140930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20140930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20140930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Liquidity" xlink:href="aemd-20140930.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20140930.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20140930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurements" xlink:href="aemd-20140930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20140930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20140930.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20140930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20140930.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20140930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableTables" xlink:href="aemd-20140930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:href="aemd-20140930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20140930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20140930.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20140930.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:href="aemd-20140930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aemd-20140930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:href="aemd-20140930.xsd#NotesPayableDetails-NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetails-Activity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20140930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20140930.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:href="aemd-20140930.xsd#OtherCurrentLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:href="aemd-20140930.xsd#FairValueMeasurementsDetails-FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:href="aemd-20140930.xsd#FairValueMeasurementDetails-Level3" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:href="aemd-20140930.xsd#StockCompensationDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20140930.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20140930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:href="aemd-20140930.xsd#WarrantsDetails-WarrantActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:href="aemd-20140930.xsd#WarrantsDetails-Assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20140930.xsd#DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20140930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20140930.xsd#SegmentsDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Disclosure - Document And Entity Information">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DocumentAndEntityInformationAbstract" xlink:label="loc_aemdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_aemdConsolidatedBalanceSheetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedBalanceSheetsAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedBalanceSheetsAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedBalanceSheetsAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedBalanceSheetsAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_aemdConsolidatedBalanceSheetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedBalanceSheetsAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConsolidatedStatementsOfOperationsAbstract" xlink:label="loc_aemdConsolidatedStatementsOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedStatementsOfOperationsAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedStatementsOfOperationsAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdConsolidatedStatementsOfOperationsAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnDebtConversion" xlink:label="loc_aemdLossOnDebtConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_aemdLossOnDebtConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnExtensionOfWarrants" xlink:label="loc_aemdLossOnExtensionOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_aemdLossOnExtensionOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_CondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:label="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnExtensionOfWarrants" xlink:label="loc_aemdLossOnExtensionOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aemdLossOnExtensionOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LossOnDebtConversion" xlink:label="loc_aemdLossOnDebtConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aemdLossOnDebtConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_CashPaidDuringPeriodForAbstract" xlink:label="loc_aemdCashPaidDuringPeriodForAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_aemdCashPaidDuringPeriodForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdCondensedConsolidatedStatementsOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtAndAccruedInterestConvertedToCommonStock" xlink:label="loc_aemdDebtAndAccruedInterestConvertedToCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdDebtAndAccruedInterestConvertedToCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:label="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable" xlink:label="loc_aemdReclassificationOfAccountsPayableToConvertibleNotePayable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdReclassificationOfAccountsPayableToConvertibleNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment" xlink:label="loc_aemdDeferredFinancingCostsRecordedInConnectionWithDebtAmendment" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdDeferredFinancingCostsRecordedInConnectionWithDebtAmendment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:label="loc_aemdReclassificationOfAccruedInterestToConvertibleNotesPayable" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdReclassificationOfAccruedInterestToConvertibleNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000006 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Liquidity" xlink:title="00000007 - Disclosure - 2. LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaapLiquidityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapLiquidityDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayable" xlink:title="00000010 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000011 - Disclosure - 6. EQUITY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - 7. RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - 8. OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - 9. FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 10. STOCK COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - 11. WARRANTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition" xlink:title="00000017 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DarpaContractAndRelatedRevenueRecognition" xlink:label="loc_aemdDarpaContractAndRelatedRevenueRecognition" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_aemdDarpaContractAndRelatedRevenueRecognition" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 14. SEGMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000020 - Disclosure - 15. SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="loc_us-gaapDerivativesEmbeddedDerivatives" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesEmbeddedDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" xlink:label="loc_aemdBeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aemdBeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RegistrationPaymentArrangementsPolicyTextBlock" xlink:label="loc_aemdRegistrationPaymentArrangementsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aemdRegistrationPaymentArrangementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OffbalanceSheetArrangementsPolicyTextBlock" xlink:label="loc_aemdOffbalanceSheetArrangementsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aemdOffbalanceSheetArrangementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableTables" xlink:title="00000023 - Disclosure - 4. NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ScheduleOfNotesPayableTableTextBlock" xlink:label="loc_aemdScheduleOfNotesPayableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_aemdScheduleOfNotesPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:label="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2010ConvertibleNotesMember" xlink:label="loc_aemdSeptember2010ConvertibleNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2010ConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2011ConvertibleNotesMember" xlink:label="loc_aemdSeptember2011ConvertibleNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2011ConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ActivityInConvertibleNotesTextBlock" xlink:label="loc_aemdActivityInConvertibleNotesTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdActivityInConvertibleNotesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000025 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsTables" xlink:title="00000026 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 10. STOCK COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 11. WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" xlink:label="loc_aemdWeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_aemdWeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 14. SEGMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LiquidityDetailsNarrative" xlink:title="00000030 - Disclosure - 2. LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LiquidityDetailsAbstract" xlink:label="loc_aemdLiquidityDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WorkingCapital" xlink:label="loc_aemdWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdLiquidityDetailsAbstract" xlink:to="loc_aemdWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdLiquidityDetailsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:label="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdLiquidityDetailsAbstract" xlink:to="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense" xlink:title="00000031 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingOfStockOptionsMember" xlink:label="loc_aemdVestingOfStockOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOfStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncrementalFairValueOfOptionsMember" xlink:label="loc_aemdIncrementalFairValueOfOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdIncrementalFairValueOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingExpenseMember" xlink:label="loc_aemdVestingExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable" xlink:title="00000033 - Disclosure - 4. NOTES PAYABLE (Details - Notes payable)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue12PercentMember" xlink:label="loc_aemdNotesPayablePastDue12PercentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue12PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue10PercentMember" xlink:label="loc_aemdNotesPayablePastDue10PercentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DirectorsNotesMember" xlink:label="loc_aemdDirectorsNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdDirectorsNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayable" xlink:label="loc_aemdAccruedInterestOnNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestOnNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 4. NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue12PercentMember" xlink:label="loc_aemdNotesPayablePastDue12PercentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue12PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NotesPayablePastDue10PercentMember" xlink:label="loc_aemdNotesPayablePastDue10PercentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdNotesPayablePastDue10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DirectorsNotesMember" xlink:label="loc_aemdDirectorsNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_aemdDirectorsNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayable" xlink:label="loc_aemdAccruedInterestOnNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestOnNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails" xlink:title="00000035 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_OctoberNovember2009ConvertibleNotes10PercentMember" xlink:label="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdOctoberNovember2009ConvertibleNotes10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2010ConvertibleNote10PercentMember" xlink:label="loc_aemdApril2010ConvertibleNote10PercentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdApril2010ConvertibleNote10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_JulyAugust201110PercentNoteMember" xlink:label="loc_aemdJulyAugust201110PercentNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdJulyAugust201110PercentNoteMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_LawFirmNoteMember" xlink:label="loc_aemdLawFirmNoteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdLawFirmNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:label="loc_aemdAmendedRestatedSeriesA12PercentConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdAmendedRestatedSeriesA12PercentConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2010ConvertibleNotesMember" xlink:label="loc_aemdSeptember2010ConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2010ConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_April2011ConvertibleNotes10PercentMember" xlink:label="loc_aemdApril2011ConvertibleNotes10PercentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdApril2011ConvertibleNotes10PercentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes10Percent2008Member" xlink:label="loc_aemdConvertibleNotes10Percent2008Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes10Percent2008Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_September2011ConvertibleNotesMember" xlink:label="loc_aemdSeptember2011ConvertibleNotesMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdSeptember2011ConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableCurrentBeforeDiscount" xlink:label="loc_aemdConvertibleNotesPayableCurrentBeforeDiscount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableCurrentBeforeDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountCurrentPortion" xlink:label="loc_aemdDebtInstrumentUnamortizedDiscountCurrentPortion" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdDebtInstrumentUnamortizedDiscountCurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestCurrentPortion" xlink:label="loc_aemdAccruedInterestCurrentPortion" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestCurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableNoncurrentPortion" xlink:label="loc_aemdConvertibleNotesPayableNoncurrentPortion" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableNoncurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_DebtInstrumentUnamortizedDiscountNonCurrent" xlink:label="loc_aemdDebtInstrumentUnamortizedDiscountNonCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdDebtInstrumentUnamortizedDiscountNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestNoncurrentPortion" xlink:label="loc_aemdAccruedInterestNoncurrentPortion" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedInterestNoncurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalConvertibleNotesPayable" xlink:label="loc_aemdTotalConvertibleNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdTotalConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_TotalAccruedInterest" xlink:label="loc_aemdTotalAccruedInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdTotalAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity" xlink:title="00000036 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details - Activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2009Member" xlink:label="loc_aemdConvertibleNotes2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2010Member" xlink:label="loc_aemdConvertibleNotes2010Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2010Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotes2011Member" xlink:label="loc_aemdConvertibleNotes2011Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdConvertibleNotes2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsOne" xlink:label="loc_aemdConvertibleNotesPayableConversionsOne" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsTwo" xlink:label="loc_aemdConvertibleNotesPayableConversionsTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsThree" xlink:label="loc_aemdConvertibleNotesPayableConversionsThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFour" xlink:label="loc_aemdConvertibleNotesPayableConversionsFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsFive" xlink:label="loc_aemdConvertibleNotesPayableConversionsFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncreaseInConvertibleNotePayableExtensionFee" xlink:label="loc_aemdIncreaseInConvertibleNotePayableExtensionFee" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIncreaseInConvertibleNotePayableExtensionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConvertibleNotesPayableConversionsSix" xlink:label="loc_aemdConvertibleNotesPayableConversionsSix" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdConvertibleNotesPayableConversionsSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000037 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="loc_us-gaapInterestExpenseLongTermDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapInterestExpenseLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_FourInvestorsMember" xlink:label="loc_aemdFourInvestorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdFourInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ThreeInvestorsMember" xlink:label="loc_aemdThreeInvestorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdThreeInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaapDebtConversionByUniqueDescriptionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtConversionByUniqueDescriptionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NoteBalanceMember" xlink:label="loc_aemdNoteBalanceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdNoteBalanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ConversionAccruedInterestMember" xlink:label="loc_aemdConversionAccruedInterestMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdConversionAccruedInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RestructuringFeeMember" xlink:label="loc_aemdRestructuringFeeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_aemdRestructuringFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderOneMember" xlink:label="loc_aemdHolderOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdHolderOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_HolderTwoMember" xlink:label="loc_aemdHolderTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_aemdHolderTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockIssuedSubscribedSharesIssued" xlink:label="loc_aemdStockIssuedSubscribedSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdStockIssuedSubscribedSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarantsIssuedToAccreditedInvestors" xlink:label="loc_aemdWarantsIssuedToAccreditedInvestors" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWarantsIssuedToAccreditedInvestors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapOtherLiabilitiesCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedLiquidatedDamages" xlink:label="loc_aemdAccruedLiquidatedDamages" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_aemdAccruedLiquidatedDamages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - 8. OTHER CURRENT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AccruedInterestOnNotesPayableInDefault" xlink:label="loc_aemdAccruedInterestOnNotesPayableInDefault" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_aemdAccruedInterestOnNotesPayableInDefault" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="00000041 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions" xlink:title="00000042 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3" xlink:title="00000043 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Level 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:label="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation" xlink:title="00000044 - Disclosure - 10. STOCK COMPENSATION (Details - Share-based compensation)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingOfStockOptionsMember" xlink:label="loc_aemdVestingOfStockOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOfStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_IncrementalFairValueOfOptionsMember" xlink:label="loc_aemdIncrementalFairValueOfOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdIncrementalFairValueOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_VestingExpenseMember" xlink:label="loc_aemdVestingExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SharebasedCompensationExpenseIncludedInNetLoss" xlink:label="loc_aemdSharebasedCompensationExpenseIncludedInNetLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdSharebasedCompensationExpenseIncludedInNetLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Assumptions" xlink:title="00000045 - Disclosure - 10. STOCK COMPENSATION (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation" xlink:title="00000046 - Disclosure - 10. STOCK COMPENSATION (Details - Option information)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000047 - Disclosure - 10. STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AmountAbstract" xlink:label="loc_aemdAmountAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAmountAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdAmountAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePriceAbstract" xlink:label="loc_aemdRangeOfExercisePriceAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Exercised" xlink:label="loc_aemdExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Granted" xlink:label="loc_aemdGranted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_Cancelledexpired" xlink:label="loc_aemdCancelledexpired" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdCancelledexpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsOutstandingMinimumRangeOfExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice" xlink:label="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsOutstandingMaximumRangeOfExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMinimum" xlink:label="loc_aemdStockOptionsExercisableRangeOfExercisePricesMinimum" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsExercisableRangeOfExercisePricesMinimum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_StockOptionsExercisableRangeOfExercisePricesMaximum" xlink:label="loc_aemdStockOptionsExercisableRangeOfExercisePricesMaximum" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePriceAbstract" xlink:to="loc_aemdStockOptionsExercisableRangeOfExercisePricesMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePriceAbstract" xlink:label="loc_aemdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWeightedAverageExercisePriceAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000048 - Disclosure - 10. STOCK COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity" xlink:title="00000049 - Disclosure - 11. WARRANTS (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_RangeOfExercisePrice" xlink:label="loc_aemdRangeOfExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsExercisedRangeOfExercisePriceMinimum" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsExercisedRangeOfExercisePriceMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsExercisedRangeOfExercisePriceMaximum" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsExercisedRangeOfExercisePriceMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsIssuedRangeOfExercisePriceMinimum" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsIssuedRangeOfExercisePriceMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsIssuedRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsIssuedRangeOfExercisePriceMaximum" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsIssuedRangeOfExercisePriceMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePrice" xlink:label="loc_aemdWarrantsCancelledExpiredRangeOfExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsCancelledExpiredRangeOfExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsCancelledExpiredRangeOfExercisePriceMaximum" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsCancelledExpiredRangeOfExercisePriceMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMinimum_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsOutstandingRangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsOutstandingRangeOfExercisePriceMaximum_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:label="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:label="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdRangeOfExercisePrice" xlink:to="loc_aemdWarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WeightedAverageExercisePrice" xlink:label="loc_aemdWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="loc_aemdWarrantsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_aemdWarrantsExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:label="loc_aemdWarrantsCancelledexpiredWeightedAverageExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_aemdWarrantsCancelledexpiredWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdWeightedAverageExercisePrice" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails-Assumptions" xlink:title="00000050 - Disclosure - 11. WARRANTS (Details - Assumptions)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000051 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointTwoMember" xlink:label="loc_aemdMileStoneTwoPointFourPointTwoPointTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointFourPointTwoPointTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointFourPointTwoPointFourMember" xlink:label="loc_aemdMileStoneTwoPointFourPointTwoPointFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointFourPointTwoPointFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMNineMember" xlink:label="loc_aemdMilestoneMNineMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMilestoneMNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointTwoPointTwoMember" xlink:label="loc_aemdMileStoneTwoPointThreePointTwoPointTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointThreePointTwoPointTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MileStoneTwoPointThreePointThreePointTwoMember" xlink:label="loc_aemdMileStoneTwoPointThreePointThreePointTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMileStoneTwoPointThreePointThreePointTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_MilestoneMFiveMember" xlink:label="loc_aemdMilestoneMFiveMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_aemdMilestoneMFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaapContractsRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesUnderYearOneContract" xlink:label="loc_aemdNumberOfMilestonesUnderYearOneContract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfMilestonesUnderYearOneContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_NumberOfMilestonesAchievedUnderYearOneContract2" xlink:label="loc_aemdNumberOfMilestonesAchievedUnderYearOneContract2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfMilestonesAchievedUnderYearOneContract2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000053 - Disclosure - 14. SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_SegmentsDetailsAbstract" xlink:label="loc_aemdSegmentsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdSegmentsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_AethlonMember" xlink:label="loc_aemdAethlonMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdAethlonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20140930.xsd#aemd_ESIMember" xlink:label="loc_aemdESIMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdESIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="loc_us-gaapPaymentsForCapitalImprovements" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForCapitalImprovements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
        <td class="nump">$ 570,741<span></span></td>
        <td class="nump">$ 1,165,335<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued legal fees</a></td>
        <td class="nump">179,465<span></span></td>
        <td class="nump">179,465<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedLiquidatedDamages', window );">Accrued liquidated damages</a></td>
        <td class="nump">362,800<span></span></td>
        <td class="nump">362,800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other accrued liabilities</a></td>
        <td class="nump">103,598<span></span></td>
        <td class="nump">147,774<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
        <td class="nump">$ 1,216,604<span></span></td>
        <td class="nump">$ 1,855,374<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedLiquidatedDamages">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued liquidated damages</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedLiquidatedDamages</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amount, as of the balance sheet date, of liabilities not separately disclosed in the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
        <td class="nump">$ 497,783<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of unrecognized compensation cost</a></td>
        <td class="text">2 years 2 months 9 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic value</a></td>
        <td class="nump">$ 0.12<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`]=+PR&P(``%P@```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VEUOVC`4!N#[2?L/D6\G
M8OR1KJT(O=C'Y59IW0_PD@.)2.S(=COX]W-"6U45HT)#VGM#!+'/>3'2<\')
MXF;;=]D#^=`Z6S*1SUE&MG)U:]<E^WGW=7;)LA"-K4WG+)5L1X'=+-^_6]SM
M!@I9VFU#R9H8AVO.0]50;T+N!K+ISLKYWL3TUJ_Y8*J-61.7\_D%KYR-9.,L
MCC78<O&95N:^B]F7;?IXG\13%UCV:;]P[%4R,PQ=6YF8DO('6[_J,GOLD*>=
MTYK0M$/XD&(P?K##>.?O#1[W?4]'X]N:LEOCXS?3IQA\V_'?SF]^.;?)CQ<Y
MD-*M5FU%M:ON^W0">1@\F3HT1+'O\NF:]Z:U3[F/])\6!SY=Q)F#C-]O*GQB
M#@F20X'DT"`Y"I`<%R`Y/H+DN`3)<0620\Q1@J"(*E!(%2BF"A14!8JJ`H55
M@>*J0(%5H,@J4625*+)*%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K`I%
M5H4BJT*15:'(JE!D52BR*A19%8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP:
M15:-(FN!(FN!(FN!(FOQOV2-:79+?'K]]Q]E*O/&\##$74?AS'_X[XN^U;DQ
MGNH?T:<I]]D#O*Q]+$>:`=]Z-X0T#?=T^BD\C;O'W;,A%2(?6WH>>!\:'#]W
M3)/TTQN^FES3.*NOJ3[0FT_/!BS_````__\#`%!+`P04``8`"````"$`M54P
M(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."
M2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA
M5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E
M/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;
MJ)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI
M^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0"$VM_[10(`
M`+D?```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"\F<UNVS`0A.\%^@X"[[6\
MNZ23%)%S*0KDVJ8/(-BT9<26#)']\=N7<`O%`=K)Q9B+`%(0.5@.O^52]P^_
M#OOJ1QS3;N@;)[.YJV*_&M:[?MNX;T^?/]RZ*N6V7[?[H8^-.\7D'I;OW]U_
MB?LVEX]2MSNFJHS2I\9U.1\_UG5:=?'0IMEPC'UYLQG&0YM+<]S6QW;UW&YC
MK?/YHAXOQW#+5V-6C^O&C8]K,5<]G8YEZK<''S:;W2I^&E;?#['/_YBC_CF,
MSZF+,9=!VW$;<^.FKE2?WXC-BF97_T=.B0=7SBV2HPNR'%T@.79'EF-W2(X*
M68X*DF.>+,<\DN.5+,<KE'/#EG.#Y(1"0NI&#W,H)UQ33LJG?0'YQ,`_;30_
M>W'@VK"-"WTK;`0+1+"R$:P0P<)&L$`$*QO!"A%L;"<;M+*Q=[G!;>[9"/80
MP?ZJ")Z.G2\4GKK^GD1]0$0.[(-Q@`=C=G!@;(3M'('.$3:3!3+9V$PVR&3/
M9K*'3`YL)@?(9'IP$'/8/H8V%G9H!/I&V;Y1Z!MEYW*%N=S81#9(9&.G*X/Y
MRK-SN8>YW+,ON3R\Y`I7K;!2UXYQ_36/Y8KSL@2^[$8,9,<&AX:=R@-,Y6P;
M0Q<+&\@"@2QL(`L$LK()J)"`1K<.](ZQ=[G!;>ZO2L"IS@2E)[YC8B=SA<G<
MLR'H(03#5<^EN?Q*BR\+=6[6YR<4P0X)%,-V+S2OL,$G$'S*!I]"\"D;?`K!
M9VSK&/2.9Q?`?JJ`ZU<_W)>_`0``__\#`%!+`P04``8`"````"$`F)`)GF\$
M```M$```#P```'AL+W=O<FMB;V]K+GAM;)277W.B2!3%W[=JOX/%^X[R1TU2
M,5.MDDS7*KJ`IO+4Q6@G4H-@`9DDWWXON.*15C9YTBOVZ7M/_^X%;K^_;Z/6
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MW8*%I>WZG%9=UJ`Q4;FG=^HB/6%3V?Z3\%WF>&SD<^(+4[_&Y0J7?>':DQ+%
M.7,OJ_2HPXY)*%Q>B9G_PW;%:.&Z-ODWX6S()]SG-J;2.^D0A<IK<<^X*Y9L
MLK#%U&8>03$EM1,);`]=05+O",^?C?XF8Z=S:C=6N`%F]$PL0T51%X_,)1]/
M]T3N=`4\W1!CYLY9<9AT!B.BA^`]N(J;(XNZ`J-N%EE/N5_67(H4BMQYL)T1
M1QV$45=HU"WAV0^*<4BBKJ"H=ZD5AAZA5!R?O:S;C@S2M*T-M^8^PDG00QH-
MA<9F(3K[:K[U$4A#`;+6DL(/?D9T>X7UR**AL-C0FJ2%.@BDH0#9T!@U'233
M4,B\V!ME99@/PKJ_?^*4/-L@9]Q!5`T5U6.?G%F+>!I->)Y9BY0:"J4PX\58
MYD$89<()TI2>47Y+,,%$."CX$JYT$!5E)E)"P9>$Z"2.0HB)^;^X5L4EN<P$
MZB`FIH)M'?M*IS0)=1`34\&V"?_QB=,("CUXU0QJUL'!T,<)8RI#MED(!X.)
M"%%0R^CL[;*""1TZ24C!N*FQ3QW"B6<J2%_2>2IS@GPL9)J"6EV7!T3!`.H@
MTI:"]"6=O46H@T1;"M'-.GCR%B)-0:VP\Q/K`#8FA$A;"M+-.B<)(=.6PG2S
M$*)HX22DX$N5X1BRD&D*OB2$8\A"J"FH"\%</SC\6(R..!?!"KSN(]26`K5^
M1H=EV>MV5[Q,@DX7H::@GD_CHQ6>V=6)D$)U\[,5"G41:PKJ&1T?K@Y#`\M!
ME+LERNWR%D"OE*L@6M&[;O%1O"R6M;8/;_IW_P(``/__`P!02P,$%``&``@`
M```A`+YU7B?.!0``_Q4``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R4
MF-N.FT@0AN]7VG=`W-NF#T!CC2>*@>Q&RDJKU1ZN&8QM%&,L8#+)VV\UC4U7
M$1_F)AG;7Q?]5U57%?WTX7MU<+X535O6QY7+YI[K%,>\WI3'W<K]Y^]/,^4Z
M;9<=-]FA/A8K]T?1NA^>?_WEZ:UNOK;[HN@<L'!L5^Z^ZT[+Q:+-]T65M?/Z
M5!SAEVW=5%D''YO=HCTU1;;I%U6'!?>\8%%EY=$U%I;-(S;J[;;,BZ3.7ZOB
MV!DC37'(.MA_NR]/[=E:E3]BKLJ:KZ^G65Y7)S#Q4A[*[D=OU'6J?/EY=ZR;
M[.4`NK\SF>5GV_V'B?FJS)NZK;?=',PMS$:GFJ-%M`!+ST^;$A1HMSM-L5VY
M']DRY<Q=/#_U#OJW+-Y:ZV^GW==OOS7EYDMY+,#;$"<=@9>Z_JK1SQO]%2Q>
M3%9_ZB/P9^-LBFWV>NC^JM]^+\K=OH-P^Z!("UMN?B1%FX-'P<R<^]I27A]@
M`_"O4Y4Z-<`CV??^_[=RT^U7K@CF?N@)!KCS4K3=IU*;=)W\M>WJZC\#]8HN
M1OA@!%8,1AB?<^4S/[AO96%VU`M,LBY[?FKJ-P>R!I[9GC*=@VP)EK4R`?XQ
M^[AHO285-&HC'[65E1NZ#BQO(3[?G@/UM/@&+LT'9/T3),)(?$:T`[79Y/S%
M:);A)>F9T-$#11=9X"Q;UL\#==Z]AO7NS\]=FR_`]D4.Q\^-IT3H8229(L1(
M.B4L(TB.>(\<#4,4K=V'Q&UK@T@+\?'NX[M$<I=(;Q%('FSD\6AI>.6"[R[!
M"8ECUP91?2+*,/)"JLX&`BF5"K'\Q`9\X0GJP=0&E/2D$A<+2!J<J<>E:9A$
M;C3;'XFU0>#I%_54VUTBN4NDMP@D+WB//`V3R,F+UXP\@P1]Y(2G%">9&R.`
MASXC0&(#(?.D((](;2"`ZJE&"T@:5+/'(Z=A(HW$96T0(\V74OAD8[$-Z(R2
MI#XF-L!8X'N2U)S4)E0@I!H!I$T/)E;5OUT>-4RT!21L!C':.`^]B)S(V`:8
MY(*3O$YL0'+E1>1$IC8@1.2QT7U(6O0>:1HFTLASUP8QTIBG/!X0(K8)%<K`
M*@6FC=D`AV+B3ZJ)33#E2[MB(74,>O/CD>MIHF_2E[7%E6L$S@*/L4GP!C,#
MPGD41B0!$HRP,!0PHN(D20GC,>%;C\(R=5]_.$&9F0*@W5R*8DC.SGI@;A7.
M^TAR'TEO(EBD[O^/BS33@MWWK--MJB<SC`E4X,N(G+(8`0QRE>1R@@#N"\;H
M24T1(CWNC[F`Y>GV;\D[CY:WBPTS0P.2.1;H0>9YL-"#)LFR>#!@?,"C"/*0
M%*-D0&3?9<CZ%*\7BJMP=!(6J&<`2^`=869B0,+(QM;,,&;OH6*2])`8`0RZ
MFT>(!!,2IA]R$E)$<`;CSY@E6)^>`A[79V8&I&\T/`3.,$8?DT($A(CU6Q54
MHY^&)AE^O+X\O;(<R](#P..RS+B`9(V=9Y!ECQ20+YY',C9F-@&'*H(^@:MC
M@A"NH`HK$ML4(X&(_/#:V=.#@*7QP;-GQ@>DE>QAS>P18Z84;'020X0((:/`
M>J_I799@,Q(:@9S*Q78"J$;66R6.J9X.WJ_7S!1([^C0(;;VW#&#QJQ(X&)F
MB"LIBY:K"'H>CGMZ93F6I^>#]\LS4P62-Y:R09YAS*O23,E0>J1>Q`PA5\*)
M&.E[0OB3PHH8<2N<G$PYCZ5OOPI/.XI..P-C])(=QL./4=\79MY\TCCN`>D-
M``64D_E&"Y10^FZWD'X5$4BBM1Z8H?WYD0BBB+XCQ0AB*@S@;4219I0@B,-[
M5"0C1HZ'OG4;IT>FH-E*SD>_&M'F7LU<.U5%LROBXG!HG;Q^U7=F`MQ]^?9R
MG_>1Z^L8\OV:+>&2:/I]`O=__?>+RP*X?CMEN^*/K-F5Q]8Y%%MXE#</P<F-
MN<`S'[KZU%^"O=0=7+SU?^[AHK6`ZR=O#O"VKKOS!WW)=+FZ??X?``#__P,`
M4$L#!!0`!@`(````(0"9*S.@+0(``*4$```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;(R4VXZ;,!"&[ROU'2S?+X8DY(`@JXVBM"NUTJKJX=HQ)EC!
M&-E.2-Z^8SNA:5.UN0$,_WSSST'DSR?9H"/71JBVP$D48\1;IDK1[@K\[>OF
M:8Z1L;0M::-:7N`S-_AY^?Y=WBN]-S7G%@&A-06NK>TR0@RKN:0F4AUOX4NE
MM*06CGI'3*<Y+7V0;,@HCJ=$4M'B0,CT(PQ558+QM6('R5L;()HWU()_4XO.
M7&F2/8*35.\/W1-3L@/$5C3"GCT4(\FRUUVK--TV4/<IF5!V9?O#'5X*II51
ME8T`1X+1^YH79$&`M,Q+`16XMB/-JP*_)-EJC,DR]_WY+GAO;IZ1J57_08OR
MDV@Y-!O&Y`:P56KOI*^E>P7!Y"YZXP?PIE')*WIH[!?5?^1B5UN8=@H%N;JR
M\KSFAD%#`1.-4D=BJ@$#<$52N,V`AM"3O_>BM'6!Q],HG<7C!.1HRXW="(?$
MB!V,5?)'$"475(",+A"X7R#)*!K-TR2=_I]"@B-?X)I:NLRUZA$L#>0T'74K
MF&1`=I6-H3]_KPQ*<C$O+LB'@MK`-([+Z6*2DR.TD%TTJWO-:%`02#XX@*RW
M#OZ=V8G!(49#YO%L.G"]NU703&XTZ:#X+3-@;C,_5KL+*C#D&!Q,%[_XP4'0
MS'UG)K,DGB1_&`B;%@;1T1W_3/5.M`8UO`)L',U@+738LW"PJO,-WRH+^^$?
M:_@=<)A&'(&X4LI>#VZ3AQ_,\B<```#__P,`4$L#!!0`!@`(````(0!O"K?'
M]P,``#42```9````>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)2876^C.!2&
M[U?:_X"X;\#Y(!]*,FH+W1UI5EJ-9F:O'7`2JX`1=IOVW^\Q)A^&SC&]:`CE
M\2N_Y_C@XZR_O!6Y]\IJR46Y\<DH]#U6IB+CY6'C__SQ=+?P/:EHF=%<E&SC
MOS/I?]G^^<?Z).IG>61,>:!0RHU_5*I:!8%,CZR@<B0J5L*3O:@+JN"V/@2R
MJAG-FD%%'HS#,`H*RDO?**SJ(1IBO^<IBT7Z4K!2&9&:Y53!_.615_*L5J1#
MY`I:/[]4=ZDH*I#8\9RK]T;4]XIT]?50BIKN<O#]1J8T/6LW-SWY@J>UD&*O
M1B`7F(GV/2^#90!*VW7&P8$.NU>S_<:_)ZN$1'ZP73<!^L792=Y\]^11G/ZJ
M>?:-EPRB#7G2&=@)\:S1KYG^%PP.>J.?F@S\6WL9V].77'T7I[\9/QP5I'L&
MCK2Q5?8>,YE"1$%F-)YII53D,`'X]`JNEP9$A+XUUQ//U''C3Z+1;!Y.".#>
MCDGUQ+6D[Z4O4HGB/P.15LJ(C%L1N+8B9#P:+V9D%GU"9=*JP/6J\MFI3%L1
MN%Y%/CT5L-Y$!:Y7E8%3"4R$FX3%5-'MNA8G#ZH`8B@KJFN*K$!89VH"^?XX
M4Y`B/>9>#VJ&`BUA>;UNHV6T#EYA2:0M\]!GQC;QV"<FH8W$?63>09(^$BWG
M%YD`;%Z\PDKH>IV"9]RK'@0Q\;T;KXN+?A./!\-`=B_,S"8>G43L)!*,L'S"
M9&]]XOXTO/%!^S+W:7B-G_%G&,R?(1;-6B!A-%_"GQV"V"F28(1E$&8RW*"&
MNP:["30,9M`0$6;0*9)@A&405N5P@QJV#4;+I1W\!\-@!IU$["02C+#\1;8_
M_=9Q5Z(>Y*I$PV`^G43L)!*,L'S.;9]X)6K8SF._$@V#^3L3^JW<>5?&YV?7
M6N^\IQ*,L)SI5NUFW\"=:;CKK%N"AL&<G8F/G)V?_=X91EC.EI]QIF';V3SL
M1/W!,)@S)Q$[B00C+'\$MO?;U`TKOF:4J_I:"+/J1F(WDJ"([5;W!X,7*C'=
M!+X;MA#JTNA,F^VBLQYB]_@$16Q_NBL8[L_T$+:_;B42`Z'^SLA'M>@>GZ"(
M[4\W!</]F1;BUM\\))V]D&!]1M/P/+J1V(TD*&*[A&#?NAQ8DWJ4LR8-A&;3
MB<3$B20H8KO5?<+PG)JNXC:G_7U1GRXA%!\6W&/[$&W>+&:VB*81Z>Z-%C*9
M+1;CR;7-L@WJ!F&X0=-.V`9[18GU'.VB-0C:A,.IW\3I]QLEBAB;YN!OSI$5
M/;!_:'W@I?1RMH=.+AS-(1NU.?:;&R6JYKRX$PJ.Z\W7(_P\P^`P&8X`W@NA
MSC?ZAX7+#S[;_P$``/__`P!02P,$%``&``@````A`+T'CV%C`P````L``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG%9=;YLP%'V?M/^`_![`*0E)
M%%*U:[M-VJ1IVL>S`R98!8QLIVG__:XQ`4R:ABX/24B.SSWWW,OEKJ^?B]QY
MHD(R7D8(NSYR:!GSA)6["/W^]3!9($<J4B8DYR6-T`N5Z'KS\</ZP,6CS"A5
M#C"4,D*94M7*\V2<T8)(EU>TA']2+@JBX%+L/%D)2I+Z4)%[4]^?>P5A)3(,
M*S&&@Z<IB^D=C_<%+94A$30G"O3+C%7RR%;$8^@*(A[WU23F10446Y8S]5*3
M(J>(5U]W)1=DFT/>SS@@\9&[OCBA+U@LN.2I<H'.,T)/<UYZ2P^8-NN$00;:
M=D?0-$(W>'6+9\C;K&N#_C!ZD+WOCLSXX;-@R3=64G`;ZJ0KL.7\44._)OHG
M..R=G'ZH*_!#.`E-R3Y7/_GA"V6[3$&Y9Y"13FR5O-Q1&8.C0.-.:QDQST$`
MO#L%TZT!CI#G^O/`$I5%Z&KNSD+_"@/<V5*I'IBF1$Z\EXH7?PT(:U$MR;0A
M@<^&!,_<8#H+%R-8/*.H3O".*+)9"WYPH&L@IJR([D&\`N9C9D9'F^NY5$&>
M)KG1+!$*D0-92*C/TR;TIVOO"3R-&\RMP<![B\$MP@,UK220T9?TNLG'R!JL
M(VNGM)1;\T,_3"?$"G-EA]&97T%GO!U.'XH0Q&B3@"JV:1@%!A/T,+,682D`
M2#_1<0KT(5#:8P_]H.4W"@QFA`+HOKZ"MW/78#OW`'<E-)$-9CFK>V#J^O8+
MWT\ZJ985\_<(T>"AD&$1#*9O0>B?*0.T[7@3-'@8N^,U)AA,8X+OAHNE94,G
MU;)`/RP&=^+E?M2';#FA/Q]T@\'TK>@$6PJ6_Z-`'[K4CP8S0@&&&[!OPML-
M6:/M[$\[L@$UU9B[>&F]%O>3,_7`>F#U"G)!BQEO_<D0X([9-$9-&:&^$:$?
MMN6RBH'U(!L?WHP].WQ7YB:\`356P+X2!)879X0,!N4%'UZ;D,,I@4>/2`Q>
M]5T8-R/K4Y>:L@'UB]$99I?B76-2+P:#>S+`79&;4EB#TA\X;Q81\YPNJ-C1
M3S3/I1/SO5XR,`S7]M=V`;J9UBM,^P?L'Q79T>]$[%@IG9RF<!2&$0069H,Q
M%XI7]1:PY0HVC_IK!ILFA6>I[P(XY5P=+_2.U.ZNFW\```#__P,`4$L#!!0`
M!@`(````(0"[.%4#+`,``(T)```9````>&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;)R676_:,!2&[R?M/UB^;S[)!XA0M53=)FW2-.WCVB0.L9K$D6U*^^]W
M'$/`24N[7902^_7KYYQCY["\?FIJ]$B%9+S-L.]X&-$VYP5KMQG^]?/^*L5(
M*M(6I.8MS?`SE?AZ]?'#<L_%@ZPH50@<6IGA2JENX;HRKVA#I,,[VL),R45#
M%#R*K2L[04G1+VIJ-_"\V&T(:[%Q6(CW>/"R9#F]X_FNH:TR)H+61`&_K%@G
MCVY-_AZ[AHB'77>5\Z8#BPVKF7KN33%J\L67;<L%V=00]Y,_(_G1NW^8V#<L
M%USR4CE@YQK0:<QS=^Z"TVI9,(A`IQT)6F;XQE^L?0^[JV6?H-^,[N79=R0K
MOO\D6/&5M12R#772%=AP_J"E7PH]!(O=R>K[O@+?!2IH27:U^L'WGRG;5@K*
M'4%$.K!%\7Q'90X9!1LGB+13SFL`@$_4,'TT("/DJ?^_9X6J,AS&3I1XH0]R
MM*%2W3-MB5&^DXHW?XS(/U@9D^!@$@+]83YP@C3RH_AM%]<0]0'>$4562\'W
M"$X-["D[HL^@OP#G8V2&8XCUM5`A1FURHUTRG&`$44BHS^,J\=*E^P@YS0^:
MVZG&MQ7KHT*7`O`&1HC\G/'EK!]1M%BCZ"IHMELS`-X#6S#:=ZI(O$%BD4"&
MWD^BQ1D&\V'C63S8&C8C2?N,^5Z<S.'/EJR-9';F$@T*BPTDYVRZDB&<],O9
MTHMLQL2;#_X&TFCB2Y`C2>2=2FLQPFD_9[S,IL5CMI.O83,:V'[(\2D[O6)]
M26&QQ?_"IL4VVZ2V1G(Q;>>2,$K3(#SEWF*#F_7^O&FQS9;XI_-L\F8TL[ZF
MH[GURW,6CVYLH[?&VV=-+[*Y9D$X.FM&\S*7F3,)#<(T2)/37;'HYO]#IQ?9
M=-.;8#072SJ2O'H3H%U9*;Q\%7JU33<Y;P>->9F,:VI-1FD\B_W313'),]W/
M-(>&BBU=T[J6*.<[W=D"."K#Z-!U;P+]GAV-W^INK,?=80*:84>V]!L16]9*
M5-,2+#TG@<LI3#LU#XIW?4O:<`5ML/]:P<\>"N]QSP%QR;DZ/N@-AA]2J[\`
M``#__P,`4$L#!!0`!@`(````(0!L?ZH@Z0,```P.```9````>&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;)Q776^C.!1]'VG_`^)]`N:;*,FH!+H[THPT6NW'
M,P$G006,L-.T_WZN<2#8I*1M']+@>^ZQC\\UOEE]>ZE*[1FWM"#U6D<+4]=P
MG9&\J`]K_=]_'K\&ND996N=I26J\UE\QU;]M_OBR.I/VB1XQ9AHPU'2M'QEK
MEH9!LR.N4KH@#:XALB=ME3)X;`\&;5J<YEU251J6:7I&E1:U+AB6[7LXR'Y?
M9#@FV:G"-1,D+2Y3!NNGQZ*A/5N5O8>N2MNG4_,U(U4#%+NB+-AK1ZIK5;;\
M?JA)F^Y*T/V"G#3KN;N'"7U59"VA9,\60&>(A4XUAT9H`--FE1>@@&^[UN+]
M6G]`RP19NK%9=1OT7X'/=/1=HT=R_K,M\A]%C6&WP2?NP(Z0)P[]GO,A2#8F
MV8^=`[]:+<?[]%2RO\GY+UP<C@SL=D$1%[;,7V-,,]A1H%E8+F?*2`D+@$^M
M*GAIP(ZD+]W_<Y&SXUJWO87KFS8"N+;#E#T6G%+7LA-EI/I?@-"%2I!8%Q+(
MN)`@:V$%+G*]^RR&6%$G,$Y9NEFUY*Q!U<"<M$EY#:(E,/?*Q#H&K6])!8V<
MY(&SK'5?UT`%!7^>-SY"*^,9]C2[8*(IQ@MER+:'\!WDO'$_<.556),>P>T#
M28,NV*VQKMM.]<OG8+[\?MY(#`#WH,=2ECI%^*8,B:<0A229(D8DDAQ;EL-M
MLJ&,YV7QI+4.DPPJ4.C*BXP$)N@\"T(_M.7X=ASWG0`I\7@<MSS3"Y1=2,8`
M%)J>>7504NA\1B%/DA4Z[I6_JZ%(8+PW%8[CMQ2.XS<5C@%S"N%XC4OR?1[R
M)%FA9P6R1Y'`"(66&]I>&*JG;SO&H,#W'-L-E'*,QQC+L9W0"9$GSY6,,2B`
M>\BQK*OEDJ/>9_3R)%DO"GUY#9'`B)J]SMVYO9V)Q3.QY'9,T@.OM[%_\V>/
M@V4=GJ6\[B*!@?(9SJ=R.K=W$?%=1#*'D/3Q;D6Y"NZ_8WB2K'/ZCA&8MT_@
M..[;@:O47#R.WSR!8P"R'*C=H6(DA>%G%/(D6:%G*U47"<R<DW<1\5U$,H>0
M="*X&CYN99<E*YUZ>0$YW>M4V8:M%`Q=Y=S&4EC)32Y!424H1,YM"Q&_\#]<
MI5V6+,VSU8OB`IIS\3XDO@])9B&RD;Q#^+A:T5?,7_S0+_.ZOOT6G0O&<T'>
MAE]I/0?^%!]%DRUZT`JW![S%94FUC)QX`VU#70VC0W/_T/7VRGB$EM`P0LNF
MC,?\QP`?-X8`].)->L`_T_90U%0K\1ZF,A<^7&:MZ.;%`R--UQ'O"(,NO/MZ
MA%]=&%I1<P'@/2&L?^`3#+_C-K\!``#__P,`4$L#!!0`!@`(````(0`N=6,,
MO`(``+,'```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)2576^;,!2&
M[R?M/UB^+V`('XE"JB95MTJ;-$W[N';`!*N`D>TT[;_?L4V^R!2E-P$GKU^>
M\Q[G,+]_:QOTRJ3BHLLQ\0*,6%>(DG>;'/_^]7278:0T[4K:B([E^)TI?+_X
M_&F^$_)%U8QI!`Z=RG&M=3_S?574K*7*$SWKX)=*R)9J6,J-KWK):&DWM8T?
M!D'BMY1WV#G,Y"T>HJIXP1Y%L6U9IYV)9`W5P*]JWJN]6UO<8M=2^;+M[PK1
M]F"QY@W7[]84H[:8/6\Z(>FZ@;K?R(06>V^[N+!O>2&%$I7VP,YWH)<U3_VI
M#TZ+><FA`A,[DJS*\0.9K5+L+^8VGS^<[=3)/5*UV'V1O/S&.P9A0YM,`]9"
MO!CI<VF^@LW^Q>XGVX`?$I6LHMM&_Q2[KXQO:@W=CJ$@4]>L?']DJH!`P<8+
M8^-4B`8`X!.UW)P,"(2^V>N.E[K.<91X<1I$!.1HS91^XL82HV*KM&C_.A$9
MK)Q).)C`=3`AH1=F,8F3#[A$@PM<CRXWHOBN+)O2(]5T,9=BA^#D`;CJJ3G'
M9`;&)IX(0OY_/)"+V?-@-MFMH%;0TM=%,@WG_BOTH1@TRTO-2+&Z5$3!P<0'
MO@,DY'8*>1W.B*$(C$[@HH.O+6#I-),337RN6%U3G+'!@VYG,^(<@_>!+<J.
M-3LVI\ELK-#==$)&:*<"0I(XBH[P9VA0W^UH1CQ&&SUYZ32)12/I=)(<'VS9
M5U<$9V3PU[F=S(C'9*.SM'0:1Q8E81:,4EU=$9R1)1\A,^(QV?BH.<V061#%
MTVS4SC/!)$W3R4%P1I9^A,R(QV1'7W?0G,8=-!*2)`E&"IC+QF509'$<7;"Y
MN>LF2D\W[#N5&]XIU+`*CGC@I9"[=%/7+;3H[>18"PW3TM[6\')D,%8"#\25
M$'J_,'/]\+I=_`,``/__`P!02P,$%``&``@````A`&Z^**M<!0``M1@``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S@N>&ULG)E;CZ,X$(7?5]K_@'B?@`WA
M$B49-6GU[D@[TFJUEV>:.`GJ`!'0E_GW6Z8<`H6'T,S#="?Y*(Y/81_'O?[Z
MD9V--U%6:9%O3+:P34/D2;%/\^/&_.?OIR^!:51UG._C<Y&+C?E#5.;7[:^_
MK-^+\J4Z"5$;4"&O-N:IKB\KRZJ2D\CB:E%<1`Z?'(HRBVMX61ZMZE**>-]<
ME)TM;MN>E<5I;F*%53FE1G$XI(EX+)+73.0U%BG%.:Y!?W5*+]6U6I9,*9?%
MY<OKY4M29!<H\9R>T_I'4]0TLF3U[9@79?Q\AG%_,#=.KK6;%X/R69J4154<
MZ@64LU#H<,RA%5I0:;O>IS`":;M1BL/&?&"KG>.8UG;=&/1O*MZKSN]&=2K>
M?RO3_1]I+L!MZ)/LP'-1O$CTVUZ^!1=;@ZN?F@[\61I[<8A?S_5?Q?OO(CV>
M:FCW$D8D![;:_W@450*.0ID%7\I*27$&`?"_D:7RT0!'XH_FYWNZKT\;T_$6
M2]]V&.#&LZCJIU26-(WDM:J+[#^$F"J%1;@J`C]5$<87/%BRI?>)*HZJ`C_;
M*O<D6#B<QIW'N(ZWZ[)X-^"1`\'5)98/,%M!P:LM.(C6J)_Y!`;)(@^RRL;T
M30,LJ*"Y;UO/9VOK#1J2*";2,&$?V5T1V4C0UXH$O[HB]3V[:I&PU")[*,5%
M^`;4;L5Q<M\AX?DWIB<%/)HN1<(;$ZJW=_9\IW_O"!FWPRS[Q`X)K[&5LY"[
MKML2/6U09+HV"5-MM[KH'#)CVI!`;<P./<Y_XAM,DJXV^9PY,(G'6RDOHAJ)
M.Q$R8QJ1"!K_'&X'MJVWS^M+')<F82K-:^NB?<B@.<XR#)<$V'4!Z"SC?ENA
MUUB86%WSQI5)F"J[U45ER*`R-[3#FR/-Y[ONYT[`O4"O2X8C63SN-U5>1/7=
MZJ,^9,::.D;TO`OG:)0748UDL8J048_^TF<N#VA_$=$/HR>2P53XO)/-541F
M0%H9*0AU>IX-_]IF8K,5,46F7*`_W7"&RWIO&0P&Z8"07H32.8;T[90+^N=U
M8@ST=/JTZPPAM),O0Q:XM.L*T0^EKY.DR;15D6EB9=CV;FHPYH7^H.U(3)$)
MS`P[Y57TZ;RE`TYTAI!>A&K[&-*W<U;(R%T@U3EL.T+8=M^SG;"S)BJ=B.B'
MTM=)DF9BVS61,VQ[-U(<%^)NT'8DIL@DL3-1IB9_`KKI80CI12@[QY"^G;-B
MB.ER:##;$5)M7VK6SLDYQ&8%47,5G41TFZ:@43<G1Q&?%47-543G8!(IZ+IV
M#MU4@'X@O9YSDD3C6Z*&)NH"NI%4D/[F^$R.(GU]LQ*(:Q*(;BHB!2D7X0L%
M=TB8[A2B'TI?YZP$XKH$HGM,!5V[';H^>6YWBI@B$YAN`MUIMZ1IN^D6DR.D
MO[EJ]QC2MW%6\LCO_`.=9#<1*0AM9'+[1E=T1>A'TI<Y*WBX+G@&W>X&3ZA3
M.3EW.,F=.\W6Y0U=QYN2&Q--#'TW#,A&9*>(*2:2N+DC3Q,S].M6Q+LQXP:@
M;S"C)^<,)SES1Q[F0F_/2V\>-24WIMX;-54FYXO\@CA]*C<TF<H^G2(*PNXZ
MH>W8U#Y%Z$?0FR+.IX*EH:D\.C44A/)\S29"`5/4S8H51Q,K@W!6D%IG0@>$
MDH3<*62*SEFQ`N>_P_60K':1@O`X)V"@DWR=5<"82CPEQG/03)1'L1/G<V4D
MQ:L\`>9P4M2^VYY./W!YHDC>C^#4NCGBM=H/X-#X$A_%][@\IGEEG,4!2MH+
M'];Z$H^=\45=7)K3U^>BAN/BYM<3_'E`P(FEO0#X4!3U]84\#VW_X+#]'P``
M__\#`%!+`P04``8`"````"$`"'55=*,"``!]!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6R,E5UOVR`4AN\G[3\@[FMLIW8^%*=*4W6KM$K3M(]K
M@K&-:HP%I&G__0ZF84ZR=;EQ#+R\?LXY'+*\>9$M>N;:"-45.(EBC'C'5"FZ
MNL`_OM]?S3`REG8E;57'"_S*#;Y9??RPW"O]9!K.+0*'SA2XL;9?$&)8PR4U
MD>IY!RN5TI):&.J:F%YS6@Z;9$O2.,Z)I*+#WF&A+_%05248OU-L)WEGO8GF
M+;7`;QK1FX.;9)?82:J?=OT54[('BZUHA7T=3#&2;/%0=TK3;0MQOR37E!V\
MA\&9O11,*Z,J&X$=\:#G,<_)G(#3:ED*B,"E'6E>%7B=+#89)JOED)^?@N_-
MZ!V91NT_:5%^$1V'9$.97`&V2CTYZ4/IIF`S.=M]/Q3@JT8EK^BNM=_4_C,7
M=6.AVAD$Y.):E*]WW#!(*-A$Z8#!5`L`\$12N),!":$OP^]>E+8I\"2/LFD\
M24".MMS8>^$L,6([8Y7\Y46)@PHFZ9O)!.C?UM,HG65)EO_?A7BB(<`[:NEJ
MJ=4>P:&!;YJ>NB.8+,#Y$)GG"+'^*U3`<R9KYU+@*480A8'R/*_R?+8DSY!3
M]J:Y/=<DQXK-0>%*`7B!$2(?,_X]ZP<4)W8H+G6.[=9/@'=@2T^^>ZZ8QD%R
M1`(9NIS$B:'2XP]?SX.OA_.:ZY$F.U9LWE,<L8')F,U5<@(G_?ULN4T%A@2$
MY.3Y*:/7S(:RSJ>3_#1]?AV>P>-/#$>$<-;'A.^3.?$)V:@J/GM>X\G2)(M/
MR<;KLWP2,NNI?+O[;I!<UWS#V]8@IG:NE5.(-\R&6V:=NH-U,G\+M\_0JR0L
M0/?WM.:/5->B,ZCE%5C&T12(M+\__,"J?NC!K;+0]\-K`]<\AX,;1R"NE+*'
M@6N+\,>Q^@T``/__`P!02P,$%``&``@````A`&PC0'`K`P``O@H``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&ULE)9=;YLP&(7O)^T_(.X+&`(D49*J
M2=5MTB9-TSZN'3#!*F!D.TW[[_?:IC2&CB6Y@!`>GQR?UU^KV^>Z<IX(%Y0U
M:Q=Y@>N0)F,Y;0YK]]?/AYNYZPB)FQQ7K"%K]X4(]W;S\</JQ/BC*`F1#B@T
M8NV64K9+WQ=926HL/-:2!MX4C-=8PB,_^*+E!.>Z45WY81`D?HUIXQJ%);]$
M@Q4%S<@]RXXU::01X:3"$OR+DK;B5:W.+I&K,7\\MC<9JUN0V-.*RA<MZCIU
MMOQR:!C'^PKZ_8QF.'O5U@\C^9IFG`E62`_D?&-TW.>%O_!!:;/**?1`Q>YP
M4JS=.[3<H=#U-RL=T&]*3N+LNR-*=OK$:?Z5-@32ACJI"NP9>U3HEUS]!(W]
M4>L'78'OW,E)@8^5_,%.GPD]E!+*'4./5,>6^<L]$1DD"C)>&"NEC%5@`*Y.
M3=70@$3PL[Z?:"[+M1LE7IP&$0+<V1,A'ZB2=)WL*"2K_Q@(=5)&).Q$X-Z)
MH-`+YS&*DRM4HDX%[F\J%UKQ3;=T2O=8XLV*LY,#0P^,BQ:K@8R6(*SBB2#D
M]^.!7%2;.]5(-P5:0$V?-DF4KOPGJ$/6,=LQ$]K$;DQ$08_XX*\W";F=FYPV
MI^"U"]?>7!BA7E=W8&N8N;:.%@%\;&!W#D0V8#F#R"YWIF#;61+-[3_>&B;1
MSJ)T!L/,!G8#(`UF/6`YFUWC3,%#9XM>UV1F&+CVN<8VL9LB+&\P<RY/3<&V
MMW$]#6-20_-X7,\)P'*67.-,P;:S<3T-T]4S29/Y8)[L+"".YBCJ4[6<I=<X
M4_#`V6PPQ+>&F:KG%&%Y4YOEV2(R/3\5;'L;U],P)K5WJOG/UY:KQ36N%&R[
M&M?2,,95`BMW7R@]07;6ZRA]>VVY0K"Z7AZ6I@>^9L/5K(.F2CF)V/X&.\)T
M,9%9Q*=7VPZR_+VM6B:\CC'APAGI?`K;_M32?/%@@Z/%_^O:0=/^SG<$-(M1
MTE??V#,G$+.WMOA`OF%^H(UP*E+`@AEX*2Q!W)P_S(-DK=Y#]TS"N4%_+>&<
M2&"##3R`"\;DZX,ZX?0GS\U?````__\#`%!+`P04``8`"````"$`*TV+6,T#
M``!H#0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R4EUUOJS@0AN]7
MVO^`N"]@/I,H2=6DZNZ1]DBKU?FX)N`D5@$C[#3MO]\Q0R@V-$IR$0)^>7D\
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MR#^>J<@@HF#C^)%RRG@!`/!ME4R5!D0D?6^/9Y;+X\H.8B=*O("`W-I1(5^8
MLK2M["0D+W^CB'16:.)W)G#L3$CDA'Z4S.YQ"3H7.%Y<_%M17)Q6&Z7G5*;K
M9<//%I0>@(LZ585,%F!\"0].I@_85_&"0"F3)^6RLA/;@E`(2/+;.@[]I?L&
MB<DZS08U\-UKB*[87A0JGX#7,T+8AHS3J;N@*+%"4:E4;!N\,'RN0;8=*P*O
M1]-(($)#$A6M`$KR.I&Z:67#0_J)QV'0^R,D:F9MZ,A\'LWU\2V.AP./J%=H
MA"`9$EXG4V*=S`^,I&Q0$W=D'GSZ![?HVZ$@F&L"C0R6R^UD2JR3Q<%,?_`&
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MYUQ>3E3OUO]'6O\/``#__P,`4$L#!!0`!@`(````(0"[0P?2?@<``%$J```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)Q:[V^C.!#]?M+]#Q'?M\%@
M0ZB:KC:L]NZD.^ETNA^?:4(:M$F(@&YW__NS&3=X!L<UK*JF63]/'L\S\XS#
MP\?OI^/B6]FT57U>!^PN#!;E>5OOJO/S.OCG[R\?5L&B[8KSKCC6YW(=_"C;
MX./CSS\]O-;-U_90EMU"1CBWZ^#0=9?[Y;+='LI3T=[5E_(L1_9U<RHZ^;9Y
M7K:7IBQV_:33<1F%8;(\%=4Y@`CWC4^,>K^OMN7G>OMR*L\=!&G*8]%)_NVA
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M^5U)2MVFDU23UH'\;9!,KO'["]D`9M5?`E_%/&(8D)L`%B=I(H;K1!2E=B9%
MMWX*3*FE^),W@.$]M4&6GG9N'T-\..;CMZYJ$N6U(KP`D]R6S`0X)9/UXR^9
M`E-J&:$&&*#&DBS+8@S(34#*LQ4;4A*)EV!F?N*I282A(`NW`0PPS+)01`20
MFX`TE54U)"1BF,YAJ"91AD-\J`C`V-/./H9X*=N<W$[4),IK6!G@!1B'<B;`
MI5R&&;H+58$I,Y)4&\``LYAE"2GDW!SG*;NUHDQV75,Z-[$>C9E%":T'#=(%
MP=,XXV2Y<P2)&.<L''HD6EE&G.(=?M#<4?<5')?CI@^Y#F3#N+9HBLFO&.4R
M0[5@:JI+&UGW#C7HZ9C:T-4AW1B`G-*9$+=TD\R!6=Q!#(NB^0$(^$6A3+M!
MFQZ1ZS"`2+,D2X;$Q>JIAFVHY]?M&+1YI&(X?()F"2"TP#@'<AW'#L$\B5]X
M\K09QTA-TQA$*/]1EK<!F"-QCG<RT6(9G+2/#0.0O2/?&,2<9GD%LY@%IWL!
M#8(<L^H&46P`S)'XQCNZ60R#CYJ?:0ARKYT1\CE#@"3,!N4Q-^(8GGEGLX[A
M$W1]`,B>_+J,71#$,R(&XL>SGX6-).&T/C1(]Q*UT*0^'`#,<9*)1!83&=6'
M!MGKX\8@YJ3Z^.3^%T'W1_UO5!\:Y-`-HM@`F.,D!XDL#C*J#PV"CXX%6]'Z
MP`#&XP&`N:DF/UT_-8ODG1@^`>HC`I"K/IP0S'.6?ZC[<\IS7!^F/436^TB$
M$+?O(Z-)#M*CB8KC"G$YB(Y`RP<K-\M!(A\'T2#(0KMRIH5$+N4F>4CDXR$:
M!.SDSCXB"9IC0!@9^S2L(/$0M[]%-N^@_J9!SMKP]@YUY#.]AOM9-/NH=VB0
MK<6!PSD`2,-XDG?T:,J-^J\&T>37O,!]Z"#F-,L[8A_OT""';I[>$4_RCAY-
M=:.YIT&Z+GA*QG,TGB;A<..'U5/M?;)SQ&`*\NJO=XT)O?O9:)"K.IP0S'.6
M<\0^SJ%!3IZF=:Q6:/>%:4ZRCAA<`<DXL@X-<M*SNPMF-LM`8A\#T2`G0]-!
MG`).<I#8QT$TR$D/XD`QB51$QJDA5I&8B-\&/[:9"=F_;S0(.$22P6B'KQ'V
M"T$T^2POZ6>1OF,<E<%^4(-H2X9^?1T<^L)PJH,9$B?Q$Y);[D8$/:;4((>0
M&N$CI&KP1GMT;QHXV`&J9T$/9#1(-^[Q*NMQ'W+$53PUM-R9A,,JZ54&D)V$
M7FL7!*^U#&.*Z,E3S:+92(N&`PC$C%D:IB0;<A<"LYSE,-SB,..:`="-FK$/
M8F[$5CP5M-C+N%H`Y%+0@<`LB<6\4RP6:QD7B^D;F6"DF')NCL<BC&]L<SBQ
M%4\!+?:2D./[31^:G*"3HQDG!$LXRU^XC[]H$"PTYROY0VE"&"L"L12S[*6?
M10N:JJE!]E*Y,8BYS3(6X6,L&F35!WJB"X%93O(5X>,K&@3L6,Q'7^-@0,38
M<"N&N1%;<9>QL-A)0IKP1H-<=N*$8'ZS[$18[&1TB*1!3IX0!V3&NS3,DMC)
M.RI:;&1T)R#>G,*VN]()^`9Q?%4G9IE)/XM4+^T@&PURZF>ZB4N_268B+&8R
M.F[5("<[TT]8QHQODO'JSO(38?$3X[M>V'IID),EQ+%#,,]9?B)\_$2#["1T
M-IJ&PL(L'KH]8IG,\I-^%LG(T=9+@UPLKQ!'S22S7*6?11G2WJA!3H;@3KJU
M.W2<Y"KRD;_Q!IMLL#8:Y&0'<>`)KF&##BL,#P7"XVZ7XKG\HVB>JW.[.)9[
M>704WJ6R837P2""\Z>I+_UC;4]W)1_GZ/P_RT<U2/O,6WDGPOJZ[MS?JH</K
MPZ"/_P,``/__`P!02P,$%``&``@````A`&B)-5$0!```/`\``!D```!X;"]W
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MH;I6IHOOAXK4R:Z`NC^0FZ37[.;'(+[,TYI0LF<&Q)GB1H<US\VY"4GK999#
M!5R[5N/]2G]%BQ@AW5PO&T'_Y/A">_]K]$@NO]5Y]D=>8;`-_<1[8$?(&T>_
M9_P0-#8'K>.F!_ZJM0SODW/!_B:7WW%^.#+H;@\JXH4MLL\(TQ2,0HQA>SPI
M)07<`'QJ9<Z'!AA)/IKO2YZQXTIW?,,++`<!KNTP97'.(W4M/5-&RG\%U%34
MA=AM"'RW(<@V[)F'//^)%*=-@>];RK.WXK8A?A?B(&/F>:X_"R8+,H6<QG64
ML&2]K,E%@P$,Y=-3PA\'M(#DJV2AI-/^R#KHYB&O/&6E![H&0BD,E?>U[SM+
M\QVZ-VV9<,C8,K$9$HXE(Y%`X+.[D!*RG23B,<($+9T;Z/2^F_L#[ZJ`PUP!
M'XC<2:@>V*@'(G&@7XSONW+!VWN,)S/Q/<;O&*DD&(%?+XG#*QW2;[+GRK5#
MP<R:/D=NX,Q=U%VY\;#I$S9R763=[JTAHC[A>I;M*;V^[0.!Z_B6`L1]P/:<
MP+\!4OGP#/7+YZ/=@8EIO&=Y(U6#4D(H&/CL5"FB-I-$)`B_4?D26/`GF]Q.
M1L1CA"0")HSG1?!&JHB9?(^A8.`^'HJ8)")!M")0X`U-3&;$8X1D`B:]YTWP
M1K()1^VM4#!C)B:)2!!7$\Z=1T,B7,L#67*/Q!*!))F2")B]GQ?!&ZDBE!DY
M%,R8B$DB$D0K`B8(M<JM!$!GJ$`L`3"#]`!)`U\^*B_$Z2F"-U(U*#-Y*)@Q
M#9-$="7X&U;IYZTX]UA1+`'(GS]4,/\_"G@C18&M*A#,F())(IHDMH(0(AQG
M'BCC,>Z?1RBXO:^D<8#@O?#\0&A:R1I\/Y"?R+"%QCQ,(U&'W!L,8R?C]N1U
M6K'FSB,'?*G4>QC&WY.P&1@,`?5='[;0V()!0NZO&"2$SP;JPR`!#@JLP2B0
MB%MS,0;$ID0LE$M<'_`&%P754G+F&PX'7M'=T6XS]&KSM9]R/$0+6`@.CV_0
M`M:#<-SL&L#>Y90<\)])?<@KJA5X#Y>R#+ZVK\7N1_Q@Y-0LVW>$P:ZE^?<(
MNU0,:T[+`'A/"+O^X!?H]KWK_P```/__`P!02P,$%``&``@````A`()`7+%B
M`P``5PL``!D```!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULE%;;;J,P$'U?
M:?\!^3V`20A)%%*UVW:WTJZT6NWEV0$3K`)&MM.T?[]C3+BEJ2`/A,OQF3/'
MPS#;F]<\LUZHD(P7(<*VBRQ:1#QFQ2%$?WX_SE;(DHH4,<EX04/T1B6ZV7W^
MM#UQ\2Q32I4%#(4,4:I4N7$<&:4T)]+F)2W@2<)%3A1<BH,C2T%)7"W*,\=S
MW:63$U8@P[`18SAXDK"(WO/HF--"&1)!,Z)`OTQ9*<]L>32&+B?B^5C.(IZ7
M0+%G&5-O%2FR\FCS="BX(/L,\G[%"Q*=N:N+"_J<18)+GB@;Z!PC]#+GM;-V
M@&FWC1EDH&VW!$U"=(LW=WB)G-VV,N@OHR?9.;=DRD]?!8N_LX*"V[!/>@?V
MG#]KZ%.L;\%BYV+U8[4#/X45TX0<,_6+G[Y1=D@5;+</&>G$-O';/941.`HT
MMN=KIHAG(`".5LYT:8`CY+7Z/[%8I2&:+VT_<.<8X-:>2O7(-"6RHJ-4//]G
M0+BF,B1>30+_-0GV[87G!ZL1+(Y15"5X3Q39;04_65`U$%.61-<@W@"SSFP.
M_A@=3:[74H4<-<FM9@E1@"Q8+F%_7G8!]K;."W@:U9@[@X%C@\$-P@$UC220
MT97TOLGGR!JL(VO3M90[<Z,;IA72"S.?$D:#0P3<C?@%;N6;R`:S]JO\/=M?
M]W\/LRM"%E.$:/!0R+SQT0@Q&#@V8@/<8GHF0/F-]UJ#A[']06R#J4UP[;7K
M>3T;&GA/QG**#`T>R@@:7F.!P:RJK7";9[V84*WC4]?@?LP`+QI>$]-@NK:W
MYO0BZ\]"YYW[N,`UN!_YLO(,IC9];J\>9E>V>STEL@8/([>\)F>#Z>8<N.U>
M]++&T%;&IUVAA]%;/TWT&M16VZ+_TK7XOA+=BD9O`#:-J__NMSG62@QH\5'!
M8=V:QH<UC:P;-L!M0G58`^KZWT+Z.4]J=WA,OZM!;<-S>S]\M>%AT#O!"(T>
M5L*P#BO*$'6-N-KS])=[0O@Q7:^B#%%M!4R"WG)$UX.198J0,7VOH@S1^XW/
MS#?F\Y]3<:!?:)9)*^)'/;M@J-WF;C-7W7K59-0\@+&F)`?Z@X@#*Z25T026
MNG8`+@DS&)D+Q<MJN-AS!0--=9K"`$OA$^W:`$XX5^<+/7HU(_'N/P```/__
M`P!02P,$%``&``@````A`'`ODO@^`P``ZPD``!D```!X;"]W;W)K<VAE971S
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MC][MR9E]Q5+!)<^5"W:>`3V/>>[-/7!:+3,&$>BT.X+F";K#BPWVD;=:M@GZ
MS>A!#GX[LN"'+X)EWUA-(=M0)UV!+>?/6OJ8Z4NPV#M;_=!6X+MP,IJ3?:E^
M\,-7RG:%@G)/("(=V")[NZ<RA8R"C1M,M%/*2P"`HU,QW1J0$?+:?A]8IHH$
MA5-W$OLA!KFSI5(],&V)G'0O%:_^&!'NK(Q)T)G`=V<21&X43.+9O[B$G0M\
M=RXXN!;%,V&U6;HGBJR6@A\<:#T`EPW1C8P78*S3$T*233!]PC[*%R1*F]QI
MEP3%R('E$HK\LHKQ=.F]0&'23K,V&CCV&CQ6;(X*74_`ZQDA;4/&]TMW1-%B
MC:)+J=G6YL+PN8'UW'-%Z/>2$0EDZ'H2+4X0F/<!QSCN?0V<T40#S62LV%Q2
MC-C`Y'HV+;;99N,GKXUFVI8SB()Y%`06_L9(X-B'>,(?P<%>&<(=V^QR*?4B
M&W)N01K-O(6$+6PUW<;<O@)P^C^`>I$%&)PZQU38:(8$<6`W_KGF@S3"#ANF
M\7+ZM-BFLUI_;32FQE&,\0S;;$8QY/^`34_,=_Y)+C/J139C:)78:(XEQI$_
M^MB\1GT%[_R<-X)VN<RK%]F\D<5K-$.".#CEK.V*S;GFI!AM')B-H[1>QFO5
M-I^U)]:=J-O8<W@?\4-K[^N1K`/M-%,<AI%_VOR&T,Q<,TTJ*G9T0\M2.BG?
MZWF*84OV5_M9?Q>TT[J_`:.V(3OZ1,2.U=(I:0Y+?3>&0@@SK,V)XDT[J[9<
MP9!M?Q;P4D7A#]YW09QSKHXG>GSTKVFKOP```/__`P!02P,$%``&``@````A
M`!!?&PHU!```JQ```!D```!X;"]W;W)K<VAE971S+W-H965T-#<N>&ULE%A=
MCZ)(%'W?9/\#X;V!*E#$B)/N[>V926:2R68_GA%*)0V4H;#M_O=[JRZ?A:W@
M@XJ>.N=^5!V\;KZ\YYGQQDJ1\B(TB>68!BMBGJ3%(33_^?OE864:HHJ*),IX
MP4+S@PGSR_;WWS877KZ*(V.5`0R%",UC59W6MBWB(\LC8?$3*^";/2_SJ(++
M\F"+4\FB1"W*,YLZSM+.H[0PD6%=3N'@^WT:LV<>GW-65$A2LBRJ('YQ3$^B
M8<OC*71Y5+Z>3P\QST]`L4NSM/I0I*:1Q^OOAX*7T2Z#O-^)%\4-M[H8T>=I
M7'+!]Y4%=#8&.LXYL`,;F+:;)(4,9-F-DNU#\Y&LGZAOVMN-*M"_*;N(WGM#
M'/GE:YDF/]*"0;6A3[(#.\Y?)?1[(C^"Q?9H]8OJP*_22-@^.F?57_SRC:6'
M8P7M7D!&,K%U\O',1`P5!1J++B13S#,(`)Z-/)5;`RH2O:O72YI4Q]!TE];"
M=UP"<&/'1/622DK3B,^BXOE_""(U%9+0F@1>:Q*RL#RZ\%<36&R,2"7X'%71
M=E/RBP&[!C3%*9)[D*R!66;F0GTPCC;7SU*%'"7)HV0)3=\T8+F`_KQM?>IO
M[#>H:5QCGA`#SRV&M`@;HFE#@C#Z(5TO<J,LP5)9%EV&\H0?]&7H=1EWCHP$
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M2.AB`Z=S76U+$`1A2([E=9MU&('TI5X$=XJ!+M97'A]Z@J#5K5,O[\PS9,<V
MYXW.O:(,S29ATIV18<*S3(Y<<;F@*V7=?03=5=:L;F*SQY[GNY[>;`3-WW^:
M!TX,:6R&OMO=1^NB(*@IRJ?[3_/"B1%<,457O^,2!,TN"M4L<EI(:I7N$]U]
M%HM2@^X5A<ZR284>_OSP_,[^:^7)-DDUF[SM"`JMI3WZ!5*#FK1IMU<&1Y-J
M;GA'>>R"8R]2E*%YTXOH+`M4Z&'"8R^J04W"GWF1G"RFNZ!"Z\JZ%]6@N\JS
M7)".77#\&Z0&-<JT\ZAADS47O-/D:^XWVMM]]X/QKC,"5,:9$4>JG)4']@?+
M,F'$_"SG00+WJ?;3=E9]I&K:;+^`4?$4'=C/J#RDA3`RMH>ECN5#!TL<-O&B
MXB<UL.UX!4.B>GN$/P48C#V.!>`]YU5S(<?9]F^&[?\```#__P,`4$L#!!0`
M!@`(````(0#TK#$%1@T``"*"```-````>&PO<W1Y;&5S+GAM;.Q=>V_;R!'_
MOT"_`\&T10^H33TH2_)9/D2*V09(T\/%10OTBH*F*)MG/E222NPK^MT[P^>L
M*))+::55<(T12**T,[]Y[NR07-Y\]^*YRF<[C)S`GZG]RYZJV+X5+!W_<:;^
M]=ZXF*A*%)O^TG0#WYZIKW:D?G?[ZU_=1/&K:W]ZLNU8`1)^-%.?XGA]K6F1
M]61[9G09K&T?OED%H6?&\#%\U*)U:)O+"`=YKC;H]:XTSW1\-:5P[5D\1#PS
M?-ZL+ZS`6YNQ\^"X3OR:T%(5S[I^_^@'H?G@`M27OFY:.>WD0X6\YUAA$`6K
M^!+(:<%JY5AV%>54FVI`Z?;&WWB&%T>*%6S\>*8.BD-*^LW[Y4R]4I54Y$6P
M!!"_^_<FB+_]3?KRY@]OWO3^]<VW__C!7O[SQ]]7O_OQ&U7+V1":8(-FFI>]
M1K+P=4I9RR2XO5D%/A%D`&I";5T_^\$7W\#OP!E`//S9[4WTL_+9=.%('^%9
M@1N$2@Q6!OF2([[IV>DO%J;K/(0._FQE>H[[FAX>X('$,;+?>0Z8"0]J*8?3
M\GE`-+E,$X3!R#3$(U0F#T0R\6"S3.9/.V1B>(W:>1VB/X97(D6S7,)X5?VB
MHL-#>!6V(GS"QX>9:AB00_J]'JJ5&NQ(S*:+'O`[&;.KT<DD&QI#8RQ4,L87
MJW9#AD-#I"I;&!IOQ^].ID[QS.JDR]+PJ2(``TZL%AT(W8;X'AOX=PH_.?&$
M=A2+5>>R)/+*U'CO>':D?+2_*#\$GNFC7NF<EOR:F9*IWXFG3HTOGOJ&N)9(
MZHF"(M"<X[I%,3@<8;D$1VYOH"Z-[=`WX(.2O;]_74.QY$,)C2K7TM^U_/HQ
M-%_[@Z1DX!L0!:ZS1!2/BZ1$RZ;(Q=6=L;A+^!)DO"AJB!K&8GP$HG?SZ4(\
MTL5T*IKHP(`_P43?CO!/,%$#_BV$Z31+DKHHD`4])79P2=6['$^GTTG_:C*9
M3/5A7]<3)3]D'NWX2_O%QE66,#55$8P`P70XF5X-`$A/GR2L3HI@"`#&H]%D
MU)\.=/B?I.7C(Q"MTY$JVZH$@22K$@22K)I4]9J`S)]%"C0X),<J02#)J@2!
M)*N.!6?@L72K$@22K$H02+)J4J4*C%5H'$J.58)`DE4)`DE6%59\9AEX*MVJ
M!($DJQ($I[9JMJRZ2_YA&JY69L+JXXP7%O%&T@7IPBM9-<(Z]2$(EW"&)S]M
MT==AC9@>N[UQ[54,(H3.XQ.^QL$:!0KB&,Z'W-XL'?,Q\$T7WFKYB/RU822<
M,8*30S,U?G*L9V#&=*%3W:0LCL6AR'HZKB;TL=X;ZZ/!5;I@$\3:LY?.QJM*
M5_#>Z9>@1M1MN^!$AW[!)'.'LBFFH14R\W&.2$R=6)IS`/A$[A*<(T3(6#:(
M>64D(_AD)`,X920C>&6$T-D57+DFE\$&3E9N&]@P)KU>VHSCY=-,D`#?X3&[
M09`Q57VV#MFAT=8Q766%_%*)C?D`_Y+J>(>D+2.J<K8,V"%ERPA>&5F_R:W+
M$"]:%YB>=R#9TC?S\_U@`*-T8(YG*PEF^0G/$:1G";C3'2MNA<^6**+X<(M!
MM`O8NDV+^S#A'M-DQVS*A@K`LEWW$\[)?U\590!TUFYO7E;D,@.X]@//P^-5
M#/@6VM?9VW3*3S^`^'6#X"J"FD&*N5Z[KQ\WWH,=&LD%(0F+Y*@!?,I/\Z16
M*3^_=9U'W[.3WJ":DOD^#&+;BI,+5I*S*'5XAC5X^ADA'CR'\-=K^(.>N/5Q
M"'_H/>VT!^A%*G]P+F[^(OT!+\W)G!I,0)VZ"8](!-!AR!&`$60@P$N),AV`
M>\I``"NW'`$X:(D`X#1XQ2%QT"?9#'R@9`G\C\42<DPN)</RB%+6I5_@WR"E
MP:3?@]1,\BTX>JEF^-``X""6=2E65HHA9H=(*U4`'QI48,"L*V;*Z]?E?&D*
M(4D7,)0:@330I!%Q7DER+O`L`31K9"ZP#B%.@:E(-@2`(P4",41?TOS;IQ@D
MS<#4&R1-P10",P>?,":H)9@94A(&P",E*LHZH<_,&"=4`X$@*T,2;QC(2I$4
M@ZP<69IB("M%$@BR,B2UA*P423'(RI'$%+)2)($`&I&2(:DE9*5(BD%6CBQ-
M,925(@D$61F26&)XY!2IT;9IVD0E_=/IU5[]4^5EU=I([=<MFL#N^?!T]92N
M',$6R5J*+*7QYBTS[YTJ3T'H_`R+3+R)RX)FJAVJ>--?[%CTR)?07-_;+[`4
M34\]O:SJ>[V`).]O;#LCB[`64\D?FNNJTH6Y</T<@.5P1;1*GBSJ6QOS6Y[!
M-K=;/:05!#9W9&-`76<8A+N`H!#!R)6M)I@DI6.@ID(\6<\9#C,U!)LK#-`<
M)I\.V>RG310[J]=N^>/PF#T@8>`R3Z@ZNH0N/_/=^6,/"R7GU+O9AQ^E9#S8
MSFMRX7G616QUZ58;\L23,#0T%_*:C\P/M>:K`N3Q,FXE[@.;2Z]@OM-8F4N)
M%32_+"4>R\HMH5Q;QPH)W7V94V7DA;T00-5095/M7D')C9!6O.>03;B!UZ23
MX78GK2F=I&=DCS9EL%A@2X_&W,:"X;9ZJP_69+HV<#RI;D_(-)1X)[TZ<V\W
M+66:F\%R;N9N`?=UF!N\X"$I]+"Q@Z<VF\S-'4('^B.Z)M>BZ_PG-OXU'E=6
M`<VP!NKN9;4ZV\=H=:"9V#@WT.A>>2N&+&BW\G<%-5M$[)FI6R<7F>!$>@!3
M-50KLNY^>ZKD4U^S@4AL\+$>L1?`<ZS.J!O@?0AL`T3!C0S27A=<3ZTU-=JI
M*MGHZA1<0C-677PU9RS6TFSL<\$3I\<C`SW#\I'3'Y-MV_C]D=%C-4$U69P[
MTENS/=?\604G+WL6T7^&VJ9^LL.-VZ!_=;;8F7[KI(#C#V6A7\F_9^!1[2=N
MZ^>3:H@(B5]>CSH$>L443<@/G6O2#54J<S:?TU3:+6?@-#4"U<WR;!14!&I2
M/7?2YW6:CM!/,5^U0-^9<,Y8U9WPLOJ5XAI=\(+:F_(YZ\G<OMM:L-19F]4>
M_*III<36S]S@J'>>^[KI8'R,0COIDVN.$(OO/*??KW=6.Z2>.%*;G`9?4W'=
M#3J3Q5J\O-:ONU[0@MZZ:FT`5M!TKW9J$5-E'AR)3$U30<U.!&SFY<+7T+E(
MMZJH5)-<ZCV!FW9'_O5FC$-,(=YGFA($!U*X2GW%=?Z'=6XN=]XKW.H`M<U[
MIRMMZA"VV/:7K#)RZ@>T5!;3(E36D'K`9_:N\X\,+=U$MY+/45&[ILOF$O7_
MTR7G[0A,5ZM9IVR^$S*9=_'%8Y_#:8B:CNUFIB9JR]*L'O?*V57D^^OU!'";
MYN>.FCZYPQ9M_'0SQDJV@AS9GJVD5)\[7:*NY&3T6H7;/;ONY==-CG*0_EMF
MLC,+R4YHN6JJ:L+8UZ_95'?\OF45^4Z_K@O#4\,]F@<?7]-[0*_+)BU:/]]L
MPB=0)3[/0*#V>70`+B1TG;MO]Q[4=^SE3UN.$*X+VF+COP@3:Z^\>L"W7%V(
MW<Y6.PWLLE)RNS;<H$VVNV0WNRQNYU;P@5CP_,[>;Y4+Y:V%[8PB$_6A"_"P
M<5S8-Q\OY\5;[2VXQS#PYNG![.;H)EK%%<`#3!F$%M0C76D!A?0LT`"W7R"T
M8$'9E1:P3VD-05I""W8"[4P+ML3(:.'F&"4N'6Z`[8H+AF2T6-V/.'6O[[)C
MLHU,B0M%YL%%:95VQ$*2T`*1N](J[0B&H[1`Y*ZT2CL"0D)+!R9=:95V!"M0
M6N!N76D5=M3!<(36B%/W5SOMR/HJ[OG`@XO2*NW(^NJ0TU<IK=*.K*^BR%UQ
ME78$JD1?.GS1E59I1S9/Z)QY@LI8VI'5_8A3]]L9E?7X`:?'IU1*V\$[HB-L
MH_#H**526HWU\B&GEZ=42GNQ_JUS^G=*I;04T",2Z?`%OT2%C8:L=G5.[<[-
M99YU68?!>88'!CSIV=JX\`3N`)_?G>QI@BML(A#N8,5%Z<FVGI4%;%%=$&+C
M`:=1'D)W+VO7],TX"%\5W,>D(,<:?<1)[H]!4.B(I3"`CSR`_@1/.X<'J2N@
MEU1#K`_C'A9=R!2QP*H'-S7L0@9&IVA8_\,6:A<R,#HEPR95K)]XR+SWUYO"
M0FPNQ:F;A\0'QW^VEZSGL!H>`$@>2A_M31R:A?^Q(37@5,Q'W-B\H,&FB.1\
MQ7;-^!'V,<^5B'>\DMC!&IH'^%\V,5$CCB)$<#W`0^3>B>$1%'D0,R00%A>)
M`/86*DAL911.&G\S0Q^CA0G=+1^MD:C<J0FJ_^5+N<E]HO?8A$=L)-O?%^L!
M4-327ID;-[XOOIRIY?L_)P]W`6?*?O6]\SF($Q(SM7S_`9^:`U$,"S-(-Q\B
M>!(+O"J;T)FI_[F;CZ?O[HS!Q:0WGUSH0WMT,1W-WUV,],7\W3MCVAOT%O\%
ME7FN'UV_]/69^A3'ZVM-BZPGVS.C2\^QPB`*5O&E!0_C"58KQ[*U:!U"4HF>
M;#OV7&W0ZTVUJ>:9R7,P@,AUY,*OPDS8#/RG\MA,)1]2^,F9-(`-]Z'D0F@1
M/BO@$S*Y_1\```#__P,`4$L#!!0`!@`(````(0"NR9+MNX````^X`0`4````
M>&PO<VAA<F5D4W1R:6YG<RYX;6RLG=MR&\FUIN\G8MZA@B%/4Q$DFP>=:,MV
M0#Q(W)9(FJ"ZW3,Q%T6@2,(-`C`.DN@K7^PWF*L=,3O"L1]@'J(?Q4\RW[]6
M9E56%4"QV]YA;U-`5>;*E>OPKT,F7O_^R]TP^U1,9X/QZ+=K.UO;:UDQZHW[
M@]'-;]<^7AYOOEK+9O-\U,^'XU'QV[7[8K;V^]_]]__V>C:;9[P[FOUV[78^
MG_SZVV]GO=OB+I]MC2?%B&^NQ].[?,X_IS??SB;3(N_/;HMB?C?\=G=[^\6W
M=_E@M);UQHO1_+=KN\_WGZUEB]'@+XOBP#]ZN?]B[7>O9X/?O9[_[G#<6]P5
MHWG6&?6SH]%\,+_/3D8^`72__G;^N]??ZE%__$7V83R:W\YXM%_TF]]VB\E6
MMK>]D>UN[SQK?GDZ_K25;;]<_N5E,;W+SJZS]T4^*YIO?M/\(-!Y4=P,9O-I
M#O6G^5W[M4XQOX6UV8>B/^CE0];56S'2`1R8VA/]XDOVA^*^^=PWV_S?JU>[
MN_L[S:]*#E[>3]HT[&QO_G'E&^?%=#`6V_O983YOO=QA8_JV.<?#_*8YRC?7
M^;#-JX/%=*KM/![,M.0?BGRZ<OQO-C>W]S;W6BLZT?::).39]\5PN/GC:/QY
ME'79&P2UGYW,9HMB^OL60:?CYD?I2-^-AXO1/)_>0]MPR>OEL]_,LHMB,I[.
M492L.\_GBUD6EM6>\X=BUIPTT&ZS9`?P]68\;6]H]RX?0D8RU<'X;I*/6D^&
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M)BL(;&"OLG7M3K:SUU+2;W[Z^T]_;\JE6:K;\;`/`ODF0ZL&O4%+>(-5F[E5
M0RBR3_D027FRO;6]O9.A`]E,INXWV?/M[0U\H/[K'T'A8GX[G@[^BCCELVQ\
MC8>8S(N[*UZ*(,#T!QO2NRV-R&^RW1>[&R]W]C9>OMJQ[W=WGVWLO]S;V']5
M#CV0BV%8J71E8W_.-!N(^FQ2]"1TPY91[_0Q>^`;#(&,R.9@E/7RR0##T&0C
M>K6X6[C2])<ST;>U@38V!#>V`'CXBW(7P@#950'"DA*!!T$>X^%09FXPFA<0
MW38-$N/'/.>$/$AE(GS&W14/_P+_<8Z8``V+N;#62G^2"IR,4)"W=3;@$#;D
M4ZQ/%+J6G-=>-KE,A;"Y<[6G7:`>?"01M-9SR]UI]Q*O^N'H%%=Z=IR=G1]=
M="Y/\+>/<:Q[CT;2>TUJ+HZ^.SK]>-1M?OYVC'D>&6`T<<E[<Y3@4S%:M)QL
MH/7T;7;TIW,!A=9@>,#K8J;8!1VY+MJNXCR_E^":%$6O$GUQB[)B5`A?2Y_S
M_MU@9+A=JME\TD58SA=W@4ZL&K%:P/NS;HOXL\MW1Q=Q:<TIWH]G6*M1UB^N
MYD`+^30ML_G8^EO"J*??#L/3O=L<0XR.9M?Y((HM-@_SVG1M+6MS$A3;[9EY
M.9M\U>(BA<47H(5HDW']G$\5ZLR:=`:.V:AAP.8CIT>7F=B4O3DZ/KLXRD[/
M3E'PRXNS]^]/$(&3T\NCBZ/N98N-]D[G\O+BY,W'R\Z;]T?9Y=FC7RXG;0YP
M</;AP]EIUKT\._C#N[/WAT<7K8G?=+HG!UGG]#`[/'G_4<C52$'!P+/^]KO.
MQ5%SG=\?G;Q]IZ<[WZ&*;UGHQP]O>`?E3%]#6S]>HKNGAUK])JBX,5MSW!76
ML*[^!YWNN^SX_=GWCU)_@>/L>CC^/,NNI^.[K))XM';PR2#>KYMTG!;S3/+8
M_+S3__-B%F"#83RDND>0);AJ+PCYZ>^>9EW,\*S(\:.F!*T"U0<H(U)HZGNG
MR.RO]D&3#H,<V14A?!_%NA,N7_K<L33H+I_^"$F.-Y!O7E"`%:!(E'97F8FF
MGV4!%>`[LUDQ_33HM:W2P>/5=`G\[22+D\Z9EO8)I94X,5+PEX^*3IP.2*[Q
MV>(D&R?QPZUM;D)YY\%CP;&$Y*O[W-RYICA6L=<#XHB+Z!5%/T@P]-D&$;,5
MXMTHC1":\SW\:BH*S3?+Y4VFXT\#DE#9U7T2*E;D+GNQ7_3(ELW,C(M'S6>,
M#?D<?'8S&(WD?U@(OH@LS:I'B?16/]1=3";#0AX9YR<Y0GL72AQ(WJ,%0$;*
M?%M+%J+K:$[_T,C`RDT;?8!OFYD;E>8^:D\/Y11-SWN]J2!X!*7!4RIVQ)@\
MM$,716](&#L@X'"SP6*#.B_UEIIB;$'VO.4YEXV5QQQ""%.=GA6A:9-OAROT
M%Z#4&T\E3F@LYG.DR`%S]'DPOW4S0(;1LW'-(5?06.>>\>R1-.YL9:>=RX\X
M:AS7FX_=D],C?+>\H3R58<US_#6XT^!FDYZSZ4T^"A9Z(SO`<(Z'@WYEP<\1
M0$FDK8^].?8\"Q*J9)M)ZRS[7YTKI59[\__='/Z?(NWB;>?TY'\N)7MY_"11
MG"VN9H/^0*G#];7PV-I&)H.S=N!)._ZY]KE8R_`,:XO9VE,L499G=R'QVR_D
M*R2T$Q)\V;5R<.PTVRMS8`J"NH]#AL*?GC$^EB#O]V'7C`3Z'78U#C@RLR=)
MD;6;;DB%36`6,ZFYF1A1[NFHX>"ZV)S?:JK"C`KRY>'G;"OKS&TA")]9S?%B
MBK@1LHXMXR2?9]]'[G0..^>7__CW_\K6._T<MTA&Y7"0#^]G@]GF^\&/1=:Y
M1L^5Q3\G9I5=R2Z+WNUH/!S?W#_-9O<S=GBCS9M)?-I6#8&@XAL,U0PC")"`
MKP3!\P'6+,OC#/WIXB;+R4Z0K3`]R?N?Q`^R2QB`._'_[@K,2N*I),&4U3BA
M94WS2;$@8,0V#9$VD\@:^V?%,(;P:.@=`4Y&.N+N>J&X'1S2&T*C`2A)`Y0,
M8&-O,.TI8B?M&Q9LY!'?.1A"YME2/8S,7PW'I.`E&N2V6<E6=C;*_FT!T;O/
M+>NYYY+V$::R,E.167:LE[3#A^)!)PEI$*KUX\/.TRR?R$/Q2CXB%6"&^,96
MR*2'+I!'7XH[@S;9^LGAT=,@<4-#A4@2-D-;"?ABU8L[QKE&L@:6`61E<U*W
MK)[5:.U10-[!I<EBBO4MIC_]/UDS?5NC?HM_$K;8%\T1[S.H)F<Q'FYDGPOX
M1H17C"S00WCYL[])QIM`B&"?A41A)_$Y<#FX'6<D`H)"L'H3#)'PCG0M107D
M^2#[-)BROO5W!]^QZ#$"#_*3N6&A>G267Q=(,"M+5Z.O$)C[K:R[Z`']9I("
M;=R0G`-L-T8PO!AS[Y23XA]_!O#:J..)4GA4PA@Z9>UD\,DRPI&AKO>L8:K$
MKV6B)?X.5Q&X')'&FC#$7(*<L0H3!5?VR)%*QY?O0=.L)FM"4%F6;ZWO^WR*
MJ$K)%&\/9V,`2D4=^$=,FQ8W4>BEDY8QA"68ISF!+$9O6@QNY-L69)PD.)]A
M)SNLO6)KS:VC;D,&@XFNA;`:0L19V:68W;[+[Q672]5"(@N!#_*.3,`LEWW^
M9N*\,?4]UO(:ANE_D=XK45?TM[)WX\_8/6PI%%T5PP'_@!3X&U?@TVOL84`6
MEB3]EOF<]9&^$":`Y<65'G(Y#/)P6PPG)N`8%6,:PCZ!&5:6&E%IX@T3(XEK
MI4?K%XBI]MIR*Y4QVVINXLDH.^O-Q\J`4I79VS"V5>YK(SOZ,IZ)HUVV!R&:
MA2SA^C_^]G^/NB?_^-M_/B673B"D+W$?G@91Z./VU5V7')>;6L^0V)";'G:Y
M%MUH?Z58@_QF-`;ORE2A8P-L8ESWC?Q:T)M_VHVUT\]G"(Q6`JT6TFFS_[(@
M)C"_*X$]NSSXXYN@5S@,5"JFAI!+@_7AJ8P$,J'B+'L['2\FN.)HO&;W=U?C
M8;;6.?IPN+76W(Q+YA!6-*<O3BUBM0O"&(.BD0Q_A$?\(R!DY!8;%Y'0;8X@
M7A48OXDJ3B)-4LW`T[X9`MN:MY[A0M"(WI0&[^L/Z9IF/I\.4$@,E06$6E;-
M($OF*/9.$>M,HO"VTSF7+$AS3#NG@[N$N"1>L(TM3>Q`1G1AP-6V_UCN7Q5H
M>RPHCJHW,P,KB!434T67W9`D=#?_!""QE<GMHZ&0>I_U21Z,YQ#2&R[Z\!0;
M$92D2<GU>#SG4999VDZLDY9C2]%>8*R+9"T5H[?PDB:;XPE>S^TY/@];)JT#
MLLCV58F.G_X.1$>"A0J1]+L<["/&+MU#D7\WF&&[^]J.:DO#FC`_DI858G&5
M#VVCK<DBU"#J-0WB&YE,,H&2(LOG(/ZAMKJ4)&!&F>-$$<%6X)B@G+/!%RFK
MVBRPRXRXK*Z"I=*J(A,&2-X`5*F0"WD-^Q-'-CLJLWT%2*)>VI-\QNGNU2/`
M1.),;5G/M\`YT^QZ,86Q$D3>H.^$O5%QA3R(&"_'T!F-%BB-5^UEG7C-!.\/
MK4F8MS;',^S][8#R4-@))?2M(KV4:R;'E9!YU:D^GCTBXQN>=7NG-1H*,`B#
MNWG=:&S9W<K>G_SQX\GAR>4/S>\N!K,?S=6@M<$9J7;Z0(RT<JC3L\NC[*&Y
M)(:R+:71^D4&BO![09;]!HW`@48<QU!8(ZI[\"W/;L9Z@,]8$AOJNZ!'P*38
M`_FF'"DD!6*[#RH8W?`9_V#S\V$(,"5I7K,V?BO?-[M6$L85.$ESL<.NWE,D
M35J+=9SBFAC@:D&8@2YOT6[BRHDTJ(9O]EDTBU1E/N%ZFBZ59Y1K8Y$K=(1)
M2=GEZ)>%>P$,65XOQP-ZM+OADXX*`72TY_-X^J,QQTN"MD:A^2\#Q)]J8O9D
M=^/9_@NKA]K\9E#`Y^Q<LUBXY.67^QM[>_:VF1UX((Z-IPV.,]><T@2ZEA-2
M6A1,MY@%+?WQ0FF:*X4T4D#O"C!#^,`F8]N)YVY&EIE1/O/.TIK:P:H<&LJ@
MCC4Q%]'`V.`AP+-]3*)4K5%DP*(^[L=\C^1D@H@Q#1)H*LY']QAJ62$$W.)Q
MG![)Y2$L_41KP[`P":CPZ#6^/D%!2&EC9ZH@VQ)>P>O(853F]-I;H5:;.98#
ML+B)>9Y17Y!2V)]`(;@3Q,_*+^Z,$#H0F;`R_QM?#I4V%\A8$`M4T>LR@2)'
M+N+43;M41SPT*XKL%/>9[>P^;5FH0X(ZR!!?'^$@#$8C"R!JV?H<\$Y781_E
M#Q^671Q1+RMI>/+BA=?YQ=VX$D2[GM%*LG:N@XI+<#B&0`#23,KK5L*2#[,P
M@.UFJW\.*;M$X;0<F%Q8Y$-D@&5##0E89"M1B/Y@2!(!@P.4!T4J@'5\8T"9
M7=*#9`\(-,3!I,X;DM0BM"PXN*P2*2CQA&-J#AJAPMV5R`AVKL1$!K8#`N-#
M8IJ^Q9]B34B+$M@B`886W-Q$(RD/[HLJ%?/)SO;&"^S%]HN7?(F[=;%L"0=V
M4U%W:':!QR%OY>N=TG6#..-7F4*=%<J9(VQFY!+=]WRQ!3G1#$3IA@NDQV"N
M@+KK%TJ/&E<`7UQTP\H?3""\>2\"!#2266ZLC.F$V(.),I21:^!$#2:;$-1"
M0S'25(S-I_#C(B>C`7**,`>F8<84!U;H+*$F+JQ:>XBS>6FV(-6E2(U@$8A)
MBZUM7<5,SP-J?<'(J!<O"65')$/@MR<,"+)$R0UD:)L3QQR(0Y@Q.$9]6+X`
MEXQK:5N8B:]0X5I^.FZ6'(487A5!]'1<K-8@3?`9``7NM89X<_(ED4$MT;J4
MP:D2+B$Y(:JN%Q8PR^,H4QPB4&V#IEA"#!P09H4)?:*`*7HLPZ!(G.!P/L`E
MZ&5HG*J4A'(FW!/#-C)U,UCZH'>K!$'?S)RE16PQR8;Y*J4Q7XK>`LF5K+AG
M8=*(."3/9(XPR!:_2<#5G&<0NHG/EW*&Q8?T.J,NC3WZC>B)/4["&/@NL,6J
MM3DL>E%"3)Z31)?>E!V2UXB^7E^V"RV&Q=")Z=14SXTZ<9[#X&#CE[\:S9#E
M#B2>=X.;6W60*#JAYVN\P"1*@`X<G6H?":D53T*\I&`%N&PQ;H^\TL</'SH7
M/ZC"T3UY>WIR?'+0.;W,.@<'9Q]/+U67/Z=K]>"DW9BB^#2&U10V+,^UNEKQ
MR^<Y%53_IRAUS;F[$]@-"*D&OZJ%3.)")G`;<R,)I03P65K0+_222PB[2^>,
M;8*TMC!K8*B".-HC.#.)CT]O6#*53H2R!E0%Y"9^43S16["W?(PD@$2($VH.
MT-((FC<-US^'1##/3=`1@QLRE+Q.\5^*>#.5/Y(LCJ_^+(=-UP/)7;@&VE4,
M%':Y9`XB9@81:7NKE()L&]Y=F%SY44FJ0EO!:`:M@GSI*&R#KW*,2A_"35YF
M#>1S9#"U)LT8HZZ?_LX[C\T0M<3[_.+D].#D_/V1E>JJ!FQ:PYJA)8NM32PU
M>NR\+,$3,I%Z^&5;$4L!X=Q#R#&*)[0=PZX_T[0YO]^DIQ\^Z&,FM29$_EE+
M5G9/"!G@<"JUVKEIX!2M'I89<<R+$Z#?(V"?BOL)8'/7594C'4I%<Q*-&7*F
M%:UJCM3.D2N5863W\,B"(8D1+GM>>$[C/`(L&Q/*!$1@9QG(5<!X)4D)+9;L
M#`V?__C;?T3`EB7PO1&0P/5Z"H,T,>NSJ(^]"3%H6$U%S).=C="3*XX47T*#
M6M`Q@U>6M8(_>_6^73[1!&QB!=[0*4M`_X<RE"I663A:ZKF49'?[5V)V^=CR
M%MU(K_$!\4$VI)BXD(VR1E433)B$U"*+T]GM8!)FL(0:,<1":7!H>[7]*_*#
M!*I`"\]&5?UX#7$GC=C;6CZHTV$Y6"43@NA(]$T"^CC8*$B6Y!(>FU(<,)Q2
MD6@J`(O*&)G8@L*<Q3QE+O:&M^1V;2+X2.F)I>@S#&5I9$5"E>5O69)+Y#>D
M/?#'VK3^SXH"H3ZP\"&%4JH&HJK%0V@]YPF:?_)J?V-G[[FG7Y[L[KS:V'VY
M+?!6EUUMUI.=77^6;]MIF=8B/W:MT8$&Q),/]-.VF@&);29FJ1W#0>;/L)!:
ME9R&7(TGZO$<,=L5T@6RB3'/+/HMEZS&&7D6MVU"\5ZJE7%B713!<35F8,K-
M+<%6+266PBH96PJ$H0THRA_*A6\2UE610\_4WO%9:."P7)FL4VVG'G#=0>@2
MNLI`0K.$;E$@1B54OABIN[<]S0`(2<JHXLH=\$-17L*Z8$%K>4.EK^K90D[D
MW6P.+1;S%8/JG=>:-6FNY=NQ.@^11MNY,K8,J9F:O]%ZU$I81N1EH]X\_Q)8
MJ]K&7(GJ:`>`&$#:_H"])()3VIX##8"/<I4M6;4F3W7BV!]')(R_Z[RG$:<E
MM`E*-6B63_N"<FP632L6LHIB^T/+@71$8+8FKR:K`]J>SC<5(Y&;!(8#7#SJ
M#-;98G031!#B%1E:<9D\B+*JEO,QO(4L^]&]1`+*N<G6C)3Y1Z"L&Y-83DIB
M@_*9&@$,BS)CZO^G),--<*W1TFRIMW!>%;V<MIK&=Z6M5'$?83H.D0@M"D1:
M]O02`8YSVV[&5!8]0&R3$-]*CG@!S-,3)C,@'3KYV')46>M3;(/)53-.$6LL
M,M(DGU4/!Q,N.*N24QFD=LMD;$65&(#'?3+&%O%H=&5?)VJ#@&W1TC-XN638
M3XC4W&/SB3S6MHRF^G5S:FN_S?LA%I9]L`WZK!"Y!$R@N%E[GB;6!(@>(*KQ
MC(*:HB^.J'=D%R?=/[0$^$#MB0B7LF;!`V+VYI_'2:P@=@_FEGLS0>"4<L]S
M2H[>W9C%$,(8D9B+`/$1BJ`L/&ZV#K&HC:RH@XJE^5<LCBS@,3NA`P7A,!T^
M/V99#L8(5F@E6E\[/CPYH!N,JK'\TNYSRVM2>\/=+>&_45AB6N,QX4(M[__2
M\O:9`G%/#T*I$>8J9BFJOD?\1'!5$X.(CD`7KF)ZD?Z^J#)U3TRL*9@)+_JG
M>$8/";B+NI9!$CP7AF!!D9^(:3Q;*88N6:=,3UW.3/2D6F&LX"?8!V-WB:&C
M5WB@,,G85GXS]O5I$NDI["I[M#YN=;>T;4!W,V),J)Y,BO'2(7LL5Q2"';.L
M4DB:OU$QA`.[V;H;4>([5(`#&M&7PU22W!3*S3W:JXQG?!3O5T_KT2(*9-E>
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M``$'T;V,[=KOZ.+#!D2C*SV3TXO>64/4@%.5DS6,ZS:IBMX%-1>DL(3"()'>
M2X[G@U5NYDB6#09MJ!XF6H0'18!J/%_@E:B?V<,\Y`_&3B!##KS]*8=U2B2&
MZ#5X@,#&H*$D?D'^.%S@OY\;<;#WV5"<9F?.R#D-EL@B50M#+:!HA:,WP#&A
MS25[5G6G23:TP@2'3LB">076CJ2WU+<+JCA5`6_?+4]BP?%7S7-B[$MKA/,+
MG6R[_,':O84OSZ7TKQO="N=+CZ<;<RVTM+T2B69JT?MP@`?Q4NJ&=+BJ4N*`
M%JB>,:5Z0>4(&7W.MS2WFH?3MY7`@>[4<BGL'E"4,H&>OHY0WJMG9()NV$Q#
MU"`&Q.%:*77KPMC*+K#^`]HQQ&"#%V`HJ:!D`_!%W[$YQA">"-N@H=X.P/!L
M[.`.I_PIE*'L+4^2Z"@RS:WD&WU=@&HY%4)XW%#T-KQ*:!,RC\+>$WWCPER:
M2@W*TJS&(.T2(\1/HUG_*-==J_A/*E:;YY%OKR4"0HADB0`?,R8<6'.9%3#N
M/I`6(+UX]H'#>)T_M:-E.5/KG*CB'B.Z9LQM=;TQK0`ZO!V4+M9S]*+4'MZH
M#9%]FL^G@ZN%>T#V4H1[T*3OT;KY9[7'M=936?AD94&KL-9!.208FI+^Q0%8
ML*0?5JE)@*\@@78C^6";0PD^O5!8"&Z\6L^?TF-."_=4N?:*-MF]A+BZ6[$W
M76Y;'!)+*O*3H-C#%I==+3B:W3()H#<KTA5/".EA_[3P]2OH%'N))+#VYK9Y
M@=ISGZ63Z$!^:"L$R52Q;!V.@'Y:VZO`92,<NPNYG"NTMM1<$^#\BQG80-JZ
MM^`^A53C*400[!5N@ZVLAQTT=V1=M$-.%@#B\%(C,_/FKF;:'E@>:^`F%DO(
M4\='L,Z>"EC2?G7RX1SD(U.7G5UPZ+-[?M8%]A"CO#\[?;OY_N0[G>KL=KFU
MI&D+WS?S"69'`+"#0L5WVP_R^H.I&0#Q2FW&5DD$5+-;GDGT`$8G!^Z05I/[
MT$\GOXOK8WD(;0-I*3Y*5A<*=.IC(5GI"L%&F&B;DR:;5\]^R./3AX1_520.
M>_42)DH%$5'O)59*/.$0(I])_BU228Z/&G8U69:@R4#&!5O^D4DD6:[OM3(Z
M>#=YV*VO>ENP$!6:3?)#'CE+EG]!3-#R=H\ZU?L&P]#S/"J&VR^?$-M*3T9,
MV*=X9!Y=S`DR7J$*;!8/E\GND)U7]DK<_DQ?_*WA&^1"1QM&"[O#`K,?W_+;
M?M+&D80EGBC3]CI%ADHP9.I*8;ML`Y83'N&'X-*R19+4IY58<N&6#^`SMN87
MV1CSBDA.""-9M'7G:D75`F+M'R197XN-Z<BI`GOI`C$0*=IQ[CD?E(^PAFAO
MM#?$Y`*8M)$%?OL;(194F\XG=*,+L7;RP#(;[%C(<4M7%80Z1ZGOR"BI&FK6
M#2&0W%FW3YNO\MA:^XQS>@$P5M2L7@G.QY8"J\4^3&\,)MR]T'&F'.$5EK[L
M-&()32/4,6>R(M3VHP`Y,$C'0)&3G;U]NGIV-U[M/+<E[>R]W-C?>[[Q?'=_
M%=-U+,"JF`)M##%SQEKMU[MLTLVSX@N%!9EF7$_9VR3^,0YRON06']?Z-B-,
MLNRDP.-XT3UZNS10?4<-EGP<48TZRS\#S=AG"RQ4%0%YSHH;L]$NFVP$2L&.
M!)?6Z#=DK\O38WY8!0\:SI!$KW9((L14V1(2?UD0"X4#)O%<5=]DIH):8JW*
M+&ADF`]YLS,4.J5&!E,'Q-CLJJ;%.K@=+:[%9@;QAJ7`^UB=DFRG-%L=V@_(
M.IK0M'HHF:_VS'H97.P\6](=>'1\=$$Z+PLY`QHH#LZZ;6]YH*NT<`:.V@.8
MDQ['6J%GV5&F4,CSZWV0&Y`.4B.\R%ME_!M!>ADNZ+"CN"A=C-/8F%6\X9HE
MW%<.XT''UD_<8U2B("EC>AX_3A5'A0REO4I$-%8:7^IAL9EHH$Q%C737=.S)
MJQ=[::'C%[@OE3*J*X5:-B!<RY)='!V<T=&BFV":9N*P<W'>T9%<3VUM;F;?
MZWQQ&%:,C8FWX*ZEP*8K,H.`1G&,#-6R_E&/.'T&Z;F9]<KKER.;R?!D%Z;`
M"#%$D/>Q%]I=-NX#41;*FD2#90\:XQB0,-07A#KS6>-P(677Z1YD+[:?;^Z^
MRCC3<J'6+9)#%\GK__C;_TFF^F"!)^=>;+_0JZN00.5/Z[USD2)B\V`N]M,F
M\XB>"JR7]$2F^M+K"_196YLI26SNWHD*NL3QVJ<0*8;8R="(\])VBTH%WN+:
M\46?90A9D)(PG^U^1O%A`-\EG=JVPI$_[M%ZIFLOLS3WB-B7"<<0233H.*,'
M,E7#3&DV\>'Q\%R/X@?:D1LX1MMPV@88I"]@8GABY@EM,F*1`T[>FC56HDJ(
MN&_7E(;[.N"`V*C4*%WH4#+FFL!+^P0O!8\\-8.L>-<E#%(<@[USK8Z9AP>6
MX4Y<LP0SJ)1.W,E4"&M+LV<EQ33^Y73O!DM4YU=KMSOTND6)%ZGT4R"M<^F0
M&"1,$@:Z9L7CSV9E\,!DZ6`J19#>K'5SP_K.4W$$2\J(:JNQYGV,7JW#;VY\
MM.*N+55W_'B3N5ZK:7T)`YTVZWH4+@FMD/@E;IL=]<=3:WY0,#";5?Z4:$X&
M-'3GAY>P)-7"^V/D<T0:+0)_E1-I;%!,X@#4UZ)'5JZG4;/U><0NK:Z<J[4!
MZ[O&K,!V=<J.1\R>+"^``52&SC+/Z_`W6D`'$-N%-A737V>6"&"FA!&`#,P"
M=:<>M]AA'Q2#4V&`%3H'@0NQP[9(EGI41&E9JE@^2)OVO:?6FE*VI&JI88\,
M//K0*%S9B@L,)(VMS5&&0I,FN4J?MC5-*J/E5D74;]-Y'MKMAF@8DYM2)A^L
M+5E*6"2+PZP2<;JQ%-HO)B%I-D%P%`1)WBFFE"S3@&$A?)6C^@NY)&W`O0E<
MPN<6[9>\;&U\%(+,1'LL:@NOK*.@:6(\$B*-NB"S)M)&0BE.W$V@*#M8"K3?
M!HH=?YB"&&BEUG0ID8G6,$4TC*F6-)29?X:%R["Y-BNZ,>@=C09YIZC5RZPD
M57AUXI5R][6%FC-<:I.B/ZXXP^+A2V0LLR2:N\IDE8^[$6>)BATIT2W,Y5AF
M,Y4FB<9R77%/::W:=0-0$ZMB1.+#3Q5$CGE+@620L2N?A`^C'Y[@E__%3/.?
MFDS^<J5>36@3!$1+%5D:'9T`-7;>M0FNHT?J#DAL#RZT-1BF0[I1'PR&*Z[G
MYCUW>0QM25(K348.I:)L@"D8%((4%62X4%$!K30L'(XO2Q>5<-2F?6H`,D"2
M5&*;1*>&"%+E#N)`=?D*Y_R;.4)T+/;UK""%Y3L[X:,$H#J[4UMUH%402%P)
MD$Q+7A]L%5N6P2PMI0_YP`8]137ME(ZGR>KR6JXPJ`0I-DPW]A,LJE*"=@P5
M`-\&HMAY7>W-ORI[7*T6M@4E)[6A%59?15.6Z*E&2:?;2D!SY+S3517SK@8T
M2CK<LI`A'4XP4W=$I9\I=14O0#FI')7E=JBKU[.\]4E3\U7Y^]1FAI/')/&%
MP(GH2?/826[^+L%J2'4F*N.LB>%>Q:('A:YEUJNP>3>@=?Q$E1I*VO&2`\YL
MI\49E,F@F!/.92S3&O]-[$SH)DT+BNP``?6@#7[#.0_]RL.G'K:5@WS@V@EK
M9J>CQ7IKZ'@@>HK?VZT`B(.W$2BML97%[ZQGMJ<&-LX9W8>8S.V_1*S5&Q$<
MOE\)I,A$+?DN1XW]+KNH&G&>!(G@3*DWQ8KHX`PM4%].LE0:B870#$,NG<N3
MW6@?1)9K2080>%%(OTF_Q]T59X;-+/J^D%2+QX;B,0!+&ZF2Q`9PCQM0,ISM
MD6$(6AI#1_$EG2G)ZI;Y`:FYA+:5W-MKB8+:BJ(=</KL2$^YZ5)[G8VBM@]'
M8)>5%..R/-R:#!<\Q;<P\I:>/JNB;]+`)-].RQG<)#.%,;<8QS?6J@7:\](!
MZ@SW^)Y;6[-U<]?E%QH!N,<^\YW#!35CE,]C!<L]H,H/$H17$(2=Y\XKE5>/
MT/&(7J.:\,!$)5EV/B35^1?"=`?UZJQ%W^?EN"VVV4V@F]QM1OJ*PJ;NHUUZ
M0]A16!3A*)<JQ_2F.3_:_&XQR/*[H8&OEB$-;PBL<F!H$H2<LPL0CO`&SP%+
MQ9&X<Q2PR\:64!7W5C7K'5`.TY*PX=B;#&B\[U(26W6$JZU0:,W./4H(U=OA
M-WS6#JGXW1@X!)=7'8K6]MIKF2+$I,:G+Q+J`E#*54AT1>+4&R>KV5G4'OS/
M`R$;+-JJ";!R[%EPLZ%?HWQ#DQSXF1B:/H0!D5KG?=F%A6#H,74T:VG^+A^V
MKGIY\\:M`'".I8@@6QCRIBE*S@6-B+6J*$Z!#(R4I>D1:RJ^4-1X4=LG5LMX
MXY8%Q''1Q-S&&57:R.*SS9#)DRR[PU_#S'[>8/L%_%T0_8)G[JE)Z!!$J#SP
M1C"6-L"FK2!A/T]:K[CY>PE3>C.,V%,:4"D)9S2)<\0!?<5_.=!I<=H\"J(X
MZ2D7ZL)5Y?B7KQ<;Y^5\`I3VHF.67>3\P@76UY5,EX"R<D5FFM4JG&=O!JIH
M(8+O\:(FJ!XX28[$A;LQB,^T,O!8'R:<3^0Z[FURBGZ[G2>_9(U5#L=;&JS!
M2??8@]]55EFFT2'Y'%+GH@)&AB*,W&#4KDB%/A,_0Q4)\2GK@&RC*9*F^B<S
MTJT(KLO5,1_`&/$7>MI>ZUD3SC=?:7[_G3C/>F%UU^SNF6W1K/G<D^8')R/:
M'!2ML[W+M@Q"Z=2P&VO0A^;;Y(:;'T5*COP7/ZC#E(&$.;F#H[/L`FJ1'2FY
M4_M6*M\<Z=(J<?;`YAL3?QF8T@B%"9IO??]+"L7*<8-QZ\7+YLC04']@N;0T
M7UO7KS0T/VS=F@\."EKH#A^&E,?T:&X?#RW'.0L7*F,;JWMU@2]THYC;1#E(
MAR"Q`#Z_0Z`TLF7WIF""'BYMF__22BVK4Y6!ZC(A9:G'%67RV*(YTZ9:6N"&
M.Q@QH]5=T$_U#XW3'GD)K;%X;?&98*MY;;\S3LU2N%_WX8*;?CE5PCG2_#+<
MFFT)46B_[A`I>2I-'^%7".OMD$9LZ30D*U.A9/'/H!R[R(A$1DTZ#0PI1>'L
M7)0I.AZV5#QH-OK&:ML(*&CL(\?-%2Z"2"@L1Y'FH0`0'55]]>2QL>!&<YD2
M]RJ>737:LDSXZV-M3S)*$"C?1RM7Y>$R`BO)5VF?E)7D,PG(Y)@U]Y+%B->^
MMW+:O.K7Y.CI,LV>!)G:=3E6NY=L77MA^UEZ_(A68HVT[5+()Z]8F>9,FIL-
M:U:D*12PFV\P65J/0G(`S#6I-9,+60V\_P/+K"AM+S/L6HP]6J"[YU2K0[&V
M)Q)3)1C-Q4%_65U!2`2ZF,DRZ%<$*%;KPE\&K!N$+LWA`ONM#%,5Y8R?+,TQ
ME=(:++!"0`XO;6$MDC%D1%>T=:UVT^QX#O9$B.VF&6.A6;T>*4;%,GAM8VA`
M;+)47A:!'@.)>EI;L"#9724G@.P"RM5W]A8W1X(P`^#V`X&,YZF-R+_D%05=
M1HQ!U.#$:B7N_!JZ:V<$ME](0$.Y2\5WMD$+"/DE_9G,$$"2%""TM<5PH*0N
M>3J]AH*/;=ROA[W/+,^`6%=G5EH[=<XYSB6'XLYA@$H>`<7[P35FMHM)I7I]
M6@K9F1YFR)XTUIK/X?_%W$+X#A;XC0?(6"LV?V88LVIAL+59;,$&Q0$T8_P[
M#$9,IZY&'O*TG34NY3W/!86VHM`'0>*`0%ACXH3D/K07=N:!OQE`_ZP2ET,R
M$6J=5G.$/5H[04%-7#B8+C<>V/!B3#0X<2RGU(6-:S<"%:IU&`4/+LLL#ZA<
M7852`?5-!%72QB<=@![\ZOM6IV(HX&!.:8!J5\<MBL_./UX<O.MTC[+O.Q<7
MG24R@!(;1JZ:DI!HEE^[T$:\2]?/]W!X6<^2]K#]=!*I:GUV<BK[7G;&-JWJ
MAT*LZJ?H@D/1L,%2+R%/_2QF^U+#9WE*Q9I1"<DF5/D#!*(Q-3-(K<%7I*\!
M3CF=/S.KJE65(.Z%`[R5MT%IH2M9$6[RB(.$S$8I)NQZV6T3@IE*;+$Z=L^0
M)L`!8/DJF+:Z6R?[WLH$4FB_"V`)JV*P8Y%#W`O+*B_C.QJF'0F`4=9NY<!A
MHVJ^*PI#V-^4_\&(V@W_L"))`(??_^(7$R;Z_2_N@:1R8QUJ<76I2PS31N*]
M@<NH]LV4&U&&KCSLD?C_EIGDIV\X/WQ)<_-#![S0F+(IY)ISJ[J`VRW?\FFR
M=41>?6_]/M14S\Q`A>3'[/@#X#8L@:2A[%A"9JP#A:4R&"M*CP^PS3(057\\
M!%&0DVGWHY7!4L!S)G0D69M`YWB^0!O?:J`H(][2:"[\FO,A\\T!@,C^H$AO
M053[O,RE5&)(2:F,)&4OT:5E.X`XH7->X]5&+04G5>MV?=B(($Q5JTIXJ+R'
MS+'JD1,52PB8W44[@*O8ZS1$DEU<@K>(4%-::,-BV:#1CE6[E4/&:D1%_\BZ
M:.36S7C$7@X0JAY@9<AE7E`KKSV4Y9@XV+*&_.I,7LE?)S;A;"H44ER%^^$>
MC`;J"W!%DFFU_.9":,D(AMS9C+BLTEZ!>A.:92=GM/E)-Z<D%6X"68$<./:G
M!MLXVM)2Q3='IT?<0:6SEIR3YN>CNK3O9<='Y>]P^*>7)_H5K%.NANIFYYT?
M.OSK=>-LEDEDXJ^X85]@4I3%9BPWL?$@8PBX/1V/``DEZF$;P_IN30S8XRN[
M$RJD:1TCZRY\KF\*<Y@<T.NBL`)&AOXDP4:3VK4W''[0C79`D8-J^&-_>XU?
MUWAS<+Q&2A:3D[JV51Y-@LH;VBS[S87DY$3`3WHB64B-3H7#H<B&(;@2P)M8
M4UO2"D$U:YZ8#I.2D,Q@4?(G\259;,E0\*G&,F.1J`MD4)W7#Z'HS:7W73W:
M"=L&;CGO_S4.MR60%T=O3SCS:X40B9J=C3%,]=9_<K`I=^Q9FN:1MF.%,,I<
MKS4<^$]/F$&VZTUBM35V(<%)TY3/JAF84[U&;1@D:<AQ;"@3Y[^[;56LV':0
M=`PD>^)01D%F+.,&SBN!6J4"^!41')MYD`"R></\THIEN+4IJP36+&8)&0P@
M2A#S*^RTZXY]BJ)=663]F2R6?DKA"OPEM._\"0+5Y$PT3`[#-@3?(?S&=-0_
M(TA'7XW<YLOJ9$.RRW8.?C@AU@J6['CWJ`-ZSNQW[_B-Q_=G=O@S_HYAZ^03
M.XY94^E`8L^OSNAG5D5NVBH?L!X\6917G?U3AWB4^=*%W99G\7(,.&U$VH2B
MRH)8"%M/@8T-CC#3CI5ZRT[010EJO&M-0D:[K!("$K=212M043?J#C&^OEZ;
M2K5-]SWA4!-VT-/_[8;-6A#9U*[+],80I:!:O3S*HY/7+V]M;XYP=GQ,C?-]
M]?O;V5>TV3)B6)H,'5;&"R9C)Z5+=+I3HZA=2E]UF*'C0@WV-K+JFA*ZB72+
MC)_D&_L#H()0>N+1(+RQD)[4+EH.=YG];`ET>K$C3?$ZW)?>[WAQ=LI=CP?+
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MVMGV1[_^Y*'=?T(+#/MCHZ_/6O49*T8UISBLK/4C4G(A$:ML@ML)[`6D1P,,
M\Y[L[&_L/]]'>(<&@+`DXB?LM9A`R<TR/2`$:O5IJ?THW8Z6BAO3A(:;]!_K
M[']G<;.`C)W]_7UF\SO6/W!>=G=[^[F17+-LT8%PGF#J+?8)IHC-*O6\4(TX
MQQI4CNL75<M:$@SRXP79NI:\5FZTD.[9*/0`<%1("KR-QM)FHU]-E\QQ_[9?
MA1[DKWQ7G%-*"G9K4&8-TA?MLO3^R<N=C9?/7VD@;,F2Z]-?O'JYL;VW%PO)
M/(=?K+HL,./@!\-&YAR9T.(!5<<-?_`S[;O/Y>!\!-I3EN5"/02M2`].N**Y
MRC`]V7EE]ZW[6<`H_S*.@`K[&06W:%>`#=G%4F8@57P(#Y5!S,[S7[5E1MJS
M3&:6$__3W]5;5JI<1!!E4NR)$XR7B.2:S4TI]C0L(IW^E#S[HU5XXYNIR\]8
M0^6>Z(S1'=*>Z@#WS,*IGRKUF\X:I<.#=,")=D6B$M=7)<>#@(G+XJR+.FK;
ME)`T'#1P2A1E1PM47E-A3[>ARP>6YZ%;.W)X@GN^/+OHFI5:MC4G^DT\@DIU
M')KFNI(B_4^>!0TI;_M`BF4X_.HG=?]YW*"KP_:WJ<'9>7D,C#SP$TR![O?W
M*E&4*C&CE"Q36EH@3V6(U/]H4F["AD/2W1[*"+A["">[+;\(PY"(`2[[FE\8
MN2]_F&L__54_<34>![=</Q9I0.$3K1Z3-%"/D:EY0\FU8RV-#LMDKXQ4K:!L
M$5FBV>CN]JM7E?*Z=6*A!U5D?BY%MYY/S;@^@"!A'F69RQPVDY0];S79(+C&
MJO/U<]@9&%3I?&6_&G2SO3J3B.%I]Y!!\\[>;D4S6U%VTBH`9U<0-/T8DN[B
M"JU.MM'\.]R45VYL3'2@`BV)O!2$G;`Y;`>+<&(3VR=VQ"QO@TS;QK+`*#G1
MD7!9:.\H*I1A&LQTUR-S$`H:4J:8;5$,CR&6(?5IG>5EP$IW$$:>PY$69Z$)
MN\DO=KR@?;X,B\K9N;8V<AY"JBIGT%G19';<\75J^;4^;8/H7['0<I:=W6H:
M6^O*N2RSXV>?E2)2$#753U:]X/CY#L?17ZWR1))D?LN8S*91E.Q'$"P7^:5Z
M@26V[@*DHOK-%#*<7T*'8ABA%.CX_#K%-)V]CWF`Z/V81,T557U(QYS:9?D$
M07W]PF6QN=(-*"H-T](EZ0%^Q(<?Y3!I<S.#%?(F:`UF_$"53";X$13,^&+`
M#XAA-T@\I)+=W'6O.E3+*_4H])ZY;3+AU20MU4G6_2CD*&HKP*-_<=<B(;DM
M(=H_3?KS6;2[O;'W;-\-X2XGL?<V]E^\2$2L)?9",IHGD2^\!+\\FT<UTI)K
M:M=:_W,Z2BV#^XA<[8%;=[LLU27XW+'_`[_M]2\8G.4IJ(&I0?;+L$8UB5H>
MPH+*U<'.ZT:0\[$J##>_4OBF,WO-ST^+UD<=`U?-!T,`U?QX-0_5^G80T@OG
M?H*DM9+X<YG_([^;_`:1XU8O__5,XFC!@-;HS>F]@U?(?>GSS<<-Q4BG0VS"
MBSM+7YRM#O_>YY_YT6PJIJ<(8W,";RVTI:\4KB6,:0[36G<6)5,OG](J]#7.
M\H.22E,9NKP@&K2PKTLD!/3J&.YLS=$DHI)$YR]8]:OOE/L!6Q_S_&/YM63)
M37)]J!:%D7.MQQVL"+%0/*O2^`ER)_BR=)L!VI4#J[B"(E?<VB.*A&//6K;I
MY]IFT(FR3*NC^OV7>*%='OJ947TOD<T14@Q@0R=*:)8F#L(=&HTI"!FI<O[5
M3U*P^/(6CA(N8<277#72GEAA0+P;IR0@F:W]AKSO#A?0OWK1YO#J36*<!XRN
M@SI`T'*#^PN4:;7](.9Y]7-M3B5<;K$>I5K_8@&O\Z@EW!U*5(>ZIHWKT2^X
MS9\>L,.L2XL#M=)@<)I^N:F2%F8"HF1NV@FBG[<)YV2@P(CZ$?A3DW#/_BP=
MQ!Y8\Q.P!D!B3(BHQ:(M."R.YQHS40<5%0^`=&A3(<I<X#?\-^]BX*Z3_5;9
M!T.7%Q(%0=N.U?K\A@(8-;H4A9:Y`H%-#Y.Y5:S*"WX%U>YYVB=9R9,=3Y6P
M*($LYTI0+P=X-*55*%@6(>IA*]BUX#8--[TQ+=)<V5``35UN+#Q\\BKDF31)
MS-NT)(J&>WX6Q`A-ZM6O&YB'%-Z_+20TSUQYVX(3DV@J"E1AU1'7.H^R"\5$
M-LUQSA'3^^R"TW4]*Q->\B/U\S(LMW\I%J]G"'/L_@,^M7Q=W/:W/29(I$?Q
M<M6*(6_B=T(0"(5\&G$V::8`CLM:J6^P4UEM8^1FLI,RF.EO.K9V,VZ;'MQ[
MMK>!A7+4KKP80:J@:FVSFWO02@-D3E;(72+ZGW,[AT4\OVDWN"EKX_$OBA5_
MK]%2$7Z=61D.)HP*:L9HDE^;P3*XOOV<WY+3%5<H)H?&#SH*[/YC_1R5_Z9C
MN*:Y'-]^5;)))^.C"[KR;36U+7']"-[2W00XTUC.7KY%HEZ9#9`'O^*S35PD
MAB_9N)I3+C?)^QDD4#'`3'@D8:H$1YE;V&4*$"T,F[R[M[&G7W!Y_@P-+W=X
M%AJP/'^7[K>A`UWANVF_HEKR3D-[<VRX8O_%QJOM?>ZQ>_90E(=)6)Y=VMI^
MEB27.+H:HN?:448M4`R$</M5W\I"HP-E,<-%*^UP3GADOUW2=TLJ=^K=1_XC
M`7M`JMW=W5]&_PZ.O<S&9^L]3D;0<0O?0G),%V$=5.F]_\_>F>[&=61Y_E42
MAJI'!B@5<^'F=A=`4;2+U=J*I&STQR29HK**S"28I&37:_2G^3"`G\5/-K__
M.;'=&S>YR+*\E('I&HMY;]R($V=?#S34P(92N%_SR3BDQ>M\S>11_26!76@1
M+JN#),S?IN?;9&Z,,>F38Z\Q@@R;M1XS$Y;B!`0OMOHKHT&_PG3D=#5P*O#'
M_ZMR"OE,S5L')GIE218YADOMK3F"H0GZ.8&8JL8)F]Q(@4)TO5!<;8!'!)5%
M+F*RIWRA>KSS!@PX7=#<<*'922=-&I'74PXU.?7>3"!.>1JMF34?3>XNQTR=
M314W#I?E!]">'[3H0M>?YNKJ0*CK4^5<<)<QA_#.BYM![&KOIKD'0U&)U@U'
M-U0K3R8O!4.>S'&?O)#FS&F4`;,=K1*WI/].C-$N/.&B>;,\6\O8E_(=BOAE
M(%4MX*P>-B\ZH\-&A9I/5+&V:^9N;_<[',C"P[:X>AG"&9M19&!H<4&:$XK!
MW'L/4?*F6,S5Y36E'Q;KRGN/(8GMR.;-19_\M>'KW.TV[=%F%+FRI?B.__B+
MZ1$'YL(6))EV/L>Y+JS)P=5T(G=L@M]6&&6N<;UD"2["6MU#DY_H9Q42'*=@
M?5Z,2PWO,(O.8>X5=;R3GG)9&8`W%F@M"N.8;IC4@>?ZJB2AZ*0HYNZC#/`7
MYT2(FPN4C#R]O<_/6TPO8T\5(^(M]_Y[H)-_WE=S25L2G49&U,&C6%J/^H$K
M/'9E0@]T`R@<S?7VK$V$DR5=(EG4'U-[6%E#+FR.UIU`7#U<KCRX91#N-82O
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M=Y!6`$,>>&4^&)V6O9&E9E<XECV#MWG*T&"R2["_4>@QS7ML1O:R6R9_J?`$
MFR#UCK*(%WE+Y<02WBH+J;`?1QN;*WV2%S);+M3CIE(,:"V,G@0A8J]I,[87
M']`=?76KM"";*R[C]^13;*V7YA<#+5PW6"=GY!!)ZD>SD&T32G;P`*K4"=,E
M;"3I]BX?C-96MJC.!3K7,PL`-SUG;39D'3ZOS4.0N8.C4&KK&\G$70,Q*ZM(
M6FJ^;P06%T/34(!83@5J?K\M`@>9Y:ENL;3.V/N#=?C^UM#]D.10%4GY%7:^
M)$?HR>Y^+\3J7GZS^US_!)5"K.XVI(6%QGB?2*X1[7,V/:;\0#E%:(G*"DHM
M,1<:Y6.80\8/HU-X*(TIUA4H5!@T(@OFBKK(]_LL?N[.X47E!`I5[OTBG:ZP
M$]@7^DC,9)3E(V>>CZ`I(F,ZO2="$GW4/Y2?5>[?O#:5\B!5!\6)TKD??RBP
M,UF453J@3I+A9&P^*6#LEXZUEETF=UGEV$E)1=<S+_C`)DMN!T#>N;LE24/-
M)$60,]6)"7UO\73HD:-<N%0</)83L1L])"KV0%9BYF,P`]2(P3VX&.,LL2SU
M>*;7\+XA3:NJQ\C*^S1$#F]7W/1I5Z0"IL=\N8%A=N`WHW7T6<@E,\XF;P,5
M!N#^QNI:MAQ`^W07C:>#`9%9_%@C+HUP=!3WCD#3IV3>7NBF<9=4;IL"G(#!
M<FWL99>)9Q8UKG@93S[8M`\]+,-W^O-PJ+\'*DI,WRPW(UKY:`<)YX-7Q/N@
M(*K)+UO=6,K#N[E:\P3BRQM;Z]6-'`K14J>2T/CI[?R]JZAY#<L'59EL3.@-
MR!$90L6XNB-YRC@L`C15WL.VW(+>H^S^O.;+5@1D3U4(8]**TJ:#M==^<"=Y
MYI()(DHH-HHE*96E@=Y5BZ&'&\:>/\[J_?8R#_ON=VK__<,V/V@O\[`/@3$)
MMOWW#UM^V%[FH5-@^\\?MOKHCLO<(=&KO=*34#_DKIFL2T;_3/MY%,X&4CA;
MNY.;1B0#KSHV;VA0C1LN?4@L1ED3Q^!O13K=3/PLAC(AK:A26ZRCXFG9!!!'
M\J&_TA*$ZY&.[ZP1)"WK07"')CG>G7'DV6E'*M7]W-L7(K8]+3/:`<%UV=+2
M@`^C#[7/!QO$(-;74.?@OR:BY2J"D],.+]6Y5QP.F9.OT5T"[X/']0Z.M'_+
M"\AI_$1=-2\!UB<D":B*O-2_W#$=\$>8&)4,EXX)98\F"$,W>[V1C[FU,S**
M#MJ5J<VO^9=BT#W(]V(SUMI;BCZ[*&O"*EPX:#1\S&@1J;O422HU0GO*EN)]
M"2;1RVUT<A=#$S<CCJF-K=+4;.A`@ND][4NMN7'CFJC92Q39_NHP:R=N*2PU
M*@N>E<<K'"<)+$*OC,K^)K;OYH9^N[=5"7>I<E0LZO#SWV50]]QBC0%`&6E+
M3-NLJ.C^DH^ZK)3)IFZF."&F_\M"^9(#5NKJY5IFUP<+N$@1[J_5N>';K_;W
MGEF6D6MO+</URTJ_BD5BJR$OB8&Y9J@&D5#;J3A,J/AJF:IVY?9%1X/<T,A1
MJ?U7,SYB[UA24Q;'))!?A^H4MS>ETT<*52C;J`])42YUFS$9'C9/!S?C)0DM
M6U*ZI<*S<[=ST5Q]R]&Z))JYL.[Y/N_'4S"6VY3#4/9S']M26^C<6\7]?BX#
M,V/B3S(PV5ZV)4VN)_OT#FV7LH.1*&FC:Y-E"<$YNM@]I(-H2B7E1QK8J]S6
MS(\L1"<*NX5O5]#^!33#R`ABX<*-&J$4IRR$@<\GUP@CH^K4`MO,YF#WU6%T
MK,6D]A9_JJIM&]Y@0D%P@H[\25+54`MHZ.@]EE-<,8:;Y`;JX%JA;I8HSJMK
M.DP0VE(Y\__[_,<?$#=A[&J,8<C-89,$Q=?-:0>\2UY422@]2(8S_N,+BDZD
M["9]*JA?V?-<B(U<_HE#!:T&GT-D2&X+QX[D68XL.3Q?)H_(?1/"J\XC%*6`
MYE^LCG&WO6Z06[<.Z_-2ONZX7/+UM)6#X<H&.5MRBRYN2-1:KKL,^_W2#^?Q
M;6H**2K\Q#L9#=<VUMIZU(U8HLK0K">@`5Y0RB)'A24D(!JQL71YX]E,18^Q
MM%!)'!A;UB7B(3YB3_0*DG,^:V8,E(:;XU+&/%QH"X3J>,'H@\OY,:D)H9\(
M_G-#/D]>2$'VF-83G4C!EY_4(>$YH:5KLF.F-.>Q&5TQ9,:]1YF?D3%*B%I1
MJ%"Q[4L.H/$.Y5)!!*AH2YMN<`L^!<$+(!WSE"`!D-$%K"'V]QG$U#O2(=:_
M,"8.%@>)\4'7"#"*)[A?(W$>49YK4CT)GZ9RKXB&B@ZY:'CHD[/Y7-5!I[UG
MCU\]3G'3S!7.QY?_I,D'%^N!%1VTL2#1C1.L-ZL>C",*(NL2KH`C-,GC(=T/
ME<HDW<I?;O_48L!:T]S%L5**FYS\<AJGYIHYZ1"C$H-/'/<H\Q=3(AQ=BE5<
MMU%G-G['W0UB(Z]1;V=RB@Y7^3,M.;%0T]\&SO!D</)_5+`TVC*%UEK>!L4R
MD\1A0_M/'27?>0-"QBX]`U=/N<:3\O+4988F?W7SS[8.0!8NO@=R7"UHX$@6
M9SU:!G[HSS*O"XI,@_TV]EYLI!4XU!!$>8DR\VJY_.I,Q-SC"FDW[,(,C*$9
MX7M*=&GJ0(S@9J'5O:L7<@W8AB34DACK?CB>T)X'R[I*"83)W;&D5$A`'PWB
M;QL&M*SWD=\K'8"TOIPYHNLLGD!#J&%?Z7:OHM:OMS/4_2+LO+$"%JHVOBJ?
MMAU?^B9P#!GL-CLW#%B,LA(#27P$?I$LP,C&+R[.&`R@\6?A_?R(>+MSP;P?
MU^\D#[3/M(^8>5A.`O5-P[M<S?7,1[+%G&/`X^BA:"-O>"0DY<O,9.X<Q&P]
M<4WM+EH?FMI=#J);#JM`J5I&F>().@8QO:8>X)TG-FY7)'4&V+,GLG<E_51L
M)PXM"7@>CY/DC5)3L4;)9522:#)7.S]EO/C-E%;4A?3D"PZA=%5I"KQ%AV"8
MI#W1WDPD+^YI--^&A/R1LA.SVQC\O-0,>[LXLJ%I[T[S58*+5V0^N3Z8^7N0
MHD'`.`B0"SJZ'2F6D?'`@_4MTGC65RUHS/^$R>MX5M=71FMU1O-3S_'4AH&B
M4K)LQ89I#49\-3D"9R^M$895&DQZB8U@747!@,!"O4+.93%A##X'@\GI72.!
M3I3"?Q8A+\K&O%36KJ$X.T\FV)?@R0JN`T1+1B;FS2]OU*QJUL,Q`<.Y).[U
M@F+JP!"5BEU4;J0Y-L5T7MY,`43-4K'R?;,Y2R6[5<\?JUV\-1<D#-RL66G,
MFS+(B4NT\J"A.QNU`[8IO1Z]6;8'>J#G56;NT.'LC&X+>7);J2TD"VVL]`G`
M9@DIK-CQ/F&6Z\5_JTF/S0_I(#4]'G/.X6]YG?(]8"R:RB`RD[R9EM)$K0ZX
M0:`EV-H`^K+EQSID8QDL3HIB']IP&U6C&F=(!3(O:=[@EY.X0SYKE1X06B%&
M\R9.UM.WHRPTFFD?0ESEW?3R"ETY$'X^@LNA5EIPTB7CLGY0<P^:'T!RPJB[
MF9^1A:-+SS6CSOS7(%37A6!_&V-GP`9<?&Q4<E.07AYM#@/`-*#*8%]\0V)9
MR2P[QCG<09@871&GO3&@+)C>9<TV?CP<T9>+7+GJ[VY@M_^\%WDWQ\B,*MI`
M,FZ`E)AS]KY@X[172;Y8"L9U\-M\'7O1;',%IZUFWN+DP$E^#Q>'%/Y?WL,Q
M]%K)8/J%$HO,]C_8KV$,7D3UD;P;89\?Y-WX\8<1K@W]WX>Z-SZ2<^,C;.33
M^#9$+)+U'\F;`:E>1Y_&\`^?QA\^C9_;IS'H\&GT?SF?1ELL(6:B#E?JCV*5
M]_26;E(IIP3T&W0CJ;S+(LZ=/MO[;N+''W[B+DJ>%C7L'`XPT801EWP>98XU
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MNZ.OW<#*@!JU?;;-[/NRL]V0I$.1-"T;U\JJT(:`AM*4L5]J*-4=?OLS%7LX
M!(2E12X.Y0\;*UN#]?L5?+#%GR<?Y\N6_VW7IC`*H1JIU,&1'$.RYN52+"NX
MN^R6_+CFQY9W/?4E#\@HW$GM)*HN3N:AYY&$6^:<5^+$)J4FMVFFX@)\)K56
M\4]6V6(E4E=8@#:=&1:.FX[X(#0SOU2<W_-'8FN%F)P20]81*CFI4;G@#A[(
MU3D_I)Q##`1!"*LJ"\B?@B=%MW[L]V9$V'B[&:5PMZ&MD51<EDE9Z.V"N^.<
MRMTGY6.X/A0KJ=QRL8D%*'QFA3;P2,L'"Q\I'&?!FV9WX7GT8<'EQ5/5)<A1
M1.B>"(N8<;Z/+$"`6VJ9S?K6ND6?S,`N(P\U,Q<Y)B0+'!YIY4<7M/)"?A<6
MF?:TBC2)"($PW!RL;"`SBEGN'5F<C4PIU,([>`[SH9/W,+C<81TDV!`P@NHJ
M#A_KN-T?ZVRO#-K(5F8DCI\I)F\0QBH8=./+@^IN_K!"?A-62.,6_[!$IF<A
M`O)'`+W0VDP__PU8(C%T&20);#CI'"T\?R$UUX)MBEE%E=]B:/1!%]=$H*"3
MJ(W\ERVEYQ#YD2-V_]9!1X#TTP*'6?5:5J;:NKB=PF:P2[Q/76JEKW0PO/9M
M/_0>H]6?USLK1A_VUZEWJ0..=XHLWAA5)).O"QFQG6?@LIE,.IY;L58-[+'D
MK*`4!NI=`!&5!E>S8Q.I<NK>'8HT*[7@V?:WO:_V]I_;P)PV4)/.,*`8$WW&
M2S(;27?CWJO<MO8%)W=UVH/SEV2:R*@]HY\Y<W;/4T9ESK,)-8^14Z1\(DXI
MH)R/_X&V0\97,%7"BZB1Y'GRB-19M"5;G/_?_J%QM&[0MK=6*$Y*I1G7B5PI
M[2TH[EY(+J/!Z,$-9SZT5N1"^;=TZV33QENR)&[;$5OU=/APA%!-;Q;2+1Y[
M\P;$Q%P_K$!B.:CHQL>)FS:,YJ`-6VX:3WE1329LOR",(9)=K1NOE@ESR_-3
M)F+D22CZ3?I!P_X72==7<G17,[7GZE>ANWLJ'`BG-Q3ANM0B89[,),]R("N"
M.T>7[[`=^$VZ_VS^WO"BE9'AJP<#3+=@;1B*I+WVIY@1]U&\7,_*3OT5<7VX
M/71_*R@:08:'9O60XV3IY&%8$Q<0ZU($27F"8BT%/_55<4_$+&*2%P#<;!ZM
M/^[M_OWUWN'_]!@C^^)@>^>0D<95Z<@N(WA!@N43_>ZP1O>7ZBSAG9?/GS-5
M^>#PY<Y_6YOP;VT$YF&UJ4-X2TZ?4=;D-K,229OL/2<9F^9G*Z3='3^V9*QP
M@,,\3=:B/L:S&<GY',_%VT5OUZH%LG2,-F^%%'O!6*WF?7KKR?B>N0NYC=`>
MT4I017.INL9HKDB_7FBB=W?N"7&NE+F6_!?!+!VL]+<&.$='-X8/01CZ"&^M
M6^?:Y*&`4%,(K4K'4MK[C-PO1\)8TR`L'#*V95/E-&;3IM7,K=SL8DIZ/@U.
MY8]R51!?(*V$^"R<:3`L>C%54(:ZQ3BOK>(ZNI*]61,9S2<Y&;/#=VLM0!OW
M$&"%ZK&!9VFP6<Z8D2\57BR9'XGG:G[\S\BN`[ODW$6W@0,R0"D3"$WK*Q4*
M?;EJ.9!9LSP]9<_;U'F[=I?P51.)8@HK/5S.-B&GK'5>MOOV%HK/VQ6&'M[\
M=^7[$W<I&[N:*%GVG;$G#I=M4$GA*MK0(T,]7]8(HNEL1JI`A9>Q2,].J\2T
M&X%+K#PTE\S2=]GN;H'"36T^!86R;=R'0.'+EJ5S<\AA*=H.&,W9'RQULI?<
M051\\&@3-UHQ@=M:1%IK^V/UGA,YZCFSN<!Z%,-53U7MO5(W6FY,_QNJ<Y*>
M(D=^D88L+(YS!,4JSIA.0"JK=S?&%#0OWXP_@7E7E_,STZQ42*?/Q\=,)V"O
MS&^BSL**3:M'RM(,[[2`\".N@&MZL+Z9N_:)GS<:,:2/>(X>7<_N=Q^U+#`4
M#KQDN*9YJ24C:7"/3W@IYB1V[M]]*4+EQ?$4O5^]070A%9`-<`[7D9KK%=T0
M/S5<MY@)MMHOI-DRXKX!3\OP60M/8W#+7>K6V_@6@`1>F/I8?V*`]#%3-\@/
M*O/-EX$$R:K=58$BY_ZYFX`I0)6(LE$(4"S4;/+)WXK]#;-T$CXE)S[@U2=S
M)61A&V[V5X;D!>FBA'5UOC[V2=G0OR)0#%CODD8X*`6%`@&*1Y4M)[OFQRV#
MDTZ@5NQH7(V!!1+ZMGR85M"G#Q3PW[QE`&]3Z9$Q(V99SL'4PD\OJ95@I#<;
M/W@[?HM!A(I#;!+.YY99@X%HBS'*4R9+A86TPIV;A@S"G#TV=M^F(>J/5R>;
M$Z9OUZ.5^R+R1685RKA=7IBGVG6YF<7V_^A0:EBSK$,IT:V;.Y2:W1B4U4_3
MH12Q6LX[6N8"DMA1XETHR"_JMG*&NC;?#I&2QFXX]!-[DMZL<V4$[+(7P.DW
MTI2BS%CT!BOK9#P,AG>13U@F\^M3G]!J1E1B$]"A%49'`H^CCE$I1ALC\0][
MOBG@TMM)(VLUK8?E,",&==KT8B\Z5+H(17T3T_XXSE4SP:-4:.#BYPA%9E6'
MQY-AQWNW-.3M@$J#F<$*)"2\O87UJ,)NT%_R-]Y.J`W\SKN^?5Q-S=0?.@"Y
M1;>T!KBKV]3#,=7J3(YZ"ZJJN2G@NUYH/;S'YJ_6N.5D/F9[I&U,:]3;9=!.
M*5]"O4GW9"5-=J4^P,D6J<SFU:V^MB^''HV/;0=']"JH,XWU5++I5:.IVM2X
M:<_:_[S0K1JW!+[%&U`>EMK05^8[1KOO@[2%?`B?U:`:2G>29X*)>_$NYH[6
M+<'-[#*KZC#I1&VM,[J\1$K9;4O\K8T1LKF<Q-,\3I:@(-MM.#S:W*#/<4G7
M.T417R6\-A[W]G>?V02[5]O[M[C0]D/VQBMF37W/6"JFP:O"2W,UEKO5[K[\
MT]>[O<.7C?TP4J]M[.R$,DW`+/1DZ#DWC%M<R.1F>$PR,3V0RS>'SOCDG?)M
MJ,:#2T$&F';96TQY,/P&J%\P1L7GR["<AB];E@A>7O[.2M"_OGDT>3L^PZ6A
MN1LH@Q0W7OY3YN#Q^&*J^EN68P8WO2YPKA@6$&^\9@'*?MF`-JKRYZAZ/I);
M7Z\7I=:^9Z^4M)$(>D^M3*W4K'W`J+M2)<I<DMGWMA=N97XVE?>=GA*A!R9S
MF2<@9AND+V%AEVY(\+#`!K65MRO'I-Q8R#(>F)PM)N\M`],_S.DD^`PY98.D
MSX9&\D`DF>[UQQG&\_+PK[37WGF]O[_[XK#W;&_[R=ZSO<..N_>-/IN.CV@F
M8N/.GOJN`.P-*'C/]4-U=N,^3'45>"^M'QK()[:?7;=TZCY?5+6**?NM#7$*
M>B^O`67$@66_NS<"3]1BZ1-3_-I^RR?C<_J05$\ZT*)[K$"R]I(^5M9IJ`,&
M[<=Q;08P6(C'_IN0!Z*7NNZ5U,^A4*^$^;4)A_?%&B!$+$[&$+`..;11Z4*U
M'*&WC!A;]A!RF)ZX+\``&;IBNU3!6%/:[N=.1Q3>JZ%<#K-I(\+IBS'Q'XC*
M=#;]@=WAV*%9`\$DF0:3]Z(E!TD>BV`].TY-&3&D]UY\EI@85W2*0'GI&G-M
MZHI%_EIH`#X87C7.B\-[1+L[)GP>,\6(8\3Y2]!=Z&O`'V=&@;S?<=&<TT&<
MXBB+7H!3W3)PZW'OJ^V]_=XWV\_@Q\]WMP]>[^\R\;0.7GPU)@'SF_$93"F3
MX4VBX([K?AL)BXT</.EM'^ST-K'\>I\M>=\B+$_W#G:>O=1>#S[K/53K%'_-
MVHX`%FYVAHVJKA`>E<(CKP&&8$)!$KE?.TI$F7$(7$$(4840`A\*F)Y#CQ(%
MT]";6EFZI_KO^<PU@%/1)Z)'PYG.Y&[G84F1$UR8[Q`V9,D6.S!4%&[0Z$:M
M6MFCO)(%RTLMY3NV*+G2WJ:\FNJ`%]H].'UV>!$#P#@F'`5U$$SD"V$/;3BE
M1.X&F&Q`R!%D=,9K..G`2[V810<7480?,OOTZ,<QZ'U*<'RR^$(M@\-!G=,*
MUY);M&C%D&6,OJ3S%W]Q^#4\7OF;Q?6^G=+"B99OWU<<_!F^%7*_ONC]_1H"
M$PO)46_S/EF)>XR&NP'D;(G@701>\P(K\>O?&'S1>TG:ZN4[8X;A.[[UZ>P"
M<U-X<#V;YV?"G_V:C'E=7LZ/+-7!VDB%->#.XR7?''[1>WW3BC`5".?NJQXB
M$Q,LC26!`%8_D9#JVO#_'&HYG_[+NZ%<P\B0'EUGTYU"+O9$/GAQ,!STA'[>
MC:=G`IML=X*/L?>P2#7?<@4#[3;_K"V(+$6_-H>\FSX5U8_K@P\)M[IVGV[F
M%CA&EX,2!GJ.#<-$0Q"%L1((PK>VA'$DY;34]>2S+([H6<B65FW(6_R4CBT2
M!0P-12ZK;P8E.(EMJE;FMI>*.]A9Z`9D@@]^M`2^R/6<X=]T`7-=TQFL5",`
M--WB\CITU[+FN/!,L_9@.<T&+G'HKLV=(H2@#.8;G^SJ^P5("F@%UN2?!\92
M!I^+@_12IKWS6:&@J4>F762VF/!&;XJON=7!5M_.T.@0"<9X)-53#I?/<CA2
MP_6*3SVU[FN6X/-E*UH7.-<KLX3;/W+;-J'!MD]/.>-@[8<>!B[X>?N'@RF2
M#EL'B/=<S<PLK/UL6&1PTR+M=TKFU/XMK#>LUGN:Y>JS+#;;K[NRNVT2HOI-
MC"&-T"`'YHRYV9*'N'Z*$[\WYY=D7(@Q(O2NS^T.U%B+'V!=N%6F9,<[IRLP
M:#I#+O.#%)(+I"V:K'HI=6@JHL;H01<_G-`:\.2$U5V5]KB&IW85)%72Q_45
MYM*_A(HZPI/I#(<G)/1L?'5ER5O^LDA"S]![?W)6(=C!K2DFPS88]Z>+?Y(P
M08%/-'.LUJO]&+X@6J<\ZJT^7A_\J?WC=@"M3'#+;=!HL?9#)&&L,7'X?WM#
MF^Y364"[\>5W\S,@CNGX?7N)C<W'6]I$?W7T>*W:15K@A%DF&!TGU2=>H-:T
MUSP$V`7-$J=Q\KIZ"YL'4Q!CEE!XG!FR[J=`DB"2HDCHYG[2[QPUO_,NH4MK
M_T9?]'[\H<Y6B@WBVOO?CY+PQ>1]+U-5^[$;B&PG5?!$,L!_EC4YR1P8R+^<
MQ4$$A-7-J)PG"=/^&'L*3-3E8OMW(';[3O%NS'NOQM.3]MNB/O?AM']1FNWZ
M!B'E]8WV3[^Z:QY6Q)ONH;WWYK6T?XT(T/Z[Z^'Y]MJ_1XP0G-N_W8Q+7$!`
M@_9[NB[X2/O/HI"ER++\+M<)1%<)_&K*X2E[Y.^]VB634(F$[2]F4U>Z$,[5
M[#.,_M&=^>)JL:+HZ.7DD4OZ5['J:[FC]/9/=V^P)FAA9)9?@07A!/DGQ'7M
MRHI<6;`LFIQ&O7=1[%:_)D]H\GZ:V]&D".WO/#%3\LC3BC5]"S5`TE`Z.SOP
MAFU22P$!^1KZN_75XQD+BG%OR##K,&?+U>EP>N4.V>2V-''U88>*+_%3ID:V
MK_,;D0!2C[ND1RKY<N$X[><L4U_Z'H*S8&&&?R;$RY$UE7B(7PFPK+PY.[LO
MA?@Q@<]W8@!M[\/UEMLNZ\/>@KXT?M?9L7(F=4WMI;93^:T#+"!X%\H$@X7U
MBD3'^]QG-(RN%))AF0<TNEQ9WURU"W_0)^"RODK.-I"3=H`G1?T1L:+*<^#[
M(FT+6QQ<BH[S>`VP&V$J+C,0/CO.D?"A]W'V92\U@7[\P9/.?DXX6*T]%E0<
M.WYGDJH(PJQ(^36=@KLV#<&.Z1E-%&!RB1M4Q.M^C>.@IR`\C;ZC9@L-"*"F
MGHW15)'Q\\LWD^D57GF:7E)M!9.08_)*77#S;_86WAY\8^XI.[X^5P:=/&*1
M>6#<G_SCVDE4'RW>MI(.*3\R%^.-XCF]O)K^R_5J]IV%%$AAVX;KJ.MI:[$H
M"(4]?DZ&BQX67.Q-^>G<UL<AH\7<A=7@6,'EMEP?0Z\7LA9&175A+Y5]0NB6
MPD//')(Y\&0N*`/WIR'Q!IOY0NF!0-H/=H:1*+9F/"3H5&)3YGTA7F:MGQNQ
MLYC#8P]KD1VGB4J9J$3ZX;SWG-2?OXW/N>YM_F/^_3&N&,*<H>($A(F!]W;L
MLZ^.43^E&5Z1(N<QV]ARW2U\\6<`%L6,<WA'A!BU,!#Y93<9NU6HET)!WA1!
MIO&FW>&#P6A=I\!S\.,/ASP23J[&V]P)MPP,VB?U;=CG?4E#YI[>T=5%E.8(
M#R@35\-`89?Y6/5,6%40/6%2+)<+==7?*'M"AX(7]8:<S2"SRP611RZ-3^A<
M>2N/\0M:$W9"D_BL+]E,2&F0%Q+&@`-/L0@'>3BL[8Q=*TTFX^Q@5.%T0)C]
M^<F,;(F#Q[W_GO`U6/>=4(:1AK\#A!D1UKD%7S9IJ##,*7OW0)<^TS?6O5?Z
MS>C2^0G'DHPAJ>HMXX=AHKV<ZS5\?T2Y&6]2X%?'VY\$NYP=/2&:=3G^IXIZ
M__V0RP18%R?JO/;B=I<SHG]WS%+RZ_X4#0'Y^U>$QO79V?2NN/6[X%M4*ZAD
M:IF,ZZ\;YS'[!+ER#YY%(Q28W>T2KO,+=V59]G(N=OBUL*R]+,.E*$@6>]C,
M:-*4!VDQ45];$6"SA%63H65:H;7W*55#IW*I1<%1S?>L\=*$$K_Y]V2::`?+
MU+6A#T2.YG^7=H6.!*>-^D((M$B'4=%<3K7[Z<I:SIIOJVWJ45;J;6C'2Q4W
M-RB%T'HK`J6AM_5IB/Z!@IBTA0$53W?`ZLYOW!FM[>U?GRCNP&OC#%UF9U1W
M)7M$`#+IK<ZGO,EHS\PL+F8TXKAO'H+E-FU[\0YC[08K+;@3Q,].YU+-VRHZ
M@9]&<D[AO\%`)+]<9,"YW/:LPZ8[V;+&R!L$^TX&6/+"O;J<0[KG;6\,$/;*
M$NN*(+BY;9C,P?$-B_5L:BJY,O;1\`4ES$2_B_NT9,#($7?-]K'E@XV)&%@K
M[,^NS7*/$)[BO2&3,9KU%ZGL@N2_-BOK.$0T6)&[#)0Q#J6GRFU+ISS!4-'?
MT[;+!RRVYE7'\QE^#:6*1)Y7G$.3J2QQ5-T;5:TZIGKX/3F/TU/KI1`M;K?#
M<"]H#J@X7LS_20PV5KF3'4K$I\EQ(W^-<E*MN-P1*@L5\$]YQ0+5OMS1Q-!.
MN59<AC.S%HM-?A9!($8D^:K^&6WBYABRRC".I&?R@`30$WVT8SJ8LR5^B(9C
M,:_!5(."DYK]X1FX9C?:*^1HJ!LC?+EAT/;_//1:(#^T?DQ_NH<9VS#/*^-S
MVZ%W1&4I-C`'!$:V>'&(%?_+Y+NIF^+ITA,:(",++(F^I1+?O`&0'3]A2;"P
M)0V9]BR+OD(.BZU\O#O6[4.::8J+O%B&$C_MCJUB/@K+;&(&?6^IV&K>#*T-
M2&R;7.L&%`LX)SE9%Z)TUQ72@2(Y-Z":;B#>";W\IS@`$XQ1I7PVHC-"<C.9
M<L;JK*H//:!`1H:W:;"=C,(O3MXT0KW9OY<#*F']<F42UK:O<<(8K*=73)2B
M1$Z!SD<TN]#W5IJ1(EV)/P9+:SS67N9<X7Y;QV9&+%VG]9Q1UK,)K)?"F0EB
M1*FRJ4Y/V_+^135Y0)0`4Z%8(]5E[+160=\3YR<!`@;5WZ0Y`2.:2\EM3#L2
ML3B/BV`U&`',:6>+J(D9"UB8I,V#@`L2[7$D(4LCZV;-CNW<Y@XZ:'WX'-N`
M3LA%U!=BB<,C9Z5!!$W-!X^:0KJ5?&@-3UC8O!B8L=^FV,J8VRDTE2WI_2*4
M8\]W'OGHN2S2659^[7/"49+&:M#I9'Y!#",.;LJJ0T8VUT*DWYM),#Z+[QJM
M5.`X9-6,]I\T#\8$8(CKR"`I42DJ@1^0UB)+0)Z@^T:DOJB#K!2IF0QK:V0"
MFM1-"X?DA!-S$S=D-(U:*9DE,)H?<JZ4WE:NBX@P,EI#*RY<48/&4I\MB`SQ
MM!)NSVD@,S_Y3-YAV%=S).?![L[_(5`;$Y)#.4G4JD`UX5%4;N7E=0F-1P]M
MP,,W<4^Q0,#W%J\$I$0LL@NN3$0>SPBF.4U4.(8,>(XB`8\?HO8$'[0O0)),
MKO:G?F>Z4&^%(XM]!':GFVP\IK1%6)<2TAB29[UMK.]SV*;$=ICM3,-O%\%9
M!ZL4(C0M:^5][*(#"[:H>.LZ2M3%.4M8+).A"-9YOG;MTHG+S=P@$;AN0:S4
MLL9YQ(HWNRB`X]AOPA&@C49X#%%P@8Y($6]2LO8RGEC46ZYXR03`"TH:(AHL
MU):%&`4O3@ER"Q577)]-OJ#1R)]<+J!?>R\M7!/U']>Z_N@S`NN'J5`323'L
M$3EHH8IP8:8@^`37*%<$N"XX6?4.!.',#&%MX113P,)B`5^/R5Y6-#/`$>*S
MZC([?BNT8M\,KV'/2(K-X"V^@B&N84U^WW_).5QQ[5240?)978ZALW]"'APM
M/\*@B<,41(P"-P[6R:^&.=?I3LP1WE0RW^#QVFJ5RQ=R!/EY&0??&CU>]US`
MP>.-ZOV7P6\FS25.[@QV+H:@:`3N97R),%ABY2"*D0]("+'6Y=I6CE1@:%NJ
MO##TU[OA^^T'OHW)J#%C<C=$[&B,2)+GK8_O3\[1DZ7O[!3<_A`9(./F?V2M
MM=?XQL[:_NMNE'WAR.W?M\O4QP:Q2M%ZIQYM]\P6`5=%@)`?D.].C]Z7WP#H
MM3=S(Y!ZWYV??;&XH([\OSZS#UR^FWSVEPK0[34/RC0B^')&$\1)0UT=M5]5
M7?3&.JC)?XRJ_+2XV2IMD=376C_YVM.QVI_8D5`Y(YGFSUP4D=IJL5@2WG[Q
MQF/5"'WSZW#8R^/IPDI=@,KMKV.UUP^9S@V521\RX?F=I5HC?!Z,MC96-NAW
M`L%<SZ0LASQ3*2C)IW9,GAZ:])DBV:9D%BEPI`U9=G_!$$MB/O)JC+"J50&/
M45^FIV^-_$/6<L@U81,#.;]-7ZS4!AQ@74>30"_)0W7,4G9F-*BR%!F2JBE&
M4V:=YV,N<%-ZFGET]]R2`@'@HT$NY_P@.^==PU2A@6F$U;G"]5%`*=XB(%>[
MK8[9[U/:MJ0-XM.<LK]7U'6(B_YU<F*-][:=.2A;H<C`7)Y-N>Q3#?:3TNI_
M/L[39A=MNO@V#H"_-Z.@XY`QBL%:>\V'-%-<7V>V;R>#H6N@<N7MRMMO[ID!
MW_ZKV%+Z6K7FP_Y*?[C.[(?JEV5GJ]&]_<7TYKT9Q2?6E[+DJ=6B@%W4@MR_
M_J)MJ+I[X0ZYDU6ZUNKC#:ML&#P>;/VI,_V_J\1"#]8R92VX;84_&]WF;Q+_
MV:KUM;K6VX+M2-/:6GN\62E:::636'11;Z@_H$7C]OZK[1Y#,>C^NG-HQ<"Q
MY\3^[C>[+ZABWM_=>?GU"UH*U.G<^VJ>=3WI[;N,L%3>Y5SEIWUKNVP&BE;U
M@BB6["3,7BDOLIMAZGAG5-IC%K<'`F36^)=QL%;$`U]]G7RE_IAE8=JZY@NS
MZ,MD=DIW`)-S)ZHMFU^8A4PIW\4$!#W&6_!.S)SOLQ%Z[1CK1Z;(L'$FOYA<
MD`NJD,@;[`"<1[1N/B%I>3*6DOA&*;CF`4:PS-_(?D0KLY*.X%DXF8P]$H(4
M/AI?T0'C'Z2($EFBJPU)9L%J#2FDBIKY:4R\$Z3^;G+RR`5.$SP7@)&2/S;D
M4<`HNG64:].W'ZRO;&R-5H:;6]E^/49D+4QVF2O<97/O*WTEB+7X%6616DFT
M0816`E/@)^5`@H^,U:LIS7$57F)>0,@0/Y^2/7=%@KVY/:-O6O=H'>G\B$'-
M-4/2G10A6A,NO[Q7=\;P/:T1-V8W;-YO%`T<EN>]&"@K]Z+N)(`";G3";GB]
M=8(4:"TV;7VK48Y2EU[["KULYH8B+'(JG6=F4%!(P6Y'?0;L+]Z_8-%51WE)
M'(U$125J6QA.&Y*E:=RD]]#A0+YK/./GIHMX.K`B;3%^8=$7N5W?TH&=K:P$
M9,E%^:B!44]Q-VSP`84@A2>JB:].R>61JB%7"OAIF*"K+4$=V<Q;5$W]/:P%
MAAGE.MV6+]A&[31"+_=AE`!&;94NFMJ)T*_*PE&$GM1I>()&)-\SVSJF^E"M
MH*DENSREA,Q%0>L2_:*@L\7\G)4!:(J+9-3-$2O1J:TM5)L>0?_\P8XL8.BY
M(@JJ(A%SMK0@<BC_--_"$ZX.,"IJN,;H,,X!"X"KC2GYA3+`#_/G.JCKU24Z
M\;PK_N-!SP)00%A@55>>Q1MWQ<>[*5!09^'P@BBM$K2%\$&XF+DQ6]=I6:P*
M3K-)^S8GL%8_^I:3:.CSUD0#.(&)"QCY=;B@[QUSVQ_09ZV7`WN")H[A*D:(
M-2"U\3BG"S=HOX-JGB*@`,31]0D((*YJA2+<F2X9J+KC]JF&]UT9`;*;I_0T
MHHQ!9-;[:G)T24(_3CD"47P#KYRS5N?T3AZ+8RJI!%OI\I'\M#DG"'>F\K_6
M#,YX9NO,CN2VI.$3K_J:;^8$-`"`%I:A;H72;&ORW5SH"D:_FU[RA'N;3:K`
M@N<T[L*F.64+L=3;TOKU&4Q^7SI_S:[1SV,8<T'MBD7LDSCH`#VADP>;:PQE
MI&.6&7'+SFI7*3X^NX*O&)Y-S-+C0(_\7K35`)%D*<K"1`+Y_>21&PT6XS>1
M`)[<;D+%>#\%00C53:KS1JC6,?=3>ERPM^I^OT=M(#CZC9#@)%S%T9A2)Z\Q
M9\^&F0;`\=FYC&+)4PQC!?C?4+9J`%59O2=%G+`OUYILA<)5&*,"125T90@^
M=<JQS5!4?/.X2C`5$@V"YR1@K<L`5785<#'9KSM@RN9H96,P='2D5P/-(4P+
M("Z"G"E>:;N%VU;(\RC%,=]'CU&@S7!ZRL4K_UVL#^>0'%9!/Q#IV9?&N(UI
M`:,?P&"1;E03*&?3?XYG$YK918[>D@Y)C$KQH<II`]L*/??Y>(8"9^3-U<O?
MC#L<XE_D(QF3@%G2GU\A$,M,`15@<ZPTHYE'#@4'G+S@IEC5$)=Y)3RD8G-[
MQQ$1W<SP0/+"^R`9_R:,A$PFLT5"_L<?OE4K(FX20G5G2N2MDA#FY0$&J6V&
MH=-'`YZ^?VBT<L%^;/<4=$TNS!OHH=%(7$ZBYI+G`'1H$#>BI,\A!6$)*:.6
M(S``28O9V"_HN6BUEQ5"M]%D9&CR%1BP>"M&*N[EJK%HE^)Z[@5>#-U1MBY6
M<0GDK;"00`V<'28?T@Y@]-HR7,JHY7M\R]*TZ9(#F&.[W8303;SQ;./?)MH$
M&,&G=&Z@5``F*@0&#/&Y"`U%/(6;`JQ8G]T=,@!,%\.((>]4HN,-.GY1?'F^
M9:AR:(J=V,D5]E#O/TZO_K.WM?HGSM8;C%!P,53\"%1D3M2R;!@Y!^B#['RG
M[E-NC4FQ<0$J&14J?*]-C`J44EO5=P>M,J+:'9@/%N9OGOE$X#;]Q#=#&=W/
M5>Z/`>9?G$WMN19RNP]IN$SF6JPYL1N$C\IR3>1NKC)@=[B5:.MC2=UADKI?
M8=ZJ.%3\F6(WS"&R&VC&XKI+4II,D[&,6Z$[_/W=5(+V`KL-(^R)DOY<DY[2
M2%?L^`H>2V>.,\_7R*IF7-Z>N3[2*=6_XQ9J65M9V_P]4`L,,T!;8.R"N,%%
M)LD'`O)7RZV[_)2EA,\H^2U3Q3PSPI$(GQ=.%O\+8A\?&HKTY>E<[7:.I0J:
MX1.Q,*1Y)2.N$/&E5/M=(-S\R)(P,8$OY?*,=(<86G0`C3_78+.72-K%VW`O
MR'TR*7\[WH`Y)NYWHNAM*H?FL<@".MD0-(FZQ$X*[$ZJC'D,"Z^G"2F&,LC[
M@7%BF)3DW2FJ)<8RUI*B^S>BTT!<_#?`O[+Y+>Z4-)F/"D[#M_:'7#_#7JI!
M^BO!L^?>".O>&F7P[@1UYR9M\G>!0;<;JXE^+O!$I;R"&_5%AV%P`<7FXG>&
MZ"=#H+:7@[8Y1,^>/]\[M"Z_%D!3-&WOQ=>[+W8ZNG##9S"*W=DA5KZ#$QG6
MXOW.[Q:=O]?WGM&#>+?<8O,$EW_Y\HJL'`2L)0`U%?P!0YA6>PNU,\&Q*P<S
M]T-8P/,D^8><`=2:D>2CNIK-+9+"7GMK!/EO=K3F)9WRY,8^8(`DC3BH&.P=
M((:>3DD0)Q]_N[<UZ-.1FM?%CJPM"1\AYC1B:!#6O;NXY`4D<";+U,("LN3$
MJGD-'X`R<63$Y>B>W+3!@2SP*J]>KT@1M9=\SQ('^JIYT72VZ$GF8@@EO+&@
M'&&3%W@WK9`@I66>\Y<4;U2)$]YU:XVG5=I`7",KJ03BV5R]>M&@KWI;Z\.U
MGI*-!)Q].2^8$(2'HP"2WQ?WI/_WBO^9_ODO7R[^I;R5__IL\S/^<3P_\X.<
MDVO5UU\NOP*K_(E#W".+GAJ'[<_/QS/]^F:,&?*]_VR/_]G6O>I.V5KI53OX
M6;[^EX`+5#%90';<&VZ%F_';-A$/ZD2%6BB+)5.@S.K:**.,73\);8HW<LMX
M^G1/MI3ZZ(7KBO&+%")1EK3P0J@6$)QXT@F>2?Q.ABUR8.J:A3FV7/!I<35_
M7DRY&_[/:,KF'&J7+8SHKVS49$4+7C4?UN<30?7[:YMKO0-Z"+/(7-W":?3!
M/8[!3J>G_NI6@2K0$R8ENY]-QT97=#YOT=5P92L,\`M(+[K"TU&15;3^0!3S
MY84T96P^HG;>I@2*BP0C>C.AKV>3I]]F;Y^`Z;S3?'CM(]Q.`;';;JC)\Z[^
M\I++W?7X2>_`ADTHCK+'L%AS_TY/IHKW".KMW#ARG]?6&M0,)@0\$3LO-E5<
M(_$DD.<5[:\3>9.Q]+;WY/)ZMG@_5='BB[]UW-7:EH]'_4W?U>[!GI75I%:#
M$.UM%U:YB?=%1G+W$I4KR8FV9M1+J1A0T'^POFG_'1E[<M>(+="XZH8R9;T.
M%@^;#=&J?3S;_7K[6>_Y]N'A[OY!&ZV^4MJ%)I<+X?7_D]%^-IZJ$`0!>CX^
M8>NG)`KC-,&M`D6(A=`OFY@^Z)9S*H[D<R1^AROI+>TR]`L.%VQ@@A]Z3>,[
ME,>H)OD[X0-LORBDSD_8I_'F_@,?C=.A`L\`\YJPJG6RLE$@.O[U[,WX'4R(
M7N"POROT=R2'?WM^3'!J!>)@-U`X^$ADB#V'J1DKZBTM$N)^QJ1T\!XL5!DJ
M,_/=*\=X_G9ZQ+Z1P)S=G$PXCLP!)O;#XS0?D]-I+M/?WK>D&[W`D3UZ$I*<
M6;^ZF$.!4KOD<*@C$L.SKA-I,37T3XD;CAGAG*'65CV'+^4FHW"&0!$91J8+
M2`N17/";L&!50NH0=)!&$E;D2&^NS2<=D(]R;2Y<0H2M"8I<`W<(?]25F-]0
M>#(CU'3AL168+R4T6+QJ!FK;!L"@"[%2KP%DGWK?)YU8U)?)U[/3&CQ2APYV
MO^X<17$P.;7`V+X-']'JRW.X4!7]R/S_0")B*A=.-H8/'&'3,=!]1;,L5\T-
MJ1;^(=5[^J#NB.`\XP<&IJPJ*,7$JO@%$F\(-(%`0C-A*VQER>MP[],9@5C\
M1AUO<PMVA1?$NQJ[\L"PI7NE8)MBO:$#GVB5MEV*,03AGYT("6N]U#RDB#$F
M0KO$Y6(31GQ]X5Z!-($))$:UE$/5[3D##(VWQI`R6@ZFA#K,@Q7<"%V2I>H9
MN149'S&D)R^TIS$'B/9.YERE,/![M/U0"VK37)3GMS"I;7_5(]RW-[S4F=!-
MI-8J8`1XF`(`?-F%J4UO54HKE@@(!9"`!YTTG,MU[':((K(1^#G2,N=G\>_0
M_9LZ4U*SC"*XU8A@AB#.,@I8F^;/T?6VG5S[X=^Y3V5CU),MDCI7ZE3%6@%?
M@;+=('!WZJDR2`]N;/W=EB#[(4.F6B9<=OMYH-G^TZ'B"NS&4VW:O[Z$%W%+
MT/@S4CR8%=)^@(3D`=E^H[5AQR^2CVM;@^J7T6B-!L]5"K-OI?G)ZEVTX0VF
M*:ZNMG]YP<4OVR0ETJN#E<V->I,T;UL;DL&]V5[NX7"-QL7#K?;?XV>(;X`8
M,O9FCV24J^^IX+0G(Y8X1U7!\W`D6*R,-JL4\IWQXFT%6`>&?FKOP'_9MF[Z
MU6L[82S:KG0?BN3A/_6E=3W4_@H)3BCF#$$2B8K<MXMNG]5G?4\WOM/^0`04
MFK6I:4O6;#_67J:/;7#P^LG![M]?[[XX["D)N9Z>=.L#1<A568<357D84Q1=
MH%XHRX.\5"E",*;L.(@30+,(@T=8H8=Q#W&,NS2\S86*B8&0;08>H2@I@R@E
MV!UH+)))-1=JWWD]L=S1FJNJNP(K6P/EN#QG;N$PKB6J^4K,M<T]5ET3LG%\
M<OW3E%@2#*9ENES7/BNV_+5,7\]6-<)`$E?$<'`+/$V[P5$10H6T_%1B3C_8
M^A+ZS4PNE_$YZ>P)XQ94>:6+@V6'_&ZR7\E]!)X/MJ#%-0/A>_'T])T^TZ?)
M"FPCV=/)T14\4JHF(&[_>J?#6,8CEI])M9R=EM0@VXP2+,0\4"-(424G3RJD
MD,@UHU@U:)7/_S$^O_A/.F&<7O,\IDB?A,,_R3\(]'UJ]POB/V@_?MVI,U#L
MZ0\8P'370+C?,-V,Q]4.QX9NIF2^JQ1['M(<=6.TV<MUM`P9_FGPX-N6!*IC
MEG4Y&3)1S(H+M2$4`?1L_)Y\<CPM.K2?@<Q^N&=*U$$@QRY!6@B=NBS[[JO9
MVF`57,@]TA<W'U,TQ_5XK9Z*>>S&/@@8V@GW,>QOK/2I7<M5\G$[5N9(-;T^
M8BQ()'#P:!,*/J6U@60T6TG,@V.`!5'-V49=EUL%)%D-VWT%>LF!H/_E266E
M`6\WA*Q8R3UCMA%1?TPV%W-QZT$P+%H&0&0R-_7)!7.U6(I^(JF%TH/AU@H0
M;FK']G-4CM-+Z,;J!5./\]TEMQK#!H?Q%4)6!;[F%?\I\+8SA"F_/EQ9`_TP
MB:0.DYK&-^:D`_F4W]B_2QM8V*0[G1G@&YC?,"3Q<_.,W7?NK_!^/]SB[,K4
M\_+6;Q@#G%J*E9CH+<5D5NH^L;,FZ+FJM:SG\M)3#&&FZ^Z/C/T\_"CS@<O=
M",=B84#<$>YKJS(T*T-?QPT;]D$?W;S?$N"];T/IGH[WTR8',XS"'*KP`[M*
MC['EVUXZ.AC];75]A8[(!7TVSPI)&'K&S>I8L?O8]87]"WI+,S?9P8#U4#_)
MNLLT7Z[Y8;PUL!-]G>_5*.T'-ULFXZ\>+;?67]FD;];&UN:2K1G&W/.X6I-:
MX1O6-);4Q!BQ"*')ZC`CAU^:W9_K2?G(HJ=XF][A3'^!5N%S/K_)?#V-LS[H
M;S)N9G-#G[J>F:C.XL>D!4`4AT[B1UG>0=W`:0'3*L?:(SCTS2SEH]_;97:*
M#V'%;'5*;8.MEO!Q0<:XNZ2[I3@LR,TVJ;?V.1OQ)"R,^"40.?+\ULQQ')2A
MBBC`2?PO.5GX;VU%WB>X2!,N"1ZEY,YJV$P:2#J,_^OM!.>D[0+>\!;N"X,R
M5=<GNU:,OSO,%$@,X\%[I?M7]H(4UCTJAI4(\?4%XC$^&R)4.?AR)P4NP+--
M)K)D*<IM2.V2@NWT"VG>CRP4^3[6($?VMAMU^+A9DRW0KGT0#.[B&[=_]7:^
MN[I%:FO@_QXW<#G!WY8+0]QA<K^Z&AO)#.<TE>)T:]YYBY\7E>CM^*TJ%T]`
MF&-$:'R^C705G"I8W$3<"&;=JE&W%+W$-=A=30<)[AG_)N=MWF^4W[[A!VO,
MHAJL87SH<^57].GB2R4-I,_=00"6%['6YG%R,GAO-+2\.`/>8FQ0(B-M53!`
MFX(Y:9JBVF0IGE([="'`RQ_LM2125,*^XJS'2KX8(W$C0LSRPPRW):2",V@P
M6-E2>-LG&K&[!@J`>3)T.B16>=>W<'(LQ:WU-9W\OIR\XN+%W88C:8=<>D;\
M)>RT$#>FA^5;M:M#G%'D_V5K>&1@`(E/?53@TXU[1.?B_K!_$_2MB=?-\"\)
M(&%Y#:D8?D^/.QRX%C]\AH@385K*9$%\"\\%:HD9<C8B`UY""UVB23!)61/3
M!6._F2AD/EW5N6+.1_^YXLI6E8.[F:L]MK"\1Y(4EXJ?8(5#KE2VHD_A"!)%
M&&1.C[0S+'-,'-,"`M?!1#\[2U[L#B!$9@_>I%YH;?Y"W^I5"DC61\,E-U,1
MZ5XAYIQ6"X._C55W$FX(=QP/IM]`?V0+')'%.+7N2[WM4_(9+>+CS&49A;KE
M)B9C+BB12=RG&5K4P@FF#Z>?1RW#2P;;NA/FIF@L*VC_G[7KZVWCAN%?10\%
MD@'IAB1=D&+#`#=Q4`-V[#EVBJ#80YJF0X#4'>`$6(%]^/U(BI)..I[NG#XF
M/E$418E_128J1W@H^NK7(RHZ(W'<_0?`#"_+]8YCGWV@NLA1I"C!K7MX8NOP
M4$#]`VME$%)YHF5\<IISKIQUV8'B"OF$/.2H-4(8\-*D:*H$/+ZP!D@40HR"
MG&W@>.T222;[B?!G)`=N]BT"K>S;4+8&?SU[C^&K-U)MU/$#*G*`L?>+]D4L
M=RKY2AOAR^+^QBBICP7_)PS;2$[_%Q4NJ(;0NM`G3#:"-&*TG'N@W#1._V+-
M!\R.NHO\##VR`WD6OSUOGOS)2UQ6!?W(<$T)["FHS\L%6]$B.9,[=,O#0LA'
M<N?].>Q`P6#=W,:>IN5X$)O&)=.N=>&IXR$XZ,BZ0GD]0)B0QAMM".[HFVD\
M6^2#A.N$*E>2#D:DC3*Q@3,KTU)Y+VX`,*0_]&8J+HAC\HG/9J/EC9M?N*L)
MZG%<3,Y&\(^/SL[F:\XW=(OY=$(IAVY_\>T1&L+]MFCO.Q#.B@*D)12H@Z$W
M(]9&WGZ^,_.;"C'GR_D*""U&-Z-WT[';MP#Z["+B8N%(^*=H[APB8@/(KKP>
M+U<3@M</>GJC=D)7JX[.;MVFV[J/,TX+_"O'<B2A:IALF])_FW\<8P]B%:*=
M;XKP)5M<UDR-P7`8#QI\"MU_]7Z\=&?KY9)B+=/)Z-UDBDHOQ$/&5DD*PQGG
M63PY;58*7LO7]1;-@T:3I;L>3==C-T,:ZGHYEB19"_9%[&[;Z!'>B,&3EU$D
M=.CWG4^==M8NRF\EKZMQQ9(MW*_/]`YUB`J\?E3;XAQP>V]3<P^AH\/R@8K`
M8H/OJ8ZF$I301SH1Y`U(Y6\U.B)R9X?>I3E2H7B7.J1WI'P.=\Y:#&6*A.*`
M^2?BPO<RQ2>.%%VKTYIJ)JFNXI;YRQG6#">BA`(IG$3"]+`1>@DM?`0GD2XJ
M)G:IC963*DT,LJG@,X2@)R`3`YR00\$+^^GDS_7D?+*Z<?MXY,]E`RY)6Z;G
MX3^Y_?75N7M5R*/I`X(`<,]_]T-&>'M/Q9)S^!]0AH<8$`\+'I#>D/]\CM@(
M3&<R#E#!!#%!*1^01,;@U\(QYXA#/GB@3-3%O2:O2*L8A"7"`7!SU04W2'U>
MDGZJ*GA[.G(4"GV1>73'2ICO!)ROA&J*$I4`1TZ`'A5+?"#C-51=:O8!\F>G
MT9?7E'<ZKP_\.Z0R-#JZ4(/>)7"#VDW6EN#&)39-D#MN2IWCSDC-?L9K+HJ#
M?W;B)LT)N8#0A7>4*BV!WD_@T$=<_^`N?_O=_^LSG]CZ'"^N<@!I;@5M!X*Q
M]\A,Q)V)1$*.XW%QDWP8B,3/'&63X6-$H3$VU#Q'%4*VU+`B>UZRYN`5*9,7
M86RS(WRBD6I8*YMT9(XCZ1@">B$ZFKF'Y."F+RG8R)>DQ8:QBK<`MKZS5UO?
M][`^3TH1:B+^-UWK#0/)NOL]\_!TZZ-^+TS:EWJ>DO2U4PUK01=NF:*PWH!S
M\0M5(U#K"U?$G=?+^)HN1YD3'L#E^(3QE5F567";2EK#[C-B,LZT\@@/6R:-
M?.E2>\S>LMQ-?>85)^"E&W3NS>.<>[JW(_]:X"I.RI;Y5[4`DW6V.`6%M)AJ
M`HIYWILI&]9$FKQ`<Y%08"_W%2Y%.#%&A06SX:-IPH+5_^AS90:9/@C4G;8&
MZFRCKM=1!U>K\6>>>@X2EEMOK9&MPD&?'PXP(`4P1P:T*ALY(N0U)C\[T8QD
M;IFHZ7$YU_4CSLMNZ;O$K21LX>5*CHPI?"7;C7U9A22%5PX9AZ2^HA+JY16*
MH:+>*<Q@E:=UW$&@GYU%(-%Y?-`!+CSRQGZB%M!>HY!?\I5\N$6("%::'P<5
M]A;B.L]GR4<MU(GH?>.)ZY<.G5H/^;`&BN0STQ2>"I(=XPSM2E\*:%8<:4@;
M4A3T#+C_W'L))%-P4O_;B3!<+=#*N%>0@AN"=^OPEZ._@F_=0C\>/4*8-K:1
MD*##^M&"U6MD,SZS<GF!#((?/[YK,1?DFXU1-)T\W[+$"E!+AQVYPN"Z84-'
MM>_3BF-?=9R$?S5+R,(A_ZI]SF1]<++$;$*+'MTNN)K^*+ZXQ`>'!Z!>G[)?
M\)A3W@RY['(UA#I17K*L5A46)\JGH.;;V>49U.OVM8O.0%.2HA\$;EQYE'V<
MS\+CKREC\8`,4I0?8JLJH9:;X4DX6X&P>9:4B,V'A^Y(*(>(-OI_O*.PI/LX
MI:J%$Q21VQ8.WS@7,AG_@='NIF2\N<-P"FWLFB..!H\X-D>8=(X;#74%(;VO
MXE$KO#,0/R)_E'UQ%\WP_/KK\U=STH04"6@F_8R;:^&Q^M_RQ+I]5W)*[1W+
M*_!"8K=B=XMJ$QW8`1B7#\TGZ44JV=-CDQW!0H^WR-E'501Q4+/AW^*9@ASG
MQ!0<$<.A!5`(@<.VHS?K2*C*O5LM_G;+!QQ/E.6O,A=4!YEL,:#('9D[G0Y<
MN^]OSVHA5&.Q6663ZV@+BI!74'/D(=E@[-O7FO-5[#S$Q$?R/OG*RKXQP2/8
MWH"H][!EO1&1!4N/AL/#`Z_X'Y[@Z<OWXN"5BR+''[OVP-F49)V3H;J\P0!Z
M+;0&=<]WE<$]S2NF@I%]%IPOKS?#:>A@1VX3IVPC\H'W'HC%4W&J'"EAT+8A
M>#Q0_=[G2K3%8)>^'51(:VIODF7/K^=[!]01\-?3O\-HG;@/`9+H4IBRS[B$
M<$%6#A[G+[BAX]J_KW%GW;)==S:!RADO'':-^\GS=T[#@%)%S:3X<0ND8W=W
MJ1SPWI$(;W>D%]3;UN,*UQ@4N=#;*0?3C/M%\>CUB1#?,\5BH7CD,VC0</Y%
M$Y:#5ZCK:;UJ6_,8]<DAAZG'/JGML_G%!(I=BZ#12:JMS,)4R4DP)TNXWOPF
M@7,0KRUXS(P+18_/#P0HY\H$&(CZ`J1ZP:C@(5OW`B3J`"H8%-QA(V-2L['?
M<C794(9M=AU:97U^ETB\4<\0DH<OP&T@M`IN"=U<N$O;]4*3]I$+=X7@66C7
MX24#[0II`#ET*TVRW,NMR<'(@?A84J-I`85+4RUFT_CQW<!R5(/*>OV-<FXX
MD6'9$GC<,SJ(#>_I%9T!=44@+>4K/1UTG?DZZ$MH@/"82/>'-Z;#(,)$07<+
M7.I;+SP]Z5Q28-@"T_R22LIV?;EE_%$4U/H('ES.5D$LF:MMY$3PAA+4@+#(
M+9[JP9[GGK#\\D9A]!H[DO99]"JQ%Q!?!82<6ZIV'41<X/^B;N<'^)G1U\\0
M4\ZQJ9:Y',)%:2VO8B+$^+5.48!I:F(>\<)"C25'4.\`54[R6:CF1_LO6DGC
M/BFWD8_6T*OF^>2_^UHM)MM0"9R2I7[9;I_^^!\``/__`P!02P,$%``&``@`
M```A`,@Y8R";`@``)@<``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R4
ME5MOVC`8AN\G[3]8OB?.@82#"%6AZU9IDZ9IAVN3.,1J'$>V*>V_WV<;&(&!
M*!<DAO=[_7R'.+.[5]&@%Z8TEVV.HR#$B+6%+'F[SO&OGX^#,4;:T+:DC6Q9
MCM^8QG?SCQ]F6ZF>=<V80>#0ZAS7QG130G11,T%U(#O6PC^55((:6*HUT9UB
MM'1!HB%Q&&9$4-YB[S!5MWC(JN(%>Y#%1K#6>!/%&FJ`7]>\TWLW4=QB)ZAZ
MWG2#0HH.+%:\X>;-F6(DBNG3NI6*KAK(^S4:TF+O[19G]H(72FI9F0#LB`<]
MSWE")@2<YK.20P:V[$BQ*L?WT72983*?N?K\YFRKC^Z1KN7VL^+E5]XR*#:T
MR39@)>6SE3Z5]B<()F?1CZX!WQ4J644WC?DAMU\87]<&NIU"0C:O:?GVP'0!
M!06;($ZM4R$;`(!O)+B=#"@(?777+2]-G>,D"])1F$0@1RNFS2.WEA@5&VVD
M^.-%T<[*F\0[$[CN3*(XB,=IE&;O<$EV+G#]YW(C"O%IN2H]4$/G,R6W""8/
MP'5'[1Q'4S"VY1E>+`_4Q<;<VR`7"FH-+7V99\F,O$`;BIUD<2Z)^XKEN2()
M#Q(">`=&*-LQX_];MV>S8F@21@>V-#W8.OR%EPR/)7W%\IJBAP;['*/9\B4P
MH]<1;5".88\#8C;L`RR\9.)J&WT:G%1W>?'O'AQD>`QW'<J*3Z!.Z^8EF8-*
MP]VG#[Z\KNGAP9C=CF?%)WA9?^N%EWB\.(M'43(:1WW-LJ>)AY-1,AE?F+KL
M/7A6?((WZF^]\)+K>#W-!3Q_U/F'N*-K]HVJ-6\U:E@%\Q0&(\A1^8/.+XSL
MW,.ZD@8.*'=;P_N(P9,<!B"NI#3[A3U*#V^X^5\```#__P,`4$L#!!0`!@`(
M````(0#)[Q[JNP4``$D7```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
MG)AO;Z,X$,;?GW3?`?&^"3:V@:KI:F&U=RO=2:?3_7E-"6E00XB`;G>__8T9
M-V9,R\+MB[;9/`P_SXSG`=]]^%:?O*]EVU7->>>S3>![Y;EH]M7Y<>?__=?G
MF]CWNCX_[_-3<RYW_O>R\S_<__S3W4O3/G7'LNP]B'#N=OZQ[R^WVVU7',LZ
M[S;-I3S#-X>FK?,>/K:/V^[2EOE^N*@^;7D0J&V=5V<?(]RV2V(TAT-5E)^:
MXKDNSST&:<M3W@-_=ZPNW6NTNE@2KL[;I^?+3='4%PCQ4)VJ_OL0U/?JXO;+
MX[EI\X<3K/L;$WGQ&GOX,`E?5T7;=,VAWT"X+8).UYQLDRU$NK_;5[`"G7:O
M+0\[_R.[S4+N;^_OA@3]4Y4OW>AOKSLV+[^TU?ZWZEQ"MJ%.N@(/3?.DI5_V
M^K_@XNWDZL]#!?YHO7UYR)]/_9_-RZ]E]7CLH=P25J07=KO__JGL"L@HA-EP
MJ2,5S0D`X*=75[HU("/YM^'W2[7OCSL_5!L9!2$#N?=0=OWG2H?TO>*YZYOZ
M7Q0Q$PJ#<!,$?IL@C&]X+)E4*Z*$)@K\ME$6HFQQ64.6/N5]?G_7-B\>M!Z`
M=Y=<-S*[A<`Z/2$D^>WT0%[T-1_U1<.EH.Z@IE_O>7*W_0IE*(PD?4-"%=E4
M$097R1;PKHR0MC'C/)L6PQI\[\H6LFO8`3]%B1A))%5D<PJ"!O=9CJ;%.Q]B
M6S1.;YRB)!YR*KEB<40%V5@`+1CPR&:>D,'REI-IL4,6TANG*%%8;1FKR$'/
MQH)$LLB2$R[8-<NYM-CA$@X72I!+0<)L.H9B9^/OXY`EMAD(EJ)8R_:!OLC!
M<SHI10GB"<:$O3WBC;^7@4HL/L&+*-[\%M!B!TLY64,)8L4)GZ9M+&`B2D)A
M0Q`R;92C`3)/IL4.F6T3W)PH0;(H8+&3T&S\?2S>;?]D#986.UBQDS"4(!8+
MHB1PN#,B8%R,&I'DB\%T79ZP0>V@V1;!C!F-88N3V&'/9@04S3&#^5HR'.#C
M<2;L`#=HJ'E-&W2:<N@S$\9(%$R.P$X6BJ>G\N)68SC#85Y>IZV[^5*C@<EU
MU;CM-BNA>'HT+\?#04ZR9]=MLH<:3(T*$B:=H9RQL0)FKI)VOE`X/9V7P^$L
M)W#.K5,VGO=Q'$?1I.V((H0M8]N#PJWR!/WTYNQ6X9J"T9BF2@+X1_=S1A3`
M-E90N/_E#&QJ#<)IK=1H$%+$H>"V>$,#9$3!0@7UM4$HY2J#8%.'&(UWTWRH
M$8/A3[)'["%0,`^5'8B4;)5!L*E#"!O8D(TM@'&F5.#4/S-A3/UC*</(2BC>
M*J-@4Z<03MNG1H/W#L,X2J2U3E-78A92B3AF=I6$CZ^RBT%-GWZ%,W!3HX'-
M^>[0FY50/,<RECTW\:EU2*?%4J/!-"9)(+FCR(@BBI1X;_CQ5<8QJ*GEC@)C
M"QK-'!S:#RIFX5;9!I_:AG1MPVCPUB*,8A&Y#4@D3`D.[QJVCVF%]10?.<?"
M"N/L'SN(:UXI1PUI1+M+<:?,:RCH*A?1[]W@(I!.NPOL;#551@T!=&S$A'E;
M0O'>\!$6P!WFG[+XU$C<<9(:#1:<*QXQIR4RJN`BB6VB*>4J'^%3'Y%VCIDD
MCJTBDDJ*V.V$S,3!!<A$R82%-@X%7&4G?&HGTO:Y`1S;R0V\Z81R^G1O`B'A
M301NS>5HJ131L12]8\2/"SVU%CD9W6/?N`D%TP\-;D<2#1.)B$5H]S\AU2<]
MX[T]WXJ#F@Y&Y<SDU&@P3XQ#'9U-E1$%O'CR]YX*0\=:?@`WM13E/$ZE0\2=
M;XH8<G@=F;S&40V\^88!/&!<<TS3M\I7X)33?6Y53O%2H\'S'Q:\];Y$)6^^
M+^%A*![S7?+'\O>\?:S.G7<J#]"*P2:"9FSQ*!0_],UE.,Y[:'HXPAS^/,*1
M=0EG?<$&Q(>FZ5\_Z,/6ZR'X_7\```#__P,`4$L#!!0`!@`(````(0#[8J5M
ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O
M;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[
M=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN
M>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%
M2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A
M/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'
M&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&
MP-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=
M3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q
M!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#0
M0(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>
M?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q
M%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);
MY`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?
MW7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>U
MO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+
M33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<
ME9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;
M1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<K
MW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3J
MMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%
MU^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4
MF0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ
M'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(
M9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+
M=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>
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MH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?
MJ5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&
M#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]
M69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5P
MD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L
M:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I
M"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP``
M`/__`P!02P,$%``&``@````A`)K.6W4.!P``CR,``!D```!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&ULE)I=;Z,X%(;O5]K_$.6^#0;"1]1VU(2/'6E76JWV
MXYHFI$&3A`CH=.;?[S''H1S;M<E-9X(?7MNO#^9-X.'+C]-Q]KULVJH^/\[9
MO3.?E>=MO:O.KX_S?_[.[J+YK.V*\ZXXUN?R<?ZS;.=?GG[]Y>&];KZUA[+L
M9J!P;A_GAZZ[K!:+=GLH3T5[7U_*,[3LZ^94=/"Q>5VTEZ8L=OU)I^/"=9Q@
M<2JJ\QP55LT4C7J_K[9E4F_?3N6Y0Y&F/!8=C+\]5)?VJG;:3I$[%<VWM\O=
MMCY=0.*E.E;=SUYT/CMM5U]?SW53O!QAWC^87VROVOT'1?Y4;9NZK??=/<@M
M<*#JG.-%O`"EIX==!3/@ML^:<O\X?V:KW(WFBZ>'WJ!_J_*]'?U_UA[J][RI
M=K]7YQ+<AG7B*_!2U]\X^G7'#\')"^7LK%^!/YO9KMP7;\?NK_K]M[)Z/72P
MW$N8$9_8:O<S*=LM.`HR]^Z2*VWK(PP`_LY.%2\-<*3XT?_[7NVZP^/<C>_=
M:,F6`?"SE[+MLHIKSF?;M[:K3_\AQ806JKA"!<X0*LR]7240*N%891DZ'K,/
M98'SZFU*BJYX>FCJ]QG4'@R\O12\DMD*A*_^X&0&QSXS#)SB(L]<Y7$.YX,5
M+:SR]Z<PBAX6WV%EMH)9JTP04V1S1?@Z<-WD>N!#E]%3TBMQ/27#`^@_U\A'
M!Q8PZ6'FL"CCF>LKXCI!#O,)7KM9XP'0'F;LTI%M5")T*)*HB"22JH0LDJF(
M)_63JT@0A\-8B"O>+:YP&*Z(D0EA)*WI&IFH+PH_C)UP.73<K_%F#`2^'T4?
M(\,B&`-+S_%"N0;&0.0[?N31+C($_-$XI4'D)H+X`R+3JX;#DC^QM#9K9(+>
MG[O`82R6:F!#"->-PSB@\TL(P<+0@[L,15**.,Q;ROUDB,#?H:1EETP$<0DV
MNNDN<5AV25KB-3+"I2B*6"RM\880GN?'@7RE)`3QP0`_DF:8$L0+EAX+I'TL
M0\1DDXD@-L&./MTF#E.;/*E2UHB@2TLW8/*EM!D#4;CT:9$DXV;=^>D84,_/
MQLUP4W+<4-H-<HEPPX\A$&?@5C+=&0Y39WRI_->(H#/,B6)7N?>,"9_!92A)
M)&-`*Y&."9U$-@98$"^9(ZU@CH2^N(A!/*".[MOFNQ>'J4&A?/6OD='WC!NU
ME4BN!`\`DGVIH2V[MGV^\Y@(XDM\BR\<IK[$'_783WJ-B,D6*Y$@(8HO"D)I
M^T['[7[H2O>_S-I!;B*(.PP"]/2RZ6GJ3RCONVL!F1RR(XE`A$?+((REG2,E
MA,L"V%WH[I79N\F-"'6*Q\;)%QC#D$F2D%)*`C(ZA3H&)+&KI'8DLR.Y$:%>
M\7PYW2M,H\0K)34RA`Q&;.Q((A!Q0]1%1T)HLZ.]F]R(4*=XSISN%*92XI1\
M6UHS4W3%C=N.)`)!I^Z8&_O^4DI8J<1H,Z2]J]R(4+=@^6]PB]/R;B7G2(:0
ML:ZL2")4A%N^Z[A1J+B%,H+11TG[:'(C0MWBL7-Z;6%('=>6$B?Y#R7@*$[!
M#Z-`2LL;`JAY,"'M&H&4`*I`)MH-RY4;$6H0#Y_3#<*H.C9(295L'&=]WX/`
M2^])&TKH8B4E-!HI)30:F2",-N%0]0BUB6?0Z39A8AW;I&9+9HJU8H^R(LF@
MHHN7IL9L:/P\8!H1Z@_/HM/]P>0Z]D<-!J9T*^RQ(@E#!*]6^(HL7:PI:=?$
M3-&NKY!^%+D1H2;Q2#K=)`RP8Y,T0=.4<H5+5B1AB*!+\"NN)FB."7W0M':3
MBV[T9A*GW)LB>4_+-SEII=<"TG>.3MF1Q(ZD=B2S([D1H5[=%,I=32A7@J:`
MC%[90_F@HMN:3(W9T/CYUF1$J#]P!4V_ZEQ.R[4D?6U?"\CH#^H8D$2HB#`$
MV3(8_?#35V0Z=*2Q,!L:#2Z91D%=NBF$N[H0+L=*`1DLV-B11"#")6\)/S_*
MWX('%:U+UJ\"^7"^SDCJ$DSFAEKB-*TE)4ZZR.#T(`UZKO0-?B,(O_\Q7*K$
MQ'IZ:CH]&QIU,\?;FQ&AYMR4M?GC.<D<)4H*!LT)_,#U%7-0Y1-SQE%==WHJ
M.M">G@V-!G.NW>L0:LY-.=M5<[8:(`5DO+Y,`;=?WV10T5P\J:DQ&QIUDQ?%
M8^J?^G-3P';5@*T$2,$8[;'G:Z&")0A/F:1-+AUZT=B7#8T&ATQ#H`[Q*#LY
M/<+[`_+EI:9'`1DMLF=LH8)/,Z4-*C4U9O;^^7L0?![Z(:(_^)X#/L`_E<UK
MN2F/QW:VK=_X.PP>[)O#T>']BF>7/[66CJ_9"IZVJ\<3MH)'ZG!\,9P`KT-<
MBM?RCZ)YK<[M[%CNH2OG/H3]H,$7*O!#5U_ZUPE>Z@[>@^C_>X`77TIX!N_<
M`[ROZ^[Z@7<PO$KS]#\```#__P,`4$L#!!0`!@`(````(0#/BGO'B`(``.4%
M```9````>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;(R46V^;,!B&[R?M/UB^
M+P9R@**0JDG5K=(J3=,.UXXQ8!5C9#N'_OM]Q@DCS9;U)L'VZX?W.[&X.\@&
M[;@V0K4YCH(0(]XR58BVRO&/[X\W*4;&TK:@C6IYCE^YP7?+CQ\6>Z5?3,VY
M14!H38YK:[N,$,-J+JD)5,=;."F5EM3"4E?$=)K3HK\D&Q*'X9Q(*EKL"9E^
M#T.5I6#\0;&MY*WU$,T;:L&_J45G3C3)WH.35+]LNQNF9`>(C6B$?>VA&$F6
M/56MTG330-R':$K9B=TO+O!2,*V,*FT`..*-7L9\2VX)D):+0D`$+NU(\S+'
M]U&VGF*R7/3Y^2GXWHR>D:G5_I,6Q1?1<D@VE,D58*/4BY,^%6X++I.+VX]]
M`;YJ5/"2;AO[3>T_<U'5%JH]@X!<7%GQ^L`-@X0")HAGCL14`P;@%TGA.@,2
M0@_]_UX4ML[Q9![,DG`2@1QMN+&/PB$Q8EMCE?SE1=$1Y2'Q$3(!]\?S.(C3
M632;_Y]"O*,^P`=JZ7*AU1Y!T\`[34=="T89D%UD$\B/]S'$^J]0(48'N7>4
M'"<8P74#Y=DMDW2^(#O(*3MJ5I>:Z%RQ/BE<*<#>X!$B'WO\>]9/5IS867%5
M<-Y6?@/8@[?XS7LO%4DX2,Z<0(;&3D[9NN[(78*LC@S,)M.![TUZS72L.5>L
MKRG./`)D[/&Z-R?.,21@2$Z2)N=O7GE-VI<UG8;AG]STWF'P',.?S]/QN??E
MQ\IWG>2ZXFO>-`8QM74C$P-WV!VF^3YV!7RSOX(I[V>"#`<P91VM^#/5E6@-
M:G@)R#!(8*RTGU._L*KK>WVC+,Q7_UC#YY1#@X0!B$NE[&GAVF_X0"]_`P``
M__\#`%!+`P04``8`"````"$`J1\VXI<"``!3!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6R,55UOFS`4?9^T_V#YO1@("4D44K6+LE5:I6G:Q[-C
M#%C%&-G.1__]KG%"2--.><'8G'ON.??:9G%_D#7:<6V$:C(<!2%&O&$J%TV9
MX=^_UG=3C(RE34YKU?`,OW*#[Y>?/RWV2K^8BG.+@*$Q&:ZL;>>$&%9Q24V@
M6M[`ET)I22U,=4E,JSG-NR!9DS@,)T12T6#/,->W<*BB$(RO%-M*WEA/HGE-
M+>@WE6C-B4VR6^@DU2_;]HXIV0+%1M3"OG:D&$DV?RH;I>FF!M^'**'LQ-U-
MKNBE8%H95=@`Z(@7>NUY1F8$F):+7(`#5W:D>9'AAVC^.,%DN>CJ\T?PO1F\
M(U.I_5<M\N^BX5!L:)-KP$:I%P=]RMT2!).KZ'77@!\:Y;R@V]K^5/MO7)25
MA6Z/P9#S-<]?5]PP*"C0!/'8,3%5@P!X(BG<SH""T$,W[D5NJPR/)L$X#4<1
MP-&&&[L6CA(CMC56R;\>%!VI/$E\)('Q2!+'01*/T^D-+,0KZ@RNJ*7+A59[
M!)L&<IJ6NBT8S8'YY,SKZ+U^9!4\.I('QY+A%"-P8:`]NV4ZFBW(#FK*CIA'
MCX%GCXEZ!`$UO220,93T?I%/F1W8979%=U(>_<(P3?Q^FM%E&N<\^;"GIW0N
M"+HW,)$D9WZOP&.2`6;\O@*`W&[4@3,,[OKRI4G8\_K,'C/M&I#,TG0ZZ@$7
M%0:;P\2W67=!;P6<.^@%>,S0>CHHSX6&R:6&_W?9@=_F/GOSN3UFUID/@^C<
M%9_6'VZ_]R77)?_"Z]H@IK;NX$80UJ_V=\I#W%T+_0<XTRTM^3/5I6@,JGD!
MH6&0@FWM;P4_L:KM3M9&63C-W6L%ES>'_1D&`"Z4LJ>)NW?ZW\'R'P```/__
M`P!02P,$%``&``@````A`&EH:GCP!```V14``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&ULG)A;CZLV%(7?*_4_(-X',-<D2G(TR73:([5259W3/A/B
M)&@`1\!,9OY]M]GF8H=XF.0A%UC>^;Q\6<C+;^]Y9KS1LDI9L3*)Y9@&+1*V
M3XOCROSYX_EA9AI5'1?[.&,%79D?M#*_K7_]97EAY4MUHK0VH$)1K<Q379\7
MMETE)YK'E<7.M(`[!U;F<0T_RZ-=G4L:[YM&>6:[CA/:>9P6)E98E%-JL,,A
M3>@32UYS6M18I*197`-_=4K/55LM3Z:4R^/RY?7\D+#\#"5V:9;6'TU1T\B3
MQ?=CP<IXET&_WXD?)VWMYL=5^3Q-2E:Q0VU!.1M!K_L\M^<V5%HO]RGT@-MN
ME/2P,A_)8NO.3'N];`SZ-Z67:O#=J$[L\GN9[O],"PINPSCQ$=@Q]L*EW_?\
M$C2VKUH_-R/P=VGLZ2%^S>I_V.4/FAY/-0QW`#WB'5OL/YYHE8"C4,9R`UXI
M81D`P+N1IWQJ@"/Q>_-Y2??U:65ZH15$CD=`;NQH53^GO*1I)*]5S?+_4$1$
M*2SBBB+P*8H0]\M%/%$$/MLB\\\(;.Q-8\Y37,?K9<DN!LPXX*W.,9^_9`$%
M6U>P#YU/MVP"?WB11UYE94:F`0Y4,+9OZ\CWE_8;C$<B-)MKC>?(DBU*X+TK
MXW8*&X`[:O!O2#T^ABT<%W,X/J:<=J->V.*%X?]&?C#^S^#1\)^Y7Q[,13T!
M;P2Z0;\B/^SJ(Q1J_(&F)V@46YU"<@>*#!GU;%R\,L&!SO/(CQ0VU(0XL$[D
MS/U(A=-*)#I8+=/IN%BEFRETJ`&`K@<J'"J0_\$E84B<?G9*<.%7X+A8A9LK
M<*C1P:$"X4C@14%(;L#!^IKN'!<K<(&RWC:HT<&A0CA'B!=ZX0TXGI.#C40_
MZ;A8A2.*<ZC13KJA9.9&,S=T^RK2N,(&.9V.BU6Z?B/"Y8H:G76H0'X]'($-
M9#I=HU9V$Z_O-N()D8Y/*Y',(WQ?'HSMM$VO::7:Z"F#+$3S9FOQ+7@F&KZ\
MWQX4W[>BP7C'9&J^JW^=&K-`V@^#?LH+=U&$U/QY0>[5EN#]*9!\4_\Z)$:!
M#*E`;(@N+S!1A`3[,;."N?22W)>MA9[=0<U;J1-"C4&"HG'K!#5*6O=)/T5D
M2"5H)L[:D<0)U#SDSXW0$RTD2J9,;)E:2:")U"-1%*@Y23[/(B%IK77[B2]#
M*DDT$7(LDM2\))]GDI"TD*3?4V1()9$F0HY$4ZCF)D'1E,$54W9Z`[D/2FY-
M[,-(@(57"8&BUL7K/>SF?8G05;)K&F'32MD*PGX=XRXK1+I5)B13!D*FOBO1
M7-Y*I>YGGZ!&D98:)2/6RY`\10;9H'^D<C%S8-/O'H/]2-T"A$@+-SF[W+NR
MJVFEFMCO,\)$S*[6H<$2Q_4DBHS<EQV$C@X=G#@Y>2N54$U7%T5:)U'2078/
M"3+C73'%SQRN&-4L%2(MXS"F(FOX\`7?H^'SETQ]5TRY(S$5JN$J1%IJK-,Y
MVZ]!&?*NF')'8BJ\6D@H&B$0$U2Y?V/L[XHH."6['GLU1X5(Z^(PE!RK#P@T
M$4_2\+`HI^61;FF654;"7ODIF0M/[-W5[@3OT>6G+,KU#5ELFNMV=P,.UL[Q
MD?X5E\>TJ(R,'J"D8T4P&TL\FL,?-3LW1U0[5L.16O/U!$>H%$YQ'`O$!\;J
M]@<__.L.9=?_`P``__\#`%!+`P04``8`"````"$`AX5V200#``#6"```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6R45EMOFS`4?I^T_V#Y/8!)B$,4
M4K5KNTW:I&G:Y=D!$ZP"1K;3M/]^QSCADK13D@<"Y..[G&-SLKIYJ4KTS)46
MLDXP\0*,>)W*3-3;!/_^]3A98*0-JS-6RIHG^)5K?+/^^&&UE^I)%YP;!`RU
M3G!A3+/T?9T6O&+:DPVOX9=<JHH9N%1;7S>*LZQ]J"K],`CF?L5$C1W#4EW"
M(?-<I/Q>IKN*U\:1*%XR`_YU(1I]9*O22^@JIIYVS22550,4&U$*\]J28E2E
MRZ_;6BJV*2'W"YFQ],C=7IS15R)54LO<>$#G.Z/GF6,_]H%IO<H$)+!E1XKG
M";XERSM"L+]>M07Z(_A>#\Z1+N3^LQ+9-U%SJ#;TR79@(^63A7[-["UXV#][
M^K'MP`^%,IZS76E^ROT7+K:%@79'D,@&6V:O]URG4%&@\<+(,J6R!`-P1)6P
M2P,JPE[:[[W(3)'@Z=R+:#`E`$<;KLVCL)08I3MM9/77@=I$'4EX(('O`PF)
MO%D8T<4%++YSU`:\9X:M5TKN$:P:T-0-LVN0+('YF,SYZ+*^%Q4R6I);RY)@
MBA&DT-"?YS6EP<I_AIJF!\R=P\"QPY`.X8.;SA+8&%IZN\A'90NVRK;HULJ=
MNS&4"=^6F5XC8\$)!N[._(S0CM<I.\RBC=^''T6;7:-IP6--2F8GF@X#Q\Y7
MU"%&RK#.+B^J!8^59Z1OEDOK,''DNNW%P>BS>)A,WS8RO\:(!9\:Z7F=$8<9
MEH#2WNRH"+!`+R^"!8^U*>V7DM-VF$,1`B@"&56AAX]LV+$PV'/_7^`6?&*#
M]#UV-AQF6((>,5*.KU&VX+'R^2IPF$,!0B^,'R;OA";PUKT\=8L^%3_M_`$T
MS$UI#QHEA_%PC;Q[60WW^WGS6\H$]]V/:#S\S$\V@!LO[NU;<;7EGWA9:I3*
MG1T=!#92=[<;:[=A.YBZ'V"J-&S+OS.U%;5&)<_AT<"CL!N5FTONPLBF?;=O
MI(%YTIX6\/^!PQLR\`"<2VF.%W;R=?](UO\```#__P,`4$L#!!0`!@`(````
M(0!JZQT.S`,``%0.```9````>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)27
M78^B,!2&[S?9_T"X7S[%HE$GHXB2[":;S7Y<(U0E`Y30.L[\^SVEP$!U1&]$
M#D]?>MZ>?C![>LM2Y167-"'Y7#4U0U5P'I$XR0]S]<]O_YNK*I2%>1RF),=S
M]1U3]6GQ]<OL3,H7>L28*:"0T[EZ9*R8ZCJ-CC@+J48*G,.3/2FSD,%M>=!I
M4>(PKAIEJ6X9QEC/PB17A<*TO$>#[/=)A#T2G3*<,R%2XC1DT']Z3`K:J&71
M/7)96+Z<BF\1R0J0V"5IPMXK457)HFEPR$D9[E+(^\T<A5&C7=U<R&=)5!)*
M]DP#.5UT]#+GB3[106DQBQ/(@-NNE'@_5Y_-:8!4?3&K_/F;X#/M_%?HD9PW
M91)_3W(,9L,P\0'8$?+"T2#F(6BL7[3VJP'X62HQWH>GE/TBYRU.#D<&H^U`
M0CRO:?SN81J!H2"C60Y7BD@*'8!?)4MX98`AX5MU/2<Q.\Y5>ZPYR+!-P)4=
MILQ/N*2J1"?*2/9/0&8M)42L6L2&WM?/+<UR'=,9/Z`RJE7@6JM88VUD.<A]
MI"_0ZRHAN'ZH/)K0N!:!:R-B/]X55*O`5&M4'O=V4HO`M1&YORNZ&.VJ>+R0
MA8M92<X*3$@83UJ$?'J;4U!NJD:,<5M'GY41U`\7>>8J<Q72A`JA4/JO"X1&
M,_T5ZC6JF>4E8_:)54/PXN2RGAQ8RP%?#FSDP%8.!)V`#B:T3D#M=IVX/F^:
MA#G,$VZZNFP"'PY84G:7!#+ZB"<0Z&!KXQA),NL[&/\.9G/)(.3V^[.]@PEN
M,SV'856XWV$.]QR6`RLYX(E`USZ$G'Y*ZVO,N,_XUQC49S;7F$F?V5YA7&G(
M@VO,Q[SHV0?+X?WV<7BNPN"TI81<J926@G&K^3H:C9!E]Q-8=0'7<)$M9>@)
M`'[;M\A^#Q+^(+$9)+:#1'"+Z+D,VT779;X@VK`9WUX.>"/9;<G,I6!&E=O2
MLU7S[%,?O4%B/4CX@\1FD-@.$L$MHN<T[*F/.\T;R4[+.XU@8,0_J\I50_"=
M2FKM-<\^;;T>)/Q!8C-(;`>)X!;1<QHVYL>=YHUDIZ79O13,+:<'"4\08A4R
M)\@>2\O4N@LXAB&MH'[W<=7^8_FL3A&;/N`XK@1LNX`%RYP,P+&=6R&Z*`'"
M9W$J%P>K#)<'O,)I2I6(G/B)F\_Y-MI^##S;_/0@Q9?PD5`=J>6X-5U>XU?6
M%/9!T-';!G"H+\(#_A&6AR2G2HKWT`5#0S`O2_%9(&X8*:KCWXXP.,Y7?X_P
M]8;AX&5H`.\)8<T-?T'[/;CX#P``__\#`%!+`P04``8`"````"$`3+<1J[D#
M``";#0``&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)2776_B.!2&[U>:
M_Q#Y?D@<"BV(,&I2=7>D'6FU\['7)C%@-8DSMBGMOY_C.`3;@=EP`R1Y\Y['
MQS[V8?7IK2J#5RHDXW6"\"1"`:US7K!ZEZ#OWYX_/J!`*E(7I.0U3=`[E>C3
M^L,?JR,7+W)/J0K`H98)VBO5+,-0YGM:$3GA#:WAR9:+BBBX%+M0-H*2HGVI
M*L,XBN9A15B-C,-2C/'@VRW+Z1//#Q6ME3$1M"0*^.6>-?+D5N5C["HB7@[-
MQYQ7#5AL6,G4>VN*@BI??M[57)!-">-^PW<D/WFW%P/[BN6"2[Y5$[`+#>AP
MS(MP$8+3>E4P&(%.>R#H-D&/>)GA.0K7JS9!/Q@]2NMW(/?\^*=@Q=^LII!M
MF"=%-E]I27-%"Y@Y%.@9V7#^HE_]#+<B"");@0XB?Y["/,8Z2MB'L7^?0CZW
MT_:/"`JZ)8=2_<N/?U&VVRN(-(,TZ&PLB_<G*G.8!H@UB6?:-><E6,!G4#&]
MGB"-Y,W0L4+M$S2=3V;WT12#/-A0J9Z9MD1!?I"*5_\9$>ZLC$G<F<#WT3R/
M;S>9=B;PW9G@>"Q):$;5)NR)*+)>"7X,8+D"MVR(7OQX"<:7LP+IT-I'+4[0
M/<Q;@B1,S>LZ6H6OD/R\4Z1&`9^]`KN*[*30\P<,/0BD9CR(%FL0/5V:+#4W
M[+BQ%W>HF/8*!P2R,!Y$BV%%6..]ZUT-F5'<68J9J\A^IW#(P&0\F18G"$;=
MS\3<C9L:A4UV[RJRH>+,[I!!)8PGTV*7[,&-FQJ%3;9P%=E0<85L?@N9%KMD
MV%_@1F*C87^%#R57V*"0QF=-BSTV;XFG1C)K"_,.+[#W/#//;?8K8/K`'+TI
M:+$'=JXL4P-&8@?&7IED0\D5ML4M;%KLL9UM#9N1.&Q>H61#R=G$*0,,1YJ=
M.'W63.'>_^RJ^BV/TJO$M'5.D(/I54UV07.-4V_"HR<8FRW;WDJP5X]II_D]
MG_&Q-=?X]&8]GL]L[39?[)<M-AH[=NS7[07--3Z]98_G,QN\P^>59HJ'AT#L
M55%V07.-#\9I\XU<A_HM=QW&7IFFV&CL/)X9VH+*.LF\W8;BQ0S/([PX^[@%
M<]/!H=LV']"+GG8:&S#VZ_F"YFSC\MUT?$#O.^`;%/+P=(@'A3S4^'RF]36=
M7$7%CF:T+&60\X-N93'DOK_;]^9=T]P_@"ZW(3OZA8@=JV50TBV\&DWN(<O"
M],GF0O&F[1,W7$%_V_[<PY\@"GU7-`'QEG-UNM!=7?^W:OT+``#__P,`4$L#
M!!0`!@`(````(0!FE]=,2@,``)X)```9````>&PO=V]R:W-H965T<R]S:&5E
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M]N%"OJ(99X+MI`-RK@[TTO/4G;J@M)SG%!RHM%N<[!;V@S_;Q+:[G+?Y^4W)
M40R^6Z)@QT^<YE]I32#94"95@"UC3PK]DJLEV.Q>['YL"_"=6SG9X4,I?[#C
M9T+WA81JAV!(^9KEKRD1&2049!P4*J6,E1``?%H559T!"<$O[=\CS66QL(/(
M"6,O\`&WMD3(1ZHD;2L[",FJ/QKR3U):!)U$8,=)Q$<.2D(_C&ZKN#JBUF"*
M)5[..3M:T#3P3M%@U8+^#)25LP#RH^/HO?[+*GA4(@]*96''M@7;!93G>1D%
M:.X^0TZS$[-Z@YF:R+I#5`:5;MHMG'5]<\NF(U3YP%+O"[(U]/5VI;KP%:S"
M[]Z[T@N@W?L9N5E?$K%GAI9>(B.1S24Q$#'L!/]C1\%0QD'T?A"9P:TT,QDP
MH4FL;Q+I36)SC3#\02#O+Y>"%S8DKZ].%`1F]"O-)&TOHCCRO%%UUAJ`SUYD
ME(#TEL3FFH3A#@[6T%UWR*XWI=HT=CD9N=1,U+KT@VD4H\0?V5B;3#P-PA"-
M#EYJ,!,?H3"8CIB-P00)BJ<3=(['\!N9?J_[5/#8Y\C#2C-7BK6^2:2:T+E"
M?NB-#V.GH&ZO)#KWD^$,KKAA):\[4_#8V?@<:N;4IZ$7)(E9XK4!0/&242.G
M0R`*XAB=0V\O41B,*@S]B@A%47!^A?:FYYX>"Q7A>[(F92FLC!W43`N@N_K5
M?MP^('5;CM97_@SN\,OU%,9SN^[V&V`\-GA/OF&^I[6P2K*#5WE.#%W&]8#5
M#Y(U[9#:,@F#L?U:P.\@`M/!<P#>,2:[!S4#^E]6R[\```#__P,`4$L#!!0`
M!@`(````(0#YX:EA]@(``"8(```9````>&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;)256X^;,!"%WROU/UA^7ZX!DBADM0G:=J56JJI>GATP8"U@9#N;W7_?
M,4Y(G&S3]"$7S.'CS!DS+.Y?VP:]4"$9[U+L.QY&M,MYP;HJQ3]_/-Y-,9**
M=`5I>$=3_$8EOE]^_+#8<?$L:TH5`D(G4UPKU<]=5^8U;8ET>$\[.%-RT1(%
MAZ)R92\H*8:+VL8-/"]V6\(Z;`AS<0N#ER7+:<;S;4L[92""-D2!?UFS7AYH
M;7X+KB7B>=O?Y;SM`;%A#5-O`Q2C-I\_51T79--`W:_^A.0']G!P@6]9+KCD
MI7(`YQJCES7/W)D+I.6B8%"!CAT)6J;XP9]G,7:7BR&?7XSNY,E_)&N^^R18
M\85U%,*&-ND&;#A_UM*G0B_!Q>[%U8]#`[X)5-"2;!OUG>\^4U;5"KH=04&Z
MKGGQEE&90Z"`<8)(DW+>@`'X1BW3.P,"(:_#[XX5JDYQ&#M1XH4^R-&&2O7(
M-!*C?"L5;W\;D;]'&4BPAX3@?G\^<()IY$?Q?U`F>PK\'BDW6G%-64-*&5%D
MN1!\AV#G@7'9$[V/_3F`#_&88L;`_I87!*4A#YJ2X@0CB$)"CU^6<1`NW!=H
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M),KY5L_<`'(<5\?7P4.@G]6S]94_A_D`Z^YX`L9T3RKZE8B*=1(UM`2DYR20
MKC"#WAPHW@]S;L,5#.CA;PWO8PH3QG-`7'*N#@?Z!N,;?OD'``#__P,`4$L#
M!!0`!@`(````(0!!"9H4S@(``"$(```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;)15VVZ;0!!]K]1_6.U[N-HF1L:1TRAMI$:JJEZ>U[#`*L"BW76<
M_'UG6$PA3AOR8LQP]IPY,\.PN7JJ*_+(E1:R2:CO>)3P)I69:(J$_OQQ>W%)
MB3:LR5@E&Y[09Z[IU?;CA\U1J@==<FX(,#0ZH:4Q;>RZ.BUYS;0C6][`DURJ
MFAFX586K6\59UAVJ*S?PO)5;,]%0RQ"K.1PRST7*;V1ZJ'EC+(GB%3.0ORY%
MJT]L=3J'KF;JX=!>I+)N@6(O*F&>.U)*ZC2^*QJIV+X"WT_^@J4G[N[FC+X6
MJ9):YL8!.M<F>NYY[:Y=8-IN,@$.L.Q$\3RA.S^^]GWJ;C==@7X)?M2C_T27
M\OA9B>RK:#A4&_J$'=A+^8#0NPQ#<-@].WW;=>";(AG/V:$RW^7Q"Q=%::#=
M2W"$QN+L^8;K%"H*-$ZP1*945I``_)):X&A`1=A3=SV*S)0)#1=.<+GTERO`
MDSW7YE8@)R7I01M9_[:HSM+`$O0L<#VQK)QEY(7^VR2NS:@S>,,,VVZ4/!*8
M&I#4+<,9]&,@?MT16$'L#L$)C2B!7#6TX7$;KM8;]Q%*E_:8:XN!WP'C#P@7
M1`=E4)NOC&!4QMIB*M<V,)8)7I<)WR.#8&C.*/DP\@9>JVPQBQ%F.2`F!@$R
MWR""H0=C0V'TMW)6VH)F2,-0S9=&<"<]%+>/P'LR-''<Z(G+U7ND$#R5ZB/V
M_1N/!TS9?`L(GO+VD8F%Z!\C@FMZ]CN`X*E4'SFWL)[RXM:(U@X4]_]O&1Z;
M*O21J9GP]:GS`37?38>>BIU"YWYP.L?4:`@6V9N&NG,O1)`*0E-+BQ>6[$*V
M^ZKFJN"?>%5IDLH#+ML`-M`0'3X$NP"7Q,OX(MY!%O#`'9[`@FY9P>^9*D2C
M2<5SX/2<".PHN^+MC9$M)`I;6AK8S-W?$C[%'+:0A]YS*<WI!@6&C_OV#P``
M`/__`P!02P,$%``&``@````A`+`6HD,?!@``)1D``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3,N>&ULK)E=DZ)6$(;O4Y7_8'&_\JDHI6Z-\EU)52JU2:X9
M1*5&Q`)F9O??IYO#`<YIUQV3O5G7Q^X7^J4/-&=6G[\6Y\E;5M5Y>5DK^E13
M)MDE+??YY;A6_OKB?UHHD[I)+OOD7%ZRM?(MJY7/FU]_6;V7U4M]RK)F`@J7
M>JV<FN;JJ&J=GK(BJ:?E-;O`+X>R*I(&OE9'M;Y66;)ODXJS:FC:7"V2_*(P
M!:?ZB$9Y..1IYI;I:Y%=&B929>>D@?.O3_FUYFI%^A&Y(JE>7J^?TK*X@L1S
M?LZ;;ZVH,BE2)SI>RBIY/D/=7W4K2;EV^X7(%WE:E75Y:*8@I[(3I34OU:4*
M2IO5/H<*T/9)E1W6RI/NQ+JMJ)M5:]#?>?9>C_X_J4_E>U#E^]_R2P9NPW7"
M*_!<EB\8&NT10;)*LOWV"OQ13?;9(7D]-W^6[V&6'T\-7.X95(2%.?MO;E:G
MX"C(3(T9*J7E&4X`_IT4.;8&.))\;3_?\WUS6BNF-;5U;6G:H/*<U8V?HZ0R
M25_KIBS^84%Z)\5$C$X$/KG(?#JS-5.'8]Y+-+M$^.2)VE2WM/D/\JPN#SZ[
MO/G=X\!9M%7"9Q=OS*:+V<R:+[#,.Z6!;IMI]YGFA\X0UE>;!Y\?.L-E%P^?
M#YZA#CW#+B$V3W<-[YVCREJ@[2@W:9+-JBK?)[!,X2+7UP07O>Z@*N\E9D_?
M7=]K+N@J5'E"F;4"AD'?U+`BWC;02ROU#;HX[6*V-$87(W8\`EL695T9>#+P
M91#(()1!)(-X!%2PI?<&6OMG>(,RZ`VO:LO!8)8A&<$C>(HK`T\&O@P"&80R
MB&00CX!@!"S5GV$$RL"]1FB2N5CYMHN!,^D[2>JC71_2NT.(1XA/2$!(2$A$
M2#PF@DEP7_H9)J$,+$;HR=X`T[8EEUB0><^E/J1WB1"/$)^0@)"0D(B0>$P$
ME^#.*[AT^YG%;RL8W9K!B]@R8L)5&-DC=T@?Q--<0CQ"?$("0D)"(D+B,1%J
MA^?*`[5CM%@[(U`[+VM'B$N(1XA/2$!(2$A$2#PF0J'P''B@4(P6"V5$NL@+
M<0WL^B#NADN(1XA/2$!(2$A$2#PF0NTX9(\?J/<;'*/%VADQV+"%#\$=(2XA
M'B$^(0$A(2$1(?&8"(7"U/)`H1@M%MH18^AF0EQ&C/%]SM"78B-X?1!O!)\(
M!82$?=;X1B))1WT0EX['0H(=.#P)?K!):HJS9G/*TY=M"7<LN*W?:`@3)J9N
MCD(5T:=6&-#(*(K<#ADH];8Q--V27!H">"T^E0DH"H?$V\K1$,"58T%&M`F'
MK8^O#WP.RGXPA&\+PR-@H8GE[KI$B.(GY0YH2-27T@SJ=5&FU1H)+S2V)87X
M@Q#7#B@*!W3G<)%X.%V?STQ3>IS%@Q(<3W03)[8'W,1PJ;L8,F"9C]R4*MY!
M\V$B1/&*78J\#IFSUCK=7EISJ12?9@44A11%/]:.A2S1)AS:'K")S7A@.Z]V
MJS,D-9T\M@]1/-&ER.M0UV'FW%AH4O?Z-"N@**0H^K%V+&2)-N'4-K;IO]W"
MV.PGN,>0U&2FO&3[J,$]AJQA%7MZAQ:LR31SMI0F`[\+&75K0%'(A0;MB*-.
MV[)M6[J-QH*0Z![.??_?/38]"NXQ)/6>=&([W`#")3J4XW($<UJ_MF_<\+I$
MFQEJZ/.Y)HG[7&D0#R@*.;I[O(A'=<>#'1F3NCPN1G09A\Y[+G\IK]][S((W
M_7.6S:Z"S0R-)R^=()<BCR*?HH"BD**(HEA`HA<XA,I>&,84S'MT^X:-LX(=
M_80[-(^YD.[G.]CFQ*X;O9.X%'D4^10%%(44113A7NMP$LPAMG?*=KJ*K#IF
MN^Q\KB=I^8K[HF#I9M5CMFF[G3GPY@9W'IG/'7C1N<%M!UX";O"%`S/S#:Z#
M$!SXUB\@!3707]RE`],MY>'2@=&4<I@"'0]F+_H+3'$.#FKT%]BL?FI'2[EN
MW,2^$;\U'-@GHCI;TX&]$<J?+.?I9G%;RX%M`DA0^R/#)O4U.6:_)]4QO]23
M<W:`BZ6U(W3%MKG9EZ9;X\]E`]O3[7(_P9\C,GA;TK#[#V79\"]X@/X/')M_
M`0``__\#`%!+`P04``8`"````"$`IX,6CW,5``#R?@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6RLW=MRVSBV@.'[7;7?P>7[B:U38JN23+4E\7PF
MQ7WM=I3$U7&4LMW3TV\_"R(A$/C9CC6[+V;B_K"P"'&1%`E1U/M__OOAV]F_
M=H]/]_OO'\XG;R[/SW;?[_:?[K]_^7"^;;Q_7)V?/3W??O]T^VW_???A_,_=
MT_D_/_[O_[S_8__XV]/7W>[Y3#)\?_IP_O7Y^<?RXN+I[NONX?;IS?['[KNT
M?-X_/MP^RW\^?KEX^O&XN_UTZ/3P[6)Z>?GVXN'V_OMYEV'Y^)H<^\^?[^]V
MZ_W=[P^[[\]=DL?=M]MG&?_3U_L?3SK;P]UKTCW</O[V^X]_W.T??DB*7^^_
MW3__>4AZ?O9PMPR_?-\_WO[Z35[WOR?SVSN=^_`?2/]P?_>X?]I_?GXCZ2ZZ
M@?(U7U]<7TBFC^\_W<LK4*O][''W^</Y+Y-EN[@^O_CX_K""VOO='T^#O\^>
MON[_\!_O/R7WWW>RMJ5.J@*_[O>_J=#PDR+I?('>WJ$"Q>/9I]WGV]^_/5?[
M/X+=_9>OSU+NA;PB]<*6G_Y<[Y[N9(U*FC?3A<ITM_\F`Y#_/WNX5YN&K)';
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MW(7"A=*%RH7:A<:%K0OM`"ZDQ,<Z2VG_CCJK-*K.ND(W&DSAITY1=83NLG9A
MXX+G@N]"X$+H0N1"[$+B0NI"YD+N0N%"Z4+E0NU"X\+6A78`5E'EP/YW%%6E
MD1,%:^=]9U?QIH^1D1SW\(4=LCJ&'"L-V4`\B`\)("$D@L20!))",D@.*2`E
MI(+4D`:RA;1#L8HO;]%_1_%5&CGXRW'C6-C9U95=VILN:/92]8\AQ^I#-A`/
MXD,"2`B)(#$D@:20#))#"D@)J2`UI(%L(>U0K.K+>9E5_?$+!/WVK*(/1=;%
MN>ED)EO7H.S.._;J&*2[K2$;B`?Q(0$DA$20&))`4D@&R2$%I(14D!K20+:0
M=BA63>5\^82:JFB[IIU(376Y5I`U9`/Q(#XD@(20"!)#$D@*R2`YI("4D`I2
M0QK(%M(.Q2J@G/^>4$`5;1>P$V>GO+:/Q:MCD*[R&K*!>!`?$D!"2`2)(0DD
MA620'%)`2D@%J2$-9`MIAV+55,VL#2^07C[0JFB[IIT,=TK(&K*!>!`?$D!"
M2`2)(0DDA620'%)`2D@%J2$-9`MIAV(54*[J3RB@BK8+V(F]4UY?.COE,>BX
M4T(V$`_B0P)("(D@,22!I)`,DD,*2`FI(#6D@6PA[5"LFJHIM1.*>@BWJ]K3
M<+\DK4D;DD?R20$I)$6DF)204E)&RDD%J215I)K4D+:DUB*[KFKZXO5'6W75
MXNRM/3F[*R::NHZ#ZJ]-1[T+;T@>R2<%I)`4D6)20DI)&2DG%:225)%J4D/:
MDEJ+[%*K28T32MW-@4@^79X;-24NU1\4<45:DS8DC^23`E)(BD@Q*2&EI(R4
MDPI22:I(-:DA;4FM179=U83%"77MYC>LNO93'M:UZ;4[K:@^U;"KOR9M2![)
M)P6DD!218E)"2DD9*2<5I))4D6I20]J26HOL4JO9B1-*W4UF6*7NYS<&EZSJ
MHR>WKJ`-HSR23PI((2DBQ:2$E)(R4DXJ2"6I(M6DAK0EM1;9=54S%"?4M9O0
ML.IZG.,83"]=SYR39O7AHEMJT(91'LDG!:20%)%B4D)*21DI)Q6DDE21:E)#
MVI):B^Q2J[F,$TK=37U8I1[.AAP^M5NI#W[=NH(VC/)(/BD@A:2(%),24DK*
M2#FI()6DBE23&M*6U%IDUU7-9YQ0UV[ZPZKK<49DN`O/W5WX&*5/R];J4WR[
M^AN21_))`2DD1:28E)!24D;*206I)%6DFM20MJ36(KO4:N;CA%)W$R56J8=S
M)_TN#%JK.RO<NH(\1OFD@!22(E),2D@I*2/EI()4DBI236I(6U)KD5U7-?MQ
M0EV[R1*KKL?YD^$N['YL.SE&F5T8M&&41_))`2DD1:28E)!24D;*206I)%6D
MFM20MJ36(JO4ZNZA$TI]"+>GLWH:7@N3UJ0-R2/YI(`4DB)23$I(*2DCY:2"
M5)(J4DUJ2%M2:Y%=U].FL]2M8'*$'>["/3G36>[GM";JN`N3-B2/Y),"4DB*
M2#$I(:6DC)23"E))JD@UJ2%M2:U%=JE/F\Y2M]JYI>9T5A\UV*O7I`W)(_FD
M@!22(E),2D@I*2/EI()4DBI236I(6U)KD5U7-<WT^G=A=:>T6]?C1-7P7=BY
MOVK5=[1*?>RH]^H-HSR23PI((2DBQ:2$E)(R4DXJ2"6I(M6DAK0EM1;9I5;3
M3">4NIN5LH[6'<E10E=L-06M21N21_))`2DD1:28E)!24D;*206I)%6DFM20
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M)I,^)B6:S%!34J;)Y,I)A29[J,YU1VFB]%`K32.%5)-%__]"=E-.5B$[4D>%
MP6K%"=8Q2H]U/>U)]N]CQ\FU4X^-CGIWV-<GEV_?7<O_['E03P=UW\E3WUWQ
M28&F%Q<8]E&+X>N9N!^>1#J766),2C2]N,3T54O,="ZSQ)Q4:'IQB:6.>FFE
M5CKHL$#[.*\FJ+`MR5<'^V-"L_]Q.":<<(#HIKRL[:HC-8KCYC&_Q+O^,<IL
M5SW)/\>.(]M5%S6[?'&[0G9_"@HTO;C`L(]:V)5QCOV1SG5U/(>-28FF%Y>8
MOFJ)F<YEEIB3"DTO+K'LHUY<J95.=5B@M5U)OY'M:F'>;/2&-?)F(\<?_6YS
M2&-/Y/0T>&M9D=:D#<DC^:2`%)(B4DQ*2"DI(^6D@E22*E)-:DA;4FN17>_3
M)NAFG*#KR9J@FU\ZI^`K$W4\2)`V)(_DDP)22(I(,2DAI:2,E),*4DFJ2#6I
M(6U)K45VJ>6<U'K+^,DNK,*=7;BCP13-2GTC2J(&M"9M2![))P6DD!218E)"
M2DD9*2<5I))4D6I20]J26HOLNJI9LN&IP$_JVDVJ#=_GU;[;%=&\78_LPL<H
MLPN#-B:7CO)(/BD@A:2(%),24DK*2#FI()6DBE23&M*6U%IDE_JT";H9)^AZ
MLMZ%.4''J`W)(_FD@!22(E),2D@I*2/EI()4DBI236I(6U)KD5U7.6VW=N'_
MZA)_IK(X1^R.YN:*9=5'#6C=T\(ZSY^8*1=[K'+V;(WU)X<;%>X,JB/[<G7B
M7'6N9L<H?2!9]R2/GQD<IR9F.LX>ISMM\I-Q<GYDUI%]^3-Q+A=6)LJ,L^OX
M5LZECY<_\\$,F3U.=0U^PN&[NV2W#M\=.>O3F7-:S8Y19IP=.>O3S''8XY2U
M?LHX5;A3]XZ<]>E,)*QFQR@SSHZ<]6FN0ZUQSMTKF)?K?@BWQ]G3\!A)6I,V
M)(_DDP)22(I(,2DAI:2,E),*4DFJ2#6I(6U)K45V74^[4IGS2J4G]?8ZV"W=
M*Q43==S^2!N21_))`2DD1:28E)!24D;*206I)%6DFM20MJ36(KO4IUVIS'FE
MTI.U"W=1`UHS:D/R2#XI((6DB!23$E)*RD@YJ2"5I(I4DQK2EM1:9-=572Z\
M_JUNWEU=#-_J>I*[%?3.N=)DIO/7FJ3B9D>?FO.9PR<B&Q.E<WF:3"Z?%&BR
MTSOG+Z&)TNDC329]3$HTV>F=TX[41.GTF2:3/B<5FNSTSL=WI8G2Z2M-)GU-
M:C0-TT\GSD%V:Z)T^E;3(;V]V9QVU3/G54]/UF;#JQX3I1[?-?*9I@G0H_8T
MF97BDP)-PY4RGYH3U\,&&9HHG3[29-+'I$23V2M24J;)Y,I)A29[J,[)9&FB
M]%`K329]36HT_=7GQEL3H#.WF@Z9[2W#O6[ZR;D>+Y#D,DB=IEI;1D_FA:P9
MM2%YFDQ'GQ1H,L4*29$FDRLF)9I,KI24:3*Y<E*AR2Z\N1@X;*.EB=+EJ329
M]#6IT62&NB6UF@ZY[%*[EYW_U27RG%>C/5E;0'_I:5[16D>9CY8W)$^3Z>B3
M`DTF5TB*-)E<,2G19'*EI$R3R963"DW6^?'4N3XK3939`K"^:AUEEMAH,D/=
MDEI-AX[V%G#:!?V<%_0]R06H'OJ*M"9M>I*W*-W18Y1/"D@A<T6,BDD)*66N
MC%$YJ2"5S%4QJB8UI"USM5:475<U"W'"66$W:6&=%1ZG-@;G>\Z1:S4_!ND:
MK@V9?OR8NH^2V3MU6O`7MS^85#J[3PH,O;#`L(]2UT?'TU?>_F!RZ27&I,30
M,)=SKIJ^:HF9R:67F),*0R\LL1Q;XGQJIG0.[S;5>"[G9+(V47I<C:$7!K$=
M&P16=&MR27I[RU7S4B=LN=TTEK7E]I-=YC"YFH/6I`W)(_FD@!22(E),2D@I
M*2/EI()4DBI236I(6U)KD577Q6E3B(=P>PJQ)WNJ:>ILN"L3I3?<-6E#\D@^
M*2"%I(@4DQ)22LI(.:D@E:2*5),:TI;46F27^K19Q05G%7L:S"NM2&O2AN21
M?%)`"DD1*28EI)24D7)202I)%:DF-:0MJ;7(KJM<QIQP:%ZH<&<7[LE<L*QT
ME*%U3X/J;T@>._JD@!U#4L2.,2G1':VKN9DS!9::*'T`RI@K)Q6FHWE_G4_=
M2203I=-7S%63&MW1O"UN2:W5T:[^:1.-"TXT:C*E7I'6/5G5[W(-R&-'GQ0P
M5TB*V#$F);JC77WWK,]$Z?)DS)63"M-Q6'UWCLA$Z?05<]6D1G<<5A]KM;4Z
MVM4_;;YPP?E"3</J]U&&UGW4H-0;DL=</BG0'>V*N3.$)DJOTHBY8E)B.@XJ
M-G/GE$V43I\Q5TXJ3,=A>AP.^BE7LPHKYJI)C4X_W"#Z7(9:JZ.]09PV3:CN
M.W??#'HR0U_I*$/KGF0J:;`:\+F#B=)KV6,NGQ28CH/T,V>W"TV43A\Q5TQ*
M3,=A>N<R.C51.GW&7#FI,!V'Z=W9)1.ETU?,59,:T]&DY^<.)DJG;ZU<]F;S
MMTPYJKO-W:VI)[/IK'24H75/\G7-_N,(9W?=F`#]8CRF\4F!Z6C6%3^.,%$Z
M?<1<,2DQ'0?I9\ZU?6JB=/J,N7)283H.TSO75J6)TNDKYJI)C>DXOMJW)D!G
M;JTT]C9TVJ2E?!<+&TM'PTG+/FI`:]*FI^&D):-\4D`*F2MB5$Q*2"ES98S*
M206I9*Z*436I(6V9J[6B[+J>-FFI;JUS#P(=J1M>CK-\<^=HN^K[R:U=>EM;
M&S+].&G91_63EK/%U=5TYNPBGLFDD_NDP-`+RPO[J)_,69I<>HDQ*3'TPA+3
M/JI_A=/9U?3JG?-NDIE,>GDYJ3#TPO+*/LIZA?.Y<T55C>=RUGQMHO2X&D,O
M#&+;1_4O>G'U=OYVXIP`M":3)+<WVM/F*]5]@>Y&B\G)51\U.`M>DS8DC^23
M`E)(BD@Q*2&EI(R4DPI22:I(-:DA;4GJ5Q=5.;H5W=6U^Q7%[N?,'G:/7W:K
MW;=O3V=W^]_5+R1.Y!FU']\?O?O]QIO%M?X!1[=E-EVJKQG(5H.6F;0</OQ"
MRUQ:YF-]YI=+=3??2+:Y_(2D[$9C+3("N7UHI&4J?;I7[HY@*GVZ#V_1(J.6
MLZ>Q;#)J>5S"2,M,1BW?EAIKD1'(EVM&6B:+I7K`Y%C+6VEY.]KR3EH.7[QV
M1SVYDI;#)Y1HD<K)([1&EC.54<M#F$9:I,MHCXGTD*>0C_28R.OL/J+`\F5-
MRR8UUD?6M#PE=ZQ%UK0\9Y4M\CNBOXSGD@XC\3>JS&.N-LT1_V6^_$7V&"[X
M1D8T-J`;J>)H$:6&HR64"HX64.HW5CZY.EQNY&*#(Y(+NZ6Z;&.+7),MU147
M6^1R:EF.MLB5T'([VB)7%#*"L=<B5P0R@K$6.9F7$8RUR'FXC&"L14ZA901C
M+3)A)B,8*Y=,?\D(QEID,DM&,-8B\U`R@K$6F4*2$8RUR*2-C&"L_C(%(R,8
M:Y'9$QG!6(M,?,@(QEIDSD)&,-8B-[K)!CB^=J8RMK&-7*:&96QC+3+1*V,;
M:Y$Y6AG;6(M,K\K8QEINYG*\D,_%N+W=+.2`(1^CC+7(`4,FXMDB=PPNJ]%7
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M_T,MX/AK]1__(P````#__P,`4$L#!!0`!@`(````(0#WMKAV-!D```R<```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*S=6W/;.);`\?>MVN_@\OO$
MUEUR)=GJB/<[6;.[SVY'25P=QRG;W3WS[?=`!`0"?T8Q>WL>QND?@4.*AR!Y
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MHV,&FJ>+CX=/M[]_?>D>_TP.]Y^_O$BZ5_*)U`>[^?COX/!\)WM4PKR9KU2D
MN\>OL@'R_Q</]^K0D#UR^Z]WEW-9\?W'ER_O+A?K-ZO-]6(FS2]^/3R_1/<J
MY.7%W>_/+X\/_]LWFNE0?9"%#B(_=9#5F_EV-5NM59`S'9>ZH_S\ZVN751P_
M@OPT05;V(YQ9^UIWE)^ZX_)5_3:ZG_S4_>;;5W6407?<4OFI.[YR/^UT1_EI
M/N+RS7*^VFR/:3KS&6=R1!W7J?XQZ5/.S*&A_C'M<\[D:.I7:@^KUZ5D9@XE
M]0_S4>=O9LOKGQU*,W,LJ7],^Z#F`%+C9N('-8?0S!Y#KTSIS!Q%ZA_FDTJ.
MSN72'#\S>P"=/6*O^L%^/'<$MR^W[]\^/?YY(2=DR>CS]UMU>I_=J&#FK-&O
M_'0>^=%I1,X?*LHO*LR[2]E^.4,\R[GOC_?+Y>SMU1]ROKK3;3ZPC==B;UJH
MDY,*&_@0^A#Y$/N0^)#ZD/F0^U#X4/I0^5#[T/C0^M`-X$K2<\J1#)V_(T<J
MC,J1V;L?#-BDS=V4[4T+TR7P(?0A\B'V(?$A]2'S(?>A\*'TH?*A]J'QH?6A
M&X"3$#DC(2%+.66,7VK-&%&]Y*+JC!%OAW_0;63%IX&T\G)R:G)*"B2$1)`8
MDD!22`;)(06DA%20&M)`6D@W%"='<NY'CM1I?>*)3861<Z,,S5-"ELN%FY(/
M?:/%N:R=FIRR!@DA$22&))`4DD%R2`$I(16DAC20%M(-Q<F:),C)VOD1I5H?
MDV-VZH=>%G)4#-*U=-.U/S4RW0)("(D@,22!I)`,DD,*2`FI(#6D@;20;BA.
M+N1&9D(N5&LW%[U(+LQNWD,"2`B)(#$D@:20#))#"D@)J2`UI(&TD&XHSHZ7
MVZ@).UZU=G=\+]X@\"\CIT8F.P$DA$20&))`4D@&R2$%I(14D!K20%I(-Q0G
M%W)+/"$7JK6;BU[F?96L[FGWD``20B)(#$D@*22#Y)`"4D(J2`UI("VD&XJS
MXZ7`G;#C56MWQVN9V[,/).AE/KQN+Y=K]VH1GAJ9@1(A4`Q)3KV&%R(O='IJ
M9$)G")1#BE,O&WJVW;E;79X:F=`5`M60YM3K3.CVU,B$[H:!G"2JJ08GBWUY
M^68C%YV7+_=WOWUXE.NTW%R-7.<74D;JXE)%<;-[#"PT2"\IT#1?]A7I;#?S
M[K=#V\)\F(AQ8E)B.QZ+W=EJN7$SD-H6)G3&.#FIL!W[T-CJTK8PH2O&J4F-
M[?B#K6YM"Q.Z<^*XZ545ZW#V8"2-,N]WRF-?X,K-M(G]0=U82VKG<AH8W+!Y
MNW)O6YF.`2G4M%`K_./]=K?9>??I$3O%I(24NJ$WB^W*&\H9.^6D@E2ZH>?K
MZ_7VVCV2*O:J20VI=6//YLNY7[IT3B\WN:KZG9!<U=P;I#TM9?@.DKMU/]U>
M31&J0Z"?D^ZG?4"A;K64X^44:\8$HV/,\`DIM>'5L;-;>4=@QBXYJ2"5-O"9
M[:[8L28UI%;3HC_#R0G.JW4ZIX^;7U4Z#_.KSLURJIQR8NZK;SF&S+C\H&9K
M)9M+2<0I3\NE=W7:ZU8R[$W'P'2TAT&H:?V3G/=K',2*32Q[=4@,V?#IJ\)G
MNM4@?&YBV?"%(1N^?%7XBN%K$\N&;PS9\*VA[?%LMU[*_]R!U3FAW=2K^MM/
M_6PU];+<5_%.]GMR1_S*.Y_MU;R\/^(U24UT.FSD:'8_4:@[KN<_/L,C=*P[
MR3:98RTQ&W!V;:F[MLUR._.N)YF)8].2<VV%:75V;:6[MO'K`#Y<S=4UKUI=
M:UIMCKMRMKM>7WM[NS--CI_./7[4G,&YX^>?C]]_=%LWO!_HIQZ<`ZBGP6C;
MJTD[=;0,SQ6@4+=:VMF&B!UC4D)*&2MCJYQ4D$K&JMBJ)C6DEK$ZIY6;(S6]
MX.=HXNE=A?`NZ3UY`]P[<O;J&9@_P#7)CW,#O&]U;H`C=*S7Y@SPUZPMU1WU
MVD;OZK"VG&LKS,>5QC_^;*6[MO$!CM757%WSJM6UIM6Y`3Y<G7OPJ/D0_^`9
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M@XP%I)`4D6)20DI)&2DG%:225)%J4D-J29U#;GKDFC0E/:JY=\/3TV#'[^6V
M!KD`A6P5D6)20DI)&2DG%:225)%J4D-J29U#;B[D7F-*+E1S+Q<]>4/%FWW>
MST^M[%4%%+)51(I)"2DE9:2<5)!*4D6J20VI)74.N>E1<QH3SF3]%(AS)M.S
M(K:BV\]!`2DD1:28E)!24D;*206I)%6DFM206E+GD)L+-:4QS,7Q[05YOCSV
MNH*,./.<6R:W,&9Z6B]/LR-[W4K(%EG+E?>:5C#>RLY"N!NLJNWA!O_DCK$O
MSIV#IZ?-<#M!P1P4DB)23$I(*2DCY:2"5)(J4DUJ2"VI<\C)Q6*T]O_YP7/L
MYYYP-0T/'DOG#I[Q5G::P-U@OR0\?_`L6/IIDI=[S"E_3PI((2DBQ:2$E)(R
M4DXJ2"6I(M6DAM22.H?<7/BEWRO//.H5=.]JK<DY>/I6/SGSV([#0\S..K@;
M/*T84O<._G;V).6P/7A`@>XX:!62(E),2D@I*2/EI()4DBI236I(+:ESR,V%
M*E*&5X'7'CQ]<3.\',A[)2I/SL%SHN%AX5^V;,=AJQ],1JF3HK/!/SGS]'?Y
MSG;V-#@L]L>@\MC8'D\!*21%I)B4D%)21LI)!:DD5:2:U)!:4N>0>_"H>W3_
MX)G/W\@.GOB;,XO^;M])TZD`&!P5:^^9QUYWE`/<G`D"4DB*2#$I(:6DC)23
M"E))JD@UJ2&UI,XA-W/3*H<%*P=-@QV_)P6DD!218E)"2DD9*2<5I))4D6I2
M0VI)G4-N+OS*X2=G-!8,BY[46?[T"&:Y]IZ=[FTK.U1.'0V%;!618E)"2DD9
M*2<5I))4D6I20VI)G4-N>E3],CS)_20]?;GCG,EZ<H8**%B`0E)$BDD)*25E
MI)Q4D$I21:I)#:DE=0XYN5#/,"?DXMC<+8\T>4/%?\IA6YEQ$9!"4D2*20DI
M)66DG%202E)%JDD-J25U#KGIF585JO>SO1M[3<.A0@I((2DBQ:2$E)(R4DXJ
M2"6I(M6DAM22.H?<7(Q5A7_IWDR]GNVGJ2=O%/D/0'3'03(#4DB*2#$I(:6D
MC)23"E))JD@UJ2&UI,XA-W.JDGW]!4?>H$%Z4`OO=:MAA4,*21$I)B6DE)21
M<E)!*DD5J28UI);4.>3F8JP\_FNCB`7SLB=O%/G/1FPK>RTZ=304LE5$BDD)
M*25EI)Q4D$I21:I)#:DE=0ZYF9LV3Z"^D<,_R?4T.'WM=:L!!:20%)%B4D)*
M21DI)Q6DDE21:E)#:DF=0VXN_'F"\[?02TX&:/*&BC>1M+>MS+@(2"$I(L6D
MA)22,E).*D@EJ2+5I(;4DCJ'W/1,FPQ8<C)`DY.>V=K.X!U_-7=O6]GT]+$&
M`RIDJX@4DQ)22LI(.:D@E:2*5),:4DOJ''+3,VU^8,GY`4U.>I9K^UQ0IP>3
M`8'M:#(6DB)23$I(*2DCY:2"5)(J4DUJ2"VI<\A-CZK;)]RN]67^<'Y@B<I_
M3PI((2DBQ:2$E)(R4DXJ2"6I(M6DAM22.H><7*RFS0\<F[OS`YJ\H6*?@O9#
MQ;8RXR(@A:2(%),24DK*2#FI()6DBE23&E)+ZAQRTS-M?F#%^0%-@S)F3PI(
M(2DBQ:2$E)(R4DXJ2"6I(M6DAM22.H?<7/CS`^?OR5:<!-"DWAZSL\[^;^SL
M;2L[5/I8Z_Z[%^1QT<[]7_@/.Q_G;O.TRGC%REB3>E%FL,W^Q(5M9;>YC[66
M$XSMN/[!`^Z57S7^9-^R-#Q&.'[/P6!U,_]^U[:RV]G'TOOV^LWN>CYW]N[I
MMZ3=/3NM6E*_7>!52YJ\/8L39]]16MDM[LG=L[,?[=EIE<2*E80FYPS2MQI0
MP%8A*2+%I(24DC)23BI():DBU:2&U)(ZA]QC9EK9L&+9H,F[V/IE@VUECQF6
M#6P5D6)20DI)&2DG%:225)%J4D-J29U#;GJFE0TKE@V:!L79GA200E)$BDD)
M*25EI)Q4D$I21:I)#:DE=0ZYN9A6(ZQ8(VARA\K&?QO"MK)#!<5%R%81*28E
MI)24D7)202I)%:DF-:26U#GDI$==>R:4<,?F;MF@:3A42`$I)$6DF)204E)&
MRDD%J215I)K4D%I2YY";"[]&.'[3T%]YITA]%9!WDZ+)&T7^BQ*VU6D4D4)2
M1(I)"2DE9:2<5)!*4D6J20VI)74.N9F;5E'(-VD@/3TYHP@4Z(Z#5B$I(L6D
MA)22,E).*D@EJ2+5I(;4DCJ'W%Q,JY34+V_[0Z4G;ZC8PJR?"-$=![D(2"$I
M(L6DA)22,E).*D@EJ2+5I(;4DCJ'W/1,*Q#5R]=^>GH:U"Q[W6I``2DD1:28
ME)!24D;*206I)%6DFM206E+GD)N+::6O5-;(A2YJY8>=&\!$B.XHTR7VJM)W
M5#<FMN/&SD:XVSFM]%VS]-7DE>AV=7I(ZVIX4*+KCNJB/=A.^Z#:W<YI9>&:
M9:$F;V+)G_RPK>S^[&-Y^]-V=+=S6GVT9GVDR=N?_I2';66WLX_E[L\?37FL
MI]4.Q^;>S6E?`@Q.#'O=:D`!*21%I)B4D%)21LI)!:DD5:2:U)!:4N>0<\QL
MIA4*Q^9N+C2YEU4\*;6M3L<,*21%I)B4D%)21LI)!:DD5:2:U)!:4N>0FQZ_
M=C@_[[IA@:!I<#^S)P6DD!218E)"2DD9*2<5I))4D6I20VI)G4-N+J95`QM6
M`YK<H;+QGUK;5G:HH&8(V2HBQ:2$E)(R4DXJ2"6I(M6DAM22.H?<]$PK$#8L
M$#0-+B%[4D`*21$I)B6DE)21<E)!*DD5J28UI);4.>3FPJ\&SDQYO/Z+\.77
MLOT;54/VRX+WI$"3^@*5P=V>=UL3VE9FW$6,%9,2VW$8WC[O.=Z%IK:5"9\Q
M5DXJ;,=A>.^90FE;F?"5$\O-C[I-?_T;'NKO%7C5FJ'ACM>M+`6ZE?RFK]FH
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M7_=-QYN^'A^^`JC)N9E"U1ZP54B*2#$I(:6DC)23"E))JD@UJ2&UI,XA)T?;
M:27ZL;E;HFN27-B!L/2_*GAO6YD#)R"%I(@4DQ)22LI(.:D@E:2*5),:4DOJ
M''+3,ZU$W[)$US0<*J2`%)(B4DQ*2"DI(^6D@E22*E)-:D@MJ7/(S<6T$GW+
M$EV3DXN^U8`"W4H5HZ<KRW+CW7*%MI494!'#QZ3$=AR$WWK3VJEM9<)GC)63
M"MMQ&-Y.*A_KE=*V,N$K)Y:[X_WBV[^.O.HOG6U9DVL:[/P]*=`D!:G9UI`4
ML6-,2FS'X=ZQCP;Z:LZV,FO,&"LG%;;CF?"E;67"5TXL=^?[U?;Y2<(MRVA-
M7C7BWRG95F:C`E*HR50CZ]EBL;SVAD;$?C$I(:6:U&\)VY&W]<)G[)B3"DLV
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M*2<5I))4D6I20VI)G4-NCJ95^CM6^IK<!\`[[X9R;UN90S(@A:2(%),24DK*
M2#FI()6DBE23&E)+ZAQRTS.M^-^Q^-<T?%>"%)!"4D2*20DI)66DG%202E)%
MJDD-J25U#KFY\.<#SI>D.Q;^FKRAXIU0][:5'2I]K$$20[:*2#$I(:6DC)23
M"E))JD@UJ2&UI,ZA/CU7SU\.AY?@]N7V_=N'P]/GP_[P]>OSQ=WC[]_DNB:5
M[(`OG@Z?WEU^V,YNU(R;[-]3![UD=WVCSI9C2Z2/#-2Q)7-9<GQ"C&@+67*<
MP/&7;&0]\HK42+2-K$=>V!E;(NN1Z;FQ);*>?J((Z]G)DN,-A+]D*UL@,\`C
MT=:R1-YZ'%LBVR:_6C"V1+9-7G0?6R+;)N]8CRU9RI+CU]+[V[:6K9;W^T;Z
MK&3;Y%?7QY;(MLDO4H\M6<N2XTVOOY[51I8<GXAAR5:6'&]IL$2V3=Y='5G/
M4CZ/?-71V)*5+#D68'ZTI6R;?.?+6!_9-OFZD;$ELFWR31=C2V3;Y'L71I8L
MI(]\>^;8$NDCW^4XLF0I^UJ^1G!LB>SK_F$</H\<!_*E:6-]Y#B0>9J1)7/9
M`OG6_9$E"UE/_Z*%OYZ%1.M/AU@B^UJ^#'DLFNSKOK1"']G74I&,])G+YY$_
M&#6V1+9`WKX96R+'@?SEG+$ELFU]%>5OP5RV3?Z$R%@?V3;Y@Q8C2]3A-N:R
MDM'/+ZL878.L8#2^'#*C1\Q<LM+?>GN?0N;J;]24,;=5INQOU,PQE\C,_8V:
MEQ];LI`E8WUDTOY&S1VSSR^SFU_&8GV031X]-ZCTCL3YH`ZO$?]E>?/+^`E=
M-NG#Z";M98F:W^?&RB.7&S6GSR7R3.5&3>USB3Q:N5$S_%PB3UANU/.3L24+
M63+61]XBNU'OB(WTD27J]2XND7>W;M2;65PBKT9)M+%#3UYTDFAC2^2U)8DV
MMB38W81C)X5D=Y..>;&[*<>\V=VT8Q[,KF_"V=CI+9$EZ>B20I:4HTL:6=+V
M2ZY.H^+Y_=OOMY\/Y>W3Y_MOSQ=?#Y_DAN3ZC7H'Z^G^LZJ&^_]XT7];_=?'
MEY?'!REU+R^^'&X_'IY4`VG\Z?'QQ?R'[/:K/Q^??CO>]+S_/P$```#__P,`
M4$L#!!0`!@`(````(0!"->`AYP,``(X/```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;)1778^C-A1]K]3_@'C?@"$ADRC):J:C:5=JI:KJ;I\9<!)K
M`"/;F<S\^]YK`\%\;.`E"3?'Y_CXXQCOOG[DF?-.A62\V+MDX;L.+1*>LN*T
M=[__^_+EP76DBHLTSGA!]^XGE>[7PZ^_[*Y<O,DSI<H!AD+NW;-2Y=;S9'*F
M>2P7O*0%_'/D(H\5/(J3)TM!XU0WRC,O\/W(RV-6N(9A*Z9P\..1)?29)Y><
M%LJ0")K%"OHOSZR4-5N>3*'+8_%V*;\D/"^!XI5E3'UJ4M?)D^VW4\%%_)J!
M[P^RC).:6S_TZ'.6""[Y42V`SC,=[7O>>!L/F`Z[E($#''9'T./>?23;IV#C
M>H>='J`?C%YEZ[<CS_SZNV#IGZR@,-HP3S@#KYR_(?1;BB5H[/5:O^@9^%LX
M*3W&ETS]PZ]_4'8Z*YCN%3A"8]OT\YG*!$84:!;!"ID2GD$'X-/)&2X-&)'X
M0W]?6:K.>S=8+LC2CP#MO%*I7A@RNDYRD8KG_QD,J9@,1U!QP'?%$4:+U=H/
MR7T2S_1'VWN.57S8"7YU8,V`I"QC7(%D"\3#?L`(8A\1O'?7K@-]E3`)[X=P
M%>Z\=QBXI,(\&0Q\-AC2(#P0;91!;;HR@E$91Q:[\F0*;9E@6":<(X/@O0N?
M3>?#U;+A-<H&LVQA5@W",@B0Z081#'/0-A2N;L1&VH`F2,.BFBZ-8"W=#&Y5
M@5W2&H=HV&4T1PK!ME15,;NOO3Q@E4VW@&";MZK8%M;#%C"D)^\!!-M25:5O
M86/S8F:$RP4,[L]W&3:S%:J*;>9AV`P!U'0W&FV+U:6^'UR=;6HTM/$7Z[N.
M=,.."G)!R?:T&?$T*RM(E0TF/75:U*4!3YU\T,$>;>[/$C$Y`-::;5.7+$^1
M/^)I5CR0)A]N:E5IP!/NW]:"GCY/U<9O>ZI*MJ>12">SPD"C.ZMB-`Y()P_0
MTWK*-/6C05-UEUXT<GR06>&@T1U+H_%`!O(A>L#WASL!H1MV5(8B(KJ=S=;!
M%,R*"(VVU>I2?^D%`Q$QR9-NV%$9BHCH=AS;GF9%1-"/B+HTX&DH(D@X8:*"
M?D;4)7L_W0YZV]2LC`CZ&5&7!DP-9`19PF;Y^=F$B[-S.-4EV]'(VT(P*R$T
MNK,H1A,B&$@(XL-$WW'4#PC-!+*VHY&7AV!60&ATQ]%H0,"%II?C4^:HRH)6
MBFNFGJ/N&X2Y_9CK04[%B?Y&LTPZ";_@S2:`%_ZFVMRZ'@,\_[KUY?;1W,:\
MYA^X#97QB?X5BQ,KI)/1(W":EP=A[E/F0?$2.@J7(J[@(J1_GN'>2^&EW\=3
M^<BYJA]`V6MNTH?_`0``__\#`%!+`P04``8`"````"$`961ZR+@S``#A2P$`
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLW5N3VT:>IO'[C=COH-#]
M6$6RC@[;$V,>`!`@#HS9W6NU++<5;5D.26UW?_M]DYD)Y#\?J*J@\5ZL>W^;
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MJQZ`_N\7[]^YYX:^):__=?GOG^]^^OS+]R\WU]_<W%UM5AK^XF]O/WT^O'-3
MOGSQYI^?/G]X___\H%68RD^R#I/HOW&2V\63;,(D^F^89+W^YGI]<W=_>2B/
M?/GK<*3^&XY,3N&1XW2"EW/7?V<>]B,'WH8#]=]XX#?W-S?7M_=WFNN1`^_"
M@?KOPG/4@KT\5OUWT3D^A./TW_@5-]_<K:X>-D\\U)6>BOZ9H?;QT&<&6<4G
MA/L?BQ[N*CX+W/\(1VZ2Y](CW]M5?!JXI__2!QR+KJ:DSWL.K6)2]S_"5UW=
M?K.ZOKIU"^BQQQN3KJ:F3SSC7_G%>WDMV+W^_/J'[SY^^/.%7F&5Z-/OK]WK
M]>I;-UU\%?!??GQ=^-++@EX/W"S_Y:;Y_J5.1"O^DU[,_OAA?7W_W:L_]/KS
M)HSYD6-6=L0VCG`O-F[:70[['`XY%#F4.50Y''.H<VAR..70YM#ET.<PY'!.
MX)7RC(VT%/Z*1FX:URA^=W^,D$3+@L01\9!=#OL<#CD4.90Y5#D<<ZAS:'(X
MY=#FT.70YS#D<$[`!-$KS%\1Q$VC=TVS:!YL@1_#&#V2<67=V"';<<A8";*'
M'"`%I(14D".DAC20$Z2%=)`>,D#.J9AH>I'_*Z*Y:?1BJ;4Z!EG?7-DD/_I!
MF\>JC4/&:I`]Y``I("6D@APA-:2!G"`MI(/TD`%R3L54TSNAJ39_=1K?AMSH
M2YSX3?W1R]KDRM^9MN.@>-@.LH<<(`6DA%20(Z2&-)`3I(5TD!XR0,ZIF!:Z
MPEG0PHVV+;RH1?PV;R$[R!YR@!20$E)!CI`:TD!.D!;207K(`#FG8K[QNJY:
M\(UWH^TWWHM=!#?YQ=<X*-;90?:0`Z2`E)`*<H34D`9R@K20#M)#!L@Y%=-"
MU\@+6KC1MH67=!%`=I`]Y``I("6D@APA-:2!G"`MI(/TD`%R3L5\X[4/7?"-
M=Z/M-]Y+^HV'[(*D[]OKF[5]<]^/@^)".6"B`E*.1Z77#1L[=34.BE,?,5$-
M:<:CTJFSJ\33."A.W6*B#M*/1Z53W]E'/8R#XM3G="(3T=T;,!7]?O,;=TOA
M\R_OWOSCQP_^GM',^_Q&^\JPVW2SV+J7B;]_F>8E[2)=;JM=YMJ3#I&F-ZJ"
M5$;2!6=R)7AMOS?5-"I^<XZ1INEK4A/)3G]KIS]-H^+T;:1I^H[41TJG7ZVR
MZ]AA&A6G/T>Z3&_;NOUK>B]AIJ'N;(P1_7975])Q[A_=5;6Z7BMO\BW-[B-L
MPRA-%0_<D?9QKFGZ`T<5I))4<:XC1]6DAG3B7"U'=:2>-'"NLQEE\[C=;)K'
M+;WUQMW<_<(]W[&4.S);;IZN[2MEMGG=NIMX.G!]GY0::4J\>LBN1?;AP(U[
MMOSQP\V5_H]]XA\X=4$J)WKDJU5AU+59"P_9:_-QFBL^[6I2,]$C7_$41GWY
M_-IIGOC5.E(_T2-?;;!?;7U_\Y`MJ?,TC[Z:?=;HFV*>-4\L:C<\>ZIXLHOZ
M-NNY=7=MW5,E7=2@?1BUN;X\+^[<$R-_7N"@@E.7I"K0=;I3U,]?[/1''EB3
M&M(IT)<?><N#.E)/&NS4FYO5/?*FWQ2;UVV\O^Y%P6_9]7H3GZ`_NOOH:FA?
M%&ZSM;T-H\R+@C\PH7T8%5;(^GYSO<XF.G"B@E22JD!/K7<\J)IS-:13H$<>
M>LNC.E)/&NS<#[=W:[1.'[9M[3;V>>O5S=)K+W][P'3WY-Y(IK?MV^RR>>M^
MN)*O<$^;V_$YM`^C-O=?7N&8I^#499QGFKJ*I*W=^#!G5CBFKSE]$^>:IC]%
M^N(C;SE/1^KC/-/40R0_]</U7?9&>S;3V.CNID(>?:WGR(*K;7]?PA3W=.WF
M&7_@<YN]6&[=C\1<\?3M/QPXO<SOPZCKVTOQ:[?2LZ?.@1,5\:CK\:E31IKF
MKB(]D1R/LXX'3M,WD:;I3Y&^_-#;,"3Y'G3QJ&GN/M(T]Q#)-U_=/CSD;T9G
M,[>M[FY?I-6?>-?V=SM,84]ZUXXO[UOW<\I\`8/V893>1^.!!QY8D$I2Q;F.
M'%63&M*)<[4<U9%ZTL"YSF:4;>'N:*0MGG_=[>^%F"R>LK?8;-.Y=3_(S1<>
M:!]&Z6UP*H51!><J217G.G)436I()\[5<E1'ZDD#YSJ;4;:4NVWQ=:7\#0]3
MRE-VV9O=E=FNPIV2:>'O2/M`X>)QK9\W\;H7$Q6<J"15@9ZZ[L7T->=J2*=`
MCSSTED=UI)XTV+D?\$W1YZ>25RR3>IW?AWK\!?(RW&YK`F4K,;L_LPVCDI?_
M'6D?*%PQ;E9W5W?Y6R"/*D@EJ0KTQ,4N#ZQ)#>D4Z)&'WO*HCM23!COWP\TJ
MN\`XFV-LW_Q>U%?=9W0_,='K:+JL`V7+.KLCN@VCTMULH/1:-\[UX*]\KN^O
M\Y],'CA1$8^:WIE+SET%NDEOI?%BE]/7G+[A]*<XZLL/O>7<73QJ>N@]YQXB
MA2N?S?5-]OYV-E/;[N[V$E["%UWNKOT=*A/=4W:YF^V\MN%`L];#@=/+^SZ,
M"I>[#P]7-^O\'@8G*N)1TS5C&6F:NXJDJ[+QLGPFNG]0R>.LXX'3]$VD:?I3
M)'^Y._?0VS`DF;N+1TUS]Y&FN8=(/OIFI:VMO?5R-E/;Z.[V1AY]\<9V[6^2
MF.Z>;M)[0NO;;/.U#0>:Q1YNN&ACD83(;F#LPX$WZ\OZ7UW?;1ZNLS$'3E[$
MPZ8K[#*.>O3K5?%`/;CD464OJL<XUQ2GC@=.7[&)HQ[]BJ=XX"-GV,:9IJ_7
MQ<.FK]?'48]^O2&.NKM\1]=7>AIEB^L<AUR^G'T:N3LGCSV-_OO#[WHS>.IN
MN=M<YV\:GO2R%:^TMV%40CO2GG0@%:225)&.I)K4D$ZDEM21>M)`.ANRC=S=
MF;31$]=M_F:.6=/A_HY9TW?9LV3K[F6Y'=14;$?:DPZD@E22*M*15),:THG4
MDCI23QI(9T,VCY;GDCQN>'9]Y2GYQF_7H!UI3SJ0"E))JDA'4DUJ2"=22^I(
M/6D@G0W9%N[>S(*EXF_EF*42[N[8I9*]0VW7XZCXXK8C[4D'4D$J217I2*I)
M#>E$:DD=J2<-I+,AF\?=:EF0Q]^9,7G"S9HTC^X3VLNFK2[%\$H&VG/4@520
M2E)%.I)J4D,ZD5I21^I)`^ELR.9QMPX6Y/%W&DR></,AS;/.]_7;]3AJ6CV@
M/4<=2`6I)%6D(ZDF-:03J25UI)XTD,Z&3)[-LOLWE^'VC290^D9#VI'VI`.I
M()6DBG0DU:2&="*UI([4DP;2V9!MH6?X@J6R<<.S%IY,"]`N'.CV@>/VA9_.
MFT;%!76(-%W,%:0RDIT^VQU5TZ@X_3'2-'U-:B+9Z;/[P:=I5)R^C31-WY'Z
M2';Z;`\]3*/B].=(E^EM5\UENG[5/33W2Q!Y;D\F-V@7#M1^+3[6/>D0:?KN
M%*0R4KKS7>>WE:II5/R*QTC3]#6IB62GS^X%GZ91<?HVTC1]1^HCI=/SLWK3
MJ#C].=),6\UEVCZ^C]JXX=F:]61OA-[D]\3"@=HQQ`>U(^T#I3\SY*B"5)(J
MSG7DJ)K4D$Z<J^6HCM23!LYU-J/LTIN[%?&LS^KI!RTHY<G^I.(N>V';A@-U
M1325"K<M=+DXON#RLWKAP/`3@/O[F1].<>Z"5$[TR)>KPJ@G?IXQS17/IB8U
M$SWR%4]AU",GV$X3Q2_7D?J)'OER@_UR-W<W^/6R\S21OIQ]XBR[/Z)SPK/%
MDUW7=]D=^&TXT*SK<,MD6NK[,$H/]_(;P7//#!Q4<.J25`5ZXL>6/+`F-:13
MH"\_\I8'=:2>--BIM9YPI]L<9//F]U>>_5D"_=P)I3W9UX6;?/\8#C2O"^&&
MS/12L0^C],B_](%=SE.02E(5Z*D%C\=4<ZZ&=`KTY4?>\J".U),&._7Z]NHA
MNQX[FX-LZ65W;S:\>Q/(+N3\=O@VC#(+.=S021>RI[`<YCYWRWD*4DFJ`CVU
MD/&8:L[5D$Z!OOS(6Q[4D7K28*?>K*XWV=7/V1QD\[I;,.GMA><O9'_S)KW3
MH`]+NK5M%S(^=QM&F87L#TQH'T:%Y:"_H7)[D^U1#IRH()6D*M!3*QD/JN9<
M#>D4Z)&'WO*HCM23!COWP]7Z)KNZ/YN#;&MW/R=OO?C'DQM_5\AT#S>*]!XZ
M7I^M\;G;<*!9X?Y`O?K$RY5]&*6S<"_@LRM\_&KQH()3EW&>:>HJDI;P^##Y
M4VG.59.:.-<T_2G2%Q]YRWDZ4A_GF:8>(H6I;Z^RRZ"SF<9$=R^[B.Y^KO7\
MS]U>IK";KD#9!Q'R2_DP*EG6NWA@\IH>R?\T?[6YG5GJG*F(ATT_SB\C39-7
MD1YOSNGK>.`T?1-IFOX4Z9''WG+R+AXV3=Y'FB8?(H7JUP_Z,U+VIOK9S&V[
M+[L9YM[VLHUU('V)N,ZV@=(E3-K'`Z>;"0>.*D@EJ>)<1XZJ20WIQ+E:CNI(
M/6G@7&<SRK:8NX'UK%VT>RO-LWC*WF2S%X1M.-`LO7!K*[E:#J/T1A@3'WA@
M02I)%><Z<E1-:D@GSM5R5$?J20/G.IM1MM2RVU'N"B+/,W<[ZC9[D]Z&`\U"
M\@<FM`^CPC7C[,<Q.5%!*DE5(/>D?>3-D`?6I(9T"O3(0V]Y5$?J24,V]\W5
M)GOVG\U!-K"[E91>`SU^O]&]P>6!/;GGT/B-6^=;YVTXT*P_?V!"^S`J7"GJ
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M\:AI[C[2-/<0R5_G7M^M\N_*V4QMH^M\$7WQGO;:S9+M<#P]\9';<*!9[OY`
M]WFH\0G#'U:$`\-';M>KZ^O557:1<.#D13QLNK0NXZA'OUX5#WSBW2`\]BE.
M'0^<OF+SK*]XB@?ZC]S.GF$;9YJ^7A</F[Y>'T<]>H9#'.4_<GOW</N0_Q[H
M.0ZY?#G[-'+W>O+7CO1I]+R/W%[[6T;F]2/<19K.9QM&)3]VWI'VI`.I()6D
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M`!?^Z?$;-U/VBN8I6T7YYB$<F&3:D?:D`ZD@E:2*="35I(9T(K6DCM23!M+9
MD"WG[J<L6$7^]DMZ/7#C*?G&;TD[TIYT(!6DDE21CJ2:U)!.I);4D7K20#H;
MLBWRNRZ/7YO=\/9*H&RIY!\"F49-;SA^KB3BGJ,.I()4DBK2D523&M*)U)(Z
M4D\:2&=#-H^[/;%@J;CAV2N9I^2[O+T![4A[TH%4D$I213J2:E)#.I%:4D?J
M20/I;,BV<'OL!2W\EMR\;'FR2^4^_\W!FW'4M%1`>XXZD`I22:I(1U)-:D@G
M4DOJ2#UI()T-V3SYG8`G7LFXX[_Q9)8*:,=1>]*!5)!*4D4ZDFI20SJ16E)'
MZDD#Z6S(MEBVX[_ACC]0ME2RF^W;:=2T5'`38,]1!U)!*DD5Z4BJ20WI1&I)
M':DG#:2S(9/G=MF._S+<OJL$2I<*:4?:DPZD@E22*M*15),:THG4DCI23QI(
M9T.V1;[C_^IMS"UO!@3*5E'V693M-&I<1:0]Z4`J2"6I(AU)-:DAG4@MJ2/U
MI(%T-F3++;L9<,N;`8',*N+-`([:DPZD@E22*M*15),:THG4DCI23QI(9T.V
MQ5]V,^"6-P,"9:LH_\S<-&I:1>-=A$A[CCJ0"E))JDA'4DUJ2"=22^I(/6D@
MG0W9<LMN!MSR9D`@LXIP?V#'47O2@5202E)%.I)J4D,ZD5I21^I)`^ELR+98
M=C/@EC<#`F5+)?N4SW8:%=?%CK0G'4@%J215I".I)C6D$ZDE=:2>-)#.AFR>
M93<#;GDS()!9*KP9P%%[TH%4D$I213J2:E)#.I%:4D?J20/I;,BV<#OR]&;`
MUU^V^;U]>I_@=MSN)S_#N<\_L32-FE;1>&"D/4<=2`6I)%6D(ZDF-:03J25U
MI)XTD,Z&;+EE]PEN>9\@D'F1XY]-F4;%%CO2GG0@%:225)&.I)K4D$ZDEM21
M>M)`.ANR>?);!U^_L'A7X7:\.9`NK/QS!-.HJ=QX8*0]1QU(!:DD5:0CJ28U
MI!.I)76DGC20SH9,N;ME=Q4NP^U=A4#IVQ-I1]J3#J2"5)(JTI%4DQK2B=22
M.E)/&DAG0[;%7W97X8YW%0*9U[_U??X1@VE47#([TIYT(!6DDE21CJ2:U)!.
MI);4D7K20#H;LN66W56XXUV%0&85\:X"1^U)!U)!*DD5Z4BJ20WI1&I)':DG
M#:2S(=LBOZOP^(\4[GCK(%"V5/+/$4RCIJ7"6P<<=2`5I))4D8ZDFM203J26
MU)%ZTD`Z&[)YEMTZN..M@T!FJ?#6`4?M20=202I)%>E(JDD-Z41J21VI)PVD
MLR';(K]U\-67;>X?<LQ^AATH6T7Y1PRF4=,J\G,E??<<=2`5I))4D8ZDFM20
M3J26U)%ZTD`Z&[+EEMU5N.-=A4#)=WE+VI'VI`.I()6DBG0DU:2&="*UI([4
MDP;2V9!MD=]5>.(-A[<.[L8[`,D.YR'_B,$T:EHJXX&1]AQU(!6DDE21CJ2:
MU)!.I);4D7K20#H;LGF6W3JXXZV#0&:I^%$)[3AJ3SJ0"E))JDA'4DUJ2"=2
M2^I(/6D@G0W9%G_9?8([WB<(I";I*LH_?3"-BDMF1]J3#J2"5)(JTI%4DQK2
MB=22.E)/&DAG0Z;<_;+[!)?A]CY!H&3);$D[TIYT(!6DDE21CJ2:U)!.I);4
MD7K20#H;LBWR^P2/O^'<\V9`H&RIY!\QF$:-2X6T)QU(!:DD5:0CJ28UI!.I
M)76DGC20SH9LGF4W`^YY,R"062J\&<!1>]*!5)!*4D4ZDFI20SJ16E)'ZDD#
MZ6S(MEAV,^">-P,"94LE_QS!-&I:*KP9P%$'4D$J217I2*I)#>E$:DD=J2<-
MI+,AFV?9S8![W@P(E/QVYY:T(^U)!U)!*DD5Z4BJ20WI1&I)':DG#:2S(=MB
M[F9`^DNY/W[0[Z;IO63FW6:C/Q_VYL7'[U_^USUO!`1R_P+/],MM#_G'"Z91
MTPKR<Z5_"IJC#H;L&2W;)-]SDQQ(OW">/O3\9[K3J.FA^[G,@?RU]'!@^+,M
MUS?Z^W+9IN]@YK9GEV\[+S=O-M^XKSF32#PVX@[TWI/^HD)ZHOG/V*91TXF.
M!T;:AU'F3Z&L\[^!>9CFFK[BZF&Z/63/-=_#/?]<N9V[]V3:K!_RV[O3J'AB
M.](^D/F[/NOD+"Z+XC`=^)QSG=TC/:LK]T3WGDS73?ZOB&ZG4=.YC@=&VH=1
MINOF*MM?'::YGG&N#_FNXME=+T?:#48@TW5SE5_43J/BB>U(^T"FZ^8J>]<_
M3`<^YUSSJ_;GGRLOX!\\95WSU]1IU'2NXX&1]F&4Z8H_770P<YG%^9!?[UY.
M3&_5S_^;AY<ILIK^@C>KF;_TA@,U*I[.+E#Z!X`BZ;5J?`>:.</Q*VHN>X;Y
M5:0[P\5OC0^\N`R49<Q?=J=1TTGZN=R_E)*<4;86]^%`_1L>7_KSS&9J>\[Y
MI5E^SL_[&QT/O&0+E%ZRD7:D/>E`*D@EJ2(=236I(9U(+:DC]:2!=#9D&[D+
MI/3S;(^_[S_XZZGT0VN!S.YF<Y5_*F`:-3T!_5S)%G7/40=202I)%>E(JDD-
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M:9L,&U?0C*G8.%T<IV(P%8.I&$S%8"H&4S&8BL%4#*9B,!6#J1A,Q6`JEEI6
M+-_V/E7,;R_35[S5E3>[H&!:4##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY
M8,H#4QZ8\J26Y<GW[$_EX>Y\=>4M6U#9+EL+:AP6%XJ*P50,IF(P%8.I&$S%
M8"H&4S&8BL%4#*9B,!6#J1A,Q6`JEEI6++_C\%0QWEI877FS"PJF/##E@2D/
M3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\J26Y5EVLV%UQ;L-T;(%E=^B
M388E"XHW'&;&J1C&J1A,Q6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93L=2R8LON
M/^A/(N-#O-'L@O+C$M."@FE!P90'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!
M*0],>5++\N2W))YZO>.-A]75W)V'5?9S"KU#C<.2!053,9B*P50,IF(P%8.I
M&$S%8"H&4S&8BL%4#*9B,!6#J5AJ6;%EMR)65[P7$2U9/,J#&Q1:4##E@2D/
M3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\J26Y7'W`?Z2NQ/Z-R)F7@K'
MVPS3SUPV5_E=OGAH$E@QQT/C^E-,F&+"%!.FF##%A"DF3#%AB@E33)ABPA03
MII@PQ80I9FHVYFKA_8K+^.Q^1;`DQ79%V\W8?L8.,U;,6#ECU8P=9ZR>L6;&
M3C/6SE@W8_V,#3-VMI;E<1OCOV:M:4><_^[0*IC*I6LMOQ>8#(OK2C'3+?OE
MGJ%BPA03II@PQ80I)DPQ88H)4TR88L(4$Z:8,,6$#3.FF.FX+*;;1J<QG[@2
M6?EMMV:,W_8?5\%,,?Y]A618/%3%TEU\+`93,9B*P50,IF(P%8.I&$S%8"H&
M4S&8BL%4#*9B,!5++2OFMM%+BOEMMRTV;L63-;;*/T.R6HW#DF(PK3&8BL%4
M#*9B,!6#J1A,Q6`J!E,QF(K!5`RF8C`5@ZE8:EDQM[->4LSOQ&VQ='?N?QRR
M6L&TH&#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'ICPPY4DMR^.VT6D>
M]_-A]Z]?+?RS]*N5WX_;;N,>/5UI^6>9XJ')Y8I2CH?&U:>4,*6$*25,*6%*
M"5-*F%+"E!*FE#"EA"DE3"EA2@E3RM2RE&[+G:9\ZMW,;]%ML73;'E<:3'E@
MR@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.5)+<OC]M=+\OC]N,TS
M[M'3!95_;D[_D*&^U/<O[8*"J1A,Q6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93
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M,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@RI-:EL=MII?D\9MOFV?<D*<+
M"O<1W>\FYA>*-!7#.!6#J1A,Q6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93L=2R
M8FY_O:28WX_;8ND>/5PHNG]6&GE@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8
M\L"4!Z8\,.5)+<OC]LQ+\O@]MLTS[KN3!;7&9PS=KVVA&$S%8"H&4S&8BL%4
M#*9B,!6#J1A,Q6`J!E,QF(K!5`RF8JEEQ=PV>DDQO^VVQ;SI?3!>+.AJ$*9W
M*)CRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>5++\K@]<YHG_QVY
M9_W*_&KMM]ZVFC?W8CO^@M]FC8\>AD,U+,95R/'0:`H)4\C4LA-SN\WTQ)ZZ
M,O*[4WL&WMRS>SR#]0-N>KK??=0KA8;%1ZLS&&TZE+\]'X>%7Y^_N][<YK_9
MK),<I]+TV4FZ75AZDI=]\W-^T7KE?N]2#]J>K[?L=SGYRC@.2\X7IF+>S&_E
M;M;91^5T?N.AZ;=JNL"QIZS?!/W:4[X<FIUR,).8OW&]FH9-ITS;QW'VEZ[7
MV8>9#G&8^:I?_,L!JXV[_O^ZRI=#\U/VVXFL,GYH%@[5L.24QT.CZ92]V<KX
M/?,XS'S51T[975-_Y2G[RW'SQ-YX,]_OS9JG/`Z+I[=;38=&TRG[<6'5;C8/
M=WA2F\.R9["[^L2YZ9KG^;]LOG+;ZWSU!C/?X<T57JVF8?&$=))^.OVP*)I.
MTIO[)US'%S_^QGD<YI\FV8FZZ[C\1!?_SOE*WV:>JS<;]`IWS\.A&A;/2^<:
M#M5[8G)>V=N23C\,N[O\XOEF=7<U$WE\%)H^.W=W1?38N3_O=\]7&W]E99_-
MWLSE4!B7F,X4XW1:,+T:P8H9*V>LFK'CC-4SULS8:<;:&>MFK)^Q8<;.UK)L
M[DHIS?;$58/^1`.?F][<^AF?8)LUU^$X+'ENPE0,IF(P%8.I&$S%8"H&4S&8
MBL%4#*9B,!6#J1A,Q6`JEEI6S%T"+BGF+QGM@O*F8C'%=K6!:4'!E`>F/##E
M@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,J36I;'7;RF>;[V0PD;?Q5LNWG+
M5AK?!<9A,:]2PI02II0PI80I)4PI84H)4TJ84L*4$J:4,*6$*25,*6%*F5J6
MTEVGIRF?>FWTU_6VF#>[TF#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'
MICPPY8$I3VHVSW6^,7HBSV5\MC4(EBTH_*!T&C8M*-I^13O,6#%CY8Q5,W:<
ML7K&FAD[S5@[8]V,]3,VS-C96E8LW]<]5<SOM,R"<CM->Y=RNZ+M9DQY<*SR
MP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*4]J61ZWRUOP>G?M=X4V3]@I
MVFM!_#0T')J\+*K8>&A<9"H&4S&8BL%4#*9B,!6#J1A,Q6`J!E,QF(K!5`RF
M8C`52RTKYK:L2XKY+:XMYBU)H04%4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`
ME`>F/##E@2D/3'E2R_*X[7*:Y^L_Y7/M=]ZVG+?LS6NZCQA^$A<.30(KYGAH
MLM9@B@E33)ABPA03II@PQ80I)DPQ88H)4TR88L(4$Z:8J64QW4V#-.:_5M>O
MWWS[T[]W;S^]>?N;=KY7[N^XQC_8NG(?1,[O6`5+4FBM^7&)*0],:PVF/##E
M@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,J36I;'[9C3//^#M>8WWW:MC1OR
MY!['BN]KX["XKA03II@PQ80I)DPQ88H)4TR88L(4$Z:8,,6$*29,,6&*"5/,
MU+*8;G^=QGQJK?G]N"V6[M'C2R%,>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY4DMR^/VS$OR^#VVS3/NN],%Q3>O<5BRH&`J!E,QF(K!5`RF
M8C`5@ZD83,5@*@93,9B*P50,IF(P%4LM*^:VT4N*^6VW+99NQ>."@FE!P90'
MICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*DYK-<[/P5L9E?'8K(YB]
M&MS@9]G3L&E!T?8KVF'&BADK9ZR:L>.,U3/6S-AIQMH9ZV:LG[%AQL[6LF)N
M&[U@0=WX;;=94,&2*[_MBK:;,>5)M_&7Q:@\,.6!*0],>6#*`U,>F/+`E`>F
M/##E@2D/3'E@RI-:EL?MF9?D\7MLFV?<=R?O4)OLYZ8J-@Y+%A1,Q6`J!E,Q
MF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,IF*I9<7<-GI),;_MML72K7AXA[J!
M:4'!E`>F/##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,J36I;';8R7Y/$;
M:9MGW%RG"RK[)(D6U#@L65`P%8.I&$S%8"H&4S&8BL%4#*9B,!6#J1A,Q6`J
M!E,QF(JEEA5S>^4EQ?S>VA9+]]MQ0<&TH&#*`U,>F/+`E`>F/##E@2D/3'E@
MR@-3'ICRP)0'ICPPY4DMR^-VOTOR^-VRS3/NH-,%E7WX3@MJ')8L*)B*P50,
MIF(P%8.I&$S%8"H&4S&8BL%4#*9B,!6#J1A,Q5++BKD-\9)B?@-MBZ6;ZKB@
M8%I0,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRI);E<;O?)7G\
M;MGF&7?0Z8+"QR9OQF')@H*I&$S%8"H&4S&8BL%4#*9B,!6#J1A,Q6`J!E,Q
MF(K!5"RUK)C;$"\IYC?0MEBZJ8X+"J8%!5,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY8$I3VHVS^W"FQ*7\=E-B6#930E\-'`:-BTHVGY%.\Q8,6/E
MC%4S=IRQ>L::&3O-6#MCW8SU,S;,V-E:5LQMB!<LJ%N_@38+*IBY*4';K6C*
MDV[(+XM1>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0GM2R/V_TNR>-W
MRS;/N(-.WZ'P"<#;<5BRH&`J!E,QF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,
MIF(P%4LM*^8VQ$N*^0VT+99NJL,[U"U,"PJF/##E@2D/3'E@R@-3'ICRP)0'
MICPPY8$I#TQY8,H#4Y[4LCQN][LDC]\MVSSC#CI=4/@$X.TX+%E0,!6#J1A,
MQ6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93,9B*I985<QOB)<7\!MH62S?5<4'!
MM*!@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.5)+<OC=K]+\OC=
MLLTS[J#3!85/2MR.PY(%!5,QF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,IF(P
M%8.I6&I9,;<A7E+,;Z!ML713'1<43`L*ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\
M,.6!*0],>6#*`U.>U+(\;O>[)(_?+=L\XPXZ75#XI,3M."Q94#`5@ZD83,5@
M*@93,9B*P50,IF(P%8.I&$S%8"H&4S&8BJ66%7,;XB7%_`;:%DLWU7%!P;2@
M8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E2<WFN<MO2GS]Q_PN
M4V7W*X+9^Q77^!#%-&Q::[2]?H=63R;SQRP/,U;,6#ECU8P=9ZR>L6;&3C/6
MSE@W8_V,#3-VMI;%='OE!6OMSN^MS5H+9NY7T'8KFO*D>_7+.E4>F/+`E`>F
M/##E@2D/3'E@R@-3'ICRP)0'ICPPY4DMR^,VQFF>_\%:\WML6V[<=R?O:_Q(
M[=TX+%EK,,6$*29,,6&*"5-,F&+"%!.FF##%A"DF3#%AB@E33)ABII;%=-OH
M-.83'ZF]\]MN6RS=BH?WM3`N67]::QBG/##E@2D/3'E@R@-3'ICRP)0'ICPP
MY8$I#TQY8,H#4Y[4LCQNS[PDC]]CVSSCOCM94-?XP-+=."Q94#`5@ZD83,5@
M*@93,9B*P50,IF(P%8.I&$S%8"H&4S&8BJ66%7/;Z"7%_+;;%DNWXG%!P;2@
M8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E22W+X_;,2_+X/;;-
M,^Z[TP6%#RS=C<.2!053,9B*P50,IF(P%8.I&$S%8"H&4S&8BL%4#*9B,!6#
MJ5AJ63&WC5Y2S&^[;3%OR5^%V:[N8%I0,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E@R@-3'ICRI);E<7OF-(^[&ES^QXWN_-;;5O-F_W#>-3['%`XU?SB/
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MC%4S=IRQ>L::&3O-6#MCW8SU,S;,V-E:]M;JKIG2;$^]`OEK+)O'6W;?&3_C
MN1^'Q96H8C`5@ZD83,5@*@93,9B*P50,IF(P%8.I&$S%8"H&4S&8BJ66%7,7
M@TN*^8M'6\Q;<M]++YXPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0_L_W-V_LMI
M&U$4?A5/'J!>`9)83>H9@VU^V(#M-W!;V<G4*1E,IZ_?[R"7`/=D,NE?B<_1
M!>W]D'2U*^V")VC@"1IX@@:>H('G4#O!HS+V9_!T9>\QGDX[/J#*6*#N-SLX
MH((&L:!!+&@0"QK$@@:QH$$L:!`+&L2"!K&@02QH$`L:Q((&L:!![%`[)I9/
M[RY^<`K<;7]R2_&N'1U04;LJHG9MM!NC38PV-=K,:'.CW1KMSF@+HRV-MC+:
MO=$>C/9XK)W@T4W$X0'U_P=R<G<_<G2LO6LGQ]I)T3NF9&(OC@9#@1DT8`8-
MF$$#9M"`&31@!@V800-FT(`9-&`&#9A!`V;0@!DT8`8-F(?:"4S='AW"_-&Q
MUMU.'1/KM.-C+6C@"1IX@@:>H($G:.`)&GB"!IZ@@2=HX`D:>((&GJ"!)VC@
M"1IX@@:>0^T$CV[M?@9/=RMXC.?]!I)_]K<2_3)T->3]9M\N7E&#6-@.8D&#
M6-`@%C2(!0UB08-8T"`6-(@%#6)!@UC0(!8TB`4-8H=:1^S\[5/;;J^>MD\7
M'[^TFY=VW+Z^OIW]OOY;DWEIL.Y`/]NTS[]^&'&6;?BPI#OA?<S>*^3MUFR)
M7D]>S\?UY>WF8@YQ=85'I[G[OKJ65UMOJ#ANTES<4'&4Q]8;RMLM@1#V99CE
M91M7*R\\[N(^LU9>>,[`>LH+P];64U[`8+V!O('W2GF[WHK0ADIQ/*#L/K-2
M'$_'6D_YY#E,ZRF?/`1H/>63Q\VLIWSRK)/S2L7Q[ISU%,>+6\ZKQ('7I*PG
M#KR?8CUQX$T(ZXD#C^$[KU0<TSI83W',*6`]<:#WR'KB0#^*]<2!EW2M)PZ\
M(>J\@>*8<<QZBF.Z*^N)`Q,K64\<F-7'>:4X,(>.]<2!R4N<-U`<TPA;3W%T
M&%M/')@IU'KB0*^K]<2!60^M)PY=KU\XCGK*)\LLN;B^XEACP7J*8W9[ZXD#
M4ZM;3QR8J]MZXL!$T<[K*9\LI&H]Y;/K_8KM4SY9Z-#&*9_=*%2,4SY9S\W&
M*2]=UV*(*Q3'6O<NKE`<BZ=;3_EDY6[K*9^L$6T]Y9,%BJVG?++>K?.2XI*/
M2XI+/JX0A\)S*,2A*X!B7L2A\!P*<2C\[SHI+OFXI+CTG3AQ2)Y#$H?D.21Q
M2)Y#$H=D.63"LHW*!&4?`X)L"60`9)__I/PGG_^D_"=[7AEB,01E?@E#$LQ(
MC7-(+P,<SB&YC`@8)^-D[Y#T;'->X_BKO(HF7S.I9/(54TU6&20V^U:35496
MC3,DJ0QG&J<BQE_952CY.DEEDJ^2:G+M:Z2:7/L*J2:COCZJB/%7<Q5'OC92
M:>0KHXI<^[JH(M>^*JK(M:^)2F+\%5P%D:^'2G+MJR$50[X6JLBUKX0J<NWK
MH#Z?QA)HAO:`??,UPH!]\Q6""@1?'Y3LFZ\.5&SY6JL'.7_5Z4'.7W-T"?=7
M\!X46&G0M+1'2QE"=`XM96&[Z%P6S:4]3]!,>V:AD79[?K;NK'(Y:"Z_<_=$
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MKK_L_ONI??JCW6@#-GY>K[?__<&A>O[/>O/GKF/JXE\```#__P,`4$L#!!0`
M!@`(````(0!BFUTR&PP``+E%```8````>&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULK-S94N-(%H#A^XF8=R!\WX!ELT9!1V%KWQ4],]<N8\!1@`G;M?3;STGM
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MR^UFMWG8'TNXDVI#^9VO3JY.)-+MI_NU?`/5[$?;U</-Z//XNIB<CTYN/Y4-
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M;3ON'_5;Z;`JRF<5YF8DWT!ZY$X.-M]O+>O\T\EW.4`LZS)W+#/62\R:$NIH
MH,+.3;!-<$QP3?!,\$T(3`A-B$R(34A,2$W(3,A-*'IP(NEI<R1[_S^1(Q5&
MY:AIW;L&>DDS$M*4:*K,3;!-<$QP3?!,\$T(3`A-B$R(34A,2$W(3,A-*'J@
M)42.*?]$0E28FY'\V^LT%WH&[NHRLB5MH3.]R*PMTF8)8D,<B`OQ(#XD@(20
M"!)#$D@*R2`YI.B+EC0YO/\325-AY&`I?;5-B&5=ZBFYJPI-WLM:6Z3-&L2&
M.!`7XD%\2``)(1$DAB20%))!<DC1%RUK<B[6LC9\^=B<AE3I,CE-H]Y5,I&]
MHI>N*SU=L[904VT.L2$.Q(5X$!\20$)(!(DA"22%9)`<4O1%RX5<VQR0"U5:
MST4EDHNFF6>0.<2&.!`7XD%\2``)(1$DAB20%))!<DC1%ZWAY;KJ@(97I?6&
MKT3O!)-3HQ.TA9KLS"$VQ(&X$`_B0P)("(D@,22!I)`,DD.*OFBYD&OD`W*A
M2NNYJ,2JAJGJ(G<&F4-LB`-Q(1[$AP20$!)!8D@"22$9)(<4?=$:7H:<6L-7
M(Y7C"SE<[9_6RZ]W&SG"RVEYX`PQD1%)-4Y10?1\U&)U!R7(O!)K6@YLIN.K
ML:7W';LMT/0=!^)"/(@/"2J1`7`3.81$;2TU[IJ.+RSC_!:W!9H@"22%9)`<
M4E12;9Z6+37N__OI*J/H^6JH:Y$9:5[31+:O.^]/C/&FW95J&L9A+)?D=17[
MX8V]PN]*->$#Q@I)45>Q'][8^K@KU81/&"LE95W%?GACZ_.N5!.^T&+IZ59C
MU_X\PD`OE.FOIANJRV>C']:DYLAZ&9OH'6W6E6HV:MY15U&ZJ%[1KDM-JCX\
MOCP[/35.@$X7J(GMDKR.WEF=KZ]N<GYQ?FF,[((N4+.ZD!1U],[J8GUU0]\N
MZ0(UJTM)64?OK"[75S<YFUR.C40572!9G;ZKJ%'U`;M*-0B7>,UVWZGI0-E[
M+#E5]':5J9[Q65>JJ3@GV35-U+[Y_79HKVA7UH1Q&<8C^7KD<YG]U3<P8)V0
M%)%B/3*W.6&=E)21<CWR^>3"V.9"JZ.G50V\^VG]2^=G-5UK'A@J,@X,QH;-
MZHI2JDG3O*;J)D=Y^K<;DJN[=L\97QG[KL-8+LEK8I7W4,KP?D/OA@\8*R1%
M3:PN?-S09;FOROTL',,2!DI)61.HBYTW5,4>3\_&QO1MH<714Z]&[W\_]=4<
M@-;1*S(ZNK%ALW%;JDM]3?W3_\`YH2HU.2W;<WS%]G08VR5Y#;V[.K\N5:]N
M<C&5FU#F(0%?)6QB7[8[=M30NZN+C=4-?+ND"=3%3DE90^^N+C=6=S&].#6.
MR$43J%R=O@>I.8?W]J#?-F]_=''?OZRHIBZT7:BB_GA+W=]1IX_NC#(GV22'
MY)(\DD\*2"$I(L6DA)22,E).*C32<Z2F)_HY^I-+O&HV0\M%.\'1'7VMB7%=
M-%.WT"0]O6FB.<DF.227Y)%\4D`*21$I)B6DE)21<E*AD9X>-6-Q0'JJ"0XM
M/17U&GXV!LU)-LDAN22/Y),"4DB*2#$I(:6DC)23"HWT7*A)C`-R4<UY:+FH
MR)BR,VXSS-0-6[.K@&R6<D@NR2/YI(`4DB)23$I(*2DCY:1"(ST]<B8[)#VJ
MN#$)49'654!S=1M?3X]-<D@NR2/YI(`4DB)23$I(*2DCY:1"(RT7UM`\D64=
MRSGZP$<0RDAZFFHR>I$Q.S;K2K77CR2;Y)!<DD?R20$I)$6DF)204E)&RDF%
M1GKF#IORD<LMLQ?5U.]%I#G))CDDE^21?%)`"DD1*28EI)24D7)2H9&>B\/F
M5"S.J=2D=Y6I,44VZTIU7:6*U4NBS5(.R25Y))\4D$)21(I)"2DE9:2<5&BD
MI\><&WG_TMGB)$A-O5:>D>8DF^207))'\DD!*21%I)B4D%)21LI)A49Z+M00
M^^/79G+3!X>M>MI`LM1.(EE38\)Y5E?L96Q.LDD.R25Y))\4D$)21(I)"2DE
M9:2<5&BDIT<-S@](3S66[U\ZJXG"ZJJK2\_X'"?]ME1W)`/97:RFE$-R21[)
M)P6DD!218E)"2DD9*2<5&NGI.6P2P.(D0$W&B<:8")MUI9J&GY-LDD-R21[)
M)P6DD!218E)"2DD9*2<5&NGI.6P2P.(D0$V]P]:,-"?9)(?DDCR23PI((2DB
MQ:2$E)(R4DXJ--)SH4;B!QS)JH&[=B1KQ_+=D<R:&G<K9FIV7!]ESDDVR2&Y
M)(_DDP)22(I(,2DAI:2,E),*C?3TJ,'Y`>FIQO):>C"\GUF@.<DF.227Y)%\
M4D`*21$I)B6DE)21<E*AD98+N26BYT+=._Q+DP!E)'T2H";CA&/<FYAUI=H3
M#LDF.227Y)%\4D`*21$I)B6DE)21<E*AD9ZYPR8!)IP$J*E_PB'-23;)(;DD
MC^23`E)(BD@Q*2&EI(R4DPJ-]%R8DP!_O1=Q?D`]RVY>55M3\RY\5ZKK16W%
MAFR6<D@NR2/YI(`4DB)23$I(*2DCY:1"(SUSA\T/J$.9Y*)_+JI)ZT55J1[-
M6<HF.227Y)%\4D`*21$I)B6DE)21<E*AD9Z+P^8'Y($RY&)P?L!\:J&N*!O2
M](LYR28Y))?DD7Q20`I)$2DF):24E)%R4J&1GAXU2/_X99L\UX7T8)@_JTMI
MN4`IFZ4<DDOR2#XI((6DB!23$E)*RD@YJ=!(S\5ADP'R(!9R49'JC;VI-/.)
M@+JBEIZV8M-[;)9R2"[)(_FD@!22(E),2D@I*2/E)/4.OVK5JG&J]%3OY%>O
M^;ZLMH^KV>KY>7>TW'Q3[]M/U"->+5<_!G`WF<BO`92'(BR9RI*I.DAAR9DL
M*9^WPY)S65(^7&8NL2ZNU9!Y()IU*4O*)X-0YTJ67`W5F9S*>LJ?(3#K3-2O
M&Y0/^&"))4O*A\?-)9;4D5LL0]LF=61V?VB)M)O,-0\MD7:3:<ZA)=)N,L,V
MM$3:329W!I:,I8X\FC.T1.K(4R%#2Z2MY1F%H272UG)[?&B)M+7<K!U88DE;
MR\U`+I$?DO@\V#;2G,.M*8$&XMRI77#`/T^O/P_O3-+"@PTL;3785-)2@PTE
M[3383-)*0XTTO[J6%S78$-'5=3[D\C+"M7K5@#7D/8)K]98`E\@K`-?J`7\N
MD:?WK]6S^;+DI-V#Y8<SWA:/JWBQ?5R_[HZ>5P_2T4_+=V.VU4]O5/_9UX_1
M?=GLY1<SY!)27OB7GTA9R6M(I^J6^\-FLV_^HU;0_NC*[?\!``#__P,`4$L#
M!!0`!@`(````(0#LN`R3]P4``!`8```8````>&PO=V]R:W-H965T<R]S:&5E
M=#4N>&ULG)C;;J-($(;O5]IW0-S;T$USLN*,`J/LCK0CK59[N"88VVB,L8`D
M,V^_U50;N@N'D,E%$IN?\M=_55>9OOOTO3I9+T73EO5Y:[.U:UO%.:]WY?FP
MM?_Y^W$5V5;;9>===JK/Q=;^4;3VI_M??[E[K9MO[;$H.@LBG-NM?>RZR\9Q
MVOQ85%F[KB_%&:[LZZ;*.GC9')SVTA39KK^I.CG<=0.GRLJSC1$VS9(8]7Y?
MYL7G.G^NBG.'09KBE'7`WQ[+2WN-5N5+PE59\^WYLLKKZ@(AGLI3V?WH@]I6
ME6^^',YUDSV=8-W?F<CR:^S^Q21\5>9-W=;[;@WA'`2=KCEV8@<BW=_M2EB!
MM-UJBOW6?F";U/-LY_ZN-^C?LGAMM?^M]EB__M:4NS_*<P%N0YYD!I[J^IN4
M?MG)M^!F9W+W8Y^!/QMK5^RSYU/W5_WZ>U$>CAVDVX<5R85M=C\^%VT.CD*8
M-?=EI+P^`0#\MJI2E@8XDGWO_[Z6N^ZXM;U@[8>NQT!N/15M]UC*D+:5/[==
M7?V'(J9"81"N@GA`KZ[S-8]\Y@?O1W&0J%_@YZS+[N^:^M6"JH'/;"^9K$&V
M@<AR91[X@QS#6M]:*JQ1!GF04;9V:%MP>POY>;F/W3OG!2S-E2292IBI2*\*
MF0F@&Q!AX3KB;=.O)%(L2602)%J";T#L`8V3SYTJPA'>(`&#EI-(,9BI?7!,
M5IR@1&@2G[#-*0PT"+(<38JW-JQ[\"0FIB0HB?I<KH0?<Q%1-D/B!;['@FC`
M-^"@R'6X:Y'-9U+>1/SSAO"86Y0`Q[`.RCBG,!`#$W$>38J)?X*@H23H_6-1
M$`;F]52_+D(>#I<-*MA1NG'S5%),J(@="4J0B@=N$(V%WCN:Z@(6NX$[EJP!
M)B<;:1L"O)X'E#<10&)+@A)E6\`]?ZPH!-0%/!">&&O"`(RG@+*OS0/*FPC@
MF!@L.92(/J_4/+RFW/4B'H7CW08<`Q+=OGFJ7FUB1>.J$4MIE''"\P*B2)6"
MDIM<L@5K:7V'"QNVWD9H/24,-<H3:!&,3\!TB7"Y/]:$"2?[M`:WK(LP[.XZ
M9$QJ*E$:!<E\ES3#U!`(/QP#F(2R6W^<$'L\_!ZZ6!P/[4"E=VX.X,9@<Q(3
M4S9N#?.=+&.;UPWT2`H3AAHT<,4"+F+2>5(B8<(=.Z9))UNV1K<PS=CH#4J"
MD,AO;+"]D3+V)ZW%N+[B/M?JP$0DPV(AXG1J,)>TD(3I<X$%7B#&W:#RK"M6
MGL?>^K+"/C0\>K799+36JJI0GPXB#MUQ'R@V71`S5XP;R320C(]W*G`Z-Y@V
MEQ2;/AA6S(N%%TRL,S2A$)#B8:.9@&1\O`.(C5_?P4RK'05XG1SC-B<%FK(Y
MB<''R0!95H']76:.F4OWLA+1.8$)5A=Q"PE7_MPVD)-)LA!P.E&@B(9/0"/[
MT-=M'(0N#XDB-12<1V]3RN'PX5[#Y5W41I++1(G0J=N4&$8IYBAE9]<HYXN1
MXQS0.R%SR4Y(E`@_>Q5RX=('@-24,!:\N5GXA^9)KZ;NC=^35([U@0(/R9!D
M,A)3%0>7`!*]#,R]0@;*._9-!PFC?2Z1S]O#)/%YP"*R@-101*$_EJC)]E.3
MA.,(,/L-\2=1(C!R^%I!:C2=E9B<'YHE',>`48)L;!0JQ2AZH\_<OF@RD2&R
ML,7@##"\8^-#CF)#T:QW<Q*3D\R2A9PX"TP/QW&J.%&D]H#KAH%'EI)R72*X
M*X(Q$0:F?#K2N\PRS/XNLIL9'2E*=,4,0GBPI!N&:GQMPIN</S59O!N3A8V;
M$NU4HMLEJ2[B(D3XYDSQ9%O7NO5"'^5=U$>R7Y,^]'7R^3I!SY^JZY3?M(\,
MDX5X-X8*HT,%3F#E&O#,B/OAY/N7*7"AJ0^C'1GQ`!;/)ZNB.11I<3JU5EX_
MR\-5#@_=P[O#P>\#EV=]Y/T$#H3[TU-GN`#GL9?L4'S-FD-Y;JU3L8>0[CJ$
M5M[@B2Z^Z.I+?RKZ5'=P$MO_>X23]P+.$MTUB/=UW5U?R)/*X2S__G\```#_
M_P,`4$L#!!0`!@`(````(0#OY-+[00,``(`*```8````>&PO=V]R:W-H965T
M<R]S:&5E=#8N>&ULE%;?;YLP$'Z?M/\!^;T!DZ1IHI`J7=6MTB9-TWX\.V""
M5<#(=IKVO]\=!HH3DJ8O"([S]]UW=SY[>?M2Y-XS5UK(,B)T%!"/E[%,1+F-
MR)_?#U<WQ-.&E0G+9<DC\LHUN5U]_K3<2_6D,\Z-!PBECDAF3+7P?1UGO&!Z
M)"M>PI]4JH(9^%1;7U>*LZ1>5.1^&`37?L%$22S"0EV"(=-4Q/Q>QKN"E\:"
M*)XS`_'K3%2Z12OB2^`*IIYVU54LBPH@-B(7YK4&)5X1+QZWI51LDX/N%SIA
M<8M=?QS!%R)64LO4C`#.MX$>:Y[[<Q^05LM$@`),NZ=X&I$U7=S1&?%7RSI!
M?P7?Z]Z[IS.Y_ZI$\EV4'+(-=<(*;*1\0M?'!$VPV#]:_5!7X*?R$IZR76Y^
MR?TW+K:9@7)/01$*6R2O]US'D%&`&8531(IE#@'`TRL$M@9DA+U$)`1BD9@L
M(N/KT706C"FX>QNNS8-`2.+%.VUD\<\ZT3HHBU6'=L\,6RV5W'M0;_#6%</N
MH0L`;F.R"%V4IX*$Z!!DC2@1F1$/^#5D]GE%Z6SI/T,VXL;GSOK`\\VG\_`A
MFBXD"*,?TG!Z6F9T1F9,%X9R9PU]FG"89NS2H/+)R6JT=+@(\MX706\Z?!N!
M]9GT?*:=AR,47"X7BLY0I+XP2N<=L*6V3A=0@]`^-8H/Q]AV)[JQU8_KZBBZ
M?#<6V`UO=>W5WA%\[;*>KRPZNU2-Q>ZR?L=`X_75G,=%9Q>WL3@2PJ!+K2,!
MAW%OOYRG0F>7JK$<2YB[N'5!YI=4!!>Z'(W%E4.'Y5#PNEQ/[>V2M:9C1=BJ
M?>AZM`2P/<_GK%YVP(%(8'(5G=C6]$/CH_8^8&LFR("B@9$QA>9Y1Y"=!Z"K
MVS.T,;F"QB=*]*$Q0;LY\<;6F`8$#8R!\63T[A3`4^N@Z5J3*VER0M*'!@$]
MG@2M:4#2P2RH-])T?H&FX[D`EX&!OCL<YO:\MX=JP=66?^%YKKU8[O`L#^$T
M[*S=/6,=8C,<VB>+M;U_^-T?./\KMN4_F-J*4GLY3P$S&,V@`,K>(.R'D15T
M,=P"I(&3OW[-X*;'X40,4'LJI6D_@-GO[HZK_P```/__`P!02P,$%``&``@`
M```A`'>7/*T6`P``V`D``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6R4
M5MMNXC`0?5]I_\'R>Q,<[@BHZ%;=K;0KK59[>3:)0ZPF<62;TO[]SM@A38"J
MX07(<'S.G/'8D^7M2Y&39Z&-5.6*LF!`B2ACE<ARMZ)_?C_<S"@QEI<)SU4I
M5O15&'J[_OQI>5#ZR61"6`(,I5G1S-IJ$88FSD3!3:`J4<(_J=(%M_"H=Z&I
MM.")6U3D83083,*"RY)ZAH7NPZ'25,;B7L7[0I36DVB1<POYFTQ6YLA6Q'WH
M"JZ?]M5-K(H**+8RE_;5D5)2Q(O'7:DTW^;@^X6->'SD=@]G](6,M3(JM0'0
MA3[1<\_S<!X"TWJ92'"`92=:I"NZ88L[-J;A>ND*]%>*@VG])B93AZ]:)M]E
M*:#:L$^X`UNEGA#ZF&`(%H=GJQ_<#OS4)!$IW^?VESI\$W*76=CN,3A"8XOD
M]5Z8&"H*-$'DTHA5#@G`)RDDM@94A+^X[X-,;+:B0Q:,HO%TQ@!/ML+8!XF<
ME,1[8U7QSZ,89M6P1#4+?!]9)L%X.ACV(`E]1L[@/;=\O=3J0*!K0-)4''N0
M+8#XLB-(`K$;!*_HE!+(U<`V/*]9-%F&SU"ZN,;<>0Q\OF$:1`BBC3*H]5=&
M,"IC/3"5.Q]HRT2798;7R"`8-J>=?#1M>+VRQXQ:F'&#Z!@$2'^#"(8]:!MB
MT:PA]M(>U$,:FJJ_-(*==%/<.@+GY&T3HWF33,?EY!HI!'>EZH@_?^WV@"YK
M6\`C%XUF>+X^:%)<V-6H(QT[P\%E.WAE]SX/".Y*U9%S._,NK[M!HE'PH1M<
MUY6H(UTW[+(;!JC^=ARZ*W8,G1O"5FU3.T?#<3#]T));>2*#9!#JFGKG1+.K
M;@Z'/E&K+X\+IDYN"S0UZ=-TS-\*8*TY1,=0U]/PG8VZZK)@S6WQIE:'+GC"
MT]QJZ?Z><.%)Y>I0U]/HQ).?HW[,%$+OQ!>1YX;$:H\S,H+!T42;^;V)L'*G
M\=%BX^=ZV/P#<[7B._&#ZYTL#<E%"IP#UW;:3V;_8%4%N<-P518&JON9P1N4
M@.$QP&.7*F6/#Z`<-N]DZ_\```#__P,`4$L#!!0`!@`(````(0`780(&2!\`
M`)["```8````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK)U;;]Q(DH7?%]C_
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MKH>Q#__`\+<WU_=W#W<?'U]IN)/^0)GS]F1[HI'>OOYPHPR"[$?W^X]OCM\5
M%UVQ61V?O'U]4.A_;_9_/"3__^CA\]T?]?W-A_^X^;J7W)JH,`6_W-W]&D+;
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MUS'F?2;&1EP.$:%FP[`[#TH/*@]J#QH/6@^Z!)Q(EE$;G2`_0YLP3-!FR.K]
M`":Q%DZ((6+HLO.@]*#RH/:@\:#UH$N`$4(G^<\0(@RCBXTIDHW-_'V,T9&,
ME>3JZ'(,&=4!*4$JD!JD`6E!NI08D71A^QDBA6%T,JHF1P&*Y9E3J0]:/J72
M&#*J!%*"5"`U2`/2@G0I,2KITFM4RM^TALM*B#Z(,23QOB=+S4(BS[F5YW(,
M&KKM0$J0"J0&:4!:D"XE)G?=B&;D'J)M[CU1[D-:ER`[D!*D`JE!&I`6I$N)
M253W`9-HN*DL%J\DS,S;2AC(:M`3-_];-_]CT"#4#J0$J4!JD`:D!>E28F21
M/S"R/%W[(=KFWI-T_D%V("5(!5*#-"`M2)<2DZ@,S8Q$0[1-M"=VDE>G;I+'
MH'&204J0"J0&:4!:D"XE)O=@HF8D?PBWV4>4SC/1CJ@DJHAJHH:H)>H,LCD'
M!^5=Y&K^Z1[N>JX4(G*U4+A:F*+&8B`JB2JBFJ@A:HDZ@ZP^P5BE^CQ]YA>]
M#]-X0S;O(S(UT4<E:,>HDJ@BJHD:HI:H,\CF'(S2C)Q[7V5RCE;+W.M7WBH7
M8]0@UHZH)*J(:J*&J"7J#+(R!"<T0X;>.!D9HI=*;OL%T(ZH)*J(:J*&J"7J
M#+(Y!P<T(^?>,)F<>^3.^J4_Z\>H:>J!RK`THHM*<IY41#510]02=099&8(_
MFB%#;Z>,#*G#.KPCOBR`=D0E4454$S5$+9&6MQ));<[!_*0Y!^NW7+Z:EEQ^
M?$FA]U%&C]%:)>Y_M?)E,49-90%4%D`544W4$+5$G4%6HF";4HF>N1GT+LO(
MD!JO6!9`NP*H)*J(:J*&J"7J#+(Y![LT(^?>79F<1\.53KU?&BC&J&GJ@4I&
M540U44/4$G4&&1D6\[SA(=QZPXB2B]DET8ZH)*J(:J*&J"7J#+(YY[SARZX(
M"]K#B-R-PBTJ74Y18UD0E40544W4$+5$G4%6HGGV<$%[&)$I"]I#1I5$%5%-
MU!"U1)U!-N=@VW[\BK#H75YZ18C(3;U;*;N<HJ:IAV,L&541U40-44O4&61E
MF&</%[2'$9FIISUD5$E4$=5$#5%+U!ED<PZ&+)WZ%R\/A0^`W/O%B%Q5^`7"
M*6JJ"MC$DE$544W4$+5$G4%6H>"O4H6>M@B+WHZ9DR-U:+U%B%%)H>R(2J**
MJ"9JB%JBSB";<_!C:<XOKXK>V1DY1K.7N@>_;+@8HZ:J`"H951'51`U12]09
M9!4*ABY5Z)FJZ/V?D0&6\#)\:FO?'>V(2J**J"9JB%JBSB";<W!O,W+NS9[)
M>?1_R=2O_6+B8HR:IAZH9%1%5!,U1"U19Y"183G/.!["K7&,*#G[+XEV1"51
M1503-40M46>0S3EG'%_T*<*2OC$B>YM8^V7%*6JL"J*2J"*JB1JBEJ@SR"HT
MSS>&CPO=W3(B4Q7TC8PJB2JBFJ@A:HDZ@VS.WC>^^#81YM[+,3K#]%KA5QQC
MQT2T'5%)5!'51`U12]099!6:9RF7M)01Z26&LK\DVA&51!513=00M42=039G
M;RF?OC4NZ1LC"K).'RRO_8KC%#4HLR,JB2JBFJ@A:HDZ@ZP,\WSCDKXQ(C/U
ML)([1I5$%5%-U!"U1)U!-N?@T'[<(2Q[0Y<ZA(C<U/M5Q2EJFGJ:0T951#51
M0]02=099&>:9PR7-841FZFD.&542540U44/4$G4&V9R#0TNG_N7W@M[KF:H8
M[5]Z0?`+CLLQ:JH*H))1%5%-U!"U1)U!1J'5/-]X"+>^,:*T*HAV1"511503
M-40M46>0S=G[QJ?O!2N:PXC<!<$O*DY1X]03E40544W4$+5$G4%6AGGF<$5S
M&)&9>II#1I5$%5%-U!"U1)U!-N><.7S96O.*[C`B5Q9^P7&*FLIBM)4#*AE5
M$=5$#5%+U!ED)9KG#E=TAQ&9LNBC$K1C5$E4$=5$#5%+U!ED<Y[G#L,75]P;
M@XC<U/M5Q2EJF.<=44E4$=5$#5%+U!ED99CG#E=TAQ$E\WQ)M",JB2JBFJ@A
M:HDZ@VS.WAV^V"*L:!PC<E7A5Q6GJ*DJ:!P951'51`U12]099!6:9QQ7-(X1
MF:J@<6142501U40-44O4&61S#A8M-8[/6(3>T:7N<#6:O,0=;ORJXA0U3?W8
M<4`EHRJBFJ@A:HDZ@XP,ZWGN\!!NW6%$Z=03[8A*HHJH)FJ(6J+.()NS=X?A
M@O`RB["F<XS(7A$V?EEQBAIJ8$=4$E5$-5%#U!)U!EF)YCG'-9UC1*8LZ!P9
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ME913R:B*J"9JB%JBSB`KPT^SDAM:R8BL0F=^M6F*FA2BE6141503-40M46>0
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MHLX@*\,\OWA&OQB1E6'C_>(4-<E`O\BHBJ@F:HA:HLX@*X/WB\]4`TWAV>CM
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M,:HDJHAJHH:H)>H,LCG/<X#G=(`1V:D_]\N"4]0T]72`C*J(:J*&J"7J#+(R
MS'.`YW2`$9FIIP-D5$E4$=5$#5%+U!ED<_8.\.5?0CNG.XS(E85?,IRBIK+H
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M,C),S^`.KV6>+:N'<(/I*=Q@>@PWF)[##:8'<8/I2=PI<^G/,Y'%*5WDP%PA
M^$7&)&RLA`R3(OU+)&I*$3`I`B9%P*0(F!1)F5-DGI\L3FDH!Z9G.`ZI7F:8
M"J+OF\0I?3"E#Z;TP90^F-('4_HI<^E[:_GTFG-Q2@,YL"0MI=_')4SI1Z:C
MF9ZB<N[6(:7(&#:H*44PG!0!DR)CW_0EW'J71!K#AI>02.EP3B3O+H/3*M:'
MYQ8_?KZY_O7]70#9;9"6VN_H\(B]=\4I7>?`$IVD71^7,&D7V?34'0D%)J'0
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M.@73Z0XF)2,[[%IYN)?IW$:<E`.3<F"2">-)EC3.RG+862;]/?X+SN:X.TWZ
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ML>O`-!%@4AU,$H-)8C#I"2;Q4N:4"M[<*_6RAU<4<?L>JU;O_<W[?EV!K)]0
M)8]A@S)2"TQJ@4DM,*D%)K7`I!:8U$J94RLX[E2M9]ZNQ)U\K"*]:T^6+I0^
MF-('4_I@2A],Z8,I?3"E#Z;T4^;2#^YY3OK1;9M+6\]<03C'(T7&L*0@P*0(
MF!0!DR)@4@1,BH!)D90Y18(/GJ-(],U&D9[9@@!308`I?3"E#Z;TP90^F-('
M4_HI<^D'7SHG_>AC3?H]<P6!MYEF)Z"#GY0B8]>A2*0(F!0!DR)@4@1,BH!)
MD90Y18(EG:-(M+!&D9[9@@!3^F!*'TSI@RE],*4/IO3!E'[*;/J'37MFI!\W
M^3$7R&GCG^D&NSAU"P67Q10V3+XV*^Q-;**<=BL$TW:%8-JO$$P;%H)IQT(P
M;5F8,J=(,)!S%(F&,RT(+>JYSP24/IC2!U/Z8$H?3.F#*7TPI0^F]%/FT@^^
M+4W_\#[L)1OW%G'G'ULKO2UT%P^W7"&QQK"D5L`D%IC$`I-88!(+3&*!2:R4
M.;&"3TO%>L9>Q$V`K"*]UTM.`:4/IEH!4_I@2A],Z8,I?3"E#Z;T4^;2#\9K
M3OJ]4;/IC^8MO7A@B<AL)13O)F129!QN*!PI`B9%P*0(F!0!DR(I<XH$+S9'
MD=Z[6452/W=(504!IH(`4_I@2A],Z8,I?3"E#Z;T4^;2#\8K3?]O7#QZ#V>5
M&7U=6BMN\45BC6%##4@L,(D%)K'`)!:8Q`*36&`2*V5.K&#34K&>NWCTMLXJ
MDEJ]H5;`E#Z8T@=3^F!*'TSI@RE],*6?,I=^\&1STN\]G$U_]'5I06#9Q>PM
M-%P\QJY#D4@1,"D")D7`I`B8%`&3(BESB@2;-D>1WM9915*K-Q0$F`H"3.F#
M*7TPI0^F],&4/IC23YE-_[`-4)I^N'B\<&4C;BEDI)FV&4J+Q:V@7193V%`8
MVDPZM8L'5;6;-)BVDP;3?M)@VE`:3#M*@VE+Z90YM8*%2]5ZYNH1MQ"RBJ0V
M,!:+V6HHGBMD2A]]E3Z8T@=3^F!*'TSII\RE'TS9G/1[$V?3'XU=6A!NK50%
M,88E!0$F1<"D")@4`9,B8%($3(JDS"D2?-H<17I?9Q5)O=Y0$&`Z'\"4/IC2
M!U/Z8$H?3.F#*?V4N?2#*4O3?[GUB'L,665&SY?42H%E4;,]T7#VC%V'^I%8
M8!(+3&*!22PPB04FL5+FQ`H6+A7KN8M';_FL(JD-'&H%3+4"IO3!E#Z8T@=3
M^F!*'TSII\RE'TQ9FO[?J)7>WUEE1L^7U@I63,U^1D.MC%V36@&36&`2"TQB
M@4DL,(F5,B=6L'"I6,_52F_YK"*C#9P4*?@1C-G::%!D[)HH`B9%P*0(F!0!
MDR)@4B1E3I%@X>8HTEL^J\AH`R=%%@464<W&1X,B8]=$$3`I`B9%P*0(F!0!
MDR(I<XH$5S='D=X%6D529SA<3\!T/0'3]01,Z8,I?3"E#Z;TP91^RFSZAXV(
M9J0?-RXRZ4^;&:4%@474*6R8_%U!5F98E6%UAC49UF989YE3)#BW.8KT3L\J
MDKJ_6!!FKZ-X/I`I??15^F!*'TSI@RE],*6?,I=^L&EI^G_CK4S<ZLA*,]K`
MM%BPBFIV21K4&KL.!22UP*06F-0"DUI@4@M,:J7,J15<7:K6,W>8N+.1521U
MAD.Q@.E<`5/Z8$H?3.F#*7TPI0^F]%/FT@\^;4[ZO:^SZ8]>+RT(K**:_9&&
M@AB[)@4!)D7`I`B8%`&3(F!2)&5.D6#=YBC26SVK2&K_AH(`4T&`J2#`E#Z8
MT@=3^F!*'TSII\RE'\Q8FO[+[6G<%<DJ,WJ]M%:PBFHV5!IJ9>R:U`J8Q`*3
M6&`2"TQB@4FLE#FQ@D]+Q?JS6%U=7WSX:[=_N-Y_U1+2:?AIU/BUR;@+DE4D
M]7I#K8"I5L!4*V!*'TSI@RE],*4/IO13YM(/IFQ.^KV)L^F/QBXM"*RBFKV4
MAH(8NR8%`29%P*0(F!0!DR)@4B1E3I'@T^8HTOLZJTC/]#'ID-9E$?=02I@*
M`G$J"#"E#Z;TP90^F-('4_HIL^D?MCU*TW_YQ2/NH&24F7952FL%BZA3V"#@
MKB`K,ZS*L#K#F@QK,ZRSS(D5+%PJUC,7C[AADE6DMX%)75P6,2YA2A]Q2A],
MZ8,I?3"E#Z;TP91^RESZP9/-2;_W<#;]R*:O32I],*7?L_!A^OC]U47A%ENE
MR!@V%(X4P7!2!$R*C'V?>`F)-(8-+R&1TN&<2,&YI2*%$RK],O6/?6LX;KAD
MM>M-H;XJ.QR)M`.3=CW3)_&'GS.=^I_)2+8Q8AA)LF$DR08FV<:^<73WIE.*
MC1'#Z%(L'<DI%IQ=JMAS9U7O!*TTD1EIP"1-S_1)P7!H$@-,8J"OQ`"3&.BK
M],&4?MK7I1^<79K^"PNF-XA6E9Z%3^"GD\C_-$`U-(8-HDBHR.2DQJ[ZP97]
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MTC-]!#BDH((`4T&`*7TPI0^F],&4/IC2!U/Z*;/I'S:;FI%^W)S*I#]M6)46
MA+M`7!93V*#2+L/*#*LRK,ZP)L/:#.LL<XH$4SI'D=[$6D5Z9@K";%H5SP<R
MI8^^2A],Z8,I?3"E#Z;T4^;2#W9S3OK1GDXNYWTQ[565%@36@*>PI"#ZX1+E
MI`B8%`&3(F!2!$R*@$F1E#E%@IV<HTBTGT:1GB5IZ7P`T_D`IO3!E#Z8T@=3
M^F!*'TSII\RE'^QDFO[+W[7'C:SLJ1(=K`Y@=""+!9:'S1Y8P]DS=AWJ1V*!
M22PPB04FL<`D%IC$2EDOULG#Y_W^<7?U>/7V]>W^_M/^<O_ER\/1]=UO89FO
MT/Y4"3^ZWW]\<_Q>E^6+P[591S_V&=HVIVK3%3/;5H2V0WFQWR*T'=Z:L&T9
MV@XW*;:M0MOAUZ]H6YVK3<M:N6-9A1RTYI-K6X<<M+22;0LYZ/U_MNTLM)WE
MV\*QZ':>Z[<*N>O#G&Q;R%V?=&3;0NY:\\^VK4/;X:$)U&43VC;Y?B$'+8[F
MQER&?OI:0[8M]-,'_-FVD+L^ZLZVA7G0Y\"YME68!WT2FVT+\Z"/"W-MR]!/
MGC_;%OKU;VVARS+,@[X.ENT7YJ&_#+)?F`=]-2C;+\R#OC>3:UN$?OKF>[8M
M]-.;TFQ;F`=]"SK;%N9!7Q'.MH5YT+NM;%N8!WV3--=6A'[ZO5>V+?33CZ%R
M;8LP#_I94+8MS$/_3@1Z+L(\:%4KVR_,@U9M,FU;'8H>8)9IT8.]U$M/]\JV
MA2/1<ZZR;>%(]!"H7%L1CD2_*LZVA9G5;V@S;5MUT^,X<RWJI(=6YEI4#'I8
M8ZY%I:!'&N9:5`AZRE^N1=.I9^%E6L[51X^4SK6HCQZ\G&N1ZGK><*9E*]'U
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MA4GKO`<+%BSOP-0E>Z4JU$//0<J]OI3NWP+3L:DE>]4YF*3L5:>0TEF']*ZX
M>)<?2QURQQ6F.<?#"97A[U87[[[SCC&<G)D>[S6-V5G4)&;G4%.8G4%-8.Y>
M([UUK.&QD51=BZ^+"ZVVYC+40NKB0BNGN3;U6X9^.074;QGZY=K4;Q7ZY8Y%
M_5:A7ZY-SVL*Q?Z=:C^4^W?JO0@%_YV*ER[O\[J$!Z5>')[XF=-,;7KZ6NXX
M]0"VY87^DVO3@]B6%_I/KDT/9`N:Z5FG?#VU!5WZ?B?CR?'P]O6WJT_[_[RZ
M_W3S]>'HR_ZCEE1.#\\^O;_Y%%:C^G\\QH?3_7+W^'AW>WA.W>?]U8>]'G5X
M&CYR^WAW]SC\0R]^\L?=_:^'99NW_R\`````__\#`%!+`P04``8`"````"$`
M<JYZ[\D#```D#0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R<5UUO
MFS`4?9^T_X!X7\!\&(A"IB;0;=(F3=,^G@DX"2I@A)VF_?>[QH5@R$C7/K3!
M]]QCGWLNSNWJXU-9:(^D83FM0ATM3%TC54JSO#J$^J^?]Q]\76,\J;*DH!4)
M]6?"](_K]^]69]H\L",A7`.&BH7ZD?-Z:1@L/9(R80M:DPHB>]J4"8?'YF"P
MNB%)UB:5A6&9)C;*)*]TR;!L7L-!]_L\)1%-3R6IN"1I2)%P.#\[YC7KV,KT
M-71ETCR<Z@\I+6N@V.5%SI];4ETKT^670T6;9%>`[B?D)&G'W3Y,Z,L\;2BC
M>[X`.D,>=*HY,`(#F-:K+`<%HNQ:0_:A?H>6,4*ZL5ZU!?J=DS,;?-;8D9X_
M-7GV-:\(5!M\$@[L*'T0T"^96()D8Y)]WSKPO=$RLD].!?]!SY])?CARL-L%
M14+8,GN."$NAHD"SL%S!E-("#@"_M3(7K0$529[:O^<\X\=0M_'"]4P;`5S;
M$<;O<T&I:^F)<5K^D:!644]BO9!`Q@L)LA:6[R(7WV8QY(E:@5'"D_6JH6<-
MN@;V9'4B>A`M@5DHLZ$^\AR]UG])!8V"Y$ZPA+JG:Y#.P)_'-;:\E?$(-4U?
M,)LKF$"%;#N(J*#@C;J%"R]24^(.(>P#2;TNJ-90UW6GNN,+L#A^M^]&+@!W
MK\=2]]U.$9ZI0J(I9$023Q$#$D6.K<KI;)J7)9)"'3;I5:#`50^YD1B_]<P/
MO,!6X]MAW'-\-(I'P[B%3>R/JA`/`2@PL7EQ4%'HO$6A2%(58LM7%6PD!K<*
M+3>P<1"@RQG:/ML.,<CWL&.[_LBL:(BQ'-L)G`!A=:]XB$$^W-*.95T*HNB%
MEVW8H*]S5"2I>E$P?L\D1CIZV5OJG(E%,['X>DS1@U4]\YTIP*H.;(TN@XW$
M0$7[[AWU[O8F(KJ)B.<0BCZXW/[?+Y&DZIR^@1(C^_/:&SB,>[;OCGHN&L:O
MOH%#`+(<Z-V^:Q6%8EJY\E4P[Z1(4A5B>]1U&XF9<_(F(KJ)B.<0BL[@+3I%
MDJISZJ3$..U-,ZK!=A@+W-$[&PVCH\Q8QF1_H``YU\U#\*7]_^ZU6:HL;(\N
MQ\T+:,Z_VY#H-B2>A2@6PK#W%K5R6)C_0FRI0_WZ_3D7C.:"8CP5#21IL0,_
M(Q_E\"EGLY(T![(E1<&TE)[$8&E#4_6K_=![9XF19;2^04L8I*;KD1B2Q;K1
M)\",6B<'\BUI#GG%M(+L82MSX<%UW\@I5SYP6K>3XHYRF$[;CT?X;X3`B&8N
M`+RGE'</8H/^_YOU7P```/__`P!02P,$%``&``@````A`&\?0U\^"```%B0`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULK)K?CZ,V$,??*_5_B/)^
M"1`(`6VVVO";4*FJKNTSFY`-VB1$P-[>_?<=8QMC#Y?;]-J'<OMA9K"_'MMC
MR,-O7\^GR9>B;LKJLI[J,VTZ*2Z[:E]>7M;3OSZ'GU;32=/FEWU^JB[%>OJM
M:*:_/?[ZR\-[5;\VQZ)H)Q#ATJRGQ[:]NO-YLSL6Y[R95=?B`G<.57W.6_BS
M?IDWU[K(]YW3^30W-&TY/^?E94HCN/5'8E2'0[DK_&KW=BXN+0U2%Z>\A?8W
MQ_+:\&CGW4?"G?/Z]>WZ:5>=KQ#BN3R5[;<NZ'1RWKG)RZ6J\^<3]/NK;N8[
M'KO[`X4_E[NZ:JI#.X-P<]I0W&=G[LPATN/#OH0>$-DG=7%83Y]T-S/,Z?SQ
MH1/H[[)X;P;_GC3'ZCVJRWU67@I0&\:)C,!S5;T2TV1/$#C/D7?8C<`?]61?
M'/*W4_MG]1X7Y<NQA>&VH$>D8^[^FU\T.U`4PLP,BT3:52=H`/Q_<BY):H`B
M^=?N^E[NV^-ZNEC.+%M;Z&`^>2Z:-BQ)R.ED]]:TU?D?:J2S4#2(P8+`=23(
M#<<%<X0K<]3-V<JRS.7*AL??\#29)URYIS.S=<U9_,`1PG8=ABMW-&>ZJ2U)
M?V\\<,G\X,K\C)EI6/:J$^J&H\T<X2H>^*$^PASMF@I7[KD28W/CD0YSA"MW
M_*"L.B0@S0>2B72LS9FQLG3K1P+I?2K!/_AC(>L^Y,LS2!<I](-,F--$[N:%
MG[?YXT-=O4]@L8&G-]><+%VZ2\+Q&4'UZN?(]Z8(S`T2Y8F$64]AT"#[&YC7
M7QY-QWZ8?X&YN&,V&VRCRQ8>MR`3CX3U51"H(%1!I()8!8D*4A5L59`-P!R$
MZ]4#P?X/]4@8HA[O]X8#(:>A2,4MN(NO@D`%H0HB%<0J2%20JF"K@FP`)*E@
MT4)2+6#:C"^]/*^(%RRR4EZM9"DVS`8>W">?)9MXO4DO%R(!(B$B$2(Q(@DB
M*2);1+(AD72#)1OI1K:L.R<H"0-S'!*Y%\ET'%FF#35:W%*R-^F51"1`)$0D
M0B1&)$$D162+2#8DDI(@FJ3D[<PCUIU@O*,;2A8P4@,)E47.ZXVXFX](@$B(
M2(1(C$B"2(K(%I%L2"1]8*^^0Q]B+>M#">C#N^XAXB,2(!(B$B$2(Y(@DB*R
M120;$DD,V,KN$(-8RV)0(B6+I6GR?/-Z(ZZ8CTB`2(A(A$B,2()(BL@6D6Q(
M)'W(B6A8-]R>3,1:UH<2@U;&9*_W$/$1"1`)$8D0B1%)$$D1V2*2#8DD!E2.
M=XA!K&4Q*!F*@8A/B3U<FPUK*2=4T!OQA`I1H`B1F'G!9BP6MM5"#IT@MY2Y
M#5MD:4I)M^V->(NR82!)15)-2S+26G1&CBCML=R];BIH'^Q@([FV@)J35:(D
MBBQO%W@]'>J+D<^0+=:O`*,0.T88Q=Q1VFY7IB(I=DRYH[3)J(Y;8=6K*L62
M927%Z\>G*BD15/TH(D>^/D$L3:U(F2-8\4;Y&`4,+<SND&!KMN:8ME*NA=@O
MPBAFR(*$&C1+S5OLF`HD''5'S5QF9>I=2[69KD3.1!CHL"PYS(E[)"?F2LI2
M9,"2T_?-7"F5KT<.;.`(5D)RA`)F90YSRM*49`Q%+/%$7:T0(V'%GQ@SM!PN
M'Y:F#&F"'5.!AD]$PT`[!*TGITH8!GD292(*&@524]^1^,1<&06*E,17%EU/
M[ZVX)CY&`4,L\74+WKPL=30(*%2$0\4,*8FO5*()=DP%NJDX;01+?'NFR?_9
MP2=EZF<B+AH#4HT/Q^"_K>FTIH<)QQ7>Z!3)$T2=PYZPXHX^0Z98I@*&+`C9
M3S9+4R9;*&()JY$)TK>+/S%FCO:29["RD"0B,O=)&8)6#A^FY/Z664'#V=Q0
M(F=29'F)(L>`GQ\8$D69,Q0I<T8Y:7KD!$M6+C$*/D.+93_(`4>KKG\KPUX9
M2T,1(<2A(HQBAI0YH^B58,>4(6C6S9&@_5G8?"3456K87WD@R!'DYP>"'F2D
M&4*1-$,L73V"Z+T5SSV?(V<P$-0*WM>01/O>0*!0$0\E-JB8(66[0`.!8J4\
MUG"[']FUJ:/53S9U((:!Y8$@9YU;`_&YND*JCY:?D,=]_4F/3-)(4"35GPCY
M.D(!1B%&$48Q1@E&*49;C#()R8J1`Y&JF&',(-?O?#NETZ.5)!I%\@E:5R:_
MQQP'+QU\C`*,0HPBC&*,$HQ2C+8891*2=21'HJ&.(P><88;1$Y0D%D52AB'D
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M"T.C<MN%-Y,C?.7"2[H1KH,#[&-C=\`%5N:Q.P[<Z6H@Y>FIX\)K+>P!+V]<
M\FH&W\E(J+$;\'N')V/$80._@^B&7WGTQ@"EQNP7+GQ!P@]^,B%^]WL*-1!(
M/LHM%SX0X$`;Q]V,]L!S7&_TAN^XY/T9#A4Z+GF+AF]$CDO>I>$;B>,F],:\
M[P;\*N.:OQ2_Y_5+>6DFI^(`V:5U[PIK^KL.^D?+BK;GJH7?8W3UVQ%^?U/`
M&V>-%"J'JFKY'_#D>?^+GL=_`0``__\#`%!+`P04``8`"````"$`021JJ'4#
M```1#```&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R45MMNVS`,?1^P
M?S#\WOB:I`GB%.F*;@4V8!AV>59L.1%J6X:D-.W?CY)LU8J=U'D)8OKHD(<4
M::[N7LO"><&,$UHE;C#Q70=7*<U(M4O</[\?;VY=APM49:B@%4[<-\S=N_7G
M3ZLC9<]\C[%P@*'BB;L7HEYZ'D_WN$1\0FM<P9N<LA()>&0[C]<,HTP=*@LO
M]/V95R)2N9IAR<9PT#PG*7Z@Z:'$E=`D#!=(0/Q\3VK>LI7I&+H2L>=#?9/2
ML@:*+2F(>%.DKE.FRZ==11G:%J#[-8A1VG*KAQY]25)&.<W%!.@\'6A?\\);
M>,"T7F4$%,BT.PSGB;L)EO=AX'KKE4K07X*/O//?X7MZ_,I(]IU4&+(-=9(5
MV%+Z+*%/F33!8:]W^E%5X"=S,IRC0R%^T>,W3'9[`>6>@B(I;)F]/6">0D:!
M9A).)5-*"P@`?IV2R*L!&4&OB1N"8Y*)?>)&L\ET[D<!P)TMYN*12$K720]<
MT/*?!BE%GN92H3T@@=8K1H\.U!O0O$;R]@1+(&YCT@PFRG-!0G229"-9$G?N
M.N"?0V9?UM,H6GDOD(VTP=QK#/P:3&`0'D1C0H(PNB$-IZ?U+,'2LTR7#.5>
M&[INPF$WD>U&*H^@II?=R4.`ZXB81K'AUQ%H3-S%&(0E%"#CA4HP%*DK;!I-
M#;%VK4$C7,.%&>]:@I5KD^3&`NDRQ>P6W%(YN\:5!-NN&HMNK>XU@=LV7H($
MV[R-Q98P,_FT),@)W&F2RU=$@FU7C:4O86'SJN:+(;#+#N0IVT%CL;7,A[4$
M@!HO1J%M9ZVI+T=>SBZUU+/P)W.X+9<5J8,G7B07F&Q-MV<T734R@F9$J,&H
M^Z8U#6@:&!.!#PP?*-)#`(29G@D:DZUH<4;15;,A,,/AW5MC&E!TTOMJ\,63
MCXO4-'U74F.R),7^&4E7#8*@/PE:TX"DJV9!T!\&K<D6<N;[%%PU#A3ZY&Z?
M'0C!P$28+T;4IC\3%-5I`\5GOH4A".]V[N7+K="VI-;4KTTX,!1FMW+#^:"%
MU,$3+T-#(7Y?-/30U@N8WG)*S';X"RX*[J3T()>K$-838S6+WR:4C7IJCY<;
MB`)>>.8-+&0UVN$?B.U(Q9T"Y\"I9QS3*YU^$+2&V&$MHP)6,?5W#ZLWAA7%
ME_7,*17M@W1@EOGU?P```/__`P!02P,$%``&``@````A``MX2/T%$0``MEL`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK)S;<MLX$H;OMVK?P>7[
MC:V#+9N59,L2Q?-)U&&O'5M)5&-;+DN9S+S]-D0TF\"/4:S=N9BQ\Z'QHXD&
M0:`)\^.__WA^.OM]_;;;;%\^G?<^7)Z?K5\>MH^;EV^?SI>+X%\WYV>[_?W+
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MW[<_P[?-8[9Y65-O4YQ4!+YLM[\IT_A1(:I\`;6#0P2JM[/']=?['T_[>OLS
M6F^^?=]3N*_HBM2%>8]_^NO=`_4HR7SH7RFEA^T3.4#_/WO>J*%!/7+_Q^'G
MS\WC_ONG\\'UAZO1Y:!'YF=?UKM]L%&2YV<//W;[[?-_&J/#%;4B?2U"/[5(
MKR-RI.)`5Z2?NN*M-'ZDWE#7HY^Z7O_FP\W5U?#Z9D1N'ZE)I8?KI9]MB[WA
MY;6ZVB/5KG6U4:=:VTM'ZM%M=FCNMJWW3C][-!*:P%#7MYZ^I\D>1T/]HFN2
M&T><['$8U"^Z1G<4'*O*D5!C[C0WN4M[](NNV7M?#'L4A:9ONN$8]2YO![^(
M?H_CH7YI&WU7KU($FS8EE.\;JWV.I/JE;?-=@[7/=Z?Z15>]^="_N>I=_6K`
M]GD4J%]TU:/^7C03PV&>\>_W]Y\_OFU_GM'D34WO7N_5HZ#G*3&>89I1T<XY
M?S7ET%RC5.Z4S*=S"AC-)CN:)W__?'UY^_'B=YK;'K3-&&UZIL6$+=1$IF1]
M&TQM$-@@M$%D@]@&B0U2&V0VR&U0V*"T066#F0UJ&\QML+#!T@:K#KB@$+=Q
MIM#^'7%6,BK.'*$Q`PE\WPHJ6W`5WP93&P0V"&T0V2"V06*#U`:9#7(;%#8H
M;5#98&:#V@9S&RQLL+3!J@.,H-*$_G<$5<G0RJ!S\PYN1F84Q]J&/&GO\"O3
M9-*:M)$&,@42``F!1$!B(`F0%$@&)`=2`"F!5$!F0&H@<R`+($L@JRXQ@D_/
MYK\C^$J&)G^:-]K`7O<NS=".&Z/!L>BW)FWT@4R!!$!"(!&0&$@")`62`<F!
M%$!*(!60&9`:R!S(`L@2R*I+C.C3@LR(OGM'P(]G97T(,@=GW!"U\FC#/KBU
M;OI):\35?"!3(`&0$$@$)`:2`$F!9$!R(`60$D@%9`:D!C('L@"R!++J$B.F
MM%0^(:;*VHQI0RBF'*X)$!_(%$@`)`02`8F!)$!2(!F0'$@!I`12`9D!J8',
M@2R`+(&LNL0((*U_3PB@LC8#V!#KIKPQY^)):\11]C7ISLZ#D;7ZGK9&7"T`
MH1!(U-;J3A.6=-P:L70"0BF0K*TETL-+:_&8MT8L78!0":1J:W6EAV8_SEHC
MEJZ[0D9<:3MY0ER5M1G7AG1O3""^)OW#YJE_V;/<G;;E[&X`&B&0J*W5[0GK
MZ1ZW1BR=@%`*)&MK=:4'9B?GK1%+%R!4`JG:6EUI:[DY:XU8NNX*&?&C3;T1
MOV:3^T&E$_;?-P^_C;?T$*1'H>,A.J!X-%M<)6*&M2%7LAN:-*03:%^303LG
M3X$$4"L$$K6UNEUB[9_CUHB[)`&A%$@&M7(@!=0J@51MK:Z+U^:`F+5&[&+=
M%3*BII)D_W_8#BIFW#122<%V\3.\M!<_8L6N^HSH`=!6[-U:49BRU>AP*_<N
MKT>W])_9#P$;-5E;E>P($46,CC88:ZNK[O7T;JU;,6$M:3%%E#$ZVF+^KA8+
MUI(62T05HZ,MSMCJ6*?6;'1HT!Q+*B\">2Y*8^L98+%]/<P`[Y\.U([)F@\T
MZM,\U`Z/X:7]_!8K&5>-5I]NA;:B8UPU5H/+H^-*2]VT$TZ(#4:,CC88:ZLK
M,S(PKJ#%E.7%B8S1T1;S=[58L);(EX@J1D=;G&FKHYU:L]2A07-<J=0,C*LK
M>;3PP'(\6FC^X6>+2N;;@ZE!G6?)1%MUD(]HBBA`%"**$,6($D0IH@Q1CJA`
M5"*J$,T0U8CFB!:(EHA6!C+CK=(Q&&]^`?/^?'F3UE$#J[WCKWO6DV2LWMC0
ML#B:=Q$;F4[::HRF:!4@"A%%B&)$":(4488H1U0@*A%5B&:(:D1S1`M$2T0K
M`YF#0F5INH/B%S=[D]2AV'-XQKT&T9TMPV%HOT"9B!57]!%-$06(0D01HAA1
M@BA%E"'*$16(2D05HAFB&M$<T0+1$M'*0&:H:<%P2JB5N;7X;%!G$I^HMZMD
MU4$^HBFB`%&(*$(4(TH0I8@R1#FB`E&)J$(T0U0CFB-:(%HB6AG(C"NM<8RX
M_D];1/6RVPYW@X:R!IYHJP[R-;HR5HZ=++SIJ\I3G##=-&D-8[K1F0X:=^W3
M9V@_?2;J1;P:EN*ZK]%5=TTU[$G2QO13[<=/\+/9OAM^-LA<4/>L!>A$O>U7
M?LIRT-?HFG:0G0N4E(KI)UW-*7XJ<^N>;I"YH>Q9"8M)K[62Z;M!5G_*GMGP
M4YTP.,'/@[GIIT96?UI;TXE8M7YJ9/6G[&Q,/]6&X/UQ5P\]JS\UZDR($T0^
MHBFB`%&(*$(4(TH0I8@R1#FB`E&)J$(T0U0CFB-:(%HB6AG(C*M[KW/RVE<=
M,VD"+C?G=6<2.:3;QMKJZ-I7;&2D-N)4C=$4K0)$(:((48PH090BRA#EB`I$
M):(*T0Q1C6B.:(%HB6AE('-0V!NBXVO??KOOX?",-5+CKC-76^\8)F+%%7U$
M4T0!HA!1A"A&E"!*$66(<D0%HA)1A6B&J$8T1[1`M$2T,I`9ZM.V.7W<YFA$
MH>8@3A#YB*:(`D0AH@A1C"A!E"+*$.6("D0EH@K1#%&-:(YH@6B):&4@,ZYJ
M^W'"\[K9K737:6KAHU9@,NE.&$FH?48T0\N-WK=>1DW%BL=(P$BT0D01(U/>
M2JG$8L7R"2.13Q%EC$QY:RV:BQ7+%XQ$OD14,3+E9<5Z>"C.Q(KE:T8B/T>T
M8-25[_>L278I5BR_8G20-X>-O67ZQ<R/>Z-^@XQAHY%<C2]6ZEBIX\VH&+#7
M`2.1"1%%C+J=,NS+;N;0Y[%8L7S"2.131!DCN2MR1`4CT2H158Q,5ZT=QDRL
MV-6:D<C/$2T8_=7;YZ48L/**T4'9'!FG;5#[N$'5R!@9>C<J%^*CU111P$@J
MAH@B1A*L&%'"2+121!DCT<H1%8Q$JT14,3(#+SM$/2_HSI$6:ZXH\G-$"T92
M<8EHQ>B@98;:WN/_3WD3M2&UMX!Z4R^.3;159_7@,^J\7D<4,)*N"!%%C$0K
M1I0P$JT44<9(M')$!2/1*A%5C&CEW'EL6IOVF5CQ#5HS$ODYH@4C<76):,7H
MH&6.`)7".&'UT&0\C-6#SHM(_F:BWH2J!84@']%4HZ&X'J!5B"A"%*-6@E8I
MH@Q1CEH%6I6(*D0SU*K1:HYH@6B)6BO#RH@KO1$]):X'<S/;I)%:0<C`M6:N
MB1CQN/4%23U\&ZZM!L-C;\-%BM5#1)&@(PW&VHK^W*]K92T`$]'B%E-$F:"N
MEK56S=_58B%:W&*)J!)TI,69J\5A7_)\AZ=-[=:R%I-SL6*_%H*..+%T.0''
M65:B1?+FR#TM_SC`_*-&G2?-!)&/:(HH0!0BBA#%B!)$*:(,48ZH0%0BJA#-
M$-6(YH@6B):(5@8RXTIKH!.>-"IS:"TJ-#)337UKX$[$B@>NCVB**$`4(HH0
MQ8@21"FB#%&.J$!4(JH0S1#5B.:(%HB6B%8&,D-]6E9Q@%E%C8Q;N+'J(!^M
MIH@"1"&B"%&,*$&4(LH0Y8@*1"6B"M$,48UHCFB!:(EH92`SKJ>E$.GA#K>P
M1IU]`5L)\C7JA'J**,"*(:((*\:($JR8(LJXHK&;&U@IL%RL>`(J4*M$5$E%
M>;X.^W822:Q8OD:M.:(%5Y0-Q1+1RJAH1O^T1.,`$XV,)-031+Y&1O1UAE)<
M#[!BB"A"K1A1@A531!E7-*,/JS[MJEQC@5HEHLHIW[=S1&(ET=<=+2W.47[!
M%:4+EXA61D4S^J?E"P>8+V0D?DX0^1H9T8>L8H`50T01:YD1LS.$8L5=FJ!6
MBBB3BIW[=6!M*7*Q8OD"M4I$E53LRL-TH#M'>K5&K3FB!<MW!P1T],JH:`Z(
MT]*$`TP3,A+7)XA\C=0[3-F'PGL'L>)>#E`K1!1)Q8[\P+KM8K%B^02U4D29
M5.S*6]OH7*Q8OD"M$E$E%;OR=G9)K%B^1JTYHH54%'E\[R!6++\RM,QA\[>D
M'`>8<F34'4W:2I"OK>@UJ7X=8=VN4S'@BPE0.404247I*WP=(58LGZ!6BBB3
MBAWY@;6WS\6*Y0O4*A%54K$K;^VM9F+%\C5JS1$MI**[VY=BP,HK0\8<0Z<E
M+0>8M-2HDZ&<(/(1337J)BW1*D04(8I1*T&K%%&&*$>M`JU*1!6B&6K5:#5'
MM$"T1*V5867$=7A:TO)@;B8M-5(_Y&%AS;83;42931YKOB"IATE+;45+9#6*
M!U<W-_V!=8L$HL3B(:)(T)'V8FWUBYRE:'&+*:),T)$6<VVEK[`_N.G?C*RG
M22%*W%Z)J!)TI+V9MC*N<#BT=E2U6\OJ^;E8L5\+04><6&HK?=%7-]?#:_OT
MYTJ42-P<M*?E*]6E6GDMC3I+W@DB']$448`H1!0ABA$EB%)$&:(<48&H1%0A
MFB&J$<T1+1`M$:G/_QU>51U6P4U<F\_Y-9_9>EZ_?5M/UD]/N[.'[0_UJ;[;
M:[KY6]Q\1W`\;#\D:)7<]0;>71-8JX3^.LA3?Y1"PPE*AE0R=)9<4<EAVK+K
M],D#9SMW_;YW1U?I:(=*U-%`5PGY1DLD5PGY1F>1'"4#\H"ROUA"7UF\<[9"
M%5SV8^660V=,3KE\NAMZ=_0G7]CPF'QUNDJ]Z.S$:X\^#N'0Z9%'SA9H<^)-
M::V+=6A?X:E=`Y;0EL!3"WXLH=6\-W.6T$+<6SI+:$%+'AQ>M%I#@A:DY(&K
MA-:2Y(&KA):!Y(&KA%9PY(&KA/(UY(&K/RG[0AZX2BB70AZX2B@-0AZX2BB#
M01ZX2BAG0!ZX(D<9`/+`54*;=_+`54+[;O+`54);9O+`54+GK&C,NGMG2+ZY
M1B%E)LDW5PGE&<DW5PFE",DW5PEE]\@W5\EX0*.7<O4XWL8#=4>Y;BDZEN:I
M`PA8ATZG>>H<`I;0(35/'4%SE5"_T7DC5PF-:SJ>XBJA\>9LAT[D>>KL!=:A
M@WF>.H*!)70^SU.G[UPE%&VG;W1VATI<OM&9#BIQM4-GTCQUX@S;H1-*5.)2
MHY,K5.)2HZ.-GCJQ@FITPM%3!U>PA`XZ>NJP"I;4(Z^^=?`QU1@[:]`I4$\=
MVT$M.@SJJ:.>KA*Z%YT]0.>]J,35`W0.B$I<[=#944^=_\%VZ`BIIXX!80F=
M)*7^=/F6T<3K:C^CZ="EE-UZ]"T-;*$8>?1%#>3ER*/O:B"O:""YVJUH&+G:
MK6X]^M`&ZH0CCSXM@CRBH>72CVA@N?2C6X^^-8(ZR<BC+XX@3T<>?7<$^7CD
MC5U\,O(F+N[3`'#YZ5/X77[ZMQY];@7;#48>?72%^$7[R*.O)K_>?UOG]V_?
M-B^[LZ?U5UJJ71[^CO^M^>YR\X^]_E#$E^V>OI=,>T?Z9"I]'WM-'_"X5%^3
M^+K=[OD?JH'VB]N?_RL`````__\#`%!+`P04``8`"````"$`ZEU!GJ@1``"Q
M7@``&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RLG-MRV[BRAN]WU7X'
ME^_'%B7J6(E7V3P?1:K67NM:L95$-;;EDI1DYNUW@P`(-GY:EE(S%R/G8_</
M$(U3@Y0^_>NOE^>KGYO]8;M[_7SMW`RNKS:OC[NG[>NWS]?_]^_PC]GUU>&X
M?GU:/^]>-Y^O_]X<KO]U][__\^G7;O_GX?MF<[PBA=?#Y^OOQ^/;XO;V\/A]
M\[(^W.S>-J]TY>MN_[(^TC_WWVX/;_O-^JEQ>GF^'0X&D]N7]?;U6BHL]N=H
M[+Y^W3YN_-WCCY?-ZU&*[#?/ZR/5__!]^W;0:B^/Y\B]K/=__GC[XW'W\D82
M7[;/V^/?C>CUU<OC(OGVNMNOOSS3??_EN.M'K=W\`^1?MH_[W6'W]7A#<K>R
MHGC/\]OY+2G=?7K:TAV(9K_:;[Y^OKYW%JNQ>WU[]ZEIH/]L-[\.G;^O#M]W
MOZ+]]BG?OFZHM2E.(@)?=KL_A6GR)!`YWX)WV$2@VE\];;ZN?SP?5[M?\6;[
M[?N1PCVF.Q(WMGCZV]\<'JE%2>9F.!9*C[MGJ@#]_^IE*[H&M<CZK\_70RIX
M^W3\_OEZ-+D93P<CA\ROOFP.QW`K)*^O'G\<CKN7_THC1TE)D9$2H4\EXK@W
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MMS]I;GI4-@]HXW`+3UN(B4C(^C8(;!#:(+)!;(/$!JD-,AOD-BAL4-I@:8/*
M!K4-5AUP2^%I8T0#Z)^(D9`1,=*M^Z"!"=K0"HBVT"Z^#0(;A#:(;!#;(+%!
M:H/,!KD-"AN4-EC:H+)!;8-5!["`T+0$`7%IWNA?5O48$5ZT@';&B.M:#?Z@
M;*C@=B"-K9BT)FU0@`1`0B`1D!A(`B0%D@')@11`2B!+(!60&LBJ2UB,:/Z'
M&(FY_<*)3<C0W$A#LPW(Q'%Y2!ZDT>A4U%J3-FI``B`AD`A(#"0!D@+)@.1`
M"B`ED"60"D@-9-4E+&H4(!:UTR-*6#?!T8WZ(,F(>D4;+M>U1U!KI-U\(`&0
M$$@$)`:2`$F!9$!R(`60$L@22`6D!K+J$A8+VLY<$`MAS6,AR5`F`V(Y]X#X
M0`(@(9`(2`PD`9("R8#D0`H@)9`ED`I(#635):SA:1MU0<,+:][PB@S;E=X#
MXDLR[$Y9KCOA\UK0&NF!$H)0!"1NO;ICT)).6B,MG8)0!B1OO8RT,YOS6A>M
MD98N06@)I&J]3DC7K9&67G6%6!!I+\V"*#?6-V)??_R^??SS84<S%"TK/3/<
MB#;0<ELM1'AL%>G$%H@OR=!M]N&N,W>L74;0&NC;"$$D`A*W7F)[[SIC=\H;
M/FD-M&P*(AF0O/62LE#;HC70LB6(+(%4K=<[M:U;`RV[ZHJP6%*ZS6+9$S,Z
MR]!!$]8\:)(,2;^S*EFMY[5&NCX^D$"2D2CKY]UL/IU;.58(+A&0&$C"9*>C
MV=@:K2FX9$!R(`63'4X&D]F`]Y@2?)9`*B`UTW6&[M"UFF'5]6&1%.<?%X2R
M,>>Q5,@EH4XP9_S&/&5%O:*-)J)`:W5WEP[$%!TC1#&BQ,B+[C(?6STN19<,
M48ZH,,*F#:#>)3HN$56(:H5&<@*C^<O:;Z^8#X^OR*'M\PR:"2^8<\5>WQJ_
M"KE\M;36'4]9T3`W,9=:E!MJ%"BKR0<QEXX=K<A40FO%&AGYY"SY5%EUY#.M
M95:67",C7YPE7Z+\4FL9^4HC(U]K-&LFN(E+__&!M6+2//04'0B],[YPQ17'
MEG;T)>(C?FQ-99YR9"->.@YIH]=.%=2;^1T%RG$R?'=21^E((:J3Z0SGE);P
MTJ;NS#ZF2[&T#$O+M=7)>RMX:;U+@!8RO6")Q57:ZF1QM;::-DWIS`>3@=7:
M*VW2%,?[CSA*L*>.;O_Y]^[MO1U;9_479]9V!Y*H,]H\9=5!/J)`(7?41CE$
MJPA1C"A!K12M,D0YH@*U2K1:(JH0U:BU8E8\1N+@P([1A=.[/'N@>42/G`?Q
MK(!"9@UPJ^=XRHH-<.GXT0"75J<&N-(Q8R`R==+5C'4%3HZ!1%FITOHV<UK'
ME)9A:;FV.EE:P4OK'^!P<TLLKCJKN%I;G1K@W>)XYQ$G'7;G^8T!+@],6`>2
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MSCK9$L^:[5$J$5N&G;F5M'K*D8U2Z?C1,BRM)MUG`\[<2MQ#(]^=*JQ4+U)6
M;/M]3B42Y7BZ$NE9E<BP$KEVI)GL_8RC.*L2I=;BDZ;5$DNL1*4=3U:B5E9C
M+F^%8Z6UN)6I!.^9XMCG5,\\<P<O3X_8`J\.E,R$XCF`?$0!HA!1A"A&E"!*
M$66(<D0%HA+1$E&%J$:T8HC%:&@?P/WF"R>-3K/*FYX^<:PG?0_*ZN2366.C
M=]H^H@!1B"A"%"-*$*6(,D0YH@)1B6B)J$)4(UHQQ`,I3JBZ@^WTH3@]!K3G
M>X7$1SM9N1-[OC=6)CSJ<,R,Q@"M0D01HAA1@BA%E"'*$16(2D1+1!6B&M&*
M(1X><1IT07CDX5%WSA//!L7VR+2RA\A'%"`*$46(8D0)HA11ABA'5"`J$2T1
M58AJ1"N&>"SLDZ4/A@J>(`W5"5)W&73MI,,S5F:H2,>)?&(TO!G/^7_!'R:U
MX'46:?0%_4=FW:S_J$2<]D5F>-NGC9[([:Q-N$(3]H1E8G8&O)[4))?44YCS
MY%!DA:(&O&VME<0S5J9MI:-JV\'-?#`<LM9M#WIYC46:>4'+RJR4M:Q$=+;0
M;5F8.%LK4V.)>,LZ[[6LR'(NJ*=,BE@]59[4G4$`^4-``:(0480H1I0@2A%E
MB')$!:(2T1)1A:A&M&*(]QF17%P0"YF+L%A()!8,,QJG9O`W[QMXHDOQ.=]'
M%"`*$46(8D0)HA11ABA'5"`J$2T158AJ1"N&>'CLQ..#"1X3C"%D$QXB'U&`
M*$04(8H1)8A21!FB'%&!J$2T1%0AJA&M&&*Q&-D)QNE8-.9\05#(6A"L$S[/
M6+73JT)CBF5GC)EW$W@]Q2;V_"$]DGO>[I!62'1+4QPLL,;*U%-J\65@:IZT
M\GI>MI$4J9:UP"IDM:>]P!HK4T^I9;6G<>3UO&R3)5X1M>NI-EF\/>UE53E2
MJYMZJDT6V["\MZS26PT\[K^9`#<ZD`!;)[D/RNID`FQLS!W)71FY:12@58@H
M0A0C2A"EB#)$.:("48EHB:A"5"-:,<0[G-C^73"`Y6Z1#6")K#79"J%';WO9
M:S*B`%&(*$(4(TH0I8@R1#FB`E&):(FH0E0C6C'$PR/VNA>$1VZ-67C4!KJS
M?1T!\A$%B$)$$:(848(H190ARA$5B$I$2T05HAK1BB$>"['%[\;BMUZ&'<E$
M@85((3-/>=K*(%\AD1Z;A7)J3>R!L=)S7HA:$:+8.';E35;5;*T38Z7E4]3*
M$.7&L2MOCL`;^<)8:?F2:?%XB&U^-QX?[)%D5L`:7B'3RMX(D*\0;4%TI0)$
M(3I&B&)T3!"EZ)@ARM&Q0%0R1]Y^E^WW1[C?5XCOB>S78SUCI=O/1Q0H1"N5
M>,V37H>=TS-7JW>'Z!<AB@TR?0W>6$N4E>LT!=)7QZTE*S4RNMX9HAQ1P95'
M-W-+N60^+";BL2'KT[\UQS0J/!U0B&^S9W8Z8*ST+?L*=5_^U$B^W^A.'6=F
MG^*%J!0AB@TZ%2E=GOA&P<^[YJOB@^Y_UEVD1E7?188H1U3P@N8W]I.8DOGP
MP-F)T.\%#O,CZI]BXS2A-;N=]H<CJT=YRHI&HKYE7SN:K\H&&LG`#>?T,Q:#
MD37%AR@5:3_SCD2,*-%HWM8A1:U,6QFM'*T*A>A#WT_)K'C;V\F=W?;G/3$5
M+T9;R91"W:<'B'Q$`:(0480H1I0@2A%EB')$!:(2T1)1A:A&M&*(QTADE]W%
M6L;H\F^RRBR55G$S'":.M4X\T'LN(I0G$T9CH[N8CRA`%"**$,6($D0IH@Q1
MCJA`5"):(JH0U8A6#/%`VIG_Z5V7*W/P[JY+(9XPVB^'><;*A$=J=49C@%8A
MH@A1C"A!E"+*$.6("D0EHB6B"E&-:,40#\]E^;SXOK\]YT&F[BFK3L/[B`)$
M(:((48PH090BRA#EB`I$):(EH@I1C6C%$(^%R+.[<]X'0T6FY6RH0*;NN8!\
MA::T?K5;!!<R0V.E!U2(6A&BV#AVY&?F0%AFAL9*RZ>HE2'*C6-7WIR/RLS0
M6&GYDFGQAO]',G47,W6%.@/!0^0K-#5?>`@0A>@8(8J-8[=US"FW:GQ9U4Z)
M*6IEB/*SY`MC91I?EBA;@C?^96FYBVFY0E9:"5M>Z<BVO(`"I:732OH]GY$[
ML+8+H2E0WU^$*$:4*"2VIF;DS2SY%!TS1+E!1@NRUL*4*'.AH3502B-#]\(#
M<UF^[V*^KY"51%H)A&>L=&OZB`*%Q$:C;3KX]F6(CA&B&%%REGR*CAFB'%'1
M)^_:W^$OF2.+Q=C.\T\O#8TY3^@5XH-D;KVD[AFK-A:(`H7T()E/AY.1E52'
MZ!8ABA$E"M$84=F[=>B7HD^&*#>HVU^L6A8?%58:&7MXC$6BW5VM[2SRK#?"
M&Q4K4C*#YZ/&_@*EIQR[3^04H@V&#EZ@$/W:HFD%=VZ]`!$:+6/ES*UVCXR5
MEH^QQ,24^%[XVMO3,ADJYZA<?*1<,AD^?#[*^,^+%2;\8XFL467M=3QCI6_9
M5XB>'F@4:'3RM`6E(D2QEC+JB4:T#K?SIPM+#VIEB'*M15O+5@N7'FTEOQ9#
M!Z;6+J1DRCQ>_=G_A=]J'K>YOV[C!X6LL655S#-6VM'7R!Q6!0K1^P^BI[]S
M`JW]S(/S"%&LD5%/%!IWV[@G7O(6.[-`IK5,B;E&M$*?BI?4HA+55L':095:
MIE'F\;*3?'LN/.]$34Q35G:I4'<'C<A'%"`*$46(8D0)HA11ABA'5"`J$2T1
M58AJ1.)W=443=O?9\G=RY>]?OFSVWS;>YOGY</6X^R%^`Y<&X=VG%JL?Z'5'
MBWM2HMYO7:&3LH4X[.F[XM*5?I\Q76D6)5MM3#[]Y0SG"_&Z$Y9S/W(7]W1N
MB%?HM8^%>'.A[PK5@!Z:]UV9T)5FFK3KY@ZIUKWEB!OMTZ)">LN@(GI+<.@>
MZ3LC6*O[X6!Q3Z_<X!7Z;@>U2_/[!W9]A_2KRC+L<(7NA-[3[E.;TI7FP!]\
M9G2E&>C6%<K2%R)91#5*UA<B9\0KE+,O"DJ_^ZY,Z4J?#Z7KB[+W"OU\]'WO
MW5`#-.?_5HT?Q.WWE/U`7;FOC>^I@_6&Y8&J]-!;)3IE68C,'F^0#EL6(IO'
M*W2:LA!)/5ZA0Y6%R.WQ"IVM+)+>AJ3$GZ[T^="+``OQF+]'C:Z()_1XA1Z_
M+\3#=;Q"3[=)K:]CT+-J4NN[0D^>2:WOBD]5ZRLEIHKU\9RJU<>KZ:+NXSY5
MMJ_<F*K:QW.J:!^O9HNZX;=MWZ(?#'];?]L4Z_VW[>OAZGGSE2;30;-#V<N?
M')?_.*K?S_BR.])/A=-.GWYMF'X:?D._##BXH:/3K[O=4?^#FONV_;'YN_\7
M````__\#`%!+`P04``8`"````"$`-?[?2B((```A(P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6RLFEV3HL@2AN\W8O^#X?THA2!*=/=&JWS*1IPX
ML;OGFE:Z)4;%`'IZYM]O%O4!E>DZ;>R9BZ%]S$R*-S.I*O#AM^^GX^A;43=E
M=7X<LXDU'A7G7;4OSV^/XS__"+\LQJ.FS<_[_%B=B\?QCZ(9__;TZR\/'U7]
MM3D413N"".?F<7QHVXL_G3:[0W'*FTEU*<[PS6M5G_(6/M9OT^92%_F^<SH=
MI[9ES:>GO#R/102__DR,ZO6UW!6;:O=^*LZM"%(7Q[R%\3>'\M*H:*?=9\*=
M\OKK^^7+KCI=(,1+>2S;'UW0\>BT\Y.W<U7G+T>X[N_,R7<J=O>!A#^5N[IJ
MJM=V`N&F8J#TFI?3Y10B/3WL2[@"+ONH+EX?Q\_,S^S9>/KTT`GT5UE\-(._
M1\VA^HCJ<I^5YP+4ACSQ#+Q4U5=NFNPY`N<I\0Z[#/RG'NV+U_S]V/ZW^HB+
M\NW00KI=N")^8?[^QZ9H=J`HA)G8+H^TJXXP`/A_="IY:8`B^??N^%'NV\/C
M>#:?N)XU8V`^>BF:-BQYR/%H]]ZTU>E_PHC)4"*(+8/`\4J0&XXSZ0A'Z<B<
MR<)UG?G"@]/?\'2D)QR5YW+B,6LY^XDCA.TN&([*T9DPQYKSZ[UQPKGT@Z/T
MLR>.[7J+3J@;CIYTA&-_PD]=(_1H-U0X*L]%GYL;IUQ*1S@JQT_*RJ``13WP
M2A2Y=B;VPF7NSP1BNI3@#W5:J+I/^:H*8GT)_:02IJ*0N[[8Y&W^]%!7'R.X
MV<#9FTO.;UW,Y^%41PB]=(_\4XM`;_`HSSS,XQB2!M7?0%]_>YJSQ</T&_3B
M3MJLJ`TS+=;*@C<>#[O!(,`@Q"#"(,8@P2#%8(M!-@!3$$ZK!X+]/]3C8;AZ
MZKI7"O1RVD@J9:%<-A@$&(081!C$&"08I!AL,<@&P)`*;EI$JAFTS?5;KZHK
M[@4WV4%=.4M<5](&3JR+ST5J:1,M%R$!(2$A$2$Q(0DA*2%;0K(A,72#6S;1
MC4]9=S8H#P,]#H6L19JSI2G32AC-;BFI3;22A`2$A(1$A,2$)(2DA&P)R8;$
M4!)$,Y2\77G<NA-,7>A*$'LHH6M9IH1K;:3<-H0$A(2$1(3$A"2$I(1L"<F&
MQ-`'YNH[].'6ICZ"@#[JTM>$;`@)"`D)B0B)"4D(20G9$I(-B2$&3&5WB,&M
M33$$&8I!R$80;]ANMCLW"RK01DK5D`2*"(FE%]Q?=;L[BYD9.B%NJ70;CLBU
MT"R]U49J1-DPD*$BWS?1U<6$+SK;0[G[NJI@>-!05UIQ!JL(L;;@04QQ!1F*
M2\A&$*_;3'1Q`D)"XA41$DNO8=<["P<I2=Q2Z0:W]4$"D-M6&VDEAX$,)6%Q
M:BAY13%8DBO)N+4IF2!\U:['XUIX4:&-U'@VA`2"S)QND>=9GK5T/#3=AL0K
M(B06Q(7#8$"X0HE;JDGOQI:X0H61P[HQ6A.&PF8Z"%RGH3)?T-\A<V=NZBR1
M#8G4U^4LT))EW5MII2D*)'*&1>1:J(C"WK$_(UNBJ3WJK=098XGFPYN$:Z%<
M)M0Q[='PC#@)T@I&S[<#D`6S9[(^"LD"--L]6>#F*`L"H7)'M]8U7PV!(U@I
M3384!1+)BF<N;)GGC"2!A(IHJ%@B5/2>*4Q"'=,>W51<#$+6O3>QS']>\`4U
M?-;')3F`.<#(@=@8WGGKYCM*G!J!S`;!';R6CF#5IT8X.GVV`FGEPI)/-YMK
MH68+^UB]U94&T>-29XREHS=7%8SN(TD?6?FD$L$HAR=#M;^55C!PV1LH<F9$
M-F]1?*?PK^=4)O8;D'\U\I5$J&?0?63=6RG'C42SN8X5*+3HKF]A>PM[;B,1
M0AHJHBB6"/4,TBNACJE$,*R;F1!"S#R5";,9,R.PF0B^T?CWB1#;%2,1`AD=
MXC*\T6#:JD^$1,M!(@2"C38OM']*!`D5T>BQ1&BZ((D@L5(5"V9=W:5TSI96
MKFXVG(AA8#,1?$=S*Q%_5!>8'JZN,J':U9J);ZKQO4J@X4)36@W0AJ*`HI"B
MB**8HH2BE*(M19F!3,7XMH<J=O=#!2:V3WP6T9F=VZA25]+JYF.%WJ:O9A$<
MW!0*J%5(44113%%"44K1EJ+,0*:L?!^$9;7M"531G4]KF-A1&7<%O<GJM789
MNJ>NI:-1GMJQUY&@D#I&%,44)12E%&TIR@QDZLAW04,=;V]VF-@T&6(-]U'=
M[F\MK0QEB%5`K4**(HIBBA**4HJV%&4&,I7A.Y<[E!$;'4,9O??IR\BA9:2M
M5,ULF$#F/,SZ!:4Q3ON^?51G;J[@)4*3()IMUKV5'J=$YC0U6*^;X^0KYL_K
M"<6#IPB)S%430YNH=6_5CU/$0GKV6Q1SG'QQ>L<XQ5IVF'=;+V_[O+L,;3W6
MO54_3N%HZ.D,WNV8X\2+T]N="Z]ZB9X"#=IT+:T&:$-10%%(44113%%"44K1
MEB+^[II?D!BJ4$:\BQ;OW$Y%_5:LB^.Q&>VJ=_Z>&1R>'C06+\%7<Q^>2T("
M,&>NSR=U^LTSF_O/$(I^`Y,O^%R/YL$WW3LG<IX%?-/MO/`W]DR]GT??I)X/
MSP7I^=.%#T^Y*,_@Y-<X_`#@N9OP4?P5_#"@VZM@;L.`KL1?P4"OZ?'L^,]7
M)5PY/KPYH`-=@>;7)%]Y_NK:!:P]?WV-;SP?'D#2^*'GPV-(RB//AX>1E">>
MGW1\JI6`'RA<\K?B][Q^*\_-Z%B\0F%9W4Z]%C]Q$!]:N0Q^J5KX:4*W(C[`
M3U$*>-%J\37*:U6UZ@.<>*I_W/+T-P```/__`P!02P,$%``&``@````A`*AW
MQ*S7#```O#\``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULK%O;;N,X
M$GU?8/_!\/O$EBS)%R09='2EL`LL%K.[SVY'28R.[<!V7^;OIR@615:55G$N
M+^/ID^(A>5BLBVQ=__YK]SSZT1Q/V\/^9AQ<3<>C9K\YW&_WCS?C__Q1_+88
MCT[G]?Y^_7S8-S?C/YO3^/?;O__M^N?A^.WTU#3G$3#L3S?CI_/Y9369G#9/
MS6Y]NCJ\-'OXR\/AN%N?X9_'Q\GIY=BL[]M!N^=).)TFD]UZNQ\;AM7Q$H[#
MP\-VTV2'S?==LS\;DF/SO#[#^D]/VY>39=MM+J';K8_?OK_\MCGL7H#BZ_9Y
M>_ZS)1V/=IN5>MP?CNNOS[#O7T&TWECN]A^"?K?='`^GP\/Y"N@F9J%RS\O)
M<@),M]?W6]B!EGUT;!YNQE^"51TMQI/;ZU:@_VZ;GR?O_T>GI\//\KB]_\=V
MWX#:<$[Z!+X>#M^TJ;K7$`R>B-%%>P+_.H[NFX?U]^?SOP\_JV;[^'2&XXYA
M1WICJ_L_L^:T`46!YBJ,-=/F\`P+@/^.=EOM&J#(^E?[^7-[?WZZ&8?SJWDP
M7<[FP/*U.9V+K:8<CS;?3^?#[G_&*$`J0Q(B"7PBR2RYBN?360!S#@V<X4#X
MQ(%!=+6(XRA9Z.D'IHQP)'S:*0?M@:W=)WRB?1A>16$\7[RVQ@1'PJ<=>='>
MYC@./M^X-[B;[5KA\Z*]+=$>/NU,,W>&`R(&X&[F]+7?X?$/;6YBO*=UQFQ]
M7M]>'P\_1W##P3].+VL=+X*59K5N:";O'//_^24XI&;YHFENQJ`8N-P)+M./
MVR0,KB<_X`)LT.9.VC"+U%IH;]>T&0=R#A0<*#E0<4!QH/:`"<C2:0.WXC.T
MT31:&[NK.PLXL4(J56HM[)",`SD'"@Z4'*@XH#A0>P`1`F[Y9PBA:6[&\-_.
M2>(HICN_0QM8B3.B)FEGTJDCD%P@A4!*@50"40*I?82(!`'M,T32-'`9P2<[
M`9*0^<>=,9H-J=29="H))!=((9!2()5`E$!J'R$J01@7*D%`[W+&Q1%'$[4Z
MV?W=&60&!]0I%T<+YCR=D1V6"2072"&04B"50)1`:A\ALD".(K+T5P$VVFIK
MNG>#A":[Z]"9"B032"Z00B"E0"J!*('4/D(V"BF";-3DFRM=-)R?MIMO=P<X
M/'#^'@%FD%=,MM$D=/^(A%V03062&22D_K&D_I%W1M8_"H&4`JD$H@12&R1H
MET@DT16]3,%OE$234$D0\2012&:0V;+-V.$TB)@:W=\[-01'*9"J&Z7K`&"=
M45;5_=VRUCX'T08J(Z)-CUM`I6K]0EM3$0RBBUD7$^(I74_:&=GU9`+)#1*Y
M"U8(FU(@E4"4X*E]&[)W78Z]8?.M.=T]0A%$8V_[HNK2\T#[T#8[6'=UD!L8
M+-G`'.EG^@!^W,:SZ6S.3`HT\;A+"54.&IA.T>D6T31:,,^J'1$<)153%WD?
MOF4Z+3,/0V@.Q^AIS!)VBE;@B)V/(31+.BA':.$G_V#)-EE(KA(A6(2EKR2]
MLA!$HFZI@KXF]%1#71]^7$-39<(T=JUW$!2UK`M2S\1LWRE:>;Z46<@7O\=/
MD3X:\%-CXG&7;E%VG=5%TRFTFDW;Z?K]U)^.:JSKRR&-_SB\P"7O39!>)`Q,
MF4I$-I#G@BE:>5`FH1PA/_9)JU)"E824Y*J)%=5"5Y&^%L/1/S!%)]FS@>!8
MG<?#0PH6_W&@=_B9A'*$HEGGMX6T*B5424A)KII841ETU?@&&4R1260P$(M1
M+%:G^NF3S@-^C.H@IU_/_3)6X"#.*HY99U<X>F<5+%G]53HK=^LN683"@6P1
M"3WJVM'W+X(*KZM87_AW%:N!J87)>1B(Y661,["(]O,R#G1'E"-]Y`?U.)[3
M?1=H12Y"C_C=NISX8D:%7+%?5?2D$7_U5%9="7]<5JRG_31BH`7,W.6W..8=
M8&"LB)LCY`_L<7.DI\&$.7#AZ-TB>I3NENJ4OF01"NECN!/>'H6;(Y=OY2^"
MGH>NOH?.X\*4@T6\?R`&\@)K&@@HDU".$(FU8F`I!U824I*K)E94"UV-^UJ\
MDG),\4[NMH'`O;P#2GC+$716]OPS">4(D<PK!I9R8"4A);EJ8D5D"-_6>K3F
MM/5`B(4XGG+0RG.0S$%./WD7+3UIYA-&7_1SL1M;.BM[%I6#!A:A^A?!PGC=
MS^460877#8;O?^]*.?`<B+<I"+$2@*TU12L_-B+DMRD(D38E3EBY7C@N7T.W
M[[;3+-'*[USDC,I"$-:ZJ"=3CIL1#I+*JNOMC\MJJG;_MH<&HIU+P@M,M")N
MCAT`7&=O1\R!<TOO6\4)KZP<O<\EE.Z6ZMS\DD4HI(_][!@GS'7JUQ9!S^-S
MNAS]+(^UXPAY'IQ**)-0CI`?:Z55*:%*0DIRU<2*:O&V+B>470Y"I+B+$U83
MI,[*GG\FH1PA/_-*JU)"E824Y*J)%95!5_G^%1W.O#J_\J,W$`MQ[$JE.-!S
MD,Q!_OUA`W.TFIFG"-%\(>^A68!'73IJ*WKEH('9%)T-OE1G,:5V-"+8Z<K;
M5_)].42SL)QN();362!(0V-%@AT.]-H6M(J2]B$)J#GC7W(5DJBTHZ*N!Z\L
MY+@50J\T*(2>NJ*NGC\NH*G!2;8P$&U0$M:KI:&Q@@.V/I-9"'0<RA9FX-(\
M>(K#)%@P[L(2.>X2(5B4G:ZR5H/3*6LU-\^Y>ES4WPA56!?S0PI?UG+HB,=]
M5+0)*5H1AQ16.5J1P">L2LE524A)KII842UT1>]K\4K@,PT`<2L#Z8C0>4><
M\+XW[*SL.6<2RA$B:5`,+.7`2D)*<M7$BL@`CTO?(D-K3L,30BP\L3">HA6<
M1R>#@YQ^LN5`*_RV(XIFTY#?+D=DN4L)50X:F$ZQZ8(@6+(FLG9$,!T5\U/:
MB)EL(Q!B.9:G`+3R(QA"?AN!T#)HXT<2)6'$B`I)5"+D-PR26UD((E!W)63#
M0.BI@+HR]B_ENW*H_H$&BT\(D88AFO*[BE;$22^IU7-+;XJ48+I8A@EK!`I)
M7MIA[LOBREK!Y?<49+=)H15XHOX*,.KU4EQX>^&HR)_3!>A??'"5#>0Y8(I6
M'I1)*$?(#W_2JI10)2$EN6IB1;5X6Q<`5:C8LX%THND.+.:'G^)`XEG=0!NU
M<K3RDZ$<6$JHDI"27#6QHC+H$MJ_=\/)$(*QD,%`+$(QOTUQ(/$&,Q`@IU]/
M%C!6X""^%7_V(>E+"54.\KG84A5:#<]8.RZ1"W3Q[4OZOE!F2GB_[(!8KL5G
M^9:%\!2MB,/A0%>$YI9K,%X7DJNT`[V.P$*.7B'T2D=`Z*E;ZDKVXQJ:>IAH
M:"#:$<Q9HD]GQHIX*T(@97?;>[P5Z?V8(-)@(>E+A/RFP%H-SJC0BGP_(6:L
M+5=[1%1I77,/*7U99S`SI3N1VD">(Z9HY4&9A'*$2#`47*4<6$E(2:Z:6%$M
M=.'M:_%*,#1U.MES5[H[+XGYCW12^/V7OLC$O024HQ5)C<*JE%R5A)3DJHD5
MD2%Z6V?0FM/.`"$6J5B@3='*]P8'.?WD+4,K",&Z"%HL%OP!K:.Q&;:44.6@
M@<D4G2R:\R:D=C0\$^@40OSI79F@96'ZFD:!Y5R>"7"@[V8(0>"UPN0(85>P
MG/-?G162ID3([PDDL[(0Q$0O9++471-ZZH>?TA-$LB=`B/0$\5S(Y]?1YF=Z
M.%`WU=Z.F%_GEAY[@D4R9X^&"\OC>N+2#O(Z`FLU.)M"*]L1]/BGOP\J\.?T
M`Q"H>5&(D.=ZJ80R">4(@5-8!RVD52FA2D)*<M7$BFKQMGY`AS;6`R$$X<PY
M1SQG[IXZ*[O!3$(Y0K!<:U5(JU)"E824Y*J)%95!E]N7I\#(5.=^"D2(Q29V
M1U*T\APD<Y#3KR?VFQFAH]&Q/XB3.?])4^&(K'BEA"H'#4RGT`JG"X,DGK(X
M43LBF(Z*J>MN7\SWQ7]3O1.-#:2/L8M#<<P6EL*S_K;,<%$F0PB6;*7)+308
MI0O)5=J!7B=@(4>O$'JE$R#T5$-=47]<0U.7$PT-Q#H!]JU/JG_FQ4HU"X&Z
MG?@]?FH&XG<#_7XJN$OD]MN`BZ93ULI\-]#OI_YT5&-=70]I?%D/`&_OBIB(
M=;L+YRE:P6\'K`MF$LHE5$BHE%`E(24A_:)Q>ZSM(HP6YL5A\Z[FKCD^-FGS
M_'P:;0[?]4O!\!OCV^L.-F\LWR4K>.\&=L'Q:&%?969_R>8K>%%%CL@6J[R]
MI<R^6JS@Y0UI#^]*?VD+!69_!^]0MUOB>+B"=PTES]UL!>_72?Q+M/H"$LD_
MW$6PLSX\7L&[5F`_Z6:&=Z=?UH_-/]?'Q^W^-'IN'D#&:?N6S=&\?6W^<<;?
M5W\]G.&M:5`:WHF%M^0;>*=JJE]3>S@<SO8?>H+NO?O;OP```/__`P!02P,$
M%``&``@````A`./;6=3L`P``?`\``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3<N>&ULG%=1;Z,X$'X_Z?X#XGU#;)*TB9*LVJVZM]*MM%K=[3Z[X"16`2/;
M:=I_?V,;*`:3PKT@F(SGF\\S_N+9?G[-L^"%"LEXL0O1;!X&M$AXRHKC+OSW
MG\=/MV$@%2E2DO&"[L(W*L//^S__V%ZX>)8G2E4`$0JY"T]*E9LHDLF)YD3.
M>$D+^.7`14X4?(IC)$M!26H6Y5F$Y_-5E!-6A#;"1HR)P0\'EM`'GIQS6B@;
M1-",*,A?GE@IZVAY,B9<3L3SN?R4\+R$$$\L8^K-!`V#/-E\.Q9<D*<,>+^B
M!4GJV.:C%SYGB>"2']0,PD4VT3[G=;2.(-)^FS)@H+<]$/2P"^_0YAZOPVB_
M-1OTB]&+;+T'\L0O7P5+_V8%A=V&.ND*/''^K%V_I=H$BZ/>ZD=3@1\B2.F!
MG#/UDU_^HNQX4E#N)3#2Q#;IVP.5">PHA)GAI8Z4\`P2@&>0,]T:L"/D=1=B
M`&:I.NW">#5;WLQC!.[!$Y7JD>F089"<I>+Y;^N$3%(VEDGM@2BRWPI^":#>
MX"U+HKL';2!PG9.-T&0YE"1DIX/<Z2B[\"8,`%_"SK[LE^AV&[W`;B25S[WU
M@6?C@QJ/"+)I4H(TVBGYMZ=&ULX:66^73N7>&MHPV`\33X'1SK#?K>27:-W$
MM<C69]'V:3P<@N`RGJ!VAN*T"2WQO`ELH:W3"&AHE#:T+C>.=;L-=&&]S7J=
MR:+9Y\H"IZ"I9[OF#N&5BWJ]HMK9A:HL]G2U.P4:KLL&W<YG-Q_2T0M=C,KB
MT,$##:H%N75FKM/1SBY49>G36;MQS5E<0S]?!]"K7(#*XG(9.`4(O,:3,=XN
M6&WJT]$]VPYM^*S6LP^K8Q9V4'0L,+F<XN88..V&)BF(\>Z@52+BX=11#<UI
ML1S1<<BJ`U!K3E!M<CDM!CA-$@W4J,8[6F7R<-)'N=7/ID[Q*%*5"+1)52:7
MU'*`U"1A0'UEJ$T>4CYMP(L1S=?7!N05A]4`ITGJ@/KR4)L\G'P"L8#DK@L$
MZBM$;7*K=.-GA,&KW1_7T8RW>YQJ4Y\1]DC$J.-D%G90O!+Q?@MQ)`)/D@CC
MW4$;E`CLD0CT<97,L@Y&I1ENE=ZO'2ZC20*!^P)1FSQ5^M\"H2\6G3^GVN20
MBM\O-"ZI20*!^P)1FSRD?`(QHDQ]><`^>8@'[@YXDCP8[TY3#%X?8'9QSNEX
M'3<K.S"^2T3<O4386<<.%#D51_J%9ID,$G[6<PR&2:"Q-C/6'=9_@5W[8G-G
M9Z^H^05FGY(<Z7<BCJR0048/$-/>[H2=GNR'XB7D#A,05S#UF-<33+D4IH&Y
MUOL#YZK^`.2HF9OW_P$``/__`P!02P,$%``&``@````A`.<3T#A]!0``1A4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULK)A;CZLV$,??*_4[(-Y/
MN%^"DAQM0KBIE:KJM'UF"4G0AA`!>SG?OF.,'>Q)L[OJOBR;7\9_,W^/8>+%
M][?ZI+R4;5<UYZ5JS'15*<]%LZO.AZ7ZUX_HFZ\J79^?=_FI.9=+]6?9J=]7
MO_ZR>&W:I^Y8EKT""N=NJ1[[_A)H6E<<RSKO9LVE/,,W^Z:M\QX^M@>MN[1E
MOAL&U2?-U'57J_/JK%*%H/V(1K/?5T49-L5S79Y[*M*6I[R'^^^.U:5C:G7Q
M$;DZ;Y^>+]^*IKZ`Q&-UJOJ?@ZBJU$60'LY-FS^>(.\WP\X+ICU\0/)U5;1-
MU^S[&<AI]$9QSG-MKH'2:K&K(`-BN]*6^Z7Z8`298:O::C$8]'=5OG:3_Y7N
MV+S&;;7[K3J7X#:L$UF!QZ9Y(J'ICB`8K*'1T;`"?[3*KMSGSZ?^S^8U*:O#
ML8?E=B`CDEBP^QF670&.@LS,=(A2T9S@!N"O4E>D-,"1_&VXOE:[_KA4+6?F
M.X[M^A[(/)9='U5$4U6*YZYOZG]HE#%J415S5('KJ&+J,]MT/-^`63^J8H\J
M<!U5C,FMW)D>IAB2@.LXT)^9OF,X+IG]SD#8!<-`N-Z8\8/)ST<1N(XBWN2V
M[XMH=#F&U0WS/E\MVN95@2T#?G>7G&Q`(S"@*MBZTF3X2O_70L,*$Y4'(K-4
M/56!)>R@.E]6KNXMM!>HJ&*,6>,80XS8L`A2/D0VE,%6!I$,8ADD,DAED$V`
M!K9P;Z#*OL(;(D.\85FM&;B:94I&L`@V))3!5@:1#&(9)#)(99!-@&"$]35&
M$!G8]Y,BL3Q7S'P]QL"=\$IRQ)`-#^'N(+)%)$(D1B1!)$4DFQ+!)'B:?$6U
M$!G8C%"3W`!7]T4+UC3(NN<2#^$N(;)%)$(D1B1!)$4DFQ+!)7A."B[=?G^P
MQPJ)'LQ@2:PI,:?V6)YDSX8'L6$A(EM$(D1B1!)$4D2R*1%R=S^5.XD6<Z<$
M<F=I;1`)$=DB$B$2(Y(@DB*238F0*+P'/K'()%I,="3F-5%$0DK,Z18PC;FX
M3[8\B#D6(:$8D82/NFY!RY.D4Q[$I+.ID&`'Z8'Q.W9&^I[^6!5/ZX8V/C?V
M@@7O4OJ&)2*B2R.9N(1(2(E)9%Y6IF[8DD'\>Y9%A#1B1!(^ZK9JRK]GJME4
M0_`&FAG!FQL>0&_%3"#1H@F4D/:+/RXM7Q>SW/`@=C\A)]=AQEQJ1[8TR+('
M\QQ/]VPI(N(R3#A&).'DSE2I,)5AN(YE2:^]C.O`7(*%I&W[A(=#N&CBB$Q8
MI8F+4K*;:Q3+-L1H.R*++-K+RO#FMBME$N%1,48)1NG[VIDP2K2)M'G3;7B_
MU,@;6*JU$4G%)O=NUZBK350+!C*T':/&XK)<T]>EJHVP4(Q1@E'ZOG8FC!)M
M(DW@U";ZB^"33RN#J$A%1I%49):T5<>!$,6L"D=D3]VC6K9/BTRWG+G4`T18
M*,8HP=HI0Z.V[7F>]-3,!"'1/=(>_G_W:),)B\1,6!L42;4GW=CF&L4&A@S!
MRYKO;?RH8U$>-=0T7%>7Q",6<UV'&*.$H;OSI2QJG`\.`BSL,D\9DA%=)NWE
M/9=_-!<HOG=_M-(N5;"9HFF/!:<JI)0G*,1HBU&$48Q1@E&*$3G:N=X$]8(>
MU=`?\W79'LI->3IU2M$\DV,8,'BUX)B>$:V=`)I3,%/F;@"]W`UNV.Q021H1
M>@'T5GA$X@70&&$>^L%VV-&23N('T"S@>#C->ACZ&BE^34ZY;L2OS0!^O&*=
MM17`#S;,'^S@`2S%7ZPAXX%K?&8XQ;KDA_+WO#U4YTXYE7NP5Q^>ART]!Z,?
M^K'F'IL>CJ^&\CO">64)YQCZ#/J3?=/T[`-,K/$3T-6_````__\#`%!+`P04
M``8`"````"$`7=O];,8&``!L'0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6RLF5USHD@4AN^W:O^#Q?VH@)]4S%04\0L5K=G=:X(8J:A80"8S_WY.
M`]W2_;I64C,W49^<?D_3[VGH;AZ^_C@=:]_#)(WB\T#3ZTVM%IZ#>!>=7P;:
M/]^<+SVMEF;^>><?XW,XT'Z&J?;U\>^_'M[CY#4]A&%6(X5S.M`.67:Q&HTT
M.(0G/ZW'E_!,_]G'R<G/Z&?RTD@O2>CO\D:G8\-H-CN-DQ^=M4+!2CZB$>_W
M41#:<?!V"L]9(9*$1S^C_J>'Z))RM5/P$;F3G[R^7;X$\>E"$L_1,<I^YJ):
M[118LY=SG/C/1[KN'WK+#[AV_@/D3U&0Q&F\S^HDUR@ZBM?<;_0;I/3XL(OH
M"MBPUY)P/]">=&NKFUKC\2$?H'^C\#VM?*^EA_A]DD0[-SJ'--KD$W/@.8Y?
M6>ALQQ`U;D!K)W?`2VJ[<.^_';-M_#X-HY=#1G:WZ8K8A5F[GW:8!C2B)%,W
MVDPIB(_4`?I;.T6L-&A$_!_YYWNTRPX#S6C7]5:S0]&UYS#-G(@I:K7@+<WB
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M,(_XZ`XYN)IF*(;P"-[$5L%8!8X*)BJ8JF"F@KD*%BIP5;!4P4H%:Q5X*MBH
M8%L!DB$TP?^$(4QFH-%?,6D,HRL[,"QCJ"<BJ"V'C$2(<`G(&(@#9`)D"F0&
M9`YD`<0%L@2R`K(&X@'9`-E6B60:/:G^A&E,AFZ6-%>%(9UF4[9D6`29]UP3
M(<(U(&,@#I`)D"F0&9`YD`40%\@2R`K(&H@'9`-D6R62:[0JD%R[O4[BCR$6
MG9O#!W58$*-JEV$J=HU$$&]F`QD#<8!,@$R!S(#,@2R`N$"60%9`UD`\(!L@
MVRJ1O*#5R2>\8-&R%P4A+_@PCX#80,9`'"`3(%,@,R!S(`L@+I`ED!60-1`/
MR`;(MDJD@:=UE33PQ2*MSI;:V2$*7H<QW8NHQ&],#I,68\42C8G(?I3$N/H!
MQ"Z(T<K7="V]KRM+A+$(X*8Z0"9`ID!F0.8%H74X5UX`<44KMN1LZ5U#670N
M10`760%9`_&`;(!L"U)T3W*+;=5Q2?U)MYB([%9)KL,Q`F(7Q*3-CG@X&::R
MRAZ+(#XD#@A-@$Q%JZJT4@PS$<2EYR"T`.**5E5II==+$<2E5R"T!N*)5E5I
MI=<;$<2EMU4AR5L:6<G;&S..-K)\RK%HV<2"L+UNQ2!37CV,1!#OCRW(M1E-
M1;G9N`@RBZFJ]]I-=5GB"!DN/`$R%>1.JIF4RNQT.SUEW3H7,CS5`H@KR)U4
M2RG5K:M:"1F>:@W$$^1.JHV4RFR;/5UQ9BMD*)54%SH=!'VB,/)PN3)*9%#I
M54JC)7L\ND;QB[41C4MDLDJDG3@6`K:9()HBFLG*'3IUDCLXQS8+1"ZBI:R,
M?5YAFS4B#]%&5N[0"97<YZW41K:5;<E_^U[.-@O*?:!$RHU`Z=CH&G5UN]`R
M.^*I."ZC3'H@B<K1^TKI.J@U033E6E?Y&4=WY>>HM4#D<JVK_)*C7EZK=!H-
MU;I"H34BCPM=M3<<%=IZJZUW5.N+X20?8$:SS?_O6U\<(5!'N(-#=K!(U:!,
M=*5CHVL4;VAS1#>ABL_J4Z",,IOY>.I]'$^'"_5$IR:(IAS=33>3TYG=%IWD
MRF,\YT+7=`M$+D=WTRV5=#>N;L6%KNG6B#R.[J;;*.FZK6Y3N2-ON5">3KYY
ML*.(>Q7T+;[0,^#FLKVRB&#GRNK=HT#5G50954$VHC$B!]$$T131#-$<T0*1
MBVB):(5HC<A#M$'$7NCD4RZ?A85'Q0N:XBC\%"8OX2@\'M-:$+^QER_T1N;Q
M06#Q9N@I7WPK?,C>&+&9I'+#H@/$&]RTZ)`*^5/+>J*.XC^&+8O.1V[PMK7-
M[UMJXHY%6\D;\3IEOIG![EJT_\(6;M>BC0]RNV?1+@+YM&?1%@"YV[-H_8[<
MZUFT^";>$)=`[[HN_DNX]).7Z)S6CN&>[&CFFZ>D>%M6_,C*N?,<9_2:*Y]&
M!WJK&=);@V:=EM?[.,[X#Y9`O"=]_`4``/__`P!02P,$%``&``@````A`$W/
M,13X#0``648``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK)S=;^,X
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M&[J)ZC7/A_,A6+J[>=C`"JS;K_;KQ]O!EVC1I,E@>'?3.NB_F_6/`_G_J\/S
M[H?9;Q[^L7E=@[=AG^P.?-WMOEG1^L$B4!XJ[;+=@7_MKQ[6C\OO+\=_[WY4
MZ\W3\Q&V.X45V84M'O[,UX<5>!3,7,>IM;3:O<`$X+]7VXT-#?#(\H_V]<?F
MX?A\.XBGU]-H-!]/P<K7]>%8;JS)P=7J^^&XV_[/"45HRAF)T0B\HI'QY#J=
MCL81C'E*<8R*\!I&CV=IE$[>T4Q0$UY1,[U.XG0Z>V](F%"[8'B];*X35(17
M5$S.6N,4]>#UPC7"&6VG"J^7K7&.BO#JATROHV3TGE,C"#\7#38.W4Z?7.30
M15,;G/GRN+R[V>]^7,&)AW@YO"UM_H@6UJH/2Q=$7:#^+$XA0*V5+];,[0`\
M!R%X@,/U^UV:)#?#W^%`K%#F7LM$7"+S$C;ZK=E<@D*"4@(C025!+4%#P!#<
MTOD&3LEG^,::L;[QJ[KW(#@K%H[P$EXEEZ"0H)3`2%!)4$O0$,`<`:?^,QQA
MS=P.X+\D2%*^\GN4@9D$(2Z2=2*==Q0I%"D5,8I4BM2*-)0P)T&"^PPG63-P
M&"$F.P=$DS%WP;T3&I_R4B?2>4F10I%2$:-(I4BM2$,)\Q)D<^:E_NO/IQ4K
MW3K#+^+>D3'L0N<>E6FR3LBKY8H4BI2*&$4J16I%&DK8VN%"NF#M5IJOW1%8
MNU]6IDBN2*%(J8A1I%*D5J2AA"T4[@&V4'NIQ/$U..;":\4:XCYP1.S_A!^/
MK!/RCLH5*10I%3&*5(K4BC24,+?84I[>M:=CWTKSM3M"]U^17)%"D5(1HTBE
M2*U(0PE;*)0S%RS42O.%.B(V>2HVN1/J-EF10I%2$:-(I4BM2$,)6[LMHBY8
M?"O.5X^([K-&N4:%1J5&1J-*HUJCAB&^9EM!G1_9]G(3.XY(;/E,;'F0ZO9<
MHT*C4B.C4:51K5'#$'>#K9\N<(,KM\">7\U]Y%`<4*91KE&A4:F1T:C2J-:H
M88BOV=9#=,VN@;BV3>GQ>;/Z=K^#Y`\;WI/LQM`H8/O@JBKF"D1QYYTL4BA'
M%,,[I!Z8\[@I@I3W=*F1T:C2J-:H001.`O/<.[8.^NO><=44\PXBZAV%\LBA
M\;SMR.)1)%JR(@@$QR@S!J7<^MH-JX*B[?7`LJA0ZR#@+3?,#'>3+9FHFWJ"
M!1XS=-'B*BSF#X?LLX@0!^F(QT%FG[=`X@$I/ZD<T32T9P6B)!S"4BL:C2J-
M:FVK85+<#;:@NL`-KOYB;G`H@3TD;E!MMI.*9\0-#DWA2N\4H[E0+"(G-;9;
M`1W^>#2>"I$218AMHU$5T(GA:C[<+!DE,Q%F33"DCIXMPZ@S/Y:87#''?.S0
M%"J`SE5I*COXR$FQ4'-HUCXG;(]1@5(SUNW-Q2)+;<L@@DGX2*X0C2<=JCV"
M@;NI1M)\P\SS@+05WE_WH:L3F0\=FK$&-A7KSB(G16(I1S2C^;XG3M%\<B).
ME6WC;8><6OD9T+U6P]4H-1ZUP_7'*1V.^]A6DJ=\_-ON[6<7*,V)KB!E3G:(
MA&`6*90C8@G02;$$J!2-ME5I5",BMAHFQ7P17U8[M^*\=D8$(1,B/DW%M9<%
M*7]Z<D20`#TJ$"6AWRZUHM&HTJC6MAHFQ=UP63D-U:(LIQ&)'"5R=892)$!R
MK\@SAE`L4`HVE7I9/,HK@_D@%<U%;6:"E'=\%1!5%).H^R<A'@4T_;;")+CC
M90'_H3LCUG4](G$ORSL#I6B^0S0+%4OA;=$M2E/1'9?!%O5A6'=[_QAOJ_W<
MRU5V'H41:T3PZ1BU);)U$T:$C>1NM77[J11W5H]@:WS1-2*:05G2W6]I*KM&
ME&)A[FS-J`]57B^\>9Y,A`_+8#Y,HB?,<<1P.U=>D<Y>3:)&J917MBK,G7E8
M8_\D^'[8$O_4?IQWY<38*80Z^1X1B>!,HQP1R[7.%LNU#A%;1MNJ-*H1$5L-
MD^*^L"T!]<7IUL,Z6`:A0\SUZ42V'J@(+S[-Y8CHS8N(W):E5C0:51K5VE;#
MI+@;;&5_@1M<(T"KC=@AD>)$TLY0BFQJCNB=UL.;AS@/1WTBS)?!?)#J.8MN
MJF025;^B,%_W3T*D\:;?5D@;W/&0@ICC/W;E6"NB$G)(E`!BKEGLI"`P0E@Z
M1-L4E&)M2BH_E"J#K9/.[^;E1ZQ0D78N'H%PM]VZ<PDCJBO'UMLTGC_F5E>U
MLS!WB'<N$U5@.BD283G\O]VB=SH7+P7E=K?N=*(JJ\Y\D.H)\VZJP=.H2,WW
M7#E.*H5C0B8A0J?!J=J73HI.@H>Y[1].[<>95XYK0]B&.$0B.(L5RA&Q7.ND
M6*Y5BD;;JC2J$1%;#9-BOH`^D?OB])73BO.SC8BY/IV(FB`+4G[_<T3TYD5$
M;LM2*QJ-*HUJ;:MA4MP-EW4Y8]WE(!(I3B3M#*5(@.1>D6<7H5B@U-@]14BF
M,W4.M6FC4140/2ABM)J/-IO*IK4)9F2RLW\'</)PG55?MU9$G+E.1MSI(A%D
MJ`C1&.+,*=*V!:622?N0!+PYCH6A4ALR7HLT*!Z%*ZM&]$Z#PLSS4+35\ZGL
M=)X#70U.DY/]/,LF?9Y)1:^6H12+4%1\)T*=U-P]>$KC2303MDMMVX1)^?VJ
MO!2=I[X7O-34/>?J"5$W'[<0[N'/:3G@+,HZ!Q&)ODRC'!%+?+KET(I&HTJC
M&A%)H@V3XKZXK.6`I^UJS;TMA^Q[49&%E5.DUR!*D:NKU(I&HTJC6MMJF!1W
M@ZW"Z:%[YQJTXB(].232DTBL&9255I$$2([HG98#I6`%]M..)!F/8G6ZE&VC
MAZL".GD!.%M^N"B*YJ*);((A=078JIHZ\T/U[MA:$3YV2-RQ(G-GJ,A"S2G2
M-@*EYE'KT$DRB1-AJ-2&#"*804A7SC:XPZ,:I>P+J4;E,RIFGD>CK7G_N@-=
MY<RN`(=8PY",U%EU4BQ(41%R*EF1B.YBC%*N2(E&LWD\":UF^TBO1!EBW'@U
M\EF'EX(:^.?CU2@%95U[*'JCE*Z%.]G6UZ><?%X7`)]GJS!5E7N&4BPFG11+
M?PZQ]*=L&6VKTJA&1&PU3(KY(KFL"VC%^=%$!-L:-BR5FY\%*7]6<D3T,D1$
M+K!2*QJ-*HUJ;:MA4MP-EW4!X%NY]8A$AA+G)$,I&@U>D:<,H5B@E'TAQT(D
MEE*;-QI5`5%;8L0:I>S+ST=L@BUY%R2?T@ZT5D3`G=4.H"+)-CDBV@X@2KCS
ME5O=B,26\8JD(_"(=`2(WND(4,J9YV%I*]E3F>JLC@".DXI6AWA',!47?8:*
M+%I1D3M,Q$Z!BC.:$]1SLU*;-UXQ7*F5EX*ZA,2A&+%&*?;YA!JQ\;;:+>*>
M_IS.P!:!HG1!1((GTRA'Q)*A[@RTHM&HTJA&!.OWZ;=A4MP7EW4&B>X,$$'@
MA#U+Y1_I9$'*3RI'1*]&1)!HO%2I%8U&E4:UMM4P*>X&6PG3PW>Z,X!'"FKK
M';*>[D(W347H9JA(`B1']$YG@%)8JL]F,_F`5ELV&E4!A5GJKIL/EDQE$]($
M,^HF@&3!'/FAKL#F:'FT'!)WKBCF,U1D6<PITJX`I;`KF$_E7YV5VHQ!1'L"
M1+0G\`C&[**@)S6Y*;E9\CBTA2R-PX^YSY7#M"=('&(]03I5[G-2+#Q1$>X"
MLB(1UX4WCSW!;#(5CX9+E""FC5<B'8&7@GKXYZ/5*.4[@I[XI.O@#K:5]BD'
MG]</)*Y@9QY6-7R&4BP:G11+>@ZQI*=L&6VKTJA&1&PU3(KY(KVL'VC%>7F&
M"#8U;%<Z%255%J1\5L\1T2L0$;FV2JUH-*HTJK6MADEQ-US6#Z2Z'T`D<I,X
M(QE*T6CPBCQ=",4"I>#QGFV`X?O/4_DG3:6V;32J`@K;I;,_'RZ.)NE(Y(DF
M&)+Y/_V43J"U(D+MK$X`%4F6R1'13@"13=8DRXBP+;4MXQ5))^`1Z000O=,)
M,/,\(&W=?2I'G=4)I*YZIRD*D>@$Y"?)*,7B]*Q.`!7QLX'^.'6&B&T3)N6S
M0^5G<+H-\%+NLX'^.*7#<1]_3@]@]U@4*HC@KP#]>C*-<HT*C4J-C$:51K5&
M]I<F[%3=O)POW"]'N"_G;]?[IW6V?GDY7*UVW^VO0L#?&-_==-C]9`5\76AA
MOYH#2Y/OI(G_-0OYSF0!W]OLT9@NX(N+/7RV@._Y]?#Y`KX#U\.C$<RI_1-W
M.7($O[#A#H!X![[%L[#?J]'6X!LL"_LE%?U.!>_8+YGH=^"'/+[T^L0.WR-_
M#T[LE1\OX,O>/?:3Q1?8/OW&/?B\EZ>P%U9^V*T;?MCC;?FT_N=R_[1Y/5R]
MK!]ABT?MEZ;V[J=!W#^.^+??7W='^$D/B`+X@0;X"9<U_#;"R'Z=]G&W._I_
MV`&Z'X6Y^S\```#__P,`4$L#!!0`!@`(````(0`=*F@ONP0``"D5```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)28VXZC.!"&[T?:=T#<3PB')!`E
M&75OJW=&FI56JSU<T^`DJ`$C3#K=;S]5MB%@3`??)*%2KO+OLK]4O/OV7N36
M&ZE91LN][2Z6MD7*A*99>=K;__[S_#6T+=;$91KGM"1[^X,P^]OAMR^[*ZU?
MV9F0QH(()=O;YZ:IMH[#DC,I8K:@%2GAFR.MB[B!Q_KDL*HF<<H'%;GC+9=K
MIXBSTA81MO6<&/1XS!+R1)-+0<I&!*E)'C<P?W;.*M9&*Y(YX8JX?KU47Q-:
M5!#B)<NSYH,'M:TBV?XXE;2.7W+0_>X&<=+&Y@^C\$66U)318[.`<(Z8Z%AS
MY$0.1#KLT@P4X+);-3GN[0=W^QCXMG/8\07Z+R-7UOMLL3.]_E%GZ<^L)+#:
M4">LP`NEK^CZ(T43#'9&HY]Y!?ZJK90<XTO>_$VOWTEV.C=0[A4H0F';]..)
ML`16%,(LO!5&2F@.$X!7J\AP:\"*Q._\_9JES7EO>YO%QEU&_@:BO!#6/&<8
MTK:2"VMH\;]P<F4H$<230>!=!O'7B]5FZ;N0\TX01TR(ZWN*F_BPJ^G5@DT#
M*5D5XQ9TMQ!8+PB4H.\#.N_MC6W!7!E4X>VPVJQVSANL7")]'H4/O'8^;N?A
M0-(N,V2;GQF=,3,N+4[E41CZ:3Q]&M\D#3KO;7CM)K\*5('")^C[Z#.#RWR!
MZ`PUZ`M:;=9=8"%:.,U(#?MA?FITYJF[Q946.":W=>@5>E#&M4DJ=!ZFDA9Q
M_/K;`W997P*>N$VT@)E]OD5QV#"#M,"&Z8G9="L[$(.\GGT:T'F82EH\SI*^
MF,@D+CH/XPI+-)00ZB6X4+7Y&KCW,%EK&JO`W=D/C34)5@M$V.=%X0.5+!@+
M3$--T80F/.VSZX(QE05L31I-1GQPQ>$'/=U9D:9A<<+EA!`C)K@=%&[9I$DC
M!`]M;XVP."O8^W<J(X]Z7Y`T#2H33D#<-3K^W%O9!Q(`&D$:`LP0-`:`JR-`
M./%SX1HA@'LK@B8AX!I1@'LKH74<"'W]5O.,.,"]A]E:T[@RGH8#<]C,QRE)
M=!@(@PE)1ACPQAAH31I)1ACPQAB0)@4#M]YA\#/C&6&`>RO+-HD!;`55#+CK
M&3^<?*"214N"6U,RU&1$`D\>^QYW6I.F.!H2S-,TAH&GA<%$.^`9P8![*RLX
M"0-/@0'BVO/QW\,=8O.!2A8M%R;Z`]^("]Q[F*TUC>OD:[C@ALL9#0(?J:01
M9(C@J-WZMG"B0?"-R,"]E6P2%OV6%[:8GD.^$2RXMY)-\"."4WS3%DWT#+X1
M++BWDDW"8MQC^QI8S`$Y'Z<D$:P8EBN:Z!I\(U9P;R6;Q(=&DL**S]L??PP(
M:5)J,]$M^$:`X-Z*$`D(C1`-(%PON/\/R!<TZ/>HTJ049Z)Q"(P`P;V'FEK3
M&!"!`HC/B\.]E=`2"G!:>P=GHET(C*#`O95L$@H:(0H!!+UA,]U1),Y]OS1P
M:S7^'Q2I?8.XF!(7-P6I3^1WDN?,2N@%+YT\N(KIK-V%V`.?MFH/M@_BHLSI
MOH&+JBH^D3_C^I25S,K)$6(*:M?BJDL\-+2"]8&;)MK`%17_>(8K20+7,4O<
MED=*F_8!_K`XW27GX1<```#__P,`4$L#!!0`!@`(````(0`+>V=ZV!<``&R"
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*R=6W/;.++'WT_5^0XN
MOV^L*V6IDFQ%%&_BG;5G]]GC*(EK8BME>R8SW_XT!(!`]Y_6);7S,$E^ZOX3
M8`-@HTE1[__YU^/WJS]WSR\/^Z</U^-WH^NKW=/]_O/#T]</U__WK_@?M]=7
M+Z]W3Y_OON^?=A^N_]Z]7/_SX__^S_N?^^??7[[M=J]7I/#T\N'ZV^OKC]7-
MS<O]M]WCW<N[_8_=$WWR9?_\>/=*_WS^>O/RXWEW]_G@]/C]9C(:!3>/=P]/
MUUIA]7R.QO[+EX?[W69__\?C[NE5BSSOOM^]4OM?OCW\>+%JC_?GR#W>/?_^
MQX]_W.\??Y#$;P_?'U[_/HA>7SW>K[*O3_OGN]^^4[__&L_N[JWVX1\@__AP
M_[Q_V7]Y?4=R-[JAV.?ES?*&E#Z^__Q`/5"G_>IY]^7#]:?QJELLKV\^OC^<
MH'\_['Z^>'^_>OFV_YD\/WPN'IYV=+8I3BH"O^WWORO3[+-"Y'P#WO$A`LWS
MU>?=E[L_OK]V^Y_I[N'KMU<*]YQZI#JV^OSW9O=R3V>49-Y-YDKI?O^=&D#_
MOWI\4$.#SLC=7Q^N)W3@A\^OWSY<3X-W\\5H.B;SJ]]V+Z_Q@Y*\OKK_X^5U
M__@?;30V4EID9D3H3R,R?G<[G\^"V\7Y(F1Y:`G]:47F[Q;CT7)Z@4A@1.A/
M*W)Q;VAJ'!I"?_8:%_=F:43H3R.RO+@A8PK*H27J+[_>E/'4RM!?K,SEIW9L
MSZWZBY6Y/,SCA6T-_<7(G#WB;O3H/4R&S=WKW<?WS_N?5[3"T/A\^7&GUJOQ
M:DR!L]-`#]I^8KPU+VA"*)5/2N;#-36,AOP+3>8_/P:C\?N;/VD"WAN;-=H(
MB]!:J-FF9#<21!+$$B02I!)D$FPER"4H)"@EJ"2H)6@D:"7H/'!#X>EC1(/X
MOQ$C):-B9,_NV@(7M`D/66@MK,M&@DB"6()$@E2"3(*M!+D$A02E!)4$M02-
M!*T$G0=80&@Y^&\$1,G0O*.P>[-&A&"MC:;4E-YH+J+4F_1A`A(!B8$D0%(@
M&9`MD!Q(`:0$4@&I@31`6B"=3UC4Z"++HC9\I;<KFK(^!,>>U+4F$S]<D[E<
MPGHCZ[8!$@&)@21`4B`9D"V0'$@!I`12`:F!-$!:()U/6"PH5[D@%LJ:QT(3
MBH4]S2&0#9`(2`PD`9("R8!L@>1`"B`ED`I(#:0!T@+I?,)./*4@%YQX9<U/
MO";^B0>R,<1?LB9SL:Y%O9&-8`Q""9"T]W*KX60^Y>MAUAM9Z2T(Y4"*WLN7
M%DMMV1M9Z0J$:B!-[^5++WBKV][(2G>^$`LBY5DLB#II>Z?2_==O#_>_K_=Z
MYS&PPDTI.=,IFQ+AL=7$CRV0C2'3?N)%0&+P2H"DO9=_2F;\E&2]D3TE6Q#*
M@12]ER\=<.FR-[+2%0C50)K>RTF/QR,NW?9&5KKSA5@@53'!S[X'`D:[21LQ
M9<TCILF,-K]]<C"9W_+VA-K(;&(/:;4F"Y<*1D;(K:<Q>"5`4B`9Z&S!)@=2
M`"E!IP*;&D@#I`6=SK=AL:`-)XN%FE23J=K\OU$3L&%1CCPLFLSX`K@48=%&
MD]M^)FTT65`+^VB.ER+!B+315(V*/S_.1_0?UXU!-P&2]N3(D3)M-*-\RFN.
M6&NWO9(=[#F0HB>^D.A7J8W>[E?5J]@CU4":GAPY4LN.-+F=+\6$Z7H5.A(;
M(F.::&R,')^O!W,^,@SB,S80(0R-E3]E#?+GK$'3V6$H+-18$$,!=1)$*:+,
MH)F?ZXZ7,O;HF",J$)4&O=WR"IUJ1`VBEDM/Y^-;&5WFQ,.K-N#^<GSV$J#V
M<&(-,(@O`H$8]:&Q\E<!@V@9L`,],LA,CLGM=#810C$*)8A21)E!)Z8Y.N:(
M"D2E04>:7J%7C:A!U'+M9;"80*QU7/3IY;%6>WL9ZS$5]R[*H51]4<9=(W79
MZ)?-22"RW]`XLAFN'6\/9>M#BA89J^GMVS.\/YH=+`E*IU8GZ(=49A&E)GTS
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M]X)0@MHIHLR@4WDOR.>H52`J#3K2]`J]:D0-HI9K+V$ST#$?'FI5G_!#?6*!
MU.4,%E^-Q$P4-9=0W<&4,U$C-A,U,AGC=+P8+>`2"$():J>(,H-.);L@GZ-6
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M6:/ZI<E^4.'9ED%SOR8T"<3F*S16WD#?&'3+`R$*&)&5GQSF_WBVF"YGPB9&
M\<2ZN:PXM59TE?8"+[0RZTC;'<]*+*I;J^6"DUM'=\3"6AT]8FD=C_2PLDKN
M>+5U<\=KK-71X[76:G$XHY,1#2,QN3IK<C@<'T9#M3#_FO&O_0\:'Z=JXW0S
M2:W]_OIAD'^;"=$&480H1I0@2A%EB+:(<D0%HA)1A:A&U"!J$74,\1BIZHR_
MOA_/VR:ZF,-B8>H[;$[+="LTCM00N]YN$$6(8D0)HA11AFB+*$=4("H158AJ
M1`VB%E''$`^/JJ1<$!Y=>&'A,;48=^+#":`-H@A1C"A!E"+*$&T1Y8@*1"6B
M"E&-J$'4(NH8XK%0A9@+8J'K-BP6&GF3(%2IE$IL77@V%M&\ZJ\J^.R#L[(3
M*K;(:26(4HNXO+AH9<[*RF\M<O(YHL(B+B^VZ:6SLO*514Z^1M18Q.5%:M,Z
M*RO?6720YW%5=14_KK^6[>CJ#`NW*=BX'H64TT"X#7*5GLA:.11;Y+021*E%
M-,&]H2.R_<Q9V;.SM<C)YX@*B[B\V**7SLK*5Q8Y^1I18Y$OCX]&."LKWUET
MD.>Q5646/[8G+F_*7*0:&O']*3P?,=%6U!#;J`VBR""O_!JC58(H192AUA:M
M<D0%HA*U*K2J$36(6M3JF!4/CZJ2^.$YNT`XT?45-MTTX@6DA5C80N/H;:@V
M#KE9@P]-&"M3F+F]':@9.B$["A)$J4-'#I<9JQ-E)J=ECY@C*APZ<L326!WI
M8.6$[.%J1(U#1P[7\L/-%W.JPHH=JA.BP_&!H^HL_L`Y,:]U68:-%E,K\NLY
MDX58*D,:)H?UVI_7@")C96NR0R,#G!*43A%E!IVH)J-CCJA`5!KT=LLK=*H1
M-8A:+DWS"0H0S(F'5U54_/">OR[H6@R+M$9\79A#T0&*.)L)H,@@,T=4H,68
MC=$I090BR@PZ->&A33EJ%8A*@]YN>85.-:(&4<NE)\%H*?*QCCFQ2$]EJ>GX
M1#Z8\PNT0?P"+:L4H;'R+]"((H/,=!AZ'`J=$D0IHLR@$Q,9'7-$!:+2H+=;
M7J%3C:A!U'+IZ7@V%87:CCGQ\`Z5@,YZ(G**51^#^$2&QZ&,%2TN]AJU0109
M9*;#9+X(YF*/$J-7@BA%E!ET8B:C8XZH0%0:=*3I%7K5B!I$+==>CB9SD=UW
MS(G'FO9DL&C[Y;ZS'BE7WU(2*;A!*LMWNQIX',I9N;AK+>\V3F2LCCP.A3H)
MHM3J>'>(+.(U:I%_;E$K1U18+2=?6J0+^@-K4X4Z-:+&ZCCIUB(C'8Q$&M0Q
M&1YT54N"*S45-<Y_'&JJ),2:KI&X/R1.96@<V4PWCBY?BXR5>1QJ/`V&IKIV
M\Y02Z^;NLJ06.?',HA,Q!_G<.CKYPB(G7UJD;Q`-MKTR-E[;:^OFQ!N+G'AK
MD8GZ;'D[%C?).Z;-XZ[J5G[<3URW=9G+3\OH4J7"[MUV#0UB%VEMY:'(.KIB
M0HR.":(4489:6[3*$16(2M2JT*I&U"!J4:MC5CP6JH+DQ^+L;)FN(3#U-!(7
M6;$@A,;1&W0;1)%!="&T2W*,5@FB%%&&6ENTRA$5B$K4JM"J1M0@:E&K8U8\
M4I>5H^C"!>$9*D<%XB(=&D=OUFP010;1P%+?`QE\2@:]$D0IHLR@4^DNE,UR
MU"H0E08=:7J%7C6B!E$KM.>CJ1C]'7/B`58U*'\JGE@6=<F*+8L:B?DG-E3A
M5%NQ^0<H,E8T'E6`Z6$8?!X&A1)$*:+,H%-)+C0J1ZT"46G0D:97Z%4C:A"U
M7'L\&8_%Z>V8$P^P*N3X`?ZEFP64?L+$UHAO8Q=B3Q(:1S:QM2.-2;O(1L9J
MIA\F4F]Q$4\NQ*B36"?W+%%JD">=&73B,2B4SU&^0/G26KW9\@JE:^OD6MZ@
M=&L1C<A^%P'/\G1,GD=>55YDY-5=I0LR75V\8=-=(Y'IB@UV.(6JS\:@F4OH
M(HMTMKA8!#/Y:H$8A1+KY9+%U"*GG5ET].QM43ZWCDZ^L,C)EQ:]W?0*M6OK
MY;0;BYQV:Y'.<V>+L3PK'9-F05?3$8)^\9[VH,)W.`:=>!+*6/G3W2*Z<GK#
M6,SOR,KKYX0FX]EL/!))0FR5W*E*K)M+K5-K=?1XF76DC8[7*K%AVUHM=\3<
M.KHC%M;JZ!%+ZWBDAY55<L>KK9L[7F.MCAZOM5;Z2:C%,EC*K^=TUN1P.#Z,
MALI@_C`Z[TDHE4V)G;)!WO,#(:(-H@A1C"A!E"+*$&T1Y8@*1"6B"E&-J$'4
M(NH8XC$:*E^IRN;Q%$XE:A03^G\_\(.1&/AK8Z3**+V5O+0[&WL=WR"*$,6(
M$D0IH@S1%E&.J$!4(JH0U8@:1"VBCB$>-E5;D9=E]964"]\^IA)9/;=<B*`0
MMC96QP.IE<C&!1)0Y)2L58PH090BRA!M$>6("D0EH@I1C:A!U"+J&.*!5)4>
M/Y`GYITN#/FYE$JBU%2D5;*?91/Y);_06=D3OT$4(8H1)8A21!FB+:(<48&H
M1%0AJA$UB%I$'4,\/++(="(\6%FB5-6$QY[X$-$&480H1I0@2A%EB+:(<D0%
MHA)1A:A&U"!J$74,\5A0JL*FRB]M0JDB;E8\&X^U0>H92&\&B?)'Z*RLXP91
MA"AFB/=(U0DNF/RZK,`FOT:4*OM-AXML;^6:WB/GB$__S+25*3C-YG1G3-[Y
M-R8Z6>>]&RH:G'47=(:%`H.H]./:.UF*Y#YT5JZC6LNK&47&2BW*7KQ%-21V
M6LYJO'0/4/"^#FZ3SWD'#I4K8#R:?2\/JMP=&T>V2^H=;?<C8Z420*^OKA>'
M+QC%3LM9O=E7505AH_;LPOO!D^\(#6)QG<K'2T)G93NV0109Q.(ZE2]3C9WC
M.7T=VL*<-8;5'E?L6@QBDW4Z$G>?0F?E^JJUO%!'QHK%=2HS\-AIG=/7H:W`
M>7W5NP%_89IK).(JUU1GY?K:.UH4&2L65ZAAQ4R+3<ZYRD/]9?8P8"^J81TD
MQ,C5V:V(IEQZC:,7NHU!7GTQLHB6VWZ6#O2P/R*=&MY#F47^TJ5QCLFE02*,
M<MEU5C9F&XMH1?)Z)`LVQHKVFV^]D\OJ')YKX7U6B96,ZN75A;G.S]C8U<BO
M+A@K#VT018AB1`FB%%&&:(LH1U0@*A%5B&I$#:(64<<0C]%0RG:ZNC#7.1JM
M!/W8"49B9JV-T=%-J;-Q`U-K>_O4"*UB1`FB%%&&:(LH1U0@*A%5B&I$#:(6
M4<<0#YM*^W!J75Q=F.OTD>:6'TAQ$5@;J^.!-(FH5UUP;C:V$:(848(H190A
MVB+*$16(2D05HAI1@ZA%U#'$`RE3\./;USGFW0:QZL)4?M4\=%8V%AM$$:(8
M48(H190AVB+*$16(2D05HAI1@ZA%U#'$PZ/R=7^>G0B/3N_9I<ID_*ZP'\X!
M;1!%B&)$":(4489HBRA'5"`J$56(:D0-HA91QQ"+13"TJ_'3B;.>XSRH\#S1
M(%9=F,JW$(;.JI]!B")$,4.\1W+O<GQT!;AA,8BEN).EN!"'SLHUO=^PN(4?
MJPO&T507%K-I(#=^,=/FO5/[!'_NG+T+#?0.PY]&!HDT5Y0Z0F?E.HJ[%6/%
M=BM3>!>=T_+/D-N7\[X.;F#.J2X$>LO`^MKO(MR1<1=J'/U]"Z+((+X+G8C[
M0+%S=$=\L[H0#&UESMJ%'CS%W-,[&A%7D8"$QI&L7%Q[1XLB8\7C"CMNIW5.
M7X>V,.?U%7<M@=FUT!]]UCR=0%][*]NQC7.T*#+(/F@V7<HW&\3,B0_6H9S_
MLB=&`IVCLU%KM@1^_6\J]P2A<621U(Y45G:]TTAM+?LSA;MMIL5[.)P>7_@&
MU*!/CFW#U@:Q]78JGV`(G95UW%A$'?-Z)'?;UDK?S!]\\M&:X,W\0*:2:KV=
MCERGS[N9?Y"1-XY%/6%MC([N")R-.PLZ??6W=F@5(TH0I8@R1%M$.:("48FH
M0E0C:A"UB#J&^-B5*:>N%%V\M0OZ7-2-.+QQ;*R.!U(K>5';.#<;VPA1C"A!
ME"+*$&T1Y8@*1"6B"E&-J$'4(NH88H%<R'SU>'9W,.<71X/XUFXFR]'.RL9B
M@RA"%"-*$*6(,D1;1#FB`E&)J$)4(VH0M8@ZAGAX+DN^%YA\&^25'$-$&T01
MHAA1@BA%E"':(LH1%8A*1!6B&E&#J$74,<1C,;15N'AKM\!M@T%\:S<3Z6_H
MK-P,,ML&]Q61"*UBAGB/Y(;@Q.3'7<!B8!>`6SMGY9H^X(A;.^-H$DCZH:&%
M_&YRS+1Y[WYY"[#0:;N?.!HDM@!R:^>L7$=Q"V"L^!9@)E+LV&FY2^.;VQWU
MUOQ?V\8>/,6*WB?W[LBXM3.._M8.4600W]K-Q-X_=H[NB&_W5>7=O[1E7^B,
MG<55(Q%7$8O0./H;`D2102*N(BN-G>,Y?95[A!,S%#<#].;FPX-#;#\W$T\I
MA,[*#=S>T:+(6)GI2-_\$%N#F,GPR3B4]U^VG5._RR-NA1LDHB=&5^BL;$\V
M!OG;.8/8=FX*K\!U6N=$;SA+=IN=LXJ!]"/,T&^-3NSPC".;H<;Q^`[/.*H;
M<MX^4%R08B:O@ZU_[%G_ONWC[OGK+MQ]__YR=;__0_V0,Q6K/K[OL?F5Z?EB
M]8FVBQ09\0G=T%FI>Q)#G]S2)X<R"_@LZ9/#CU;+3P+RH?T,JGT*EJM/U!?\
M9$V?J-1YX)/%B'X<^_"5&7F<A?K9[$,=77SR:39=?:)3.J!&GZAG.X<^F=$G
MAV]H"+7U;$Z?#*K-Z9/AX\P#^N3P52>A1K_U_>EP3TSP-75FJ"_KR:H;LO]$
M7:2E?J`CU,/A#E(OANQ5'X;XA%JD<UG9U(EJTU"CUA,Z."57V"IZ(=Y*O>YN
MZ),Y?3+4`GH7'JD-?4(/`*[44WJHM@Y&*U5A'_AD,5FI!&W@DQGU=/A<SJBG
M]$PW^M!;!E?J;73X";UL<*5>2H>?T#L'5^J-@D.?S.F3(1]ZW>!*O98.?>BM
M@ROU=CK\I`E6[="Y:1:K=FB2=S16A_B:CK`>/`*]#G*EWA&(QZ:W0J[4>P'Q
M$WKMXTJ]'A`_H;<_KM1;`O$3>@GD*AL\8_0*0?IDR&<;K.BG$U$K#U;T`XK(
MBV!%/W4YP!<K^N5$Y%6PHM]/1%X'*_H51>3K8+4>XF&P"H?X)EA%0SRF(3_$
MDV"5#/$T6-&O@V)[TL6*?FR2^$T_K5\^OO]Q]W57WCU_?7AZN?J^^T*7$%TH
M?'[XJNI-IFIHWH/\V_[U=?](F2S]AOKN[O..?LUG](ZN8%_V^U?[#W6`G_OG
MWP\_P_[Q_P4```#__P,`4$L#!!0`!@`(````(0"228X=LB```*W$```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*R=76_;2):&[Q?8_Q#D?A)3EF3+
MZ&1@2?S$+K!8S.Y>NQVG8W02![9[>N;?[UMBD:QSGHH<:C(7[<E3AT6>EX?%
MER6)]<M?__'E\ZN_WST^W3]\??>Z>'/V^M7=U]N'#_=??WOW^G_^5OWE\O6K
MI^>;KQ]N/C]\O7OW^I]W3Z__^O[?_^V7/Q\>?W_Z='?W_$H]?'UZ]_K3\_.W
MJ[=OGVX_W7VY>7KS\.WNJUH^/CQ^N7G6/Q]_>_OT[?'NYL-AHR^?WR[.SM9O
MO]S<?WW=]W#U^"-]/'S\>'][MW^X_>/+W=?GOI/'N\\WSSK^IT_WWYZ&WK[<
M_DAW7VX>?__CVU]N'[Y\4Q>_WG^^?_[GH=/7K[[<7K6_?7UXO/GUL_+^1[&\
MN1WZ/OP#W7^YOWU\>'KX^/Q&W;WM#Y0Y;]YNWJJG][]\N%<&0?97CW<?W[V^
M+JZZ8GWV^NW[7PX*_>_]W9]/R?]_]?3IX<_Z\?[#?]Q_O9/<.E'A%/SZ\/![
M"&T_!*2-WV+KZG`*_NOQU8>[CS=_?'[^[X<_F[O[WSX]ZWROE%+([.K#/_=W
M3[>25-V\6:Q"3[</GW4`^N^K+_>A-B3)S3_>O5YHQ_<?GC^]>WV^?K.Z.#LO
M%/[JU[NGY^H^=/GZU>T?3\\/7_ZO#RIB5WTGY[$3_8V=+%1@1S98Q@WT-VZP
MFG9Z9#L=TN%H]7?8T>;-XG)5K-;A<(]LN8Y;ZF_<<OGFHCC;G%\<W^XB;J>_
MPQZ/IZ;6PR'J[ZS4-G$[_1UV](.I%2J:PR[#__F1Y-[V-7`HJ?W-\\W[7QX?
M_GRE"U5G^>G;3;CLBZO0V5!,O:YC>7VONE16H9?KT,V[UU),A?.D:^+O[U>;
M]2]O_ZXROHTQ6\84-F(W1(2:#=WN/2@]J#RH/6@\:#WH$O!6LHS:Z`+Y&=J$
M;H(V0U;;`4QB+9P00\2PR=Z#TH/*@]J#QH/6@RX!1@A=Y#]#B-"-!IND2(IS
M7R0Q1D<R59(39PP9U0$I02J0&J0!:4&ZE!B1-+#]#)%"-[H859.C`,7RS$JP
M[8/.CZDTAHPJ@90@%4@-TH"T(%U*C$H:>HU*^9O6,*R$Z(,80Q+;GISK+'Q?
MGMT8-&RV!RE!*I`:I`%I0;J4F-QU(YJ1>XBVN?=$N0]I[4#V("5(!5*#-"`M
M2)<2DZCN`R;1<%-92I:9-Y70C56@)^[L^[O(&#3(M`<I02J0&J0!:4&ZE!A1
MY`Z,*,<K/T3;W'N2GGV0/4@)4H'4(`U("]*EQ"0J.S,CT1!M$^V).\G^#CD&
MC2<9I`2I0&J0!J0%Z5)B<@\6RB1_JI\*_1QD2<>Y<W<;..Q-=]1C]X$I9E2*
MJ"2JB&JBAJ@EZ@RR@@7SE1K0XY=%N"^Z<HG(U8N3:C=%33+T?2575,FHBJ@F
M:HA:HLX@*T.P7C-D".'VJBEZE&2S(]H3E40544W4$+5$G4$VYV"ETIS#M7)^
M_F9Z//OQQX_>E4G?X>QNBVC4K%-8VBMH-T4-&^Z)2J**J"9JB%JBSB`K4?!1
M7J+PK#_S3EKT?BS47V*;5E:,;8PZ/IRDSBX^I`&54T^#K!513=00M42=05:P
M8+Y2P5X83GJO9NJF1VXX<5+MPCG0!9A<;7NBDJ@BJHD:HI:H,\C*$*S9#!EZ
M)V=D2,W=X3SO"J`]44E4$=5$#5%+I)FU1'B;<W!>:<[_PG#2FSBCQ^CKTBO(
M/;WNBC%JJ/L]44E4$=5$#5%+U!ED)0J>S4L4JFCN<-)[/S><7/CA)#K$H^YD
MC)D$`RH+H(JH)FJ(6J+.("M8,'JI8"\,)[TO-'4S6L6T;IQ4NV*,FF0`*AE5
M$=5$#5%+U!ED9%AX5WM<AD.X=2<1)>/ECFA/5!)51#510]02=0;9G+TQ#</)
M8O%F_M6RH&>-R-UD+NT%M)NBQJH@*HDJHIJH(6J).H.L0O,\ZX*>-2)3%;"Q
M>T:51!513=00M42=03;GG&<]K2IH61=9R[KQ53%&354!5$Y]#5$544W4$+5$
MG4%6H9]D61<YR[KR$Z$QZJAEG6(&*?9$)5%%5!,U1"U19Y`5+%C)'[_'A`^]
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MHLX@*X,WG>'B..$1-CB&_C::7@=N>G`;HX[:BREF$BR:V,4X'5DRJB*JB1JB
MEJ@SR`H6O&$ZFKQ0-[V53(>,4##]<'E$JMT4-<DP;CB@DE$544W4$+5$G4%6
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M%6[]WQU.IIA1,**2J"*JB1JBEJ@SR`HVS]0N:6HC<G7CI-I-49,,?5_)!5@R
MJB*JB1JBEJ@SR,H0_.*/>[1E;R]3CQ91DLV.:$]4$E5$-5%#U!)U!MF<@SE,
M<S[9G"Q[FVGD&)WG=&D4*S^3&C=,1-L3E40544W4$+5$G4%6(6]93QU-1B^;
MB+'V,ZG+:&^/CB9CS'09`9533T-41503-40M46>0%<S[W>/F)'PCT<VD1F1'
M$R_5;HH:$MP3E40544W4$+5$G4%6AN`7TROK!1EZ>VDNG^@XDT>=)=">J"2J
MB&JBAJ@EZ@RR.7M?&JZ5T\S)DIXU(E<6?BIUBIK*8C2[`RH951'51`U12]09
M9"6:YUF7]*P1)>/ECFA/5!)51#510]02=0;9G+UG?>%2H"]=CO8R'3S]?.D4
M-9SG/5%)5!'51`U12]099&18_21?>NC'^]*UFT'<QJBCOG2*&04C*HDJHIJH
M(6J).H.L8/-\Z8J^-"(W9#BI=E/4)`-]*:,JHIJH(6J).H.L#/-\Z8J^-*)T
MR"#:$Y5$%5%-U!"U1)U!-N>?YDM7]*41N:IPL\Z[*6JJBM'0#JAD5$54$S5$
M+5%GD%4H6+[47YSH2U>]=93Q2(=6-R&VC5''1Q.8T/VTV208HBI&U40-44O4
M&60%F^=+5_2E$;FZ<5+MIJ@AYSU12501U40-44O4&61EF.=+5_2E$9G1A+Z4
M42511503-40M46>0S3GG2T_ZA']%6QJ1JPH_E3I%355!6\JHBJ@F:HA:HLX@
MJY"WI:>.)J-?34<3-X&X7?51QT>3,682#*B<>AJB*J*:J"%JB3J#K&#S/.V*
MGC8B5S=.JMT4-22X)RJ)*J*:J"%JB3J#C`QZPX*]"QVW]H=P^QV`B-+1A&A/
M5!)51#510]02=0;9G+TM#=?*2:/)FHXU(E<5?B9UBAJK@J@DJHAJHH:H)>H,
ML@K-<ZQK.M:(G`Q^ZG"*FF3H^TK*J6141503-40M46>0E>&GF=@U36Q$5J$+
M-Y^XFZ(FA6AB&541U40-44O4&605\B;VA>%C]*I#-MMUM)/))!G1GJ@DJHAJ
MHH:H)>H,LCG/\Z%K^M"(W*GW$V%3U"#6GJ@DJHAJHH:H)>H,LC+,\Z%K^M"(
MDDM]1[0G*HDJHIJH(6J).H-LSC_-AZ[I0R-R5>'GR*:HJ2KH0QE5$=5$#5%+
MU!ED%0H6+WVJ?6%`Z!UA.FN^CB8Q'1"`]HPJB2JBFJ@A:HDZ@VS.\ZSDFE8R
M(G?J_337%#6=^KZOY!(J&541U40-44O4&61DN)AG)0_AUDI&E&2S(]H3E405
M44W4$+5$G4$V9V\ECY?[!?UB1.[4^[FL*6H\]40E4454$S5$+5%GD)5AGE^\
MH%^,R,JP]GYQBIIDH%]D5$54$S5$+5%GD)7!^\47JH&F\&+T=LGC]X6?H9JB
M)AG&#0=4,JHBJHD:HI:H,\C*,,\47M`41F0&`OC$/:-*HHJH)FJ(6J+.()OS
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MC"J)*J*:J"%JB3J#;,[S'.`E'6!$]M1?^FG!*6HZ]72`C*J(:J*&J"7J#+(R
MS'.`EW2`$9E33P?(J)*H(JJ)&J*6J#/(YNP=8+@7G/;=N4NZPXA<6?@IPREJ
M*HN^KT3(DE$544W4$+5$G4%6HGGN\)+N,*(DFQW1GJ@DJHAJHH:H)>H,LCG/
M<X>7=(<1N5/OYP6GJ.G4TQTRJB*JB1JBEJ@SR,HPSQU>TAU&9$Y]'Y6@/:-*
MHHJH)FJ(6J+.()OS3W.'EW2'$;FJ\%.&4]14%7U?B6@EHRJBFJ@A:HDZ@XQ"
MFWGN\!!NW6%$238[HCU12501U40-44O4&61S]N[PY&>&#8UC1*XJ_&SB%#56
M!5%)5!'51`U12]099!7RQC$H=,*/TS>CHTP>JR_=9-HV1AW]+LL4,PD6C6CR
MXW1&540U44/4$G4&6<'FN<X-76=$KFZ<5+LI:I*!KI-1%5%-U!"U1)U!5H9Y
MKG-#UQF1&4WH.AE5$E5$-5%#U!)U!MF<<ZYSM0Y+ELQ]'>&&KC,B5Q9^3G**
MFLJ"KI-1%5%-U!"U1)U!5J)YKG-#UQF1*8L^*D%[1I5$%5%-U!"U1)U!-N=Y
MKG-#UQF1._5^3G**FDX]72>C*J*:J"%JB3J#K`SS7.>&KC,BO;YO2'!'M"<J
MB2JBFJ@A:HDZ@VS.WG4>GX[>T%I&9'+NHQ*T'Z)T']3MN5^MIKATTY/E%#7H
M5PUHDK0F:@9DNW=38.T4-73?#>C0O5&F./-VLS<6AU=E/W^ZO_U]^Q"<1G:5
MGG,MQW-X&]IUWXVUH0-+!-IEV'YDT[<;]-+X<%CZ!N+$]-;XR!*1,DSOC8]Q
MR\-J0<MBM727J-XC/X:,&HTL)Y+WI\?KISBC"QV9.7D;/XF5A`U')H%B=W93
M-]$AS6)8."U_?[]8GZW]')DT'+L:NM>K]\&DX<B22MZX74I'L\MBL5PLW>.6
M7M`_=J5=NN)31C.^&5.<A7A?99%9<?Q4P+CIY$VEZ[CI((9$C$P69[J$-RXI
MZ8A-I2.8=`23:)'UYZG8%.Y91)*E6SG)O*\]/"J%HYUQL=+L%F>1:<])WN[(
M=/V.88-DDC&R?D6XL+J69(Q,EB#ICC*B.\D()AFQ"\D8V<6AW-=+_<^^ZD4Z
MIETY'8.'3;^4=>*XUUOA],M:Q5ED5DK_X)"$)5+&3773361SEYW4C6&;8U?Z
M>!1#]Y(63-+^R"ZEMMEEL3E;G[G#DMQI]T[NG"<O5M-MYF\/W[YWFY%OG^XS
M-.3%6633I:TZ!5.=@DG)R):CE]&UC3@I!R;EP"03^I,L:9R3Q?OP4ZYFFO/B
M+#);@OXA)0D;:D0JQ4TO1T6D4F2QWI;GR\UR4[CN)-RXUZ$["0<FX;`+"6=V
M45QJZ<_E8N%NC](R[<YIZ?V]OZ)_M,1H_(NSR$R)@4D\,(D7F2DQQ$DI,"D%
M)J70GV1)XYPLWN][67[0X/$YH#B+S%:9,UNZ%L>PH2PD5&3Z<W2@Z\/"N]23
M,&>H57CC'M(P9XRE\!@V'(@4CDQ_DCVXH4VB]V''#T3G8=Q#VMMT(.[4^,<2
M?VI^M&+YO*+%2'L#;<X-OCR8A`V2Z-R,FPY,10PFU<$D,9@D!I.>8!(O95:I
MPRI/_FY]V@>)15PQRMRRAU6DY!?&*M`(9/V$5GKJ'QO2&8X,TUI/B--B3V!:
M[0E,RSV!:;TG,"WXE#*G5G#<J5HO/*Z$WTE[6QU9DJK2[^,2ML\PI8\XI0^F
M],&4/IC2!U/Z*7/IJ^9GI1_BW5/%M+946A!N6)`B_:96$3`I`B9%P*0(F!0!
MDR)@4B1E3I'@@^<41/3-TY/VMC!+2<5E>\A4$/VVB21*'TSI@RE],*4/IO3!
ME'[*7/K!E\Y)/_I8DW[/E%9:$'C,'-:/FN8MI,BXZ32>DDD1Q$D1,"D")D7`
MI$C*G"+!DLY1)%I8HTC/DA.MZP%,Z8.I(,"4/IC2!U/Z8$H?3.FGS*4?7.2<
M]*/K-.GWS!6$>\*5(F/8</*E")@4`9,B8%($3(J`21$P*9(RIT@PD',4B8;3
M*-(S6Q!@2A],Z8,I?3"E#Z;TP90^F-)/F4L_^+8T_<-SV"E+\A1QR2?=GX83
MKK&SMX6N5MQTA6IE#!LVE5A@$@M,8H%)+#")!2:QP"16RIQ8P:=YL<+5-G>M
MK[@L5+B5)Z[+391(O=X7'OTT.@E*M!LW')BT`Y-V8-(.3-J!23LP:9<RJ]UA
M5:A4NQ>L65Q%RE139*Z:G&Q:HC,UB(<;MM;H!-,BG6!:I1-,RW2":9U.,"W4
M"::5.E/F%`E&;HXBO?&SBJ1F,'H3?>P07%TR&BE],*4/IO3!E#Z8T@=3^F!*
M/V4N_>#:TO1/'WGBVE)6F=$4II>8F[E1K8QAPY4BL<`D%IC$`I-88!(+3&*!
M2:R4.;&"Q_-BG3+RQ$6FW,CC9BZVQ;`6E8YH'*!XG47C.<T-23LP:0<F[<"D
M'9BT`Y-V8-(N94Z[X`93[5X:>7KW:*MI=)23'HLS)YNJ:0Q+J@E,BH!)$3`I
M`B9%P*0(F!1)F5,D&,0YBO2&TBJ2FLQAY`%308`I?3"E#Z;TP90^F-('4_HI
M<^D'-YBF'T:>$^=4XD)45IK1;:;%XN;N5"QC6%(L8%(+3&J!22TPJ04FM<"D
M5LJ<6L$\>K5.&GIZ%^J&GFF*\%!$&GJB63T^](Q!B79@T@Y,VH%).S!I!R;M
MP*1=RIQVP4NFVKTT]/3>TU;3Z$?3:G*RJ9K&L$01,"D")D7`I`B8%`&3(F!2
M)&5.D>`0YRC2.TJK2'29TU2#T@?3T`.F],&4/IC2!U/Z8$H?3.FGS*9_6(LJ
M3?]TTQ.7M3+*3$M=);528#9W"IMJA4Q+M*?F]7!Y:HUV,"W2#J95VL&T3#N8
MUFE/F1,KF,=4K!>NGKC"E54D-:#Q-F56PCHP+5"/.*4/IO3!E#Z8T@=3^F!*
M/V4N_6`'T_3_A5KIG:55IF?V8:K`1&]X^/1/$V02"W$2"TQB@4DL,(D%)K%2
MYL0*_B\5ZZ5:Z?VB521Z2/T936_!3XZ"8E`$3(J`21$P*0(F1<"D")@429E3
M)/B_.8KT?M$J,GK(29%%@;E?LUS6<$&-FPYCC!0!DR)@4@1,BH!)$3`IDC*G
M2+"$J2+A@CK%R<3%KR15*HN;`=T6PQI9JMJQGO`0-04-.FDPBMYU>K"2=F#2
M#DS:@4D[,&D')NU2YK0+!C'5[J7KJS>4MII&DSGIL2B<;+MB6"EKNKU+D7'3
M024I`B9%P*0(F!0!DR)@4B1E3I%@^^8HTMM$JTBTCE.J2A],Z8,I?3"E#Z;T
MP90^F-('4_HI<^D'CY>F_R\\1,4%LJPTHX=,BP4SQV9MK6'H&3=-B@5,:H%)
M+3"I!2:UP*16RIQ:P1)ZM4X:>GIOZ88>-ZIHZ(D6]/C0,P8-.JG2P%1I8-(.
M3-J!23LP:0<F[5)FM3LL=95J]\+0$Y?&,M4T+)>EV^4X%"\*)]NNF,(F1<C*
M3%R5876&-1G69EAGF5,DF,8YBO0FTRJ2&L]HC,UJ6O%B(E/ZV%;I@RE],*4/
MIO3!E'[*7/K!!J;IGVZ,XUI:5IG19::U@IECLPS7(-:XZ5`_$@M,8H%)+#")
M!2:QP"16RIQ8P2%ZL4X9>>*B6F[D<5.@VV)8>TM'-%YIO,ZB;9T,SC[9,-$.
M<=(.3-J!23LP:0<F[5+FM`M>,M7N'\7RYO;JPS_W=T^W=U^5WUGX;=WX'=VX
MC):MIM&/3GHL"B>;1IXQ;,A>BH"IFL"D")@4`9,B8%($3(JDS"D2'.(<17I'
M:17IF3X:&E)5^F!*'TSI@RE],*4/IO3!E#Z8TD^92S_8P33]?V'DZ9VE569T
MFVFM8.+8+-DUC#SCIH.H$@M,8H%)+#")!2:QP"16RIQ8P3RF8KUT]?1FTRK2
M,ULK8*H5,*4/IO3!E#Z8T@=3^F!*/V4N_>`&YZ3?NT>;?F33.*E+!4SI]RQ\
M@#@.NHO"S1%+D3%L*!(I@NZD")@4&;<]L@N)-(8-NY!(:7=.I&#[4I'Z1_+I
MUQ$_]AWMN$R7U:YWE/IRX'`DT@Y,VO5,'R`>?CQVYG^4)-G&B*$GR8:>)!N8
M9!NWC;V[QUTI-D8,O4NQM">KV&&!K52Q%ZZJN""7D69@J31D^R(RS5$.AU9F
M6#6P1.HZPYJ!)?VU&=8-K._/I1]L89K^:043U^>RJO2.,WQP.%U$_H<8NR)N
MJK!!%`D5-]5@.&ZJG[?9;U%+NQC6_W!KL3H[]S^1E9;C40S=2TLP:?DCNY2\
M=I>;\Y7_::3D3KMW<@=C";G7;X)&X6=WP_?T9_P&+RX39J7O_6OXW&C4;[%P
M^DGZ,6S01M)'IBMFW#0G?1^F3QO"=;@^O[A8N"M1TJ-[20\FZ7]DEY+>[G*Q
M7I^[6[FD3[MWT@=?"NGG_W`L+CHFO2>!%@LWA[LMAK7)=$"CCO#M4U!R`E+_
M?'`C*G0PJ0LF=<&D+IBD!)-T*7/2!0.;2O?2&-D;7EN2HPF>](!L*LDQ+%$$
M3(J`21$P*0(F1<"D")@429E3)'C:.8KT'M@JTC-]Y#"DJO3!=$6"*7TPI0^F
M],&4/IC2!U/Z*7/I!Y<Z)_W>U=KT1Z>;%H0;1*3(&#:H)$7`I`B8%`&3(F!2
M!$R*@$F1E#E%@G%-%>GOH_._RAI7(7/#BYNGU?#2&^7P"=Z1X64,2K0#DW9@
MT@Y,VH%).S!I!R;M4N:T"WXVU>ZEX27ZW\E&28^>A<_O1CT6"R>;JFD,2Q0!
MDR)@4@1,BH!)$3`I`B9%4N84"7YUCB+1WQI%>F:'%S!=3&!*'TSI@RE],*4/
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M87_Z\#7;%O:G3R:S;4'K[/YT&!L=BV;*L]N%\Z#/H')MRW`>]"E0MJT(;8=A
MC.=A$=IR^[O6=P:#+OGSH+;#EPIS^UN$_/28E&T+.>B[9[FV\Y"#'GZR;2&'
M_ID<.9R'''33SFX7ZJP?KKE=J+-L?M?ZD8ARUU15KD^U'7Y%DFM;A!ST>XIL
M6\BAGR7$L2Q"#MG]Z3#"=:0OOV;[#/EI6BC;%O+3-ZRS;:&N^^D!'DNHZ^_L
MKPC[TX\Y<WT687_Z66.V+>Q/G^ADV\+^].NW;%NH,_TT+-L6ZDR_A,JT;22U
M7M?)ENO-0F)^9R.=`[VRDAMM-\I:;W',M2AGO>LPUZ*,]8J_7(ORU8OP<BW*
M5N^&R[4H5[U!+=.B'^9+!OTZ/]-VJ6/0RZUS+3H&O0(ZUZ)CT%N1<RTZ!KT[
M.->B0]`[<S,M&UT/>K-LIN5"VV@5ADS+I;;16@6Y%IU6W8-S+3IW>LE]KD7G
M3N]]S[7HW.GMZ)F6"VVCU8)R+=I&:^KD6J2UEIG)M4AK+<:2:Y'66I\DUR*M
MM8I'IF6M;;2:7:Y%VVC-MUR+M-8R:)F6"VFMQ<)R+=):ZV?E6J2UEI1BR_7J
M\NHZ>]EI_>6KL+0QM]FN=&QY<Q&\1=9:;-<Z-JT%F^EMK6/3\JBY%IU3+0N:
M:]$YU>*9N1:=4ZTGF6O1.=6JBVRY7IU=7><-GUHZS59SF^U*^6B",]>B?/(6
M*CC+['ZN5TL=0;9"U!*6J\_M1YGF[>9*F6;-YE9>,ZSOS=ZNY>"N]?$`6[;!
MV^6M77!V>6.WU!'D;=U21Y`U==NEZDT?Z>2.0/66/;;K\_75==Y>J:7+&[US
M'4'>YIWK"+(F;RN/UV7W<RT7=YTWQ<'?Y>W=4K63-W=+U4[6VFV#^\[OYUR]
M96W6M5S6==X(!_^5MU_GVD_>?)VK#K+6:QL<=WX_P2-E+=)6#JG+FJ#KA2HQ
MF\]6+5W>'"UT!'EKM%`=Y(U1\,/ZC4VFWH(;SIOAA>H@;X6#$\X:83T;R+YD
M]W-P7]EKNU`^W[%>RN<[QDOY9/=S76B,SVJ]54N7=U8'QYP=#X)?SMOEA2HQ
M;Y8E6ZZOZT)7SW>LJ?:B-_)DSDZAO?3S&+3!:LG>20X>.'<GN2XD378OZBK'
M0T'G>+AL,OQ:)S^7^38,JIGXK4Y\_NZEFU<N7B<]6ULZL;FQ5&^N#;KFA`T?
M]U\=/LRGZ/K`^?+J\"D\V\)'W6&[7)K:;A.VR[5IRNU,VV5OKYH^.]-VV3:]
MOR#4QO>*XU`=V5-7%#IY^D].1LFRS<NR4]/A-;N9S-6D-WGEQ-0+B*_T0J]<
MDUY$?*7W>N6:]$+BJ_"Z8>Y*+_T*@O1;O1T+_^G]+]]N?KO[SYO'W^Z_/KWZ
M?/=1<UYGAZ\Y/-[_%J8+^W\\QY=!_OKP_/SPY?!>R$]W-Q_N]&K1L_"AZ\>'
MA^?A']KYVS\?'G\_S*N]_W\!````__\#`%!+`P04``8`"````"$`81%4O5T&
M``#Y&0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RLF5UOHT84AN\K
M]3\@[M<V&!N#;%<QWZB5JFK;7A.,8Q1C+"#)[K_O&88#S!S6<JK=BW7\Y,S+
MG'?.?##9_O:MN"CO657GY76G:K.%JF37M#SFUY>=^O=7_\M&5>HFN1Z32WG-
M=NKWK%9_V__ZR_:CK%[K<Y8U"BA<ZYUZ;IJ;/9_7Z3DKDGI6WK(K_.945D72
MP-?J95[?JBPYMHV*RUQ?+-;S(LFO*E>PJT<TRM,I3S.W3-^*[-IPD2J[)`WT
MOS[GMQK5BO01N2*I7M]N7]*RN('$<W[)F^^MJ*H4J1V]7,LJ>;Y`WM\T(TE1
MN_U"Y(L\K<JZ/#4SD)OSCM*<K;DU!Z7]]IA#!LQVI<I.._5)LV/-5.?[;6O0
M/WGV48]^5NIS^1%4^?'W_)J!VS!.;`2>R_*5A49'AJ#QG+3VVQ'XLU*.V2EY
MNS1_E1]AEK^<&QCN%63$$K./W]VL3L%1D)GI*Z:4EA?H`/RO%#DK#7`D^;93
M=7AP?FS..W6YGJW,Q5*#<.4YJQL_9Y*JDK[535G\RX.T3HJ++#L1^.Q$M)'(
MG89&UQ`^NX;&3-^LM-6:/?U.0_AMVVWX[!KJ^LS4%M;2O-]PW36$3VSX4#NS
M:P>?GTL1)EK;4_CL&BX?2]'J&L(G/M%\K*4&5=0^D_WP2)9S7A1MC;E)D^RW
M5?FAP,2%8:]O"5L&-)N)877QD>GK[4?E!G7&5)Z8S$X%ZZ"2:I@C[_N596[G
M[U#7:1=SH#&:&.%@!"MB)NO*P).!+X-`!J$,(AG$(S`'6WIO8,;\#&^8#/,&
MLSH@&,S2)2,P`INX,O!DX,L@D$$H@T@&\0@(1L"L_QE&,!E8?49%HBW78N:'
M+@9Z,E22&.+T(;T[A'B$^(0$A(2$1(3$8R*8!"O<SS")R<!DA)H<#+`VH@4'
M'K2\YU(?TKM$B$>(3TA`2$A(1$@\)H)+L'83EV!A[Y?TAU<<)M3ZA/D=.%G"
M`/7.:1MI$7+Z(&SF$N(1XA,2$!(2$A$2CXE@"VQ6@BW3FSNNMBQ:S)T3G6_:
M;.ET"'$)\0CQ"0D("0F)"(G'1$@4MHA/),JBQ40Y&2=*B-N1\>S0-M(4\OH@
M+`2?"`6$A'VK<8U9XNR,^B"4CL="@AWLD$ZWWQD[XC3G/'T]E%#+L!9,U,,2
MMEF^^3(1T25.QBX1XG9DV>]+'B$^:140$G;$:'=]0UL9TI2+^H#>CK&(8`><
MA`0[)M*&8R/FS:+%O#LBC+RU$(?'Z8.P/VY/1J-J28<3KPMBMK_O]?5BO9&$
M_5X&A0-"PI[<>50D/$K3#=U8BCG$O0P\2G"0G>$^86$;+GJ(2#11/J$,49BL
M2Y&'"+:#84VVI&1\C-+[4@PH"BF*$/$QT2S-D&S"@%99](D=^N29I[-^/CSM
MV!XMU1\BT3NI5\X0-7C7:?$7.+:`>Q@%2^D][[J&8^\("E%KD(\0F6T]KPWX
M)YLWUA'-@_R(>=KJD\N6QE2DVNN0Z-]*[)B##8><742PLHS,DJ<P1ED_GL,8
M,F@'%(6([CXNPBC^.,U:K!=2CV(,F2A0=M"4"W3L\=?R!N9-;@VC-5+CYU48
M;:RU`Z(A18<BER(/D=%K^8@&K8"BD*((T:`5(YKP@ATG92\^.5GYB53PH4-B
ML4DO)([61Z&!+J)-[X.'J*LL8VE8AJ5)6CY&C=TB\B%&#?(1HJZ2-G`%9^BZ
MM/_$&#5A(#MXR@;^CV+BYU?!Q`X-*3GL<HK-ZP&Y%'F(A@+P$0T-`XI"BB)$
M@U:,:,(+=C:]Y\5#9RZ-GW`%*SHDUI-T&G*PX9"DB^CN:N)U43IL\*,E3CK6
M^J@E=D(ZH09#%!9UB.AN)Z*'.A&CUH\Z(6XF['!\;SP>7.CX&5L8D/&QNSTJ
M.W!1RVIS=#)V*?(H\BD**`HIBBABM\5#)[@7_/:7W\P56?62.=GE4BMI^<9N
M=J'!?MMC?NT<FW;<KA`2A^OHI[:V)'Y@U]1LP9*Y;L.]SP1?VG#70?F383]!
M?^@O#H8-K_T3?&7#>^\$7]OPFCC!-<AL^@FF?9A*V3%M9XJ[I@WO-/0)OFG#
MFPWE@6G#^PWEH6G#.]T$W]CP<@-\WGL*%^^WY"7[(ZE>\FNM7+(3#-^B/1A5
M_.J>?VFZS?NY;.#*O=W'S_`GE@P.?@MV&7(JRP:_L`?T?[39_P<``/__`P!0
M2P,$%``&``@````A`-):QT>``P``Y`P``!``"`%D;V-0<F]P<R]A<'`N>&UL
M(*($`2B@``$`````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````G%==<YLZ
M$'WOS/T/'MX;_)4VS6`Z,BB)IAB[2';&3QH5RS%3#`Q2/,G]]7?!M4UR9:;Q
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M?0XC.@V(CQA,QBA`H8<O@/0^@J$,HDT^%.8/Q!RFQT/$YA'FTSL^GE,28DHY
M"JM\**%&9GT>D)]SXA.V-.X/.)U/)BA:5CXIN0_)'?%0R#CRO.G<"!GR<,HP
MY3.T1./`G-UU5>\%CA@!B[^P_\(QL&1+SB(44N0Q`NTR1O_*(QS439RAZ&\`
M-WS*'G#$O7D484@L(&A,`L((-@?XQN\0B?@"!7/,)QA1*/@$@&;K7I=3-O5^
M0+Z3&2@-5<R-Q'L]_H@B2.^<IS[W431#5>6@"AZT`#I[2-;L<E"%G1!6\ZOM
M*S`)[W'H$3-DR"F^;\GG&@0QIM"-JE9X<3;Q=N&8]=N.Z1L)OU,;9^(7'"%&
MTQ;1`<P(:1''.<A9?=34C%&,(FG+I*&55K-3,]O,&F<`]Z462:IX*,H2[J:=
M-!)N;]3@`LS0B'G?W".[7$O%/P:I$S)"VG3AFPO0#C&KNQUC5K?QW#LVR9A-
MFV3/9',.LJPC&:.<5WG5HP]!]NE<`#&7V?PQ'91C#-,.N22,N9OM<<R?33O&
M_-DTCX=#XH^5_C/-16PNP>GV.<H+*?6\+:H'JAG2>B&=J5KKC70&TSC%_F33
MY//F.?GN`1DDV6\U+UCN"RT/+^2WBP[=B%*NX.UXV#\M.`_P."[3RHFW$=F3
M7!UL_K]1O><7^Y\6MS>\Z@ZZ\%1OK#GVZ??$_0\``/__`P!02P,$%``&``@`
M```A`/\8Z]\Q`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````)R104_#(!B&[R;^AX9[
M2]G<8DC+$C4[N<3$&8TWA&\ML5`":+=_+^VZ.J,GC^1]>7B^CV*UUTWR"<ZK
MUI2(9#E*P(A6*E.5Z&F[3J]1X@,WDC>M@1(=P*,5N[PHA*6B=?#@6@LN*/!)
M)!E/A2U1'8*E&'M1@^8^BPT3PUWK-`_QZ"ILN7CG%>!9GB^QAL`E#QSWP-1.
M1#0BI9B0]L,U`T`*#`UH,,%CDA'\W0W@M/_SPI"<-;4*!QMG&G7/V5(<PZF]
M]VHJ=EV7=?-!(_H3_+*Y?QQ&397I=R4`L7X_#?=A$U>Y4R!O#FS_YIK$^[K`
MO[-"BL&."@<\@$SB>_1H=TJ>Y[=WVS5BLYQ<I82D)-^2)9T3NEB\%OC4&N^S
M":A'@7\33P`V>/_\<_8%``#__P,`4$L!`BT`%``&``@````A`#UTO#(;`@``
M7"```!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"
M+0`4``8`"````"$`M54P(_4```!,`@``"P````````````````!4!```7W)E
M;',O+G)E;'-02P$"+0`4``8`"````"$`A-K?^T4"``"Y'P``&@``````````
M``````!Z!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`
M"````"$`F)`)GF\$```M$```#P````````````````#_"@``>&PO=V]R:V)O
M;VLN>&UL4$L!`BT`%``&``@````A`+YU7B?.!0``_Q4``!@`````````````
M````FP\``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````
M(0"9*S.@+0(``*4$```9`````````````````)\5``!X;"]W;W)K<VAE971S
M+W-H965T-#`N>&UL4$L!`BT`%``&``@````A`&\*M\?W`P``-1(``!D`````
M`````````````Q@``'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4
M``8`"````"$`O0>/86,#````"P``&0`````````````````Q'```>&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+`0(M`!0`!@`(````(0"[.%4#+`,``(T)
M```9`````````````````,L?``!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L!`BT`%``&``@````A`&Q_JB#I`P``#`X``!D`````````````````+B,`
M`'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`+G5C
M#+P"``"S!P``&0````````````````!.)P``>&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+`0(M`!0`!@`(````(0!NOBBK7`4``+48```9````````````
M`````$$J``!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`%``&``@`
M```A``AU572C`@``?08``!D`````````````````U"\``'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"+0`4``8`"````"$`;"-`<"L#``"^"@``&0``
M``````````````"N,@``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(M
M`!0`!@`(````(0`K38M8S0,``&@-```9`````````````````!`V``!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A`+M#!])^!P``
M42H``!D`````````````````%#H``'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"+0`4``8`"````"$`:(DU41`$```\#P``&0````````````````#)
M00``>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0""
M0%RQ8@,``%<+```9`````````````````!!&``!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L!`BT`%``&``@````A`'`ODO@^`P``ZPD``!D`````````
M````````J4D``'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"+0`4``8`
M"````"$`$%\;"C4$``"K$```&0`````````````````>30``>&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;%!+`0(M`!0`!@`(````(0#TK#$%1@T``"*"```-
M`````````````````(I1``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A
M`*[)DNV[@```#[@!`!0`````````````````^UX``'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L!`BT`%``&``@````A`,@Y8R";`@``)@<``!@`````````````
M````Z-\``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````
M(0#)[Q[JNP4``$D7```8`````````````````+GB``!X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P``````
M``````````"JZ```>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````
M(0":SEMU#@<``(\C```9`````````````````&_O``!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L!`BT`%``&``@````A`,^*>\>(`@``Y04``!D`````
M````````````M/8``'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"+0`4
M``8`"````"$`J1\VXI<"``!3!@``&0````````````````!S^0``>&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M`!0`!@`(````(0!I:&IX\`0``-D5
M```9`````````````````$'\``!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L!`BT`%``&``@````A`(>%=DD$`P``U@@``!D`````````````````:`$!
M`'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"+0`4``8`"````"$`:NL=
M#LP#``!4#@``&0````````````````"C!`$`>&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+`0(M`!0`!@`(````(0!,MQ&KN0,``)L-```8````````````
M`````*8(`0!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"```
M`"$`9I?73$H#``">"0``&0````````````````"5#`$`>&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0#YX:EA]@(``"8(```9````
M`````````````!80`0!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`
M%``&``@````A`$$)FA3.`@``(0@``!D`````````````````0Q,!`'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"+0`4``8`"````"$`L!:B0Q\&```E
M&0``&0````````````````!(%@$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+`0(M`!0`!@`(````(0"G@Q:/<Q4``/)^```9`````````````````)X<
M`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`/>V
MN'8T&0``#)P``!D`````````````````2#(!`'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"+0`4``8`"````"$`0C7@(><#``".#P``&0``````````
M``````"S2P$`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(
M````(0!E9'K(N#,``.%+`0`9`````````````````-%/`0!X;"]W;W)K<VAE
M971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`&*;73(;#```N44``!@`
M````````````````P(,!`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M
M`!0`!@`(````(0#LN`R3]P4``!`8```8`````````````````!&0`0!X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`[^32^T$#``"`
M"@``&``````````````````^E@$`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L!`BT`%``&``@````A`'>7/*T6`P``V`D``!@`````````````````M9D!
M`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0`780(&
M2!\``)["```8``````````````````&=`0!X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"+0`4``8`"````"$`<JYZ[\D#```D#0``&0``````````````
M``!_O`$`>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````
M(0!O'T-?/@@``!8D```9`````````````````'_``0!X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L!`BT`%``&``@````A`$$D:JAU`P``$0P``!D`````
M````````````],@!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4
M``8`"````"$`"WA(_041``"V6P``&0````````````````"@S`$`>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#J74&>J!$``+%>
M```9`````````````````-S=`0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L!`BT`%``&``@````A`#7^WTHB"```(2,``!D`````````````````N^\!
M`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4``8`"````"$`J'?$
MK-<,``"\/P``&0`````````````````4^`$`>&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+`0(M`!0`!@`(````(0#CVUG4[`,``'P/```9````````````
M`````"(%`@!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@`
M```A`.<3T#A]!0``1A4``!D`````````````````10D"`'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`7=O];,8&``!L'0``&0``
M``````````````#Y#@(`>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M
M`!0`!@`(````(0!-SS$4^`T``%E&```9`````````````````/85`@!X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`!TJ:"^[!```
M*14``!D`````````````````)20"`'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"+0`4``8`"````"$`"WMG>M@7``!L@@``&0`````````````````7
M*0(`>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0"2
M28X=LB```*W$```9`````````````````"9!`@!X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L!`BT`%``&``@````A`&$15+U=!@``^1D``!D`````````
M````````#V("`'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"+0`4``8`
M"````"$`TEK'1X`#``#D#```$`````````````````"C:`(`9&]C4')O<',O
M87!P+GAM;%!+`0(M`!0`!@`(````(0#_&.O?,0$``$`"```1````````````
M`````%EM`@!D;V-0<F]P<R]C;W)E+GAM;%!+!08`````/@`^`.00``#!;P(`
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Details - Option information) (Stock Options [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Vested</a></td>
        <td class="nump">24,294,227<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested</a></td>
        <td class="nump">$ 0.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Vested</a></td>
        <td class="text">3 years 11 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Expected to vest</a></td>
        <td class="nump">4,711,811<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expected to vest</a></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Expected to vest</a></td>
        <td class="text">9 years 1 month 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares</a></td>
        <td class="nump">29,006,038<span></span></td>
        <td class="nump">26,133,407<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>4. NOTES PAYABLE (Details - Notes payable) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">$ 190,000<span></span></td>
        <td class="nump">$ 390,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">374,312<span></span></td>
        <td class="nump">374,704<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">12% Notes Payable [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">185,000<span></span></td>
        <td class="nump">185,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">367,687<span></span></td>
        <td class="nump">353,813<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">10% Note payable [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">6,625<span></span></td>
        <td class="nump">6,375<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Directors Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 14,516<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedInterestOnNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Interest on notes payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedInterestOnNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Current Liabilities</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Other current liabilities were comprised of the following items:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%">Accrued interest</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">570,741</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">1,165,335</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Accrued legal fees</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">179,465</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">179,465</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Accrued liquidated damages</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">362,800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">362,800</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Other accrued liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">103,598</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">147,774</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Total other current liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,216,604</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,855,374</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>11. WARRANTS (Details - Assumptions) (Warrants [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.79%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
        <td class="nump">90.10%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">2.29%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
        <td class="nump">95.80%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of dividends expected to be paid to holders of the underlying shares or contracted instruments over the term of the instruments life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. FAIR VALUE MEASUREMENT (Details - Assumptions)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions and Methodology for Assets and Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.02%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Average expected life</a></td>
        <td class="text">3 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">78.90%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions and Methodology for Assets and Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.62%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Average expected life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">104.50%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Inputs Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions and Methodology for Assets and Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense related to convertible notes payable</a></td>
        <td class="nump">$ 97,362<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred finance fees</a></td>
        <td class="nump">$ 21,502<span></span></td>
        <td class="nump">$ 863<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate amount of interest paid or due on all long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
        <td class="nump">$ 84,000<span></span></td>
        <td class="nump">$ 68,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Details - Option activity) (Stock Options [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AmountAbstract', window );"><strong>Amount</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding beginning</a></td>
        <td class="nump">26,133,407<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
        <td class="nump">2,972,631<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
        <td class="num">(100,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding ending</a></td>
        <td class="nump">29,006,038<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
        <td class="nump">24,294,227<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePriceAbstract', window );"><strong>Range of Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice', window );">Stock options outstanding Minimum beginning</a></td>
        <td class="nump">$ 0.076<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice', window );">Stock options outstanding at Maximum beginning</a></td>
        <td class="nump">$ 0.41<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_Exercised', window );">Exercised</a></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_Granted', window );">Granted</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_Cancelledexpired', window );">Cancelled/Expired</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice', window );">Stock options outstanding Minimum ending</a></td>
        <td class="nump">$ 0.076<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice', window );">Stock options outstanding Maximum ending</a></td>
        <td class="nump">$ 0.41<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsExercisableRangeOfExercisePricesMinimum', window );">Stock options exercisable Minimum ending</a></td>
        <td class="nump">$ 0.076<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockOptionsExercisableRangeOfExercisePricesMaximum', window );">Stock options exercisable Maximum ending</a></td>
        <td class="nump">$ 0.41<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding beginning</a></td>
        <td class="nump">$ 0.25<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Expired</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding ending</a></td>
        <td class="nump">$ 0.24<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable ending</a></td>
        <td class="nump">$ 0.26<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AmountAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AmountAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_Cancelledexpired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of exercise price - cancelled/expired</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_Cancelledexpired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_Exercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of exercise price - exercised</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_Exercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_Granted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of exercise price - granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_Granted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_RangeOfExercisePriceAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockOptionsExercisableRangeOfExercisePricesMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options exercisable Maximum ending</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_StockOptionsExercisableRangeOfExercisePricesMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockOptionsExercisableRangeOfExercisePricesMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options exercisable Minimum ending</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_StockOptionsExercisableRangeOfExercisePricesMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options outstanding at Maximum beginning</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_StockOptionsOutstandingMaximumRangeOfExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options outstanding Minimum beginning</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_StockOptionsOutstandingMinimumRangeOfExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WeightedAverageExercisePriceAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>4. NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4. NOTES PAYABLE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notes payable consist of the following:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">March 31, 2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal Balance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued Interest</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal Balance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%">12% Notes payable, past due</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">185,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">367,687</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">185,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">353,813</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>10% Note payable, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,625</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,375</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Directors&#146; Note(s)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">200,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">14,516</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-indent: 27pt">Total</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">374,312</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">390,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">374,704</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2014,
we recorded interest expense of $19,959 related to the contractual interest rates of our notes payable.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12% NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From August 1999 through May 2005, we entered
into various borrowing arrangements for the issuance of notes payable from private placement offerings (the &#34;12% Notes&#34;).
On April 21, 2010, a holder of $100,000 of the 12% Notes converted the principal balance and $71,758 of accrued interest into 687,033
shares of common stock at an agreed conversion price of $0.25 per share. At September 30, 2014, the 12% Notes in the principal
amount of $185,000 were past due, in default, and bearing interest at the default rate of 15%.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10% NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2014,&#160;one 10% Note in
the amount of $5,000 is past due and in default, remains outstanding and bears interest at the default rate of 15%.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management's plans to satisfy the remaining
outstanding balance on these 12% and 10% Notes include converting the notes to common stock at market value or repayment when funds
are available.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DIRECTORS&#146; NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, we borrowed $400,000 from two
of our directors under two 90 day notes for $200,000 each bearing 10% interest (the &#147;Notes&#148;). At the discretion of
the holders, if not paid off by October 9, 2013, the noteholders were entitled to (i) convert the principal and accrued interest
under the Notes into shares of common stock at $0.088 per share (the &#147;Conversion Price&#148;) and (ii) receive warrants
to purchase common stock equal to 50% of the principal converted under the Notes, with an exercise price of $0.132 per share. Additionally,
there was a provision for a penalty interest rate of 12%.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">That potential conversion price and warrant
exercise price were based on the same pricing mechanism that we have used in prior equity unit financings since March 2012 (see
Note 6) which are based on 80% of the then current market price of our common stock and with the warrant exercise price based on
120% of the same then current market price. We initially reserved 6,931,818 shares of common stock to support the conversion of
the Notes and accrued interest in full as well as the exercise of the warrants in full (should such conversion and/or issuance
occur).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended March 31, 2014,
the principal of $200,000 and accrued interest of $9,367 were paid on one of the Notes, which extinguished all potential common
stock and warrant issuance provisions related to that Note.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2014,
the holder of the second Note converted the principal of $200,000 and accrued interest of $20,349 into 2,503,966 shares of our
common stock per the conversion formula of the Note (see Note 6).</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>29
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ7TY!
M5%5215]/1E]"55-)3D534U]!3D1?0D%325,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93XR7TQ)455)1$E463PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C-?4U5-34%265]/1E]324=.249)
M0T%.5%]!0T-/53PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/C1?3D]415-?4$%904),13PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/C5?0T].5D525$E"3$5?3D]415-?4$%904),13PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C9?15%525197U12
M04Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/C=?4D5,051%1%]005)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XX7T]42$527T-54E)%3E1?3$E!
M0DE,251)15,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93XY7T9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^,3!?4U1/0TM?0T]-4$5.4T%424]./"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^,3%?5T%24D%.
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ,E]$
M05)005]#3TY44D%#5%]!3D1?4D5,051%1%\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93XQ,U]#3TU-251-14Y44U]!3D1?0T].5$E.
M1T5.0TD\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ
M-%]314=-14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/C$U7U-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^,U]354U-05)97T]&7U-)1TY)1DE#04Y47T%#
M0T]5,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C-?
M4U5-34%265]/1E]324=.249)0T%.5%]!0T-/53(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93XT7TY/5$537U!!64%"3$5?5&%B;&5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^-5]#3TY6
M15)424),15].3U1%4U]005E!0DQ%7U1A/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^.%]/5$A%4E]#55)214Y47TQ)04))3$E42453
M7U1A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^.5]&
M04E27U9!3%5%7TU%05-54D5-14Y44U]486)L/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^,3!?4U1/0TM?0T]-4$5.4T%424].7U1A
M8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C$Q
M7U=!4E)!3E137U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/C$T7U-%1TU%3E137U1A8FQE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/C)?3$E154E$25197T1E=&%I;'-?3F%R
M<F%T:79E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M,U]354U-05)97T]&7U-)1TY)1DE#04Y47T%#0T]5,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C-?4U5-34%265]/1E]324=.249)
M0T%.5%]!0T-/530\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93XT7TY/5$537U!!64%"3$5?1&5T86EL<U].;W1E<U\\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XT7TY/5$537U!!64%"3$5?
M1&5T86EL<U].87)R870\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S0N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93XU7T-/3E9%4E1)0DQ%7TY/5$537U!!64%"3$5?1&4\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XU7T-/3E9%4E1)0DQ%
M7TY/5$537U!!64%"3$5?1&4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,V+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^-5]#3TY615)424),15].3U1%4U]005E!0DQ%7T1E,CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C9?15%52519
M7U1204Y304-424].4U]$971A:6QS7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/CA?3U1(15)?0U524D5.5%],24%"24Q)5$E%4U]$
M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/CA?3U1(
M15)?0U524D5.5%],24%"24Q)5%E?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/CE?1D%)4E]604Q515]-14%355)%345.5%-?
M1&5T83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/CE?
M1D%)4E]604Q515]-14%355)%345.5%]$971A:3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/CE?1D%)4E]604Q515]-14%355)%345.
M5%]$971A:3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93XQ,%]35$]#2U]#3TU014Y3051)3TY?1&5T86EL<U\\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M-#0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ,%]35$]#2U]#3TU014Y3051)
M3TY?1&5T86EL<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^,3!?4U1/0TM?0T]-4$5.4T%424].7T1E=&%I;'-?,CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C$P7U-43T-+7T-/35!%
M3E-!5$E/3E]$971A:6QS7S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93XQ,%]35$]#2U]#3TU014Y3051)3TY?1&5T86EL<U\T/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^,3%?5T%24D%.
M5%-?1&5T86EL<U]787)R86YT7V%C/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^,3%?5T%24D%.5%-?1&5T86EL<U]!<W-U;7!T:6]N
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#4P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^,3)?1$%2
M4$%?0T].5%)!0U1?04Y$7U)%3$%4141?,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/C$S7T-/34U)5$U%3E137T%.1%]#3TY424Y'
M14Y#23$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ
M-%]314=-14Y44U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4S+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-
M"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S
M<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\
M>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^
M#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S
M/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\
M+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O
M<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W
M-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U
M,C=A,S<R92]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.1T%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@
M26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.
M;W8N(#`W+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E1E<FT@3V8@3&5A<V4\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.
M86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG065T:&QO;B!-
M961I8V%L($EN8SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#`X.#(R.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M43QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=F86QS93QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E
M;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<M+3`S+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27,@16YT:71Y(&$@5V5L;"UK;F]W;B!3
M96%S;VYE9"!)<W-U97(_/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<R!%;G1I='D@82!6;VQU;G1A<GD@1FEL97(_/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F\\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<R!%;G1I='DG<R!297!O
M<G1I;F<@4W1A='5S($-U<G)E;G0_/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4VUA;&QE<B!297!O<G1I;F<@0V]M
M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-2PQ-C`L,3DT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG43(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&
M;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]+04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%
M1"!"04Q!3D-%(%-(14544R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#=7)R96YT(&%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3(V+#$X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR-3`L,C<Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E
M:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3@L-C<R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.34L,3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!F:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8V+#$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+#$Y,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E
M;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0Q+#$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#8Y.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.3(L,3@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT-SDL,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#$X-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T+#(W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT
M<R!A;F0@<&%T96YT<R!P96YD:6YG+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P-RPY,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,3(L-#@Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L.3@X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L.3@X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X.2PR
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#8Y-2PQ,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P
M.2PQ-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,3<L-C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$=64@=&\@<F5L871E9"!P87)T:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#@L-S<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,Y+#`W,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DP+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4L(&-U<G)E;G0@
M<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@S+#0R
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,S8W+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#8W.2PP-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E
M;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C$V+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L.#4U+#,W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S@W+#DU-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M+#8T."PX,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3F]N8W5R<F5N="!L:6%B:6QI=&EE<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE(&YO=&5S('!A>6%B;&4L(&YO;F-U<G)E;G0@<&]R=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DP+#4R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W-BPT-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!N;VYC=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY.3`L-3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S<V+#0U,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,W."PT-S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-BPT,C4L,C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H3F]T
M92`Q,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@1&5F
M:6-I=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("0P+C`P,2!P97(@<VAA<F4[
M(#4P,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%S(&]F(%-E<'1E;6)E
M<B`S,"P@,C`Q-"!A;F0@36%R8V@@,S$L(#(P,30[(#(V,BPW,3,L-S@Q(&%N
M9"`R,C0L.3<S+#DX,"!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A
M<R!O9B!397!T96UB97(@,S`L(#(P,30@86YD($UA<F-H(#,Q+"`R,#$T+"!R
M97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M,BPW,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C0L.3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L-C4T+#@U,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y+#8U.2PQ
M,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<Y+#,S-2PY,#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-S0L.#,R+#4U-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!971H
M;&]N($UE9&EC86PL($EN8RX@<W1O8VMH;VQD97)S)R!D969I8VET(&)E9F]R
M92!N;VYC;VYT<F]L;&EN9R!I;G1E<F5S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,L-#$X+#,T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PY-#@L-#,V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N8V]N=')O
M;&QI;F<@:6YT97)E<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,CDL,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$X+#(W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@9&5F:6-I=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPR.#DL,C`W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#<S,"PQ-C8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;&EA8FEL:71I97,@86YD(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PP.#DL,C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8Y-2PQ,#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X7S5E,V5?
M-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W,F4O
M5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D9!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.
M0T4@4TA%1513("`H56YA=61I=&5D*2`H4&%R96YT:&5T:6-A;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!$969I8VET/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K('!A<B!V86QU92`H:6X@1&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C(L
M-S$S+#<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R-"PY-S,L.3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V,BPW,3,L-S@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(T
M+#DW,RPY.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y-#-?
M83AF85\T8V,S-3(W83,W,F4O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%14Q!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY$14Y3140@
M0T].4T],241!5$5$(%-4051%345.5%,@3T8@3U!%4D%424].4R`H56YA=61I
M=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2159%3E5%4SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]V
M97)N;65N="!C;VYT<F%C="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0W.2PP-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8T-"PX.#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S,"PS-S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@T,"PT
M.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3U!%4D%424Y'($584$5.4T53/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]F97-S:6]N86P@
M9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`X+#@R,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R
M-RPU,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW,3`L-#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C4Q+#4X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y<F]L;"!A;F0@<F5L871E9"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30T+#,U-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M-"PX-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$V-2PP-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-C,L-#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(W+#`Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M,BPS,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,C@L,#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,Y+#`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.#`L,C8W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<T
M+#8X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,S`S+#4W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.#4T+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]015)!5$E.1R!,3U-3/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,#$L,3DR*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R.2PW.38I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW
M-S,L,C`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,#$S+#4Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3U1(15(@15A014Y313PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!O;B!D96)T(&-O;G9E<G-I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8U+#0Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$W+#0V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-3,Q+#$R,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#(U-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A:6XI+VQO
M<W,@;VX@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B
M:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY,BPP
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPS.#(L.#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A;F0@;W1H97(@9&5B="!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@L,30U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#0P
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T-"PW.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,38L-#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&5X=&5N<VEO;B!O9B!W87)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30S+#,V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#,L
M,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&]T:&5R(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Q.2PX-S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@Q.2PR.#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8S.2PU
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@3$]34R!"149/4D4@3D].0T].5%)/3$Q)3D<@24Y415)%4U13
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.#@L,3DS*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,S0Y
M+#8W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T+#4Y,BPT.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RPV-3,L,38X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3$]34R!!5%1224)55$%"3$4@
M5$\@3D].0T].5%)/3$Q)3D<@24Y415)%4U13/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T,"PW.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@Y+#$S-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,@0514
M4DE"551!0DQ%(%1/($-/34U/3B!35$]#2TA/3$1%4E,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H.#0W+#0P.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L,S0Y+#8W,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L
M-3`S+#,U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#,L-C4S+#$V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!4TE#($%.1"!$24Q55$5$($Q/4U,@
M4$52($-/34U/3B!32$%213PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XP,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y714E'2%1%1"!!5D5204=%
M($Y534)%4B!/1B!#3TU-3TX@4TA!4D53($]55%-404Y$24Y'("T@0D%324,@
M04Y$($1)3%54140\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M.2PS-CDL.3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@W+#8T,RPU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-#,L-#DT+#DQ-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,BPP,#0L,C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U)04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%
M1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%5N875D:71E9"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L-3DR
M+#0X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#,L-C4S+#$V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C
M;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8W-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(V,"PV.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.3`L-C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(&UA<FME="!V86QU92!O9B!C
M;VUM;VX@<W1O8VLL('=A<G)A;G1S(&%N9"!O<'1I;VYS(&ES<W5E9"!F;W(@
M<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,BPS
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-C0L,S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPS.#(L.#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W-S(&]N(&5X=&5N<VEO;B!O9B!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30S+#,V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@
M9&5B="!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4S,2PQ,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,"PR-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!D96)T(&1I<V-O
M=6YT(&%N9"!D969E<G)E9"!F:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Q+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG
M97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,38R+#0Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,2PT,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C
M=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-2PR,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!O=&AE<B!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-C,L-C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S,L,3<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1'5E('1O(')E;&%T960@<&%R=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL-S`X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$L,#0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS.30L,S8V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<T-"PU,C`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-A<V@@9FQO=W,@9G)O;2!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M('1H92!I<W-U86YC92!O9B!N;W1E<R!P87EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!T:&4@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-S`L,C<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H
M('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-S`L,C<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D96-R
M96%S92!I;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M,C0L,#DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Q-BPU,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&)E9VEN;FEN9R!O9B!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C4P+#(W.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PR
M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3(V+#$X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L-S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A
M;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF;W)M871I;VXZ/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!N;VXM8V%S:"!I;G9E<W1I
M;F<@86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@86YD(&%C8W)U960@
M:6YT97)E<W0@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#<L-C,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(P+#0V,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;&%S
M<VEF:6-A=&EO;B!O9B!W87)R86YT(&1E<FEV871I=F4@;&EA8FEL:71Y(&EN
M=&\@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PV
M-SDL,#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`V+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5C;&%S<VEF:6-A=&EO;B!O9B!A8V-O=6YT<R!P
M87EA8FQE('1O(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&9I;F%N
M8VEN9R!C;W-T<R!R96-O<F1E9"!I;B!C;VYN96-T:6]N('=I=&@@9&5B="!A
M;65N9&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C;&%S<VEF:6-A=&EO;B!O9B!A8V-R=65D(&EN=&5R97-T('1O(&-O
M;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C4L-S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PP,C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A
M7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W,F4O5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^,2X@3D%455)%($]&($)54TE.15-3($%.1"!"05-)4R!/1B!04D53
M14Y4051)3TX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<F=A;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R
M97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M05154D4@3T8@0E5324Y%4U,@04Y$($)!4TE3($]&(%!215-%3E1!5$E/3CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXQ+B!.05154D4@3T8@0E5324Y%
M4U,@04Y$($)!4TE3($]&(%!215-%3E1!5$E/3CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^3U)'04Y)6D%424]./"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY!971H;&]N($UE9&EC86PL($EN8RX@86YD('-U8G-I
M9&EA<GD@*"8C,S0[065T:&QO;B8C,S0[+`T*=&AE("8C,S0[0V]M<&%N>28C
M,S0[+"`F(S,T.W=E)B,S-#L@;W(@)B,S-#MU<R8C,S0[*2!I<R!A(&UE9&EC
M86P@9&5V:6-E(&-O;7!A;GD@9F]C=7-E9"!O;B!C<F5A=&EN9R!I;FYO=F%T
M:79E(&1E=FEC97,@=&AA=`T*861D<F5S<R!U;FUE="!M961I8V%L(&YE961S
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M(&9E87-I8FEL:71Y('-T=61Y('!R;W1O8V]L+`T*=V4@=VEL;"!E;G)O;&P@
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M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@3V-T;V)E<B`R,#$S
M+"!O=7(@<W5B<VED:6%R>2P@17AO<V]M92!38VEE;F-E<RP-"DEN8RX@*"8C
M,30W.T53228C,30X.RDL(&-O;6UE;F-E9"!O<&5R871I;VYS('=I=&@@82!F
M;V-U<R!O;B!A9'9A;F-I;F<@97AO<V]M92UB87-E9"!S=')A=&5G:65S('1O
M(&1I86=N;W-E(&%N9"!M;VYI=&]R('1H92!P<F]G<F5S<VEO;@T*;V8@8V%N
M8V5R+"!I;F9E8W1I;W5S(&1I<V5A<V4@86YD(&]T:&5R(&QI9F4M=&AR96%T
M96YI;F<@8V]N9&ET:6]N<RXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D]U<B!C;VUM;VX@<W1O8VL@:7,@<75O=&5D(&]N('1H92!/
M5$-10B!M87)K971P;&%C90T*861M:6YI<W1E<F5D(&)Y('1H92!/5$,@36%R
M:V5T<R!'<F]U<"!U;F1E<B!T:&4@<WEM8F]L("8C,S0[045-1"XF(S,T.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&%C8V]M<&%N>6EN
M9R!U;F%U9&ET960@8V]N9&5N<V5D(&-O;G-O;&ED871E9`T*9FEN86YC:6%L
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M8F%L86YC92!S:&5E="!A<R!O9B!-87)C:"`S,2P@,C`Q-"!W87,@9&5R:79E
M9"!F<F]M(&]U<B!A=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!/<&5R
M871I;F<@<F5S=6QT<PT*9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B`S,"P@,C`Q-"!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@
M;V8@=&AE(')E<W5L=',@=&AA="!M87D@8F4@97AP96-T960@9F]R('1H92!Y
M96%R(&5N9&EN9PT*36%R8V@@,S$L(#(P,34N($9O<B!F=7)T:&5R(&EN9F]R
M;6%T:6]N+"!R969E<B!T;R!O=7(@06YN=6%L(%)E<&]R="!O;B!&;W)M(#$P
M+4L@9F]R('1H92!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!W:&EC:"!I
M;F-L=61E<PT*875D:71E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@9F]O
M=&YO=&5S(&%S(&]F($UA<F-H(#,Q+"`R,#$T(&%N9"`R,#$S(&%N9"!F;W(@
M=&AE('EE87)S('1H96X@96YD960N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X9F%?
M-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V
M-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE971S
M+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SXR+B!,25%5241)5%D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY2:7-K<R!A;F0@56YC97)T86EN=&EE<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,25%5241)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M3D]412`R+B!,25%5241)5%D\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M#0IA="!397!T96UB97(@,S`L(#(P,30@87)E(&EN(&1E9F%U;'0@;VX@8V5R
M=&%I;B!D96)T(&%G<F5E;65N=',L(&AA=F4@;F5G871I=F4@=V]R:VEN9R!C
M87!I=&%L(&]F(&%P<')O>&EM871E;'D@)#(L-#DV+#`P,"P@86YD#0IH879E
M(&%N(&%C8W5M=6QA=&5D(&1E9FEC:70@;V8@87!P<F]X:6UA=&5L>2`D-SDL
M,S,V+#`P,"X@5&AE<V4@9F%C=&]R<RP@86UO;F<@;W1H97(@;6%T=&5R<RP@
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M;W(@=&AE(&9I<V-A;"!Y96%R(&5N9&EN9R!-87)C:"`S,2P@,C`Q-2!T:')O
M=6=H(&1E8G0@86YD+V]R(&5Q=6ET>2!F:6YA;F-I;F<@87)R86YG96UE;G1S
M(&%S('=E;&P@87,@=&AR;W5G:`T*<F5V96YU97,@86YD(')E;&%T960@8V%S
M:"!R96-E:7!T<R!U;F1E<B!O=7(@9V]V97)N;65N="!C;VYT<F%C=',@*'-E
M92!.;W1E(#$R*2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U
M<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR,#$T
M+"!W92!C;VYV97)T960@82!P87-T(&1U92!C;VYV97)T:6)L92!N;W1E(&EN
M('1H92!A;6]U;G0@;V8@)#8V,"PP,#`@86YD(')E;&%T960@86-C<G5E9"!I
M;G1E<F5S="!I;G1O(&5Q=6ET>2!A;F0@86QS;PT*<F5S=')U8W1U<F5D(&%N
M9"!E>'1E;F1E9"!A(&9O<FUE<FQY('!A<W0@9'5E(&-O;G9E<G1I8FQE(&YO
M=&4@:6X@=&AE(&%M;W5N="!O9B`D,C(U+#`P,"X@5V4@86QS;R!E;&EM:6YA
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M;W5N="!O9B`D,3`L-C<Y+#`V-R!I;G1O(&5Q=6ET>2X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
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M=F5D(&9R;VT@861D:71I;VYA;`T*<')I=F%T92!I;G9E<W1M96YT<R!W:6QL
M(&)E('-U9F9I8VEE;G0@=&\@;65E="!O=7(@;&EQ=6ED:71Y(&YE961S(&9O
M<B!F:7-C86P@,C`Q-2X@2&]W979E<BP@;F\@87-S=7)A;F-E(&-A;B!B92!G
M:79E;B!T:&%T('=E#0IW:6QL(')E8V5I=F4@86YY(&9U;F1S(&EN('1H92!F
M;W)M(&]F(')E=F5N=65S(&]R(&EN(&-O;FYE8W1I;VX@=VET:"!C87!I=&%L
M(')A:7-I;F<@86-T:79I=&EE<R!I;B!A9&1I=&EO;B!T;R!T:&4@9G5N9',@
M=V4@:&%V90T*86QR96%D>2!R96-E:79E9"X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<W5C
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M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&1O(&YO=`T*:6YC;'5D92!A;GD@861J=7-T;65N
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M;VYC97)N+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y
M-#-?83AF85\T8V,S-3(W83,W,F4O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,RX@4U5-34%2
M62!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N
M=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y354U-05)9($]&(%-)1TY)1DE#04Y4
M($%#0T]53E1)3D<@4$],24-)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^3D]412`S+B!354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@
M4$],24-)15,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!S
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M96YS960-"F-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!224Y#25!,15,@3T8@0T].
M4T],241!5$E/3CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE
M(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;`T*<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!!971H;&]N
M($UE9&EC86PL($EN8RX@86YD(&ET<R!M86IO<FET>2UO=VYE9"!A;F0@8V]N
M=')O;&QE9"!S=6)S:61I87)Y+"!%4TDN($%L;"!S:6=N:69I8V%N=`T*:6YT
M97)C;VUP86YY(&)A;&%N8V5S(&%N9"!T<F%N<V%C=&EO;G,@:&%V92!B965N
M(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX@5&AE($-O;7!A;GD@8VQA
M<W-I9FEE<R!T:&4@;F]N8V]N=')O;&QI;F<@:6YT97)E<W1S#0II;B!%4TD@
M87,@<&%R="!O9B!C;VYS;VQI9&%T960@;F5T(&QO<W,@:6X@=&AE('-I>"!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"!I;F-L=61E<R!T
M:&4@86-C=6UU;&%T960@86UO=6YT(&]F(&YO;F-O;G1R;VQL:6YG#0II;G1E
M<F5S=',@87,@<&%R="!O9B!S=&]C:VAO;&1E<G,F(S$T-CL@97%U:71Y+B!$
M=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!%
M4TD@<F%I<V5D(&-A<&ET86P@:6X@=&AE(&%M;W5N=`T*;V8@)#$L-3`P+#`P
M,"!I;B!E>&-H86YG92!F;W(@=&AE(&ES<W5A;F-E(&]F(#,P,"PP,#`@<VAA
M<F5S(&]F($5322!C;VUM;VX@<W1O8VL@=&\@15-))B,Q-#8[<R!I;G9E<W1O
M<G,L(')E<')E<V5N=&EN9R`R,"4@;V8-"D53228C,30V.W,@:7-S=65D(&%N
M9"!O=71S=&%N9&EN9R!C87!I=&%L('-T;V-K+B!!<R!A(')E<W5L="P@065T
M:&QO;B!-961I8V%L+"!);F,N)B,Q-#8[<R!O=VYE<G-H:7`@;V8@15-)('=A
M<R!R961U8V5D('1O(#@P)2X-"DEF(&$@9G5R=&AE<B!C:&%N9V4@:6X@065T
M:&QO;B!-961I8V%L($EN8RXF(S$T-CMS(&]W;F5R<VAI<"!O9B!%4TD@<F5S
M=6QT<R!I;B!L;W-S(&]F(&-O;G1R;VP@86YD(&1E8V]N<V]L:61A=&EO;BP@
M86YY(')E=&%I;F5D#0IO=VYE<G-H:7`@:6YT97)E<W0@=VEL;"!B92!R96UE
M87-U<F5D('=I=&@@=&AE(&=A:6X@;W(@;&]S<R!R97!O<G1E9"!I;B!O=7(@
M<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY4:&4@;&]S<V5S(&%T($5322!D=7)I;F<@=&AE('-I>"!M
M;VYT:',@96YD960-"E-E<'1E;6)E<B`S,"P@,C`Q-"!R961U8V5D('1H92!N
M;VYC;VYT<F]L;&EN9R!I;G1E<F5S=',@;VX@;W5R(&-O;G-O;&ED871E9"!B
M86QA;F-E('-H965T(&)Y("0X.2PQ,S4@9G)O;2`D,C$X+#(W,"!A="!-87)C
M:"`S,2P-"C(P,30@=&\@)#$R.2PQ,S4@870@4V5P=&5M8F5R(#,P+"`R,#$T
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^55-%($]&($535$E-
M051%4SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@<')E<&%R
M92!O=7(@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"G-T871E
M;65N=',@:6X@8V]N9F]R;6ET>2!W:71H($=!05`L('=H:6-H(')E<75I<F5S
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M<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-!4T@@04Y$($-!
M4T@@15%5259!3$5.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D%C8V]U;G1I;F<@<W1A;F1A<F1S(&1E9FEN92`F(S,T.V-A<V@@86YD(&-A
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M97%U:79A;&5N=',N($%S(&]F(%-E<'1E;6)E<@T*,S`L(#(P,30@86YD($UA
M<F-H(#,Q+"`R,#$T+"!W92!H860@;F\@87-S971S('1H870@=V5R92!C;&%S
M<VEF:65D(&%S(&-A<V@@97%U:79A;&5N=',N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY#3TY#14Y44D%424].4R!/1B!#4D5$250@4DE32U,\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-A<V@@:7,@;6%I;G1A
M:6YE9"!A="!T=V\@9FEN86YC:6%L(&EN<W1I='5T:6]N<PT*:6X@8VAE8VMI
M;F<@86-C;W5N=',@86YD(')E;&%T960@8V%S:"!M86YA9V5M96YT(&%C8V]U
M;G1S+B!!8V-O=6YT<R!A="!T:&5S92!I;G-T:71U=&EO;G,@87)E('-E8W5R
M960@8GD@=&AE($9E9&5R86P@1&5P;W-I="!);G-U<F%N8V4-"D-O<G!O<F%T
M:6]N("@F(S,T.T9$24,F(S,T.RD@=7`@=&\@)#(U,"PP,#`N($]U<B!397!T
M96UB97(@,S`L(#(P,30@8V%S:"!B86QA;F-E<R!W97)E(&%P<')O>&EM871E
M;'D@)#(W-BPP,#`@;W9E<B!S=6-H(&EN<W5R960-"F%M;W5N="X@5V4@9&\@
M;F]T(&)E;&EE=F4@=&AA="!T:&4@0V]M<&%N>2!I<R!E>'!O<V5D('1O(&%N
M>2!S:6=N:69I8V%N="!R:7-K('=I=&@@<F5S<&5C="!T;R!I=',@8V%S:"X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%L;"!O9B!O=7(@86-C
M;W5N=',@<F5C96EV86)L92!A="!397!T96UB97(-"C,P+"`R,#$T(&%N9"!-
M87)C:"`S,2P@,C`Q-"!A;F0@86QL(&]F(&]U<B!R979E;G5E(&EN('1H92!S
M:7@@;6]N=&@@<&5R:6]D<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@86YD
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M8F5R(#,P+"`R,#$T#0IO<B!-87)C:"`S,2P@,C`Q-"X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/D9!25(@5D%,544@3T8@1DE.04Y#24%,($E.
M4U1254U%3E13/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@
M8V%R<GEI;F<@86UO=6YT(&]F(&]U<B!C87-H+"!A8V-O=6YT<R!R96-E:79A
M8FQE+`T*86-C;W5N=',@<&%Y86)L92P@86YD(&]T:&5R(&-U<G)E;G0@;&EA
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M;65N=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^36%N86=E;65N="!H87,@8V]N8VQU9&5D('1H
M870@:70@:7,@;F]T('!R86-T:6-A;`T*=&\@9&5T97)M:6YE('1H92!E<W1I
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M97-E(&EN<W1R=6UE;G1S+`T*86YD(&%N(&EN9&5P96YD96YT('9A;'5A=&EO
M;B!W;W5L9"!N;W0@8F4@<')A8W1I8V%B;&4@9'5E('1O('1H92!L86-K(&]F
M(&1A=&$@<F5G87)D:6YG('-I;6EL87(@:6YS=')U;65N=',L(&EF(&%N>2P@
M86YD('1H92!A<W-O8VEA=&5D#0IP;W1E;G1I86P@8V]S=',N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY3964@3F]T92`Y('=I=&@@<F5S<&5C
M="!T;R!D97)I=F%T:79E(&QI86)I;&ET:65S+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^4%)/4$525%D@04Y$($5154E0345.5#PO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
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M960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^24Y#3TU%(%1!6$53/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY$969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI
M=&EE<R!A<F4@<F5C;V=N:7IE9`T*9F]R('1H92!F=71U<F4@=&%X(&-O;G-E
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M<R!M87D@;F]T(&)E(')E86QI>F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^24U004E2345.5"!/4B!$25-03U-!3"!/1B!,3TY'+4Q)5D5$
M($%34T544SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M<B`S,"P@,C`Q-"!A;F0@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/DQ/4U,@4$52($-/34U/3B!32$%213PO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
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M=&EV92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&]F(%-E
M<'1E;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q,RP@82!T;W1A;"!O9@T*,3,Y+#8W
M,BPX,34@86YD(#$S-RPY,S4L-3(Y('!O=&5N=&EA;"!C;VUM;VX@<VAA<F5S
M+"!C;VYS:7-T:6YG(&]F('-H87)E<R!U;F1E<FQY:6YG(&]U='-T86YD:6YG
M('-T;V-K(&]P=&EO;G,L('=A<G)A;G1S(&%N9"!C;VYV97)T:6)L90T*;F]T
M97,@<&%Y86)L92!W97)E(&5X8VQU9&5D(&%S('1H96ER(&EN8VQU<VEO;B!W
M;W5L9"!B92!A;G1I9&EL=71I=F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY314=-14Y44SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M;&EC871I;VYS("A3964@3F]T92`Q-"DN/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY$149%4E)%1"!&24Y!3D-)3D<@0T]35%,\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
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M92!R96QA=&5D('1O(&]U<B!D969E<G)E9"!O9F9E<FEN9R!C;W-T<R!O9B`D
M,C$L-3`R(&%N9"`D.#8S(&1U<FEN9R!T:&4@<VEX(&UO;G1H('!E<FEO9',@
M96YD960@4V5P=&5M8F5R(#,P+`T*,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV
M96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4D5614Y512!2
M14-/1TY)5$E/3CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M<F%C="!U;F1E<B!!4T,@-C`U+3(X("8C,30W.U)E=F5N=64@4F5C;V=N:71I
M;VX@)B,Q-3`[($UI;&5S=&]N92!-971H;V0F(S$T.#L@86YD('=E#0IB96QI
M979E('=E(&UE970@=&AE(')E<75I<F5M96YT<R!U;F1E<B!!4T,@-C`U+3(X
M(&9O<B!R97!O<G1I;F<@8V]N=')A8W0@<F5V96YU92!U;F1E<B!T:&4@36EL
M97-T;VYE($UE=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.R8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
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M:&4-"G-E<&%R871E('5N:71S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^02!M:6QE<W1O;F4@:7,@86X@979E;G0@:&%V:6YG(&%L;"!O9B!T
M:&4@9F]L;&]W:6YG#0IC:&%R86-T97)I<W1I8W,Z/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
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M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^*#(I(%1H92!E=F5N="!C86X@;VYL
M>2!B92!A8VAI979E9"!B87-E9"!I;@T*=VAO;&4@;W(@:6X@<&%R="!O;B!E
M:71H97(Z("AA*2!T:&4@=F5N9&]R)B,Q-#8[<R!P97)F;W)M86YC93L@;W(@
M*&(I(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I;F<@9G)O;2!T:&4@=F5N
M9&]R)B,Q-#8[<R!P97)F;W)M86YC92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B@S*2!)9B!A8VAI979E9"P@=&AE(&5V96YT('=O=6QD(')E
M<W5L="!I;B!A9&1I=&EO;F%L#0IP87EM96YT<R!B96EN9R!D=64@=&\@=&AE
M('9E;F1O<BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.R8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D$@;6EL97-T;VYE(&1O97,@;F]T(&EN8VQU9&4@979E;G1S(&9O<B!W:&EC
M:`T*=&AE(&]C8W5R<F5N8V4@:7,@96ET:&5R.B`H82D@8V]N=&EN9V5N="!S
M;VQE;'D@=7!O;B!T:&4@<&%S<V%G92!O9B!T:6UE.R!O<B`H8BD@=&AE(')E
M<W5L="!O9B!A(&-O=6YT97)P87)T>28C,30V.W,@<&5R9F]R;6%N8V4N/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<&]L:6-Y(&9O<B!R
M96-O9VYI>FEN9R!D96QI=F5R86)L92!C;VYS:61E<F%T:6]N#0IC;VYT:6YG
M96YT('5P;VX@86-H:65V96UE;G0@;V8@82!M:6QE<W1O;F4@;75S="!B92!A
M<'!L:65D(&-O;G-I<W1E;G1L>2!T;R!S:6UI;&%R(&1E;&EV97)A8FQE<RX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!A<W-E<W-M96YT
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M=&EV93H\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B@Q*2!4:&4@
M8V]N<VED97)A=&EO;B!I<R!C;VUM96YS=7)A=&4@=VET:"!E:71H97(Z#0HH
M82D@=&AE('9E;F1O<B8C,30V.W,@<&5R9F]R;6%N8V4@=&\@86-H:65V92!T
M:&4@;6EL97-T;VYE.R!O<B`H8BD@=&AE(&5N:&%N8V5M96YT(&]F('1H92!V
M86QU92!O9B!T:&4@9&5L:79E<F5D(&ET96T@;W(@:71E;7,-"F%S(&$@<F5S
M=6QT(&]F(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I;F<@9G)O;2!T:&4@
M=F5N9&]R)B,Q-#8[<R!P97)F;W)M86YC92!T;R!A8VAI979E('1H92!M:6QE
M<W1O;F4[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXH,BD@5&AE
M(&-O;G-I9&5R871I;VX@<F5L871E<R!S;VQE;'D@=&\@<&%S=`T*<&5R9F]R
M;6%N8V4[(&%N9#PO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^*#,I
M(%1H92!C;VYS:61E<F%T:6]N(&ES(')E87-O;F%B;&4@<F5L871I=F4-"G1O
M(&%L;"!O9B!T:&4@9&5L:79E<F%B;&5S(&%N9"!P87EM96YT('1E<FUS("AI
M;F-L=61I;F<@;W1H97(@<&]T96YT:6%L(&UI;&5S=&]N92!C;VYS:61E<F%T
M:6]N*2!W:71H:6X@=&AE(&%R<F%N9V5M96YT+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^02!M:6QE<W1O;F4@:7,@;F]T(&-O;G-I9&5R960@
M<W5B<W1A;G1I=F4@:68-"F%N>2!P;W)T:6]N(&]F('1H92!A<W-O8VEA=&5D
M(&UI;&5S=&]N92!C;VYS:61E<F%T:6]N(')E;&%T97,@=&\@=&AE(')E;6%I
M;FEN9R!D96QI=F5R86)L97,@:6X@=&AE('5N:70@;V8@86-C;W5N=&EN9R`H
M:2YE+BP@:70-"F1O97,@;F]T(')E;&%T92!S;VQE;'D@=&\@<&%S="!P97)F
M;W)M86YC92DN(%1O(')E8V]G;FEZ92!T:&4@;6EL97-T;VYE(&-O;G-I9&5R
M871I;VX@:6X@:71S(&5N=&ER971Y(&%S(')E=F5N=64@:6X@=&AE('!E<FEO
M9`T*:6X@=VAI8V@@=&AE(&UI;&5S=&]N92!I<R!A8VAI979E9"P@=&AE(&UI
M;&5S=&]N92!M=7-T(&)E('-U8G-T86YT:79E(&EN(&ET<R!E;G1I<F5T>2X@
M36EL97-T;VYE(&-O;G-I9&5R871I;VX@8V%N;F]T(&)E(&)I9G5R8V%T960-
M"FEN=&\@<W5B<W1A;G1I=F4@86YD(&YO;BUS=6)S=&%N=&EV92!C;VUP;VYE
M;G1S+B!);B!A9&1I=&EO;BP@:68@82!P;W)T:6]N(&]F('1H92!C;VYS:61E
M<F%T:6]N(&5A<FYE9"!F<F]M(&%C:&EE=FEN9R!A(&UI;&5S=&]N90T*;6%Y
M(&)E(')E9G5N9&5D(&]R(&%D:G5S=&5D(&)A<V5D(&]N(&9U='5R92!P97)F
M;W)M86YC92P@=&AE(')E;&%T960@;6EL97-T;VYE(&ES(&YO="!C;VYS:61E
M<F5D('-U8G-T86YT:79E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^4V5E($YO=&4@,3(@9F]R('1H92!A9&1I=&EO;F%L(&1I<V-L;W-U<F4@
M:6YF;W)M871I;VX-"G)E<75I<F5D('5N9&5R($%30R`V,#4M,C@N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY"871T96QL92!3=6)C;VYT<F%C
M="`M+2!792!E;G1E<F5D(&EN=&\@82!S=6)C;VYT<F%C=`T*86=R965M96YT
M('=I=&@@0F%T=&5L;&4@365M;W)I86P@26YS=&ET=71E("@F(S$T-SM"871T
M96QL928C,30X.RD@:6X@36%R8V@@,C`Q,RX@0F%T=&5L;&4@=V%S(&-H;W-E
M;B!B>2!$05)002!T;R!B92!T:&4@<')I;64-"F-O;G1R86-T;W(@;VX@=&AE
M('-Y<W1E;7,@:6YT96=R871I;VX@<&]R=&EO;B!O9B!T:&4@;W)I9VEN86P@
M1$%24$$@8V]N=')A8W0@86YD('=E(&%R92!O;F4@;V8@<V5V97)A;"!S=6)C
M;VYT<F%C=&]R<R!O;B!T:&%T('-Y<W1E;7,-"FEN=&5G<F%T:6]N('!R;VIE
M8W0N(%1H92!"871T96QL92!S=6)C;VYT<F%C="!I<R!C;W-T+7)E:6UB=7)S
M86)L92!U;F1E<B!A('1I;64@86YD(&UA=&5R:6%L<R!B87-I<RX@5V4@8F5G
M86X@9V5N97)A=&EN9R!R979E;G5E<PT*=6YD97(@=&AE('-U8F-O;G1R86-T
M(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P
M,3,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=7(@<F5V96YU
M92!U;F1E<B!T:&ES(&-O;G1R86-T(&ES(&$@9G5N8W1I;VX-"F]F(&-O<W0@
M<F5I;6)U<G-E;65N="!P;'5S(&%N(&]V97)H96%D(&UA<FLM=7`@9F]R(&AO
M=7)S(&1E=F]T960@=&\@=&AE('!R;VIE8W0@8GD@<W!E8VEF:6,@96UP;&]Y
M965S("AW:71H('-P96-I9FEC(&AO=7)L>2!R871E<PT*9F]R('1H;W-E(&5M
M<&QO>65E<RDN($)A='1E;&QE(&5N9V%G97,@=7,@87,@;F5E9&5D+B!%86-H
M('!A>6UE;G0@<F5Q=6ER97,@87!P<F]V86P@8GD@=&AE('!R;V=R86T@;6%N
M86=E<B!A="!"871T96QL92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/E-43T-++4)!4T5$($-/35!%3E-!5$E/3CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
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M;B!S=&]C:R`H9&5F:6YE9"!A<R!T:&4@8VQO<VEN9R!P<FEC92!A<PT*<75O
M=&5D(&]N('1H92!/5$-"0B!O;B!T:&4@9&%T92!O9B!G<F%N="DN($-O;7!E
M;G-A=&EO;B!C;W-T(')E8V]G;FEZ960@8GD@=&AE($-O;7!A;GD@:6YC;'5D
M97,@*&$I(&-O;7!E;G-A=&EO;B!C;W-T(&9O<B!A;&P@97%U:71Y#0II;F-E
M;G1I=F4@87=A<F1S(&=R86YT960@<')I;W(@=&\@07!R:6P@,2P@,C`P-BP@
M8G5T(&YO="!Y970@=F5S=&5D+"!B87-E9"!O;B!T:&4@9W)A;G0M9&%T92!F
M86ER('9A;'5E(&5S=&EM871E9"!I;B!A8V-O<F1A;F-E#0IW:71H('1H92!O
M<FEG:6YA;"!P<F]V:7-I;VYS(&]F('1H92!T:&5N(&-U<G)E;G0@86-C;W5N
M=&EN9R!S=&%N9&%R9',L(&%N9"`H8BD@8V]M<&5N<V%T:6]N(&-O<W0@9F]R
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M;G1E9"`H<V5E($YO=&4@,3`I+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!F;VQL;W=I;F<@
M=&%B;&4@<W5M;6%R:7IE<R!S:&%R92UB87-E9"!C;VUP96YS871I;VX-"F5X
M<&5N<V5S(')E;&%T:6YG('1O('-H87)E<R!A;F0@;W!T:6]N<R!G<F%N=&5D
M(&%N9"!T:&4@969F96-T(&]N(&QO<W,@<&5R(&-O;6UO;B!S:&%R92!D=7)I
M;F<@=&AE('-I>"!M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)E<@T*,S`L
M(#(P,30@86YD(#(P,3,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^4VEX($UO;G1H<R!%;F1E9"!397!T96UB97(@,S`L(#(P,30\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY3:7@@36]N=&AS($5N9&5D/"]P/@T*
M("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY397!T96UB97(@,S`L(#(P,3,\+W`^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E)SY697-T:6YG(&]F
M(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI
M9VXZ(')I9VAT)SXR-C`L-C@P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI
M9VXZ(')I9VAT)SXQ,C0L,C0S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/DEN8W)E;65N=&%L(&9A:7(@
M=F%L=64@;V8@;W!T:6]N($UO9&EF:6-A=&EO;G,\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/C$L.3$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#Y697-T
M:6YG($5X<&5N<V4@07-S;V-I871E9"!W:71H($-%3R!297-T<FEC=&5D(%-T
M;V-K($=R86YT/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C8T+#0T-#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^5&]T86P@4W1O8VLM
M0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/C(V,"PV.#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0G/C$Y,"PV,#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#Y796EG:'1E9"!A=F5R
M86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG("8C,34P
M.R!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT)SXR-#,L-#DT+#DQ-CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.#(L,#`T+#(R,#PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/D)A
M<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R(&-O;6UO;B!S:&%R93PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H="<^*#`N,#`\+W1D/@T*("`@(#QT9#XI/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT)SXH,"XP,#PO=&0^#0H@("`@/'1D/BD\+W1D
M/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#LF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY792!A8V-O=6YT(&9O<B!T<F%N<V%C=&EO;G,@:6YV;VQV:6YG('-E<G9I
M8V5S#0IP<F]V:61E9"!B>2!T:&ER9"!P87)T:65S('=H97)E('=E(&ES<W5E
M(&5Q=6ET>2!I;G-T<G5M96YT<R!A<R!P87)T(&]F('1H92!T;W1A;"!C;VYS
M:61E<F%T:6]N('5S:6YG('1H92!F86ER('9A;'5E(&]F('1H92!C;VYS:61E
M<F%T:6]N#0IR96-E:79E9"`H:2YE+B!T:&4@=F%L=64@;V8@=&AE(&=O;V1S
M(&]R('-E<G9I8V5S*2!O<B!T:&4@9F%I<B!V86QU92!O9B!T:&4@97%U:71Y
M(&EN<W1R=6UE;G1S(&ES<W5E9"P@=VAI8VAE=F5R(&ES(&UO<F4@<F5L:6%B
M;'D-"FUE87-U<F%B;&4N($EN('1R86YS86-T:6]N<RP@=VAE;B!T:&4@=F%L
M=64@;V8@=&AE(&=O;V1S(&%N9"]O<B!S97)V:6-E<R!A<F4@;F]T(')E861I
M;'D@9&5T97)M:6YA8FQE(&%N9"`H,2D@=&AE(&9A:7(@=F%L=64@;V8-"G1H
M92!E<75I='D@:6YS=')U;65N=',@:7,@;6]R92!R96QI86)L>2!M96%S=7)A
M8FQE(&%N9"`H,BD@=&AE(&-O=6YT97)P87)T>2!R96-E:79E<R!E<75I='D@
M:6YS=')U;65N=',@:6X@9G5L;"!O<B!P87)T:6%L('-E='1L96UE;G0-"F]F
M('1H92!T<F%N<V%C=&EO;G,L('=E('5S92!T:&4@9F]L;&]W:6YG(&UE=&AO
M9&]L;V=Y.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M9&%T92!O9B!I<W-U86YC92DN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SYB*2!&;W(@=')A;G-A8W1I;VYS('=H97)E('1H92!I;G-T<G5M96YT
M<R!A<F4-"FES<W5E9"!O;B!A(&9U;&QY('9E<W1E9"P@;F]N+69O<F9E:71A
M8FQE(&)A<VES+"!T:&4@97%U:71Y(&EN<W1R=6UE;G1S(&%R92!V86QU960@
M;VX@;W(@86)O=70@=&AE(&1A=&4@;V8@=&AE(&-O;G1R86-T+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^8RD@1F]R(&%N>2!T<F%N<V%C=&EO
M;G,@;F]T(&UE971I;F<@=&AE(&-R:71E<FEA#0II;B`H82D@;W(@*&(I(&%B
M;W9E+"!W92!R92UM96%S=7)E('1H92!C;VYS:61E<F%T:6]N(&%T(&5A8V@@
M<F5P;W)T:6YG(&1A=&4@8F%S960@;VX@:71S('1H96X@8W5R<F5N="!S=&]C
M:R!V86QU92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(')E
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M=&5R($UA<F-H(#,Q+"`R,#`V(&ES(')E8V]G;FEZ960@:6X@=&AE('!E<FEO
M9"!T:&4@9F]R9F5I='5R92!E<W1I;6%T92!I<R!C:&%N9V5D+@T*5&AE(&5F
M9F5C="!O9B!F;W)F96ET=7)E(&%D:G5S=&UE;G1S(&9O<B!T:&4@<VEX(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@=V%S(&EN<VEG;FEF:6-A
M;G0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY0051%3E13/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY0871E;G1S(&EN8VQU9&4@
M8F]T:"!F;W)E:6=N(&%N9"!D;VUE<W1I8R!P871E;G1S+@T*5&AE<F4@=V5R
M92!S979E<F%L('!A=&5N=',@<&5N9&EN9R!A="!397!T96UB97(@,S`L(#(P
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M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY35$]#2R!055)#
M2$%312!705)204Y44SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M<75I='DL(&%R92!C;VYS:61E<F5D(&ES<W5E9`T*:6X@8V]N;F5C=&EO;B!W
M:71H(&5Q=6ET>2!T<F%N<V%C=&EO;G,@86YD('1H92!W87)R86YT(&9A:7(@
M=F%L=64@:7,@<F5C;W)D960@=&\@861D:71I;VYA;"!P86ED+6EN+6-A<&ET
M86PN($QA<W1L>2P@=V%R<F%N=',@;F]T#0IM965T:6YG(&5Q=6ET>2!C;&%S
M<VEF:6-A=&EO;B!A<F4@<F5C;W)D960@87,@9&5R:79A=&EV92!I;G-T<G5M
M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1%4DE6051)
M5D4@24Y35%)5345.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
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M<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!C;&%S<VEF
M:6-A=&EO;B!O9B!A(&1E<FEV871I=F4@:6YS=')U;65N=`T*:7,@<F5A<W-E
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M92!N=6UB97(@;V8@=&EM97,@82!C;VYT<F%C=`T*;6%Y(&)E(')E8VQA<W-I
M9FEE9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.R8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY"14Y%1DE#24%,($-/3E9%4E-)3TX@1D5!5%5212!/1B!#
M3TY615)424),10T*3D]415,@4$%904),13PO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
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M:6%L($-O;G9E<G-I;VX-"D9E871U<F4F(S,T.R`H)B,S-#M"0T8F(S,T.RDN
M(%=E(&UE87-U<F4@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H92!"
M0T8@:6X@8VER8W5M<W1A;F-E<R!I;B!W:&EC:"!T:&4@8V]N=F5R<VEO;B!F
M96%T=7)E#0II<R!N;W0@<F5Q=6ER960@=&\@8F4@<V5P87)A=&5D(&9R;VT@
M=&AE(&AO<W0@:6YS=')U;65N="!A;F0@86-C;W5N=&5D(&9O<B!S97!A<F%T
M96QY+"!A;F0@<F5C;W)D('1H870@=F%L=64@:6X@=&AE(&-O;G-O;&ED871E
M9`T*9FEN86YC:6%L('-T871E;65N=',@87,@82!D:7-C;W5N="!F<F]M('1H
M92!F86-E(&%M;W5N="!O9B!T:&4@;F]T97,N(%-U8V@@9&ES8V]U;G1S(&%R
M92!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92!O=F5R('1H90T*=&5R
M;2!O9B!T:&4@;F]T97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY214=)4U12051)3TX@4$%9345.5"!!4E)!3D=%345.5%,\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
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M=&EM871E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E)%4T5!
M4D-(($%.1"!$159%3$]0345.5"!%6%!%3E-%4SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@:6YC
M=7)R960@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S#0ID=7)I
M;F<@=&AE('1H<F5E(&%N9"!S:7@@;6]N=&@@<&5R:6]D<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,30@86YD(#(P,3,L('=H:6-H(&%R92!I;F-L=61E9"!I
M;B!V87)I;W5S(&]P97)A=&EN9R!E>'!E;G-E(&QI;F4-"FET96US(&EN('1H
M92!A8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE
M;G1S(&]F(&]P97)A=&EO;G,N($]U<B!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@97AP96YS97,@:6X@=&AO<V4@<&5R:6]D<PT*=V5R92!A<R!F;VQL;W=S
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z
M(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R)SY397!T96UB97(@,S`L/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY397!T96UB97(@,S`L/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXR,#$S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#8X)2<^5&AR964@;6]N=&AS(&5N9&5D/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H="<^,C4P+#,X.#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,3,E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,CDS+#4X,#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^4VEX(&UO;G1H<R!E;F1E
M9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^-C,W+#<R,SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^-C(V+#8S.#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/
M1D8M0D%,04Y#12!32$5%5"!!4E)!3D=%345.5%,\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/E=E(&AA=F4@;F]T(&5N=&5R960@:6YT;R!A;GD@
M;V9F+6)A;&%N8V4@<VAE970-"F%R<F%N9V5M96YT<R!T:&%T(&AA=F4@;W(@
M87)E(')E87-O;F%B;'D@;&EK96QY('1O(&AA=F4@82!C=7)R96YT(&]R(&9U
M='5R92!M871E<FEA;"!E9F9E8W0@;VX@;W5R(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/E-)1TY)1DE#04Y4(%)%0T5.5"!!0T-/54Y424Y'(%!23TY/54Y#14U%
M3E13/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-86YA9V5M96YT
M(&ES(&5V86QU871I;F<@<VEG;FEF:6-A;G0@<F5C96YT#0IA8V-O=6YT:6YG
M('!R;VYO=6YC96UE;G1S('1H870@87)E(&YO="!Y970@969F96-T:79E(&9O
M<B!T:&4@0V]M<&%N>2P@:6YC;'5D:6YG('1H92!N97<@86-C;W5N=&EN9R!S
M=&%N9&%R9"!O;B!R979E;G5E(')E8V]G;FET:6]N+`T*05-5(#(P,30M,#D@
M*%1O<&EC(#8P-BDL(&%N9"!H87,@;F]T('EE="!C;VYC;'5D960@=VAE=&AE
M<B!A;GD@<W5C:"!P<F]N;W5N8V5M96YT<R!W:6QL(&AA=F4@82!S:6=N:69I
M8V%N="!E9F9E8W0@;VX@=&AE($-O;7!A;GDF(S$T-CMS#0IF=71U<F4@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X7S5E,V5?
M-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W,F4O
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^-"X@3D]415,@4$%904),13QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@1&ES8VQO
M<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.3U1%4R!005E!0DQ%/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DY/5$4@-"X@3D]415,@4$%904),13PO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^3F]T97,@<&%Y86)L92!C;VYS:7-T(&]F('1H
M92!F;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97(G/DUA<F-H(#,Q+"`R,#$T/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^4')I;F-I<&%L($)A;&%N8V4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^06-C<G5E9"!);G1E<F5S=#PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY0<FEN8VEP86P@0F%L86YC93PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!8V-R=65D
M($EN=&5R97-T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S8E
M)SXQ,B4@3F]T97,@<&%Y86)L92P@<&%S="!D=64\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.#4L,#`P/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXS-C<L-C@W/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.#4L,#`P/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXS-3,L.#$S/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9#XQ,"4@3F]T92!P87EA8FQE+"!P87-T
M(&1U93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU
M+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXV+#8R-3PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU+#`P
M,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXV+#,W-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^1&ER96-T
M;W)S)B,Q-#8[($YO=&4H<RD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXR,#`L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT)SXQ-"PU,38\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,C=P="<^5&]T86P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G
M/C$Y,"PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0G/C,W-"PS,3(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0G/C,Y,"PP,#`\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C,W-"PW,#0\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1'5R:6YG('1H
M92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"P-"G=E(')E
M8V]R9&5D(&EN=&5R97-T(&5X<&5N<V4@;V8@)#$Y+#DU.2!R96QA=&5D('1O
M('1H92!C;VYT<F%C='5A;"!I;G1E<F5S="!R871E<R!O9B!O=7(@;F]T97,@
M<&%Y86)L92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/C$R)2!.
M3U1%4SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1G)O;2!!=6=U
M<W0@,3DY.2!T:')O=6=H($UA>2`R,#`U+"!W92!E;G1E<F5D#0II;G1O('9A
M<FEO=7,@8F]R<F]W:6YG(&%R<F%N9V5M96YT<R!F;W(@=&AE(&ES<W5A;F-E
M(&]F(&YO=&5S('!A>6%B;&4@9G)O;2!P<FEV871E('!L86-E;65N="!O9F9E
M<FEN9W,@*'1H92`F(S,T.S$R)2!.;W1E<R8C,S0[*2X-"D]N($%P<FEL(#(Q
M+"`R,#$P+"!A(&AO;&1E<B!O9B`D,3`P+#`P,"!O9B!T:&4@,3(E($YO=&5S
M(&-O;G9E<G1E9"!T:&4@<')I;F-I<&%L(&)A;&%N8V4@86YD("0W,2PW-3@@
M;V8@86-C<G5E9"!I;G1E<F5S="!I;G1O(#8X-RPP,S,-"G-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870@86X@86=R965D(&-O;G9E<G-I;VX@<')I8V4@;V8@
M)#`N,C4@<&5R('-H87)E+B!!="!397!T96UB97(@,S`L(#(P,30L('1H92`Q
M,B4@3F]T97,@:6X@=&AE('!R:6YC:7!A;`T*86UO=6YT(&]F("0Q.#4L,#`P
M('=E<F4@<&%S="!D=64L(&EN(&1E9F%U;'0L(&%N9"!B96%R:6YG(&EN=&5R
M97-T(&%T('1H92!D969A=6QT(')A=&4@;V8@,34E+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^,3`E($Y/5$53/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY!="!397!T96UB97(@,S`L(#(P,30L)B,Q-C`[;VYE
M(#$P)2!.;W1E(&EN#0IT:&4@86UO=6YT(&]F("0U+#`P,"!I<R!P87-T(&1U
M92!A;F0@:6X@9&5F875L="P@<F5M86EN<R!O=71S=&%N9&EN9R!A;F0@8F5A
M<G,@:6YT97)E<W0@870@=&AE(&1E9F%U;'0@<F%T92!O9B`Q-24N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-86YA9V5M96YT)W,@
M<&QA;G,@=&\@<V%T:7-F>2!T:&4@<F5M86EN:6YG#0IO=71S=&%N9&EN9R!B
M86QA;F-E(&]N('1H97-E(#$R)2!A;F0@,3`E($YO=&5S(&EN8VQU9&4@8V]N
M=F5R=&EN9R!T:&4@;F]T97,@=&\@8V]M;6]N('-T;V-K(&%T(&UA<FME="!V
M86QU92!O<B!R97!A>6UE;G0@=VAE;B!F=6YD<PT*87)E(&%V86EL86)L92X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3!P=#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^1$E214-43U)3)B,Q-#8[($Y/5$53/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*=6QY(#(P,3,L('=E(&)O
M<G)O=V5D("0T,#`L,#`P(&9R;VT@='=O#0IO9B!O=7(@9&ER96-T;W)S('5N
M9&5R('1W;R`Y,"!D87D@;F]T97,@9F]R("0R,#`L,#`P(&5A8V@@8F5A<FEN
M9R`Q,"4@:6YT97)E<W0@*'1H92`F(S$T-SM.;W1E<R8C,30X.RDN($%T('1H
M92!D:7-C<F5T:6]N(&]F#0IT:&4@:&]L9&5R<RP@:68@;F]T('!A:60@;V9F
M(&)Y($]C=&]B97(@.2P@,C`Q,RP@=&AE(&YO=&5H;VQD97)S('=E<F4@96YT
M:71L960@=&\@*&DI(&-O;G9E<G0@=&AE('!R:6YC:7!A;"!A;F0@86-C<G5E
M9"!I;G1E<F5S=`T*=6YD97(@=&AE($YO=&5S(&EN=&\@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A="`D,"XP.#@@<&5R('-H87)E("AT:&4@)B,Q-#<[0V]N
M=F5R<VEO;B!0<FEC928C,30X.RD@86YD("AI:2D@<F5C96EV92!W87)R86YT
M<PT*=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&5Q=6%L('1O(#4P)2!O9B!T
M:&4@<')I;F-I<&%L(&-O;G9E<G1E9"!U;F1E<B!T:&4@3F]T97,L('=I=&@@
M86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3,R('!E<B!S:&%R92X@061D:71I
M;VYA;&QY+`T*=&AE<F4@=V%S(&$@<')O=FES:6]N(&9O<B!A('!E;F%L='D@
M:6YT97)E<W0@<F%T92!O9B`Q,B4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY4:&%T('!O=&5N=&EA;"!C;VYV97)S:6]N('!R:6-E(&%N9"!W
M87)R86YT#0IE>&5R8VES92!P<FEC92!W97)E(&)A<V5D(&]N('1H92!S86UE
M('!R:6-I;F<@;65C:&%N:7-M('1H870@=V4@:&%V92!U<V5D(&EN('!R:6]R
M(&5Q=6ET>2!U;FET(&9I;F%N8VEN9W,@<VEN8V4@36%R8V@@,C`Q,B`H<V5E
M#0I.;W1E(#8I('=H:6-H(&%R92!B87-E9"!O;B`X,"4@;V8@=&AE('1H96X@
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M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE(&9I<V-A;"!Y96%R
M(&5N9&5D($UA<F-H(#,Q+"`R,#$T+`T*=&AE('!R:6YC:7!A;"!O9B`D,C`P
M+#`P,"!A;F0@86-C<G5E9"!I;G1E<F5S="!O9B`D.2PS-C<@=V5R92!P86ED
M(&]N(&]N92!O9B!T:&4@3F]T97,L('=H:6-H(&5X=&EN9W5I<VAE9"!A;&P@
M<&]T96YT:6%L(&-O;6UO;@T*<W1O8VL@86YD('=A<G)A;G0@:7-S=6%N8V4@
M<')O=FES:6]N<R!R96QA=&5D('1O('1H870@3F]T92X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,30L#0IT:&4@:&]L9&5R(&]F('1H92!S96-O
M;F0@3F]T92!C;VYV97)T960@=&AE('!R:6YC:7!A;"!O9B`D,C`P+#`P,"!A
M;F0@86-C<G5E9"!I;G1E<F5S="!O9B`D,C`L,S0Y(&EN=&\@,BPU,#,L.38V
M('-H87)E<R!O9B!O=7(-"F-O;6UO;B!S=&]C:R!P97(@=&AE(&-O;G9E<G-I
M;VX@9F]R;75L82!O9B!T:&4@3F]T92`H<V5E($YO=&4@-BDN/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?
M-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A
M,S<R92]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SXU+B!#3TY615)424),12!.3U1%4R!005E!
M0DQ%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TY6
M15)424),12!.3U1%4R!005E!0DQ%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/C4N($-/3E9%4E1)0DQ%($Y/
M5$53(%!!64%"3$4\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@8V]N<VES=&5D(&]F('1H92!F
M;VQL;W=I;F<@870@4V5P=&5M8F5R#0HS,"P@,C`Q-#H\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY0<FEN8VEP86P\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^56YA;6]R=&EZ960@/&)R
M("\^#0I$:7-C;W5N=#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY.970@/&)R("\^#0I!;6]U;G0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^06-C<G5E9"`\8G(@+SX-"DEN=&5R97-T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%
M145%144G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#0E.R!P861D:6YG
M+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D-O;G9E<G1I8FQE($YO
M=&5S(%!A>6%B;&4@)B,Q-3`[($-U<G)E;G0@4&]R=&EO;CH\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T
M)SY/8W1O8F5R("8C,S@[($YO=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE
M($YO=&5S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU,"PP
M,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3`L,#`P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXR."PU.3@\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^07!R:6P@,C`Q,"`Q,"4@0V]N
M=F5R=&EB;&4@3F]T93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXW-2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C<U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS-2PQ.#@\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z
M("TY<'0G/DIU;'D@86YD($%U9W5S="`R,#$Q(#$P)2!#;VYV97)T:6)L92!.
M;W1E<RP@<&%S="!D=64\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,C@S+#0R,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,C@S+#0R,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXY-BPW,C@\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^
M#0H@("`@/'1D/DQA=R!&:7)M($YO=&4\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C<U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT)SXW-2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0G/CDL-#<Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3EP="<^5&]T86P@
M)B,Q-3`[($-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q-3`[($-U<G)E
M;G0@4&]R=&EO;CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXT.#,L-#(R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,G!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T
M.B`R,G!T.R!T97AT+6%L:6=N.B!R:6=H="<^-#@S+#0R,CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT)SXQ-CDL.3DS/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D-O
M;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q-3`[($YO;BU#=7)R96YT(%!O
M<G1I;VXZ/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T
M)SY!;65N9&5D(&%N9"!297-T871E9"!397)I97,@02`Q,B4@0V]N=F5R=&EB
M;&4@3F]T97,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,C(U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,C(U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXY+#`P,#PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP
M="<^4V5P=&5M8F5R(#(P,3`@,3(E($-O;G9E<G1I8FQE($YO=&5S/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,Q-RPP-S(\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,Q-RPP-S(\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^.2PU,3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^07!R:6P@,C`Q
M,2`Q,B4@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`Y<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXT-#@L-#0X/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE
M9G0Z(#EP=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@.7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D
M9&EN9RUL969T.B`Y<'0[('1E>'0M86QI9VXZ(')I9VAT)SXT-#@L-#0X/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`Y<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,3,L-#4T/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3EP
M="<^5&]T86P@)B,Q-3`[($-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q
M-3`[($YO;BU#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,G!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^.3DP+#4R,#PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M
M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/CDY,"PU
M,C`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,S$L.38W/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M:6YD
M96YT.B`M.7!T)SY4;W1A;"!#;VYV97)T:6)L92!.;W1E<R!087EA8FQE/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('!A9&1I;F<M;&5F=#H@-#1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L
M-#<S+#DT,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@-#1P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@-#1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@-#1P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@
M-#1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-#<S+#DT,3PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@-#1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT)SXR,#$L.38P/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/E1H97)E('=E<F4@;F\@9&ES8V]U;G1S(')E;6%I;FEN9R!O;B!A
M;GD@;V8@;W5R($-O;G9E<G1I8FQE($YO=&5S#0I087EA8FQE(&%S(&]F(%-E
M<'1E;6)E<B`S,"P@,C`Q-"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/D1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@
M,S`L(#(P,30L('=E(')E8V]R9&5D(&EN=&5R97-T#0IE>'!E;G-E(&]F("0Y
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M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#LF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY#;VYV97)T:6)L92!.;W1E
M<R!087EA8FQE(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&%T($UA<F-H
M(#,Q+`T*,C`Q-#H\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SY0<FEN8VEP86P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^56YA;6]R=&EZ960@/&)R("\^#0I$:7-C;W5N=#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY.970@/&)R("\^#0I!
M;6]U;G0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M06-C<G5E9"`\8G(@+SX-"DEN=&5R97-T/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D-O
M;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q-3`[($-U<G)E;G0@4&]R=&EO
M;CH\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#0T)3L@<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT
M.B`M.7!T)SY!;65N9&5D(&%N9"!297-T871E9"!397)I97,@02`Q,B4@0V]N
M=F5R=&EB;&4@3F]T97,L('!A<W0@9'5E/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E
M.R!T97AT+6%L:6=N.B!R:6=H="<^.#@U+#`P,#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[
M('1E>'0M86QI9VXZ(')I9VAT)SXX.#4L,#`P/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[
M('1E>'0M86QI9VXZ(')I9VAT)SXU-S4L,C4P/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T
M.R!T97AT+6EN9&5N=#H@+3EP="<^,C`P."`Q,"4@0V]N=F5R=&EB;&4@3F]T
M97,L('!A<W0@9'5E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C(U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^,C4L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$Y+#$V-SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@
M+3EP="<^3V-T;V)E<B`F(S,X.R!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV97)T
M:6)L92!.;W1E<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXU,"PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C4P+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR-BPP.3<\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@
M+3EP="<^07!R:6P@,C`Q,"`Q,"4@0V]N=F5R=&EB;&4@3F]T93PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXW-2PP,#`\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C<U+#`P,#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXS,2PT,S@\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/DIU;'D@86YD($%U9W5S
M="`R,#$Q(#$P)2!#;VYV97)T:6)L92!.;W1E<RP@<&%S="!D=64\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C4W+#8U-3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C4W+#8U-3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXY,"PR-38\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/DQA=R!&:7)M($YO
M=&4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C<U+#`P,#PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXW-2PP,#`\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C<L-C`T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T
M97AT+6EN9&5N=#H@+3EP="<^5&]T86P@)B,Q-3`[($-O;G9E<G1I8FQE($YO
M=&5S(%!A>6%B;&4@)B,Q-3`[($-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG
M+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#,V-RPV-34\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXQ+#,V-RPV-34\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^
M-S0Y+#@Q,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T)SY#;VYV97)T:6)L92!.;W1E<R!0
M87EA8FQE("8C,34P.R!.;VXM0W5R<F5N="!0;W)T:6]N.CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^4V5P=&5M8F5R(#(P,3`@
M,3(E($-O;G9E<G1I8FQE($YO=&5S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/C,Q-RPP-S(\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/C,Q-RPP-S(\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S4L,#,T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E
M>'0M:6YD96YT.B`M.7!T)SY!<')I;"`R,#$Q(#$R)2!#;VYV97)T:6)L92!.
M;W1E<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT
M-#@L-#0X/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT
M-#@L-#0X/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/C$R+#$Q-SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T
M)SY397!T96UB97(@,C`Q,2`Q,B4@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D
M9&EN9RUL969T.B`Y<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ,"PY,S$\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#EP="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`Y<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$P+#DS,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UI;F1E;G0Z("TY<'0G/E1O=&%L("8C,34P.R!#;VYV97)T:6)L92!.;W1E
M<R!087EA8FQE("8C,34P.R!.;VXM0W5R<F5N="!0;W)T:6]N/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I
M;F<M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C<W-BPT-3$\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXW-S8L-#4Q/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C0W
M+#$U,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`T
M-'!T.R!T97AT+6EN9&5N=#H@+3EP="<^5&]T86P@0V]N=F5R=&EB;&4@3F]T
M97,@4&%Y86)L93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXR+#$T-"PQ,#8\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#0T<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z
M(#0T<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z
M(#0T<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P
M861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR+#$T-"PQ
M,#8\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#0T<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^-SDV+#DV,SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE<F4@=V5R92!N;R!D:7-C;W5N=',@
M<F5M86EN:6YG(&]N(&%N>2!O9@T*;W5R($-O;G9E<G1I8FQE($YO=&5S(%!A
M>6%B;&4@87,@;V8@36%R8V@@,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY!345.1$5$($%.1"!215-4051%1"!315))15,@02`Q
M,B4@0T].5D525$E"3$4-"DY/5$53/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY);B!*=6YE(#(P,3`L('=E(&5N=&5R960@:6YT;R!!;65N9&5D
M(&%N9"!297-T871E9`T*4V5R:65S($$@,3(E($-O;G9E<G1I8FQE(%!R;VUI
M<W-O<GD@3F]T97,@*'1H92`F(S,T.T%M96YD960@86YD(%)E<W1A=&5D($YO
M=&5S)B,S-#LI('=I=&@@=&AE(&AO;&1E<G,@;V8@8V5R=&%I;B!P<F]M:7-S
M;W)Y(&YO=&5S#0IP<F5V:6]U<VQY(&ES<W5E9"!B>2!U<RP@97AT96YD:6YG
M('1H92!D=64@9&%T92!T;R!$96-E;6)E<B`S,2P@,C`Q,"!O;B!T:&4@86=G
M<F5G871E('!R:6YC:7!A;"!B86QA;F-E(&]F("0Y,#`L,#`P+B!$=7)I;F<@
M=&AE#0IF:7-C86P@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q,RP@=&AE(&AO
M;&1E<G,@;V8@)#$U+#`P,"!O9B!T:&4@3F]T97,@8V]N=F5R=&5D('1H96ER
M('!R:6YC:7!A;"!A;F0@<F5L871E9"!A8V-R=65D(&EN=&5R97-T(&EN=&\-
M"F-O;6UO;B!S=&]C:RX@5&AE(&)A;&%N8V4@<F5M86EN:6YG(&%T($UA<F-H
M(#,Q+"`R,#$T('=A<R`D.#@U+#`P,"!A;F0@<&%S="!D=64N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY796EN97(@3F]T92!#;VYV97)S:6]N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*=6YE(#(T+"`R
M,#$T+"!W92!E;G1E<F5D(&EN=&\@86X@86=R965M96YT#0IW:71H('1H92!%
M;&QE;B!2+B!796EN97(@1F%M:6QY(%)E=F]C86)L92!4<G5S="`H=&AE("8C
M,30W.U1R=7-T)B,Q-#@[*2P@82!H;VQD97(@;V8@82!397)I97,@02`Q,B4@
M0V]N=F5R=&EB;&4@3F]T92`H=&AE("8C,30W.TYO=&4F(S$T.#LI+`T*=VAI
M8V@@<')E=FEO=7-L>2!W87,@8VQA<W-I9FEE9"!A<R!B96EN9R!I;B!D969A
M=6QT+B!!<R!P97(@=&AE(&%G<F5E;65N="P@=&AE(%1R=7-T(&-O;G9E<G1E
M9"!P87-T(&1U92!P<FEN8VEP86P@;V8@)#8V,"PP,#`@86YD#0IA8V-R=65D
M(&EN=&5R97-T(&)A;&%N8V4@;V8@)#,T,RPR,#`@:6YT;R!R97-T<FEC=&5D
M(&-O;6UO;B!S=&]C:RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D%D9&ET:6]N86QL>2P@=&AE(%1R=7-T(&%G<F5E9"!T;R!W86EV92!A;G1I
M+61I;'5T:6]N#0IP<FEC92!P<F]T96-T:6]N('5N9&5R;'EI;F<@=V%R<F%N
M=',@<')E=FEO=7-L>2!I<W-U960@=&\@=&AE(%1R=7-T+B!/;B!*=6YE(#(V
M+"`R,#$T+"!T:')E92!O=&AE<B!P87)T:65S('=H;R!H96QD('-I;6EL87(@
M=V%R<F%N=',-"F%L<V\@86=R965D('1O('=A:79E('1H96ER(&%N=&DM9&EL
M=71I;VX@<')I8V4@<')O=&5C=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/E5N9&5R(&ET<R!A9W)E96UE;G0L('1H92!4<G5S="!C;VYV
M97)T960@=&AE#0IE;G1I<F4@)#$L,#`S+#(P,"!P87-T(&1U92!P<FEN8VEP
M86P@86YD(&EN=&5R97-T(&)A;&%N8V4@;VX@=&AE($YO=&4L('=H:6-H('!R
M979I;W5S;'D@=V%S(&EN(&1E9F%U;'0L(&EN=&\@86X@86=G<F5G871E(&]F
M(#(S+#,Q."PR-30-"G)E<W1R:6-T960@<VAA<F5S(&]F(&]U<B!C;VUM;VX@
M<W1O8VL@86YD(&9I=F4M>65A<B!W87)R86YT<R!T;R!A8W%U:7)E('5P('1O
M(#8L.#`Y+#4R-"!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES90T*<')I8V4@;V8@)"XP-#(@<&5R('-H87)E("AW:&EC:"!E>&5R
M8VES92!P<FEC92!W87,@=&AE(')E<W5L="!O9B!C97)T86EN(&-O;G1R86-T
M=6%L('!R:6-E(&%D:G5S=&UE;G1S('!R979I;W5S;'D@;6%D92!D=7)I;F<@
M,C`Q,2D-"F%N9"!U<"!T;R`S.3<L,C(R('-H87)E<R!O9B!O=7(@8V]M;6]N
M('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0N,3`X('!E<B!S:&%R
M92`H8V]L;&5C=&EV96QY+"!T:&4@)B,Q-#<[0V]N=F5R<VEO;B!396-U<FET
M:65S)B,Q-#@[*2X-"D)A<V5D(&]N('1H92!F86ER('9A;'5E(&]F('1H92!W
M87)R86YT<R!A;F0@<VAA<F5S(&ES<W5E9"!T;R!T:&4@5')U<W0@9F]R('1H
M92!A8V-R=65D(&EN=&5R97-T+"!W92!R96-O<F1E9"!A(&QO<W,@;VX@<V5T
M=&QE;65N=`T*;V8@;F]T97,@;V8@)#$L-SDQ+#0R,2X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&5X8VAA;F=E(&9O<B!T:&4@5')U<W0F
M(S$T-CMS(&-O;G9E<G-I;VX-"FEN(&9U;&P@;V8@=&AE($YO=&4@86YD(&%C
M8W)U960@:6YT97)E<W0@86YD(&9O<B!T:&4@=V%I=F5R<R!O9B!A;G1I+61I
M;'5T:6]N('!R:6-E('!R;W1E8W1I;VX@:6X@=&AE('!R979I;W5S;'D@:7-S
M=65D('=A<G)A;G1S+`T*:6X@861D:71I;VX@=&\@=&AE($-O;G9E<G-I;VX@
M4V5C=7)I=&EE<RP@=V4@:7-S=65D('1O('1H92!4<G5S="`W-2PP,#`@<F5S
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M,3@N(%=E('9A;'5E9"!T:&4@-S4L,#`P('-H87)E('-E<G9I8V4@9F5E(&%T
M("0Q,BPP,#`@8F%S960@;VX@;W5R(&-L;W-I;F<@<')I8V4@;VX@=&AE(&1A
M=&4@;V8@=&AE#0IA9W)E96UE;G0@86YD(')E8V]R9&5D('1H870@=F%L=64@
M87,@:6YT97)E<W0@97AP96YS92!D=7)I;F<@=&AE($IU;F4@,C`Q-"!P97)I
M;V0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY":7)D($5S=&%T
M92!%>'1E;G-I;VX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N
M($IU;'D@."P@,C`Q-"P@=V4@97AE8W5T960@82!W<FET=&5N(')E<W1R=6-T
M=7)I;F<-"F%G<F5E;65N="`H=&AE("8C,30W.T%G<F5E;65N="8C,30X.RD@
M=VET:"!T:&4@17-T871E(&]F($%L;&%N($)I<F0@*'1H92`F(S$T-SM%<W1A
M=&4F(S$T.#LI+"!A(&AO;&1E<B!O9B!A(%-E<FEE<R!!(#$R)2!#;VYV97)T
M:6)L90T*3F]T92`H=&AE("8C,30W.TYO=&4F(S$T.#LI+"!W:&EC:"!P<F5V
M:6]U<VQY('=A<R!C;&%S<VEF:65D(&%S(&)E:6YG(&EN(&1E9F%U;'0N(%-I
M;F-E('1H92!N96=O=&EA=&EO;G,@9F]R('1H92!!9W)E96UE;G0@=V5R90T*
M8V]M<&QE=&5D(&EN('1H92!M;VYT:"!O9B!*=6YE+"!W92!R96-O<F1E9"!T
M:&4@:6UP86-T(&]F('1H92!!9W)E96UE;G0@87,@;V8@2G5N92`S,"P@,C`Q
M-"X@26X@=&AE($%G<F5E;65N="P@=&AE($5S=&%T92!A9W)E960-"G1O(&5X
M=&5N9"!T:&4@97AP:7)A=&EO;B!D871E(&]F('1H92!.;W1E('1O($%P<FEL
M(#$L(#(P,38L('1O(&-O;G9E<G0@87!P<F]X:6UA=&5L>2`D,3$V+#DW,"!O
M9B!A8V-R=65D(&EN=&5R97-T('1O(&5Q=6ET>2P@86YD#0IT;R!W86EV92!A
M;G1I+61I;'5T:6]N('!R:6-E('!R;W1E8W1I;VX@=6YD97)L>6EN9R!T:&4@
M3F]T92!A;F0@=V%R<F%N=',@<')E=FEO=7-L>2!I<W-U960@=&\@=&AE($5S
M=&%T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.R8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E5N
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M:79E+7EE87(@=V%R<F%N=',@=&\@86-Q=6ER92!U<"!T;R`R+#,R,2PT,CD@
M<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@86X-"F5X97)C:7-E('!R
M:6-E(&]F("0N,#0R('!E<B!S:&%R92`H=VAI8V@@97AE<F-I<V4@<')I8V4@
M=V%S('1H92!R97-U;'0@;V8@8V5R=&%I;B!C;VYT<F%C='5A;"!P<FEC92!A
M9&IU<W1M96YT<R!P<F5V:6]U<VQY(&UA9&4-"F1U<FEN9R`R,#$Q*2X@0F%S
M960@;VX@;W5R(&-O;6UO;B!S=&]C:R!P<FEC97,@9'5R:6YG(&$@<&5R:6]D
M(&]F(&YE9V]T:6%T:6]N('=I=&@@=&AE($5S=&%T92!I;F-L=61I;F<@9'5R
M:6YG(&-A;&5N9&%R('EE87(@,C`Q,RP-"G1H92!%<W1A=&4@86QS;R!R96-E
M:79E9"!F:79E+7EE87(@=V%R<F%N=',@=&\@86-Q=6ER92!U<"!T;R`Q,S4L
M-#$W('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E
M('!R:6-E(&]F("0N,3`X("AC;VQL96-T:79E;'D-"FMN;W=N(&%S('1H92`F
M(S$T-SM#;VYV97)S:6]N(%-E8W5R:71I97,F(S$T.#LI+B!"87-E9"!O;B!T
M:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@86YD('-H87)E<R!I<W-U
M960@=&\@=&AE($5S=&%T92!F;W(-"G1H92!A8V-R=65D(&EN=&5R97-T+"!W
M92!R96-O<F1E9"!A(&QO<W,@;VX@<V5T=&QE;65N="!O9B!N;W1E<R!O9B`D
M-C8S+#(P.2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&5X
M8VAA;F=E(&9O<B!T:&4@17-T871E)B,Q-#8[<R!E>'1E;G-I;VX-"F]F('1H
M92!.;W1E+"!C;VYV97)S:6]N(&]F(&%C8W)U960@:6YT97)E<W0@86YD(&9O
M<B!T:&4@=V%I=F5R<R!O9B!A;G1I+61I;'5T:6]N('!R:6-E('!R;W1E8W1I
M;VX@:6X@=&AE('!R979I;W5S;'D@:7-S=65D('=A<G)A;G1S+`T*:6X@861D
M:71I;VX@=&\@=&AE($-O;G9E<G-I;VX@4V5C=7)I=&EE<RP@=V4@86QS;R!I
M<W-U960@=&\@=&AE($5S=&%T92`R-2PP,#`@<F5S=')I8W1E9"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&%S(&%N(&5X=&5N<VEO;@T*9F5E(&%N9"!E>'1E
M;F1E9"!T:&4@97AP:7)A=&EO;B!D871E(&]F(&%L;"!O9B!T:&4@<')E=FEO
M=7-L>2!I<W-U960@=V%R<F%N=',@=&\@2G5L>2`Q+"`R,#$X+B!792!V86QU
M960@=&AE(#(U+#`P,"!S:&%R92!E>'1E;G-I;VX-"F9E92!A="`D-"PU,#`@
M8F%S960@;VX@;W5R(&-L;W-I;F<@<')I8V4@86YD(')E8V]R9&5D('1H870@
M=F%L=64@87,@82!D969E<G)E9"!F:6YA;F-I;F<@8V]S="P@=VAI8V@@=V4@
M=VEL;"!A;6]R=&EZ92!O=F5R('1H90T*97AT96YD960@='=O('EE87(@;&EF
M92!O9B!T:&4@;F]T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXR,#`X(#$P)2!#3TY615)424),
M12!.3U1%4SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@4V5P
M=&5M8F5R(#$W+"`R,#$T+"!W92!I<W-U960@=&\@=&AE(&AO;&1E<@T*;V8@
M=&AE(')E;6%I;FEN9R`R,#`X(#$P)2!#;VYV97)T:6)L92!.;W1E('5N:71S
M(&-O;G-I<W1I;F<@;V8@86X@86=G<F5G871E(&]F(#0W."PQ.#@@<VAA<F5S
M(&]F(')E<W1R:6-T960@8V]M;6]N('-T;V-K(&%N9"!U;FET#0IW87)R86YT
M<R!T;R!A8W%U:7)E('5P('1O(&%N(&%G9W)E9V%T92!O9B`R,SDL,#DT('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@
M)#`N,#DV('!E<B!S:&%R92`H<V5E($YO=&4@-BDN#0I4:&4@=6YI=',@=V5R
M92!I<W-U960@=&\@=&AE($YO=&4@:&]L9&5R('5P;VX@=&AE(&-O;G9E<G-I
M;VX@;V8@86X@86=G<F5G871E(&]F("0T-2PY,#8@;V8@=6YP86ED('!R:6YC
M:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S=`T*9'5E('5N9&5R('1H92!.;W1E
M+"!W:&EC:"!R97!R97-E;G1E9"!T:&4@96YT:7)E(&%M;W5N="!O=71S=&%N
M9&EN9R!U;F1E<B!T:&4@3F]T92!A;F0@=&AE($YO=&4@=V%S(')E=&ER960N
M(%=E(')E8V]R9&5D(&$@;&]S<PT*;VX@9&5B="!C;VYV97)S:6]N(&]F("0V
M-2PT.3,@;VX@=&AI<R!T<F%N<V%C=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D]#5$]"15(@)B,S.#L@3D]614U"15(@,C`P.2`Q,"4@
M0T].5D525$E"3$4-"DY/5$53/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);B!/8W1O8F5R(&%N9"!.;W9E;6)E<B`R,#`Y+"!W92!R86ES960@
M)#0S,"PP,#`-"F9R;VT@=&AE('-A;&4@=&\@86-C<F5D:71E9"!I;G9E<W1O
M<G,@;V8@,3`E(&-O;G9E<G1I8FQE(&YO=&5S("@F(S,T.T]C=&]B97(@)B,S
M.#L@3F]V96UB97(@,C`P.2`Q,"4@0V]N=F5R=&EB;&4@3F]T97,F(S,T.RDN
M#0I4:&4@3V-T;V)E<B`F(S,X.R!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV97)T
M:6)L92!.;W1E<R!M871U<F5D(&%T('9A<FEO=7,@9&%T97,@8F5T=V5E;B!!
M<')I;"`R,#$Q(&%N9"!-87D@,C`Q,2!A;F0@87)E(&-O;G9E<G1I8FQE#0II
M;G1O(&]U<B!C;VUM;VX@<W1O8VL@870@82!F:7AE9"8C,38P.V-O;G9E<G-I
M;VX@<')I8V4@;V8@)#`N,C4@<&5R('-H87)E+B!4:&4@:6YV97-T;W)S(&%L
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M;W1E<R!A;F0@<F5C;W)D960@82`Q,#`E(&1I<V-O=6YT(&%G86EN<W0@=&AE
M('!R:6YC:7!A;"!O9B!T:&4@;F]T97,N(%-U8V@-"F1I<V-O=6YT('=A<R!F
M=6QL>2!A;6]R=&EZ960@870@36%R8V@@,S$L(#(P,30N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*=6QY(#(P,3(L('=E(&ES<W5E9"`T
M-C$L-#`Y('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K(&%N9"`R,S`L-S`U('=A
M<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!T;R!T:&4@:&]L9&5R
M(&]F(&$@)#(U+#`P,"!N;W1E(&EN('1H:7,@9W)O=7!I;F<@:6X@97AC:&%N
M9V4@9F]R('1H92!C;VYV97)S:6]N#0IO9B!S=6-H(&YO=&4@86YD(')E;&%T
M960@86-C<G5E9"!I;G1E<F5S="!O9B`D."PP,#`@*&9O<B!A('1O=&%L(&]F
M("0S,RPP,#`I+B!4:&4@=V%R<F%N=',@97AP:7)E9"!I;B`R,#$R(&%N9"!A
M<F4@97AE<F-I<V%B;&4-"F%T("0P+C$P-R!P97(@<VAA<F4@*'-E92!.;W1E
M(#8I+B!792!R96-O<F1E9"!A(&QO<W,@;VX@8V]N=F5R<VEO;B!O9B`D-#4L
M-SDV+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&9O;&QO
M=VEN9R!T86)L92!S:&]W<R!T:&4@8V]N=F5R<VEO;G,@:6YT;PT*<')I;F-I
M<&%L(&]F('1H92!/8W1O8F5R(&%N9"!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV
M97)T:6)L92!.;W1E<R!B>2!F:7-C86P@>65A<CH\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O
M;'-P86X],T0U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!8W1I=FET>2!I;B!/8W1O8F5R
M("8C,S@[($YO=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE($YO=&5S/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@.#0E)SY);FET:6%L('!R:6YC:7!A;"!B86QA;F-E/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^-#4P+#(U,#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^0V]N=F5R<VEO;G,@
M9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q,#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH-S`L,#`P
M/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%
M)SX-"B`@("`\=&0^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!F:7-C86P@>65A
M<B!E;F1E9"!-87)C:"`S,2P@,C`Q,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXH,3<U+#`P,#PO=&0^#0H@("`@/'1D/BD\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y#;VYV97)S:6]N
M<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$R
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@Q,S`L
M,C4P/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!F:7-C86P@
M>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXH,C4L,#`P/"]T9#X-"B`@("`\=&0^*3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D-O;G9E<G-I
M;VYS(&1U<FEN9R!T:&4@9FES8V%L('EE87(@96YD960@36%R8V@@,S$L(#(P
M,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE('-I
M>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y"86QA;F-E(&%S(&]F
M(%-E<'1E;6)E<B`S,"P@,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^
M-3`L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D]N($UA<F-H(#,Q+"`R,#$R+"!W92!A9W)E960@=&\@97AT96YD
M('1H92!E>'!I<F%T:6]N#0ID871E(&%N9"!T;R!C:&%N9V4@=&AE(&5X97)C
M:7-E('!R:6-E(&]F(&-E<G1A:6X@=V%R<F%N=',@;V8@;VYE(&]F('1H92!N
M;W1E(&AO;&1E<G,@8GD@='=O('EE87)S(&EN(&5X8VAA;F=E(&9O<B!T:&4@
M97AT96YS:6]N#0IO9B`D-3`L,#`P(&]F('1H92!/8W1O8F5R("8C,S@[($YO
M=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE($YO=&5S(&%N9"!T:&4@)#<U
M+#`P,"!!<')I;"`R,#$P(#$P)2!#;VYV97)T:6)L92!.;W1E("AS964@8F5L
M;W<I#0IB>2!T:&%T('-A;64@='=O('EE87(@<&5R:6]D+B!792!R96-O<F1E
M9"!A(&-H87)G92!O9B`D-S<L,C8U(')E;&%T:6YG('1O('1H:7,@;6]D:69I
M8V%T:6]N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@4V5P
M=&5M8F5R(#(P,3,L('=E(&%G<F5E9"!T;R!E>'1E;F0@=&AE(&5X<&ER871I
M;VX-"F1A=&4@;V8@8V5R=&%I;B!W87)R86YT<R!O9B!O;F4@;V8@=&AE(&YO
M=&4@:&]L9&5R<R!B>2!T=V\@>65A<G,@:6X@97AC:&%N9V4@9F]R('1H92!E
M>'1E;G-I;VX@;V8@)#4P+#`P,"!O9B!T:&4@3V-T;V)E<B`F(S,X.PT*3F]V
M96UB97(@,C`P.2`Q,"4@0V]N=F5R=&EB;&4@3F]T97,@86YD('1H92`D-S4L
M,#`P($%P<FEL(#(P,3`@,3`E($-O;G9E<G1I8FQE($YO=&4@*'-E92!B96QO
M=RD@8GD@=&AA="!S86UE('1W;R!Y96%R('!E<FEO9"X@36%N86=E;65N=`T*
M87-S97-S960@=&AE(&-H86YG92!I;B!T:&4@=F%L=64@;V8@=&AE(&YO=&5S
M(&%N9"!R96QA=&5D('=A<G)A;G1S(&)E9F]R92!A;F0@869T97(@=&AA="!E
M>'1E;G-I;VX@86YD(&1E=&5R;6EN960@=&AA="!T:&4@8VAA;F=E#0II;B!V
M86QU92!R96QA=&5D('1O('1H92!C:&%N9V4@:6X@=&5R;7,@=V%S(&YO="!S
M:6=N:69I8V%N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E-U
M8G-E<75E;G0@=&\@4V5P=&5M8F5R(#,P+"`R,#$T+"!W92!I<W-U960-"G1O
M('1H92!H;VQD97(@;V8@=&AE(')E;6%I;FEN9R!/8W1O8F5R("8C,S@[($YO
M=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE($YO=&4@86YD('1H92!!<')I
M;"`R,#$P(#$P)2!#;VYV97)T:6)L92!.;W1E('5N:71S(&-O;G-I<W1I;F<-
M"F]F(&%N(&%G9W)E9V%T92!O9B`Q+#@S-2PW.3@@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!A;F0@=6YI="!W87)R86YT<R!T;R!A8W%U:7)E('5P('1O(&%N
M(&%G9W)E9V%T92!O9B`Q+#@S-RPW.3@@<VAA<F5S(&]F(&-O;6UO;@T*<W1O
M8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3`S('!E<B!S:&%R92X@
M5&AE('5N:71S('=E<F4@:7-S=65D('1O('1H92!N;W1E(&AO;&1E<B!U<&]N
M('1H92!C;VYV97)S:6]N(&]F(&%N(&%G9W)E9V%T92!O9@T*)#$X.2PP.#<@
M;V8@=6YP86ED('!R:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!D=64@
M=6YD97(@='=O('!R;VUI<W-O<GD@;F]T97,@*'1H92!R96UA:6YI;F<@3V-T
M;V)E<B`F(S,X.R!.;W9E;6)E<B`R,#`Y(#$P)0T*0V]N=F5R=&EB;&4@3F]T
M92!A;F0@=&AE($%P<FEL(#(P,3`@,3`E($-O;G9E<G1I8FQE($YO=&4I+B!4
M:&4@86UO=6YT<R!C;VYV97)T960@<F5P<F5S96YT960@=&AE(&5N=&ER92!P
M<FEN8VEP86P@86YD(&EN=&5R97-T#0IO=71S=&%N9&EN9R!U;F1E<B!T:&4@
M;F]T97,@86YD('1H92!N;W1E<R!H96QD(&)Y('1H870@:&]L9&5R('=E<F4@
M<F5T:7)E9"`H<V5E($YO=&4@,34I+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^05!224P@,C`Q,"`Q,"4@0T].5D525$E"3$4@3D]413PO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@07!R:6P@,C`Q,"P@=V4@
M<F%I<V5D("0W-2PP,#`@9G)O;2!T:&4@<V%L90T*=&\@86X@86-C<F5D:71E
M9"!I;G9E<W1O<B!O9B!A(#$P)2!C;VYV97)T:6)L92!N;W1E+B!4:&4@8V]N
M=F5R=&EB;&4@;F]T92!W87,@;W)I9VEN86QL>2!S8VAE9'5L960@=&\@;6%T
M=7)E(&EN($]C=&]B97(@,C`Q,2!A;F0-"FES(&-O;G9E<G1I8FQE(&EN=&\@
M;W5R(&-O;6UO;B!S=&]C:R!A="!A(&9I>&5D(&-O;G9E<G-I;VX@<')I8V4@
M;V8@)#`N,C4@<&5R('-H87)E('!R:6]R('1O(&UA='5R:71Y+B!4:&4@:6YV
M97-T;W(@86QS;R!R96-E:79E9`T*=&AR964@>65A<B!W87)R86YT<R!T;R!P
M=7)C:&%S92`S,#`L,#`P('5N<F5G:7-T97)E9"!S:&%R97,@;V8@;W5R(&-O
M;6UO;B!S=&]C:R!A="!A('!R:6-E(&]F("0P+C(U('!E<B!S:&%R92X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY792!M96%S=7)E9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R
M<F%N=',@86YD#0IT:&4@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4@
M;V8@=&AE(&YO=&5S(&%N9"!R96-O<F1E9"!A(#$P,"4@9&ES8V]U;G0@86=A
M:6YS="!T:&4@<')I;F-I<&%L(&]F('1H92!N;W1E<RX@5V4@86UO<G1I>F5D
M('1H:7,-"F1I<V-O=6YT('5S:6YG('1H92!E9F9E8W1I=F4@:6YT97)E<W0@
M;65T:&]D(&]V97(@=&AE('1E<FT@;V8@=&AE(&YO=&4N($%S(&]F(%-E<'1E
M;6)E<B`S,"P@,C`Q-"P@=&AE<F4@:&%V92!N;W0@8F5E;B!A;GD@8V]N=F5R
M<VEO;G,-"F]F('1H92!!<')I;"`R,#$P(#$P)2!#;VYV97)T:6)L92!.;W1E
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@36%R8V@@,S$L
M(#(P,3(L('=E(&%G<F5E9"!T;R!E>'1E;F0@=&AE(&5X<&ER871I;VX-"F1A
M=&4@86YD('1O(&-H86YG92!T:&4@97AE<F-I<V4@<')I8V4@;V8@8V5R=&%I
M;B!W87)R86YT<R!O9B!T:&4@;F]T92!H;VQD97(@8GD@='=O('EE87)S(&EN
M(&5X8VAA;F=E(&9O<B!H:7,@97AT96YS:6]N(&]F("0U,"PP,#`-"F]F('1H
M92!/8W1O8F5R("8C,S@[($YO=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE
M($YO=&5S(&%N9"!T:&4@)#<U+#`P,"!!<')I;"`R,#$P(#$P)2!#;VYV97)T
M:6)L92!.;W1E(&)Y('1H870@<V%M92!T=V\@>65A<@T*<&5R:6]D+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@4V5P=&5M8F5R(#(P,3,L
M('=E(&%G<F5E9"!T;R!E>'1E;F0@=&AE(&5X<&ER871I;VX-"F1A=&4@;V8@
M8V5R=&%I;B!W87)R86YT<R!O9B!O;F4@;V8@=&AE(&YO=&4@:&]L9&5R<R!B
M>2!T=V\@>65A<G,@:6X@97AC:&%N9V4@9F]R('1H92!E>'1E;G-I;VX@;V8@
M)#4P+#`P,"!O9B!T:&4@3V-T;V)E<B`F(S,X.PT*3F]V96UB97(@,C`P.2`Q
M,"4@0V]N=F5R=&EB;&4@3F]T97,@86YD('1H92`D-S4L,#`P($%P<FEL(#(P
M,3`@,3`E($-O;G9E<G1I8FQE($YO=&4@*'-E92!B96QO=RD@8GD@=&AA="!S
M86UE('1W;R!Y96%R('!E<FEO9"X@36%N86=E;65N=`T*87-S97-S960@=&AE
M(&-H86YG92!I;B!T:&4@=F%L=64@;V8@=&AE(&YO=&5S(&%N9"!R96QA=&5D
M('=A<G)A;G1S(&)E9F]R92!A;F0@869T97(@=&AA="!E>'1E;G-I;VX@86YD
M(&1E=&5R;6EN960@=&AA="!T:&4@8VAA;F=E#0II;B!V86QU92!R96QA=&5D
M('1O('1H92!C:&%N9V4@:6X@=&5R;7,@=V%S(&YO="!S:6=N:69I8V%N="X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E-U8G-E<75E;G0@=&\@
M4V5P=&5M8F5R(#,P+"`R,#$T+"!W92!I<W-U960-"G1O('1H92!H;VQD97(@
M;V8@=&AE(')E;6%I;FEN9R!/8W1O8F5R("8C,S@[($YO=F5M8F5R(#(P,#D@
M,3`E($-O;G9E<G1I8FQE($YO=&4@86YD('1H92!!<')I;"`R,#$P(#$P)2!#
M;VYV97)T:6)L92!.;W1E('5N:71S(&-O;G-I<W1I;F<-"F]F(&%N(&%G9W)E
M9V%T92!O9B`Q+#@S-2PW.3@@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@
M=6YI="!W87)R86YT<R!T;R!A8W%U:7)E('5P('1O(&%N(&%G9W)E9V%T92!O
M9B`Q+#@S-RPW.3@@<VAA<F5S(&]F(&-O;6UO;@T*<W1O8VL@870@86X@97AE
M<F-I<V4@<')I8V4@;V8@)#`N,3`S('!E<B!S:&%R92X@5&AE('5N:71S('=E
M<F4@:7-S=65D('1O('1H92!N;W1E(&AO;&1E<B!U<&]N('1H92!C;VYV97)S
M:6]N(&]F(&%N(&%G9W)E9V%T92!O9@T*)#$X.2PP.#<@;V8@=6YP86ED('!R
M:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!D=64@=6YD97(@='=O('!R
M;VUI<W-O<GD@;F]T97,@*'1H92!R96UA:6YI;F<@3V-T;V)E<B`F(S,X.R!.
M;W9E;6)E<B`R,#`Y(#$P)0T*0V]N=F5R=&EB;&4@3F]T92!A;F0@=&AE($%P
M<FEL(#(P,3`@,3`E($-O;G9E<G1I8FQE($YO=&4I+B!4:&4@86UO=6YT<R!C
M;VYV97)T960@<F5P<F5S96YT960@=&AE(&5N=&ER92!P<FEN8VEP86P@86YD
M(&EN=&5R97-T#0IO=71S=&%N9&EN9R!U;F1E<B!T:&4@;F]T97,@86YD('1H
M92!N;W1E<R!H96QD(&)Y('1H870@:&]L9&5R('=E<F4@<F5T:7)E9"`H<V5E
M($YO=&4@,34I+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^4T505$5-0D52(#(P,3`@,3`E($-/3E9%4E1)0DQ%($Y/5$53/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!397!T96UB97(@,RP@,C`Q
M,"P@=V4@96YT97)E9"!I;G1O(&$@4W5B<V-R:7!T:6]N#0I!9W)E96UE;G0@
M=VET:"!T:')E92!A8V-R961I=&5D(&EN=F5S=&]R<R`H=&AE("8C,30W.U!U
M<F-H87-E<G,F(S$T.#LI)B,Q-C`[<')O=FED:6YG(&9O<B!T:&4@:7-S=6%N
M8V4@86YD('-A;&4@;V8@8V]N=F5R=&EB;&4-"G!R;VUI<W-O<GD@;F]T97,@
M86YD(&-O<G)E<W!O;F1I;F<@=V%R<F%N=',@:6X@=&AE(&%G9W)E9V%T92!P
M<FEN8VEP86P@86UO=6YT(&]F("0Q+#0S,"PP,#`N(%1H92!I;FET:6%L(&-L
M;W-I;F<@=6YD97(@=&AE(%-U8G-C<FEP=&EO;@T*06=R965M96YT(')E<W5L
M=&5D(&EN('1H92!I<W-U86YC92!A;F0@<V%L92!O9B`H:2D@8V]N=F5R=&EB
M;&4@<')O;6ES<V]R>2!N;W1E<R!I;B!T:&4@86=G<F5G871E('!R:6YC:7!A
M;"!A;6]U;G0@;V8@)#<T,RPV,#`L#0HH:6DI(&9I=F4M>65A<B!W87)R86YT
M<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@,RPW,3@L,#`P('-H87)E
M<R!O9B!O=7(@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F
M("0P+C,Q,3(U('!E<B!S:&%R92P-"F%N9"`H:6EI*2!F:79E+7EE87(@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#,L-S$X+#`P,"!S
M:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,"XT,S4W-0T*<&5R('-H87)E+B!4:&4@8V]N=F5R=&EB;&4@<')O
M;6ES<V]R>2!N;W1E<R!B96%R(&EN=&5R97-T(&-O;7!O=6YD960@;6]N=&AL
M>2!A="!T:&4@86YN=6%L(')A=&4@;V8@=&5N('!E<F-E;G0@*#$P)2D@86YD
M(&UA='5R90T*;VX@07!R:6P@,2P@,C`Q-B`H<V5E(&)E;&]W*2X@5&AE(&%G
M9W)E9V%T92!G<F]S<R!C87-H('!R;V-E961S('=E<F4@)#8U,"PP,#`L('1H
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M8F5R9R!,+E`N(&9O<B!T:&4@<')I;F-I<&%L(&UA<FME="!O;B!W:&EC:"!T
M:&4@8V]M;6]N('-T;V-K('1R861E<R!O<B!I<R!Q=6]T960-"F9O<B!T:&4@
M=&5N("@Q,"D@=')A9&EN9R!D87ES('!R96-E9&EN9R!T:&4@<')O<&]S960@
M8V]N=F5R<VEO;B!D871E+B!3=6)J96-T('1O(&%D:G5S=&UE;G0@87,@9&5S
M8W)I8F5D(&EN('1H92!N;W1E<RP@=&AE(&-O;G9E<G-I;VX-"G!R:6-E(&UA
M>2!N;W0@8F4@;6]R92!T:&%N("0P+C,P(&YO<B!L97-S('1H86X@)#`N,C`N
M(%1H97)E(&%R92!N;R!R96=I<W1R871I;VX@<F5Q=6ER96UE;G1S('=I=&@@
M<F5S<&5C="!T;R!T:&4@<VAA<F5S(&]F(&-O;6UO;@T*<W1O8VL@=6YD97)L
M>6EN9R!T:&4@;F]T97,@;W(@=&AE('=A<G)A;G1S+B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@36%R8V@@,S$L(#(P,30L('=E
M(&5N=&5R960@:6YT;R!S97!A<F%T90T*06UE;F1M96YT<R!T;R!#;VYV97)T
M:6)L92!.;W1E<R!A;F0@5V%R<F%N=',@*&-O;&QE8W1I=F5L>2P@=&AE("8C
M,30W.T%M96YD;65N=',F(S$T.#LI('=I=&@@=&AR964@86-C<F5D:71E9"!I
M;G9E<W1O<G,@*&-O;&QE8W1I=F5L>2P-"G1H92`F(S$T-SM);G9E<W1O<G,F
M(S$T.#LI('=H;R!O=VX@8V5R=&%I;B!C;VYV97)T:6)L92!P<F]M:7-S;W)Y
M(&YO=&5S("AC;VQL96-T:79E;'DL('1H92`F(S$T-SM.;W1E<R8C,30X.RD@
M86YD('=A<G)A;G1S#0HH8V]L;&5C=&EV96QY+"!T:&4@)B,Q-#<[5V%R<F%N
M=',F(S$T.#LI('!R979I;W5S;'D@:7-S=65D(&)Y('5S(&]N('9A<FEO=7,@
M9&%T97,@8F5T=V5E;B!$96-E;6)E<B`U+"`R,#`W(&%N9"!397!T96UB97(@
M,C,L#0HR,#$Q+"!I;F-L=61I;F<@=&AE(%-E<'1E;6)E<B`R,#$P($-O;G9E
M<G1I8FQE($YO=&5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M;"`Q+"`R,#$V+"!W:&EC:"!P97)M:71S('5S('1O(&-L87-S:69Y('1H96T@
M87,@;&]N9RUT97)M(&QI86)I;&ET:65S+B!!<R!A(')E<W5L=`T*;V8@=&AE
M($%M96YD;65N=',L('1H92!.;W1E<R!A<F4@;F\@;&]N9V5R(&EN(&1E9F%U
M;'0@86YD('1H92!N;VXM9&5F875L="!I;G1E<F5S="!R871E(&9O<B!A;&P@
M;V8@=&AE($YO=&5S('=A<R!S970@870@,3(E('!E<@T*86YN=6TL('=H:6-H
M(')E<')E<V5N=',@82!R961U8W1I;VX@9G)O;2!T:&4@9&5F875L="!I;G1E
M<F5S="!R871E<R!O9B!F:69T965N('!E<F-E;G0@870@=VAI8V@@:6YT97)E
M<W0@:&%D(&)E96X@86-C<G5I;F<N($)Y#0IE;G1E<FEN9R!I;G1O('1H92!!
M;65N9&UE;G1S+"!W92!A;'-O(&%G<F5E9"!T;R!I;F-R96%S92!T:&4@8W5R
M<F5N=&QY(&]U='-T86YD:6YG('!R:6YC:7!A;"!A;6]U;G0@;V8@=&AE($YO
M=&5S(&)Y(#$R)2!F<F]M(&$-"G1O=&%L(&]F("0V.3,L,C8P('1O(&$@=&]T
M86P@;V8@)#<W-BPT-3$N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY$=7)I;F<@=&AE('!E<FEO9"!F<F]M($]C=&]B97(@,C`Q,2!T;R!&96)R
M=6%R>0T*,C`Q-"P@=&AE($EN=F5S=&]R<R!H860@8V]N=F5R=&5D+"!A="!C
M;VYV97)S:6]N('!R:6-E<R!B971W965N("0N,#4T-B!A;F0@)"XP-R!P97(@
M<VAA<F4L('!O<G1I;VYS(&]F('!R:6YC:7!A;"!A;F0@:6YT97)E<W0@;W5T
M<W1A;F1I;F<-"G5N9&5R('1H92!.;W1E<R!A;F0@8V5R=&%I;B!O=&AE<B!C
M;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&5S('!R979I;W5S;'D@:7-S=65D
M('1O('1H96T@8GD@=7,N($-E<G1A:6X@86YT:61I;'5T:6]N('!R;W9I<VEO
M;G,-"F%P<&QI8V%B;&4@=&\@<W5C:"!N;W1E<R!S:&]U;&0@:&%V92!R97-U
M;'1E9"!I;B!S=6-H(&-O;G9E<G-I;VYS(&)E:6YG(&5F9F5C=&5D(&%T(&$@
M8V]N=F5R<VEO;B!P<FEC92!O9B`D+C`T,B!P97(@<VAA<F4N($%C8V]R9&EN
M9VQY+`T*<'5R<W5A;G0@=&\@=&AE($%M96YD;65N=',L('=E(&ES<W5E9"!T
M;R!T:&4@:6YV97-T;W)S(&%N(&%G9W)E9V%T92!O9B`T+#4P-RPQ,#4@<VAA
M<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!#;VUM;VX@4W1O8VLL('=H:6-H
M#0IR97!R97-E;G1S('1H92!A9&1I=&EO;F%L('-H87)E<R!O9B!#;VUM;VX@
M4W1O8VL@=&AA="!W;W5L9"!H879E(&)E96X@:7-S=65D('1O('1H92!);G9E
M<W1O<G,@:&%D('-U8V@@8V]N=F5R<VEO;G,@8F5E;B!E9F9E8W1E9`T*870@
M)"XP-#(@<&5R('-H87)E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M97!T96UB97(@,C,L(#(P,38@=&\@2F%N=6%R>2`Q+"`R,#$W+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/E1H92!F;VQL;W=I;F<@=&%B;&4@<VAO=W,@=&AE(&%C=&EV:71Y(&EN
M('1H90T*4V5P=&5M8F5R(#(P,3`@,3`E($-O;G9E<G1I8FQE($YO=&5S(&)Y
M(&9I<V-A;"!Y96%R.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#4@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97(G/D%C=&EV:71Y(&EN('1H92!397!T96UB97(@,C`Q,"`Q,"4@
M0V]N=F5R=&EB;&4@3F]T97,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%
M12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X-"4G/DEN:71I86P@<')I
M;F-I<&%L(&)A;&%N8V4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI
M9VXZ(')I9VAT)SXW-#,L-C`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N
M9&5D($UA<F-H(#,Q+"`R,#$R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B@T,#4L-3`P/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^0V]N=F5R<VEO;G,@
M9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q,SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,S`L,#`P
M/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D/D-O;G9E<G-I;VYS(&1U<FEN9R!T:&4@9FES8V%L('EE87(@
M96YD960@36%R8V@@,S$L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^*#(U+#`P,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/DEN8W)E87-E(&EN
M('!R:6YC:7!A;"!B86QA;F-E(&1U92!T;R`Q,B4@97AT96YS:6]N(&9E93PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS,RPY-S(\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE('-I>"!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/D)A;&%N8V4@87,@;V8@4V5P
M=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXS,3<L
M,#<R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D%04DE,(#(P,3$@,3`E($-/3E9%4E1)0DQ%($Y/5$53/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!!<')I;"`R,#$Q+"!W92!E;G1E
M<F5D(&EN=&\@82!3=6)S8W)I<'1I;VX-"D%G<F5E;65N="!W:71H('1W;R!A
M8V-R961I=&5D(&EN=F5S=&]R<R`H=&AE("8C,30W.U!U<F-H87-E<G,F(S$T
M.#LI('!R;W9I9&EN9R!F;W(@=&AE(&ES<W5A;F-E(&%N9"!S86QE(&]F(&-O
M;G9E<G1I8FQE('!R;VUI<W-O<GD-"FYO=&5S(&%N9"!C;W)R97-P;VYD:6YG
M('=A<G)A;G1S(&EN('1H92!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O
M9B`D,S@U+#`P,"X@5&AE(&-L;W-I;F<@=6YD97(@=&AE(%-U8G-C<FEP=&EO
M;B!!9W)E96UE;G0@<F5S=6QT960-"FEN('1H92!I<W-U86YC92!A;F0@<V%L
M92!B>2!U<R!O9B`H:2D@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<R!I
M;B!T:&4@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#,X-2PP,#`L
M("AI:2D@9FEV92UY96%R#0IW87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R
M96=A=&4@;V8F(S$V,#LT+#`P-"PP,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@
M<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3(U('!E<B!S:&%R
M92P@86YD("AI:6DI#0IF:79E+7EE87(@=V%R<F%N=',@=&\@<'5R8VAA<V4@
M86X@86=G<F5G871E(&]F)B,Q-C`[-"PP,#0L,#`P('-H87)E<R!O9B!O=7(@
M8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C$W-2!P
M97(@<VAA<F4N#0I4:&4@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<R!B
M96%R(&EN=&5R97-T(&-O;7!O=6YD960@;6]N=&AL>2!A="!T:&4@86YN=6%L
M(')A=&4@;V8@,3`E(&%N9"!M871U<F4@;VX@07!R:6P@,2P@,C`Q-B`H<V5E
M(&)E;&]W*2X-"E1H92!A9V=R96=A=&4@9W)O<W,@8V%S:"!P<F]C965D<R!T
M;R!U<R!W97)E("0S-3`L,#`P+"!T:&4@8F%L86YC92!O9B!T:&4@<')I;F-I
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M='D@<&5R8V5N="`H.#`E*2!O9B!T:&4@879E<F%G92!O9B!T:&4@=&AR964@
M;&]W97-T(&-L;W-I;F<@8FED('!R:6-E<R!O9B!T:&4@8V]M;6]N#0IS=&]C
M:R!A<R!R97!O<G1E9"!B>2!";&]O;6)E<F<@3"Y0+B!F;W(@=&AE('!R:6YC
M:7!A;"!M87)K970@;VX@=VAI8V@@=&AE(&-O;6UO;B!S=&]C:R!T<F%D97,@
M;W(@:7,@<75O=&5D(&9O<B!T:&4@=&5N("@Q,"D@=')A9&EN9PT*9&%Y<R!P
M<F5C961I;F<@=&AE('!R;W!O<V5D(&-O;G9E<G-I;VX@9&%T92X@4W5B:F5C
M="!T;R!A9&IU<W1M96YT(&%S(&1E<V-R:6)E9"!I;B!T:&4@;F]T97,L('1H
M92!C;VYV97)S:6]N('!R:6-E(&UA>2!N;W0@8F4@;6]R90T*=&AA;B`D,"XR
M,"!N;W(@;&5S<R!T:&%N("0P+C$P+B!4:&5R92!A<F4@;F\@<F5G:7-T<F%T
M:6]N(')E<75I<F5M96YT<R!W:71H(')E<W!E8W0@=&\@=&AE('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@=6YD97)L>6EN9R!T:&4-"FYO=&5S(&]R('1H92!W
M87)R86YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&%D
M9&ET:6]N+"!W92!I<W-U960@*&DI(&9I=F4M>65A<B!W87)R86YT<PT*=&\@
M<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#@Q,BPU,#`@<VAA<F5S(&]F(&]U
M<B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3(U
M('!E<B!S:&%R92P@86YD("AI:2D@9FEV92UY96%R('=A<G)A;G1S#0IT;R!P
M=7)C:&%S92!A;B!A9V=R96=A=&4@;V8F(S$V,#LX,3(L-3`P('-H87)E<R!O
M9B!O=7(@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P
M+C$W-2!P97(@<VAA<F4@=&\@=&AE(%!U<F-H87-E<G,N#0I4:&5S92!W87)R
M86YT<R!W97)E(&ES<W5E9"!A<R!A;B!A;G1I9&EL=71I;VX@861J=7-T;65N
M="!U;F1E<B!C97)T86EN(&-O;6UO;B!S=&]C:R!P=7)C:&%S92!W87)R86YT
M<R!H96QD(&)Y('1H92!0=7)C:&%S97)S('1H870-"G=E<F4@86-Q=6ER960@
M9G)O;2!U<R!I;B!397!T96UB97(@,C`Q,"X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D]N($UA<F-H(#,Q+"`R,#$T+"!W92!E;G1E<F5D(&EN
M=&\@<V5P87)A=&4-"D%M96YD;65N=',@=&\@0V]N=F5R=&EB;&4@3F]T97,@
M86YD(%=A<G)A;G1S("AC;VQL96-T:79E;'DL('1H92`F(S$T-SM!;65N9&UE
M;G1S)B,Q-#@[*2!W:71H('1H<F5E(&%C8W)E9&ET960@:6YV97-T;W)S("AC
M;VQL96-T:79E;'DL#0IT:&4@)B,Q-#<[26YV97-T;W)S)B,Q-#@[*2!W:&\@
M;W=N(&-E<G1A:6X@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<R`H8V]L
M;&5C=&EV96QY+"!T:&4@)B,Q-#<[3F]T97,F(S$T.#LI(&%N9"!W87)R86YT
M<PT**&-O;&QE8W1I=F5L>2P@=&AE("8C,30W.U=A<G)A;G1S)B,Q-#@[*2!P
M<F5V:6]U<VQY(&ES<W5E9"!B>2!U<R!O;B!V87)I;W5S(&1A=&5S(&)E='=E
M96X@1&5C96UB97(@-2P@,C`P-R!A;F0@4V5P=&5M8F5R(#(S+`T*,C`Q,2P@
M:6YC;'5D:6YG('1H92!!<')I;"`R,#$Q($-O;G9E<G1I8FQE($YO=&5S+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
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M92!O9B!E86-H(&]F('1H92!.;W1E<R!T;R!!<')I;"`Q+"`R,#$V+"!W:&EC
M:"!P97)M:71S('5S('1O(&-L87-S:69Y('1H96T@87,@;&]N9RUT97)M(&QI
M86)I;&ET:65S+B!!<R!A(')E<W5L=`T*;V8@=&AE($%M96YD;65N=',L('1H
M92!.;W1E<R!A<F4@;F\@;&]N9V5R(&EN(&1E9F%U;'0@86YD('1H92!N;VXM
M9&5F875L="!I;G1E<F5S="!R871E(&9O<B!A;&P@;V8@=&AE($YO=&5S('=A
M<R!S970@870@,3(E('!E<@T*86YN=6TL('=H:6-H(')E<')E<V5N=',@82!R
M961U8W1I;VX@9G)O;2!T:&4@9&5F875L="!I;G1E<F5S="!R871E<R!O9B`Q
M-24@870@=VAI8V@@:6YT97)E<W0@:&%D(&)E96X@86-C<G5I;F<N($)Y(&5N
M=&5R:6YG(&EN=&\-"G1H92!!;65N9&UE;G1S+"!W92!A;'-O(&%G<F5E9"!T
M;R!I;F-R96%S92!T:&4@8W5R<F5N=&QY(&]U='-T86YD:6YG('!R:6YC:7!A
M;"!A;6]U;G0@;V8@=&AE($YO=&5S(&)Y(#$R)2!F<F]M(&$@=&]T86P@;V8@
M)#8Y,RPR-C`-"G1O(&$@=&]T86P@;V8@)#<W-BPT-3$N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE('!E<FEO9"!F<F]M($]C
M=&]B97(@,C`Q,2!T;R!&96)R=6%R>0T*,C`Q-"P@=&AE($EN=F5S=&]R<R!H
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M:6YG(&5F9F5C=&5D(&%T(&$@8V]N=F5R<VEO;B!P<FEC92!O9B`D+C`T,B!P
M97(@<VAA<F4N($%C8V]R9&EN9VQY+`T*<'5R<W5A;G0@=&\@=&AE($%M96YD
M;65N=',L('=E(&ES<W5E9"!T;R!T:&4@:6YV97-T;W)S(&%N(&%G9W)E9V%T
M92!O9B`T+#4P-RPQ,#4@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!#
M;VUM;VX@4W1O8VLL('=H:6-H#0IR97!R97-E;G1S('1H92!A9&1I=&EO;F%L
M('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=&AA="!W;W5L9"!H879E(&)E96X@
M:7-S=65D('1O('1H92!);G9E<W1O<G,@:&%D('-U8V@@8V]N=F5R<VEO;G,@
M8F5E;B!E9F9E8W1E9`T*870@)"XP-#(@<&5R('-H87)E+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
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M>2`Q+"`R,#$W+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^07,@
M;V8@4V5P=&5M8F5R(#,P+"`R,#$T+"!T:&5R92!H879E(&YO="!B965N#0IA
M;GD@8V]N=F5R<VEO;G,@;V8@=&AE($%P<FEL(#(P,3$@,3`E($-O;G9E<G1I
M8FQE($YO=&5S(&%N9"!T:&4@,3(E(&5X=&5N<VEO;B!F964@;F]T960@86)O
M=F4@:6YC<F5A<V5D('1H92!P<FEN8VEP86P@8F%L86YC92!B>0T*)#0X+#`T
M."!T;R!A('!R:6YC:7!A;"!B86QA;F-E(&]F("0T-#@L-#0X+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^2E5,62`F(S,X.R!!54=54U0@,C`Q
M,2`Q,"4@0T].5D525$E"3$4@3D]415,\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B`S,"P-"C(P,3$L('=E(')A:7-E9"`D,S4W+#8U-B!I;B!F:79E('-E
M<&%R871E(#$P)2!C;VYV97)T:6)L92!N;W1E<RX@5&AO<V4@;F]T97,@:&%D
M(&$@9FEX960@8V]N=F5R<VEO;B!P<FEC92!O9B`D,"XP.2!P97(@<VAA<F4@
M86YD#0IC87)R:65D(&%N(&EN=&5R97-T(')A=&4@;V8@,3`E+B!4:&4@8V]N
M=F5R=&EB;&4@;F]T97,@;6%T=7)E9"!I;B!*=6QY(&%N9"!!=6=U<W0@,C`Q
M,BX@5V4@86QS;R!I<W-U960@=&AO<V4@:6YV97-T;W)S(&9I=F4@>65A<@T*
M=V%R<F%N=',@=&\@<'5R8VAA<V4@,RPY-S,L.34W('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@870@)#`N,3(U('!E<B!S:&%R92X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!M
M96%S=7)E9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@86YD#0IT
M:&4@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4@;V8@=&AE(&YO=&5S
M(&%N9"!R96-O<F1E9"!A("0R-3<L.3(V(&1I<V-O=6YT(&%G86EN<W0@=&AE
M('!R:6YC:7!A;"!O9B!T:&4@;F]T97,N(%=E(&%M;W)T:7IE9`T*=&AI<R!D
M:7-C;W5N="!U<VEN9R!T:&4@969F96-T:79E(&EN=&5R97-T(&UE=&AO9"!O
M=F5R('1H92!T97)M(&]F('1H92!N;W1E+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^169F96-T:79E($UA<F-H(#,Q+"`R,#$T+"!T:&4@:&]L
M9&5R<R!O9B!T:')E90T*;V8@=&AE(&9I=F4@;F]T97,@=&]T86QI;F<@)#$P
M,"PP,#`@8V]N=F5R=&5D(&%L;"!O9B!T:&5I<B!P<FEN8VEP86P@86YD(&%C
M8W)U960@:6YT97)E<W0@:6YT;R`Q+#0S."PW,#`@<VAA<F5S(&]F(&]U<B!C
M;VUM;VX@<W1O8VL-"F%T('1H92!C;VYT<F%C='5A;"!C;VYV97)S:6]N('!R
M:6-E(&]F("0P+C`Y('!E<B!S:&%R92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN(%-E<'1E;6)E<B`R,#$T+"!W92!E;G1E<F5D(&EN=&\@
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M:6X@=&AE(%-E<'1E;6)E<B`R,#$T('!E<FEO9"!R96QA=&5D('1O('1H:7,-
M"G=A<G)A;G0@97AT96YS:6]N(&1U92!T;R!T:&4@8VAA;F=E(&EN('1H92!F
M86ER('9A;'5E(&]F('1H92!W87)R86YT<RX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/E-U8G-E<75E;G0@=&\@4V5P=&5M8F5R(#,P+"`R,#$T
M+"!W92!P86ED(&]F9@T*:6X@9G5L;"!T:&4@<F5M86EN:6YG(&]U='-T86YD
M:6YG('!R:6YC:7!A;"!B86QA;F-E(&%N9"!I;G1E<F5S="!B86QA;F-E<R!O
M;B!T:&4@='=O(')E;6%I;FEN9R!N;W1E<R!W:71H(&-A<V@@<&%Y;65N=',@
M;V8@)#,X,BPW-#@-"BAS964@3F]T92`Q-2DN/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY315!414U"15(@,C`Q,2!#3TY615)424),12!.3U1%
M4SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@4V5P=&5M8F5R
M(#(P,3$L('=E(&ES<W5E9"`D,C4S+#<V,"!O9B!C;VYV97)T:6)L90T*;F]T
M97,L(&-O;G9E<G1I8FQE(&%T("0P+C`W('!E<B!S:&%R92X@4W5C:"!N;W1E
M<R!O<FEG:6YA;&QY(&UA='5R960@:6X@4V5P=&5M8F5R(#(P,3(N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!-87)C:"`S,2P@,C`Q-"P@
M=V4@96YT97)E9"!I;G1O('-E<&%R871E#0I!;65N9&UE;G1S('1O($-O;G9E
M<G1I8FQE($YO=&5S(&%N9"!787)R86YT<R`H8V]L;&5C=&EV96QY+"!T:&4@
M)B,Q-#<[06UE;F1M96YT<R8C,30X.RD@=VET:"!T:')E92!A8V-R961I=&5D
M(&EN=F5S=&]R<R`H8V]L;&5C=&EV96QY+`T*=&AE("8C,30W.TEN=F5S=&]R
M<R8C,30X.RD@=VAO(&]W;B!C97)T86EN(&-O;G9E<G1I8FQE('!R;VUI<W-O
M<GD@;F]T97,@*&-O;&QE8W1I=F5L>2P@=&AE("8C,30W.TYO=&5S)B,Q-#@[
M*2!A;F0@=V%R<F%N=',-"BAC;VQL96-T:79E;'DL('1H92`F(S$T-SM787)R
M86YT<R8C,30X.RD@<')E=FEO=7-L>2!I<W-U960@8GD@=7,@;VX@=F%R:6]U
M<R!D871E<R!B971W965N($1E8V5M8F5R(#4L(#(P,#<@86YD(%-E<'1E;6)E
M<B`R,RP-"C(P,3$L(&EN8VQU9&EN9R!T:&4@4V5P=&5M8F5R(#(P,3$@0V]N
M=F5R=&EB;&4@3F]T97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY0<FEO<B!T;R!T:&4@06UE;F1M96YT<RP@=&AE($YO=&5S('=E<F4@<&%S
M=`T*;6%T=7)I='D@86YD('=E<F4@:6X@9&5F875L="P@<F5S=6QT:6YG(&EN
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M;"!O9B!T:&4@3F]T97,@=V%S('-E="!A="`Q,B4@<&5R#0IA;FYU;2P@=VAI
M8V@@<F5P<F5S96YT<R!A(')E9'5C=&EO;B!F<F]M('1H92!D969A=6QT(&EN
M=&5R97-T(')A=&5S(&]F(#$U)2!A="!W:&EC:"!I;G1E<F5S="!H860@8F5E
M;B!A8V-R=6EN9RX@0GD@96YT97)I;F<@:6YT;PT*=&AE($%M96YD;65N=',L
M('=E(&%L<V\@86=R965D('1O(&EN8W)E87-E('1H92!C=7)R96YT;'D@;W5T
M<W1A;F1I;F<@<')I;F-I<&%L(&%M;W5N="!O9B!T:&4@3F]T97,@8GD@,3(E
M+"!W:&EC:"!I;B!T:&4@8V%S92!O9@T*=&AE(%-E<'1E;6)E<B`R,#$Q($YO
M=&5S+"!T:&5Y(&EN8W)E87-E9"!F<F]M("0Y+#<V,"!T;R`D,3`L.3,Q/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE('!E<FEO
M9"!F<F]M($]C=&]B97(@,C`Q,2!T;R!&96)R=6%R>0T*,C`Q-"P@=&AE($EN
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M9B`D+C`T,B!P97(@<VAA<F4N($%C8V]R9&EN9VQY+`T*<'5R<W5A;G0@=&\@
M=&AE($%M96YD;65N=',L('=E(&ES<W5E9"!T;R!T:&4@:6YV97-T;W)S(&%N
M(&%G9W)E9V%T92!O9B`T+#4P-RPQ,#4@<VAA<F5S(&]F('1H92!#;VUP86YY
M)B,Q-#8[<R!#;VUM;VX@4W1O8VLL('=H:6-H#0IR97!R97-E;G1S('1H92!A
M9&1I=&EO;F%L('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=&AA="!W;W5L9"!H
M879E(&)E96X@:7-S=65D('1O('1H92!);G9E<W1O<G,@:&%D('-U8V@@8V]N
M=F5R<VEO;G,@8F5E;B!E9F9E8W1E9`T*870@)"XP-#(@<&5R('-H87)E+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
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M,3<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9F]L;&]W
M:6YG('1A8FQE('-H;W=S('1H92!C;VYV97)S:6]N<R!I;G1O#0IP<FEN8VEP
M86P@;V8@=&AE(%-E<'1E;6)E<B`R,#$Q($-O;G9E<G1I8FQE($YO=&5S(&)Y
M(&9I<V-A;"!Y96%R.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#4@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97(G/D%C=&EV:71Y(&EN('1H92!397!T96UB97(@,C`Q,2!#;VYV
M97)T:6)L92!.;W1E<SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#@T)2<^26YI=&EA;"!P<FEN8VEP
M86P@8F%L86YC93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@
M<FEG:'0G/C(U,RPW-C`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D/D-O;G9E<G-I;VYS(&1U<FEN9R!T:&4@9FES8V%L('EE87(@96YD960@
M36%R8V@@,S$L(#(P,3(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^*#$U+#`P,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/D-O;G9E<G-I;VYS(&1U<FEN
M9R!T:&4@9FES8V%L('EE87(@96YD960@36%R8V@@,S$L(#(P,3,\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#8P+#`P,#PO=&0^
M#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D
M($UA<F-H(#,Q+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B@Q-CDL,#`P/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^26YC<F5A<V4@:6X@<')I
M;F-I<&%L(&)A;&%N8V4@9'5E('1O(&5X=&5N<VEO;B!F964\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PQ-S$\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@
M4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH,3`L
M.3,Q/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0^0F%L86YC92!A<R!O9B!397!T96UB97(@,S`L(#(P
M,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!N;W1E9"!I
M;B!T:&4@86)O=F4@=&%B;&4L('1H92!R96UA:6YI;F<@8F%L86YC90T*;V8@
M=&AE(%-E<'1E;6)E<B`R,#$Q($-O;G9E<G1I8FQE($YO=&5S(&-O;G9E<G1E
M9"!I;G1O(&5Q=6ET>2!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@4V5P
M=&5M8F5R(#,P+"`R,#$T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^3$%7($9)4DT@3D]413PO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^3VX@36%R8V@@,C(L(#(P,3(L('=E(&5N=&5R960@:6YT;R!A(%!R;VUI
M<W-O<GD-"DYO=&4@=VET:"!O=7(@8V]R<&]R871E(&QA=R!F:7)M(&9O<B!T
M:&4@86UO=6YT(&]F("0W-2PP,#`L('=H:6-H(')E<')E<V5N=&5D('1H92!M
M86IO<FET>2!O9B!T:&4@86UO=6YT('=E(&]W960@=&\@=&AA="!F:7)M#0IA
M="!T:&%T('1I;64N(%1H92!0<F]M:7-S;W)Y($YO=&4@;W)I9VEN86QL>2!H
M860@82!M871U<FET>2!D871E(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"!B
M96%R<R!I;G1E<F5S="!A="`U)2!P97(@86YN=6TN(%1H90T*;F]T92!I<R!C
M;VYV97)T:6)L92!A="!T:&4@;W!T:6]N(&]F('1H92!H;VQD97(@:6YT;R!S
M:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A(#$P)2!D:7-C;W5N="!T
M;R!T:&4@;6%R:V5T('!R:6-E(&]F('1H92!C;VUM;VX-"G-T;V-K(&]N('1H
M92!D871E('!R:6]R('1O(&-O;G9E<G-I;VX@=VET:"!A(&9L;V]R('!R:6-E
M(&]N('-U8V@@8V]N=F5R<VEO;G,@;V8@)#`N,#@@<&5R('-H87)E+B!4:&4@
M:&]L9&5R('-U8G-E<75E;G1L>2!A9W)E960-"G1O(&5X=&5N9"!T:&4@36%T
M=7)I='D@1&%T92!O9B!T:&4@3F]T92!F:7)S="!T;R!/8W1O8F5R(#$L(#(P
M,3,L('1H96X@=&\@4V5P=&5M8F5R(#,P+"`R,#$S+"!A;F0@;F]W('1H92!E
M>'!I<F%T:6]N(&1A=&4@;V8@=&AI<PT*;F]T92!I<R!A9V%I;B!E>'1E;F1E
M9"!T;R!/8W1O8F5R(#$L(#(P,30N($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q
M-"P@=&AE<F4@:&%V92!N;W0@8F5E;B!A;GD@8V]N=F5R<VEO;G,@;V8@=&AE
M($QA=R!&:7)M($YO=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`X<'0G/E-U8G-E<75E;G0@=&\@4V5P=&5M8F5R(#,P+"`R,#$T
M+`T*=V4@<&%I9"!O9F8@:6X@9G5L;"!T:&4@;W5T<W1A;F1I;F<@<')I;F-I
M<&%L(&)A;&%N8V4@86YD(&EN=&5R97-T(&)A;&%N8V4@;VX@=&AE(&YO=&4@
M=VET:"!A(&-A<V@@<&%Y;65N="!O9B`D-3`L,#`P(&%N9"!A;B!I<W-U86YC
M90T*;V8@,3<P+#`R,"!C;VUM;VX@<VAA<F5S("AS964@3F]T92`Q-2DN/"]F
M;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^-BX@15%52519(%12
M04Y304-424].4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%455)5%D@5%)!3E-!0U1)
M3TY3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/C8N($5154E462!44D%.
M4T%#5$E/3E,F(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D-/34U/3B!35$]#2R!!3D0@5T%24D%.5%,\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/E1H92!F;VQL;W=I;F<@87)E($%E=&AL;VX@365D:6-A
M;"P@26YC+B8C,30V.W,-"D5Q=6ET>2!4<F%N<V%C=&EO;G,@:6X@=&AE(%-I
M>"!-;VYT:',@16YD960@4V5P=&5M8F5R(#,P+"`R,#$T+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!*=6YE(#,P+"`R,#$T+"!W90T*8V]M<&QE=&5D('5N:70@<W5B<V-R:7!T
M:6]N(&%G<F5E;65N=',@=VET:"!S979E;B!A8V-R961I=&5D(&EN=F5S=&]R
M<R!P=7)S=6%N="!T;R!W:&EC:"!W92!I<W-U960@,BPQ.3(L-#0T('-H87)E
M<R!O9B!O=7(@8V]M;6]N#0IS=&]C:R!A;F0@,2PP.38L,C(R('=A<G)A;G1S
M('1O('!U<F-H87-E(&]U<B!C;VUM;VX@<W1O8VL@9F]R(&YE="!C87-H('!R
M;V-E961S(&]F("0S,C`L.#`P+B!3=6-H('=A<G)A;G1S(&AA=F4@97AE<F-I
M<V4@<')I8V5S#0IR86YG:6YG(&9R;VT@)#`N,3DS('1O("0P+C(S-B!P97(@
M<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!D:7-C
M=7-S960@86)O=F4@:6X@3F]T92`U+"!D=7)I;F<@=&AE('1H<F5E#0IM;VYT
M:',@96YD960@2G5N92`S,"P@,C`Q-"P@=V4@:7-S=65D(#$U+#<Q-"PR.#8@
M<VAA<F5S(&]F(')E<W1R:6-T960@8V]M;6]N('-T;V-K('1O('1H92!H;VQD
M97(@;V8@;VYE(&]F('1H92!397)I97,@02`Q,B4@0V]N=F5R=&EB;&4-"DYO
M=&5S(&EN(&5X8VAA;F=E(&9O<B!T:&4@8V]N=F5R<VEO;B!I;B!F=6QL(&]F
M('1H92`D-C8P+#`P,"!P<FEN8VEP86P@8F%L86YC92!O9B!T:&%T(&YO=&4L
M(#<L-C`S+#DV."!S:&%R97,@;V8@<F5S=')I8W1E9"!C;VUM;VX-"G-T;V-K
M(&EN(&5X8VAA;F=E(&9O<B!C;VYV97)S:6]N(&]F("0S-#,L,C`P(&]F(&%C
M8W)U960@:6YT97)E<W0@86YD(#<U+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E
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M:6YT97)E<W0@86YD(#(U+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E9"!C;VUM
M;VX@<W1O8VL@87,@82!R97-T<G5C='5R:6YG#0IF964N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!*=6YE(#,P+"`R,#$T+`T*=V4@:7-S=65D(#(Q.2PQ,C<@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!O=7(@4RTX(')E9VES=')A
M=&EO;B!S=&%T96UE;G0@8V]V97)I;F<@;W5R($%M96YD960@,C`Q,"!3=&]C
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M9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R!T:&4@
M=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P-"C(P,30L('=E(&ES
M<W5E9"`S-3DL.34V('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@
M=&\@;W5R(%,M."!R96=I<W1R871I;VX@<W1A=&5M96YT(&-O=F5R:6YG(&]U
M<B!!;65N9&5D(#(P,3`@4W1O8VL@4&QA;@T*870@86X@879E<F%G92!P<FEC
M92!O9B`D,"XQ-"!P97(@<VAA<F4@:6X@<&%Y;65N="!F;W(@;&5G86P@86YD
M('-C:65N=&EF:6,@8V]N<W5L=&EN9R!S97)V:6-E<R!V86QU960@870@)#0Y
M+#`Y,"!B87-E9"!O;B!T:&4@=F%L=64-"F]F('1H92!S97)V:6-E<R!P<F]V
M:61E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P-"C(P,30L('=E
M(&ES<W5E9"`S.3`L,S`Q('-H87)E<R!O9B!R97-T<FEC=&5D(&-O;6UO;B!S
M=&]C:R!A="!A;B!A=F5R86=E('!R:6-E(&]F("0P+C$Y('!E<B!S:&%R92!I
M;B!P87EM96YT(&9O<B!I;G9E<W1O<B!R96QA=&EO;G,-"F-O;G-U;'1I;F<@
M<V5R=FEC97,@=F%L=65D(&%T("0W-2PP,#`@8F%S960@;VX@=&AE('9A;'5E
M(&]F('1H92!S97)V:6-E<R!P<F]V:61E9"X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B`S,"P-"C(P,30L('=E(&ES<W5E9"`Q+#DS-RPU,#4@<VAA<F5S
M(&]F(')E<W1R:6-T960@8V]M;6]N('-T;V-K('1O('1H92!H;VQD97)S(&]F
M('1H<F5E(&-O;G9E<G1I8FQE(&YO=&5S(&EN(&5X8VAA;F=E(&9O<B!T:&4@
M<&%R=&EA;`T*;W(@9G5L;"!C;VYV97)S:6]N(&]F('!R:6YC:7!A;"!A;F0@
M:6YT97)E<W0@:6X@=&AE(&%G9W)E9V%T92!A;6]U;G0@;V8@)#@Q+#,W-2!A
M="!A(&-O;G9E<G-I;VX@<')I8V4@;V8@)#`N,#0R('!E<B!S:&%R92X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($IU;'D@,C0L(#(P,30L
M('=E(&ES<W5E9"!A;B!A9V=R96=A=&4@;V8-"C(L-3`S+#DV-B!S:&%R97,@
M;V8@<F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@86YD(&$@<V5V96XM>65A<B!W
M87)R86YT('1O(&ES<W5E('5P('1O(#$L,C4Q+#DX,R!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E#0IP<FEC92!O9B`D,"XQ,S(@<&5R
M('-H87)E('1O($1R+B!#:&5T86X@4VAA:"P@82!D:7)E8W1O<BX@5&AE(&-O
M;6UO;B!S=&]C:R!A;F0@=V%R<F%N="!W97)E(&ES<W5E9"!T;R!$<BX@4VAA
M:"!U<&]N('1H92!C;VYV97)S:6]N#0IO9B!A;B!A9V=R96=A=&4@;V8@)#(R
M,"PS-#D@;V8@=6YP86ED('!R:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S
M="!D=64@=6YD97(@82`Q,"4@0V]N=F5R=&EB;&4@3F]T92!P<F5V:6]U<VQY
M(&ES<W5E9"!T;R!$<BX-"E-H86@@8GD@=7,@;VX@2G5L>2`Y+"`R,#$S+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@4V5P=&5M8F5R(#$W
M+"`R,#$T+"!W92!I<W-U960@=&\@=&AE(&AO;&1E<@T*;V8@=&AE(')E;6%I
M;FEN9R`R,#`X(#$P)2!#;VYV97)T:6)L92!.;W1E('5N:71S(&-O;G-I<W1I
M;F<@;V8@86X@86=G<F5G871E(&]F(#0W."PQ.#@@<VAA<F5S(&]F(')E<W1R
M:6-T960@8V]M;6]N('-T;V-K(&%N9"!U;FET#0IW87)R86YT<R!T;R!A8W%U
M:7)E('5P('1O(&%N(&%G9W)E9V%T92!O9B`R,SDL,#DT('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,#DV('!E
M<B!S:&%R92`H<V5E($YO=&4@-2DN#0I4:&4@=6YI=',@=V5R92!I<W-U960@
M=&\@=&AE(&YO=&4@:&]L9&5R('5P;VX@=&AE(&-O;G9E<G-I;VX@;V8@86X@
M86=G<F5G871E(&]F("0T-2PY,#8@;V8@=6YP86ED('!R:6YC:7!A;"!A;F0@
M86-C<G5E9"!I;G1E<F5S=`T*9'5E('5N9&5R('1H92!P<F]M:7-S;W)Y(&YO
M=&4L('=H:6-H(')E<')E<V5N=&5D('1H92!E;G1I<F4@86UO=6YT(&]U='-T
M86YD:6YG('5N9&5R('1H92!N;W1E+B!792!R96-O<F1E9"!A(&QO<W,@;VX@
M9&5B="!C;VYV97)S:6]N#0IO9B`D-C4L-#DS(&]N('1H:7,@=')A;G-A8W1I
M;VXN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR,#$T+"!W92!I
M<W-U960@=&\@9F]U<B!I;G9E<W1O<G,@,BPV-S,L,C,Q('-H87)E<R!O9B!R
M97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!T:')O=6=H('1H92!C87-H(&5X97)C
M:7-E(&]F(&5I9VAT('=A<G)A;G1S(&9O<B`D,C4Y+#0W-`T*;V8@8V%S:"!A
M="!A;B!A=F5R86=E(&5X97)C:7-E('!R:6-E(&]F(&%P<')O>&EM871E;'D@
M)#`N,3`@<&5R('-H87)E+B!!<R!A;B!I;F1U8V5M96YT('1O('1H;W-E(&EN
M=F5S=&]R<RP@=V4@:7-S=65D('1H96T@<F5P;&%C96UE;G0-"G=A<G)A;G1S
M('1O(&%C<75I<F4@=7`@=&\@86X@86=G<F5G871E(&]F(#(L-C<S+#(S,2!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K(&]N('1H92!S86UE('1E<FUS(&%S('1H
M92!W87)R86YT<R!T:&5Y(&5X97)C:7-E9"X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B`S,"P-"C(P,30L('=E(&ES<W5E9"!A;F0@<V]L9"!T;R!T:')E
M92!A8V-R961I=&5D(&EN=F5S=&]R<R!U;FET<R!C;VYS:7-T:6YG(&]F("AA
M*2!O;F4@:'5N9')E9"!T:&]U<V%N9"`H,3`P+#`P,"D@<F5S=')I8W1E9"!S
M:&%R97,-"F]F(&]U<B!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D+C`P,2!P
M97(@<VAA<F4L(&%T('!R:6-E<R!P97(@<VAA<F4@<F%N9VEN9R!F<F]M("0P
M+C`Y,2!T;R`D,"XP.30@86YD("AB*2!A(&9I=F4M>65A<B!W87)R86YT('1O
M#0IP=7)C:&%S92!F:69T>2!T:&]U<V%N9"`H-3`L,#`P*2!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&%T(&5X97)C:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@
M)#`N,3,V('1O("0P+C$T,R!P97(@<VAA<F4N($EN('1O=&%L+"!T:&4-"FEN
M=F5S=&]R<R!P=7)C:&%S960@9F]R(&-A<V@@86X@86=G<F5G871E(&]F("0Y
M,"PP,#`@;V8@=6YI=',N(%1H92!I;G9E<W1O<G,@86-Q=6ER960@86X@86=G
M<F5G871E(&]F(#DW-"PY.#(@<VAA<F5S(&]F(&-O;6UO;@T*<W1O8VL@86YD
M('=A<G)A;G1S('1O(&%C<75I<F4@=7`@=&\@86X@86=G<F5G871E(&]F(#0X
M-RPT.3$@<VAA<F5S(&]F($-O;6UO;B!3=&]C:RX\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D-C<T8S<V.%\U93-E7S0Y
M-#-?83AF85\T8V,S-3(W83,W,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E+U=O
M<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/C<N(%)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5,051%1"!0
M05)462!44D%.4T%#5$E/3E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M-RX@4D5,051%1"!005)462!44D%.4T%#5$E/3E,\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D1512!43R!214Q!5$5$(%!!4E1)15,\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-E<G1A:6X@;V8@;W5R(&]F9FEC
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M86YY:6YG(&-O;G-O;&ED871E9`T*8F%L86YC92!S:&5E=',N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=&AE<B!R96QA=&5D('!A<G1Y('1R
M86YS86-T:6]N<R!A<F4@9&ES8VQO<V5D#0IE;'-E=VAE<F4@:6X@=&AE<V4@
M;F]T97,@=&\@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^."X@3U1(15(@0U524D5.5"!,
M24%"24Q)5$E%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D]T:&5R($QI86)I;&ET:65S($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3U1(15(@0U524D5.5"!,24%"24Q)5$E%4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXX+B!/5$A%4B!#55)214Y4($Q)04))3$E42453/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=&AE<B!C=7)R96YT(&QI
M86)I;&ET:65S('=E<F4@8V]M<')I<V5D(&]F#0IT:&4@9F]L;&]W:6YG(&ET
M96US.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P
M<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R)SY397!T96UB97(@,S`L/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY-87)C:"`S,2P\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXR,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97(G/C(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`V."4G/D%C8W)U960@:6YT97)E<W0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[
M('1E>'0M86QI9VXZ(')I9VAT)SXU-S`L-S0Q/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[
M('1E>'0M86QI9VXZ(')I9VAT)SXQ+#$V-2PS,S4\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H@("`@/'1D/D%C8W)U960@;&5G86P@9F5E<SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ-SDL-#8U/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C$W.2PT-C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/D%C8W)U960@;&EQ
M=6ED871E9"!D86UA9V5S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C,V,BPX,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S8R+#@P,#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D/D]T:&5R(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0G/C$P,RPU.3@\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C$T-RPW-S0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/E1O
M=&%L(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0G/C$L,C$V+#8P-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^,2PX-34L,S<T/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&]F('1H92!D871E
M(&]F('1H:7,@<F5P;W)T+"!V87)I;W5S('!R;VUI<W-O<GD-"F%N9"!C;VYV
M97)T:6)L92!N;W1E<R!P87EA8FQE(&EN('1H92!A9V=R96=A=&4@<')I;F-I
M<&%L(&%M;W5N="!O9B`D-#<S+#0R,B`H87,@:61E;G1I9FEE9"!I;B!.;W1E
M<R`T(&%N9"`U(&%B;W9E*2!H879E(')E86-H960-"FUA='5R:71Y(&%N9"!A
M<F4@<&%S="!D=64N(%=E(&%R92!C;VYT:6YU86QL>2!R979I97=I;F<@;W1H
M97(@9FEN86YC:6YG(&%R<F%N9V5M96YT<R!T;R!R971I<F4@86QL('!A<W0@
M9'5E(&YO=&5S+B!!="!397!T96UB97(-"C,P+"`R,#$T+"!W92!H860@86-C
M<G5E9"!I;G1E<F5S="!I;B!T:&4@86UO=6YT(&]F("0T-S$L,#0Q(&%S<V]C
M:6%T960@=VET:"!T:&5S92!D969A=6QT960@;F]T97,@:6X@86-C<G5E9"!L
M:6%B:6QI=&EE<R!P87EA8FQE#0HH<V5E($YO=&5S(#0@86YD(#4I+CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^.2X@1D%)4B!604Q512!-14%355)%
M345.5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9!25(@
M5D%,544@345!4U5214U%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CDN($9!25(@5D%,544@345!4U5214U%3E13/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY792!F;VQL;W<@1D%30B!!4T,@.#(P+"`F(S,T.T9!
M25(@5D%,544@345!4U5214U%3E13#0I!3D0@1$E30TQ/4U5215,F(S,T.R`H
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M<R!M96%S=7)E9`T*870@9F%I<B!V86QU92!O;B!A(&YO;BUR96-U<G)I;F<@
M8F%S:7,@9F]R(&%N>2!P97)I;V0@<F5P;W)T960N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
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M:&EE<F%R8VAY.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3&5V
M96P@,3H@475O=&5D(&UA<FME="!P<FEC97,@:6X@86-T:79E(&UA<FME=',-
M"F9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3&5V96P@,CH@3V)S97)V86)L92!M
M87)K970@8F%S960@:6YP=71S(&]R('5N;V)S97)V86)L90T*:6YP=71S('1H
M870@87)E(&-O<G)O8F]R871E9"!B>2!M87)K970@9&%T82X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/DQE=F5L(#,Z(%5N;V)S97)V86)L92!I
M;G!U=',@=&AA="!A<F4@;F]T(&-O<G)O8F]R871E9`T*8GD@;6%R:V5T(&1A
M=&$N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@:&EE<F%R
M8VAY(&YO=&5D(&%B;W9E(')E<75I<F5S('5S('1O(&UI;FEM:7IE#0IT:&4@
M=7-E(&]F('5N;V)S97)V86)L92!I;G!U=',@86YD('1O('5S92!O8G-E<G9A
M8FQE(&UA<FME="!D871A+"!I9B!A=F%I;&%B;&4L('=H96X@9&5T97)M:6YI
M;F<@9F%I<B!V86QU92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/E1H92!F86ER('9A;'5E(&]F(&]U<B!R96-O<F1E9"!D97)I=F%T:79E(&QI
M86)I;&ET:65S#0II<R!D971E<FUI;F5D(&)A<V5D(&]N('5N;V)S97)V86)L
M92!I;G!U=',@=&AA="!A<F4@;F]T(&-O<G)O8F]R871E9"!B>2!M87)K970@
M9&%T82P@=VAI8V@@:7,@82!,979E;"`S(&-L87-S:69I8V%T:6]N+B!792!R
M96-O<F0-"F1E<FEV871I=F4@;&EA8FEL:71I97,@;VX@;W5R(&)A;&%N8V4@
M<VAE970@870@9F%I<B!V86QU92!W:71H(&-H86YG97,@:6X@9F%I<B!V86QU
M92!R96-O<F1E9"!I;B!O=7(@8V]N<V]L:61A=&5D('-T871E;65N=',@;V8-
M"F]P97)A=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!
M="!397!T96UB97(@,S`L(#(P,30L('=E(&YO(&QO;F=E<B!H860@86YY#0ID
M97)I=F%T:79E(&QI86)I;&ET:65S(&%S(&%L;"!O9B!T:&4@:&]L9&5R<R!O
M9B!T:&4@9FEN86YC:6%L(&EN<W1R=6UE;G1S('1H870@:&%D('!R:6-E(&%N
M=&ED:6QU=&EO;B!P<F]T96-T:6]N('=A:79E9"!S=6-H('!R:6-E#0IA;G1I
M9&EL=71I;VX@<')O=&5C=&EO;BXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D]U<B!F86ER('9A;'5E(&UE87-U<F5M96YT<R!A="!T
M:&4@36%R8V@@,S$L#0HR,#$T(')E<&]R=&EN9R!D871E(&%R92!C;&%S<VEF
M:65D(&)A<V5D(&]N('1H92!V86QU871I;VX@=&5C:&YI<75E(&QE=F5L(&YO
M=&5D(&EN('1H92!T86)L92!B96QO=SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@
M,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^1&5S8W)I<'1I;VX\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^36%R8V@@,S$L(#QB<B`O/@T*,C`Q-#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY1=6]T960@4')I
M8V5S(#QB<B`O/@T*:6X@06-T:79E($UA<FME=',@9F]R(#QB<B`O/@T**$QE
M=F5L(#$I/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G
M/E-I9VYI9FEC86YT($]T:&5R($]B<V5R=F%B;&4@/&)R("\^#0HH3&5V96P@
M,BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^4VEG
M;FEF:6-A;G0@/&)R("\^#0I5;F]B<V5R=F%B;&4@/&)R("\^#0HH3&5V96P@
M,RD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S-B4G/D1E<FEV
M871I=F4@3&EA8FEL:71I97,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ,"PV
M-SDL,#8W/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,R4[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,3,E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,3`L-C<Y+#`V-SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^5&]T86P@07-S971S
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ,"PV-SDL,#8W/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^,3`L-C<Y+#`V-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9F]L;&]W:6YG(&]U=&QI;F5S('1H
M92!S:6=N:69I8V%N="!W96EG:'1E9`T*879E<F%G92!A<W-U;7!T:6]N<R!U
M<V5D('1O(&5S=&EM871E('1H92!F86ER('9A;'5E(&EN9F]R;6%T:6]N('!R
M97-E;G1E9"P@:6X@8V]N;F5C=&EO;B!W:71H(&]U<B!W87)R86YT(&%N9"!E
M;6)E9&1E9"!C;VYV97)S:6]N#0IO<'1I;VX@9&5R:79A=&EV92!I;G-T<G5M
M96YT<R!U=&EL:7II;F<@=&AE($)I;F]M:6%L($QA='1I8V4@;W!T:6]N('!R
M:6-I;F<@;6]D96PZ/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
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M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^4VEX($UO
M;G1H<R!%;F1E9"!397!T96UB97(@,S`L(#(P,3,\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W-"4G
M/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,C4E.R!T97AT+6%L:6=N.B!C96YT97(G/C`N,#(E("T@,"XV,B4\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y!=F5R86=E
M(&5X<&5C=&5D(&QI9F4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/C`N,C4@)B,Q-3`[
M(#,@>65A<G,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@
M/'1D/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/C<X
M+CDE("T@,3`T+C4E/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0^17AP96-T960@9&EV:61E;F1S/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY.
M;VYE/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!T86)L92!B96QO=R!S
M971S(&9O<G1H(&$@<W5M;6%R>2!O9B!C:&%N9V5S#0II;B!T:&4@9F%I<B!V
M86QU92!O9B!O=7(@3&5V96P@,R!F:6YA;F-I86P@:6YS=')U;65N=',@9F]R
M('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#H@)B,Q
M-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!<')I;"`Q+"`\8G(@
M+SX-"C(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^4F5C;W)D960@3F5W($1E<FEV871I=F4@/&)R("\^#0I,:6%B:6QI=&EE
M<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY#:&%N
M9V4@:6X@97-T:6UA=&5D(&9A:7(@=F%L=64@<F5C;V=N:7IE9"!I;B!R97-U
M;'1S(&]F(&]P97)A=&EO;G,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^4F5C;&%S<VEF:6-A=&EO;B`\8G(@+SX-"F]F($1E<FEV
M871I=F4@/&)R("\^#0I,:6%B:6QI='D@=&\@4&%I9"`\8G(@+SX-"FEN(&-A
M<&ET86P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M4V5P=&5M8F5R(#,P+"`\8G(@+SX-"C(P,30\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,S`E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^1&5R:79A
M=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^,3`L-C<Y+#`V-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B@Q,"PV-SDL,#8W/"]T9#X-"B`@("`\=&0^*3PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!T
M86)L92!B96QO=R!S971S(&9O<G1H(&$@<W5M;6%R>2!O9B!C:&%N9V5S#0II
M;B!T:&4@9F%I<B!V86QU92!O9B!O=7(@3&5V96P@,R!F:6YA;F-I86P@:6YS
M=')U;65N=',@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^0VAA;F=E(&EN/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M)SY296-L87-S:69I8V%T:6]N/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,CXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G
M/F5S=&EM871E9"!F86ER/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R)SYO9B!$97)I=F%T:79E/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/E)E8V]R9&5D/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R)SYV86QU92!R96-O9VYI>F5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY,:6%B:6QI='D@=&\\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<B<^07!R:6P@,2P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97(G/DYE=R!$97)I=F%T:79E/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M)SYI;B!R97-U;'1S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SY086ED(&EN/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY397!T96UB97(@
M,S`L/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SY,:6%B:6QI=&EE<SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SYO9B!O<&5R871I;VYS/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/F-A<&ET86P\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^,C`Q,SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,"4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M:6YD96YT
M.B`M,3%P="<^1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,RPU.#@L,C,Y/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/C(L,S@R+#@W-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#$P-BPU,#$\+W1D
M/@T*("`@(#QT9#XI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXU+#@V-"PV,34\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SXF(S$V,#L\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C$P+B!35$]#2R!#3TU014Y3051)
M3TX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$:7-C;&]S=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S
M+"!3:&%R92UB87-E9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y35$]#2R!#3TU014Y3
M051)3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^,3`N(%-43T-+($-/
M35!%3E-!5$E/3B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M9"!397!T96UB97(@,S`L(#(P,30@86YD(#(P,3,N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/E1H<F5E($UO
M;G1H<R!%;F1E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<B<^5&AR964@36]N=&AS($5N9&5D/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY3
M:7@@36]N=&AS($5N9&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R)SY3:7@@36]N=&AS($5N9&5D/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@,C`Q,SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY397!T96UB97(@
M,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#,V)2<^5F5S=&EN9R!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXX.2PW.3,\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^-S,L
M.#4V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G
M/C(V,"PV.#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R
M:6=H="<^,3(T+#(T,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M:6YD96YT
M.B`M,3%P="<^26YC<F5M96YT86P@9F%I<B!V86QU92!O9B!O<'1I;VX@;6]D
M:69I8V%T:6]N<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.34W/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#DQ-#PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UI;F1E;G0Z("TQ,7!T
M)SY697-T:6YG(&5X<&5N<V4@87-S;V-I871E9"!W:71H($-%3R!R97-T<FEC
M=&5D('-T;V-K(&=R86YT/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,3%P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M
M;&5F=#H@,3%P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT)SXV-"PT-#0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UI;F1E;G0Z("TQ,7!T
M)SY4;W1A;"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M86QI9VXZ(')I9VAT)SXX.2PW
M.3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#$Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXW-"PX,3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#$Q<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXR-C`L-C@P/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0G/C$Y,"PV,#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M:6YD96YT.B`M,3%P="<^5&]T86P@
M<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:6YC;'5D960@:6X@
M;F5T(&QO<W,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL969T.B`Q,7!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^.#DL-SDS/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,7!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL969T.B`Q,7!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^-S,L.#4V/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN
M9RUL969T.B`Q,7!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C8P+#8X,#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.3`L-C`Q/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\
M=&0^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O
M=71S=&%N9&EN9R`F(S$U,#L@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^,C4Y+#,V.2PY,3$\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,3@W+#8T
M,RPU.#(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H="<^,C0S+#0Y-"PY,38\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,3@R+#`P-"PR,C`\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M
M:6YD96YT.B`M,3%P="<^0F%S:6,@86YD(&1I;'5T960@;&]S<R!P97(@8V]M
M;6]N('-H87)E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,3%P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^*3PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT)SXH,"XP,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^06QL(&]F('1H92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@
M97AP96YS90T*<F5C;W)D960@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D
M(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q,RP@=VAI8V@@=&]T86QE9"`D
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M(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q,R!H860@;F\@:6UP86-T(&]N
M(&)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R(&-O;6UO;B!S:&%R92X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M964@86YD('-I>"!M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)E<B`S,"P@
M,C`Q-"!W87,@:6YS:6=N:69I8V%N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D]N($IU;F4@-BP@,C`Q-"P@;W5R($)O87)D(&]F($1I<F5C
M=&]R<R!A<'!R;W9E9`T*=&AE(&9O;&QO=VEN9R!G<F%N=',@;V8@;W!T:6]N
M<R!T;R!C97)T86EN(&]F9FEC97)S(&%N9"!D:7)E8W1O<G,@;V8@=&AE($-O
M;7!A;GDZ/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C!P>"<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,P<'@G/F\\+W1D/@T*
M("`@(#QT9#Y4;R!-<BX@2F%M97,@02X@2F]Y8V4L(&%N(&]P=&EO;B!T;R!A
M8W%U:7)E(&%N(&%G9W)E9V%T92!O9B`Q+#4P,"PP,#`@<VAA<F5S(&]F(&]U
M<B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3D@
M<&5R('-H87)E+"!T:&4@8VQO<VEN9R!P<FEC92!O9B!O=7(@8V]M;6]N('-T
M;V-K(&]N('1H92!D871E(&]F(&=R86YT+B!4:&4@9F%I<B!V86QU92!O9B!T
M:&ES('-T;V-K(&]P=&EO;B!A="!T:&4@9&%T92!O9B!G<F%N="!W87,@)#(T
M-BPP,#`N)B,Q-C`[)B,Q-C`[5&AE(&]P=&EO;B!V97-T960@87,@=&\@-3`P
M+#`P,"!S:&%R97,@;VX@=&AE(&=R86YT(&1A=&4@9F]R(&$@=F5S=&EN9R!E
M>'!E;G-E(&]F("0X,BPP,#`@86YD('=I;&P@=F5S="!A<R!T;R!A;B!A9&1I
M=&EO;F%L(#4P,"PP,#`@<VAA<F5S(&]N(&5A8V@@;V8@=&AE(&9I<G-T('1W
M;R!A;FYI=F5R<V%R:65S(&]F('1H92!G<F%N="!D871E+B!5;FQE<W,@96%R
M;&EE<B!E>&5R8VES960@;W(@=&5R;6EN871E9"P@=&AE(&]P=&EO;B!W:6QL
M(&5X<&ER92!*=6YE(#8L(#(P,C0N/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`Q:6X[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#8P<'@G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,'!X)SYO/"]T9#X-"B`@("`\=&0^
M5&\@37(N(%)O9&YE>2!3+B!+96YL97DL(&%N(&]P=&EO;B!T;R!A8W%U:7)E
M(&%N(&%G9W)E9V%T92!O9B`R-3`L,#`P('-H87)E<R!O9B!O=7(@8V]M;6]N
M('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C$Y('!E<B!S:&%R
M92P@=&AE(&-L;W-I;F<@<')I8V4@;V8@;W5R(&-O;6UO;B!S=&]C:R!O;B!T
M:&4@9&%T92!O9B!G<F%N="X@5&AE(&9A:7(@=F%L=64@;V8@=&AI<R!S=&]C
M:R!O<'1I;VX@870@=&AE(&1A=&4@;V8@9W)A;G0@=V%S("0T,2PP,#`N)B,Q
M-C`[)B,Q-C`[5&AE(&]P=&EO;B!V97-T960@87,@=&\@.#,L,S,S('-H87)E
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M2G5N92`V+"`R,#(T+CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XU:6X[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#8P<'@G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`S,'!X)SYO/"]T9#X-"B`@("`\=&0^5&\@37(N
M($IA;65S($(N($9R86ME<RP@86X@;W!T:6]N('1O(&%C<75I<F4@86X@86=G
M<F5G871E(&]F(#(U,"PP,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@
M870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3D@<&5R('-H87)E+"!T:&4@
M8VQO<VEN9R!P<FEC92!O9B!O=7(@8V]M;6]N('-T;V-K(&]N('1H92!D871E
M(&]F(&=R86YT+B!4:&4@9F%I<B!V86QU92!O9B!T:&ES('-T;V-K(&]P=&EO
M;B!A="!T:&4@9&%T92!O9B!G<F%N="!W87,@)#0Q+#`P,"X@5&AE(&]P=&EO
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M960L('1H92!O<'1I;VX@=VEL;"!E>'!I<F4@2G5N92`V+"`R,#(T+CPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C!P>"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,P<'@G/F\\+W1D
M/@T*("`@(#QT9#Y4;R!$<BX@4FEC:&%R9"!(+B!4=6QL:7,L(&%N(&]P=&EO
M;B!T;R!A8W%U:7)E(&%N(&%G9W)E9V%T92!O9B`U,"PP,#`@<VAA<F5S(&]F
M(&]U<B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N
M,3D@<&5R('-H87)E+"!T:&4@8VQO<VEN9R!P<FEC92!O9B!O=7(@8V]M;6]N
M('-T;V-K(&]N('1H92!D871E(&]F(&=R86YT+B!4:&4@9F%I<B!V86QU92!O
M9B!T:&ES('-T;V-K(&]P=&EO;B!A="!T:&4@9&%T92!O9B!G<F%N="!W87,@
M)#@L,C`P+B!4:&4@;W!T:6]N('9E<W1E9"!A<R!T;R`Q-BPV-C<@<VAA<F5S
M(&]N('1H92!G<F%N="!D871E(&9O<B!A('9E<W1I;F<@97AP96YS92!O9B`D
M,BPW,S,@86YD('=I;&P@=F5S="!A<R!T;R!A;B!A9&1I=&EO;F%L(#$V+#8V
M-R!S:&%R97,@;VX@=&AE(&9I<G-T(&%N;FEV97)S87)Y(&]F('1H92!G<F%N
M="!D871E(&%N9"`Q-BPV-C8@<VAA<F5S(&]N('1H92!S96-O;F0@86YN:79E
M<G-A<GD@;V8@=&AE(&=R86YT(&1A=&4N(%5N;&5S<R!E87)L:65R(&5X97)C
M:7-E9"!O<B!T97)M:6YA=&5D+"!T:&4@;W!T:6]N('=I;&P@97AP:7)E($IU
M;F4@-BP@,C`R-"X@/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&%D9&ET
M:6]N('1O('1H92!A8F]V92!G<F%N=',@=&\@;W5R(&]F9FEC97)S+`T*;VX@
M2G5N92`V+"`R,#$T+"!O=7(@0F]A<F0@;V8@1&ER96-T;W)S(&%L<V\@87!P
M<F]V960@=&AE(&=R86YT(&]F(&]P=&EO;G,@=&\@9FEV92!E;7!L;WEE97,@
M=&\@86-Q=6ER92!A;B!A9V=R96=A=&4@;V8@,S<P+#`P,`T*<VAA<F5S(&]F
M(&]U<B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N
M,3D@<&5R('-H87)E+"!T:&4@8VQO<VEN9R!P<FEC92!O9B!O=7(@8V]M;6]N
M('-T;V-K(&]N('1H92!D871E(&]F(&=R86YT+@T*5&AE(&%G9W)E9V%T92!F
M86ER('9A;'5E(&]F('1H;W-E('-T;V-K(&]P=&EO;G,@870@=&AE(&1A=&4@
M;V8@9W)A;G0@=V%S("0V,"PV.#`N(%1H;W-E(&]P=&EO;G,@=F5S=&5D(&%S
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M92!O<'1I;VX@=VEL;`T*97AP:7)E($IU;F4@-BP@,C`R-"X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&%D9&ET:6]N('1O('1H92!S:&%R
M92UB87-E9"!C;VUP96YS871I;VX-"F5X<&5N<V4@9F]R('1H92!S<&5C:69I
M8R!S=&]C:R!O<'1I;VX@9W)A;G1S(&YO=&5D(&%B;W9E+"!O=7(@=&]T86P@
M<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('1H92!T:')E
M92!A;F0@<VEX(&UO;G1H<PT*96YD960@4V5P=&5M8F5R(#,P+"`R,#$T(&EN
M8VQU9&5S(&]N9V]I;F<@=F5S=&EN9R!E>'!E;G-E(&%S<V]C:6%T960@=VET
M:"!S=&]C:R!G<F%N=',@9G)O;2!P<FEO<B!P97)I;V1S+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^0VAA;F=E<R!T;R`R,#$R($)O87)D($-O
M;7!E;G-A=&EO;B!0<F]G<F%M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);B!*=6QY(#(P,3(L('1H92!";V%R9"!A<'!R;W9E9"!A($)O87)D
M($-O;7!E;G-A=&EO;@T*4')O9W)A;2`H=&AE("8C,30W.S(P,3(@4')O9W)A
M;28C,30X.RDL('=H:6-H(&UO9&EF:65D(&%N9"!S=7!E<G-E9&5D('1H92`R
M,#`U($1I<F5C=&]R<R!#;VUP96YS871I;VX@4')O9W)A;2!T:&%T(&AA9"!B
M965N(&EN#0IE9F9E8W0@<')E=FEO=7-L>2X@3VX@2G5N92`V+"`R,#$T+"!T
M:&4@0F]A<F0@87!P<F]V960@8V5R=&%I;B!C:&%N9V5S('1O('1H92`R,#$R
M(%!R;V=R86TN(%5N9&5R('1H92!M;V1I9FEE9"`R,#$R(%!R;V=R86TL(&EN
M#0IW:&EC:"!O;FQY(&YO;BUE;7!L;WEE92!$:7)E8W1O<G,@;6%Y('!A<G1I
M8VEP871E+"!A(&YE=R!E;&EG:6)L92!$:7)E8W1O<B!W:6QL(')E8V5I=F4@
M86X@:6YI=&EA;"!G<F%N="!O9B`D-3`L,#`P('=O<G1H(&]F(&]P=&EO;G,-
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M86YD('=I;&P@=F5S="`Q+S,@=7!O;B!G<F%N="!A;F0@,2\S('5P;VX@96%C
M:"!O9B!T:&4@9FER<W0@='=O(&%N;FEV97)S87)I97,@;V8@=&AE(&1A=&4@
M;V8@9W)A;G0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY!="!T:&4@8F5G:6YN:6YG(&]F(&5A8V@@
M9FES8V%L('EE87(L(&5A8V@@97AI<W1I;F<-"D1I<F5C=&]R(&5L:6=I8FQE
M('1O('!A<G1I8VEP871E(&EN('1H92`R,#$R(%!R;V=R86T@86QS;R!W:6QL
M(')E8V5I=F4@82!G<F%N="!O9B`D,S4L,#`P('=O<G1H(&]F(&]P=&EO;G,@
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M,#`N(%1H92!M;V1I9FEE9"`R,#$R(%!R;V=R86T@86QS;R!P<F]V:61E<R!F
M;W(@=&AE#0IF;VQL;W=I;F<@86YN=6%L(')E=&%I;F5R(&9E97,Z($%U9&ET
M($-O;6UI='1E92!#:&%I<B`M("0U+#`P,"P@0V]M<&5N<V%T:6]N($-O;6UI
M='1E92!C:&%I<B`M("0U+#`P,"P@075D:70@0V]M;6ET=&5E(&UE;6)E<B`M
M#0HD-"PP,#`L($-O;7!E;G-A=&EO;B!#;VUM:71T964@;65M8F5R("T@)#0L
M,#`P(&%N9"!,96%D(&EN9&5P96YD96YT(&1I<F5C=&]R("T@)#$U+#`P,"X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY!<R!A(')E<W5L="!O9B!T:&4@;6]D:69I960@,C`Q,B!0
M<F]G<F%M(&]N#0I*=6YE(#8L(#(P,30L('=E(&ES<W5E9"`Q.#0L,C$Q('-T
M;V-K(&]P=&EO;G,@=&\@96%C:"!O9B!O=7(@=&AR964@;W5T<VED92!D:7)E
M8W1O<G,N(%1H;W-E(&=R86YT<R!V97-T(&]V97(@=&AE(&9I<V-A;"!Y96%R
M(&5N9&EN9PT*36%R8V@@,S$L(#(P,34@86YD(&AA=F4@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#`N,3D@<&5R('-H87)E+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^06QL(&]F('1H92!F;W)E9V]I;F<@86-T:6]N
M<R`M('1H92!C:&%N9V5S(&EN#0IB87-E('-A;&%R:65S+"!T:&4@;W!T:6]N
M(&=R86YT<R!A;F0@=&AE(&-H86YG97,@=&\@=&AE($1I<F5C=&]R<R!#;VUP
M96YS871I;VX@4')O9W)A;2!D:7-C=7-S960@:&5R96EN("T@=V5R92!A<'!R
M;W9E9"!A;F0@<F5C;VUM96YD960-"F)Y('1H92!#;VUP86YY)B,Q-#8[<R!#
M;VUP96YS871I;VX@0V]M;6ET=&5E('!R:6]R('1O(&%P<')O=F%L(&)Y('1H
M92!";V%R9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#HF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`W-"4G/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C4E.R!T97AT+6%L:6=N.B!C96YT
M97(G/C(N-B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/C$P
M('EE87)S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SXY,"XR
M,R4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y%>'!E
M8W1E9"!D:79I9&5N9',\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/DYO;F4\+W1D/CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($UA>2`R,#$S
M+"!W92!G<F%N=&5D('1O(&$@<V-I96YT:69I8R!A9'9I<V]R>0T*8F]A<F0@
M;65M8F5R(&%N9"!A('-C:65N=&EF:6,@8V]N<W5L=&%N="!A('1H<F5E('EE
M87(@;W!T:6]N('1O('!U<F-H87-E(#$R-2PP,#`@<VAA<F5S(&]F(&]U<B!C
M;VUM;VX@<W1O8VL@870@82!P<FEC92!O9B`D,"XQ,0T*<&5R('-H87)E+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*=6QY(#(P,3,L
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M;&]W:6YG('-C:&5D=6QE.B`R-24@;VX@2G5L>2`Q+`T*,C`Q-"P@,C4E(&]N
M($IU;'D@,2P@,C`Q-2P@,C4E(&]N($IU;'D@,2P@,C`Q-B!A;F0@,C4E(&]N
M($IU;'D@,2P@,C`Q-RX@5&AE(&YU;6)E<G,@;V8@<VAA<F5S('5N9&5R;'EI
M;F<@96%C:"!O9B!T:&4@<W1O8VL@;W!T:6]N#0IG<F%N=',@=V5R92!A<R!F
M;VQL;W=S.B`R+#`P,"PP,#`@<VAA<F5S('1O(&]U<B!C:&EE9B!E>&5C=71I
M=F4@;V9F:6-E<B!A;F0@-3`P+#`P,"!S:&%R97,@96%C:"!T;R!O=7(@<')E
M<VED96YT+"!C:&EE9B!S8VEE;F-E#0IO9F9I8V5R(&%N9"!C:&EE9B!F:6YA
M;F-I86P@;V9F:6-E<B`H<V5E($YO=&4@,3`I+CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#<T)2<^
M4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`R-24[('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XS."4@+2`R+C4P)3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D%V97)A9V4@
M97AP96-T960@;&EF93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^,R!Y96%R<R`M(#$P
M('EE87)S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SXY-"XV
M)2`M(#$P,BXW)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D/D5X<&5C=&5D(&1I=FED96YD<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^3F]N
M93PO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@97AP96-T960@=F]L871I
M;&ET>2!W87,@8F%S960@;VX@=&AE(&AI<W1O<FEC#0IV;VQA=&EL:71Y+B!4
M:&4@97AP96-T960@;&EF92!O9B!O<'1I;VYS(&=R86YT960@=V%S(&)A<V5D
M(&]N('1H92`F(S,T.W-I;7!L:69I960@;65T:&]D)B,S-#L@87,@9&5S8W)I
M8F5D(&EN('1H92!314,G<R!G=6ED86YC90T*9'5E('1O(&-H86YG97,@:6X@
M=&AE('9E<W1I;F<@=&5R;7,@86YD(&-O;G1R86-T=6%L(&QI9F4@;V8@8W5R
M<F5N="!O<'1I;VX@9W)A;G1S(&-O;7!A<F5D('1O(&]U<B!H:7-T;W)I8V%L
M(&=R86YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]P=&EO
M;G,@;W5T<W1A;F1I;F<@=&AA="!H879E('9E<W1E9"!A;F0@87)E#0IE>'!E
M8W1E9"!T;R!V97-T(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q-"!A<F4@87,@
M9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY.=6UB97(@;V8@3W!T:6]N<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SY796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E=E:6=H
M=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@:6X@665A
M<G,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#4R)2<^5F5S=&5D/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E
M>'0M86QI9VXZ(')I9VAT)SXR-"PR.30L,C(W/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[
M('1E>'0M86QI9VXZ(')I9VAT)SXP+C(V/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S
M)3L@=&5X="UA;&EG;CH@<FEG:'0G/C,N.38\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D/D5X<&5C=&5D('1O('9E<W0\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C0L-S$Q+#@Q,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,"XQ-#PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXY+C$U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#`N,C5I;B<^5&]T86P\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!P861D:6YG+6QE9G0Z(#`N,C5I;B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@<&%D9&EN9RUL969T.B`P+C(U:6X[('1E>'0M86QI9VXZ(')I9VAT
M)SXR.2PP,#8L,#,X/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`P+C(U:6XG/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,"XR-6EN)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#`N,C5I
M;CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,"XR
M-6EN)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/D$@<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T
M:79I='D@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<@T*
M,S`L(#(P,30@:7,@<')E<V5N=&5D(&)E;&]W.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/DYU;6)E<B!O9B!/<'1I;VYS/"]B
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY2
M86YG92!O9CPO8CX\8G(@+SX-"CQB/D5X97)C:7-E(%!R:6-E/"]B/CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY796EG:'1E
M9"!!=F5R86=E(#PO8CX\8G(@+SX-"CQB/D5X97)C:7-E(%!R:6-E/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)2<^4W1O8VL@;W!T
M:6]N<R!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q-#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,C8L,3,S+#0P
M-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXD
M,"XP-S8@+2`D,"XT,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R
M:6=H="<^,"XR-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^
M17AE<F-I<V5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-3`[)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9#Y'<F%N=&5D/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(L.3<R+#8S,3PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXP+C$Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C$Y/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0^0V%N8V5L;&5D+T5X<&ER960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Q
M,#`L,#`P/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^
M,"XQ.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M="<^,"XQ.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C145%145%)SX-"B`@("`\=&0^4W1O8VL@;W!T:6]N<R!O=71S=&%N
M9&EN9R!A="!397!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C(Y+#`P-BPP,S@\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B0P+C`W-B`M("0P+C0Q/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^,"XR-#PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/E-T;V-K
M(&]P=&EO;G,@97AE<F-I<V%B;&4@870@4V5P=&5M8F5R(#,P+"`R,#$T/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(T+#(Y-"PR,C<\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^
M)#`N,#<V("T@)#`N-#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0G/C`N,C8\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^070@4V5P=&5M8F5R(#,P+"`R,#$T+"!T
M:&5R92!W87,@87!P<F]X:6UA=&5L>0T*)#0Y-RPW.#,@;V8@=6YR96-O9VYI
M>F5D(&-O;7!E;G-A=&EO;B!C;W-T(')E;&%T960@=&\@<VAA<F4M8F%S960@
M<&%Y;65N=',L('=H:6-H(&ES(&5X<&5C=&5D('1O(&)E(')E8V]G;FEZ960@
M;W9E<B!A('=E:6=H=&5D#0IA=F5R86=E('!E<FEO9"!O9B`R+C$Y('EE87)S
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@4V5P=&5M8F5R
M(#,P+"`R,#$T+"!O=7(@<W1O8VL@;W!T:6]N<R!H860-"F$@;F5G871I=F4@
M:6YT<FEN<VEC('9A;'5E('-I;F-E('1H92!C;&]S:6YG('!R:6-E(&]F(&]U
M<B!C;VUM;VX@<W1O8VL@;VX@=&AA="!D871E(&]F("0P+C$R('!E<B!S:&%R
M92!W87,@8F5L;W<@=&AE('=E:6=H=&5D#0IA=F5R86=E(&5X97)C:7-E('!R
M:6-E(&]F(&]U<B!S=&]C:R!O<'1I;VYS+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X7S5E,V5?-#DT,U]A
M.&9A7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W,F4O5V]R:W-H
M965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^,3$N(%=!4E)!3E13/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV92!);G-T<G5M96YT
M<R!A;F0@2&5D9VEN9R!!8W1I=FET:65S($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5T%24D%.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^,3$N(%=!4E)!
M3E13/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!('-U;6UA<GD@
M;V8@=V%R<F%N="!A8W1I=FET>2!D=7)I;F<@=&AE('-I>`T*;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"!I<R!P<F5S96YT960@8F5L;W<Z/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^06UO=6YT
M/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY286YG92!O9CPO
M8CX\8G(@+SX-"CQB/D5X97)C:7-E(%!R:6-E/"]B/CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SX\8CY796EG:'1E9"!!=F5R86=E/"]B/CQB<B`O/@T*/&(^17AE<F-I
M<V4@4')I8V4\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-3(E)SY787)R86YT<R!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q-#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^
M-S`L-S`Y+#0W-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L
M:6=N.B!C96YT97(G/B0P+C`T,B`M("0P+C(U/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,"XQ,SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0^17AE<F-I<V5D/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B@R+#$V-BPQ,#0\+W1D/@T*("`@(#QT
M9#XI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R)SXD,"XP.#8@)B,Q-3`[("0P+C$R/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C$P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*
M("`@(#QT9#Y)<W-U960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,34L,S<U+#8Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<B<^)#`N,#0R("T@)#`N,C0\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C`N,#<\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y#86YC96QL
M960O17AP:7)E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L,3,V+#,V-#PO
M=&0^#0H@("`@/'1D/BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B0P+C$S/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^,"XQ,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^5V%R<F%N=',@;W5T
M<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT)SXX,BPW.#(L-C(Q/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R)SXD,"XP-#(@+2`D,"XR-3PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9"<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C`N,3`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9#Y787)R86YT<R!E>&5R8VES86)L92!A="!3
M97!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M="<^.#(L-S@R+#8R,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<B<^)#`N,#0R("T@)#`N,C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0G/C`N,3`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
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M9RP@=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T.CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E)SX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#<T)2<^4FES:R!F<F5E
M(&EN=&5R97-T(')A=&4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-24[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XW.24@+2`R+C(Y)28C,38P.R8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D/D%V97)A9V4@97AP96-T960@;&EF928C,38P.R8C
M,38P.R8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^-2!Y96%R<R`F(S$U,#L@
M-R!Y96%R<SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C145%145%)SX-"B`@("`\=&0^17AP96-T960@=F]L871I;&ET>28C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<B<^.3`N,24@+2`Y-2XX)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D5X<&5C=&5D(&1I=FED
M96YD<R8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^3F]N93PO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C,38P.SPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,3(N($1!4E!!($-/3E1204-4
M($%.1"!214Q!5$5$(%)%5D5.544@4D5#3T=.251)3TX\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E;G5E(%)E
M8V]G;FET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1!4E!!($-/3E1204-4($%.1"!214Q!5$5$
M(%)%5D5.544@4D5#3T=.251)3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^,3(N($1!4E!!($-/3E1204-4($%.1"!214Q!5$5$(%)%5D5.544@4D5#
M3T=.251)3TX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&1I
M<V-U<W-E9"!I;B!.;W1E(#$L('=E(&5N=&5R960@:6YT;R!A(&-O;G1R86-T
M#0IW:71H('1H92!$05)002!O;B!397!T96UB97(@,S`L(#(P,3$N(%5N9&5R
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M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3W)I9VEN86QL>2P@;VYL>2!T
M:&4@8F%S92!Y96%R("AY96%R(&]N92!C;VYT<F%C="D-"G=A<R!E9F9E8W1I
M=F4@9F]R('1H92!P87)T:65S+"!H;W=E=F5R+"!$05)002!S=6)S97%U96YT
M;'D@97AE<F-I<V5D('1H92!O<'1I;VX@;VX@=&AE('-E8V]N9"P@=&AI<F0@
M86YD(&9O=7)T:"!Y96%R<R!O9B!T:&4@8V]N=')A8W0N#0I$05)002!H87,@
M=&AE(&]P=&EO;B!T;R!E;G1E<B!I;G1O('1H92!C;VYT<F%C="!F;W(@>65A
M<B!F:79E+B!4:&4@;6EL97-T;VYE<R!A<F4@8V]M<')I<V5D(&]F('!L86YN
M:6YG+"!E;F=I;F5E<FEN9R!A;F0@8VQI;FEC86P-"G1A<F=E=',L('1H92!A
M8VAI979E;65N="!O9B!W:&EC:"!I;B!S;VUE(&-A<V5S('=I;&P@<F5Q=6ER
M92!T:&4@<&%R=&EC:7!A=&EO;B!A;F0@8V]N=')I8G5T:6]N(&]F('1H:7)D
M('!A<G1Y('!A<G1I8VEP86YT<R!U;F1E<@T*=&AE(&-O;G1R86-T+B!4:&5R
M92!C86X@8F4@;F\@87-S=7)A;F-E('1H870@=V4@86QO;F4L(&]R('=I=&@@
M=&AI<F0@<&%R='D@<&%R=&EC:7!A;G1S+"!W:6QL(&UE970@<W5C:"!M:6QE
M<W1O;F5S('1O('1H92!S871I<V9A8W1I;VX-"F]F('1H92!G;W9E<FYM96YT
M(&%N9"!I;B!C;VUP;&EA;F-E('=I=&@@=&AE('1E<FUS(&]F('1H92!C;VYT
M<F%C="!O<B!T:&%T('=E('=I;&P@8F4@<&%I9"!T:&4@9G5L;"!A;6]U;G0@
M;V8@=&AE(&-O;G1R86-T(')E=F5N=65S#0ID=7)I;F<@86YY('EE87(@;V8@
M=&AE(&-O;G1R86-T('1E<FTN(%=E(&-O;6UE;F-E9"!W;W)K('5N9&5R('1H
M92!C;VYT<F%C="!I;B!/8W1O8F5R(#(P,3$N)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY$=64@=&\@8G5D9V5T(')E<W1R:6-T:6]N
M<R!W:71H:6X@=&AE($1E<&%R=&UE;G0-"F]F($1E9F5N<V4L(&]N($9E8G)U
M87)Y(#$P+"`R,#$T+"!$05)002!R961U8V5D('1H92!S8V]P92!O9B!O=7(@
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M;VYT<F%C="!B>2`D.#4X+#0Y,2!O=F5R('EE87)S('1H<F5E('1H<F]U9V@@
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M=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@
M=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$T+`T*=V4@
M:6YV;VEC960@1$%24$$@9F]R('1H<F5E(&UI;&5S=&]N97,@=&]T86QI;F<@
M)#0T-"PW,C,N(%1H92!D971A:6QS(&]F('1H;W-E(&UI;&5S=&]N97,@=V5R
M92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M36EL97-T;VYE(#(N-"XR+C(@)B,Q-3`[($1E=&5R;6EN92!C87!A8VET>0T*
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M;6ET=&5D('1H97)E869T97(N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^36EL97-T;VYE(#(N-"XR
M+C0@)B,Q-3`[($9I;FES:"!C;VYS=')U8W1I;VX-"F%N9"!D96QI=F5R>2!O
M9B`R-2!E>'!E<FEM96YT86P@8V%R=')I9&=E<R!F;W(@=&5S=&EN9R!B>2!T
M:&4@<WES=&5M(&EN=&5G<F%T;W(N(%1H92!M:6QE<W1O;F4@<&%Y;65N="!W
M87,@)#4P+#`P,"X@36%N86=E;65N=`T*8V]N<VED97)S('1H:7,@;6EL97-T
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M('1H97)E869T97(N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-
M:6QE<W1O;F4@33D@)B,Q-3`[(%1A<F=E="!C87!T=7)E("8C-C([(#DP)0T*
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M96QY(#DP)2!I;B`R-"!H;W5R<R!F;W(@870-"FQE87-T(#-F('1A<F=E=',@
M97@@=FEV;R!I;B!B;&]O9"!O<B!B;&]O9"!C;VUP;VYE;G1S('5S:6YG('1H
M92!O<'1I;6EZ960@8V%R=')I9&=E+B8C,38P.R8C,38P.U1H92!R97!O<G0@
M=V%S(&%C8V5P=&5D(&)Y('1H90T*8V]N=')A8W1I;F<@;V9F:6-E<B=S(')E
M<')E<V5N=&%T:79E(&%N9"!T:&4@:6YV;VEC92!W87,@<W5B;6ET=&5D('1H
M97)E869T97(N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!T
M:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,L#0IW92!I
M;G9O:6-E9"!$05)002!F;W(@9F]U<B!M:6QE<W1O;F5S('1O=&%L:6YG("0X
M,#@L-S,Y+B8C,38P.R8C,38P.U1H92!D971A:6QS(&]F('1H;W-E(&UI;&5S
M=&]N97,@=V5R92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^36EL97-T;VYE(#(N,RXR+C(@)B,Q-3`[($9O<FUU;&%T92!I
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M-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-:6QE
M<W1O;F4@,BXS+C(N,B`F(S$U,#L@5W)I=&4@86YD('1E<W0@<V]F='=A<F4-
M"F%N9"!C;VYD=6-T(&5R9V]N;VUI8R!R97-E87)C:"X@0F5G:6X@9&ES8W5S
M<VEO;G,@=VET:"!T:&4@<WES=&5M<R!I;G1E9W)A=&]R+B!4:&4@;6EL97-T
M;VYE('!A>6UE;G0@=V%S("0Q.34L-3@Q+B!-86YA9V5M96YT(&-O;G-I9&5R
M<PT*=&AI<R!M:6QE<W1O;F4@=&\@8F4@<W5B<W1A;G1I=F4@87,@:70@=V%S
M(&YO="!D97!E;F1E;G0@;VX@=&AE('!A<W-A9V4@;V8@=&EM92!N;W(@=V%S
M(&ET(&)A<V5D('-O;&5L>2!O;B!A;F]T:&5R('!A<G1Y)W,@969F;W)T<RXF
M(S$V,#LF(S$V,#M790T*;V)T86EN960@=W)O=&4@86YD('1E<W1E9"!S;V9T
M=V%R92!A;F0@8V]N9'5C=&5D(&5R9V]N;VUI8R!R97-E87)C:"!A;F0@8F5G
M86X@9&ES8W5S<VEO;G,@=VET:"!T:&4@<WES=&5M<R!I;G1E9W)A=&]R+B!4
M:&4@<F5P;W)T#0IW87,@86-C97!T960@8GD@=&AE(&-O;G1R86-T:6YG(&]F
M9FEC97(G<R!R97!R97-E;G1A=&EV92!A;F0@=&AE(&EN=F]I8V4@=V%S('-U
M8FUI='1E9"!T:&5R96%F=&5R+B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^36EL97-T;VYE(#(N,RXS+C(@)B,Q-3`[($-A
M<G1R:61G92!C;VYS=')U8W1I;VX-"G=I=&@@;W!T:6UI>F5D(&%F9FEN:71Y
M(&UA=')I>"!D97-I9VX@9F]R(&5A8V@@<&]T96YT:6%L('1A<F=E="X@0V]M
M<&QE=&4@=&AE(&-A<'1U<F4@86=E;G0@<V-R965N:6YG+B!4:&4@;6EL97-T
M;VYE('!A>6UE;G0@=V%S#0HD,C`X+#<X,2X@36%N86=E;65N="!C;VYS:61E
M<G,@=&AI<R!M:6QE<W1O;F4@=&\@8F4@<W5B<W1A;G1I=F4@87,@:70@=V%S
M(&YO="!D97!E;F1E;G0@;VX@=&AE('!A<W-A9V4@;V8@=&EM92!N;W(@=V%S
M(&ET(&)A<V5D#0IS;VQE;'D@;VX@86YO=&AE<B!P87)T>2=S(&5F9F]R=',N
M)B,Q-C`[)B,Q-C`[5V4@8V]M<&QE=&5D('1H92!C87)T<FED9V4@8V]N<W1R
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M)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-
M:6QE<W1O;F4@334@)B,Q-3`[(%1A<F=E="!C87!T=7)E("8C-C([(#DP)0T*
M:6X@,C0@:&]U<G,@9F]R(&%T(&QE87-T('1H<F5E('1A<F=E=',@:6X@8FQO
M;V0@;W(@8FQO;V0@8V]M<&]N96YT<RX@5&AE(&UI;&5S=&]N92!P87EM96YT
M('=A<R`D,C`X+#<X,2X@36%N86=E;65N="!C;VYS:61E<G,-"G1H:7,@;6EL
M97-T;VYE('1O(&)E('-U8G-T86YT:79E(&%S(&ET('=A<R!N;W0@9&5P96YD
M96YT(&]N('1H92!P87-S86=E(&]F('1I;64@;F]R('=A<R!I="!B87-E9"!S
M;VQE;'D@;VX@86YO=&AE<B!P87)T>2=S(&5F9F]R=',N)B,Q-C`[)B,Q-C`[
M5V4-"F1E;6]N<W1R871E9"!T:&%T('=E('=E<F4@86)L92!T;R!C87!T=7)E
M(&%P<')O>&EM871E;'D@.3`E(&EN(#(T(&AO=7)S(&9O<B!A="!L96%S="!T
M:')E92!O9B!T:&4@86=R965D('1A<F=E=',@:6X@8FQO;V0@;W(@8FQO;V0-
M"F-O;7!O;F5N=',N(%1H92!R97!O<G0@=V%S(&%C8V5P=&5D(&)Y('1H92!C
M;VYT<F%C=&EN9R!O9F9I8V5R)W,@<F5P<F5S96YT871I=F4@86YD('1H92!I
M;G9O:6-E('=A<R!S=6)M:71T960@=&AE<F5A9G1E<BX\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/C$S+B!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.
M0TE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U
M<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^,3,N($-/34U)5$U%3E13($%.1"!#
M3TY424Y'14Y#2453/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY,
M14%312!#3TU-251-14Y44SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^5V4@<F5N=&5D(&%P<')O>&EM871E;'D@,BPS,#`@<W%U87)E(&9E970@
M;V8-"F5X96-U=&EV92!O9F9I8V4@<W!A8V4@870@.#DQ,"!5;FEV97)S:71Y
M($-E;G1E<B!,86YE+"!3=6ET92`V-C`L(%-A;B!$:65G;RP@0T$@.3(Q,C(@
M870@=&AE(')A=&4@;V8@)#8L-#<U('!E<B!M;VYT:"!O;B!A(&9O=7(-"GEE
M87(@;&5A<V4@=&AA="!E>'!I<F5D(&EN(%-E<'1E;6)E<B`R,#$T+B!792!C
M;VYT:6YU960@;&5A<VEN9R!T:&%T('-P86-E(&9O<B!T:&4@;6]N=&@@;V8@
M3V-T;V)E<B!A;F0L(&5F9F5C=&EV92!.;W9E;6)E<B`Q+`T*,C`Q-"P@;6]V
M960@:6YT;R!A(&YE=R!F86-I;&ET>2!O9B!A<'!R;WAI;6%T96QY(#(L-3<V
M('-Q=6%R92!F965T(&QO8V%T960@870@.38S-2!'<F%N:71E(%)I9&=E($1R
M:79E+"!386X@1&EE9V\\:3XL(#PO:3Y#02`Y,C$R,PT*=6YD97(@82`S.2!M
M;VYT:"!L96%S92!W:71H(&%N(&EN:71I86P@<F5N=&%L(')A=&4@;V8@)#8L
M,#4T('!E<B!M;VYT:"X@5V4@8F5L:65V92!T:&ES(&YE=R!L96%S960@9F%C
M:6QI='D@=VEL;"!B92!S871I<V9A8W1O<GD-"F9O<B!O=7(@;V9F:6-E(&YE
M961S(&]V97(@=&AE('1E<FT@;V8@=&AE(&QE87-E+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^5V4@86QS;R!R96YT(&%P<')O>&EM871E;'D@
M,2PW,#`@<W%U87)E(&9E970-"F]F(&QA8F]R871O<GD@<W!A8V4@870@,3$U
M.#4@4V]R<F5N=&\@5F%L;&5Y(%)O860L(%-U:71E(#$P.2P@4V%N($1I96=O
M+"!#86QI9F]R;FEA(#DR,3(Q(&%T('1H92!R871E(&]F("0S+#DQ-R!P97(@
M;6]N=&@@;VX@80T*;VYE('EE87(@;&5A<V4@=&AA="!P<F5V:6]U<VQY('=A
M<R!S8VAE9'5L960@=&\@97AP:7)E(&EN($]C=&]B97(@,C`Q-"!A;F0@=V%S
M(')E8V5N=&QY(&5X=&5N9&5D('1O(&EN($]C=&]B97(@,C`Q-2X@5V4@8F5L
M:65V90T*=&AI<R!N97<@;&5A<V5D(&9A8VEL:71Y('=I;&P@8F4@<V%T:7-F
M86-T;W)Y(&9O<B!O=7(@;&%B;W)A=&]R>2!N965D<R!O=F5R('1H92!T97)M
M(&]F('1H92!L96%S93PO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M3W5R($5X;W-O;64@4V-I96YC97,L($EN8RX@<W5B<VED:6%R>2!R96YT<PT*
M87!P<F]X:6UA=&5L>2`R+#`U-2!S<75A<F4@9F5E="!O9B!O9F9I8V4@86YD
M(&QA8F]R871O<GD@<W!A8V4@870@,3$@1&5E<B!087)K($1R:79E+"!3;W5T
M:"!"<G5N<W=I8VLL($Y*(&%T('1H92!R871E(&]F("0S+#4Y-@T*<&5R(&UO
M;G1H(&]N(&$@;VYE('EE87(@;&5A<V4@=&AA="!P<F5V:6]U<VQY('=A<R!S
M8VAE9'5L960@=&\@97AP:7)E(&EN($]C=&]B97(@,C`Q-"!A;F0@=V%S(')E
M8V5N=&QY(&5X=&5N9&5D('1O(&EN($]C=&]B97(@,C`Q-2X-"E=E(&)E;&EE
M=F4@=&AI<R!N97<@;&5A<V5D(&9A8VEL:71Y('=I;&P@8F4@<V%T:7-F86-T
M;W)Y(&9O<B!%4TDF(S$T-CMS(&]P97)A=&EO;F%L(&YE961S(&]V97(@=&AE
M('1E<FT@;V8@=&AE(&QE87-E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^4F5N="!E>'!E;G-E(&%P<')O>&EM871E9"`D.#0L,#`P(&%N9"`D
M-C@L,#`P#0IF;W(@=&AE('-I>"!M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E
M;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3$5'04P@34%45$524SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
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M<B!E;F=A9VEN9R!I;B!O=&AE<B!A8W1I=FET:65S+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X9F%?
M-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V
M-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE971S
M+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SXQ-"X@4T5'345.5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY396=M96YT(%)E<&]R=&EN9R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y314=-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXQ-"X@4T5'
M345.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&]P97)A
M=&4@;W5R(&)U<VEN97-S97,@<')I;F-I<&%L;'D@=&AR;W5G:`T*='=O(')E
M<&]R=&%B;&4@<V5G;65N=',Z($%E=&AL;VXL('=H:6-H(')E<')E<V5N=',@
M;W5R('1H97)A<&5U=&EC(&)U<VEN97-S(&%C=&EV:71I97,L(&%N9"!%4TDL
M('=H:6-H(')E<')E<V5N=',@;W5R(&1I86=N;W-T:6,-"F)U<VEN97-S(&%C
M=&EV:71I97,N($]U<B!R97!O<G1A8FQE('-E9VUE;G1S(&AA=F4@8F5E;B!D
M971E<FUI;F5D(&)A<V5D(&]N('1H92!N871U<F4@;V8@=&AE('!O=&5N=&EA
M;"!P<F]D=6-T<R!B96EN9R!D979E;&]P960N#0I%4TD@9&ED(&YO="!H879E
M(&%N>2!O<&5R871I;VYS(&EN('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B`S,"P@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D%E=&AL;VXF(S$T-CMS(')E=F5N=64@:7,@9V5N97)A=&5D('!R:6UA<FEL
M>0T*9G)O;2!G;W9E<FYM96YT(&-O;G1R86-T<R!T;R!D871E(&%N9"!%4TD@
M9&]E<R!N;W0@>65T(&AA=F4@86YY(')E=F5N=65S+B!792!H879E(&YO="!I
M;F-L=61E9"!A;GD@86QL;V-A=&EO;B!O9B!C;W)P;W)A=&4@;W9E<FAE860-
M"G1O('1H92!%4TD@<V5G;65N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/E1H92!F;VQL;W=I;F<@=&%B;&5S('-E="!F;W)T:"!C97)T86EN
M(&EN9F]R;6%T:6]N#0IR96=A<F1I;F<@;W5R('-E9VUE;G1S(&%N9"!O=&AE
M<B!O<&5R871I;VYS('1H870@8V]N9F]R;7,@=&\@=&AE(&-O;G-O;&ED871E
M9"!B86QA;F-E('-H965T(&%N9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!P
M<F5S96YT960-"FEN('1H:7,@4F5P;W)T.CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H
M.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97(G/E-I>"!-;VYT:',@16YD960@4V5P=&5M8F5R
M(#,P+#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97(G/C(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^4F5V96YU
M97,Z/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E.R!P
M861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^065T:&QO
M;CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C4S,"PS-S$\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C@T,"PT.#,\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T
M97AT+6EN9&5N=#H@+3$P<'0G/D5323PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P
M861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#(P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`S,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0G/E1O=&%L(%)E=F5N=65S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4S,"PS
M-S$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#,P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^.#0P+#0X,SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%
M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y/<&5R871I
M;F<@3&]S<V5S.CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^065T:&QO;CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^*#$L,CDT+#0U,SPO=&0^#0H@("`@/'1D/BD\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@Q+#`Q,RPU.3(\+W1D
M/@T*("`@(#QT9#XI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N
M=#H@+3$P<'0G/D5323PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE
M9G0Z(#(P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-#0U+#8W-#PO=&0^#0H@
M("`@/'1D/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z
M(#(P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T
M86P@3W!E<F%T:6YG($QO<W,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D
M9&EN9RUL969T.B`S,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L-S<S+#(P
M,#PO=&0^#0H@("`@/'1D/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#,P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L,#$S+#4Y,CPO=&0^#0H@
M("`@/'1D/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^3F5T($QO<W-E<SH\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T)SY!971H;&]N/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH
M-"PR,#(L.#<S/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^*#,L-C4S+#$V.#PO=&0^#0H@("`@/'1D/BD\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%4TD\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^*#,U-BPU,SD\+W1D/@T*("`@(#QT9#XI/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,S!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY.970@3&]S<R!"969O<F4@3F]N
M+4-O;G1R;VQL:6YG($EN=&5R97-T<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-"PU
M.3(L-#@U/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,S!P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXH,RPV-3,L,38X/"]T
M9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y#87-H.CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%
M145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^065T:&QO;CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M-#<L.#8U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXX+#<U-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%4TD\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^-#<X+#,R,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,S!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY4;W1A;"!#87-H/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C4R-BPQ.#<\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^."PW-30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%
M)SX-"B`@("`\=&0^5&]T86P@07-S971S.CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/D%E=&AL;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0T,RPP,C<\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/C0Q,2PQ.3`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,C!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%4TD\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^-C0V+#(T,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^5&]T86P@07-S971S/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$L,#@Y+#(V.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXT
M,3$L,3DP/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-%145%144G/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D/D-A<&ET86P@17AP96YD:71U<F5S.CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M
M,3!P="<^065T:&QO;CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z
M(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^15-)/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%
M12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY#87!I=&%L($5X<&5N9&ET=7)E<SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@
M("`@/'1D/D1E<')E8VEA=&EO;B!A;F0@06UO<G1I>F%T:6]N.CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/D%E=&AL;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C@L.#@U
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXT+#<R-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5323PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXY+#<Y,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T86P@1&5P<F5C:6%T:6]N(&%N
M9"!!;6]R=&EZ871I;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN
M9RUL969T.B`S,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3@L-C<V/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`S,'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C0L-S(W/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/DEN=&5R97-T($5X<&5N<V4Z
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,C!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY!971H;&]N/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXQ-38L-SDY/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,38L-3`R/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/D5323PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(P
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T86P@
M26YT97)E<W0@17AP96YS93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D
M:6YG+6QE9G0Z(#,P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ-38L-SDY/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`S,'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(Q-BPU,#(\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S
M95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R
M92]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SXQ-2X@4U5"4T51545.5"!%5D5.5%,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY396=M
M96YT(%)E<&]R=&EN9R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXQ-2X@4U5"4T51545.5"!%5D5.5%,\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M:6YD96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G
M/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY-86YA9V5M96YT(&AA<R!E=F%L
M=6%T960@979E;G1S#0IS=6)S97%U96YT('1O(%-E<'1E;6)E<B`S,"P@,C`Q
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`X<'0G/CQU/D=O=F5R;FUE;G0@0V]N=')A8W1S/"]U/CPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M:6YD
M96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY3=6)S97%U96YT('1O(%-E
M<'1E;6)E<B`S,"P@,C`Q-"P-"G=E(&-O;&QE8W1E9"`D,C0W+#,V,2!U;F1E
M<B!O=7(@1$%24$$@8V]N=')A8W0L(&%N9"!U;F1E<B!T:&4@0F%T=&5L;&4@
M<W5B8V]N=')A8W0@=V4@8FEL;&5D("0Y+#4Y-2!A;F0@=V4@8V]L;&5C=&5D
M("0Q,2PS,3$N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#AP="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/CQU/D1E
M8G0@4F5D=6-T:6]N/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^4W5B<V5Q=65N="!T;R!397!T
M96UB97(@,S`L(#(P,30L#0IW92!P86ED(&]F9B!T:&4@<F5M86EN:6YG('!R
M:6YC:7!A;"!A;F0@:6YT97)E<W0@8F%L86YC97,@;VX@=&AE('1W;R!R96UA
M:6YI;F<@2G5L>2`F(S,X.R!!=6=U<W0@,C`Q,2`Q,"4@0V]N=F5R=&EB;&4@
M3F]T97,L('=H:6-H#0IH860@8F5E;B!C;&%S<VEF:65D(&%S(&)E:6YG(&EN
M(&1E9F%U;'0L('=I=&@@8V%S:"!P87EM96YT<R!T;W1A;&EN9R`D,S@R+#<T
M."`H<V5E($YO=&4@-2DN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY3=6)S97%U96YT('1O(%-E<'1E
M;6)E<B`S,"P@,C`Q-"P-"G=E('!A:60@;V9F(&EN(&9U;&P@=&AE(&]U='-T
M86YD:6YG('!R:6YC:7!A;"!B86QA;F-E(&%N9"!I;G1E<F5S="!B86QA;F-E
M(&]N('1H92!,87<@1FER;2!.;W1E('=I=&@@82!C87-H('!A>6UE;G0@;V8@
M)#4P+#`P,`T*86YD(&%N(&ES<W5A;F-E(&]F(#$W,"PP,C`@8V]M;6]N('-H
M87)E<R`H<V5E($YO=&4@-2DN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X
M<'0G/CQU/D-O;6UO;B!3=&]C:R!)<W-U86YC97,\+W4^/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X<'0G/E-U8G-E<75E;G0@=&\@4V5P=&5M8F5R(#,P
M+"`R,#$T+`T*=V4@:7-S=65D(#,Q-RPQ,3D@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!P=7)S=6%N="!T;R!O=7(@4RTX(')E9VES=')A=&EO;B!S=&%T96UE
M;G0@8V]V97)I;F<@;W5R($%M96YD960@,C`Q,"!3=&]C:R!0;&%N(&%T(&%N
M#0IA=F5R86=E('!R:6-E(&]F("0P+C$R-"!P97(@<VAA<F4@:6X@<&%Y;65N
M="!F;W(@;&5G86P@86YD('-C:65N=&EF:6,@8V]N<W5L=&EN9R!S97)V:6-E
M<R!V86QU960@870@)#,Y+#$W,"!B87-E9"!O;B!T:&4@=F%L=64-"F]F('1H
M92!S97)V:6-E<R!P<F]V:61E9"X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP="<^/'4^17%U:71Y(%5N:70@26YV97-T;65N=',\+W4^/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`X<'0G/E-U8G-E<75E;G0@=&\@4V5P=&5M8F5R
M(#,P+"`R,#$T+`T*=V4@:7-S=65D(&%N9"!S;VQD('1O(&5I9VAT(&%C8W)E
M9&ET960@:6YV97-T;W)S('5N:71S("AT:&4@)B,Q-#<[56YI=',F(S$T.#LI
M(&-O;G-I<W1I;F<@;V8@*&$I(&]N92!H=6YD<F5D('1H;W5S86YD("@Q,#`L
M,#`P*0T*<F5S=')I8W1E9"!S:&%R97,@;V8@=&AE(%)E9VES=')A;G0F(S$T
M-CMS(&-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("0N,#`Q('!E<B!S:&%R92`H
M=&AE("8C,30W.T-O;6UO;B!3=&]C:R8C,30X.RDL(&%T('!R:6-E<PT*<&5R
M('-H87)E(')A;F=I;F<@9G)O;2`D,"XQ,#4@=&\@)#`N,3$T(&%N9"`H8BD@
M82!F:79E+7EE87(@=V%R<F%N="!T;R!P=7)C:&%S92!F:69T>2!T:&]U<V%N
M9"`H-3`L,#`P*2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K#0IA="!E>&5R8VES
M92!P<FEC97,@<F%N9VEN9R!F<F]M("0P+C$U-"!T;R`D,"XQ-C<@<&5R('-H
M87)E("AT:&4@)B,Q-#<[56YI="!787)R86YT<R8C,30X.RDN($EN('1O=&%L
M+"!T:&4@:6YV97-T;W)S('!U<F-H87-E9`T*9F]R(&-A<V@@86X@86=G<F5G
M871E(&]F("0U,#$L-S`P(&]F(%5N:71S+B!4:&4@:6YV97-T;W)S(&%C<75I
M<F5D(&%N(&%G9W)E9V%T92!O9B`T+#4P-BPR-3`@<VAA<F5S(&]F($-O;6UO
M;B!3=&]C:R!A;F0@56YI="!787)R86YT<PT*=&\@86-Q=6ER92!U<"!T;R!A
M;B!A9V=R96=A=&4@;V8@,BPR-3,L,3(U('-H87)E<R!O9B!#;VUM;VX@4W1O
M8VLN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/E-U8G-E<75E;G0@
M=&\@4V5P=&5M8F5R(#,P+"`R,#$T+`T*=V4@:7-S=65D('1O(&%N(&%C8W)E
M9&ET960@:6YV97-T;W(@56YI=',@8V]N<VES=&EN9R!O9B!A;B!A9V=R96=A
M=&4@;V8@,2PX,S4L-SDX('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@86YD(%5N
M:70@5V%R<F%N=',@=&\-"F%C<75I<F4@=7`@=&\@86X@86=G<F5G871E(&]F
M(#$L.#,W+#<Y."!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%T(&%N(&5X97)C
M:7-E('!R:6-E(&]F("0P+C$P,R!P97(@<VAA<F4N(%1H92!5;FET<R!W97)E
M(&ES<W5E9`T*=&\@=&AE(&EN=F5S=&]R('5P;VX@=&AE(&-O;G9E<G-I;VX@
M;V8@86X@86=G<F5G871E(&]F("0Q.#DL,#@W(&]F('5N<&%I9"!P<FEN8VEP
M86P@86YD(&%C8W)U960@:6YT97)E<W0@9'5E('5N9&5R('1W;R!P<F]M:7-S
M;W)Y#0IN;W1E<R`H=&AE(')E;6%I;FEN9R!/8W1O8F5R("8C,S@[($YO=F5M
M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE($YO=&4@86YD('1H92!!<')I;"`R
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M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M="<^/'4^5V%R<F%N="!%>&5R8VES97,@86YD($ES<W5A;F-E#0IO9B!.97<@
M5V%R<F%N=',@57!O;B!%>&5R8VES92`\+W4^/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/E-U8G-E<75E;G0@=&\-
M"E-E<'1E;6)E<B`S,"P@,C`Q-"P@=V4@:7-S=65D(&%N(&%G9W)E9V%T92!O
M9B`U+#8W,2PQ,3D@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!A;F0@<V5V96XM
M>65A<B!W87)R86YT<R`H=&AE("8C,30W.T5X8VAA;F=E(%=A<G)A;G1S)B,Q
M-#@[*0T*=&\@:7-S=64@=7`@=&\@86X@86=G<F5G871E(&]F(#4L-C<Q+#$Q
M.2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%T(&5X97)C:7-E('!R:6-E<R!R
M86YG:6YG(&9R;VT@)#`N,#DS('1O("0P+C$Q-B!P97(@<VAA<F4@=&\-"F5I
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M>2!T:&5M+B!4:&4@:6YV97-T;W)S('!A:60@86X-"F%G9W)E9V%T92!O9B`D
M-3<Y+#(U,2!U<&]N(&5X97)C:7-E(&]F('1H92!P<F5V:6]U<VQY(&]U='-T
M86YD:6YG('=A<G)A;G1S(&%T(&5X97)C:7-E('!R:6-E<R!R86YG:6YG(&9R
M;VT@)#`N,#DS('1O("0P+C$Q-2!P97(-"G-H87)E+B!4:&4@9F]R96=O:6YG
M('1R86YS86-T:6]N('=A<R!P<FEV871E;'D@;F5G;W1I871E9"!W:71H('1H
M92!G<F]U<"!O9B!P87)T:6-I<&%T:6YG('=A<G)A;G0@:&]L9&5R<RX\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^/'4^3F]T92!#;VYV97)S
M:6]N<SPO=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^4W5B<V5Q=65N="!T
M;PT*4V5P=&5M8F5R(#,P+"`R,#$T+"!W92!I<W-U960@86X@86=G<F5G871E
M(&]F(#,L-3(R+#DW-B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O('1W;R!A
M8V-R961I=&5D(&EN=F5S=&]R<R!U<&]N('1H92!C;VYV97)S:6]N#0IO9B!A
M;B!A9V=R96=A=&4@;V8@)#$T-RPY-C4@;V8@=6YP86ED('!R:6YC:7!A;"!A
M;F0@86-C<G5E9"!I;G1E<F5S="!D=64@=6YD97(@<')O;6ES<V]R>2!N;W1E
M<R!P<F5V:6]U<VQY(&ES<W5E9"!T;R!T:&4@:6YV97-T;W)S#0IB>2!T:&4@
M4F5G:7-T<F%N="X@5&AE(&-O;G9E<G-I;VX@<')I8V4@<&5R('-H87)E('=A
M<R`D,"XP-#(\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^/'4^5V%R<F%N
M=`T*17AE<F-I<V5S/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY3=6)S
M97%U96YT('1O#0I397!T96UB97(@,S`L(#(P,30L('=E(&ES<W5E9"!A;B!A
M9V=R96=A=&4@;V8@,38L-#(S+#$S,2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M('1O('1H<F5E(&%C8W)E9&ET960@:6YV97-T;W)S('5P;VX@=&AE(&5X97)C
M:7-E#0IO9B!W87)R86YT<R!P<F5V:6]U<VQY(&ES<W5E9"!W:71H(&%N(&5X
M97)C:7-E('!R:6-E(&]F("0P+C`T,B!P97(@<VAA<F4N(%1H92!W87)R86YT
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M('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`R,"PP-3`L-C0S('-H87)E<R!O
M9B!#;VUM;VX@4W1O8VLN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SX\=3Y)<W-U86YC92!O9B!#;VYV
M97)T:6)L92!.;W1E<SPO=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M="<^4W5B<V5Q=65N="!T;R!397!T96UB97(@,S`L(#(P,30L#0IW92!E;G1E
M<F5D(&EN=&\@82!3=6)S8W)I<'1I;VX@06=R965M96YT('=I=&@@='=O(&%C
M8W)E9&ET960@:6YV97-T;W)S('!R;W9I9&EN9R!F;W(@=&AE(&ES<W5A;F-E
M(&%N9"!S86QE(&]F("AI*2!C;VYV97)T:6)L90T*<')O;6ES<V]R>2!N;W1E
M<R!I;B!T:&4@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#4R-RPW
M.#`@86YD("AI:2D@9FEV92!Y96%R('=A<G)A;G1S('1O('!U<F-H87-E('5P
M('1O(#(L,S4V+#$V,"!S:&%R97,-"F]F($-O;6UO;B!3=&]C:R!A="!A(&9I
M>&5D(&5X97)C:7-E('!R:6-E(&]F("0P+C$V."!P97(@<VAA<F4N(%1H92!C
M;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&5S(&)E87(@:6YT97)E<W0@870@
M=&AE(&%N;G5A;"!R871E#0IO9B`Q,"4@86YD(&UA='5R92!O;B!!<')I;"`Q
M+"`R,#$V+B!4:&4@86=G<F5G871E(&=R;W-S(&-A<V@@<')O8V5E9',@=&\@
M=7,@=V5R92`D-#$U+#`P,"!A9G1E<B!S=6)T<F%C=&EN9R!L96=A;"!F965S
M(&]F("0S-2PP,#`[#0IT:&4@8F%L86YC92!O9B!T:&4@<')I;F-I<&%L(&%M
M;W5N="!O9B!T:&4@;F]T97,@<F5P<F5S96YT<R!A("0R-RPW.#`@9'5E(&1I
M;&EG96YC92!F964@86YD(&%N(&]R:6=I;F%L(&ES<W5A;F-E(&1I<V-O=6YT
M+B!4:&4-"F-O;G9E<G1I8FQE('!R;VUI<W-O<GD@;F]T97,@87)E(&-O;G9E
M<G1I8FQE(&%T('1H92!O<'1I;VX@;V8@=&AE(&AO;&1E<G,@:6YT;R!S:&%R
M97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A(&9I>&5D('!R:6-E(&]F#0HD
M,"XQ,3(@<&5R('-H87)E+"!F;W(@=7`@=&\@86X@86=G<F5G871E(&]F(#0L
M-S$R+#,R,2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K+B!4:&5R92!A<F4@;F\@
M<F5G:7-T<F%T:6]N(')E<75I<F5M96YT<R!W:71H(')E<W!E8W0-"G1O('1H
M92!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N9&5R;'EI;F<@=&AE(&YO=&5S
M(&]R('1H92!W87)R86YT<RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X
M9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE
M971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5'2D%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/C,N(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.
M1R!03TQ)0TE%4R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y04DE.0TE03$53($]&($-/3E-/3$E$051)3TX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^4%))3D-)4$Q%4R!/1B!#3TY33TQ)1$%424].
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@86-C;VUP86YY
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M9"!397!T96UB97(@,S`L(#(P,30@86YD(&EN8VQU9&5S('1H92!A8V-U;75L
M871E9"!A;6]U;G0@;V8@;F]N8V]N=')O;&QI;F<-"FEN=&5R97-T<R!A<R!P
M87)T(&]F('-T;V-K:&]L9&5R<R8C,30V.R!E<75I='DN($1U<FEN9R!T:&4@
M9FES8V%L('EE87(@96YD960@36%R8V@@,S$L(#(P,30L($5322!R86ES960@
M8V%P:71A;"!I;B!T:&4@86UO=6YT#0IO9B`D,2PU,#`L,#`P(&EN(&5X8VAA
M;F=E(&9O<B!T:&4@:7-S=6%N8V4@;V8@,S`P+#`P,"!S:&%R97,@;V8@15-)
M(&-O;6UO;B!S=&]C:R!T;R!%4TDF(S$T-CMS(&EN=F5S=&]R<RP@<F5P<F5S
M96YT:6YG(#(P)2!O9@T*15-))B,Q-#8[<R!I<W-U960@86YD(&]U='-T86YD
M:6YG(&-A<&ET86P@<W1O8VLN($%S(&$@<F5S=6QT+"!!971H;&]N($UE9&EC
M86PL($EN8RXF(S$T-CMS(&]W;F5R<VAI<"!O9B!%4TD@=V%S(')E9'5C960@
M=&\@.#`E+@T*268@82!F=7)T:&5R(&-H86YG92!I;B!!971H;&]N($UE9&EC
M86P@26YC+B8C,30V.W,@;W=N97)S:&EP(&]F($5322!R97-U;'1S(&EN(&QO
M<W,@;V8@8V]N=')O;"!A;F0@9&5C;VYS;VQI9&%T:6]N+"!A;GD@<F5T86EN
M960-"F]W;F5R<VAI<"!I;G1E<F5S="!W:6QL(&)E(')E;65A<W5R960@=VET
M:"!T:&4@9V%I;B!O<B!L;W-S(')E<&]R=&5D(&EN(&]U<B!S=&%T96UE;G0@
M;V8@;W!E<F%T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/E1H92!L;W-S97,@870@15-)(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E
M9`T*4V5P=&5M8F5R(#,P+"`R,#$T(')E9'5C960@=&AE(&YO;F-O;G1R;VQL
M:6YG(&EN=&5R97-T<R!O;B!O=7(@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE
M970@8GD@)#@Y+#$S-2!F<F]M("0R,3@L,C<P(&%T($UA<F-H(#,Q+`T*,C`Q
M-"!T;R`D,3(Y+#$S-2!A="!397!T96UB97(@,S`L(#(P,30N/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^55-%
M($]&($535$E-051%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY54T4@
M3T8@15-424U!5$53/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY7
M92!P<F5P87)E(&]U<B!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;`T*<W1A=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@1T%!4"P@=VAI8V@@
M<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME(&5S=&EM871E<R!A;F0@87-S
M=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE(')E<&]R=&5D(&%M;W5N=',-"F]F
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@86YD(&1I<V-L;W-U<F4@;V8@8V]N
M=&EN9V5N="!A<W-E=',@86YD(&QI86)I;&ET:65S(&%T('1H92!D871E(&]F
M('1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',-"F%N9"!R
M97!O<G1E9"!A;6]U;G1S(&]F(')E=F5N=65S(&%N9"!E>'!E;G-E<R!D=7)I
M;F<@=&AE(')E<&]R=&EN9R!P97)I;V1S+B!3:6=N:69I8V%N="!E<W1I;6%T
M97,@;6%D92!B>2!M86YA9V5M96YT(&EN8VQU9&4L(&%M;VYG#0IO=&AE<G,L
M(')E86QI>F%T:6]N(&]F(&QO;F<M;&EV960@87-S971S+"!E<W1I;6%T:6YG
M(&9A:7(@=F%L=64@87-S;V-I871E9"!W:71H(&1E8G0@86YD(&5Q=6ET>2!T
M<F%N<V%C=&EO;G,@86YD('9A;'5A=&EO;B!O9B!D969E<G)E9`T*=&%X(&%S
M<V5T<RX@06-T=6%L(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@=&AO<V4@
M97-T:6UA=&5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^0T%32"!!3D0@0T%32"!%455)5D%,
M14Y44SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^06-C;W5N=&EN
M9R!S=&%N9&%R9',@9&5F:6YE("8C,S0[8V%S:"!A;F0@8V%S:`T*97%U:79A
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M<RX@07,@;V8@4V5P=&5M8F5R#0HS,"P@,C`Q-"!A;F0@36%R8V@@,S$L(#(P
M,30L('=E(&AA9"!N;R!A<W-E=',@=&AA="!W97)E(&-L87-S:69I960@87,@
M8V%S:"!E<75I=F%L96YT<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TY#14Y44D%424].4R!/1B!#4D5$
M250@4DE32U,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^0T].0T5.5%)!
M5$E/3E,@3T8@0U)%1$E4(%))4TM3/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY#87-H(&ES(&UA:6YT86EN960@870@='=O(&9I;F%N8VEA;"!I
M;G-T:71U=&EO;G,-"FEN(&-H96-K:6YG(&%C8V]U;G1S(&%N9"!R96QA=&5D
M(&-A<V@@;6%N86=E;65N="!A8V-O=6YT<RX@06-C;W5N=',@870@=&AE<V4@
M:6YS=&ET=71I;VYS(&%R92!S96-U<F5D(&)Y('1H92!&961E<F%L($1E<&]S
M:70@26YS=7)A;F-E#0I#;W)P;W)A=&EO;B`H)B,S-#M&1$E#)B,S-#LI('5P
M('1O("0R-3`L,#`P+B!/=7(@4V5P=&5M8F5R(#,P+"`R,#$T(&-A<V@@8F%L
M86YC97,@=V5R92!A<'!R;WAI;6%T96QY("0R-S8L,#`P(&]V97(@<W5C:"!I
M;G-U<F5D#0IA;6]U;G0N(%=E(&1O(&YO="!B96QI979E('1H870@=&AE($-O
M;7!A;GD@:7,@97AP;W-E9"!T;R!A;GD@<VEG;FEF:6-A;G0@<FES:R!W:71H
M(')E<W!E8W0@=&\@:71S(&-A<V@N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY!;&P@;V8@;W5R(&%C8V]U;G1S(')E8V5I=F%B;&4@870@4V5P
M=&5M8F5R#0HS,"P@,C`Q-"!A;F0@36%R8V@@,S$L(#(P,30@86YD(&%L;"!O
M9B!O=7(@<F5V96YU92!I;B!T:&4@<VEX(&UO;G1H('!E<FEO9',@96YD960@
M4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S('=E<F4@9&ER96-T;'D@9G)O
M;0T*=&AE(%4N4RX@1&5P87)T;65N="!O9B!$969E;G-E(&]R(&9R;VT@82!S
M=6)C;VYT<F%C="!U;F1E<B!"871T96QL92`H9&5F:6YE9"!H97)E:6XI+"!W
M:&EC:"!I<R!A('!R:6UE(&-O;G1R86-T;W(@=VET:"!T:&4@52Y3+@T*1&5P
M87)T;65N="!O9B!$969E;G-E+"!A;F0@87,@<W5C:"!N;R!A;&QO=V%N8V4@
M9F]R('5N8V]L;&5C=&%B;&4@86-C;W5N=',@<F5C96EV86)L92!I<R!D965M
M960@;F5C97-S87)Y(&%T(%-E<'1E;6)E<B`S,"P@,C`Q-`T*;W(@36%R8V@@
M,S$L(#(P,30N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1D%)4B!604Q512!/1B!&24Y!3D-)04P@24Y35%)5
M345.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1D%)4B!604Q512!/
M1B!&24Y!3D-)04P@24Y35%)5345.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
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M<VEM:6QA<B!I;G-T<G5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
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M;V-I871E9`T*<&]T96YT:6%L(&-O<W1S+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^4V5E($YO=&4@.2!W:71H(')E<W!E8W0@=&\@9&5R:79A
M=&EV92!L:6%B:6QI=&EE<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y04D]015)462!!3D0@15%525!-14Y4
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!23U!%4E19($%.1"!%455)
M4$U%3E0\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!R;W!E<G1Y
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M:&4@8V]N<V]L:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<RX\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)3D-/344@5$%815,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^24Y#
M3TU%(%1!6$53/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$969E
M<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A<F4@<F5C;V=N:7IE
M9`T*9F]R('1H92!F=71U<F4@=&%X(&-O;G-E<75E;F-E<R!A='1R:6)U=&%B
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M>F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DE-4$%)4DU%3E0@3U(@1$E34$]304P@3T8@3$].1RU,259%
M1"!!4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^24U004E2345.
M5"!/4B!$25-03U-!3"!/1B!,3TY'+4Q)5D5$($%34T544SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^3&]N9RUL:79E9"!A<W-E=',@87)E(')E
M=FEE=V5D(&9O<B!I;7!A:7)M96YT#0IW:&5N979E<B!E=F5N=',@;W(@8VAA
M;F=E<R!I;B!C:7)C=6US=&%N8V5S(&EN9&EC871E('1H870@=&AE:7(@8V%R
M<GEI;F<@86UO=6YT<R!M87D@;F]T(&)E(')E8V]V97)A8FQE+B!)9B!T:&4@
M8V]S="!B87-I<R!O9B!A#0IL;VYG+6QI=F5D(&%S<V5T(&ES(&=R96%T97(@
M=&AA;B!T:&4@<')O:F5C=&5D(&9U='5R92!U;F1I<V-O=6YT960@;F5T(&-A
M<V@@9FQO=W,@9G)O;2!S=6-H(&%S<V5T+"!A;B!I;7!A:7)M96YT(&QO<W,@
M:7,@<F5C;V=N:7IE9"X-"E=E(&)E;&EE=F4@;F\@:6UP86ER;65N="!C:&%R
M9V5S('=E<F4@;F5C97-S87)Y(&1U<FEN9R!T:&4@=&AR964@86YD('-I>"!M
M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-"!A;F0@,C`Q
M,RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,3U-3(%!%4B!#3TU-3TX@4TA!4D4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^3$]34R!015(@0T]-34].(%-(05)%/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY"87-I8R!L;W-S('!E<B!S:&%R92!I<R!C
M;VUP=71E9"!B>2!D:79I9&EN9PT*;F5T(&EN8V]M92!A=F%I;&%B;&4@=&\@
M8V]M;6]N('-T;V-K:&]L9&5R<R!B>2!T:&4@=V5I9VAT960@879E<F%G92!N
M=6UB97(@;V8@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE
M('!E<FEO9"!O9B!C;VUP=71A=&EO;BX-"D1I;'5T960@;&]S<R!P97(@<VAA
M<F4@:7,@8V]M<'5T960@<VEM:6QA<B!T;R!B87-I8R!L;W-S('!E<B!S:&%R
M92!E>&-E<'0@=&AA="!T:&4@9&5N;VUI;F%T;W(@:7,@:6YC<F5A<V5D('1O
M(&EN8VQU9&4@=&AE(&YU;6)E<@T*;V8@861D:71I;VYA;"!C;VUM;VX@<VAA
M<F5S('1H870@=V]U;&0@:&%V92!B965N(&]U='-T86YD:6YG(&EF('!O=&5N
M=&EA;"!C;VUM;VX@<VAA<F5S(&AA9"!B965N(&ES<W5E9"P@:68@<W5C:"!A
M9&1I=&EO;F%L(&-O;6UO;@T*<VAA<F5S('=E<F4@9&EL=71I=F4N(%-I;F-E
M('=E(&AA9"!N970@;&]S<V5S(&9O<B!A;&P@<&5R:6]D<R!P<F5S96YT960L
M(&)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E(&%R92!T:&4@<V%M
M92P@86YD(&%D9&ET:6]N86P-"G!O=&5N=&EA;"!C;VUM;VX@<VAA<F5S(&AA
M=F4@8F5E;B!E>&-L=61E9"!A<R!T:&5I<B!E9F9E8W0@=V]U;&0@8F4@86YT
M:61I;'5T:79E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^07,@
M;V8@4V5P=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S+"!A('1O=&%L(&]F#0HQ
M,SDL-C<R+#@Q-2!A;F0@,3,W+#DS-2PU,CD@<&]T96YT:6%L(&-O;6UO;B!S
M:&%R97,L(&-O;G-I<W1I;F<@;V8@<VAA<F5S('5N9&5R;'EI;F<@;W5T<W1A
M;F1I;F<@<W1O8VL@;W!T:6]N<RP@=V%R<F%N=',@86YD(&-O;G9E<G1I8FQE
M#0IN;W1E<R!P87EA8FQE('=E<F4@97AC;'5D960@87,@=&AE:7(@:6YC;'5S
M:6]N('=O=6QD(&)E(&%N=&ED:6QU=&EV92X\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y314=-14Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY314=-14Y44SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M9&EA9VYO<W1I8PT*87!P;&EC871I;VYS("A3964@3F]T92`Q-"DN/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1$5&15)2140@1DE.04Y#24Y'($-/4U13/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D1%1D524D5$($9)3D%.0TE.1R!#3U-44SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M-C`[)B,Q-C`[5V4@<F5C;W)D960-"F%M;W)T:7IA=&EO;B!E>'!E;G-E(')E
M;&%T960@=&\@;W5R(&1E9F5R<F5D(&]F9F5R:6YG(&-O<W1S(&]F("0R,2PU
M,#(@86YD("0X-C,@9'5R:6YG('1H92!S:7@@;6]N=&@@<&5R:6]D<R!E;F1E
M9"!397!T96UB97(@,S`L#0HR,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4D5614Y512!214-/1TY)5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY2159%3E5%(%)%0T]'3DE424]./"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY$05)002!#;VYT<F%C="`M+2!7:71H(')E<W!E8W0@
M=&\@<F5V96YU92!R96-O9VYI=&EO;BP-"G=E(&5N=&5R960@:6YT;R!A(&=O
M=F5R;FUE;G0@8V]N=')A8W0@=VET:"!$05)002!A;F0@:&%V92!R96-O9VYI
M>F5D(')E=F5N=64@=6YD97(@<W5C:"!C;VYT<F%C="X@5V4@861O<'1E9"!T
M:&4@36EL97-T;VYE(&UE=&AO9`T*;V8@<F5V96YU92!R96-O9VYI=&EO;B!F
M;W(@=&AE($1!4E!!(&-O;G1R86-T('5N9&5R($%30R`V,#4M,C@@)B,Q-#<[
M4F5V96YU92!296-O9VYI=&EO;B`F(S$U,#L@36EL97-T;VYE($UE=&AO9"8C
M,30X.R!A;F0@=V4-"F)E;&EE=F4@=V4@;65E="!T:&4@<F5Q=6ER96UE;G1S
M('5N9&5R($%30R`V,#4M,C@@9F]R(')E<&]R=&EN9R!C;VYT<F%C="!R979E
M;G5E('5N9&5R('1H92!-:6QE<W1O;F4@365T:&]D+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
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M:&4@8V]N<VED97)A=&EO;B!R96-E:79E9`T*:7,@86QL;V-A=&5D(&%M;VYG
M('1H92!S97!A<F%T92!U;FET<R!O9B!A8V-O=6YT:6YG+"!A;F0@=&AE(&%P
M<&QI8V%B;&4@<F5V96YU92!R96-O9VYI=&EO;B!C<FET97)I82!A<F4@87!P
M;&EE9"!T;R!E86-H(&]F('1H90T*<V5P87)A=&4@=6YI=',N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!(&UI;&5S=&]N92!I<R!A;B!E=F5N
M="!H879I;F<@86QL(&]F('1H92!F;VQL;W=I;F<-"F-H87)A8W1E<FES=&EC
M<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B@Q*2!4:&5R92!I
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M:6QE<W1O;F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXH,BD@
M5&AE(&5V96YT(&-A;B!O;FQY(&)E(&%C:&EE=F5D(&)A<V5D(&EN#0IW:&]L
M92!O<B!I;B!P87)T(&]N(&5I=&AE<CH@*&$I('1H92!V96YD;W(F(S$T-CMS
M('!E<F9O<FUA;F-E.R!O<B`H8BD@82!S<&5C:69I8R!O=71C;VUE(')E<W5L
M=&EN9R!F<F]M('1H92!V96YD;W(F(S$T-CMS('!E<F9O<FUA;F-E+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^*#,I($EF(&%C:&EE=F5D+"!T
M:&4@979E;G0@=V]U;&0@<F5S=6QT(&EN(&%D9&ET:6]N86P-"G!A>6UE;G1S
M(&)E:6YG(&1U92!T;R!T:&4@=F5N9&]R+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M<R!P97)F;W)M86YC92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/E1H92!P;VQI8WD@9F]R(')E8V]G;FEZ:6YG(&1E;&EV97)A8FQE(&-O;G-I
M9&5R871I;VX-"F-O;G1I;F=E;G0@=7!O;B!A8VAI979E;65N="!O9B!A(&UI
M;&5S=&]N92!M=7-T(&)E(&%P<&QI960@8V]N<VES=&5N=&QY('1O('-I;6EL
M87(@9&5L:79E<F%B;&5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M;VYS:61E<F5D('-U8G-T86YT:79E.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
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M(&%C:&EE=F4@=&AE(&UI;&5S=&]N93L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B@R*2!4:&4@8V]N<VED97)A=&EO;B!R96QA=&5S('-O;&5L
M>2!T;R!P87-T#0IP97)F;W)M86YC93L@86YD/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXH,RD@5&AE(&-O;G-I9&5R871I;VX@:7,@<F5A<V]N
M86)L92!R96QA=&EV90T*=&\@86QL(&]F('1H92!D96QI=F5R86)L97,@86YD
M('!A>6UE;G0@=&5R;7,@*&EN8VQU9&EN9R!O=&AE<B!P;W1E;G1I86P@;6EL
M97-T;VYE(&-O;G-I9&5R871I;VXI('=I=&AI;B!T:&4@87)R86YG96UE;G0N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!(&UI;&5S=&]N92!I
M<R!N;W0@8V]N<VED97)E9"!S=6)S=&%N=&EV92!I9@T*86YY('!O<G1I;VX@
M;V8@=&AE(&%S<V]C:6%T960@;6EL97-T;VYE(&-O;G-I9&5R871I;VX@<F5L
M871E<R!T;R!T:&4@<F5M86EN:6YG(&1E;&EV97)A8FQE<R!I;B!T:&4@=6YI
M="!O9B!A8V-O=6YT:6YG("AI+F4N+"!I=`T*9&]E<R!N;W0@<F5L871E('-O
M;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E*2X@5&\@<F5C;V=N:7IE('1H92!M
M:6QE<W1O;F4@8V]N<VED97)A=&EO;B!I;B!I=',@96YT:7)E='D@87,@<F5V
M96YU92!I;B!T:&4@<&5R:6]D#0II;B!W:&EC:"!T:&4@;6EL97-T;VYE(&ES
M(&%C:&EE=F5D+"!T:&4@;6EL97-T;VYE(&UU<W0@8F4@<W5B<W1A;G1I=F4@
M:6X@:71S(&5N=&ER971Y+B!-:6QE<W1O;F4@8V]N<VED97)A=&EO;B!C86YN
M;W0@8F4@8FEF=7)C871E9`T*:6YT;R!S=6)S=&%N=&EV92!A;F0@;F]N+7-U
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M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY3964@3F]T92`Q,B!F;W(@=&AE(&%D9&ET
M:6]N86P@9&ES8VQO<W5R92!I;F9O<FUA=&EO;@T*<F5Q=6ER960@=6YD97(@
M05-#(#8P-2TR."X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D)A
M='1E;&QE(%-U8F-O;G1R86-T("TM(%=E(&5N=&5R960@:6YT;R!A('-U8F-O
M;G1R86-T#0IA9W)E96UE;G0@=VET:"!"871T96QL92!-96UO<FEA;"!);G-T
M:71U=&4@*"8C,30W.T)A='1E;&QE)B,Q-#@[*2!I;B!-87)C:"`R,#$S+B!"
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M(%-E<'1E;6)E<B`S,"P@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-+
M+4)!4T5$($-/35!%3E-!5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY35$]#2RU"05-%1"!#3TU014Y3051)3TX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
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M="!T;R!!<')I;"`Q+"`R,#`V+"!B87-E9"!O;B!T:&4@9W)A;G0M9&%T92!F
M86ER('9A;'5E(&5S=&EM871E9"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE('!R
M;W9I<VEO;G,@;V8@<W5B<V5Q=65N=`T*86-C;W5N=&EN9R!S=&%N9&%R9',N
M(%=E('5S92!A($)I;F]M:6%L($QA='1I8V4@;W!T:6]N('!R:6-I;F<@;6]D
M96P@9F]R(&5S=&EM871I;F<@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT
M960@*'-E92!.;W1E(#$P*2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!S:&%R92UB87-E
M9"!C;VUP96YS871I;VX-"F5X<&5N<V5S(')E;&%T:6YG('1O('-H87)E<R!A
M;F0@;W!T:6]N<R!G<F%N=&5D(&%N9"!T:&4@969F96-T(&]N(&QO<W,@<&5R
M(&-O;6UO;B!S:&%R92!D=7)I;F<@=&AE('-I>"!M;VYT:"!P97)I;V1S(&5N
M9&5D(%-E<'1E;6)E<@T*,S`L(#(P,30@86YD(#(P,3,Z/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^4VEX($UO;G1H<R!%;F1E9"!3
M97!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/@T*("`@("`@
M("`\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY3:7@@
M36]N=&AS($5N9&5D/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SY397!T96UB97(@,S`L(#(P,3,\+W`^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@-C@E)SY697-T:6YG(&]F(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXR-C`L-C@P/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXQ,C0L,C0S/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M/DEN8W)E;65N=&%L(&9A:7(@=F%L=64@;V8@;W!T:6]N($UO9&EF:6-A=&EO
M;G,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C$L.3$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9#Y697-T:6YG($5X<&5N<V4@07-S;V-I871E9"!W:71H
M($-%3R!297-T<FEC=&5D(%-T;V-K($=R86YT/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C8T+#0T-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^5&]T86P@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(V,"PV.#`\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$Y,"PV,#$\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9#Y796EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S
M(&]U='-T86YD:6YG("8C,34P.R!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT)SXR-#,L-#DT+#DQ-CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.#(L
M,#`T+#(R,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D/D)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R(&-O
M;6UO;B!S:&%R93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^*#`N,#`\+W1D
M/@T*("`@(#QT9#XI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXH,"XP,#PO
M=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY792!A8V-O=6YT(&9O<B!T<F%N<V%C=&EO
M;G,@:6YV;VQV:6YG('-E<G9I8V5S#0IP<F]V:61E9"!B>2!T:&ER9"!P87)T
M:65S('=H97)E('=E(&ES<W5E(&5Q=6ET>2!I;G-T<G5M96YT<R!A<R!P87)T
M(&]F('1H92!T;W1A;"!C;VYS:61E<F%T:6]N('5S:6YG('1H92!F86ER('9A
M;'5E(&]F('1H92!C;VYS:61E<F%T:6]N#0IR96-E:79E9"`H:2YE+B!T:&4@
M=F%L=64@;V8@=&AE(&=O;V1S(&]R('-E<G9I8V5S*2!O<B!T:&4@9F%I<B!V
M86QU92!O9B!T:&4@97%U:71Y(&EN<W1R=6UE;G1S(&ES<W5E9"P@=VAI8VAE
M=F5R(&ES(&UO<F4@<F5L:6%B;'D-"FUE87-U<F%B;&4N($EN('1R86YS86-T
M:6]N<RP@=VAE;B!T:&4@=F%L=64@;V8@=&AE(&=O;V1S(&%N9"]O<B!S97)V
M:6-E<R!A<F4@;F]T(')E861I;'D@9&5T97)M:6YA8FQE(&%N9"`H,2D@=&AE
M(&9A:7(@=F%L=64@;V8-"G1H92!E<75I='D@:6YS=')U;65N=',@:7,@;6]R
M92!R96QI86)L>2!M96%S=7)A8FQE(&%N9"`H,BD@=&AE(&-O=6YT97)P87)T
M>2!R96-E:79E<R!E<75I='D@:6YS=')U;65N=',@:6X@9G5L;"!O<B!P87)T
M:6%L('-E='1L96UE;G0-"F]F('1H92!T<F%N<V%C=&EO;G,L('=E('5S92!T
M:&4@9F]L;&]W:6YG(&UE=&AO9&]L;V=Y.CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
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M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SYB*2!&;W(@=')A;G-A8W1I;VYS('=H
M97)E('1H92!I;G-T<G5M96YT<R!A<F4-"FES<W5E9"!O;B!A(&9U;&QY('9E
M<W1E9"P@;F]N+69O<F9E:71A8FQE(&)A<VES+"!T:&4@97%U:71Y(&EN<W1R
M=6UE;G1S(&%R92!V86QU960@;VX@;W(@86)O=70@=&AE(&1A=&4@;V8@=&AE
M(&-O;G1R86-T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^8RD@
M1F]R(&%N>2!T<F%N<V%C=&EO;G,@;F]T(&UE971I;F<@=&AE(&-R:71E<FEA
M#0II;B`H82D@;W(@*&(I(&%B;W9E+"!W92!R92UM96%S=7)E('1H92!C;VYS
M:61E<F%T:6]N(&%T(&5A8V@@<F5P;W)T:6YG(&1A=&4@8F%S960@;VX@:71S
M('1H96X@8W5R<F5N="!S=&]C:R!V86QU92X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
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M<V4@86UO<G1I>F%T:6]N(&%F=&5R($UA<F-H(#,Q+"`R,#`V(&ES(')E8V]G
M;FEZ960@:6X@=&AE('!E<FEO9"!T:&4@9F]R9F5I='5R92!E<W1I;6%T92!I
M<R!C:&%N9V5D+@T*5&AE(&5F9F5C="!O9B!F;W)F96ET=7)E(&%D:G5S=&UE
M;G1S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P
M,30@=V%S(&EN<VEG;FEF:6-A;G0N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4$%414Y44SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY0051%3E13/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY0871E;G1S(&EN8VQU9&4@8F]T:"!F;W)E:6=N(&%N9"!D
M;VUE<W1I8R!P871E;G1S+@T*5&AE<F4@=V5R92!S979E<F%L('!A=&5N=',@
M<&5N9&EN9R!A="!397!T96UB97(@,S`L(#(P,30N(%=E(&-A<&ET86QI>F4@
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M=F5D#0IA<W-E="!P;VQI8WD@86)O=F4N)B,Q-C`[/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TL@4%52
M0TA!4T4@5T%24D%.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4U1/
M0TL@4%520TA!4T4@5T%24D%.5%,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/E=E(&=R86YT('=A<G)A;G1S(&EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@:7-S=6%N8V4-"F]F(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4@86YD
M('1H92!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A<V@N(%=H96X@
M<W5C:"!W87)R86YT<R!A<F4@8VQA<W-I9FEE9"!A<R!E<75I='D@86YD(&ES
M<W5E9`T*:6X@8V]N;F5C=&EO;B!W:71H(&1E8G0L('=E(&UE87-U<F4@=&AE
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M;BUC87!I=&%L+B!,87-T;'DL('=A<G)A;G1S(&YO=`T*;65E=&EN9R!E<75I
M='D@8VQA<W-I9FEC871I;VX@87)E(')E8V]R9&5D(&%S(&1E<FEV871I=F4@
M:6YS=')U;65N=',N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1$52259!5$E612!)3E-44E5-14Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$15))5D%4259%($E.4U1254U%3E13
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!E=F%L=6%T92!F
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M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@8VQA<W-I9FEC871I;VX@;V8@82!D
M97)I=F%T:79E(&EN<W1R=6UE;G0-"FES(')E87-S97-S960@870@96%C:"!R
M97!O<G1I;F<@9&%T92X@268@=&AE(&-L87-S:69I8V%T:6]N(&-H86YG97,@
M87,@82!R97-U;'0@;V8@979E;G1S(&1U<FEN9R!A(')E<&]R=&EN9R!P97)I
M;V0L('1H92!I;G-T<G5M96YT#0II<R!R96-L87-S:69I960@87,@;V8@=&AE
M(&1A=&4@;V8@=&AE(&5V96YT('1H870@8V%U<V5D('1H92!R96-L87-S:69I
M8V%T:6]N+B!4:&5R92!I<R!N;R!L:6UI="!O;B!T:&4@;G5M8F5R(&]F('1I
M;65S(&$@8V]N=')A8W0-"FUA>2!B92!R96-L87-S:69I960N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);G-T<G5M96YT<R!C;&%S
M<VEF:65D(&%S(&1E<FEV871I=F4@;&EA8FEL:71I97,-"F%R92!R96UE87-U
M<F5D(&5A8V@@<F5P;W)T:6YG('!E<FEO9"`H;W(@=7!O;B!R96-L87-S:69I
M8V%T:6]N*2!A;F0@=&AE(&-H86YG92!I;B!F86ER('9A;'5E(&ES(')E8V]R
M9&5D(&]N(&]U<B!C;VYS;VQI9&%T960@<W1A=&5M96YT#0IO9B!O<&5R871I
M;VYS(&EN(&]T:&5R("AI;F-O;64I(&5X<&5N<V4N/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D5.149)0TE!
M3"!#3TY615)324].($9%05154D4@3T8@0T].5D525$E"3$4@3D]415,@4$%9
M04),13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY"14Y%1DE#24%,($-/
M3E9%4E-)3TX@1D5!5%5212!/1B!#3TY615)424),10T*3D]415,@4$%904),
M13PO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
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M(S,T.R`H)B,S-#M"0T8F(S,T.RDN(%=E(&UE87-U<F4@=&AE(&5S=&EM871E
M9"!F86ER('9A;'5E(&]F('1H92!"0T8@:6X@8VER8W5M<W1A;F-E<R!I;B!W
M:&EC:"!T:&4@8V]N=F5R<VEO;B!F96%T=7)E#0II<R!N;W0@<F5Q=6ER960@
M=&\@8F4@<V5P87)A=&5D(&9R;VT@=&AE(&AO<W0@:6YS=')U;65N="!A;F0@
M86-C;W5N=&5D(&9O<B!S97!A<F%T96QY+"!A;F0@<F5C;W)D('1H870@=F%L
M=64@:6X@=&AE(&-O;G-O;&ED871E9`T*9FEN86YC:6%L('-T871E;65N=',@
M87,@82!D:7-C;W5N="!F<F]M('1H92!F86-E(&%M;W5N="!O9B!T:&4@;F]T
M97,N(%-U8V@@9&ES8V]U;G1S(&%R92!A;6]R=&EZ960@=&\@:6YT97)E<W0@
M97AP96YS92!O=F5R('1H90T*=&5R;2!O9B!T:&4@;F]T97,N/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5'
M25-44D%424].(%!!64U%3E0@05)204Y'14U%3E13/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/E)%1TE35%)!5$E/3B!005E-14Y4($%24D%.1T5-14Y4
M4SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
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M87-O;F%B;'D@97-T:6UA=&5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%4T5!4D-(($%.1"!$159%3$]0
M345.5"!%6%!%3E-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY215-%
M05)#2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&EN
M8W5R<F5D(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<PT*9'5R
M:6YG('1H92!T:')E92!A;F0@<VEX(&UO;G1H('!E<FEO9',@96YD960@4V5P
M=&5M8F5R(#,P+"`R,#$T(&%N9"`R,#$S+"!W:&EC:"!A<F4@:6YC;'5D960@
M:6X@=F%R:6]U<R!O<&5R871I;F<@97AP96YS92!L:6YE#0II=&5M<R!I;B!T
M:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M
M96YT<R!O9B!O<&5R871I;VYS+B!/=7(@<F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT(&5X<&5N<V5S(&EN('1H;W-E('!E<FEO9',-"G=E<F4@87,@9F]L;&]W
M<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<B<^4V5P=&5M8F5R(#,P+#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^4V5P=&5M8F5R(#,P+#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/C(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`V."4G/E1H<F5E(&UO;G1H<R!E;F1E9#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/C(U,"PS.#@\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(Y,RPU.#`\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/E-I>"!M;VYT:',@96YD
M960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C8S-RPW,C,\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C8R-BPV,S@\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3T9&
M+4)!3$%.0T4@4TA%150@05)204Y'14U%3E13/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D]&1BU"04Q!3D-%(%-(1454($%24D%.1T5-14Y44SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@:&%V92!N;W0@96YT97)E
M9"!I;G1O(&%N>2!O9F8M8F%L86YC92!S:&5E=`T*87)R86YG96UE;G1S('1H
M870@:&%V92!O<B!A<F4@<F5A<V]N86)L>2!L:6ME;'D@=&\@:&%V92!A(&-U
M<G)E;G0@;W(@9G5T=7)E(&UA=&5R:6%L(&5F9F5C="!O;B!O=7(@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-)1TY)1DE#04Y4
M(%)%0T5.5"!!0T-/54Y424Y'(%!23TY/54Y#14U%3E13/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/E-)1TY)1DE#04Y4(%)%0T5.5"!!0T-/54Y424Y'
M(%!23TY/54Y#14U%3E13/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY-86YA9V5M96YT(&ES(&5V86QU871I;F<@<VEG;FEF:6-A;G0@<F5C96YT
M#0IA8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S('1H870@87)E(&YO="!Y970@
M969F96-T:79E(&9O<B!T:&4@0V]M<&%N>2P@:6YC;'5D:6YG('1H92!N97<@
M86-C;W5N=&EN9R!S=&%N9&%R9"!O;B!R979E;G5E(')E8V]G;FET:6]N+`T*
M05-5(#(P,30M,#D@*%1O<&EC(#8P-BDL(&%N9"!H87,@;F]T('EE="!C;VYC
M;'5D960@=VAE=&AE<B!A;GD@<W5C:"!P<F]N;W5N8V5M96YT<R!W:6QL(&AA
M=F4@82!S:6=N:69I8V%N="!E9F9E8W0@;VX@=&AE($-O;7!A;GDF(S$T-CMS
M#0IF=71U<F4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,RX@4U5-34%262!/1B!324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N
M=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
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M,C`Q-"!A;F0@,C`Q,SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY3:7@@36]N=&AS($5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9"<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!C96YT97(G/E-I>"!-;VYT:',@16YD960\+W`^#0H@
M("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G
M/E-E<'1E;6)E<B`S,"P@,C`Q,SPO<#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V."4G/E9E<W1I;F<@;V8@
M4W1O8VL@3W!T:6]N<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(V,"PV.#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG
M;CH@<FEG:'0G/C$R-"PR-#,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^26YC<F5M96YT86P@9F%I<B!V
M86QU92!O9B!O<'1I;VX@36]D:69I8V%T:6]N<SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M,2PY,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/E9E<W1I
M;F<@17AP96YS92!!<W-O8VEA=&5D('=I=&@@0T5/(%)E<W1R:6-T960@4W1O
M8VL@1W)A;G0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^-C0L-#0T/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#Y4;W1A;"!3=&]C:RU"
M87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H="<^,C8P+#8X,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H="<^,3DP+#8P,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/E=E:6=H=&5D(&%V97)A
M9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@)B,Q-3`[
M(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L92<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0G/C(T,RPT.30L.3$V/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0G/C$X,BPP,#0L,C(P/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^0F%S
M:6,@86YD(&1I;'5T960@;&]S<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT)SXH,"XP,#PO=&0^#0H@("`@/'1D/BD\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^*3PO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C
M,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^-"X@3D]415,@4$%9
M04),12`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1E8G0@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/DYO=&5S('!A>6%B;&4@8V]N
M<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q
M,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@,C`Q-#PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY-87)C:"`S,2P@,C`Q-#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/E!R:6YC:7!A;"!"86QA;F-E/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/D%C8W)U960@26YT97)E<W0\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^4')I;F-I<&%L
M($)A;&%N8V4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^06-C<G5E9"!);G1E<F5S=#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#,V)2<^,3(E($YO=&5S('!A>6%B;&4L('!A<W0@9'5E/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,3@U+#`P,#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,S8W+#8X-SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,3@U+#`P,#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H="<^,S4S+#@Q,SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^,3`E($YO=&4@<&%Y
M86)L92P@<&%S="!D=64\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^-2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-BPV,C4\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^-2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-BPS-S4\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@
M/'1D/D1I<F5C=&]R<R8C,30V.R!.;W1E*',I/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^,C`P+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^,30L-3$V/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#(W<'0G/E1O=&%L/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT)SXQ.3`L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT)SXS-S0L,S$R/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXS.3`L,#`P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXS-S0L-S`T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,3!P="<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S95\T
M.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92]7
M;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%24%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/C4N($-/3E9%4E1)0DQ%($Y/5$53(%!!64%"3$4@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY#;VYV97)T:6)L
M92!.;W1E<R!087EA8FQE(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&%T
M(%-E<'1E;6)E<@T*,S`L(#(P,30Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P
M,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^4')I;F-I<&%L/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97(G/E5N86UO<G1I>F5D(#QB<B`O/@T*1&ES8V]U
M;G0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^3F5T
M(#QB<B`O/@T*06UO=6YT/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97(G/D%C8W)U960@/&)R("\^#0I);G1E<F5S=#PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT
M.B`M.7!T)SY#;VYV97)T:6)L92!.;W1E<R!087EA8FQE("8C,34P.R!#=7)R
M96YT(%!O<G1I;VXZ/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`T-"4[('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^
M3V-T;V)E<B`F(S,X.R!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV97)T:6)L92!.
M;W1E<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@
M=&5X="UA;&EG;CH@<FEG:'0G/C4P+#`P,#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E
M>'0M86QI9VXZ(')I9VAT)SXU,"PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C(X+#4Y.#PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%
M144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X
M="UI;F1E;G0Z("TY<'0G/D%P<FEL(#(P,3`@,3`E($-O;G9E<G1I8FQE($YO
M=&4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-S4L,#`P/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXW-2PP,#`\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M,S4L,3@X/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y
M<'0[('1E>'0M:6YD96YT.B`M.7!T)SY*=6QY(&%N9"!!=6=U<W0@,C`Q,2`Q
M,"4@0V]N=F5R=&EB;&4@3F]T97,L('!A<W0@9'5E/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C(X,RPT,C$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C(X,RPT,C$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.38L-S(X/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*
M("`@(#QT9#Y,87<@1FER;2!.;W1E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT)SXW-2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^-S4L,#`P/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXY+#0W.3PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E
M;G0Z("TY<'0G/E1O=&%L("8C,34P.R!#;VYV97)T:6)L92!.;W1E<R!087EA
M8FQE("8C,34P.R!#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6%L:6=N.B!R:6=H="<^-#@S
M+#0R,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C0X,RPT,C(\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(R<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H="<^,38Y+#DY,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M
M:6YD96YT.B`M.7!T)SY#;VYV97)T:6)L92!.;W1E<R!087EA8FQE("8C,34P
M.R!.;VXM0W5R<F5N="!0;W)T:6]N.CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^
M06UE;F1E9"!A;F0@4F5S=&%T960@4V5R:65S($$@,3(E($-O;G9E<G1I8FQE
M($YO=&5S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(R-2PP,#`\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(R-2PP,#`\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^.2PP,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/E-E<'1E;6)E<B`R,#$P(#$R
M)2!#;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS,3<L
M,#<R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS,3<L
M,#<R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CDL-3$S/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D%P
M<FEL(#(P,3$@,3(E($-O;G9E<G1I8FQE($YO=&5S/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M-#0X+#0T.#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^-#0X+#0T.#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$S+#0U-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TY<'0G/E1O=&%L("8C,34P.R!#;VYV
M97)T:6)L92!.;W1E<R!087EA8FQE("8C,34P.R!.;VXM0W5R<F5N="!0;W)T
M:6]N/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,C)P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/CDY,"PU,C`\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(R<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE
M9G0Z(#(R<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P
M861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M86QI9VXZ(')I9VAT)SXY.3`L-3(P
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`R,G!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C,Q+#DV-SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`T-'!T.R!T97AT+6EN9&5N
M=#H@+3EP="<^5&]T86P@0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L93PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXQ+#0W,RPY-#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#0T<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE
M9G0Z(#0T<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#0T<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!P861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#0W
M,RPY-#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#0T<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,C`Q+#DV,#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@8V]N<VES=&5D
M(&]F('1H92!F;VQL;W=I;F<@870@36%R8V@@,S$L#0HR,#$T.CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E!R:6YC:7!A;#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY5;F%M;W)T:7IE
M9"`\8G(@+SX-"D1I<V-O=6YT/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/DYE="`\8G(@+SX-"D%M;W5N=#PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!8V-R=65D(#QB<B`O/@T*26YT
M97)E<W0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M.7!T.R!T97AT+6EN9&5N=#H@+3EP="<^0V]N=F5R=&EB;&4@3F]T97,@4&%Y
M86)L92`F(S$U,#L@0W5R<F5N="!0;W)T:6]N.CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#0E.R!P861D
M:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D%M96YD960@86YD
M(%)E<W1A=&5D(%-E<FEE<R!!(#$R)2!#;VYV97)T:6)L92!.;W1E<RP@<&%S
M="!D=64\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT
M)SXX.#4L,#`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$U,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G
M/C@X-2PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G
M/C4W-2PR-3`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T
M)SXR,#`X(#$P)2!#;VYV97)T:6)L92!.;W1E<RP@<&%S="!D=64\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C4L,#`P/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR-2PP,#`\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,3DL,38W/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T)SY/8W1O8F5R("8C,S@[
M($YO=F5M8F5R(#(P,#D@,3`E($-O;G9E<G1I8FQE($YO=&5S/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C4P+#`P,#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3`L,#`P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C(V+#`Y-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T)SY!<')I;"`R,#$P(#$P
M)2!#;VYV97)T:6)L92!.;W1E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/C<U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^-S4L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,Q+#0S.#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN
M9&5N=#H@+3EP="<^2G5L>2!A;F0@075G=7-T(#(P,3$@,3`E($-O;G9E<G1I
M8FQE($YO=&5S+"!P87-T(&1U93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXR-3<L-C4U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXR-3<L-C4U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDP+#(U-CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0^3&%W($9I<FT@3F]T93PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H="<^-S4L,#`P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C<U+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^-RPV,#0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M:6YD96YT.B`M.7!T)SY4
M;W1A;"`F(S$U,#L@0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L92`F(S$U,#L@
M0W5R<F5N="!0;W)T:6]N/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/C$L,S8W+#8U-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@
M,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I
M;F<M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L,S8W+#8U-3PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#H@,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXW-#DL.#$R/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z
M("TY<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z
M("TY<'0G/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q-3`[($YO;BU#
M=7)R96YT(%!O<G1I;VXZ/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD
M96YT.B`M.7!T)SY397!T96UB97(@,C`Q,"`Q,B4@0V]N=F5R=&EB;&4@3F]T
M97,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S$W
M+#`W,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S$W
M+#`W,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXS-2PP,S0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/D%P
M<FEL(#(P,3$@,3(E($-O;G9E<G1I8FQE($YO=&5S/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0T."PT-#@\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0T."PT-#@\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,3(L,3$W/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#EP=#L@=&5X="UI;F1E;G0Z("TY<'0G/E-E<'1E;6)E<B`R,#$Q(#$R
M)2!#;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#EP=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C$P+#DS,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@.7!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`Y
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M
M;&5F=#H@.7!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3`L.3,Q/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`Y<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3EP="<^5&]T
M86P@)B,Q-3`[($-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@)B,Q-3`[($YO
M;BU#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,G!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^-S<V+#0U,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@
M,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,C)P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I
M;F<M;&5F=#H@,C)P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C<W-BPT-3$\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#(R<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^-#<L,34Q/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#0T<'0[('1E>'0M:6YD96YT.B`M
M.7!T)SY4;W1A;"!#;VYV97)T:6)L92!.;W1E<R!087EA8FQE/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A
M9&1I;F<M;&5F=#H@-#1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(L,30T+#$P
M-CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@-#1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@-#1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@-#1P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@-#1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C(L,30T+#$P-CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@-#1P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT)SXW.38L.38S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3!P="<^
M)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3V-T;V)E<B!A;F0@3F]V96UB97(@,C`P.2`Q,"4@0V]N
M=F5R=&EB;&4@3F]T97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C=&EV:71Y(&EN($-O;G9E<G1I8FQE($YO=&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/E1H92!F;VQL;W=I;F<@=&%B;&4@<VAO=W,@=&AE(&-O;G9E<G-I;VYS
M(&EN=&\@<')I;F-I<&%L(&]F('1H92!/8W1O8F5R#0IA;F0@3F]V96UB97(@
M,C`P.2`Q,"4@0V]N=F5R=&EB;&4@3F]T97,@8GD@9FES8V%L('EE87(Z/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!C;VQS<&%N/3-$-2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^06-T:79I
M='D@:6X@3V-T;V)E<B`F(S,X.R!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV97)T
M:6)L92!.;W1E<SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#@T)2<^26YI=&EA;"!P<FEN8VEP86P@
M8F%L86YC93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG
M:'0G/C0U,"PR-3`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M/D-O;G9E<G-I;VYS(&1U<FEN9R!T:&4@9FES8V%L('EE87(@96YD960@36%R
M8V@@,S$L(#(P,3`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^*#<P+#`P,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T5%145%12<^#0H@("`@/'1D/D-O;G9E<G-I;VYS(&1U<FEN9R!T
M:&4@9FES8V%L('EE87(@96YD960@36%R8V@@,S$L(#(P,3$\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#$W-2PP,#`\+W1D/@T*
M("`@(#QT9#XI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-
M87)C:"`S,2P@,C`Q,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXH,3,P+#(U,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/D-O;G9E<G-I;VYS(&1U<FEN
M9R!T:&4@9FES8V%L('EE87(@96YD960@36%R8V@@,S$L(#(P,3,\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#(U+#`P,#PO=&0^
M#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D
M($UA<F-H(#,Q+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^0V]N=F5R<VEO;G,@
M9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^
M0F%L86YC92!A<R!O9B!397!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0G/C4P+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C
M,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-E<'1E;6)E<B`R,#$P(#$R)2!#;VYV97)T:6)L92!.;W1E
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-T:79I='D@:6X@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^5&AE(&9O;&QO
M=VEN9R!T86)L92!S:&]W<R!T:&4@86-T:79I='D@:6X@=&AE(%-E<'1E;6)E
M<B`R,#$P(#$P)0T*0V]N=F5R=&EB;&4@3F]T97,@8GD@9FES8V%L('EE87(Z
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$-2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^06-T
M:79I='D@:6X@=&AE(%-E<'1E;6)E<B`R,#$P(#$P)2!#;VYV97)T:6)L92!.
M;W1E<SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#@T)2<^26YI=&EA;"!P<FEN8VEP86P@8F%L86YC
M93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C<T
M,RPV,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D-O;G9E
M<G-I;VYS(&1U<FEN9R!T:&4@9FES8V%L('EE87(@96YD960@36%R8V@@,S$L
M(#(P,3(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M*#0P-2PU,#`\+W1D/@T*("`@(#QT9#XI/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I
M<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$S/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@S,"PP,#`\+W1D/@T*("`@(#QT
M9#XI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^0V]N
M=F5R<VEO;G,@9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-87)C:"`S
M,2P@,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXH,C4L,#`P/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C145%145%)SX-"B`@("`\=&0^26YC<F5A<V4@:6X@<')I;F-I<&%L(&)A
M;&%N8V4@9'5E('1O(#$R)2!E>'1E;G-I;VX@9F5E/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,S+#DW,CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M/D-O;G9E<G-I;VYS(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0^0F%L86YC92!A<R!O9B!397!T96UB97(@,S`L(#(P
M,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C,Q-RPP-S(\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G
M/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-E<'1E;6)E<B`R,#$Q(#$R)2!#;VYV97)T:6)L92!.;W1E<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-T
M:79I='D@:6X@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^5&AE(&9O;&QO=VEN
M9R!T86)L92!S:&]W<R!T:&4@8V]N=F5R<VEO;G,@:6YT;R!P<FEN8VEP86P@
M;V8@=&AE(%-E<'1E;6)E<@T*,C`Q,2!#;VYV97)T:6)L92!.;W1E<R!B>2!F
M:7-C86P@>65A<CH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O;'-P86X],T0U('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY!8W1I=FET>2!I;B!T:&4@4V5P=&5M8F5R(#(P,3$@0V]N=F5R
M=&EB;&4@3F]T97,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X-"4G/DEN:71I86P@<')I;F-I<&%L
M(&)A;&%N8V4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT)SXR-3,L-S8P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D($UA
M<F-H(#,Q+"`R,#$R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B@Q-2PP,#`\+W1D/@T*("`@(#QT9#XI/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9#Y#;VYV97)S:6]N<R!D=7)I;F<@
M=&AE(&9I<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$S/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@V,"PP,#`\+W1D/@T*
M("`@(#QT9#XI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-
M87)C:"`S,2P@,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXH,38Y+#`P,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/DEN8W)E87-E(&EN('!R:6YC
M:7!A;"!B86QA;F-E(&1U92!T;R!E>'1E;G-I;VX@9F5E/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$L,3<Q/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B`S,"P@,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#$P+#DS
M,3PO=&0^#0H@("`@/'1D/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%
M12<^#0H@("`@/'1D/D)A;&%N8V4@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`Q,'!T)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C@N($]4
M2$52($-54E)%3E0@3$E!0DE,251)15,@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!,:6%B
M:6QI=&EE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R($-U<G)E;G0@3&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^3W1H97(@8W5R<F5N="!L:6%B:6QI=&EE<R!W97)E
M(&-O;7!R:7-E9"!O9B!T:&4@9F]L;&]W:6YG(&ET96US.CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY397!T
M96UB97(@,S`L/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R)SY-87)C:"`S,2P\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXR,#$T
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/C(P,30\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%
M145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V."4G/D%C8W)U960@
M:6YT97)E<W0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT)SXU-S`L-S0Q/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT)SXQ+#$V-2PS,S4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D/D%C8W)U960@;&5G86P@9F5E<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXQ-SDL-#8U/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$W.2PT
M-C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D/D%C8W)U960@;&EQ=6ED871E9"!D86UA9V5S
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,V,BPX
M,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,S8R+#@P,#PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D]T:&5R
M(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C$P
M,RPU.3@\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$T-RPW-S0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D/E1O=&%L(&]T:&5R(&-U<G)E
M;G0@;&EA8FEL:71I97,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$L,C$V
M+#8P-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H="<^,2PX-34L,S<T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3!P="<^)B,Q-C`[
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A
M7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5(2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXY+B!&04E2(%9!3%5%($U%
M05-54D5-14Y44R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@1&ES8VQO<W5R97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!M96%S=7)E;65N=',@8F%S960@;VX@=&AE
M('9A;'5A=&EO;B!T96-H;FEQ=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^3W5R(&9A:7(@=F%L=64@;65A
M<W5R96UE;G1S(&%T('1H92!-87)C:"`S,2P@,C`Q-"!R97!O<G1I;F<@9&%T
M90T*87)E(&-L87-S:69I960@8F%S960@;VX@=&AE('9A;'5A=&EO;B!T96-H
M;FEQ=64@;&5V96P@;F]T960@:6X@=&AE('1A8FQE(&)E;&]W.CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M)SY$97-C<FEP=&EO;CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY-87)C:"`S,2P@/&)R
M("\^#0HR,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97(G/E%U;W1E9"!0<FEC97,@/&)R("\^#0II;B!!8W1I=F4@36%R:V5T<R!F
M;W(@/&)R("\^#0HH3&5V96P@,2D\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^4VEG;FEF:6-A;G0@3W1H97(@3V)S97)V86)L92`\
M8G(@+SX-"BA,979E;"`R*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SY3:6=N:69I8V%N="`\8G(@+SX-"E5N;V)S97)V86)L92`\
M8G(@+SX-"BA,979E;"`S*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#,V)2<^1&5R:79A=&EV92!,:6%B:6QI=&EE<SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0G/C$P+#8W.2PP-C<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,3,E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ,"PV-SDL,#8W/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#Y4;W1A;"!!<W-E=',\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$P+#8W
M.2PP-C<\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ,"PV-SDL,#8W/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P(#`@,3!P="<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@=V5I9VAT960@
M879E<F%G92!A<W-U;7!T:6]N<R!U<V5D('1O(&5S=&EM871E('1H92!F86ER
M('9A;'5E(&EN9F]R;6%T:6]N('5T:6QI>FEN9R!T:&4@0FEN;VUI86P@3&%T
M=&EC92!O<'1I;VX@<')I8VEN9R!M;V1E;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^5&AE(&9O;&QO=VEN9R!O=71L
M:6YE<R!T:&4-"G-I9VYI9FEC86YT('=E:6=H=&5D(&%V97)A9V4@87-S=6UP
M=&EO;G,@=7-E9"!T;R!E<W1I;6%T92!T:&4@9F%I<B!V86QU92!I;F9O<FUA
M=&EO;B!P<F5S96YT960L(&EN(&-O;FYE8W1I;VX@=VET:"!O=7(@=V%R<F%N
M=`T*86YD(&5M8F5D9&5D(&-O;G9E<G-I;VX@;W!T:6]N(&1E<FEV871I=F4@
M:6YS=')U;65N=',@=71I;&EZ:6YG('1H92!":6YO;6EA;"!,871T:6-E(&]P
M=&EO;B!P<FEC:6YG(&UO9&5L.CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T
M:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E-I>"!-;VYT:',@16YD960@4V5P
M=&5M8F5R(#,P+"`R,#$S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-S0E)SY2:7-K(&9R964@:6YT
M97)E<W0@<F%T93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(U)3L@=&5X
M="UA;&EG;CH@8V5N=&5R)SXP+C`R)2`M(#`N-C(E/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^079E<F%G92!E>'!E8W1E9"!L:69E
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SXP+C(U("8C,34P.R`S('EE87)S/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9#Y%>'!E8W1E9"!V
M;VQA=&EL:71Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SXW."XY)2`M(#$P-"XU)3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D5X<&5C=&5D
M(&1I=FED96YD<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^3F]N93PO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C,38P.SPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@8VAA;F=E<R!I;B!T:&4@9F%I<B!V86QU92!O9B!O
M=7(@3&5V96P@,R!F:6YA;F-I86P@:6YS=')U;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^5&AE('1A
M8FQE(&)E;&]W('-E=',@9F]R=&@@82!S=6UM87)Y(&]F(&-H86YG97,@:6X@
M=&AE(&9A:7(@=F%L=64-"F]F(&]U<B!,979E;"`S(&9I;F%N8VEA;"!I;G-T
M<G5M96YT<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P
M+"`R,#$T.B`F(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P
M)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/D%P
M<FEL(#$L(#QB<B`O/@T*,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SY296-O<F1E9"!.97<@1&5R:79A=&EV92`\8G(@+SX-
M"DQI86)I;&ET:65S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97(G/D-H86YG92!I;B!E<W1I;6%T960@9F%I<B!V86QU92!R96-O9VYI
M>F5D(&EN(')E<W5L=',@;V8@;W!E<F%T:6]N<SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY296-L87-S:69I8V%T:6]N(#QB<B`O
M/@T*;V8@1&5R:79A=&EV92`\8G(@+SX-"DQI86)I;&ET>2!T;R!086ED(#QB
M<B`O/@T*:6X@8V%P:71A;#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SY397!T96UB97(@,S`L(#QB<B`O/@T*,C`Q-#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,"4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@
M(#QT9#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXQ,"PV-SDL,#8W/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#$P+#8W.2PP-C<\+W1D/@T*
M("`@(#QT9#XI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^5&AE('1A8FQE(&)E;&]W
M('-E=',@9F]R=&@@82!S=6UM87)Y(&]F(&-H86YG97,@:6X@=&AE(&9A:7(@
M=F%L=64-"F]F(&]U<B!,979E;"`S(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!F
M;W(@=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S.CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SY#:&%N9V4@:6X\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/E)E8VQA<W-I
M9FEC871I;VX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^97-T:6UA=&5D
M(&9A:7(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97(G/F]F($1E<FEV871I=F4\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,CXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^4F5C;W)D960\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/G9A;'5E
M(')E8V]G;FEZ960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97(G/DQI86)I;&ET>2!T;SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY!
M<')I;"`Q+#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<B<^3F5W($1E<FEV871I=F4\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/FEN(')E<W5L
M=',\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97(G/E!A:60@:6X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SXR,#$S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97(G/DQI86)I;&ET:65S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/F]F(&]P97)A=&EO;G,\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^8V%P:71A;#PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXR,#$S/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#,P)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UI;F1E;G0Z("TQ,7!T)SY$
M97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXS+#4X."PR,SD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,BPS.#(L.#<W/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,3`V+#4P,3PO=&0^#0H@("`@/'1D
M/BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C4L.#8T+#8Q
M-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"`P(#$P<'0G/B8C,38P.SPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X7S5E,V5?
M-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W,F4O
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T%!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SXQ,"X@4U1/0TL@0T]-4$5.4T%424].("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T
M<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&]N96YT<R!O
M9B!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS97,@<F5L871I;F<@
M=&\@<VAA<F5S(&%N9"!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
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M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,30@86YD(#(P,3,N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G
M/E1H<F5E($UO;G1H<R!%;F1E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^5&AR964@36]N=&AS($5N9&5D
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R)SY3:7@@36]N=&AS($5N9&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SY3:7@@36]N=&AS($5N
M9&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^4V5P=&5M8F5R(#,P+"`R,#$T/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@
M,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY3
M97!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#,V)2<^5F5S=&EN9R!O9B!S=&]C:R!O<'1I;VYS
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT
M)SXX.2PW.3,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R
M:6=H="<^-S,L.#4V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(V,"PV.#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT
M+6%L:6=N.B!R:6=H="<^,3(T+#(T,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%
M144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0[('1E
M>'0M:6YD96YT.B`M,3%P="<^26YC<F5M96YT86P@9F%I<B!V86QU92!O9B!O
M<'1I;VX@;6]D:69I8V%T:6]N<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.34W/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+#DQ-#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UI;F1E
M;G0Z("TQ,7!T)SY697-T:6YG(&5X<&5N<V4@87-S;V-I871E9"!W:71H($-%
M3R!R97-T<FEC=&5D('-T;V-K(&=R86YT/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M;&5F=#H@,3%P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('!A9&1I;F<M
M;&5F=#H@,3%P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXV-"PT-#0\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P=#L@=&5X="UI;F1E
M;G0Z("TQ,7!T)SY4;W1A;"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP
M96YS93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXX.2PW.3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#$Q<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXW-"PX,3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE
M9G0Z(#$Q<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR-C`L-C@P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`Q,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0G/C$Y,"PV,#$\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q<'0[('1E>'0M:6YD96YT.B`M,3%P
M="<^5&]T86P@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:6YC
M;'5D960@:6X@;F5T(&QO<W,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL969T.B`Q,7!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^.#DL-SDS/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL
M969T.B`Q,7!T.R!T97AT+6%L:6=N.B!R:6=H="<^-S,L.#4V/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`Q,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@<&%D9&EN9RUL969T.B`Q,7!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C8P
M+#8X,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXQ.3`L-C`Q/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%
M)SX-"B`@("`\=&0^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9R`F(S$U,#L@8F%S:6,@86YD(&1I;'5T960\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,C4Y+#,V.2PY,3$\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M="<^,3@W+#8T,RPU.#(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^,C0S+#0Y-"PY,38\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,3@R+#`P
M-"PR,C`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$Q
M<'0[('1E>'0M:6YD96YT.B`M,3%P="<^0F%S:6,@86YD(&1I;'5T960@;&]S
M<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,3%P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^*3PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@
M,3%P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@("`\=&0^
M*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3%P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M
M;&5F=#H@,3%P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`P/"]T9#X-"B`@
M("`\=&0^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,3%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT)SXH,"XP,#PO=&0^#0H@("`@/'1D/BD\+W1D/CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SXF(S$V
M,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&%S<W5M<'1I;VYS('5S960@=&\@
M97-T:6UA=&4@=&AE(&9A:7(@=F%L=64@:6YF;W)M871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@
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M('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#HF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`W-"4G/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C4E.R!T97AT+6%L:6=N.B!C96YT
M97(G/C(N-B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/C$P
M('EE87)S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SXY,"XR
M,R4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y%>'!E
M8W1E9"!D:79I9&5N9',\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/DYO;F4\+W1D/CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY4:&4@9F]L;&]W:6YG(&]U
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M+"!A;F0@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`W-"4G/E)I<VL@9G)E92!I;G1E<F5S="!R
M871E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C4E.R!T97AT+6%L:6=N
M.B!C96YT97(G/C`N,S@E("T@,BXU,"4\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/@T*("`@(#QT9#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97(G/C,@>65A<G,@+2`Q,"!Y96%R<SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^17AP96-T960@=F]L871I;&ET
M>3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<B<^.30N-B4@+2`Q,#(N-R4\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y%>'!E8W1E9"!D:79I9&5N
M9',\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97(G/DYO;F4\+W1D/CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SX\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/D]P=&EO;G,@;W5T<W1A;F1I;F<@=&AA="!H879E
M('9E<W1E9"!A;F0@87)E(&5X<&5C=&5D('1O('9E<W0@87,-"F]F(%-E<'1E
M;6)E<B`S,"P@,C`Q-"!A<F4@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY.=6UB97(@;V8@3W!T:6]N<SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97(G/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O
M;G1R86-T=6%L(%1E<FT@:6X@665A<G,\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)2<^5F5S=&5D/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXR-"PR.30L
M,C(W/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXP+C(V
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C,N
M.38\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D5X<&5C=&5D
M('1O('9E<W0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C0L-S$Q+#@Q,3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^,"XQ-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXY+C$U/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#`N,C5I;B<^5&]T86P\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#`N
M,C5I;B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL969T.B`P+C(U
M:6X[('1E>'0M86QI9VXZ(')I9VAT)SXR.2PP,#8L,#,X/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`P+C(U:6XG/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#H@,"XR-6EN)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#`N,C5I;CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,"XR-6EN)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,3!P="<^)B,Q-C`[/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@;W!T:6]N(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/D$@<W5M;6%R>2!O9B!S
M=&]C:R!O<'1I;VX@86-T:79I='D@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<@T*,S`L(#(P,30@:7,@<')E<V5N=&5D(&)E;&]W.CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/DYU;6)E
M<B!O9B!/<'1I;VYS/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SX\8CY286YG92!O9CPO8CX\8G(@+SX-"CQB/D5X97)C:7-E
M(%!R:6-E/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SX\8CY796EG:'1E9"!!=F5R86=E(#PO8CX\8G(@+SX-"CQB/D5X97)C
M:7-E(%!R:6-E/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#4R)2<^4W1O8VL@;W!T:6]N<R!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@
M,C`Q-#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R
M:6=H="<^,C8L,3,S+#0P-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M
M86QI9VXZ(')I9VAT)SXD,"XP-S8@+2`D,"XT,3PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E
M.R!T97AT+6%L:6=N.B!R:6=H="<^,"XR-3PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0^17AE<F-I<V5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9#Y'<F%N=&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C(L.3<R+#8S,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C$Y/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP
M+C$Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0^0V%N8V5L;&5D+T5X<&ER960\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B@Q,#`L,#`P/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^,"XQ.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H="<^,"XQ.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^4W1O8VL@
M;W!T:6]N<R!O=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L(#(P,30\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C(Y+#`P-BPP,S@\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B0P+C`W-B`M("0P+C0Q/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,"XR-#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D/E-T;V-K(&]P=&EO;G,@97AE<F-I<V%B;&4@870@4V5P=&5M
M8F5R(#,P+"`R,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(T
M+#(Y-"PR,C<\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H="<^)#`N,#<V("T@)#`N-#$\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C`N,C8\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`Q,'!T)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/C$Q+B!705)204Y44R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F4@26YS=')U
M;65N=',@86YD($AE9&=I;F<@06-T:79I=&EE<R!$:7-C;&]S=7)E(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET>2!E>&5R8VES86)L92!A
M;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^02!S=6UM87)Y(&]F('=A<G)A;G0@86-T
M:79I='D@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<@T*
M,S`L(#(P,30@:7,@<')E<V5N=&5D(&)E;&]W.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/D%M;W5N=#PO8CX\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^/&(^4F%N9V4@;V8\+V(^/&)R("\^#0H\8CY%
M>&5R8VES92!0<FEC93PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^5V5I9VAT
M960@079E<F%G93PO8CX\8G(@+SX-"CQB/D5X97)C:7-E(%!R:6-E/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)2<^5V%R<F%N=',@
M;W5T<W1A;F1I;F<@870@36%R8V@@,S$L(#(P,30\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C<P+#<P.2PT-S4\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@8V5N=&5R)SXD
M,"XP-#(@+2`D,"XR-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG
M;CH@<FEG:'0G/C`N,3,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D/D5X97)C:7-E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXH,BPQ-C8L,3`T/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<B<^)#`N,#@V("8C,34P.R`D,"XQ,CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,"XQ,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^27-S=65D
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$U+#,W
M-2PV,30\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G
M/B0P+C`T,B`M("0P+C(T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXP+C`W/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^0V%N8V5L;&5D+T5X<&ER960\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B@Q+#$S-BPS-C0\+W1D/@T*("`@(#QT9#XI
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SXD,"XQ,SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9"<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/C`N
M,3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D/E=A<G)A;G1S(&]U='-T86YD:6YG(&%T(%-E
M<'1E;6)E<B`S,"P@,C`Q-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^.#(L-S@R
M+#8R,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^
M)#`N,#0R("T@)#`N,C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXP+C$P/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0^5V%R<F%N=',@97AE<F-I<V%B;&4@870@4V5P=&5M8F5R(#,P+"`R
M,#$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C@R+#<X,BPV,C$\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B0P+C`T
M,B`M("0P+C(U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXP+C$P/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P(#`@,3!P="<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G
M92!A<W-U;7!T:6]N<R!U<V5D('1O(&5S=&EM871E('1H92!F86ER('9A;'5E
M+"!W:71H(')E<W!E8W0@=&\@=V%R<F%N=',@=71I;&EZ:6YG('1H92!":6YO
M;6EA;"!,871T:6-E(&]P=&EO;B!P<FEC:6YG(&UO9&5L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/E1H92!F
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M=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q-#H\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`W-"4G/E)I<VL@9G)E92!I;G1E<F5S="!R871E
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C4E.R!T97AT+6%L:6=N.B!C
M96YT97(G/C`N-SDE("T@,BXR.24F(S$V,#LF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4F(S$V,#LF(S$V,#LF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97(G/C4@>65A<G,@)B,Q-3`[(#<@>65A<G,\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^
M#0H@("`@/'1D/D5X<&5C=&5D('9O;&%T:6QI='DF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/CDP+C$E("T@.34N
M."4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/@T*("`@(#QT9#Y%>'!E8W1E9"!D:79I9&5N9',F(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97(G/DYO;F4\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/C$T+B!314=-14Y44R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E9VUE;G0@
M4F5P;W)T:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-E9VUE;G0@<F5P;W)T:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
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M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E-I>"!-;VYT:',@16YD
M960@4V5P=&5M8F5R(#,P+#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/C(P,30\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^,C`Q,SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@
M("`\=&0^4F5V96YU97,Z/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E.R!P861D:6YG+6QE9G0Z(#(P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^065T:&QO;CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C4S,"PS-S$\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C@T,"PT.#,\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5323PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG
M+6QE9G0Z(#(P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#(P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`S,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G
M/E1O=&%L(%)E=F5N=65S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C4S,"PS-S$\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^.#0P+#0X,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#Y/<&5R871I;F<@3&]S
M<V5S.CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P
M="<^065T:&QO;CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M*#$L,CDT+#0U,SPO=&0^#0H@("`@/'1D/BD\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B@Q+#`Q,RPU.3(\+W1D/@T*("`@(#QT9#XI/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5323PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-#0U
M+#8W-#PO=&0^#0H@("`@/'1D/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#(P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M:6YD96YT
M.B`M,3!P="<^5&]T86P@3W!E<F%T:6YG($QO<W,\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL
M969T.B`S,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L-S<S+#(P,#PO=&0^
M#0H@("`@/'1D/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#,P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L,#$S+#4Y,CPO=&0^#0H@("`@/'1D
M/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0^3F5T
M($QO<W-E<SH\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UI;F1E;G0Z("TQ
M,'!T)SY!971H;&]N/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXH-"PR,#(L.#<S/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^*#,L-C4S+#$V.#PO=&0^#0H@("`@/'1D/BD\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%
M4TD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M*#,U-BPU,SD\+W1D/@T*("`@(#QT9#XI/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`R,'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T)SY.970@3&]S<R!"969O<F4@3F]N+4-O;G1R;VQL:6YG($EN
M=&5R97-T<SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXH-"PU.3(L-#@U/"]T9#X-"B`@("`\=&0^*3PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXH
M,RPV-3,L,38X/"]T9#X-"B`@("`\=&0^*3PO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C145%145%)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9#Y#87-H.CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^065T:&QO;CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^-#<L.#8U/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX+#<U-#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY%4TD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^-#<X+#,R,CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#H@,S!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY4;W1A;"!#87-H
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C4R-BPQ.#<\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#,P<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^."PW-30\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0^5&]T86P@07-S971S.CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R
M,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D%E=&AL;VX\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/C0T,RPP,C<\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0Q,2PQ
M.3`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P
M=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%4TD\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`R
M,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-C0V+#(T,CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,C!P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T86P@
M07-S971S/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C$L,#@Y+#(V.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L92<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M)SXT,3$L,3DP/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/D-A<&ET86P@17AP96YD:71U<F5S
M.CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^
M065T:&QO;CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^15-)/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,C!P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,S!P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T)SY#87!I=&%L($5X<&5N9&ET=7)E<SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!P861D:6YG
M+6QE9G0Z(#,P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#,P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D
M/D1E<')E8VEA=&EO;B!A;F0@06UO<G1I>F%T:6]N.CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D%E=&AL;VX\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C@L.#@U/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT+#<R
M-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T
M.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5323PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXY+#<Y,3PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#,P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T86P@1&5P
M<F5C:6%T:6]N(&%N9"!!;6]R=&EZ871I;VX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@<&%D9&EN9RUL969T
M.B`S,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3@L-C<V/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`S,'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SXD/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0G/C0L-S(W/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D/DEN=&5R
M97-T($5X<&5N<V4Z/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C!P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T)SY!971H;&]N/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXQ-38L-SDY/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR,38L-3`R/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0G/D5323PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!P861D:6YG+6QE9G0Z(#(P<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$U,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(P<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#,P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&]T86P@26YT97)E<W0@17AP96YS
M93PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!P861D:6YG+6QE9G0Z(#,P<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ-38L-SDY/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`S,'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C(Q-BPU
M,#(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A
M7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$541T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C(N($Q)455)1$E462`H
M1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EQ=6ED:71Y1&5T86EL
M<T%B<W1R86-T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=O<FMI;F<@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@R+#0Y-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC
M:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Y+#,S-2PY,#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<T+#@S,BPU-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>2!R96-L87-S:69I
M960@:6YT;R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3`L-C<Y+#`V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3`V+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%1C1!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SXS+B!354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],
M24-)15,@*$1E=&%I;',@+2!3:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP
M96YS92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#@Y+#<Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-S0L.#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-C`L-C@P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.3`L-C`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG("T@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U.2PS-CDL.3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@W+#8T,RPU.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#,L-#DT+#DQ-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M,BPP,#0L,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!C;VUM;VX@
M<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F5S=&EN9R!O9B!3=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3=&]C:RU"
M87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#DL-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S,L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8P+#8X,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PR-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E
M;65N=&%L(&9A:7(@=F%L=64@;V8@;W!T:6]N(&UO9&EF:6-A=&EO;G,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG($5X
M<&5N<V4@07-S;V-I871E9"!W:71H($-%3R!297-T<FEC=&5D(%-T;V-K($=R
M86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-"PT
M-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M4D]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXS+B!354U-05)9($]&(%-)
M1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*$1E=&%I;',@3F%R<F%T
M:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O
M;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@=6YI;G-U<F5D(&%M;W5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-S8L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!O=&5N=&EA;&QY(&%N=&ED:6QU=&EV92!S:&%R97,@97AC;'5D960@
M9G)O;2!%4%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S.2PV
M-S(L.#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,W+#DS-2PU,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#$L,C(U+#,Y.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S."PR-SDL-#(T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R
M=&EZ871I;VX@;V8@9&5F97)R960@;V9F97)I;F<@8V]S=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L-3`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C4P+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,CDS+#4X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C,W+#<R,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C(V+#8S
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W
M-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C
M8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(
M2T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/C0N($Y/5$53(%!!64%"3$4@
M*$1E=&%I;',@+2!.;W1E<R!P87EA8FQE*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I
M<&%L($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3DP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,SDP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!);G1E<F5S="!O;B!N;W1E<R!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S0L,S$R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<T+#<P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^,3(E($YO=&5S(%!A>6%B;&4@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W)U960@26YT97)E<W0@;VX@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S8W+#8X-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,RPX,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$P)2!.;W1E
M('!A>6%B;&4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<FEN8VEP86P@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!);G1E<F5S="!O;B!N
M;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$:7)E8W1O<G,@3F]T97,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@26YT97)E<W0@;VX@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L
M-3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14]3044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^-"X@3D]415,@4$%904),
M12`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E(')E;&%T
M960@=&\@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q.2PY-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@0F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DP+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@
M26YT97)E<W0@;VX@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S<T+#,Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W-"PW,#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$R)2!.;W1E<R!087EA8FQE
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I;F-I<&%L($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($EN=&5R97-T(&]N(&YO=&5S
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-RPV
M.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-3,L.#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XQ,"4@3F]T92!P87EA8FQE(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&%L
M($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@26YT97)E<W0@;VX@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPV,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,W-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E
M<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&ER96-T;W)S($YO=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&%L($)A;&%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D($EN=&5R97-T(&]N(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#4Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?
M-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A
M,S<R92]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$52,T%)/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/C4N($-/3E9%4E1)0DQ%($Y/5$53(%!!
M64%"3$4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E
M<R!087EA8FQE("T@0W5R<F5N="!0;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0X,RPT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S8W+#8U-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YA;6]R=&EZ
M960@9&ES8V]U;G0@+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!087EA8FQE
M+"!N970@+2!#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0X,RPT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,V-RPV-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0@
M+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V.2PY.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW-#DL.#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!087EA8FQE
M("T@3F]N+4-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3DP+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<W-BPT-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO<G1I>F5D(&1I<V-O=6YT
M("T@3F]N+6-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4L(&YE="`M
M($YO;BU#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDY,"PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-S8L-#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T("T@;F]N
M+6-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$L.38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#<L,34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#;VYV97)T:6)L92!.;W1E<R!087EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0W,RPY-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#$T-"PQ,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(%5N86UO<G1I>F5D($1I<V-O=6YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@3F]T97,@4&%Y86)L92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0W,RPY-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#$T-"PQ,#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%C8W)U960@
M26YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,2PY
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW.38L.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/8W1O8F5R(&%N9"!.;W9E;6)E<B`R,#`Y(#$P)2!#;VYV
M97)T:6)L92!.;W1E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@+2!#=7)R
M96YT(%!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YA;6]R=&EZ960@9&ES8V]U;G0@+2!C=7)R96YT('!O
M<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!.;W1E<R!087EA8FQE+"!N970@+2!#=7)R96YT(%!O<G1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!I;G1E<F5S="`M(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L-3DX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L,#DW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<')I;"`R,#$P
M(#$P)2!#;VYV97)T:6)L92!.;W1E(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L
M92`M($-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;F%M;W)T:7IE9"!D:7-C;W5N="`M(&-U
M<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4L(&YE="`M($-U<G)E;G0@
M4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T("T@8W5R<F5N="!P;W)T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PQ.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PT,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DIU
M;'D@86YD($%U9W5S="`R,#$Q(#$P)2!#;VYV97)T:6)L92!.;W1E<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE($YO=&5S(%!A>6%B;&4@+2!#=7)R96YT(%!O<G1I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,RPT,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3<L-C4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F%M
M;W)T:7IE9"!D:7-C;W5N="`M(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A
M>6%B;&4L(&YE="`M($-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C@S+#0R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-RPV-34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E
M<W0@+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDV+#<R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDP+#(U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&%W($9I<FT@3F]T92!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M($YO=&5S(%!A>6%B;&4@+2!#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YA;6]R=&EZ960@
M9&ES8V]U;G0@+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!087EA8FQE+"!N
M970@+2!#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E<F5S="`M(&-U<G)E
M;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UE;F1E9"!A;F0@4F5S=&%T960@4V5R:65S($$@,3(E($-O
M;G9E<G1I8FQE(&YO=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L92`M($-U
M<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@X-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5N86UO<G1I>F5D(&1I<V-O=6YT("T@8W5R<F5N="!P;W)T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@3F]T97,@4&%Y86)L92P@;F5T("T@0W5R<F5N="!0;W)T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E
M9"!I;G1E<F5S="`M(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4W-2PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A
M>6%B;&4@+2!.;VXM0W5R<F5N="!0;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YA;6]R=&EZ960@9&ES8V]U;G0@
M+2!.;VXM8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L92P@;F5T("T@
M3F]N+4-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0@+2!N;VXM8W5R<F5N
M="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-E<'1E;6)E<B`R,#$P(#$R)2!#;VYV97)T:6)L92!.;W1E<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE($YO=&5S(%!A>6%B;&4@+2!.;VXM0W5R<F5N="!0;W)T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3<L,#<R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$W+#`W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M56YA;6]R=&EZ960@9&ES8V]U;G0@+2!.;VXM8W5R<F5N="!P;W)T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@
M3F]T97,@4&%Y86)L92P@;F5T("T@3F]N+4-U<G)E;G0@4&]R=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$W+#`W,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-RPP-S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@:6YT97)E<W0@+2!N;VXM8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#`S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07!R:6P@,C`Q
M,2`Q,B4@0V]N=F5R=&EB;&4@3F]T97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!087EA
M8FQE("T@3F]N+4-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#0X+#0T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0T."PT-#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO<G1I>F5D(&1I<V-O
M=6YT("T@3F]N+6-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4L(&YE
M="`M($YO;BU#=7)R96YT(%!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T."PT-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-#@L-#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T("T@
M;F]N+6-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L-#4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L,3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#`X(#$P)2!#;VYV97)T:6)L92!.;W1E
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4@+2!#=7)R96YT(%!O<G1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N86UO
M<G1I>F5D(&1I<V-O=6YT("T@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T97,@4&%Y
M86)L92P@;F5T("T@0W5R<F5N="!0;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T("T@8W5R
M<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3DL,38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y397!T96UB97(@,C`Q,2`Q,B4@0V]N=F5R=&EB;&4@3F]T97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!.;W1E<R!087EA8FQE("T@3F]N+4-U<G)E;G0@4&]R=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DS,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YA
M;6]R=&EZ960@9&ES8V]U;G0@+2!.;VXM8W5R<F5N="!P;W)T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T
M97,@4&%Y86)L92P@;F5T("T@3F]N+4-U<G)E;G0@4&]R=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DS,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E
M<F5S="`M(&YO;BUC=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%15)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SXU
M+B!#3TY615)424),12!.3U1%4R!005E!0DQ%("A$971A:6QS("T@06-T:79I
M='DI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^,C`P.2!#;VYV97)T:6)L
M92!.;W1E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$T/&)R/C(P,3`@0V]N=F5R=&EB;&4@3F]T97,@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CXR,#$Q($-O;G9E<G1I8FQE($YO=&5S(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L
M('!R:6YC:7!A;"!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L-#<S+#DT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,BPQ-#0L,3`V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-3`L,C4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-#,L-C`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-3,L-S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R
M(&5N9&5D($UA<F-H(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;G,@9'5R:6YG('1H92!F
M:7-C86P@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q,3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-S4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N<R!D
M=7)I;F<@=&AE(&9I<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S,"PR-3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`U+#4P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE(&9I<V-A;"!Y96%R
M(&5N9&5D($UA<F-H(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C`L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;G,@
M9'5R:6YG('1H92!F:7-C86P@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q-#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V.2PP
M,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-R96%S92!I;B!P<FEN8VEP86P@8F%L86YC92!D=64@=&\@,3(E
M(&5X=&5N<VEO;B!F964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,S+#DW,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N<R!D=7)I;F<@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3`L.3,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A<R!O9B!397!T
M96UB97(@,S`L(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2PT-S,L.30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+#$T-"PQ,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S$W+#`W,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W-&,W
M-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U
M,C=A,S<R92]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5'0D%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C4N($-/3E9%4E1)0DQ%($Y/5$53
M(%!!64%"3$4@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYV
M97)T:6)L92!.;W1E<R!087EA8FQE(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E
M;G-E(')E;&%T960@=&\@8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-RPS-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M871I;VX@;V8@9&5F97)R960@9FEN86YC92!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(Q+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P145+0D<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^-BX@15%52519(%1204Y304-424].4R`H1&5T86EL<R!.
M87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@<W5B<V-R:6)E9"P@<VAA<F5S
M(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3DR
M+#0T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R86YT<R!I<W-U960@=&\@86-C<F5D:71E9"!I;G9E<W1O<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Y-BPR,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<W5B<V-R:7!T:6]N(&%N9"!W87)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(P+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S
M=65D(&9O<B!S97)V:6-E<RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S4Y+#DU-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q.2PQ,C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E
M9"!F;W(@<V5R=FEC97,L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#DL,#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@L,C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@8F%L86YC92!O9B!N
M;W1E(%M-96UB97)=('P@2&]L9&5R($]N92!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!I;B!E>&-H
M86YG92!O9B!N;W1E+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PW,30L,C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&EN(&5X
M8VAA;F=E(&]F(&YO=&4L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!B86QA;F-E(&]F(&YO=&4@
M6TUE;6)E<ET@?"!(;VQD97(@5'=O(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&EN(&5X8VAA;F=E
M(&]F(&YO=&4L('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-3DQ+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!I;B!E>&-H86YG
M92!O9B!N;W1E+"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q-BPY-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&%C8W)U960@:6YT97)E<W0@
M6TUE;6)E<ET@?"!(;VQD97(@3VYE(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&EN(&5X8VAA;F=E
M(&]F(&YO=&4L('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L-C`S+#DV.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!I;B!E>&-H86YG
M92!O9B!N;W1E+"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,T,RPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-T<G5C='5R:6YG($9E92!;365M8F5R72!\($AO
M;&1E<B!/;F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!I<W-U960@:6X@97AC:&%N9V4@;V8@;F]T92P@<VAA
M<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S=')U8W1U<FEN9R!&964@6TUE;6)E<ET@?"!(;VQD97(@5'=O
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@:7-S=65D(&EN(&5X8VAA;F=E(&]F(&YO=&4L('-H87)E<R!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O
M=7(@:6YV97-T;W)S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@:7-S=65D+"!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C<S+#(S
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<W1R:6-T960@8V]M;6]N('-T;V-K(&ES<W5E9"P@86UO=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3DL-#<T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&AR964@
M:6YV97-T;W)S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@:7-S=65D+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!I<W-U960L(&%M;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@86-Q=6ER
M960L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<T
M+#DX,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&%C<75I<F5D+"!A;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0X-RPT.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D($-O;6UO;B!3
M=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&ES<W5E9"!F;W(@<V5R=FEC97,L('-H87)E<R!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,"PS,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!I<W-U960@9F]R('-E<G9I8V5S+"!A;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!I;B!E>&-H
M86YG92!O9B!N;W1E+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#DS-RPU,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@:6X@97AC
M:&%N9V4@;V8@;F]T92P@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#@Q+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,D=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SXX
M+B!/5$A%4B!#55)214Y4($Q)04))3$E42453("A$971A:6QS*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/=&AE<B!,:6%B:6QI=&EE<RP@0W5R<F5N="!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5E9"!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U-S`L-S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$V-2PS,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&5G86P@
M9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Y+#0V-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M.2PT-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@;&EQ=6ED871E9"!D86UA9V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-C(L.#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8R+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@86-C
M<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`S+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T-RPW-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!C=7)R96YT(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C$V
M+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PX-34L,S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15)%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/C@N($]4
M2$52($-54E)%3E0@3$E!0DE,2519("A$971A:6QS($YA<G)A=&EV92D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]T:&5R($QI86)I;&ET:65S($1I<V-L;W-U<F4@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!);G1E<F5S="!/;B!.;W1E<R!087EA8FQE(&EN
M(&1E9F%U;'0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#<Q
M+#`T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A
M7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T-#$N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4S1D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/CDN($9!25(@5D%,544@
M345!4U5214U%3E13("A$971A:6QS("T@1F%I<B!V86QU92D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL
M:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@
M0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E($QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PV-SDL,#8W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P+#8W.2PP-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!);G!U=',@3&5V96P@,2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U
M<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5R:79A=&EV92!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($EN<'5T
M<R!,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA
M8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I
M;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E($QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A
M:7(@5F%L=64@26YP=71S($QE=F5L(#,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@
M07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@
M86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I
M=F4@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PV-SDL,#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PX-C0L-C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU.#@L,C,Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#8W.2PP-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#8W
M-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT,U]A.&9A7S1C
M8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T-#(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"
M1T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/CDN($9!25(@5D%,544@345!
M4U5214U%3E0@*$1E=&%I;',@+2!!<W-U;7!T:6]N<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@6TUE;6)E<ET@
M?"!-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S=6UP=&EO;G,@86YD($UE
M=&AO9&]L;V=Y(&9O<B!!<W-E=',@86YD($QI86)I;&ET:65S/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@
M:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%V97)A9V4@97AP96-T960@;&EF93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S,@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."XY,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S(%M-96UB97)=('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<W5M
M<'1I;VYS(&%N9"!-971H;V1O;&]G>2!F;W(@07-S971S(&%N9"!,:6%B:6QI
M=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N-C(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#0N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER(%9A;'5E($EN<'5T<R!,979E;"`S(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M5F%L=64@07-S=6UP=&EO;G,@86YD($UE=&AO9&]L;V=Y(&9O<B!!<W-E=',@
M86YD($QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14Y004,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^.2X@1D%)4B!604Q512!-14%355)%345.5"`H1&5T86EL<R`M($QE
M=F5L(#,I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#8W.2PP-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S:69I
M8V%T:6]N(&]F(&1E<FEV871I=F4@;&EA8FEL:71Y('1O('!A:60@:6X@8V%P
M:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-C<Y+#`V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P-BPU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64@26YP=71S($QE=F5L(#,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PV-SDL,#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPU.#@L,C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296-O<F1E9"!N97<@9&5R:79A=&EV92!L
M:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-H86YG92!I;B!E<W1I;6%T960@9F%I<B!V86QU92!R96-O9VYI>F5D(&EN
M(')E<W5L=',@;V8@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S@R+#@W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;&%S<VEF:6-A=&EO;B!O9B!D97)I
M=F%T:79E(&QI86)I;&ET>2!T;R!P86ED(&EN(&-A<&ET86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#8W.2PP-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#8L-3`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I
M=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4L.#8T+#8Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R
M-V$S-S)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X
M7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T
M-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5(04%'/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/C$P+B!35$]#2R!#3TU014Y3051)3TX@*$1E=&%I;',@+2!3:&%R92UB87-E
M9"!C;VUP96YS871I;VXI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3=&]C
M:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X.2PW.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<T+#@Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8P+#8X,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DP
M+#8P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@
M:6YC;'5D960@:6X@;F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@Y+#<Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<T+#@Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(V,"PV.#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`L-C`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A
M=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG("T@
M8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U.2PS-CDL.3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3@W+#8T,RPU.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#,L-#DT+#DQ-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,BPP,#0L
M,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!C;VUM;VX@<VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5F5S=&EN9R!O9B!3=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#DL-SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S,L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8P+#8X,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PR-#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E;65N=&%L
M(&9A:7(@=F%L=64@;V8@;W!T:6]N(&UO9&EF:6-A=&EO;G,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3$T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG($5X<&5N<V4@
M07-S;V-I871E9"!W:71H($-%3R!297-T<FEC=&5D(%-T;V-K($=R86YT(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-"PT-#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C-S8X
M7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R90T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W
M83,W,F4O5V]R:W-H965T<R]3:&5E=#0U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4$E!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXQ,"X@4U1/0TL@0T]-4$5.4T%424].
M("A$971A:6QS("T@07-S=6UP=&EO;G,I("A3=&]C:R!/<'1I;VYS(%M-96UB
M97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP
M96-T960@=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`N,C,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN=&5R97-T
M(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,S@E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"XV,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED
M96YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU
M;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!=F5R86=E(&5X<&5C=&5D(&QI9F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R
M+C<P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@9&EV:61E;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%1T)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXQ,"X@
M4U1/0TL@0T]-4$5.4T%424].("A$971A:6QS("T@3W!T:6]N(&EN9F]R;6%T
M:6]N*2`H4W1O8VL@3W!T:6]N<R!;365M8F5R72P@55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!3:&%R97,L(%9E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C0L,CDT+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4L(%9E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A
M8W1U86P@5&5R;2!I;B!996%R<RP@5F5S=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,R!Y96%R<R`Q,2!M;VYT:',@,38@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!3:&%R97,L($5X<&5C=&5D('1O('9E<W0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L-S$Q+#@Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4L($5X<&5C=&5D('1O('9E<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A
M9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@:6X@665A<G,L($5X<&5C
M=&5D('1O('9E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Y
M('EE87)S(#$@;6]N=&@@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#`P-BPP,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPQ,S,L
M-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15=4044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,3`N(%-43T-+($-/35!%
M3E-!5$E/3B`H1&5T86EL<R`M($]P=&EO;B!A8W1I=FET>2D@*%-T;V-K($]P
M=&EO;G,@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%M;W5N=#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@;W!T:6]N<R!O=71S=&%N9&EN9R!B96=I;FYI;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(V+#$S,RPT,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-S(L-C,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC96QL960O
M17AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`P+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<@96YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP,#8L,#,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I
M;VYS(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-"PR.30L,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG($UI;FEM=6T@8F5G:6YN:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O
M<'1I;VYS(&]U='-T86YD:6YG(&%T($UA>&EM=6T@8F5G:6YN:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&QE
M9"]%>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<@36EN:6UU;2!E;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;G,@;W5T<W1A;F1I;F<@36%X:6UU;2!E;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!E
M>&5R8VES86)L92!-:6YI;75M(&5N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!E>&5R8VES86)L
M92!-87AI;75M(&5N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<@8F5G:6YN:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&QE
M9"]%>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<@96YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,C0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@
M97AE<F-I<V%B;&4@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%0T%!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXQ,"X@4U1/
M0TL@0T]-4$5.4T%424].("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H
M87)E+6)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C;VUP
M96YS871I;VX@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T.3<L-S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E('!E<FEO9"!F;W(@<F5C;V=N
M:71I;VX@;V8@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!C;W-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y96%R<R`R(&UO;G1H<R`Y
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=')I;G-I8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P149!04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^,3$N
M(%=!4E)!3E13("A$971A:6QS("T@5V%R<F%N="!A8W1I=FET>2D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,30\8G(^5V%R<F%N=',@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!/
M9B!787)R86YT($%C=&EV:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L-S`Y+#0W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<P+#<P.2PT-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(L,38V+#$P-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#,W-2PV,30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S($-A;F-E;&QE9"]%>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PQ,S8L,S8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@;W5T<W1A;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#<P.2PT-S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,BPW.#(L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!E>&5R8VES86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@R+#<X,BPV,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F%N9V4@
M;V8@17AE<F-I<V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9RP@8F5G:6YN
M:6YG("T@4F%N9V4@;V8@17AE<F-I<V4@4')I8V4@36EN:6UU;3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&]U
M='-T86YD:6YG+"!B96=I;FYI;F<@+2!286YG92!O9B!%>&5R8VES92!0<FEC
M92!-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!%>&5R8VES960@+2!286YG92!O9B!%>&5R8VES92!0
M<FEC92!-:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V5D("T@4F%N9V4@;V8@17AE<F-I
M<V4@4')I8V4@36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@27-S=65D("T@4F%N9V4@;V8@17AE<F-I
M<V4@4')I8V4@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($ES<W5E9"`M(%)A;F=E(&]F($5X97)C
M:7-E(%!R:6-E($UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($-A;F-E;&QE9"]%>'!I<F5D("T@4F%N
M9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!E;F1I;F<@
M+2!286YG92!O9B!%>&5R8VES92!0<FEC92!-:6YI;75M/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#0R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@
M;W5T<W1A;F1I;F<L(&5N9&EN9R`M(%)A;F=E(&]F($5X97)C:7-E(%!R:6-E
M($UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XR
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V%B;&4L(&5N9&EN9R`M(%)A;F=E
M(&]F($5X97)C:7-E(%!R:6-E($UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L92P@
M96YD:6YG("T@4F%N9V4@;V8@17AE<F-I<V4@4')I8V4@36%X:6UU;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XR-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY7
M96EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@;W5T<W1A
M;F1I;F<@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!%>&5R8VES960@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!)<W-U960@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@
M0V%N8V5L;&5D+T5X<&ER960@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@;W5T<W1A;F1I;F<@5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC92P@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I<V%B;&4@5V5I9VAT960@
M079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]D-C<T8S<V.%\U93-E7S0Y-#-?83AF85\T8V,S-3(W83,W
M,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#8W-&,W-CA?-64S
M95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E+U=O<FMS:&5E=',O4VAE970U,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15E.04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,3$N
M(%=!4E)!3E13("A$971A:6QS("T@07-S=6UP=&EO;G,I("A787)R86YT<R!;
M365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@
M<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW.24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V
M97)A9V4@97AP96-T960@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(%9O;&%T:6QI='D@4F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`N,3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K
M(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BXR.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%V97)A9V4@97AP96-T960@;&EF93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(%9O;&%T
M:6QI='D@4F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34N
M.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Y-044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,3(N($1!4E!!($-/3E12
M04-4($%.1"!214Q!5$5$(%)%5D5.544@4D5#3T=.251)3TX@*$1E=&%I;',@
M3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0X/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/DUI;&5S=&]N92`R+C0N,BXR
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^36EL95-T;VYE(#(N-"XR+C0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB
M<CY-:6QE<W1O;F4@33D@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CY-:6QE4W1O;F4@,BXS+C(N
M,B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$S/&)R/DUI;&53=&]N92`R+C,N,RXR(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\
M8G(^36EL97-T;VYE($TU(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C="!R979E;G5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0T-"PW,C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@P."PW,SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!/9B!-:6QE<W1O;F5S(%5N9&5R(%EE87(@3VYE($-O;G1R86-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R($]F($UI;&5S=&]N97,@06-H:65V960@56YD97(@665A<B!/;F4@0V]N
M=')A8W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2979E;G5E(%)E8V]G;FET:6]N+"!-:6QE<W1O;F4@365T:&]D+"!2979E
M;G5E(%)E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q.3<L,S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3DW+#,V,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DU+#4X,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`X+#<X
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C`X+#<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT
M,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+U-H965T-3(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5&2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXQ,RX@0T]-34E4
M345.5%,@04Y$($-/3E1)3D=%3D-)15,@*$1E=&%I;',@3F%R<F%T:79E*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V."PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%449!23X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SXQ-"X@4T5'345.5%,@*$1E=&%I;',I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#<Y+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-C0T+#@X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3,P+#,W,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#0P+#0X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<&5R871I;F<@;&]S<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V,#$L,3DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(R.2PW.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PW-S,L,C`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#$S+#4Y,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#@X+#$Y
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#,T.2PV-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-"PU.3(L-#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-C4S+#$V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(V+#$X-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S4T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(V+#$X
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L-S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PR-3`L,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#(W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X.2PR-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3$L,3DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.#DL
M,C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#$Q+#$Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-CDU+#$P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<&ET86P@97AP96YD:71U<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA
M=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X+#8W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#<Y.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q-BPU,#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^065T:&QO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,S`L,S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#0P+#0X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,CDT+#0U,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#`Q,RPU.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!L;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-"PR,#(L.#<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-C4S+#$V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L.#8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PW-30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPX-C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0T,RPP,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,3$L,3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0S+#`R-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q,2PQ.3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A
M;"!E>'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E
M<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U-BPW.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,38L-3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5322!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T-2PV-S0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,U-BPU,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-S@L,S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0W."PS,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0V+#(T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#8L,C0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87!I=&%L(&5X<&5N9&ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT
M97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#8W-&,W-CA?-64S95\T.30S7V$X9F%?-&-C,S4R-V$S-S)E#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0V-S1C-S8X7S5E,V5?-#DT
M,U]A.&9A7S1C8S,U,C=A,S<R92]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO
M9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB
M;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970T.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-3,N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V0V-S1C
C-S8X7S5E,V5?-#DT,U]A.&9A7S1C8S,U,C=A,S<R92TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. FAIR VALUE MEASUREMENT (Details - Level 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
        <td class="nump">$ 10,679,067<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity', window );">Reclassification of derivative liability to paid in capital</a></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="nump">106,501<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Inputs Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="nump">3,588,239<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Recorded new derivative liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Change in estimated fair value recognized in results of operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,382,877<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity', window );">Reclassification of derivative liability to paid in capital</a></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="nump">106,501<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 5,864,615<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226000-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35708913&amp;loc=d3e50896-113970<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>14. SEGMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment reporting</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables set forth certain information
regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented
in this Report:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Revenues:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 68%; padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">530,371</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">840,483</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Revenues</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">530,371</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">840,483</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Operating Losses:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(1,294,453</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(1,013,592</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">(445,674</td>
    <td>)</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Operating Loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">(1,773,200</td>
    <td>)</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(1,013,592</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Net Losses:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(4,202,873</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(3,653,168</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">(356,539</td>
    <td>)</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Net Loss Before Non-Controlling Interests</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">(4,592,485</td>
    <td>)</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(3,653,168</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cash:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">47,865</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">8,754</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">478,322</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Cash</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">526,187</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">8,754</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Total Assets:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">443,027</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">411,190</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">646,242</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">1,089,269</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">411,190</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Capital Expenditures:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Capital Expenditures</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Depreciation and Amortization:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">8,885</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4,727</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">9,791</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Depreciation and Amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">18,676</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">4,727</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Interest Expense:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">156,799</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">216,502</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Interest Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">156,799</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">216,502</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8721-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8813-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 22<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8736-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>11. WARRANTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of warrant activity exercisable and outstanding</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">A summary of warrant activity during the six months ended September
30, 2014 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Range of</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted Average</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Warrants outstanding at March 31, 2014</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">70,709,475</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">$0.042 - $0.25</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.13</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,166,104</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.086 &#150; $0.12</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.10</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Issued</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">15,375,614</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.24</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.07</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cancelled/Expired</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,136,364</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.13</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.13</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Warrants outstanding at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">82,782,621</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.25</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.10</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Warrants exercisable at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">82,782,621</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.25</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock', window );">Weighted average assumptions used to estimate the fair value, with respect to warrants utilizing the Binomial Lattice option pricing model</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice option pricing models
at, and during, the six months ended September 30, 2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.79% - 2.29%&#160;&#160;</td></tr>
<tr style="background-color: white">
    <td>Average expected life&#160;&#160;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">5 years &#150; 7 years</td></tr>
<tr style="background-color: #EEEEEE">
    <td>Expected volatility&#160;&#160;&#160;&#160;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">90.1% - 95.8%</td></tr>
<tr style="background-color: white">
    <td>Expected dividends&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average assumptions used to estimate the fair value, with respect to warrants utilizing the Binomial Lattice option pricing model</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WeightedAverageAssumptionsUsedToEstimateFairValueWithRespectToWarrantsUtilizingBinomialLatticeOptionPricingModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Details - Share-based compensation) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">$ 89,793<span></span></td>
        <td class="nump">$ 74,813<span></span></td>
        <td class="nump">$ 260,680<span></span></td>
        <td class="nump">$ 190,601<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_SharebasedCompensationExpenseIncludedInNetLoss', window );">Total share-based compensation expense included in net loss</a></td>
        <td class="nump">89,793<span></span></td>
        <td class="nump">74,813<span></span></td>
        <td class="nump">260,680<span></span></td>
        <td class="nump">190,601<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
        <td class="nump">259,369,911<span></span></td>
        <td class="nump">187,643,582<span></span></td>
        <td class="nump">243,494,916<span></span></td>
        <td class="nump">182,004,220<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted loss per common share</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vesting of Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">89,793<span></span></td>
        <td class="nump">73,856<span></span></td>
        <td class="nump">260,680<span></span></td>
        <td class="nump">124,243<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Incremental fair value of option modifications [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">957<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,914<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vesting Expense Associated with CEO Restricted Stock Grant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 64,444<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_SharebasedCompensationExpenseIncludedInNetLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total share-based compensation expense included in net loss</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_SharebasedCompensationExpenseIncludedInNetLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>2. LIQUIDITY (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LiquidityDetailsAbstract', window );"><strong>LiquidityDetailsAbstract</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WorkingCapital', window );">Working capital</a></td>
        <td class="num">$ (2,496,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(79,335,907)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(74,832,557)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity', window );">Derivative liability reclassified into equity</a></td>
        <td class="nump">$ 10,679,067<span></span></td>
        <td class="nump">$ 106,501<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LiquidityDetailsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_LiquidityDetailsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WorkingCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Working capital</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WorkingCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35708913&amp;loc=d3e50896-113970<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EF4AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">$ 89,793<span></span></td>
        <td class="nump">$ 74,813<span></span></td>
        <td class="nump">$ 260,680<span></span></td>
        <td class="nump">$ 190,601<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
        <td class="nump">259,369,911<span></span></td>
        <td class="nump">187,643,582<span></span></td>
        <td class="nump">243,494,916<span></span></td>
        <td class="nump">182,004,220<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted loss per common share</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vesting of Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">89,793<span></span></td>
        <td class="nump">73,856<span></span></td>
        <td class="nump">260,680<span></span></td>
        <td class="nump">124,243<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Incremental fair value of option modifications [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">957<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,914<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vesting Expense Associated with CEO Restricted Stock Grant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-Based Compensation Expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 64,444<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The summary of our significant accounting policies
presented below is designed to assist the reader in understanding our condensed consolidated financial statements. Such financial
statements and related notes are the representations of our management, who are responsible for their integrity and objectivity.
These accounting policies conform to GAAP in all material respects, and have been consistently applied in preparing the accompanying&#160;condensed
consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PRINCIPLES OF CONSOLIDATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial
statements include the accounts of Aethlon Medical, Inc. and its majority-owned and controlled subsidiary, ESI. All significant
intercompany balances and transactions have been eliminated in consolidation. The Company classifies the noncontrolling interests
in ESI as part of consolidated net loss in the six months ended September 30, 2014 and includes the accumulated amount of noncontrolling
interests as part of stockholders&#146; equity. During the fiscal year ended March 31, 2014, ESI raised capital in the amount
of $1,500,000 in exchange for the issuance of 300,000 shares of ESI common stock to ESI&#146;s investors, representing 20% of
ESI&#146;s issued and outstanding capital stock. As a result, Aethlon Medical, Inc.&#146;s ownership of ESI was reduced to 80%.
If a further change in Aethlon Medical Inc.&#146;s ownership of ESI results in loss of control and deconsolidation, any retained
ownership interest will be remeasured with the gain or loss reported in our statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The losses at ESI during the six months ended
September 30, 2014 reduced the noncontrolling interests on our consolidated balance sheet by $89,135 from $218,270 at March 31,
2014 to $129,135 at September 30, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">USE OF ESTIMATES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our condensed consolidated financial
statements in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among
others, realization of long-lived assets, estimating fair value associated with debt and equity transactions and valuation of deferred
tax assets. Actual results could differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CASH AND CASH EQUIVALENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards define &#34;cash and cash
equivalents&#34; as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates. For the purpose
of financial statement presentation, we consider all highly liquid investment instruments with original maturities of three months
or less when purchased, or any investment redeemable without penalty or loss of interest to be cash equivalents. As of September
30, 2014 and March 31, 2014, we had no assets that were classified as cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CONCENTRATIONS OF CREDIT RISKS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash is maintained at two financial institutions
in checking accounts and related cash management accounts. Accounts at these institutions are secured by the Federal Deposit Insurance
Corporation (&#34;FDIC&#34;) up to $250,000. Our September 30, 2014 cash balances were approximately $276,000 over such insured
amount. We do not believe that the Company is exposed to any significant risk with respect to its cash.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our accounts receivable at September
30, 2014 and March 31, 2014 and all of our revenue in the six month periods ended September 30, 2014 and 2013 were directly from
the U.S. Department of Defense or from a subcontract under Battelle (defined herein), which is a prime contractor with the U.S.
Department of Defense, and as such no allowance for uncollectable accounts receivable is deemed necessary at September 30, 2014
or March 31, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FAIR VALUE OF FINANCIAL INSTRUMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of our cash, accounts receivable,
accounts payable, and other current liabilities approximate their estimated fair values due to the short-term maturities of those
financial instruments. The carrying amount of the notes payable approximates their fair value due to the short maturity of the
notes and since the interest rate approximates current market interest rates for similar instruments.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has concluded that it is not practical
to determine the estimated fair value of amounts due to related parties because the transactions cannot be assumed to have been
consummated at arm's length, the terms are not deemed to be market terms, there are no quoted values available for these instruments,
and an independent valuation would not be practicable due to the lack of data regarding similar instruments, if any, and the associated
potential costs.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 9 with respect to derivative liabilities.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PROPERTY AND EQUIPMENT</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five
years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement
of property and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss
included in the consolidated statements of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INCOME TAXES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to the difference between the consolidated financial statements and their respective
tax basis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards.
We record a valuation allowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable
future, it is more likely than not that some portion of the deferred tax assets may not be realized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a
long-lived asset is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized.
We believe no impairment charges were necessary during the three and six month periods ended September 30, 2014 and 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">LOSS PER COMMON SHARE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing
net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation.
Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number
of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common
shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional
potential common shares have been excluded as their effect would be antidilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2014 and 2013, a total of
139,672,815 and 137,935,529 potential common shares, consisting of shares underlying outstanding stock options, warrants and convertible
notes payable were excluded as their inclusion would be antidilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEGMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, we operated in one segment that
was based on our development of therapeutic devices. However in the December 2013 quarter, we initiated the operations of ESI to
develop diagnostic tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic
applications (See Note 14).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DEFERRED FINANCING COSTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs related to the issuance of debt are capitalized
and amortized to interest expense over the life of the related debt using the effective interest method.&#160;&#160;We recorded
amortization expense related to our deferred offering costs of $21,502 and $863 during the six month periods ended September 30,
2014 and 2013, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REVENUE RECOGNITION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DARPA Contract -- With respect to revenue recognition,
we entered into a government contract with DARPA and have recognized revenue under such contract. We adopted the Milestone method
of revenue recognition for the DARPA contract under ASC 605-28 &#147;Revenue Recognition &#150; Milestone Method&#148; and we
believe we meet the requirements under ASC 605-28 for reporting contract revenue under the Milestone Method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to account for this contract, we identify
the deliverables included within the contract and evaluate which deliverables represent separate units of accounting based on if
certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received
is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the
separate units.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone is an event having all of the following
characteristics:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) There is substantive uncertainty at the
date the arrangement is entered into that the event will be achieved. A vendor&#146;s assessment that it expects to achieve a
milestone does not necessarily mean that there is not substantive uncertainty associated with achieving the milestone.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The event can only be achieved based in
whole or in part on either: (a) the vendor&#146;s performance; or (b) a specific outcome resulting from the vendor&#146;s performance.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) If achieved, the event would result in additional
payments being due to the vendor.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone does not include events for which
the occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&#146;s performance.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The policy for recognizing deliverable consideration
contingent upon achievement of a milestone must be applied consistently to similar deliverables.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assessment of whether a milestone is substantive
is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of
the following for the milestone to be considered substantive:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The consideration is commensurate with either:
(a) the vendor&#146;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items
as a result of a specific outcome resulting from the vendor&#146;s performance to achieve the milestone;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The consideration relates solely to past
performance; and</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) The consideration is reasonable relative
to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone is not considered substantive if
any portion of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it
does not relate solely to past performance). To recognize the milestone consideration in its entirety as revenue in the period
in which the milestone is achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated
into substantive and non-substantive components. In addition, if a portion of the consideration earned from achieving a milestone
may be refunded or adjusted based on future performance, the related milestone is not considered substantive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 12 for the additional disclosure information
required under ASC 605-28.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Battelle Subcontract -- We entered into a subcontract
agreement with Battelle Memorial Institute (&#147;Battelle&#148;) in March 2013. Battelle was chosen by DARPA to be the prime
contractor on the systems integration portion of the original DARPA contract and we are one of several subcontractors on that systems
integration project. The Battelle subcontract is cost-reimbursable under a time and materials basis. We began generating revenues
under the subcontract during the six months ended September 30, 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenue under this contract is a function
of cost reimbursement plus an overhead mark-up for hours devoted to the project by specific employees (with specific hourly rates
for those employees). Battelle engages us as needed. Each payment requires approval by the program manager at Battelle.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK-BASED COMPENSATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employee stock options and rights to purchase
shares under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is
measured when all granting activities have been completed, generally the grant date, based on the fair value of the award. The
exercise price of options is generally equal to the market price of the Company's common stock (defined as the closing price as
quoted on the OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity
incentive awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance
with the original provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards
granted subsequent to April 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent
accounting standards. We use a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 10).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes share-based compensation
expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September
30, 2014 and 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Six Months Ended</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2013</p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 68%">Vesting of Stock Options</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">260,680</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">124,243</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Incremental fair value of option Modifications</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,914</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Vesting Expense Associated with CEO Restricted Stock Grant</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">64,444</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Total Stock-Based Compensation Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">260,680</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Weighted average number of common shares outstanding &#150; basic and diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">243,494,916</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">182,004,220</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Basic and diluted loss per common share</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for transactions involving services
provided by third parties where we issue equity instruments as part of the total consideration using the fair value of the consideration
received (i.e. the value of the goods or services) or the fair value of the equity instruments issued, whichever is more reliably
measurable. In transactions, when the value of the goods and/or services are not readily determinable and (1) the fair value of
the equity instruments is more reliably measurable and (2) the counterparty receives equity instruments in full or partial settlement
of the transactions, we use the following methodology:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">a) For transactions where goods have already
been delivered or services rendered, the equity instruments are issued on or about the date the performance is complete (and valued
on the date of issuance).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">b) For transactions where the instruments are
issued on a fully vested, non-forfeitable basis, the equity instruments are valued on or about the date of the contract.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">c) For any transactions not meeting the criteria
in (a) or (b) above, we re-measure the consideration at each reporting date based on its then current stock value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting
the forfeiture rate for all expense amortization after March 31, 2006 is recognized in the period the forfeiture estimate is changed.
The effect of forfeiture adjustments for the six months ended September 30, 2014 was insignificant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PATENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents include both foreign and domestic patents.
There were several patents pending at September 30, 2014. We capitalize the cost of patents and patents pending, some of which
were acquired, and amortize such costs over the shorter of the remaining legal life or their estimated economic life, upon issuance
of the patent. The unamortized costs of patents and patents pending are subject to our review for impairment under our long-lived
asset policy above.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK PURCHASE WARRANTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We grant warrants in connection with the issuance
of convertible notes payable and the issuance of common stock for cash. When such warrants are classified as equity and issued
in connection with debt, we measure the relative estimated fair value of such warrants and record it as a discount from the face
amount of the convertible notes payable. Such discounts are amortized to interest expense over the term of the notes using the
effective interest method. Warrants issued in connection with common stock for cash, if classified as equity, are considered issued
in connection with equity transactions and the warrant fair value is recorded to additional paid-in-capital. Lastly, warrants not
meeting equity classification are recorded as derivative instruments.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DERIVATIVE INSTRUMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We evaluate free-standing derivative instruments
(or embedded derivatives) to properly classify such instruments within equity or as liabilities in our financial statements. Our
policy is to settle instruments indexed to our common shares on a first-in-first-out basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The classification of a derivative instrument
is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument
is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract
may be reclassified.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Instruments classified as derivative liabilities
are remeasured each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement
of operations in other (income) expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE
NOTES PAYABLE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible feature of certain notes payable
provides for a rate of conversion that is below market value. Such feature is normally characterized as a &#34;Beneficial Conversion
Feature&#34; (&#34;BCF&#34;). We measure the estimated fair value of the BCF in circumstances in which the conversion feature
is not required to be separated from the host instrument and accounted for separately, and record that value in the consolidated
financial statements as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the
term of the notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REGISTRATION PAYMENT ARRANGEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for contingent obligations to make
future payments or otherwise transfer consideration under a registration payment arrangement separately from any related financing
transaction agreements, and any such contingent obligations are recognized only when it is determined that it is probable we will
become obligated for future payments and the amount, or range of amounts, of such future payments can be reasonably estimated.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RESEARCH AND DEVELOPMENT EXPENSES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We incurred research and development expenses
during the three and six month periods ended September 30, 2014 and 2013, which are included in various operating expense line
items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods
were as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%">Three months ended</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">250,388</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">293,580</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Six months ended</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">637,723</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">626,638</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">OFF-BALANCE SHEET ARRANGEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not entered into any off-balance sheet
arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management is evaluating significant recent
accounting pronouncements that are not yet effective for the Company, including the new accounting standard on revenue recognition,
ASU 2014-09 (Topic 606), and has not yet concluded whether any such pronouncements will have a significant effect on the Company&#146;s
future consolidated financial statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EROAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured amount</a></td>
        <td class="nump">$ 276,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 276,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive shares excluded from EPS</a></td>
        <td class="nump">139,672,815<span></span></td>
        <td class="nump">137,935,529<span></span></td>
        <td class="nump">141,225,399<span></span></td>
        <td class="nump">138,279,424<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,502<span></span></td>
        <td class="nump">863<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
        <td class="nump">$ 250,388<span></span></td>
        <td class="nump">$ 293,580<span></span></td>
        <td class="nump">$ 637,723<span></span></td>
        <td class="nump">$ 626,638<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashUninsuredAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITY (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayableInDefault', window );">Accrued Interest On Notes Payable in default</a></td>
        <td class="nump">$ 471,041<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedInterestOnNotesPayableInDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Interest On Notes Payable in default</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedInterestOnNotesPayableInDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQFAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>14. SEGMENTS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 479,075<span></span></td>
        <td class="nump">$ 644,887<span></span></td>
        <td class="nump">$ 530,371<span></span></td>
        <td class="nump">$ 840,483<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating losses</a></td>
        <td class="num">(601,192)<span></span></td>
        <td class="num">(229,796)<span></span></td>
        <td class="num">(1,773,200)<span></span></td>
        <td class="num">(1,013,592)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses</a></td>
        <td class="num">(888,193)<span></span></td>
        <td class="num">(3,349,670)<span></span></td>
        <td class="num">(4,592,485)<span></span></td>
        <td class="num">(3,653,168)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">526,187<span></span></td>
        <td class="nump">8,754<span></span></td>
        <td class="nump">526,187<span></span></td>
        <td class="nump">8,754<span></span></td>
        <td class="nump">1,250,279<span></span></td>
        <td class="nump">125,274<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">1,089,269<span></span></td>
        <td class="nump">411,190<span></span></td>
        <td class="nump">1,089,269<span></span></td>
        <td class="nump">411,190<span></span></td>
        <td class="nump">1,695,102<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,676<span></span></td>
        <td class="nump">4,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">156,799<span></span></td>
        <td class="nump">216,502<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Aethlon [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">530,371<span></span></td>
        <td class="nump">840,483<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,294,453)<span></span></td>
        <td class="num">(1,013,592)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,202,873)<span></span></td>
        <td class="num">(3,653,168)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">47,865<span></span></td>
        <td class="nump">8,754<span></span></td>
        <td class="nump">47,865<span></span></td>
        <td class="nump">8,754<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">443,027<span></span></td>
        <td class="nump">411,190<span></span></td>
        <td class="nump">443,027<span></span></td>
        <td class="nump">411,190<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,885<span></span></td>
        <td class="nump">4,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">156,799<span></span></td>
        <td class="nump">216,502<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">ESI [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(445,674)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(356,539)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">478,322<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">478,322<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">646,242<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">646,242<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,791<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 12<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 18<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForCapitalImprovements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 526,187<span></span></td>
        <td class="nump">$ 1,250,279<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">258,672<span></span></td>
        <td class="nump">95,177<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
        <td class="nump">66,189<span></span></td>
        <td class="nump">83,191<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">41,141<span></span></td>
        <td class="nump">50,699<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">892,189<span></span></td>
        <td class="nump">1,479,346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">70,185<span></span></td>
        <td class="nump">84,279<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Patents and patents pending, net</a></td>
        <td class="nump">107,907<span></span></td>
        <td class="nump">112,489<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
        <td class="nump">18,988<span></span></td>
        <td class="nump">18,988<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">1,089,269<span></span></td>
        <td class="nump">1,695,102<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">609,153<span></span></td>
        <td class="nump">517,651<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
        <td class="nump">888,778<span></span></td>
        <td class="nump">839,070<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="nump">190,000<span></span></td>
        <td class="nump">390,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, current portion</a></td>
        <td class="nump">483,421<span></span></td>
        <td class="nump">1,367,655<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,679,067<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump">1,216,604<span></span></td>
        <td class="nump">1,855,374<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">3,387,956<span></span></td>
        <td class="nump">15,648,817<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, noncurrent portion</a></td>
        <td class="nump">990,520<span></span></td>
        <td class="nump">776,451<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
        <td class="nump">990,520<span></span></td>
        <td class="nump">776,451<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">4,378,476<span></span></td>
        <td class="nump">16,425,268<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 500,000,000 shares authorized as of September 30, 2014 and March 31, 2014; 262,713,781 and 224,973,980 shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively</a></td>
        <td class="nump">262,712<span></span></td>
        <td class="nump">224,984<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">75,654,853<span></span></td>
        <td class="nump">59,659,137<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(79,335,907)<span></span></td>
        <td class="num">(74,832,557)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Aethlon Medical, Inc. stockholders' deficit before noncontrolling interests</a></td>
        <td class="num">(3,418,342)<span></span></td>
        <td class="num">(14,948,436)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
        <td class="nump">129,135<span></span></td>
        <td class="nump">218,270<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total deficit</a></td>
        <td class="num">(3,289,207)<span></span></td>
        <td class="num">(14,730,166)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and deficit</a></td>
        <td class="nump">$ 1,089,269<span></span></td>
        <td class="nump">$ 1,695,102<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Details - Assumptions) (Stock Options [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">2.60%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">90.23%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividends</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.38%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">94.60%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividends</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">2.50%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">102.70%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividends</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ORGANIZATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon Medical, Inc. and subsidiary (&#34;Aethlon&#34;,
the &#34;Company&#34;, &#34;we&#34; or &#34;us&#34;) is a medical device company focused on creating innovative devices that
address unmet medical needs in cancer, infectious disease and other life-threatening conditions. At the core of our developments
is the Aethlon ADAPT&#153; (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that converges
single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that
selectively remove harmful particles from the entire circulatory system without loss of essential blood components. On June 25,
2013, the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that allows us to
initiate human feasibility studies of the Aethlon Hemopurifier&#174; in the United States. Under the feasibility study protocol,
we will enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of this study will allow us the opportunity to initiate pivotal studies that are
required for market clearance to treat HCV and other disease conditions in the United States.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we intend to sell this device. Some of our patents may
expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R) treatment technology.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2013, our subsidiary, Exosome Sciences,
Inc. (&#147;ESI&#148;), commenced operations with a focus on advancing exosome-based strategies to diagnose and monitor the progression
of cancer, infectious disease and other life-threatening conditions.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is quoted on the OTCQB marketplace
administered by the OTC Markets Group under the symbol &#34;AEMD.&#34;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America
(&#147;GAAP&#148;) for interim financial information and with the instructions to Form 10-Q and applicable sections of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
In the opinion of management, all adjustments&#160;necessary to make the financial statements not misleading have been included.
The condensed consolidated balance sheet as of March 31, 2014 was derived from our audited financial statements. Operating results
for the six months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending
March 31, 2015. For further information, refer to our Annual Report on Form 10-K for the year ended March 31, 2014, which includes
audited financial statements and footnotes as of March 31, 2014 and 2013 and for the years then ended.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER3AI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="nump">$ 483,421<span></span></td>
        <td class="nump">$ 1,367,655<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="nump">483,421<span></span></td>
        <td class="nump">1,367,655<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="nump">169,993<span></span></td>
        <td class="nump">749,812<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableNoncurrentPortion', window );">Convertible Notes Payable - Non-Current Portion</a></td>
        <td class="nump">990,520<span></span></td>
        <td class="nump">776,451<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent', window );">Unamortized discount - Non-current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, net - Non-Current Portion</a></td>
        <td class="nump">990,520<span></span></td>
        <td class="nump">776,451<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestNoncurrentPortion', window );">Accrued interest - non-current portion</a></td>
        <td class="nump">31,967<span></span></td>
        <td class="nump">47,151<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_TotalConvertibleNotesPayable', window );">Total Convertible Notes Payable</a></td>
        <td class="nump">1,473,941<span></span></td>
        <td class="nump">2,144,106<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total Unamortized Discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable, net</a></td>
        <td class="nump">1,473,941<span></span></td>
        <td class="nump">2,144,106<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_TotalAccruedInterest', window );">Total Accrued Interest</a></td>
        <td class="nump">201,960<span></span></td>
        <td class="nump">796,963<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">October and November 2009 10% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="nump">28,598<span></span></td>
        <td class="nump">26,097<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">April 2010 10% Convertible Note [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="nump">35,188<span></span></td>
        <td class="nump">31,438<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">July and August 2011 10% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="nump">283,421<span></span></td>
        <td class="nump">257,655<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="nump">283,421<span></span></td>
        <td class="nump">257,655<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="nump">96,728<span></span></td>
        <td class="nump">90,256<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Law Firm Note [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="nump">9,479<span></span></td>
        <td class="nump">7,604<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Amended and Restated Series A 12% Convertible notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">885,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">885,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableNoncurrentPortion', window );">Convertible Notes Payable - Non-Current Portion</a></td>
        <td class="nump">225,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent', window );">Unamortized discount - Non-current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, net - Non-Current Portion</a></td>
        <td class="nump">225,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestNoncurrentPortion', window );">Accrued interest - non-current portion</a></td>
        <td class="nump">9,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">September 2010 12% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableNoncurrentPortion', window );">Convertible Notes Payable - Non-Current Portion</a></td>
        <td class="nump">317,072<span></span></td>
        <td class="nump">317,072<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent', window );">Unamortized discount - Non-current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, net - Non-Current Portion</a></td>
        <td class="nump">317,072<span></span></td>
        <td class="nump">317,072<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestNoncurrentPortion', window );">Accrued interest - non-current portion</a></td>
        <td class="nump">9,513<span></span></td>
        <td class="nump">35,034<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">April 2011 12% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableNoncurrentPortion', window );">Convertible Notes Payable - Non-Current Portion</a></td>
        <td class="nump">448,448<span></span></td>
        <td class="nump">448,448<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent', window );">Unamortized discount - Non-current portion</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, net - Non-Current Portion</a></td>
        <td class="nump">448,448<span></span></td>
        <td class="nump">448,448<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestNoncurrentPortion', window );">Accrued interest - non-current portion</a></td>
        <td class="nump">13,454<span></span></td>
        <td class="nump">12,117<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2008 10% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount', window );">Convertible Notes Payable - Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion', window );">Unamortized discount - current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, net - Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestCurrentPortion', window );">Accrued interest - current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,167<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">September 2011 12% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableNoncurrentPortion', window );">Convertible Notes Payable - Non-Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,931<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent', window );">Unamortized discount - Non-current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, net - Non-Current Portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,931<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestNoncurrentPortion', window );">Accrued interest - non-current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedInterestCurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedInterestCurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedInterestNoncurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedInterestNoncurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableCurrentBeforeDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableCurrentBeforeDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableNoncurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableNoncurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DebtInstrumentUnamortizedDiscountCurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DebtInstrumentUnamortizedDiscountCurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DebtInstrumentUnamortizedDiscountNonCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DebtInstrumentUnamortizedDiscountNonCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_TotalAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_TotalAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_TotalConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_TotalConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes share-based compensation
expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September
30, 2014 and 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Six Months Ended</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2013</p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 68%">Vesting of Stock Options</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">260,680</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">124,243</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Incremental fair value of option Modifications</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,914</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Vesting Expense Associated with CEO Restricted Stock Grant</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">64,444</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Total Stock-Based Compensation Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">260,680</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Weighted average number of common shares outstanding &#150; basic and diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">243,494,916</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">182,004,220</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Basic and diluted loss per common share</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EERAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE (Details - Activity) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>2009 Convertible Notes [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>2010 Convertible Notes [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>2011 Convertible Notes [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Initial principal balance</a></td>
        <td class="nump">$ 1,473,941<span></span></td>
        <td class="nump">$ 2,144,106<span></span></td>
        <td class="nump">$ 450,250<span></span></td>
        <td class="nump">$ 743,600<span></span></td>
        <td class="nump">$ 253,760<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsOne', window );">Conversions during the fiscal year ended March 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(70,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsTwo', window );">Conversions during the fiscal year ended March 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(175,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsThree', window );">Conversions during the fiscal year ended March 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(130,250)<span></span></td>
        <td class="num">(405,500)<span></span></td>
        <td class="num">(15,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsFour', window );">Conversions during the fiscal year ended March 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(25,000)<span></span></td>
        <td class="num">(30,000)<span></span></td>
        <td class="num">(60,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsFive', window );">Conversions during the fiscal year ended March 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(25,000)<span></span></td>
        <td class="num">(169,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_IncreaseInConvertibleNotePayableExtensionFee', window );">Increase in principal balance due to 12% extension fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,972<span></span></td>
        <td class="nump">1,171<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ConvertibleNotesPayableConversionsSix', window );">Conversions during the three months ended June 30, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(10,931)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Balance as of September 30, 2014</a></td>
        <td class="nump">$ 1,473,941<span></span></td>
        <td class="nump">$ 2,144,106<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="nump">$ 317,072<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the fiscal year ended March 31, 2014</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the fiscal year ended March 31, 2013.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the fiscal year ended March 31, 2010.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsSix">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the three months ended June 30, 2014</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsSix</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the fiscal year ended March 31, 2012.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ConvertibleNotesPayableConversionsTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversions during the fiscal year ended March 31, 2011.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ConvertibleNotesPayableConversionsTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_IncreaseInConvertibleNotePayableExtensionFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in principal balance due to 12% extension fee</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_IncreaseInConvertibleNotePayableExtensionFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Convertible notes payable</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at September
30, 2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Unamortized <br />
Discount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net <br />
Amount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued <br />
Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Current Portion:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%; padding-left: 9pt; text-indent: -9pt">October &#38; November 2009 10% Convertible Notes</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">50,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">50,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">28,598</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2010 10% Convertible Note</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">35,188</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">July and August 2011 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">283,421</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">283,421</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">96,728</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Law Firm Note</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">9,479</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">483,422</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">483,422</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">169,993</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Non-Current Portion:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">Amended and Restated Series A 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">225,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">225,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9,000</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2010 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9,513</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">448,448</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">448,448</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">13,454</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Non-Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">990,520</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">990,520</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">31,967</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 44pt; text-indent: -9pt">Total Convertible Notes Payable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">1,473,941</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">1,473,941</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">201,960</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at March 31,
2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Unamortized <br />
Discount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net <br />
Amount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued <br />
Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Current Portion:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%; padding-left: 9pt; text-indent: -9pt">Amended and Restated Series A 12% Convertible Notes, past due</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">885,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">885,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">575,250</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">2008 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">19,167</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">October &#38; November 2009 10% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">26,097</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2010 10% Convertible Note</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">31,438</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">July and August 2011 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">90,256</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Law Firm Note</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">7,604</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">1,367,655</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">1,367,655</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">749,812</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Non-Current Portion:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2010 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">35,034</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">448,448</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">448,448</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">12,117</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">10,931</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">10,931</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Non-Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">776,451</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">776,451</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">47,151</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 44pt; text-indent: -9pt">Total Convertible Notes Payable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">2,144,106</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">2,144,106</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">796,963</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">October and November 2009 10% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ActivityInConvertibleNotesTextBlock', window );">Activity in Convertible Notes</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following table shows the conversions into principal of the October
and November 2009 10% Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in October &#38; November 2009 10% Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">450,250</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2010</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(70,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2011</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(175,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(130,250</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(25,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">50,000</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">September 2010 12% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ActivityInConvertibleNotesTextBlock', window );">Activity in Convertible Notes</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following table shows the activity in the September 2010 10%
Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in the September 2010 10% Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">743,600</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(405,500</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(30,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(25,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Increase in principal balance due to 12% extension fee</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">33,972</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">317,072</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"></p><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">September 2011 12% Convertible Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ActivityInConvertibleNotesTextBlock', window );">Activity in Convertible Notes</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following table shows the conversions into principal of the September
2011 Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in the September 2011 Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">253,760</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(15,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(60,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(169,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Increase in principal balance due to extension fee</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,171</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(10,931</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ActivityInConvertibleNotesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Activity in Convertible Notes</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ActivityInConvertibleNotesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(e),(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDebtInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>2. LIQUIDITY<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2. LIQUIDITY</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of
assets and satisfaction of liabilities in the ordinary course of business. We have incurred continuing losses from operations and
at September 30, 2014 are in default on certain debt agreements, have negative working capital of approximately $2,496,000, and
have an accumulated deficit of approximately $79,336,000. These factors, among other matters, raise substantial doubt about our
ability to continue as a going concern. A significant amount of additional capital will be necessary to advance the development
of our products to the point at which they may become commercially viable. We intend to fund operations, working capital and other
cash requirements for the fiscal year ending March 31, 2015 through debt and/or equity financing arrangements as well as through
revenues and related cash receipts under our government contracts (see Note 12).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30,
2014, we converted a past due convertible note in the amount of $660,000 and related accrued interest into equity and also
restructured and extended a formerly past due convertible note in the amount of $225,000. We also eliminated the antidilution
price protection on all the remaining outstanding notes and warrants which held such price protection. The combination of all
of those actions allowed us to reclassify our derivative liability in the amount of $10,679,067 into equity.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are currently addressing our liquidity issue
by seeking additional investment capital through private placements of common stock and debt and by applying for additional grants
issued by government agencies in the United States. We believe that our cash on hand and funds expected to be received from additional
private investments will be sufficient to meet our liquidity needs for fiscal 2015. However, no assurance can be given that we
will receive any funds in the form of revenues or in connection with capital raising activities in addition to the funds we have
already received.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful outcome of future
contract-based and fundraising activities cannot be determined at this time and there is no assurance that, even if achieved,
we will have sufficient funds to execute our intended business plan or generate positive operating results.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements do not
include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts
or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RisksAndUncertaintiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
        <td class="nump">262,713,781<span></span></td>
        <td class="nump">224,973,980<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
        <td class="nump">262,713,781<span></span></td>
        <td class="nump">224,973,980<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DarpaContractAndRelatedRevenueRecognition', window );">DARPA CONTRACT AND RELATED REVENUE RECOGNITION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 1, we entered into a contract
with the DARPA on September 30, 2011. Under the DARPA award, we have been engaged to develop a therapeutic device to reduce the
incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from DARPA
was a fixed-price contract with potential total payments to us of $6,794,389 over the course of five years. Fixed price contracts
require the achievement of multiple, incremental milestones to receive the full award during each year of the contract. Under the
terms of the contract, we will perform certain incremental work towards the achievement of specific milestones against which we
will invoice the government for fixed payment amounts.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Originally, only the base year (year one contract)
was effective for the parties, however, DARPA subsequently exercised the option on the second, third and fourth years of the contract.
DARPA has the option to enter into the contract for year five. The milestones are comprised of planning, engineering and clinical
targets, the achievement of which in some cases will require the participation and contribution of third party participants under
the contract. There can be no assurance that we alone, or with third party participants, will meet such milestones to the satisfaction
of the government and in compliance with the terms of the contract or that we will be paid the full amount of the contract revenues
during any year of the contract term. We commenced work under the contract in October 2011.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to budget restrictions within the Department
of Defense, on February 10, 2014, DARPA reduced the scope of our contract in years three through five of the contract. The reduction
in scope focused our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible
payments under the contract by $858,491 over years three through five. We recently completed a re-budgeting of the expected costs
on the remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs
due to the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2014,
we invoiced DARPA for three milestones totaling $444,723. The details of those milestones were as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone 2.4.2.2 &#150; Determine capacity
requirements of affinity resin to multiple simultaneous targets. The milestone payment was $197,362. Management considers this
milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&#160;&#160;We
demonstrated that we were able to determine the capacity requirements of affinity resin to multiple simultaneous targets.&#160;&#160;The
report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone 2.4.2.4 &#150; Finish construction
and delivery of 25 experimental cartridges for testing by the system integrator. The milestone payment was $50,000. Management
considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's
efforts.&#160;&#160;We demonstrated that we delivered the 25 cartridges to the systems integrator as part of our submission for
approval.&#160;&#160;The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone M9 &#150; Target capture &#62; 90%
in 24 hours for at least 3 targets ex vivo in blood or blood components using the optimized cartridge. The milestone payment was
$197,361. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based
solely on another party's efforts.&#160;&#160;We demonstrated that we were able to capture approximately 90% in 24 hours for at
least 3f targets ex vivo in blood or blood components using the optimized cartridge.&#160;&#160;The report was accepted by the
contracting officer's representative and the invoice was submitted thereafter.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the six months ended September 30, 2013,
we invoiced DARPA for four milestones totaling $808,739.&#160;&#160;The details of those milestones were as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone 2.3.2.2 &#150; Formulate initial
design work based on work from the previous phase. Begin to build and test selected instrument design and tubing sets. The milestone
payment was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor
was it based solely on another party's efforts.&#160;&#160;We demonstrated that we were able to formulate the initial design work
and to build and test selected instrument design and tubing sets as part of our submission for approval.&#160;&#160;The report
was accepted by the contracting officer's representative and the invoice was submitted thereafter.&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone 2.3.2.2 &#150; Write and test software
and conduct ergonomic research. Begin discussions with the systems integrator. The milestone payment was $195,581. Management considers
this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&#160;&#160;We
obtained wrote and tested software and conducted ergonomic research and began discussions with the systems integrator. The report
was accepted by the contracting officer's representative and the invoice was submitted thereafter.&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone 2.3.3.2 &#150; Cartridge construction
with optimized affinity matrix design for each potential target. Complete the capture agent screening. The milestone payment was
$208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based
solely on another party's efforts.&#160;&#160;We completed the cartridge construction with optimized affinity matrix design for
each potential target and completed the capture agent screening. The report was accepted by the contracting officer's representative
and the invoice was submitted thereafter.&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Milestone M5 &#150; Target capture &#62; 90%
in 24 hours for at least three targets in blood or blood components. The milestone payment was $208,781. Management considers
this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts.&#160;&#160;We
demonstrated that we were able to capture approximately 90% in 24 hours for at least three of the agreed targets in blood or blood
components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DarpaContractAndRelatedRevenueRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>DARPA CONTRACT AND RELATED REVENUE RECOGNITION</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DarpaContractAndRelatedRevenueRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Nov. 07, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DocumentAndEntityInformationAbstract', window );"><strong>Term Of Lease</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Aethlon Medical Inc<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000882291<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--03-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">295,160,194<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. COMMITMENTS AND CONTINGENCIES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">LEASE COMMITMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rented approximately 2,300 square feet of
executive office space at 8910 University Center Lane, Suite 660, San Diego, CA 92122 at the rate of $6,475 per month on a four
year lease that expired in September 2014. We continued leasing that space for the month of October and, effective November 1,
2014, moved into a new facility of approximately 2,576 square feet located at 9635 Granite Ridge Drive, San Diego<i>, </i>CA 92123
under a 39 month lease with an initial rental rate of $6,054 per month. We believe this new leased facility will be satisfactory
for our office needs over the term of the lease.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also rent approximately 1,700 square feet
of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $3,917 per month on a
one year lease that previously was scheduled to expire in October 2014 and was recently extended to in October 2015. We believe
this new leased facility will be satisfactory for our laboratory needs over the term of the lease</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Exosome Sciences, Inc. subsidiary rents
approximately 2,055 square feet of office and laboratory space at 11 Deer Park Drive, South Brunswick, NJ at the rate of $3,596
per month on a one year lease that previously was scheduled to expire in October 2014 and was recently extended to in October 2015.
We believe this new leased facility will be satisfactory for ESI&#146;s operational needs over the term of the lease.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense approximated $84,000 and $68,000
for the six month periods ended September 30, 2014 and 2013, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">LEGAL MATTERS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, claims are made against us
in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent
uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from
selling one or more products or engaging in other activities.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of an unfavorable outcome in
any specific period could have a material adverse effect on our results of operations for that period or future periods. Other
than as mentioned here, we are not presently a party to any pending or threatened legal proceedings.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001019687-14-004132-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019687-14-004132-xbrl.zip
M4$L#!!0````(`.);:D7Z.5:/D>(``$2U"0`1`!P`865M9"TR,#$T,#DS,"YX
M;6Q55`D``T?H8%1'Z&!4=7@+``$$)0X```0Y`0``[%UI<^,XDOV^$?L?N)[8
MCMV(DDT0/%W'A,I'C;>K;(_EZM[9+Q4L$9(Q39%J'C[FUR]`B10H\0))W=R8
M[7"))/)EXB&1`!+`A[^^3FSA&7D^=IV/)^!4/!&0,W0M[(P_GGP?]/J#BYN;
M$^&OG_[]WP3R?Q_^H]<3KC&RK7/ATAWV;IR1^UZX-2?H7/B"'.29@>N]%WXS
M[9#^XEYC&WG"A3N9VBA`Y,%,TKD@GTJFT.M5*/8WY%BN]_WA)BGV*0BFYV=G
M+R\OIX[[;+ZXWA_^Z="M5MS`#;TA2LHR4?!DN\X/(/[YG]*E:$`1R*>O(Z+#
MI1F0YQ+Y-WD``/V/^`C4<TDZ5\2*L@(S"/U$EOBJBR(415&:??[A]:=GXW/Z
M7X%4@^.?O_KXXPFCW@L\=;WQF22*X.Q_OWT=#)_0Q.QAQP],9XA.XJ]L[/R1
M]1TP#.,L>AJ_NO(F%1[+@&?T\4_37Y1,`1:\OX*$/+6"Y`/V9>5L]C#U*LY\
M59V]BN-7+;3TGH^&IV/W^8P\.*,5U!-!#X+X=0^-<B&K9^1I_"+V75D"6I%^
MLS?B#T*_-S;-:?+!R/1_1B_/'V2`(4\\UT9^YC?1DXR/'-=QPDDV+BOPSH*W
M*3HC+_7(6\C#P^2[\H_2'Q`,].=L=-&3#'0FFEC)!_/V,T$6'IHV:863Z`O:
MD$[B%D)9=>Y'W'U`(R$BY/E35$VTK%[\P>FK;YW,'U/A'T]\3!W'B7`6%S5K
M,4/7"=!K(&""H^_?C688C=Y"9O(J<@(<O"6_)K]CBSX98>*=(F0H9;B88!<W
MOYY\(@U6U'5),L"'L^6/%^+.,N7-I4V)T5TK`T74?H)/"P42$?,GR^6G2HI_
MG-NCBI$@K<A]-A)58!-&^G'K!LB_-]_,GS:Z-_W@,D1`O$>D\W"";VCR$WE;
MLV-2L(_&$\08('ED$3"O4QL/\1RK8&'RYJR7GWNK\PN/M-K@VAQBF\#NOV+_
MY!-MD.?EJG\XRY3"(CS+AKCW')".EP/2,7)@&/J!._G1)QI8R'I`1%2`K`$I
M&OG]Q"07KD.BZ``3:T66.PQV7**?P0TQKA?20AAVU++&<1%FV0:)!R61I7[@
M]*B@^W&1X6X8N$2[6_<YTI*8P<BUT8%S@]\4QT65_M3#-OE97++*L?"CHO['
M18H!F@;SYK)BF$./-2KH?EQDB%L(.-8NI*H!CHL6;#M9L<R!,Z*"[L=%AJ_F
MRS7V)E3_`Z_Z%4T/M:*O/7<RDT$GY`-W;V>]B5&\@"ZO?5JHDU1)\FSE,^18
MS$?L9'G\I%4[0\;.</_M#.O8&:[3SNF5FVZ>[4#FV3:QBL42IIM:V=NIE4U3
MI9M:V8.IE4V3HIM:V>&IE6UYB&YJI>LX&%ITH^F#J^C\4=Z/:Q-[4<KFC3,-
M`_\K>D8V/(QZ3U3[_);\^3<BQ_2&3V^1HC,NK+R_:HI-$V/'1[/YLS,=GW:?
M3[LW"[74$769:#N;B;:Q8*3+2-W9C-1-I6[_F%LJLT\!AT&"-OH4L`NDV-B:
M7Q$II(X42Z8X?%)T4>?.1IU;ZC8Z,NP^&=;N&;KYC3TA`]R`9X#[OA<0;J[%
M[+61-L6DPBBT<R^[Y5ZVD:66$&00N,,_[J8!,>UAT*+_8GK6X]L4I6M_1<]N
MBI.7*K^;GF<>RNQ6#DU2.G84*1K3=K0X[&%J5[^'.?)<2J>XQ!X:!J[G'U".
M5>[219:RA]J<"WKTG%WQ-$?U,`A0>3/\0N6NLV_,'B`>'7MBE3OV-&?/@2R9
M\K!G2TNC.\Z>[$"EZZVVV%MM-^6WZVJVV-7L7-5W_<3A5GW1H5V=PS_H28GB
MJN\<_O%6?>?P#ZWJ>5>;DE^_F:]X$DX.@Q#M3$;S2'PPG?&2M)1%NX%H2S3%
M3D?3=FG*6K2C:79'"D!/U/8W06JNP+:60WY#?H"=\=V(R14YD`6Q6S,(/70W
MNGJ=DD>(B3T*E.Y:6=5-RAV!=H]`>[4K>4Z@&V?H(6H(TTZR%>]&1T*D"LIW
M'HG3(W6$VF%"[:.'FGO[N;$/G4%9VG8^J%Y4U%&F\S)%\[Y='N*!SO5FK^O^
M3VB_]<,Q^0>=[4[.CSB"4[U*-3_45=Y%=*'E1!?4!I]-F]YB.I]0G3_XFVM;
MR+MS#H@;LT4?^OOGM^\._C-$E\@?>C@*3Y=.6TG9I-VIUER:+IE\VV&/MI-A
M3P&7%_7;'PZ]$%DWY&N/1`<=LU/+GKD6ZGB^%SRGQZ%[X9#$PR3LO4:=XXZ)
ME6V8CM5[P>J22.3QQ3T^0F\W$DE,WG%Y#1[Z*`F]`QZZ8W49J_-FHOLH>+(/
MY="*`;U1AG[_.?2Q@WQ_,"O.9T^#9Q7>-EWV;A:ZHTLW`UUVWT1'D0.<=5PZ
M;Z^KZ^W6]5H/02N/&JX&-\=3YXFR7;3`&2UT-.FBA)PHH:/&X4<'71T?9E2P
M/$.V9ULE]F/.!C)VWL\S>Y?[)7X[;SE+L[N&=X^NX=V/8+F`;=VEK86Z=WQJ
MP*>5JT^/B$\YNG=\JL`G=<^CCKIV5K>QSASO>H_64_$P0%:T%_`PFFK.[O=,
M7;?=-'=S0%"0FG#MAMX-<7(^S84_#+Y0JMR-^O1LA#%:\NX9ZG:4X:3,XY.'
MT!%Q)DO?CC0YI`%+(4!,FF_81L1/.^CQQ;UWL1/0EAC]$?]P,`E0R93?%^2.
M/7/ZA(>FS?")PQ3;IAG8U0BH/LWH#QW/EFW1$:T&T7QJW&^W^%!RZZL0:EGG
MCC@Y,_"`F8$O]%!1>-'UA&6VV/;2.#_1X.X2C35S1[55:W1DJT&V6==PC9^/
MKCM<Z-P1AW,RH3NQ;8=.;-O9B86,C(:.0#M(H%U.U<CS0-T);<7*=QZ)TR-U
MA-IA0NVCA^K.;^M\4+VHJ*-,YV4J7Z3`Q)+S`PJ.Z3*%%>W+"<0CM;M088-T
M/8(K:K9`U^Z:FERZ9A^HVIVPN:,G;&[LJ-5<7[7O-=^>5UIG/6_LOLRNG@^H
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MMCFN+&9DVCZ:24@5P)9\$7H>_1G[I!;_@4R/5Y=>[`J+2ELEP._(MG]UW!=G
M0+CJ.LBZ\?V0]`=5Q=ZZ+`%R2EL5^YMKAPZ)W=^NL8T\OZ:XI5(RZ#VSPP.:
MNAZ=):++^F%U:?^@/J:LM%6I$9H+8NZQZU5O4H.):9/OA*1XX<*=3$WGC860
M*CJK(<RJ?$;@:_);=67_+J4;P4I)^>(HP_B$D;^5+'%)2;&PY#*'I=UX]^:;
M2?Y."4P'X"<"=;31`]J9"Q8:8F)B_^,)]2RR!@V9M):2\IO!H`VR$(8$9!F(
MZIIAK!Z,GGFM>Q%0A3K\K<),KB`O@@F!)FK2=G&""CC7;<KB*[TKU;BLB)*R
M79R5JER3H;IV:E:\(KVPJ2M04UO#.>^*ZKH_68<D>"\%,Y?2"J927PB@JJF*
MLG%0R:&$-#1#%MU::M*-I:3C0WX?2//YJYRM\$4:Z;I2Q6NN2Z'<DS:(!]`K
M,7:;Z&N<HM*\`UL;MZ8>MJ750RIX--"V6AU?S9=K[$V8^>O=PMKP`)[=HD[J
MK-2]I`ZKP3Y1IWS9IM!C;J=;;0F\TJ3[;3$X`4:ZP;4JO30,@>N6_H-]_=[T
M@\N0JS$K6X`G58<']#4"C)KJ7@+<C0IF75WFE9]+N%Y]?.Y@^^-)X(7H1#AK
M2"T.R6G7)%9ND[/CMM,WFMTY;4P903+2!-*'LW()C;&4.RE-UD1Y8UB:,EJ%
MFK)=L!S^`2I0!W`C<-MP9W34K&O;A<M#!57:#!7:<G7-N%C7XP%9`2J/G191
MVV3B.M$:_;WIW7G11D8K2L6/UX(K.\!D\9C!=G-[??))/!7%5)A;*K,]F*N^
M<3,P9POVT7J65<V"\R7^9522*FD`:GHV,E9,,S1+ALI#(\F&!@U=;([F+@QH
M^H5%EZ[6;2!&5@NXVC-5`:Z^[Z/`KSTH$G5#4HV%Z%EQ7$+*IV!50P&B5%\(
MK#+W3(:FAMA(D?R[9`H%RU"4M,;*U1#<KL:+\_$+.UI9E>3F5<DGM%3)2S1U
M?1SX#1N#;NCZ0E2ZT%HBRYL&CTC259O.F,Z<S)[?HN#J=6B'U"U\<5WK!=MV
M?4>@&2+#XBJR6L17;B@@R;K1#-^]YTZ1%[S=VZ83]!WKZL\03VF2`/FXKMTT
MD0S\%["*1+0`I]1,NBQI1CTX,SLVG&0CO0G05[J3G`F&*A++B2%K!I35BB+O
M/30UL17O]W*LN^`)><W<!O'#;,I'D8@6X)0:1!%5PZ@'YQ*-$#&;=8T=>B'P
MA>M'#:NN850UQ86<TIN!*&\1$!B`&P09'+FA$_@/:(CP,QT1D9<:M@U)T54V
MBZ1(1@MX2BU#@C)-JP=G)4#MA\&3Z^%_-1S$1&MBR^MBN:*:HZH6H3=#E=[1
M$@^W'\@@<392G$]RF./VIG.B?.+582M0V'90%=7F],F=[UF+/DP")O?0#H">
MJ%48VI$FIHK`D%/IGCR#3M-_JNMN%(FX7Z9]T[(XRB_O>"5%3`4;/`)@-0&2
M)M<NOSQ6T92:I=<?*VJZJC32B%]F:VI6&ZL1%:$DM:(C]^`P2]8#>D9.B"KG
M$!<V*2A"C0DFXK)Y9&9<4%D2T8NR#IO)S-KSS,VC-2E?@]#KM0@WZUHVQ$;D
MRQGWYA6W:D/4E,8ZK]PA5SS5).ML!Y8G\VY*-X"1WO/&&;H3]-7U6VGL/1(=
M0XD-^C($U<3"ZP1Z@+RG&-(ZL+3B''I`,F19@1LR5AV`6[%@M<;<(Z93V5!G
M(\;C=C2M6HS+_?1(%`W64WF\7JDG289FJ%Q0[CUWA(/6')-,>"POS3K.R^>3
MS.V&H*I`H.K-);?C=&1)E'0-KL40->!LPCH5'0I4"!9CK8;A=A\-K,'G+'1=
M!T8[K.!S#1#*AJH5JARE7OSN>G\0AW%A3G%@UEZRZ4E$6C0KE5%H2EY>SFWT
M,SV=P;]SJFX);KC_JZ>)"\B5<'%J\OCB;D@3,,\IKPZ,5Q5ZBORFE(&S?7D\
MT+:B3J7=>SU95!2>NMF>.E4V^?4`']-J:$/O[=D0U20N92BP;>A2C6>0RYMM
M39=*)%/7K@M^WI`[XU"#8-J&&M7HQ=E4MJ5+-1^F&G656:RZ)5]]=9WQ(YIM
M_VJ:@F\8HB)E;P[+$M,.JM+E#TU3925[U]=Z4<457>4*^)JG)FQ&@7B/X\J=
MVSR9Y;*LD__M2#7DW9Q>G-EEP$W3*#6`;GT#O)2_A7PS*NUER\C:_;O-EG%%
M!%B$&)>$$,]F0-S]K4N_0]YG/`J](25+?T)34A[0T#9]GYY&:#VZT<KYDVM;
MI*.@^6Q!Y;.0BEN)JAGD_Q?JM(=OLYKS3NH1S15V/\,!Z?TCN2_BQIF&@?\5
M/2,;5O*9AV&3K#"N@4TVUD+H0OYW!SOTF,-Y$;6S[C0UW5FL%KV2;.<$V,)V
M2#4:H&'HX8!T6;/T8F11T](CU$+2G9%`]6YT97JDO+$?[_;)P%O)*>4D$0$9
MD`X/LCF=K0#<F-;%#BE/:ZA+FB%+\KYJ73QKG:NUH6J2SB:V[9?6Q5/FN5IK
M!E04:>T,G]`3$/\U_V:6`4QGS&D.<!LQA`24U"ZG`G%-H7%G$:FP'K`XDW*>
M/T[3+%L)MPQ#2>_F6);".9$QP*^[-K5$(&U!B4H32SNO1+49I=G(MJ8FT;5B
MID_"H*5OYY]>O0:SH\NO-[5J`:&AQ2=!\*#;HEI5Z@D`#330*L='Q$/,MCR2
MH4%5RO5(K+1E8%^Q^1/;40?5<(<(A+IF*$QNR6K1M867IULKJJSK0..1OHC\
MVS,"$ZL7%=\"E'*3K`QYN!"%Z-%]0':T_<#T6C"-KNN:QFX7S970&$N%?56&
MR*8Z5,<2;S1JYU@O530`FW>877HC#.5;[H"FLE/UU3`P#*J]]1!JNJQE.PQ^
M<14V\LN2(K$93M7DW;K.L%DM+R_19!;>!`'W<DPE!'2O#P[HCB2_[UBDSZ-Y
M@HA$VUQ57G9<%K^4+&W+I#`*$RDE\T]-CJ`H$]02,/YC*WB!K;Y!XI_9%O5[
M.@)SG7X0>/@G&<82+_'H4AX1J)YKVU$ZZ2P"J9T>!B5B6'9/?SMX-JIE:27U
MZ)'[(E#5=:OY#3NN%Y75K%J`9`#(S.\LEUM3;H4[`72)[:_+Y+;7P'M0!O0$
MTZ(:JBV]"D$,69=A(4%6M[$$)G:0%<\KD0X]G(11;'.)1O0RJMK&T`P(E=11
M&^7"6H-7;BU-UJ&D*(W@]2T+TV9FVO<FMLA8KUF>JZ:HBJRG8KQL`<UPE$=Y
MAJJ0MJMQXV!V_$8++[67,N@)5JEEXW2Y->66NPY)-G2YNMQD1\1\\-S.Y"H4
MH<+N/UR14@L&]VJIKLBIG7#MP.#-<2=!DRBQ`]/6K,&5\:YKLJIG;?K*0_$%
M.>0-FX1/?6N"G>@2,3J:GK_?!E%D21<-QC(E(EM`R,LA2(;.0-XD0EYZ2214
M8+=;;<2&7,P#L@0E6!OA5_.GZY&7YQ,6+=(/`%4197:HFBFJ/J`:2S^ROD8\
MO-Q29!FR)Q*LP3Y<3**[R66#%P_=V8-\/^K\KU$[79P&1!DREEF640<#+UM4
M!2@Z:!<#+T,@O0.R90R\K("2I@`.#/$PBA"'KA&TZ5!D63,RUDK3DNKCX66(
M!%32@M>'AY<MF@YD9:WFX>N82",6N?%\=SQDVO3XJ"]DL$4W#-XYB[6&5KP+
MTP642&L!'/?.8@GJDLX>1[9^C+Q$V[0!.;>E&X8DLK.5G!A_1WC\1!/VGDD<
M-4:W(5W7O1NM'%'UV?3QL+7D-HET>(9L`&9VA@M(ZUK42U;3B>EEB5V@V*X6
MM9+/),6`JF&PO=[6ZZ)&,IFNJ23`U*66M%A.+8M>HLZ<9J<M'2Q8U3/G'BW?
M$T_9)EPBNP6HI7YZ=Z"6NNM"J.*&K5KLO-=DU5L4M'P&DJR($++WM:9$<,MO
M?N!(,_F\77Y/ES59-%I4O^&!$M7E<R^ZU:6(GE[/X@:Q%BUXB99GXJTIP,U4
M6=38.?K=T(*7\&U60W3.=:LK$#HP)/;8I90$;O'<XVX5&@J;Z]-,//>4L*ZE
MKKUIK#S?=`P`AIXZ(:U(_"6:>N3K*,&=_&VC:-'?L=C$]U:F9G25K9`J8MN"
MRLL>69.T9DCC``19=.L%L7MK9I14465GJ+,EU<?#O<9GB"I+]6IXZ'5&]$AY
M,K"@*Z/$FK^;GF<Z@7_M>@/D/>,A&6UX%[:))ZWX(Z!*9)S#S#3Q`&@=/;\[
M(T-_V!+ZHATM4;CLSQ(R-[S+AQ7=)F3NQJ^P6<-U$=/K`$S_Z=YSG[&%K,]O
MWWUZ?5RRYML?!OAYEA`=I2"&Y+?Y0]=IZ4A6:,B0S?5JAFG]&G(/>#193B6Z
MMJM@O/_B$L7[,)92E=,)W*TLQQN:R#HI/@1K4("W2@P@RM+F%*"]\.QFQKR$
M[=K=!539>W+J(5F?/OQS`_08C?7K,[]`)[XXIORNGKK.S5"4PH92!<CZU.'N
MWXD;*VPV[:BS>FM-2Z&5;"A5N+60VQ96[F@5R*+<#&I.)Y.$!NOOV55-3-WU
MT0S1^O7C3JN0]/15XZWJ1XH9(F3Y%-PBCF;2--=11:5"6T')[7:6#,V-,JH6
MY&'76FY)K3AY39)3F77YXIH!X[]A`*CI0_`J`XLGX&@.=,N)"FS1O&(;3`%G
MB8WV+],,CD48$;\VW\M,C[9IN<T!4=349(\[C_1687./-R515L4&J)-9/F]L
M.O.A*OG"=VULF?.Y*A(_^/1&K]0PUK2CZ[ZBO7!T(&N[])R?1Z+/9YNC3C[]
M8@?OIX(?O-GHX\F(?'0NZ--`>,03$KS>HA?AP9V8SKO9#^\$>JC=Z+TP,;TQ
M=LX%\;U`I?1,&X_)/_\9^@$>O9W\,@[>@U/AMO_X_>%*N+L6/G\?W-Q>#09"
M__92^-P?W`SHK_</5X.KV\?^X\W=+<5Q-J4?_O(7`.?_60.V^8_8L1`M3SQ5
ML!/A_<6<3-__!:CB^TU!B<3>/7SIW][\WU';8'[S@/`-67AHVN\$XHA/!=.Q
M!#_\Z6,+F]Z;\%\S<%".7T_^_2Y"1V)I(?F)3E^:SMOBE<6C%Y3\*;C>XO?0
M3_[\;P'[@BE,9G!(BZ=3<J1%164*(W<8DAA&H%.PI)N@<Q,"=AQWEFXT?]L7
M@B<SB("9ED4:L$_<R`0%2:$.[:O)=\*0=M3>._+G")%8R`U]P<)^U-M1"_Q_
M>^_:W#AR)(I^/Q'G/R!\>V*[(R`-`;YGO!O!EM1C>;LEK:2>/OZT`9&@!`\)
MT``HC?SK;SZJ"@40?`HD01&[Z[5:`E!969E9^<X`;01CY`W=D_@)EW-],:R/
M*W*B4Z,7&[CY?A"Z1C`TL(_R`'N=!30`-R(@O(B>D9CNG?=N[L5I-^N_&A][
M`V="X)^#9'F-O.CDJ_<'/#\<>C[6I-V`J3\,PK%Q[_:?_&`4/+Y^,J+7""20
M.8NJB7P:D8"P@@1\=!F2",`'>P!0/YZ.8F\"/SMRE4$X?32<1X3:>/'B)\,9
M/"-Z!OC%:(SKC!]"QW>!E"081ASP.;BXP]"9N-/8ZQM#;Q2S$CE[(I$[0E0#
MBEZ-T!T'L.TG)QP/IR-C@LZ,_@B>'H+0))P!-!Y@MN^%?2P&"X`6>>,$8C"-
MC1%&P0'S<,KX,.#A810$`Z*8P,?=G!K7OO'W*0!N-YE<\8(QZ?O?8>NP0Q+G
MD?$%7\2#/T=<Z"G^L)./7\Y[GPQG,@%MVL7'@%.>X8[Q'AVNSC+.^0`N_G3'
M$W[E\OSB$Y^#,QH%+T"'@(F`B0)6]A!Q3U-@7&,(1.>1NP!V&$\'Z+Z`7>ET
M\S?`UF0:8GN[4)!/&_@(R'AF)Z?PSP&0+OXA^^57`W8`UV`P8F2\N`:-S'9]
M#'7"X?KPX^`DHMF:H8L;DSPQ@9TR?3P%A@/GPGP#RQ+!X&I_<_&A&$C^S'CV
M0MCOQ[^=_?X)"64`\/N$3J(6(W*&;OQ*,,!.]=T)8GH]->ZF?:">"*D##Y1#
M2(P86(*W0]`3?@F]\.5@,@G">$ID#0LK5$^\YP!+\R2"^61"EV`(W7]-@=8&
M(&-"%)Q_X#3@D>N$R`3XF1@)W8#=:+)!8B81"?GG<:RWBW9^P*P8:">R9IJ/
M0V#72)Y?Q'SQ@$0G3N+AE5`9NH^2^1W9<0`^`I(;:T;QO%Q8V"#_`[;]!?($
M[<]X0?H$<A[@X8'8&3'1L$0"T@)@I,B>H&@'NAX[3(_NGQ,4.P\N?ML`QA=\
M#[0#Q*%^AL6=S/*O<)D,@4#POP'*!ZYJ/37^%KS`M0!7S0M^=N3!/X2`%KM@
M$/#;(Y#F1$I\@_F#GV%-)C<)IP<V)N!GC-"%+G;2'0D^>')'$V)PX$M"'OP\
M`:3$>(W[3CSE>XI9->&XC[>?F+[QUM($_-$2[J5O7/?CX`&0SK<%DDFB$9D@
MY8,(*>@.R!$$1,3"E)0GH2U9C?:O%W>7\A^=7S^9*,3&+EVJ0>+YX=N6=1O4
M;/CB14W#Y45.'C`L;+#L?"3)!>+4<Q[]0&@J(%D]8!!YXH\A5Y%(X?IF/6?W
MIU`V@KBF"1EH0\+7T<@#]O[7-(A9&46\7]^?_<]G<7.`RM1WA0;*6H2K"31X
MTOA&ST7&;V$PG8!^*J_KZ'7\$(P2U;AW\>W\5/WK6+%_#YAQ^L(*0-J<^@[<
MX2(S=H`^??I)V.[N@,`92G/=B)2]#MKF,XI@4',F&!O`8T$Y#A\/!W35$SN*
M2D\0JSVXP2:XD/!PX^HWH0??G:"JFG?=HX3MC6%S?8?@T`3";[W>C2812-G`
M6RKTQD8"+O`I:/"L=R*#*O7*H^'C?98;(`2^H*)OU4[^AQX3EP>Z_"-7/`2@
MW/+]*>7!W<G_.Z7-A)B./GHE31CT_\#P@QA6H.ZGJ%#)BR(+S3`(8A];\Z5N
M:MP9;4<H:JZ1A_Y3(2:%G@:LP?H<D`7<[?B(24L[`SQ^MJ$4R?DN*A-XD\'6
MQ\X?K$?FGC)N9>Q%H+_1?/7DT,7^!@S(_9,[AX",!V=$Y!`]N:`).H1)8-K^
MDU&W3+P4&L:+@^I$Z*$]0"8+7A*2+G-W;ZB0.N`N`AN,+_FA$-V1]R>*\O@I
M,FB<@:%F`!CUFE@4]6[<G42&!S0*?$I*P[.ZW,776<<`M08V#[?)A+5UN=PK
M:+>X$(!#8*2VUSQ%ZC*&TY!N!XT(3/CZ$,550!ON^?X4=GGKHM*-PE`2Y7_/
M+`1KIU$(^M"3!_\6IR)4G@48S!!@[K'@(WAIBV<3$,@Z\!D03;/1\OT*]@3.
M-I$"?H'-O9;2:WAU?7]AV*?&U\O_^7YY?GG_C^JV$;=-2C#DD27!DW.S.*"H
MC_$+Q(?2U.YSM,U%\G6,QT`L`2J:+QF"B&&,OAP$W0&A\"C4-#!B_,?(%%R.
MM7>.,(J9>3BV3@X\^$,T=/K29AYIJ1'BVJ([``4J7&UA1-+C81J!R1*!K/KA
MLMSTN/'<0,*-X*+;13IJ-%46EF4HXGFBRT.?T-`!X41./&']#+"_J@-J*Z/3
MY(5]]Y&%V@M/G00]EGOK`)ADA/WI@41"3]('VVQT6V:M!DM)&.@3#EWMLI40
M+DV-BV8_T.Z:]3I]X=2`\P=<(.:",(-]>!PN:_AEZ(`"319![+#?:1!,<1,/
MZ)4";#(>A.,E#A8=.ES'(/H??3#%0%./<4'L?(Y`JMX_:N]$00^ND;H,A:^.
MSE3S/TK]GVS<,!B`YD!J`YD)``$L%0N"(QV`+PHTT]E2"9',`3O/'BH51!&)
M23V<^KH98\Z<DC(M"(R^$SU)A8%%N13-0Q"&\+AV&Z4E>A.>`BWY\4F0"5O$
M+C?L&LI@MD&)G(_RF@"S"DU^)Y(O"R>/F!R/L(6<0V4(R/JN-XDCH8HCQAX#
ML-C]L6SG&#J(O8^1ZQK83-BP[$]':QZ?3T.6:LMT%NEO;9#GHR_C<<`!$R>*
MC<%4_1*;-*-BXTK9E'#!AU:KAIR9.C6'0WVL/6-E"/P02*H@;5BZE/"OJ#1/
M22+#7UQL`#T@*%"I<4,@\77`L>TF"XH?+JUBN",/I#R!18^JN0)"Y9Z$Y)EG
MMPQ)8Y^T7);A8Y"`B,T@*1(UA'J#NK](4!9\^N2.,#0#/V4_2G(+^?8!01$R
M'U:10B!^(F^!L`O(80KPDD<:J9]'I[R*$(:LX%:7QFL.'JR:V0*Y66NU=>0?
M+5,@-6"P@KNT`DV)Z!.?+3I8A/;'_CMV=[Z"J>:2V-1DO4>1!98\0IA*$3BA
MDZ$P3U_(.G3PZ)X)I!HI*=$R0[.0U!@4N-HJCT17(D1%#D5X6!-ZRMF:'V+X
MD?%DT@Q1%*4`R!,Q(*K?($ZCQ/(`(GE@EV5B-"4025ZA#28XB-2=%TV'>'^3
MCQ(L0#3,THCER![N4UPJ;,@H[ZL?D$K&/GVX:_&CCP"*+Q4T#HG@<@)(@\*.
MM`N!!@JN`<[574(F/,H-7W`WF>ORX%!1H.-5R5;D;Q";EK<QK_#"&A>K#B/0
M[@:O"ED[8ZM]:][13,P`L3V<HOQF34)<QL(M*LDL!]%PPF@J/Z!2!+?$&'WQ
MJ/)0("`&X.CEF,(%7I2F#B0(T\`S)H]^_PDI?9".F9&*J1$EGR)*PC_=_A2(
M&*F3-2;D+J%9(^_Z2#6/Y&1"9@XBCZWWK'O@:(6I\,PL-KN$TTH$5(7CRG_5
MO4=*7R!&\U"_$T:'5!.41@R<AL)/WG?X1SE0K)]<J&A?`6&%(8E4O@U9B`IU
M5ER0^:_K-AC[9K!KA#AM(WH*IB/6(406!=+NU">7WA(;(L^?L<C?,%/IEA@@
MB:?S!M"/5T#9O!3U4^/N^[=OO=M_8"[3W>5O5Y=?+L]Z5_=&[^SL^OO5_>75
M;\;-]=?+L\N+NV-FH6@Z'J.-*(S`E)69^+,GXIC%!4R.+A18+@;5*6:*+S(3
M(45'L70_#,@UR$:34E[%-/$\KVJ^5_0.]5GU)\X32;O\)!<+O3AT!0`3S2L7
MR5WJSF29J@#/3>`14NN%X>FQ;'X,);<'#_]T^?)X5>[AR,U#%&Z*DVP"=GQ[
MK-"C-P&CVK0<?"LB=X3F?D9D8#2(]4/TUW/\@3U&TJ;2G4\)\2B4REMP"5J/
ME>YO;B^OSBYOOEY0HN/9]=4="(+SH\[RR_-H+F3/+`_*VU52YU08'O/3!SW*
MI_@GM7\_"5Y\H:G)G@KN(!U.O[L\-7K`09J$$M<Z<)1,_Q,Q&18)H`/ZD31G
M$P[3;''6RA,O/EO(\F95PT(Y:<A/]7M0;@5A'_D((5Z[F*3&%I>&-M\5B6C"
M1%@ICH,X$F$/B5;EITR,[#18"4H0-!V>2&LW+P.,K5^E26YH#IN,NRTG)H-;
M)?_F0%DQ*>-?>A0^6&:SQIX9^+O[9_\)'7#*K^>)2@@$KRZ>BZ@=%OX&%TF9
MK2!*M72)UJ^1,`')!ZLD/>["KOTDW=W9-]B.)6&N>5/D+F@AH#/4GECE,O,I
M6/\FTFX8/7D3"36&_4)W,.WSA=BI_22BFD-T*(EXF<`%X"6SP/+OR]@=O"NS
M&P4)"-,^1=0F:;RAZ)_/1Z.^J)QCTH)&WZM#4VF3H/(C>N#AS&BQD,)XS#RD
M,4@90)>K\O8>[>6"$D0$/T![Q^,:S/>%<KQ]EO<5]2R0.^A&$8K4O*#TPZOQ
MH=,UK7J3/2D?;*MCVNT:0J9X6GE@D58_6#8_GQN@.=I#_7Y'E1(7=_>7WWKW
MQVLQ_'!EZ'(E'7Y629!Z,6K4G$<#RK&,:8K@3Z3IYRJ1`Q.IQX[T>5/8="*R
M7"A)=SB4"8U*0*5,;V&8\^NZD4T24UF_4I;2Z*IX[CN\$NY6YE.L%@%F2R4-
M7\I5R-$'T;%($QS\$ED85`V'-I%FJB78&8/%A7ROH5`H$2).R>C`*XAN33T^
M#'++?SP9D>>5=V[*+Y-WV`&#Z)E&>,!?`VS<(V\)Y4T6X964ZH6_Q]?4,@-1
M;,VE(<Z?8C%,.HJG;!O1_=8G9\?`&V(RB4CYQQ"%VNW1RJ.SWMW?J%R+?KCX
MG^^7O_>^7ES='ZU@TG+O2*ESPD%$P7Q?*SRBX`/9&/`#YW$#N0)I)EED6'B$
MOC/0F*(GX+@3]`J;QI/W^`3V.,<1].@+"1\O,AZ`H\C=@=E6>H00Y-<?/NA;
M.K<K.$3\T4=-F_T-8\S`)@YZ8B&#U1BDUV)JG\;QH1?]0=\B-9)$*[/F@]MW
MIIRIH?U-Z7DAQV:^R%S@:3@!EI(R,D=P&;H'109IP2P#ED2'QES,<":B#,\`
M=L#0@U-T1G*/JH(E=%VA%$DOZ0B=X"^8B@7PP2[@AC$IL=Y_U9<`$>*Z8_)]
MRFJ?"=:C`/JDM@H+J*US;(F0KYT[:?OPF-)V"(B4%3:3DH91F(&(!K@RB>X%
M@P3*9B2_\<Q:Q\J>9]=79R">;LG'PEZ7VXOSRWOC]O+NOX]6:&%Q.PH/C.^S
M=4::Q4N0RO2%Y^-I4N^!.M23V^>(L'2TS&2K:->_?.A4)BA+_25R4U\G+VCD
M]J=:(OH7X+"0*M<H`@6FJ8A^$2AG`0@/6?VFY.>7\\LSK5IS.B&[PF[6."4"
M\^1S+!Z"6KEOB)>R&5QMRKXR,`3#"0Z>3X8J:U8D7BGH+!*54[%G/6+B4;PY
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M@B#RQM[("5,[.H8LGV^)]O+D4"R5:W*$N15S+@Z:)NACZ`M'$Y60BRP>;@Z0
M0U:4HB%,,7&H4G&:B&Z-TH+"3Z0<&4FV$/F?6']0@245=,6(>LRZG!.._R,"
M<\9_C)\X(Q_ABU2-CA#B;)D(.J`G3)%TQ`_*0D+!&,ZS`V2A!:HC5R<14[F:
M'#3\!N[$)2&C.6%>R+,B-B.QB!_4Z'SD],G"'#@Q!D,>'2H'RZ/)I*199$MI
M_B'.&`ABT7NAC^U=C_;ZN9.IX=T9#3,GH]8[8@?7S>WUS<7M_3_(R87^K1N\
MG(\6&R$&UD02"OH3)FS9H<$62UF#K$6JKNJI+C)WJ>"2AL1,(Q6(`L&&B64G
M(Q268Q?NT0%;5FG!"7(0\RQ'-"!,E0Z*&+1P$0OG/8=VR4L+%BS6?W@B4Y5*
MZTZQ`!#$,%^09/*Z/JF\E!/]!%A@22C<WZ@>J\(B6`*UWC'U5A%)/_@6AVUQ
MNMBI\7TBZJPCAUO8A&XL2DFD>VN2BT<SG;3`R4!D.PX2[WX4*^&F%1AH=4,)
MVD6]/MB5>N!4ST$<2&,G%370`B55*)5Z+%R=77^[,.Y[_^]X(VZR,:V1Q$EF
MPU'<Y2-X])$36!N6I5.4%4TO(ZT!S;N<'Z.-,I$7/@=:\.^@%<0OKIM#HW-+
M;EEC%A>:9'Q<]L&)O.C44/OP:)P*0D3UX<.1C-MAC@R^X%(HCWC@H_/)P"K'
M($0#-X$O2@.8R;556;A)S$W'%B?_RVUH@35VA4>)$C.6]HX(V'$MO@1?O<!J
MS\>'3XQFV*0G$H#AA1>,1+`KX`>?4HAE18DJEC;]!SG'C8YPT^!<=A'S?T`[
M04II$E+.G^P88/`^LD+V22M)`"71Q4>8/(@L3*%*4YN8D?<'NME`P_9),215
MFSJ8$()D5R4W%T2L"Q3:I!SW>+Q2Z]M-[_(6U17C^M8XO[R[N;[K?45_P]?K
MJ]].OE[^?G%N].[N+H[7U_`U&V<6(NS9<U\DGXU165"7-_(`5NA0O45,)35:
M=(O:OXTQ\->G7U"S@\3SZX6S,B)%L2*M'RM8+[4+GT0721."(1L=1]9YI&XX
M(;.-:*[S3]%$@47OU!^(418B#Y`\W4/J]D;:$OD`Z8,F&6QJXR)C,-)DNQ(D
MTKD-MJ'V`FM1PGV>>`:U/`*.MK&+8FT_Z]&R]-?KNSL#[!$#])%OUU?&W=]Z
MMQ?'B@P>E$JT.<%(S)/#Q5'*RGC`J_K94UU#?')NT;V4>"ZH6"5)[A2)J3+N
M]")FI<(+-"S5\&E:JE[)*/)$M21.C<R9I,7C`!5G][)#7@S,7+`!Z>)`MTS>
M9MT_L>-/$EB"@PDHI1CE%EDMU*%ZP+T%D[QHWH3*1])*]U-[XF@R>6B2K&5]
MHW"YZQX5_5V,2W,;&TIT)<\,"YCL:IR;Q6^)^`D6)#]CYSOR7LHHMTA=%IH3
M!FZDP%"%(*;`$^=2Y>)75F1$SEB&/S)EG7-WI!*W_Q3&DR,=M*PJ"EP]Z'75
ML(UCY<],.L.L&,>>L''`;3((%*O>-5MMV^Q837K(JK?-;KUI-NWN/$(S9:$*
ME?,,Y6%1\(QKB76"Y?SM8"+[0,B*=9'O+Y-E-">Z],H39<X>/'%5E'@RJ[,7
M#L:+WXXZB/4W#\L!,"*`;<M>9+VLR%;W,;_A4>5ML6()-)4RK;3N*,+B46V+
M1:]B52XNK:MST+3&LA.D\:^I`]8B=_*4G64'HIV9ZH,C,OE%KU^QIFS9B&O%
MF.*=J41X07WO1>Z)5G\)Y):BI%)!&/\*;KUG*/$<+DW6IEJ/+67]N8_*66TU
MCKB/R<67B]M;,-A$K/CJ-]`![XZ7P6@\7[ID.EW'PYG`:=]L$H_BF7]2,Q+Q
M3NGP5>YG;#2:=3;3=Q/_-=_\WK,68&4GMMZ)5/VD/"])LE`RUE0NKVV*Y8!P
M<P3H=>*2N(B=2Q]LK&NRB94^=%KUW`J/1685`9&YDQ/7V>AX.Z3<7OQ^<?7]
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M[-%+Z@64]N>Q-21;#O9#CVKUZ38;HW>.H<%W7IY<T6M1`0S?<$=)S@I7(8R0
M*CCO1-R5F-GG/&#6;!#*AER<3L^WD>SF(V.W&![HRY)?><<LV(Z6@Y$T^\WC
MP]3V9*,!#+\Z@$<MJ2F]6*EH>Z=6M3%6;(['XK,G&L4FN963;LC#`",ZTOF%
M+ED@5E@'U>SHEV/%WT?K$U([>]I45\QG-]UN)U9D-Y!30+2NC92YK5]LR@/'
M9R%KF&4O)FR;"7\8!'(<"I53HZL]BK3JG5BT'XM86M&[PN6?G/D@<*.9MLIC
MU_$5$+)%5#Q_>YFJ.5Y+:HYJK:/EL8\VT8@X3>R^%OBC5_U$A;#V?!$4"CC3
M@\9C<&]IU\.C^(5#Q_"MV?,'O9PZ5</!T)`I#-PZ!FI56`*@6HJQT4UUCW+8
MT,)O'>^IU3]AU$PU0-,9DIQSHG>5UM1.NGR=5]:]'ESVWZM;DC%=*I3N_]I1
M(DC&%$0L%!4K4G^4#A7T.;>X3R))9PFMMCD"Y@'NFLJTJ0F()PRUX#4&8"K>
MB%6W>-(T>(Z-&R+#O5:\,)M$3RV@7H7YP.8447>BFJ95/E83DG.A`Q'<)+V0
MCD8&XVG$.<A"9TMUC,))1B)ZI>O"1WT@VH4/J)2JNY-6Z+0[6ZK>@J!E1TA*
MKG$G>BJ,IIODZ?*N$_JRB2FG&"X^5#),69-4K*RT264X)R^)@E:QIFB8)#9Q
M[(IFYB@XO`N8Q_K%6,QP$8*1X%E)7]`5Q-11I(2EZS_APUH$(2D]2!N,'@XJ
M1/T%_ELDJR7^?B:1-^LE\V$^6@JQ\RB$W;^1O!8!:]CQF_4476/$Z0''BKCZ
M'-;"=(?`%ZZ&D9/D?P:Z89QRSJ"70NA_HB;F8^)>$</L5.@Y$7FII3_I;B%=
M%A_K`66<%*@KYM\.TM>%2>J9]$[-2)V#=L4JJBVN;%"?\=W17]%ME/&X??1.
MW5-,/F5+7ZJU_-D,`^JB[!-<LD'BH\[<AAFJ]*EHVZ7YL&1[9PN-.3[#E[V?
M#+G(^'E25LVL$I;":7K)4\TQG(8MJ2-[\(;3L*_JI,BIH7\2N<0/_!/]=_K@
MVLO$IN(BK.QISE=($N>#IH>PTX.G084N=JM&UV@H^B4K^QO=^)S=J)V.G#@S
MRM#.0D(\6E9-HNNVTNRT'"VM(Y4V6(M`4C/5LA&+H\6E*M:_T^KX,6`V$P?3
M"OU9_LF)0JP0J@]]<\<!M>F]%`TR7'UHIWQ,G],'S,\U]I0HFWP)\TOZ6*3L
M8VXC![U8;^=L8=BK,@!%$P%9QD1SK"/1@I@9.,/=JJ5.)IC&<2_R[",'8GX6
MYJM@U4:"@"",>"G,\^>UI!!*UN-L9C9NU)[T=@FD6$?Q2>AZXX=I&)$2P)3I
M)!WT9=OC2):#4`KSH^/+%O?<T9Z;H!$4VL!+;;4%K11G,]Z.-U_Y6FNK(1&I
M!=ZX>05(][X2*I0IB[7GXAA%ZZ?1E$(=&#U^<IT!E2B?3"<DL9YP(ACF1`5:
M*H@@&*1U9;G@F++@U84]?20N4W_`+^"4=U0F"`H6A-3B3;[S2>,EUW]T,+U]
M2HUM<90'^O@O,&`E54G50E#-8!89Q33TUAF+QC@AFO3RNT=+)G?WUV?_??*Y
M=W=QCIGM-Q=7=T?=!/M"$%TZ7Y6;*V$^.FF\LB,9!T>UM%?Q%G41Z'L3(4!'
MCNBL)/1?4=Z2B#>M-8'(8$K/7J4EQ"035/U</Y)V%VMKJETO]DM#<XO&]F0&
MG>@-YGGZ*JBTCVJ&+0)"KU%/2ZW8+`.AM!&PJHTN!0+!_1,'P46NF#A%Q:MB
MUGVD+0*LB7.*6%"(9@?JC3AIT/0?4;KOLVK!P^F_!BI&5+!'[SJ,AIE1RY\_
MRW_(-IVT09`G9SH6A=13:2]"7*A>4;(!-SO/LR_*C'AN>RFN3QRW3LH[U?[Q
MLMA>`LP-2HCHP4\C@UKQU%J`ZVE,"O(KH`-;VXET^F0S]($3VH5V%$F-=FHZ
M,0?&9!LBI2"@,/0BF7K*E4!(#*(%B9/3/C$I:URV;R.[9P)"[ANU?:H[C?,V
MO_%&DUY+Z;TER[&&E[,S4C^PPX=C?/:P=`,0]!4N`R+%B5!\/)H9.`[`IJ7M
MYC="U6A=[E<;`%C;7>+LOIWLB9^::XIYK@BP5#17@@G9(9K=LN,(WP]D-0&U
M$<I@5V:WB-*/P$\*3?0"A;52,@F0F3*)+7K0-[GQ&*U]4%BBB8.T^9]_J?V%
M_CU!NU'\>UW(7KQ!_/0+4&KMIU^-!\K9.J$4I4GD_F+(G_Z2@(.0A'(9*MSH
M.R-)%`]!'`?CY&F<'T1O#'+V*'ZYV7,(&N#!_\^_V&K3`GP&`H"A!C;6A"*=
MWB!-OGTR#%D+`O+XQH;$Q9P*R+?#N[U]I;$MOU08GR]`5(92M[[\C'VG`;`!
MXNG'\,V4+=\0G-3J_$1/_>ZJVJ@[TF*N69`M./KTAZR?\@3#&F]^6/V%^D]I
MK).V2Q^Q6S6SU:GM#NH][]>R&Z;=J!<#=4$4Q@FU?4Y4!E4E3_T`QARH.7(+
MB*QP>25VDX_-)$M[=Q`5`[EE=C<3^P6>N10A%Z)`I9=)'SR[N#9N<72QU^>Q
MJRAF?D,]J3CLK'+W%/:Y>4RY#S(J%0):#;/1V#<YWE/),%'9R6=2YE.&M*#2
M+6/>/K6;@*U!,`5M>%6QO_Q+&U]_.R6['6_>ZL+F:]:>R:Y\=\,^("H#Y`4>
MZH]-^GMH-5\S[29VSGG%?G*N_&G4S4:W`<I(J[0R:#>8L#JV6:N!<FYO)(TK
M@?0.(2_P4#_/[U^C"Z3W=<%_K)W6EG#3I^/><0Z%_4R.V-2O"O9VE;<:Y8>;
MKN;5FZ-[_G,PHGRRR`VI3PK!0L&9@0RL>6'29OV%2N9>N'V$FX22DK%1VO1:
MBEB1`9+.:$LZ0LQ&*6>K+&1Q+6<@SF9F/P88'<#&^V(+GXQ@)DHKGLV!5_;<
MHEQ";A`CFFMB/V$@FU<M8BO:#?HI+)H<Q9T#&(BGGS7@5!=Y.7=,=K_G>088
MO+,^S4)/,,S=01I>(X&5/VA_$JA-:H!DR7*4^T',%,04X)#/'5.0W#@>I=HR
MQYE&^U08+COP)X$E#H\'H^#Q]6BK&YQ//+I-YSQF)"81BO,[(Z0()C:*^2<5
M!SKYA!@&"U7%7@[_A:X<F!Q0'VOG`6>LJ9BZR*)5E0:BAQYF%Q@?Y=1'.7(X
M'8N7+6..M[/0P]R3Y%*CU#%P9H$Z"H>8ZE6E"V"*,)S"T/4X2DA)=@N/E4\F
M_U@3\<G=/H[UA/I\0I@&DCHE%+E8JB5O'ME)0:1_4*J(K"M^")Y=$F>A>R(R
M=7+RLIV8VRXD[4;H()+.%#1C4,O7X,08.L2C/9X?LF/P_!0I8A71CTU<OMS3
M=ZCU#Q8)27HW;>X'@.X)3&<Q!&M-T2&ASL3A6;7)W^BMT,.J6\Z7E2D*0Y$^
M+UM"\*VF7J-Z-)50(X<?Z!VJG"&V&-9'>-5:Z;[`Z9H&([."VAH*:-JU:"2<
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MZS]D[K#JZXO=LP+?=_O).)Q8ZQ,IZ5N?DYT9QB>R_/3.DJF<8+K`<2"K\0/U
M(F+,I*WPS"!FH07C9UF+EKI:%DQL,VERD[A$69,UK7,'RF66IV&\-.C#BVF:
MN"%'`"0UVT-'X"$]DW`N2DZ-.UQ$?DCDE*_63Y/F)J:&'BJW"8$POYFF\4,=
M*1L?.2C+/1>J1LP[`Y-/)RD&7'P>XN!2^K<D#H%P_2R$4A0.Q&S?I*`.1-T`
M6.9$7!*GQE<GBJE)L-PA8$:X9UBU%TO+3?2%+A8FO41Q5]K<MGU,:2R;+#B_
MN+W\O7=_^?M%-5.5)*-J4#@,7?<DF5602S8$S4=,-@?M9C"@MK?RN>@359_0
M!+.1(LM7-0E;F?>B)EZ0+]H546K^D<=]KO,F.=%T;G;;\HWOD7G$'KN,7V_@
M_IDTR\T$;<E#X841'L4)_X`>!J[].U9BH,X):6%"'3YR24$X?*BS`G:OX28T
M.4Z"9&)-^M/2NLTT%!$MHT1VO*./OR+3T<QXGQ(XTL)<MG30_$7<\HO*26E^
MJAR6EP;L-.D"Z`=`EV,OEN4?20Y`3,AVC%2MKBI+3R`I%2WMJ]-JPI3I(\J?
M*,HZ!UUBJG(L0U;"B8!RB,R2[!%^4C<P$QDY^?/O8-%3/W_,H50#M;;X*)NH
M]\=''ACS22HS1U%'\_GBZN++)0TD/[N^^OWB]N[R^LKX<M&[_WY+`\OYM_>7
MG[]>$"17U_<7=\9-[Q\]_$V)>&'G<E53FX>N0SXL-!E$*]^4)JV')<5,&_;!
M*8N$!HMP;U#L33@*7F2Y(GM<6167ZY`D"\=4XIAT>_TW,Z$CLI;JC5\_N[X+
M+(0W[IE:AH#YPE]23\I>`_C2V1?U\R?R<NB&R3Q[!/\&;^:-1M,:G6B;%7N1
MTIZ#BJ+-!'<KD&V`M79F3^A@2:X*=I6DJESE2R,Q&EI8181:(2QF9TP2$/ES
M)N>;4GFCW=]@,K&?-FLVE>JZV26+W5[\=@G*/!6'H[BAX8;D]?CMXM@5?#TA
M0NOB&#S`T^)6`TH;.W_HDS<-U?H4^WW@C?>"]=-DY@[=,)OD(-IIA.ZCAX.;
MN4)5=#S0^R,G_"9Z_/BOJB&/X"@9@T@,:D,U01$EO_B6ZO>?LYWTN%GNT4MI
M"SQ-5&8AN`/57QF;*8;!@YCH1'V:17":6MJ)CPNAD<50>ARK29.=2>U`[9FG
M.9K*"9-]&9L(\U!2;E#VFLC,(^;FNXO>[=G?:+;Z^<7O%U^O:;JZ<?'_L`7$
M-F<MEP8'/]QDN#@.":#8&L4EM/%/LC:90"EJB*:<ET[)%=HX\&<'/C"-I#:,
M#BAQ*>&(=KZ913\@T4RTSST*Q'2*`3X[6'&BN,$=8I;LFY?"=BQB=UJ`)!*)
M.=OL:%^526^CG'B5\MH=Y@?O$,("\X5+6LM>]F+U18`O*+I]%T=:GMS]74&W
MP>%@:4__C\<0U+H!2M@@_,7X_R[H?]8HOK^G"UI/5EF`C.+*T-754$".NUZJ
M_H;ZH6;-K'<Z.]G]N\);MVXVBVI[4!`;@-H8N_.$UUTF.:L`(5&BLHU6O6VV
M[8TNB'>P>;MEMNH+>'@MRMM*^4IIS+KK+U]./O>^]J[.+HR[OUU<5%XJ8>Q2
M70"Z==,-<?U7'&]Z\N",*,LF>G)=T38M\2J)@?3T!726AREWRLC[0W3KYM(#
ME:*<>')D\U>M9]=,4"@W&GVLYW5W^=O5Y9?+L][5/4Y")6?KV=GU]ZM[G#]\
M<WM]!3^?'3=-?Z,^KFHJ'&=94/59DGQ,E4FS?0`G8>`'4S&A0U"W+*7")HQ)
M.I1,?1;=(/4)D!04`/AS^@L:%#.=,YNU=_>=_$$GM:[Q\3Z8>'VC56M],L4,
MUDA!`>PA9U_*B372+YO9`(V]$]RG[SYA-VT/VI00W1^]#C/^]>=I=/+H.)-?
M[I+5>@H/-Y@ZXKG1/9S<YU'0_^.__N__P<OJK_*M<_<A/E?]S=5CY&Z&?]RZ
MP__\RY<P&#.:X/^L.!`H.ZG7_O)?6Z,I#*<:C5.C"JLB,E()F6+(U,R,R\K[
M=Q#>O]:;FR26HB?BF[>AU]#LO;]725UQ-R'<<MX$I/]G5@L/TJ$(]U&("<N7
M(L1_D)NHCF)OKL1ZZR?1$/(G(W45FCR6:#!=<!A%>]6*:6W9:9JU1=TO2N$+
M+&Z_]5;;;'7:1[/?HSO?9MWL+(H:E<U':]58E*PC2;;EV,Q'Z1("*AJ88H!N
MF2V[>6A`'RBFZ^V-,+W]VQM_=>Z%+HVU2GP<Q&\?HVUWL:H:XE8(V"T"[%IM
MMQ*D5+NW&F9SLXZ8V[[G4P)4>K#L]H3AIA;*6SZ+/30)+@\A[GCS]7;#K%OV
MD6[^V$^^72O*@_B^@_+GZPSM;'"8[$6KLI^MTAD:'ZRNV6UV576#:.(D"T:Q
M,Y-ZC>9+4@+T-,PT5=@5'LIV).35PBC7L2(`XXM&;_J(8[RM;K>+.?W!]/')
M^.:\8G^M)C4!$<D2!`HE3,@D?1`<(3>E3"5*R'BQWK8DW=B$RG(F5)CKXG!(
MCN%B$H:+3!(9'_%]5?*GO(]:$2!!<^V+27HVQS*`>1SC*1@-N(#Z@\7ZH8S7
M)5Y,42DIJK,GRL$L4T`P#/VA;9GM9D=,;0^G.@\2&EJ=MEFKUPD26?.?:=""
M,7516C30*PW5P,</-9"SU&"9OG!J]/(:.YD9\&6?,PDWQ_95[=\'X03C%E+2
MO8)Q>V/@#IWI*.9`^X/KD$Q2VW)$_T-^2-6#6LV?CE=&U(Y<1N039`(,CM96
M/CV/2WF30C4B1R9&+'\3I,@MB#1JY'YAZ4$'DD*C@Z//?><"_4<D)NYBUQ(G
M]J+A:[HK&P&BXUK*/<Z2B5C6X`'(DTUZV,DB<YG]0W^$A;)R3Z\5IVI%5]9J
M4I7D$.S(I`V#\^QXHVWI(O"_5FT2EZ[1P?GE[<79_?7MG>ZI.V91<^D;?Y^.
M7F6!H"L4#+@Z/S3$3<[E[B\!4S`KLP/I\93SI%\"HULS!J##,'6B0O)!^(JX
MS8>\^9"\E731E`ZKT?Y5TSBL1@?[#O2$^/&B?NB*UC5*WK':$5'++\Q>PU9;
MJ-%@R_=K``_%9]<4>Y.<(U[BBQJ'!\<C5N,_>I\DIV54%-%?(*6/$!#),&W)
ML,D,V1R]!#2/6J>3J![9[2?=&8P;U%8T3'`3=`]`%$W/5?LPQD8R'CR]JAI]
MW02TR\Z.:F.)3I;9B<E-T$"1FAVQ#;NPZG9*@5+=SD:OICP=;*=)?1/4E&31
M\@),*6=$G:$U,XGN%+M<=\HN^?`><T$G`7;1]-3!:'HK'K\X<0(D<RQ$S*F1
MUI$S=I-ATBXVS/&B,>><OHBT;.J5Y/EB0+CHVS7UO3BIV8_`<L9;BO.7@)-L
M&C--,)#ZT?JDE14K"#H)M:7:1V>'K^LMO)A+_$'2ME'VV<ML5JY"0%AVLA3M
M>>YZU,3$PY18ZIB"1<@ACF1HF=VZ97:LSCS.19Z>3K!)4;9[B2:+6`#D20HU
MBL!!H</_33U4Y*X$]'H32WK^8_043$<#U1)!KBJF,:2;6O9AR\?;TU[S]`SA
MJ@`.>H7K1KAZTKEW2D!I<A"EFKRL<H\0'^B:]59;VG<>MYCRU>E)L4F\`%`"
M.%,O>L)F/'"4.F<C9;$!FU"\('1EOFN3Y5..)F!>7*@ZYS4\>HFFH.0$]D`>
ML/DTSRVQ$DG8-;/>Z/*U;YO-6MWLMEJ:&`E$4\.4.)F(BU;O@A2$X^G(T6F)
MQ*PA1&QN#OR<;/9LTOO7P'^\=\,Q/K[SE'=..3C5^X?M*LE]QS1+*YQIW<#X
M0KA)I['CO95)9$_U%2=()/E6*>X'D>)>7++M#B-:Q4'_7>L-CQ]_"(V?U8KG
MH@7:0>[L"C3'F1WUQ@>['YD./;.G@\J/;C1`4`B)<S)RAR!FNLK3).7:25<D
M/LR7R$DFCW$FK(4;I./`_V5Y_':?F:S6W,34?6345GNO]OZ>]EZ0/%N:I[6R
M!)..3!&([6!JZ3/;.6"?=,F?.B/EBKF?5DADF9-DO.,$G3<!NX^4SN/!KMTQ
MF]VB>HAL2;-8F1=%YD/-JN6RW0ZUPH4X;Q]DDO^^^/!8\5UOFM:B#ET'=$=2
M"!.]="*Q"CC4RK\8RU?Z9'?J9L.V#HUZ#I=;#Q3AW9;9MDMZD>*OOCHOQA<O
M'!=T$Y:J[&/7`KY4FS_ZDJ>C/OVNV6AW#T=)L.WY6@(50:7\?ALX!P_V>.?B
M:>;(&W1!%E!<-/^("M[='I%5I'0\!GQ5Q#6OGK'5-;O=7?4BW[:GI'SZ\SX@
MJB`_3LCWH_N\-0QZ%?@GJX="#^D\*L@KR`_Z.NV-.<<1?9RW+C7''5`&%7!R
MCRJ'MA0"+,#=9A^D=_R`_9N'B?#NID"7[K)-$I$Y4EAF[JQ;;;/6WF$CD6/G
MS@-%>-=L[FQ.ULZB^-:V>+,47ICN`B=,HV/"?XK;Z,S*9??!K(RJ[?OWWA.V
M*L*:X]RKFXWFKMJ^ES*,DN-<>"=R=I&WN]NMF4V[`%W\<+W=52BE(JX=2]NZ
M979;"_JOET];;326R=NY0G;+4G1K[0WG(F#V\C0;[;K9;120LC4?^\609@FP
MM7TI^J[051'7_$[/*$:+<LF]ATZC+(ZYM8U+<_NH,1$6A$9)IR^#6G2\RO8F
ML^X%A$1JR`[U"9AM7;#%#@_[0-J:?1N,O"ZL!(S>B;7;-NLM>_U.K'WM1'S5
MMB6WV:MMF<V:O@0!(7KM8=&S(WI288,\-PR3&8:PVWX0Q5$.>)G%N2M23+=\
M`G#RULP;!`/UG+0Z9J>U-UK9.M5LVDY!-7PA2*I6"E4KA<.`OFJE<"C[.?!6
M"OMJGU#XB5;Y*Q7DI8"\(-Y=ZJ;?J`G*!ME#)1\V.;\?1.==#B-<VO]BH;OG
MG6WYV(ZXV6Z:=K.@_990R;!KM<[!5&L?9&[=X:9+'2:^K:YI[34`]2[:#[W]
M'/;1*>>8N?4P\6VWS%KWH,+%58NBBC./`=]URVS4JQ9%^SX&N]DV6\V#&W5^
MN-QZH`COUL!.W>=TY*I%T<XIH12;WP>GEPH!1WWZ("L+&XA\D+GUQY=7;^$L
MGF*NR,--?JXRZRORVKVP;73-CK51_>KVE;RUK;+RZ=#'&D"O(-\]Y/O1?ZHV
M1>^/DBK(#Y9[B[Q.J\XGE5/SO2&\WC1K]0-R+^RU\4DQ*"^LBT3%FN\:X99M
M6M9["=RG[LZC[4QDU7`:>W'[/+C^,55CHHJN#B5PMA\%I^I-5(R3N]UNF8WF
MUGCB$%S<502E(JX=2]Q&V[0VP\N^=-:J-]&"]C%@@30:IE7;*.MI5>P70YHE
MP-;VI>B[0E=%7'.OEV[+[+:*:DA<;&^B/(1NI?.(P,H_IU'L#5]9'J_>G(@`
MR6U09*2;$ZEN*MMN3)3>SWZZ%<U';>_;Q=7YQ;G1NSHW;B_N[GOW\(^[B]O+
MBSM91'U]]?O%[?WEYZ\7!,K5]?W%W;&BZ](W_C[U70H$43\G:I[![9P"(Z\B
MG>"96Y5^$P9C+XJ"\%40Z4=L^\.;JS?R2]S99R8?^62\>/$3=0MZ"D8@>(BZ
M^[``L(8Q2;Z?-%F:A.ZS%TRCT:L!?\.&'P^OQA3P`)N&]61+J\$4_@,K8K>F
M<[<OFEDQP]20XZAAU.-CZ#[B4Q/9I`:TLY'C]T4WJQH53YT:2:\L@F$(3`R/
MOKI.*!IFI1BR;F9W],&B9%#9&8FQ)9I(84>I)]<+-1@08[+;E"/:FJ@V5'A8
M!$4_&(]A(U$<]/\X-4#,*-@3T:)W7B)98;R`!/D@RK5I(5G9<+12Y(?K^4`<
M>"B"O"/I;3A";%Q+(='0&K^E!(4#UQ7PC0OLS0W@%`]?C$:N;]R>&@*E7YRQ
M!WQZZSX'?;J][D.LL]'$A-5H_TJ_E/_L_/K)-!S!.\@OSN*N&-F/41F!]BT&
M\,D#%M`D!S)!?^1$D3?TD,<BX\%%=@&A,W"'SG04GQJ]R)@`""PGQ':9L7D7
M"?M*#M(X&'F^U:I))B,H9CA9%S7U1MVTX6'",/XU]/KX[123'RM-]D!!1@^@
M,QJ]ZD=`YT(-^5X<[QG.R8^]DX$WFI*[D&\+KX_G`E31I[:`8'6[X>@5#_O%
M"4,'-;'9*T4T!J153@W%$BW)$O$3+&P$\`R(;0?($3;X\A083^X(-&D/J!YN
M!OE]/OQ1%,S`RW(_!;61A?AH#_T[GI3AP?DL83]Y*\,#'BC9'RS@.F:F',9,
MM954#.BK:]DT<H5%(AA,30A*[0$8V*Z;=:MCVLT&P:)Q</3DA'JCRX2?"9@A
M$,():1**'O'S_7]-<3/3"?ZK979J7;-I-Q9^+$:@W#_=L.]%KD;]*%Y.:PV;
MQ!E]P/C(FY0/"Z+#C2(>8`78J*Z)Z0T\^5EG@&>%AY+BG[$S0-V+M"6,F7YB
MXH=]\D[JW;9IV_;J^S"T/5BUCKX'[)Z(//+L2JF07`/)/0X4UP=XD$6U>^&4
MX/KL1-BNDD]_Z``O/CNCJ2O5-'4@"+^`.$=`4+=0NB8R`C[=,]4Q1D$4X6J1
M&\>CY/J$U;CK*"F*9KMKF0W;.EJ^O\3#[S\Y_J.K,)M2$5J_2MTYDF(>2'0X
M'8UT_9H.;>;*)8X3'R49S/KY8A&,W(\OS-X3DD),"84C;BI)(+ET2'211TA<
M,F;D"H\TCP!-`AF%SPCHT`6IQ0AC10,_.,L_3H*?^1M!>++"`G'&QA4+6^S&
MZX7<97<@Q%_NQQDILPM0W37;(QW4%9GK^-L"!;RRMD,4"Q\LF_[X(-F69`=P
M%4H;L4\^*0F6O!K4#2),*\&2\1-\E5F>9'RFV_`@Z9`L[>8&XL4+!D?+G9^]
M<&!<D#%O7"!1'+VM!+3<T4VE/X'/R7`W7H#=`4/,SU.X/9&<,O28,5]ZRK!*
M[JK$1R+P#H3=&X'F8M!A9+[`SVQ@3K%_;`63*E]#6F9.W7FH:>&7??<QB#V2
M'Y$2QFKCY"F5_HW)R(U)?-,SU*(<-X'<F+Y<\<_>>`(JBA1#R0?994H<K%JY
M&Y=^^BE31S#KZ2Q+`R'[YDD^==^@"XV2.5FR@:V0-`HWG`E<)W]Z8W@)\/7!
M@C]WV^0/FKFB<$50_F+0::3EF&_@S-Y3FG&3N@:76SJ\\5))M7U:'?-)8X'9
M(<Y4&1U;,3/,)JB'G49+4Q((BOD*-;L&!?C`,"X0TFIFAVW6;=1%NTO5=49$
MCLJ^0[.#8-!-CU/C<TI1T*&FKT7RAG?$K8YK:])I1O"""!M-R<4L7NP[(Q`-
M@$3")+E^E08F90D:_FNAW:HWS8;5WMQ&2EE&!,\??O#B&P+/:UA)QILM)($%
M$/,*,>N;24;*1&JUT+KOEDI8[=M`2M_Z:"&Y2CD3-F8B>A+C*?<"*H^-1+R3
M2T_V.I:2GT$&F1.;&C5Y%M,B@\;6#9H<.,"L:9C-Q5;-`J/%F3?E1-XP@,87
M#S8BQQ@8P3-?<$)F2Q2\!"S$1MY0L3?RW,[8;)\LE;2[3>+%QE''BJ]];0B0
MU=8,G#0_LF6ARY@D^#BWB3`HJNC7%1-C*`5B.*/J--H=T^IT-,:>$Q8A]L`O
M<JQG[KTZZ[+MFK5N8Z[DF'?'UDYKW9:NU42NV%9+^!51X>(M4MI'&F/TI##(
MIA-QM69$<@;2#XVFV:VU\,>I/W&\0<:AG17A0A5RV2"843I#%\19A#$](?I8
M@W5H]@>(GQAD+$?2T^_36NH?J+:%+KXY()F7N<&9)%"??8@SV_O0`@6G6V>U
MPH.3@@.+G...=ER?W5]_OKC5>_I>_W[Q#7^5]/2MDEE26I#L@XQDF>J`S!JE
MX^&%^J%1YPZX=..&P9@GGH'BSA*B#_3KL9/A&5@G8&4'T3T[%NRC2ES9K`6S
M2GM)Q,1&'P+\Q%.\\DD3"%$Q(:4%_2[QB^OZAE96BMCYYKPF_T"9U<_X?<C8
MS#4S0*WX$VQ,=<@:*^LBT6XF$I$MS@2?:1,(8.\_L8L"@Z@I8TAZ.R;3$!3<
M"`482$&<*A8NB:3-%]9IR$!0C5TG(NSEVC3I2T1*O`?7=X=>WP.!JR%@Z-(Y
MI--Z4LJ:0Z._5-8?B'6X&]')\Y3)%I#J5G1JW$W[3RS!Y5LH:C&^\6HDPZAF
M,GN.5G1>"B\L(,'6-91&RS(;M>[,_<[^$J4YV"`?VK5F2J%7])<BLI3*P\[4
M#T*]QZ-C$PCN,TSNGPC_YXREEHE<P5<B.&_^P,*\+Z3F#BWV41]/2,DC=?S]
M)^8[M0^R:-A[BJA1O"^XQ)&\CR9([=2JM>?I-#FW.][=F4L==)1VMW6T5'B?
MFGC(TP2CI^`ERIQZE"3PS0B`N1?:G&O@X=704A&K@8H%#E1,!M,UWSZ8+O:>
MO?@5&?'-HQMV5W$D,-UI_"2DK!=[[(=-9\HNKRG8P^2>^MS)/8UFK723>^96
MV^*OSC31H46DE^0@[Z'Q;#Z^/[97&$#Q:;<DOCE:"ZB>+`BMUBK]A;>!URT0
MZPX;$"W#:GV)=#@H:MVH&&LK>%UE9M2!$.M&?:>V@=12-(K8C&Y7&#A?'/9*
M46->BL-:R`V?198"I\OL_$!V7*VZ^5BLG+,HMEBU;);MM9^YK3DVJVH9<O.C
MV('ER*!!(!)4C?S<5)GPH7P7Z./S4W%(54X'1J\,5D:Y'I:9R/<'/NRLE;V>
MRU5Z`C^(#-4E0[W8@_+@CH(7SH%'L#%R&SEC-XFVBFS2C(<%-A0^LO^RW3;M
M5I.]0B0]`_8QC8.!-P2N/^J@R:4>I.3"RW4H<VN$9ZQ`=!S!V2[A&8N)[IOC
M.X])'8(316X4";^XV)K(ZD@E_?B:FYM]E0I[#R[@0J3>#V,*'3JQAA?\P\"%
M/XP]7Z8R)*O)!!%>37Y<>%TU@.#UB'SB``FH$H\^<8(?'RT?W$T?(O=?4\R4
M`FS-7MV:5UQ&6-*.['3<?A,!J<AT&7EF0_]22&=CWI;9J:-'N3,W/B^B_@LR
MZ?*^V<[]IAX3F!]*LFKU;)1K;IC?7SO,3S!\L#I=L]9IKQSK-[0X/S!XMF:>
MD[G7.EN"8]/S%4$(SB70:]SG)!WD5^8Q4>0F(O@IH<C_HK)+*>L$SNE(1'Z"
M%LZPFI^.5DST;FXOOVI'E\EU.E:T7&KA\EHJ=4#<N*FL`2E`D7EGDP<X*IB7
M/<!\D?TM76,!F"4>%3<;4?_)'4Q'+$8XRJ^'#60,GV_**/6Y92%\8X7(/?X!
ME1FQMA>_IF/YZ5`^HV(VBI^*H-:YA\9:D?SY\?N=$L;>^E$L25%(I5V+0U@Q
M1<$O)D7AAZME(J`]DLY7F$;2T>,.AYR(GMQ78S=^PE1[D89*ZEPJX10[+^1Z
M(*@0`_;RY#S3H[!EEULG:>%5/15QR5UUM!?!GBSZK%JTT*!"(S?/H-+/=S>6
M?*X1Q0'\XZX%K<SORORNS._*_*[,[\K\/E#S>T\"X^+F7N;VSS'&CS:O/U5X
M5#?G-*MT#!2Z_=";*)U"ZR#`9;MHE^;F]V?Z&]P(4S742U^3W0-+/WO$!5+1
M0$G#H5*L>L5*`A)DZ8SZ&4F`#X/)!?P%XFB0:D#FS6]'*8MRJ#60*&60-CDG
MY,E2P81'%Z"&:ZR3E@JY6_GH?4IY%F:VLAJ\[4;=;('U3R!\]."C^=7/RE60
MO2_J9MOJ)-63:V?^URU+=QXP(+A1`&;WT#3JS793F@WZ';80U0\(G[ILL"4&
M!O2QC`+3)[`B@%4XQ_>Q2CZ472G`,(9E^M1B!.3+)SI@=BBQ=/?3W2ITO57<
M(6KSCR%F?/>="/L5!'W0[L65^Z'%6C9W2-#:&:9]!X(FU!6DNJ!PEU8/A(#K
MRS8_>,?ZRB66$*AT+JR`LTR!BT110`PAP1-FA5!ZX>!7\TDEKC+0^``^-',P
MJ>`U07<'T2U6<0`(YU'AA(42X)@.4S#N@S<0$H-Z$HA'LU7,@+V`;G*X:#^/
M@@#EXZ/Q]?3F5,FE!.,@9_]P8TS2YXJ_F0_&H3/`M8"V(N-?TT"VD9"?0OH!
MNOE$#U+#`^>5.B[T7=5B%_`^":*T8Q$-.ZQ@>?BGVR=M.&G8@)N`-4$P/23R
MAP[,S"N,8'2/G5?AZ0&"#Q&!0!S(VEAR$1HCL)C4[VP6C&@`<:]M=CB*HN[0
M)=646T?0#8&26$!)SMWY.FFFKXIH12`KY%EVG.[^OBSAU9W.E)N]MR-WXJ",
MXFL)&T3S@<"?\DWO'U(T+VSWEWPIIV_2?#T@]4GE2$T^>RD?37WU*3"PFX;6
MI&2^*%H(M584R)_6>_7PK;GH=8D:_0MSNF.C),@O%%2]L9MX9+4VP:!Y=41#
M$PP\F%K_$U(STI-E9\ZO5(K^+OG@1@91R&!3I&EJ18)T?6*G(()$!EN8`%R.
M^:A&0*RSB7HRNE30!F6??-*T0Z@!D\G(XU[+XOWDD="142B-\60#"$7]"A;I
MHW.=_E.ZPG&VTY5H9H2.)?CFE!X1#<'0+'3'*/Q'@?]X0M[^D><\P*V/?3[(
MV^^(/:9\][EX$Y(=/X7-8166-(O4/\G=.=V26D</<0X`5^02^K`=VD2T,D!M
M:CQ3+L^`#J;<\$1%!7.7HXMDZ`UC5]/$8!7^I'KTR1F(*`:>*9SQJ?&96_:0
MV.1#SZ$DV1PE<;8";X8NZJUTE_+D-)`"NA6?IZ4GJ`!!@2B@;3G"3R4+#%O=
MNFFW:G2A:W6'8J+4T3)Z,A9`-I`B[*6BM8"R+^X#\&OX*B4I![(,=;L0%2A7
MC8EDDHW5)@+[PVFMV6@1O<./6LVF:4QX3AZ1WIR.QQHY$#3I!@_"2!47&[>W
M7GB]S>LG-^9KY]0X$]_"YD%:[R"PJ)-@G2:S4$.0U;`1ED].1P,.]^F&*SVB
M5U1RMT&.-7)IM),?[4[W(P/9T\<@*+PL[W^P_M#>B/.D]TSO$ZW"/=N[Q&S6
MVJ95:VI:);YQ!O:;X[_J?9K.6"V_0T532!R"1),Z)-A5"W3MD_J[['U[23!&
M8B4-<)KB<M`(;T@L\M'$,S@[5E[/W)LD??'FR/B5B=;T>^R*+1P'[WQLPQ3E
M!4S5Q;#`".T#D8$9)/T3`\WA(S5!$AWJP-B`84+__&H\>V&<1)&RUVNF_96B
M6*5_TX9)-U$]HTC8I=7)K.NNJ7PN*9V270[8.<OQ43(*3:)]%/D=2$GS*\4=
MK5HX%NTH,IIV50S^/HK!<XRHJOY[P9N%U'\+KW0Q4)>W2K$\);6-6A/[&RY>
MIRJI71NO]3W5U;_GDMJ]U2DOH=5+:=S35+SLJ#J,HF#?8+#>DUR?H5O`J-]B
ML%JOF]WV1@)ICR1;E2B7L9[\N(J4ZU;;K!7&.>^[2ED5MUA5/LV\ZA9KHT2:
MESEM,E=)HS'6SY[1O(P$3D'9,W4>>2K2!Q;FS!BS^3(B36#.!D2,K;#,&0&K
M::2S9@B(57)5$E)KP'<:;TA:22?0&"IYAI,%UDJ@*1"H=JHD"$'95AX-BI(D
M<\98F#6C`%F<.0,HFLK\F?JF^3/&G-P9X6[;7?Z,,9L[0S#L-G_&R,N=T1(X
M=I$_8\S+G2$X=ID_8^3FSH@(K\R5F<V?L8K-GS'R<F<TB3Z3/W.\%[0,[N@Q
MIH^Y&8HB+CL_2[%CV31-HDAQOPD@"3+?")$NZR6I):J&$KJ15A6IEP/P_(]4
M^%%C*;[_DTP>?4*0W)CZ;)+FKD-`<3>^F8EUN`)"!$>F=..G?;Q'2^A5>MA1
MI8=I+>BKU+`J-:Q*#4NEAEG-GU9-!S-2J6#J-':9#F;,I(+)^[]*!ZO2P:IT
ML"H=[-AXO4H'>T_I8&6CKK4ZX`B<IKK@J'--E/#%[2UF@L<D=$%X/@34O(>U
MB4'&3R9=E@]\F7UH=,Q:H\-IXK-/H<AMP"/PGZ,]V;]___H/K?J_]_VW[W?W
M5=AJD2[%)OK\6+QF@6J]V^K-MMEJME!!0.^5<BWDCW9#XR>(5$,#9["L:UJM
MJ[FEI..]#]+1<ZF`-6U@<"0AOP5<,LW-$X.LD"=[TT?`!F5R<;LM?10N@9JH
M&[2_Q0$BS,"`_S3;\]RT8@A4U6QMV\W6/MA`F%V[M7G#-0&$%QD%-5P[5AES
MH7"5]4OJ`2["%$@@78LCCO.%QP/,7\3^!TMT.DR:KB0^!2"J)7UDR/^)+1XZ
M9GNAMUQJXD+3C$.G'T_3=#A/4!WM26<[E>6XGAWT`F&4F'*:"<?9AB+S6S9A
MCH0*\*NYVXDW!JPWYY5:VOG2N2*]`I+HA&&NWF80TDX=T5`-OY/T_-+:HBWH
M(V\UZF:]5<]-.V](=T6JYY=HZB@6TI1#D6Y(])=J4S9?=AXMX:W4&HS:3`7#
MH4PRP5&?&0++]]M)Q3KETQ&_C`S1]`JI(_D0TQ\1-*<E.*]LP7+>B6VV&QV.
M+92V9]-.ST_OU&15ZOD\@6KI_C!0<>IFNU7+:XLD$A8RZ25X3[5U3]Q=XO;3
MNB-KBG)J=?MHZ;.*J1Y53#7-<U5<M8JK5G'5@XRKF@I"_A!^4;0@S>'S*Y7E
M]ZJY8@D;'[ITTP)D8'^:W;IUK!*@"KY6P=<J^'H<O%X%7V>"KU7P=,7^&CJ3
MJ7M_QNV^3-&NNFT<?K>-G&/=;4'K.^^T(;Q`Q4"]QTKP@^FT896S><&A-]IH
M58TVMD"KK6XIB76E3ANE[+)AF5;;VF21/9+K\379^*AY:<I$]\?56*/P5B?O
MO+=&)+)!I3><DD)IRV8F4"U55<WJ7FI+)0DS%+#"0F-TAJ\E)H[6VOW:^V%\
MN;S]=M0C?%48U+:U@9:9_)Z;=%\1RFV@>"6[=\))0$&+D?,":E0X5O7\^D@;
MT9<C$Z40N8-CYY\!Q7%D\P)^$2`)7J3CSXGIXTD2%_X_V"Y'B1(0.?5"BWUS
M3NI,J$@%$Z4U0F[C!S$D,8E4-2G20NTMQK26BL8;F3G""[H]Y#1[R!F48NG3
M9(6W4S144-[?^"FG2X-(6!F(OB@<T-/\>718CC$<!4$H/Y7C@19Y;YWLK#BQ
MATBEY&"J+05V..Z2&ECY32+Z7$[4$?Y#/+Z(]B5#"\)>(4GHYZ;YU+F4W@]>
M\OQ[_'61;B5/A))"4^Z]]'*--X[)E5OZ"M3^!:E]IP-Q]RDK\,/X/?W;)Y'W
M;Y<66"UKBS/CDLPM0\_:6C]72U*^KT22D\K.(I(6`TW%@"39UT5>M%8;_FS7
M%#LRC^8D<>%VE19#./_KS]/HY-%Q)K]\#?S'>S<<G[L/\3V@[_,(V/*__N__
M0:7HK_(ABG"(Y-@+NJIQ@7-@^%&`>=3J1<I.A7_<NL/__,L7D&R(NI,:_)\5
M!_QS]Z1>^\M_;>VH6Z?&Q?]\O[S_AW%_V[NZZYW=7UY?W56#>LZNOWV[OC+N
M[J_/_MOH79T;/WJW@*#[HTUG2X<,,..AY\9/(V"D;^X`[2O3N/3[IUJLD.!A
M\C?N0\>/G'XL8@JL](+*^HU5UHM*99U)'IQ3U_/WJ>^F<F,)$.S6-7)C5PR<
MC?16;2I)6R2U1NZS2/.8R3W3X\DJ1UL$96W3ZMIFH]'(U6XT'07%KV76NBW3
MMNW\OF<S6A$JDCYH/^D^8)1P:]?,#C:EHWS'I-,,WMSIL"03'/SYD7KI4>I'
M[=3JUBGUHW9JUUM58!@-5=0\IS1'6Y8N\@78-'6+,JGH6$Q_DCZLIMF&W]B=
MED8@>(7#V<14):8W!\O.=]9&FN->X.T>Y3Z=99)CKV0)P<QL<TT+EJJ&^."'
M%ONG\^LMR;Y`M<(TVF:K5C>[K<ZB'6B4G@4C/3SY0[U1-VT>L#Y3RX),(L:E
M+\>6(Y+1XG#:C^F$"(BA"VJ[2NJ!77!63Y*3I8KA7)$=DR[.F(=HX7.PS6;7
M,CN-A>>Y.C8LJV5VV_.Q81>`C6-EZL6EH&F6E8JY%.M6U[3LN46/^HV`4OON
MI)-N>@=Z?,PE0'TLG^-*C)`3-O#S.+*!,WYN1IAWA(?-IKWH6YAN9::5C&)X
M02CW0VK$]XC91&[XC++>9.+QN:HK#H,1CVP7.:GR,5%:^#@=.3&Z#))'F'#E
M8WI&,]?G4%[6AWK'M$$</%`&BS!!4N4[Z@O<Q=4=5#2X>CERZOZH-[MFM]G:
M$2%*[Q*29!XA-I81(G6V[7O8:W3H]7-I3Z.C1A<4HEH.'>E>X(J6"J.E;LVL
MUZQ5+I/Y)-"=3P)28^9R0)4:NH0(Q'U?"9/M$X!E=NMMLYG*:%U)%TV*F7.Z
M$.2IG1,GQ%0DYN.0]<ZTYC,GMWFFS[7F1.]89KW=7)`97*O27&54@_I!V(U9
M@R3;;I7H!&@"-?Q5;!1R([*UG&KL2C4.N(0QG=!0$=-N`KUUZ@L:1VB]6PF.
ME*"IV^G^K>?AJ7'VY,;PTMV3\V1B)VLO!/4D"&5_C`R8$C*]K:OX$'X!`!7B
M)C-!''7Q3"[X!QL,[GJCBS]/??+>+BG+QXP/3NYU<COHY*?=`VP$`L&GRL'H
M,+L<$3AFHDXDG-6>I>R4Q-(UB"3(#'9G)_\TT$'$NC+H3J0ES1)!H]TQK<Y"
M,UBC/OPB6Q6:KT=T^14\DEW`KJ-"U%B-8S+-&C0OCN:];VK=Y7F+&690T0-A
M!.?P1!XJ/C2:9K?66ID="(B$);AC2:H.95YL%%7),+D&M!!)\BEJ1I)I83#"
M!OH8*',?XAP&_]!JFHUNG14.+\*6Z](5>[0<]E;U`LAIB,9%XCFUS5:[;MKU
M571.6#*8/C[)LK:GA-"QL!$S<!(_)ZH9'VPPC1KMACQ1>B>MN,ZRBC,!LOO3
M&P,9@TBEWO6I4J*(6S`-IGTVFHA#4DV34AO&(BD@V)'#CZ_+[CG82:%$L&+D
MC+GY3B0K3Y(UL+)/;K-2C#>E7#);00#R><\M0L^[)#XZG\A-^P3BB'M!P9U.
M_>]%6Y]/.L7S04N2S3K\3=2;A?'SX;0&IIK>4S^6582)H,^Z]6M=2[CU\1HA
M*!X^44>R3!M^0]:OR-@#3IQ_U8!O"MCG7T69,,,,+%:])6"Q&G6=R3"*@[V/
M*-V`H$B%6D1A%/E*B:6S5T^7W=9T]<!YL/*GE?')1OK9%[OM!NBC]LR6,D&:
MU?FWT6G#':)SKU[+IS%C$BA?.0:>#9[?<H>=&["K7O6P82G#Y^U3X_;B:^_^
MXMRXZ=UFH^C'*J.^7QCWURG$7!YO'QA94RRD8#`<@A`)V3/-41G94XI<"4)F
M4GS3&3QCE&J`QM$0I"Y63*HR^X$[I'KG\<0%'N%(KS_X&?.^4$MU_\3?<X\C
M7/?!?7)&0TX7PS9W+T'X!PJQOC/QL#OY@)KUN:#9NJF1(5/X2'\:BJL#&QE(
M3?<$4^CP$UKC!+V6E]IR\'P14120V:C6.8(+C0D>8'7,#G=D4:\,U45/KGO$
M;;*N9TCE55?EN0G%@&6DP)P[BMR7)]&X(Z;3E`WY4FB&*]$'%&-!G7*B1[E"
M?0W9G!7K!/_7A%)**<X[I\;U_=\N;HVS[[>W%U?WQM?+WN?+KY?'++^8\$0?
MCQ2ODX&-K!M2/UFM.4>2*`1ZY3BJ:G\+K/TMO&1*U1+;:M-S:H73YL6;5]X"
MA*J4KZ"BE;(>T(;%WCNN;]P_X!L<Z=LJU%N=GT19?<8M.!]+92Q,;[9K9KNQ
MH`:O:*CWO%_+M%I-LUYO%@-W062WL%Y44ABG(PS==&N&+7/VXC+;=M=LM!:@
MLFAP]@[V]L5,ZL2]?TV%YCYPQLYC>4Z^WK(Q6??03OX-8.^"TUD#=]3I*PV\
M.+R4HO#;JM7-9K>S>ZHHQ^X;;;/=+JF6@[^ZYREV\\S!+1_'CLO?+=.V6F:K
MMH=V(.78?J<)^E!AY/CNB_]%`H9>K"KFJ9NJQW&2!T#@4//*F1RSB?-*[HF9
M]+"\GJD?&NVZV;!MXZ,3&=Z`DU&Y"0'G\'-HK,F%'I]D;TJG_R1<A*D>OX[H
M_HON6IZGPE/N8\^?4H$UYO&XY-9A*2#\AE0/AD$Q5[7-#EW.91B-U!?EG)9>
MG(0I"894,0G5<,\._LA6F3?:EEEK6(8#Z.Q[I`K)"121ZGWK#I*\O9S;4Z*:
M@%"))`IGGW(]H"NX,;.>SR^.%_Z.D<[DV:A$/L_NJ?&E=WEK_-[[^OW"^';1
MN_M^>_'MXHA+'7](!R8@YNZST;L[,SHV$*F82=;X=1Z^$"JL%3V_O#O[>HV_
MOU/O&!^UQO#\1;U%.K=L]UWNXLP%SE'D\DRE%-6J64S8)T$;)^)350Q>S-QD
M)!+E\E&J4ML3G?,P?^C1IQZM'%9^1)."JJ^QORT'"3!N!!>(]^S0"*!4@^P?
MS*M^(.'$S/@<,%G4S8**D:0,N-P,VW]-9JV@_#SB9`]!)X`("LY'7.653Q<$
MB9JNEL+WBP=B^,&5O<\]$<M3P2(D/JW^3FL,RGG0(%X?`RP5^\5(9H'QHZEQ
M-DEG9`(FB2K)R*'V&]Y#*A4^65?[[)/GANC3?=UB#*'<1/#5?79'AO6+\3]3
M:C"D]PD15QMQ)_^>Z8!J%$@=Z"?(3C/HT3(5X]/^Q;A^P'H+4K8$3ID</7\R
M971-_4`](])WZ$_,AJ0<A6'P0$UQ:*:%^`YH@<Z1X[?^B_%=PYZ1Q1PV7=&Q
MQZ'^"H-D:#]I<B\U9%9=!#S,8@RW^=C[MZOBKE/.(9WF8)Y&403\Q`SA([I-
MPP,1_NQX(VY:]H*M>@8N9F-R2GDBE8_Z9-)W'JI(*A<[7U=BR1$I7**HD/=>
MWDG-Y9&,A%$#,K`>6G"=NN/[#JMV*E6<H,@'4*4(Z9DV,SH$CD.CTB>Z=+0_
MJ>U[OLCSU%)+DH02F1\0@';'-7-'2T:Z"9SNI9!,D2%#V']==&Q8")]T.4C5
MK[E:3@].3@VGPC1'VL)/BT;^F3D7L;0_'%A+C%Q(1@3,>?IT]U@LVX%>`]EK
M'"%49#%Z(1;=TF1F`D)"(R79OD'12FXC4B@2%7VF3)1S_`#I3[X']IPQ(I9/
M=9WDS)8'%_3H*N>FR'[[JP<*SEW5>:<`EW!Q&11)DVO\]$-H_*S6.]BL$&$1
MW;`I-+,O8(J>&EZ,MA$Y&&8>^R@LK$\'B8,[^`7=]WYL<*!0LVOF[=4^_+W.
M;"UE;LS;>'VCC6\_OI9)+JFW?A+"1%W\7U>)M!686Z/D:0%Q*#W_Y@TQJ9K9
M:G?-6JN]$P2\)]2MTLR[0EV%NG(S;$%B>&&N#2<Y],AC^LY"^BN<1N%W?XGV
M_[:!!M7^#WW_;Z/_'-GSOG-:TOU^@VD\\GPW$K,F$C7\A?H5R#"OZ$;@1-%T
M/.&RM&G$Y8HN?!J;$63CAIX/1MG8$3XET0_#S(N'HV]1%G6C-QO=9X.!*Y-H
MDIX7W/96<YKI'K!I#%KTOV4-_6?/#\;H)/OJQ#%U3IC$LM,2/C,.!NZH!*''
M4;HA^\)++4TOL\W,=T`\Z\";(C0^P&7$9FR5T`0,2XG-V!*A;?_$WK<#;RV=
M;R\IP%O-*$[Y2Y9U6*\ON>.VZ^9HBW&>MU[TAS'$7)/4M/H=F$UV\Z>YV*N=
MUNR?C!/@DI;]TZ[MD)YJ[#/A*>$C;UC`'+TEY9,U4*2,1%$TZC0F<<<S7_%7
M%W+;SP$VV!QY\>O6-]_NG';QO*U:X[2Y\P-7.QYXV/K3'Q1H?L[9\%7@NTNV
M^?YU7"UD9D0B1D#394"S&..L<.R>PW%O&528S7Q#;4%&X/,#K[)=Z`ISVGXQ
M-'3L`#'O6QM8=`W-X8N21C]ZH"N.C'<5P+N5J2-($EJP8V:'*T4_2KS1,VX:
MC`V$A7DRR*;0@)GS;X[D@P(T'<4\8$4ERQSDMN%\4_E(LP=+\_F6G_LK6G8W
MV-=HYA$TX+B'T4&B*"W_"V/M;:LLV8!E;7\-`#9YTYK;">!0=E#MO=I[M??R
M[7TW]O%Y?J9Q(1?@"E&8\D08WP3P/D)BQP7PQU5IHJ"$M#UA-H?I*\_)SCTG
M]2KG^4#Z#&Y#1ATB#$L<4<IK4$KHLL;]H1[C!AI;Q2^EI,BT;ZV4(*;\78=Z
MD!7'%"0_R?E=2N"R?NE2`JE[ARM>VM<IR+A4*4DD'5@J)8A)Q*>4X%'4I:0J
MZ)L;DA\0]VW>.;N^W[/;$/!##_D>?O3VD,.JFY+]!@*ABIL>T@ZJO5=[K_9>
MOKT7)'A72#X7SO>3D3N,<8N3../C/\'?T1=*&6:MF\U.Q[3KW=U=S&^"]^""
MEK99[]AFIWTH8>R/5JUE-FL+IK7@K_8=86V:G5;#;%E%#=@H-L`*_VO5)KFB
M+=,!>F$[YVSOYSL<F)J:@MKS!_3+S]C>Z<9YI2!GB=I!6[53X^[^^NR_C;/K
M;S<75W<]G&6Z^S!S&2/>6F=<CGV'KO-'A,6Q8I#\>!+X>)X$BHANT\S<$^[F
ME9K6J29TTE!'^FH@)^S2<%!1V/B(18BB9R_-B1\.W7Z,G<&P:W)?]/(=3:E*
M"&?!3UPY;)G@X`'*@^S@:)H$O;P:@9Y#:VJ+W?JJX/H.?6;W=/IZ6>!^#?S#
M!C-;8OEN@=Q`/S\P3^FL[-OO81:UC<-T_U:G4;QQO+)74K2?^QT3*K#[QQ`>
M0.U4J"3E]EG,G_+8Z9KM[H(#*`/TV]AWNVYVFJUR0[^-?=NMFMGJ+)CK5P;P
MM[%QRVZ8=J,@2B](^!3KF;OT^]Q@&6>?IC.*N;'*.!BHS,32S,?<EROL[9!W
MFSOVAATSLBVS6^ZJSS485>H0PMLQ,['M[.(:TU_BT.OSO`#4,\CE41R6=]R-
M9RYVMDJB\\^FX`U6^*KP=5#XRL=-JV$V&B4=M[N!G.7&M<N<S5N6J5MKZ;DZ
MR2^S\<I"[B5`5;MA=HKP#AT!JI9:DN\>5W,TU2[@95GD>3^Z:CE5^WU`5$%^
MG)`?L)YB>'Y_-!5#Y7PWIL!VI;R\^UMF#>5EB4^[0E6EO%3*2YFNHPKR"O(R
M*2_XJQ_9B0+^E(+UV+J&,NAD0EXPC:/8\5'LZ0VR9S+P=JZC%/O)N5=(LVO6
M6UVS:VTD+M\1)JQ.VVPU,`??/G),V("%1K<!-%&`&G;0F+`ZMEFK-4S;WDC)
MJI2)8[K8*LC?HS*Q@2?D\[+L?=8]=BXS=VZ??JR=UI8(S@7%2P=KE%8(JA"T
M#6UD763D",?WW;RT-QJA@4=-13'=:%&\'`$)Y90*K89JG<HI$U6S_I,1H^L;
M'OT@''+TP`?AA3(Q"PI'`'G/[NC5-+Q(^<`)",\'?G@-`X`=7Z.:,?A6XB\G
ML)P^[L+Q7Q'.?H`8YZWYE`OA<(H5_!?W5DWU*#E-CL.XFX,7`D6N^5:\&$_.
MP/`#PP.(5RQHXRMQBZ5H.>2R)RK]@0A^]N`+<X,E\'^.\:^I$\9N.'HE<!"#
MW#-7M-[%HD*J&I1C$>',U5`QY\4)!_CTT/5B+&0U>!7\<#^>8FZM^AN]%7JN
MWW=/#:R&[$_'TQ$7Q\N2Q"'!X`QH'X(BM"_@4#>"S0$J5@F!XP#TKW_SCKPH
M,PL%OX#+!H/LQ]2&X!W>ZX#@8A*5`.EO,%SIKL(YM9!BO04$_.(@<VJ3*7=&
MD&43I=>^\?>I[QHMQHQ)%:^?`Z0J['3IP6'&01@9SF02!L]"E,6I4EK*]8R2
MS&VBV#[HY`X<?S`$!+MA)&2"_)R0WF<LZZJVSVM7IL;!9(4ZH%9M\N>FU0EU
M^>Z2SHSW@?$M/#7^[N#N>_!#\-IW33AOF<@/U.#T_S7UD(%!+#T^ANZCD&.6
MV:S5S%JMIKRT7'(M[PK*)79P@"M(&S?L>R!N<.`JO?RA=FIUZ6JAETTNX8;[
M!HE2/37SN8!ETD"`0-3+\C!=AA`_@5S2JZ80D)DW291\L!LMW(5V`2<_X9?%
M!YY!Y*'0)@[)[IS!XH\.E)RE=_3T:]PX>:M8^WCQ0!+C,^*KB&&@45P.A/_L
M&JX#>HS@OJ$7PGOQ"[[E>S@4UX'K03%G`LJI\=T?N7"/NTXX\@#A\C!`2(`4
M=L.QYSLTC#=.-DN0`=1X[HF(L1NG.U5=N3&$YU?B8+?BX#88^.ZK<7=J_+<+
MM/.ZHD"PF^]!'#2LM:5!IV[6Z_5-A`&8)ZU6>P5AD+L$RX"$_U]GN9\^32\W
M,B]'+EHHB]\^=-E!DJ*2'OM0)CZ?&E]"YP_<]O$)#Z.2%(<C*2KYL#OY<([:
MA==_0A/U;\`FT]'(6U5"O`L!T3'M1?+!:A&7;R`?;+,-7+]</.2NL*IXH)=;
M>Q</QJ'(AZUX?2Z3\Y3N1><A>':E+P=^AZ0LG3<F01.LZBH:18'R%VF'F'80
M#<GM.)Z,@E>7G9SSF+;>)JXE&/;,N00#,EX"8):/@\A-,7*T@),YBH"LC&_)
MY]/<;&?N8N6`6XVE:Z9MKW+ESZRSD*D)B"QCVSN_^&4P(__R/T)O;@Y?SXL]
MI`)!:D3?Q.VC1SQ]%0FAX`=$EB@GF/?CU2I!%GCJN<_B7#>]B)\A,3T&2-I9
M$G<RO0BTY@.1,0R#,3(X+"\"`D=+%V=)*`D0:PNI?::?UDT8`-[&QXJA2[S<
M1J^$'I8SC"-UCSDY2".0!.*,C_B2@+[1_I7P+)$J?MOY]9,,)7-W&]$4-)H"
M@0+_B.L2U+NF=I_F'1,\!]<*AE\?7-?'Z2Y:T&R"8<=@&HU>3XV9^$[.UF2L
M)A-PU'>`(AIL"/J]`EU_P)0P\/8"'W#I!_Z)O.&U_8R=5V/BH(7A38!U074W
M?#@Y%P[%0UM(/LDW%OSLHJK@X"Y!LH'$4>K$!Z'/O]#<TD2_X#LRT2@2K4&_
MXDTA,Z8`+W_RP24A@Y?Y0%[;&85"A5=)9Q(YY^)&DTK%@S?@IU-M9%/:A92)
MI`7%H4-IZ0/G-<+#Z[L#%7NE"QC^D/CL(S#,C%>X*LD$T/0&0M>3@[BB2Y->
M<?E4\/DHHP98/]>-Z43*=[[#Y:_6"!-D-*121?*VDWW"A/'@PH.^Z*Y'^-+.
MQN3?N']Z=&$10(JN%:4#B6J,(*/E.ENQ,IUF!(W^Z\U<^I]#P@3%)F2LA6N1
MA._>1,($18J,[Y`#4U1,]+G,L,P8U2#!07F<XF]0V1^[+JD*0Q=/=ZJD%V(W
M);=GY$XT(WA@<4RE8+$9NB@LX6OP93Z$6N*PRY6-?(@H;#U49@3B&`\JBB[6
MT+\>_6+TIJ#-$=Z].(;UX"('<^,$)!^N::;OAN2Q?N:Q[&?&K&B=$`P?&@N_
M)9\U^#F2$U]=!Y,[!N[$):Y4D7U\S&IR].,(4GQZ(%/%[#=)E?D4('2%]%7\
M@JDO$3*JU6F8MF5E#$<0#U(.D[I-^C/6,0$9);D4TGP46B^SSK,;9J\+S(:1
MHNB;$\)WZQ9!TJ0CY8MC!0.Z5$KTWO,/@9E=MDV</I_:"0M1H4L)K0CEK1$Y
M([HY4W:L.#;9&SZC@RW1`@=PO-,(1?F3&X+R`HN_N.A"45HK91JBZD%&%L/R
MJN?>2-VT]6LT3P*P#15+IP[0D_@$"<02T`,LAFNHS-M%E35IBL'7E`MP/Y,(
M@*%'(/$CD7VI4M+@)+FTD5/RQ!T-%N]T+.3#%`\>A81,I(O3?F7/!^H<\VG"
MG1QA4^.!T'I%KBI-+,BQ]:>Q-_+^+:_PSYX?C$'S)DB^.G%,DF$B/NQAU`+E
MGCM"9Y?)J5YK993^L@M&?J_1F3>5NPA0V@UN('OK1:#9X3WC80=LO$LPYW/E
M.,[FS7#M9J89KCX+\+3UTQ)_?>'U=CW!<"K5=N0-"RSEF;-3JT9W=;2%W2XI
MI+Z0^WP.,"<8AS)O?;?=VJE=W_G)JIT./%3(_4&!?6GF#3$.?'?)-M]WP.G^
M2>.DA,(H#)*R19_`8`[@2B%PD@?9NDKQHF[OR@D[,Y_C[=8;OT;>>#)BQ7SL
MQD_!0/T%PR%@EO5#[R')6+^[./L/^.S4&SA^GTVUP90,]D2QHP>E1QH=+JS%
MX0"H4"3?2SC[TS!$,RE]R5*E1\AW."KX<N_2Q54&?_6!J5:7OO'->95%.ZXB
M#%1>C:COP?8HON$,GKTH"$7)!=GUPL[%(TP]BJ4W8-^1BTS88&1.)=D&DRE8
M4ZC@6W9SE?R"M&EEL5NF1.;5X9VY=-W#H:\#/9P.@98*6_65W8.DL*`4@O@?
M#7@4$5RI@M/"<K1I#'=S/)T(`DSL_A3+;J*DWD5*LKX3AAP6F&.)U_10MO+V
M^DR3)&\0[(P70!D;4?_)'4Q'+NE;1B`P9W&`G[T2Z3^0@R#OERVN`IOY?9M%
M-;=A(1X0W$`NN!'5M>G>91U?25@Y$G9L)&"/`&#R4FGL):1F_\ESAPE.9=("
M@9?)?Z=UQ6MH$.'M#_8*?X%87LAZ_1O\UZ'GPS%C]$'^[6,$)'(5@-EEU3Z=
M[H_\#XU=]V#]RJ";IVD'VF4[<&)GL5FL$V:^:6QLP2RN5W51E3$\8TO43NN=
MGXP3PSYMUH[$*JZS40R;/C+[N'':^HEV;9^V*SNYLI,K.[FL=O*>JK?%N>K-
M#45FT+.K$DG1H@U=E?#7%P:QS`4%O.?U>$BKWY4F<EBS@S><=GFENF=>+YL4
M6>)=J*:@4EVYD*;T#9K2[V-/M^[8\2C_Z$R3I/>8^`4R]Q]9+6G5#6R@6>R+
MQLO3(J^";C>*>,9,:MK)F-M%G7L+L\NV,^2T8=I=[#VZ8$!C&7;PTZJ=SY9O
MN79J'^$TV_IIMZ!=[]3\$ZIB<<9?*:;'-<RV99F=7;;#7I%]YK',+@>HO\6>
MUV;.GEK-<E\DZ8Z1():D#4)3;K9,\@N[96JP[&*AN9=3UZS56F:MWBD.&85L
M=&L?63**LU"V>=,FBN'1PE6^]^"@XRQ?(YJ.QZ+@(%V;CTT^T2VW4CB'`$IJ
M&J,D%]-X<$?!2^5;.0[?"G[P`7_(=[(\)`QU8*X)M;%;=/EB$]'4?AY"X^?4
MN3ZP>CGCDGD'&)CQTNP:%7NSP>]2I2NZ0]J)C52]R0(UMMSVF]TRK7K=;-0.
MPE`O=N\?:J>U=@O+NVJGC04V4QEV4:RC8H$%4SZ37?3-*(L!*+Y0R/CZ"O*U
M(2^Y-Q=_]1M'I,N"/-OLMFVS5=^Q5^CM@&.-YFYA?HLG:R-0=R%!SS"-831R
M!S]?4%NA;8\#W+77\Z/%&;&+M[5@U,I![GJWS/$NMKX;Z;_0:)A-2GEG9U.D
M;_4@$;"J4;%')&PZZ&D%QK0WHN==W()IMA1U*.06W`=;[F\\ZO*X_$XI<U^(
M*"6;[G@FV^*,A;78]3T$2!9VQYJ5$-3Q)'0I[YC*Y_ZDDATQ\NI#H]LVVYTZ
M>L2GOC8^*E.7A_478FH:UN=H?2<GSBM-A=(*??1,UP=7'TI%97%.?H&1F%2%
MS>2QZ0W5&AQO=K&?>Y39*L<(^Q`R%@T?F^)B%9[GQR%.V.J+:JS(PR+)-5KO
M.K%J\(5ECW92]LC9ZQ@YH^_EGN-L[>0,U-JQ_O7G:73RZ#B37^YP@:=@!%(B
MNOC7U(M?>_Z`?OD9">U&T-D]8.SS"#[V7__W_Z`4^*MZ7]177@_I#DU]"6L%
M?S@A9:Q?A[<(=?(A2H>'?]RZP__\RY<P&".N3VKP?U8<\,_=DWKM+_^UM=.V
MK%/C1^_VMG=U?W>L%)\*^;[P6<V+]A(DRR8E5M'>HX_V]L:@=W/VW*X#G.\J
MK+N+<.VN=[A]+\N<:*V\A]YGH+9=,]NUKMEH%Q2[V]:;"ZI\T>9JV&QS%16"
MW&'4U*H7`_(NO!VEBYI^M$VKU3*MVA+/2H%N^@54V&G)KN9-4#1(%R\&46\)
M("T)8.S3IWU)+5W+0DM6TZRWFV9KE\GC*Q"5$FT%@?4&6EJ4S;-?P?3^@Y&F
M56^9]589Y-RB&VL+V-UB7&&SG>Q&.,[3.]]]K*]CFVWX3\O>@__\C2KF@5'_
M/E6#A>)<T?ZQ!M2.G0=V'K(JC!?>=\BJ9/W87Z2<6-QICL!8I=N<N7H7]JUA
M_;VXIM]S6[EVE]O*V=V?M&^O?UT6TE(N#X#=70M-T7!.<WRTUVP\5TB#N<58
MV`=FNG"K()ETFZ>=U3O2O;WSW.YVN/,>=/"_5FV26XV;C4YO&EV686K''0]^
M.7?"B2-[!O7\P2WG5-RZSZX_=6\Y44*D7.P[)FV?&N>]VYN><79]=7_;.[LW
M>E?GQNW%U][]!?[W[Q=7WR_@O\^N?[NZO+^\OMJ5XE`V':87:<.`/%\T)J8>
MZ$3:]%OJ@B[[[A$\I'O0H"'"<I"3\6'ILQ_Y,0=4E`%]F_K,T0A*UW\$*4[Z
MSP`H:11,J%TZR/:)"XI,'W^+J1CP=P!FRLD@!(/G]Y').4TC<B<1C7,'Q0FG
MRSZ,@F`0Q:'K8%LK'&_IR?208(A]KWGZENHS.'`='H77#\8/#A[0/Z>X>;`:
M!Y[+T[)<W@`/B*4=,2XP.<D8>G^Z@Q-.&Y&H8A5M`BCU:0`E#[Z524>XI2FU
MT?O0,MO=AEGO=)/>V_U@&O(P9AJ4QQE%QA=<Q4BOPM,B0Y=G5M)@/NP]_>R.
M71[W-X:->I.1B[,V^R']&L`8>R-0(0*?.V++J76D>DY'([%5D;I`#;"Y>[V8
M]2?6ULZ8H.`VC9F'Z,1I-M[$#5&559-#=7A>@O`/@`27C?)VH68,:X`[C_`5
MT(,X>^O%%;0)*WG^<^")S*%'1*I/W\$9>D/&(9^"X5"8/3K=/?^5311<@PGH
M^<YH]&KR'%::5HGS">CD/_+Y^\FY?E+DSP-DD7[D=$>:3XGK/P4O<(BA*41`
M-'V(@%)AQ[!`,J];&VR6&@".-H@7<B]*;(4?/PD-*TN'!`HO\>1$^O?0L$))
MQG),?XF`I5TABXE!C!IQA2YE$H8\47QH3$8.#>XT46B!J>>&/(!Q8/3!\D-/
M#_,`H-J-Q;2V#!&+-$,?Y,H8O@[(55,C$_9-9GM2TPC9\]1[F#*"A@(I^)PV
M$I=,/^1&AB+%I?>41@GF*.8T^@&9GZ'#J74.FJB&,X)-FP:-SR79GK^"R>#B
ME$R>@)L6(W1R`'<TY+%V;&P.LVR(>_)H9,)DY!$8ZD+)E2`TSUT`2NL_():\
M@2:NB(UGW@M9.6$1*829X[_FRC):^M3X0:<^QHMEP$(I&0*J'@7@K_MQ@-<=
M7765]#CG]KT/TP$0/]ZN0+!].9H5J(FY^MQ%8D(:D)1Q[@YQ)#N*'..+^Q!.
M,8O.4DFCS-)\\_-Q1_U@HN5_)@?"@H$GK<#_#Z:/3WQWSMQ9R.CT246BR)'T
MW6'0)W<,?AQ=+9370D/I`V190,FS%TZ1;9&&2<O`":U]-Z+D5+R-PBG=:/AM
M7,J+Q*?5BI+CI38#&@*\C98!@J+4@QRR>W@U/G2:';/1M5A3F+=G(F.\TTG.
M$I^YU-/7P-QG.B,Q@3C6^SYCKK08/LWG%:IFH2FQRZ>2@*6WA)9GI4M2.2<4
MWNB/ICRO7`P95E@A58S/5`(A6D+SJ3LC3(5$+^8(]422ILB=A$QG-,8T;]2S
M0G>$:9C#R.4%0&J)0<D#*0[X"UHK:]D_6O/*'6WV]OE:$QAY`@Q.I&6%:R!H
M@_4`),O4!0&*'G[\0Z/1,-MVG5EQ@+.+1X*X<"2M]DIVG,NQGLHWB1+#/FV<
MVJ>V[F,Z=_'J\E`U<]#E&;_J)@%+$T"N,QP"+\.%CB-L2#&2E@&<])AF5;D!
M6"1"@<DH1$IC1H7O@]5MF_46F-G?'!_L-_H#3KSRT+.`V@-S</(VEU.@^H<C
ML6A`-G`\?\T/8B.9"2WDR`2844X7!VS!0R$][$EY`Z89L3JJ2`%:C*RN_`>I
MHT&8UNG53S]$MWD7"!MD-5>%2-6"B$U,6!\HI)((%H@UWHK4/)CD,*?0G0#<
M7.W2[R.O#>3(7"EK66K3)"'8*+S`\0`NGI##@*7Q@Q\"C--8J@&7TCA@_(9'
M,6,[RS$-G6.^P)E%3T2Q<%\G>@!%/]P1CHRG7'Z[29=CZ`DCM0\4%GJ#1SF.
M74PG$(<4O48@'LD]_PB4%80+6:@IYK\G'$0@I+G(V`L'$2"+N<C(Y2"!.Z&J
M`?8TA,F;G)`4:5C"?>#"JMP&218T(H`+(.!S$1.DY[&/\>Y8I[P7T+>NSDGW
M)-=0/L;34`X$:=F_&MW:3U*UMAO&$[JSB&>`4$:N`\I:7<I$8#'0JI\#5`!9
MHX;'^`?47&%-4H<CJ9:@83_F0C])70L8C8`0]Y6UX+[:)J<1#)O>5_F<EKJK
M)/93-9)X`L8L]@D6<0+#(H]@?=:4\JYBSR*&6:XX'&Z1QD[3)G,5]DZM8[;K
MW;F'7.GPZVDD]:P._R4(05O$[`]4)SWA2QRXF$G"AJZR5NE?%(0@V0-&K8<:
MY@1GR9X:G]U'UD,?IMZ(/:>HIAB1.V(C/_%1&.+S],ST@09]SBK^NE="*O]-
ML]G9H3!5CN8W*_\K"-.A.@F6.'0:AG822E-\"Y(7*SW&B@I/$H#:KM(S+V6@
MXN(T%_\(O=C5R"$8QB]RAI9PY*.[RW##QP#3LOK*R2@95T1CE>-TCLZ\Q#A?
MP)\B.K`OTV(5XSQXP.@@NM_#0$,G?981:FC(A%_/HI/=L^ZCLR9&*[8J!5O5
MTVQU)I7,68N=3C111Y4[!G3@$)0A(7Q1I%(06PO&D^9[:IP)Y[AT\[`B_8C$
M'O5#UT7O]U+SPD;U:)<W8H'F11(=8`SDH=I8&<WL.LA#M>#9]&(+T/U&DSZY
MI2M6W-C4;Q9CZHL`E;`U%]F8"^^UA5QV`/=:L89\"K<B,.<\PC\&\S$M+.XT
MMO?@._OKS^NE%&;[Y8#0AL^3$QY>PR\`A*[?]]SH'*[[41`!%LO4)*<.%\WU
MMV^7]]\NKN[O*!L14Q,OKWZ[N#J[O#C:SCE?+WIW%SIJCA41%*^G=C]IWK?-
M>JUF1/^:HM8[Q+2;8,AW[)]N?QIS?@,RIH'5#E08UNE:->.[CX[X"._H,\Y_
M^NI@@L_=%"V45JL&/X)R?.ZYCX%IG/6,KFW9MB&C\K*%5@N[85`/+7(KD>`C
M-Q'!0&DT*(9$'I'+]<8H=Q+'$S*82*M!-IUBJCZ\HF8.,]PR<4PL,U3Y-0YF
M@24)9E?!,W_68D<6IXF,X;<J4]6'8Q@Z?9Z`C2&Z#$*;[58*H2`B2"(#+-U6
MO6E@;W%$TBVI0><A+*LA"RG`PQ,S*2_\9_I9X*].(''BAF/4NV(WC"%2H1Q?
M>11"#BEIJ*XU&PFJ"64/[@C3QUB#Q'W1IP;)]F0VE$JZ"D(._B(^T:\@B,.'
M:R%*LDLQM"GO#/KDT3I.?V#J6Q08G/^1HA3+;*=93^8LC9R'@&S&UX3I+*O9
M:1IW`262!,;OSFCDO@)4SD#RG%7KIGD.H(%3\CV':,>:X;VZV;7:&=X3R3DB
M)U-C/>D&'/'0]TBD_'-A&;%E)FFM0?<V/JORA`!%[#6.@\S#39T:$TUK58HT
M)#5JF%M&D<=*D->`I@O.-C/N0*'Q^_C^I=\_)476&WB8(8=4%B6A44VZU9K-
MS'4A90">=S[I&N<N',.-$_ZAQ%TP!8K['$[]Z,7K_V$:5W_/H<]FM\7>X?3]
ML`_Z)#@VE9A$GQ=WE^+(&ZU?@3)A4Y3$!S*ZDIYSB/46I29F2/A1RF@9&!\Z
M#4QOH$/\T.K0\`!Y+Z4B5:)WZH)FB/@)BES):E>@T-'KT>+\Z\5OO:_&M][]
M_<7MT:K+7RC\A28ZII7`?YM&?^1X8T[;'SL#5Q6'3"/IG*#(=3CP?)2@28'-
M`\:UW4AU`8:_C`:B0`CE#(@-[U'D\YZ)18`DG2@*^I[#I:?R"5H>Y/0_15&V
MYZ/Y*U)[IKXH?,'2"/K&U!\ZSR"0T?P'B=O'%&.Q?M#O3T.3D^Q!"`*ON#'"
M/7#&SB,B:XA`F\`^(*'H@P'6./P3%N%T6F#&)^_!(]M]&E'`D!V%[HABNBBE
M`Y3;(081`W2ETS>H(HN3F0UV<8A.IK#&T3(=^DGH1$)9<0:*7,[I`=*$X_$U
MJ5@2W:'Y7"D1VD''*?P6[A9G@'::*TP<O$!%[CF5I^'M+2\BD7-&MZGH-QT:
MPRDYC(00/36N\<2$A@8@(N6@%S;`<`J2(A5C(9&B_TNX<>!J=42M!QI0`#JZ
MQ8A&.(L78/7);'O$^C5,=W?QS_F]D-?SS<QT0G8?\=5;\DG!B^5TYX!!>W?Q
MV[$[+)@R72)8*41=%#Q8FCG!2C)9E,`$^1((7R-Q3,0G'?UB]-SX:13X4OXJ
M]V)$7]:+0>4JFDCBEA6@O,UY'?3E1S\`N/L$1,X7@&F(XV8@T\I453;P(%WM
MX#O$?D(93$(>2J`^N,A'HK35';">"M`"7`/B098'P',:GWLK9_,<K4`6-*-K
M[+*Z`Q1_D#<NN]F!&.%KGA@90%DS6B&:JJ&EC&]'!)OI>`*78P2OKG9&LIZ,
MS&'Z+3[BR:H6?`3('OU)HE*O'X23@)D$%GUR1<=[D0N+"PEB.]J#O$]UT2$&
MC#!#!B\[L`Z24F'5!$?DRC\Z(=]1F#TC.1:/CY46C9WHRH2CQB^H/&0,'&%+
M,**2!V=$98C1DRL"E5$,?Y!EF]JW5`.>1*D$>N/KJFJ$<Q`]VEMO[0-^!W+Y
M&\OEBUFYO`FH"[N@E`%G;^Z=7DQ_NOT`7N+&F")4*I)J"^]O,W*'N0UF-NB8
M6^3Q%DXN6X2\(#J8V_@HTZNKU0&Q+.3["1[?+Z`G3N+,-7*B.@=)/6HI;@KH
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M$/V^WFR9S7JWTN_+I-\7Z<F7-Z3QV1UB2O55X)]0:7/`Z=:78FC3<:K\#51N
MS49GR:R\(U+YRRG2*Z6_4O7$RF=.]%0I^^^<`H[*F=]HFYU6`=-:=Z+S=\QV
M<Z.,R1*:@<>J]3?:';-N+W'J57D\AR+[5O#NXZ5YC`I^TVZ95J>]+4H_6#6_
MM%*\4O0K-4^MS;*K%V%CXDKE?^>T<$3^_4:C;M;L`FZEG6C\#<LRK>Z2H'BY
M-*)*Z\\YQU:C9=J-2NLOI]9??/8^WYO'J/5;9JW3->W6DK#6$>K]I9;EE>Y?
MZ7O*R3_Q4(9=_$DM?["9264!O'>*."JG_]N4CCV8`8>H)55V0%7(>WBF0+$!
M@+RK]!B-@NV3_<%:!:6@^BHD4"F!R^W#<^RBB.UMJ:FM/S!Z8VS(^6_Z164A
MO'/B.*(80<?L+,M*+8UIT##;FT4S2FDX'JM=T#7;W:WU.ZE,@I)%!Q9>I,=H
M'U@=L]5N5;;!X<CVRC"H=#^QLJQB8B]'Y%:6P#NGAJ.*%5C-%NAF!42S=V(-
MV%;+;-8VRC,IH9EXK-9`%24HN4FPC3*![#5ZE'9`4<+VG1D"Q8KUGVD*1.I7
MNYI&D8R$6F&HT\P<J.E#Y/YK"F]=/.-D#_5@":8_-4^-N^^?[R[^Y_O%U;UQ
M\?LNQT#-Q?;"95'\K+PN/+K@H.'C^$W]^R>1]V^7]J8>^1E_K_ZQ!0!7!>:;
MXSN//,CER8D,]]D936GDB_NL1JA&BM9P.$S.!$HQQ8KFQM"4()HH@_]R^OU@
M/''\5VSQ`)0Y0&D^2`^7&7J^X_=Q*I0:*A,9+RX.:/5&8I`,#8?&#]ZY_6GH
MJ0&!%W_VGQS_T35HJEH4H1.)IL"%CA\Y8M)?,O2&-R4&88T='%CTKRG.5G4&
M2#]RG@V\\'.`H[$D&Q(,GL_3!O/@/=W)H;Z)ZM(\41;ZPT>F^,-OR=2I,SEU
MBH";[HQGWB%Z[Y:P+@^)?W%I,)';I\FT=J-MUEN6P7/:<7S4>>_VIJ>&@9EB
M-.=`C/O][,2Q.QK17$_Y#$Y1?/!&.,#X0]=L=IL\K3BUCF69=<NJ..>MG'/N
M/L3&K8OS]*3+?'<\<^!(7)D_)HXWP$'A/.+;'3N>CU>:FN5(].U)LT7,2XOD
M&$0>[2A?^OMT]&HP0NJ=7XW>]!'N'ES.@HW^A.*/K"^<3G85Q*X<O$N@/#D#
MGKC8'SEPW0T]'*LGQRAZ.(AQZ$Q'P*-T8_:=Z`E`?^4[-4;;"I_[4._89KO1
M,3Y&+J]A-#_MAA&/CE[@3(;3T8B'*T]C4!EX=&Q".7*X7AX%20+ZZKP87[QP
MS(=%9^ND3I<FSC=K:HXX36#V#5")IHZ8R&NUX<]V#43P>`R?C9X<6&D/)/">
M9?$9X_8N1DOL4B"_TF-VQW=(\"`2ZU;;M*RN)'*:-,I43R<SF89X-/0Q5'#N
M3CH@GQ^]*.8YEHEF#^^!,)9S-'MC'C0+2];$(=^,<(PT#L5DOH.GP:!"]F:N
M^U`[M>P&#J!F8%`@2)Y%2X6'1M-(S;Z'TW%Q(C;:1R#%<=G(#9\]O$K0,D-A
M'X/X[IK`S.E)N_1G`D$,VU4O3L+@V1O@;-V*^-[&W1=@+,:OQG??BXU+N*39
M8JS8>^?L3>P2C`;XM(N>070TA.[`0\/"HY,)P@AL%`_4GH_(#6+CC?:O>'J1
M_&?GUT_$;,#YQ.-#XZ/S"5C*-9[`P($O`BL%TPC7^VC5Z'K]1+#@)0TLCNLE
M,@87NA5B!!`KUL#9R[KT,7&6//.K\>&T5K,TX9"!5;].-)!-E`(D8=A!D[P/
MZS[B1FB0,XJ>6A-QA#]9#4+;QX=/H#H,O6?WY-4%.%Z<,!22$*1B_PED"OQU
MB+/NU<Y9K_BD[30%&,F]V'#_=,.^%PG9%\W"TFQ(6%KM^7LF[OK!4.GG=`HL
MQRJL28A.CEG"S:XB%*JD&:%<?GS$0<BQ*]0CRVS7:O@S$<&I<9_ZCM,G9]!@
MYLV&V:RU3+M9FX,!0FP:;H0$-BL^:4PGN/7L=VWX9MVT[.:<[U82>T?R1)S-
MK`QA0LF(B.PQ6F:GWC3;W<[*Y`$+,M<L)`_\;GOA=U'MR/"=U#EJ]83%F-!Y
M*^18Y6U+(M6Y"4`1"D6?S-!(#&J?82:KTS5KG3;^//7)VDG;PHC,J:M9-`,0
M=\)I!-8P*"7HKPU"'CSOHYW+DB"QDZ_[<8"GEIC*5Z",T4':M5HWUUBFM?$S
M/0!GQ(I:[G-)[-20%A!!TOR$,\R?/9!]8*4G])%"TL-K1M8SAIUQ,/697'`Q
M>#%TU4!T>@,5O-"=YS;0[$.")?&Q,7[DWOA?3RY<@`0)T,$3W(;P+)UNZ.(B
ME;[W9GU/L*MQ(3B,3T":=5+9QL458W]']I'/&Y5FN`34F1R3-64[P9,CWPU=
M5TQ++IPC966,PQEI'6&D**4@S>B1*O24HZM(R4H@S)'NR^%8KE+5NG6EWK4T
ME4H@9KYJ?&I<^ZY461,-R(N,\_#4.'MR00P9=T_.$ZB:Q@"D21_%WHR*RV)O
M!GL2-02$8@WMYLD*U$B[=E!U4_N&%6>EL3J11`*ZXZPR1U>2-,K3:F"["WJ7
MQ4OJ*^'RVFJZMTXMN>:A-/%0.(B:7,38__XQP%>T,"4L@::Z]PQ@PN(^/!%[
M%!]5L4_,NYD02AQ,SH'[(]9@$U?`;D.1Z>![0?)GGY(HE4:PQE5!.L694IGV
MY!/8RG&\[^N@;C9MV^RV6_/$,(JJEV".@V%6699:P:S"W&B;W59S$X4Y49:%
MZK=40V4#=(Z:JFGV;#(D%P<*(11AHCU;1;:[D!WBAB2HE*I9"9`#$2!6RVS8
M==.J6XLDR%/HNDMDB-0KI`11.D>.!D0!P#FF/S!OUO1_2>E@\BV*'7`8<>1&
M`'>HJ;>^&R<*+4L3)_)`<>SU^T&(2M'HE=`R`$D&4@FLSK[K/:,!_HH"J^^Z
M@XAU(LJ:DHL*KYM:5%?`Z$$%*Z!R.F)<(7X(ACX:7J,1!VD6*X>Z0W/&\58S
M:\V:V6K4]^IY*RDOK2W`+K4H\TSV0F4#[\R;Z9+J0"H$*"P&OM</O0DQ2P_(
MGR.:;$_,4VDX6DCV3,"^)Y5#0(:Q,Z)C_NA]DFXN/&H.0V35%&9<C?4TC8=<
M96R/V6VSW:EQ=,*#[V)PPDC;WCHSLSEMFS@R#LY*<+"4FC,.4OC<GYC/FNLE
M;76RHE+;U*S>]8!`*05-YKCZ_A1V%#JQ$MWH<<3MC!UL<X1BEMV1%AU82W@+
M%5K`L`-)R.D<4G+"%J="7G]H6$T,P!C.,$9@IP^48X=GQ-'CH<L2[$.=GF,*
M1=!4%HDT;F?1G_@3E:\2K%SC@S@45$(''MRJ+GYGZ#(5@#P-0@\H&3ZER`/3
M9?&KM#N6UHMPB>JF_H#`9C"1LAW_)6Q:INA$5&,L/A70UPY:GB]!0$:X=AV:
M1-7Y#IF&V;:`JNQY]SCM"W.%0\18.E]`Y!&+W&5D,/C`Q.W'NH]]3C("Z?@C
MRI!.#D/PGF2`>?>15D,PKR`@6SEPIG*O`?`;^*G_6J+B@9O;RZNSRYNO%W?&
M]1?C[/KJ[OKKY7GO_O+Z:D4Q_&8XUBKBV$$UP_VZ>?3L;TIRZ8'I1].!JQ+R
M*48!5"BJ38UO<`GT,:QZZ?=/.2(!#XR=?P*/QZ\GP8LO0NZ4W1M05B_6!,`U
MX82@!%[<78):.!H9$<".^2O2F"%)*0!/<B(IBJ'GYS\Y(.\IJ=$=>6/8A5#Z
M^CJE*E<C?4QE/T:"9WP)&^=!REF2(F\?(,0L2?2;,?MI:`-%UQBA_!6W5>3]
M:0!SQD^@FU*R3T[!`T=M"*N11.MT/!W1!Q/9F@8K00F"IL-#<D"(NB1KP'`I
MW>34.)^&4C@,0<:"S*7+D:'[YL"U:-0M::C@5D.'M/N^Z+@GKV&"2UY1'RRS
MR0D-^'=7.K-G+GUTD8CG$OF%BZ1D&$@X+%#5,AZ41F$F%PONPH:K40CG[!M)
M;H?N>I6[B%@&]_!V8M/`S*=@_9M(NV'TY$TDU.C@"#%7FGTFG=I/IP3+Y1`O
MD&E(92("%X"7S`++O\^0$3$143&U(0G0Q@9NBJA-LI9"-W8\7\1CDR\J/>/%
M`]YZH,BHZV`YBNX3AC?QLJ#%0BH@8^;!*S+)8L,[$RY!6E1<)D<J24<TI1T5
M!CRN0<):6;Z?XPI(J&>!W$&-CW443=!(92QZ<D'D/+P:'SI=TZHW1>#`MCJF
MW:XA9(JG"08NL0J`8VU^'IZ8A>LT3RE8=-=G]8+OD7L]O`!D@=+J1OO7!+[?
M7:`*<'%W?_FM=W^QLPK"LA'M#PI*35#K%"2UYN6/#X)8'V/J(LF-WWJ]&U%3
M(!57O.Y5(2#0VMCY`\Q)10RD\X-X'D_XQJ:4`V<X!`57%$0(P2,R()03G$8_
MT.LCSWD`.T)5[B7%=5)&`@?AZO/>B9/R0F$<+*TB5)GP6?CP"R&&>*<"&I?K
MS"-=((2R'!?-!R\81*?&7:+@:-@9.Z!<`3]K*!3*@8D+BIN?*A#I-H1#_K?R
M8,'M\G@R`HMW('9NRB^3#>YX,E40_AKTM8C@`,M^"';.2ITI>>123K',P!VZ
M82AS?IP_Q6+HSHO)>A7W%FB'(SP<.-N0!5/\%$0:+>3*F;3LF+$XP+#M^0/\
M+\R@!;CP<$IG>ISU[OYF]*[.#?KAXG^^7_[>^[K+VN6R29X>VPJ4A8[:F!,.
M(B0DT%5D3E;C5Y%J.2#W!6<=)&>LGD)M%U6=Z`E8Z@1NR;%I/'F/3Z-78')X
M7GJ@6/Z@=/$B[#F!`LH9>/"8[BH``?6'#XJ2SLX*CHB=^#ZJR,!RP#_DA2$6
M$67)Z*`FA116U6P6(_2B/^A;I/^1[&3>>W#[SI1]U-K?E((6$F,87X3N/)F&
MDR#QX^=()KF^4`)?6)9Y&.MS0->;BQD`-PZGFI=!>6'$'CV9B(SA!M9F&`PL
M-(BP\AFL+)4O:Z+FB,>B+0$RPG7'V!2!5@!-',0?K`#HDVIF,$RV#D?Q(),V
MDG,G-1T>4VH*`9$RG[)V"^``:]O\0%X`=%CD_TJ7NLVLE:OXK")R<CPC?=<7
M+IU;H(4S<H_B3R603M=79R",;LD5PLZ1VXOSRWOC]O+NOX]61.$!HZC`E%$V
MHDA1>`DTKD.F\>(I78S2(=!_<OM_H&!3_A!6$]B")Q+3;G/Y$`>_IB(/"%@]
M<E-?)]=@A!T*7)F79'P!?@JYSV404=T(Z#PJ??`L`%$A?(@?E;3\<GYYIO[Q
M2;@K/]B<AG]J7&/%TJQA0E`K+PMQCC.9A,&?="N#//E@MUMDR&-)$P?;/)_L
M25:4QNR]!85S$%!([\$=>:`E)>T<I/O%P[@=RCB1.OUJS(A1W0F*#U$:-4!X
MM,8G.LB$ZUH1'<=,'>'^7EE:LCZ>?$^HLC,>+*FX+G9DP0]U)A=.]`-*0<5/
M!1&^G]Z=(ODZH6J0<0[:I(_WH=`1G53M/R>MJ+8`'UEE&!CH/??\3]+T\-"3
M,PD!CZJU`'Q/>39P68(A=VE3V"1,QGAKC$;!"]G7Y.'W1:,!QFT.OCU498"]
MT0$(_!(YX6N^82WOS_01S#.WYUT@V;OF"RCVOZ-N<3W\(B7597*[\TVU_UOG
M2^_RU@`U^#O9XE\NKWI79Y>]K\;EU=W][?=OQZP=<Q9#&))+/O'YDHT.<L[,
MHSI35'V(/TR<5_JMUJ$&[HX0*3UE^B927&BTTAH;:`9B1+$Z%6J2>O:,9B@U
MT_0%*>A.)F?,;"N)3`F@=:@B`99FK69A291P_IA6]4%*NX><RQELFE*=7D3B
M!@[G#S?.J-_$]I$W]D84HDUV=*STF>GL!**$7!(#85Z1A867_(1BR7WA.8(S
M&[A(-VCD4592#JE109`PO<1!2]6)4I,I4LX6$W6_T#T3H"&P:L$.)=8@5`1(
MAHWA+[PH^IG"\7]$8+[XC_$3E_XA?)&(P\92C+,E(FB#GJ"'DX#MOZ8!?E$P
MB_/L`*D@(8N0A]#E!-F8RG>$713@3'%H$>(R\:J\D*M$;$9B$3^HT3ZUM4/W
MBQ-CU.+1H<RI/#HU#0^31E]-5>63.'PXNP*@!V,<^+4?1$=,UW>R7T5W1L<$
MM0/SYS%]1).?N5?U2O=O]M*^"3&($K]BS7\,YB6:EA-\OG2^K)O;ZYN+V_M_
MD#\+75DW>%<?*\G(<U/NT@F;=6BMQ5+,(%>=IL81L+%(Q=N3*3XUC52P"&0:
M%M><C%!.CEVX5@=L5J5E)HC`X71DH']758A+42G=O<(1S^%7\KB"^1H'E`9%
M(&"T%V[F6]"#O3`2B45X^_F<EH4NDB?``@M!X<I&W1@N5;PR![@$JKQC3.X2
M<0%ZBT.KWK_=P2E7KM'>*,4K%&6$^+3T9$UR\6BF$PNH#)T-QT'BJ8]B)=?4
M_K68^4"?`B&R6U]3P4UAN8L[S%-I]TD$0`MZS`MW)OR_*BMG1<`E&!9C]][Y
MLW0L?WEU=OWMPKCO_;_CC96=BRB'D40X9@-)1)_]X-%'NF=56#ANAU-*U\.7
MD;(HG8HR5N(X]!ZF;$R*FYU#))05]^#&+YB]LE),2K*!%\J;2[(Y+BMRK-4^
M/"(WA(@2](8C&7'#K!5\P:4@7"0[5\`BZ$\"6S:!+TH#F-;MZ4W&E-)X=&PA
M:I)M:"$Q]G$G-<GR<RK4AF\FX*L73-6%@M!,!C(#!2^\8(B!K?X??$HAR`E-
MYTI;^8.<XT8/MYFTQD%S[`&-!"F3220Y?[(/@,'[R)K7)RE5L#XO<EU'YK4R
M69A"9Q[#7P%%?Z!'#51IGS1`TJDC_!@A*$E@S`,1&X\*M9&#@;)6.R.CYLF:
M&9DTQHL!J>LZ//<B0+,SNAY^#?S'KQA7[-&JY9-7WVYZE[>HEAC7M\;YY=W-
M]5WO*[H9OEY?_7;R]?+WBW.C=W=W<;PNAJ_9V+`07L^>^R(Y3)T])X$#];O/
M2:?;(-0#5GTOA"L78WE]^@7F-&G=>KUP5CJD:)5Z82%;G!J7VL5.0HOD",&0
MC6@CTSP"H<>D'3F^2$4._LE]0(70G?HR?UCDY)$[>PCLKE>1T`=-LLG4QD7V
M7J1)=25"I`<;S#_M!=:6A(\\<?]IL7]1KT.>B;6=J?G,O`&39AG]P@FQ,49T
MXX9WF(M7.I[^>GUW9X#A88`J\NWZRKC[6^_VXEBY]S.P19^)4^O^IID3#WA+
M<[&%"%G'\DI*O!.@;NB9EC(A7D277JC$'SE-])WSIT236HZY2-K4,BHU.F>:
M%H\#5)QJRVYW;T10+MB`=&.@ZR5OL^Z??>"2)'P$!Q-0?B\*+C)/0"R(()*>
MI,R;4$E$`U`1`"SR?.A[X@@Q>6&2%&)]HW"OZUX3_5W51Y6S3LG[PA(FNQHG
M5/%;(DH"B`&>Q70@U$1DY%KD$0NE"<,S4F*H'C"FP!,G0.7BE]HWD!4VED$.
M!=&,'RB](Y5%_:>PDASIF&4M4>`*76_P`;6-8^7/3(K"K!S'WA?4<$PF+%OU
MKMEJVV;'XG[65KUM=NM-LVEWYQ&:F>D=)0Y+J_G0"9:3J;D$!CT#JNL$)]^G
MJJW2WGA1V)D]>.*J*/%6SC_[Y*9:<LO,3*+(#*_@QTMW-=U=_';4X:J_>9B-
MCWY^4;?+#A*1+.YCWL*CRKYB71+[2NMVU``TJ5$PD9%8=*X[$Q<(J8]_PEXH
MI\;?@A?2/X4I=0[*E6C89=6-?TT=,`U#KJ;V/='?A*N^I+=&)M*+6FRQ)DA+
MY]$'91/6BC'#.E,(\((JWHO<$ZW^$L@M14FA@+#T%=S.9#)")5@E3>+29%JJ
M]=@LUI_[J%S05N-3+@NMQ!-91L(^[J5CF_.++Q>WMV")B=COU6^@V]T=+QN=
M8>Q%N3!EUPVM6(;3<M/.U226Q+-MI<8CXI?28ZO\QR-OZ&:]Q?3=Q`'--SI&
M.M1GV`M]JB%&_:2<*4FJCYJQJY;7-L7<+CP7`3J2N.XL8G_1!QN+AVQBF`^=
M5CVWC&*1O934-21W;>(-&[WF,E4.?V19Z)8386[9$"QE@>,MSD/Z?F'<7IQ=
M_W9U><R%C3Q61$Y[,4Y.C!^9@)Y,;`J3`YU7[/Z8S(])AI#@YW@5I#/2D!,G
M@?HZYRN1]B]?I2PX9P":F+B@OGDC+&=3P1YIG.1`J&KHTF-3Q#*]NS.C56N>
MV!VMV8:@6T,C7+U!9;+X-UY<->808U4(&NGK>$$875F8H=4ESP`PI"B/=.DJ
M0--X2>_^FQ`R)2+9_1#O)4:F"#^!C'V)@_<B;50.:CH#:NO^JA+J!BYZQ\B1
MIHISN:@C"6OQ25"<38SD$G'"U,NJLA)4G8E#J@_WO$:S.<G>5UJ<QW9,'^P(
M#*WU0P]XR'/HOAJC8XVAH:YR3RXE)&D`8Q>%49)1PC4!(Z0*S@H1MR%FWCD/
MF-4:A*JG`B6WRUIY:A0SD.%5].GW9>6LO$46;$?+D&"M#.V?/#Y,;8^>%1%2
M!_"HI2&E%RL5;>_4'C;&BLWQ6'QV(J/8)(\PYYMR@`3#,-)MA=Y4(%98!]7E
MZ)=CQ=]'ZY/H$.%%5!\?HZG]C&0E&"Y^%7GC;-J(?#Z#K'Q9.!:E+S;E.^.S
MD*7`0,$48`<SR(`_#()0KTI&+WD4:;4TK&/VN9&*>%=XZY,S'P0N9X1)CSB6
MW8Q=<M@S$+PU?&3N]C)%:KR6U`W56D?+8Q]MHA%QFGWLH^(#EK43%<+:\T4\
M)^!D#)H:@MT"@"L]/(I?.-X+WYH]?]"\L>`339)?\67N^8]:%4T7":8Q.9G9
M>%:M2Y=^ZWA/K?X)`U[RB$R=(<FMQIC$0\HZ:^7L+1[0I64&,J9+A=+]7SM*
M!,EH@`ACHF*5S$`CAU&?LX'[)))TEM!*B2-@'N`NU6%O`N()@R1XC0&8BC=8
M4Z8C1$W#X#!DB`SW6O'";-K[A*L3V'Q@<XJH.U%-TRJ?S.J5YT('(KA)S5S5
MR&",\_`>$IU-N-#A2<RY"%3<2=>%C_I`M`L?&T<*U=U)*W3:G2U5;T'0HFJ.
MLN\Q8J?EKVBZ29XN[SHA5O:H^V/9H9)ARIJD8F6E32K#.7E)E)>*-47?(;&)
M8U<T,T?!@5G`/-87RB&!0C`2/"OI"[J"F#J*E+!T_2=\6(L$)(4!:8,1++`Q
MZ2_PWR+#+/';,XF\62^9#_/14HB=1R'LX(WDM8@]%9V(8STIC1',ZZ-%7'T.
M:V&B`FAU[&H8.4G29J`;QBGG#'HIY*0_KECYF+A7N-HK"1HG(B^U]"?=+:3+
MXF,]H(R3`G7%_-M!^KJH'7$Z)U,S4N>@7;&*4-:3F409WQW]%=U&&8_;1^_4
M/<6,4;;TI5K+G\TPH"[*/L$E&R0^ZLQMF*%*GXJJ71HI1+9WMA"8(S`B<U[X
M#]-?1#]/RJJ95<)2.$TO>:HYAM.P)55>#]YP&O95%1,W\M0^B5SB!_Z)_CM,
M,()O4CWB96)3<8E4]C3G*R2)\T'30]CIX;QR1N-P2L$IS-<9()DI^QO=^)R8
MJ)V.F8K(K4B(1\NJ293<5IJ=EEVE-8#RJ#]58BJ(J,5@)F)QM+A4Q?1W6IT]
M!LQFXF!:(3[+OW3?9_6A;^XX"#UJ:<@-+%S9@`(#4O(Q?4XF,#_7P%..:_(E
MS!/I8UFQCUF)'/1BO9T3?6&OR@`41?ZRTN@U0K600MB/@H$SW*T:W&2":1SW
M(L]^P).,<&03-MK0$(#]K`/AOA1K22&4K,>)R&S<J#WI[0Q(L8[BD]#UQ@_3
M,"(E@"G3(3^";/6,L891)&LX*/OXT?$-,'E).H$<DCW'"(HDO*:OMJ`CX6RN
M6OUH&>)::WLA$:D%WKBY!$CWOA(JE..*U>+B&$4CIM&40AT8/7YRG0$5$)],
M)R2QG@)X#G.;`BW90Q`,TKJR7-SQ9!2\8A?NC\1EZ@_X!;CIJ4*=H&!!2!W5
MY#N?-%YR_4<',].GU!_6=UV<VVQ<8,!*JI*J8Q_5QC_C`/E7"1@0]5@TK@G1
MI)??S<VG6)HL,9/IA]F`G_%ZQ#XP8&@2!UV3OZ#G#RZI^07<>%A35YH.%G?W
MUV?_??*Y=W=QCEGI-Q=7=T?=3?I"D%TZUY3;'V$N>:K7OI[[++(D>'YZ,H`,
M12B>-P=9^[*"@YNP2`&GM0X064KI,2*TQ`EK7GV-MH"-65]3?6^Q?QD:7(^8
M&,L-G(#DN%8MR8#&;XQ<2KAFZ3L:,8_0:]1$TDR/3T\W-R!5!8O1DE[VL_,#
M).JPO$4M`LP)'"E$A6A&H-Z(DQ9*_Y&>"9TTR>'470-5(ZJSHW<=1H/H8"!`
MOKX_^_Q9_D/VQ:0-@D31.53*/97X(@2&ZN8D.UFS^SS[HLQFYSZ3X@(5K,Y8
MBGA9;KX?4$J$-N^@U@)<3V-2D5\!'=AJ3J3")YNA#YS0+K2C2`JI/1K/"Q2C
M6F>I1D%*1:#1%9%,(N4R'B0&T3;$R6EGF%0C+MNWD=TS`2'W':5&=&0WO_%&
MDVY(Z;TER[&.E[,S4D"P`X=C?/:P[`(0]!6N`R+%22R'?^$[XP"L6MIN?N=1
MC=;E?C]&2KFO?3I:)>0^Y;WF\F#J7!("FT5SI9J0)Z+C++N3\'TUX8+:`64P
M+G->1"E'X">%(WK!P5JIF`3(3-G#%OWJFYP<HQ6G/D43!^GU/_]2^PO]>X+6
MI/CWNI"]>(/X"6?VU'[ZU7B@3*X32ER:1.XOAOSI+PDX"$DHEZ%"C+XSDD3Q
M$,1Q,$Z>1K6)WACD[%'\<K/G$#3`@_^??['5I@7X#`0`0TUGK`G%/[U!FGS[
M9"ZR9@3D\8W-BXLY)8UOAW=[^TIC6WZI,#Y?@*@,I6Y]^1FK3P-@`\33C^&;
M*5N^(3BIU?F)GOK=5;5./(.)[8-HP=&G/V3]E"<8UGCSP^HOU']*8YTT8/J(
MW:J9K4YM=U#O>;^6W3#M1KT8J`NB,$ZS[7/Z,HZYRE%)@#$'U'=T"9$5+J_$
M;O*QF>1N[PZB8B"WS.YF8K_`,Y<BY$(4IO0R285G%]?&+3P#ZBO^CL7,;S1"
MM3#LK'+W%/:Y>4RY#S(J%0):#;/1V#<YWE,),%'9"7F_TL:UH-(M8]X^M9N`
MK4$P!6UX5;&__$L;7W\[);L=;][JPN9KUI[)KGQWPSX@*@/D!1[JCTWZ=6B5
M8#/M(W;.><5^<J[\:=3-1K<!RDBKM#)H-YBP.K99JX%R;F\DC2N!]`XA+_!0
M/\_O1Z,+I/=UP7^LG=:6<-.GX]YQ#H7]3([8U*\*]G:5MT;EAYNN\=4;FGO^
M<S"B++/(#:D+"L'"<]1EL,T+D];H+U1(]\)M(]PDO)2,=M)&PU(4BPR0=)Y;
MT@EB-G(Y6WLA2VXY+W$V7_LQP.@`-M`76_@D!U#/?CT'7ME#BS(,N?V+Z).)
MC8"!;%ZU**[H'^BGL&AR9'<.8"">?M:`4YW?Y6PPV;&>YQ)@0,_Z-`L]P3!W
M!VEXC016_J#]2:`VJ0R2A<Q1[@<Q?Q`3@T,^=TQ,<N-XE.JG'&>:XU.YN.R:
MGP26.&0>C(+'UZ.M>7`^\7@UG?.8D9A$*/;OC)`BF-@H#R"I0]#))\0P6*CJ
M^'+X+W3E-.*`&E`[#S@'3<7916ZMJC\0/?$PX\#X*$<ORGF^Z?B\;!5SO$'3
MA[DGR05(J6/@;`-U%`XQU:M*(<#$83B%H>MQE)!2[Q8>*Y],_K$FXI-[@!SK
M"?7YA#`U)'5**'*Q@$O>/+*_@D@)H?0166W\$#R[),Y"]T1D[^1D:SLQ-V-(
MFI#0023]*F@.H);#P<DR=(A'>SP_9`O@^6E3Q"JBVYJX?+E)[U!K""R2E/3&
MV-PE`-T3F.)B"-::HD-"G8G#`V.3O]%;H8>UN)Q%*U,4AB*I7C:*X%M-O495
M:BK)1DXMT#M3.4/L&:P/WJJUTHU^TY4.1F8%M344T+1KT1DX#:7V!@,\5D7'
MJZ7A-B@'.C5+-+\MW/H)E+/S!V+8!S:![%''X"_81\^E%L)ER;B\Z=T?<Z/%
M&R<6&B"7L-,46VPI#T^RH1V,76ID..$G%4F&HHVGS&07?\?YJ^0'S)_[CGE>
M2:\Y(60C(FSY`:Y$2WW,Y&[U5"TLZ^IY9&2?:R]$[UG1L$YVQZ(&<+)-'0WV
M8N=ENDAJY#XZ(]'%3@[A33+<@'DQ'ZU/#YA<#"[5(ETS9HA9I$S]I'6>:D.W
M8'L\VV7Z\$_12$Q,242AF>Z:+I)4\>])WW*"PJ'>Y:+4G>ZSTSR*TMOU+V'-
MV8:/<EQ1=`%G.@#9HOUJ_XQ,J=/&S??;L[_U[BZ,'[W;V]X1,_8/F3ZLVO)B
M"ZW`]]U^,K8FUMI!2F+61U=G9NB)I#Z]@60J+9CN:YR::OQ`-8BX,.D*/#,;
M62B]^%E6FJ5JE@43NTF:W"DNT<UD8>O<F6^9Y6EB+HWH\&(:\&W(%OY)X?;0
M$7A(CQ*<BY)3XPX7D1\2:>6KM<VD<8>I687*2T(@S.^9:?Q01\JV1@[*<L^%
M2A+SSL#DTTDJ`A>?ASBXE+HMB4,@7#\+H0.%`S&`-ZFJ`[DV`)8Y$3?"J?'5
MB6+J^"MW")@1WAC6Y,72<A-]H7J%2<M0W)4V6BU_N*+>IW.16%L@!$O7J_/\
MXO;R]][]Y>\7U<!3DG^J%^$P=-V39*!`+G$0-!\QJUQ0@?9<](G*3&@(UT@1
MWZL:2IV:<@_\(H@4C84H-9_(X];4>9.6:%`V^V+Y$O?(YF$W7,99-W#_3#K?
M9B*QY';PP@B/XH1_0+<!E_D=*S%0DX2TR*!F'KFD(+PXU$0!&]5POYD<RS^9
M*Y/^M#19,[U#1'<HD?+NZ..IR!XT,RZE!(ZTR);=&S0G$'?WHLI1&F0J1]>E
M`3M-&O[Y`=#EV(MEG4<2V(\)V8Z1*LM5%>@))*6BI7TU54V8,GU$^:,]6;.@
MJTJ5B&7(2G@&4`Z1I9$]PD_JGF4B(\]]_DTKVN#G#QV4RI[6R1YE$[7Y^,A3
M73Y)E679M3FG#M-QQX-?/KN^"["#J#LC'0IK@KZX.%S9O1Z>)6H5%N=$-ZQ4
ME>YB_7QQ=?'EDB:)GUU?_7YQ>W=Y?65\N>C=?[^E2>/\V_O+SU\O"+%7U_<7
M=\9-[Q\]_$V)^&3G,E=3G(=\[&0TB(Z^*5U:CT.*H33L=%,V"4T&X1:AV*)P
M%+S(FD5VL;(R+M<A*1>.J<XQ:?KZ;V901Z0IU1N_)B1J)#1*P`A"54_*E@/X
MTMD7]?,G<FKHILD\BP3_!F_F#3?3^IUHFQ5[D3<!1Q%%MPEN6B"[`6M=S9[0
MGY)<(^P9296ZRI=&8GZSL(L(M4*0S,Z')"#R9T3.-Z;R9K*_P6ABQVS6<$H)
MJ*+$3DJ,W;J/'@[1I;)SKFSO)>V-RF<*W%[\=@D6`)6.HQRBN87D$/GMXMBM
M`CTU0NOR&#S`T^(J!!(<.W_HXS0-U1H5^X'@-?F"U=5D`0_=,)ON(-IMA!K9
MJ(X(>O_DA!%%#R#_537L$:PFHQ&)K6VH)BFB(!C?4O,`<K:3GB'+/7PI@8%'
MA,I\!'>@^B]CL\4P>!"SFJB/LPA34\L[\7$A3;(82L]8-6DX,^DJJ'+SH$93
M^6>R+V.389XTR@W,7A-A.LOFZ['E[/B-R,5@3<\'BU_-"A()\F4)3]Q>W%WT
M;L_^1J/1SR]^O_AZ3</1C8O_A\TAMCD\N4Q,JV:#A^+0.#:AC7B2%<H$2E&S
M,>6X<TJQT*9Y/SOP@6DDU6?T2XF;"B>L\W4M>@6)1J-][EX@)E<,\-G!B@/!
M#>X>LV3?O!2V:A&[TX(DD4C/V6:W^ZI8>AM%Q:L4V>XP2WB'$)8T%;S`BO:R
MEZPO`GQ!Z>V[.-+R9/#O"KH-#@<+?/I_/(:@T@U0P@;A+\;_=T'_LT8)_CU=
MT'K*RO+4\@**T=754$"FNUZP_H8JHF;-K'<Z.]G]N\);MVXVBVI^4!`;@-H8
MN_.$UUTF1:L`(5&BXHU6O6VV[8TNB'>P>;MEMNH+>'@MRDN*6/0^B$NMUI3K
MZGHX?'!&Z&:\>W+=<KNMKK]\.?G<^]J[.KLP[OYV<5'YK(3Y2_4"Z/U-M\_U
M7W'<Z8DX7R/"`Q9!IN24V:E#7T"?>IARKHR\/T1O;RY)4*G+B5]'MHK5>GG-
MQ)5R`]HS[IK523'KJ@'T]537N)LP\(.I&.@0E76`]^5O5Y=?+L]Z5_<X/)7\
MKV=GU]^O[G$H\<WM]17\?';<A/V-6K^J07*<K4&E:4EF,I4MS38.G*1H@$E<
MUEEAU\8D>4KF18OVD?K02`H@`/PY#0D-BKW.&>?:N_MN""(R/MX'$Z]OM&JM
M3Z88VQHI*(`*Y;A,.>1&NFHS&Z!)>8(%]=TG/*?M01LLHKNHU^/(35EKILUN
M_\D=3$?N]5#V:KWCRJ7\]/$>C\_$1/+AK?))WY#+BJ95EXB'JX:)E0^P!+Z(
MJF$B_T^A?%XU3*P:)E8-$W?F(ZD:)I8#\JIA8HGZ!58-$ZN&B57#Q*IA8DGN
MAJH_V9L/M6J86#5,K!HFEH.M#Q?R`@^U:IB8OZ6J8>)V&R;"_UJU22XS9+O,
M;"M^D(J")ZOH)1_W]/]V'7`@I%RE.BM0^4"DRF14T*'RU1^$K[[U9E]]*5SS
M;]Z&WOMJ[VZFDH9E;D+/QUF4(^,SYT+LXZ3?O(M>OQ]BYY%+4:EWD)NHCF)O
MR;_UUD\B+O&3D;H*3?@APKG2"PZCG!&63A,,N>.)*-5;;;/5:1_-?H_N?)MU
ML[.HSJ-L6=56C47).I)DMUZ!)0143E=&RVS9S4,#^D`Q76]OA.GMW][XJW,O
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MC0;<_2NS]W4_#C#PSZ#7.^A4>^9<`+M6ZQKHUIX1`<OQ6$BGEUS>7R.ZD/V&
MYJ!=8MP<9#!E_G97<:B]LRT?V0G;';/9+:AW4PF5D-XD]$9HQM5R!5+IU8WV
M04:$]N&'/V9\UYNFM:@!V_Y5C)49]N_3$4_6ZDT?IU&,K&OEZQ)%QLFWS,5V
MIVXV[(TJMRHV/B*$=UMFV]XG'R\)I7]U7HPO7C@N^.Y<QY&R$5=N%D[<]5U0
MJECJT8?2C_KTNV:CW3T<?<*VYRL47":ONQPW\$N^(UDW%W,S1-"@2[2`,/;\
M0RMX=WM$5I'R\ACP51'7O,R95M?L=G?5IW[;_I=MZ\Y59*>"_``AWX^:]-9@
M[57@GU0!VP,AL0KR@V7K0@,@8VZNBRY5;$Y'[>HPZ0M8O&=@&>,:0=J2L+1M
M'Z27_H#=J8>)\.ZF0)?N>D[Z+'`H\R#9MFZUS5I[AVGQQ\ZV!XKPKMG<V9RV
MG>4?6-MFVI(Y%KL+7#^-C@G_*6[K,RN7W?.S,JJV[U5\3]BJ"&N.2[%N-IJ[
M:FM4RG!.CN?BW4K>15[W;K=F-C?KV/E>O.Y52*<BKAW+W[IE=EL+.@Z53Z-M
M-)9)X+EB=\MR=4$9[CJ9_JM\>RY*<J93--IUL]LH(.%L_GD40ZQ;*XA>'5O;
MEZOO"ET5<<WO=H*"M2@/WVZK[7F-`A9:$KY;7/&N&I\2)%6U>U7M?AC05]7N
MA[*?JMI]?E9I`<D3ZU[;5;R^@OQ=Y$ALIZA]@VR)DC=^GE_YVWF7C8&K6O8C
M/N)FNVG:S8+V6T(EPZ[5.MLOABWFECC,E*'#3?8X3'Q;7=/:JVN\N!RM@AOB
M[/8<EG4]*2?U'"ZW'B:^[999ZQY4(&N?K6&*P?EA=B0Y7,X\3'S7+;-1KSK`
M[/L8[&;;;#4/;NS(X7+K@2*\6P,[=9^3"LK8Z&5'V3A'W=AC'YQ>*@0<]>F#
MK"QL.,%!Y@'O*0=XCTF9EDD##XNX(@\W+;/*^:W(:_?"MM$U.YM-`=J^DK>V
M558^'?I8`^@5Y+N'?#_Z3SG[M93A/"K(*\@/^CK=34.'8I!_H&T$#M>I>:`(
MKS?-6OV`W`M[;=M0#,H+JWBO6/-=(]RR3<MZ+X'[U-VYY[XJ6W:]+&AV8=7,
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M'OG+?[T1.WQMI#JV<#>4Z"EXB:B72Y]`B$`+CPS/CP-C(KMZR&XO`FXZ+<RI
M7J$DR7AX-89>!%>D\>HZ8=40IL"&,$ECC>;;&VLPC</!&V\N/=N=QB0PW6EP
MZ>VE[\4>4%I"N`_.R/'[Y2RFK\^M/&XT:Z6K/)[K+<!?G6FB8S`-2;J@K$D8
MW^!6"*I%%$4JWWZ_KGM8^?C^V%ZA@.[3;DE\<[3N<%#M$K1:J^1';P.O6R#6
M'090EV&UOD0Z'!2U;J1,;@6OJ]2\'PBQ;A0W+U]L=J]T&WE_&F-0^9XB@>$D
M4@@,6!"62^4C*\5A+>2&SZS.&4Z$)LG.#V3'UO;F9?TE,+97-9VW;&HK&D%]
M,_O1W=G6CF9?X;^S&7NUG^A4*O/Y\,WG_..M+.:M6LSM1MUL%=6;K+QZ77F,
MD$:M:3;?C<E<'B.DOB=/Q'LV0O9FV2VAU4N_'[I.Y.*M,2.`L1&)$0>4D`B[
M<GU$OS%T2].=I%XWNYNEE>^19"NCKHP6^'&9=4L+,K)!8[F&?=I<&#?>K=57
M;EO/VI^MMSR.J@"E0Z&\\\KR>X>67\ZQ5E9?@5:?W:R;[44C>RJKK^#04SD5
MZ4,W^EJ5T;<%6FUU2TFL*UE]I;3X+--J[S.%NC+X5C'X/JY2<[4'NC\N(Z]P
ML[N<EIQ,J>WU:4A:)`H0Q)RNKY[SX(U`UW2CGC^X!GX,M5_A9+51$$U#5Q2!
MK6OW%6/,$5A&7]2AC1+XC!<W1&MN#%(ZRAMY"-)H'%6&V8&-.)QCR*4$T@YO
MW-4A3,9K[N8*WM<!;6B)[UCYW#_@.W<?M#H_"9\'3V'TE@Y=+*77H-FNF>U%
M`Y"+AGK/^P6UO=4TZ_4%737+YB>1%#9R'\$V`A.H-#URK';7;+0.KD7\&\#>
MC76@3MS[U]0;T*3$@3-V'LMS\O66;78.<);'YF#O@M-9^W;4Z2OM^YU9Y5:M
M;C:[.VSU5*[=-]IFNUU2+0=_Q07UP3Q3<,O'L6/?A&7:5FO3YOWO8?N=)NA#
MA9'COLJ8B_6Y9#TZ7QPO_-T935WM[6^N@Z\.KOU;%[G$\Q\_.Y&W=L"^(,?-
M-#2&`*7QC&`:8P:."KD-)R9?33HT883N!-L,^8\&:AAT6@ZZ>$9.%'E##RZ@
M!X<\/1S+Q>\ZV)4("*G_Y(-FXH)&^NR.##^(R?ZAQ]CE\N".@I?*&51DE'[U
M&^S<C?JA-RFH@U1QIGU"?_CIA]#X6:UWL.Z*_YD2\=^$7A^H9&9?P!3D/R;F
M^\,%7AP&X>QC'[\2(UF?#A('=_`+$!A]!]0$UF"O'R(W?.8.9W/V:A_^7F>V
M]MT/EF^\OM'&MZ_X9;P>]=9/0IB$WK-#)/QU%16P0*>/DJ<%*$BZ8^@-RE+-
M;+6[9FW16.52^,O*A[I50H`5ZBK4E9MA=^$$8NN[%T6@+KPS6W.%TWC/MO;;
MTB"J_1_Z_M]&_R5RMFSD#IGK4V%1U_,'B[\&#UP%?ICZ^._2*7$O?1+1/:)D
M/SX8_`:^JBAE@>!/5TT$TWCD^2Z53-!11IJ=\>(B!8&5Z<`-XSQBTE@T'9-]
M'QE3=-%@CF04>V,G=CDK)W$$>3Y8G&-VW$Q"-T)39F"BMP8PX[M]^L.+%S\!
M#*'QXH0A+,G.(']@8`[(`!,%DS(.(Z"5C4%B&'A)TT!C&L,)_ELF''[V_&",
MR?5?G1CN1E>^/`%[&9\9!P-WQ'XB1)RB\\IIM+;3:*.FYCN-AVPUO)*RT?\T
MOG&6ZT5^EFM]B5S=KFG=%H4GMU[TAS$,75?ECABALV@F>&&JNMW\:2[V:J<U
M^R?C!+BD9?^T:]VW)R2<^^<$1!/%0(<%-G">NV6[J;?BKU-"_XZKD_!7%W+;
MS\'(04$:OVY]\^W.:1?/VZHU3IL[/W"UXX'W[(%X'A1H\LS9,"@1[I)M[EVO
MVJ9*]);8EN[AO/0G4]"K0#/HPUMBR7VH7??IL),1"3\[Z#2.`9H2//V*^<K]
M)\=_=",9J4J4)#ID>``U(.&D-8:>[\#&0'71M1OTWJ]82/&+H9WU4CVCTFXV
M#XG-X?.21A!X_MV["H*A$`B1"Y`DM(#!S`Y7BB"4>*-G)$%0@$AS:Z#;6B"(
M`S#;_LW1<%#HIJ.8ZGN"":@U9*\=Y+;A?$520)\-R9F#A3VN<NZO:*G>.-X@
M-U+:=R9>[(P.$D5I^5\8:V];!<L&_6K[R^[>Y$UK;IKWH>R@VGNU]VKOY=O[
M;NQ][<XL-+\6?[5")*,\4;HW`;R/L-)Q`?QQ59HH**EK3YC-8?IB/4%O,-7?
MI9.D7J4('TB]^#;$T2'"L,3GI!P$I80N:\<?ZC%NH)Q5_%)*BDR[T4H)8LJU
M=:@'67%,0?*3_-RE!"[K@BXED+HCN.*E?9V"#$&5DD32,:12@I@$=TH)'@58
M2JJ"OKFQU`%QW^8=D';9C+4XP`\]NGOX@=I#CJ!N2O8;"(0J1'I(.ZCV7NV]
MVGOY]EZ0X%TA;UZ.?AFYPQBW.(DS/OX3_!U]H901U;K9['1,N][=W<7\)G@/
M+CYIF_6.;7;:AQ*Q_FC56F:SMDY;\CU`V30[K8;9LHIJE+CWK/H"$]RS2?1)
M*ZGKX=V3$[J?L7?263">N'Y$K_:PLNZ1.S)]?DV>N7%>\7>]%R<<[#Q_/GU7
M_',:Q=[P-:<^442.0]?Y(\)B13'::3P)?-P/G:>(#4>XLQ-N'=77]D\U/7X$
M8(4N%K?@5P-^.C*PUC`0%8V/6(&(U8[P.US&'0[=?HQMJ."C7I]^/_!&4RH/
M"J+(F&";NF`\#GR"@SZI3SV(G[#&"E];(6V?GD-;Y#0A)2;7`FBV"DWOWN-T
M3Z>OUP/NUSP^;#"SM97O%L@-M-L#\S-N8^A(&;9QF,[3ZC2*-RU7]NF)7F>_
M8SH"=F,8P@.HA0F5I-P6__Q>]YVNV>XN.(`R0+^-?;?K9J?9*C?TV]BWW:J9
MK4Y!$R#+]^:"H0YVP[0;!5%Z0<*G6+\6S<E#.Q$G0"05AQ2R(NMJ'`Q47E]I
MI@3LRY'T=LB[S1W[DHX9V9;9+7=YY!J,*G4(X>W`7DU!WZ,41^JR='9QC<DC
M<>A1VPO6,\CE41R6=]R&9RYVMDJB\\^FX`U6^*KP=5#XRL=-JV$V&B4=.K*!
MG.4NJ<N<S5N6J5OK'[DZR2^S\<I"[B5`5;MA=HKP#AT!JI9:DN\>5W,TU2[@
M95G<=C^Z:CE5^WU`5$%^G)`?L)YB>'Y_-!UPXRC?C2FP72DO[_Z664-Y6>+3
MKE!5*2^5\E*FZZB"O(*\3,H+_NI'=I2`/Z5@/39^H0PZF9`73.,H=GP4>WIG
M[)D,O)WK*,5^<NX5TNR:]5;7[%H;B<MWA`FKTS9;#<Q@MX\<$S9@H=%M`$T4
MH(8=-":LCFW6:@W3MDL[2?V]70\5Y!7D95(F-O"$?%Z6O<^ZQ\YEYL[MTX^U
MT]H2P;F@].=@C=(*016"MJ&-K(N,'.&XK\JT@JO&LD5I=_TG=S`=I3ZNOWB'
MR4?7G..LQL;TDN%R>QRE-W\\GK'J:#PZR@W'XU&J%OP3AQ-1F9J6#L[96BM.
MNB,@4M/N(L.)3;X&DQ*U5>;)Y)$2DVL!-'L4E6GO>6R;?=HZDFEM5NV8QK-U
M:Z=VO1K+MH=KNC#9NJ\+S<0S[C\97F1PY!GNKB</KK(0*<08.+&SP4U'4*PT
MUW7#FZYJ"E[=;WDS.NL='%-IGS9K1W+1B3&D-)OSJ*Z\!N@RM&O[M%U=?=N^
M^G+LTF(-QU7,TCDV[SR35ZX-PLD=]/R!/+3[`']UG00O]VC""AA3H=3XR8F-
M)[C;C6<"G6Y';%>B)`M<P?@GN/?IH(-A;H^2$!4#H4]$U7UY8)U*-JRMOU*Q
M^NME=>DEWH5*09"7ZL6?;MCW(M>X`>5QSPV?B]K3K3MV/!\Y_@P(/'3Z\124
MY7LW'&."YS^R=_D6XSK[HO'R!.0JZ':C+F:4^::=--58E"=4F/6PG98*#=/N
M8J;#@G+P,NS@IU7C+,NW7#NUC[!W1OVT6]"N=VJD"'6Q.!.E%+6J#;-M669G
ME\EW*[+//);99;NFMUB=6H>+T\(:>^XDMP3$DK1!J*9FRR2_,#:OP;*+A>9>
M3EVS5FN9M7JG.&04LM&M?>0MO:UWNHEB>+1PE6]?B0[[<_G,.)_>N/YO%!*Y
M]&\`%\%`&G["[J,_GCNQJUH.[]'_U-/'NJ;".F".>L\XA&NEN`Q1BG(]>5&2
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MI(ZUV'5O,:1]1F[6S6'6,Z1[(MQ2EE@0X`1W6X6!JC#06V(%O3%<R)QYM.O(
MQ[N*]^PBCK/K'6[?_)H3QOG!LNV=1G#:-;-=ZYJ-=D%._6V]N:".#Y6QALW*
M6%&QB1V&4Q;-#ZC"*4L\IQ]MTVJU3*NVQ.0JT'^W@`H[+;VS)?S&*JC#X5L\
MR_MLJ+?$V7491=/RT)+5-.OMIMG:Z9S4Y42E1%M!8+V!EA:%^?<KF-Y_E,*T
MZBVSWBJ#G"MRXLU^'8Y[G26\K+'R'+WSW0<!.K;9AO^T[#TXUMZH8AX8]9>V
MUZZB_6/UM!\[#^S<EUT8+Y2U'F*Y^U@ZI!UW//@EX\SN)9TXOD=8(7$AFD4I
MY_8/+WZZY:9/]X'DW^^RS9/L[B2:.S$<-]S:Z1MV=JH:0\IV62]2]JW4#3+3
M'XL`2??(,E=O!ZG(JG*WYU]O[[D95KO+S;#L[D_:M]=7`0IIA)4'P.ZNNJ9H
MDZ4Y<]IKMLLJI"W68BSL`S-=N"F13+K-T\[J?;3>WB]K=SLL7=/(O_Y<@@MY
M0;#:?<2P^*T["4(<4W^9W'*?7\4?=WZOI\7</Z>`F^%KSF5/!QD9D1O#+T.X
MA_M@OSB>K]_5=,:A^^B$`]8/@*QY6Q'=L@%<KR'<QG`LG!U$';E@H_B%"&]T
MO'_AWV2-.13==D;HKS*B)Q=6QH^`@1]3Q@%&T[5O*3V!H`#`XB<O,AC9U7U]
M$.'QUEM#L'>@NGUCU>UB5G7;D0E_8"D%Q;@&]@-XB7V2M^ZSZT]=T1^P!#&;
M?92=E`'R;3OA,I9#J_-3MH^(7<L9S"/UF)X;/XW@ZMR^35-D++X)XK3>/IY2
MSDZC9C8ZY4H_6+N)ST(ZO+B[W+*C<GO!D;G;W&IEYGPD%[S!'063WH:;78G9
M-+;KBTB:I[_+BWC+U+VCP53U!<2]5"B_C;+KA5'VCD,62X7WOG7%]Z9R'2[D
MVY9B^*MK]EGXC\;7((HJ"V'OD)=2'UMJ%ZRS[XT3V3Y:5,;6:"Z1G@4D4[T5
MSII5-YO=)5FDRV81[D!EJ;3P7S\V&DVSU=X\0:]2O<L@OU90OM-WW?M7P4$.
MM=MUTRY\0.S!*M^EE,SO48LY7,AW8V1=N7&E<)<#\A(J7B51MQMP==AFIUUV
M=;MNMIIUTVHM:3ZS#:%>N;TW4+CKS9;9K"]IYE0IW*667PO5;7F[&9_=81"Z
MQE7@G]#TJV`T0O7[4B10'H,.WD!MTVQTEF3>'Y$.7DYQ_1Y5F\.%?!<VUYD3
M/57:]_LXZ/?H[FZTS4ZK@(*MG0#;,=O-4G8!K-3P>9/5VAVS;A?0Z*)2Q\L@
MT%;P?^.%]_XU[B8.M^@4T.GRG>G=I970[U&M.5S(=V-IL4#J19$;5Q[P?4->
M0A6L)!IXHV[6=MDT^6W06I9I=4O:-JQ2P^=<RZU&R[0;E1I>3C6\^`QPOO/>
MOQINF;5.U[1;!8PK>6>*>*GE]'O4;PX7\EV87F?.Q$/!A-T;_($73\,J*67O
MD)=2(2N'4OXVO>#@`"ZA<78<BGF1=%;IYF40;@NU\[QK\/UKZ=LG\H-5TTM!
MXY73_"`@WXU==NY.0K?O<2=*[#[5&V/OKG_3+RJ5_7W0P/OSHG?,SK+LQ]+H
MZ@VSO9F_OY0&VW$HZEVSW=U:GXE*1R^9_WSA)?C^%7:K8[;:&\WO?-?*>HGE
M]GO4=0X7\EW89;*\A7T)D5NIYN_CT-^C-]UJMD!]*B!(NQ-H;:ME-FL;)4N4
MT#P[#O6\\J.77$??1JIY]@H\`L6\*$'ZSC3S8D5VL2,<UNJ:GSNR:9TA"ME9
M#+=NY.(LZIX_.'>?W5$PP<<%PZPZ<<&8^AX_]/WN_"_&`$SCL3.*L&?_?[7J
M[;9=3^!>N.";H:MKT-57@<YNM>J=74$'H+77P9W=K-4[.X.NKD&W"N[L;KW9
MJ:T)'8TC.0M\NAF`BZZ"V(UNG%?DJ+-I&,(;7*]_[D5]N"#B%*2]Z'JX(NX:
MG7K#ML3\DW46+!K2^DG=6@BI56^U6\UF24#]W_XT`O'ZO[TQC?J"0\7I(@.4
M6F[4L^P;-\2)`]G5OM%,B87[['2:M5JM9-O,?LZJB0W:M5IGA4W9)=S3=3\.
M`.ZKX)G@AYUTYVYSA2WB#LNVQ=XD]$;PZUKFN^OLJUW"H_OJO'SQPC%^ZH!V
M@,+XG1.?OL7W1'SZO@Z?^/X^';WVIH_P#_B;I<YCQ1W995(9"MI2LPC5XMQ]
MB"_]*`ZGJ-%]]QV.=KD#^;3XQ`W^.O`W5=DD-:VYW!9`7:JSE0O4[>ELY=SG
M6Y6V<NZJX)NSG)LLXNXLY\[6NSW+LX<M*F_EW.3[(L'-%;AR[N%M^DYY]E2<
M#E?$GGK]?CAU!S(B4HR^9K6ZW6Y=0+=PA3?#LE0A:S>Z'<O>&2S;T[B:[:;=
MK.U\(V]5J:RNU6KO'.J"[RN[5>ON?A-%W$=UJX%AC!U#OJ;#H%5K[`3$+6HT
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MG^/'V3KLA5"I95O6KJFA:!&_"[BW*\R[B0&PZ\V\E0.Z36M.U&/[YU`(`]0;
MS8TXF,IJYM@#&P>1&NUZMR&%X:(5W@K*4JEL6XV&56NM`8I,?5]ZX:V!G3\C
M[Q??&_WG7^!K[E^,GXM::Q5K9>4U9L\B0TB;D@,\UFW5]"/(?'C3E9=[][JM
M;JN^ZLIW<=#_XS**X.]WTX>H'WH/\-.3`P_R;U>HG6FED<%OZU!=7GU!JNS:
MC8;DUZ7KIJ#\X82.'XN_W`>X(7?@Q;BG9]A1$$:%@6G5NBW;EFZ0Y0MGR?HF
M#/JN.X@0!GS-\?ON]1"^0Q]:'\P<Q<6N=6H:D2]>,0N?AOCS:>CYCR!OO2"%
M^B]!"!?CL]=WY\&[H/IG#EKKS6X7G?6;@;&536Q$PI;=+M4FLB?QO^+K_XLJ
M3NCU4<G!=6:NTWGGU*W5:]:6M_B[,YJZ!=!:CD'2K75K2Z'/7W\;P*_'V!V[
MU2D1\!O3UMPD^T*VQKI,!$K=]9`^I!.CM>I>A"**VM!G9X0RD[<A__"W8#1P
MPVM_-A`Y[^)HMJV&W=%DW&)`M[JMY&.9R_^-FVRW:O6N3J1[W"-1X;0?$P%]
M<=]Z?AD2W>/&EM#D_4NPZI[L9M?J-,I!DJL<UUI;V_MQO?&JM;IUH+EF87OH
MC=&BV9D8S"E";]46GTD*PJWNY\WR+^=V;H#B78[=;2`@<AP65JO;WO-^-E<H
M.A8PSZ;`+U1J,[#T7IQP\%L81"MK2>(LO@334%F)*TNU5KMNUU?5O^>"NI<-
MWS^%KKOVCJU:;175L)@-DX*YFP/.JV'L-MJ-U93@4FUTR<'F^\17U/:+(>%>
M_U]3+_+0T;L;JNUBGKZ](M7JT*US?MO;55Z;$=C1<KDS`U?*3?<5SNW:O_@S
M=GT6Q6NXO59PL-?KRJ\Y=Z7-X5FWY4YM>Z"LZ_78`6K6ZJBS,FKR7)AS(R`;
MTLT<3^FB,,@ZX*Q+-HW,?;<,)D+DK=L?.5'D#;T^]<.Z'H):BPJ.?/H^R$1X
MBD7@VX#8WE;61GX[B=86LYUS=^B&H3OXXOF@CH.</`NB&/24/O9X`ZL#/N&[
M??S^#R]^PG@4A:#'V6R6#<]&2S]]`R3;W-&F8K6H[>0>LVX1SAQSD<('^U:T
M%A'<2I!L<4/K'@^8P':[L`U)(7@=/[GA5\]Y\$:@5KC1&U-J+=MJ49'6DN^_
M#8SE#=$ZS6:]O3X8$GWIOB:;(J/9KK4;FF:7__4WP;`<$U:K6:\WUP5"D!-<
MD4,W0@W"&7UQ%=IZ_B!)\]B85-K=1DL#;(TEBX=V.1[?#JV>+?/5`T5^@(E0
MY\[8><P$@M9)3&S9G6P:U,S'WP+!4LRL!<$\?MR8B&IU*J><]]T-UUU.#HUV
M>Y%\692U=>WK`OG2A_O6F8XV;U/9MFJ-.:F@<Y::30@*O6>X2)[=+XX7DJ5Y
M/4Q^*??UNC&V:JUVM];2XO>KKK@%2)7K4WWATI],X^@K=ARU5LN@+/LV[(/8
M!KE-\L"O'P3X=`J;@E\.EJB_\1":G5:C937WOHFE#+'*9NK-3L>N=]^^F5X4
MN7&DWL&,QU$03<.-TTIGB67N$D7`4J2$W!^@:\K`[0):G)A8&4[U"+PQ'4_(
M9WSK17]\(?\TZP>WH**M:&PK7`M/H@A_RM]^<_[TQM/QS)9N`+(9'W[MM%9K
M:3[\54'=\Q8]?[TMUK:T16R(CG&;>S<<;^/T_NNF_H_%D.L0[`GBU&$`Q-^V
M`_'OP0B$/4KY/?&*=5IK-%?;6QK6O>]R/79I=[K;WN6Y]^P-7'^PSAY7$]SS
M14!MM4WIH,W=TC?704&/CE;TO'[W@X?(#9_9M$/HT$?K]P$WY!14^LD]G$XT
M=,,(!$W`.UC1(5F$=KX-\/>%HLTIY!VAZ'H:7P]W0T8G=KUC=]KM;:!*V\;>
M<%5Z>EJ`I-YH%/2IE!-3+3X[D3LX"\8XJH6^5>``(+M5:^EC8E9;N3AXUXW4
M6*"QZY4<NX8WCZI$=LKOH&9Z_J-(U;OF2VBUOH9E.X*W;LFR&W:C7LI3NO3[
MS+3.2/,\K+ZU<A[46W=E=:U&*8]+4*!X^6#/9^UMM!I45;K'$UDK5ZO3;7?W
MR._KIG*U&QUKO^)I7HKCIA*W?`?PUAVUZQV]M+9$9W385\B\<WKKKKK-=BE/
MZ\!ND"5LM,-M`$$$8Q>S71&Z,X#6\Z?(R1,WI/>B&S>$CWE]G"GIC:9R@8WL
M$O@6O9SKZM%3;#8$:JN[6VK%'/3NEBH#![V[I;K#KG>7SZ0]]`,_DH#^_)H\
M<N.\XJ^HPF1;(1OMXE[9.VOK73&VO:'28["8N)YM=RND%AY);%=(7<3KFR-6
MG]Q=(78!8M<5`\W:OA'[L'S!AU46U"/'\\JKU[B6_NO&JOTC@YNM@%I>I*R6
M@]"NL+1"WD/SR+&TZEV0SFFI,+6(\_8IH(JZ)HK);-G`JNC6[/J6KK[5,F!*
MB,9"3(MN<UNZVGO#ZWI*<#?5=+#":Y$&1K>Q+1?#>\3MFFF1J7Z@!X[;'Z[W
M^`1+]I[=T'ETLVF!1=Y;"[WPN]S402-TJ42HT%PLFN<(AW*C>1.]640S,98&
MB_D#I3,'^*OK:1S%CC_P_,<,0+?NV`%:Q'8-?APZ_7CJC`KS6=3_85G?K-9Y
M`79!X?O;$>8O_G3#OA=A[N0N,=_]A_7-;FP?\1MLKS#)(B#3SOYJBMM?5#>Z
MRE4WIX68W:W56L6X?N=!OB_4I*KB-D%-RZK7&[4B-*N54;.H@9N>CR,H=*7!
M"&\ED57;(N;"5_3A_\:3$'Q>>`>[M[MMNU4OPBS,W4'1^`%!YHGP]0Z1=#+3
M/[/X;:3:2&R%_I?G#J373D%$Q[I+>"PYW%NLG(+F#+ORCD;NP$5$[@6L+`AK
M4WJTE$;X'!2%S&BE_/>;T.L7ZNU</<=DMWLL',-I454.]%KKA/^+V^`6J'=&
MPKU#!*^YRRR6+\:34?#JNF((1SXX5P%UF(4OXL*1F#26_!U;]ET%\3_<&"N\
M'GV<O+5Q@Z%NN]W18AI;`W!GF.!#^1*$XE?XW*K&&IAD]C_L;]WS'2`D%\[M
M:I?TKW,GQOP*4'8CKT]^D*+392U[6\KEG`W,=-''_HFJ+>YU>(L,JMDJJ[5J
MF:,:MFOM6K>1ZI*_9+F"P)L?'5H.=,=N=^R6;>T<Z)3-NB;0;\?TQM0'#,T$
M>/&OJ1>_)L,.-S=4U]S\"3;;M/1NF]O<3&&(FUF"FN?=/SE^RD.UJ2FW)A*M
M9KW=;%E%(''-C>V$$I4JLFU:M*QZJ][:-BVJ[:PD>]CA=#V\<_O3D/N^.FB=
M?7Z5[=#%@XOZ3VY9GJX.8\K857],)-LM(O9ZF%(N171JY<9CBVR\AC::<XVU
MBP=[I5,IT68X=%7$&=C--:'FI8N'NH`C*'(OZI):E9C>(`"7$%:GE=G6*K!M
ML*F<X]G:IJPLLZP"6NZ>V(^^_U.:8?^E@*V[G5V>C]U8?3<+#D=Y+R_8>YGW
M_HX(KI[9T"J@+6(B#&OVXG.W3W#4+8#4+LG%LQF$A6QVYR)^,P!W9WDH)TW&
M8:><"BHQI(C;W"HB4;C`/1T0GHN0,46$[HX3^RMY;`Z3]O/5G"*C%)M3Z_JP
M[8ZF%D:5EA#6]M2\(O)8BM[Z8M5+!(Y+0'!S5;`50-R7K[`D=+>;JV7-K6_2
M*5?`4YCS</4L@G6@F_$%BCS%Z-9]=OT-@U?9(&BCT=8+N[)K;`+#NGTE.[5.
M6Y]/,`\&8EOI5_SFC7`4J>]&W_V!&_[#=7#JMGQU?=3D5F-(6;':HDO@[/6?
M/-C0(.]5>WT\Y@+<F`OPPM6SIRP0KX5GU8>^N?%3,$@_D`W")PBW-(2WM(Y*
M^+D[_-S]2W`3>'Z,HX_I!_F+%4>.=]MUO>/^^H"7<.OXBU6&E*2R]`YDY_RY
M*\]?I8T6G:Y5OCW6M3W6EYPNS4W>B+*;S<[[V;N.A57Z\L*5<("[Y\]]\9Y7
MH>[B]_C5!66KY\.#V$FPP$[5G49*UN2NLS$PZZH+K<[ZP&2T2!6<1(U-B\]\
M3K<(6Q]U\Q+/&_5&M]&UM*K9S2#:WKX6G\*\)(..7:LU;+M6WGTU%C;0FW=>
MS6Z]U>U:5GGWM;AUWMSS:K<:]6;'+FI?I&SF5VX)3KST^Z,IS5>^<F/LT%=D
MY_P-EB\8\DU[Z.\?\L6,,;?+\?X!W[#A]!L`E[PB#?,O07CF3#RX;B['DS!X
M=M=Q)JQ:Y+MXL;>#ML$8]5V!EN>"$5I6#S2AT;K5_WM`9:GA78#?B[O+<L&Z
M`+=;AO7<G83P(?9K^H/>.`AC[]_TSR)8W>JTVIH^N&"U-P*V+J,WVG9[%W`5
MPN6=3J>Y)R2N#VP),+L:S\!5;^T9JVLS]QI0RAZ;!5K(5K/5[FH^[,P2&T"P
M+MO:5JNI3^9\.P2%,.A.$+,^6#O%UMJTO%4D%04-*=2H)E_[Y^Y#?(8Y"6%4
MT.UX8C?KEF5+O3UOF8W@6)>K3AHUN]DJ&HIU;:^35K/1W08NUC*D3JQV`T<V
M+X6BJ`JXY;UTMMM/I6%W&W8A[=C6W-#N$;ER8L8&Z%V23%E$*\%"]KDCK&O)
MHELEWT;;LCI6@=U.5MW/[O&X/^HMI,"ND'T6WWUF-V1:O)2=2Y#L`M1:&VF"
M0>2?+ZT-*)B"3FMMJ5VL#]AV]K5RKZW][HMSZ'=^7@UKR;;FP[6=;15S7-O8
MEL:'>>]%:Q2E%$R&*T*V^<Y6KT`I]L16!&R+;?SV=153L=B.]U,N-!8C".SF
MP:.Q!(IAH5;-Z@K@7W_^\R$<>;_@_X=__O]02P,$%`````@`XEMJ17SMY?5N
M#P``6;D``!4`'`!A96UD+3(P,30P.3,P7V-A;"YX;6Q55`D``T?H8%1'Z&!4
M=7@+``$$)0X```0Y`0``[5W=<YM($G^_JOL?.&]=5?9!7Y:=C;W);6$))]3)
MDDZ2LY>G%(:1/;4(%`9D>__ZFT$@"^:#P1(PWKH\))$TT_2ONZ>[Z6F&C[\]
MK5QM`P($?>_32:_=/=&`9_L.].X_G=S.6_I\8)HG&@HMS[%<WP.?3CS_Y+=_
M_?UO&O[S\1^MEG8-@>M<:D/?;IG>TO]5&ULK<*E]!AX(K-`/?M6^6FY$OO&O
MH0L";>"OUBX(`?YA>^%+[:Q]:FFME@39K\!S_.!V9N[(/H3A^K+3>7Q\;'O^
MQGKT@S]0V_;ER,W]*+#!CI8%P@>,\GNO^^.?I\/N1;_;.VL_+3&&H17BWT_Q
M9_Q#KT?^ZBYZ[R]/3R_/NY+7"JTP0KMK=9\^=+O];K=[NIW^T87>'Y?DKSL+
M`0TKQD.73PA^.ME#^-AO^\%]Y[3;[77^>S.:VP]@9;6@1Q1D@Y-T%J'"FM>[
MN+CHQ+^F0ZF13W>!FUZCWTG9V5'&OT+!^#U.$+Q$,7LCW[;"V+X*+Z-Q1Y!/
MK718BWS5ZIVV^KWV$W).4N''$@Q\%\S`4B/_8CO97371[0HXT+9<;"&K#AG2
MP6J*5L`+=<\QO!"&ST1GP2IF&<.(:3X$8/GIQ`(KIT5,@!@&N?!/,G/#YS5>
M-0@2HS_1.@?Q.O`]!W@(./@_R'>A@ZW2N;)<(O+Y`P`A*N)8GD*]?$^M`,OQ
M`81DXN$@F.0J1T16."#V@";+R9JX/VP'KU.)F%2M2`86>KAV_<?#@5"4CHEC
MC+UK`";+JPA!#R"$U^25A2"^[#0`"#,@M:++43DF_R/X(X(.]B%%+%(#C\G%
M/%JMK.!YLIS#>P\N\8_8N]FV'V'WYMU/L59M"`HMH1R5HUJ!'P*\^I^M.T*K
M0->,L4=>63BU"B$F7X:M@FG'Y-#`EA0^+P++0Y8MY:SX,X[)UPRXQ'=@+UZ.
MNZ)YQ^1Q@L-+,(@"$FA&T+J#+@PEED;!M&-R>&W!($XV;X"%L%>+O7`1?\))
M1_4TH6__0>X%<,B0<LW<"<?DZG<KP'93+*;\N&/R,+2"M86]0!A@\\4!*+'J
M&=@`+\*4;!\[5:GTM"RAXWJ_U0J&L?G@2Q,NL.O'-Y<2:T1BZE$M$=Q++8W\
MN./&W3L$?D28O+&1XH4SOOY<X+@Y096Y@1P'"Q)LCX0F2ZNJ/$>.8_Z,&G(>
M.1:E)M<0P^6XE9I<>3R7XU5B:J6Q77)1B:=5$>?E&&./KB(&20J*.;J2N]$A
M""WHHC&10`@WA7<OA1/K]^@))ZWY@Q6`%BD@.OM&9CR1_Q8"J^):C<E"6IV'
M4:TJXJ52?NW=OFA^Q3Q+2UYF;@V1.[GT*T-W;G9]_+9T?.>_D:BFE213'P)I
M0RE)IMKZ45GFY2G4D/=)VKK<[*KY+1V92Q&I/&]-%]CNQU>EL%PJ5?._\P\(
M1:NU5'&R))FZ$(S`!KC]0YC/4JCT/J(@O2I]@R%)KQ9,)4RI#(U:>)_$URRQ
M<UZ>4HTX9'.'DF3J0""?V,L2J.*N.Y53\EE6WI+3J^2XQ"*5F-K(KD%92SF8
M<$V["N7SYM*DJJCX2":=G.$BCO#E[,B-%_<(?\[,`$\A\!S@I'0(2T=IE<)?
M$TK=[9^>UM*&$-FN3Y(&\B$AH6$:VI:(EJ%2,802_4\9(*>8]UTK"_[_8#(>
M&N.Y,23_FT]&YE!?X`]7^D@?#PQM_L4P%G/MW:UG10[$E_@Y;5)+D;F^G4'C
MDBXY/\B:00(F;H5;6N@N[H>+4.O>LM8=8AX=X(8H_28VF%:WE[3%_91\_1T[
M'HPKR?S3"[C6'7#CRWY/QN6&=9ICF/0)\?G<_IIG;\]2],#6_,`!P:>37K>;
M$K(".V,A=(]A,J*#2,V+$&IAS:W2^<O`7XGDE<C&9_"Z+S9\D1/M$<#[AQ"S
MUZB8AV`),//.-?2(^0]\%*(Q$%@(=X*<,DX;5D8!7N7TD]19$0ZQ`&Y(30=S
M6[R,A;/D--5O6%,RR)53US0`:PLZ28D?Q[>XX+*%RU>7>):<NLX:5I<,<N74
M5:28<BJH/M#PE@I3/ZH)>QKX:Q"$SU/7VJ://R*X)JF4,-Z(9ZD2=+B+HABR
M<GHRO=#R[LE6PA8;YM5XLMV(/!#TV?>=1^BZ?'W)S58E!''T5D8$RNEO"-8^
M@OB&ML"YY<>I$F>XF1L+EG+2W]L,*DS36&,5R#63S4/I+#,_OOEHR5<")\ED
M0U;.N(816/A[#>XR1B::TWSXE-94,73EM+6_$U^H)N;@YL.DM'X$8)53#*=;
MHE!'1?.:CZ#2ZI(3@7*:&X(`;N)R?)DX*YXEI[5S%;0F`U\YG<6%@#+JXDZ0
MT]1[%315`%HY)>VQ.O8]NT3FNC]<#9\^\KW[!0A6K,Y.H5-G3U0JG:65PW?L
M(CFH;(!29J>87CC:.-0#-)J0%V-B6*-J=A7WN#SX+A8<VC::\LV+-;91E[9:
M^5[,5*:OD>7#\B.;7QQ\P5,>BPU3.5/2'2?N<;'<J04=TQM8:QA:@EHH=T+S
MRUQ:.P6@E5/2C/3&>,`QK,"#WCW2;3M:17'98`B6T(:"K$9F;O.WY-*JDQ>%
M<EJD,9I>4G^?^D$L[#`,X%T4Q@^'^B00D>XTW\6LW)M>"`*`!)H^%GT5W>PA
MDLI9D,#45+.8&^CY08R^2/?T2!7=\1&UR!.-<CK<RRQUSRF3N17/;'ZERJ(K
M7(,'F8;ZMQUEA,,]/8>'\&,G#W"$/S?=;\H^JB[3?-I_5?/I?O>I]BYSF9^;
MZ;,M.-0N@_E,#O-\@?^Y,<88[^1:FTR-F;XP\0!%6F\3E-Y]TALEJ&\PAC;;
ML+,$",7)_S40\4V/;-[=<L5.]^@P4:H7':T[/WAY]B)WC``C)G+&-^_L954C
M1JR<@K;'';N88=U900^B</OD2*&F"B<V?],IJS))&2BGNQT^G%SY*S#RD8R;
MWA_<:,TC?@Q+P/'+"(4<,RUJJH"1Q:5J\BJ/B+^,:&@M!;9M)5*6[+!7,4P_
MZ4:^^4[D./&&X"[<;FJAO4?,]A@A8]E#%;!UEA!3F^`SKJI-W'H!L%SX)W`^
M6]!+>4][$@164CA1@44L4I4L#%45EY8!<%PFME:8D?#&*Y"(2*A)C/:(N8?0
M<1GDGIFLY\DR?U(LTWLQQS??4B;IP@1HE4OVR"T?#,4YWOZ8YN,(S3$OL6"D
M((IF3<68F):GG&\=@U#FIB$WK'F;8O+-*([D=*3:8L[`.&Q7\!6DFE]&,FI\
MM8P*5ILRU73Q&T8R1>7SUQ25!_K\BW8]FORN2E&9/`N-<>+UN8%8@E?/MU@B
MIK<+`\EY.*3O+#[4),+?T>5VYA(XB.[_HWJYI7L$);X]EST$ZP#8,#ERBKP(
MCLC<<_05V=#\,W.6#/.Y18G92CCFXVNWC.B4TWM\PMX5[X`]1I<.9WSS=Z&5
MZ%8L'N6T:2(4D2WLR3+>KL=&F-[X7?O!'`0;:`,T"0:N!5<"EUR23/,WQ)7H
M_E7"5,XDFJX/5OF05B5J?\,%11MSCL`0;/\U/?J\'E%Y469V\X][5;/42XCN
M+2@^.?DG/5FKY-E'KZ4G9QR_O'WC*"/>MV`NN2,72.YJVT$$'*DGP%Y+3\Y<
M/KQ]<RDC7N7RAT(XV0,@#C"3/"$Y^[CXR]D'6Z#*&<;^[>UDN3V\$>./CV\D
MNWP0;5'Q+4*>@G1=Z(W90ED9_@7W27MOIYI7]\YJPSTX;Z<0]_:Z=CCX=Q[@
MR'L%TG2;W2NP`7#0-;:5E]++WI/(PBV$HJG*[BR45#F]LR`G-.72AWW.Y4X%
MX<]0=F/A>,I]$P>&Q"(``?2=?)++UZIH3O.+MA@1O:U_C,"F:'_0L<11=ETH
M]_S@V`JC`'O:JPA!#R"2K%]9"*+)<AH`!+PPNT^4Z79XGW_Y1J^MC?7%[<P@
M;0U7MW-S;,SGFCXFCP[.S;C983HSYL9X$3]$5_E#@KMWQ;+Y_R7/_VE;&YG_
MN36'YN);Y<S)O?F4S?F'/.?]MC:_O;G19]^(D.?FY[%Y;0[T\4+3!X/)[7AA
MCC]KT\G(')C&O')H3!^?`7"1!W"&36>R,.;:5/^F7XV,.AX@91U2R&2WU\VS
M>]XF'3U?C=G"Q,S6S#K]3DLVU]3+<=ZW-0.;]^*;MICIX[D^B!]EK9S?O3J0
M!->G>:Y_:6LS8Q0W3DWU6=W,<U[&R>:]G^?]0UN;++X8,VUP.YMAOX?]BWYE
MCLQ%'<N0^49+-N-G><8OVMJU;LZTK_KHUM!N#'V.W7K<LE:]8\R_.8[-\CD5
M?;K8"2XF@W_CI7DS-;")U!)DJ+I)ADLZ1N(@^;L^PR9<@RBE7ZW&9IX*D#T<
M(8?Z;*H3[X>7X6`11_=T><Z,K\88F\O,&$QP!*I%_(*WK+%!4;&SUR?._.;&
M7&Q;,@DB`@^'3&-<2[Q,W[W&9IB*E3T<+.?&YYI68W2'P(\(LV=LN#R>4@&R
M=TXRDJLYCC?$[1'#J(59F9Q*F%N=4E&S5&ZEO4NI5W\&AAS:!4EK.%BI6%L2
MZY9V]4CW,S01'BK^YM/*^ECFY)<B[JD@+,HRZT/"R8!$2*C8+,J#ZD/"3(A$
M.*CHS4^+ZD-!Y4<B!'0(9V9)]7&?IDLBIND0O9<TU2CH)"R+6!4&Y_I8W54Z
MN&^6W>>Z3X7K_<J']BXAHNVHJ!++"EZGGG\8-X/YT+B>"J6E[5U=L_<NKX'M
M]1635H$M')H#-&`L^P$U-8G"(DY?(CEXT7%,3EMOZ36"J$!M5++`1U.C9CA9
M3_ZETADD5+(@3GL26DUC:5%OA<^`HC('*5!X7$JV:7P%YD?E%7+X:C1%NDHJ
MAXQ*/MA5TT8P<5)QX?*B,A1Q+KY;7G_%E[HT<"J*[/N?>..;WSHN>MT,^WR4
M-_+2IZ2!.7]08\*V[CDR;ZPI1:3YS>]R"GV%A*IO'=SUG9/;GOC0>6MEW3.[
MMLEX_O#F'_>4U(88AJ*K*X]-WH6K\#!FN77"PZI>SP<KBY`K')Q1A0-N,M%,
M&8%9X4LS]MV/;&Q4@4!4['M)V`E5;4/(-@-O=S^"L%FO^1OK9]2-/A=?YG[D
MA6RS^$9@`]P^&QIU:R\%+::H]1NHV!;4L=@@J3M^7BFWN%+5(.1",Y7<UV_,
M1KG()C$'IK?T@Y5`C71'0"&^+64-OI!N'*:P^G$FO>M`8;1J*W_P`!9$0'IO
MH@!:C=$OW5M)595\%NN*WL'(;+:\:"BA5J.*\GB*?,<YW8;`P5*KQY#NPI&R
MP',J3RG?E=-0;9C;J2,'G$I@"CMWFMG*2K8-156Y<RICR>X;9HO<R4T"^8O$
M<OS-_P!02P,$%`````@`XEMJ12JU*A/%(0``>6`"`!4`'`!A96UD+3(P,30P
M.3,P7V1E9BYX;6Q55`D``T?H8%1'Z&!4=7@+``$$)0X```0Y`0``[5W=4^,Z
MEG_?JOT?O$QMU9T'((&FN^FYO5,F,7VS`PF3!'KO$V42`:YV+-JR:;A__4J.
M$^S8DB5'MN3@?F@@D8[/[YRCC_,A^?=_OBQ<XQGXR('>U[WN06?/`-X,SAWO
MX>O>]63?G/0&@ST#!;8WMUWH@:]['MS[Y__\YW\8^-_O_[6_;YP[P)U_,?IP
MMC_P[N$_C*&]`%^,;\`#OAU`_Q_&C>V&Y!-X[KC`-WIP\>2"`.`OE@_^8GPX
M.+*-_7T.LC?`FT/_>CQ8DWT,@J<OAX>_?OTZ\."S_0OZ/]#!#/*1F\#0GX$U
M+1L$CQCE;;?S\[^/^IW3XT[WP\'+/<;0MP/\_1'^&W_1[9+_.M/NQR]'1U].
M.IS/"NP@1.MG=5X^=SK'G4[G:-G]=]?Q?GPA_]W9"!A8,1[Z\H*<KWL)A+^.
M#Z#_<'C4Z70/_^_R8C)[!`M[W_&(@F9@;]6+4,GKUST]/3V,OETUS;1\N?/=
MU3..#U?LK"GC;^?!ND.R\<GA\LMD4X=!.L$T<KZ@",D%G-E!9(J%'!G4%N2O
M_56S??+1?O=H_[A[\(+F>RL]1<+VH0O&X-X@/[%)K9\:F\$"S)V9[6)C6AR2
M)H=8H^$">('IS2TO<()7HEY_$;&,840T'WUP_W7/!HOY/K$68D/DP7_CZ1N\
M/N$!AAPR/O:,PZUX[4%O#CP$YO@7!%UGC@UX?F:[1.231P`"5,0Q/X5Z^;ZR
M?2S'1Q"0CMN#R"57.2(R&0!B#VAT/WHB,R6V@W(J89.J%4G/1H_G+ORU/9`,
M)9DXAG@B]L'H_BQ$C@<0PF/RS$8.?NR5#Q!F@&M$BU&1R?^%\S-TYG@.*6(Q
MTU`F%Y-PL;#]U]']Q'GPG'O\)9[=9C,8XNG->[C"6ITYH-`2Q*A(M0(8`#SZ
M7^T[0JM`USEM)8\LO`L+'$Q>A*V";C(YM+`E!:]3W_:0/>.:K.@]9/(U!BZ9
M._`L+L9=43^9/([P\N+W0I\L-!>.?>>X3L`Q-`JZR>3PW';\:%]Z"6R$9[5H
M%B[BC]E)ZDP3P-D/XC;@)8-K:J9VD,G5=]O'=E,LILUV,GGHV_Z3C6>!P,?F
MBQ>@V*K'X!EX(:8T@WA2Y=J>BA*2._LM%DX0F0]^-.$"3_W8#^48(QQ=I5HB
M>.`:&IOMY*Z[=PC\##%YZYF+%TK[^O<"<O<$5>X-^#B8DL56$IHTK:KV.7P<
MTWO4L.?A8Y&K<PUK.!^W7)TK7\_Y>.7H6NG:SCFHV-VJ6.?Y&,MO7<4:Q"FH
MW-:5>*-]$-B.BX9$`H'S7.B]%':L?T:/.=F?/-H^V"<!Q'G2R*P7\FLAL"J>
MI4P6W.K<CFI5*]Y*RF6]?5;_BGGFECQ/WQI6[OC1)9?NC=[U\;MO8L__F2.:
M)DBF/@3<AB)(IMKXD2CS_!1JV/=QVCI?[ZKY%5Z9A8A4OF]=#;#UEZ6VL%0J
M5?._GA\0"A=/7,%)03)U(;@`S\`]WH;Y-(5*_8B"[96P@\%)KQ9,`J8D0J,6
MWD?1,P4RY^*4:L3!NW<0)%,'`OZ-/2^!*KSNE9SBOWGES=F]2HX%!BE'5R59
M`U%+V9IP35D%\7VS,*DJ(CZ<FTY*<Q9'MC];,977./D\2MW5JOR+%%R=1&P\
M8A+^++P#^W,'\X.B"3I^4!+UFHKC!8>XZ6'<YC"70/5\KQ^V/X<+VQ%D.MN[
M!HZC)^TOP.(.^(+LIKM6SZOMNF(<1AVJY\N#@2G*VJI/K38)[NW0#4H;Y:I[
MFF?\L;.<F2_PGRF^P4L`O#F8KS@G!*542N*/":7.\E_7V#?Z#IJYD/@,Y(^8
MA(%I&$LB1HI*M0@$JA]3.(XPZ^M"-OQ[;S3L6\.)U2>_3487@[XYQ7^<F1?F
ML&<9DS\L:SHQ?KOV['#NX$?\73VP_(K(%,KC4BB3,(W?4H]1`[N@=#(%^0,?
MY,D4_[BTAACNZ-P875EC<SK`#92KF%U=F8)Z4@9JSYS\89Q?C+[7"E6P"#,%
M\^/FE-,],(;F]'IL$3QGUY/!T)I,#'-(#'DRB%!>C:T)1ASIM&ILV>K-%/N?
M-MD_.C`N!O^^'O0'TS^KYDVP;#/%^.=-QH\/C,GUY:4Y_I.(>#+X-AR<#WKF
M<&J8O=[H>C@=#+\95]CN>@-K4KE%Y25Z4OR?;O+_`=O-:&I-C"OS3_/LPJIA
M?#/+/I/<=CN;W)X<D&%\8XVG`\QKO9PS:D)33&=V`Q\/#`N;]O1/8SHVAQ.S
M%TVJ5;-;6"2:8OIHD^E/!\;8NHCFRBMS7#/O1=6C*=:/-UG_?&",IG]88Z-W
M/1[C"0_/+.;9X&(PK6$$LNM*4WQ_V.3[],`X-P=CX\:\N+:,2\N<X.D\6J,J
MGQ&I-:<ICD\RBTX'SW[34>]?>%1>7N%EMI:U)5.4FF(RNS+BI?&[.<;F6[T@
MQ4M14[QGEL4N7A?[YOC*)-,>'H&]:;2DKT;FV+JQAMA6QE9OA!>>.H3/4[2:
MPI19,;O'9!*_O!Q,E_LO`HB@PPNE-:QCE<P4N*;XS:R07;Q$3JQO]0Q$6KUK
MDL6CS++8/2&[D+,)7F;(?$>LH@Y>2U6ZII!DUDJA[13VPV+JE>_52Q7"IJ!F
M5EA!J$O:U3LE](K4%)S,JKNYD:R-8[YRVA3SF:67M:]\`Q+#6`%QX2S%O4M.
M`$,_-TP6A;?N;707Q;A"M/]@VT^')/1]"-P`K3Z)@N'[G6Y\Y/=O\<>W:X\6
MBPP,\*]K8*Y]!]SHV;=QX[RVAQJP/DWN\QELQ^TV67XS&]-?,1_'"#D#L<O`
MY)<97K.PH5EN]+2O>VBY'*PXN_?AHE">L>P@$T%2P)B1/0/Z<^!_W>MVWGC!
M%@CF7_<"/\R!7*.6^N`N&'@(\Q&%/E\<AH'EM96JK=SD29%VTD*'A1Q3M:.1
M'LCE"_TX%<.GC60/J3K)YH8H"F'(FJ64+-2L:HXZ.Z*;VVX.$EGJ665)2DYW
M6^LO`D=3X7%9%693Q>23V]$L@'?`'\+G*`MXU.F<;NX'NITK/)M@%B_C1&%&
M6X22.*$*E)A.:'(I*&?<P*U14>?&LI,C17L3\!3$C'4[FXPQU<71\S9ONM!,
M/[PPJ#-BA0KIEE8(I>=MWN#76"$L&-3Y3>WV@5RJ-`]=,+I/@T93O`2<X0?_
M8&S`"_O>GJA1(/\.G`\"37F2UZ95P=[`VS0DEC9(5XZ>^NI"!`#')OSWPYRH
M@8KL`RN@D(F,LW(0M45&>([#IF!D8N?TE$1M((I.RZ8`9`/HN1F*VIBGG*A-
M\9P-D"<2%O6).?^L;8I39FB\-DZ+C]XFF3[.!,N3I0;&;S$18TU%DU"RX`G;
M%.1MH^HKF>P;B:<;L\3C#;!\?AL3;6.B.QL37=5GQ6.-'13-;:QW5)2!3[>P
MZ`";I^\LKO!_$,^#*$##J'X9/Y&<`2X(P_'U5A,N92D!ED"A:>RT>@7J'%.5
MJ^1:`ZPW`)%M"=ZMD'WX\L0?.Q+$Z*$J)"<T="`_E+K"<@-OMO3>;'?MTY&J
M[V)E</2\_=`LI?!"HBGG@V3EQ$82CVV>H9%J>ONQ6>*G8J#)^Z/:K<,2$CE$
M0'R9LP)'*KOV\/6_/=4U'"<.@[JT*-7C=^`\/&+^S6?@VP]@&!*YX)F9P!F%
M0?2:!VR7Y`3%S/3F?<<-@S?//*O7<O2TU_,6L*@3IN*=XPPNP`5$Z!P+95EP
M&I)%>7WF"4]A&W`BM*SM9$F2VFM_.V0T`SA1&8W?\FJV5&!LVQK,^H.%W->Y
MI7!R%&>^Q?@B<L;3DEX;T&L#>CL;T.OY>'@%Y_8LNA.,'<_+:ZMW.(^.3K=H
M7IK3HN!/?FLUT3J&C%G*T#PXM[T^=`Z^;:6S6F-MR87]RD9!/P3=(Y[BQ>*.
MMVHVKLQA`$4!R)[-!-3`54-:W%%5S>@V>E!8']IW?###C5%Q_6%>4U7A9EYI
M4WF6'E>6E!!-6$=<'\5(B&8;:^\^TWBFZ4-ZP>`,;Y'G4606H&#DY7EZF5)!
M1A]]!<['.L>$7W]`@NOVZ90[GCEN2'?'$Y$%#;S9UA%O'?'6$6\=\=81;XH^
M6D=<=T=<<Y^$$X%T#T6!+Z[H.)I$7[R2DV@5^>**JHRV\L4K*2.26%")O::X
M<(.<=V,EO#.-;S_IZAH6\"S;%]<D-**[.F@\UQ23E1\:T5;@?*Q3%V"-KLA8
ML3_&D"/<\WCYLA\8KCD_#7UU6`X*=2E7&>[B?.5=*N"5.0[+OE\KIM6&O-J0
MU\Z&O-H+MO0(>;47;.D;_FHOV.('5U<H3.4%6_I?%U0.5%T^TY/ON#D72_'I
MB[-W$VY!$X%"U8UDY?QOZ+Z:X4.(`G+3U)H3PA93+87]FG#M&1^(NF+,%_:O
M<\=?%(H^TZX)%YKE,UU7T-A<1`[G&'N]T=DSX#L`F>N$@M`-<Z5HJ0H["TU/
MI8%)CTTKN:=1T4UFLN]I9-UG=E+1TIZYHE!L;2_JKNIL<IG%G0L+33^ESRA3
M]$/E!>\0/S-5P]%3556?B%9X8=`4<MJHBTV[#1@GW#BH.^"J!TDZNW0&[J$/
M2!29'/7D'"TL$K==K:MAQ:'(SH32$O\I([OV[`7$;/X%YBMN8A:OR,<P+U@3
MY=?%J&BNK%)H]`R(LNV.47W&[*>Q_@3XEYUDY4MN<XTG9A^-I<_).T<JM,(E
M:`B]&8\2>+MKK@\Q&%2GL^9E![-'GZ2X)NDW"IHK2!@)U0_59:FY@-[#%"SC
M4HPRGNQ<G==18^V)`*`ZIY6N-KQS75$WC97`SSY-!9_DJF`*`]LM>!/RAOA9
M7307?3'K-+%_UB@=G3/K\N:E<[IJK#(Q"-0`CBXKC?`*TY"1Q<,XU>.4'"*(
M1OC&#,N:QS:::BQE-LM4^2H]H,RNV-Q?O9MES7ZJ=#/S"A"NTDW<;D6VK>)L
MJSC;*LZVBK,AE8)M%:>^NFFK.*N*<Y)"1:$T]%N'!E1ELIF7/:-QB[S;$13Y
MJD,3:BP+N.?9*5<D]:ZHU+O-*:0LX)ZZ0FB9<A3WSA45]VWMG+-J]RJ>^5=I
MSNACLA*BD4>+.7+UU5<)8A`4+0M9AJ:_8&E]X+Y-U\<*`G7NJET?N'_Y$1+U
M;KQ.UB"H&]:ZM7(.0]XE/;]STW6RQD!3B>1\/`='B0L0Q56".S=>)2L,-)64
M3;]35!*]"<M&(/.6[9@UBT2/"6?GU`E,A(3>ZA%&0E.2Y'1[L=E,G)?2PP;W
MU5LM_!!H^OBD;RZEX-[7S-O(^7(I];U=QOH9.L'KU+<]9,^BUP/Q`<N\LOSC
M@6']^YJ\4'LZ-H<3LT?>LI[_PAP-4BP9@VVS0VUV2,:K!G_9_GR*G\).#&TT
MTSLGE(M)MW10_CL-33SG>`\10G3V^M8&S^%1S)X@>X/GS:]<V^-)5U3S-#5I
MJ'SUPAKP:IJ]:KXIZ9PU4V5NU23;Y%@<.??M.S-R\IN\99J:K8C;YS97E)2K
M=&:`?+#U7)$(M-%]0A+L+0&EN=Y;`R9&W6ZF3!HEMKDA].RW3Y(>4-'X$R:D
M9F%G*P=N!TG3M5N5CG5><2NT@UHK6$BX>^`]XU4`^NP#^SDM5150E!U8L!@-
M==F3G*^,4C]\@L]KJJJ(0H+DJ7"HLY_ZFLBWL.K9Z[7G_`Q!'Z"9[SQ%PBXL
M5^7HKO>61$@&\K*852B0MW`ROX>ZHE9^\;-4UX!(@3QUZ;Q_J$*EM;_+Y\S&
M+N:,?;M?IIW*>\F8`P$6,4U-/U=2RT2XW#@=Q5%Q2>VE\LXQ7K'S0*"FER4K
M(0J,A+,@]!WOX1RPC3R_L:KW*(B(G,$Y-7&L?C_6GA7:IA))M_,H[5DA?76C
M^QZJ.6>%_H`NICORV"O)1JLF7.*:QS)UJR2YS'CY[.DOR"'4=:O;STT1:IIE
MFE`_2Q9JE`D:((0W8)/PCG@D=_@WDF]"RT\I8B[L=]M5%##DJZGCY)^F!LGS
MQ7?;M[T@?O(4DATQ>>4BV13'L3.*&HH[:JX'7@!ZIBBO?#@#8([.,7@"@3B1
MH_OO49PT8.Q5V?TT5ID`_WKF,!/COA_Y05?`=V!JY)]#?P+\9V<&F,6-(G3T
MUV@9/'KZ*A0D-[8;@NT5G$^FL?IEP:'NZS0X^$I\BM%]!"IIHEVZ/MG]]%<@
M#__4*(Y>&C,7Y.XS<8VE^C508SG\4[?Y.DZA2XO;J"*+JM"^^1"572RI]/37
M\#:X:)I7>^D?:YF0IW@VN<;JG0<6U8]17++-LF1S]C-T4"3[LH,\2:*Q^J5!
MH>I4\8D.AI5NI=(,A<9JE(*$JM"$[UK_.<I1\`C\^(KR"\>^<UQ,'"#F6\1/
M-T\9?CXP1M,_K+'1NQZ/K>'4N!B89X.+P71@31)O$:_XT&0>E%>N<Y,?.MR(
M_E1Q'/3<=OS(JBZ!31B,JN=6UX:NO\R'UMV$=GI@G)N#L7%C7EQ;QJ5E3J['
MUB7&.$G>&DJH&L^$K,J3H6ML)D(@*AA,V&@LC/G(&P-R9S@>@,N*0G_UYYF-
M')09Q=DI2?)C%$[/,I`4'&65^`AM3L%68F<;JX5TU33C[.T:]MGK^M<_'.!C
MOA]?+\`S<-D5&+S]E55ER-<KQ6ZX!*A;,B-WZ<KB**HN$"2CIAQ$4%,4-8L(
M2KNZ$17JUKG"I#Z3T/DD[9KG@?<4!BC"3;_]<Q-]MI.B4[7EABA%I_FH-)_$
M$TP?E='?D=IC7U4I,`E+T[A-'MO'951XK/;\6%4J3,*BKJVJZY9]YSD*.*P!
MC.[?/ER'/%@UFGP45!4-UN&&"<E`S^EX*9TU^V_1';KFJ5UV6=5LT-11KC(<
MFS>]K=\/A%"X>$I%U].AOB/N4%_J_4!O9-M+X-I+X';V$KB=#T1Q'0]JHTEM
M-*F-)K71I!V+)FWERNZF)ZNO^_)^;V-5?$RA\5=HMK>Q:K(R-]^4=%[GV]M8
MLQ87GP,K6N=3S53E&6J\?C6+5],$Q)A@9Z_XB29ZK_89++K=6!8Q6'AA<;*1
MFG4U*\@<06M^N:FHK'5>>`3TH?-:<8EEN0@714I)-5.U5N29."Q@DSK%J_4O
M+NT7+K$GFZG*(W.(/<,F=0)2*_9D*FV5R<';ATL0/,(Y=.'#ZSGT\])LYAT*
M?'L6T%6U-6E]WX$E%2'-,C0)E"6PC1WTXSRZ/W=Y,=X8RTE,_WD45*E9JO:*
M#8,*7<]`6QX$Z^4)D'.$4^`OQ/2>[/E.])V!K&=<C\7Z#72Q\TD*6L1'>CZ-
M=Z;['/!Z^GPL$'WGV9D#;U[>!I(4WID%9*#3])^XHD:ORJ%E7BB_:.BX5-%0
M1-$X;@N&VH*AMF"H:#IM"X;4Z[`M&&H+AMJ"H;9@J"T8:E[!4(T'7_(L5:=P
MI1`0S:.2"3/^[@2/UQZ\0\!_)GN1I76.`9[O9AB/O7238FS16\+N@8\&7@#3
MK@W?5+[MT[2WDLI`ZSD_R(,["H/1?7TFE7C<.[*I3=1Z!E4M++;Y',S?)M<A
MO(#>`_#/G/O0Q\\%\^7=FQBO:R/DW#ODLO'H4K#'Z/)]9/T,F<N2O&=H;SZ2
MH7*$8.L/P46\)BN^5O&WJ-9K_VZS("P_(/=A,R#7[1P8D^FH]R^C-[J\LH83
M<SH8#9/1N`1]8Y9X0!N>:\-S.QN>&]H!'A^C>Q*F]U!!:6%N8[T#;PQ\NFW`
MHGRXLUA>?]F#*$!#&)@N>2+&5Q1MX>NM)J;&4@(L@4+3N%GU"M0Y2B97R;6^
M$^P&H,#Q'N*[X$=/.:_.WGBY#Z.'JEH\H:$#^:%0!YOD-WT.O-G2'[+=1%2&
M1QD</54EV\LJA1<2-8DN63FQD<1CFV=HI)JJ>NOMEF,BBX$F[]*OO95T&#2"
M%,2O2<N<F8EQT-<>OOZW745OTN7>B8O@D!W7I;W%CW"2<5IC3O`P=\,Y>:/:
M$`07^>]KB%Z))T1$8SV5!:/GCOT[<!X>2<CE&?CV`QB&1#IX(24`1V&``MN;
MQ]<LS4QOWG?<,,A];6-,L!P]C=4M`9>><4ULIG`!B'V2]^SU\%;9\4*RB\+N
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M\T:ZS5>V^<HV7]GF*]LD4YNOU#(VVWQ3TCE:W.8KVWSESN8K2[L9\4$.<LP`
M^Q7>?!UI@>2C1$GLLE2V`J]/D`/M3\;7*@B-0ZV5BB#C">.=IX/`E>_,JHB0
M2>&KM=QB\6@\NY:)99<5S!@0Q>+/284ZN>DVM-VJ4@W2>6R&G>LCJAV+);.%
M%`]YXO4KVE%D.&B&O=8E"([X\4Y:HU8["DZ^6LLM%@_-GC^HMV?Y2Q!=,/KL
M*$KPV`P[UT=4-)L_46_S6TP&-08CWE_402R\\%&](65&6_0I,L/@$?K.7V!^
M[6%6$R$\$O)#J?4AJJI,C+$1)<N>Z"(\7=;#53/,4Z5P:);\24-+YE\WQ%W.
MH^K6^Q+,--1NJY<)S5P_:US%8\X"YSEQ/VZZA.=3Z1(>.Z;;UN^T]3MM_4Y;
MO],67;3U.Y2(N>9I3^U-J:W?:>MWVOH=&9<M+M]]P'@C.VF5;J3J<"G?78DY
MO.YF\8G2,&/=)L#6;-4A1I81*=X5DJEC@%`(YOW0QQPO+^Y=!JR2UU.O0DVL
M\U#"M/0V@W)P=K/*X1MN&*"!MY1!=3-%^CEZVX=\J+M9DV"]/#GQI:/5&U#.
MPW;:BFAX-2X'V`IM;555V:JAW3:C/+2RTZ(4'R)*=I'7F"2R604>!:N+WOY%
M(>>R,WBT6_(3.YC$CC6^UBB/2XHJQ`DI&4F\<H=;(^/(:56IP.4%21(42"?4
M=`46(*,I\%2N`EDN%6F@UDTJ(6X^1R@O]+J-&*-]-%6(\;=-$6&27:H`)8?P
M>K8W`ZX+YH#L):F2W&S6%)'F\DV5;5DWG6.23NRQ\F"@>%WAF*4Y*35%0V6A
M4958MOY3AA*7:XL,)2XI[:02$]"H2I3L9+!*YPJ<#9ZN>CL=W`BHVM"@?E!.
M2%[-^1?>LZ$J!KNH<526+2F4#-4ZR[I6JNLA-C((ZQ!>148JE8]=M%7Y`J*:
M;%EG4A.336<O%-DK/Q/OT5@%I4--7&I>YE`\9C,9$F73JQ`G[]%FRXB(:KB:
M%]SRIV34[%EY3Q_OH)E*E`S5.K6\J'9H^V3X/;^5NJ<.MWP6/=RRIO?W!-I*
M$'TG3\(3S.JL3OPW^[#.:09/]\#X;H['YG`Z21[1B:FU9W3:,SKM&9WVC(YV
M>UU=#E:T9W0:[S;I8DKM&9UFG=&)MTA%YW-2S7;_;$X&KIXKSVKWC&&-B4.#
MAC``;SMC1H(LC;.(@/;O,1'!05.EVG'8<VV$1O<QD)$?P4AD6>@Z+.JI2GDE
M=`+%@>DY,$N'*H;06T8KK)\A=E@''A92&,UM/$=Y*GQJ8ZVH<J%0MY+-M,`,
MVE'P"/SIH^VE;H.K\$R((`?OSS++"(BZ_6RFE;(&YSH74?-,N7[N^[-(?K'0
M[%#M":?<K<;R2,WH?@)FH8\U!U#/)A6I9Z\K0<<-&8:V)>'&6I(,W#13J>$<
M$Z6D,/?L@;:^$9-CFG`E'W=9*_9MVY['$KN(6HQ([0KAD3/<"@U-69*/MO!R
MQBR6%B.R*\I*H&'EC*K0UMH;*3^P>$@T15/<6*AZDGQ0AX\QKC'%0V(W],0S
MGB0?^EDQMKP\I/Q@*NS?%`WQ`:&JIZQG65X]7&.HL/\.J(=G])1UN`K4LSZW
M9RW/[0GLKD5(-$5)W%BH>I)\*DZ$,;X!)4!IE[3&-<ADGX9+KYVD<,8,^F`6
MH3_NX@Y'6V\"!8DV1:5;H*-JMR+W2Y15D:VC(-%=U2['V"U="53B)"M-=ZPJ
M9:W#3H6<4Z6^JUFS(?2>HZS,AFBBXSY]+--SV_%O;#>LXFB`1.Z4S`B\YE17
M?DU07%1CK\A%6KO69>8<$1I-,(9RH*@J:^A-?(4FS3QVJ,<D)<AB$XQ32YE1
M;;]J5S2^ZF>+64N$5!/L8RML5#UJ\'Z\&LI>M)S#!%EL@HUJ*3.J[2M]1=GF
M:4<3H7#QE*I52IUT/.GPGG1,4&H/.;:''-M#CNTAQ_9D6GO(47)HLS6E]I!C
M>\BQ/>18J_*B!`Y[N4\TT7NISV#1[=A0Q&#1.$DU4K.H9@69(^@T#NW605%9
MZ[SJ".A#YX4B3OL7*275K`*U<*T4>28."]BDSO!J9YTX'U\H]F0S55<W<X@]
MP^:N9;O7L;9$V&GLH!_G/@`#/''X``5CO!Q6$&'E?;2^]1&U2H!F>1IX@'?%
MV.]XL%LO3V`6@/D4^(MN@<55\LQFF%IUT/5T&Z2.KQ7H&^AB,JX3O-8XO>4_
MO!E65X,,]'2D6"#ZSK,S!]X*-,.Q%:&BO4$(@Z$Z"2IS>'W;?[)[V#TB!Z#)
M^6B`+1+@'\_`"\$8S.##\G%<=[.>=#,9OJ,#HV^.KTRC-QI.QV9O:IC#OC&V
M+LRI17[>6,-K"__LC;X-!]1[6S5(I&7LH<T!MCE`F5KZ!N"#;S\]D@'*#A`R
MNN@=,"S$JMVV:VFA278+,S3T+FJ"B\5"A[P`-`T]RM22SF%):9JL)FA)*8R\
M=%PP":`'IK_@%<32.8>A'_VR^@#_I`;+"`D!"LI>@58X:&!Y/-1A)_EL?S%?
MY(,M5?5&XC;/TIJGJPU`U&%5@;(08>QRB'='A4K9;*K,OQ(5?B[C-"%_J'I$
M3'%SL-WDQ2!Q>](0I0@!HBGKI$9E)5DLK:XLD=N/#5<8!1)-91\KF\3.L9_/
M.8F]-;W]U!#QYS).$_(GM3[/*AJ$XB`0?1.]V?+V5/.872[#LCU/BJFOK@M<
MFP.Z]O!S_@2V/_+`BC.*\?-UUE?^@AAD!\&Y56+.'AUL&O,\SHZX=<.DTC0E
M%8/A"&RKJ$?*A+#?)F(0/,*-&/=?K*O(Q6GIJ^7M(%$WWBJ3&#VX6#A!E&DQ
MO3DQ3L=[`-[,`8@O;7&425L<'Y"7R5T.II<6.9M$<A8D@3$8?K.&O8$U4?%V
MN7C7L<*4#^4X`^7#@3&QOBUQK+AN,RIM1F7W,RIG(<(P$5H-',ZL2GZWAF16
M6)@US:YPQNHUR:(P!9P;?V]&]D1("XW(DI355*W9$7.YV#-#'ZDVB@.W]#A'
MELNZHK369,"4W_I[Q>$ZNNS2'$J/ODGUJ%@GE^(6MUU5J1U!]R?FE"9PM1/S
M".\1;.+*##SL`X`+B!BBSVFLOQ:H3.NY7[GRX;T3L/7PUD9_\6_R*COL)BD>
M;:-'1@P:?ZN_I-^XU#-89B($6)6[R^_UEW.23XY0E8HY)"X)/H=^SWYR`ML=
M+)Y\^`P*:J?9_?37#`__-(V5O:E-CL;ZX,D',V=9[^_-S07T`^>OZ$^ZNAB=
M]-=5(?/4#:I21:V.BY$J?`\QPG,;#?572"[#-"5\*@[%QY^3_\@I*?S)_P-0
M2P,$%`````@`XEMJ1::(!Z&T6P``YD@%`!4`'`!A96UD+3(P,30P.3,P7VQA
M8BYX;6Q55`D``T?H8%1'Z&!4=7@+``$$)0X```0Y`0``[;U[<^.VEB_Z_ZVZ
MWP$WYT[-GBIWVG;O5S(S9TJVY8YFVY)'DCN32DVE:!*R>4.1"DFYV_GT%P`?
M(HD'`4H"ECIG3IV=Q%H+_"VL'Q;>"__V'U_6$7K%:18F\;]_<_'M^3<(QWX2
MA/'SOW_SN'@W6EQ/)M^@+/?BP(N2&/_[-W'RS7_\[__[_T+D__[M_WGW#MV&
M.`J^1S>)_VX2KY)_15-OC;]''W&,4R]/TG]%G[QH2_^2W(813M%ULMY$.,?D
MA^+#WZ,_?WOIH7?O-(K]A.,@21_GD[K8ESS??/_^_>?/G[^-DU?O<Y+^FGWK
M)WK%+9)MZN.Z+`_G+\3*7R[.?_NGRYOS[SZ<7_SYVR\K8L.-EY/?+\E_DQ\N
M+NC_G"\O_OK]Y>7W?SG7_%;NY=NL_M;YE[^?GW\X/S^_+-3_+0KC7[^G__/D
M91@1Q\39]U^R\-^_:5CX^<.W2?K\_O+\_.+]?]_?+?P7O/;>A3%UD(^_J;1H
M*2*]B^^^^^X]^[42Y22_/*51]8T/[RLX=<GDUU`AWT"2A=]G#-Y=XGLYXU?O
M9Y!4@O[7NTKL'?W3NXO+=Q\NOOV2!=]4E<]J,$TB/,<KQ,S\/G_;$,YF(:7<
M-^7?7E*\$H.)TO0]U7\?XV?B\(!^Z#OZH8N_T@_]K_+/=]X3CKY!5)(P46K7
M=ZVR2J7WML$^X#1,@G$\#'57VQ%\TG;2?`\#FOK635@FN1<-`M_4M`Y[BH?5
M^$[/?DV3#@4/J^F&9AMV1/]X1_ZM!1Q_R4E/A(,*.BU+$>#8IUC<+<NN2T_\
M5KD1#99)VJX1#Z^IQ1=_ICT2LY?^Y9=IDN/LP7OSGB+\X&7YS19?G!.^^SC.
M[_'Z"=?%,!N*<K2TWG=14OU16D'U4K_'WE+BO9^0SF"3OXN*FBW45VFR-@!3
M5D^BK?)+]%1_JZA5`D=B5$LLQ1D;#Q@YM6F963V7.-<1T:/C+1R_>UQ\\[\O
MSO\)466T*931SX7X__S;^]U'AM"H-(09L?*R)V;)-GOW['F;]Y1>[W&49]5?
M&.'>G5^4G>S_*O_\RW6*@S"_]?PP"O.WT9<PZUBO$K1!K'Z@E$MR*>?TZ876
M94Q;$/U,1?=FBR3H3#9WWN?;,%U3BI:\E@<;E;2U(-,/N0XN<E'GK-##UZ7&
MY`$1#415BJ!RJ&`BH4<#GIP5`B%K9)`"K#G`2<!PO0Q6U^-6W;U,8N^W;1CG
M:H<+Q:RY7`&R=KI`!H;;Y<"ZCJ\EK7A>-+RY'#3X[&HY'7R*35`./B]/9/`I
MQ,D-/B^+P6>&'@X\^I3P:+1F\Z@YSG(Z#UN0Z3K.1C78ZR1^Q6D>$B0,EIQ:
M`PNRQK:]#*T).*@4&)S<!WJ7IF59R(L#5!6(BA+1"%$2-XI#,2,TK&G4#7[*
M)W&6IUMB2JZ81HD$;4ZCY$";TRA>RCGI>J%U244%T4[RN/.H+MWKM0%BU-_E
M44Y+S5I,,S"BCF`:.LZI8PBT2R0J@.@R3C,(30\:A"2LNL$^*__BO(N>8/JK
MG%9Z>M9X96)&32P=)1C,,D#*QZA"%5%)-QR;^7E"BI\FK^PS="E=VE3DC!M2
MBC7^#3>Q9J-Y$3"X.1AWEZEE06R(5I5&6?N=&]:.-FD8D3]WFYP&5;55[<TE
MS(S9S1[T]&`PT0PL-T.@VO3`QKF0;\>FVX*XKVQ`?)274TU+S1K-#(RH*::A
M`X->^D"[U*HU2WI=.@QG%P.Z7GU=ZP%-UQPNHO4IPN"<(5II3+MP0[K_W$9O
MHS@8;9^W63Z0?.9E6"/A4/-J,IH6`(.4`U%WR4F+88.]HJ"2IBZ&>LW(SAFC
MU_=*U9STO3U&"/M>B0X,RND#5?:]CL+@+7Y*MU[Z1GZYU*>7CI8U=NF;4).K
M7P4&M[1Q=JE5*5)F73I85EFM0A^G)!+/MNGU2XA7MV'LQ7[H1>5/BL44;5U[
M2RB&YNP63C058;#-$"VW2%+((**/2`&(E8#J(E#U.ZR]JV681WBVFL1!^!H&
M6R]2;%])9&WN8"GA-C>QA(+.>::#CCL+0F51LD([:;O;6?7BC?Y6%J?B;!M+
M`EZZA=61M\H8`N0IJ8^N&]<RS-6SW>JSR0!>1\OBX2)=$QJ'B_I4G,<B,YQ=
M5JD4K2[(UC/:@2NSO?INEF@US1*OU?8HPZ#>`,1]J[?GJ"SEB$/^PPR[%B])
MFB]QNJ8'59;D:XIAET36YK!+";<Y[!(*.N>;#CJ.6UW9`PVZ#L.?6R],V>7C
M2;S9YMD=?L71!V'$T]*PR24-Z$U&*<3!\*H?([=`032*V^.HT$%,"7T`%J=J
MRZ[>ZG_](<0IJ>B7-P99$;ATE9VP3\L@(1&5FO`XJ0-71$^U\G&GH.6J2?P\
M>DXQIB<X+\[9_RG69/M4["W(ZH'?K<:JY9TSR@`DQZ-*"]5JJ-0#%NAH#S];
MC=*4P,<]Q[@ELE;7P51P6^M@(D'GE-)!QZV#T3%8LD(-Z?)`6OS.:_QM2?XU
M\WR:IB2S':7^=O$7PR#5UG`8HT30%2&J*>Z<3OH8=0)4H7;L18SQ;]LP?YN0
M:6J6T\\JUBNDHM;HT@.VYHE$#@9!U."ZS"BD44,<6(\EFG1<&$\!+Z!,`2_,
MIH`70)BECU%W"GAQ`CR[-.;9)12>79KQ[/($>'8YB&>71U^F#[_D+_=A1.)G
M$BLR"HCE["V[*V#NEM<%0LXYT8>,6]*DHJB6!19G:$Y%-@#[B)/GU-N\A+[R
M-()"WNK2>!_LUO*X3-@YEW01=CG5%#ON;&M!HE9,J*[8UFL)6-RW$P!K;,PU
M?G7N9BDD?FN-R1PA6LCF0^'SB\J[[=_MS7P$L';3G<:/,%PK0,1-;)B(/<?>
M>4\)RQ[\MMAXOC*5E%#08CHI!=!&2BF!%`SGJZ#QJ:4J6<2$42$-;$QPE\3/
M=`_V@=31BY?AZV2]#MEL_.KMFG14SP3_;#4A/58E$2A&#(-+LSF>V-/DYFAC
M8%'.R7P8_%QFQ5(#S5:(ZJ!:"=3.?G%,^&H;1C1SNW*>+1:U2585V"8317)@
M:*8`)S[CC2I98-'RWOL2KK=K)6<Z,C;)(H379$E+``P]1*BZO"AE@/%A3O?$
M%/UAXW>;/.!@-3E0_PC&_UU$7=^SWX\[]:5C]04=JR\_)P])&.?</XFZ8F1M
MIF]MP#W$K'H<;J+LG$M#$7-QIBH"77Y+_]_ACHN9,F\68_;/6U(_`X@G4G?/
M.[E1_;3C=8&S3@I83;J+;_]LC73W!*L&N9IB]DG$@^3)LI,!1@H.F-SY]^^.
MOF/$<Y5&Q,Z_S51[2:8E.(PY.J8IPHY*'1C)3#"K@L\'\O\.MSLN7:ZL<[.+
M=[FE4B[RW@MVLR4B,#@AQ:5.?7_TR*-_><SY-3'-"V&0KWX97?*"?I5K$OO)
M&M?[IM43>8IYMU+#YDQ<`WIS;JX0=\XK?8S<LRI,`]4JJ-(Y[IR>7BN["3,_
MV2K/?@K%+";OE8)LY.KE9)RSH0>8,%MX+6J[KQG%01.J?M<C4727:T%EB#SC
M@D@+!H-,H*JZK>+1`GI9(:!,"TI]8!T9&6;[O\XV-/0IMQ`$<G8/7$E@M@]:
M=82<$ZH/&7<`A\JA0A#:D&?TV4N#GEOK'1F;#!'":[*C)0"&&2)47#(7*H/`
M74?_D5W`$G==$AF;A!#":Q*B)0"&$")474*4,L=_C2),L4^$LY[IL5C.WH!5
M`7,W8A4(.7=Z'S)NS%J)VDEI*'C=XCO]D6I3VMGPE(<L'9/N1&'PHA>?X-F:
M[^SGO>1AFB2-`Y$OSB!5G*,L<08DZ<D,QY(F02")^-IBK[1+D@BN*_:(@B6)
M^IHBR\T,?0WV/HS[3[ZU9:R>?!/!:YU\:PHX)XH*%;\_%Q_TY)LD:(QP_A+1
M&7-`+QI-8E\>,:2B]E[`4(/=/7@AEG/N?PUPW+RTD$:E^!DB"L!BQ!Q']&G1
M!R_-WYHY0J[>FK^HCDL:%&#U/*6Q8:T#E]K:SGDY&#)W9+,00TSNN-L\XR])
M1C>D_!`31V;*R"67M7?=K0?N[NJ;1-`Y2730<5?B"G%4R1\V?$F8\0EG>1@_
MSU:-%6'%PHI2W!H_-$#7%%'(PF!)/\`N44H-FH8*\OK\U,NW*9ZMQE\V.,Y4
MJ_1"29N=EP)JLY<2B#GG4#\V+FDVDZ3L*66/V_>0():R(PU>5*<-F:UZ(XV6
MFK6(8V!$'7DT=)RSQQ"HX-1*I8E6-,/+*\OP0JB5,&VT3H)P%18G68Z^IE/&
MQ9+5O9U81\YV[R6$V>VV6D(PV*)`)NNHJC@SRK+$#]F@]W.8OZ#K\0S-B4P:
M^O1O16?VD>XD67EXL'Z?KL[[3E>5Y+S14++[M*".`>VW!%4:H%X9T44+]]%`
M^I$KCX!399L0"%E\4$0"L/%^2$<"1@22P>IRX2$-8S_<D+[IJ9"F'5-\R-=F
M#C-0IJ>Y"GIFI)N\>GN,P]^V^`9G?AIN>D[Q:NK:'$P;F=,<7FLI.J?@$+3"
MHYX[9=30.NY@_(<D"G"JO+S$B5@+2!)P=3CJ_.Z<"0I078<74FAV_$1'.U:-
M?#_=XF`2YYA8W'NB5Z%B>8NS%WQGGU,J#X,A>B#%)W=9=""]EE=HHK!4/3:+
MV*A\Z^=;TH4^WZIN]<LDK7%&#;6FBE@,!D.4V/AM@X8P(M+'YD(1NY27H#D1
MRWV&_/)SYW<8_A:#DO091,S:OG;O;K:K/6SUSC4<SXH@R7:I84U"ZIMG5]LL
MC'&6+?`S2SBOD_Q6K.,D`:X*OC`)KDC!.9E,4/))4Y_+EP*.NJ6\F"CVD'<_
MVMLT[@+:[1)7OSAWJQ`.MP^\F`"+#;LU6K9$JSS@)I&U>Q1%`;=]ZD0@Z)PD
M.NB$@\)B%9WFIR2]2[&8?N2!`\W:4[Q-DJ2*O3RAF+U7AN0@=T\+\3+.>=`#
MC'MA@4B2^6$I>FS/L]PI&JX7RUGSO0IF[7R1$`SO*Y!Q#Y-147O^Y]+J4/IU
M\\G):6&D[BX]4K]1\MQ(<ET8W#('+,J*E)59D?Y,,P&Z)YUA(D"E/B#:F:0"
M5"B?"O&,D@%2YEE)!E@\;3,-^S*_\7)6F22#V6),5P@.,R3(Y+'G_CN7"0$'
M=79*?1#)`,V[.X4R''(9(E:G`731X8F2%P[FGJ@$$.R3FV:6BO*$&"C%W)>*
MT@H'BZ!\&[YJ=7U-.0=='P]3T/7MA.!P0X),T?7]Y>@)-Q)_RU[$CH-QG+.'
M:U=)NBZRV3UE>>KYN<@</3U["3D,S-@EZ-!0@D$>`Z3<L@%.U_0MFCOL9?B0
MJ\T9]K]]3E[?!S@L%IK)OW37E\F??BD`S_%S2''&^=1;XXZ-<C$;!.H#2?DB
MDW%.CQY@W-8#$T4[642%W='BFI`ZI?=^`_SE'_A-:APG9Y<8$IAM9G2$`%%#
MC$S"C5(8,6E$Q%VPHPIX-`69P*SVS[:X(`)54:#Y&PC/"P!QAU1+$9;HS:67
M'W`:)J1G"VZ\7.7NCIQMOPMA=@G0$@+%!!$R*24*842D$15WP8X1`1)0,+>1
M]RRPJ_.[+38(854L:/T(POLB1-R!I4H&42$7OK[>IBG%&&:^%_V$O50>#.2B
MMAC0![8B@TP.!"]ZP'&GE0MQ5,@CJN`T.!2#E1]Q%/TC3C['"S*[(1/F8))E
M6V[U0D/>[G"R!W9[6"D1!D$B'83<E>(,E2--#U'-=[]2553IHD+Y/]R1ZE,2
M;>/<2]]NPPBGW:.1"CF[))+`;).G(P2(-&)D*K+4&HBI.&1(&0SG>).D]/XS
M/<2YE1-%)FYY#JL$W9G*"F4!L4<)4$JB?\Y0K8$*%526Y)!-C,W5L]%2BSM2
M=KDCA-BF3$L$$%-$N"0K'TP45;+N"/&P?8I"_S9*O.[2NT3&+AD$\-I4:`@`
M(@*/2D*#0A`Q28=]##OERP[Y+EX\4AVS;9[E7DP?!)>'1:62Y?Y&PX!.KZ/0
M`$0D#9BRI=7&R>TS5"BCAK;+-;AB8E<L^]R2OXF&,PI9VVMQ4KC=]3A.$`23
M^M!)U^7*^7>Y/,=4W+.&K@;H<:8AZ88Q'%0Q7VHQ@&SI8NOC"ENK.0A3Y!D)
MLB0*`YKWJ4S;LGC!.,]4!P@TE&QF)=`SH)F70*WAG#=&,+D,@BQ_TH/WYCU%
M!UW>V^,QJ"R3,THF9/4Y*"'`UGM0+0GG#%'"XK8(%HOQ<@&)"N7$78L1G*Q]
M8DC@\OSH"`*CB1B=;+?`8SHP6'/M92\2TXJ?;'*B":9)`?IW,!YO@.$<3'Z"
MX=:17SRG.L<^#E]I?S7%><D_&9.5*E9#@P;X5H10R(.AC09(KG<I55!:Z\!@
MUPU>80(\N`UC.GBZ3K(\(]9(+)=*V\W.IX3<SL<G%`7#)#4^/N=>(8U63)RN
M\?M4`P:3'E*\\<*@RMX=![/\!:=%IRHQ7ZUBDU,ZX)O$4LF#89<&2#[A*%-!
MN-`I'EM.J!KR`0YY6D,VG6&=PX%Q[X#8*F_R)/>B.]W1L.SH/2T$)#$>TF2#
MT_SM@>!EEPI^VX8;NF8D[]O4*G:#43_X=C"2RP,*1KT@^6!4J+`@A"OY,Q3C
M@VY;#6?9),X)7IJ0NV@MQ)3Q%S_:TJV.CTD2?`XC677HJ=IDG8DQ3?;IZ(%A
MH0%8CHU>CND(GI)Q4_X[Z22I)B!*WN!-DH5YIAQW=87LCMY%`-N#]J8$&.H(
M8?%#]$((!AF4)'#A?+G3'3A;<PBD'/M`&O/<A=Y3&(5YB#/2O[(]^!>6@#6C
M?6W^UK.0K*]NDS&F1C4YI:L+)L08`NY2\FXRNIK<39:3\0*-IC=HL9Q=_^.'
MV=W->+[X9W0SOIU<3Y;@N*JWS:%2<,1'C0T/N31$SIEM?40[11B<JM98RUU=
MO27RKK"+Q7$Q8-&R>%L2#(>4\*1+X1M(N^\W6[Q,&L_>[IJ#;#BH4+`ZGNX%
MWAI;2Z7!D*D7(C?FWF*4)R@M'R/>%#HP:,7.F6@%)*&DU1=$Y5!;+XCR8F"H
M(\<F/O\#*@(UGG?39TV?DM4M?RT#6H<!E!I@:*4%4_SZ3?%:7]QDVUF]8,XN
MZB0Q#/K=X#1\]?+P%?,C0NF*B$K%[J)2/_CV$I-<'@SM-$#RRT^5"KSA.=M\
MU.:65-HFK7H@-QDE$05#)C6^+H]FK1U?<%329I%K`NEQQS%M>M=!M6G3W@^&
M3)LI\9WINI-(QQ&9Y/`EO.(5P$0F'93\\#T&R[+&P.\NB9]I>L+FJ+%_C"G6
M<C225YD@&<J+5,"P30^GP6`^WE$1U'A>V*Q,FB"`X*8=U,#VEQQ$<9<9`XYG
M#6OZ[75&FAZJ@"6(DA;@N$#O=X=Y\7Q?')"H2!.-X-B7<T.I8;=/ZX7>[L^D
MXH#ZLCZ,?#]6:[!S3"T=]"?:$Z*+#_\"@VS&)QB@G%DP.Z5P`N<2C$\B-!7^
M&=W@5>B'0`[(-9);?/*BK7P\WA6S':Q$(+L1JBD#ABT28*)8E,0H*W*%;+P4
MO5)I]/^>?WM^?H$V.$4932#RK^@OY^=GY\7_+_Y$@M<V?TG2\'<<("^CS\LO
M2(VR=P30A_,S1'W/`MP]J8,7].&B^-._HLN_7I[][>+#V=_^?L%^O[S\\]EW
M?_MP]MW?ZZ)#FIXO*"X^[#*7F'SF#)%R-MBGZ[#10=,L[7$X(@A".CGQH@<O
M#";QM;<)R1!#MJ$OD[9Z/$(-N74^0BP*IDFH\7$G)&II1"_CO`MCY!<*,+@T
MQ[D7QC@8>VE,FD8V\OWM>LMVW\M0+ZD&'46[S^SJ&M)^<[=/"PSOM*$*#NE4
M@BB`U'WS0Q'M,8OK0:#>X`_63%6*3SQA'>'\)2*=^CT.0M^+SM`D]K\MNOAZ
M-%C2"3WA59)BMO1!9B$$3D2[V3#.,;$$RIGJ^S`FPPSZ'$T!2U)-O)A-JLE`
M-HG6E0$3HB3`1"O^<&G"-Q-"_.)6T4.Q*#S*\S1\VN9TT7B9M*WI(=>A"G<;
M_?:I$'7$'%(R&/H?U!QQ4`;5?_==<>A?,96H0;J4TK,8+=2!U>]KHNU=MF:S
M8U`$;*Q./'CI+*59LG'`%BH><,I2EO:O:\@U':T2]9DB63B2J8$)C_I85<M+
MC=6E/Y')]`T)GEZ:[9:8@"QX<WEW1_4J5W_U\!J.J"B#+J%@5QPB]208E93C
M%BJ!<HR]1J+-KTK:*;?:D)6\*D3A<JJ%3\FG8ED:*(GDJ=OU5)S229*V74<>
M+K'Z4[:WV)4<+D>[1@YEUHNS7>C9:D9Z8?;,KW8RY3YM)UF5]4P2IE=6JSJG
MV#"\_,V$IQP%8<;N?M(LB$D:X`#1K8TDCNE>&>'BYS!_04\X9O,%>I*8';O+
MZ$\K[.7;%-,].)\[C$<G&=7UO\]>2I_]!;(P-,>O.-[BOK3.O)C=;1`QR/:F
M1UO&.2U[@'7Y-Q]_&D\?QT`2/%>@>VQR0P.5^\&Y7>+NCPD)$3%[)(`MEQ%B
MD`C!5&`PH`R<\7.9G;$O0BCDK=Z(ZH/=NA,E$P;#HCZ$W+VHA_%\M)Q,/Z+Q
M?S^,IPLH\>0A358XR]B9@5LLC2N\F.6TAD*0G52&+1DP3)$`$Z0LK,7(F`7*
MN=T[[RE)1W%0IE4HV2Y;^Y4(6UUA5P)NK:L+)<'P1@F/3S'X1C=V6N/9*A,O
M#")])(/SU(N(0:-@'<8AC9;TF)N:4;U:-JFE:4*38STJ8,BFAY,;*Q5:C'5>
M2P\&Y[A.6K<S=SPTTAH2P=KVD\$3[_,EE32P(%5;,8G]9(WODJR7,DU))Z3A
MH0IILQ,#2AP.H'P(?3=;`!D^3Y,X:1M0Y<Q73\HT].QF<-(THYW/J4<)3.^F
MBY1CW/*'\;R:L!UI=9L2?A;31<[K>LU2M(XJEK.V8JV"6:]-BX3LD."[@@0Q
M?J9#7U&\Z0/(I40EHBB)44"7GW?+R3#"SF.<8B^B>\,?O3"NK*HR^,CZK%XM
MFR%'TX1FP.E1@<(T,[A=WOV)"O_+^ZBDG_]"?L1TMV/EA=51E&1%:,GE:P)R
M7Z@Z64CF$K2AJ>=W,F'+SQ<H`'<>+!!(@NGFE/"Z/*N$&^_TL%!WJ`&YLKL;
M?\G)1T@XG:U^+'?=Y.%:*&RYXU,`[O1^`DGG!-&")^L`<:5!PPZL/5*6;*QO
M;M^6L9X$3CFG;PH`FY8)H$GF\BQVE&$#!B_H6GJ8*V;O30';&QEM8-TMC.)7
M6%S@<'%7;,9+-B='5^/;V7R,IK/I]6RZG,_N[NAT?3)=CN?C!90WDJ<XWZTU
M['&[9D`Y5N?T0\ULS?%-"W'>U^V+G.L&*:]'R^5\<O6X'%W=C=%R=DH$UZD>
MA\3L)1VL4"B")HV&7=9<S^[O9]/6XRHP"%-=\JXN1EQY6>C36408;7/I$>]>
M+9NDTC2A2;,>%3"13`]GEX57H\7DFCWF<S.Y>UR.;PI./HSG-0]_&,WW7M4\
M#`%_Q.'S"[%E](I3[QE/MS11RFS%'4AFIDNJR;`,F^0<9%Z3JD8%@"'N$-1=
M&O\XGGS\@;)W]&D\'WTD8\O'^RO"X=EMB\8+-'M<+I:$[K0_?H<X]A_O;'I`
MYSV![)CSM9>]W$;)Y[XSZL:EV#RK/M#$YIEUPR*<<W@_W,(S[.R4A.^G6W9Z
MO5Q]*X^DDS_E"?F/W<4*&(&9C'>HC60&^!H&.+AZ>R2U,8GK3=L135557/;M
MV?`<4)#E0>E`0SLC5\-2G!-];^C<[2!2"EK11H%H%3?.>GAU$=^KV`UA_>42
MC%\$H+@)!\X1W2^"$3)&P?^WS8I,H?0U+NJ5,,*MB=,R.4Q0.<ZG[&:J.UYE
MM=/<'?X[8)K($8WC$^S5GRI>CBL_1I_Q9FV0_I7^NT^CX#8K+JH9AT"KKWX3
M(T)V$X_\>X19XI@X&*UI#IG?V=\EU:ZG:OF%<&UC.N^&]^J!8;L!6,$;X[5J
M,1QMZ,#@8[7"0<?<:[JEI&*@3-AJOBHEX%;^*:$D&%XIX0G3-*,G*DUG+;4X
M#!+1W`@>\=QLQ7"2QE'M==\FZ0*GKZ&/LUEZ'7GA6K9`;EB&U0,K0\QKG6,Q
M*0`,08>@[O+VEAZB6GOIKZ2+KL]2^:U\TM41A^)@S(9=4:]2.Z^2%&7EEQQ-
M88YP;L[29*=]<FZ)TPSO<WQ.-ANZUC\Q!^9UC&;?/5O=AC'A.1DN7B<9>Z#A
MILQ^((M5^NI6YS:&1K7F*YJZ8(*3(6!N7M%0+\C:3'I1IL+#:4IC4%4VB5M@
MTIB2F19IK1F^P<4_R=R*'@O:3;"R#+.*:+YPA/N>T-N[5+O'2`]2!>WSIGL5
M":9Q',8.<:#/.A-L5A1K,8TH#V2RS=?#R"_"PAS[F/1.\E?^]%3=\EUNC)K4
MO!ZTH_P&F`7Y\)D@72LJ):&2\2'%]-6(F[*GJ>Y(Q0%KK44CU:X@O<+<$M;$
M8#6%=4J"3VH#*_CT%4RUOC[0N%90O4]8A&:HY*_::?F<)UU0*_9J^U\Q'%H8
MC&BM8[!>_%:5!'@L8@!?&MS+1UT%K`<WU^RM@#+AR(.7[L/Y;BF@R"XVT8CE
M[2*LTOL5IT^)>O%D&'QNOV"+BUVN(J',IA"&06/]\PK%4Y5;\K==SLF]#T&(
M"X5Y8D55`<-.KXA*!'=0>W];1`<M>C=V03>/>F%JWX-;RH(`-`,-0S6HKR@%
MS(!F,/2^@UN[A49PIQ:(L3[&079+<-*GAZM>37Z&2B)N^?*?$G3G*)I0%@SK
M>@`*LALR\8)99(#,=M3H;AY=[2YR,9=C:'@,VVT\-I*E:]2+1,\5YY1FR,@G
M5`+)0A52,SJ>S#%L08S??["K72C,7G[/P:YFB2<QV#6S13K8W93%HJ<WX9@`
M1A-A%8#3,`FZ<U])I:D4K+XJT@N\]::(5!H6)7MQBN@6E"+L<0=2@*,C-A2[
MK.XMWPS8L"I<Y%Z:]]6V_$`,;<0>?3;W.8SI35+:QQ4%0ZS@#PXJ>!PK=TI:
MN&35B^G2KT[%6CQ,N]UL(G97S8NJJVJ3>)6D:Q;Y>V;^VMI6C]N:F=0Z?ZNG
M"F9P:X:7.Z';T&8GB:(DV])WY>@`MYKIDT!;E[?WU%YV19;V!'17<9O2IVE9
M\[A-4N5]V#X5>Y=?]<#O;KJJY9USRP"D,,ZQ/=Z`Z;%I4Q'MZ+E8("M#5387
M:I]T;Z0IXB+38!.<*+\@_=TY512@9+D$85"`IO<A7)W$KP02G?W$03T3FN1X
MW;OBK:]O.4>SF5F=7,UZRF!H9XK8I/^+D_@=ZP/#JG2V<7^4!6])KT@S`NQ.
M&E0-Z+K*!K!,Y$N-`_2M]9=#S*H[3Q-E*!ON0X%_-1DBQNLG'`0XV%W-F"9W
M2?R,TZMP12J:GAP8K>G1@SGV(R_+PE5(JX1_&5X2"`[Y`:L9J0Y>,:WD50<K
M'4S$/[A)W$N.M9I?7[0H;WL)\VG3-I@@S(H\4C?0A31;=<[IT-A1/UI*-]K$
M.YW[%F:M@]C;X+JW&%R2<\(?!+X.N;WN\436@W3?P#W0OJMTH%,<)FY?B9J7
MS_A.XNOZ$=\?P_R%]:1DT!;0@9NXJ]VC.(O#H+V-;HR*!I<%@^G[&\`/EL1W
MX92O0[,K=5Y5LLUXWAP4<JU:<G1E[]+<1G0CD]4A7:LH&$S?&[]F4&]/$(X9
MU`^4IS]]]N+R=NLNE5Z1MN2!V$`GZ:V+LUZTR[+7][SQ8<JV^B[`(:NC]9[`
M(0IVWI2.80WWLE>C[#/4*IW-PIOETT97?P'M/H%^KC[R/U]!,[NIE\B6^$M^
M%<F/N!W^,R?3^!25=+!V*/C&U]$DY89Q9T%&R\?YF.;XO7I<3*9CFDM]>L.2
M^B[H7Q_FX\5XNAPM)[,IC*8W#[-?Z07V1\*_-/=(W]Q_LKY'QV:CT(+?9+A2
M`0Q==5!R0RZJP_J`EA:X8'\7_K8-@S!_TP_<:A6KC[1K@&\]U:Z0!\,V#9#<
MXR*3_WJ<W$R6/\'@5+D"10\%D,CN:R1@52A83374"[R57$@J#89+O1`E-Y'I
M4DBE`2YD+<+GF$UEXYRWKR]XZ2I;/8QF9%#K+)J6)A@Z&L'E=N(?[^]'\Y_H
MP&TQ^3B=W$ZN1],E&EU?SQZG[#WOA]G=Y'HR!O(:#EV!W(7PG@@H$[:;]E8%
MN)WH5B0)AF9*>,(=\YTTN&C7-J8OO$FEW1%)&<`DHD"IU#OAG"W'"_0P^HD^
MU06#/HV%8KH)GN.T=<_RND@O0B8W]*!4^1_J4+57B59OQ.QO>NM6P?#BP-!Y
M?QNXX[R-+0-6%"K+`A=(J<%+8C!MTKU37+&LU;FM"FYK4BL2!,,X%3J.2[/I
MI_%\.:'O'`(,I<6AH)[HV!6R>E1,"+!UW*LE`88D0EA==A1"X,(*?VR,AD']
M$9N!OM4YJ:E9K6FIKC(8!IHBYLCY7X^3Y4]H.1]-%Z-KNJ$`9!;:2-#UMDR]
M.//869;>385>-:O["II&M+86>G3`4$\3*'^FH\BFQO104Q%<B)19J!\DC4J`
MP$S-0&F@#IZO^L%R/KX;T;=8'T9SD#&3I:EM9.W47L734;1Z2$';D-:Q@UXM
M,%S4ALH=W&')51N:D)<`Y5;VGK'1T83!2/5)F'ZU$^!D7UR<+7^@SZH_SN?C
MZ1+=3497D[O)$LR&!GWTZ!-]!F=G4=\P4JUBDW@ZX)N,4\F#H9H&2.'+54RG
M$?'@#1E%EO4%NQX=UVQ3!CBE`FB^]06UV]%DCCZ-[A['Z'X\6CS.Q_<DN@$)
M:3L[6+J_^OW!<HS+;IBP!PW9$X4/WIO.4?)]"[6Z57>0"FCMZ.U5(ABJ'\0,
M;J]Y-\9,5JA9+*JF\ZS@,\2*?E<\C%D5#BY(,Y"M1;-1'.S>_ZQP]ZZ`&A=C
M_6'6`49R3[8:E`&F%0P$SAW=6<ZN_X&N9_</8S+5AW/<>G=%?!*3EK4MVG`<
M_("#YU:^2X-S/'N4:/>,QMZFM\]Q#"X.#-GWMX$_6U1G`V@4R4Z%EX6B7:F0
M5R`6_@L.ME'U9BZW45*]H#M+Y^'SBT;('UZ>U=B_K]FM3F!H86`:R+X6=)O'
MCZ/Y?`1F+C#'KSC>8GJA_#D.-1);JA3L[D'T`6]O.<BDP?"L%R*_%\844$/C
M@"%4EI'"2S<>381-/T*ZB7($SX/O6&FJ;"_;A*E!N]P2NIK.*38(+M>MC^8/
M(S*<G2[GH^LENU-8;6G-QY_&T\<Q^>?U[.-T`F>H2U.'A7DUI"GRMS_CV#<9
MW!J68?>LYP#SVJ<[#0IP3N-]4/,G..LRV,BT50KD0:F6\7TC4=-"P)%:.>8T
M*^&T:-U_FO3^?K)DB\TL1--X/9E^'$_A7!%:X&=JY!QODI0E)^W)I"X5MSHI
MZ@'=FO-(9,$PK0<@MY!5B*-:'EQ0[!ID<!!51],ET70/G_:K@:6??G1;C#\"
MVD=;;)\R_-N6F#)^U5KRE\O;?06B!W;[W0>),!PV]2#D;]1>+<;_]4@/F]!I
M"Q0RM3+"L-O!;_VC.)6*Y4MGO>`[M\JD\F"(I0&2>QIO/B$#K8>[,<NT0\9>
MB]G=Y`;0WL]CAF>K<9:':S+WE[UMUQ6RR20QP"9WVA)@V"*$U>7'XX(E9AHO
MEI/[T1+*@)P^3D)G'.0?=%G[U8MH'-6,07JZMM^$TS:G^X)6KR(8PIF@Y6:)
MH\4/Q?20_@N]QO-I=`>J+_0Q7:AD9T_"[-?K%`=A3O]-'JOE&I9[PC[HG8Y0
M)@Z':+T8!5=:K\=TG9A=;V!=X7Q\,UFB^63Q#R`<JT_U-=+M-;:KBW;4=R)0
MK>OD[*6..<(SF"I%,%PT0:LXDTD8>3N9CLA8;72')M/%<OX(:%[YD"8;G.9O
M#Y''TA+0\+ZA]NEUR?KJEA_3-C*J\Z:VEBX8FAH"YJ<1LX<QO25&NVC:.S]0
M=L(@YR3VDS5>>E_TR"@7M_MVG!IT^QTYL2P8<O4`Y-Z7FU[/[L=H.?IO*/.-
MR7I#PCAM#K/T)LPV2>9%LQ7-F7$7ON)@E&58=_HQK"BKU-O#V!8M!Y0#A[+#
MP7-TOG\@_3B-AV@V1S>3Q<-L03IQTJ/?S:8?W]U-/HUOT&BQ&$/IS<=>2M^-
MSAYPRLX0ZQ&[5\MJBA4]$UHY5]0J8)BIAY-+/3M;+-`#O;8XN[^?3='BA]$<
M2+Z>[N9*89`>Z31U76Z'*<U1;8@)%:$\A#@$-.R],9KY2H]T0DG;B1LU""40
M`Q/%Y-BX4WSCV_%\3KK(<OX[_4ABV`(*:_C#B'H<TM!S>S99@U^]2F#8IHN4
MSX`"])CH[FY7\W;B;%,^SC%AZY]DH$JG\^J5P4$E6;_8-\Q4[FZ?63%@Z#L<
MN_"&W[NKT6)\`_">WR3."5B:H[287]V&I+%B-N%2<EA#S^[:C:89[46<'B4P
M;-1%RJT1CI:01GO5E;^,?XA8=LR@3\G-Q5"5`>*[GR(-,/32@BF^N?SP.+_^
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M+<,YA_<$SLW;&R\$SL?7X\Y#@?/9E/S[-21J[Y+KC->;*'G#>('3UY`V9]$B
M[2AB6-@CV>7VP^\X>"#ST*1(3JB?@NG@WW.3HNE(U29.X73@CX%I?L>VD&NG
MC3R7?J/@(PUQ=N8U9[)+]C^JP8V>GK5AC8D9]8!&1\DY#TV1<GPJ56E^U9@]
M1[<IM($$^=S+66?&C)&UP8Z0W6>?1`#;;SLU)9P31@F+8T<EA'YF8E!R-E2P
M[L(83\B_RO:)1().V,$!%3*DEH+'DBXT!5.H*&*R4.A2AT=ZV*EQYT=_R"=7
M=#-VZS-$/`B3:<&AFRY4U:NJ!^W&)..B,@OMVR3N+O8KAT5::M9&109&U(,B
M#1WG;#($VN52I8G"&'&O]<*(:.6,OQKID?],MSAHO*$SB@/YLSKEJ\5]T>_0
M'[$9*8]30<VH>M@O.&\S1S5+_)A8*=Q\5`Q&ZZIO"C>0W6./&AC,8C)M)\##
M^)E,[D/]-W;,RG)R_WN(N<+[X"8%@6'^/NB%CT:]LD>CUD411;K08MTFB1%I
M`.SWXBV3'/LO<?C;%LBDNZZ)XE@A:?'J*B$"TR1.6S7TJ3)N6=F6*5>-+'_;
M2?NR49W"]GC,#\-KOQ:LY6:_X7,<KD+?(]W99TQS^9-F[I&1H_>,D9=EV_6F
M>&EX2]M_GB!<9GMB@6"UBQ9AO$K2=1$5MCD!_SO-F4F%KL(X68=>A.Z\/`]]
MC!)6)-JDH4]EUDF`(V#Q0R.2/L;)4X;35UK+DWBSS>FJ>.P3K=(/A^M>]3\%
MM?<UK:RAG;/N=^"U_<,;QS7U[7KMI6]TO=Q_H2<&,CI/[#1C\B.Q#]W1<RSH
M`UI5^6:(:+VD`:.M-I]MDVQ9-0Y&7+UQ;UF-/GMIT'N.^M!?<?7DWP&K2/8&
MX`$^`:9='L<N04+^31*S`39I>)EDAQ3AXBA9AE+Z?`7K5Y-"NLCCGY1]]#-]
MDP<',-IGXPDA8=VPAX6*"VB[T<MH-^+0&G0?^B..GIPZ8`5)WJ$ZP!?`M,VC
MF,6]6'6@P3#<QB@)9K)85E4HL1D'-+T7"4H^^==E0O\TV^993F(1"4Z#&ZXM
M0*X;N=V*[PL(=M"`#AY6JX!;4BYC2K+3`Q(S]JR?C^R%P$E<G!&KXNFH"*?L
MQQL2.NL)D%[8<(O)?=("R]7?G_[`$B`X\0-`+?!'6,AOU;*:5VX"`PDB/>&V
M.5:KMJ\/,H#0*1C20$"_(DPZ]/Y2X32L0YFB6/?Z7#Q;6[<1,K/&J1]FM)AB
M)GVX3EAR_J;3XAO3DL>,#B&JUQ3J"/!CF+_,<4:'&,ND>G?WL5IAKQ;7R[7U
MHGX>BI7U>[JPWG_BV34B:Z>&7!O:.9#D%H[S=@^G#@XY]3]#GPE"E!80J6`9
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MUARSXMAQLV2])JPO3ZPTUMC0.WJP//39VEM0%`^C413O#=TE679+N'.=T"0E
M6X)XML%%"C+Z>$:G8EB]2:IZC_+LOQFUA]G\HU(#"@/30/:U@$N1V"4[BDC9
MB)36:B,PF@!]9/4Q#F-V%K48N4FJ22AI^_5;"=3N6[<=,3!4DV/C#@T22;2M
M1)''9&%09D0:"&,V&:(OZ-EE=IYY_,6/MF1F4+2A]6:;EWEDNN\0*4EVH+*M
MCI4/61VMH?0A"@9#_4-:PV6,3W+ZL($716\D[NZ^4PU&</D51#V'Q@]`4H01
MF](\_+VTN'SU-7YFB99DM:A4L4I[#?`M-BODX9"T'R1W';^A0H?!`5[AE(;L
M9$7^A:UU46T8C%,F,97428\.F#2S(M(I%<"P3@<EOYQ>Z!3CS)U6?8W`T=)J
M\8+ZK>>S=;O1EU`8#'@I>$N="HS<8(V)HDH6_4REE=F%CNB!9HZU,H>!R`4"
M,7@^4('D!@$DV/KAQHO059$W]VBY=5C.B4F<XY2>!(Z;($4;(ST*%O/I:`!O
M9-)12#L/G=H0^>PY3`=52C3;`<#$@A6\LA.@Z::DJQ<"2<NO6,F@=MZMZHHY
M9U$_-NZ-YHHV93=;7-8K#@L!I%$[35D%?DX0LX1X-+,K?1+.>Y8-_DP*L/VR
MJ9EAW0=/];3!4-08LI2Y*1$_4M<H>5FF[+FO\"I),;US*U@`&J!OK>,<8E;=
MCYHH.V?;4,2J?(>L#%06@M[5>;4>Z+SY:)FAV^WE,?:*:3H.*N0EC!*%J!Z,
MB[!&R('&U9PTU(=!RV&@N\QLZ*&@5"2D]$M2;OI)><S)L[+E"2?22@UX$SI-
MO-KQY`S%.+<65#H3COX0TJ/@:NK7$QZ4TC""@0Y$V=0OK$9"1LW^\,.B*7%:
M+X/T=5T/AZ3F]`V%.$48%#-$:S($(F6\`S(,(E`ZW8M1G]M4AS/\X8W2'_KL
M=&'0T!RPYI"'DA#<L(>>)5[B="U;FM14`3WP40(V'OG8BR6=/E>K^^K7<34&
MZN^N^A1@Q`=-E!J#H=@L(.S!)'9P6M*_BFQ4RUMCD`[LFCTJ81C,T4`H/O$N
MC4D0%[T%/:;6$JM0S]T2M\(,^<JV0,DY]4R1BBG8'--4"C#8IQ?6>J6M'JSM
M#VD]HF!891;.U(.K8W9^G5Y;&IXY.;N=G01FNY/K"#GG0A\R<43I'@QP/Q<:
MVA;MSGTV+,75(O?2?,#"KW3>,XE#>J"79LHH3_4\'?54CVQAFOTYHY=`9K%P
M;*JIZ'IU3FQ([RYE2PM&RS:!*@[X3`@%V[1*T[(B(PC"L#?LI0C']*#X/3M;
M^>'B#!&JG#OCW/)S,JP*F"(@SC4,,>`<T3H5SNV@'H9S%^XX1_0'1KI2%1+O
MFL:8,(_JG0SW&F`/P[Y+9^R[)14WK!8*34#<:YIB0#VJ=BK,:V`]#/$^N"->
M^#HPZA6:D(C7,,6$>$3M9(BWPWH8XOWY2,2;Q'Z*O0QS[[R6-HV_Y#BF8&_%
MG:Z9OC42#C&KIJ*),@Q"#D#,3VB+(NAS3-RDEA`5TR/D%Y?_A'!5%EIA=[/=
M1?AE6,MDBH""8<,0@UA(M&`PSP2J9B3,Z7`1K9,X?\G*4/B?VQBC#^?]D1#V
MRM<'!RM?XS@8LN[U0>*S\NX:\MAC40M29Y@EV-%QCK/K2=6)!OUK2FT-A]>5
M1-`5UY::XLX#A#Y&DVM,?F-31/M*TQ$==M!$`^#.!6FAU<XY4+SDB.G(8>^,
M`Y*A`TMW-\FR+0X6VZ?,3\.G,AU25OQ5U(MI*%D;,F@;4`\7>C6<1P(CF.*'
M14(F@K):\ZS*GE+\<JP<O%[Q5`K[QC*ANW#T+CW=M'LE`2I)NYE0M+7LY>K5
M-F&7O[=7!0:EM'%R>0(+Q8I5I%OQ:ETR`RJ580QF'M+$QSA@V=^HI32"SE;5
MLP.2N-VG9'-(HV=`LX]4:SCGGA%,/@]$H50D>RKC6?EJ4AS4+S7`X%XC9M^P
M&5KQ8E0S:M\FZ0*GKZ&/95PT+<3J&PN##&P]K6!4`ACN#H*M[)I728JR4O[`
MG?-1R<R>=-F3R[(R`%!9;9X&D\4%0">R$K4!CR%EMMPMF,U6#'*SM5XH5WCD
M2O9/<O89P"^ER33`D%`+II)U(7UAW7^A#SC2*3-=V0`91#E+B\R7AASL*#GE
MH-``)0=;&G`Y*()ISD%(`5`Y:)F325L:TC>0"^OI>Z<?TR0;-"Q5%`:@3]<T
M6'N8*BT)#+GW@B](3EG*UQG/&\V@"KN@*<^&-P=B?%]9``BO9Z[N8/9DZ:Z%
MWI3M)Q/@1_YOVS`+V9,'0\)$6Q\`J^5F:4?NIC)T]DH1BP<E'A5,3RD>#R>H
M0!T`/Z5&Z0;:4V*G#'`?.2&%SUG^@M.[\E6Z$&=EX@7)NZ/:6C:IJ&E"DX$]
M*F"(IX>SRS>FA1IJ9W4VL9\K564N;_O';L1YX22G0KK"+@[;]">R$TN"H982
M7E]N#1CD*5$]I,D*9W05PXMN\:Z1Q,$N=8CLK(I)"5;?(C$WK75B2%\=#"'-
M,<M8&N%G+SKFB:'R0\5[T?24V8VW]IZY':`>6=MY@J1PN_F!.$'G'-%!)V5#
M+8^"0@%&].KV[9I#`+=C*YW!E'.V]``3#Y>\FBZUO*/CH9)!G\$XUO*AT)RF
MFU`=">V#*<Y?D3"_5/F[-/URK&=0)O$-7GG;2)C81%<3QL,HG"EZ+Z34:L[;
MMSG6WC=39G$GI6D8TS/(M`@8O<6M%Z;%>D.6X3PCPZ%&>[K''GM4<Q;/Z3N$
M=(6B&"^EU7_2%URSI2)MTP'+M]D_';Q:FM'U8(4[;S''LJC;KFCYB'T`E:71
M5&C9&:I+9"<6FV6BGUF!0-8C#E%!=V&,)SE>RT9T!_[&J34WKGH.W>3J#WQ5
MS:YKE;SIG:'B,ZRI-3Y4-<F`OA"F:)#L<^AG^D'$ONCJW;^ZVJ[>ZG_](<0I
MO>7^=D=?B)2]QJBG">_NE"%N%0=J-8VW&VUF,DW#5X^^9%S;-UOM_EBQ]4U2
M/_KJ=O.:FAG53F^JIPLFEAD"[E)T)]D,33#(683-VBR:A35*:,24K5C*Y:VN
M%??!;JT,RX3!$*P/H239)=."P:-F=[]=LXLZM,^_Q_E+$B11\OQVFZ2BH4#/
MKNL!RG4U6-RK&F0#Q$&%@N'YH2Q1S,$:);-A7J-L=F=!/$Z$VXCF8?;K;8IQ
M\[%(@]H5J[MN$BJC^I@OT@5-<`5@[A`B$44KFMBE?M'A$`]]'H^=-%D%/3-)
M,U485$E;S34;14;TL;"I`YI]`J#<RC"9I7G/F*4180=@HW!U`IS[E$1D4$W'
MW88Q458`%!Z*#=-E9%O[)+@IA-QE:26,7FMI^!R]"5_#`,?!0(:VU:'P4V24
M+CN;NB?!30%@*3.#4M;5+KJ511F0#Q,8HU>LT1QPU_W``::QO_1CF+\\QLD3
MO8)=[/YNMGDVQY0E!#Q+*E5;O4R].%OA-"-#T(0MJ7[H:PD'_923P'6$RA(&
MN0-^!UY`/+QQ_+TK/TEI]LH8?T;!'Z(5SK;Y;&6I&;:^=9KM4%!=QVF(C0_9
M:8G?%2TQQL_TJ*;6)MD1C.02SA97V^DU]RP/U^P4Z8HNL+VR!;:4?.`Y9F^V
M$1%B[Y8T'GH1/B%]-?NHJ^'/>/V$`Q)*=GWY-*%I-'%Z%:Z(4Z@EQ6U_4DF1
MEV7A*J0)T=A=I9<D(M$G&_^VE0R0#E>ZY0RW.?FP<@?V")8)HGRIZ#?R77+!
M_HWFF-MX(:.6[VW"W(N^YK$TP%3'QMCMC*1E>4SIG=<G+\/!=;*F27`9N\H4
MNI/8C[8!/2\YQ?D=?^%_4`GV,IP.,FV7[M1(W?G(<SAF\=XHNPS]CI5%[_/7
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M&W;Q(WN4CF4+/$-%@7^4YLV%0YSZ888?TM`_^*C]0*"^KE"@XP"[`4*%Z`\4
M-C2J@7L>JE1!U6R_4D),"V!L&;($,K0&YWCMA3%[!3!F=U>V7G24-;PC`#R)
M-;^C.>8@:X0'1P<K%D&JDMZX5!>`&B4@6@3=_?L)>^D?8R!4QF=Z6,C%/$?P
M^:]@<".M5`O#&.[;L(*$/8/[YSGUDD:>H%<PZ5R/7TUP9CS:H+ZNH`!DQJ.)
MZ`\40(XQXP$<90X_8I/7)9"YSR"`7\'<9P_'6)C[#$`'*RI!JI+#S'T`AZT]
MN@!;VSHGOG]C9:/FZ]V1&;KU`JB-<0&M?(-JF[\D*;WI\Q@'.&77/0JC'XAE
M66O`-*>UU0AC,\GV<T/%;#!@"Y+[[M]NY?=W^';PP(H';BO!<-H!.9+H#XW,
MUW\OCS1(&X3$?=RP4M6'G!\,@`$\2MBP_1`C_F.])L$NB4HR.@HE[+T.(82V
M>P6B];-SELDQ<0?M>]]5_#\SC^[X'&0&F^.9*7Z:,RES9"8[/?2$G\.81@X@
M(PK5`[F-L5<][I*>TQY0$("'934,U7X!65B*\SBW-W3^X'+Y.Q`&[]FH/Q+!
M/)O$174<*7)T/W)*:U?B"CID]]'^`IP6<PRSNJV)"7TM;6G\91.6^6F.W*"$
M7SJE5J6HJD,V+<%GOIKV);>-2[?D$7]&$0[>,QUU<P-,&D>#>8`I=(YGI/Y0
M'K-_?"V1V\ZQQ1,_GVCE(*+;$X=6FI_N&<-VX\,[K2.MKK$-A=FJM6.@6FM3
MRUM;>=.!7:_#J82=CPUT$7*Y:E@^Q61UX&T;64JTQG2YT9/<AW&XWJY%\$5F
M#BG%7FJTP2;NTJ,9%P%IT7`_$_1'$659AUL8-.2L]^40G%65XIRS_2;V<E9>
MQ,EPMM<$?<YZ.2J+.SIM9>O.W1^MD4RX/MS^!4JV"R&JHRWG2AQ8+G")H-4_
M67->!TSMNO+OH!S7QG2D=4.)T^H%$URLEXCP\3+6W"B#5_NS*P#*L1)PT!:M
M'`X#7>P>2V:\^YI@/A#L7U;ZNL9/I^)L#1,,G%T.GPZSAJ@QY&^LN(A,R$KV
M]56(=C%.!OV&1@I9JUD&8-*:6:"]Y&80H&QQMFA$>]='50Q,SK:-',;9HHQ3
MYFS+`@/.VHBSJO/FJM5C/3UKK#0QHZ:ACA*HT;<!X-.](W"8G5$'>0V^RI1M
M#G.S04S"9O^T[H`T!*=S@K>OFC*]O5A<'Z(Y1K,_,`A0K?\H%6P4!`Z*`$IO
M[=3Z4S_TW%<G[;.I+EJ\"8*3:N[F57O0MJ[_^:^NH1N;?MJ'L?OC'G<^UDW7
M;@CCI%K[P$H^</=NA.&K:_?#[(>VW_8'FFT"VO)Q9?H?_IBY@\4E[:^#ZH$.
M6Z5'.J@.IK^Q?7Q][Z6EYFX%I*8^7F^BY`WC!4Y?B2WB*ILF\6N1;H_63L;>
M!6[^?IUD^33)?\+T6?/R27N)3X[X/9O-^>C5UFS`1_N8\WL`MBSLMLW'.*U%
MVH]:^PF4G(U'JY-BZ'R;I.6?J)PL@YQM$%]%&U96L)6&+43P];=VE=G275ZO
MW.4MAA1HE:0HW:G3RT;;$X@6A\UBP/[KQLOI^^%I&&>ASUY#/-(X2_/;IS1<
M-ZK.XR79D'P83"2P:6TW`-1"Z)5*P6C&/WHI,VD4!W,:GS(2XO!-F/E1DFU3
MV3$C8VV;3<G0I&9CT%0%0V<SO-R$<;M>>^D;FJU061`:^7GX&N9OZ.=*]W]@
M\/0Z\K)LMBIQSE)F;F-Q3%)!_6HVF:EK1).2?3H0C]AH8N9&2"6;44,4!OL&
M=QMD4%GT'./?MJ1936+2J+9L[Z$W\=U1/WD20QN#RCO(B$;C>V`BOP4CI<WS
MU`ZMR*J"JX%9_H+3Y8L7MY[\.%;*,>//GT2C'5BI!VG`AM\^_<8\S&!IPR[2
M>)YXJU8%N'H_WV94;7ST)%JP404>O>.MOWCZK=7$3&D;A7*<Y"AS&8`'.+0Q
M2SV60)O-"$TJ\J7-5@OL;],P#W%V[5&:7;U5AI2"LMBY=ZG.9^+F5=!+;OTB
MP82WP]@A;0UNDNV);NPYSBJEE??`>6:HOFN/!GF?YE9SZ=6\W$5?$59%?@+3
M$NQ=J!UDVNYJK9$ZI/7%X?!U.N>SW14\]`Y)V%IE*W#,6GF&`M,2P+%6DI?`
M3/UD6:O,1[`':XMRC\S:>F%P8*35T[?.6!.S.+[J*#L?^PU%W+]$[#R2JJWI
MCZ-Z^L`XV1-#=91/B9-Z05.+DU;B9+'..C!(:BA;9Z.V01P5>S5A\5`7;L\2
MN_.HJ+"C/R1J*$-B8$\P[-4\&0;JA<%^!EJ)@?4Z=KF,K;MJ8Z9OG8<F9G%4
MU%&&Q48#Q/H[&G)N`N"D1GPT*@8D0_MBID$9I\=7S3AJ0%N=D.IZV>4PBX6`
M-O#V@:^W\%)<J]QO+.?:[8=9;3M5MW?@'\KM-A?;Z$;:*+_!/J8[=!\NB,+E
M?LMOQB6Z6OP8:+IL.<2P.*"4W\N8OK436NIAXIZ#!J"]UF=<(O@&H+<>:%C<
M5](`C!8/=1O`<7L`_10G&O(@\D#SU(22^&.?O,]_R'S/O6>2ZXO6G:JK;U/>
M>F%ZE.N_!X5V$F=YC^`,.R?U]7%!VNH'6"\Z<QITY(BDNT5KW+&9%>!ND]:L
MZS/1AK6\9@)98Y_V#]Y1*O/.`N@MC?%]'5WF0+?8Z3<-P3D/'U!KI&_[U&V/
MV7WJ<6C':5:.NZTJ`S/E>U4:A3AO#OLB-]BMVH/!)QFVOX*9#J!M%I#U<HBY
MSAFH;*FV;H;#&UP:X_LZ!I<#W>(B?<+_&5P.K1&=RY%?6_]<U\&(#*#7]0,+
MV"<F?DHB4DQ$JGI.:NN@G-;_K.7>]2A\'6`M_R)5(8YV\H@JP.@/50;>A*]A
M0#KOLD)D]]3-BK#9JPPQKME(3/2A[*'M@5W*W*"4SV!P]CJ)62;%;(Y?<2P=
M2O%B5A,B2$"V,AQT9,#$2PDP[B6>4@REA=B1%FFJ7`GW841&!TF,L\<XP.E/
MV$MG,:Y`B";^NIK6%F+,3*F77O34G-/''&N7484R3:"Z4T=,']$"$"D!5458
M8]O(?PD)P0.1'9=Z5=!3A$/^:1FG(*)2'RHC=4!K4;,JZ%@</4R'64;Q1D[]
MVH1[G+\D05M`_O;+D()L=KK##6UVR^:E..?YWM"YW#*%'&J4=+8C/BH*.T,=
ML=^A)#N\PV0F1Y-XD^&M%]&!;)S)QHD269N\5<)M4E,H"(9]*G0\P>(<X4+$
MT=)+25[AU*_ZS?(BAL;$CD,F:;K*R=H1:W6VP33S8OP\B?UDC>^23%C!`C%`
M"T8J=-WZKF511,2<U?M#FJS"7%;=NU]_^0"-T0)LW.`+YVYK=T2^+5XD*GX!
MQ-T.H&Y5LG>8D,>$8'36U3+4;9)>>YN0P)NL-VGRBE6KCGU*-KMO/0-:S5&I
M`89*6C#Y]YF99-&Y!V&^3=6MUA[1;O`FQ7Y8+/['P6B=I'GX._M/204H-6Q2
M3`-ZDU\*<6C1OQ]JEV!-#>3%`?(:.C"8-HES3.HK5\\\."F;C))`;+*H(P(F
M+(EQ"9X'8U*.9AELZ6GD^^F6[F<74&8Q?4\J(V&5[DASJVM*Z5^"Q+=6^^1;
M;']>%!NUH78=4NJ@VC&D^<94#6T*/7`>FL0W>.5M(WY%7D_MA'S6Q=SKO%F,
MF#XJ"T!AC(*B"#=^+!Y:F\37])P;Z0\()@9PB;_D5R36_RIP8J\.-`_J`N;=
M5[Y#1[S4T"U<Z,1?.'^)DO@>!Z%/AI6Q?\_N%?,^$LL!\XL2)#=`WF9YLD;C
MB`VCOW52^^3+`0[FI"%[.0X6.`UQ-KJX?,"D:N*\RRZ9;X:4`LQS>YC`M;%-
M&D9D0'C>T;HX+TLKM-WX.]G&N>BE3L'/T#PDP,95/1-R4K-Z3N>K7$\/F"^,
M0'-.VN8O2<K>X,[H:;N,#";\E.X9V'YSIV7,1;>1Z[JN3Q&F[S11=YUW-9Z.
M;R?7D]$=NIY-/XWGB\ELBF['H^7C?(QFM^5?EY.KNS&:SI;C!7H8_30B_^7"
MMU<XQJO0#^F+\]3:C%3*+?;H6M1LU:V`<@#[D$2A_R8?+1Z@3%B,.)Q!ITV6
M[K4PSO-=`5ANE*"3OA:#JV/O&Y9:YQWRZZMLV,D+:*45V<N#%P8WVS2,GXOC
M_[=)*AVR],A#<Y$.6'XA/7M!&Z*&`J:'\A?B-*:,5DGZO1,W)62X'+.#]'%&
M8D'`1LUT[%Q<YUA1T+=1\CF3>\ZX"&#.'(I?<'RV/0^OEU)N<.Z%48:F]!X+
MF;@[61EKFG?E131(+%XPSI6>56N`<Z067'[_X2DO]AW*-;&P6A/S"X^2/^4)
M^8_U.HD1F>O[O[KV7Y.>Y7D%\JN6(]6J<#VJA9L[9]!LAHZ<)AZ<DU+^+IF/
M:.B`<Y,F8+[I%>D'N1EH1E3_ZFY]18#F.TUO[41A.XG#"7!9D\=\<:[MADH4
MNALZ.$_##1?Z;K@X$3=<G)H;1G%`ARXW8>;3U5)-CPBU8#M'!?D$_*3IF%/P
MQ*E5?3GRVZV'9;=D]M7K"K$:;-<H,8NGJDRJN1BQ(BW,B]`;O?;$]M'0/3'Q
M!7VX.$/T9!10EY+*'>)2HG9R+MUA/HQ+/P!MIK-X2"LE6J?FT1WDPSCT'*A#
MER\I'N)2IG=J3FV"/HQ;+Z&Z]7,RQ*F?DY-S:0WY,`Z]<.+0&R_=>-5E9G:S
M+Z)K:_PU4\ZIVIJP'&L*FUN@&LT?1G1[<SD?72_1:'J#YN.[T7),__EI/'T<
MDW]>SSY.)\O);.K$I61F1,_9MP^#7E<KU\ODFJU;+W+1'KB),C#'FB,_T77_
MYM17-I<4R,!SEQ@@P%FDSJJTP`7]2M!\HHVXZZ1;_)1NO?2-CDS$:P1._!:F
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M*T,O&F<XSXNF1`.=W_`:O8*,2.>^)N6[&E_QMOWMXB\F?FN*0W>;`*OX'%YY
M+?P,>5&$_&V:4N]%H?=$LVB'1(`.D+=DT$9^<]-%R0<FG,_DHK#\U8N3RW^U
M6I'!0DHF.K-M>OT2XE7I<B\J?W(W5/O/;?1&5_VVSZ0W'7+7R[0`6+X<B)Z[
MN/=,FNXSF?>@=?$.,VF$9/S.CMFBP%M[S[0M.KN">><])2G-Y/*VV'B^K/T)
MI6"Y2P61:W7TX0QT70;%NS(HOL&X.M"(()=2=W1%H/E"@@_@.+V!M;^V@5=V
M_Z#[[]\B,?E#-^LR=RP6DK97-CWI(J9,$)@OU"BE:P=.7]-AR&EZX@5+=;S\
MG$@:@D`&5O7+`?)Y7I]#ZAJ6!FU39.JCCEA5`V[D[1ZX<=(R:EN(*0])&.?L
MG$OGWV:Q+&B9J0-UHPEVWL,99F=`Z#PGP*\X2C;K1MYD($XM_TFL8?^D9PZU
M/2K5A>[./N#"KNOBXEM4O4T&RG<MEIHZ3Z!\(MZ3(^^Z;T&JE?U.CTS6LR8X
M6]FM'`W%I+UO:MNO`LN+VGC%3>_\6\0.]Z#F$W!07'5I[JK+$W.5$*_051^(
MI[;KM9>^T==6%N%S'*Y"G\1,-/+9@2`ZMF&)2!R-^*<T`W(1"[@5%:D'^U2@
M>5`3+^_!0I&=66WMCA2I/M?.0N3,SQ/RZ9UEY]^9K@::%P'+JX/Q<]TAC:3E
MDZVSW5O0;#(X6[4>4G?20G77I'D/:RH"\ZL9:G$'^5<:=I\R_-N63C'&KZYF
MC2(2<7X2"<'RB0*A]+GB.I73^W&1B0E)EE?0?;$0#\4_TC4OE3!\?YW.VE=S
M,:AZP+BQ^M.7V\Y,'9CCAF#G7#G^.%DLYR-Z*X/FHKL?3Y=H-)^/IA_']-\7
M+IQJ,NGD7&JB#,NA`Y!S$;5ZZ]TKWWK?I4U#Z>X2#VV[VSBM'Z^C=S?JN2'Y
MC\S)?F;+_B'>/CDG&_E60].UUW1GA1HZ<+UF-B_4T'3C-3K.E9UL;_T*S1,\
M-+[.F8S#.?<B_$(P[IX@%=>R0`A89<L1<G5.1=&Z?BG58=TWYNCE`)6NQPGG
MZ.5T@G>->1G`/#?8`.&2!TJ*HJJ#\2Q;9ZE';VV'\3-X5X?Q_JXNRCAA5[<,
M,'!UH0?$U8V5MY*#6FLGYD7`=;01?K6?DUU1R,OK5OU$II=Q#,S;!0WW\K:\
MB-/P=B]^?6]7K=JIJY=)[/VV#>-<<8Q/(`/+67*`_#.TG*2+6J^67NN5UW+A
M5<0KV2!I0!FPO#;<@-->R>;L+M\_J%:/1L7BD3J^#BD$N/OU+3#P?[TD5Q8'
M8-&\0ML8+8[R*LO%APMZ)W!('!A6'$Q.[&6+E!V-4B''!5/C)3.K_8K[.GBA
MG&\)>4&&X%)J%*4!H,:P@8*.,FBW#QD:`+@GHV>%7BM6*I^B\XQ:J&H\!ZAQ
M#AK(:6D#]_`^0[>=BP$/V299MAT6?'LU8;I6%[;4K44!D(=;"A-[8G*OYLGY
M5"\:]_G4?2CN.1S:UUCUU&%ZUPB[U,6-4DH_SR"VW3YC>QJPGOII^EFO*6OY
MV6%[;@\H1B3PK(N5],>,9L\=9WFX]G)\ZX7I)R_:XA_#_&6.LPWV\V526?F8
MAU'X.S'Q*HR3=>A%=UZ>$\N*Y7UJ)%W93P(<+>D<4'Y>T2T<8#R$4!>]!_"\
M'2RTS8K\BKA$5N0_)_#0*\5WACX3A"@M(%+!SU4KV58HF4H%%958R\T=EKV.
MRJPI7`"MI6?><3K3C`&SBBX/VBD&H3E'>HY=1^ETG-5SKAWBO"])?R5-^MK;
MA+D7\>YI_0S,$2)L7)470L@OI!S=F7IJO()K<GU`7Q66:XQQ`US47/@O.-A&
M9-C9O'7;,W[248+E*@/$W,&/4I7.D.-F8D&4%_]+]-%3Y.BYAD]T%!0_SU;-
M@RZ2\Q\*65C>Z@<*L"5-8C]E7_>B>JQ,WXY6>41#!Y9G]`$#]%!)JW&1_D;=
M2%I"L'R@0`BPTED2R3J#9'T?2W%,K5<#ECMTX0+T3?\[9(OP"^<?+2U8/C*!
MK/G@6DZ3_J!U$N<O6?GBVG]N8XP^G+M[O)1%9R_#D[AC<&GO^$M.0@:QY%;P
M.**),BSO#D#.O^-1%(%"MOX3^^'&BU`YNB=NQW0=Z>+RGQ"NRD(K[&0JRX9$
MQ<X-S;?@I^$3^;<7C]1L\5=^M-ZG`<N;NG#%![3#8D\KJS7/4,9TRU\<[7+L
M]NN6"7U$#@=A3M^1HP^8)&DFVMGH48'E-&V\@AT,MC1;^HVT,J_6)8VQ5':5
M:.NJ"`"*O%HM"5@^D<$#.Q"A8;7SPJ+R,7NI/"P_Z($%Z)4YP9AN_9P->FZE
MF1W%8K!\H,0(L.I_2*(`I_+DMIW?856V&!S86I:G>^[\#K&6^](\`ZCE,NK=
MU8\^W!1O/G#5+1.$5>\]*+G7+\K7?ODW+YSX`N<O41)+^-[Z%5BM"Z`!Y/IX
M,9&],E?]`JM>N[``UFEW\69$)N@1S=ZC'!Q*Y6'5OQ[8$_!*M:16O*IQA5=)
MBJLGN+67$$7*L/VE@1R@\^C[Z).8#HDIA,?86R?$IM])7U9"+^UYH'_>543K
M`7@#?5@N'`8>H!<[T\D>GRFE87E(!RI`?TABPY2HJ5VCJPC+2X:H`3JL-Q(0
M6TKRF8?`G2XLMYD#!^BY3H3H;V)]"K!\I(D6H&.62>Y%DLC`.44E#,LA&DBA
M.J/#);$3.D(`*U^,$&"ET[><ZETOV0O,O`RL*I<#!%CC[/VEOBH7"<&J<P5"
M@)5.7T:?Q70PL=O?XBI=)`2KTA4(P59Z?9YEMJKN7TEJ7B`)L?KE,`'Z8([]
MR,LR]JA4SC"7[TK5I\H3\3$DP<;IP))@^7!?,P#Z^`:O,!EO![?58ZC7299G
MQ-`D#>@8A-@38Y\:2V]#TN@Q(EB#M7BB.+@L6'[>WQ"`GA:2MSG0Y,@KG<T,
M+PJ6G_>V`Z";/]).17`VLOP[+`>T04F?#6K?A47OT'.A!R(7IB('*.<$$V58
MGAJ`?/^<ITX:$/<(+ITA=E_#U7WZ5ZX+R[WFP`&&OGXC3)[<5BB?FN]Z']T&
MXKSBU9!IJ'SIOBL$SQD2A$`KO?W@-UV9&1KL%,KPG&2(_,2<U[1G@/MX]=-Q
MH!0[4!<6T>(V?.T/>CLA>.Z0(`18Z=,MQ3=;U:BSQSC`Z4_8HR>YR81/G-E&
M3PV68XPP<Z\=,V6:7FVGCI@^H@4@4@*JBH#AQY'_$N)7'(B,O-1PJ%(?NF=U
MP&NYN"H(DJ_9K<@G+\/!=>/ET3(QP"3VHRU;F)OBG*ZS<ZXV4X?EZ4'8^5=D
M<B\J[H>^8V6U7W#%16DH+(NCEX-CG*.(E`CA?-F^!Z$__!(]1=9<VK)*=8Y,
M!E-\,5^J][4DNP#B)7V@73_U:EKVU#9[]^QYFU]&68;S3'"^3RCPRZ5S/ZAQ
M<1>/F-09*N4<5?)=Z#V%49B'6%73O!2@ZE:`Z]9Y0Q10Q>^.#_;4_4X09O4+
M\"D]L)-W[X2>JH=9X3K5[*AJ6;J/%W8'-AO_M@WS-U$-\U*`*EH!3IC<I!3]
M9U0(HU&>I^'3MDQ#F*`'#P;51W&@YYT^'4"^TH:J:"G(BX/2=XZ<--O@U&LD
MCQ-&)4X(D!ODV+KU7DNB2O2T3DD"&?8KL7%<%P@[8OICG&(OHM=:/GIA7`%+
MPU?"B5<Q[WM4`'C$%&G7/SL]1!71GZCJOZ`D1@UM5Z$I?\&I,BPU!2"%)"$N
M+AQ1*5>AJ((ZQ?DD]I,U[BX'"@4`U;$8%[=NBW-4B%7,!C5"JG(,WN`J76%U
M3G:.?4R:7^=0H8D>(%\9P97F8?Q3I?XO=-6U*@'MB@#CQ(<4;[PPJ$['EDV<
M#!)9DR]68?3<JE,2:$<;&:#I^K+,*G2R,7013(ORP/"@<^A]CB.:[(=$'-GL
MW[`(T)[70V[:VLO2SE!9'BH+=-=]7GO9RT.:O(8!#J[>Z`M)D[B>:8Q\,H`J
MU@F3F/QA2W/8%S\FL:R_W:-$0(PXD"&B'IV6BZJ"T=,;^A,MF_#D7]!NCK<K
M_PSMOH!VGX!%F?H*Q<$HHUDB?,J8&F)(F;IXL)1AE4*F8TG0#;,B.LBE`;E:
M`R2WN4M4SE"AA`3]A*MT(60PT\U.4VQ#T[3'U\EZG<1L<9!;Y#%1!K#4,!QS
MUY,FA;C:2\#/]+#)'&]H>HWXN7B]2?%LE9$BH(9HAI?;A"BT4:U.&BA313^7
M_Z1E(%;(_SA9;64Y-L/\[0;G7AAETO?X9()0&EXO/GZ70:S@J$'5;P/=DV"]
M+5X,HI="'^/D*<,IF\!/XLVVN#Y*^N,H9'UNM5GRMDR].".S2/H\[FQUAU]Q
M]$'4`(_R(4`-]KCV=5E$OX8^%8^H-CY8/*C:_"0JOHG:'SU#]6?/4/UAE&QS
M>HF-?1M]<!7BZ2&_J^YYP<:3?5=O.Q$R[Z1_&GWVTJ#V0.-EW'F8_7K+DG44
MG=F<3$Z%W<.Q/PJ(J?9LY;JEQOG-YK=1X^-T$M"4*P$@AN`,[8B/&BC.$,6!
M*!!4(4$4BDL.<V=>^2I^TJEBNI[FT_$73M<74O(>Y6O06'M<(RW2M0*`*(*O
M(=!RKQ`7]MV$=&8?!T>/N3W?AT9DVV9;I+;@4>F2ZQ6J4^/[K`H:[&X_RYRZ
M[1X1/]I'O@;F]MIV!'K.=J&V_NH9*K[K[#6X$A09X6>Y%P=D8GX?QN%ZN];*
MOF%>Q"]_=DZ>?9$+SU<:%07)V]Z7O;TM+P*ZMS60ZWI;7I23MT1*`'S6HOH7
M*.M5/*!NE=<2Z.<;O/*V48[N:`%.U@G[LD$!J=4NG&Z=EK]#J-$Z>1$N<A=Q
M5=L5@%+'4ES\AE1;T'7\;PQ`1`$K*[LN90>@60847^T#7=4%:)8%WN-%][6?
MQXLR3M+C'>A[>;PHRTDFO>[<NX%+NI^EHP3%IT98N6QY&LHGNA#0&(BJK#S&
M\H#FIP$PR)7%QUQ*:&`1KG,U<S]"Y7:FMTB#LTE<G.DY.,4/BN"4EL>.8_@0
MPF>&BV<X8P>\&:BOEOELDN:.]OJ?_YHX/\#JHQ*^P/,'8#M+75P<GW48Z8TP
M?$V\'VKZD:-]#>HK:`'ZNU&V1_&:GSXEOA_88FL;@C"Y?4V?=:B?V)FE<PJR
M,?L0D;)/!]"<4!LJM[1+%>D1Q5(5)2EBRJVYF9/7272V](1;7^[=TH]-^+(%
M@(VWZDF&AO-%T&0K[&;J4+97!Z*6/6>A5PQD[TI6T\W43\V['=1#O>MP^;Q$
MV.B.1_D-]EFBR0\7E^<7ET/:\K#BH$3A`UDA8\.P8D^)'3VQ8%AQI\Z.GOVV
M_8J%MO5FM.4&QK-#MC942J<V*2^2[>U>N\]8YI#EBQ>7\[9IPM[;Q=UE$K9@
M=^/EN#X>?=`9^P%Q`>`:R.HXPER_3+O9P%EFHLD)TMU*0`U6L`[``".*N''2
MW?4E3<$5ENI0?5D#PDP4)OJ`%IT&P9;?E)3<P*E*JCCD*IO$#=ZDV"_N9]);
M^&MZ<_OWUK,*39\JQ`&Y4`<EGX9@IW.&R']%F#5_FD^J60!KOYLT";;L*5N!
MVYI_NB/_1OY<_8G\#XT<Y"__/U!+`P04````"`#B6VI%R1PXG00V``!7P@,`
M%0`<`&%E;60M,C`Q-#`Y,S!?<')E+GAM;%54"0`#1^A@5$?H8%1U>`L``00E
M#@``!#D!``#M?5USV[C2YOU6[7_0SEM;=?;"CNW,S)G,>\Z^)4MR1GMDR4>2
MDYVK*9J"9.Y0I,(/)YY?OP!)211)@`V2(%H.YV*2V`"([J<;']V-[G_\U[>M
MW7LAGF^YSC]_N+Z\^J%''--=6<[FGS\\+B[ZB\%X_$//#PQG9=BN0_[Y@^/^
M\%__^[__MQ[][Q__X^*B=V<1>_5K;^B:%V-G[?YG;VILR:^]C\0AGA&XWG_V
M/AEVR'[BWEDV\7H#=[NS24#H+^(/_]K[\?+&Z%U<`(;]1)R5ZSW.QX=AGX-@
M]^N[=U^_?KUTW!?CJ^O]Z5^:+FRXA1MZ)CF,99#@F5+YQ_75E_]Y,[SZ\/[J
M^L?+;VM*P]`(Z.]OZ+_I+ZZOV?^NEM<__WIS\^M/5\!O!480^H=O77W[Y>KJ
M_=75U4W<_1^VY?SY*_O?D^&3'@7&\7_]YEO__"%%X=?WEZZW>7=S=77][O_>
M3Q;F,]D:%Y;#`#+)#_M>;)2B?M<?/GQX%_UVWS37\MN39^^_\?[=?CJ'D>EO
M+4'[U$Q\ZU<_FM[$-8T@DJ_2S_2X+=B_+O;-+MB/+JYO+MY?7W[S5S_LF1]Q
MT'-M,B?K'ON3RLGAJPFV6[*R3,.F$K)]QYJ\HS"%6^($?6<U<@(K>&68>=MH
MRI2,:,QGCZS_^8-!MJL+)@),,-B'_P/2-WC=4:WQ+2;T/_3>U9KKP'56Q/')
MBO[%=VUK1:5R=6O8C.6+9T("OVS&\!':G?>#X5$^/I.`=:Q/1.%PRBEB&DZ8
M//BS]6S'EC\J!]4@$0_5*B4#PW^^L]VO]0G)C=0D'5.ZNGIDMKX-?<LAOD]U
M\M;P+?K9!X_X=`(@C98;I<GY3ZPOH;6B:TC9%',-FYS%(MQN#>]UMEY8&\=:
MTU_2U<TTW9`N;\[F@:)J6J14$N1&:50*W(!0[7\UGMA8)5@7M&U8L^C1*K#H
M\#+3*NG6Y`Q'5)*"UZ5G.+YA@A8K?H\FYS4G-EL[Z"HN-[NR?DW.<4:W%V\0
M>FRCF5C&DV5;`4`U2KHU.<,[P_*BP^8],7RZJD6K<-G\A)T:76D"U_R3W07H
ME@%:FKD=FIS59\.C<E/.IFR[)N<P-+R=05>!P*/B2S>@1*KGY(4X(1W)=.FB
M"CJ>R@[4[.JWW5I!)#[TTVP6=.FGETN`C@"Z-BJ)9`-2C6R[9O?=)Y]\">GP
MHQ?07#CMVS\+-'LF4'DV@,U@R3;;AJ@Y'4O5.0<V8WZ/%LX\L"F".K>PA\-F
M"^JL?#^'S1705>G>#E0J<3<5^SQL8L6M5>Q!0$85ME9R&QV2P+!L?\HX$%@O
MI;>7TH[MK^C)3"X6SX9'+I@!<946LM$W]M=2PE1\2QLOP'#6&U75CK?G<M7;
MOJB_XCF#.0_IV\+.G7RZXM:=Z=W>?"_Z].;_`K"F20[3'@5@09$<1JW]2';R
M\!%:./<!91W66_5\I7=FJ4&4GUOW"G;X9:4C+'<4U?,_K`^^'VYW(..DY#!M
M43`A+\1^7V?RIR,HO4>4'*^D+QC`\5JA24*49,9H9>ZSZ)L2GG/YD5JD`WIV
MD!RF#0K@!WOH`"INW7L^)?^&\AO87>6,)904T%6+UT!64FH/W))70?[<+#V4
M"HL/\-#):2Z:T2X5L3"A/SCI0KX%Q%F1U7X@-J=&8J7HC]E(5_%_U[V+WM#R
M3=MEIP;VCV2('AVC%P_22X^24+"GP7;-DVG;+)C,]<JXQ7[RAVBV_2<_DN?]
M0+;Q1.QH^#]87UC7=U4FF[`X"F_SB7FY<5_>K8CUCLV?_24BY.+J.@EN^P_Z
MHS_B.<S)QF*?=@(64%@P<]JTN&5VHFG)Z'MFS_56Q*.8[<<T//-$'O+Q>$F+
M=[LHT.K"?+;L@RBM/7<KR\J$;6X)(6GNTBFT#L&`L&70'E/-^?8O\BK"(-<4
M",(U/A0X5.N`84_'D@Y;S/W3%D"FWV!B>A&-.GG]0#S+I12L6!"TF.F9ID#N
MO\?(_4*J=<#0I[-9L1G=V<:FF/V9)D"V_XB)[854ZF!W8B&[HX<6P_Z=&)Y0
M\/FM@2#\A`F$,MKU;;R?B6W_RW&_.@MB^*Y#5F-ZFR*>:`/F=@$B\S,F9$!<
MT`?/)]<.*0>]U^B)CR^")=<4",??\<'!H5KC\336WSG9N1Z[S<9/CH2G5$X/
M("B_X`-%S`-]V$0R,J"+Z<;UA!>'3$,@$A_P(5%(L3X`'L(GVS+O;-<HNO4?
M9GW2#'QGP\?]`G(U+DSN=NLZD<TY<K7XLS"('I52!14N3\)^4'0P7JD!#-%Y
MYXN/@/$=Z([^C+.)")I#P4%Y]>:2KQ\3=BP'(Y)J#,4#Y66<0WH!&O]XEZ-N
M0G^@V#`N\:SVQ#Q^T[OH'5Y(TK\/9M/A:+H8#=G?%K/)>-A?TG_<]B?]Z6#4
M6_PV&BT7O;\].D:XLN@G_E>3]G+NW$N,Y8!^M75E;?A/D=R%_L7&,':QPA`[
M\/<_R6I.\N,_^KXO)B%IF&VGTV8.1F*O*AP:FE^SZN*0G,ZA<.2::S.BBSE<
M!`.'5!QHL*?8?.;'O]5F.P>QT2V8,28.)U'2_IR8Q'IA$9E3$B3$",1>V$N;
M/;T"(A#Z<2`U)&M"I[6ZLQRVT@Y</_#I7/D@<3MH,[Q7P*>$:AS0/'AD9UBK
MY-D$/3Q&0:PQF7Q\Q+VT&>8K@`2A'P=2)U0!MW6-IO@J"UH1A2GFT[G'&C6)
MJ>;.,)I>X`:&';74K&#NCGC!ZX-MQ)>S+Z&U8Y<1X0(H[J7-H%])P<KIQZ%@
M8\I!9\->><3TT0F.OIEVR"Q&'UUW]=6R;3YBL-[:K/X5D)/A!PX$AV3G^A:]
M/91L7]EVVCP`E4X5133BX'\9WR7YK<#H7WE7>BO;4>HY%5V,(_/XLVM3=OOQ
M0[%RNP%\!+W>@ZHF'ED.X5"]U*S!%B!1'WW.A:HP<%%$;2;:7^*3-Z5@\T6V
MO3[G`YSAQ>:+8LIQH#,,R=)-Y3P[$B<X7`CZ0%%29K^01JF<`SB02C_,+H6H
ML#$4&V5F"VEL!#3C`(7S<+X4G[)^4*B4636DH8)Q`@=J0^)9+]&KK#R9HCN5
MJ!<4,64F"_F%#\`%''A%%DL9J+@=H"@I,T](HU1".PZ`9+"I`XLR^X0T+"!$
MSOW^/'4=L\)5JZ@;V!&,$6$^'W"H7VKOG;C.9DF\;5%:*N$QI+@C%#9EP1(P
M%+A'$1$[<&!72*"DFL%Q:L.8`<9)2/H;6D9!:,(Q;,/`407#MX(<('5TT4HJ
MZ`1%5LUKRJIF8G`*;=U+:!4;?P-6_1LU[RZKPG4N=OS4LX63=&O%.G7:$HJ,
M,K.(M)6>1RT.+/JK591VQ[`?#&LU=@;&S@H,00P`MP,4&67F#VED2FC'`="<
MI>IQR&ID>`Y=??V^:8;;,+)5#\G:,BW!$@?I"X5-F3U$&C8X1W`@F"=09E."
M(Z3,-"*-$)_B<S\9WEN.ZT4/CP)"81#H7KXE..X:#8X\:K'JU=A)0K<>V*MM
MRM4@\*RG,(CJ/[CL1L,2T+DVG<JF',&FQH?BKLR"TH#^UN$L#FDIB[6H'@P$
M1UB9[:5.Z(B0&XVNUUA?51;7^3QY8OF^TA/+]!O+WM]./M.]N<1ZJ>^N]/6N
M]%3,9UZD*ZOHOOM`O"@Y`>B6S^^L^\UFG7M_&4O081AGD^B'P3,]__UU7'"%
MV.4[Z7[[60<S'@N08A7E\)+!:=]!]VO0^AB=DHX4'W&J&AYI51+5*(NKK(\4
M+#T-HF-B20'UDR/BC[`CXF))_[@?3>GQ<';7FSV,YOWEF#9H(Q]',3D2A\2R
M`;3:2:-,\H`<'?F66$Z&,'QRYM!BPG$LA/O9E<.A_XC'Y60QPW$Q.I$79Y,\
M\P8H@J"+UHS7M56BE!<X('OPW#7Q_<@#=4=$.I)OJ?O85L[BW!/I0EIQ(#$Q
MGESO6)4D4V"SP"3(::_[B":+BIAN'-A\)`XERJ:S[*^VEA-5<F`AZZ4@E7;4
MG<-#%BT@)W#`EB-.8A_2G])#%AHNM>?N\#P0-G;H58E,7!\"9+JQ[D0>E:',
M4WSN8$Y=QSVE;I\3J/2L".BJ-=MW[3,CF#=UEU?./9W)V<P9DJ<@#E[W4]6P
M,C?RXJ:Z$WS`&>B6D5)5VS[$VN:0#1,#_?KVZ'C$L)GU^*-A.7M:]V_N!`MI
M:4?MV46DT892]E:PWT=!T-,:$^_2TRJOO;X$(S61%C-`Z2HZ8@9@MI3,UOOZ
MF<*EM+"]]NP@-194`0.0W`[8FU;`S>"TF?;T!55UH9#<<S]-,I..%8AO!.DV
MVC,:5$4O3^BY0S<EP?%V4R]*LL)0VA,E5!6$RFS#L>B>3!^(*(*$"8V@]58T
M=__H81]"=&OXELF.6)8=!J(`D-*.VC,P5,49R!(<.OB96)MG.JL^O>P:&S(-
MMT_$FZUS\1$1$7PT)8?1GGNA*K:5V'4^,26LX,"=[7[EA)3\5"6D9-!?_-:[
MF\P^JPPI`9)5'EHB/9#>_9--B!X'7RPJ"K>OCW3J8^=@,.Z;@?42Q]27VU,K
MC*4Y3*4BYOE=N2(3<2S@JFX]RE;>ZOR6N`5I?<'\_T(_3E+`LCC24[AI165"
MCH>_I=N8WJKYFNYPFV946R42.&1M2"@RIA7A0O]NDP@@9]7?LF=Q?T4_Y\L.
MK+?N&!*E*.;RO(/9B4,`]A<,IBQ;=H`M@9S77G?H28L@BUF&`U;VA("]R:(W
M"Q:M3D5P;S:_<[T%\5XLDUXWO(%M6%O!OB\YC.X@EQ:%H!*#<<B&=B>NNA(W
M[>'?DMMW23R?U#'2H7$KJJN.TP+HK3@BWVH<3;L`O=70F_01<K:.RQ-2UD0%
M"B/;L!]79A#<],`C:(\4:'$AE^4KCCV<\H'N/SX9DOA/2CGSR!_)CPOR.JMT
M`DP"R'E<>V!]-4T:O?HWQ&"LTI(O0RLC$D6]M5=):0JQ,CG@L^[\-YD\M4FI
MU7U97,F2LU7'TQX7U98PR;#W+8I7IIX4,Y69IA>2%2C7=-7QM`=NM;U60=B+
M?:M*:#@M:U5#-K(#:0_BTB04Q0RM'%9$+UY/;CV;1=O.[3@/>$A_ED^)4<?1
M73RN]O`S-7+6#+O//9J-PX7#M;*!B`KA6/J*F[014P%@(XY=C$[<)&3EWU'V
MP,K6\'MHKX-2`XQ<P(60*_BP.WIY4JF?8"!RNFJOB*($32&?<,`*I[N1XP!X
M7'V%5)H6B&8X?.XG@(@%Q+/<5?:<Q9<A41]]E5N:EH]RSKP%[,4H(ZCWTBB>
MM9';10)!SXA><`[X_7&#H"Y,HP@RBAK!<.0@L#`NPMW.CFX;AKV_;(R=M>MM
M8WC*\VU#!]!79J;1FY8DPQ3%.$3BS.S@H<=*,D3R=.=Z9:\MRGKI+S0CR5U7
M@CA,A^O]\U`V89%)-MU*?_68:N`4$H,)#/9REY(S=E[H]-AVX*P.6\.8+A`0
MTQ-\"'W%8)JU.,DR3=%*R,*7CFZ:O9`EY7_):NF*#1%L#+DAM)=ZD>>\6Y76
MM^+:&&V?R&K%JL/M`TZG+BL+3;Q;:QUZ)E."_I8Y>>;$M`W?M]868X9,D:`F
MOP&5,75&KZHRIH`92I>/X^?-)*(MX^UC&G$H)<Z,L'S+-!NPQGA0T-49MNHL
M++49J6Q_B!>LTT!%%B))V<E*?KJ.0TPVX\]6\!PMCW0G7+'=D+M=U!@1"K+*
M!$9U=H_:S&Q3C]-;7$[\!"XFKCP#!X2"K#+/4<.:+,5*-.D7ID80>F2VO@U]
MRR$^\]&S/!'TF/N0^M9AVB>I%W[N7?18,+/M^G0,^H_KR]ZTOWR<CUB.A=O'
MQ7@Z6BQZ_2DK^K881YD7'N:CQ6BZC.IY5,JWT%!N-6]C.$F(]O&<'[^L3!-^
M"-\V[.,5`%`UH)GA=2:?JT/!42B65"AO;:&'L_DOZ<H!T2SXA:=&5;"@68\F
M%CW3KM*GVI,EY^_9)>?FLC<9__MQ/!PO?]>XGLPM_T^V=CXZ)EWU#<N!Q>.4
M=--:"C;!04J7Q;TTZR4(HUP-V'(VH-&=1;C=&M[K;+VP-DYT.'&"Y(H1526V
M+3,=CGFB6+]D%>O]96_Q>'_?G__.MNW%^.-T?#<>]*?+7G\PF#U.E^/IQ][#
M;#(>C$<+C9J7)Q"0H$301Z>G200;0/N@_37K83EB68>2%%_0J&/AN?]$Z3YD
ME>Y'>H">+4>+WD/_]_[M9*11K]C5]#BW<IWBM=>:B28])8`"<3MHUA@Q%KF$
M,4*JT:A'V0TYK2G75UE-^>F2Y??[-)HOQU1/T&A-BBAFS`V(=Q*6.@@]!C<]
MA##[0_*/4M6J-:C.,R2=[)).EDDDY/!8W%RS[C6`:/9,*6(+&O6,?0M+SW!\
MPSP-ISS1S.NL9OY\V1O1"]GR]]YRWI\N^H.H=*M&G2RNPUO@GLJTTWD2S#EY
MF,Q)[6420VC6,%"=9&F.H%&DU&,X@#K=9-7I[Y>]^6@2Y;!]Z,_Q:!6/+$AM
MX;*>6FOQ%D].2O>D!M%M%0'BF"OP*\TG-!H9O4U,-NZB5\LG"OD^JY"_7/9F
MR]]&\][@<3X?39>]R;A_.YZ,EWKM(!%1*6ID[FZ0OKH+X11.#^)>@'36[3$`
M8U=4,P?&&33:=V=8WB?##LD],=A,(]=$L>[]F-6]#Y>]N_YXWOO4GSR.>O>C
M_N)Q'F=UUZAY!X*.4P7L@N)>&K6M:&(`/2OIIEG#(!AE=`O$!S1:%9V/"Y/'
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M,E/`OBH[CG:'906<LZ_X*[$.C2(OR$9@5<I%W5S_2._`HX^Z[4C)K.=DQ]*'
MTV-/>68!;@^=)]O,I.2\EI#.FA6L#*?L413.#SP*%#[YY$M(!QV]<!7I)A>4
M<_T3"QJ]78S^_<@<(^PHV6E4$QE(3M&`Z!&_RYEI3QGMB'0&$GTMC,*^R073
M2$5A]_ZV'[U:*=LN(#L?S7=\81/-[!5T7A3U.K?@:P@/<"0I>?3);#WR`VM+
M[YNBFF.9=KJKSTI#4DPH#A!8<A1V9:!_,&O;BV&S51NN.[#NVFK!5M8B&;8@
M0=)U3,*L.)&_Q?+_''ATRPO8WX1K'[\3.#T3&M3*68`#JX.O.O7N,V5*C^4,
MX+L7=]=>=5<6/RFVX$#RP7-WQ`M>'VPCBBIGJ\6.S1:\A,)'T%Y@5Q9/6>;@
M@#0N,+<TOH$AY/?07@Y7%K(RXI%`M-W1I8))TLRC]Z^=ZQOV;,T>:DRL%[**
MRU?`X:LTFO9*M]+0UF`:#MA'AN=0>OT'XD7A'V"$2SMJKV`K"R:0%3APR]J0
MXLF"T0-VUU[D5OJ=M`Q;SC]E(7L_!\:\L#'XYH\&8@'-.%0S[^8'0P3H"@4,
MCZT&S`\<\!VC(-/1EK-=DF)H'-V'Z>[.3N"EU\I*@^DO%"V][%;G&0[0QY2]
MSH:]<([/;/2N;`4D.L2500SHJJ]Z<_4["Y`?..`[1D_Z^:2R`CMX63_MY9<K
M[(X03J!#3>(0P^^CO;YQ';04[8F<R,U;XI"UQ8R!<7('G[+HCB2),#EI2<HQ
M8D,W,K+V4L)P)!NC62G><[*Q_,2*GSSNZ+/P[PU)F8'+H)4=1'OM7SD4J_$(
MQU(ZIYRE<V`.MB$];MMN9!-."I^7G6!`G;47V*UP[P#S1)'6S=;K)\-F)1P7
MSX14T#B9`:``(3#6R)*&2=.FY&N*4,]UZ%_-]+S!1QGYD<`^?_T05Z:1BS7F
MD+8EV]$Y`6VY=#:2`6WQV%TX6\-O#D?;G>V^$K(@WHO%%J$B"T;?CN8299-.
M[%=_T1MP5#8L>G@K]2:Q\4^>6R"=<NZC63;2)WW1XI!+K9--?XI!_[7F0>4<
MK8ZBE&-UV:$*UE7[>V!(OE,X.<CT@W,I%JE*+A..*/\I!K7I$J&>I'-,2C`L
M.>5T]EM$IEV9&N;D6HDV-I\!-4MGVL^*`2:JYB0J`@2`*M46!US%PL9#(#7]
M]`5*LUO_&*39_V8)71CYMF>$0M'T4Z\-T(`P-;9DZ&X-JRB702$MZ1XX`.&+
ME1"4-"''4T^C=C(S<)^(-W5?R);^22G[D#T@7%_1<S_S(M]'37CVL@H#Z7Y(
M429G)T:SRHQ29.%<D%V03.7Z*CL5(52@GKJ?2\A@(\&*%L"XK@P&MZ?NMP]5
MP2AA!0ZS\O$6=TJFG(6)WU?WDV?NN9)K(BKC@R(E2C)MO49U2D_$ILRN`.JI
M^Z5E.1!@4I"9%#@IK44FA5PJ4%%B:PPFA3><X3I3"#JI)IN:+[U=\TE(<`<L
MEDU_YUSS9JOA-YK5H##%MF@MR*4,Y2?:QK`2O-6,VREI2Y!;S9PY848UR]E$
M=9EE,G'+#7?&&;JK\`W'R?=`0AQI3)<=,2VQE=4[(8WUCU!:$O/9L;Z$R;XO
M(RIJ/Z_[W%='MMH`!IDL`M3IT7&??.*],'+&SBX,F(O:,6FOA.!&5RGXUW3;
MLQ2O8K)L1W,BR94G$)U&\CF+"XL48#B)=-4*A"SAA+:DPAUO7W.)]_M?#6\%
M>0W1](=T1SVHJ'6@"`T<.U8JRWOAM*-5)WZ(=]R,Z88>;N.?08])37]']WE(
M354-)6#@%32.#O%4:$\Y\2F'6>Z:;SMBTK\N7?:C61CX@>&LZ$9?1RC;FI/N
M8U9K`MPNR$B$O2;U'Z/*&F,GCE7]3%B!#<J-%^(9&Q+]<DA!.AQ[P?*N=UK:
MO;'**B'IAAK-)65?%$9T-\F7?$@55T)Q(^FJ+,'W[?299._V:VK_A8RM^\:A
MLNY2388K\G!GUJC4^?/19_OT/JWN8<WZ;`7/<^*S?7SI[E>(Q\"RK;^85<9R
MW*UEV!,C""R3Q)0]>)9)?W?OKH@-"LK7/2GM]Y'FY!`#.Y%M:_MJ**)M35@3
M!<.V]E9*.1S7Q\STQL[:];81[/30%?]2;A>2&U!W3)1D&8AZ?$.CBQ/K2VBM
MZ*8W)(%AV?Z4+39LX2M4R_>Y"BLWE[W)^-^/X^%X^7OO;\D@O<,HU324LU5F
MYRI0.=:>W[S1_=OU_J2H#XR=%1@V;S_---(EZV*V%&Q<A<3AL`K,V?0=LMHG
M"NV;9K@-H[OG,,K_(BS)6-Y7VQE$!B0)>C!AET^&-7794R[BW5KKT#/9Q/M;
M%A$U)Z9M^+ZUMMA!*5\[E8]QD]_09EZL(`O-\[;AS*R84T<D++Z(+HL73]G;
M8I*NIGAOK%LK:;]Y7O127^^9J<_W2/S]+OU$]PJV0KZ'[I%K]\B5FT@IR8^7
MK'#B5ZZ%C<\(A\+YXWCG.G8"NF]O4VE5IFX0IUZA])2]>87UQH&40.+RZ6\!
M5*EY#,O<I'2)I<>&E*%8^'I/V$.WTTY&O-(700`;%-G'QXX9OQ<P[%3U)`@0
MH)ZZ2PY5!42"+8J`240B45^(2F2:ZJXO4U,7"@G'<;U.4G615;'/*W.+*3BO
M`_OK7LW`[UCE&((#Q(S3:!HR.4O<F*G`'1:&;;*DJI8=!L<[<1[4JN/I?F@.
M!KD>PW"`'E<GF[B^?T?Y,'#9_2YD&^^.Q*F063VD#`41@:(S8>4A=6^.8.AK
MLPV-/T;*3%7BK*F;Z[0A;TYG=RHH2?SH6$[THB8VQ?)I*&RL.SZB4KEA#LDX
M%MX^I6;%%@8JY@OVQ"D*[QA],^V0JG"\JFQW89`D0,U6IRM#L:'A=8<Y2^/>
M*%N12,J6^?G_2F:<E/%U-M$%0B``PEZZ#]+RN`*8@`,N8=T!D8=8V$WWH;C9
M\@OH3D'I=)Y[EUSZ9\7G'4#ZYJ./+1JNMXO'^V[S.7>.-&ARY\Z)AL1Y@]B)
M-J"'6RNX,]C[]^!5[$,K:GM&*!1-'X<'[71F91ZSXM8X@."+DQ`,M0ZQDZII
MAA\,0W)]`\D&"^FH^UXKDIVT"P#.!$7.EZ()@'+R0CKJOF760:'5?+M#RR,F
M;>R7YW0M;JK[W@?EM(A0'->\@@(`@OB5HL:ZWQ]`;=T"2AL.U&PF@6N4R3#R
MM;(7YT[1-2Z7NE781_<F`4W:"B`<\X6[Q+F0*P##OVRC\!]TU^SNFMU=L[MK
M]GFAT%VSNVNVMFNV]FM'=\U6Z4/JKMEMQ3&]G6OV_CJ3.`[9F8Z_Z!<V/I=K
MMH!2'%"T9O'0>)'N3!Y2)@]E%EFU)@]-UH!C:I_]C.>4RHC45;*]&1O!-5MF
M#-TG+K"JR3,&C0V+4\4XL4(56[%R-8?$98R3L;HZQET=XZZ.<6<V.R^S65?'
M&('9K*MCW-4Q;N-N==9UC/L[S[(+"O?"X`+WUGVKDL%(DB6*@/D_H?W:#S>A
M'[!*OH=OLXD((0'TTWU#D@$#S`:$UHF)\?7.B@^:0L@*VNDV6,M`Q"53U9*U
MC2ZL<WI9CMZ9$X^]R3AX*Z3J?U<<2[>56VHYJ\,N11!*E(P7%&SG]@3"\S,&
M>"18H?@(D"L7+W<&*.^N.PM)E4,`E"F*L.%^G5+_BQ`64$_PT1D#)!*\:&'9
MR@D&>-GB]H2B@4)!)'C1DFZ<VO)NR=KUHE*<G.?B12(E'@*]/U6>)*4`G8K3
MHV/$+YG):O_]9%(/[,=ND5TF\M3+CJ+;'@##J2)S</CTQ$(&<G[4<9-K=+X"
M"4%[)\TXCD$:6-)'MSFADL=<C7;)[51'7Y.8__#NNLT&M;8H+CMT;4]T0OP5
M#;2&IT?0;3-H:%O*,P7=EL0\O,N,AQ?LD,]WU&U-J+(IB5B`?U>"+HSEW72;
M'"KM36TOA$LW,&S.HLSAO+@+D.N_Z.4ZA&P<:UOIH@QU:1=V!:+U0?OZ!F8#
M#M3@&B6^5"`PT]6]%[6Q@&464='"E6L*9;!FFX&(SC.)#;W85WX]S/LD2/3G
M2D&BM-U^V"Y>M(L7[>)%NWA1$0*3+EY4'PI=O&@7+YH[&K,X2"EO=KJ#;G]/
M'1]VGO"63-`LVD22X\<.NMTT]3B>);P]CE_+<OSZ'$,VRPG_3N_G9W0[ES,,
M[Z*Z3G0:7J#`.,SSM48_]EG%D9G#LU,"^^K>0NJ%=A0RHN6@F^,<EE_=RF!$
M?77O+DV!D6*$/C!H_^JZD?36O?DT!DB:&=H@N7-#Z`F`U_FLW?P<5NC#(Y5W
M41Z/J/-YN/;E6*$(CZB8IN&3L9.93C*;$3,YL\G<<=<MN2'P>^_E:=*L,0OK
M6V6%B?J>AU=>BA%OZTKSQ\T9N84%-#1RKQDYJ\RM!J-CK22'\-^K.=90Y!/N
M_&K\M'#[0"^I]'"GG71??IOWM0%XA&.]UEC@3EU)B<;AE*R`UT10HYX5?O0E
MM(+7I6<X/N4&.V'`%O=?LHO[SY>]T;\?Q\O?>\MY?[KH#Y;CV11;F=F8VO*5
M.ML.@[?\+(,:BAG>Q2D@\Y`CCE/H?S6\U9)^11RBD&EV1KS/S!Q'8$)4G_?6
M\,F*5?"E)YJ$<W2?V$04^;>OQS9TGXV\_8R2(SG.ZL$V'$A0@YJOX9"!0OG-
MJI\2^FO&4316H#?P+)-E`0E<\T^N-SIISVFN^[Z@4AWRI7SY#,-QA6#DS-8I
MZL5+,Z<Y#O4$+=$<"E+7&IT;9$H*XRN.<?Q)^F!?IGO2`^%`4"B-V;U6ED0U
ML6C,"36F5U:?50,0!N@4MM1]W:XH<6E#MX`#JAYL,$\LC.G%376[I!O@NH@'
M.+869B\[>CMN7Q\=ZTM(AL0W/6L7<;HT4!G0'<?"!8Y=!E"4$CXTZ$'#F8M[
MX,!(2AZ%T*F/<&8FSUN#GC%-<>['@G:Z/=9E@I,M6%1(IE+G-)M7YAD<(+)6
MT$NW0UJ&Y4`6*`(@NA&%9A!ZEK.Y(V+AYC76_3Y<AMUB@O%LU-WSH1_U[[?=
M\Z%6G@_]YMITV)DC7GURK3!LK-!'%!P2%:WJ\=>67UT`0U.M=(<(R3,T1Z*J
M3*',7#CV?;H]+\(G=D!]HG]C1DD__BF'Q8!^Z!^;`.E0RO_/!KV#!\FWEBX[
M*;&ZD.RPE%RX.0!`.FHW@(,@@+,`QR'FP7--0E;^'26739K=*6;KSY%=110-
M4]9/MX$.',<(8P`.L%+Z/8Q.Q@_Q$["4AM^YWH)X+Y9)A*YZN7'POWRH2-@9
M@/O)L$-2'UO>,/@?452C"Q.RQTOO;!V1D9;':SZ49?UTVT\D8\7+&(`4K/Z6
M)3F3!RO33[?UI3I8A0S``99PO<^$$41A"!\]UZ^Z,0K&TWTE:V:#+&48:M"C
MG:`YS,N&.Y_L@+7XA1KR6&S[YI?0\JW(\5M1M4^'.(.\A/)$G0&<D4360K-@
M!"B8^F^BLEQ!DWMR%CP3+WEA,K&,)\NF$R6^L"[YA^SCB5\N>[/E;Z-Y;_`X
MGX^FR]YDW+\=3\;+\6B!HBYY1&6:O,/LRQ]30/IJU,?L]`;0YWRE'36;3>&8
M9701R!$<R^G>%0VM!\-KK]O""F5Z\;/#TF(P.@-4XYB!!\]=$Y]=K0S[CAP)
M3+_*X\,F-8AN^VLU+"OP29$K(YG)Q*+[[HI5\!P:6V-3:'A+U1(H:*X[9E(2
M"#$QF'0J2QA\E])OT*ZF'3R*<>)1N@UQ.^BV23>#3E-5R0*6?A[%0^FB<_XK
MZ*WTCU?@X_[OR-Y+HSSVPPKZS)QT"H"Q,R1K([1Y-1J@G;&=$LO/]#+4(;M:
MWQF6%QD`[HG!2(R>/NR+.AQ^6:QSUUF=^W#9N^N/Y[U/_<GCJ'<_ZB\>YZ-[
MJGR+=$T'-FKOA0VK4^T.M!TI\,L53MQ+X^9XF%C?]TGT>"4EP0FVJYDS)^QT
M:SF;^*CK[?]Y:_B67Y+]H,%/X`B$A(A`9@]ND`=(,C`T05'.\*A&>";8\CXT
MKG0*I&V"+MO$@:K;U\-??[.(1UG__#HA+\06A[I#^W]G,E+"#1PY+PJ/&_EY
MEX782PZ#3!)`<L^#&48QBKP4A^F-G5T8^!&)_%H)64*+.NF^&E027QZ2?*[@
ML+<43?2F"GPW6![5JX+OYES@>U\%OO=87N>K@N\]1OB&Q+->(N/48<JS]?&'
M!_,8'TOX"&B6U2;O(+G';'+\Q"$%,4,*+JH"+QZ_"YKU5R'.I1Q#;7H[E%/U
M_7"[.XW&.;&]W8!M;R?E5(_#=K:W+GUH52M8ETQ4]WMYQ,E$OR_S#@BMSD;3
MV6C.R$;3RBWQ[&PT*&^)WVGF9LWI0+O,S5WFYD8$*<D"4+;>9IKIOL:WF*FY
MD$$XEMXYHU:\[*::X%`WT)*;FC6.E)?1A$JSFJ<;X>!V3D**&-U0%N1F.'UO
M.=8VW);Q.M-,]WI4(!\93A?2A6,9N3>^@5A^VDRW*P;`\B*Z<+`\;8;>FT/I
MAG1/@F=WY=KNYO7.]8I,U!(VRNI#HT\$UARIV(5B;OE_WD7IO..@WCEEC1SV
MQ2.@N2+7AJY<)$0\Q(L\*S'(DA:P^H)RB)_VU+TUMHET$<_P(_S)M2D:S/,K
MK]V\,73OSCI0+^8C?OR'UHNU(LZJ.OJG(^A^^:<#^R(>GH6;/3;L%GO8WU?R
ML$<C]MYWWO7.N]YYUSOONCKE[KSKG7>]\ZYWWO7.N_Y=Q6!K-_O5B*.62TNQ
MBS,-!H879))3(%FU/UO!\Z/C/OG$>XD?^3-IGA/3=4S*@N0*D[`C*AY(J??'
M3N">7CM@BWO]K^E>.N0MRPJ8C6-A:8["61C,UNW)T\GG=!LW-0A4`;OE%[@/
M\0+GD`W+?:5_<1O1G7>U(JOC*CYU)ZZS(=ZMM0X]D\TRSM%-V6,;OF^M+59[
M),HG^AP5X/%'7T+A1MCD-W2;5\%RUSQCJR=YHD,1_:+6WHGJCQO]MMC&#U6,
MJ$:.52,GN^[H,<Y&DIZ.(MM;9J/XL8NG;)!9L:GVQZRI]OKJLK=8S@;_Z@UF
M]P^CZ:*_',^F:3MM:OR>F?J`3L/MD839.DWTG-ALI1BX?N!'\WY*Q=4!3+MU
MQ\5@=#Q+XV\S@';F860&1\3FX:D11-+&/'..7Q*>6MCXC'`HG#\.*V\4[6)M
MXP3[D9Y/W:!OLR]2>LJ,N[#>.)`22%Q1'NU2JM24EOU$_,!R-DG!H5GLOA96
M117VT'T#D1&O=))*`!L4I;L>.V9\[S;LU!$7`@2HI^Z,OE4!D6"+(F`2D4C4
M%Z(2F::ZB\35U(5"PG%8"6,B@J3";N[!33)S_C8"[7\NK@<Y?BC2E^-YO>#;
M5)WM<,6R`$]),"FN"A;5498<!+_IO@I5F'3M,[$VS\P<]T(\8T.F(5L.Z#[)
M2)J%@1\8SBI)06/VG=70LL.@L-QW,F#5\<[&IEZ/83A`IS+I;@D31E:<>>`Z
M=$,(V?EH1[R(XS[=53(41`2*CNZ5A]1]J`1#7YMM:&)#N>;'TOQ+/\F;')$D
M7^JLC)V5L;,RXK=N(;8R?J=91S3;%+NL(UW6D886T8/QKRP6M:"I]KMH>]E'
MN(S"<7WYCC*0:$[XU&4@:8O370:2+@/)V\]`4KJ'\;:P^EDJ6OCTN?@36D.A
M<K#>"_&>7`QQF\6F_3RKGB"L2B>*N"Z15$7?U'Z(E9)1I8Q_(\+9E![+Y@5I
MY>.ZSS=ZEE1P:I%.;AT_XX_+IN9H28!+9Z'[V*A'DH'@-"S2R'QJL2%E[*Q=
M;RL(YO]9WK,6C]RSCD-W#K;.P=8YV#H'6^=@P\G[SL'6.=@Z!UOG8,/M8*M\
M!T@"^%F(.3WT.ZN#X<5E/TJ%1\9ADPHN9](S>/-&VXJ8?"^2F+NB$L^T?/+@
M6:8*ZU=#\]*^5N(16PB`B(2YBDV[*B_FA.U!].<L5IG=R4+#5N5\4##'\[+^
M(F$:.H%O7OD3%6?7+$WGB((9O'T#;T50OA=11'60`,_K;%(%Z684.F%N?K_A
M\P+/0:+2''6_DM=]D*@!+"*!KZ'\+5H>JIL8?L8A?BK8C$B*<MH5_=3OA\&S
MZUE_D=6C0]%(&>B80<\_V0RB$,R43LTXSNY4%^F%LJU9Z<YB47-I;!<\S&(,
MWR3DKY4WZK;Y2I,!"NTO2(6V%:CPOS6/:>R;@?62SO1Z$A3S]\I!,48R;A<1
MTT7$=!$Q741,%Q&#D_==1$P7$=-%Q'01,:HB8CCI[.+R`X*C%FN5;80^5J1H
MTNBNKF_=CM>\.@I@;=^`=\;5K*)%9NS[(5D-0X\2&2=/C8U(Z=3`>_./Z/E0
MA;&T!33`!:@RA][&`O.1-@S\L1.3K6YUR7Y'6_1`:TM+,6??AM2,ONVL)`.D
M>M$I_)@V-WYK\B/@\=L0(IUG&XFB4<T[R?6=;A26E3I#`6PQK*YZ_%SS3O(6
M5[#R"#D-PL>Y($=^4E;>).4(+;DNB[O@]S27TZ#4))$^7J>6JB2#5M'$.#A4
M&4B;2Q7,=+<>@3CNL9+0QYF\&H!>-!`0^@^HH2_G%%+H1:8&UD#>?!`Y#O4C
M);(0M)ZXAL/\Z%+*9?WAMU#&J['\R3(^0Q1"M@\,QR2V35:$7>JX_,\W@P*A
MQH(F"P2/3(2(:#Q[2-P]K]78O]0?/[!<-/$=/V305V.]4G\".2/T4W?4(DK\
M1,8!\(-'@J*OQO!4!WU)9IT_^+&(-P'^?B0H^&K,/DK!/V462O!%0>\EMAY8
M5RB\FHT^,GSXCM-OE@:EM_3FM?$L&6JL6E)2I<S3(?FJ]9RC.RI'JV5B&@X.
M1D7BW?`\H%*NQH"G4LJ5`/8=+.!E?#N-Q=`DY3*3``=.O3D1EX>JD^^B6!%M
M2[GD3*"2KL;4K'<QKP3:=R#N;^0\+F'JNU%CP,=_(L=B*L0AV=JS*S6=1NE&
MC0-#HUQ7SY_4C%3C>M,^-3RVA;T<Z3UYS?Z+[&OVPWC=*W94K]A'VYWMOA*R
M(-X+E>YB)9JZSDN<CXGIB[]T`\-._YX1.'6#WTDP)Z:[<5C^$CZW%'Y2]S-#
M):_JE4.$(^I<&9GQ"?S.]9(?L7:"+$9MST-W;MCSDEDAF#@$N=GW1=&_AA2)
ML1-XEN-;9E2:2MU)$?AYW5EBU20P:1,Z-'F-/K.S&9WW/IU1\F]Q/J,/N1/@
M]67O<W\^[T^7BW06HV0T'&F,*"XOT3%T[%!!"&.9<%:_D=6&WF<3BBWB'RD#
MG/[J#(HA+<YY)C"J#V67O0A9!ITN>Y$^WG?9B[KL16\W>U%R""G+7)1IIMN<
MT&+6HD(&X;A/[8^GE)0YL\OZ]$Y(9`YHX`'09T62)0@3C`/;\/W9.IG[S(MF
MGG(F\?$K[ZE;464!<27I^ZZ"VWAKVM1UXFOVZ$M([Y&I8S\DR9'2K^JVX=63
MOS80P;$&5:8T1^`L>";>\MEP3NI5*,R9(ST#W08Z33)9$:DSET^1)AZ"D5I>
M'5/?U5V;">'ZF$,%AP2J.Z5IS<S4RCGM;84\%5(;I_N9K1?$#+W(O#HPV+OP
MV]<]:Y.&@L6F]L"ZJQ`ID")YOBI*W2/Q1!I9^AWP)9H_]YK*JRZIP4$(CHM-
M$07B-\VR@Z#+IE,$9#7.Z+Y)UX19^'I9=A!\N7CJX-SH6V75.!]NR=65&38$
MOK0_(HQEV*)H&X1-!:2'L"'PY0.JCA!7!U4@%*?XKJY`@/[X<OJ(L`$S1!\P
M(+T!],>7;J<B,*UJS"&9URA.YB5QY)<;`E\^'!$\,FQ!@!!,B:1&PI?"IBY>
M[2I6B[<SF61CS:>D47=!PV)"PW-!DT&ZO9S&]:]H9X)TZE5@/Q@2,XJ/>4^/
MX=<WM2]MTH/JS8]2\9)0D75O2BID+HK2@^I-*:):*LX\^1P/\T;>8"N+)ZF?
M;`Z#,1U[S,CA_5N&D8=W0W>&Y:EZ[=7H[/`F#6@]O$0>U',Q4E=9YN3&@(J1
M&GN.C!A5(`Y3E(<Z\1=F^<*QL$E/$2J6:NQ8J%:WBO"V92]+RA/46*GDAH)*
MAAJ+6=4%JPJ[WOJZ]5;.8C*IR=08!E&M5W*,PW#'Q*XHI^'3*+5%>HI0A6D_
MNW;K"E,17K2Y+/J^'VYWIX'6Z3P6/UU!\UBD1NI26'0I++H4%ET*"Q$"DRZ%
M19?"HDMAT:6PZ%)8="DL(L^F>-E--<&A;J`E-S7KU!MWW9PNTY&31CBXG9.0
M(D;OIXQB/4KB-<IXG6FF.U-"@7QD.%U(%XYE)`F&*&7Y:3/=B0``+"^B"P?+
M*UM:#B:2E-U@;OE_WGF$Y0,E%(1@3E=8!08R^*?/)>%1:RB\D7"5IW)6/4%8
M-?JV(V9`5DOB;04ILU5^4_L!5DI&E3+^C0AG4WJ\Y]$GUZ;#V%;PVN)ZRONX
M[O.-GB55#`6.G5PT[Z'U8JV(<T@3SA<BN5%T'[W`TE"%.0TO1WK\14/#VQD#
MUXFLZBRA1YP^?DY>B!.25)$!4%V<GZYSWJ2;R]ZP/W_H]P:SZ7+>'RQ[_>FP
M-Q]-^LL1^_/3:/HXHG\.9A^G8X0U<_*<*'<GB?I@<$.<I;>H'(C.&83,.H;8
M&728VD?B;CQC]\R61;&%4M#E'#')4X'$840VV>F5>GWX79`APY.V+$A\@FK:
M/CF1I/>631:!ZY#E5_?!M9S@S@V]Z"_[']`_N78W-H34"-K/A64RE@X;K<`;
M1?&^Y3-A/Z@)4WH(W7DK&\8ISQV%0/EL*O=3NO.5`I)OJCM1I#3C>=2VI0E+
MVIS46["$0^C.N5A/$P#<T0!4>E*5H2H:!`A6\_'?38/%YY#RA>N.WKN!"U>Z
MJ?;TE]46KCRU.(QV>\N,G]Q^^6?@?,NS\1SPB%0DX_M<LP?T_4>'<N)W8G@S
MA^PGPY%Z:&?\=G`9:EK&HT]IHZ*P*IK,#1B8DE&TWT$J(@1B#H[5*V^R.ZZX
M)'AV,V9F8=7L*F-IO[Y`5\#JC$+S\&3@;K=6L`_A9P)I.1OBF"Q\'^0ZN,FY
M#MY?]@:S^_OQ\G[$WJ(POP%S(HRG'T?3P7BT0.8I$'%`XBV*Y#`:U7M"#)]$
M/B,J239SESF^X(3"::[[F%()MHS^"CF!1D63L_%>'XO5\'U.#7^\["U&'V,=
MW&M<-3WC'``R\Q*H"&O.;8W!FW!>GC4A.SN?&F[_S02O3^TV].GD?'\O6T"_
M6G&W<\2FF!)4_C6@3PVI'TTD8<6^-+7^LWZ\Y0H-9IDV2$S\?.M8(4V*;`"C
MQ5C(N]3OD1AW^7S+T8+J,BYZ@G5H<2YQ\5F:SC]">+8C[";K;,8./;>3B>L+
M`"MLK/L^!09/0"H.C7GPW+45B"%(M\%O\RV8]%M1G('A/PN,*M%O\9M\3Z:+
M21?ZOD]$<>'[WY^-R?64(!Q,WD>8W[G>P-A9@6&/MSO/?2$E0?EE_;0?-<$+
M$X@!.,`:$LI&TXJ9Z*SZ6]<+K+^B?_*1$G;2'F,"A0E`^OEO*/OGD:5V[5Q#
M[3<4*(X<$J4,ULEOV/_8RS[ZD_\/4$L#!!0````(`.);:D6RB)21,Q(``.'+
M```1`!P`865M9"TR,#$T,#DS,"YX<V155`D``T?H8%1'Z&!4=7@+``$$)0X`
M``0Y`0``[5U;<]LXEG[>K=K_P''55O76E*Z.T[$GF2E:HM+JD26U*">3?NF"
M2$A"-44JO-CR_/H]X$TD04*@XBR9%?,02\0YX/G.A]LY(*'W_SCL#.D)VPZQ
MS`]7O7;W2L*F9NG$W'RX>E1;LCH8CZ^D?_S]O_Y3@G_O_])J22."#?U.&EI:
M:VRNK;])4[3#=])';&(;N9;]-^D3,CQZQ1H1`]O2P-KM#>QB*`CN=">]:?>1
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M;Y?O'=VU.^[+'G=`J`52V"9:K'=:*:T`-M#+^=;Y)3G6(;S38X6P'^VP3C1D
M0&_<^1JT0\&(8N`=-MV19>^&>(T\`PC\ZB&#K`G6KR07V1OLTC;O[)&&A>J,
MN@\R30MZ&8PIX15Z;;\GT(W@PG^\I^WMCOIW"2@D^@%&$MX=J$@'>J)'+99-
M73%=XK[0;FGO_/M<201@<R7HG<$._]XZ7A.3^`9V@W\]J24-H6L;EN/9F'X)
MZY*@,BFH34I4][Z3K2A1O>=@?6;^W?^\M[$#U?A*$[@0*H8B!4J`6_.,<CI'
M4W)5P@N1U[^!AX%EZMB$BN&#8QE$AS%9OT<&'1'4+<:N$[`A(,?G!$9D?[3V
MVRE\'LRF0V6J*D/Z29U-QD-Y"5_NY8D\'2B2^HNB+%7IIT<3>3J!>_U/0Q+'
M^7-D`^0M=JFB*&-I)3Y]UV?1E^1/^BEUOX;/##6Q=YW9>K:GZSPPA-?["A3X
M/+X1XU%=PI\'90H<SD;2;*XLY.48!)H.*4;@`#G;D6$]B_)WE.?3=W,.?0-9
M_44:36:?&_H"^J80--AXMK[W'&)BQX%5P3UR"/`P3V`-J!.4Y=/V-KL@Z;6E
MJ;Q\7"B4G_M'=3Q55%62IW0$5<<^:_.%H@*#?K^[8*XFY*M'H,6^!'0<O_(]
M_G/6X_VV-!G_]C@>CI=?+MB=JK?;(?MEME;)QH3H0$.PPM8TRX-%L;F9P]BD
M$1R.6H*R?"+>98FX;DOJX\.#O/A"6[DZ_C@=C\8#>;J4Y,%@]CA=CJ<?I3D,
M98.QHEXP4U/+Q;!$>T$K`X=#4?(*W^NW6:^_@0%GME14:2Y_D>\GR@4[%N;@
M)VR[!+S(^KBHD.ON7C?K[ILVG9`_*8OE&)S=N#YTO0*#M_NRM)'I("VQOLVY
MSG<X$^&_;4L*C.[++])R(4]5>>`O5R_8U0MLT$4FQ%QY#B\LY;N]GW7[SVUI
MH4S\->=<7C3>C[P_@S#7'G@V#7@G!*V(`7>-YM6B0K[OK[.^?]>69LM?E(4T
M>%PL8*4(ZQOY?CP9+R][WAPA8OL9_0>,J*?\""MP?'X1W^UOLFZ_;4LC>;R0
M/LF31T5Z4&05EO%^K'7!3E==2_N3;D)!E)L(GMC+?&??,'%2%U:+R]G@GS"=
M/LPATKWT<.@SLF&XCAIT_(WO5C;\A/CSL[R`L?JB6^T0V7L$*S[7AND/`OMP
M5ES@)VQZ>($U:Q/8$>Y("(OSZ6!BTQX$IT-Y,9?IHA%FT,'23P5$,^M"^:1,
M8:Q9*(,91$L7W@-@.-D1UQ^Z@0-*!P2CV#R&K3P!/C%,K-J[INOXAX?Q,DBF
M458H11"B*M,+CT]5O$E,K?$WOH>9N+0'@:FJ?+SX^=-;.?BK!Z"4IX13LU>Y
MSNTS46COAN9:[E6(C.CZD`XC%^YED836.4DPL618GPE;2R7#I)^BVUQR\EZ,
MD"7-VI2B,-3@$\@$P"4)#&YRR?0ELVI)DG*N\ZE@XN%LBK/Q=F&N,^EXO@B?
M`R8XYN4]&SX*\T))/O@B?#Z8^)F7(VKX*$@6)=G@"?"Y8(+NXL11PT1.!BDU
M@Q<4\AE@X^S<;%+C_6-:*>GTS#6^K]G0.9%B:CQ\#)=3S3I]C>]A;NC<>#CQ
MI,@0NX@8SI2V7Y<\X<R3(TPQU^_73%2=?))$^BFL38JKNV0*Q"*MT&4M=8ML
MW*+O*NC)L5TYT(^X3.PF6".?Z&\-SJ.6T)(29DA:P@X)!X8T3420T$P7/E.7
M3_NWAO3-`%`0W4>=DO\@4ZX4GS&!R/_8%_UZI7U0<4--RNF9[L65X%/")`**
M*6GZ27%>)O01-S$3R?`)83(!_,Q,6&E#29&[6[(&;39^#%E4F$\2DR(0(@GD
MHOH;OHHHR`QMHL)\OIB$@AA?S8B7^^AG/E,"<GR2F$Q$_J.A#3TBB>G4A'1"
MAD\+D[[@IZ:;"2F7DH+<AI@HEZ`W3)ZCD*`FZR&PB1`M!>)"SGX"*\NGBLE4
M\+86CJL&6KWT1.MOV$HS$*_;',?;[?U9IYBN/&$^7TR*H9"OU"+O6'_#5SX%
M$_R$C>O35(5R?):8M((02W[5TO4E,\3LSIU(QQ;LZ9W2XK/'9""*-OM.IVD;
M+G-8889&(4D^9X*/^S>#HCA-,]\WS&$Z)>3YE+&O$IRD++B%1([W:)@K9"*=
M9A(5YG,F_!P$PQEJ\DR%A&7WIDZ*\4EB'Z`X05(3>B6>6XGZ1?@]W8M."?&)
M89^[2#W9<NPS8;5-I\GAA5D]\`2X?-RP;SD4\-$L%7PJA-]:RQ_7SE?GT\CD
M,,J_!->,A:(OQA5MBH@K\,ED$APG7YQKN,M].C"5;\]>Y'/`I"_2SP?^_TNH
MT_]H\+[`:\D_(/>.GJ/ZX<HA]"SDJ_#:UL;K#U?T)-56=+3I'P"M?=@9D0BM
MFG-`KD]0UAOAC:,JD*TQM3`'^$(EUI[N0F*G$QD?5>`2EZHGSQ23Z'V@*71>
M`[*!5F4A@PHVOB/6":W_54'2+E429*;!?B>H@^-=7A4P=)VR@-.][3OA'<8W
M2<(-#P_N'$\/#K]G3QA^#\`MVY5,YL!BWO'5P<';$TOSJ^*HT&^M2*]%+[5Z
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M;^,Y;@F,9^A5CC79W!A[BUMFL6CEB$9X97O(?@$K^WQ`0I*5XYFMUT3#-C2L
MF6</M@2O1\2$V)X@(RS*C/WB\I5CRWH]'M+Y:Q!6K'(DQZGV5#<2DJP<3VH:
MBL>M$E/7:9W*,8;]PMS(&QO[9;U@MR$S3)P4JR&2GWLW`D`R4I7C"%Z/&4.#
M<8*=NS2`XN+*+5?)P=T^$`,LL\Q,*%]05KW-=)<;+,MTXO3%RJU4R&:;-3)S
MK7(;)VAE^3]=^J+2W&0V\Y1?6+G5M$FJM$DNGZVY14R7^;N%<2(-IJ1.?3'.
M3.S_'5F>+0@Q5Z4^"!_`S@(DJ:+Z6)QJ,YE/L^PH6EJK<IR)E'._,!G=KX^]
M_-5=?==Q0[QRZ;,A]*24C-'Y195;S`0TIIZT]$3T4R!<.:HAL;$&\YR3TWH*
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M\D*\D$EAYQ95;K&?@"@PN:"L<IN9?`KU;3:E=R(%PU7Y`1`*)/_X.K7`&&PK
M3$E>QBRGK!8V%V7RA)L>7Z?6&).6GY'CK!W.H(V-R%-A^TN556[ST-(\>D4V
M=<5T_1W%^/`&&>JD[X+&>2LA611^BC"5QQA(0"VP]'J=):MC&42GCZ6&*W]U
MB['K9/$)"-8:G$J?O/7W@FE(C(/[<E&>TJ@=W(GE.#.3IGR/$4:\D9!?5L+D
MH&P54/_A2K.Q3MPTDAUT81?9+Z^&13FXV*2FSM;'7WQ-`LH7.!^5CE??$12X
M7J=Y#;VHF0V0LQT9UG->NRRM6;OV26V<(Z(/_;AQ[M]X9-D,UE-BM0-&NQ5]
MGC,=S8?Y:*PO+?J*N67Z"<;DAE,)G=IVU`76#.0X_L\0N'Y'#'^*(/X%-2N3
MF(_/P(^2">=74%NO#/$:VW"+^$FJ@>6X#CTFPM8IVX#(Q/ZYOI^)N_7;`GU%
MA%9R;"#?4D5M/9-+=[(+,'0[(@U&M(;:^J7$CW"'[:.$PKDK:1<?W'L#1J!7
M`'B/30R4$60<5R`CC%S/QC!]Y1/F_Y;)RS*R(H+^.E75P2D+O"%T,J.*8*@?
M0-!ES":8UPOPE]:J`]39>KU*Q`T",$MIU`&BJFVQ[AG0")F?$&7`"<K6`59T
M0I@_YZ3Z%H-*3+0.H#YC^F@HUF6P$FUPXI2L1X<NOQ2H%J)W'.^DTEEV@9T]
MS+E+*PHV'EUBD'_#Y'Q/3&L'`]($N2[1<+#I.K<)G;@?+!T;^:V@<BOJ0$7V
M)^FR`4%Q>>TB@<^6_2==JJ$]<9$1LYR]>M+,X%@.]_\X/LVLHV9FWO+KE-#9
MV+[S`JM@71#^7,`]7ELVCAZ5*WJDZ(1.7:'3X&!LTCU;>OT1L%D`ZM]8CVP/
M`<WIY<0*L[3:C]&N\]&>$JHKN05M=&J96B[.$O)UA7RR80*8D#_AMIQ2^3':
M<2'%`G)UI79IN5%45Y@`."%3:V@9:E*0V+*Z0BF:%^-HW)F9^-0DFA6N<=;^
MA/W+9TL<;"#\`X.E^\LEX(;B/RY@^AR'.-Y0^@>&ZQ^,*PPWD*XK7/^1:.1@
M)A\1(HGW#T?'-EU2I[89Y=/DJ>0@SG0@7%>B_7VRL>/`_*E"'9I-5O")_K*-
M$UR-\VX"@N=F$8):7B&+@/RT3F#/TJ+K`MI2Z-(@?#HPSBR(2%8-)US7!&D<
MND<Q1#NTP4YFN9I77M<%$#<),C:'>(T\PRU8CQ=+UQ6NWS^8GZ(*W]*`\=+P
M_"W)*7;I8QEQ5RNK5=?!1=[1"#&;ELQ>K5TR<D&W2V9KY8!MC3B8YH%Q%@1?
MIG:0DN]HS3R7=@:=YK:)27;>+@],:MPOJRG>'\/DN+>CQ7[#_XYHT>%<M%S-
MBM%&YL13=?)"^7V*US7N(YUGCZ8=OU9MV(`.@(:!=7S8$_MH8<[UJDU--LJ0
M6VI/7FMTPGZ9UY[%56O4?4\:'?3,L_#&JA7CS6QF<N<=,=G:S3^\,3>_K'80
MHDWCQ+209WFF`Y;6JKHM"MJ;[G:EM6J",IXI2S`IJ%/UI"%F;CZ-@CIU@1A$
M\24H%%'X`<#EDR>B4!=P\6)+"19;O&FBI,Z/!+&`R7*J=0&<6';);G02_'6/
MG@%<?I0M7TN]9A9A^[D#<?E:JO8"9Y4JLI*M\?(OGAN%,)94JDL?S@;!9;"6
MU*T:\M2C?6JVCM^E=1Y-'=M?,*)GI$3O"40@A:7/;*[$=/$&V]\%EZQM"7["
M>I[%_6*`I]0J1YKYG<MLQ%Q87.$0\[X3_&H6?/Q?4$L!`AX#%`````@`XEMJ
M1?HY5H^1X@``1+4)`!$`&````````0```*2!`````&%E;60M,C`Q-#`Y,S`N
M>&UL550%``-'Z&!4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`XEMJ17SM
MY?5N#P``6;D``!4`&````````0```*2!W.(``&%E;60M,C`Q-#`Y,S!?8V%L
M+GAM;%54!0`#1^A@5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.);:D4J
MM2H3Q2$``'E@`@`5`!@```````$```"D@9GR``!A96UD+3(P,30P.3,P7V1E
M9BYX;6Q55`4``T?H8%1U>`L``00E#@``!#D!``!02P$"'@,4````"`#B6VI%
MIH@'H;1;``#F2`4`%0`8```````!````I(&M%`$`865M9"TR,#$T,#DS,%]L
M86(N>&UL550%``-'Z&!4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`XEMJ
M1<D<.)T$-@``5\(#`!4`&````````0```*2!L'`!`&%E;60M,C`Q-#`Y,S!?
M<')E+GAM;%54!0`#1^A@5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.);
M:D6RB)21,Q(``.'+```1`!@```````$```"D@0.G`0!A96UD+3(P,30P.3,P
M+GAS9%54!0`#1^A@5'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"!
%N0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EELAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Government contract revenue</a></td>
        <td class="nump">$ 479,075<span></span></td>
        <td class="nump">$ 644,887<span></span></td>
        <td class="nump">$ 530,371<span></span></td>
        <td class="nump">$ 840,483<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
        <td class="nump">308,821<span></span></td>
        <td class="nump">327,511<span></span></td>
        <td class="nump">710,434<span></span></td>
        <td class="nump">651,581<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
        <td class="nump">544,354<span></span></td>
        <td class="nump">404,849<span></span></td>
        <td class="nump">1,165,040<span></span></td>
        <td class="nump">863,480<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">227,092<span></span></td>
        <td class="nump">142,323<span></span></td>
        <td class="nump">428,097<span></span></td>
        <td class="nump">339,014<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">1,080,267<span></span></td>
        <td class="nump">874,683<span></span></td>
        <td class="nump">2,303,571<span></span></td>
        <td class="nump">1,854,075<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(601,192)<span></span></td>
        <td class="num">(229,796)<span></span></td>
        <td class="num">(1,773,200)<span></span></td>
        <td class="num">(1,013,592)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSE</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LossOnDebtConversion', window );">Loss on debt conversion</a></td>
        <td class="nump">65,493<span></span></td>
        <td class="nump">17,467<span></span></td>
        <td class="nump">2,531,123<span></span></td>
        <td class="nump">40,256<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain)/loss on change in fair value of derivative liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,992,002<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,382,877<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other debt expenses</a></td>
        <td class="nump">78,145<span></span></td>
        <td class="nump">110,405<span></span></td>
        <td class="nump">144,799<span></span></td>
        <td class="nump">216,443<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LossOnExtensionOfWarrants', window );">Loss on extension of warrants</a></td>
        <td class="nump">143,363<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">143,363<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total other expense</a></td>
        <td class="nump">287,001<span></span></td>
        <td class="nump">3,119,874<span></span></td>
        <td class="nump">2,819,285<span></span></td>
        <td class="nump">2,639,576<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS BEFORE NONCONTROLLING INTERESTS</a></td>
        <td class="num">(888,193)<span></span></td>
        <td class="num">(3,349,670)<span></span></td>
        <td class="num">(4,592,485)<span></span></td>
        <td class="num">(3,653,168)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</a></td>
        <td class="num">(40,784)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(89,135)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
        <td class="num">$ (847,409)<span></span></td>
        <td class="num">$ (3,349,670)<span></span></td>
        <td class="num">$ (4,503,350)<span></span></td>
        <td class="num">$ (3,653,168)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</a></td>
        <td class="nump">259,369,911<span></span></td>
        <td class="nump">187,643,582<span></span></td>
        <td class="nump">243,494,916<span></span></td>
        <td class="nump">182,004,220<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LossOnDebtConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_LossOnDebtConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LossOnExtensionOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_LossOnExtensionOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestAndDebtExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LaborAndRelatedExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 7<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4,6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>7. RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. RELATED PARTY TRANSACTIONS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DUE TO RELATED PARTIES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of our officers and other related parties
have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working capital deficiencies.
These unsecured and non-interest-bearing liabilities have been included as due to related parties in the accompanying consolidated
balance sheets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other related party transactions are disclosed
elsewhere in these notes to consolidated financial statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY TRANSACTIONS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. EQUITY TRANSACTIONS&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">COMMON STOCK AND WARRANTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following are Aethlon Medical, Inc.&#146;s
Equity Transactions in the Six Months Ended September 30, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the three months ended June 30, 2014, we
completed unit subscription agreements with seven accredited investors pursuant to which we issued 2,192,444 shares of our common
stock and 1,096,222 warrants to purchase our common stock for net cash proceeds of $320,800. Such warrants have exercise prices
ranging from $0.193 to $0.236 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed above in Note 5, during the three
months ended June 30, 2014, we issued 15,714,286 shares of restricted common stock to the holder of one of the Series A 12% Convertible
Notes in exchange for the conversion in full of the $660,000 principal balance of that note, 7,603,968 shares of restricted common
stock in exchange for conversion of $343,200 of accrued interest and 75,000 shares of restricted common stock as a restructuring
fee. During that period, we also issued the other holder of the Series A 12% Convertible Notes 2,591,846 shares of restricted common
stock in exchange for conversion of $116,970 of accrued interest and 25,000 shares of restricted common stock as a restructuring
fee.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended June 30, 2014,
we issued 219,127 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an
average price of $0.17 per share in payment for legal services, internal controls consulting services and regulatory consulting
services collectively valued at $38,268 based on the value of the services provided.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2014, we issued 359,956 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan
at an average price of $0.14 per share in payment for legal and scientific consulting services valued at $49,090 based on the value
of the services provided.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2014, we issued 390,301 shares of restricted common stock at an average price of $0.19 per share in payment for investor relations
consulting services valued at $75,000 based on the value of the services provided.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2014, we issued 1,937,505 shares of restricted common stock to the holders of three convertible notes in exchange for the partial
or full conversion of principal and interest in the aggregate amount of $81,375 at a conversion price of $0.042 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2014, we issued an aggregate of
2,503,966 shares of restricted common stock and a seven-year warrant to issue up to 1,251,983 shares of common stock at an exercise
price of $0.132 per share to Dr. Chetan Shah, a director. The common stock and warrant were issued to Dr. Shah upon the conversion
of an aggregate of $220,349 of unpaid principal and accrued interest due under a 10% Convertible Note previously issued to Dr.
Shah by us on July 9, 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 17, 2014, we issued to the holder
of the remaining 2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit
warrants to acquire up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 5).
The units were issued to the note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest
due under the promissory note, which represented the entire amount outstanding under the note. We recorded a loss on debt conversion
of $65,493 on this transaction.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2014, we issued to four investors 2,673,231 shares of restricted common stock through the cash exercise of eight warrants for $259,474
of cash at an average exercise price of approximately $0.10 per share. As an inducement to those investors, we issued them replacement
warrants to acquire up to an aggregate of 2,673,231 shares of common stock on the same terms as the warrants they exercised.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2014, we issued and sold to three accredited investors units consisting of (a) one hundred thousand (100,000) restricted shares
of our common stock, par value $.001 per share, at prices per share ranging from $0.091 to $0.094 and (b) a five-year warrant to
purchase fifty thousand (50,000) shares of common stock at exercise prices ranging from $0.136 to $0.143 per share. In total, the
investors purchased for cash an aggregate of $90,000 of units. The investors acquired an aggregate of 974,982 shares of common
stock and warrants to acquire up to an aggregate of 487,491 shares of Common Stock.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>4. NOTES PAYABLE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ScheduleOfNotesPayableTableTextBlock', window );">Schedule of notes payable</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Notes payable consist of the following:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">March 31, 2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal Balance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued Interest</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal Balance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%">12% Notes payable, past due</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">185,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">367,687</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">185,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">353,813</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>10% Note payable, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,625</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6,375</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Directors&#146; Note(s)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">200,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">14,516</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-indent: 27pt">Total</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">374,312</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">390,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">374,704</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ScheduleOfNotesPayableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of notes payable table text block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ScheduleOfNotesPayableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>14. SEGMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. SEGMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We operate our businesses principally through
two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic
business activities. Our reportable segments have been determined based on the nature of the potential products being developed.
ESI did not have any operations in the six months ended September 30, 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon&#146;s revenue is generated primarily
from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead
to the ESI segment.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables set forth certain information
regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented
in this Report:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Revenues:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 68%; padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 13%; text-align: right">530,371</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">840,483</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Revenues</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">530,371</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">840,483</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Operating Losses:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,294,453</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(1,013,592</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">(445,674</td>
    <td>)</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Operating Loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">(1,773,200</td>
    <td>)</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(1,013,592</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Net Losses:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(4,202,873</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(3,653,168</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">(356,539</td>
    <td>)</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Net Loss Before Non-Controlling Interests</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">(4,592,485</td>
    <td>)</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(3,653,168</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cash:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">47,865</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">8,754</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">478,322</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Cash</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">526,187</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">8,754</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Total Assets:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">443,027</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">411,190</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">646,242</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">1,089,269</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">411,190</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Capital Expenditures:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Capital Expenditures</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Depreciation and Amortization:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">8,885</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4,727</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">9,791</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Depreciation and Amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">18,676</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">4,727</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Interest Expense:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 20pt; text-indent: -10pt">Aethlon</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">156,799</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">216,502</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; text-indent: -10pt">ESI</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 20pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 20pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 30pt; text-indent: -10pt">Total Interest Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: left">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 30pt; text-align: right">156,799</td>
    <td>&#160;</td>
    <td style="padding-left: 30pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">216,502</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK COMPENSATION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. STOCK COMPENSATION&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table breaks out the components
of our share-based compensation expenses relating to shares and options granted and the effect on basic and diluted loss per common
share during the three and six months ended September 30, 2014 and 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Three Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Three Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Six Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Six Months Ended</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%">Vesting of stock options</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">89,793</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">73,856</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">260,680</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">124,243</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Incremental fair value of option modifications</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">957</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,914</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 11pt; text-indent: -11pt">Vesting expense associated with CEO restricted stock grant</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">64,444</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Total share-based compensation expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">89,793</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">74,813</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">260,680</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Total share-based compensation expense included in net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">89,793</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">73,856</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">260,680</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Weighted average number of common shares outstanding &#150; basic and diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">259,369,911</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">187,643,582</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">243,494,916</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">182,004,220</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Basic and diluted loss per common share</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the stock-based compensation expense
recorded during the six months ended September 30, 2014 and 2013, which totaled $260,680 and $190,601, respectively, is included
in payroll and related expense in the accompanying condensed consolidated statements of operations.&#160; Stock-based compensation
expense recorded during the six months ended September 30, 2014 and 2013 had no impact on basic and diluted loss per common share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of
adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The
effect of forfeiture adjustments for the three and six month periods ended September 30, 2014 was insignificant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 6, 2014, our Board of Directors approved
the following grants of options to certain officers and directors of the Company:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60px">&#160;</td>
    <td style="width: 30px">o</td>
    <td>To Mr. James A. Joyce, an option to acquire an aggregate of 1,500,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $246,000.&#160;&#160;The option vested as to 500,000 shares on the grant date for a vesting expense of $82,000 and will vest as to an additional 500,000 shares on each of the first two anniversaries of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60px">&#160;</td>
    <td style="width: 30px">o</td>
    <td>To Mr. Rodney S. Kenley, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000.&#160;&#160;The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60px">&#160;</td>
    <td style="width: 30px">o</td>
    <td>To Mr. James B. Frakes, an option to acquire an aggregate of 250,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $41,000. The option vested as to 83,333 shares on the grant date for a vesting expense of $13,667 and will vest as to an additional 83,333 shares on the first anniversary of the grant date and 83,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024.</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60px">&#160;</td>
    <td style="width: 30px">o</td>
    <td>To Dr. Richard H. Tullis, an option to acquire an aggregate of 50,000 shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant. The fair value of this stock option at the date of grant was $8,200. The option vested as to 16,667 shares on the grant date for a vesting expense of $2,733 and will vest as to an additional 16,667 shares on the first anniversary of the grant date and 16,666 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will expire June 6, 2024. </td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the above grants to our officers,
on June 6, 2014, our Board of Directors also approved the grant of options to five employees to acquire an aggregate of 370,000
shares of our common stock at an exercise price of $0.19 per share, the closing price of our common stock on the date of grant.
The aggregate fair value of those stock options at the date of grant was $60,680. Those options vested as to 123,333 shares on
the grant date for a vesting expense of $20,227 and will vest as to an additional 123,333 shares on the first anniversary of the
grant date and 123,334 shares on the second anniversary of the grant date. Unless earlier exercised or terminated, the option will
expire June 6, 2024.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the share-based compensation
expense for the specific stock option grants noted above, our total share-based compensation expense for the three and six months
ended September 30, 2014 includes ongoing vesting expense associated with stock grants from prior periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes to 2012 Board Compensation Program</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2012, the Board approved a Board Compensation
Program (the &#147;2012 Program&#148;), which modified and superseded the 2005 Directors Compensation Program that had been in
effect previously. On June 6, 2014, the Board approved certain changes to the 2012 Program. Under the modified 2012 Program, in
which only non-employee Directors may participate, a new eligible Director will receive an initial grant of $50,000 worth of options
to acquire shares of common stock, with such grant being valued at the exercise price based on the average of the closing bid prices
of our common stock for the five trading days preceding the first day of the fiscal year. These options will have a term of ten
years and will vest 1/3 upon grant and 1/3 upon each of the first two anniversaries of the date of grant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the beginning of each fiscal year, each existing
Director eligible to participate in the 2012 Program also will receive a grant of $35,000 worth of options valued at the exercise
price based on the average of the closing bid prices of the Common Stock for the five trading days preceding the first day of the
fiscal year. Such options will vest on the first anniversary of the date of grant. In lieu of per meeting fees, under the 2012
Program eligible Directors will receive an annual Board retainer fee of $30,000. The modified 2012 Program also provides for the
following annual retainer fees: Audit Committee Chair - $5,000, Compensation Committee chair - $5,000, Audit Committee member -
$4,000, Compensation Committee member - $4,000 and Lead independent director - $15,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the modified 2012 Program on
June 6, 2014, we issued 184,211 stock options to each of our three outside directors. Those grants vest over the fiscal year ending
March 31, 2015 and have an exercise price of $0.19 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the foregoing actions - the changes in
base salaries, the option grants and the changes to the Directors Compensation Program discussed herein - were approved and recommended
by the Company&#146;s Compensation Committee prior to approval by the Board.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following outlines the significant weighted
average assumptions used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial
Lattice option pricing models at, and during the six months ended September 30, 2014:&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">2.6%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">10 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">90.23%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected volatility was based on the historic
volatility. The expected life of options granted was based on the &#34;simplified method&#34; as described in the SEC's guidance
due to changes in the vesting terms and contractual life of current option grants compared to our historical grants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we granted to a scientific advisory
board member and a scientific consultant a three year option to purchase 125,000 shares of our common stock at a price of $0.11
per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, <font style="background-color: white">our
compensation committee and Board of Directors approved the issuance of four stock option grants to four of our executives. The
options carried an exercise price of $0.10 per share, have a ten year life and vest over the following schedule: 25% on July 1,
2014, 25% on July 1, 2015, 25% on July 1, 2016 and 25% on July 1, 2017. The numbers of shares underlying each of the stock option
grants were as follows: 2,000,000 shares to our chief executive officer and 500,000 shares each to our president, chief science
officer and chief financial officer (see Note 10).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following outlines the significant weighted
average assumptions used to estimate the fair value information, which is based on historical data, with respect to stock option
grants utilizing the Binomial Lattice option pricing models at, and during the six months ended September 30, 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.38% - 2.50%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">3 years - 10 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">94.6% - 102.7%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected volatility was based on the historic
volatility. The expected life of options granted was based on the &#34;simplified method&#34; as described in the SEC's guidance
due to changes in the vesting terms and contractual life of current option grants compared to our historical grants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options outstanding that have vested and are
expected to vest as of September 30, 2014 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term in Years</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Vested</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">24,294,227</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.26</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">3.96</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected to vest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">4,711,811</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.14</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9.15</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 0.25in">Total</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 0.25in">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 0.25in; text-align: right">29,006,038</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td style="padding-left: 0.25in; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the six months ended September
30, 2014 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Number of Options</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Range of</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted Average </b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Stock options outstanding at March 31, 2014</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">26,133,407</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">$0.076 - $0.41</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.25</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,972,631</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0.19</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.19</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cancelled/Expired</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(100,000</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.19</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.19</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Stock options outstanding at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">29,006,038</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">$0.076 - $0.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.24</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Stock options exercisable at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">24,294,227</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">$0.076 - $0.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2014, there was approximately
$497,783 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted
average period of 2.19 years.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2014, our stock options had
a negative intrinsic value since the closing price of our common stock on that date of $0.12 per share was below the weighted
average exercise price of our stock options.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. OTHER CURRENT LIABILITIES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities were comprised of
the following items:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%">Accrued interest</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">570,741</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">1,165,335</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Accrued legal fees</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">179,465</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">179,465</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Accrued liquidated damages</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">362,800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">362,800</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Other accrued liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">103,598</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">147,774</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Total other current liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,216,604</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,855,374</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this report, various promissory
and convertible notes payable in the aggregate principal amount of $473,422 (as identified in Notes 4 and 5 above) have reached
maturity and are past due. We are continually reviewing other financing arrangements to retire all past due notes. At September
30, 2014, we had accrued interest in the amount of $471,041 associated with these defaulted notes in accrued liabilities payable
(see Notes 4 and 5).</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. FAIR VALUE MEASUREMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We follow FASB ASC 820, &#34;FAIR VALUE MEASUREMENTS
AND DISCLOSURES&#34; (&#147;ASC 820&#148;) in connection with assets and liabilities measured at fair value on a recurring basis
subsequent to initial recognition. The guidance applies to our derivative liabilities. We had no assets or liabilities measured
at fair value on a non-recurring basis for any period reported.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 requires that assets and liabilities
carried at fair value will be classified and disclosed in one of the following three categories: We measure the fair value of applicable
financial and non-financial assets based on the following fair value hierarchy:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1: Quoted market prices in active markets
for identical assets or liabilities.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2: Observable market based inputs or unobservable
inputs that are corroborated by market data.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3: Unobservable inputs that are not corroborated
by market data.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The hierarchy noted above requires us to minimize
the use of unobservable inputs and to use observable market data, if available, when determining fair value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of our recorded derivative liabilities
is determined based on unobservable inputs that are not corroborated by market data, which is a Level 3 classification. We record
derivative liabilities on our balance sheet at fair value with changes in fair value recorded in our consolidated statements of
operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2014, we no longer had any
derivative liabilities as all of the holders of the financial instruments that had price antidilution protection waived such price
antidilution protection.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our fair value measurements at the March 31,
2014 reporting date are classified based on the valuation technique level noted in the table below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, <br />
2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices <br />
in Active Markets for <br />
(Level 1)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable <br />
(Level 2)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant <br />
Unobservable <br />
(Level 3)</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%">Derivative Liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Total Assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following outlines the significant weighted
average assumptions used to estimate the fair value information presented, in connection with our warrant and embedded conversion
option derivative instruments utilizing the Binomial Lattice option pricing model:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The following
outlines the significant weighted average assumptions used to estimate the fair value information presented, in connection with
our warrant and embedded conversion option derivative instruments utilizing the Binomial Lattice option pricing model:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30, 2013</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.02% - 0.62%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">0.25 &#150; 3 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">78.9% - 104.5%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes
in the fair value of our Level 3 financial instruments for the six months ended September 30, 2014: &#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">April 1, <br />
2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Recorded New Derivative <br />
Liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Change in estimated fair value recognized in results of operations</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Reclassification <br />
of Derivative <br />
Liability to Paid <br />
in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, <br />
2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 30%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Derivative liabilities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">10,679,067</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(10,679,067</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth a summary of changes
in the fair value of our Level 3 financial instruments for the six months ended September 30, 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Change in</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Reclassification</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">estimated fair</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">of Derivative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Recorded</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">value recognized</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Liability to</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">April 1,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">New Derivative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">in results</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid in</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of operations</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 30%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Derivative liabilities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,588,239</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,382,877</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(106,501</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5,864,615</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>11. WARRANTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">WARRANTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. WARRANTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of warrant activity during the six
months ended September 30, 2014 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Range of</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted Average</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Warrants outstanding at March 31, 2014</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">70,709,475</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">$0.042 - $0.25</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.13</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,166,104</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.086 &#150; $0.12</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.10</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Issued</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">15,375,614</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.24</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.07</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cancelled/Expired</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,136,364</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.13</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.13</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Warrants outstanding at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">82,782,621</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.25</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.10</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Warrants exercisable at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">82,782,621</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">$0.042 - $0.25</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following outlines the significant weighted
average assumptions used to estimate the fair value information presented, with respect to warrants utilizing the Binomial Lattice
option pricing models at, and during, the six months ended September 30, 2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.79% - 2.29%&#160;&#160;</td></tr>
<tr style="background-color: white">
    <td>Average expected life&#160;&#160;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">5 years &#150; 7 years</td></tr>
<tr style="background-color: #EEEEEE">
    <td>Expected volatility&#160;&#160;&#160;&#160;&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">90.1% - 95.8%</td></tr>
<tr style="background-color: white">
    <td>Expected dividends&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>4. NOTES PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense related to notes payable</a></td>
        <td class="nump">$ 19,959<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">190,000<span></span></td>
        <td class="nump">390,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">374,312<span></span></td>
        <td class="nump">374,704<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">12% Notes Payable [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">185,000<span></span></td>
        <td class="nump">185,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">367,687<span></span></td>
        <td class="nump">353,813<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump">15.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">10% Note payable [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="nump">6,625<span></span></td>
        <td class="nump">6,375<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="nump">15.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Directors Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Principal Balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedInterestOnNotesPayable', window );">Accrued Interest on notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 14,516<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedInterestOnNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Interest on notes payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_AccruedInterestOnNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="8">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Milestone 2.4.2.2 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>MileStone 2.4.2.4 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Milestone M9 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>MileStone 2.3.2.2 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>MileStone 2.3.3.2 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Milestone M5 [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contract revenue</a></td>
        <td class="nump">$ 444,723<span></span></td>
        <td class="nump">$ 808,739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_NumberOfMilestonesUnderYearOneContract', window );">Number Of Milestones Under Year One Contract</a></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_NumberOfMilestonesAchievedUnderYearOneContract2', window );">Number Of Milestones Achieved Under Year One Contract</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue Recognition, Milestone Method, Revenue Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 197,362<span></span></td>
        <td class="nump">$ 5,000<span></span></td>
        <td class="nump">$ 197,361<span></span></td>
        <td class="nump">$ 195,581<span></span></td>
        <td class="nump">$ 208,781<span></span></td>
        <td class="nump">$ 208,781<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_NumberOfMilestonesAchievedUnderYearOneContract2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Milestones Achieved Under Year One Contract</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_NumberOfMilestonesAchievedUnderYearOneContract2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_NumberOfMilestonesUnderYearOneContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Milestones Under Year One Contract</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_NumberOfMilestonesUnderYearOneContract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">PRINCIPLES OF CONSOLIDATION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PRINCIPLES OF CONSOLIDATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial
statements include the accounts of Aethlon Medical, Inc. and its majority-owned and controlled subsidiary, ESI. All significant
intercompany balances and transactions have been eliminated in consolidation. The Company classifies the noncontrolling interests
in ESI as part of consolidated net loss in the six months ended September 30, 2014 and includes the accumulated amount of noncontrolling
interests as part of stockholders&#146; equity. During the fiscal year ended March 31, 2014, ESI raised capital in the amount
of $1,500,000 in exchange for the issuance of 300,000 shares of ESI common stock to ESI&#146;s investors, representing 20% of
ESI&#146;s issued and outstanding capital stock. As a result, Aethlon Medical, Inc.&#146;s ownership of ESI was reduced to 80%.
If a further change in Aethlon Medical Inc.&#146;s ownership of ESI results in loss of control and deconsolidation, any retained
ownership interest will be remeasured with the gain or loss reported in our statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The losses at ESI during the six months ended
September 30, 2014 reduced the noncontrolling interests on our consolidated balance sheet by $89,135 from $218,270 at March 31,
2014 to $129,135 at September 30, 2014.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">USE OF ESTIMATES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our condensed consolidated financial
statements in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, among
others, realization of long-lived assets, estimating fair value associated with debt and equity transactions and valuation of deferred
tax assets. Actual results could differ from those estimates.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CASH AND CASH EQUIVALENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards define &#34;cash and cash
equivalents&#34; as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates. For the purpose
of financial statement presentation, we consider all highly liquid investment instruments with original maturities of three months
or less when purchased, or any investment redeemable without penalty or loss of interest to be cash equivalents. As of September
30, 2014 and March 31, 2014, we had no assets that were classified as cash equivalents.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">CONCENTRATIONS OF CREDIT RISKS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CONCENTRATIONS OF CREDIT RISKS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash is maintained at two financial institutions
in checking accounts and related cash management accounts. Accounts at these institutions are secured by the Federal Deposit Insurance
Corporation (&#34;FDIC&#34;) up to $250,000. Our September 30, 2014 cash balances were approximately $276,000 over such insured
amount. We do not believe that the Company is exposed to any significant risk with respect to its cash.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our accounts receivable at September
30, 2014 and March 31, 2014 and all of our revenue in the six month periods ended September 30, 2014 and 2013 were directly from
the U.S. Department of Defense or from a subcontract under Battelle (defined herein), which is a prime contractor with the U.S.
Department of Defense, and as such no allowance for uncollectable accounts receivable is deemed necessary at September 30, 2014
or March 31, 2014.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FAIR VALUE OF FINANCIAL INSTRUMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of our cash, accounts receivable,
accounts payable, and other current liabilities approximate their estimated fair values due to the short-term maturities of those
financial instruments. The carrying amount of the notes payable approximates their fair value due to the short maturity of the
notes and since the interest rate approximates current market interest rates for similar instruments.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has concluded that it is not practical
to determine the estimated fair value of amounts due to related parties because the transactions cannot be assumed to have been
consummated at arm's length, the terms are not deemed to be market terms, there are no quoted values available for these instruments,
and an independent valuation would not be practicable due to the lack of data regarding similar instruments, if any, and the associated
potential costs.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 9 with respect to derivative liabilities.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PROPERTY AND EQUIPMENT</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five
years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement
of property and equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss
included in the consolidated statements of operations.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INCOME TAXES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to the difference between the consolidated financial statements and their respective
tax basis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards.
We record a valuation allowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable
future, it is more likely than not that some portion of the deferred tax assets may not be realized.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a
long-lived asset is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized.
We believe no impairment charges were necessary during the three and six month periods ended September 30, 2014 and 2013.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">LOSS PER COMMON SHARE</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">LOSS PER COMMON SHARE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing
net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation.
Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number
of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common
shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional
potential common shares have been excluded as their effect would be antidilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2014 and 2013, a total of
139,672,815 and 137,935,529 potential common shares, consisting of shares underlying outstanding stock options, warrants and convertible
notes payable were excluded as their inclusion would be antidilutive.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">SEGMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEGMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, we operated in one segment that
was based on our development of therapeutic devices. However in the December 2013 quarter, we initiated the operations of ESI to
develop diagnostic tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic
applications (See Note 14).</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">DEFERRED FINANCING COSTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DEFERRED FINANCING COSTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs related to the issuance of debt are capitalized
and amortized to interest expense over the life of the related debt using the effective interest method.&#160;&#160;We recorded
amortization expense related to our deferred offering costs of $21,502 and $863 during the six month periods ended September 30,
2014 and 2013, respectively.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REVENUE RECOGNITION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DARPA Contract -- With respect to revenue recognition,
we entered into a government contract with DARPA and have recognized revenue under such contract. We adopted the Milestone method
of revenue recognition for the DARPA contract under ASC 605-28 &#147;Revenue Recognition &#150; Milestone Method&#148; and we
believe we meet the requirements under ASC 605-28 for reporting contract revenue under the Milestone Method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to account for this contract, we identify
the deliverables included within the contract and evaluate which deliverables represent separate units of accounting based on if
certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received
is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the
separate units.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone is an event having all of the following
characteristics:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) There is substantive uncertainty at the
date the arrangement is entered into that the event will be achieved. A vendor&#146;s assessment that it expects to achieve a
milestone does not necessarily mean that there is not substantive uncertainty associated with achieving the milestone.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The event can only be achieved based in
whole or in part on either: (a) the vendor&#146;s performance; or (b) a specific outcome resulting from the vendor&#146;s performance.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) If achieved, the event would result in additional
payments being due to the vendor.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone does not include events for which
the occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty&#146;s performance.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The policy for recognizing deliverable consideration
contingent upon achievement of a milestone must be applied consistently to similar deliverables.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assessment of whether a milestone is substantive
is performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of
the following for the milestone to be considered substantive:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The consideration is commensurate with either:
(a) the vendor&#146;s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items
as a result of a specific outcome resulting from the vendor&#146;s performance to achieve the milestone;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The consideration relates solely to past
performance; and</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) The consideration is reasonable relative
to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A milestone is not considered substantive if
any portion of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it
does not relate solely to past performance). To recognize the milestone consideration in its entirety as revenue in the period
in which the milestone is achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated
into substantive and non-substantive components. In addition, if a portion of the consideration earned from achieving a milestone
may be refunded or adjusted based on future performance, the related milestone is not considered substantive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 12 for the additional disclosure information
required under ASC 605-28.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Battelle Subcontract -- We entered into a subcontract
agreement with Battelle Memorial Institute (&#147;Battelle&#148;) in March 2013. Battelle was chosen by DARPA to be the prime
contractor on the systems integration portion of the original DARPA contract and we are one of several subcontractors on that systems
integration project. The Battelle subcontract is cost-reimbursable under a time and materials basis. We began generating revenues
under the subcontract during the six months ended September 30, 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenue under this contract is a function
of cost reimbursement plus an overhead mark-up for hours devoted to the project by specific employees (with specific hourly rates
for those employees). Battelle engages us as needed. Each payment requires approval by the program manager at Battelle.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK-BASED COMPENSATION</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employee stock options and rights to purchase
shares under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is
measured when all granting activities have been completed, generally the grant date, based on the fair value of the award. The
exercise price of options is generally equal to the market price of the Company's common stock (defined as the closing price as
quoted on the OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equity
incentive awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance
with the original provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards
granted subsequent to April 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent
accounting standards. We use a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 10).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes share-based compensation
expenses relating to shares and options granted and the effect on loss per common share during the six month periods ended September
30, 2014 and 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Six Months Ended</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2013</p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 68%">Vesting of Stock Options</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">260,680</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">124,243</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Incremental fair value of option Modifications</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,914</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Vesting Expense Associated with CEO Restricted Stock Grant</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">64,444</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Total Stock-Based Compensation Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">260,680</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Weighted average number of common shares outstanding &#150; basic and diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">243,494,916</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">182,004,220</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Basic and diluted loss per common share</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for transactions involving services
provided by third parties where we issue equity instruments as part of the total consideration using the fair value of the consideration
received (i.e. the value of the goods or services) or the fair value of the equity instruments issued, whichever is more reliably
measurable. In transactions, when the value of the goods and/or services are not readily determinable and (1) the fair value of
the equity instruments is more reliably measurable and (2) the counterparty receives equity instruments in full or partial settlement
of the transactions, we use the following methodology:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">a) For transactions where goods have already
been delivered or services rendered, the equity instruments are issued on or about the date the performance is complete (and valued
on the date of issuance).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">b) For transactions where the instruments are
issued on a fully vested, non-forfeitable basis, the equity instruments are valued on or about the date of the contract.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">c) For any transactions not meeting the criteria
in (a) or (b) above, we re-measure the consideration at each reporting date based on its then current stock value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting
the forfeiture rate for all expense amortization after March 31, 2006 is recognized in the period the forfeiture estimate is changed.
The effect of forfeiture adjustments for the six months ended September 30, 2014 was insignificant.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">PATENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PATENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents include both foreign and domestic patents.
There were several patents pending at September 30, 2014. We capitalize the cost of patents and patents pending, some of which
were acquired, and amortize such costs over the shorter of the remaining legal life or their estimated economic life, upon issuance
of the patent. The unamortized costs of patents and patents pending are subject to our review for impairment under our long-lived
asset policy above.&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">STOCK PURCHASE WARRANTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK PURCHASE WARRANTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We grant warrants in connection with the issuance
of convertible notes payable and the issuance of common stock for cash. When such warrants are classified as equity and issued
in connection with debt, we measure the relative estimated fair value of such warrants and record it as a discount from the face
amount of the convertible notes payable. Such discounts are amortized to interest expense over the term of the notes using the
effective interest method. Warrants issued in connection with common stock for cash, if classified as equity, are considered issued
in connection with equity transactions and the warrant fair value is recorded to additional paid-in-capital. Lastly, warrants not
meeting equity classification are recorded as derivative instruments.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">DERIVATIVE INSTRUMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DERIVATIVE INSTRUMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We evaluate free-standing derivative instruments
(or embedded derivatives) to properly classify such instruments within equity or as liabilities in our financial statements. Our
policy is to settle instruments indexed to our common shares on a first-in-first-out basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The classification of a derivative instrument
is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument
is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract
may be reclassified.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Instruments classified as derivative liabilities
are remeasured each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement
of operations in other (income) expense.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock', window );">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE
NOTES PAYABLE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible feature of certain notes payable
provides for a rate of conversion that is below market value. Such feature is normally characterized as a &#34;Beneficial Conversion
Feature&#34; (&#34;BCF&#34;). We measure the estimated fair value of the BCF in circumstances in which the conversion feature
is not required to be separated from the host instrument and accounted for separately, and record that value in the consolidated
financial statements as a discount from the face amount of the notes. Such discounts are amortized to interest expense over the
term of the notes.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RegistrationPaymentArrangementsPolicyTextBlock', window );">REGISTRATION PAYMENT ARRANGEMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REGISTRATION PAYMENT ARRANGEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for contingent obligations to make
future payments or otherwise transfer consideration under a registration payment arrangement separately from any related financing
transaction agreements, and any such contingent obligations are recognized only when it is determined that it is probable we will
become obligated for future payments and the amount, or range of amounts, of such future payments can be reasonably estimated.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RESEARCH AND DEVELOPMENT EXPENSES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We incurred research and development expenses
during the three and six month periods ended September 30, 2014 and 2013, which are included in various operating expense line
items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods
were as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%">Three months ended</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">250,388</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">293,580</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Six months ended</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">637,723</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">626,638</td>
    <td>&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_OffbalanceSheetArrangementsPolicyTextBlock', window );">OFF-BALANCE SHEET ARRANGEMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">OFF-BALANCE SHEET ARRANGEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not entered into any off-balance sheet
arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management is evaluating significant recent
accounting pronouncements that are not yet effective for the Company, including the new accounting standard on revenue recognition,
ASU 2014-09 (Topic 606), and has not yet concluded whether any such pronouncements will have a significant effect on the Company&#146;s
future consolidated financial statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTES PAYABLE</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_BeneficialConversionFeatureOfConvertibleNotesPayablePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_OffbalanceSheetArrangementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_OffbalanceSheetArrangementsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RegistrationPaymentArrangementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>REGISTRATION PAYMENT ARRANGEMENTS</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_RegistrationPaymentArrangementsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6433137&amp;loc=d3e40733-113955<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Embedded Derivative<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511375<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35682315&amp;loc=d3e50579-113967<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 5B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28244453&amp;loc=SL5844817-113951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34750511&amp;loc=d3e48542-113965<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesEmbeddedDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsFiniteLivedPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. FAIR VALUE MEASUREMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair value measurements based on the valuation technique</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Our fair value measurements at the March 31, 2014 reporting date
are classified based on the valuation technique level noted in the table below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31, <br />
2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices <br />
in Active Markets for <br />
(Level 1)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable <br />
(Level 2)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant <br />
Unobservable <br />
(Level 3)</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%">Derivative Liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double">$</td>
    <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Total Assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">10,679,067</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Significant weighted average assumptions used to estimate the fair value information utilizing the Binomial Lattice option pricing model</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The following outlines the
significant weighted average assumptions used to estimate the fair value information presented, in connection with our warrant
and embedded conversion option derivative instruments utilizing the Binomial Lattice option pricing model:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center">Six Months Ended September 30, 2013</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.02% - 0.62%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">0.25 &#150; 3 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">78.9% - 104.5%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of our Level 3 financial instruments</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The table below sets forth a summary of changes in the fair value
of our Level 3 financial instruments for the six months ended September 30, 2014: &#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">April 1, <br />
2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Recorded New Derivative <br />
Liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Change in estimated fair value recognized in results of operations</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Reclassification <br />
of Derivative <br />
Liability to Paid <br />
in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, <br />
2014</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 30%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Derivative liabilities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">10,679,067</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(10,679,067</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The table below sets forth a summary of changes in the fair value
of our Level 3 financial instruments for the six months ended September 30, 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Change in</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Reclassification</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">estimated fair</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">of Derivative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Recorded</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">value recognized</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Liability to</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">April 1,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">New Derivative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">in results</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid in</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">of operations</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 30%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Derivative liabilities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,588,239</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,382,877</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(106,501</td>
    <td>)</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5,864,615</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>11. WARRANTS (Details - Warrant activity) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Warrants [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Summary Of Warrant Activity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
        <td class="nump">70,709,475<span></span></td>
        <td class="nump">70,709,475<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,166,104)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Warrants Issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,375,614<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants Cancelled/Expired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,136,364)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
        <td class="nump">70,709,475<span></span></td>
        <td class="nump">82,782,621<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">82,782,621<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePrice', window );"><strong>Range of Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsOutstandingRangeOfExercisePriceMinimum', window );">Warrants outstanding, beginning - Range of Exercise Price Minimum</a></td>
        <td class="nump">$ 0.042<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsOutstandingRangeOfExercisePriceMaximum', window );">Warrants outstanding, beginning - Range of Exercise Price Maximum</a></td>
        <td class="nump">$ 0.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsExercisedRangeOfExercisePriceMinimum', window );">Warrants Exercised - Range of Exercise Price Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.086<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsExercisedRangeOfExercisePriceMaximum', window );">Warrants Exercised - Range of Exercise Price Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.12<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsIssuedRangeOfExercisePriceMinimum', window );">Warrants Issued - Range of Exercise Price Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.042<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsIssuedRangeOfExercisePriceMaximum', window );">Warrants Issued - Range of Exercise Price Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.24<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsCancelledExpiredRangeOfExercisePrice', window );">Warrants Cancelled/Expired - Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.13<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsOutstandingRangeOfExercisePriceMinimum', window );">Warrants outstanding, ending - Range of Exercise Price Minimum</a></td>
        <td class="nump">$ 0.042<span></span></td>
        <td class="nump">$ 0.042<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsOutstandingRangeOfExercisePriceMaximum', window );">Warrants outstanding, ending - Range of Exercise Price Maximum</a></td>
        <td class="nump">$ 0.25<span></span></td>
        <td class="nump">$ 0.25<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum', window );">Warrants Exercisable, ending - Range of Exercise Price Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.042<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum', window );">Warrants Exercisable, ending - Range of Exercise Price Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.25<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WeightedAverageExercisePrice', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Warrants outstanding Weighted Average Exercise Price</a></td>
        <td class="nump">$ 0.13<span></span></td>
        <td class="nump">$ 0.13<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsExercisedWeightedAverageExercisePrice', window );">Warrants Exercised Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants Issued Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.07<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice', window );">Warrants Cancelled/Expired Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.13<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Warrants outstanding Weighted Average Exercise Price, ending</a></td>
        <td class="nump">$ 0.13<span></span></td>
        <td class="nump">$ 0.10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercisable Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.10<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_RangeOfExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsCancelledExpiredRangeOfExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Cancelled/Expired Range of Exercise Price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsCancelledExpiredRangeOfExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Cancelled/Expired Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsCancelledexpiredWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercisable Range of Exercise Price Maximum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercisable at Range of Exercise Price Minimum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsExercisableAtDecember312012RangeOfExercisePriceMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsExercisedRangeOfExercisePriceMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsExercisedRangeOfExercisePriceMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsExercisedRangeOfExercisePriceMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercised Range of Exercise Price Minimum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsExercisedRangeOfExercisePriceMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsExercisedWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercised Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsExercisedWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsIssuedRangeOfExercisePriceMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued Range of Exercise Price Maximum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsIssuedRangeOfExercisePriceMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsIssuedRangeOfExercisePriceMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued Range of Exercise Price Minimum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsIssuedRangeOfExercisePriceMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsOutstandingRangeOfExercisePriceMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Outstanding Range Of Exercise Price Maximum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsOutstandingRangeOfExercisePriceMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsOutstandingRangeOfExercisePriceMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Outstanding Range Of Exercise Price Minimum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarrantsOutstandingRangeOfExercisePriceMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsNoteDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3FAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>9. FAIR VALUE MEASUREMENTS (Details - Fair value) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,679,067<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Inputs Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Inputs Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value Inputs Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="nump">5,864,615<span></span></td>
        <td class="nump">3,588,239<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,679,067<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226000-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="num">$ (4,592,485)<span></span></td>
        <td class="num">$ (3,653,168)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">18,676<span></span></td>
        <td class="nump">4,727<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">260,680<span></span></td>
        <td class="nump">190,601<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair market value of common stock, warrants and options issued for services</a></td>
        <td class="nump">162,358<span></span></td>
        <td class="nump">264,343<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,382,877<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LossOnExtensionOfWarrants', window );">Loss on extension of warrants</a></td>
        <td class="nump">143,363<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LossOnDebtConversion', window );">Loss on debt conversion</a></td>
        <td class="nump">2,531,123<span></span></td>
        <td class="nump">40,256<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing costs</a></td>
        <td class="nump">21,502<span></span></td>
        <td class="nump">4,578<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(162,495)<span></span></td>
        <td class="num">(11,404)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">9,558<span></span></td>
        <td class="num">(25,202)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
        <td class="nump">163,646<span></span></td>
        <td class="num">(33,170)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
        <td class="nump">49,708<span></span></td>
        <td class="nump">91,042<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(1,394,366)<span></span></td>
        <td class="num">(744,520)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from the issuance of notes payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">400,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump">670,274<span></span></td>
        <td class="nump">228,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">670,274<span></span></td>
        <td class="nump">628,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
        <td class="num">(724,092)<span></span></td>
        <td class="num">(116,520)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
        <td class="nump">1,250,279<span></span></td>
        <td class="nump">125,274<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
        <td class="nump">526,187<span></span></td>
        <td class="nump">8,754<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DebtAndAccruedInterestConvertedToCommonStock', window );">Debt and accrued interest converted to common stock</a></td>
        <td class="nump">1,007,631<span></span></td>
        <td class="nump">420,460<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity', window );">Reclassification of warrant derivative liability into equity</a></td>
        <td class="nump">10,679,067<span></span></td>
        <td class="nump">106,501<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable', window );">Reclassification of accounts payable to convertible notes payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">47,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment', window );">Deferred financing costs recorded in connection with debt amendment</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable', window );">Reclassification of accrued interest to convertible notes payable</a></td>
        <td class="nump">$ 25,766<span></span></td>
        <td class="nump">$ 20,027<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DebtAndAccruedInterestConvertedToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt and accrued interest converted to common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DebtAndAccruedInterestConvertedToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_DeferredFinancingCostsRecordedInConnectionWithDebtAmendment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LossOnDebtConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_LossOnDebtConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LossOnExtensionOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_LossOnExtensionOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ReclassificationOfAccountsPayableToConvertibleNotePayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_ReclassificationOfAccruedInterestToConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 15<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35708913&amp;loc=d3e50896-113970<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">5. CONVERTIBLE NOTES PAYABLE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at September
30, 2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Unamortized <br />
Discount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net <br />
Amount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued <br />
Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%; padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Current Portion:</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">October &#38; November 2009 10% Convertible Notes</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">28,598</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2010 10% Convertible Note</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">35,188</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">July and August 2011 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">283,421</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">283,421</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">96,728</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Law Firm Note</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">9,479</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">483,422</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">483,422</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">169,993</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Non-Current Portion:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">Amended and Restated Series A 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">225,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">225,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9,000</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2010 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9,513</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">448,448</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">448,448</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">13,454</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Non-Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">990,520</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">990,520</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">31,967</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 44pt; text-indent: -9pt">Total Convertible Notes Payable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">1,473,941</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">1,473,941</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">201,960</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">There were no discounts remaining on any of our Convertible Notes
Payable as of September 30, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">During the six months ended September 30, 2014, we recorded interest
expense of $97,362 related to the contractual interest rates of our convertible notes and interest expense of $21,502 related to
the amortization of deferred financing costs related to the convertible notes for a total interest related to convertible notes
of $118,864.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Convertible Notes Payable consisted of the following at March 31,
2014:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Unamortized <br />
Discount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net <br />
Amount</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Accrued <br />
Interest</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Current Portion:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%; padding-left: 9pt; text-indent: -9pt">Amended and Restated Series A 12% Convertible Notes, past due</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">885,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">&#150;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">885,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">575,250</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">2008 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">19,167</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">October &#38; November 2009 10% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">50,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">26,097</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2010 10% Convertible Note</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">31,438</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">July and August 2011 10% Convertible Notes, past due</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">90,256</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Law Firm Note</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">75,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">7,604</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">1,367,655</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">1,367,655</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">749,812</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">Convertible Notes Payable &#150; Non-Current Portion:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2010 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">317,072</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">35,034</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">April 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">448,448</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">448,448</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">12,117</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 9pt; text-indent: -9pt">September 2011 12% Convertible Notes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">10,931</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 9pt; text-align: right">10,931</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 22pt; text-indent: -9pt">Total &#150; Convertible Notes Payable &#150; Non-Current Portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">776,451</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 22pt; text-align: right">776,451</td>
    <td>&#160;</td>
    <td style="padding-left: 22pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">47,151</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 44pt; text-indent: -9pt">Total Convertible Notes Payable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">2,144,106</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 44pt; text-align: right">2,144,106</td>
    <td>&#160;</td>
    <td style="padding-left: 44pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">796,963</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no discounts remaining on any of
our Convertible Notes Payable as of March 31, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">AMENDED AND RESTATED SERIES A 12% CONVERTIBLE
NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2010, we entered into Amended and Restated
Series A 12% Convertible Promissory Notes (the &#34;Amended and Restated Notes&#34;) with the holders of certain promissory notes
previously issued by us, extending the due date to December 31, 2010 on the aggregate principal balance of $900,000. During the
fiscal year ended March 31, 2013, the holders of $15,000 of the Notes converted their principal and related accrued interest into
common stock. The balance remaining at March 31, 2014 was $885,000 and past due.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Weiner Note Conversion</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2014, we entered into an agreement
with the Ellen R. Weiner Family Revocable Trust (the &#147;Trust&#148;), a holder of a Series A 12% Convertible Note (the &#147;Note&#148;),
which previously was classified as being in default. As per the agreement, the Trust converted past due principal of $660,000 and
accrued interest balance of $343,200 into restricted common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Trust agreed to waive anti-dilution
price protection underlying warrants previously issued to the Trust. On June 26, 2014, three other parties who held similar warrants
also agreed to waive their anti-dilution price protection.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under its agreement, the Trust converted the
entire $1,003,200 past due principal and interest balance on the Note, which previously was in default, into an aggregate of 23,318,254
restricted shares of our common stock and five-year warrants to acquire up to 6,809,524 shares of our common stock at an exercise
price of $.042 per share (which exercise price was the result of certain contractual price adjustments previously made during 2011)
and up to 397,222 shares of our common stock at an exercise price of $.108 per share (collectively, the &#147;Conversion Securities&#148;).
Based on the fair value of the warrants and shares issued to the Trust for the accrued interest, we recorded a loss on settlement
of notes of $1,791,421.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In exchange for the Trust&#146;s conversion
in full of the Note and accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants,
in addition to the Conversion Securities, we issued to the Trust 75,000 restricted shares of common stock as a service fee, changed
the exercise price of all of the previously issued warrants to $.042 per share and extended the expiration date of all of the previously
issued warrants to July 1, 2018. We valued the 75,000 share service fee at $12,000 based on our closing price on the date of the
agreement and recorded that value as interest expense during the June 2014 period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bird Estate Extension</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2014, we executed a written restructuring
agreement (the &#147;Agreement&#148;) with the Estate of Allan Bird (the &#147;Estate&#148;), a holder of a Series A 12% Convertible
Note (the &#147;Note&#148;), which previously was classified as being in default. Since the negotiations for the Agreement were
completed in the month of June, we recorded the impact of the Agreement as of June 30, 2014. In the Agreement, the Estate agreed
to extend the expiration date of the Note to April 1, 2016, to convert approximately $116,970 of accrued interest to equity, and
to waive anti-dilution price protection underlying the Note and warrants previously issued to the Estate.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Agreement, the Estate converted the
entire $116,970 past due interest balance on the Note, which previously was in default, into an aggregate of 2,591,846 restricted
shares of our common stock. The Estate received five-year warrants to acquire up to 2,321,429 shares of our common stock at an
exercise price of $.042 per share (which exercise price was the result of certain contractual price adjustments previously made
during 2011). Based on our common stock prices during a period of negotiation with the Estate including during calendar year 2013,
the Estate also received five-year warrants to acquire up to 135,417 shares of our common stock at an exercise price of $.108 (collectively
known as the &#147;Conversion Securities&#148;). Based on the fair value of the warrants and shares issued to the Estate for
the accrued interest, we recorded a loss on settlement of notes of $663,209.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In exchange for the Estate&#146;s extension
of the Note, conversion of accrued interest and for the waivers of anti-dilution price protection in the previously issued warrants,
in addition to the Conversion Securities, we also issued to the Estate 25,000 restricted shares of common stock as an extension
fee and extended the expiration date of all of the previously issued warrants to July 1, 2018. We valued the 25,000 share extension
fee at $4,500 based on our closing price and recorded that value as a deferred financing cost, which we will amortize over the
extended two year life of the note.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2008 10% CONVERTIBLE NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 17, 2014, we issued to the holder
of the remaining 2008 10% Convertible Note units consisting of an aggregate of 478,188 shares of restricted common stock and unit
warrants to acquire up to an aggregate of 239,094 shares of common stock at an exercise price of $0.096 per share (see Note 6).
The units were issued to the Note holder upon the conversion of an aggregate of $45,906 of unpaid principal and accrued interest
due under the Note, which represented the entire amount outstanding under the Note and the Note was retired. We recorded a loss
on debt conversion of $65,493 on this transaction.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">OCTOBER &#38; NOVEMBER 2009 10% CONVERTIBLE
NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October and November 2009, we raised $430,000
from the sale to accredited investors of 10% convertible notes (&#34;October &#38; November 2009 10% Convertible Notes&#34;).
The October &#38; November 2009 10% Convertible Notes matured at various dates between April 2011 and May 2011 and are convertible
into our common stock at a fixed&#160;conversion price of $0.25 per share. The investors also received matching three year warrants
to purchase unregistered shares of our common stock at an exercise price of $0.25 per share. We measured the fair value of the
warrants and the beneficial conversion feature of the Notes and recorded a 100% discount against the principal of the notes. Such
discount was fully amortized at March 31, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2012, we issued 461,409 shares of common
stock and 230,705 warrants to purchase common stock to the holder of a $25,000 note in this grouping in exchange for the conversion
of such note and related accrued interest of $8,000 (for a total of $33,000). The warrants expired in 2012 and are exercisable
at $0.107 per share (see Note 6). We recorded a loss on conversion of $45,796.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the conversions into
principal of the October and November 2009 10% Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in October &#38; November 2009 10% Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">450,250</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2010</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(70,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2011</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(175,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(130,250</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(25,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">50,000</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2012, we agreed to extend the expiration
date and to change the exercise price of certain warrants of one of the note holders by two years in exchange for the extension
of $50,000 of the October &#38; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below)
by that same two year period. We recorded a charge of $77,265 relating to this modification.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2013, we agreed to extend the expiration
date of certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &#38;
November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management
assessed the change in the value of the notes and related warrants before and after that extension and determined that the change
in value related to the change in terms was not significant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2014, we issued
to the holder of the remaining October &#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting
of an aggregate of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common
stock at an exercise price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of
$189,087 of unpaid principal and accrued interest due under two promissory notes (the remaining October &#38; November 2009 10%
Convertible Note and the April 2010 10% Convertible Note). The amounts converted represented the entire principal and interest
outstanding under the notes and the notes held by that holder were retired (see Note 15).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">APRIL 2010 10% CONVERTIBLE NOTE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2010, we raised $75,000 from the sale
to an accredited investor of a 10% convertible note. The convertible note was originally scheduled to mature in October 2011 and
is convertible into our common stock at a fixed conversion price of $0.25 per share prior to maturity. The investor also received
three year warrants to purchase 300,000 unregistered shares of our common stock at a price of $0.25 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measured the fair value of the warrants and
the beneficial conversion feature of the notes and recorded a 100% discount against the principal of the notes. We amortized this
discount using the effective interest method over the term of the note. As of September 30, 2014, there have not been any conversions
of the April 2010 10% Convertible Note.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2012, we agreed to extend the expiration
date and to change the exercise price of certain warrants of the note holder by two years in exchange for his extension of $50,000
of the October &#38; November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note by that same two year
period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2013, we agreed to extend the expiration
date of certain warrants of one of the note holders by two years in exchange for the extension of $50,000 of the October &#38;
November 2009 10% Convertible Notes and the $75,000 April 2010 10% Convertible Note (see below) by that same two year period. Management
assessed the change in the value of the notes and related warrants before and after that extension and determined that the change
in value related to the change in terms was not significant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2014, we issued
to the holder of the remaining October &#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note units consisting
of an aggregate of 1,835,798 shares of common stock and unit warrants to acquire up to an aggregate of 1,837,798 shares of common
stock at an exercise price of $0.103 per share. The units were issued to the note holder upon the conversion of an aggregate of
$189,087 of unpaid principal and accrued interest due under two promissory notes (the remaining October &#38; November 2009 10%
Convertible Note and the April 2010 10% Convertible Note). The amounts converted represented the entire principal and interest
outstanding under the notes and the notes held by that holder were retired (see Note 15).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEPTEMBER 2010 10% CONVERTIBLE NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 3, 2010, we entered into a Subscription
Agreement with three accredited investors (the &#147;Purchasers&#148;)&#160;providing for the issuance and sale of convertible
promissory notes and corresponding warrants in the aggregate principal amount of $1,430,000. The initial closing under the Subscription
Agreement resulted in the issuance and sale of (i) convertible promissory notes in the aggregate principal amount of $743,600,
(ii) five-year warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.31125 per share,
and (iii) five-year warrants to purchase an aggregate of 3,718,000 shares of our common stock at an exercise price of $0.43575
per share. The convertible promissory notes bear interest compounded monthly at the annual rate of ten percent (10%) and mature
on April 1, 2016 (see below). The aggregate gross cash proceeds were $650,000, the balance of the principal amount representing
a due diligence fee and an original issuance discount. The convertible promissory notes are convertible at the option of the holders
into shares of our common stock at a price per share equal to eighty percent (80%) of the average of the three lowest closing bid
prices of the common stock as reported by Bloomberg L.P. for the principal market on which the common stock trades or is quoted
for the ten (10) trading days preceding the proposed conversion date. Subject to adjustment as described in the notes, the conversion
price may not be more than $0.30 nor less than $0.20. There are no registration requirements with respect to the shares of common
stock underlying the notes or the warrants.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2014, we entered into separate
Amendments to Convertible Notes and Warrants (collectively, the &#147;Amendments&#148;) with three accredited investors (collectively,
the &#147;Investors&#148;) who own certain convertible promissory notes (collectively, the &#147;Notes&#148;) and warrants
(collectively, the &#147;Warrants&#148;) previously issued by us on various dates between December 5, 2007 and September 23,
2011, including the September 2010 Convertible Notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Amendments, the Notes were past
maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended
the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result
of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per
annum, which represents a reduction from the default interest rates of fifteen percent at which interest had been accruing. By
entering into the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12% from a
total of $693,260 to a total of $776,451.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period from October 2011 to February
2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding
under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions
applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,
pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&#146;s Common Stock, which
represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected
at $.042 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Amendments also set the conversion price
of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per
share. By virtue of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015
and September 23, 2016 to January 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the activity in the
September 2010 10% Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in the September 2010 10% Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">743,600</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(405,500</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(30,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(25,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Increase in principal balance due to 12% extension fee</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">33,972</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">317,072</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">APRIL 2011 10% CONVERTIBLE NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2011, we entered into a Subscription
Agreement with two accredited investors (the &#147;Purchasers&#148;) providing for the issuance and sale of convertible promissory
notes and corresponding warrants in the aggregate principal amount of $385,000. The closing under the Subscription Agreement resulted
in the issuance and sale by us of (i) convertible promissory notes in the aggregate principal amount of $385,000, (ii) five-year
warrants to purchase an aggregate of&#160;4,004,000 shares of our common stock at an exercise price of $0.125 per share, and (iii)
five-year warrants to purchase an aggregate of&#160;4,004,000 shares of our common stock at an exercise price of $0.175 per share.
The convertible promissory notes bear interest compounded monthly at the annual rate of 10% and mature on April 1, 2016 (see below).
The aggregate gross cash proceeds to us were $350,000, the balance of the principal amount representing a due diligence fee and
an original issuance discount. The convertible promissory notes are convertible at the option of the holders into shares of our
common stock at a price per share equal to eighty percent (80%) of the average of the three lowest closing bid prices of the common
stock as reported by Bloomberg L.P. for the principal market on which the common stock trades or is quoted for the ten (10) trading
days preceding the proposed conversion date. Subject to adjustment as described in the notes, the conversion price may not be more
than $0.20 nor less than $0.10. There are no registration requirements with respect to the shares of common stock underlying the
notes or the warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we issued (i) five-year warrants
to purchase an aggregate of 812,500 shares of our common stock at an exercise price of $0.125 per share, and (ii) five-year warrants
to purchase an aggregate of&#160;812,500 shares of our common stock at an exercise price of $0.175 per share to the Purchasers.
These warrants were issued as an antidilution adjustment under certain common stock purchase warrants held by the Purchasers that
were acquired from us in September 2010.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2014, we entered into separate
Amendments to Convertible Notes and Warrants (collectively, the &#147;Amendments&#148;) with three accredited investors (collectively,
the &#147;Investors&#148;) who own certain convertible promissory notes (collectively, the &#147;Notes&#148;) and warrants
(collectively, the &#147;Warrants&#148;) previously issued by us on various dates between December 5, 2007 and September 23,
2011, including the April 2011 Convertible Notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Amendments, the Notes were past
maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended
the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result
of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per
annum, which represents a reduction from the default interest rates of 15% at which interest had been accruing. By entering into
the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12% from a total of $693,260
to a total of $776,451.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period from October 2011 to February
2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding
under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions
applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,
pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&#146;s Common Stock, which
represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected
at $.042 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Amendments also set the conversion price
of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per
share. By virtue of the Amendments, the expiration dates of the Warrants also were extended from dates between September 3, 2015
and September 23, 2016 to January 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2014, there have not been
any conversions of the April 2011 10% Convertible Notes and the 12% extension fee noted above increased the principal balance by
$48,048 to a principal balance of $448,448.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">JULY &#38; AUGUST 2011 10% CONVERTIBLE NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2011, we raised $357,656 in five separate 10% convertible notes. Those notes had a fixed conversion price of $0.09 per share and
carried an interest rate of 10%. The convertible notes matured in July and August 2012. We also issued those investors five year
warrants to purchase 3,973,957 shares of common stock at $0.125 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measured the fair value of the warrants and
the beneficial conversion feature of the notes and recorded a $257,926 discount against the principal of the notes. We amortized
this discount using the effective interest method over the term of the note.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 31, 2014, the holders of three
of the five notes totaling $100,000 converted all of their principal and accrued interest into 1,438,700 shares of our common stock
at the contractual conversion price of $0.09 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2014, we entered into a forbearance
agreement with the holder of the remaining two notes in which we agreed to repay his notes by October 31, 2014 and in which we
also agreed to extend his warrants by two years. We recorded a charge of $143,363 in the September 2014 period related to this
warrant extension due to the change in the fair value of the warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2014, we paid off
in full the remaining outstanding principal balance and interest balances on the two remaining notes with cash payments of $382,748
(see Note 15).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEPTEMBER 2011 CONVERTIBLE NOTES</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2011, we issued $253,760 of convertible
notes, convertible at $0.07 per share. Such notes originally matured in September 2012.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2014, we entered into separate
Amendments to Convertible Notes and Warrants (collectively, the &#147;Amendments&#148;) with three accredited investors (collectively,
the &#147;Investors&#148;) who own certain convertible promissory notes (collectively, the &#147;Notes&#148;) and warrants
(collectively, the &#147;Warrants&#148;) previously issued by us on various dates between December 5, 2007 and September 23,
2011, including the September 2011 Convertible Notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Amendments, the Notes were past
maturity and were in default, resulting in the accrual of interest at the applicable default interest rate. The Amendments extended
the maturity date of each of the Notes to April 1, 2016, which permits us to classify them as long-term liabilities. As a result
of the Amendments, the Notes are no longer in default and the non-default interest rate for all of the Notes was set at 12% per
annum, which represents a reduction from the default interest rates of 15% at which interest had been accruing. By entering into
the Amendments, we also agreed to increase the currently outstanding principal amount of the Notes by 12%, which in the case of
the September 2011 Notes, they increased from $9,760 to $10,931</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period from October 2011 to February
2014, the Investors had converted, at conversion prices between $.0546 and $.07 per share, portions of principal and interest outstanding
under the Notes and certain other convertible promissory notes previously issued to them by us. Certain antidilution provisions
applicable to such notes should have resulted in such conversions being effected at a conversion price of $.042 per share. Accordingly,
pursuant to the Amendments, we issued to the investors an aggregate of 4,507,105 shares of the Company&#146;s Common Stock, which
represents the additional shares of Common Stock that would have been issued to the Investors had such conversions been effected
at $.042 per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Amendments also set the conversion price
of the Notes, as well as the exercise price at which shares of our common stock can be purchased under the Warrants, at $.042 per
share. By virtue of the Amendments, the expiration dates of the Warrants also were extended to January 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the conversions into
principal of the September 2011 Convertible Notes by fiscal year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Activity in the September 2011 Convertible Notes</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%">Initial principal balance</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">253,760</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2012</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(15,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Conversions during the fiscal year ended March 31, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(60,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the fiscal year ended March 31, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(169,000</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Increase in principal balance due to extension fee</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,171</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Conversions during the six months ended September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(10,931</td>
    <td>)</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Balance as of September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#150;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted in the above table, the remaining balance
of the September 2011 Convertible Notes converted into equity during the six months ended September 30, 2014.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">LAW FIRM NOTE</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 22, 2012, we entered into a Promissory
Note with our corporate law firm for the amount of $75,000, which represented the majority of the amount we owed to that firm
at that time. The Promissory Note originally had a maturity date of December 31, 2012 and bears interest at 5% per annum. The
note is convertible at the option of the holder into shares of our common stock at a 10% discount to the market price of the common
stock on the date prior to conversion with a floor price on such conversions of $0.08 per share. The holder subsequently agreed
to extend the Maturity Date of the Note first to October 1, 2013, then to September 30, 2013, and now the expiration date of this
note is again extended to October 1, 2014. As of September 30, 2014, there have not been any conversions of the Law Firm Note.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we paid off in full the outstanding principal balance and interest balance on the note with a cash payment of $50,000 and an issuance
of 170,020 common shares (see Note 15).</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. STOCK COMPENSATION (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Components of share-based compensation expenses relating to shares and options granted</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table breaks out the components
of our share-based compensation expenses relating to shares and options granted and the effect on basic and diluted loss per common
share during the three and six months ended September 30, 2014 and 2013.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Three Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Three Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Six Months Ended</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">Six Months Ended</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2013</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 36%">Vesting of stock options</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">89,793</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">73,856</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">260,680</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">124,243</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Incremental fair value of option modifications</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">957</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,914</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 11pt; text-indent: -11pt">Vesting expense associated with CEO restricted stock grant</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-left: 11pt; text-align: right">&#150;</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">64,444</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Total share-based compensation expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">89,793</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">74,813</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">260,680</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Total share-based compensation expense included in net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">89,793</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">73,856</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">260,680</td>
    <td>&#160;</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">190,601</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Weighted average number of common shares outstanding &#150; basic and diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">259,369,911</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">187,643,582</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">243,494,916</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">182,004,220</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 11pt; text-indent: -11pt">Basic and diluted loss per common share</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 11pt; text-align: right">(0.00</td>
    <td>)</td>
    <td style="padding-left: 11pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.00</td>
    <td>)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted average assumptions used to estimate the fair value information</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information presented, with respect to stock option grants utilizing the Binomial Lattice option
pricing models at, and during the six months ended September 30, 2014:&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">2.6%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">10 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">90.23%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following outlines the significant weighted average assumptions
used to estimate the fair value information, which is based on historical data, with respect to stock option grants utilizing the
Binomial Lattice option pricing models at, and during the six months ended September 30, 2013:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 74%">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center">0.38% - 2.50%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Average expected life</td>
    <td>&#160;</td>
    <td style="text-align: center">3 years - 10 years</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: center">94.6% - 102.7%</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td style="text-align: center">None</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Options outstanding</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Options outstanding that have vested and are expected to vest as
of September 30, 2014 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term in Years</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Vested</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">24,294,227</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.26</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">3.96</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Expected to vest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">4,711,811</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.14</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">9.15</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 0.25in">Total</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 0.25in">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-left: 0.25in; text-align: right">29,006,038</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td style="padding-left: 0.25in; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Stock option activity</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the six months ended September
30, 2014 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Number of Options</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Range of</b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted Average </b><br />
<b>Exercise Price</b></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 52%">Stock options outstanding at March 31, 2014</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">26,133,407</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right">$0.076 - $0.41</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 13%; text-align: right">0.25</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#150;&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,972,631</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0.19</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">0.19</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Cancelled/Expired</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(100,000</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.19</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.19</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>Stock options outstanding at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">29,006,038</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">$0.076 - $0.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">0.24</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>Stock options exercisable at September 30, 2014</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">24,294,227</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">$0.076 - $0.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">0.26</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the following for fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position: the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>242</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 2. LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Liquidity</Role>
      <ShortName>2. LIQUIDITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 4. NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/NotesPayable</Role>
      <ShortName>4. NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayable</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 6. EQUITY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactions</Role>
      <ShortName>6. EQUITY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 7. RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactions</Role>
      <ShortName>7. RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 8. OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilities</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 9. FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/FairValueMeasurements</Role>
      <ShortName>9. FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 10. STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensation</Role>
      <ShortName>10. STOCK COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 11. WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Warrants</Role>
      <ShortName>11. WARRANTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognition</Role>
      <ShortName>12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 14. SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Segments</Role>
      <ShortName>14. SEGMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 15. SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SubsequentEvents</Role>
      <ShortName>15. SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 4. NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/NotesPayableTables</Role>
      <ShortName>4. NOTES PAYABLE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/FairValueMeasurementsTables</Role>
      <ShortName>9. FAIR VALUE MEASUREMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 10. STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationTables</Role>
      <ShortName>10. STOCK COMPENSATION (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 11. WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsTables</Role>
      <ShortName>11. WARRANTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 14. SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SegmentsTables</Role>
      <ShortName>14. SEGMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 2. LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>2. LIQUIDITY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetails-Share-basedCompensationExpense</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Share-based compensation expense)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 4. NOTES PAYABLE (Details - Notes payable)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/NotesPayableDetails-NotesPayable</Role>
      <ShortName>4. NOTES PAYABLE (Details - Notes payable)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 4. NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>4. NOTES PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details - Activity)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableDetails-Activity</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE (Details - Activity)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>6. EQUITY TRANSACTIONS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 8. OTHER CURRENT LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilityDetailsNarrative</Role>
      <ShortName>8. OTHER CURRENT LIABILITY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - 9. FAIR VALUE MEASUREMENTS (Details - Fair value)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/FairValueMeasurementsDetails-FairValue</Role>
      <ShortName>9. FAIR VALUE MEASUREMENTS (Details - Fair value)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/FairValueMeasurementDetails-Assumptions</Role>
      <ShortName>9. FAIR VALUE MEASUREMENT (Details - Assumptions)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - 9. FAIR VALUE MEASUREMENT (Details - Level 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/FairValueMeasurementDetails-Level3</Role>
      <ShortName>9. FAIR VALUE MEASUREMENT (Details - Level 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - 10. STOCK COMPENSATION (Details - Share-based compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-Share-basedCompensation</Role>
      <ShortName>10. STOCK COMPENSATION (Details - Share-based compensation)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - 10. STOCK COMPENSATION (Details - Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-Assumptions</Role>
      <ShortName>10. STOCK COMPENSATION (Details - Assumptions)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 10. STOCK COMPENSATION (Details - Option information)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionInformation</Role>
      <ShortName>10. STOCK COMPENSATION (Details - Option information)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - 10. STOCK COMPENSATION (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity</Role>
      <ShortName>10. STOCK COMPENSATION (Details - Option activity)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - 10. STOCK COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>10. STOCK COMPENSATION (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - 11. WARRANTS (Details - Warrant activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsDetails-WarrantActivity</Role>
      <ShortName>11. WARRANTS (Details - Warrant activity)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - 11. WARRANTS (Details - Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsDetails-Assumptions</Role>
      <ShortName>11. WARRANTS (Details - Assumptions)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - 12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/DarpaContractAndRelatedRevenueRecognitionDetailsNarrative</Role>
      <ShortName>12. DARPA CONTRACT AND RELATED REVENUE RECOGNITION (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - 14. SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SegmentsDetails</Role>
      <ShortName>14. SEGMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS  (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>aemd-20140930.xml</File>
    <File>aemd-20140930.xsd</File>
    <File>aemd-20140930_cal.xml</File>
    <File>aemd-20140930_def.xml</File>
    <File>aemd-20140930_lab.xml</File>
    <File>aemd-20140930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEKBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockIssuedSubscribedSharesIssued', window );">Stock issued subscribed, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,192,444<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarantsIssuedToAccreditedInvestors', window );">Warants issued to accredited investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,096,222<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from subscription and warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 320,800<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares issued</a></td>
        <td class="nump">359,956<span></span></td>
        <td class="nump">219,127<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services, amount</a></td>
        <td class="nump">49,090<span></span></td>
        <td class="nump">38,268<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Principal balance of note [Member] | Holder One [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">15,714,286<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Stock issued in exchange of note, amount</a></td>
        <td class="nump">660,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Principal balance of note [Member] | Holder Two [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">2,591,846<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Stock issued in exchange of note, amount</a></td>
        <td class="nump">116,970<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Conversion of accrued interest [Member] | Holder One [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">7,603,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Stock issued in exchange of note, amount</a></td>
        <td class="nump">343,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restructuring Fee [Member] | Holder One [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restructuring Fee [Member] | Holder Two [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Four investors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued, shares</a></td>
        <td class="nump">2,673,231<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common stock issued, amount</a></td>
        <td class="nump">259,474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Three investors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued, shares</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted common stock issued, amount</a></td>
        <td class="nump">90,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock acquired, shares</a></td>
        <td class="nump">974,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock acquired, amount</a></td>
        <td class="nump">487,491<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares issued</a></td>
        <td class="nump">390,301<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for services, amount</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued in exchange of note, shares issued</a></td>
        <td class="nump">1,937,505<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Stock issued in exchange of note, amount</a></td>
        <td class="nump">$ 81,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockIssuedSubscribedSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued subscribed, shares issued</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_StockIssuedSubscribedSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarantsIssuedToAccreditedInvestors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warants issued to accredited investors</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aemd_WarantsIssuedToAccreditedInvestors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aemd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockAmountIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>15. SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. SUBSEQUENT EVENTS</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Management has evaluated events
subsequent to September 30, 2014 through the date that the accompanying condensed consolidated financial statements were filed
with the Securities and Exchange Commission for transactions and other events which may require adjustment of and/or disclosure
in such financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Government Contracts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we collected $247,361 under our DARPA contract, and under the Battelle subcontract we billed $9,595 and we collected $11,311.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Debt Reduction</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we paid off the remaining principal and interest balances on the two remaining July &#38; August 2011 10% Convertible Notes, which
had been classified as being in default, with cash payments totaling $382,748 (see Note 5).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we paid off in full the outstanding principal balance and interest balance on the Law Firm Note with a cash payment of $50,000
and an issuance of 170,020 common shares (see Note 5).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Common Stock Issuances</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we issued 317,119 shares of common stock pursuant to our S-8 registration statement covering our Amended 2010 Stock Plan at an
average price of $0.124 per share in payment for legal and scientific consulting services valued at $39,170 based on the value
of the services provided.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Equity Unit Investments</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we issued and sold to eight accredited investors units (the &#147;Units&#148;) consisting of (a) one hundred thousand (100,000)
restricted shares of the Registrant&#146;s common stock, par value $.001 per share (the &#147;Common Stock&#148;), at prices
per share ranging from $0.105 to $0.114 and (b) a five-year warrant to purchase fifty thousand (50,000) shares of Common Stock
at exercise prices ranging from $0.154 to $0.167 per share (the &#147;Unit Warrants&#148;). In total, the investors purchased
for cash an aggregate of $501,700 of Units. The investors acquired an aggregate of 4,506,250 shares of Common Stock and Unit Warrants
to acquire up to an aggregate of 2,253,125 shares of Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we issued to an accredited investor Units consisting of an aggregate of 1,835,798 shares of Common Stock and Unit Warrants to
acquire up to an aggregate of 1,837,798 shares of Common Stock at an exercise price of $0.103 per share. The Units were issued
to the investor upon the conversion of an aggregate of $189,087 of unpaid principal and accrued interest due under two promissory
notes (the remaining October &#38; November 2009 10% Convertible Note and the April 2010 10% Convertible Note &#150; see Note
5) previously issued to the investor by the Registrant. The amounts converted represented the entire principal and interest outstanding
under the notes and the notes held by that holder were retired.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Warrant Exercises and Issuance
of New Warrants Upon Exercise </u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-size: 8pt">Subsequent to
September 30, 2014, we issued an aggregate of 5,671,119 shares of Common Stock and seven-year warrants (the &#147;Exchange Warrants&#148;)
to issue up to an aggregate of 5,671,119 shares of Common Stock at exercise prices ranging from $0.093 to $0.116 per share to
eight accredited investors. One of the investors is Dr. Chetan Shah, a director of the Registrant. The Common Stock and Exchange
Warrants were issued to the investors upon the cash exercise of previously issued warrants held by them. The investors paid an
aggregate of $579,251 upon exercise of the previously outstanding warrants at exercise prices ranging from $0.093 to $0.115 per
share. The foregoing transaction was privately negotiated with the group of participating warrant holders.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><u>Note Conversions</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-size: 8pt">Subsequent to
September 30, 2014, we issued an aggregate of 3,522,976 shares of Common Stock to two accredited investors upon the conversion
of an aggregate of $147,965 of unpaid principal and accrued interest due under promissory notes previously issued to the investors
by the Registrant. The conversion price per share was $0.042</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt"><u>Warrant
Exercises</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><font style="font-size: 8pt">Subsequent to
September 30, 2014, we issued an aggregate of 16,423,131 shares of Common Stock to three accredited investors upon the exercise
of warrants previously issued with an exercise price of $0.042 per share. The warrants were exercised on a cashless or &#147;net&#148;
basis. Accordingly, we did not receive any proceeds from such exercises. The cashless exercise of such warrants resulted in the
cancellation of previously issued warrants to purchase an aggregate of 20,050,643 shares of Common Stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt"><u>Issuance of Convertible Notes</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 8pt">Subsequent to September 30, 2014,
we entered into a Subscription Agreement with two accredited investors providing for the issuance and sale of (i) convertible
promissory notes in the aggregate principal amount of $527,780 and (ii) five year warrants to purchase up to 2,356,160 shares
of Common Stock at a fixed exercise price of $0.168 per share. The convertible promissory notes bear interest at the annual rate
of 10% and mature on April 1, 2016. The aggregate gross cash proceeds to us were $415,000 after subtracting legal fees of $35,000;
the balance of the principal amount of the notes represents a $27,780 due diligence fee and an original issuance discount. The
convertible promissory notes are convertible at the option of the holders into shares of our common stock at a fixed price of
$0.112 per share, for up to an aggregate of 4,712,321 shares of Common Stock. There are no registration requirements with respect
to the shares of common stock underlying the notes or the warrants.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
